[{"product_info": "Flucelvax Tetra - suspension for injection in pre-filled syringe \nInfluenza vaccine (surface antigen, inactivated, prepared in cell cultures)", "composition": "Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following \nstrains*: \nA/Wisconsin/588/2019 (H1N1)pdm09-like strain (A/Delaware/55/2019 CVR-45) 15 micrograms \nHA** \nA/Darwin/6/2021 (H3N2)-like strain (A/Darwin/11/2021, wild type) 15 micrograms HA** \nB/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021, wild type) 15 micrograms HA** \nB/Phuket/3073/2013-like strain (B/Singapore/INFTT-16-0610/2016, wild type) 15 micrograms HA** \nper 0.5 ml dose \n\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026. \npropagated in Madin Darby Canine Kidney (MDCK) cells \n** \nhaemagglutinin \nThe vaccine complies with the World Health Organisation (WHO) recommendation (northern \nhemisphere) and EU recommendation for the 2022/2023 SEASON. \nFlucelvax Tetra may contain traces of beta-propiolactone, cetyltrimethylammonium bromide, and \npolysorbate 80.  \nFor the full list of excipients, see section 6.1.", "indications": "Prophylaxis of influenza in adults and children from 2 years of age.  \nFlucelvax Tetra should be used in accordance with official recommendations.", "posology": "Posology \nAdults and children from 2 years of age: \nAge Group \nDose \nSchedule \n2 to < 9 years\nOne or twoa 0.5 mL doses \nIf 2 doses, administer at least \n4 weeks apart \n9 years of age and older\nOne 0.5 mL dose \nNot applicable \na Children less than 9 years of age who have not been previously vaccinated against influenza, should \nreceive a second dose. \nThe safety and efficacy of Flucelvax Tetra in children from birth to less than 2 years of age has not \nbeen established. \nMethod of administration  \nFor intramuscular injection only.  \nThe preferred site for injection is the deltoid muscle of the upper arm. Young children with \ninsufficient deltoid mass should be vaccinated in the anterolateral aspect of the thigh.  \nThe vaccine must not be injected intravenously, subcutaneously or intradermally and must not be \nmixed with other vaccines in the same syringe. \nFor instructions on the handling of the vaccine before administration, see section 6.6.", "contraindications": "Hypersensitivity to the active substance, to any of the excipients listed in section 6.1, or to possible \ntrace residues such as beta-propiolactone, cetyltrimethylammonium bromide, and polysorbate 80.", "special_warnings": "Traceability \nIn order to improve the traceability of biological medicinal products, the name and the batch number \nof the administered product should be clearly recorded. \nAppropriate medical treatment and supervision should always be readily available in case of a rare \nanaphylactic event following the administration of the vaccine. \nVaccination should be postponed in patients with acute febrile illness until the fever is resolved.  \nAs with all injectable vaccines, Flucelvax Tetra must be administered with caution to individuals with \nthrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular \nadministration. \nSyncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to \nthe needle injection. This can be accompanied by several neurological signs such as transient visual \ndisturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that \nprocedures are in place to avoid injury from faints. \nAntibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient \nto prevent influenza. \nA protective immune response may not be elicited in all vaccine recipients.", "pregnancy": "No interaction studies have been performed with Flucelvax Tetra. There are no data available on co-\nadministration of Flucelvax Tetra with other vaccines. Based on clinical experience with cell-based \ntrivalent influenza vaccine (TIVc), Flucelvax Tetra can be given at the same time as other vaccines.", "driving": "Pregnancy \nInactivated influenza vaccines, such as Flucelvax Tetra, can be given in any stage of pregnancy. \nLarger safety datasets are available on vaccine use during the second or third trimester, compared with \nthe first trimester; however, data from worldwide use of influenza vaccines do not indicate any \nadverse foetal and maternal outcomes attributable to the vaccine. \nA prospective Pregnancy Exposure Registry was conducted in the United States (US) and data were \ncollected from 665 women vaccinated with Flucelvax Tetra during 3 Northern Hemisphere influenza \nseasons (2017-18 to 2019-20), of whom 28% were exposed during their first trimester. Based on \npregnancy outcomes and predefined infant safety outcomes, there was no evidence of adverse foetal, \nnewborn or pregnancy outcomes attributable to the vaccine during any stage of pregnancy.  \nThere have been no reproductive and developmental toxicology studies with Flucelvax Tetra. \nReproductive and developmental toxicology data from cell-based trivalent influenza vaccine (TIVc) \ndo not predict an increased risk of developmental abnormalities. \nBreast-feeding \nIt is unknown whether Flucelvax Tetra is excreted in human milk. No effects on breast fed \nnewborn/infant are anticipated. Flucelvax Tetra may be given during lactation. \nFertility \nNo human fertility data are available. Animal data, with cell-based trivalent influenza vaccine (TIVc), \nhave not shown effects on female fertility. Male fertility has not been assessed in animals.", "side_effects": "Flucelvax Tetra has no or negligible influence on the ability to drive and use machines.", "shelf_life": "12 months", "storage": "Store in a refrigerator (2\u00b0C \u2013 8\u00b0C). \nDo not freeze. \nKeep the pre-filled syringe in the outer carton in order to protect from light.", "package": "0.5 ml suspension in pre-filled syringes (type I glass), with a plunger stopper (bromobutyl rubber), \nwith or without needle.  \nPack of 1 pre-filled syringe, with or without needle \nPack of 10 pre-filled syringes, with or without needles. \nNot all pack sizes may be marketed.", "marketing_authorization_numbers": "EU/1/18/1326/001 \nEU/1/18/1326/002 \nEU/1/18/1326/003 \nEU/1/18/1326/004", "filename": "flucelvax-tetra-epar-product-information_en.html", "snomed.product_info": [["385220007", "Injection suspension (product)|Conventional release suspension for injection (dose form)|Injection suspension (qualifier value)"], ["18720000", "In (attribute)"], ["272113006", "Before values (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["1181000221105", "Vaccine product containing only Influenza virus antigen (medicinal product)"], ["410679008", "Surface (qualifier value)"], ["7120007", "Antigen (substance)"], ["18720000", "In (attribute)"], ["362837007", "Entire cell (body structure)|Entire cell (cell)"]], "ncit.product_info": [["C149969", "Suspension for Injection in Pre-filled Syringe Dosage Form"], ["C29120", "Influenza Vaccine"], ["C25245", "Surface"], ["C268", "Antigen"], ["C162847", "FDA Inactivation"], ["C25625", "Preparation"], ["C16727", "India"], ["C48694", "Cell"]], "rxnorm.product_info": [["1649574", "Injection"], ["T025", "Cell"]], "loinc.product_info": [["LP70420-2", "-"], ["LA21913-1", "Suspension"], ["LA14542-7", "Injection"], ["LA22004-8", "IN"], ["LP32605-5", "pre"], ["LP188733-2", "Syringe"], ["LP74974-4", "Influenza vaccine"], ["LP73434-0", "Surface"], ["LA22004-8", "IN"], ["T025", "Cell"]], "snomed.composition": [["725894000", "Influenza virus (organism)"], ["410679008", "Surface (qualifier value)"], ["263773003", "Hemagglutinating antibody (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["80837006", "Sialidase (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255260001", "Following (attribute)"], ["269324003", "[Dislocations &/or sprains &/or strains] or subluxations (disorder)|[Dislocations &/or sprains &/or strains] or subluxations"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["427726005", "Wisconsin (geographic location)"], ["303175008", "H1N1 (qualifier value)|Serotype H1N1 (qualifier value)"], ["48532005", "Muscle strain (disorder)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["224046004", "Delaware (geographic location)"], ["264691008", "Arabic numeral 55 (qualifier value)|55 (qualifier value)"], ["1222848005", "American Joint Committee on Cancer stage IV:5 (qualifier value)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["303178005", "H3N2 (qualifier value)|Serotype H3N2 (qualifier value)"], ["48532005", "Muscle strain (disorder)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1222737005", "American Joint Committee on Cancer stage I:1 (qualifier value)"], ["262290003", "Wild (qualifier value)"], ["410657003", "Type (attribute)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["421211000", "Lymphoma staging symptom status B (tumor staging)"], ["223635007", "Austria (geographic location)"], ["48532005", "Muscle strain (disorder)"], ["421211000", "Lymphoma staging symptom status B (tumor staging)"], ["223593008", "Singapore (geographic location)"], ["262290003", "Wild (qualifier value)"], ["410657003", "Type (attribute)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["421211000", "Lymphoma staging symptom status B (tumor staging)"], ["48532005", "Muscle strain (disorder)"], ["421211000", "Lymphoma staging symptom status B (tumor staging)"], ["223593008", "Singapore (geographic location)"], ["1222743007", "American Joint Committee on Cancer stage I:6 (qualifier value)"], ["262290003", "Wild (qualifier value)"], ["410657003", "Type (attribute)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["260304006", "0.5 (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["18720000", "In (attribute)"], ["69986009", "Canine species (organism)"], ["181414000", "Entire kidney (body structure)"], ["263773003", "Hemagglutinating antibody (substance)"], ["398827000", "Vaccine (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["263775005", "Health (qualifier value)"], ["21139007", "Organization (morphologic abnormality)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["260989008", "Beta - Greek letter (qualifier value)|Greek letter beta (qualifier value)"], ["2405001", "Propiolactone (substance)|b- Propiolactone (substance)"], ["50040111000188102", "Cetrimonium bromide (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255899003", "Polysorbate-80 (substance)|Polyoxethylene sorbitan oleate (substance)|Polyoxethylenesorbitan oleate (substance)"], ["86495002", "For (qualifier value)"], ["261015003", "Full (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.composition": [["C53482", "Influenza"], ["C14283", "Virus"], ["C25245", "Surface"], ["C268", "Antigen"], ["C16289", "Andorra"], ["C162847", "FDA Inactivation"], ["C52874", "SPI1 wt Allele"], ["C53286", "Next"], ["C76246", "Blood Group A"], ["C43485", "Wisconsin"], ["C72665", "Similarity"], ["C185651", "Straining"], ["C76246", "Blood Group A"], ["C45222", "Delaware Indian"], ["C188322", "Fifty Five"], ["C175677", "Forty Five"], ["C113429", "Fifteen"], ["C158158", "Han Chinese"], ["C76246", "Blood Group A"], ["C172979", "Fear Score 6"], ["C72665", "Similarity"], ["C185651", "Straining"], ["C76246", "Blood Group A"], ["C113425", "Eleven"], ["C62195", "Wild Type"], ["C113429", "Fifteen"], ["C158158", "Han Chinese"], ["C113692", "Child-Pugh Class B"], ["C16312", "Austria"], ["C72665", "Similarity"], ["C185651", "Straining"], ["C113692", "Child-Pugh Class B"], ["C79980", "Singapore Zebrafish"], ["C62195", "Wild Type"], ["C113429", "Fifteen"], ["C158158", "Han Chinese"], ["C113692", "Child-Pugh Class B"], ["C72665", "Similarity"], ["C185651", "Straining"], ["C113692", "Child-Pugh Class B"], ["C79980", "Singapore Zebrafish"], ["C113430", "Sixteen"], ["C62195", "Wild Type"], ["C113429", "Fifteen"], ["C158158", "Han Chinese"], ["C97722", "PER1 wt Allele"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16816", "Mali"], ["C25488", "Dose"], ["C16727", "India"], ["C14201", "Dog"], ["C23349", "Murine Kidney"], ["C48938", "Cell Count"], ["C923", "Vaccine"], ["C64950", "Follow"], ["C77972", "World"], ["C25178", "Health"], ["C75419", "World Health Organization"], ["C25197", "Recommendation"], ["C45849", "North"], ["C16289", "Andorra"], ["C96599", "Ehrlich Unit"], ["C25197", "Recommendation"], ["C64956", "For"], ["C94729", "Season"], ["C106184", "May"], ["C79873", "Contain"], ["C52874", "SPI1 wt Allele"], ["C44339", "Propiolactone"], ["C16289", "Andorra"], ["C80656", "Polysorbate 80"], ["C64956", "For"], ["C25517", "Full"], ["C43432", "List"], ["C52874", "SPI1 wt Allele"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.composition": [["T005", "Virus"], ["1311565", "propiolactone"], ["8560", "polysorbate 80"]], "loinc.composition": [["LP17147-7", "Influenza virus"], ["LP73434-0", "Surface"], ["LP30821-0", "retired part"], ["LP17763-1", "A"], ["LA3577-9", "Wisconsin"], ["LP17763-1", "A"], ["LA3851-8", "Delaware"], ["LA14561-7", "15"], ["LP220355-4", "Ha"], ["LP6901-5", "*"], ["LP17763-1", "A"], ["LP20594-5", "6"], ["LP17763-1", "A"], ["LA14557-5", "11"], ["LA9658-1", "Wild type"], ["LA14561-7", "15"], ["LP220355-4", "Ha"], ["LP6901-5", "*"], ["LA14518-7", "B"], ["LA3889-8", "Austria"], ["LA14518-7", "B"], ["LA9658-1", "Wild type"], ["LA14561-7", "15"], ["LP220355-4", "Ha"], ["LP6901-5", "*"], ["LA14518-7", "B"], ["LA14518-7", "B"], ["LA14562-5", "16"], ["LA9658-1", "Wild type"], ["LA14561-7", "15"], ["LP220355-4", "Ha"], ["LP6901-5", "*"], ["LA16632-4", "0.5"], ["MTHU065481", "Dose"], ["LA22004-8", "IN"], ["LP200461-4", "Kidney"], ["MTHU001933", "Cells"], ["LP6901-5", "*"], ["LP30374-0", "Vaccine"], ["LA17983-0", "Health"], ["LP111410-9", "Recommendation"], ["LP111410-9", "Recommendation"], ["LA14161-6", "May"], ["LP34827-3", "Beta-propiolactone"], ["LP14091-0", "Bromide"], ["LA19682-6", "Full"], ["LP204165-7", "List"], ["LP20594-5", "6"], ["LA6112-2", "1"]], "snomed.indications": [["360271000", "Prophylaxis - procedure intent (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["155559006", "Influenza (disorder)|Influenza"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"]], "ncit.indications": [["C15405", "Prevention"], ["C52874", "SPI1 wt Allele"], ["C53482", "Influenza"], ["C16727", "India"], ["C16289", "Andorra"], ["C16423", "Child"], ["C25516", "From"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C16329", "Belgium"], ["C64950", "Follow"], ["C72159", "Official"]], "rxnorm.indications": [], "loinc.indications": [["LA22004-8", "IN"], ["LA31719-0", "2 years"], ["MTHU010047", "Age"], ["LA22004-8", "IN"]], "snomed.posology": [["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["424144002", "Current chronological age (observable entity)"], ["389109008", "Group (social concept)"], ["408102007", "Unit dose (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["422113007", "Arabic numeral 9 (qualifier value)"], ["258707000", "year (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["260304006", "0.5 (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["738990001", "Administer (administration method)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["258705008", "week (qualifier value)"], ["422113007", "Arabic numeral 9 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["260304006", "0.5 (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["385432009", "Not applicable (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["422113007", "Arabic numeral 9 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["65897001", "Against (qualifier value)"], ["155559006", "Influenza (disorder)|Influenza"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["81170007", "Second (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["3950001", "Birth (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["263748003", "Established (qualifier value)"], ["260686004", "Method (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["86495002", "For (qualifier value)"], ["76601001", "Intramuscular injection (procedure)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["900000000000548007", "Preferred (foundation metadata concept)"], ["10546003", "Site (qualifier value)|Site (attribute)"], ["86495002", "For (qualifier value)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["35259002", "Structure of deltoid muscle (body structure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["302538001", "Entire upper arm (body structure)"], ["84422007", "Young (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["423437008", "Insufficient (qualifier value)"], ["181620007", "Entire deltoid muscle (body structure)"], ["300848003", "Mass of body structure (finding)"], ["18720000", "In (attribute)"], ["37197008", "Anterolateral (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["302544002", "Entire thigh (body structure)"], ["398827000", "Vaccine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["26242008", "Mixed (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["18720000", "In (attribute)"], ["262126009", "Same (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["86495002", "For (qualifier value)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["398827000", "Vaccine (substance)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["732810007", "6.6 (qualifier value)"]], "ncit.posology": [["C16289", "Andorra"], ["C16423", "Child"], ["C25516", "From"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C71550", "Age Cohort"], ["C25488", "Dose"], ["C25211", "Schedule"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C159124", "GDC Treatment Outcome Terminology"], ["C120081", "Severity of Symptom Score 9"], ["C29848", "Year"], ["C66832", "One"], ["C43508", "Oregon"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16816", "Mali"], ["C25488", "Dose"], ["C198613", "CFI wt Allele"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25488", "Dose"], ["C64912", "Administer"], ["C158997", "GDC Analyte Type Terminology"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C29844", "Week"], ["C120081", "Severity of Symptom Score 9"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C16289", "Andorra"], ["C66832", "One"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16816", "Mali"], ["C25488", "Dose"], ["C48587", "Potency Not Applicable"], ["C76246", "Blood Group A"], ["C16423", "Child"], ["C61585", "Less Than"], ["C120081", "Severity of Symptom Score 9"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C25594", "Negation"], ["C25627", "Previous"], ["C189090", "Vaccinated for COVID-19"], ["C64937", "Against"], ["C53482", "Influenza"], ["C25639", "Receive"], ["C76246", "Blood Group A"], ["C25666", "Second"], ["C25488", "Dose"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C16423", "Child"], ["C25516", "From"], ["C25155", "Birth"], ["C159124", "GDC Treatment Outcome Terminology"], ["C61585", "Less Than"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C85492", "CDISC SDTM Method Terminology"], ["C52874", "SPI1 wt Allele"], ["C70962", "Agent Administration"], ["C64956", "For"], ["C28161", "Intramuscular Route of Administration"], ["C48440", "Single"], ["C42711", "Preferred"], ["C37901", "Site"], ["C64956", "For"], ["C122632", "Injection Dosing Unit"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C32446", "Deltoid"], ["C52874", "SPI1 wt Allele"], ["C32141", "Arm"], ["C16423", "Child"], ["C62355", "With"], ["C126862", "Unsatisfactory"], ["C32446", "Deltoid"], ["C126027", "Morphology, Attenuation, Size, and Structure Criteria"], ["C16329", "Belgium"], ["C189090", "Vaccinated for COVID-19"], ["C16727", "India"], ["C25422", "Anterolateral"], ["C61468", "Aspect"], ["C52874", "SPI1 wt Allele"], ["C33763", "Thigh"], ["C923", "Vaccine"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C38276", "Intravenous Route of Administration"], ["C43508", "Oregon"], ["C16289", "Andorra"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C26457", "Mixed (Normal and Tumor)"], ["C62355", "With"], ["C118472", "Other License Status"], ["C16727", "India"], ["C172515", "S-Adenosylmethionine Measurement"], ["C50207", "Syringe Device"], ["C64956", "For"], ["C42688", "Instruction"], ["C92667", "SPARC wt Allele"], ["C179594", "Handling"], ["C52874", "SPI1 wt Allele"], ["C923", "Vaccine"], ["C201357", "Before Timing Type"], ["C70962", "Agent Administration"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C172979", "Fear Score 6"]], "rxnorm.posology": [["T100", "Age Group"], ["1649574", "Injection"], ["1649574", "Injection"]], "loinc.posology": [["LA31719-0", "2 years"], ["MTHU010047", "Age"], ["T100", "Age Group"], ["MTHU065481", "Dose"], ["MTHU000002", "Clinical Class"], ["LA32970-8", "<"], ["LA10141-2", "9"], ["LA6306-0", "One"], ["LA22025-3", "OR"], ["LA16632-4", "0.5"], ["LP6323-2", "Immunofluorescence (IF)"], ["MTHU000002", "Clinical Class"], ["LA21988-3", "AT"], ["LP6941-1", "4 weeks"], ["LA10141-2", "9"], ["MTHU010047", "Age"], ["LA6306-0", "One"], ["LA16632-4", "0.5"], ["MTHU065481", "Dose"], ["LA4720-4", "Not applicable"], ["LP17763-1", "A"], ["LA16823-9", "Less"], ["LA10141-2", "9"], ["MTHU010047", "Age"], ["LA21291-2", "Not"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["LA22004-8", "IN"], ["LA16823-9", "Less"], ["LA31719-0", "2 years"], ["MTHU010047", "Age"], ["LA21291-2", "Not"], ["LP72939-9", "Method"], ["LA9429-7", "Intramuscular"], ["LA14542-7", "Injection"], ["LP73352-4", "Site"], ["LA14542-7", "Injection"], ["LP200075-2", "IS"], ["LP234848-2", "Muscle"], ["MTHU002667", "Upper arm"], ["LA28127-1", "Insufficient"], ["LP6826-4", "Mass"], ["LA22004-8", "IN"], ["LA25379-1", "Anterolateral"], ["MTHU002690", "Thigh"], ["LP30374-0", "Vaccine"], ["LA21291-2", "Not"], ["LA22025-3", "OR"], ["LA21291-2", "Not"], ["LA11840-8", "Mixed"], ["MTHU029809", "Other"], ["LA20283-0", "Vaccines"], ["LA22004-8", "IN"], ["LA11009-0", "Same"], ["LP188733-2", "Syringe"], ["LP6820-7", "Instructions"], ["MTHU021516", "Handling"], ["LP30374-0", "Vaccine"], ["LP20594-5", "6"], ["LP20594-5", "6"]], "snomed.contraindications": [["257550005", "Hypersensitivity (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["261217004", "Substance (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["260405006", "Trace (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["260989008", "Beta - Greek letter (qualifier value)|Greek letter beta (qualifier value)"], ["2405001", "Propiolactone (substance)|b- Propiolactone (substance)"], ["50040111000188102", "Cetrimonium bromide (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255899003", "Polysorbate-80 (substance)|Polyoxethylene sorbitan oleate (substance)|Polyoxethylenesorbitan oleate (substance)"]], "ncit.contraindications": [["C3114", "Hypersensitivity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C154405", "Active State"], ["C45306", "Substance"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C48547", "Trace Dosing Unit"], ["C71344", "Associate of Science"], ["C44339", "Propiolactone"], ["C16289", "Andorra"], ["C80656", "Polysorbate 80"]], "rxnorm.contraindications": [["T167", "Substance"], ["1311565", "propiolactone"], ["8560", "polysorbate 80"]], "loinc.contraindications": [["LA16666-2", "Active"], ["T167", "Substance"], ["LA22004-8", "IN"], ["LP20594-5", "6"], ["LA6112-2", "1"], ["LA22025-3", "OR"], ["LA15097-1", "Possible"], ["LA11832-5", "Trace"], ["LP34827-3", "Beta-propiolactone"], ["LP14091-0", "Bromide"]], "snomed.special_warnings": [["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["734841007", "Name (property) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["410681005", "Count of entities (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["74188005", "Medical (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["225313009", "Supervision (regime/therapy)|Supervision (procedure)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["255260001", "Following (attribute)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["398827000", "Vaccine (substance)"], ["33879002", "Administration of vaccine to produce active immunity (procedure)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["53737009", "Acute (qualifier value)"], ["416113008", "Febrile disorder (disorder)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["386661006", "Fever (finding)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["723506003", "Resolved (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["415116008", "Platelet count below reference range (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["64779008", "Blood coagulation disorder (disorder)"], ["303123004", "Bleeding (disorder)|Bleeding"], ["255260001", "Following (attribute)"], ["255559005", "Intramuscular (qualifier value)"], ["416118004", "Administration (procedure)"], ["271594007", "Syncope (finding)|Syncope (disorder)"], ["271785004", "Fainting (finding)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["255260001", "Following (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["33879002", "Administration of vaccine to produce active immunity (procedure)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["278926001", "Psychogenic (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["79068005", "Needle, device (physical object)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["261028005", "Several (qualifier value)"], ["1199008", "Neurologic (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["255276005", "Transient (disorder)|Transient"], ["255374006", "Visual (qualifier value)"], ["91019004", "Paresthesia (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["243996003", "Entire limb (body structure)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["421066005", "Place - dosing instruction imperative (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["417746004", "Traumatic injury (disorder)"], ["68498002", "Antibody (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["73979006", "Endogenous (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255405005", "Iatrogenic (qualifier value)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["423437008", "Insufficient (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["101445003", "PREVENT (substance)|PREVENT (product)"], ["155559006", "Influenza (disorder)|Influenza"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["35024006", "Immune response (function)|Immune response, function (observable entity)"], ["18720000", "In (attribute)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["398827000", "Vaccine (substance)"]], "ncit.special_warnings": [["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C52874", "SPI1 wt Allele"], ["C28226", "Biological"], ["C42614", "Name"], ["C16289", "Andorra"], ["C104504", "Batch Number"], ["C52874", "SPI1 wt Allele"], ["C25382", "Administered"], ["C40352", "Multiplicative Product"], ["C16329", "Belgium"], ["C25261", "Medical"], ["C43442", "Biomaterial Treatment"], ["C16289", "Andorra"], ["C61372", "Management"], ["C110990", "All of the Time"], ["C16329", "Belgium"], ["C25429", "Availability"], ["C16727", "India"], ["C49152", "Case"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C13634", "Retinoic Acid Response Element"], ["C74589", "Protocol Event"], ["C53286", "Next"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C923", "Vaccine"], ["C15346", "Vaccination"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C14140", "Acute"], ["C65136", "Until"], ["C143485", "Fever, CTCAE"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C118471", "Resolved License"], ["C71344", "Associate of Science"], ["C62355", "With"], ["C64916", "All"], ["C28160", "Injection Route of Administration"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C62355", "With"], ["C159124", "GDC Treatment Outcome Terminology"], ["C62355", "With"], ["C3408", "Thrombocytopenia"], ["C43508", "Oregon"], ["C76246", "Blood Group A"], ["C115221", "Bleeding Diathesis"], ["C45325", "Since"], ["C26791", "Hemorrhage"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C53286", "Next"], ["C75889", "PAX6 wt Allele"], ["C27974", "Intramuscular"], ["C70962", "Agent Administration"], ["C55592", "Syncope, CTCAE 3.0"], ["C52288", "NUP214 wt Allele"], ["C127786", "Occurrence Indicator"], ["C53286", "Next"], ["C43508", "Oregon"], ["C201357", "Before Timing Type"], ["C81168", "Any"], ["C15346", "Vaccination"], ["C71344", "Associate of Science"], ["C76246", "Blood Group A"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C63846", "Needle Shape"], ["C122632", "Injection Dosing Unit"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C158169", "Buyei Chinese"], ["C107221", "Several"], ["C25262", "Neurologic"], ["C71344", "Associate of Science"], ["C53288", "Temporary"], ["C38059", "Visual"], ["C75521", "Disturbance"], ["C16289", "Andorra"], ["C12429", "Limb"], ["C25490", "During"], ["C70827", "Recovery"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C125543", "Importance Rating Score 0"], ["C102700", "Procedure Domain"], ["C68869", "Are"], ["C16727", "India"], ["C126366", "Placement"], ["C159124", "GDC Treatment Outcome Terminology"], ["C3671", "Injury"], ["C25516", "From"], ["C16295", "Antibody"], ["C165206", "Responsive Disease"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C28223", "Endogenous"], ["C43508", "Oregon"], ["C15261", "Immunosuppressive Therapy"], ["C106184", "May"], ["C16329", "Belgium"], ["C126862", "Unsatisfactory"], ["C159124", "GDC Treatment Outcome Terminology"], ["C53482", "Influenza"], ["C76246", "Blood Group A"], ["C17930", "Immune Response Process"], ["C106184", "May"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C16727", "India"], ["C64916", "All"], ["C923", "Vaccine"]], "rxnorm.special_warnings": [["T051", "Event"], ["1649574", "Injection"]], "loinc.special_warnings": [["LA22004-8", "IN"], ["LA25433-6", "Biological"], ["MTHU008539", "Name"], ["LP18011-4", "Number"], ["LP94823-9", "Treatment"], ["LA9933-8", "Always"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA15679-6", "Rare"], ["MTHU019184", "Event"], ["LP30374-0", "Vaccine"], ["LA22004-8", "IN"], ["LA18821-1", "Acute"], ["LP74849-8", "Fever"], ["LP200075-2", "IS"], ["LA9041-0", "Resolved"], ["LA18187-7", "All"], ["LA20283-0", "Vaccines"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LA20352-3", "Bleeding disorder"], ["LA7418-2", "Bleeding"], ["LA14161-6", "May"], ["LA9429-7", "Intramuscular"], ["MTHU020851", "Syncope"], ["LA16987-2", "Fainting"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LP208081-2", "Needle"], ["LA14542-7", "Injection"], ["LP89782-4", "Neurological"], ["LP145904-1", "Visual"], ["LA30858-7", "Paraesthesia"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA17713-1", "Injury"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LA14161-6", "May"], ["LA28127-1", "Insufficient"], ["LP17763-1", "A"], ["LA27183-5", "Immune"], ["LA14161-6", "May"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA18187-7", "All"], ["LP30374-0", "Vaccine"]], "snomed.pregnancy": [["373067005", "No (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["420862001", "On (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["420862001", "On (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["362837007", "Entire cell (body structure)|Entire cell (cell)"], ["1181000221105", "Vaccine product containing only Influenza virus antigen (medicinal product)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["262126009", "Same (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"]], "ncit.pregnancy": [["C159586", "Preoperative IV Sedation was Not Administered"], ["C54216", "Interaction"], ["C101282", "Have"], ["C38000", "Performed"], ["C62355", "With"], ["C68869", "Are"], ["C53269", "No Information Available"], ["C92667", "SPARC wt Allele"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C62355", "With"], ["C118472", "Other License Status"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C123619", "Clinical Response"], ["C54627", "Experience"], ["C62355", "With"], ["C48694", "Cell"], ["C48055", "Base"], ["C2643", "Trivalent Influenza Vaccine"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C64974", "Give"], ["C158997", "GDC Analyte Type Terminology"], ["C172515", "S-Adenosylmethionine Measurement"], ["C25330", "Duration"], ["C71344", "Associate of Science"], ["C118472", "Other License Status"]], "rxnorm.pregnancy": [["T025", "Cell"]], "loinc.pregnancy": [["LA32-8", "No"], ["LA19974-7", "Performed"], ["LA32-8", "No"], ["LA21996-6", "CO"], ["MTHU029809", "Other"], ["LA20283-0", "Vaccines"], ["LP7787-7", "Clinical"], ["T025", "Cell"], ["LP74974-4", "Influenza vaccine"], ["LP29256-2", "given"], ["LA21988-3", "AT"], ["LA11009-0", "Same"], ["LP73517-2", "Time"], ["MTHU029809", "Other"], ["LA20283-0", "Vaccines"]], "snomed.driving": [["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["155559006", "Influenza (disorder)|Influenza"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["18720000", "In (attribute)"], ["258214002", "Stage (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["263768009", "Greater (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["420862001", "On (qualifier value)"], ["398827000", "Vaccine (substance)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["81170007", "Second (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255248002", "Third trimester (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255246003", "First trimester (qualifier value)"], ["260676000", "Use of (attribute)"], ["155559006", "Influenza (disorder)|Influenza"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1269485005", "Maternal (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["398827000", "Vaccine (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["18720000", "In (attribute)"], ["258698007", "Microsecond (qualifier value)|us (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732839007", "665 (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["155559006", "Influenza (disorder)|Influenza"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222781002", "American Joint Committee on Cancer stage II:8 (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["255246003", "First trimester (qualifier value)"], ["420862001", "On (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["133931009", "Infant (person)"], ["41647002", "No evidence of (contextual qualifier) (qualifier value)"], ["133933007", "Newborn (person)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["398827000", "Vaccine (substance)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["258214002", "Stage (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["373067005", "No (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["278923009", "Developmental (qualifier value)"], ["409967009", "Toxicology (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["278923009", "Developmental (qualifier value)"], ["409967009", "Toxicology (qualifier value)"], ["362837007", "Entire cell (body structure)|Entire cell (cell)"], ["1181000221105", "Vaccine product containing only Influenza virus antigen (medicinal product)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["278923009", "Developmental (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["261665006", "Unknown (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["226789007", "Breast milk (substance)"], ["373067005", "No (qualifier value)"], ["420862001", "On (qualifier value)"], ["169741004", "Breast fed (finding)"], ["133933007", "Newborn (person)"], ["133931009", "Infant (person)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["63158009", "Lactation (function)|Lactation, function (observable entity)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["373067005", "No (qualifier value)"], ["338930006", "Human (organism)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["387961004", "Kingdom Animalia (organism)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["362837007", "Entire cell (body structure)|Entire cell (cell)"], ["1181000221105", "Vaccine product containing only Influenza virus antigen (medicinal product)"], ["420862001", "On (qualifier value)"], ["248152002", "Female (finding)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["248153007", "Male (finding)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["18720000", "In (attribute)"], ["387961004", "Kingdom Animalia (organism)"]], "ncit.driving": [["C191656", "Pregnant Subject"], ["C162847", "FDA Inactivation"], ["C53482", "Influenza"], ["C71344", "Associate of Science"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C64974", "Give"], ["C16727", "India"], ["C81168", "Any"], ["C16899", "Neoplasm Stage"], ["C52874", "SPI1 wt Allele"], ["C191656", "Pregnant Subject"], ["C49508", "Large"], ["C49667", "Safety Study"], ["C68869", "Are"], ["C25429", "Availability"], ["C92667", "SPARC wt Allele"], ["C923", "Vaccine"], ["C25340", "Use"], ["C25490", "During"], ["C25666", "Second"], ["C43508", "Oregon"], ["C92896", "Third Trimester"], ["C49156", "Comparison"], ["C62355", "With"], ["C92799", "First Trimester"], ["C25474", "Data"], ["C25516", "From"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C53482", "Influenza"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C81168", "Any"], ["C188368", "ELN Adverse-Risk Category"], ["C16289", "Andorra"], ["C89336", "Maternal"], ["C25358", "Attribution"], ["C159124", "GDC Treatment Outcome Terminology"], ["C923", "Vaccine"], ["C76246", "Blood Group A"], ["C172297", "Prospective Tissue Collection"], ["C191656", "Pregnant Subject"], ["C49587", "Exposure Domain"], ["C15753", "Cancer Registry"], ["C154196", "Washo Language"], ["C16727", "India"], ["C17234", "United States"], ["C115503", "Ultrasound Study File"], ["C16289", "Andorra"], ["C25474", "Data"], ["C170548", "Collected Value"], ["C25516", "From"], ["C189090", "Vaccinated for COVID-19"], ["C62355", "With"], ["C25490", "During"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C45849", "North"], ["C53482", "Influenza"], ["C111798", "Eighteen"], ["C159124", "GDC Treatment Outcome Terminology"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C52874", "SPI1 wt Allele"], ["C126888", "Twenty Eight"], ["C25490", "During"], ["C92799", "First Trimester"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C191656", "Pregnant Subject"], ["C16289", "Andorra"], ["C27956", "Infant"], ["C49667", "Safety Study"], ["C154196", "Washo Language"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C188368", "ELN Adverse-Risk Category"], ["C16731", "Newborn"], ["C43508", "Oregon"], ["C191656", "Pregnant Subject"], ["C25358", "Attribution"], ["C159124", "GDC Treatment Outcome Terminology"], ["C923", "Vaccine"], ["C25490", "During"], ["C81168", "Any"], ["C16899", "Neoplasm Stage"], ["C52874", "SPI1 wt Allele"], ["C191656", "Pregnant Subject"], ["C101282", "Have"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C90448", "Reproductive and Developmental Toxicology"], ["C62355", "With"], ["C90448", "Reproductive and Developmental Toxicology"], ["C25474", "Data"], ["C25516", "From"], ["C48694", "Cell"], ["C48055", "Base"], ["C2643", "Trivalent Influenza Vaccine"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C168182", "Developmental Finding"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C160764", "Unknown Molecular Analysis"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C14225", "Human"], ["C13257", "Mammary Gland Milk"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25492", "Effect"], ["C92667", "SPARC wt Allele"], ["C25389", "Chest"], ["C16731", "Newborn"], ["C27956", "Infant"], ["C68869", "Are"], ["C25501", "Expected"], ["C106184", "May"], ["C16329", "Belgium"], ["C64974", "Give"], ["C25490", "During"], ["C95089", "Fertility Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C14225", "Human"], ["C95089", "Fertility Domain"], ["C25474", "Data"], ["C68869", "Are"], ["C25429", "Availability"], ["C14182", "Animal"], ["C25474", "Data"], ["C62355", "With"], ["C48694", "Cell"], ["C48055", "Base"], ["C2643", "Trivalent Influenza Vaccine"], ["C101282", "Have"], ["C25594", "Negation"], ["C25492", "Effect"], ["C92667", "SPARC wt Allele"], ["C46110", "Female Gender"], ["C95089", "Fertility Domain"], ["C46107", "Male, Self-Report"], ["C95089", "Fertility Domain"], ["C101282", "Have"], ["C25594", "Negation"], ["C25217", "Assessment"], ["C16727", "India"], ["C14182", "Animal"]], "rxnorm.driving": [["T025", "Cell"], ["T016", "Human"], ["T016", "Human"], ["T008", "Animal"], ["T025", "Cell"]], "loinc.driving": [["LP207970-7", "Pregnancy"], ["LA20283-0", "Vaccines"], ["LP29256-2", "given"], ["LA22004-8", "IN"], ["LP73395-3", "Stage"], ["LP207970-7", "Pregnancy"], ["LA17589-5", "Safety"], ["LP30374-0", "Vaccine"], ["LP208036-6", "Second or third trimester"], ["LP208035-8", "First trimester"], ["LA20283-0", "Vaccines"], ["LA14426-3", "Do not"], ["LA26320-4", "Maternal"], ["LP30374-0", "Vaccine"], ["LP17763-1", "A"], ["LP207970-7", "Pregnancy"], ["LA22004-8", "IN"], ["LA3597-7", "United States"], ["LP207608-3", "US"], ["LP20591-1", "3"], ["LA19282-5", "20"], ["LP208035-8", "First trimester"], ["LP207970-7", "Pregnancy"], ["LA19747-7", "Infant"], ["LA17589-5", "Safety"], ["LA32-8", "No"], ["LP7744-8", "Newborn"], ["LA22025-3", "OR"], ["LP207970-7", "Pregnancy"], ["LP30374-0", "Vaccine"], ["LP73395-3", "Stage"], ["LP207970-7", "Pregnancy"], ["LA32-8", "No"], ["LA18285-9", "Reproductive"], ["LP74364-8", "Toxicology studies"], ["LA18285-9", "Reproductive"], ["T025", "Cell"], ["LP74974-4", "Influenza vaccine"], ["LA14426-3", "Do not"], ["LA24544-1", "Increased risk"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA4489-6", "Unknown"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA19711-3", "Human"], ["LP29290-1", "Milk"], ["LA32-8", "No"], ["LP199961-6", "Breast"], ["LP7744-8", "Newborn"], ["LA19747-7", "Infant"], ["LA18412-9", "Anticipated"], ["LA14161-6", "May"], ["LP29256-2", "given"], ["LP190569-6", "Lactation"], ["MTHU000074", "Fertility"], ["LA32-8", "No"], ["LA19711-3", "Human"], ["MTHU000074", "Fertility"], ["LA30681-3", "Animal"], ["T025", "Cell"], ["LP74974-4", "Influenza vaccine"], ["LA21291-2", "Not"], ["LP32818-4", "Female fertility"], ["LP32817-6", "Male fertility"], ["LA21291-2", "Not"], ["LA22004-8", "IN"]], "snomed.side_effects": [["373067005", "No (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["86137003", "Negligible (qualifier value)"], ["420862001", "On (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["247750002", "Drive (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"]], "ncit.side_effects": [["C101282", "Have"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43508", "Oregon"], ["C121660", "Influence"], ["C92667", "SPARC wt Allele"], ["C121232", "Ability to Drive"], ["C16289", "Andorra"], ["C25340", "Use"]], "rxnorm.side_effects": [], "loinc.side_effects": [["LA32-8", "No"], ["LA22025-3", "OR"]], "snomed.shelf_life": [["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258706009", "month (qualifier value)"]], "ncit.shelf_life": [["C156842", "12 Months"]], "rxnorm.shelf_life": [], "loinc.shelf_life": [["LP189870-1", "12 months"]], "snomed.storage": [["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["21546008", "Refrigerator, device (physical object)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["18720000", "In (attribute)"], ["261074009", "External (qualifier value)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["371268001", "Light color (qualifier value)"]], "ncit.storage": [["C60824", "Storage"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C178971", "Refrigerator"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67900", "Centi"], ["C66839", "Eight"], ["C67900", "Centi"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C48160", "Freezing"], ["C99569", "Retain"], ["C97716", "Pre-filled Syringe"], ["C16727", "India"], ["C187054", "Outer Surface"], ["C54702", "Carton Dosing Unit"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25516", "From"], ["C64650", "Light"]], "rxnorm.storage": [], "loinc.storage": [["LA22004-8", "IN"], ["LP17763-1", "A"], ["MTHU000002", "Clinical Class"], ["LP17128-7", "C"], ["LP36791-9", "8"], ["LP17128-7", "C"], ["LA14426-3", "Do not"], ["LP32605-5", "pre"], ["LP188733-2", "Syringe"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LA15831-3", "Light"]], "snomed.package": [["260304006", "0.5 (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["739008005", "Suspension (basic dose form)"], ["18720000", "In (attribute)"], ["272113006", "Before values (qualifier value)"], ["75797008", "Syrinx (morphologic abnormality)"], ["258191002", "Type 1 (qualifier value)"], ["32039001", "Glass (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["43230003", "Rubber (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["45169001", "Without (attribute)"], ["79068005", "Needle, device (physical object)"], ["257260002", "Pack (physical object)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["45169001", "Without (attribute)"], ["79068005", "Needle, device (physical object)"], ["257260002", "Pack (physical object)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["75797008", "Syrinx (morphologic abnormality)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["45169001", "Without (attribute)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["257260002", "Pack (physical object)"]], "ncit.package": [["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16816", "Mali"], ["C42994", "Suspension Dosage Form"], ["C16727", "India"], ["C25629", "Prior"], ["C54093", "Fill"], ["C181852", "Protocol Therapy Status"], ["C68254", "Dietary Iodine"], ["C45301", "Glass"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C50297", "Plunger Device"], ["C96139", "Stopper Container Closure"], ["C62355", "With"], ["C43508", "Oregon"], ["C25718", "Without"], ["C63846", "Needle Shape"], ["C84731", "Packing"], ["C52874", "SPI1 wt Allele"], ["C105723", "ECOG Performance Status 1"], ["C97716", "Pre-filled Syringe"], ["C62355", "With"], ["C43508", "Oregon"], ["C25718", "Without"], ["C63846", "Needle Shape"], ["C84731", "Packing"], ["C52874", "SPI1 wt Allele"], ["C69122", "Ten"], ["C25629", "Prior"], ["C54093", "Fill"], ["C62355", "With"], ["C43508", "Oregon"], ["C25718", "Without"], ["C25594", "Negation"], ["C64916", "All"], ["C84731", "Packing"], ["C106184", "May"], ["C16329", "Belgium"]], "rxnorm.package": [["746839", "Pack"], ["746839", "Pack"], ["746839", "Pack"]], "loinc.package": [["LA16632-4", "0.5"], ["LA21913-1", "Suspension"], ["LA22004-8", "IN"], ["LP32605-5", "pre"], ["LA26022-6", "Type I"], ["LP17763-1", "A"], ["LA22025-3", "OR"], ["LP208081-2", "Needle"], ["LA6112-2", "1"], ["LP32605-5", "pre"], ["LP188733-2", "Syringe"], ["LA22025-3", "OR"], ["LP208081-2", "Needle"], ["LA13942-0", "10"], ["LP32605-5", "pre"], ["LA22025-3", "OR"], ["LA21291-2", "Not"], ["LA18187-7", "All"], ["LA14161-6", "May"]], "snomed.marketing_authorization_numbers": [["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"]], "ncit.marketing_authorization_numbers": [["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C111798", "Eighteen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C111798", "Eighteen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C111798", "Eighteen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C111798", "Eighteen"], ["C16267", "Afghanistan"]], "rxnorm.marketing_authorization_numbers": [], "loinc.marketing_authorization_numbers": [["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"]]}, {"product_info": "Skilarence 30 mg gastro-resistant tablets \nSkilarence 120 mg gastro-resistant tablets", "composition": "Skilarence 30 mg gastro-resistant tablets \nEach gastro-resistant tablet contains 30 mg dimethyl fumarate. \nExcipient with known effect \nEach gastro-resistant tablet contains 34.2 mg lactose (as monohydrate). \nSkilarence 120 mg gastro-resistant tablets \nEach gastro-resistant tablet contains 120 mg dimethyl fumarate. \nExcipient with known effect \nEach gastro-resistant tablet contains 136.8 mg lactose (as monohydrate). \nFor the full list of excipients, see section 6.1.", "indications": "Skilarence is indicated for the treatment of moderate to severe plaque psoriasis in adults in need of \nsystemic medicinal therapy.", "posology": "Skilarence is intended for use under the guidance and supervision of a physician experienced in the \ndiagnosis and treatment of psoriasis. \nPosology \nTo improve tolerability of Skilarence, it is recommended to begin treatment with a low initial dose \nwith subsequent gradual increases. In the first week, a 30 mg dose is taken once daily (1 tablet in the \nevening). In the second week, a 30 mg dose is taken twice daily (1 tablet in the morning and 1 in the \nevening). In the third week, a 30 mg dose is taken three times daily (1 tablet in the morning, 1 at \nmidday, and 1 in the evening). From the fourth week, treatment is switched to only 1 tablet of \na 120 mg dose in the evening. This dose is then increased by one 120 mg tablet per week at different \ntimes of day for the subsequent 5 weeks, as shown in the table below.  \nThe maximum daily dose allowed is 720 mg (six 120 mg tablets). \nWeek \nNumber of tablets \nTotal daily dose (mg) \nMorning \nMidday \nEvening \nof dimethyl fumarate  \nSkilarence 30 mg \n30 \n60 \n90 \nSkilarence 120 mg \n120 \n240 \n360 \n480 \n600 \n9+ \n720 \nIf a particular dose increase is not tolerated, it may be temporarily reduced to the last tolerated dose. \nIf treatment success is observed before the maximum dose is reached, no further increase of dose is \nnecessary. After clinically relevant improvement of the skin lesions has been achieved, consideration \nshould be given to gradual reduction of the daily dose of Skilarence to the maintenance dose required \nby the individual. \nDose modifications may also be necessary if abnormalities in laboratory parameters are observed (see \nsection 4.4). \nElderly patients \nClinical studies of Skilarence did not include sufficient numbers of patients aged 65 years and above \nto determine whether they respond differently compared to patients under 65 years (see section 5.2). \nBased on the pharmacology of dimethyl fumarate, a need for dose adjustment in the elderly is not \nexpected. \nRenal impairment \nNo dose adjustment is needed in patients with mild to moderate renal impairment (see section 5.2). \nSkilarence has not been studied in patients with severe renal impairment, and use of Skilarence is \ncontraindicated in these patients (see section 4.3). \nHepatic impairment \nNo dose adjustment is needed in patients with mild to moderate hepatic impairment (see section 5.2). \nSkilarence has not been studied in patients with severe hepatic impairment, and use of Skilarence is \ncontraindicated in these patients (see section 4.3). \nPaediatric population \nThe safety and efficacy of Skilarence in children below the age of 18 years have not been established. \nThere are no data available with Skilarence in paediatric population. \nMethod of administration \nFor oral use. \nTablets must be swallowed whole with fluid during or immediately after a meal. \nThe coating of the gastro-resistant tablets is designed to prevent gastric irritation. Therefore, the tablets \nshould not be crushed, divided, dissolved or chewed.", "contraindications": "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. \nSevere gastrointestinal disorders. \nSevere hepatic or renal impairment. \nPregnancy and breast-feeding.", "special_warnings": "Haematology \nSkilarence may decrease leukocyte and lymphocyte counts (see section 4.8). It has not been studied in \npatients with pre-existing low leukocyte or lymphocyte counts. \nBefore treatment \nPrior to initiating treatment, a current complete blood count (including differential blood count and \nplatelet count) should be available. Treatment should not be initiated if leukopenia below 3.0x109/L, \nlymphopenia below 1.0x109/L or other pathological results are identified. \nDuring treatment \nDuring treatment, a complete blood count with differential should be performed every 3 months. \nAction is needed in the following circumstances: \nLeukopenia\nIf a marked decrease in the total number of white blood cells is found, the situation should be \nmonitored carefully and treatment should be discontinued at levels below 3.0x109/L. \nLymphopenia\nIf the lymphocyte count falls below 1.0x109/L but is \u2265 0.7 x109/L, blood monitoring should be \nperformed monthly until levels return to 1.0x109/L or higher for two consecutive blood tests at which \npoint monitoring can again be performed every 3 months. \nIf the lymphocyte count falls below 0.7x109/L, the blood test must be repeated and if the levels are \nconfirmed to be below 0.7x109/L, then treatment must be stopped immediately. Patients developing \nlymphopenia should be monitored after stopping treatment until their lymphocyte count has returned \nto the normal range (see section 4.8). \nOther haematological disorders \nTherapy should be discontinued and caution is advised if other pathological results occur. In any case, \nblood counts should be monitored until values have returned to the normal range. \nInfections \nSkilarence is an immunomodulator and may affect the way the immune system responds to infection. \nFor patients with pre-existing infections of clinical relevance, the physician should decide if treatment \nshould only be initiated once the infection has resolved. If a patient develops an infection during \ntreatment, suspension of treatment should be considered and the benefits and risks should be \nreassessed prior to re-initiation of therapy. Patients receiving this medicinal product should be \ninstructed to report symptoms of infection to a physician. \nOpportunistic infections/progressive multifocal leukoencephalopathy (PML) \nCases of opportunistic infections, particularly of progressive multifocal leukoencephalopathy (PML) \nhave been reported with other dimethyl fumarate-containing products (see section 4.8). PML is an \nopportunistic infection caused by the John-Cunningham virus (JCV) that can be fatal or cause severe \ndisabilities. PML is probably caused by a combination of factors. \nA previous infection with JCV is considered a prerequisite for the development of PML. Risk factors \ncan include previous immunosuppressive treatment and the existence of certain concomitant disorders \n(such as some autoimmune disorders or malignant haematological conditions). A modified or \nweakened immune system as well as genetic or environmental factors can also constitute risk factors. \nPersistent moderate or severe lymphopenia during treatment with dimethyl fumarate is also considered \na risk factor for PML. Patients who develop lymphopenia should be monitored for signs and \nsymptoms of opportunistic infections, particularly for symptoms indicative of PML. Typical \nsymptoms associated with PML are diverse, become worse over days to weeks and include \nprogressive weakness on one side of the body or clumsiness of limbs, disturbance of vision and \nchanges in thinking, memory and orientation leading to confusion and personality changes. If PML is \nsuspected, treatment should be stopped immediately and further appropriate neurological and \nradiological examinations performed. \nPrior and concomitant treatment with immunosuppressive or immunomodulating therapies \nLimited data are available on the efficacy and safety of Skilarence in patients who have been \npreviously treated with other immunosuppressive or immunomodulating therapies. When switching \npatients from such therapies to Skilarence, the half-life and mode of action of the other therapy should \nbe considered in order to avoid additive effects on the immune system. \nNo data are available on the efficacy and safety of Skilarence when taken concomitantly with other \nimmunosuppressive or immunomodulating therapies (see section 4.5). \nPre-existing gastrointestinal disease \nSkilarence has not been studied in patients with pre-existing gastrointestinal disease. It is \ncontraindicated in patients with severe gastrointestinal disease (see sections 4.3). Gastrointestinal \ntolerability can be improved by following the dose titration schedule on initiating treatment and by \ntaking the gastro-resistant tablet(s) with food (see sections 4.2 and 4.8). \nRenal function \nDuring the Phase III placebo-controlled clinical study, renal function was not seen to deteriorate \nduring therapy across treatment groups. However, Skilarence has not been studied in patients with \nsevere renal impairment, and some cases of renal toxicity have been reported during post-marketing \nsurveillance with fumaric acid esters. Hence, Skilarence is contraindicated in patients with severe \nrenal impairment (see section 4.3). \nRenal function (e.g. creatinine, blood urea nitrogen and urinalysis) should be checked prior to \ninitiation of treatment and every 3 months thereafter. In the event of a clinically relevant change in \nrenal function, particularly in the absence of alternative explanations, consideration should be given to \ndose reduction or treatment discontinuation. \nFanconi syndrome \nEarly diagnosis of Fanconi syndrome and discontinuation of Skilarence treatment are important to \nprevent the onset of renal impairment and osteomalacia, as the syndrome is usually reversible. The \nmost important signs are: proteinuria, glucosuria (with normal blood sugar levels), \nhyperaminoaciduria and phosphaturia (possibly concurrent with hypophosphatemia) (see section 4.8). \nProgression might involve symptoms such as polyuria, polydipsia and proximal muscle weakness. In \nrare cases hypophosphataemic osteomalacia with non-localised bone pain, elevated alkaline \nphosphatase in serum and stress fractures may occur. Importantly, Fanconi syndrome can occur \nwithout elevated creatinine levels or low glomerular filtration rate. In case of unclear symptoms, \nFanconi syndrome should be considered and appropriate examinations should be performed. \nHepatic function \nSkilarence has not been studied in patients with severe hepatic impairment and is contraindicated in \nthese patients (see section 4.3).  \nIt is recommended to monitor hepatic function (SGOT, SGPT, gamma-GT, AP) prior to initiation of \ntreatment and every 3 months thereafter, since elevation of hepatic enzymes has been observed in \nsome patients in the Phase III study (see section 4.8). In the event of a clinically relevant change in \nhepatic parameters, particularly in the absence of alternative explanations, consideration should be \ngiven to dose reduction or treatment discontinuation (see section 4.2). \nFlushing \nPatients should be made aware that they are likely to experience flushing in the first few weeks of \ntreatment (see section 4.8). \nExcipients \nLactose \nThis medicinal product contains lactose. Patients with rare hereditary problems of galactose \nintolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine. \nSodium \nThis medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially \n\u2018sodium free\u2019.", "pregnancy": "No interaction studies have been performed. \nSkilarence should be used cautiously in combination with other systemic antipsoriatic therapy (e.g. \nmethotrexate, retinoids, psoralens, ciclosporin, immunosuppressants or cytostatics) (see section 4.4). \nDuring treatment, simultaneous use of other fumaric acid derivatives (topical or systemic) should be \navoided. \nConcurrent therapy with nephrotoxic substances (e.g. methotrexate, ciclosporin, aminoglycosides, \ndiuretics, non-steroidal anti-inflammatory drugs (NSAIDs) or lithium) may increase the potential for \nrenal adverse reactions (e.g. proteinuria) in patients taking Skilarence. \nIn cases of severe or prolonged diarrhoea during treatment with Skilarence, absorption of other \nmedicinal products may be affected. Caution should be exercised when prescribing medicinal products \nwith a narrow therapeutic index that require absorption in the intestinal tract. The efficacy of oral \ncontraceptives may be reduced and the use of an alternative barrier contraceptive method is \nrecommended to prevent possible failure of contraception (see the prescribing information of the oral \ncontraceptive). \nConsumption of large quantities of strong alcoholic drinks (more than 30% alcohol by volume) should \nbe avoided because it may lead to increased dissolution rates of Skilarence and, therefore, may \nincrease the frequency of gastrointestinal adverse reactions. \nVaccination during treatment with Skilarence has not been studied. Immunosuppression is a risk factor \nfor the use of live vaccines. The risk of vaccination should be weighed against the benefit. \nThere is no evidence for interaction with cytochrome P450 and the most common efflux and uptake \ntransporters, thus no interactions are expected with medicinal products metabolised or transported by \nthese systems (see section 5.2).", "driving": "Women of child-bearing potential \nSkilarence is not recommended in women of child-bearing potential not using appropriate \ncontraception. Additional contraceptive methods in case of stomach and intestinal problems that could \nreduce the effectiveness of oral contraceptives could be necessary (see section 4.5). \nPregnancy \nThere are limited data from the use of dimethyl fumarate in pregnant women. Animal studies have \nshown reproductive toxicity (see section 5.3). Skilarence is contraindicated during pregnancy (see \nsection 4.3). \nBreast-feeding \nIt is unknown whether dimethyl fumarate or its metabolites are excreted in human milk. A risk to \nnewborns or infants cannot be excluded. Therefore, Skilarence is contraindicated during breast-\nfeeding (see section 4.3). \nFertility \nThere are no human or animal data on the effects of Skilarence on fertility.", "side_effects": "Skilarence may have a minor influence on the ability to drive and use machines. Dizziness and fatigue \nmay occur following administration of Skilarence (see section 4.8).", "shelf_life": "3 years.", "storage": "This medicinal product does not require any special storage conditions. \n14", "package": "Skilarence 30 mg gastro-resistant tablets \n42, 70 and 210 gastro-resistant tablets in PVC/PVDC-aluminium blister packs. \nSkilarence 120 mg gastro-resistant tablets \n40, 70, 90, 100, 120, 180, 200, 240, 300, 360 and 400 gastro-resistant tablets in \nPVC/PVDC-aluminium blister packs. \nNot all pack sizes may be marketed.", "marketing_authorization_numbers": "EU/1/17/1201/001 \nEU/1/17/1201/002 \nEU/1/17/1201/003 \nEU/1/17/1201/004 \nEU/1/17/1201/005 \nEU/1/17/1201/006 \nEU/1/17/1201/007 \nEU/1/17/1201/008 \nEU/1/17/1201/009 \nEU/1/17/1201/010 \nEU/1/17/1201/011 \nEU/1/17/1201/012 \nEU/1/17/1201/013 \nEU/1/17/1201/014", "filename": "skilarence-epar-product-information_en.html", "snomed.product_info": [["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["30714006", "Resistant (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["30714006", "Resistant (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"]], "ncit.product_info": [["C70541", "Lansky Performance Status 30"], ["C16818", "Mammography"], ["C128681", "CDISC SDTM Gastrointestinal Test Name Terminology"], ["C41546", "Resistance Process"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C128681", "CDISC SDTM Gastrointestinal Test Name Terminology"], ["C41546", "Resistance Process"]], "rxnorm.product_info": [], "loinc.product_info": [["LA28855-7", "30"], ["LP15217-0", "Mg"], ["LA6676-6", "Resistant"], ["LA32059-0", "120"], ["LP15217-0", "Mg"], ["LA6676-6", "Resistant"]], "snomed.composition": [["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["30714006", "Resistant (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["419473009", "Each (qualifier value)"], ["385059007", "Gastro-resistant oral tablet (dose form)|Gastro-resistant tablet (product)|Gastro-resistant tablet (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["724035008", "Dimethyl fumarate (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["36692007", "Known (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["419473009", "Each (qualifier value)"], ["385059007", "Gastro-resistant oral tablet (dose form)|Gastro-resistant tablet (product)|Gastro-resistant tablet (qualifier value)"], ["784558005", "34.2 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["423291009", "Product containing lactose (medicinal product)|Lactose (product)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["30714006", "Resistant (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["419473009", "Each (qualifier value)"], ["385059007", "Gastro-resistant oral tablet (dose form)|Gastro-resistant tablet (product)|Gastro-resistant tablet (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["724035008", "Dimethyl fumarate (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["36692007", "Known (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["419473009", "Each (qualifier value)"], ["385059007", "Gastro-resistant oral tablet (dose form)|Gastro-resistant tablet (product)|Gastro-resistant tablet (qualifier value)"], ["732498009", "136 (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["423291009", "Product containing lactose (medicinal product)|Lactose (product)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["261015003", "Full (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.composition": [["C70541", "Lansky Performance Status 30"], ["C16818", "Mammography"], ["C128681", "CDISC SDTM Gastrointestinal Test Name Terminology"], ["C41546", "Resistance Process"], ["C64933", "Each"], ["C42905", "Delayed Release Tablet Dosage Form"], ["C79873", "Contain"], ["C70541", "Lansky Performance Status 30"], ["C16818", "Mammography"], ["C63670", "Dimethyl Fumarate"], ["C42637", "Pharmaceutical Excipient"], ["C62355", "With"], ["C80137", "Known"], ["C71600", "Effect, Appearance"], ["C64933", "Each"], ["C42905", "Delayed Release Tablet Dosage Form"], ["C79873", "Contain"], ["C186749", "Human Papillomavirus-34"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16818", "Mammography"], ["C28166", "Lactose"], ["C71344", "Associate of Science"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C128681", "CDISC SDTM Gastrointestinal Test Name Terminology"], ["C41546", "Resistance Process"], ["C64933", "Each"], ["C42905", "Delayed Release Tablet Dosage Form"], ["C79873", "Contain"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C63670", "Dimethyl Fumarate"], ["C42637", "Pharmaceutical Excipient"], ["C62355", "With"], ["C80137", "Known"], ["C71600", "Effect, Appearance"], ["C64933", "Each"], ["C42905", "Delayed Release Tablet Dosage Form"], ["C79873", "Contain"], ["C16391", "Cayman Islands"], ["C66839", "Eight"], ["C16818", "Mammography"], ["C28166", "Lactose"], ["C71344", "Associate of Science"], ["C64956", "For"], ["C25517", "Full"], ["C43432", "List"], ["C52874", "SPI1 wt Allele"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.composition": [["1373478", "dimethyl fumarate"], ["6211", "lactose"], ["1373478", "dimethyl fumarate"], ["6211", "lactose"]], "loinc.composition": [["LA28855-7", "30"], ["LP15217-0", "Mg"], ["LA6676-6", "Resistant"], ["LA6676-6", "Resistant"], ["LP136501-6", "Tablet"], ["LA28855-7", "30"], ["LP15217-0", "Mg"], ["LP15583-5", "Fumarate"], ["LA6676-6", "Resistant"], ["LP136501-6", "Tablet"], ["LA19315-3", "34"], ["MTHU000002", "Clinical Class"], ["LP15217-0", "Mg"], ["LP32533-9", "Lactose"], ["LA32059-0", "120"], ["LP15217-0", "Mg"], ["LA6676-6", "Resistant"], ["LA6676-6", "Resistant"], ["LP136501-6", "Tablet"], ["LA32059-0", "120"], ["LP15217-0", "Mg"], ["LP15583-5", "Fumarate"], ["LA6676-6", "Resistant"], ["LP136501-6", "Tablet"], ["LP36791-9", "8"], ["LP15217-0", "Mg"], ["LP32533-9", "Lactose"], ["LA19682-6", "Full"], ["LP204165-7", "List"], ["LP20594-5", "6"], ["LA6112-2", "1"]], "snomed.indications": [["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["371924009", "Moderate to severe (qualifier value)"], ["200965009", "Plaque psoriasis (disorder)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["31099001", "Systemic (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"]], "ncit.indications": [["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C159124", "GDC Treatment Outcome Terminology"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C16727", "India"], ["C16727", "India"], ["C41204", "Need"], ["C52874", "SPI1 wt Allele"], ["C13310", "Systemic"], ["C49236", "Therapeutic Procedure"]], "rxnorm.indications": [], "loinc.indications": [["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA32820-5", "Moderate to severe"], ["LA15165-6", "Psoriasis"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LP267221-2", "Therapy"]], "snomed.posology": [["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["86495002", "For (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["351726001", "Below (qualifier value)"], ["243073001", "Advice (regime/therapy)|Advice (regime/therapy)(procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["225313009", "Supervision (regime/therapy)|Supervision (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["309343006", "Physician (occupation)"], ["18720000", "In (attribute)"], ["439401001", "Diagnosis (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["156369008", "Psoriasis|Psoriasis (disorder)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["62482003", "Low (qualifier value)"], ["884001", "Initial (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255343009", "Gradual (qualifier value)"], ["18720000", "In (attribute)"], ["255216001", "First (qualifier value)"], ["258705008", "week (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["18720000", "In (attribute)"], ["3157002", "Evening (qualifier value)"], ["18720000", "In (attribute)"], ["81170007", "Second (qualifier value)"], ["258705008", "week (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["229799001", "Twice a day (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["73775008", "Morning (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["18720000", "In (attribute)"], ["3157002", "Evening (qualifier value)"], ["18720000", "In (attribute)"], ["70905002", "Third (qualifier value)"], ["258705008", "week (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["229798009", "Three times daily (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["73775008", "Morning (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["71997007", "Noon (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["18720000", "In (attribute)"], ["3157002", "Evening (qualifier value)"], ["29970001", "Fourth (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["18720000", "In (attribute)"], ["3157002", "Evening (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421067001", "Then - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["259038000", "/week (qualifier value)|per week (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["272106006", "Temporal periods of day (qualifier value)"], ["86495002", "For (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["258705008", "week (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["86407004", "Table, device (physical object)"], ["351726001", "Below (qualifier value)"], ["123128001", "Daily -RETIRED-|Daily (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["732858003", "720 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["68244004", "Six (qualifier value)|6 (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["258705008", "week (qualifier value)"], ["410681005", "Count of entities (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["255619001", "Total (qualifier value)"], ["123128001", "Daily -RETIRED-|Daily (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["73775008", "Morning (qualifier value)"], ["71997007", "Noon (qualifier value)"], ["3157002", "Evening (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["724035008", "Dimethyl fumarate (substance)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["732814003", "60 (qualifier value)"], ["732899009", "90 (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["732608008", "240 (qualifier value)"], ["732700008", "360 (qualifier value)"], ["732763007", "480 (qualifier value)"], ["725127002", "600 (qualifier value)"], ["422113007", "Arabic numeral 9 (qualifier value)"], ["732858003", "720 (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["260400001", "Reduced (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["255234002", "After (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["181469002", "Entire skin (body structure)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255343009", "Gradual (qualifier value)"], ["289928003", "Reduction plasty (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["123128001", "Daily -RETIRED-|Daily (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["385435006", "Individual (person)"], ["408102007", "Unit dose (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["261904005", "Laboratory (environment)"], ["252116004", "Observation parameter (observable entity)"], ["732727007", "4.4 (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["51117008", "Sufficient (qualifier value)"], ["260299005", "Number (qualifier value)|Numbers (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["264695004", "65 (qualifier value)|Arabic numeral 65 (qualifier value)"], ["258707000", "year (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["352730000", "Supra- (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["351726001", "Below (qualifier value)"], ["264695004", "65 (qualifier value)|Arabic numeral 65 (qualifier value)"], ["258707000", "year (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["724035008", "Dimethyl fumarate (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["103325001", "Patient need for (contextual qualifier) (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["18720000", "In (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410525008", "Needed (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["371923003", "Mild to moderate (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["732766004", "5.2 (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410536001", "Contraindicated (qualifier value)"], ["18720000", "In (attribute)"], ["732725004", "4.3 (qualifier value)"], ["40226000", "Impairment (finding)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410525008", "Needed (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["371923003", "Mild to moderate (qualifier value)"], ["40226000", "Impairment (finding)"], ["732766004", "5.2 (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["40226000", "Impairment (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410536001", "Contraindicated (qualifier value)"], ["18720000", "In (attribute)"], ["732725004", "4.3 (qualifier value)"], ["376171000221106", "Pediatric population (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["351726001", "Below (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["258707000", "year (qualifier value)"], ["263748003", "Established (qualifier value)"], ["373067005", "No (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["376171000221106", "Pediatric population (qualifier value)"], ["260686004", "Method (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["86495002", "For (qualifier value)"], ["26643006", "Oral route (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["420004004", "Swallowed whole (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255765007", "Fluid (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["255234002", "After (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["30714006", "Resistant (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["101445003", "PREVENT (substance)|PREVENT (product)"], ["162027003", "Indigestion symptoms (finding)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"]], "ncit.posology": [["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25725", "Intent"], ["C64956", "For"], ["C25340", "Use"], ["C192973", "Guidance"], ["C16289", "Andorra"], ["C61372", "Management"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C25741", "Physician"], ["C16727", "India"], ["C15220", "Diagnosis"], ["C16289", "Andorra"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C3346", "Psoriasis"], ["C159124", "GDC Treatment Outcome Terminology"], ["C98791", "Tolerability Study"], ["C52874", "SPI1 wt Allele"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25431", "Begin"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C139301", "IPSS Risk Category Low"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C25488", "Dose"], ["C62355", "With"], ["C53286", "Next"], ["C16727", "India"], ["C25509", "First"], ["C29844", "Week"], ["C76246", "Blood Group A"], ["C70541", "Lansky Performance Status 30"], ["C16818", "Mammography"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25701", "Taken"], ["C125004", "Once Daily"], ["C105723", "ECOG Performance Status 1"], ["C154605", "Tablet Dosage Form Category"], ["C16727", "India"], ["C64936", "Evening"], ["C16727", "India"], ["C25666", "Second"], ["C29844", "Week"], ["C76246", "Blood Group A"], ["C70541", "Lansky Performance Status 30"], ["C16818", "Mammography"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25701", "Taken"], ["C64496", "Twice Daily"], ["C105723", "ECOG Performance Status 1"], ["C154605", "Tablet Dosage Form Category"], ["C16727", "India"], ["C168169", "Chief Complaint Present in the Morning"], ["C16289", "Andorra"], ["C105723", "ECOG Performance Status 1"], ["C16727", "India"], ["C64936", "Evening"], ["C16727", "India"], ["C25260", "Third"], ["C29844", "Week"], ["C76246", "Blood Group A"], ["C70541", "Lansky Performance Status 30"], ["C16818", "Mammography"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25701", "Taken"], ["C64527", "Three Times Daily"], ["C105723", "ECOG Performance Status 1"], ["C154605", "Tablet Dosage Form Category"], ["C16727", "India"], ["C168169", "Chief Complaint Present in the Morning"], ["C105723", "ECOG Performance Status 1"], ["C158997", "GDC Analyte Type Terminology"], ["C168165", "Chief Complaint Present at Midday"], ["C16289", "Andorra"], ["C105723", "ECOG Performance Status 1"], ["C16727", "India"], ["C64936", "Evening"], ["C25516", "From"], ["C49465", "Fourth"], ["C29844", "Week"], ["C43442", "Biomaterial Treatment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C48440", "Single"], ["C105723", "ECOG Performance Status 1"], ["C154605", "Tablet Dosage Form Category"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C25488", "Dose"], ["C16727", "India"], ["C64936", "Evening"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C65106", "Then"], ["C164135", "Increased"], ["C158169", "Buyei Chinese"], ["C66832", "One"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C154605", "Tablet Dosage Form Category"], ["C67069", "Weekly"], ["C158997", "GDC Analyte Type Terminology"], ["C46003", "Difference"], ["C52874", "SPI1 wt Allele"], ["C25301", "Day"], ["C64956", "For"], ["C53286", "Next"], ["C163771", "Illness Intrusiveness Rating 5"], ["C29844", "Week"], ["C71344", "Associate of Science"], ["C16727", "India"], ["C48441", "Table"], ["C75330", "Below"], ["C82868", "Maximum Value Derivation Technique"], ["C70888", "Daily Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16818", "Mammography"], ["C66837", "Six"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C29844", "Week"], ["C25463", "Count"], ["C52874", "SPI1 wt Allele"], ["C70888", "Daily Dose"], ["C16818", "Mammography"], ["C168169", "Chief Complaint Present in the Morning"], ["C168165", "Chief Complaint Present at Midday"], ["C64936", "Evening"], ["C52874", "SPI1 wt Allele"], ["C63670", "Dimethyl Fumarate"], ["C70541", "Lansky Performance Status 30"], ["C16818", "Mammography"], ["C70541", "Lansky Performance Status 30"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C182728", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 90"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C192184", "One Hundred Twenty"], ["C16728", "Indonesia"], ["C16827", "Mauritius"], ["C16953", "Paraguay"], ["C120081", "Severity of Symptom Score 9"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C25488", "Dose"], ["C25533", "Increase"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C38267", "Intrathecal Route of Administration"], ["C106184", "May"], ["C16329", "Belgium"], ["C25640", "Reduced"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25551", "Last"], ["C25488", "Dose"], ["C198613", "CFI wt Allele"], ["C43442", "Biomaterial Treatment"], ["C25362", "Success"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25599", "Observed"], ["C201357", "Before Timing Type"], ["C82868", "Maximum Value Derivation Technique"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25519", "Further"], ["C25533", "Increase"], ["C52874", "SPI1 wt Allele"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C38008", "Post"], ["C70664", "Relevance"], ["C94226", "Improvement"], ["C52874", "SPI1 wt Allele"], ["C12470", "Skin"], ["C101282", "Have"], ["C113416", "Consideration"], ["C16329", "Belgium"], ["C64974", "Give"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25640", "Reduced"], ["C52874", "SPI1 wt Allele"], ["C70888", "Daily Dose"], ["C52874", "SPI1 wt Allele"], ["C159124", "GDC Treatment Outcome Terminology"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25488", "Dose"], ["C25652", "Requirement"], ["C158169", "Buyei Chinese"], ["C25190", "Person"], ["C25488", "Dose"], ["C106184", "May"], ["C16329", "Belgium"], ["C198613", "CFI wt Allele"], ["C16727", "India"], ["C37984", "Laboratory"], ["C68869", "Are"], ["C25599", "Observed"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16268", "Elderly"], ["C16960", "Patient"], ["C15206", "Clinical Study"], ["C52874", "SPI1 wt Allele"], ["C163546", "Double Immunodiffusion"], ["C25594", "Negation"], ["C74521", "Include"], ["C63351", "Sufficient"], ["C52874", "SPI1 wt Allele"], ["C16960", "Patient"], ["C25150", "Age"], ["C188329", "Sixty Five"], ["C29848", "Year"], ["C16289", "Andorra"], ["C75329", "Above"], ["C159124", "GDC Treatment Outcome Terminology"], ["C136827", "Determine"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16960", "Patient"], ["C188329", "Sixty Five"], ["C29848", "Year"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C16974", "Pharmacology"], ["C52874", "SPI1 wt Allele"], ["C63670", "Dimethyl Fumarate"], ["C76246", "Blood Group A"], ["C41204", "Need"], ["C64956", "For"], ["C82495", "Dose Adjustment"], ["C16727", "India"], ["C16268", "Elderly"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C41333", "Expected Adverse Event"], ["C114592", "Renal Impairment"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C156242", "Mild Hallucination"], ["C159124", "GDC Treatment Outcome Terminology"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C114592", "Renal Impairment"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C114592", "Renal Impairment"], ["C16289", "Andorra"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C37933", "Contraindicated"], ["C16727", "India"], ["C16960", "Patient"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C156242", "Mild Hallucination"], ["C159124", "GDC Treatment Outcome Terminology"], ["C148420", "Moderate Hepatic Insufficiency"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C16289", "Andorra"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C37933", "Contraindicated"], ["C16727", "India"], ["C16960", "Patient"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C17005", "Population Group"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C16423", "Child"], ["C75330", "Below"], ["C106312", "Advanced Glycation End Product"], ["C52874", "SPI1 wt Allele"], ["C111798", "Eighteen"], ["C29848", "Year"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C68869", "Are"], ["C53269", "No Information Available"], ["C62355", "With"], ["C16727", "India"], ["C17005", "Population Group"], ["C85492", "CDISC SDTM Method Terminology"], ["C52874", "SPI1 wt Allele"], ["C70962", "Agent Administration"], ["C64956", "For"], ["C38288", "Oral Route of Administration"], ["C16329", "Belgium"], ["C25326", "Whole"], ["C62355", "With"], ["C25278", "Fluid"], ["C25490", "During"], ["C43508", "Oregon"], ["C64597", "Immediately"], ["C124898", "Refrain from Smoking After a Meal"], ["C25450", "Coat"], ["C52874", "SPI1 wt Allele"], ["C128681", "CDISC SDTM Gastrointestinal Test Name Terminology"], ["C41546", "Resistance Process"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C12391", "Stomach"], ["C50624", "Irritation"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C132259", "Study Site Dissolved"], ["C43508", "Oregon"]], "rxnorm.posology": [["1373478", "dimethyl fumarate"], ["1373478", "dimethyl fumarate"]], "loinc.posology": [["LP200075-2", "IS"], ["LP34220-1", "Guidance"], ["LP17763-1", "A"], ["MTHU010489", "Physician"], ["LA22004-8", "IN"], ["MTHU008876", "Diagnosis"], ["LP94823-9", "Treatment"], ["LA15165-6", "Psoriasis"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LP17763-1", "A"], ["LA9194-7", "Low"], ["LA6662-6", "Initial"], ["MTHU065481", "Dose"], ["LA14961-9", "Increases"], ["LA22004-8", "IN"], ["LP6974-2", "first"], ["LA14216-8", "Week"], ["LP17763-1", "A"], ["LA28855-7", "30"], ["LP15217-0", "Mg"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA6305-2", "Once daily"], ["LA6112-2", "1"], ["LP136501-6", "Tablet"], ["LA22004-8", "IN"], ["LA14972-6", "Evening"], ["LA22004-8", "IN"], ["LA14216-8", "Week"], ["LP17763-1", "A"], ["LA28855-7", "30"], ["LP15217-0", "Mg"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA14664-9", "Twice"], ["LA14435-4", "Daily"], ["LA6112-2", "1"], ["LP136501-6", "Tablet"], ["LA22004-8", "IN"], ["LA14971-8", "Morning"], ["LA6112-2", "1"], ["LA22004-8", "IN"], ["LA14972-6", "Evening"], ["LA22004-8", "IN"], ["LA14216-8", "Week"], ["LP17763-1", "A"], ["LA28855-7", "30"], ["LP15217-0", "Mg"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA6395-3", "Three"], ["LA14435-4", "Daily"], ["LA6112-2", "1"], ["LP136501-6", "Tablet"], ["LA22004-8", "IN"], ["LA14971-8", "Morning"], ["LA6112-2", "1"], ["LA21988-3", "AT"], ["LA6112-2", "1"], ["LA22004-8", "IN"], ["LA14972-6", "Evening"], ["LA14216-8", "Week"], ["LP94823-9", "Treatment"], ["LP200075-2", "IS"], ["LA6112-2", "1"], ["LP136501-6", "Tablet"], ["LP17763-1", "A"], ["LA32059-0", "120"], ["LP15217-0", "Mg"], ["MTHU065481", "Dose"], ["LA22004-8", "IN"], ["LA14972-6", "Evening"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA24377-6", "Increased"], ["LA6306-0", "One"], ["LA32059-0", "120"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["LA9582-3", "per week"], ["LA21988-3", "AT"], ["LP121628-4", "Day"], ["LP20593-7", "5"], ["LA9000-6", "Weeks"], ["LA22004-8", "IN"], ["LA14987-4", "Below"], ["LP6972-6", "maximum"], ["LA14435-4", "Daily"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP15217-0", "Mg"], ["LA32059-0", "120"], ["LP15217-0", "Mg"], ["LA14216-8", "Week"], ["LP18011-4", "Number"], ["LA6661-8", "Total"], ["LA14435-4", "Daily"], ["MTHU065481", "Dose"], ["LP15217-0", "Mg"], ["LA14971-8", "Morning"], ["LA14972-6", "Evening"], ["LP15583-5", "Fumarate"], ["LA28855-7", "30"], ["LP15217-0", "Mg"], ["LA28855-7", "30"], ["LA28853-2", "60"], ["LA28891-2", "90"], ["LA32059-0", "120"], ["LP15217-0", "Mg"], ["LA32059-0", "120"], ["LA14010-5", "600"], ["LA10141-2", "9"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LA32048-3", "Increase"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LP200077-8", "IT"], ["LA14161-6", "May"], ["LA32619-1", "Reduced"], ["MTHU065481", "Dose"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP94823-9", "Treatment"], ["LP200075-2", "IS"], ["LP6425-5", "Observed"], ["LP6972-6", "maximum"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LA32048-3", "Increase"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP130014-6", "Skin"], ["LA32245-5", "Achieved"], ["LP29256-2", "given"], ["LP267357-4", "Reduction"], ["LA14435-4", "Daily"], ["MTHU065481", "Dose"], ["MTHU065481", "Dose"], ["LA12070-1", "Individual"], ["MTHU065481", "Dose"], ["LA14161-6", "May"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA22004-8", "IN"], ["MTHU029808", "Laboratory"], ["LP6425-5", "Observed"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP7787-7", "Clinical"], ["LA21291-2", "Not"], ["LA28126-3", "Sufficient"], ["LA25497-1", "Numbers"], ["LA19751-9", "Aged"], ["LA14991-6", "Above"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LP213637-4", "Pharmacology"], ["LP15583-5", "Fumarate"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LA22004-8", "IN"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["MTHU065909", "Renal"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA15008-8", "Mild to moderate"], ["MTHU065909", "Renal"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["MTHU065909", "Renal"], ["LP200075-2", "IS"], ["LA4216-3", "Contraindicated"], ["LA22004-8", "IN"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA15008-8", "Mild to moderate"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["LP200075-2", "IS"], ["LA4216-3", "Contraindicated"], ["LA22004-8", "IN"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LP62263-6", "Population"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["LA22004-8", "IN"], ["LA14987-4", "Below"], ["MTHU010047", "Age"], ["LA21291-2", "Not"], ["LA32-8", "No"], ["LA22004-8", "IN"], ["LP62263-6", "Population"], ["LP72939-9", "Method"], ["LA9367-9", "Oral"], ["MTHU004941", "Fluid"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LA6676-6", "Resistant"], ["LP200075-2", "IS"], ["LA20332-5", "Gastric"], ["LA7449-7", "Irritation"], ["LA21291-2", "Not"], ["LA22025-3", "OR"]], "snomed.contraindications": [["257550005", "Hypersensitivity (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["261217004", "Substance (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["64572001", "Disease (disorder)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"]], "ncit.contraindications": [["C3114", "Hypersensitivity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C154405", "Active State"], ["C45306", "Substance"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C53802", "Adverse Event Associated with the Gastrointestinal System"], ["C2991", "Disease or Disorder"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C13308", "Hepatic"], ["C43508", "Oregon"], ["C114592", "Renal Impairment"], ["C191656", "Pregnant Subject"], ["C16289", "Andorra"], ["C25389", "Chest"], ["C88198", "Feeding"]], "rxnorm.contraindications": [["T167", "Substance"]], "loinc.contraindications": [["LA16666-2", "Active"], ["T167", "Substance"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP20594-5", "6"], ["LA6112-2", "1"], ["LA6750-9", "Severe"], ["LA16968-2", "Gastrointestinal"], ["LA6750-9", "Severe"], ["LA22025-3", "OR"], ["MTHU065909", "Renal"], ["LP207970-7", "Pregnancy"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"]], "snomed.special_warnings": [["269967004", "Haematology (& serum blood tests)|Haematology (& serum blood tests) (procedure)"], ["260370003", "Decrease (qualifier value)"], ["52501007", "Leukocyte (cell)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["56972008", "Lymphocyte (cell)"], ["258734002", "counts (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["62482003", "Low (qualifier value)"], ["52501007", "Leukocyte (cell)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["56972008", "Lymphocyte (cell)"], ["258734002", "counts (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["288556008", "Before (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["15240007", "Current (qualifier value)"], ["26604007", "Complete blood count (procedure)"], ["55919000", "Including (qualifier value)"], ["263735002", "Differential (qualifier value)"], ["87612001", "Blood (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["365632008", "Finding of platelet count (finding)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["419188005", "Decreased blood leukocyte number (finding)|Blood leukocyte number below reference range (finding)"], ["351726001", "Below (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["420744004", "Roman numeral L (qualifier value)"], ["48813009", "Lymphocytopenia (disorder)"], ["351726001", "Below (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["420744004", "Roman numeral L (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["29458008", "Pathologic (qualifier value)"], ["7882003", "Identified (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["26604007", "Complete blood count (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["263735002", "Differential (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["396129006", "Every three months (qualifier value)"], ["273248003", "Action (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410525008", "Needed (qualifier value)"], ["18720000", "In (attribute)"], ["255260001", "Following (attribute)"], ["419188005", "Decreased blood leukocyte number (finding)|Blood leukocyte number below reference range (finding)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["46998006", "Massive (qualifier value)"], ["260370003", "Decrease (qualifier value)"], ["18720000", "In (attribute)"], ["255619001", "Total (qualifier value)"], ["410681005", "Count of entities (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["52501007", "Leukocyte (cell)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["410546004", "Discontinued (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["258395000", "Levels (qualifier value)"], ["351726001", "Below (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["420744004", "Roman numeral L (qualifier value)"], ["48813009", "Lymphocytopenia (disorder)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["142942007", "Lymphocyte count|Lymphocyte count (procedure)"], ["161898004", "Falls (finding)"], ["351726001", "Below (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["420744004", "Roman numeral L (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["732391002", "0.7 (qualifier value)"], ["420744004", "Roman numeral L (qualifier value)"], ["87612001", "Blood (substance)"], ["398166005", "Performed (qualifier value)"], ["123177009", "Monthly -RETIRED-|Nodular (qualifier value)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["258395000", "Levels (qualifier value)"], ["7528007", "Return to (contextual qualifier) (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["420744004", "Roman numeral L (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["87612001", "Blood (substance)"], ["272393004", "Tests (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["396129006", "Every three months (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["142942007", "Lymphocyte count|Lymphocyte count (procedure)"], ["161898004", "Falls (finding)"], ["351726001", "Below (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["420744004", "Roman numeral L (qualifier value)"], ["396550006", "Blood test (procedure)"], ["27582007", "Repeat (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["258395000", "Levels (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["351726001", "Below (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["420744004", "Roman numeral L (qualifier value)"], ["421067001", "Then - dosing instruction fragment (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["48813009", "Lymphocytopenia (disorder)"], ["255234002", "After (attribute)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["142942007", "Lymphocyte count|Lymphocyte count (procedure)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["260395002", "Normal range (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["74964007", "Other (qualifier value)"], ["64572001", "Disease (disorder)"], ["277132007", "Therapeutic procedure (procedure)"], ["410546004", "Discontinued (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["29458008", "Pathologic (qualifier value)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["87612001", "Blood (substance)"], ["258734002", "counts (qualifier value)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["260395002", "Normal range (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["734544007", "Immunomodulator (disposition)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["116003000", "Structure of immune system (body structure)|Immune system structure (body structure)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["309343006", "Physician (occupation)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["422114001", "Once - dosing instruction fragment (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["723506003", "Resolved (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["257551009", "Infection (disorder)|Infection"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["739008005", "Suspension (basic dose form)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["288556008", "Before (attribute)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["763158003", "Medicinal product (product)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["309343006", "Physician (occupation)"], ["22255007", "Progressive multifocal leukoencephalopathy (disorder)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["22255007", "Progressive multifocal leukoencephalopathy (disorder)"], ["733985002", "Reported (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["724035008", "Dimethyl fumarate (substance)"], ["42504009", "Containing (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["42752001", "Due to (attribute)"], ["49872002", "Virus (organism)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["399166001", "Fatal (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["2931005", "Probable diagnosis (contextual qualifier) (qualifier value)"], ["42752001", "Due to (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["9130008", "Previous (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["9130008", "Previous (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["17162000", "Certain (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["64572001", "Disease (disorder)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["263680009", "Autoimmune (qualifier value)|Autoimmune process (qualifier value)"], ["64572001", "Disease (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["21594007", "Malignant (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["18307000", "Altered (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["116003000", "Structure of immune system (body structure)|Immune system structure (body structure)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["20572008", "Good (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["255222005", "Persistent (qualifier value)"], ["1255665007", "Moderate (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["48813009", "Lymphocytopenia (disorder)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["724035008", "Dimethyl fumarate (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["80943009", "Risk factor (qualifier value)|Risk factor (observable entity)"], ["86495002", "For (qualifier value)"], ["48813009", "Lymphocytopenia (disorder)"], ["86495002", "For (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["47429007", "Associated with (attribute)"], ["390772001", "Deterioration of status (qualifier value)"], ["21481007", "Over (qualifier value)"], ["258703001", "day (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258705008", "week (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255314001", "Progressive (qualifier value)"], ["13791008", "Asthenia (finding)"], ["420862001", "On (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["182353008", "Side (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["7006003", "Clumsiness (finding)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["61402003", "Vision (qualifier value)|Vision, function (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["275275008", "Thinking|Thinking (observable entity)"], ["13108000", "Memory, function (observable entity)|Memory (function)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["43173001", "Orientation, function (observable entity)|Orientation (function)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["163609008", "Confused (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["71565002", "Personality, function (observable entity)|Personality (function)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["415684004", "Suspected (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1199008", "Neurologic (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["420862001", "On (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["74964007", "Other (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["273248003", "Action (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["182812006", "Other therapy (procedure)|Other therapy (regime/therapy)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["260364009", "Additive (qualifier value)"], ["420862001", "On (qualifier value)"], ["116003000", "Structure of immune system (body structure)|Immune system structure (body structure)"], ["373067005", "No (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["420862001", "On (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["74964007", "Other (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["64572001", "Disease (disorder)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["64572001", "Disease (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410536001", "Contraindicated (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["64572001", "Disease (disorder)"], ["732725004", "4.3 (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["24588000", "Attenuated by (contextual qualifier) (qualifier value)"], ["255260001", "Following (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["420862001", "On (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["385059007", "Gastro-resistant oral tablet (dose form)|Gastro-resistant tablet (product)|Gastro-resistant tablet (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255620007", "Food (substance)|Foods (substance)"], ["732724000", "4.2 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["50741009", "Urinary tract function (observable entity)|Urinary tract function (function)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["21191007", "Phase (attribute)|Phase (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["224699009", "Study (environment)"], ["50741009", "Urinary tract function (observable entity)|Urinary tract function (function)"], ["47492008", "Not seen (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["261586004", "Groups (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["236514003", "Toxic nephropathy (disorder)"], ["733985002", "Reported (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["288563008", "After values (qualifier value)"], ["225419007", "Surveillance (procedure)|Surveillance (regime/therapy)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["102646006", "Fumaric acid (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410536001", "Contraindicated (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["732725004", "4.3 (qualifier value)"], ["50741009", "Urinary tract function (observable entity)|Urinary tract function (function)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["15373003", "Creatinine (substance)"], ["72341003", "Blood urea nitrogen (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["27171005", "Urinalysis (procedure)"], ["288556008", "Before (attribute)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["396129006", "Every three months (qualifier value)"], ["18720000", "In (attribute)"], ["272379006", "Events (event)|Event (event)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263703002", "Changed status (qualifier value)"], ["50741009", "Urinary tract function (observable entity)|Urinary tract function (function)"], ["18720000", "In (attribute)"], ["2667000", "Absent (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["289928003", "Reduction plasty (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["40488004", "Fanconi syndrome (disorder)"], ["264499004", "Early (qualifier value)"], ["439401001", "Diagnosis (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["40488004", "Fanconi syndrome (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["101445003", "PREVENT (substance)|PREVENT (product)"], ["77374008", "Onset of (contextual qualifier) (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["190639009", "(Vitamin D deficiency) or (osteomalacia) or (rickets) (disorder)|(Vitamin D deficiency) or (osteomalacia) or (rickets)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["64572001", "Disease (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["35174006", "Reversible (qualifier value)"], ["4757001", "Most (qualifier value)"], ["236719005", "Proteinuria [Ambiguous]|Proteinuria (disorder)"], ["45154002", "Glycosuria (finding)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["17621005", "Normal (qualifier value)"], ["87612001", "Blood (substance)"], ["74801000", "Simple carbohydrate (substance)|Sugar (substance)"], ["258395000", "Levels (qualifier value)"], ["42930003", "Inborn error of amino acid metabolism (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["60022001", "Possible diagnosis (contextual qualifier) (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["4996001", "Hypophosphatemia (disorder)"], ["732732008", "4.8 (qualifier value)"], ["246450006", "Progression (attribute)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["162114000", "(Frequency of micturition) or (polyuria)|(Frequency of micturition) or (polyuria) (finding)"], ["161848000", "(Excessive fluid intake) or (polydipsia) (finding)|(Excessive fluid intake) or (polydipsia)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["249939004", "Proximal muscle weakness (finding)"], ["18720000", "In (attribute)"], ["89292003", "Rare (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["190639009", "(Vitamin D deficiency) or (osteomalacia) or (rickets) (disorder)|(Vitamin D deficiency) or (osteomalacia) or (rickets)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255471002", "Localized (qualifier value)"], ["203507006", "Bone pain (finding)|Bone pain"], ["123126002", "Elevated (qualifier value)|Elevated -RETIRED-"], ["736208004", "Phosphatase (disposition)|Phosphoric monoester hydrolase (disposition)"], ["18720000", "In (attribute)"], ["67922002", "Serum (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["262188008", "Stress (qualifier value)"], ["40488004", "Fanconi syndrome (disorder)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["45169001", "Without (attribute)"], ["123126002", "Elevated (qualifier value)|Elevated -RETIRED-"], ["15373003", "Creatinine (substance)"], ["258395000", "Levels (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["62482003", "Low (qualifier value)"], ["80274001", "Glomerular filtration rate (observable entity)|Glomerular filtration rate (function)|Glomerular filtration rate, function (observable entity)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["40488004", "Fanconi syndrome (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["79036002", "Liver function (function)|Liver function (observable entity)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["40226000", "Impairment (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410536001", "Contraindicated (qualifier value)"], ["18720000", "In (attribute)"], ["732725004", "4.3 (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["13288007", "Monitor, device (physical object)"], ["79036002", "Liver function (function)|Liver function (observable entity)"], ["26091008", "Aspartate aminotransferase (substance)"], ["56935002", "Alanine aminotransferase (substance)"], ["421416008", "Greek letter gamma (qualifier value)"], ["288556008", "Before (attribute)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["396129006", "Every three months (qualifier value)"], ["255456001", "Elevation - value (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["18720000", "In (attribute)"], ["21191007", "Phase (attribute)|Phase (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["224699009", "Study (environment)"], ["732732008", "4.8 (qualifier value)"], ["18720000", "In (attribute)"], ["272379006", "Events (event)|Event (event)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263703002", "Changed status (qualifier value)"], ["252116004", "Observation parameter (observable entity)"], ["18720000", "In (attribute)"], ["2667000", "Absent (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["289928003", "Reduction plasty (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["732724000", "4.2 (qualifier value)"], ["238810007", "Flushing (disorder)"], ["2931005", "Probable diagnosis (contextual qualifier) (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["238810007", "Flushing (disorder)"], ["18720000", "In (attribute)"], ["255216001", "First (qualifier value)"], ["57176003", "Few (qualifier value)"], ["258705008", "week (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["423291009", "Product containing lactose (medicinal product)|Lactose (product)"], ["763158003", "Medicinal product (product)"], ["423291009", "Product containing lactose (medicinal product)|Lactose (product)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["255404009", "Hereditary (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["423410006", "Galactose (product)|Product containing galactose (medicinal product)"], ["29544009", "Intolerance, function (observable entity)|Intolerance (function)"], ["255619001", "Total (qualifier value)"], ["237975008", "Lactase deficiency (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["190749000", "Glucose-galactose malabsorption (disorder)"], ["419652001", "Take (qualifier value)|Take - dosing instruction imperative (qualifier value)"], ["2533004", "Drug (substance)"], ["39972003", "Sodium (substance)"], ["763158003", "Medicinal product (product)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258718000", "mmol (qualifier value)|millimole (qualifier value)"], ["39972003", "Sodium (substance)"], ["1222776006", "American Joint Committee on Cancer stage II:3 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["39972003", "Sodium (substance)"]], "ncit.special_warnings": [["C106184", "May"], ["C25640", "Reduced"], ["C12529", "Leukocyte"], ["C16289", "Andorra"], ["C23469", "Murine Lymphocytes"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C38267", "Intrathecal Route of Administration"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C73621", "Pre-existing"], ["C139301", "IPSS Risk Category Low"], ["C12529", "Leukocyte"], ["C43508", "Oregon"], ["C23469", "Murine Lymphocytes"], ["C54734", "Pre-Therapy"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43442", "Biomaterial Treatment"], ["C76246", "Blood Group A"], ["C48434", "Electrical Current"], ["C28133", "Blood Cell Count"], ["C166400", "Inclusive"], ["C46003", "Difference"], ["C17610", "Blood Sample"], ["C48485", "Count Dosing Unit"], ["C16289", "Andorra"], ["C51951", "Platelet Count"], ["C16329", "Belgium"], ["C25429", "Availability"], ["C43442", "Biomaterial Treatment"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C198613", "CFI wt Allele"], ["C26816", "Leukopenia"], ["C75330", "Below"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C173011", "MATCH Arm EAY131-L"], ["C26823", "Lymphopenia"], ["C75330", "Below"], ["C105723", "ECOG Performance Status 1"], ["C173011", "MATCH Arm EAY131-L"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C18189", "Pathology"], ["C68869", "Are"], ["C25737", "Identification"], ["C175242", "During Treatment"], ["C175242", "During Treatment"], ["C76246", "Blood Group A"], ["C28133", "Blood Cell Count"], ["C62355", "With"], ["C46003", "Difference"], ["C16329", "Belgium"], ["C38000", "Performed"], ["C64537", "Every Three Months"], ["C25404", "Action"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C53286", "Next"], ["C26816", "Leukopenia"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C182282", "Marked Heterogeneity Morphology"], ["C25640", "Reduced"], ["C16727", "India"], ["C127787", "Total Number"], ["C52874", "SPI1 wt Allele"], ["C12529", "Leukocyte"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25626", "Present"], ["C16329", "Belgium"], ["C16289", "Andorra"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C158997", "GDC Analyte Type Terminology"], ["C75330", "Below"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C173011", "MATCH Arm EAY131-L"], ["C26823", "Lymphopenia"], ["C198613", "CFI wt Allele"], ["C51949", "Lymphocyte Count"], ["C75330", "Below"], ["C105723", "ECOG Performance Status 1"], ["C173011", "MATCH Arm EAY131-L"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C173011", "MATCH Arm EAY131-L"], ["C17610", "Blood Sample"], ["C61256", "Monitoring"], ["C16329", "Belgium"], ["C38000", "Performed"], ["C168157", "Chief Complaint is Present Monthly"], ["C65136", "Until"], ["C71900", "Return"], ["C159124", "GDC Treatment Outcome Terminology"], ["C105723", "ECOG Performance Status 1"], ["C173011", "MATCH Arm EAY131-L"], ["C43508", "Oregon"], ["C25227", "High"], ["C64956", "For"], ["C66833", "Two"], ["C47939", "Consecutive"], ["C17610", "Blood Sample"], ["C25294", "Laboratory Procedure"], ["C158997", "GDC Analyte Type Terminology"], ["C70656", "Point"], ["C61256", "Monitoring"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C38000", "Performed"], ["C64537", "Every Three Months"], ["C198613", "CFI wt Allele"], ["C51949", "Lymphocyte Count"], ["C75330", "Below"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C173011", "MATCH Arm EAY131-L"], ["C49286", "Hematology Test"], ["C16329", "Belgium"], ["C16289", "Andorra"], ["C198613", "CFI wt Allele"], ["C68869", "Are"], ["C25458", "Confirmation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C75330", "Below"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C173011", "MATCH Arm EAY131-L"], ["C65106", "Then"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C64597", "Immediately"], ["C16960", "Patient"], ["C26823", "Lymphopenia"], ["C16329", "Belgium"], ["C38008", "Post"], ["C43442", "Biomaterial Treatment"], ["C65136", "Until"], ["C51949", "Lymphocyte Count"], ["C101282", "Have"], ["C106328", "Quantity Final Containers Returned"], ["C159124", "GDC Treatment Outcome Terminology"], ["C71474", "Reference Range"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C118472", "Other License Status"], ["C2991", "Disease or Disorder"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C16289", "Andorra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C198613", "CFI wt Allele"], ["C118472", "Other License Status"], ["C18189", "Pathology"], ["C127786", "Occurrence Indicator"], ["C16727", "India"], ["C81168", "Any"], ["C49152", "Case"], ["C17610", "Blood Sample"], ["C16329", "Belgium"], ["C65136", "Until"], ["C101282", "Have"], ["C106328", "Quantity Final Containers Returned"], ["C159124", "GDC Treatment Outcome Terminology"], ["C71474", "Reference Range"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C75889", "PAX6 wt Allele"], ["C16289", "Andorra"], ["C106184", "May"], ["C12735", "Immune System"], ["C167391", "Pet Responds to Presence"], ["C159124", "GDC Treatment Outcome Terminology"], ["C128320", "Infection"], ["C64956", "For"], ["C16960", "Patient"], ["C62355", "With"], ["C73621", "Pre-existing"], ["C52874", "SPI1 wt Allele"], ["C123619", "Clinical Response"], ["C70664", "Relevance"], ["C25741", "Physician"], ["C198613", "CFI wt Allele"], ["C43442", "Biomaterial Treatment"], ["C48440", "Single"], ["C16329", "Belgium"], ["C64576", "Once"], ["C128320", "Infection"], ["C101282", "Have"], ["C118471", "Resolved License"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C75889", "PAX6 wt Allele"], ["C128320", "Infection"], ["C25490", "During"], ["C43442", "Biomaterial Treatment"], ["C42994", "Suspension Dosage Form"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C16289", "Andorra"], ["C25387", "Benefit"], ["C16289", "Andorra"], ["C16329", "Belgium"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C17095", "Reunion"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C16960", "Patient"], ["C25639", "Receive"], ["C142605", "Medicinal Product"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C97107", "Regulatory Report"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C128320", "Infection"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C25741", "Physician"], ["C26815", "Progressive Multifocal Leukoencephalopathy"], ["C24686", "PML Gene"], ["C52874", "SPI1 wt Allele"], ["C52874", "SPI1 wt Allele"], ["C26815", "Progressive Multifocal Leukoencephalopathy"], ["C24686", "PML Gene"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C62355", "With"], ["C118472", "Other License Status"], ["C63670", "Dimethyl Fumarate"], ["C79873", "Contain"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C24686", "PML Gene"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C75889", "PAX6 wt Allele"], ["C3289", "Opportunistic Infection"], ["C158169", "Buyei Chinese"], ["C14283", "Virus"], ["C14229", "JC Virus"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C48275", "Death Related to Adverse Event"], ["C43508", "Oregon"], ["C16390", "Etiology"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C24686", "PML Gene"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C85550", "Likely"], ["C158169", "Buyei Chinese"], ["C76246", "Blood Group A"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C25627", "Previous"], ["C128320", "Infection"], ["C62355", "With"], ["C14229", "JC Virus"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C64956", "For"], ["C18732", "Development"], ["C52874", "SPI1 wt Allele"], ["C24686", "PML Gene"], ["C17103", "Risk Factor"], ["C52288", "NUP214 wt Allele"], ["C74521", "Include"], ["C25627", "Previous"], ["C574", "Immunosuppressant"], ["C43442", "Biomaterial Treatment"], ["C16289", "Andorra"], ["C52874", "SPI1 wt Allele"], ["C107561", "Certain"], ["C25730", "Concomitant"], ["C2991", "Disease or Disorder"], ["C71344", "Associate of Science"], ["C65099", "Some"], ["C37916", "Autoimmune"], ["C2991", "Disease or Disorder"], ["C43508", "Oregon"], ["C14143", "Malignant"], ["C25457", "Condition"], ["C76246", "Blood Group A"], ["C25572", "Modification"], ["C43508", "Oregon"], ["C12735", "Immune System"], ["C71344", "Associate of Science"], ["C128793", "Microplate Well"], ["C71344", "Associate of Science"], ["C15238", "Gene Therapy"], ["C43508", "Oregon"], ["C19688", "Exogenous Factors"], ["C52288", "NUP214 wt Allele"], ["C17103", "Risk Factor"], ["C43623", "Persistent"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C43508", "Oregon"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C26823", "Lymphopenia"], ["C175242", "During Treatment"], ["C62355", "With"], ["C63670", "Dimethyl Fumarate"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C17103", "Risk Factor"], ["C64956", "For"], ["C24686", "PML Gene"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C26823", "Lymphopenia"], ["C16329", "Belgium"], ["C64956", "For"], ["C16289", "Andorra"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C64956", "For"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C24686", "PML Gene"], ["C102843", "Usual"], ["C168422", "Rheumatic Fever Symptom"], ["C25281", "Associated"], ["C62355", "With"], ["C24686", "PML Gene"], ["C68869", "Are"], ["C62263", "Diversity"], ["C71686", "Worse"], ["C25490", "During"], ["C25301", "Day"], ["C159124", "GDC Treatment Outcome Terminology"], ["C29844", "Week"], ["C16289", "Andorra"], ["C74521", "Include"], ["C25254", "Progressive"], ["C50809", "Weakness"], ["C92667", "SPARC wt Allele"], ["C66832", "One"], ["C25306", "Side"], ["C52874", "SPI1 wt Allele"], ["C12258", "Body of Stomach"], ["C43508", "Oregon"], ["C52874", "SPI1 wt Allele"], ["C30140", "Extremities"], ["C75521", "Disturbance"], ["C52874", "SPI1 wt Allele"], ["C38533", "Sight"], ["C16289", "Andorra"], ["C16727", "India"], ["C54226", "Thinking"], ["C50047", "Memory Device"], ["C16289", "Andorra"], ["C48673", "Genomic Orientation"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C37928", "Confusion"], ["C16289", "Andorra"], ["C38002", "Personality"], ["C198613", "CFI wt Allele"], ["C24686", "PML Gene"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C71458", "Suspected"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C64597", "Immediately"], ["C16289", "Andorra"], ["C25519", "Further"], ["C25262", "Neurologic"], ["C16289", "Andorra"], ["C38000", "Performed"], ["C25629", "Prior"], ["C16289", "Andorra"], ["C25730", "Concomitant"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C574", "Immunosuppressant"], ["C43508", "Oregon"], ["C142988", "Limited"], ["C25474", "Data"], ["C68869", "Are"], ["C25429", "Availability"], ["C92667", "SPARC wt Allele"], ["C88183", "Efficacy"], ["C16289", "Andorra"], ["C49667", "Safety Study"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C16124", "Prior Therapy"], ["C62355", "With"], ["C118472", "Other License Status"], ["C574", "Immunosuppressant"], ["C43508", "Oregon"], ["C65140", "When"], ["C16960", "Patient"], ["C25516", "From"], ["C159124", "GDC Treatment Outcome Terminology"], ["C70916", "Half Life"], ["C16289", "Andorra"], ["C146999", "Mode of Action"], ["C52874", "SPI1 wt Allele"], ["C15645", "Other Therapy"], ["C16329", "Belgium"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C63495", "Additive"], ["C25492", "Effect"], ["C92667", "SPARC wt Allele"], ["C12735", "Immune System"], ["C53269", "No Information Available"], ["C68869", "Are"], ["C25429", "Availability"], ["C92667", "SPARC wt Allele"], ["C88183", "Efficacy"], ["C16289", "Andorra"], ["C49667", "Safety Study"], ["C52874", "SPI1 wt Allele"], ["C65140", "When"], ["C25701", "Taken"], ["C62355", "With"], ["C118472", "Other License Status"], ["C574", "Immunosuppressant"], ["C43508", "Oregon"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C73621", "Pre-existing"], ["C53802", "Adverse Event Associated with the Gastrointestinal System"], ["C2991", "Disease or Disorder"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C73621", "Pre-existing"], ["C53802", "Adverse Event Associated with the Gastrointestinal System"], ["C2991", "Disease or Disorder"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C37933", "Contraindicated"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C53802", "Adverse Event Associated with the Gastrointestinal System"], ["C2991", "Disease or Disorder"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C53802", "Adverse Event Associated with the Gastrointestinal System"], ["C98791", "Tolerability Study"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C125459", "Improved"], ["C158169", "Buyei Chinese"], ["C53286", "Next"], ["C25488", "Dose"], ["C181463", "Titrimetry"], ["C25211", "Schedule"], ["C92667", "SPARC wt Allele"], ["C43442", "Biomaterial Treatment"], ["C16289", "Andorra"], ["C158169", "Buyei Chinese"], ["C42905", "Delayed Release Tablet Dosage Form"], ["C42555", "Siemens"], ["C67010", "With Food"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C164220", "Renal Function"], ["C25490", "During"], ["C48281", "Trial Phase"], ["C133421", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8"], ["C49648", "Placebo Control"], ["C15206", "Clinical Study"], ["C164220", "Renal Function"], ["C154196", "Washo Language"], ["C25594", "Negation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C175242", "During Treatment"], ["C81171", "Cross"], ["C43442", "Biomaterial Treatment"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C114592", "Renal Impairment"], ["C16289", "Andorra"], ["C65099", "Some"], ["C52874", "SPI1 wt Allele"], ["C115459", "Renal Toxicity"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C25490", "During"], ["C38008", "Post"], ["C53292", "Marketing"], ["C15719", "Surveillance"], ["C62355", "With"], ["C63655", "Fumaric Acid"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C37933", "Contraindicated"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C114592", "Renal Impairment"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C164220", "Renal Function"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C399", "Creatinine"], ["C61019", "Blood Urea Nitrogen Measurement"], ["C16289", "Andorra"], ["C17241", "Urinalysis"], ["C16329", "Belgium"], ["C182796", "Kurtzke Functional System Scores KFSS1SET1 Original Result - Checked"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C16289", "Andorra"], ["C64537", "Every Three Months"], ["C16727", "India"], ["C74589", "Protocol Event"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C70664", "Relevance"], ["C54126", "Delta"], ["C16727", "India"], ["C164220", "Renal Function"], ["C16727", "India"], ["C52874", "SPI1 wt Allele"], ["C97927", "Gene Variant"], ["C113416", "Consideration"], ["C16329", "Belgium"], ["C64974", "Give"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49505", "Dose Reduced"], ["C43508", "Oregon"], ["C43442", "Biomaterial Treatment"], ["C25484", "Discontinue"], ["C3034", "Fanconi Syndrome"], ["C61589", "Early"], ["C15220", "Diagnosis"], ["C52874", "SPI1 wt Allele"], ["C3034", "Fanconi Syndrome"], ["C16289", "Andorra"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C68869", "Are"], ["C125543", "Importance Rating Score 0"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25279", "Onset"], ["C52874", "SPI1 wt Allele"], ["C114592", "Renal Impairment"], ["C16289", "Andorra"], ["C26838", "Osteomalacia"], ["C71344", "Associate of Science"], ["C168217", "Genetic Syndrome Associated with Congenital Heart Defect"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C114711", "Usually"], ["C25258", "Most"], ["C125543", "Importance Rating Score 0"], ["C68869", "Are"], ["C38012", "Proteinuria"], ["C143238", "Glucosuria, CTCAE"], ["C62355", "With"], ["C12801", "Tissue"], ["C94312", "Blood Glucose"], ["C16289", "Andorra"], ["C67236", "Phosphaturia"], ["C25456", "Concurrent"], ["C62355", "With"], ["C143573", "Hypophosphatemia, CTCAE"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C17747", "Disease Progression"], ["C168422", "Rheumatic Fever Symptom"], ["C71344", "Associate of Science"], ["C118303", "Polyuria"], ["C50700", "Polydipsia"], ["C16289", "Andorra"], ["C91404", "Proximal Muscle"], ["C50809", "Weakness"], ["C16727", "India"], ["C13634", "Retinoic Acid Response Element"], ["C26838", "Osteomalacia"], ["C62355", "With"], ["C14460", "NON Mouse"], ["C14146", "Localized"], ["C146741", "Bone Pain, CTCAE 5.0"], ["C162107", "High Platelet Count"], ["C16981", "Phosphatase"], ["C16727", "India"], ["C13325", "Serum"], ["C16289", "Andorra"], ["C35041", "Stress"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C3034", "Fanconi Syndrome"], ["C52288", "NUP214 wt Allele"], ["C127786", "Occurrence Indicator"], ["C25718", "Without"], ["C78249", "Increased Creatinine"], ["C43508", "Oregon"], ["C139301", "IPSS Risk Category Low"], ["C90505", "Glomerular Filtration Rate"], ["C16727", "India"], ["C49152", "Case"], ["C52874", "SPI1 wt Allele"], ["C150000", "Unclear State of Matter"], ["C168422", "Rheumatic Fever Symptom"], ["C3034", "Fanconi Syndrome"], ["C16329", "Belgium"], ["C16289", "Andorra"], ["C16329", "Belgium"], ["C38000", "Performed"], ["C13308", "Hepatic"], ["C25518", "Function"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C16289", "Andorra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C37933", "Contraindicated"], ["C16727", "India"], ["C16960", "Patient"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C41201", "Study Monitor"], ["C13308", "Hepatic"], ["C25518", "Function"], ["C64467", "Aspartate Aminotransferase Measurement"], ["C64433", "Alanine Aminotransferase Measurement"], ["C37959", "Gamma-Glutamyl Transpeptidase"], ["C16276", "Alkaline Phosphatase"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C16289", "Andorra"], ["C64537", "Every Three Months"], ["C45325", "Since"], ["C25494", "Elevation"], ["C52874", "SPI1 wt Allele"], ["C13308", "Hepatic"], ["C16554", "Enzyme"], ["C101282", "Have"], ["C25599", "Observed"], ["C16727", "India"], ["C65099", "Some"], ["C16960", "Patient"], ["C16727", "India"], ["C15602", "Phase III Trial"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C16727", "India"], ["C74589", "Protocol Event"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C70664", "Relevance"], ["C54126", "Delta"], ["C16727", "India"], ["C13308", "Hepatic"], ["C16727", "India"], ["C52874", "SPI1 wt Allele"], ["C97927", "Gene Variant"], ["C113416", "Consideration"], ["C16329", "Belgium"], ["C64974", "Give"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49505", "Dose Reduced"], ["C43508", "Oregon"], ["C43442", "Biomaterial Treatment"], ["C25484", "Discontinue"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C57997", "Flushing, CTCAE 3.0"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C54070", "Awareness"], ["C68869", "Are"], ["C85550", "Likely"], ["C159124", "GDC Treatment Outcome Terminology"], ["C54627", "Experience"], ["C57997", "Flushing, CTCAE 3.0"], ["C16727", "India"], ["C25509", "First"], ["C64942", "Few"], ["C29844", "Week"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C28166", "Lactose"], ["C142605", "Medicinal Product"], ["C79873", "Contain"], ["C28166", "Lactose"], ["C16960", "Patient"], ["C62355", "With"], ["C13634", "Retinoic Acid Response Element"], ["C27998", "Hereditary"], ["C52874", "SPI1 wt Allele"], ["C68482", "Galactose"], ["C71437", "Intolerance"], ["C25304", "Total"], ["C107438", "Beta-Galactosidase"], ["C94372", "Deficiency"], ["C43508", "Oregon"], ["C2831", "Glucose"], ["C68482", "Galactose"], ["C3214", "Malabsorption Syndrome"], ["C25594", "Negation"], ["C65105", "Take"], ["C459", "Medication"], ["C830", "Sodium"], ["C142605", "Medicinal Product"], ["C79873", "Contain"], ["C61585", "Less Than"], ["C105723", "ECOG Performance Status 1"], ["C48513", "Millimole"], ["C830", "Sodium"], ["C126885", "Twenty Three"], ["C16818", "Mammography"], ["C97722", "PER1 wt Allele"], ["C154605", "Tablet Dosage Form Category"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C830", "Sodium"], ["C63628", "Empty"]], "rxnorm.special_warnings": [["1373478", "dimethyl fumarate"], ["T005", "Virus"], ["1373478", "dimethyl fumarate"], ["T168", "Food"], ["8375", "placebo"], ["25389", "fumaric acid"], ["2913", "creatinine"], ["11002", "urea"], ["7456", "nitrogen"], ["T051", "Event"], ["2913", "creatinine"], ["T051", "Event"], ["6211", "lactose"], ["6211", "lactose"], ["4626", "galactose"], ["41397", "lactase"], ["4850", "glucose"], ["4626", "galactose"], ["9853", "sodium"], ["9853", "sodium"], ["9853", "sodium"]], "loinc.special_warnings": [["LA14161-6", "May"], ["LA32049-1", "Decrease"], ["LP30914-3", "Lymphocyte"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP200077-8", "IT"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP32605-5", "pre"], ["LA9194-7", "Low"], ["LA22025-3", "OR"], ["LP30914-3", "Lymphocyte"], ["LP94823-9", "Treatment"], ["LA33028-4", "Prior"], ["LP94823-9", "Treatment"], ["LP17763-1", "A"], ["LP267470-5", "Complete"], ["MTHU029981", "Blood"], ["LA28708-8", "Differential"], ["MTHU029981", "Blood"], ["LP16772-3", "Platelet"], ["LP94823-9", "Treatment"], ["LA21291-2", "Not"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA14987-4", "Below"], ["LP20591-1", "3"], ["LA14987-4", "Below"], ["LA6112-2", "1"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LP40035-5", "Identified"], ["LP93408-0", "during treatment"], ["LP93408-0", "during treatment"], ["LP17763-1", "A"], ["LP267470-5", "Complete"], ["MTHU029981", "Blood"], ["LA28708-8", "Differential"], ["LA19974-7", "Performed"], ["LA18435-0", "3 months"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LA17968-1", "Marked"], ["LA32049-1", "Decrease"], ["LA22004-8", "IN"], ["LA6661-8", "Total"], ["LP18011-4", "Number"], ["LP7720-8", "White blood cells"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA21988-3", "AT"], ["LA14987-4", "Below"], ["LP20591-1", "3"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP30914-3", "Lymphocyte"], ["LA17133-2", "Falls"], ["LA14987-4", "Below"], ["LA6112-2", "1"], ["LP200075-2", "IS"], ["LA24584-7", "0.7"], ["MTHU029981", "Blood"], ["LA20297-0", "Monitoring"], ["LA19974-7", "Performed"], ["LA18876-5", "Monthly"], ["LA6112-2", "1"], ["LA22025-3", "OR"], ["LA6404-3", "Two"], ["MTHU029981", "Blood"], ["LA21988-3", "AT"], ["LA20297-0", "Monitoring"], ["LA19974-7", "Performed"], ["LA18435-0", "3 months"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP30914-3", "Lymphocyte"], ["LA17133-2", "Falls"], ["LA14987-4", "Below"], ["LA6111-4", "0"], ["MTHU029981", "Blood"], ["LA7556-9", "Test"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA15290-2", "Confirmed"], ["LA14987-4", "Below"], ["LA6111-4", "0"], ["LP94823-9", "Treatment"], ["LP94823-9", "Treatment"], ["LP30914-3", "Lymphocyte"], ["LA6626-1", "Normal"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["MTHU029809", "Other"], ["LP267221-2", "Therapy"], ["LP200075-2", "IS"], ["LP6323-2", "Immunofluorescence (IF)"], ["MTHU029809", "Other"], ["LA22004-8", "IN"], ["MTHU029981", "Blood"], ["LA6626-1", "Normal"], ["LP74970-2", "Infections"], ["LP200075-2", "IS"], ["LA14161-6", "May"], ["MTHU013246", "Immune system"], ["LP266919-2", "Infection"], ["LP32605-5", "pre"], ["LP74970-2", "Infections"], ["LP7787-7", "Clinical"], ["MTHU010489", "Physician"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP94823-9", "Treatment"], ["LA14312-5", "Once"], ["LP266919-2", "Infection"], ["LA9041-0", "Resolved"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LP266919-2", "Infection"], ["LP94823-9", "Treatment"], ["LA21913-1", "Suspension"], ["LP94823-9", "Treatment"], ["MTHU043138", "Risks"], ["LA33028-4", "Prior"], ["LP267221-2", "Therapy"], ["MTHU002737", "Report"], ["LP75708-5", "Symptoms"], ["LP266919-2", "Infection"], ["LP17763-1", "A"], ["MTHU010489", "Physician"], ["LP74970-2", "Infections"], ["LA25478-1", "Progressive"], ["LP96203-2", "PML"], ["LP270144-1", "Cases"], ["LP74970-2", "Infections"], ["LA25478-1", "Progressive"], ["LP96203-2", "PML"], ["LP6486-7", "Reported"], ["MTHU029809", "Other"], ["LP15583-5", "Fumarate"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP96203-2", "PML"], ["LP200075-2", "IS"], ["LP266919-2", "Infection"], ["LP14855-8", "Virus"], ["LA32822-1", "Fatal"], ["LA22025-3", "OR"], ["LA6750-9", "Severe"], ["LP96203-2", "PML"], ["LP200075-2", "IS"], ["LA18076-2", "Probably"], ["LP17763-1", "A"], ["LA12701-1", "Combination"], ["LP17763-1", "A"], ["LP266919-2", "Infection"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LP96203-2", "PML"], ["46467-7", "Risk factors:Find:Pt:^Patient:Nom"], ["LP94823-9", "Treatment"], ["LA14973-4", "Some"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LA22025-3", "OR"], ["MTHU013246", "Immune system"], ["LA18365-9", "Well"], ["LA22025-3", "OR"], ["46467-7", "Risk factors:Find:Pt:^Patient:Nom"], ["LA6751-7", "Moderate"], ["LA22025-3", "OR"], ["LA6750-9", "Severe"], ["LP93408-0", "during treatment"], ["LP15583-5", "Fumarate"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LP96203-2", "PML"], ["LP75708-5", "Symptoms"], ["LP74970-2", "Infections"], ["LP75708-5", "Symptoms"], ["LP96203-2", "PML"], ["LP75708-5", "Symptoms"], ["LP96203-2", "PML"], ["LA11011-6", "Worse"], ["LA8999-0", "Days"], ["LA9000-6", "Weeks"], ["LA25478-1", "Progressive"], ["LP75880-2", "Weakness"], ["LA6306-0", "One"], ["LP73349-0", "Side"], ["LA22025-3", "OR"], ["MTHU002838", "Limbs"], ["MTHU014733", "Vision"], ["LA22004-8", "IN"], ["LP75116-1", "Memory"], ["LP36328-0", "Confusion"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP96203-2", "PML"], ["LP200075-2", "IS"], ["LA15291-0", "Suspected"], ["LP94823-9", "Treatment"], ["LP89782-4", "Neurological"], ["LA19974-7", "Performed"], ["LA33028-4", "Prior"], ["LP94823-9", "Treatment"], ["LA22025-3", "OR"], ["LP75725-9", "Therapies"], ["LA6484-5", "Limited"], ["LA26687-6", "Efficacy"], ["LA17589-5", "Safety"], ["LA22004-8", "IN"], ["MTHU029809", "Other"], ["LA22025-3", "OR"], ["LP75725-9", "Therapies"], ["LP75725-9", "Therapies"], ["MTHU029809", "Other"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["MTHU013246", "Immune system"], ["LA32-8", "No"], ["LA26687-6", "Efficacy"], ["LA17589-5", "Safety"], ["MTHU029809", "Other"], ["LA22025-3", "OR"], ["LP75725-9", "Therapies"], ["LA15768-7", "4.5"], ["LP32605-5", "pre"], ["LA10532-2", "Gastrointestinal Disease"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP32605-5", "pre"], ["LA10532-2", "Gastrointestinal Disease"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA4216-3", "Contraindicated"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["LA10532-2", "Gastrointestinal Disease"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LA16968-2", "Gastrointestinal"], ["LA65-8", "Improved"], ["MTHU065481", "Dose"], ["LP94823-9", "Treatment"], ["LA6676-6", "Resistant"], ["LP136501-6", "Tablet"], ["LP15241-0", "S"], ["MTHU065486", "Food"], ["LP20592-9", "4"], ["MTHU000002", "Clinical Class"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP31398-8", "Renal function"], ["LA15459-3", "III"], ["LP7787-7", "Clinical"], ["LP74341-6", "Study"], ["LP31398-8", "Renal function"], ["LA21291-2", "Not"], ["LP267221-2", "Therapy"], ["LP94823-9", "Treatment"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["MTHU065909", "Renal"], ["LA14973-4", "Some"], ["LP270144-1", "Cases"], ["MTHU065909", "Renal"], ["LP6486-7", "Reported"], ["LP32606-3", "post"], ["LP200075-2", "IS"], ["LA4216-3", "Contraindicated"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["MTHU065909", "Renal"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LP31398-8", "Renal function"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["MTHU002337", "Creatinine"], ["MTHU029981", "Blood"], ["LP14492-0", "Urea nitrogen"], ["MTHU000144", "Urinalysis"], ["LA33028-4", "Prior"], ["LP94823-9", "Treatment"], ["LA18435-0", "3 months"], ["LA22004-8", "IN"], ["MTHU019184", "Event"], ["LP17763-1", "A"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["LP31398-8", "Renal function"], ["LA22004-8", "IN"], ["LA30091-5", "Alternative"], ["LP148736-4", "Explanations"], ["LP29256-2", "given"], ["MTHU065481", "Dose"], ["LP267357-4", "Reduction"], ["LA22025-3", "OR"], ["LP94823-9", "Treatment"], ["LA12111-3", "Early"], ["MTHU008876", "Diagnosis"], ["LP94823-9", "Treatment"], ["MTHU065909", "Renal"], ["LP200075-2", "IS"], ["LA14747-2", "Usually"], ["LA18970-6", "Proteinuria"], ["LA6626-1", "Normal"], ["MTHU029981", "Blood"], ["MTHU026696", "Sugar"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP75708-5", "Symptoms"], ["LA25323-9", "Polyuria"], ["LP234848-2", "Muscle"], ["LP75880-2", "Weakness"], ["LA22004-8", "IN"], ["LA15679-6", "Rare"], ["LP270144-1", "Cases"], ["LP74560-1", "Bone pain"], ["LA32146-5", "Elevated"], ["LA22004-8", "IN"], ["LP7567-3", "Serum"], ["LP207491-4", "Stress"], ["LA22219-2", "Fractures"], ["LA14161-6", "May"], ["LA32146-5", "Elevated"], ["MTHU002337", "Creatinine"], ["LA22025-3", "OR"], ["LA9194-7", "Low"], ["LP266917-6", "Glomerular filtration rate"], ["LA22004-8", "IN"], ["LP75708-5", "Symptoms"], ["LA19974-7", "Performed"], ["LA8916-4", "Function"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["LP200075-2", "IS"], ["LA4216-3", "Contraindicated"], ["LA22004-8", "IN"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA8916-4", "Function"], ["LP220552-6", "AP"], ["LA33028-4", "Prior"], ["LP94823-9", "Treatment"], ["LA18435-0", "3 months"], ["LA25349-4", "Elevation"], ["LP31392-1", "Enzymes (see also Inborn errors metabolism lysosomal)"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LA14973-4", "Some"], ["LA22004-8", "IN"], ["LA15459-3", "III"], ["LP74341-6", "Study"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA22004-8", "IN"], ["MTHU019184", "Event"], ["LP17763-1", "A"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LA30091-5", "Alternative"], ["LP148736-4", "Explanations"], ["LP29256-2", "given"], ["MTHU065481", "Dose"], ["LP267357-4", "Reduction"], ["LA22025-3", "OR"], ["LP94823-9", "Treatment"], ["LP20592-9", "4"], ["MTHU000002", "Clinical Class"], ["LA15587-1", "Likely"], ["LA22004-8", "IN"], ["LP6974-2", "first"], ["LA15680-4", "Few"], ["LA9000-6", "Weeks"], ["LP94823-9", "Treatment"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP32533-9", "Lactose"], ["LP32533-9", "Lactose"], ["LA15679-6", "Rare"], ["MTHU015041", "Hereditary"], ["LP15263-4", "Galactose"], ["LA6661-8", "Total"], ["LP207986-3", "Lactase"], ["LA22025-3", "OR"], ["MTHU001675", "Glucose"], ["LP15263-4", "Galactose"], ["LA21291-2", "Not"], ["LA16120-0", "Medicine"], ["LP15099-2", "Sodium"], ["LA16823-9", "Less"], ["LA6112-2", "1"], ["LP15099-2", "Sodium"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["LP200075-2", "IS"], ["LP15099-2", "Sodium"]], "snomed.pregnancy": [["373067005", "No (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["31099001", "Systemic (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["387467008", "Ciclosporin (substance)|Cyclosporine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["260676000", "Use of (attribute)"], ["74964007", "Other (qualifier value)"], ["102646006", "Fumaric acid (substance)"], ["359540000", "Topical (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["31099001", "Systemic (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["105590001", "Substance (substance)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["387467008", "Ciclosporin (substance)|Cyclosporine (substance)"], ["324116004", "Product containing aminoglycoside (product)|Aminoglycosides (product)|Aminoglycosides (substance)"], ["255387000", "Inflammatory|Inflammatory (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["321719003", "Lithium (product)|Lithium product (product)|Lithium product (substance)|Product containing lithium (medicinal product)|Product containing lithium (product)"], ["260366006", "Increase (qualifier value)"], ["86495002", "For (qualifier value)"], ["281647001", "Adverse reaction (disorder)|Adverse reactions (disorder)|Adverse reactions (finding)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["236719005", "Proteinuria [Ambiguous]|Proteinuria (disorder)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255224006", "Prolonged (qualifier value)"], ["162105005", "Diarrhoea (disorder)|Diarrhoea"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["74964007", "Other (qualifier value)"], ["247591002", "Affecting (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["134223000", "Narrow (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["18720000", "In (attribute)"], ["361358007", "Entire intestinal tract (body structure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["738956005", "Oral (intended site)"], ["108899006", "Contraceptives (product)|Medicinal product acting as contraceptive (product)|Contraceptives (substance)"], ["260400001", "Reduced (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["260686004", "Method (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["101445003", "PREVENT (substance)|PREVENT (product)"], ["371930009", "Possible (qualifier value)"], ["76797004", "Failure (finding)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["146680009", "Contraception|Contraception (finding)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["738956005", "Oral (intended site)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255509001", "Large (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["260404005", "Strong (qualifier value)"], ["228281002", "Problem drinker (life style)|Problem drinker (finding)"], ["226465004", "Drinks (substance)"], ["242762006", "More (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["53041004", "Substance with alcohol structure (substance)|Alcohol (substance)"], ["118565006", "Volume (property) (qualifier value)"], ["88488004", "Lead (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["260864003", "Frequency (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["281647001", "Adverse reaction (disorder)|Adverse reactions (disorder)|Adverse reactions (finding)"], ["33879002", "Administration of vaccine to produce active immunity (procedure)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["116680003", "Is a (attribute)"], ["80943009", "Risk factor (qualifier value)|Risk factor (observable entity)"], ["86495002", "For (qualifier value)"], ["260676000", "Use of (attribute)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["33879002", "Administration of vaccine to produce active immunity (procedure)"], ["65897001", "Against (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["41647002", "No evidence of (contextual qualifier) (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["424446007", "Cytochrome p450 enzyme (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["4757001", "Most (qualifier value)"], ["72906007", "Common (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["732766004", "5.2 (qualifier value)"]], "ncit.pregnancy": [["C159586", "Preoperative IV Sedation was Not Administered"], ["C54216", "Interaction"], ["C101282", "Have"], ["C38000", "Performed"], ["C16329", "Belgium"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C118472", "Other License Status"], ["C13310", "Systemic"], ["C49236", "Therapeutic Procedure"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C642", "Methotrexate"], ["C804", "Retinoic Acid Agent"], ["C406", "Cyclosporine"], ["C43508", "Oregon"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C175242", "During Treatment"], ["C25456", "Concurrent"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C118472", "Other License Status"], ["C63655", "Fumaric Acid"], ["C13344", "Topical"], ["C43508", "Oregon"], ["C13310", "Systemic"], ["C16329", "Belgium"], ["C15212", "Multimodality Therapy"], ["C62355", "With"], ["C28368", "Nephrotoxic"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C642", "Methotrexate"], ["C406", "Cyclosporine"], ["C2363", "Aminoglycoside Antibiotic"], ["C448", "Diuretic"], ["C14460", "NON Mouse"], ["C256", "Anti-Inflammatory Agent"], ["C257", "Nonsteroidal Antiinflammatory Drug"], ["C43508", "Oregon"], ["C1318", "Lithium Carbonate"], ["C106184", "May"], ["C25533", "Increase"], ["C62230", "Potential"], ["C64956", "For"], ["C25225", "Renal"], ["C188368", "ELN Adverse-Risk Category"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C38012", "Proteinuria"], ["C16727", "India"], ["C16960", "Patient"], ["C16727", "India"], ["C52874", "SPI1 wt Allele"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C43508", "Oregon"], ["C149870", "Prolonged Release Mechanism of Action"], ["C175242", "During Treatment"], ["C62355", "With"], ["C71731", "Material Absorption"], ["C52874", "SPI1 wt Allele"], ["C118472", "Other License Status"], ["C106184", "May"], ["C16329", "Belgium"], ["C64917", "Affected"], ["C16329", "Belgium"], ["C65140", "When"], ["C154633", "Prescribing Domain"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C120270", "Narrow Therapeutic Index"], ["C71731", "Material Absorption"], ["C16727", "India"], ["C9157", "Gastric Intestinal-Type Adenocarcinoma"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C25311", "Oral"], ["C106184", "May"], ["C16329", "Belgium"], ["C25640", "Reduced"], ["C16289", "Andorra"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C75889", "PAX6 wt Allele"], ["C97927", "Gene Variant"], ["C49838", "Barrier Device"], ["C42734", "Contraceptive Device"], ["C85492", "CDISC SDTM Method Terminology"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C25745", "Failure"], ["C52874", "SPI1 wt Allele"], ["C37932", "Contraception"], ["C163702", "Staphylococcal Enterotoxin E"], ["C154633", "Prescribing Domain"], ["C48191", "Information"], ["C52874", "SPI1 wt Allele"], ["C25311", "Oral"], ["C42734", "Contraceptive Device"], ["C66716", "Consumption of Goods"], ["C52874", "SPI1 wt Allele"], ["C49508", "Large"], ["C52874", "SPI1 wt Allele"], ["C62223", "Strong"], ["C167414", "Pet Drinks Adequately"], ["C61584", "Greater Than"], ["C70541", "Lansky Performance Status 30"], ["C74693", "Ethanol Measurement"], ["C158169", "Buyei Chinese"], ["C74720", "Volume Measurement"], ["C16329", "Belgium"], ["C38267", "Intrathecal Route of Administration"], ["C106184", "May"], ["C25552", "Lead"], ["C159124", "GDC Treatment Outcome Terminology"], ["C164135", "Increased"], ["C113023", "Dissolution Mixing"], ["C52874", "SPI1 wt Allele"], ["C16289", "Andorra"], ["C106184", "May"], ["C25533", "Increase"], ["C71113", "CDISC SDTM Frequency Terminology"], ["C52874", "SPI1 wt Allele"], ["C53802", "Adverse Event Associated with the Gastrointestinal System"], ["C188368", "ELN Adverse-Risk Category"], ["C15346", "Vaccination"], ["C175242", "During Treatment"], ["C62355", "With"], ["C101282", "Have"], ["C25594", "Negation"], ["C15261", "Immunosuppressive Therapy"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C17103", "Risk Factor"], ["C64956", "For"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C89279", "Reside"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C15346", "Vaccination"], ["C16329", "Belgium"], ["C64937", "Against"], ["C25387", "Benefit"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43583", "Evidence"], ["C64956", "For"], ["C54216", "Interaction"], ["C62355", "With"], ["C16484", "Cytochrome P450"], ["C16289", "Andorra"], ["C25258", "Most"], ["C43461", "Common"], ["C16289", "Andorra"], ["C71688", "Uptake"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C68869", "Are"], ["C41333", "Expected Adverse Event"], ["C62355", "With"], ["C43508", "Oregon"], ["C158169", "Buyei Chinese"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"]], "rxnorm.pregnancy": [["6851", "methotrexate"], ["25389", "fumaric acid"], ["6851", "methotrexate"], ["6448", "lithium"], ["6260", "lead"]], "loinc.pregnancy": [["LA32-8", "No"], ["LA19974-7", "Performed"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["MTHU029809", "Other"], ["LP267221-2", "Therapy"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP16198-1", "Methotrexate"], ["LA22025-3", "OR"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP93408-0", "during treatment"], ["MTHU029809", "Other"], ["LA9456-0", "Topical"], ["LA22025-3", "OR"], ["LP267221-2", "Therapy"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP16198-1", "Methotrexate"], ["MTHU003217", "Diuretics"], ["LP18046-0", "Drugs"], ["LP31430-9", "NSAIDS"], ["LA22025-3", "OR"], ["MTHU004197", "Lithium"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["MTHU065909", "Renal"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LA18970-6", "Proteinuria"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LP270144-1", "Cases"], ["LA6750-9", "Severe"], ["LA22025-3", "OR"], ["LP93408-0", "during treatment"], ["MTHU029809", "Other"], ["LA14161-6", "May"], ["LP17763-1", "A"], ["LA9191-3", "Narrow"], ["LP263807-2", "Therapeutic"], ["LA22004-8", "IN"], ["LA26027-5", "Intestinal"], ["LA26687-6", "Efficacy"], ["LA9367-9", "Oral"], ["LA14161-6", "May"], ["LA32619-1", "Reduced"], ["LA30091-5", "Alternative"], ["LP72939-9", "Method"], ["LP200075-2", "IS"], ["LA15097-1", "Possible"], ["LA9664-9", "Failure"], ["LA9367-9", "Oral"], ["LA8981-8", "Large"], ["LA14974-2", "Strong"], ["LA16824-7", "More"], ["LA15246-4", "30%"], ["LA28139-6", "Alcohol"], ["MTHU003070", "Volume"], ["LP200077-8", "IT"], ["LA14161-6", "May"], ["LP14259-3", "Lead"], ["LA24377-6", "Increased"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["MTHU029777", "Frequency"], ["LA16968-2", "Gastrointestinal"], ["LP93408-0", "during treatment"], ["LA21291-2", "Not"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LA20283-0", "Vaccines"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LP209065-4", "Uptake"], ["LA32-8", "No"], ["LA22025-3", "OR"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"]], "snomed.driving": [["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["410601007", "Childhood age person (person)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["410601007", "Childhood age person (person)"], ["261583007", "Using (attribute)"], ["146680009", "Contraception|Contraception (finding)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["181246003", "Entire stomach (body structure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1255345008", "Intestinal (intended site)"], ["255403003", "Effectiveness (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["738956005", "Oral (intended site)"], ["108899006", "Contraceptives (product)|Medicinal product acting as contraceptive (product)|Contraceptives (substance)"], ["732729005", "4.5 (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["260676000", "Use of (attribute)"], ["724035008", "Dimethyl fumarate (substance)"], ["18720000", "In (attribute)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["387961004", "Kingdom Animalia (organism)"], ["75478009", "Poisoning (disorder)"], ["769082003", "5.3 (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410536001", "Contraindicated (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["732725004", "4.3 (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["261665006", "Unknown (qualifier value)"], ["724035008", "Dimethyl fumarate (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["226789007", "Breast milk (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410536001", "Contraindicated (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["732725004", "4.3 (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["373067005", "No (qualifier value)"], ["338930006", "Human (organism)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["387961004", "Kingdom Animalia (organism)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420862001", "On (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"]], "ncit.driving": [["C52874", "SPI1 wt Allele"], ["C150886", "Child Relation"], ["C49842", "Bearing Device"], ["C62230", "Potential"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C16727", "India"], ["C52874", "SPI1 wt Allele"], ["C150886", "Child Relation"], ["C49842", "Bearing Device"], ["C62230", "Potential"], ["C25594", "Negation"], ["C37932", "Contraception"], ["C25406", "Additional"], ["C42734", "Contraceptive Device"], ["C16847", "Technique"], ["C16727", "India"], ["C49152", "Case"], ["C52874", "SPI1 wt Allele"], ["C12391", "Stomach"], ["C16289", "Andorra"], ["C9157", "Gastric Intestinal-Type Adenocarcinoma"], ["C142522", "Effectiveness"], ["C52874", "SPI1 wt Allele"], ["C389", "Oral Contraceptive"], ["C16329", "Belgium"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C191656", "Pregnant Subject"], ["C68869", "Are"], ["C142988", "Limited"], ["C25474", "Data"], ["C25516", "From"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C63670", "Dimethyl Fumarate"], ["C16727", "India"], ["C73435", "Gravida"], ["C14182", "Animal"], ["C101282", "Have"], ["C17087", "Reproduction"], ["C27990", "Toxicity"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C37933", "Contraindicated"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C160764", "Unknown Molecular Analysis"], ["C63670", "Dimethyl Fumarate"], ["C43508", "Oregon"], ["C79395", "Other Toxicity Studies: Metabolites"], ["C68869", "Are"], ["C16727", "India"], ["C14225", "Human"], ["C13257", "Mammary Gland Milk"], ["C76246", "Blood Group A"], ["C17102", "Risk"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C16329", "Belgium"], ["C82931", "Exclusion"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C37933", "Contraindicated"], ["C25490", "During"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C95089", "Fertility Domain"], ["C68869", "Are"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C14225", "Human"], ["C43508", "Oregon"], ["C14182", "Animal"], ["C25474", "Data"], ["C92667", "SPARC wt Allele"], ["C25492", "Effect"], ["C52874", "SPI1 wt Allele"], ["C92667", "SPARC wt Allele"], ["C95089", "Fertility Domain"]], "rxnorm.driving": [["1373478", "dimethyl fumarate"], ["T008", "Animal"], ["1373478", "dimethyl fumarate"], ["T016", "Human"], ["T016", "Human"], ["T008", "Animal"]], "loinc.driving": [["LA9949-4", "Child"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA22004-8", "IN"], ["LA9949-4", "Child"], ["LA21291-2", "Not"], ["LP263791-8", "Additional"], ["LA22004-8", "IN"], ["MTHU003059", "Stomach"], ["LA26027-5", "Intestinal"], ["LA9367-9", "Oral"], ["LA15768-7", "4.5"], ["LP207970-7", "Pregnancy"], ["LA6484-5", "Limited"], ["LP15583-5", "Fumarate"], ["LA22004-8", "IN"], ["LA29507-3", "Pregnant women"], ["LA30681-3", "Animal"], ["LA18285-9", "Reproductive"], ["LP20593-7", "5"], ["LP20591-1", "3"], ["LP200075-2", "IS"], ["LA4216-3", "Contraindicated"], ["LP266032-4", "during pregnancy"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA4489-6", "Unknown"], ["LP15583-5", "Fumarate"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LA19711-3", "Human"], ["LP29290-1", "Milk"], ["LP17763-1", "A"], ["LA22025-3", "OR"], ["LP200075-2", "IS"], ["LA4216-3", "Contraindicated"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["MTHU000074", "Fertility"], ["LA32-8", "No"], ["LA19711-3", "Human"], ["LA22025-3", "OR"], ["LA30681-3", "Animal"], ["MTHU000074", "Fertility"]], "snomed.side_effects": [["422097006", "Upper case Roman letter A (qualifier value)"], ["410599005", "Minor (person)"], ["420862001", "On (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["247750002", "Drive (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["404640003", "Dizziness (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["139126000", "Fatigue (finding)|Fatigue"], ["255260001", "Following (attribute)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732732008", "4.8 (qualifier value)"]], "ncit.side_effects": [["C106184", "May"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C45367", "Minor"], ["C121660", "Influence"], ["C92667", "SPARC wt Allele"], ["C121232", "Ability to Drive"], ["C16289", "Andorra"], ["C25340", "Use"], ["C125409", "Have Dizziness"], ["C16289", "Andorra"], ["C122347", "Fatigue Subordinate Domain"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C53286", "Next"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"]], "rxnorm.side_effects": [], "loinc.side_effects": [["LA14161-6", "May"], ["LP17763-1", "A"], ["LA29633-7", "Minor"], ["LA7428-1", "Dizziness"], ["MTHU013358", "Fatigue"], ["LA14161-6", "May"], ["LP20592-9", "4"], ["LP36791-9", "8"]], "snomed.shelf_life": [["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258707000", "year (qualifier value)"]], "ncit.shelf_life": [["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C29848", "Year"]], "rxnorm.shelf_life": [], "loinc.shelf_life": [["LA31720-8", "3 years"]], "snomed.storage": [["763158003", "Medicinal product (product)"], ["717896003", "Does not (qualifier value)"], ["67995009", "Special (qualifier value)"], ["440276004", "Storage (procedure)"], ["1222741009", "American Joint Committee on Cancer stage I:4 (qualifier value)"]], "ncit.storage": [["C142605", "Medicinal Product"], ["C86066", "Do"], ["C25594", "Negation"], ["C81168", "Any"], ["C101704", "Special Storage Condition"], ["C113428", "Fourteen"]], "rxnorm.storage": [], "loinc.storage": [["LA21291-2", "Not"], ["LA14560-9", "14"]], "snomed.package": [["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["30714006", "Resistant (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["1222845008", "American Joint Committee on Cancer stage IV:2 (qualifier value)"], ["732853007", "70 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222783004", "American Joint Committee on Cancer stage II:10 (qualifier value)"], ["30714006", "Resistant (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["18720000", "In (attribute)"], ["35233000", "Polyvinyl chloride (substance)"], ["255977005", "Aluminum material (substance)"], ["732984005", "Blister (unit of presentation)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["30714006", "Resistant (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["732853007", "70 (qualifier value)"], ["732899009", "90 (qualifier value)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["732554007", "180 (qualifier value)"], ["725123003", "200 (qualifier value)"], ["732608008", "240 (qualifier value)"], ["725125005", "300 (qualifier value)"], ["732700008", "360 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732733003", "400 (qualifier value)"], ["30714006", "Resistant (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["18720000", "In (attribute)"], ["35233000", "Polyvinyl chloride (substance)"], ["255977005", "Aluminum material (substance)"], ["732984005", "Blister (unit of presentation)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["257260002", "Pack (physical object)"]], "ncit.package": [["C70541", "Lansky Performance Status 30"], ["C16818", "Mammography"], ["C128681", "CDISC SDTM Gastrointestinal Test Name Terminology"], ["C41546", "Resistance Process"], ["C175676", "Forty Two"], ["C105790", "Seventy"], ["C16289", "Andorra"], ["C128681", "CDISC SDTM Gastrointestinal Test Name Terminology"], ["C41546", "Resistance Process"], ["C16727", "India"], ["C10268", "Cisplatin/Cyclophosphamide/Etoposide"], ["C43168", "Blister Pack"], ["C62653", "Pack Dosage Form"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C128681", "CDISC SDTM Gastrointestinal Test Name Terminology"], ["C41546", "Resistance Process"], ["C105795", "Forty"], ["C105790", "Seventy"], ["C182728", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 90"], ["C105814", "One Hundred"], ["C192184", "One Hundred Twenty"], ["C17266", "Congo, the Democratic Republic of the"], ["C159711", "Two Hundred"], ["C16645", "Greece"], ["C16728", "Indonesia"], ["C16289", "Andorra"], ["C16765", "Jordan"], ["C128681", "CDISC SDTM Gastrointestinal Test Name Terminology"], ["C41546", "Resistance Process"], ["C16727", "India"], ["C10268", "Cisplatin/Cyclophosphamide/Etoposide"], ["C43168", "Blister Pack"], ["C62653", "Pack Dosage Form"], ["C25594", "Negation"], ["C64916", "All"], ["C84731", "Packing"], ["C106184", "May"], ["C16329", "Belgium"]], "rxnorm.package": [["746839", "Pack"]], "loinc.package": [["LA28855-7", "30"], ["LP15217-0", "Mg"], ["LA6676-6", "Resistant"], ["LA6676-6", "Resistant"], ["LA22004-8", "IN"], ["LA19024-1", "Blister"], ["LA32059-0", "120"], ["LP15217-0", "Mg"], ["LA6676-6", "Resistant"], ["LA28858-1", "40"], ["LA28891-2", "90"], ["LA19244-5", "100"], ["LA32059-0", "120"], ["LA14008-9", "400"], ["LA6676-6", "Resistant"], ["LA22004-8", "IN"], ["LA19024-1", "Blister"], ["LA21291-2", "Not"], ["LA18187-7", "All"], ["LA14161-6", "May"]], "snomed.marketing_authorization_numbers": [["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"]], "ncit.marketing_authorization_numbers": [["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113431", "Seventeen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113431", "Seventeen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113431", "Seventeen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113431", "Seventeen"], ["C16267", "Afghanistan"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113431", "Seventeen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113431", "Seventeen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113431", "Seventeen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113431", "Seventeen"], ["C16271", "Albania"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113431", "Seventeen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113431", "Seventeen"], ["C18007", "Antarctica"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113431", "Seventeen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113431", "Seventeen"], ["C16274", "Algeria"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113431", "Seventeen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113431", "Seventeen"]], "rxnorm.marketing_authorization_numbers": [], "loinc.marketing_authorization_numbers": [["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"]]}, {"product_info": "Humira 20 mg solution for injection in pre-filled syringe", "composition": "Each 0.2 ml single dose pre-filled syringe contains 20 mg of adalimumab. \nAdalimumab is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary cells.\nFor the full list of excipients, see section 6.1.", "indications": "Juvenile idiopathic arthritis\nPolyarticular juvenile idiopathic arthritis\nHumira in combination with methotrexate is indicated for the treatment of active polyarticular juvenile \nidiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or \nmore disease-modifying anti-rheumatic drugs (DMARDs). Humira can be given as monotherapy in case \nof intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the \nefficacy in monotherapy see section 5.1). Humira has not been studied in patients aged less than 2 years.\nEnthesitis-related arthritis\nHumira is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and \nolder, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section \n5.1).\nPaediatric plaque psoriasis\nHumira is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from \n4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy \nand phototherapies.\nPaediatric Crohn's disease \nHumira is indicated for the treatment of moderately to severely active Crohn's disease in paediatric \npatients (from 6 years of age) who have had an inadequate response to conventional therapy including \nprimary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or \nhave contraindications for such therapies.\nPaediatric Uveitis\nHumira is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from \n2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in \nwhom conventional therapy is inappropriate.", "posology": "Humira treatment should be initiated and supervised by specialist physicians experienced in the diagnosis \nand treatment of conditions for which Humira is indicated. Ophthalmologists are advised to consult with \nan appropriate specialist before initiation of treatment with Humira (see section 4.4). Patients treated with \nHumira should be given the Patient Reminder Card.\nAfter proper training in injection technique, patients may self-inject with Humira if their physician \ndetermines that it is appropriate and with medical follow-up as necessary. \nDuring treatment with Humira, other concomitant therapies (e.g., corticosteroids and/or \nimmunomodulatory agents) should be optimised.\nPosology\nPaediatric population\nJuvenile idiopathic arthritis\nPolyarticular juvenile idiopathic arthritis from 2 years of age\nThe recommended dose of Humira for patients with polyarticular juvenile idiopathic arthritis from 2 years \nof age is based on body weight (Table 1). Humira is administered every other week via subcutaneous \ninjection.\nTable 1. Humira Dose for Patients with Polyarticular Juvenile Idiopathic Arthritis \nPatient Weight\nDosing Regimen\n10 kg to < 30 kg\n20 mg every other week\n\u2265 30 kg\n40 mg every other week\nAvailable data suggest that clinical response is usually achieved within 12 weeks of treatment. Continued \ntherapy should be carefully reconsidered in a patient not responding within this time period.\nThere is no relevant use of Humira in patients aged less than 2 years for this indication.\nHumira may be available in other strengths and/or presentations depending on the individual treatment \nneeds.\nEnthesitis-related arthritis\nThe recommended dose of Humira for patients with enthesitis-related arthritis from 6 years of age is based \non body weight (Table 2). Humira is administered every other week via subcutaneous injection.\nTable 2. Humira Dose for Patients with Enthesitis-Related Arthritis \nPatient Weight\nDosing Regimen\n15 kg to < 30 kg\n20 mg every other week\n\u2265 30 kg\n40 mg every other week\nHumira has not been studied in patients with enthesitis-related arthritis aged less than 6 years.\nHumira may be available in other strengths and/or presentations depending on the individual treatment \nneeds.\nPaediatric plaque psoriasis\nThe recommended Humira dose for patients with plaque psoriasis from 4 to 17 years of age is based on \nbody weight (Table 3). Humira is administered via subcutaneous injection.\nTable 3. Humira Dose for Paediatric Patients with Plaque Psoriasis \nPatient Weight\nDosing Regimen\n15 kg to < 30 kg\nInitial dose of 20 mg, followed by \n20 mg given every other week \nstarting one week after the initial \ndose\n\u2265 30 kg\nInitial dose of 40 mg, followed by \n40 mg given every other week \nstarting one week after the initial \ndose\nContinued therapy beyond 16 weeks should be carefully considered in a patient not responding within this \ntime period.\nIf retreatment with Humira is indicated, the above guidance on dose and treatment duration should be \nfollowed.\nThe safety of Humira in paediatric patients with plaque psoriasis has been assessed for a mean of \n13 months.\nThere is no relevant use of Humira in children aged less than 4 years for this indication.\nHumira may be available in other strengths and/or presentations depending on the individual treatment \nneeds.\nPaediatric Crohn's disease\nThe recommended dose of Humira for patients with Crohn\u2019s disease from 6 to 17 years of age is based on \nbody weight (Table 4). Humira is administered via subcutaneous injection.\nTable 4. Humira Dose for Paediatric Patients with Crohn\u2019s disease\nPatient \nWeight\nInduction Dose\nMaintenance \nDose\nStarting at\nWeek 4\n< 40 kg\n 40 mg at week 0 and 20 mg at week 2\nIn case there is a need for a more rapid response to therapy with the \nawareness that the risk for adverse events may be higher with use of the \nhigher induction dose, the following dose may be used:\n 80 mg at week 0 and 40 mg at week 2\n20 mg every \nother week\n\u2265 40 kg\n 80 mg at week 0 and 40 mg at week 2\nIn case there is a need for a more rapid response to therapy with the \nawareness that the risk for adverse events may be higher with use of the \nhigher induction dose, the following dose may be used:\n 160 mg at week 0 and 80 mg at week 2\n40 mg every \nother week\nPatients who experience insufficient response may benefit from an increase in dosage:\n< 40 kg: 20 mg every week\n\u2265 40 kg: 40 mg every week or 80 mg every other week\nContinued therapy should be carefully considered in a subject not responding by week 12.\nThere is no relevant use of Humira in children aged less than 6 years for this indication.\nHumira may be available in other strengths and/or presentations depending on the individual treatment \nneeds.\nPaediatric Uveitis\nThe recommended dose of Humira for paediatric patients with uveitis from 2 years of age is based on \nbody weight (Table 5). Humira is administered via subcutaneous injection.\nIn paediatric uveitis, there is no experience in the treatment with Humira without concomitant treatment \nwith methotrexate.\nTable 5. Humira Dose for Paediatric Patients with Uveitis\nPatient Weight\nDosing Regimen\n< 30 kg\n20 mg every other week in \ncombination with methotrexate\n\u2265 30 kg\n40 mg every other week in \ncombination with methotrexate\nWhen Humira therapy is initiated, a loading dose of 40 mg for patients < 30 kg or 80 mg for patients \n\u2265 30 kg may be administered one week prior to the start of maintenance therapy. No clinical data are \navailable on the use of a Humira loading dose in children < 6 years of age (see section 5.2).\nThere is no relevant use of Humira in children aged less than 2 years in this indication.\nIt is recommended that the benefit and risk of continued long-term treatment should be evaluated on a \nyearly basis (see section 5.1).\nHumira may be available in other strengths and/or presentations depending on the individual treatment \nneeds.\nRenal and/or hepatic impairment\nHumira has not been studied in these patient populations. No dose recommendations can be made.\nMethod of administration\nHumira is administered by subcutaneous injection. Full instructions for use are provided in the package \nleaflet.\nHumira is available in other strengths and presentations.", "contraindications": "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. \nActive tuberculosis or other severe infections such as sepsis and opportunistic infections (see section 4.4).\nModerate to severe heart failure (NYHA class III/IV) (see section 4.4).", "special_warnings": "Traceability\nIn order to improve traceability of biological medicinal products, the name and the batch number of the \nadministered product should be clearly recorded.\nInfections\nPatients taking TNF -antagonists are more susceptible to serious infections. Impaired lung function may \nincrease the risk for developing infections. Patients must therefore be monitored closely for infections, \nincluding tuberculosis, before, during and after treatment with Humira. Because the elimination of \nadalimumab may take up to four months, monitoring should be continued throughout this period.\nTreatment with Humira should not be initiated in patients with active infections including chronic or \nlocalised infections until infections are controlled. In patients who have been exposed to tuberculosis and \npatients who have travelled in areas of high risk of tuberculosis or endemic mycoses, such as \nhistoplasmosis, coccidioidomycosis, or blastomycosis, the risk and benefits of treatment with Humira \nshould be considered prior to initiating therapy (see \nOther opportunistic infections\nPatients who develop a new infection while undergoing treatment with Humira should be monitored \nclosely and undergo a complete diagnostic evaluation. Administration of Humira should be discontinued if \na patient develops a new serious infection or sepsis and appropriate antimicrobial or antifungal therapy \nshould be initiated until the infection is controlled. Physicians should exercise caution when considering \nthe use of Humira in patients with a history of recurring infection or with underlying conditions which \nmay predispose patients to infections, including the use of concomitant immunosuppressive medications.\nSerious infections\nSerious infections, including sepsis, due to bacterial, mycobacterial, invasive fungal, parasitic, viral, or \nother opportunistic infections such as listeriosis, legionellosis and pneumocystis have been reported in \npatients receiving Humira.  \nOther serious infections seen in clinical trials include pneumonia, pyelonephritis, septic arthritis and \nsepticaemia. Hospitalisation or fatal outcomes associated with infections have been reported. \nTuberculosis\nTuberculosis, including reactivation and new onset of tuberculosis, has been reported in patients receiving \nHumira. Reports included cases of pulmonary and extra-pulmonary (i.e. disseminated) tuberculosis. \nBefore initiation of therapy with Humira, all patients must be evaluated for both active or inactive \n(\u201clatent\u201d) tuberculosis infection. This evaluation should include a detailed medical assessment of patient \nhistory of tuberculosis or possible previous exposure to people with active tuberculosis and previous \nand/or current immunosuppressive therapy. Appropriate screening tests (i.e. tuberculin skin test and chest \nX-ray) should be performed in all patients (local recommendations may apply). It is recommended that the \nconduct and results of these tests are recorded in the Patient Reminder Card. Prescribers are reminded of \nthe risk of false negative tuberculin skin test results, especially in patients who are severely ill or \nimmunocompromised. \nIf active tuberculosis is diagnosed, Humira therapy must not be initiated (see section 4.3). \nIn all situations described below, the benefit/risk balance of therapy should be very carefully considered.\nIf latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be \nconsulted.\nIf latent tuberculosis is diagnosed, appropriate treatment must be started with anti-tuberculosis prophylaxis \ntreatment before the initiation of Humira and in accordance with local recommendations. \nUse of anti-tuberculosis prophylaxis treatment should also be considered before the initiation of Humira in \npatients with several or significant risk factors for tuberculosis despite a negative test for tuberculosis and \nin patients with a past history of latent or active tuberculosis in whom an adequate course of treatment \ncannot be confirmed.  \nDespite prophylactic treatment for tuberculosis, cases of reactivated tuberculosis have occurred in patients \ntreated with Humira. Some patients who have been successfully treated for active tuberculosis have \nredeveloped tuberculosis while being treated with Humira.\nPatients should be instructed to seek medical advice if signs/symptoms suggestive of a tuberculosis \ninfection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after \ntherapy with Humira. \nOther opportunistic infections\nOpportunistic infections, including invasive fungal infections have been observed in patients receiving \nHumira. These infections have not consistently been recognised in patients taking TNF-antagonists and \nthis has resulted in delays in appropriate treatment, sometimes resulting in fatal outcomes. \nFor patients who develop the signs and symptoms such as fever, malaise, weight loss, sweats, cough, \ndyspnoea, and/or pulmonary infiltrates or other serious systemic illness with or without concomitant shock \nan invasive fungal infection should be suspected and administration of Humira should be promptly \ndiscontinued. Diagnosis and administration of empiric antifungal therapy in these patients should be made \nin consultation with a physician with expertise in the care of patients with invasive fungal infections. \nHepatitis B reactivation\nReactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including Humira, who are \nchronic carriers of this virus (i.e. surface antigen positive). Some cases have had a fatal outcome. Patients \nshould be tested for HBV infection before initiating treatment with Humira. For patients who test positive \nfor hepatitis B infection, consultation with a physician with expertise in the treatment of hepatitis B is \nrecommended.\nCarriers of HBV who require treatment with Humira should be closely monitored for signs and symptoms \nof active HBV infection throughout therapy and for several months following termination of therapy. \nAdequate data from treating patients who are carriers of HBV with anti-viral therapy in conjunction with \nTNF-antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV \nreactivation, Humira should be stopped and effective anti-viral therapy with appropriate supportive \ntreatment should be initiated. \nNeurological events \nTNF-antagonists including Humira have been associated in rare instances with new onset or exacerbation \nof clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease \nincluding multiple sclerosis and optic neuritis, and peripheral demyelinating disease, including Guillain-\nBarr\u00e9 syndrome. Prescribers should exercise caution in considering the use of Humira in patients with pre-\nexisting or recent-onset central or peripheral nervous system demyelinating disorders; discontinuation of \nHumira should be considered if any of these disorders develop. There is a known association between \nintermediate uveitis and central demyelinating disorders. Neurologic evaluation should be performed in \npatients with non-infectious intermediate uveitis prior to the initiation of Humira therapy and regularly \nduring treatment to assess for pre-existing or developing central demyelinating disorders. \nAllergic reactions\nSerious allergic reactions associated with Humira were rare during clinical trials. Non-serious allergic \nreactions associated with Humira were uncommon during clinical trials. Reports of serious allergic \nreactions including anaphylaxis have been received following Humira administration. If an anaphylactic \nreaction or other serious allergic reaction occurs, administration of Humira should be discontinued \nimmediately and appropriate therapy initiated. \nImmunosuppression\nIn a study of 64 patients with rheumatoid arthritis that were treated with Humira, there was no evidence of \ndepression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in \nenumeration of effector T-, B-, NK-cells, monocyte/macrophages, and neutrophils.\nMalignancies and lymphoproliferative disorders\nIn the controlled portions of clinical trials of TNF-antagonists, more cases of malignancies including \nlymphoma have been observed among patients receiving a TNF-antagonist compared with control \npatients. However, the occurrence was rare. In the post marketing setting, cases of leukaemia have been \nreported in patients treated with a TNF-antagonist. There is an increased background risk for lymphoma \nand leukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, \nwhich complicates the risk estimation. With the current knowledge, a possible risk for the development of \nlymphomas, leukaemia, and other malignancies in patients treated with a TNF-antagonist cannot be \nexcluded.\nMalignancies, some fatal, have been reported among children, adolescents and young adults (up to \n22 years of age) treated with TNF-antagonists (initiation of therapy \u2264 18 years of age), including \nadalimumab in the post marketing setting. Approximately half the cases were lymphomas. The other cases \nrepresented a variety of different malignancies and included rare malignancies usually associated with \nimmunosuppression. A risk for the development of malignancies in children and adolescents treated with \nTNF-antagonists cannot be excluded. \nRare postmarketing cases of hepatosplenic T-cell lymphoma have been identified in patients treated with \nadalimumab. This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal. \nSome of these hepatosplenic T-cell lymphomas with Humira have occurred in young adult patients on \nconcomitant treatment with azathioprine or 6-mercaptopurine used for inflammatory bowel disease. The \npotential risk with the combination of azathioprine or 6-mercaptopurine and Humira should be carefully \nconsidered. A risk for the development of hepatosplenic T-cell lymphoma in patients treated with Humira \ncannot be excluded (see section 4.8).\nNo studies have been conducted that include patients with a history of malignancy or in whom treatment \nwith Humira is continued following development of malignancy. Thus, additional caution should be \nexercised in considering Humira treatment of these patients (see section 4.8).\nAll patients, and in particular patients with a medical history of extensive immunosuppressant therapy or \npsoriasis patients with a history of PUVA treatment should be examined for the presence of non-\nmelanoma skin cancer prior to and during treatment with Humira. Melanoma and Merkel cell carcinoma \nhave also been reported in patients treated with TNF-antagonists including adalimumab (see section 4.8).\nIn an exploratory clinical trial evaluating the use of another TNF-antagonist, infliximab, in patients with \nmoderate to severe chronic obstructive pulmonary disease (COPD), more malignancies, mostly in the lung \nor head and neck, were reported in infliximab-treated patients compared with control patients. All patients \nhad a history of heavy smoking. Therefore, caution should be exercised when using any TNF-antagonist in \nCOPD patients, as well as in patients with increased risk for malignancy due to heavy smoking.\nWith current data it is not known if adalimumab treatment influences the risk for developing dysplasia or \ncolon cancer. All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma \n(for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had \na prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before \ntherapy and throughout their disease course. This evaluation should include colonoscopy and biopsies per \nlocal recommendations.\nHaematologic reactions\nRare reports of pancytopenia including aplastic anaemia have been reported with TNF-antagonists.  \nAdverse events of the haematologic system, including medically significant cytopenia (e.g. \nthrombocytopenia, leukopenia) have been reported with Humira. All patients should be advised to seek \nimmediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. \npersistent fever, bruising, bleeding, pallor) while on Humira. Discontinuation of Humira therapy should be \nconsidered in patients with confirmed significant haematologic abnormalities.\nVaccinations \nSimilar antibody responses to the standard 23-valent pneumococcal vaccine and the influenza trivalent \nvirus vaccination were observed in a study in 226 adult subjects with rheumatoid arthritis who were \ntreated with adalimumab or placebo. No data are available on the secondary transmission of infection by \nlive vaccines in patients receiving Humira.  \nIt is recommended that paediatric patients, if possible, be brought up to date with all immunisations in \nagreement with current immunisation guidelines prior to initiating Humira therapy.\nPatients on Humira may receive concurrent vaccinations, except for live vaccines. Administration of live \nvaccines (e.g., BCG vaccine) to infants exposed to adalimumab in utero is not recommended for 5 months \nfollowing the mother\u2019s last adalimumab injection during pregnancy.\nCongestive heart failure\nIn a clinical trial with another TNF-antagonist worsening congestive heart failure and increased mortality \ndue to congestive heart failure have been observed. Cases of worsening congestive heart failure have also \nbeen reported in patients receiving Humira. Humira should be used with caution in patients with mild \nheart failure (NYHA class I/II). Humira is contraindicated in moderate to severe heart failure (see section \n4.3). Treatment with Humira must be discontinued in patients who develop new or worsening symptoms \nof congestive heart failure.\nAutoimmune processes\nTreatment with Humira may result in the formation of autoimmune antibodies. The impact of long-term \ntreatment with Humira on the development of autoimmune diseases is unknown. If a patient develops \nsymptoms suggestive of a lupus-like syndrome following treatment with Humira and is positive for \nantibodies against double-stranded DNA, further treatment with Humira should not be given (see section \n4.8).\nConcurrent administration of biologic DMARDS or TNF-antagonists\nSerious infections were seen in clinical studies with concurrent use of anakinra and another \nTNF-antagonist, etanercept, with no added clinical benefit compared to etanercept alone. Because of the \nnature of the adverse events seen with the combination of etanercept and anakinra therapy, similar \ntoxicities may also result from the combination of anakinra and other TNF-antagonists. Therefore, the \ncombination of adalimumab and anakinra is not recommended. (See section 4.5).\nConcomitant administration of adalimumab with other biologic DMARDS (e.g, anakinra and abatacept) or \nother TNF-antagonists is not recommended based upon the possible increased risk for infections, \nincluding serious infections and other potential pharmacological interactions. (See section 4.5).\nSurgery\nThere is limited safety experience of surgical procedures in patients treated with Humira. The long half-\nlife of adalimumab should be taken into consideration if a surgical procedure is planned. A patient who \nrequires surgery while on Humira should be closely monitored for infections, and appropriate actions \nshould be taken. There is limited safety experience in patients undergoing arthroplasty while receiving \nHumira. \nSmall bowel obstruction\nFailure to respond to treatment for Crohn\u2019s disease may indicate the presence of fixed fibrotic stricture \nthat may require surgical treatment. Available data suggest that Humira does not worsen or cause \nstrictures.\nElderly\nThe frequency of serious infections among Humira treated subjects over 65 years of age (3.7%) was \nhigher than for those under 65 years of age (1.5%). Some of those had a fatal outcome. Particular attention \nregarding the risk for infection should be paid when treating the elderly.\nPaediatric population\nSee Vaccinations above.", "pregnancy": "Humira has been studied in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriatic \narthritis patients taking Humira as monotherapy and those taking concomitant methotrexate. Antibody \nformation was lower when Humira was given together with methotrexate in comparison with use as \nmonotherapy. Administration of Humira without methotrexate resulted in increased formation of \nantibodies, increased clearance and reduced efficacy of adalimumab (see section 5.1). \nThe combination of Humira and anakinra is not recommended (see section 4.4 \u201cConcurrent administration \nof biologic DMARDS or TNF-antagonists\u201d). \nThe combination of Humira and abatacept is not recommended (see section 4.4 \u201cConcurrent \nadministration of biologic DMARDS or TNF-antagonists\u201d).", "driving": "Women of childbearing potential\nWomen of childbearing potential should consider the use of adequate contraception to prevent pregnancy \nand continue its use for at least five months after the last Humira treatment.\nPregnancy\nA large number (approximately 2100) of prospectively collected pregnancies exposed to adalimumab \nresulting in live birth with known outcomes, including more than 1500 exposed during the first trimester, \ndoes not indicate an increase in the rate of malformation in the newborn.\nIn a prospective cohort registry, 257 women with rheumatoid arthritis (RA) or Crohn\u2019s disease (CD)\ntreated with adalimumab at least during the first trimester and 120 women with RA or CD not treated with \nadalimumab were enrolled.  The primary endpoint was the birth prevalence of major birth defects. The \nrate of pregnancies ending with at least one live born infant with a major birth defect was 6/69 (8.7%) in \nthe adalimumab-treated women with RA and 5/74 (6.8%) in the untreated women with RA (unadjusted \nOR 1.31, 95% CI 0.38-4.52) and 16/152 (10.5%) in the adalimumab-treated women with CD and 3/32 \n(9.4%) in the untreated women with CD (unadjusted OR 1.14, 95% CI 0.31-4.16). The adjusted OR \n(accounting for baseline differences) was 1.10 (95% CI 0.45-2.73) with RA and CD combined. There were \nno distinct differences between adalimumab-treated and untreated women for the secondary endpoints \nspontaneous abortions, minor birth defects, preterm delivery, birth size and serious or opportunistic \ninfections and no stillbirths or malignancies were reported. The interpretation of data may be impacted due \nto methodological limitations of the study, including small sample size and non-randomized design.\nIn a developmental toxicity study conducted in monkeys, there was no indication of maternal toxicity, \nembryotoxicity or teratogenicity. Preclinical data on postnatal toxicity of adalimumab are not available \n(see section 5.3).\nDue to its inhibition of TNF\n\uf061, adalimumab administered during pregnancy could affect normal immune \nresponses in the newborn.  Adalimumab should only be used during pregnancy if clearly needed.\nAdalimumab may cross the placenta into the serum of infants born to women treated with adalimumab \nduring pregnancy. Consequently, these infants may be at increased risk for infection. Administration of \nlive vaccines (e.g., BCG vaccine) to infants exposed to adalimumab in utero is not recommended for \n5 months following the mother\u2019s last adalimumab injection during pregnancy.\nBreast-feeding\nLimited information from the published literature indicates that adalimumab is excreted in breast milk at \nvery low concentrations with the presence of adalimumab in human milk at concentrations of 0.1% to 1% \nof the maternal serum level. Given orally, immunoglobulin G proteins undergo intestinal proteolysis and \nhave poor bioavailability. No effects on the breastfed newborns/infants are anticipated. Consequently, \nHumira can be used during breastfeeding.\nFertility\nPreclinical data on fertility effects of adalimumab are not available.", "side_effects": "Humira may have a minor influence on the ability to drive and use machines. Vertigo and visual \nimpairment may occur following administration of Humira (see section 4.8).", "shelf_life": "2 years", "storage": "Store in a refrigerator (2\n\uf0b0C \u2013 8\uf0b0C). Do not freeze. Keep the pre-filled syringe in its outer carton in order to \nprotect from light.  \nA single Humira pre-filled syringe may be stored at temperatures up to a maximum of 25\u00b0C for a period of \nup to 14 days. The syringe must be protected from light, and discarded if not used within the 14-day \nperiod.", "package": "Humira 20 mg solution for injection in single-use pre-filled syringe (type I glass) with a plunger stopper \n(bromobutyl rubber) and a needle with a needle shield (thermoplastic elastomer). \nPacks of:\n2 pre-filled syringes (0.2 ml sterile solution), each with 1 alcohol pad, in a blister.", "marketing_authorization_numbers": "EU/1/03/256/022", "filename": "humira-epar-product-information_en.html", "snomed.product_info": [["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["385219001", "Injection solution (qualifier value)|Conventional release solution for injection (dose form)|Injection solution (product)"], ["18720000", "In (attribute)"], ["272113006", "Before values (qualifier value)"], ["733020007", "Syringe (unit of presentation)"]], "ncit.product_info": [["C65216", "Adalimumab"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C16818", "Mammography"], ["C149919", "Solution for Injection in Pre-filled Syringe Dosage Form"]], "rxnorm.product_info": [["353484", "Humira"], ["1649574", "Injection"]], "loinc.product_info": [["LA16779-3", "Humira"], ["LA19282-5", "20"], ["LP15217-0", "Mg"], ["LA14542-7", "Injection"], ["LA22004-8", "IN"], ["LP32605-5", "pre"], ["LP188733-2", "Syringe"]], "snomed.composition": [["419473009", "Each (qualifier value)"], ["732349004", "0.2 (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["408102007", "Unit dose (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["407317001", "Adalimumab (substance)"], ["116680003", "Is a (attribute)"], ["338930006", "Human (organism)"], ["312312006", "Monoclonal antibody (substance)|Monoclonal antibody"], ["18720000", "In (attribute)"], ["392392002", "Cricetulus griseus (organism)"], ["181464007", "Entire ovary (body structure)"], ["86495002", "For (qualifier value)"], ["261015003", "Full (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.composition": [["C64933", "Each"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16816", "Mali"], ["C48440", "Single"], ["C25488", "Dose"], ["C97716", "Pre-filled Syringe"], ["C79873", "Contain"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C16818", "Mammography"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C14353", "Recombinants"], ["C14225", "Human"], ["C20401", "Monoclonal Antibody"], ["C16727", "India"], ["C77091", "Chinese Hamster"], ["C12404", "Ovary"], ["C48938", "Cell Count"], ["C64956", "For"], ["C25517", "Full"], ["C43432", "List"], ["C52874", "SPI1 wt Allele"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.composition": [["327361", "adalimumab"], ["327361", "adalimumab"], ["T016", "Human"]], "loinc.composition": [["LA24577-1", "0.2"], ["LA17717-2", "Single"], ["MTHU065481", "Dose"], ["LP32605-5", "pre"], ["LP188733-2", "Syringe"], ["LA19282-5", "20"], ["LP15217-0", "Mg"], ["LP173592-9", "Adalimumab"], ["LP173592-9", "Adalimumab"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LA19712-1", "Recombinant"], ["LA19711-3", "Human"], ["LA22004-8", "IN"], ["LA4168-6", "Chinese"], ["LP206706-6", "Ovary"], ["MTHU001933", "Cells"], ["LA19682-6", "Full"], ["LP204165-7", "List"], ["LP20594-5", "6"], ["LA6112-2", "1"]], "snomed.indications": [["410502007", "Juvenile idiopathic arthritis (disorder)"], ["16044751000119106", "Polyarticular juvenile idiopathic arthritis (disorder)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["55561003", "Active (qualifier value)"], ["255205008", "Polyarticular (qualifier value)"], ["282035009", "Juvenile|Juvenile (qualifier value)"], ["54690008", "Unknown (origin) (qualifier value)"], ["372091005", "Arthritis (finding)"], ["18720000", "In (attribute)"], ["424144002", "Current chronological age (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["242762006", "More (qualifier value)"], ["64572001", "Disease (disorder)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["29544009", "Intolerance, function (observable entity)|Intolerance (function)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["900000000000494007", "Inappropriate component (foundation metadata concept)"], ["86495002", "For (qualifier value)"], ["18720000", "In (attribute)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["18720000", "In (attribute)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["359643005", "Enthesitis (disorder)"], ["262094002", "Related (finding)"], ["372091005", "Arthritis (finding)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["55561003", "Active (qualifier value)"], ["359643005", "Enthesitis (disorder)"], ["262094002", "Related (finding)"], ["372091005", "Arthritis (finding)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255333006", "Conventional (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["200965009", "Plaque psoriasis (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["200965009", "Plaque psoriasis (disorder)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["900000000000494007", "Inappropriate component (foundation metadata concept)"], ["86495002", "For (qualifier value)"], ["359540000", "Topical (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["266517004", "Crohn's disease (& [regional enteritis]) (disorder)|Crohn's disease (& [regional enteritis])"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["55561003", "Active (qualifier value)"], ["266517004", "Crohn's disease (& [regional enteritis]) (disorder)|Crohn's disease (& [regional enteritis])"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255333006", "Conventional (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["55919000", "Including (qualifier value)"], ["261424001", "Primary operation (qualifier value)"], ["386373004", "Nutrition therapy (regime/therapy)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["734544007", "Immunomodulator (disposition)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["267719008", "Iris &/or ciliary body disorders (& [cyclitis] or [uveitis]) (disorder)|Iris &/or ciliary body disorders (& [cyclitis] or [uveitis])"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["267619000", "Non-infectious anterior uveitis (disorder)"], ["18720000", "In (attribute)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255333006", "Conventional (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["255333006", "Conventional (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["900000000000494007", "Inappropriate component (foundation metadata concept)"]], "ncit.indications": [["C114357", "Juvenile Idiopathic Arthritis"], ["C114357", "Juvenile Idiopathic Arthritis"], ["C65216", "Adalimumab"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C642", "Methotrexate"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C154405", "Active State"], ["C28242", "Idiopathic"], ["C2883", "Arthritis"], ["C16727", "India"], ["C16960", "Patient"], ["C25516", "From"], ["C106312", "Advanced Glycation End Product"], ["C52874", "SPI1 wt Allele"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C168268", "Inadequate Daily Salt Intake"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C66832", "One"], ["C43508", "Oregon"], ["C128667", "More"], ["C2991", "Disease or Disorder"], ["C65216", "Adalimumab"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C64974", "Give"], ["C71344", "Associate of Science"], ["C157514", "Single Agent Therapy"], ["C16727", "India"], ["C49152", "Case"], ["C52874", "SPI1 wt Allele"], ["C71437", "Intolerance"], ["C159124", "GDC Treatment Outcome Terminology"], ["C642", "Methotrexate"], ["C43508", "Oregon"], ["C65140", "When"], ["C53279", "Continue"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C642", "Methotrexate"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C74958", "Inappropriate"], ["C64956", "For"], ["C88183", "Efficacy"], ["C16727", "India"], ["C157514", "Single Agent Therapy"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C65216", "Adalimumab"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C16960", "Patient"], ["C25150", "Age"], ["C61585", "Less Than"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C119024", "Enthesitis-Related Arthritis"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C154405", "Active State"], ["C119024", "Enthesitis-Related Arthritis"], ["C16727", "India"], ["C16960", "Patient"], ["C172979", "Fear Score 6"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C16289", "Andorra"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C168268", "Inadequate Daily Salt Intake"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C52874", "SPI1 wt Allele"], ["C97149", "Conventional Therapy"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C4981", "Chronic Graft Versus Host Disease"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C16727", "India"], ["C16423", "Child"], ["C16289", "Andorra"], ["C16266", "Adolescents"], ["C25516", "From"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C168268", "Inadequate Daily Salt Intake"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C68869", "Are"], ["C74958", "Inappropriate"], ["C64956", "For"], ["C13344", "Topical"], ["C49236", "Therapeutic Procedure"], ["C16289", "Andorra"], ["C2965", "Crohn Disease"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C125256", "Moderate Response"], ["C159124", "GDC Treatment Outcome Terminology"], ["C70667", "Severe"], ["C154405", "Active State"], ["C2965", "Crohn Disease"], ["C16727", "India"], ["C16960", "Patient"], ["C25516", "From"], ["C172979", "Fear Score 6"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C168268", "Inadequate Daily Salt Intake"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C97149", "Conventional Therapy"], ["C166400", "Inclusive"], ["C99531", "Primary Cause of Death"], ["C65017", "Nutritional Therapy"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C211", "Therapeutic Corticosteroid"], ["C48928", "And/Or"], ["C75889", "PAX6 wt Allele"], ["C43508", "Oregon"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C101282", "Have"], ["C64956", "For"], ["C26909", "Uveitis"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C4981", "Chronic Graft Versus Host Disease"], ["C14460", "NON Mouse"], ["C26726", "Infectious Disorder"], ["C35109", "Anterior Uveitis"], ["C16727", "India"], ["C16960", "Patient"], ["C25516", "From"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C168268", "Inadequate Daily Salt Intake"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C97149", "Conventional Therapy"], ["C43508", "Oregon"], ["C16727", "India"], ["C97149", "Conventional Therapy"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C74958", "Inappropriate"]], "rxnorm.indications": [["353484", "Humira"], ["6851", "methotrexate"], ["353484", "Humira"], ["6851", "methotrexate"], ["6851", "methotrexate"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"]], "loinc.indications": [["LA31871-9", "Idiopathic"], ["MTHU020793", "Arthritis"], ["LA31871-9", "Idiopathic"], ["MTHU020793", "Arthritis"], ["LA16779-3", "Humira"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP16198-1", "Methotrexate"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA16666-2", "Active"], ["LA31871-9", "Idiopathic"], ["MTHU020793", "Arthritis"], ["LA22004-8", "IN"], ["MTHU010047", "Age"], ["LA31719-0", "2 years"], ["LA8914-9", "Inadequate"], ["LA6306-0", "One"], ["LA22025-3", "OR"], ["LA16824-7", "More"], ["LA18199-2", "Disease"], ["LP18046-0", "Drugs"], ["LA16779-3", "Humira"], ["LP29256-2", "given"], ["LA22004-8", "IN"], ["LP16198-1", "Methotrexate"], ["LA22025-3", "OR"], ["LP94823-9", "Treatment"], ["LP16198-1", "Methotrexate"], ["LP200075-2", "IS"], ["LP31488-7", "Inappropriate"], ["LA26687-6", "Efficacy"], ["LA22004-8", "IN"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LA16779-3", "Humira"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LA16823-9", "Less"], ["LA31719-0", "2 years"], ["LA31343-9", "Related"], ["MTHU020793", "Arthritis"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA16666-2", "Active"], ["LA31343-9", "Related"], ["MTHU020793", "Arthritis"], ["LA22004-8", "IN"], ["LP20594-5", "6"], ["MTHU010047", "Age"], ["LA8914-9", "Inadequate"], ["LA22025-3", "OR"], ["LA32139-0", "Conventional"], ["LP267221-2", "Therapy"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LA15165-6", "Psoriasis"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA6750-9", "Severe"], ["LA28752-6", "Chronic"], ["LA15165-6", "Psoriasis"], ["LA22004-8", "IN"], ["LA31721-6", "4 years"], ["MTHU010047", "Age"], ["LA8914-9", "Inadequate"], ["LA22025-3", "OR"], ["LP31488-7", "Inappropriate"], ["LA9456-0", "Topical"], ["LP267221-2", "Therapy"], ["LA10554-6", "Crohn's Disease"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA13939-6", "Moderately"], ["LA28568-6", "Severely"], ["LA16666-2", "Active"], ["LA10554-6", "Crohn's Disease"], ["LA22004-8", "IN"], ["LP20594-5", "6"], ["MTHU010047", "Age"], ["LA8914-9", "Inadequate"], ["LA32139-0", "Conventional"], ["LP267221-2", "Therapy"], ["LA21208-6", "Primary"], ["LP172860-1", "Nutrition"], ["LP267221-2", "Therapy"], ["LP17763-1", "A"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LP75725-9", "Therapies"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA28752-6", "Chronic"], ["LP220551-8", "anterior"], ["LA22004-8", "IN"], ["LA31719-0", "2 years"], ["MTHU010047", "Age"], ["LA8914-9", "Inadequate"], ["LA22025-3", "OR"], ["LA32139-0", "Conventional"], ["LP267221-2", "Therapy"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LA32139-0", "Conventional"], ["LP267221-2", "Therapy"], ["LP200075-2", "IS"], ["LP31488-7", "Inappropriate"]], "snomed.posology": [["421829000", "And - dosing instruction fragment (qualifier value)"], ["309395003", "Hospital specialist (occupation)"], ["18720000", "In (attribute)"], ["439401001", "Diagnosis (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86495002", "For (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["309395003", "Hospital specialist (occupation)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["28995006", "Treated with (attribute)"], ["116154003", "Patient (person)"], ["255234002", "After (attribute)"], ["118629009", "Training (procedure)|Training (regime/therapy)|Functional training (procedure)"], ["18720000", "In (attribute)"], ["447120003", "Injection technique (qualifier value)"], ["740685003", "Inject (administration method)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["309343006", "Physician (occupation)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["183642001", "Medical follow-up (administrative concept)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["79440004", "Product containing corticosteroid (product)|Product containing corticosteroid and/or corticosteroid derivative (product)|Corticoid preparation (product)|Product containing corticosteroid and corticosteroid derivative (product)|Corticoid preparation (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["376171000221106", "Pediatric population (qualifier value)"], ["410502007", "Juvenile idiopathic arthritis (disorder)"], ["16044751000119106", "Polyarticular juvenile idiopathic arthritis (disorder)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["16044751000119106", "Polyarticular juvenile idiopathic arthritis (disorder)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420862001", "On (qualifier value)"], ["248345008", "Body weight [dup] (observable entity)|Body weight (observable entity)"], ["86407004", "Table, device (physical object)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258705008", "week (qualifier value)"], ["764295003", "Subcutaneous (intended site)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["86407004", "Table, device (physical object)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["16044751000119106", "Polyarticular juvenile idiopathic arthritis (disorder)"], ["116154003", "Patient (person)"], ["726527001", "Weight (property) (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258705008", "week (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258705008", "week (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["18720000", "In (attribute)"], ["900000000000475002", "Time (foundation metadata concept)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["260676000", "Use of (attribute)"], ["18720000", "In (attribute)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["86495002", "For (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["74964007", "Other (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420862001", "On (qualifier value)"], ["385435006", "Individual (person)"], ["359643005", "Enthesitis (disorder)"], ["262094002", "Related (finding)"], ["372091005", "Arthritis (finding)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["359643005", "Enthesitis (disorder)"], ["262094002", "Related (finding)"], ["372091005", "Arthritis (finding)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420862001", "On (qualifier value)"], ["248345008", "Body weight [dup] (observable entity)|Body weight (observable entity)"], ["86407004", "Table, device (physical object)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258705008", "week (qualifier value)"], ["180251004", "Subcutaneous injection (& for local action) (procedure)|Subcutaneous injection (& for local action)"], ["86407004", "Table, device (physical object)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["359643005", "Enthesitis (disorder)"], ["262094002", "Related (finding)"], ["372091005", "Arthritis (finding)"], ["116154003", "Patient (person)"], ["726527001", "Weight (property) (qualifier value)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258705008", "week (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["359643005", "Enthesitis (disorder)"], ["262094002", "Related (finding)"], ["372091005", "Arthritis (finding)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258707000", "year (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["74964007", "Other (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420862001", "On (qualifier value)"], ["385435006", "Individual (person)"], ["200965009", "Plaque psoriasis (disorder)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["200965009", "Plaque psoriasis (disorder)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420862001", "On (qualifier value)"], ["248345008", "Body weight [dup] (observable entity)|Body weight (observable entity)"], ["86407004", "Table, device (physical object)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["180251004", "Subcutaneous injection (& for local action) (procedure)|Subcutaneous injection (& for local action)"], ["86407004", "Table, device (physical object)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["200965009", "Plaque psoriasis (disorder)"], ["116154003", "Patient (person)"], ["726527001", "Weight (property) (qualifier value)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["884001", "Initial (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["367409002", "Followed by (attribute)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258705008", "week (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["884001", "Initial (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["884001", "Initial (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["367409002", "Followed by (attribute)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258705008", "week (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["884001", "Initial (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["1222743007", "American Joint Committee on Cancer stage I:6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["18720000", "In (attribute)"], ["900000000000475002", "Time (foundation metadata concept)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["352730000", "Supra- (qualifier value)"], ["243073001", "Advice (regime/therapy)|Advice (regime/therapy)(procedure)"], ["420862001", "On (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["762636008", "Duration (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["200965009", "Plaque psoriasis (disorder)"], ["86495002", "For (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255586005", "Mean (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222740005", "American Joint Committee on Cancer stage I:3 (qualifier value)"], ["258706009", "month (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["260676000", "Use of (attribute)"], ["18720000", "In (attribute)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["258707000", "year (qualifier value)"], ["86495002", "For (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["74964007", "Other (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420862001", "On (qualifier value)"], ["385435006", "Individual (person)"], ["266517004", "Crohn's disease (& [regional enteritis]) (disorder)|Crohn's disease (& [regional enteritis])"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420862001", "On (qualifier value)"], ["248345008", "Body weight [dup] (observable entity)|Body weight (observable entity)"], ["86407004", "Table, device (physical object)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["180251004", "Subcutaneous injection (& for local action) (procedure)|Subcutaneous injection (& for local action)"], ["86407004", "Table, device (physical object)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["116154003", "Patient (person)"], ["726527001", "Weight (property) (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["116680003", "Is a (attribute)"], ["103325001", "Patient need for (contextual qualifier) (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["242762006", "More (qualifier value)"], ["255358001", "Rapid (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["312012004", "Cognitive function: awareness (observable entity)|Cognitive function: awareness (function)"], ["86495002", "For (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["255260001", "Following (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["725128007", "80 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["725128007", "80 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["116680003", "Is a (attribute)"], ["103325001", "Patient need for (contextual qualifier) (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["242762006", "More (qualifier value)"], ["255358001", "Rapid (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["312012004", "Cognitive function: awareness (observable entity)|Cognitive function: awareness (function)"], ["86495002", "For (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["255260001", "Following (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["732529007", "160 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["725128007", "80 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258705008", "week (qualifier value)"], ["423437008", "Insufficient (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["18720000", "In (attribute)"], ["260911001", "Dosage (attribute)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["14497002", "Weekly (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["14497002", "Weekly (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["725128007", "80 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258705008", "week (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["260676000", "Use of (attribute)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258707000", "year (qualifier value)"], ["86495002", "For (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["74964007", "Other (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420862001", "On (qualifier value)"], ["385435006", "Individual (person)"], ["267719008", "Iris &/or ciliary body disorders (& [cyclitis] or [uveitis]) (disorder)|Iris &/or ciliary body disorders (& [cyclitis] or [uveitis])"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["267719008", "Iris &/or ciliary body disorders (& [cyclitis] or [uveitis]) (disorder)|Iris &/or ciliary body disorders (& [cyclitis] or [uveitis])"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420862001", "On (qualifier value)"], ["248345008", "Body weight [dup] (observable entity)|Body weight (observable entity)"], ["86407004", "Table, device (physical object)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["180251004", "Subcutaneous injection (& for local action) (procedure)|Subcutaneous injection (& for local action)"], ["18720000", "In (attribute)"], ["267719008", "Iris &/or ciliary body disorders (& [cyclitis] or [uveitis]) (disorder)|Iris &/or ciliary body disorders (& [cyclitis] or [uveitis])"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["45169001", "Without (attribute)"], ["79970003", "Simultaneous (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["86407004", "Table, device (physical object)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["267719008", "Iris &/or ciliary body disorders (& [cyclitis] or [uveitis]) (disorder)|Iris &/or ciliary body disorders (& [cyclitis] or [uveitis])"], ["116154003", "Patient (person)"], ["726527001", "Weight (property) (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258705008", "week (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258705008", "week (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["86495002", "For (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["725128007", "80 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["86495002", "For (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["258705008", "week (qualifier value)"], ["288556008", "Before (attribute)"], ["226630009", "Start (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["314122007", "Maintenance therapy (procedure)"], ["373067005", "No (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["420862001", "On (qualifier value)"], ["260676000", "Use of (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["18720000", "In (attribute)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["732766004", "5.2 (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["260676000", "Use of (attribute)"], ["18720000", "In (attribute)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["18720000", "In (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["263803006", "Long-term (qualifier value)"], ["420862001", "On (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["53281000", "Annual (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["74964007", "Other (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420862001", "On (qualifier value)"], ["385435006", "Individual (person)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["40226000", "Impairment (finding)"], ["18720000", "In (attribute)"], ["116154003", "Patient (person)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["260686004", "Method (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["180251004", "Subcutaneous injection (& for local action) (procedure)|Subcutaneous injection (& for local action)"], ["261015003", "Full (qualifier value)"], ["86495002", "For (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["18720000", "In (attribute)"], ["1681000175101", "Package - unit of product usage (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["74964007", "Other (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"]], "ncit.posology": [["C65216", "Adalimumab"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C16289", "Andorra"], ["C158169", "Buyei Chinese"], ["C73456", "Specialist Physician"], ["C16727", "India"], ["C15220", "Diagnosis"], ["C16289", "Andorra"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C25457", "Condition"], ["C64956", "For"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C41188", "Consultation"], ["C62355", "With"], ["C75889", "PAX6 wt Allele"], ["C73456", "Specialist Physician"], ["C201357", "Before Timing Type"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C16329", "Belgium"], ["C64974", "Give"], ["C53691", "Veterinary Patient"], ["C54270", "Reminder"], ["C160555", "CaRD Regimen"], ["C38008", "Post"], ["C17705", "Training"], ["C16727", "India"], ["C122632", "Injection Dosing Unit"], ["C16847", "Technique"], ["C16960", "Patient"], ["C106184", "May"], ["C25200", "Self"], ["C64978", "Inject"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C198613", "CFI wt Allele"], ["C25741", "Physician"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16289", "Andorra"], ["C62355", "With"], ["C25261", "Medical"], ["C99158", "Clinical Study Follow-up"], ["C64499", "As Needed"], ["C175242", "During Treatment"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C118472", "Other License Status"], ["C25730", "Concomitant"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C211", "Therapeutic Corticosteroid"], ["C48928", "And/Or"], ["C16329", "Belgium"], ["C17005", "Population Group"], ["C114357", "Juvenile Idiopathic Arthritis"], ["C114357", "Juvenile Idiopathic Arthritis"], ["C25516", "From"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C64956", "For"], ["C16960", "Patient"], ["C62355", "With"], ["C114357", "Juvenile Idiopathic Arthritis"], ["C25516", "From"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C95085", "Body Weight Domain"], ["C48441", "Table"], ["C105723", "ECOG Performance Status 1"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25382", "Administered"], ["C71127", "Every Two Weeks"], ["C113553", "SEMA6A wt Allele"], ["C13353", "Subcutaneous"], ["C122632", "Injection Dosing Unit"], ["C48441", "Table"], ["C105723", "ECOG Performance Status 1"], ["C65216", "Adalimumab"], ["C25488", "Dose"], ["C64956", "For"], ["C16960", "Patient"], ["C62355", "With"], ["C114357", "Juvenile Idiopathic Arthritis"], ["C81328", "Body Weight"], ["C165496", "GDC Regimen Terminology"], ["C69122", "Ten"], ["C16771", "Kyrgyzstan"], ["C159124", "GDC Treatment Outcome Terminology"], ["C70541", "Lansky Performance Status 30"], ["C16771", "Kyrgyzstan"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C16818", "Mammography"], ["C71127", "Every Two Weeks"], ["C70541", "Lansky Performance Status 30"], ["C16771", "Kyrgyzstan"], ["C105795", "Forty"], ["C16818", "Mammography"], ["C71127", "Every Two Weeks"], ["C25429", "Availability"], ["C25474", "Data"], ["C48313", "Suggestion"], ["C123619", "Clinical Response"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C114711", "Usually"], ["C25282", "Within"], ["C113426", "Twelve"], ["C29844", "Week"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C53279", "Continue"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C25594", "Negation"], ["C25282", "Within"], ["C25616", "Period"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C70664", "Relevance"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16727", "India"], ["C16960", "Patient"], ["C25150", "Age"], ["C61585", "Less Than"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C64956", "For"], ["C41184", "Indication"], ["C65216", "Adalimumab"], ["C106184", "May"], ["C16329", "Belgium"], ["C25429", "Availability"], ["C16727", "India"], ["C118472", "Other License Status"], ["C48928", "And/Or"], ["C92667", "SPARC wt Allele"], ["C25190", "Person"], ["C43442", "Biomaterial Treatment"], ["C41204", "Need"], ["C119024", "Enthesitis-Related Arthritis"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C64956", "For"], ["C16960", "Patient"], ["C62355", "With"], ["C119024", "Enthesitis-Related Arthritis"], ["C25516", "From"], ["C172979", "Fear Score 6"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C95085", "Body Weight Domain"], ["C48441", "Table"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25382", "Administered"], ["C71127", "Every Two Weeks"], ["C113553", "SEMA6A wt Allele"], ["C13353", "Subcutaneous"], ["C122632", "Injection Dosing Unit"], ["C48441", "Table"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C65216", "Adalimumab"], ["C25488", "Dose"], ["C64956", "For"], ["C16960", "Patient"], ["C62355", "With"], ["C119024", "Enthesitis-Related Arthritis"], ["C81328", "Body Weight"], ["C165496", "GDC Regimen Terminology"], ["C113429", "Fifteen"], ["C16771", "Kyrgyzstan"], ["C159124", "GDC Treatment Outcome Terminology"], ["C70541", "Lansky Performance Status 30"], ["C16771", "Kyrgyzstan"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C16818", "Mammography"], ["C71127", "Every Two Weeks"], ["C70541", "Lansky Performance Status 30"], ["C16771", "Kyrgyzstan"], ["C105795", "Forty"], ["C16818", "Mammography"], ["C71127", "Every Two Weeks"], ["C65216", "Adalimumab"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C119024", "Enthesitis-Related Arthritis"], ["C25150", "Age"], ["C61585", "Less Than"], ["C172979", "Fear Score 6"], ["C29848", "Year"], ["C65216", "Adalimumab"], ["C106184", "May"], ["C16329", "Belgium"], ["C25429", "Availability"], ["C16727", "India"], ["C118472", "Other License Status"], ["C48928", "And/Or"], ["C92667", "SPARC wt Allele"], ["C25190", "Person"], ["C43442", "Biomaterial Treatment"], ["C41204", "Need"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C25197", "Recommendation"], ["C65216", "Adalimumab"], ["C25488", "Dose"], ["C64956", "For"], ["C16960", "Patient"], ["C62355", "With"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C25516", "From"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C159124", "GDC Treatment Outcome Terminology"], ["C113431", "Seventeen"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C95085", "Body Weight Domain"], ["C48441", "Table"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25382", "Administered"], ["C113553", "SEMA6A wt Allele"], ["C13353", "Subcutaneous"], ["C122632", "Injection Dosing Unit"], ["C48441", "Table"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C65216", "Adalimumab"], ["C25488", "Dose"], ["C64956", "For"], ["C16960", "Patient"], ["C62355", "With"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C81328", "Body Weight"], ["C165496", "GDC Regimen Terminology"], ["C113429", "Fifteen"], ["C16771", "Kyrgyzstan"], ["C159124", "GDC Treatment Outcome Terminology"], ["C70541", "Lansky Performance Status 30"], ["C16771", "Kyrgyzstan"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C16818", "Mammography"], ["C53286", "Next"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C16818", "Mammography"], ["C64974", "Give"], ["C71127", "Every Two Weeks"], ["C66832", "One"], ["C29844", "Week"], ["C38008", "Post"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C25488", "Dose"], ["C70541", "Lansky Performance Status 30"], ["C16771", "Kyrgyzstan"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C105795", "Forty"], ["C16818", "Mammography"], ["C53286", "Next"], ["C105795", "Forty"], ["C16818", "Mammography"], ["C64974", "Give"], ["C71127", "Every Two Weeks"], ["C66832", "One"], ["C29844", "Week"], ["C38008", "Post"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C25488", "Dose"], ["C53279", "Continue"], ["C49236", "Therapeutic Procedure"], ["C151408", "Beyond"], ["C113430", "Sixteen"], ["C29844", "Week"], ["C16329", "Belgium"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C25594", "Negation"], ["C25282", "Within"], ["C25616", "Period"], ["C198613", "CFI wt Allele"], ["C54055", "Retreatment"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C75329", "Above"], ["C192973", "Guidance"], ["C92667", "SPARC wt Allele"], ["C25488", "Dose"], ["C16289", "Andorra"], ["C198202", "Treatment Duration in Days"], ["C16329", "Belgium"], ["C16033", "Follow-Up"], ["C49667", "Safety Study"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C101282", "Have"], ["C25217", "Assessment"], ["C64956", "For"], ["C76246", "Blood Group A"], ["C181249", "Mean Based on Unspecified Calculation"], ["C52874", "SPI1 wt Allele"], ["C113427", "Thirteen"], ["C29846", "Month"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C70664", "Relevance"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16727", "India"], ["C16423", "Child"], ["C25150", "Age"], ["C61585", "Less Than"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C29848", "Year"], ["C64956", "For"], ["C41184", "Indication"], ["C65216", "Adalimumab"], ["C106184", "May"], ["C16329", "Belgium"], ["C25429", "Availability"], ["C16727", "India"], ["C118472", "Other License Status"], ["C48928", "And/Or"], ["C92667", "SPARC wt Allele"], ["C25190", "Person"], ["C43442", "Biomaterial Treatment"], ["C41204", "Need"], ["C2965", "Crohn Disease"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C64956", "For"], ["C16960", "Patient"], ["C62355", "With"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C25516", "From"], ["C172979", "Fear Score 6"], ["C159124", "GDC Treatment Outcome Terminology"], ["C113431", "Seventeen"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C95085", "Body Weight Domain"], ["C48441", "Table"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25382", "Administered"], ["C113553", "SEMA6A wt Allele"], ["C13353", "Subcutaneous"], ["C122632", "Injection Dosing Unit"], ["C48441", "Table"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C65216", "Adalimumab"], ["C25488", "Dose"], ["C64956", "For"], ["C16960", "Patient"], ["C62355", "With"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C53691", "Veterinary Patient"], ["C48192", "Importance Weight"], ["C158876", "Induction Therapy"], ["C25488", "Dose"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25488", "Dose"], ["C158997", "GDC Analyte Type Terminology"], ["C29844", "Week"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C105795", "Forty"], ["C16771", "Kyrgyzstan"], ["C105795", "Forty"], ["C16818", "Mammography"], ["C158997", "GDC Analyte Type Terminology"], ["C29844", "Week"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C16289", "Andorra"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C16818", "Mammography"], ["C158997", "GDC Analyte Type Terminology"], ["C29844", "Week"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16727", "India"], ["C49152", "Case"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C41204", "Need"], ["C64956", "For"], ["C76246", "Blood Group A"], ["C128667", "More"], ["C65069", "Rapidly"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49236", "Therapeutic Procedure"], ["C62355", "With"], ["C54070", "Awareness"], ["C17102", "Risk"], ["C64956", "For"], ["C49562", "Adverse Event Domain"], ["C106184", "May"], ["C16329", "Belgium"], ["C25227", "High"], ["C62355", "With"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C25227", "High"], ["C158876", "Induction Therapy"], ["C25488", "Dose"], ["C53286", "Next"], ["C25488", "Dose"], ["C106184", "May"], ["C16329", "Belgium"], ["C105710", "Karnofsky Performance Status 80"], ["C16818", "Mammography"], ["C158997", "GDC Analyte Type Terminology"], ["C29844", "Week"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C16289", "Andorra"], ["C105795", "Forty"], ["C16818", "Mammography"], ["C158997", "GDC Analyte Type Terminology"], ["C29844", "Week"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C16818", "Mammography"], ["C64651", "Every"], ["C118472", "Other License Status"], ["C29844", "Week"], ["C105795", "Forty"], ["C16771", "Kyrgyzstan"], ["C105710", "Karnofsky Performance Status 80"], ["C16818", "Mammography"], ["C158997", "GDC Analyte Type Terminology"], ["C29844", "Week"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C16289", "Andorra"], ["C105795", "Forty"], ["C16818", "Mammography"], ["C158997", "GDC Analyte Type Terminology"], ["C29844", "Week"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16727", "India"], ["C49152", "Case"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C41204", "Need"], ["C64956", "For"], ["C76246", "Blood Group A"], ["C128667", "More"], ["C65069", "Rapidly"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49236", "Therapeutic Procedure"], ["C62355", "With"], ["C54070", "Awareness"], ["C17102", "Risk"], ["C64956", "For"], ["C49562", "Adverse Event Domain"], ["C106184", "May"], ["C16329", "Belgium"], ["C25227", "High"], ["C62355", "With"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C25227", "High"], ["C158876", "Induction Therapy"], ["C25488", "Dose"], ["C53286", "Next"], ["C25488", "Dose"], ["C106184", "May"], ["C16329", "Belgium"], ["C16818", "Mammography"], ["C158997", "GDC Analyte Type Terminology"], ["C29844", "Week"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C16289", "Andorra"], ["C105710", "Karnofsky Performance Status 80"], ["C16818", "Mammography"], ["C158997", "GDC Analyte Type Terminology"], ["C29844", "Week"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C105795", "Forty"], ["C16818", "Mammography"], ["C64651", "Every"], ["C118472", "Other License Status"], ["C29844", "Week"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C54627", "Experience"], ["C126862", "Unsatisfactory"], ["C165206", "Responsive Disease"], ["C106184", "May"], ["C25387", "Benefit"], ["C25516", "From"], ["C75889", "PAX6 wt Allele"], ["C25533", "Increase"], ["C16727", "India"], ["C94394", "Cumulative Dose"], ["C105795", "Forty"], ["C16771", "Kyrgyzstan"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C16818", "Mammography"], ["C67069", "Weekly"], ["C105795", "Forty"], ["C16771", "Kyrgyzstan"], ["C105795", "Forty"], ["C16818", "Mammography"], ["C67069", "Weekly"], ["C43508", "Oregon"], ["C105710", "Karnofsky Performance Status 80"], ["C16818", "Mammography"], ["C71127", "Every Two Weeks"], ["C53279", "Continue"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C79916", "Investigative Subject"], ["C25594", "Negation"], ["C158169", "Buyei Chinese"], ["C29844", "Week"], ["C113426", "Twelve"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C70664", "Relevance"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16727", "India"], ["C16423", "Child"], ["C25150", "Age"], ["C61585", "Less Than"], ["C172979", "Fear Score 6"], ["C29848", "Year"], ["C64956", "For"], ["C41184", "Indication"], ["C65216", "Adalimumab"], ["C106184", "May"], ["C16329", "Belgium"], ["C25429", "Availability"], ["C16727", "India"], ["C118472", "Other License Status"], ["C48928", "And/Or"], ["C92667", "SPARC wt Allele"], ["C25190", "Person"], ["C43442", "Biomaterial Treatment"], ["C41204", "Need"], ["C26909", "Uveitis"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C64956", "For"], ["C16960", "Patient"], ["C62355", "With"], ["C26909", "Uveitis"], ["C25516", "From"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C95085", "Body Weight Domain"], ["C48441", "Table"], ["C163771", "Illness Intrusiveness Rating 5"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25382", "Administered"], ["C113553", "SEMA6A wt Allele"], ["C13353", "Subcutaneous"], ["C122632", "Injection Dosing Unit"], ["C16727", "India"], ["C26909", "Uveitis"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C54627", "Experience"], ["C16727", "India"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C25718", "Without"], ["C25730", "Concomitant"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C642", "Methotrexate"], ["C48441", "Table"], ["C163771", "Illness Intrusiveness Rating 5"], ["C65216", "Adalimumab"], ["C25488", "Dose"], ["C64956", "For"], ["C16960", "Patient"], ["C62355", "With"], ["C26909", "Uveitis"], ["C81328", "Body Weight"], ["C165496", "GDC Regimen Terminology"], ["C70541", "Lansky Performance Status 30"], ["C16771", "Kyrgyzstan"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C16818", "Mammography"], ["C71127", "Every Two Weeks"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C642", "Methotrexate"], ["C70541", "Lansky Performance Status 30"], ["C16771", "Kyrgyzstan"], ["C105795", "Forty"], ["C16818", "Mammography"], ["C71127", "Every Two Weeks"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C642", "Methotrexate"], ["C65140", "When"], ["C65216", "Adalimumab"], ["C49236", "Therapeutic Procedure"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C71584", "Load"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C105795", "Forty"], ["C16818", "Mammography"], ["C64956", "For"], ["C16960", "Patient"], ["C70541", "Lansky Performance Status 30"], ["C16771", "Kyrgyzstan"], ["C43508", "Oregon"], ["C105710", "Karnofsky Performance Status 80"], ["C16818", "Mammography"], ["C64956", "For"], ["C16960", "Patient"], ["C70541", "Lansky Performance Status 30"], ["C16771", "Kyrgyzstan"], ["C106184", "May"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C66832", "One"], ["C29844", "Week"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C68616", "Start Date"], ["C52874", "SPI1 wt Allele"], ["C15688", "Maintenance Therapy"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C15783", "Clinical Data"], ["C68869", "Are"], ["C25429", "Availability"], ["C92667", "SPARC wt Allele"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C65216", "Adalimumab"], ["C71584", "Load"], ["C25488", "Dose"], ["C16727", "India"], ["C16423", "Child"], ["C172979", "Fear Score 6"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C70664", "Relevance"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16727", "India"], ["C16423", "Child"], ["C25150", "Age"], ["C61585", "Less Than"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C16727", "India"], ["C41184", "Indication"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C25387", "Benefit"], ["C16289", "Andorra"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C53279", "Continue"], ["C25322", "Long-Term"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C25214", "Evaluation"], ["C92667", "SPARC wt Allele"], ["C76246", "Blood Group A"], ["C74924", "Per Year"], ["C25430", "Basis"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C65216", "Adalimumab"], ["C106184", "May"], ["C16329", "Belgium"], ["C25429", "Availability"], ["C16727", "India"], ["C118472", "Other License Status"], ["C48928", "And/Or"], ["C92667", "SPARC wt Allele"], ["C25190", "Person"], ["C43442", "Biomaterial Treatment"], ["C41204", "Need"], ["C25225", "Renal"], ["C48928", "And/Or"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C65216", "Adalimumab"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C53691", "Veterinary Patient"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25488", "Dose"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C85492", "CDISC SDTM Method Terminology"], ["C52874", "SPI1 wt Allele"], ["C70962", "Agent Administration"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25382", "Administered"], ["C158169", "Buyei Chinese"], ["C13353", "Subcutaneous"], ["C122632", "Injection Dosing Unit"], ["C25517", "Full"], ["C42688", "Instruction"], ["C64956", "For"], ["C25340", "Use"], ["C68869", "Are"], ["C80514", "Provide"], ["C16727", "India"], ["C79887", "Package"], ["C97006", "Leaflet"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25429", "Availability"], ["C16727", "India"], ["C118472", "Other License Status"], ["C16289", "Andorra"]], "rxnorm.posology": [["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["1649574", "Injection"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["1649574", "Injection"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["1649574", "Injection"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["1649574", "Injection"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["1649574", "Injection"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["1649574", "Injection"], ["353484", "Humira"], ["6851", "methotrexate"], ["353484", "Humira"], ["6851", "methotrexate"], ["6851", "methotrexate"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["1649574", "Injection"], ["353484", "Humira"]], "loinc.posology": [["LA16779-3", "Humira"], ["LP94823-9", "Treatment"], ["LA28116-4", "Specialist"], ["LA22004-8", "IN"], ["MTHU008876", "Diagnosis"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["LA28116-4", "Specialist"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA16779-3", "Humira"], ["LP29256-2", "given"], ["LP66710-2", "Patient"], ["LP29708-2", "Cardiology"], ["LA22004-8", "IN"], ["LA14542-7", "Injection"], ["LA14161-6", "May"], ["LA15312-4", "Self"], ["LA16779-3", "Humira"], ["LP6323-2", "Immunofluorescence (IF)"], ["MTHU010489", "Physician"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP422890-6", "Follow-up"], ["LP93408-0", "during treatment"], ["LA16779-3", "Humira"], ["MTHU029809", "Other"], ["LP75725-9", "Therapies"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LA22025-3", "OR"], ["LP62263-6", "Population"], ["LA31871-9", "Idiopathic"], ["MTHU020793", "Arthritis"], ["LA31871-9", "Idiopathic"], ["MTHU020793", "Arthritis"], ["LA31719-0", "2 years"], ["MTHU010047", "Age"], ["MTHU065481", "Dose"], ["LA16779-3", "Humira"], ["LA31871-9", "Idiopathic"], ["MTHU020793", "Arthritis"], ["LA31719-0", "2 years"], ["MTHU010047", "Age"], ["LP200075-2", "IS"], ["MTHU001885", "Body weight"], ["LA6112-2", "1"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["MTHU029809", "Other"], ["LA14216-8", "Week"], ["LA9451-1", "Subcutaneous"], ["LA14542-7", "Injection"], ["LA6112-2", "1"], ["LA16779-3", "Humira"], ["MTHU065481", "Dose"], ["LA31871-9", "Idiopathic"], ["MTHU020793", "Arthritis"], ["LP66710-2", "Patient"], ["LP221195-3", "Weight"], ["LA13942-0", "10"], ["LA32970-8", "<"], ["LA28855-7", "30"], ["LA19282-5", "20"], ["LP15217-0", "Mg"], ["MTHU029809", "Other"], ["LA14216-8", "Week"], ["LA28855-7", "30"], ["LA28858-1", "40"], ["LP15217-0", "Mg"], ["MTHU029809", "Other"], ["LA14216-8", "Week"], ["LP7787-7", "Clinical"], ["LP200075-2", "IS"], ["LA14747-2", "Usually"], ["LA32245-5", "Achieved"], ["LA14558-3", "12"], ["LA9000-6", "Weeks"], ["LP94823-9", "Treatment"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LA21291-2", "Not"], ["LP125120-8", "Time period"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LA16779-3", "Humira"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LA16823-9", "Less"], ["LA31719-0", "2 years"], ["LA16779-3", "Humira"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["MTHU029809", "Other"], ["LA22025-3", "OR"], ["LA12070-1", "Individual"], ["LP94823-9", "Treatment"], ["LA31343-9", "Related"], ["MTHU020793", "Arthritis"], ["MTHU065481", "Dose"], ["LA16779-3", "Humira"], ["LA31343-9", "Related"], ["MTHU020793", "Arthritis"], ["LP20594-5", "6"], ["MTHU010047", "Age"], ["LP200075-2", "IS"], ["MTHU001885", "Body weight"], ["MTHU000002", "Clinical Class"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["MTHU029809", "Other"], ["LA14216-8", "Week"], ["LA9451-1", "Subcutaneous"], ["LA14542-7", "Injection"], ["MTHU000002", "Clinical Class"], ["LA16779-3", "Humira"], ["MTHU065481", "Dose"], ["LA31343-9", "Related"], ["MTHU020793", "Arthritis"], ["LP66710-2", "Patient"], ["LP221195-3", "Weight"], ["LA14561-7", "15"], ["LA32970-8", "<"], ["LA28855-7", "30"], ["LA19282-5", "20"], ["LP15217-0", "Mg"], ["MTHU029809", "Other"], ["LA14216-8", "Week"], ["LA28855-7", "30"], ["LA28858-1", "40"], ["LP15217-0", "Mg"], ["MTHU029809", "Other"], ["LA14216-8", "Week"], ["LA16779-3", "Humira"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA31343-9", "Related"], ["MTHU020793", "Arthritis"], ["LA19751-9", "Aged"], ["LA16823-9", "Less"], ["LP20594-5", "6"], ["LA16779-3", "Humira"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["MTHU029809", "Other"], ["LA22025-3", "OR"], ["LA12070-1", "Individual"], ["LP94823-9", "Treatment"], ["LA15165-6", "Psoriasis"], ["LA16779-3", "Humira"], ["MTHU065481", "Dose"], ["LA15165-6", "Psoriasis"], ["LP20592-9", "4"], ["MTHU010047", "Age"], ["LP200075-2", "IS"], ["MTHU001885", "Body weight"], ["LP20591-1", "3"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["LA9451-1", "Subcutaneous"], ["LA14542-7", "Injection"], ["LP20591-1", "3"], ["LA16779-3", "Humira"], ["MTHU065481", "Dose"], ["LA15165-6", "Psoriasis"], ["LP66710-2", "Patient"], ["LP221195-3", "Weight"], ["LA14561-7", "15"], ["LA32970-8", "<"], ["LA28855-7", "30"], ["LA6662-6", "Initial"], ["MTHU065481", "Dose"], ["LA19282-5", "20"], ["LP15217-0", "Mg"], ["LA19282-5", "20"], ["LP15217-0", "Mg"], ["LP29256-2", "given"], ["MTHU029809", "Other"], ["LA14216-8", "Week"], ["LA6306-0", "One"], ["LA14216-8", "Week"], ["LA6662-6", "Initial"], ["MTHU065481", "Dose"], ["LA28855-7", "30"], ["LA6662-6", "Initial"], ["MTHU065481", "Dose"], ["LA28858-1", "40"], ["LP15217-0", "Mg"], ["LA28858-1", "40"], ["LP15217-0", "Mg"], ["LP29256-2", "given"], ["MTHU029809", "Other"], ["LA14216-8", "Week"], ["LA6306-0", "One"], ["LA14216-8", "Week"], ["LA6662-6", "Initial"], ["MTHU065481", "Dose"], ["LP267221-2", "Therapy"], ["LA14562-5", "16"], ["LA9000-6", "Weeks"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LA21291-2", "Not"], ["LP125120-8", "Time period"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["LA14991-6", "Above"], ["LP34220-1", "Guidance"], ["MTHU065481", "Dose"], ["MTHU048674", "Treatment duration"], ["LA17589-5", "Safety"], ["LA16779-3", "Humira"], ["LA22004-8", "IN"], ["LA15165-6", "Psoriasis"], ["LP17763-1", "A"], ["LP6971-8", "mean"], ["LA14559-1", "13"], ["MTHU068094", "Months"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LA16779-3", "Humira"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LA16823-9", "Less"], ["LA31721-6", "4 years"], ["LA16779-3", "Humira"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["MTHU029809", "Other"], ["LA22025-3", "OR"], ["LA12070-1", "Individual"], ["LP94823-9", "Treatment"], ["LA10554-6", "Crohn's Disease"], ["MTHU065481", "Dose"], ["LA16779-3", "Humira"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LP20594-5", "6"], ["MTHU010047", "Age"], ["LP200075-2", "IS"], ["MTHU001885", "Body weight"], ["LP20592-9", "4"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["LA9451-1", "Subcutaneous"], ["LA14542-7", "Injection"], ["LP20592-9", "4"], ["LA16779-3", "Humira"], ["MTHU065481", "Dose"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LP66710-2", "Patient"], ["LP221195-3", "Weight"], ["MTHU065481", "Dose"], ["MTHU065481", "Dose"], ["LA21988-3", "AT"], ["LA14216-8", "Week"], ["LP20592-9", "4"], ["LA32970-8", "<"], ["LA28858-1", "40"], ["LA28858-1", "40"], ["LP15217-0", "Mg"], ["LA21988-3", "AT"], ["LA14216-8", "Week"], ["LA6111-4", "0"], ["LA19282-5", "20"], ["LP15217-0", "Mg"], ["LA21988-3", "AT"], ["LP248532-6", "week 2"], ["LA22004-8", "IN"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LP17763-1", "A"], ["LA16824-7", "More"], ["LA24868-4", "Rapid"], ["LP267221-2", "Therapy"], ["MTHU058708", "Events"], ["LA14161-6", "May"], ["MTHU065481", "Dose"], ["MTHU065481", "Dose"], ["LA14161-6", "May"], ["LP15217-0", "Mg"], ["LA21988-3", "AT"], ["LA14216-8", "Week"], ["LA6111-4", "0"], ["LA28858-1", "40"], ["LP15217-0", "Mg"], ["LA21988-3", "AT"], ["LP248532-6", "week 2"], ["LA19282-5", "20"], ["LP15217-0", "Mg"], ["MTHU029809", "Other"], ["LA14216-8", "Week"], ["LA28858-1", "40"], ["LP15217-0", "Mg"], ["LA21988-3", "AT"], ["LA14216-8", "Week"], ["LA6111-4", "0"], ["LA28858-1", "40"], ["LP15217-0", "Mg"], ["LA21988-3", "AT"], ["LP248532-6", "week 2"], ["LA22004-8", "IN"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LP17763-1", "A"], ["LA16824-7", "More"], ["LA24868-4", "Rapid"], ["LP267221-2", "Therapy"], ["MTHU058708", "Events"], ["LA14161-6", "May"], ["MTHU065481", "Dose"], ["MTHU065481", "Dose"], ["LA14161-6", "May"], ["LP15217-0", "Mg"], ["LA21988-3", "AT"], ["LA14216-8", "Week"], ["LA6111-4", "0"], ["LP15217-0", "Mg"], ["LA21988-3", "AT"], ["LP248532-6", "week 2"], ["LA28858-1", "40"], ["LP15217-0", "Mg"], ["MTHU029809", "Other"], ["LA14216-8", "Week"], ["LA28127-1", "Insufficient"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["LA22004-8", "IN"], ["LP6801-7", "Dosage"], ["LA32970-8", "<"], ["LA28858-1", "40"], ["LA19282-5", "20"], ["LP15217-0", "Mg"], ["LA14216-8", "Week"], ["LA28858-1", "40"], ["LA28858-1", "40"], ["LP15217-0", "Mg"], ["LA14216-8", "Week"], ["LA22025-3", "OR"], ["LP15217-0", "Mg"], ["MTHU029809", "Other"], ["LA14216-8", "Week"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP427044-5", "Subject"], ["LA21291-2", "Not"], ["LA14216-8", "Week"], ["LA14558-3", "12"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LA16779-3", "Humira"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LA16823-9", "Less"], ["LP20594-5", "6"], ["LA16779-3", "Humira"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["MTHU029809", "Other"], ["LA22025-3", "OR"], ["LA12070-1", "Individual"], ["LP94823-9", "Treatment"], ["MTHU065481", "Dose"], ["LA16779-3", "Humira"], ["LA31719-0", "2 years"], ["MTHU010047", "Age"], ["LP200075-2", "IS"], ["MTHU001885", "Body weight"], ["LP20593-7", "5"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["LA9451-1", "Subcutaneous"], ["LA14542-7", "Injection"], ["LA22004-8", "IN"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LP94823-9", "Treatment"], ["LP16198-1", "Methotrexate"], ["LP20593-7", "5"], ["LA16779-3", "Humira"], ["MTHU065481", "Dose"], ["LP66710-2", "Patient"], ["LP221195-3", "Weight"], ["LA32970-8", "<"], ["LA28855-7", "30"], ["LA19282-5", "20"], ["LP15217-0", "Mg"], ["MTHU029809", "Other"], ["LA14216-8", "Week"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP16198-1", "Methotrexate"], ["LA28855-7", "30"], ["LA28858-1", "40"], ["LP15217-0", "Mg"], ["MTHU029809", "Other"], ["LA14216-8", "Week"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP16198-1", "Methotrexate"], ["LA16779-3", "Humira"], ["LP267221-2", "Therapy"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LA28858-1", "40"], ["LP15217-0", "Mg"], ["LA32970-8", "<"], ["LA28855-7", "30"], ["LA22025-3", "OR"], ["LP15217-0", "Mg"], ["LA28855-7", "30"], ["LA14161-6", "May"], ["LA6306-0", "One"], ["LA14216-8", "Week"], ["LA33028-4", "Prior"], ["LP190656-1", "start"], ["LP267221-2", "Therapy"], ["LA32-8", "No"], ["LP221469-2", "Clinical data"], ["LP17763-1", "A"], ["LA16779-3", "Humira"], ["MTHU065481", "Dose"], ["LA22004-8", "IN"], ["LA32970-8", "<"], ["LP20594-5", "6"], ["MTHU010047", "Age"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LA16779-3", "Humira"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LA16823-9", "Less"], ["LA31719-0", "2 years"], ["LA22004-8", "IN"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA18950-8", "Term"], ["LP94823-9", "Treatment"], ["LP17763-1", "A"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LA16779-3", "Humira"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["MTHU029809", "Other"], ["LA22025-3", "OR"], ["LA12070-1", "Individual"], ["LP94823-9", "Treatment"], ["MTHU065909", "Renal"], ["LA22025-3", "OR"], ["LA16779-3", "Humira"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP66710-2", "Patient"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP72939-9", "Method"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["LA9451-1", "Subcutaneous"], ["LA14542-7", "Injection"], ["LA19682-6", "Full"], ["LP6820-7", "Instructions"], ["LA22004-8", "IN"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["MTHU029809", "Other"]], "snomed.contraindications": [["257550005", "Hypersensitivity (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["261217004", "Substance (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["427099000", "Active tuberculosis (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["186392004", "(Septicaemia NOS) or (sepsis)|(Septicaemia NOS) or (sepsis) (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["371924009", "Moderate to severe (qualifier value)"], ["155374007", "Heart failure (disorder)|Heart failure"], ["258394001", "Class 3 (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["732727007", "4.4 (qualifier value)"]], "ncit.contraindications": [["C3114", "Hypersensitivity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C154405", "Active State"], ["C45306", "Substance"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"], ["C3423", "Tuberculosis"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C71344", "Associate of Science"], ["C3364", "Septicemia"], ["C16289", "Andorra"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C159124", "GDC Treatment Outcome Terminology"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C143529", "Heart Failure, CTCAE"], ["C7922", "New York Heart Association Class III/IV"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"]], "rxnorm.contraindications": [["T167", "Substance"]], "loinc.contraindications": [["LA16666-2", "Active"], ["T167", "Substance"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP20594-5", "6"], ["LA6112-2", "1"], ["LA16666-2", "Active"], ["MTHU020835", "Tuberculosis"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LA6750-9", "Severe"], ["LP74970-2", "Infections"], ["LP74970-2", "Infections"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA32820-5", "Moderate to severe"], ["LP269421-6", "Heart failure"], ["LP264302-3", "NYHA"], ["LA28406-9", "Class III"], ["LP200078-6", "IV"], ["LP20592-9", "4"], ["LP20592-9", "4"]], "snomed.special_warnings": [["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["734841007", "Name (property) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["410681005", "Count of entities (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["242762006", "More (qualifier value)"], ["263890004", "Susceptible [dup] (qualifier value)|Susceptible (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["260379002", "Impaired (qualifier value)"], ["181216001", "Entire lung (body structure)"], ["277064003", "Function (attribute)"], ["260366006", "Increase (qualifier value)"], ["86495002", "For (qualifier value)"], ["86495002", "For (qualifier value)"], ["55919000", "Including (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255234002", "After (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["63911002", "Excretory function (observable entity)|Excretory function (function)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["419652001", "Take (qualifier value)|Take - dosing instruction imperative (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["9362000", "Four (qualifier value)|4 (qualifier value)"], ["258706009", "month (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["55919000", "Including (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255471002", "Localized (qualifier value)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["18720000", "In (attribute)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["15508007", "High risk of (contextual qualifier) (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["266214005", "(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses) (disorder)|(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["266218008", "Other mycoses (& [aspergillosis] or [coccidioidomycosis] or [histoplasmosis] or [piedra] or [sporotrichosis])|Other mycoses (& [aspergillosis] or [coccidioidomycosis] or [histoplasmosis] or [piedra] or [sporotrichosis]) (disorder)"], ["266218008", "Other mycoses (& [aspergillosis] or [coccidioidomycosis] or [histoplasmosis] or [piedra] or [sporotrichosis])|Other mycoses (& [aspergillosis] or [coccidioidomycosis] or [histoplasmosis] or [piedra] or [sporotrichosis]) (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["266217003", "(Other dermatophytosis) or (blastomycosis)|(Other dermatophytosis) or (blastomycosis) (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["288556008", "Before (attribute)"], ["277132007", "Therapeutic procedure (procedure)"], ["74964007", "Other (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255219008", "New infection (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255594003", "Complete (qualifier value)"], ["261004008", "Diagnostic - procedure intent (qualifier value)|Diagnostic intent (qualifier value)"], ["129265001", "Evaluation - action (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["410546004", "Discontinued (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["261021004", "New (qualifier value)|New [dup] (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["186392004", "(Septicaemia NOS) or (sepsis)|(Septicaemia NOS) or (sepsis) (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["768680004", "Antimicrobial (disposition)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["718526003", "Antifungal therapy (procedure)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["256235009", "Exercise (observable entity)|Exercise (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["55919000", "Including (qualifier value)"], ["260676000", "Use of (attribute)"], ["79970003", "Simultaneous (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["55919000", "Including (qualifier value)"], ["186392004", "(Septicaemia NOS) or (sepsis)|(Septicaemia NOS) or (sepsis) (disorder)"], ["42752001", "Due to (attribute)"], ["10179008", "Invasive (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["186315001", "Listeriosis|Listeriosis (disorder)"], ["26726000", "Legionella infection (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["115987006", "Pneumocystis (organism)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["74964007", "Other (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["30190008", "Seen (qualifier value)"], ["18720000", "In (attribute)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["266391003", "Pneumonia and influenza &/or pneumonia|Pneumonia and influenza &/or pneumonia (disorder)"], ["45816000", "Pyelonephritis (disorder)"], ["372939007", "Suppurative arthritis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["154313001", "Septicaemia|Septicaemia (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["399166001", "Fatal (qualifier value)"], ["47429007", "Associated with (attribute)"], ["733985002", "Reported (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["55919000", "Including (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["261021004", "New (qualifier value)|New [dup] (qualifier value)"], ["77374008", "Onset of (contextual qualifier) (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["738985004", "Pulmonary (intended site)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["738985004", "Pulmonary (intended site)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["65709003", "Disseminated (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["86495002", "For (qualifier value)"], ["51440002", "Right and left (qualifier value)"], ["55561003", "Active (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["73425007", "Inactive (qualifier value)"], ["44104002", "Latent (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["257551009", "Infection (disorder)|Infection"], ["129265001", "Evaluation - action (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["225886003", "Medical assessment (procedure)|Medical assessment (regime/therapy)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["116154003", "Patient (person)"], ["161414005", "History of tuberculosis (situation)|History of - tuberculosis (context-dependent category)|History of - tuberculosis (situation)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["9130008", "Previous (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["257496000", "Person [dup] (person)|Person (person)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["427099000", "Active tuberculosis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["9130008", "Previous (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["15240007", "Current (qualifier value)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["360156006", "Screening - procedure intent (qualifier value)"], ["272393004", "Tests (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["164976005", "Tuberculin test - Mantoux (& [Heaf] or [Mantoux])|Tuberculin test - Mantoux (& [Heaf] or [Mantoux]) (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["51185008", "Thoracic structure (body structure)"], ["363680008", "Radiographic imaging procedure (procedure)"], ["398166005", "Performed (qualifier value)"], ["18720000", "In (attribute)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["255470001", "Local (qualifier value)"], ["738991002", "Apply (administration method)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["844005", "Behavior finding (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["272393004", "Tests (qualifier value)"], ["18720000", "In (attribute)"], ["116154003", "Patient (person)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["61707005", "False negative (qualifier value)"], ["164976005", "Tuberculin test - Mantoux (& [Heaf] or [Mantoux])|Tuberculin test - Mantoux (& [Heaf] or [Mantoux]) (procedure)"], ["18720000", "In (attribute)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["161900002", "Feels unwell (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["427099000", "Active tuberculosis (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["732725004", "4.3 (qualifier value)"], ["18720000", "In (attribute)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["351726001", "Below (qualifier value)"], ["705235004", "Balance (physical object)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["260358002", "Very (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["44104002", "Latent (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["415684004", "Suspected (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["309343006", "Physician (occupation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["44104002", "Latent (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["385652002", "Started (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["699618001", "Administration of prophylactic antituberculosis agent (procedure)|Tuberculosis prophylaxis (procedure)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255470001", "Local (qualifier value)"], ["260676000", "Use of (attribute)"], ["699618001", "Administration of prophylactic antituberculosis agent (procedure)|Tuberculosis prophylaxis (procedure)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["261028005", "Several (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["394653002", "Significant|Significant (qualifier value)"], ["86495002", "For (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["394426005", "Negative|Negative (qualifier value)"], ["86495002", "For (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["127452003", "Past medical history of (contextual qualifier) (context-dependent category)"], ["44104002", "Latent (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["427099000", "Active tuberculosis (disorder)"], ["18720000", "In (attribute)"], ["88323005", "Adequate (qualifier value)"], ["260908002", "Course (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["169443000", "Preventive procedure (procedure)"], ["86495002", "For (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["59086009", "Reactivated (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["69845001", "Received therapy or drug for (contextual qualifier) (qualifier value)"], ["427099000", "Active tuberculosis (disorder)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["28995006", "Treated with (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["74188005", "Medical (qualifier value)"], ["243073001", "Advice (regime/therapy)|Advice (regime/therapy)(procedure)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["7196007", "Suggestive of (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["257551009", "Infection (disorder)|Infection"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["284523002", "Persistent cough (finding)"], ["816160009", "Measured weight loss (observable entity)"], ["304213008", "Low grade pyrexia (finding)"], ["20602000", "Indifference (finding)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255234002", "After (attribute)"], ["277132007", "Therapeutic procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["55919000", "Including (qualifier value)"], ["10179008", "Invasive (qualifier value)"], ["266214005", "(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses) (disorder)|(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["79409006", "Resulting in (attribute)"], ["399166001", "Fatal (qualifier value)"], ["86495002", "For (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["386661006", "Fever (finding)"], ["367391008", "Malaise (finding)"], ["816160009", "Measured weight loss (observable entity)"], ["415690000", "Sweating (finding)"], ["161921002", "(Cough (& [symptom])) or (sputum - symptom)|(Cough (& [symptom])) or (sputum - symptom) (finding)"], ["267036007", "Dyspnea (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["738985004", "Pulmonary (intended site)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["264578000", "Systemic illness (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["45169001", "Without (attribute)"], ["79970003", "Simultaneous (qualifier value)"], ["267302008", "Shock (& [post abortion]) (disorder)|Shock (& [post abortion])"], ["12391000132109", "Invasive fungal infection (disorder)"], ["415684004", "Suspected (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["410546004", "Discontinued (qualifier value)"], ["439401001", "Diagnosis (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["718526003", "Antifungal therapy (procedure)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["11429006", "Consultation (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["309343006", "Physician (occupation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["10179008", "Invasive (qualifier value)"], ["266214005", "(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses) (disorder)|(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["55919000", "Including (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["49872002", "Virus (organism)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["410679008", "Surface (qualifier value)"], ["7120007", "Antigen (substance)"], ["394424008", "Positive|Positive (qualifier value)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["399166001", "Fatal (qualifier value)"], ["86495002", "For (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["394424008", "Positive|Positive (qualifier value)"], ["86495002", "For (qualifier value)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["11429006", "Consultation (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["309343006", "Physician (occupation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["55561003", "Active (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["277132007", "Therapeutic procedure (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["261028005", "Several (qualifier value)"], ["258706009", "month (qualifier value)"], ["255260001", "Following (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["88323005", "Adequate (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["101445003", "PREVENT (substance)|PREVENT (product)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["254648000", "Effective (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1199008", "Neurologic (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["8612007", "Tumor necrosis factor (substance)"], ["55919000", "Including (qualifier value)"], ["18720000", "In (attribute)"], ["89292003", "Rare (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["261021004", "New (qualifier value)|New [dup] (qualifier value)"], ["246100006", "Onset (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258106000", "Radiographic (qualifier value)"], ["18669006", "Evidence of (contextual qualifier) (qualifier value)"], ["278199004", "Entire central nervous system (body structure)"], ["64572001", "Disease (disorder)"], ["55919000", "Including (qualifier value)"], ["155023009", "Multiple sclerosis (disorder)|Multiple sclerosis"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["267743006", "Optic neuritis &/or retrobulbar neuritis (disorder)|Optic neuritis &/or retrobulbar neuritis"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["14414005", "Peripheral (qualifier value)"], ["64572001", "Disease (disorder)"], ["55919000", "Including (qualifier value)"], ["64572001", "Disease (disorder)"], ["256235009", "Exercise (observable entity)|Exercise (qualifier value)"], ["18720000", "In (attribute)"], ["260676000", "Use of (attribute)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["263852005", "Recent episode (qualifier value)"], ["246100006", "Onset (attribute)"], ["26216008", "Central (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["3058005", "Peripheral nervous system structure (body structure)"], ["64572001", "Disease (disorder)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["64572001", "Disease (disorder)"], ["116680003", "Is a (attribute)"], ["36692007", "Known (qualifier value)"], ["263534001", "Association (attribute)"], ["11896004", "Intermediate (qualifier value)"], ["314429009", "Intermediate uveitis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["26216008", "Central (qualifier value)"], ["64572001", "Disease (disorder)"], ["1199008", "Neurologic (qualifier value)"], ["129265001", "Evaluation - action (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["788963006", "Intermediate uveitis due to infectious disease (disorder)"], ["288556008", "Before (attribute)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["26216008", "Central (qualifier value)"], ["64572001", "Disease (disorder)"], ["42745003", "Serious (qualifier value)"], ["47429007", "Associated with (attribute)"], ["89292003", "Rare (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["42745003", "Serious (qualifier value)"], ["47429007", "Associated with (attribute)"], ["103356009", "Uncommon (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["55919000", "Including (qualifier value)"], ["39579001", "Anaphylaxis (disorder)"], ["255260001", "Following (attribute)"], ["416118004", "Administration (procedure)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["263851003", "Reaction (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["419076005", "Allergic reaction (disorder)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["410546004", "Discontinued (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["224699009", "Study (environment)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732829001", "64 (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["28995006", "Treated with (attribute)"], ["41647002", "No evidence of (contextual qualifier) (qualifier value)"], ["255339005", "Depression - motion (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["410657003", "Type (attribute)"], ["257550005", "Hypersensitivity (qualifier value)"], ["255339005", "Depression - motion (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["112133008", "Immunoglobulin (substance)"], ["258395000", "Levels (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["263703002", "Changed status (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["771387000", "Substance with effector mechanism of action (substance)"], ["257998006", "Lower case Roman letter t (qualifier value)|t (qualifier value)"], ["421211000", "Lymphoma staging symptom status B (tumor staging)"], ["55918008", "Monocyte (cell)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["64572001", "Disease (disorder)"], ["18720000", "In (attribute)"], ["31509003", "Controlled (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["242762006", "More (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["55919000", "Including (qualifier value)"], ["1163043007", "Malignant lymphoma (morphologic abnormality)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["246106000", "Control (attribute)"], ["246454002", "Occurrence (attribute)"], ["89292003", "Rare (qualifier value)"], ["18720000", "In (attribute)"], ["288563008", "After values (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1162768007", "Leukemia (morphologic abnormality)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["86495002", "For (qualifier value)"], ["1163043007", "Malignant lymphoma (morphologic abnormality)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1162768007", "Leukemia (morphologic abnormality)"], ["18720000", "In (attribute)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255511005", "Long (qualifier value)"], ["10904000", "Orthostatic body position (finding)"], ["55561003", "Active (qualifier value)"], ["128139000", "Inflammatory disorder (disorder)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["15240007", "Current (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1162768007", "Leukemia (morphologic abnormality)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["399166001", "Fatal (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["84422007", "Young (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222775005", "American Joint Committee on Cancer stage II:2 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["28995006", "Treated with (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["55919000", "Including (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["18720000", "In (attribute)"], ["288563008", "After values (qualifier value)"], ["26175008", "Approximate (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["74964007", "Other (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["47429007", "Associated with (attribute)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["28995006", "Treated with (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["89292003", "Rare (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["445406001", "Hepatosplenic T-cell lymphoma (disorder)"], ["7882003", "Identified (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["407317001", "Adalimumab (substance)"], ["89292003", "Rare (qualifier value)"], ["410657003", "Type (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1163404000", "Peripheral T-cell lymphoma (morphologic abnormality)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260358002", "Very (qualifier value)"], ["255325005", "Aggressive course (qualifier value)"], ["64572001", "Disease (disorder)"], ["260908002", "Course (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["399166001", "Fatal (qualifier value)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["57184004", "T lymphocyte (cell)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["84422007", "Young (qualifier value)"], ["255397009", "Adult (qualifier value)|Adult"], ["420862001", "On (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["372574004", "Azathioprine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386835005", "Mercaptopurine (substance)"], ["86495002", "For (qualifier value)"], ["266516008", "Inflammatory bowel disease (& [noninfective enteritis/colitis]) (disorder)|Inflammatory bowel disease (& [noninfective enteritis/colitis])"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["372574004", "Azathioprine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386835005", "Mercaptopurine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["445406001", "Hepatosplenic T-cell lymphoma (disorder)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["732732008", "4.8 (qualifier value)"], ["373067005", "No (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["255260001", "Following (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["74188005", "Medical (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["41118005", "Extensive (qualifier value)"], ["372823004", "Immunosuppressant (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["156369008", "Psoriasis|Psoriasis (disorder)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["64049009", "Examined for (contextual qualifier) (qualifier value)"], ["52101004", "Present (qualifier value)"], ["2092003", "Malignant melanoma, no ICD-O subtype (morphologic abnormality)|Malignant melanoma, morphology (morphologic abnormality)|Malignant melanoma, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|Malignant melanoma (morphologic abnormality)"], ["372130007", "Malignant neoplasm of skin (disorder)"], ["288556008", "Before (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["2092003", "Malignant melanoma, no ICD-O subtype (morphologic abnormality)|Malignant melanoma, morphology (morphologic abnormality)|Malignant melanoma, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|Malignant melanoma (morphologic abnormality)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["253001006", "Merkel cell carcinoma (disorder)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["55919000", "Including (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["732732008", "4.8 (qualifier value)"], ["18720000", "In (attribute)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["260676000", "Use of (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["371924009", "Moderate to severe (qualifier value)"], ["13645005", "Chronic obstructive lung disease (disorder)|Chronic obstructive pulmonary disease (disorder)"], ["13645005", "Chronic obstructive lung disease (disorder)|Chronic obstructive pulmonary disease (disorder)"], ["242762006", "More (qualifier value)"], ["18720000", "In (attribute)"], ["181216001", "Entire lung (body structure)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["361355005", "Entire head and neck (body structure)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["386891004", "Infliximab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["246106000", "Control (attribute)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["410712002", "Heavy sensation quality (qualifier value)"], ["365981007", "Finding of tobacco smoking behavior (finding)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["261583007", "Using (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["18720000", "In (attribute)"], ["13645005", "Chronic obstructive lung disease (disorder)|Chronic obstructive pulmonary disease (disorder)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["20572008", "Good (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["86495002", "For (qualifier value)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["42752001", "Due to (attribute)"], ["410712002", "Heavy sensation quality (qualifier value)"], ["365981007", "Finding of tobacco smoking behavior (finding)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["15240007", "Current (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["36692007", "Known (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["86495002", "For (qualifier value)"], ["25723000", "Dysplasia (morphologic abnormality)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["302508007", "Entire colon (body structure)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["266447004", "Ulcerative colitis (disorder)|Ulcerative colitis"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["86495002", "For (qualifier value)"], ["25723000", "Dysplasia (morphologic abnormality)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["302508007", "Entire colon (body structure)"], ["1187425009", "Carcinoma (morphologic abnormality)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255511005", "Long (qualifier value)"], ["10904000", "Orthostatic body position (finding)"], ["266447004", "Ulcerative colitis (disorder)|Ulcerative colitis"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["197441003", "Primary sclerosing cholangitis (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["25723000", "Dysplasia (morphologic abnormality)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["302508007", "Entire colon (body structure)"], ["1187425009", "Carcinoma (morphologic abnormality)"], ["86495002", "For (qualifier value)"], ["25723000", "Dysplasia (morphologic abnormality)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["17854005", "Regular (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["64572001", "Disease (disorder)"], ["260908002", "Course (attribute)"], ["129265001", "Evaluation - action (qualifier value)"], ["271997005", "Colonoscopy [Ambiguous]|Colonoscopy (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["255470001", "Local (qualifier value)"], ["57407000", "Hematologic (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["127034005", "Pancytopenia (disorder)"], ["55919000", "Including (qualifier value)"], ["306058006", "Aplastic anemia (disorder)"], ["733985002", "Reported (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["272379006", "Events (event)|Event (event)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["57407000", "Hematologic (qualifier value)"], ["1231568003", "System (basic dose form)"], ["55919000", "Including (qualifier value)"], ["394653002", "Significant|Significant (qualifier value)"], ["50820005", "Cytopenia (finding)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["415116008", "Platelet count below reference range (finding)"], ["419188005", "Decreased blood leukocyte number (finding)|Blood leukocyte number below reference range (finding)"], ["733985002", "Reported (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["394433005", "Immediate (qualifier value)|Immediate"], ["74188005", "Medical (qualifier value)"], ["247759001", "Attention [Ambiguous]|Attention (finding)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["7196007", "Suggestive of (attribute)"], ["87612001", "Blood (substance)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["255222005", "Persistent (qualifier value)"], ["386661006", "Fever (finding)"], ["308492005", "Contusion - lesion (morphologic abnormality)|Bruise - lesion (morphologic abnormality)"], ["303123004", "Bleeding (disorder)|Bleeding"], ["398979000", "Pale complexion (finding)"], ["420862001", "On (qualifier value)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["394653002", "Significant|Significant (qualifier value)"], ["57407000", "Hematologic (qualifier value)"], ["170310008", "Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)]) (procedure)|Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)])"], ["68498002", "Antibody (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222776006", "American Joint Committee on Cancer stage II:3 (qualifier value)"], ["981000221107", "Vaccine product containing only Streptococcus pneumoniae antigen (medicinal product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["155559006", "Influenza (disorder)|Influenza"], ["49872002", "Virus (organism)"], ["33879002", "Administration of vaccine to produce active immunity (procedure)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["224699009", "Study (environment)"], ["18720000", "In (attribute)"], ["255397009", "Adult (qualifier value)|Adult"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["28995006", "Treated with (attribute)"], ["407317001", "Adalimumab (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["420862001", "On (qualifier value)"], ["2603003", "Secondary (qualifier value)"], ["258150004", "Transmission (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["18720000", "In (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["410672004", "Date property (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["170310008", "Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)]) (procedure)|Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)])"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["15240007", "Current (qualifier value)"], ["243188009", "Immunisation [Ambiguous]|Immunisation (procedure)"], ["288556008", "Before (attribute)"], ["277132007", "Therapeutic procedure (procedure)"], ["420862001", "On (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["170310008", "Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)]) (procedure)|Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)])"], ["5185003", "Except for (attribute)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["396419007", "BCG vaccine (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["18720000", "In (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["86495002", "For (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["258706009", "month (qualifier value)"], ["255260001", "Following (attribute)"], ["394651000", "Mother (person)|Mother"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["195108009", "Heart failure: [right] or [congestive]|Heart failure: [right] or [congestive] (disorder)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["230993007", "Worsening (qualifier value)"], ["195108009", "Heart failure: [right] or [congestive]|Heart failure: [right] or [congestive] (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["42752001", "Due to (attribute)"], ["195108009", "Heart failure: [right] or [congestive]|Heart failure: [right] or [congestive] (disorder)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["230993007", "Worsening (qualifier value)"], ["195108009", "Heart failure: [right] or [congestive]|Heart failure: [right] or [congestive] (disorder)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255604002", "Mild (qualifier value)"], ["155374007", "Heart failure (disorder)|Heart failure"], ["258392002", "Class 1 (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410536001", "Contraindicated (qualifier value)"], ["18720000", "In (attribute)"], ["371924009", "Moderate to severe (qualifier value)"], ["155374007", "Heart failure (disorder)|Heart failure"], ["732725004", "4.3 (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["410546004", "Discontinued (qualifier value)"], ["18720000", "In (attribute)"], ["261021004", "New (qualifier value)|New [dup] (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["230993007", "Worsening (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["195108009", "Heart failure: [right] or [congestive]|Heart failure: [right] or [congestive] (disorder)"], ["263680009", "Autoimmune (qualifier value)|Autoimmune process (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["263680009", "Autoimmune (qualifier value)|Autoimmune process (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["263803006", "Long-term (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["263680009", "Autoimmune (qualifier value)|Autoimmune process (qualifier value)"], ["64572001", "Disease (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["261665006", "Unknown (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["7196007", "Suggestive of (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["80258006", "Drug-induced lupus erythematosus (disorder)"], ["255260001", "Following (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["10828004", "Positive (qualifier value)"], ["65897001", "Against (qualifier value)"], ["1305003", "Double (qualifier value)"], ["24851008", "Deoxyribonucleic acid (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["42745003", "Serious (qualifier value)"], ["30190008", "Seen (qualifier value)"], ["18720000", "In (attribute)"], ["58147004", "Clinical (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["260676000", "Use of (attribute)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["387045004", "Etanercept (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["387045004", "Etanercept (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["246425008", "Nature (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["30190008", "Seen (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387045004", "Etanercept (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["277132007", "Therapeutic procedure (procedure)"], ["394617004", "Result (navigational concept)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421777009", "Abatacept (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["420771004", "Upon - dosing instruction fragment (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["86495002", "For (qualifier value)"], ["55919000", "Including (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["56183000", "Pharmacologic (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["387713003", "Surgical procedure (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387713003", "Surgical procedure (procedure)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["255511005", "Long (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["30507006", "Into (attribute)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["387713003", "Surgical procedure (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["397943006", "Planned (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["387713003", "Surgical procedure (procedure)"], ["420862001", "On (qualifier value)"], ["86495002", "For (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["18720000", "In (attribute)"], ["442095009", "Repair of joint (procedure)"], ["281255004", "Small bowel obstruction (disorder)"], ["76797004", "Failure (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["52101004", "Present (qualifier value)"], ["261010008", "Fixed (qualifier value)"], ["27551008", "Stricture (morphologic abnormality)"], ["83578000", "Surgical (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["717896003", "Does not (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["260864003", "Frequency (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["21481007", "Over (qualifier value)"], ["264695004", "65 (qualifier value)|Arabic numeral 65 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["732655003", "3.7 (qualifier value)"], ["86495002", "For (qualifier value)"], ["351726001", "Below (qualifier value)"], ["264695004", "65 (qualifier value)|Arabic numeral 65 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["732425003", "1.5 (qualifier value)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["399166001", "Fatal (qualifier value)"], ["247759001", "Attention [Ambiguous]|Attention (finding)"], ["86495002", "For (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["376171000221106", "Pediatric population (qualifier value)"], ["170310008", "Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)]) (procedure)|Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)])"], ["352730000", "Supra- (qualifier value)"]], "ncit.special_warnings": [["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C52874", "SPI1 wt Allele"], ["C28226", "Biological"], ["C42614", "Name"], ["C16289", "Andorra"], ["C104504", "Batch Number"], ["C52874", "SPI1 wt Allele"], ["C25382", "Administered"], ["C40352", "Multiplicative Product"], ["C16329", "Belgium"], ["C16960", "Patient"], ["C18368", "TNF Gene"], ["C68869", "Are"], ["C128667", "More"], ["C16505", "Susceptibility"], ["C159124", "GDC Treatment Outcome Terminology"], ["C54035", "Serious"], ["C21055", "Impairment"], ["C23402", "Murine Lung"], ["C25518", "Function"], ["C106184", "May"], ["C25533", "Increase"], ["C17102", "Risk"], ["C64956", "For"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C64956", "For"], ["C166400", "Inclusive"], ["C3423", "Tuberculosis"], ["C201357", "Before Timing Type"], ["C25490", "During"], ["C16289", "Andorra"], ["C54735", "Post-Therapy"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C106184", "May"], ["C65105", "Take"], ["C64643", "Up to"], ["C66835", "Four"], ["C29846", "Month"], ["C61256", "Monitoring"], ["C16329", "Belgium"], ["C53279", "Continue"], ["C25616", "Period"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C154405", "Active State"], ["C166400", "Inclusive"], ["C4981", "Chronic Graft Versus Host Disease"], ["C43508", "Oregon"], ["C14146", "Localized"], ["C65136", "Until"], ["C68869", "Are"], ["C82500", "Disease Controlled"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C159124", "GDC Treatment Outcome Terminology"], ["C3423", "Tuberculosis"], ["C16289", "Andorra"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C16727", "India"], ["C52874", "SPI1 wt Allele"], ["C122458", "High Risk Acute Leukemia"], ["C52874", "SPI1 wt Allele"], ["C3423", "Tuberculosis"], ["C43508", "Oregon"], ["C27122", "Endemic Burkitt Lymphoma"], ["C71344", "Associate of Science"], ["C77201", "Histoplasmosis"], ["C84642", "Coccidioidomycosis"], ["C43508", "Oregon"], ["C34428", "Blastomycosis"], ["C17102", "Risk"], ["C16289", "Andorra"], ["C25387", "Benefit"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C16329", "Belgium"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49236", "Therapeutic Procedure"], ["C163702", "Staphylococcal Enterotoxin E"], ["C118472", "Other License Status"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C76246", "Blood Group A"], ["C94522", "New Lesion Identification"], ["C128320", "Infection"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C16329", "Belgium"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C127315", "Complete Pharyngeal Contraction"], ["C25482", "Diagnostic"], ["C25214", "Evaluation"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C76246", "Blood Group A"], ["C94522", "New Lesion Identification"], ["C54035", "Serious"], ["C128320", "Infection"], ["C43508", "Oregon"], ["C3364", "Septicemia"], ["C16289", "Andorra"], ["C258", "Antibiotic"], ["C43508", "Oregon"], ["C15704", "Antifungal Therapy"], ["C16329", "Belgium"], ["C65136", "Until"], ["C128320", "Infection"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C82500", "Disease Controlled"], ["C16567", "Exercise"], ["C65140", "When"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C128320", "Infection"], ["C43508", "Oregon"], ["C62355", "With"], ["C154417", "Underlying"], ["C25457", "Condition"], ["C106184", "May"], ["C16960", "Patient"], ["C159124", "GDC Treatment Outcome Terminology"], ["C166400", "Inclusive"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C25730", "Concomitant"], ["C574", "Immunosuppressant"], ["C459", "Medication"], ["C54035", "Serious"], ["C54035", "Serious"], ["C166400", "Inclusive"], ["C3364", "Septicemia"], ["C89272", "Due To"], ["C93159", "Invasive Procedure"], ["C28176", "Parasite"], ["C27985", "Viral"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C71344", "Associate of Science"], ["C82994", "Listeriosis"], ["C128334", "Legionellosis"], ["C16289", "Andorra"], ["C124358", "Pneumocystis"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C65216", "Adalimumab"], ["C118472", "Other License Status"], ["C54035", "Serious"], ["C16727", "India"], ["C71104", "Clinical Trial"], ["C74521", "Include"], ["C3333", "Pneumonia"], ["C79604", "Pyelonephritis"], ["C26699", "Bacterial Arthritis"], ["C16289", "Andorra"], ["C43508", "Oregon"], ["C48275", "Death Related to Adverse Event"], ["C25281", "Associated"], ["C62355", "With"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C3423", "Tuberculosis"], ["C3423", "Tuberculosis"], ["C166400", "Inclusive"], ["C124063", "Reactivation"], ["C16289", "Andorra"], ["C94522", "New Lesion Identification"], ["C25279", "Onset"], ["C52874", "SPI1 wt Allele"], ["C3423", "Tuberculosis"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C65216", "Adalimumab"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C105692", "Pulmonary Medicine"], ["C16289", "Andorra"], ["C63758", "Supernumerary"], ["C105692", "Pulmonary Medicine"], ["C68254", "Dietary Iodine"], ["C68800", "Elementary Charge"], ["C28222", "Disseminate"], ["C3423", "Tuberculosis"], ["C201357", "Before Timing Type"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C64916", "All"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C25214", "Evaluation"], ["C64956", "For"], ["C49636", "Both"], ["C154405", "Active State"], ["C43508", "Oregon"], ["C45422", "Absence of Biochemical Activity"], ["C28225", "Latent"], ["C128377", "Tuberculosis Infection"], ["C25214", "Evaluation"], ["C74521", "Include"], ["C76246", "Blood Group A"], ["C25480", "Details"], ["C25305", "Medical Examination"], ["C52874", "SPI1 wt Allele"], ["C53691", "Veterinary Patient"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C3423", "Tuberculosis"], ["C43508", "Oregon"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C25627", "Previous"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C95553", "People"], ["C62355", "With"], ["C3423", "Tuberculosis"], ["C16289", "Andorra"], ["C25627", "Previous"], ["C48928", "And/Or"], ["C48434", "Electrical Current"], ["C15261", "Immunosuppressive Therapy"], ["C48261", "Screening"], ["C25294", "Laboratory Procedure"], ["C68254", "Dietary Iodine"], ["C68800", "Elementary Charge"], ["C85994", "Tuberculin Skin Test"], ["C16289", "Andorra"], ["C25389", "Chest"], ["C38101", "X-Ray Imaging"], ["C16329", "Belgium"], ["C38000", "Performed"], ["C16727", "India"], ["C64916", "All"], ["C16960", "Patient"], ["C25388", "Local-Regional"], ["C106184", "May"], ["C64915", "Apply"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C16326", "Behavior"], ["C16289", "Andorra"], ["C52874", "SPI1 wt Allele"], ["C25294", "Laboratory Procedure"], ["C68869", "Are"], ["C16727", "India"], ["C53691", "Veterinary Patient"], ["C54270", "Reminder"], ["C160555", "CaRD Regimen"], ["C68869", "Are"], ["C52874", "SPI1 wt Allele"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C93283", "False Negative"], ["C85994", "Tuberculin Skin Test"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C70667", "Severe"], ["C43508", "Oregon"], ["C14139", "Immunocompromised"], ["C198613", "CFI wt Allele"], ["C3423", "Tuberculosis"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C15220", "Diagnosis"], ["C65216", "Adalimumab"], ["C49236", "Therapeutic Procedure"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16727", "India"], ["C64916", "All"], ["C75330", "Below"], ["C25387", "Benefit"], ["C17102", "Risk"], ["C73497", "Balance"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C116076", "Very"], ["C198613", "CFI wt Allele"], ["C28225", "Latent"], ["C3423", "Tuberculosis"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C71458", "Suspected"], ["C76246", "Blood Group A"], ["C25741", "Physician"], ["C62355", "With"], ["C16727", "India"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C3423", "Tuberculosis"], ["C16329", "Belgium"], ["C198613", "CFI wt Allele"], ["C28225", "Latent"], ["C3423", "Tuberculosis"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C15220", "Diagnosis"], ["C101247", "Appropriate Treatment"], ["C16329", "Belgium"], ["C62355", "With"], ["C3423", "Tuberculosis"], ["C15405", "Prevention"], ["C43442", "Biomaterial Treatment"], ["C201357", "Before Timing Type"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16289", "Andorra"], ["C64950", "Follow"], ["C25388", "Local-Regional"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C3423", "Tuberculosis"], ["C15405", "Prevention"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C201357", "Before Timing Type"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C107221", "Several"], ["C43508", "Oregon"], ["C41130", "Significant"], ["C17103", "Risk Factor"], ["C64956", "For"], ["C3423", "Tuberculosis"], ["C76246", "Blood Group A"], ["C160366", "FGFR3 Gene Rearrangement Negative"], ["C82541", "Test Name"], ["C64956", "For"], ["C3423", "Tuberculosis"], ["C16289", "Andorra"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C126474", "EHD1 wt Allele"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C28225", "Latent"], ["C43508", "Oregon"], ["C3423", "Tuberculosis"], ["C16727", "India"], ["C75889", "PAX6 wt Allele"], ["C168111", "Adequate Daily Fluid Intake"], ["C25379", "Course"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C25458", "Confirmation"], ["C95560", "Prophylactic"], ["C64956", "For"], ["C3423", "Tuberculosis"], ["C52874", "SPI1 wt Allele"], ["C3423", "Tuberculosis"], ["C101282", "Have"], ["C54069", "Occur"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C65099", "Some"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C25705", "Treating"], ["C64956", "For"], ["C3423", "Tuberculosis"], ["C101282", "Have"], ["C3423", "Tuberculosis"], ["C89327", "Be"], ["C25705", "Treating"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25261", "Medical"], ["C198613", "CFI wt Allele"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C3423", "Tuberculosis"], ["C128320", "Infection"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C43623", "Persistent"], ["C124215", "Cough Frequency"], ["C125292", "How Often Weight Loss"], ["C35292", "Low Grade Fever"], ["C127786", "Occurrence Indicator"], ["C49640", "During or After"], ["C49236", "Therapeutic Procedure"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C118472", "Other License Status"], ["C166400", "Inclusive"], ["C93159", "Invasive Procedure"], ["C101282", "Have"], ["C25599", "Observed"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C65216", "Adalimumab"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C16960", "Patient"], ["C18368", "TNF Gene"], ["C16289", "Andorra"], ["C101282", "Have"], ["C16727", "India"], ["C16727", "India"], ["C101247", "Appropriate Treatment"], ["C90025", "Sometimes"], ["C16727", "India"], ["C48275", "Death Related to Adverse Event"], ["C64956", "For"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C16289", "Andorra"], ["C168422", "Rheumatic Fever Symptom"], ["C71344", "Associate of Science"], ["C143485", "Fever, CTCAE"], ["C143665", "Malaise, CTCAE"], ["C125292", "How Often Weight Loss"], ["C36172", "Sweating"], ["C124215", "Cough Frequency"], ["C48928", "And/Or"], ["C102531", "Pulmonary Infiltrate"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C54035", "Serious"], ["C13310", "Systemic"], ["C62355", "With"], ["C43508", "Oregon"], ["C25718", "Without"], ["C25730", "Concomitant"], ["C35016", "Shock"], ["C75889", "PAX6 wt Allele"], ["C93159", "Invasive Procedure"], ["C3245", "Fungal Infection"], ["C16329", "Belgium"], ["C71458", "Suspected"], ["C16289", "Andorra"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C15220", "Diagnosis"], ["C16289", "Andorra"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C54726", "Empiric"], ["C15704", "Antifungal Therapy"], ["C16727", "India"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C16727", "India"], ["C41188", "Consultation"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C25741", "Physician"], ["C62355", "With"], ["C16727", "India"], ["C80233", "Care Of"], ["C16960", "Patient"], ["C62355", "With"], ["C93159", "Invasive Procedure"], ["C143211", "Hepatitis B Reactivation, CTCAE"], ["C124063", "Reactivation"], ["C52874", "SPI1 wt Allele"], ["C3097", "Hepatitis B Infection"], ["C101282", "Have"], ["C54069", "Occur"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C76246", "Blood Group A"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C166400", "Inclusive"], ["C65216", "Adalimumab"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C4981", "Chronic Graft Versus Host Disease"], ["C52874", "SPI1 wt Allele"], ["C14283", "Virus"], ["C68254", "Dietary Iodine"], ["C68800", "Elementary Charge"], ["C25245", "Surface"], ["C268", "Antigen"], ["C36659", "CTNNB1 Gene Mutation"], ["C65099", "Some"], ["C101282", "Have"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C48275", "Death Related to Adverse Event"], ["C20200", "Outcome"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C64956", "For"], ["C189553", "Hepatitis B Virus Measurement"], ["C128320", "Infection"], ["C201357", "Before Timing Type"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C64956", "For"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C82541", "Test Name"], ["C36659", "CTNNB1 Gene Mutation"], ["C64956", "For"], ["C3097", "Hepatitis B Infection"], ["C41188", "Consultation"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C25741", "Physician"], ["C62355", "With"], ["C16727", "India"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C3097", "Hepatitis B Infection"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C52874", "SPI1 wt Allele"], ["C189553", "Hepatitis B Virus Measurement"], ["C75419", "World Health Organization"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C16329", "Belgium"], ["C64956", "For"], ["C16289", "Andorra"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C154405", "Active State"], ["C189553", "Hepatitis B Virus Measurement"], ["C128320", "Infection"], ["C49236", "Therapeutic Procedure"], ["C16289", "Andorra"], ["C64956", "For"], ["C107221", "Several"], ["C29846", "Month"], ["C53286", "Next"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C168111", "Adequate Daily Fluid Intake"], ["C25474", "Data"], ["C25516", "From"], ["C25705", "Treating"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C52874", "SPI1 wt Allele"], ["C189553", "Hepatitis B Virus Measurement"], ["C62355", "With"], ["C62713", "Oncolytic Virus Therapy"], ["C16727", "India"], ["C79874", "Conjunction"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C49236", "Therapeutic Procedure"], ["C159124", "GDC Treatment Outcome Terminology"], ["C189553", "Hepatitis B Virus Measurement"], ["C124063", "Reactivation"], ["C68869", "Are"], ["C126101", "Not Available"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C189553", "Hepatitis B Virus Measurement"], ["C124063", "Reactivation"], ["C65216", "Adalimumab"], ["C16329", "Belgium"], ["C16289", "Andorra"], ["C49287", "Effective"], ["C62713", "Oncolytic Virus Therapy"], ["C62355", "With"], ["C37902", "Support"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C25262", "Neurologic"], ["C150901", "Event Unit"], ["C18368", "TNF Gene"], ["C166400", "Inclusive"], ["C65216", "Adalimumab"], ["C101282", "Have"], ["C25281", "Associated"], ["C16727", "India"], ["C13634", "Retinoic Acid Response Element"], ["C62355", "With"], ["C94522", "New Lesion Identification"], ["C25279", "Onset"], ["C43508", "Oregon"], ["C124138", "Exacerbation"], ["C52874", "SPI1 wt Allele"], ["C123619", "Clinical Response"], ["C168422", "Rheumatic Fever Symptom"], ["C48928", "And/Or"], ["C192332", "Radiographic Staging"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C12438", "Central Nervous System"], ["C34527", "Demyelinating Disorder"], ["C166400", "Inclusive"], ["C3243", "Multiple Sclerosis"], ["C16289", "Andorra"], ["C84950", "Optic Neuritis"], ["C16289", "Andorra"], ["C25233", "Peripheral"], ["C34527", "Demyelinating Disorder"], ["C166400", "Inclusive"], ["C168217", "Genetic Syndrome Associated with Congenital Heart Defect"], ["C16567", "Exercise"], ["C16727", "India"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C25629", "Prior"], ["C43508", "Oregon"], ["C25280", "Recent"], ["C25279", "Onset"], ["C185326", "Central Imaging Review"], ["C43508", "Oregon"], ["C12465", "Peripheral Nervous System"], ["C2991", "Disease or Disorder"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16329", "Belgium"], ["C198613", "CFI wt Allele"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C2991", "Disease or Disorder"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C80137", "Known"], ["C73471", "Chemical Association"], ["C94545", "Between"], ["C35110", "Intermediate Uveitis"], ["C16289", "Andorra"], ["C185326", "Central Imaging Review"], ["C2991", "Disease or Disorder"], ["C12755", "Nervous System"], ["C25214", "Evaluation"], ["C16329", "Belgium"], ["C38000", "Performed"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C14460", "NON Mouse"], ["C26726", "Infectious Disorder"], ["C35110", "Intermediate Uveitis"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C49236", "Therapeutic Procedure"], ["C16289", "Andorra"], ["C175242", "During Treatment"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25217", "Assessment"], ["C64956", "For"], ["C73621", "Pre-existing"], ["C43508", "Oregon"], ["C185326", "Central Imaging Review"], ["C2991", "Disease or Disorder"], ["C37910", "Allergic"], ["C54035", "Serious"], ["C37910", "Allergic"], ["C25281", "Associated"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C13634", "Retinoic Acid Response Element"], ["C25490", "During"], ["C71104", "Clinical Trial"], ["C14460", "NON Mouse"], ["C54035", "Serious"], ["C37910", "Allergic"], ["C25281", "Associated"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C25490", "During"], ["C71104", "Clinical Trial"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C54035", "Serious"], ["C37910", "Allergic"], ["C166400", "Inclusive"], ["C143282", "Anaphylaxis, CTCAE"], ["C101282", "Have"], ["C25639", "Receive"], ["C53286", "Next"], ["C65216", "Adalimumab"], ["C70962", "Agent Administration"], ["C198613", "CFI wt Allele"], ["C75889", "PAX6 wt Allele"], ["C25637", "Reaction"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C54035", "Serious"], ["C168250", "History of Allergic Reaction"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C64597", "Immediately"], ["C16289", "Andorra"], ["C49236", "Therapeutic Procedure"], ["C15261", "Immunosuppressive Therapy"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C45319", "Study Object"], ["C52874", "SPI1 wt Allele"], ["C188328", "Sixty Four"], ["C16960", "Patient"], ["C62355", "With"], ["C2884", "Rheumatoid Arthritis"], ["C25705", "Treating"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C154196", "Washo Language"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C124639", "Depression"], ["C52874", "SPI1 wt Allele"], ["C3115", "Type IV Hypersensitivity"], ["C124639", "Depression"], ["C52874", "SPI1 wt Allele"], ["C81869", "Immunoglobulin Measurement"], ["C43508", "Oregon"], ["C54126", "Delta"], ["C16727", "India"], ["C45674", "Enumeration"], ["C52874", "SPI1 wt Allele"], ["C25728", "T Category"], ["C113692", "Child-Pugh Class B"], ["C12536", "Natural Killer Cell"], ["C48938", "Cell Count"], ["C12547", "Monocyte"], ["C74798", "Macrophage Count"], ["C16289", "Andorra"], ["C51950", "Neutrophil Count"], ["C16289", "Andorra"], ["C2991", "Disease or Disorder"], ["C16727", "India"], ["C82500", "Disease Controlled"], ["C52874", "SPI1 wt Allele"], ["C71104", "Clinical Trial"], ["C52874", "SPI1 wt Allele"], ["C18368", "TNF Gene"], ["C128667", "More"], ["C52874", "SPI1 wt Allele"], ["C166400", "Inclusive"], ["C7587", "Adult Lymphoma"], ["C101282", "Have"], ["C25599", "Observed"], ["C16960", "Patient"], ["C25639", "Receive"], ["C76246", "Blood Group A"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C49156", "Comparison"], ["C62355", "With"], ["C64355", "Scientific Control"], ["C16960", "Patient"], ["C25275", "Occurrence"], ["C154196", "Washo Language"], ["C13634", "Retinoic Acid Response Element"], ["C16727", "India"], ["C38008", "Post"], ["C53292", "Marketing"], ["C127262", "CDISC SDTM Environmental Setting Terminology"], ["C52874", "SPI1 wt Allele"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C45782", "Background"], ["C17102", "Risk"], ["C64956", "For"], ["C7587", "Adult Lymphoma"], ["C16289", "Andorra"], ["C16727", "India"], ["C2884", "Rheumatoid Arthritis"], ["C16960", "Patient"], ["C62355", "With"], ["C25248", "Long"], ["C62166", "Standing"], ["C25227", "High"], ["C154405", "Active State"], ["C93210", "Inflammatory Disorder"], ["C17102", "Risk"], ["C25498", "Estimate"], ["C62355", "With"], ["C48434", "Electrical Current"], ["C76246", "Blood Group A"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C17102", "Risk"], ["C64956", "For"], ["C18732", "Development"], ["C52874", "SPI1 wt Allele"], ["C16289", "Andorra"], ["C118472", "Other License Status"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C16329", "Belgium"], ["C82931", "Exclusion"], ["C65099", "Some"], ["C48275", "Death Related to Adverse Event"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16423", "Child"], ["C16266", "Adolescents"], ["C16289", "Andorra"], ["C64643", "Up to"], ["C126884", "Twenty Two"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C25705", "Treating"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C111798", "Eighteen"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C166400", "Inclusive"], ["C65216", "Adalimumab"], ["C16727", "India"], ["C38008", "Post"], ["C53292", "Marketing"], ["C127262", "CDISC SDTM Environmental Setting Terminology"], ["C45828", "Approximate"], ["C81009", "Half"], ["C118472", "Other License Status"], ["C76246", "Blood Group A"], ["C69085", "Assortment"], ["C52874", "SPI1 wt Allele"], ["C46003", "Difference"], ["C16289", "Andorra"], ["C13634", "Retinoic Acid Response Element"], ["C114711", "Usually"], ["C25281", "Associated"], ["C62355", "With"], ["C15261", "Immunosuppressive Therapy"], ["C76246", "Blood Group A"], ["C17102", "Risk"], ["C64956", "For"], ["C18732", "Development"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C16423", "Child"], ["C16289", "Andorra"], ["C16266", "Adolescents"], ["C25705", "Treating"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C16329", "Belgium"], ["C82931", "Exclusion"], ["C13634", "Retinoic Acid Response Element"], ["C52874", "SPI1 wt Allele"], ["C8459", "Hepatosplenic T-Cell Lymphoma"], ["C101282", "Have"], ["C25737", "Identification"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C13634", "Retinoic Acid Response Element"], ["C181852", "Protocol Therapy Status"], ["C52874", "SPI1 wt Allele"], ["C3466", "T-Cell Non-Hodgkin Lymphoma"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C116076", "Very"], ["C14138", "Aggressive"], ["C2991", "Disease or Disorder"], ["C25379", "Course"], ["C16289", "Andorra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C114711", "Usually"], ["C48275", "Death Related to Adverse Event"], ["C65099", "Some"], ["C52874", "SPI1 wt Allele"], ["C12476", "T-Lymphocyte"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C101282", "Have"], ["C54069", "Occur"], ["C16727", "India"], ["C91107", "Young Adult"], ["C16960", "Patient"], ["C92667", "SPARC wt Allele"], ["C25730", "Concomitant"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C290", "Azathioprine"], ["C43508", "Oregon"], ["C195", "Mercaptopurine"], ["C64956", "For"], ["C3138", "Inflammatory Bowel Disease"], ["C62230", "Potential"], ["C17102", "Risk"], ["C62355", "With"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C290", "Azathioprine"], ["C43508", "Oregon"], ["C195", "Mercaptopurine"], ["C16289", "Andorra"], ["C65216", "Adalimumab"], ["C16329", "Belgium"], ["C76246", "Blood Group A"], ["C17102", "Risk"], ["C64956", "For"], ["C18732", "Development"], ["C52874", "SPI1 wt Allele"], ["C8459", "Hepatosplenic T-Cell Lymphoma"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C16329", "Belgium"], ["C82931", "Exclusion"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C101282", "Have"], ["C74521", "Include"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C9305", "Malignant Neoplasm"], ["C43508", "Oregon"], ["C16727", "India"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C53279", "Continue"], ["C53286", "Next"], ["C18732", "Development"], ["C52874", "SPI1 wt Allele"], ["C9305", "Malignant Neoplasm"], ["C25406", "Additional"], ["C16329", "Belgium"], ["C16727", "India"], ["C65216", "Adalimumab"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C16960", "Patient"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C64916", "All"], ["C16960", "Patient"], ["C16289", "Andorra"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C198967", "Extensive Extracapsular Extention"], ["C574", "Immunosuppressant"], ["C49236", "Therapeutic Procedure"], ["C43508", "Oregon"], ["C3346", "Psoriasis"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C29973", "PUVA Photochemotherapy"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C25500", "Examined"], ["C64956", "For"], ["C25626", "Present"], ["C52874", "SPI1 wt Allele"], ["C25594", "Negation"], ["C103113", "NCI CTEP SDC Melanoma Sub-Category Terminology"], ["C2920", "Malignant Skin Neoplasm"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16289", "Andorra"], ["C175242", "During Treatment"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C103113", "NCI CTEP SDC Melanoma Sub-Category Terminology"], ["C16289", "Andorra"], ["C9231", "Merkel Cell Carcinoma"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C166400", "Inclusive"], ["C65216", "Adalimumab"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C16727", "India"], ["C75889", "PAX6 wt Allele"], ["C71104", "Clinical Trial"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C1789", "Infliximab"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C159124", "GDC Treatment Outcome Terminology"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C3199", "Chronic Obstructive Pulmonary Disease"], ["C128667", "More"], ["C25258", "Most"], ["C16727", "India"], ["C23402", "Murine Lung"], ["C43508", "Oregon"], ["C23352", "Murine Head and Neck"], ["C188308", "Reported Information"], ["C16727", "India"], ["C1789", "Infliximab"], ["C25705", "Treating"], ["C16960", "Patient"], ["C49156", "Comparison"], ["C62355", "With"], ["C64355", "Scientific Control"], ["C16960", "Patient"], ["C64916", "All"], ["C16960", "Patient"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C68807", "Heavy"], ["C17934", "Tobacco Smoking"], ["C16329", "Belgium"], ["C65140", "When"], ["C81168", "Any"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C16727", "India"], ["C3199", "Chronic Obstructive Pulmonary Disease"], ["C16960", "Patient"], ["C71344", "Associate of Science"], ["C128793", "Microplate Well"], ["C71344", "Associate of Science"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C164135", "Increased"], ["C17102", "Risk"], ["C64956", "For"], ["C9305", "Malignant Neoplasm"], ["C89272", "Due To"], ["C68807", "Heavy"], ["C17934", "Tobacco Smoking"], ["C62355", "With"], ["C48434", "Electrical Current"], ["C25474", "Data"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C17998", "Unknown"], ["C198613", "CFI wt Allele"], ["C65216", "Adalimumab"], ["C43442", "Biomaterial Treatment"], ["C17102", "Risk"], ["C64956", "For"], ["C4086", "Dysplasia"], ["C43508", "Oregon"], ["C4910", "Colon Carcinoma"], ["C64916", "All"], ["C16960", "Patient"], ["C62355", "With"], ["C2952", "Ulcerative Colitis"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C158997", "GDC Analyte Type Terminology"], ["C164135", "Increased"], ["C17102", "Risk"], ["C64956", "For"], ["C4086", "Dysplasia"], ["C43508", "Oregon"], ["C4910", "Colon Carcinoma"], ["C64956", "For"], ["C48175", "Example"], ["C16960", "Patient"], ["C62355", "With"], ["C25248", "Long"], ["C62166", "Standing"], ["C2952", "Ulcerative Colitis"], ["C43508", "Oregon"], ["C4828", "Primary Sclerosing Cholangitis"], ["C43508", "Oregon"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C25629", "Prior"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C4086", "Dysplasia"], ["C43508", "Oregon"], ["C4910", "Colon Carcinoma"], ["C16329", "Belgium"], ["C64956", "For"], ["C4086", "Dysplasia"], ["C158997", "GDC Analyte Type Terminology"], ["C25647", "Regular"], ["C201357", "Before Timing Type"], ["C49236", "Therapeutic Procedure"], ["C16289", "Andorra"], ["C2991", "Disease or Disorder"], ["C25379", "Course"], ["C25214", "Evaluation"], ["C74521", "Include"], ["C16450", "Colonoscopy"], ["C16289", "Andorra"], ["C97722", "PER1 wt Allele"], ["C25388", "Local-Regional"], ["C13634", "Retinoic Acid Response Element"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C34889", "Pancytopenia"], ["C166400", "Inclusive"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C49562", "Adverse Event Domain"], ["C52874", "SPI1 wt Allele"], ["C149975", "System Dosing Unit"], ["C166400", "Inclusive"], ["C41130", "Significant"], ["C2979", "Cytopenia"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C3408", "Thrombocytopenia"], ["C26816", "Leukopenia"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C64916", "All"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C64597", "Immediately"], ["C25261", "Medical"], ["C41209", "Attention Concentration"], ["C198613", "CFI wt Allele"], ["C16289", "Andorra"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C17610", "Blood Sample"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C43623", "Persistent"], ["C143485", "Fever, CTCAE"], ["C37921", "Bruise"], ["C26791", "Hemorrhage"], ["C50685", "Pallor"], ["C92667", "SPARC wt Allele"], ["C65216", "Adalimumab"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C25458", "Confirmation"], ["C41130", "Significant"], ["C72665", "Similarity"], ["C16295", "Antibody"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81893", "Standard"], ["C126885", "Twenty Three"], ["C923", "Vaccine"], ["C16289", "Andorra"], ["C53482", "Influenza"], ["C14283", "Virus"], ["C15346", "Vaccination"], ["C25599", "Observed"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C45319", "Study Object"], ["C16727", "India"], ["C16557", "Equatorial Guinea"], ["C52678", "Legal Adult"], ["C62355", "With"], ["C2884", "Rheumatoid Arthritis"], ["C75419", "World Health Organization"], ["C25705", "Treating"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C43508", "Oregon"], ["C49648", "Placebo Control"], ["C53269", "No Information Available"], ["C68869", "Are"], ["C25429", "Availability"], ["C92667", "SPARC wt Allele"], ["C25666", "Second"], ["C17214", "Disease Transmission"], ["C52874", "SPI1 wt Allele"], ["C128320", "Infection"], ["C158169", "Buyei Chinese"], ["C89279", "Reside"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C65216", "Adalimumab"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C16960", "Patient"], ["C198613", "CFI wt Allele"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C16329", "Belgium"], ["C64643", "Up to"], ["C48871", "Date Data Type"], ["C62355", "With"], ["C64916", "All"], ["C16727", "India"], ["C25369", "Agreement"], ["C62355", "With"], ["C48434", "Electrical Current"], ["C17564", "Guideline"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C65216", "Adalimumab"], ["C49236", "Therapeutic Procedure"], ["C16960", "Patient"], ["C92667", "SPARC wt Allele"], ["C65216", "Adalimumab"], ["C106184", "May"], ["C25639", "Receive"], ["C25456", "Concurrent"], ["C151896", "Other Than"], ["C64956", "For"], ["C89279", "Reside"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C89279", "Reside"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C298", "BCG Vaccine"], ["C159124", "GDC Treatment Outcome Terminology"], ["C159124", "GDC Treatment Outcome Terminology"], ["C65216", "Adalimumab"], ["C49641", "In Utero"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C64956", "For"], ["C163771", "Illness Intrusiveness Rating 5"], ["C29846", "Month"], ["C53286", "Next"], ["C25189", "Mother"], ["C42555", "Siemens"], ["C25551", "Last"], ["C65216", "Adalimumab"], ["C122632", "Injection Dosing Unit"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C3080", "Congestive Heart Failure"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C71104", "Clinical Trial"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C3080", "Congestive Heart Failure"], ["C16289", "Andorra"], ["C164135", "Increased"], ["C16880", "Mortality Rate"], ["C89272", "Due To"], ["C3080", "Congestive Heart Failure"], ["C101282", "Have"], ["C25599", "Observed"], ["C52874", "SPI1 wt Allele"], ["C3080", "Congestive Heart Failure"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C65216", "Adalimumab"], ["C65216", "Adalimumab"], ["C16329", "Belgium"], ["C62355", "With"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C156242", "Mild Hallucination"], ["C143529", "Heart Failure, CTCAE"], ["C66904", "New York Heart Association Class I"], ["C62395", "WHO Central Nervous System Grade 2"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C37933", "Contraindicated"], ["C16727", "India"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C159124", "GDC Treatment Outcome Terminology"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C143529", "Heart Failure, CTCAE"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C119238", "New or Worsening Symptom"], ["C52874", "SPI1 wt Allele"], ["C3080", "Congestive Heart Failure"], ["C37916", "Autoimmune"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C106184", "May"], ["C20200", "Outcome"], ["C16727", "India"], ["C25513", "Formation"], ["C52874", "SPI1 wt Allele"], ["C37916", "Autoimmune"], ["C16295", "Antibody"], ["C62534", "Arginine/Omega-3 Fatty Acids/Nucleotides Oral Supplement"], ["C52874", "SPI1 wt Allele"], ["C25322", "Long-Term"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C92667", "SPARC wt Allele"], ["C18732", "Development"], ["C52874", "SPI1 wt Allele"], ["C37916", "Autoimmune"], ["C2991", "Disease or Disorder"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C160764", "Unknown Molecular Analysis"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C27153", "Lupus Erythematosus"], ["C72665", "Similarity"], ["C168217", "Genetic Syndrome Associated with Congenital Heart Defect"], ["C53286", "Next"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C16289", "Andorra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C36659", "CTNNB1 Gene Mutation"], ["C64956", "For"], ["C16295", "Antibody"], ["C64937", "Against"], ["C449", "DNA"], ["C25519", "Further"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C64974", "Give"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C28226", "Biological"], ["C43508", "Oregon"], ["C18368", "TNF Gene"], ["C54035", "Serious"], ["C16727", "India"], ["C15206", "Clinical Study"], ["C62355", "With"], ["C25456", "Concurrent"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C38717", "Anakinra"], ["C16289", "Andorra"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C2381", "Etanercept"], ["C62355", "With"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C45330", "Added"], ["C142422", "Clinical Benefit"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C2381", "Etanercept"], ["C48440", "Single"], ["C52874", "SPI1 wt Allele"], ["C25447", "Characteristic"], ["C52874", "SPI1 wt Allele"], ["C49562", "Adverse Event Domain"], ["C62355", "With"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16289", "Andorra"], ["C38717", "Anakinra"], ["C49236", "Therapeutic Procedure"], ["C72665", "Similarity"], ["C106184", "May"], ["C20200", "Outcome"], ["C25516", "From"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C38717", "Anakinra"], ["C16289", "Andorra"], ["C118472", "Other License Status"], ["C18368", "TNF Gene"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16289", "Andorra"], ["C38717", "Anakinra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C25730", "Concomitant"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C62355", "With"], ["C118472", "Other License Status"], ["C28226", "Biological"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C38717", "Anakinra"], ["C16289", "Andorra"], ["C28898", "Abatacept"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C18368", "TNF Gene"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C48055", "Base"], ["C65137", "Upon"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C164135", "Increased"], ["C17102", "Risk"], ["C64956", "For"], ["C166400", "Inclusive"], ["C54035", "Serious"], ["C16289", "Andorra"], ["C118472", "Other License Status"], ["C62230", "Potential"], ["C16974", "Pharmacology"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C160609", "Surgical Procedure was Curative Therapy"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C142988", "Limited"], ["C49667", "Safety Study"], ["C54627", "Experience"], ["C52874", "SPI1 wt Allele"], ["C15329", "Surgical Procedure"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C25248", "Long"], ["C81009", "Half"], ["C20203", "Laser-Induced Fluorescence Endoscopy"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C25544", "Into"], ["C113416", "Consideration"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C15329", "Surgical Procedure"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25619", "Plan"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C75419", "World Health Organization"], ["C160609", "Surgical Procedure was Curative Therapy"], ["C92667", "SPARC wt Allele"], ["C65216", "Adalimumab"], ["C16329", "Belgium"], ["C64956", "For"], ["C16289", "Andorra"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C142988", "Limited"], ["C49667", "Safety Study"], ["C54627", "Experience"], ["C16727", "India"], ["C16960", "Patient"], ["C51691", "Arthroplasty"], ["C25639", "Receive"], ["C65216", "Adalimumab"], ["C12386", "Small Intestine"], ["C3284", "Obstruction"], ["C25745", "Failure"], ["C159124", "GDC Treatment Outcome Terminology"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43442", "Biomaterial Treatment"], ["C64956", "For"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C106184", "May"], ["C25626", "Present"], ["C52874", "SPI1 wt Allele"], ["C192305", "Fixed Basis Relative Biological Effectiveness"], ["C50754", "Stenosis"], ["C106184", "May"], ["C15329", "Surgical Procedure"], ["C43442", "Biomaterial Treatment"], ["C25429", "Availability"], ["C25474", "Data"], ["C48313", "Suggestion"], ["C65216", "Adalimumab"], ["C86066", "Do"], ["C25594", "Negation"], ["C43508", "Oregon"], ["C16390", "Etiology"], ["C16268", "Elderly"], ["C71113", "CDISC SDTM Frequency Terminology"], ["C52874", "SPI1 wt Allele"], ["C54035", "Serious"], ["C65216", "Adalimumab"], ["C25705", "Treating"], ["C25490", "During"], ["C188329", "Sixty Five"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C154196", "Washo Language"], ["C25227", "High"], ["C64956", "For"], ["C188329", "Sixty Five"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C161429", "CDISC SDTM Model Version 1.5"], ["C65099", "Some"], ["C52874", "SPI1 wt Allele"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C48275", "Death Related to Adverse Event"], ["C20200", "Outcome"], ["C41209", "Attention Concentration"], ["C17102", "Risk"], ["C64956", "For"], ["C128320", "Infection"], ["C16329", "Belgium"], ["C173947", "Paid Hours"], ["C65140", "When"], ["C25705", "Treating"], ["C16268", "Elderly"], ["C17005", "Population Group"], ["C163702", "Staphylococcal Enterotoxin E"], ["C75329", "Above"]], "rxnorm.special_warnings": [["353484", "Humira"], ["327361", "adalimumab"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["10908", "tuberculin"], ["10908", "tuberculin"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["T005", "Virus"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["327361", "adalimumab"], ["T025", "Cell"], ["327361", "adalimumab"], ["T025", "Cell"], ["T025", "Cell"], ["353484", "Humira"], ["1256", "azathioprine"], ["103", "mercaptopurine"], ["1256", "azathioprine"], ["103", "mercaptopurine"], ["353484", "Humira"], ["T025", "Cell"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["T025", "Cell"], ["327361", "adalimumab"], ["191831", "infliximab"], ["191831", "infliximab"], ["327361", "adalimumab"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["T005", "Virus"], ["327361", "adalimumab"], ["8375", "placebo"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["327361", "adalimumab"], ["1656695", "adalimumab Injection"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["72435", "anakinra"], ["214555", "etanercept"], ["214555", "etanercept"], ["214555", "etanercept"], ["72435", "anakinra"], ["72435", "anakinra"], ["327361", "adalimumab"], ["72435", "anakinra"], ["327361", "adalimumab"], ["72435", "anakinra"], ["614391", "abatacept"], ["353484", "Humira"], ["327361", "adalimumab"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"], ["353484", "Humira"]], "loinc.special_warnings": [["LA22004-8", "IN"], ["LA25433-6", "Biological"], ["MTHU008539", "Name"], ["LP18011-4", "Number"], ["LP74970-2", "Infections"], ["LA16824-7", "More"], ["LA24225-7", "Susceptible"], ["LA30751-4", "Serious"], ["LP74970-2", "Infections"], ["LA13035-3", "Impaired"], ["LP199934-3", "Lung"], ["LA8916-4", "Function"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["LP74970-2", "Infections"], ["LP74970-2", "Infections"], ["MTHU020835", "Tuberculosis"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LP173592-9", "Adalimumab"], ["LA14161-6", "May"], ["LA33103-5", "Four"], ["MTHU068094", "Months"], ["LA20297-0", "Monitoring"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA16666-2", "Active"], ["LP74970-2", "Infections"], ["LA28752-6", "Chronic"], ["LA22025-3", "OR"], ["LP74970-2", "Infections"], ["LP74970-2", "Infections"], ["LA22004-8", "IN"], ["MTHU020835", "Tuberculosis"], ["LA22004-8", "IN"], ["LA19541-4", "High risk"], ["MTHU020835", "Tuberculosis"], ["LA22025-3", "OR"], ["LA10477-0", "Histoplasmosis"], ["LA10444-0", "Coccidioidomycosis"], ["LA22025-3", "OR"], ["LA10436-6", "Blastomycosis"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LA33028-4", "Prior"], ["LP267221-2", "Therapy"], ["MTHU029809", "Other"], ["LP74970-2", "Infections"], ["LP17763-1", "A"], ["LA9039-4", "New"], ["LP266919-2", "Infection"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LP17763-1", "A"], ["LP267470-5", "Complete"], ["LP249287-6", "Diagnostic"], ["LA27332-8", "Evaluation"], ["LA16779-3", "Humira"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LP17763-1", "A"], ["LA9039-4", "New"], ["LA30751-4", "Serious"], ["LP266919-2", "Infection"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LP267221-2", "Therapy"], ["LP266919-2", "Infection"], ["LP200075-2", "IS"], ["LP207667-9", "Exercise"], ["LA16779-3", "Humira"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP7800-8", "History"], ["LP266919-2", "Infection"], ["LA22025-3", "OR"], ["LA26681-9", "Underlying"], ["LA14161-6", "May"], ["LP74970-2", "Infections"], ["LP230280-2", "Medications"], ["LA30751-4", "Serious"], ["LP74970-2", "Infections"], ["LA30751-4", "Serious"], ["LP74970-2", "Infections"], ["LP102225-2", "Invasive"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LP74970-2", "Infections"], ["LA10485-3", "Listeriosis"], ["LA10483-8", "Legionellosis"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LA16779-3", "Humira"], ["MTHU029809", "Other"], ["LA30751-4", "Serious"], ["LP74970-2", "Infections"], ["LA22004-8", "IN"], ["MTHU854704", "Clinical trials"], ["MTHU020831", "Pneumonia"], ["MTHU020793", "Arthritis"], ["LA22025-3", "OR"], ["LA32822-1", "Fatal"], ["LP74970-2", "Infections"], ["LP6486-7", "Reported"], ["MTHU020835", "Tuberculosis"], ["MTHU020835", "Tuberculosis"], ["LA9039-4", "New"], ["MTHU020835", "Tuberculosis"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LA16779-3", "Humira"], ["LP270144-1", "Cases"], ["54542-6", "Pulmonary:-:Pt:^Patient:-"], ["54542-6", "Pulmonary:-:Pt:^Patient:-"], ["LA15457-7", "I"], ["LA13503-0", "E"], ["MTHU020835", "Tuberculosis"], ["LP267221-2", "Therapy"], ["LA16779-3", "Humira"], ["LA18187-7", "All"], ["LA14331-5", "Both"], ["LA16666-2", "Active"], ["LA22025-3", "OR"], ["LA18632-2", "Inactive"], ["LA24776-9", "Latent"], ["MTHU020835", "Tuberculosis"], ["LP266919-2", "Infection"], ["LA27332-8", "Evaluation"], ["LP17763-1", "A"], ["LP73913-3", "Assessment"], ["LP66710-2", "Patient"], ["LP7800-8", "History"], ["MTHU020835", "Tuberculosis"], ["LA22025-3", "OR"], ["LA15097-1", "Possible"], ["LA16666-2", "Active"], ["MTHU020835", "Tuberculosis"], ["LA22025-3", "OR"], ["LP267221-2", "Therapy"], ["LP200187-5", "Screening"], ["LA15457-7", "I"], ["LA13503-0", "E"], ["LP32625-3", "Tuberculin"], ["LP130014-6", "Skin"], ["LA7556-9", "Test"], ["LP7138-3", "Chest"], ["LP21166-1", "X-ray"], ["LA19974-7", "Performed"], ["LA22004-8", "IN"], ["LA18187-7", "All"], ["LA4583-6", "Local"], ["LA14161-6", "May"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP66710-2", "Patient"], ["LP29708-2", "Cardiology"], ["LA14496-6", "False"], ["LA6577-6", "Negative"], ["LP32625-3", "Tuberculin"], ["LP130014-6", "Skin"], ["LA7556-9", "Test"], ["LA22004-8", "IN"], ["98971-5", "Severely ill:Find:Pt:^Patient:Ord"], ["LA22025-3", "OR"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA16666-2", "Active"], ["MTHU020835", "Tuberculosis"], ["LP200075-2", "IS"], ["LA16779-3", "Humira"], ["LP267221-2", "Therapy"], ["LA21291-2", "Not"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LA22004-8", "IN"], ["LA18187-7", "All"], ["LA14987-4", "Below"], ["LP267221-2", "Therapy"], ["LA29696-4", "Very"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA24776-9", "Latent"], ["MTHU020835", "Tuberculosis"], ["LP200075-2", "IS"], ["LA15291-0", "Suspected"], ["LP17763-1", "A"], ["MTHU010489", "Physician"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["MTHU020835", "Tuberculosis"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA24776-9", "Latent"], ["MTHU020835", "Tuberculosis"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["MTHU020835", "Tuberculosis"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LA22004-8", "IN"], ["LA4583-6", "Local"], ["MTHU020835", "Tuberculosis"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LA28474-7", "Significant"], ["46467-7", "Risk factors:Find:Pt:^Patient:Nom"], ["MTHU020835", "Tuberculosis"], ["LP17763-1", "A"], ["LA6577-6", "Negative"], ["LA7556-9", "Test"], ["MTHU020835", "Tuberculosis"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP7800-8", "History"], ["LA24776-9", "Latent"], ["LA22025-3", "OR"], ["LA16666-2", "Active"], ["MTHU020835", "Tuberculosis"], ["LA22004-8", "IN"], ["LA8913-1", "Adequate"], ["LP94823-9", "Treatment"], ["LA15290-2", "Confirmed"], ["LP94823-9", "Treatment"], ["MTHU020835", "Tuberculosis"], ["LP270144-1", "Cases"], ["MTHU020835", "Tuberculosis"], ["LA22004-8", "IN"], ["LA16779-3", "Humira"], ["LA14973-4", "Some"], ["LA16666-2", "Active"], ["MTHU020835", "Tuberculosis"], ["MTHU020835", "Tuberculosis"], ["LA16779-3", "Humira"], ["LP417559-4", "Safe Environment for Every Kid"], ["LA14523-7", "Advice"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP75708-5", "Symptoms"], ["LP17763-1", "A"], ["MTHU020835", "Tuberculosis"], ["LP266919-2", "Infection"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LA30866-0", "Persistent cough"], ["MTHU020881", "Weight loss"], ["LA32394-1", "Low grade"], ["LP74849-8", "Fever"], ["LA22025-3", "OR"], ["LP267221-2", "Therapy"], ["LA16779-3", "Humira"], ["MTHU029809", "Other"], ["LP74970-2", "Infections"], ["LP74970-2", "Infections"], ["LP102225-2", "Invasive"], ["LP74970-2", "Infections"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LA16779-3", "Humira"], ["LP74970-2", "Infections"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA10082-8", "Sometimes"], ["LA22004-8", "IN"], ["LA32822-1", "Fatal"], ["LP75708-5", "Symptoms"], ["LP74849-8", "Fever"], ["MTHU020881", "Weight loss"], ["LA16122-6", "Cough"], ["LA22025-3", "OR"], ["54542-6", "Pulmonary:-:Pt:^Patient:-"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LA30751-4", "Serious"], ["LA22025-3", "OR"], ["LA7473-7", "Shock"], ["LP102225-2", "Invasive"], ["LP266919-2", "Infection"], ["LA15291-0", "Suspected"], ["LA16779-3", "Humira"], ["MTHU008876", "Diagnosis"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LA7553-6", "Consultation"], ["LP17763-1", "A"], ["MTHU010489", "Physician"], ["LA22004-8", "IN"], ["LP68340-6", "Continuity assessment record and evaluation"], ["LP102225-2", "Invasive"], ["LP74970-2", "Infections"], ["LA18126-5", "Hepatitis B"], ["LA18126-5", "Hepatitis B"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA16779-3", "Humira"], ["LA28752-6", "Chronic"], ["LP14855-8", "Virus"], ["LA15457-7", "I"], ["LA13503-0", "E"], ["LP73434-0", "Surface"], ["LA6576-8", "Positive"], ["LA14973-4", "Some"], ["LP270144-1", "Cases"], ["LP17763-1", "A"], ["LA32822-1", "Fatal"], ["LP32426-6", "tested"], ["LP266919-2", "Infection"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LA7556-9", "Test"], ["LA6576-8", "Positive"], ["LA18126-5", "Hepatitis B"], ["LP266919-2", "Infection"], ["LA7553-6", "Consultation"], ["LP17763-1", "A"], ["MTHU010489", "Physician"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA18126-5", "Hepatitis B"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LP75708-5", "Symptoms"], ["LA16666-2", "Active"], ["LP266919-2", "Infection"], ["LP267221-2", "Therapy"], ["MTHU068094", "Months"], ["LP267221-2", "Therapy"], ["LA8913-1", "Adequate"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LP267221-2", "Therapy"], ["LA7338-2", "Not available"], ["LA22004-8", "IN"], ["LA16779-3", "Humira"], ["LP267221-2", "Therapy"], ["LP94823-9", "Treatment"], ["LP89782-4", "Neurological"], ["MTHU058708", "Events"], ["LA16779-3", "Humira"], ["LA22004-8", "IN"], ["LA15679-6", "Rare"], ["LA9039-4", "New"], ["LA22025-3", "OR"], ["LP7787-7", "Clinical"], ["LP75708-5", "Symptoms"], ["LA22025-3", "OR"], ["LA4174-4", "Central Nervous System"], ["LA18199-2", "Disease"], ["LP75152-6", "Multiple sclerosis"], ["LA24844-5", "Peripheral"], ["LA18199-2", "Disease"], ["LP207667-9", "Exercise"], ["LA22004-8", "IN"], ["LA16779-3", "Humira"], ["LA22004-8", "IN"], ["LP32605-5", "pre"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LA24844-5", "Peripheral"], ["LP7441-1", "Nervous system"], ["LA16779-3", "Humira"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LA16550-8", "Intermediate"], ["LA16973-2", "Neurologic"], ["LA27332-8", "Evaluation"], ["LA19974-7", "Performed"], ["LA22004-8", "IN"], ["LA16550-8", "Intermediate"], ["LA33028-4", "Prior"], ["LA16779-3", "Humira"], ["LP267221-2", "Therapy"], ["LP93408-0", "during treatment"], ["LP32605-5", "pre"], ["LA22025-3", "OR"], ["LA30751-4", "Serious"], ["LA16779-3", "Humira"], ["LA15679-6", "Rare"], ["MTHU854704", "Clinical trials"], ["LA30751-4", "Serious"], ["LA16779-3", "Humira"], ["MTHU854704", "Clinical trials"], ["LA30751-4", "Serious"], ["LA7413-3", "Anaphylaxis"], ["LA32660-5", "Received"], ["LA16779-3", "Humira"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP73228-6", "Reaction"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LA30751-4", "Serious"], ["LA9532-8", "Allergic reaction"], ["LA16779-3", "Humira"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP74341-6", "Study"], ["LA15161-5", "Rheumatoid Arthritis"], ["LA16779-3", "Humira"], ["LA32-8", "No"], ["LP74718-5", "Depression"], ["LP266901-0", "Delayed"], ["LP6886-8", "Type"], ["LP74718-5", "Depression"], ["LA22025-3", "OR"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["LA14518-7", "B"], ["MTHU001933", "Cells"], ["LP411256-3", "Monocyte"], ["LP14314-6", "Macrophages"], ["MTHU006207", "Neutrophils"], ["LA22004-8", "IN"], ["MTHU854704", "Clinical trials"], ["LA16824-7", "More"], ["LP270144-1", "Cases"], ["LA15685-3", "Lymphoma"], ["LP6425-5", "Observed"], ["LP17763-1", "A"], ["LP7741-4", "Control"], ["LA15679-6", "Rare"], ["LA22004-8", "IN"], ["LP32606-3", "post"], ["MTHU047625", "Setting"], ["LP270144-1", "Cases"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP200075-2", "IS"], ["LA24377-6", "Increased"], ["LA15685-3", "Lymphoma"], ["LA22004-8", "IN"], ["LA15161-5", "Rheumatoid Arthritis"], ["MTHU046607", "Standing"], ["LA16666-2", "Active"], ["LA18199-2", "Disease"], ["LP17763-1", "A"], ["LA15097-1", "Possible"], ["MTHU029809", "Other"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA14973-4", "Some"], ["LA32822-1", "Fatal"], ["LP6486-7", "Reported"], ["MTHU010047", "Age"], ["LP267221-2", "Therapy"], ["MTHU010047", "Age"], ["LP173592-9", "Adalimumab"], ["LA22004-8", "IN"], ["LP32606-3", "post"], ["MTHU047625", "Setting"], ["LP270144-1", "Cases"], ["MTHU029809", "Other"], ["LP270144-1", "Cases"], ["LP17763-1", "A"], ["LA15679-6", "Rare"], ["LA14747-2", "Usually"], ["LP17763-1", "A"], ["LA22004-8", "IN"], ["LA15679-6", "Rare"], ["LP270144-1", "Cases"], ["LP14634-7", "T-cell"], ["LA15685-3", "Lymphoma"], ["LP40035-5", "Identified"], ["LA22004-8", "IN"], ["LP173592-9", "Adalimumab"], ["LA15679-6", "Rare"], ["LP6886-8", "Type"], ["LP14634-7", "T-cell"], ["LA15685-3", "Lymphoma"], ["LP17763-1", "A"], ["LA29696-4", "Very"], ["LA18199-2", "Disease"], ["LP200075-2", "IS"], ["LA14747-2", "Usually"], ["LA32822-1", "Fatal"], ["LA14973-4", "Some"], ["LP14634-7", "T-cell"], ["LA16779-3", "Humira"], ["LA22004-8", "IN"], ["LA13524-6", "Adult"], ["LP94823-9", "Treatment"], ["LA31624-2", "Azathioprine"], ["LA22025-3", "OR"], ["LP20594-5", "6"], ["LP15173-5", "Mercaptopurine"], ["LA15162-3", "Inflammatory Bowel Disease"], ["LA12701-1", "Combination"], ["LA31624-2", "Azathioprine"], ["LA22025-3", "OR"], ["LP20594-5", "6"], ["LP15173-5", "Mercaptopurine"], ["LA16779-3", "Humira"], ["LP17763-1", "A"], ["LP14634-7", "T-cell"], ["LA15685-3", "Lymphoma"], ["LA22004-8", "IN"], ["LA16779-3", "Humira"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA32-8", "No"], ["LP17763-1", "A"], ["LP7800-8", "History"], ["LP128794-7", "Malignancy"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["LP128794-7", "Malignancy"], ["LP263791-8", "Additional"], ["LA22004-8", "IN"], ["LA16779-3", "Humira"], ["LP94823-9", "Treatment"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA18187-7", "All"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP128548-7", "Medical history"], ["LP267221-2", "Therapy"], ["LA22025-3", "OR"], ["LA15165-6", "Psoriasis"], ["LP17763-1", "A"], ["LP7800-8", "History"], ["LA16783-5", "PUVA"], ["LP94823-9", "Treatment"], ["LP149220-8", "Presence"], ["LA14279-6", "Melanoma"], ["LA10543-9", "Skin Cancer"], ["LA33028-4", "Prior"], ["LP93408-0", "during treatment"], ["LA16779-3", "Humira"], ["LA14279-6", "Melanoma"], ["T025", "Cell"], ["LA15448-6", "Carcinoma"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LP173592-9", "Adalimumab"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["LA32820-5", "Moderate to severe"], ["LA28200-6", "Chronic obstructive pulmonary disease"], ["LA10559-5", "COPD"], ["LA16824-7", "More"], ["LA13938-8", "Mostly"], ["LA22004-8", "IN"], ["LP199934-3", "Lung"], ["LA22025-3", "OR"], ["LP33999-1", "Head and Neck"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LP7741-4", "Control"], ["LA18187-7", "All"], ["LP17763-1", "A"], ["LP7800-8", "History"], ["LA6213-8", "Heavy smoking"], ["LA22004-8", "IN"], ["LA10559-5", "COPD"], ["LA18365-9", "Well"], ["LA22004-8", "IN"], ["LA24544-1", "Increased risk"], ["LP128794-7", "Malignancy"], ["LA6213-8", "Heavy smoking"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA14748-0", "Not known"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP173592-9", "Adalimumab"], ["LP94823-9", "Treatment"], ["LA22025-3", "OR"], ["LA10537-1", "Colon Cancer"], ["LA18187-7", "All"], ["LA21988-3", "AT"], ["LA24544-1", "Increased risk"], ["LA22025-3", "OR"], ["LP199922-8", "Colon"], ["LA15448-6", "Carcinoma"], ["MTHU046607", "Standing"], ["LA22025-3", "OR"], ["LA21208-6", "Primary"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LA33028-4", "Prior"], ["LP7800-8", "History"], ["LA22025-3", "OR"], ["LP199922-8", "Colon"], ["LA15448-6", "Carcinoma"], ["LA21988-3", "AT"], ["LA15487-4", "Regular"], ["LP267221-2", "Therapy"], ["LA18199-2", "Disease"], ["LA27332-8", "Evaluation"], ["LA15380-1", "Colonoscopy"], ["LA4583-6", "Local"], ["LA15679-6", "Rare"], ["LP6486-7", "Reported"], ["MTHU058708", "Events"], ["LA28474-7", "Significant"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP6486-7", "Reported"], ["LA16779-3", "Humira"], ["LA18187-7", "All"], ["LP417559-4", "Safe Environment for Every Kid"], ["LP32637-8", "Immediate"], ["LA22668-0", "Attention"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP75708-5", "Symptoms"], ["MTHU029981", "Blood"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP74849-8", "Fever"], ["LA7418-2", "Bleeding"], ["LA16779-3", "Humira"], ["LA16779-3", "Humira"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LA15290-2", "Confirmed"], ["LA28474-7", "Significant"], ["MTHU000146", "Vaccinations"], ["LP20607-5", "standard"], ["55021-0", "Pneumococcal vaccine:-:Pt:^Patient:-"], ["LP14855-8", "Virus"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP74341-6", "Study"], ["LA22004-8", "IN"], ["LA13524-6", "Adult"], ["LA15161-5", "Rheumatoid Arthritis"], ["LP173592-9", "Adalimumab"], ["LA22025-3", "OR"], ["LA32-8", "No"], ["LP263805-6", "Secondary"], ["MTHU050362", "Transmission"], ["LP266919-2", "Infection"], ["LA20283-0", "Vaccines"], ["LA22004-8", "IN"], ["LA16779-3", "Humira"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA15097-1", "Possible"], ["LP182451-7", "Date"], ["LA18187-7", "All"], ["LA22004-8", "IN"], ["MTHU052654", "Agreement"], ["LA33028-4", "Prior"], ["LA16779-3", "Humira"], ["LP267221-2", "Therapy"], ["LA16779-3", "Humira"], ["LA14161-6", "May"], ["MTHU000146", "Vaccinations"], ["LA20283-0", "Vaccines"], ["LA20283-0", "Vaccines"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP102323-5", "Bromocresol green (BCG) dye binding method"], ["LP30374-0", "Vaccine"], ["LP173592-9", "Adalimumab"], ["LA22004-8", "IN"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP20593-7", "5"], ["MTHU068094", "Months"], ["LP6983-3", "Mother"], ["LP15241-0", "S"], ["LP173592-9", "Adalimumab"], ["LA14542-7", "Injection"], ["LP266032-4", "during pregnancy"], ["LP74648-4", "Congestive heart failure"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP7787-7", "Clinical"], ["LP74648-4", "Congestive heart failure"], ["LA24377-6", "Increased"], ["LP74648-4", "Congestive heart failure"], ["LP6425-5", "Observed"], ["LP270144-1", "Cases"], ["LP74648-4", "Congestive heart failure"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LA16779-3", "Humira"], ["LA16779-3", "Humira"], ["LA22004-8", "IN"], ["LA6752-5", "Mild"], ["LP269421-6", "Heart failure"], ["LP264302-3", "NYHA"], ["LA28404-4", "Class I"], ["LA15458-5", "II"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["LA4216-3", "Contraindicated"], ["LA22004-8", "IN"], ["LA32820-5", "Moderate to severe"], ["LP269421-6", "Heart failure"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LA22004-8", "IN"], ["LA9039-4", "New"], ["LA22025-3", "OR"], ["LP75708-5", "Symptoms"], ["LP74648-4", "Congestive heart failure"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LP17807-6", "Antibodies"], ["LA18950-8", "Term"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LP130888-3", "Autoimmune diseases"], ["LP200075-2", "IS"], ["LA4489-6", "Unknown"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LP75708-5", "Symptoms"], ["LP17763-1", "A"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["LA6576-8", "Positive"], ["LP17807-6", "Antibodies"], ["MTHU003299", "DNA"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LA21291-2", "Not"], ["LP29256-2", "given"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA31430-4", "Biologic"], ["LA22025-3", "OR"], ["LA30751-4", "Serious"], ["LP74970-2", "Infections"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LP191906-9", "Anakinra"], ["MTHU054569", "Etanercept"], ["LA32-8", "No"], ["LP7787-7", "Clinical"], ["MTHU054569", "Etanercept"], ["LA27350-0", "Alone"], ["MTHU058708", "Events"], ["LA12701-1", "Combination"], ["MTHU054569", "Etanercept"], ["LP191906-9", "Anakinra"], ["LP267221-2", "Therapy"], ["LA14161-6", "May"], ["LA12701-1", "Combination"], ["LP191906-9", "Anakinra"], ["MTHU029809", "Other"], ["LA12701-1", "Combination"], ["LP173592-9", "Adalimumab"], ["LP191906-9", "Anakinra"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA15768-7", "4.5"], ["LP173592-9", "Adalimumab"], ["MTHU029809", "Other"], ["LA31430-4", "Biologic"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP191906-9", "Anakinra"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA15097-1", "Possible"], ["LA24544-1", "Increased risk"], ["LP74970-2", "Infections"], ["LA30751-4", "Serious"], ["LP74970-2", "Infections"], ["MTHU029809", "Other"], ["LA15768-7", "4.5"], ["LP7616-8", "Surgery"], ["LP200075-2", "IS"], ["LA6484-5", "Limited"], ["LA17589-5", "Safety"], ["LP212523-7", "Surgical procedures"], ["LA22004-8", "IN"], ["LA16779-3", "Humira"], ["LP173592-9", "Adalimumab"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP7616-8", "Surgery"], ["LP200075-2", "IS"], ["LA20099-0", "Planned"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LP7616-8", "Surgery"], ["LA16779-3", "Humira"], ["LP74970-2", "Infections"], ["LP200075-2", "IS"], ["LA6484-5", "Limited"], ["LA17589-5", "Safety"], ["LA22004-8", "IN"], ["LA16779-3", "Humira"], ["MTHU002916", "Small bowel"], ["LP222112-7", "Obstruction"], ["LA9664-9", "Failure"], ["LP94823-9", "Treatment"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LA14161-6", "May"], ["LP149220-8", "Presence"], ["LA14109-5", "Fibrotic"], ["LP263828-8", "Stricture"], ["LA14161-6", "May"], ["LA31426-2", "Surgical"], ["LP94823-9", "Treatment"], ["LA16779-3", "Humira"], ["LA21291-2", "Not"], ["LA22025-3", "OR"], ["MTHU029777", "Frequency"], ["LA30751-4", "Serious"], ["LP74970-2", "Infections"], ["LA16779-3", "Humira"], ["MTHU010047", "Age"], ["LP20591-1", "3"], ["LP36790-1", "7"], ["MTHU010047", "Age"], ["LA15765-3", "1.5"], ["LA14973-4", "Some"], ["LP17763-1", "A"], ["LA32822-1", "Fatal"], ["LA22668-0", "Attention"], ["LP266919-2", "Infection"], ["LP62263-6", "Population"], ["MTHU000146", "Vaccinations"], ["LA14991-6", "Above"]], "snomed.pregnancy": [["18720000", "In (attribute)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["16044751000119106", "Polyarticular juvenile idiopathic arthritis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["372091005", "Arthritis (finding)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["68498002", "Antibody (substance)"], ["261122009", "Lower (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["45169001", "Without (attribute)"], ["387381009", "Methotrexate (substance)"], ["18720000", "In (attribute)"], ["35105006", "Increased (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["260695007", "Clearance (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260400001", "Reduced (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421777009", "Abatacept (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"]], "ncit.pregnancy": [["C65216", "Adalimumab"], ["C101282", "Have"], ["C16727", "India"], ["C2884", "Rheumatoid Arthritis"], ["C114357", "Juvenile Idiopathic Arthritis"], ["C16289", "Andorra"], ["C2883", "Arthritis"], ["C16960", "Patient"], ["C65216", "Adalimumab"], ["C71344", "Associate of Science"], ["C157514", "Single Agent Therapy"], ["C16289", "Andorra"], ["C25730", "Concomitant"], ["C642", "Methotrexate"], ["C16295", "Antibody"], ["C25513", "Formation"], ["C154196", "Washo Language"], ["C25309", "Lower"], ["C65140", "When"], ["C65216", "Adalimumab"], ["C154196", "Washo Language"], ["C64974", "Give"], ["C63802", "Together"], ["C62355", "With"], ["C642", "Methotrexate"], ["C16727", "India"], ["C49156", "Comparison"], ["C62355", "With"], ["C25340", "Use"], ["C71344", "Associate of Science"], ["C157514", "Single Agent Therapy"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C25718", "Without"], ["C642", "Methotrexate"], ["C16727", "India"], ["C164135", "Increased"], ["C25513", "Formation"], ["C52874", "SPI1 wt Allele"], ["C16295", "Antibody"], ["C164135", "Increased"], ["C199688", "Drug Clearance"], ["C16289", "Andorra"], ["C25640", "Reduced"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16289", "Andorra"], ["C38717", "Anakinra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C28226", "Biological"], ["C43508", "Oregon"], ["C18368", "TNF Gene"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16289", "Andorra"], ["C28898", "Abatacept"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C28226", "Biological"], ["C43508", "Oregon"], ["C18368", "TNF Gene"]], "rxnorm.pregnancy": [["353484", "Humira"], ["353484", "Humira"], ["6851", "methotrexate"], ["353484", "Humira"], ["6851", "methotrexate"], ["353484", "Humira"], ["6851", "methotrexate"], ["327361", "adalimumab"], ["353484", "Humira"], ["72435", "anakinra"], ["353484", "Humira"], ["614391", "abatacept"]], "loinc.pregnancy": [["LA16779-3", "Humira"], ["LA22004-8", "IN"], ["LA15161-5", "Rheumatoid Arthritis"], ["LA31871-9", "Idiopathic"], ["MTHU020793", "Arthritis"], ["MTHU020793", "Arthritis"], ["LA16779-3", "Humira"], ["LP16198-1", "Methotrexate"], ["LA16779-3", "Humira"], ["LP29256-2", "given"], ["LP16198-1", "Methotrexate"], ["LA22004-8", "IN"], ["LP266973-9", "Comparison"], ["LA16779-3", "Humira"], ["LP16198-1", "Methotrexate"], ["LA22004-8", "IN"], ["LA24377-6", "Increased"], ["LP17807-6", "Antibodies"], ["LA24377-6", "Increased"], ["LP267658-5", "Clearance"], ["LA32619-1", "Reduced"], ["LA26687-6", "Efficacy"], ["LP173592-9", "Adalimumab"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LA12701-1", "Combination"], ["LA16779-3", "Humira"], ["LP191906-9", "Anakinra"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA31430-4", "Biologic"], ["LA22025-3", "OR"], ["LA12701-1", "Combination"], ["LA16779-3", "Humira"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA31430-4", "Biologic"], ["LA22025-3", "OR"]], "snomed.driving": [["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["260676000", "Use of (attribute)"], ["88323005", "Adequate (qualifier value)"], ["146680009", "Contraception|Contraception (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["101445003", "PREVENT (substance)|PREVENT (product)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["86495002", "For (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["34001005", "Five (qualifier value)|5 (qualifier value)"], ["258706009", "month (qualifier value)"], ["255234002", "After (attribute)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255509001", "Large (qualifier value)"], ["410681005", "Count of entities (property) (qualifier value)"], ["26175008", "Approximate (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["79409006", "Resulting in (attribute)"], ["3950001", "Birth (finding)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["36692007", "Known (qualifier value)"], ["55919000", "Including (qualifier value)"], ["242762006", "More (qualifier value)"], ["732516007", "1500 (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["255246003", "First trimester (qualifier value)"], ["717896003", "Does not (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["21390004", "Developmental anomaly (morphologic abnormality)"], ["18720000", "In (attribute)"], ["133933007", "Newborn (person)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["282254003", "candela (qualifier value)"], ["28995006", "Treated with (attribute)"], ["407317001", "Adalimumab (substance)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["255246003", "First trimester (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["282254003", "candela (qualifier value)"], ["28995006", "Treated with (attribute)"], ["407317001", "Adalimumab (substance)"], ["261424001", "Primary operation (qualifier value)"], ["3950001", "Birth (finding)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255603008", "Major (qualifier value)"], ["3950001", "Birth (finding)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["133931009", "Infant (person)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255603008", "Major (qualifier value)"], ["276720006", "Dysmorphism (disorder)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["264698002", "Arabic numeral 69 (qualifier value)|69 (qualifier value)"], ["732875009", "8.7 (qualifier value)"], ["18720000", "In (attribute)"], ["407317001", "Adalimumab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["732860001", "74 (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222812008", "American Joint Committee on Cancer stage III:1 (qualifier value)"], ["732906005", "95 (qualifier value)"], ["282109005", "Curie (qualifier value)|Ci (qualifier value)"], ["732370005", "0.38 (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["732782003", "52 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222743007", "American Joint Committee on Cancer stage I:6 (qualifier value)"], ["732442009", "10.5 (qualifier value)"], ["18720000", "In (attribute)"], ["407317001", "Adalimumab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["282254003", "candela (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["1222813003", "American Joint Committee on Cancer stage III:2 (qualifier value)"], ["422113007", "Arabic numeral 9 (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["282254003", "candela (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["732410003", "1.14 (qualifier value)"], ["732906005", "95 (qualifier value)"], ["282109005", "Curie (qualifier value)|Ci (qualifier value)"], ["732361007", "0.31 (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["1222743007", "American Joint Committee on Cancer stage I:6 (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["732906005", "95 (qualifier value)"], ["282109005", "Curie (qualifier value)|Ci (qualifier value)"], ["732374001", "0.45 (qualifier value)"], ["732582000", "2.73 (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["282254003", "candela (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["373067005", "No (qualifier value)"], ["11896004", "Intermediate (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["2603003", "Secondary (qualifier value)"], ["5054005", "Spontaneous (qualifier value)"], ["410599005", "Minor (person)"], ["3950001", "Birth (finding)"], ["386217009", "Non-human parturition, function (observable entity)"], ["3950001", "Birth (finding)"], ["246115007", "Size (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["280452008", "Interpretation (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["134293005", "Impacted (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["224699009", "Study (environment)"], ["55919000", "Including (qualifier value)"], ["255507004", "Small (qualifier value)"], ["246115007", "Size (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["278923009", "Developmental (qualifier value)"], ["75478009", "Poisoning (disorder)"], ["224699009", "Study (environment)"], ["18720000", "In (attribute)"], ["71653005", "No indication of (contextual qualifier) (qualifier value)"], ["1269485005", "Maternal (qualifier value)"], ["75478009", "Poisoning (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["58694006", "Teratogenesis (finding)"], ["420862001", "On (qualifier value)"], ["263844007", "Maternal postnatal period (qualifier value)|Postnatal (qualifier value)"], ["75478009", "Poisoning (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["769082003", "5.3 (qualifier value)"], ["42752001", "Due to (attribute)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["407317001", "Adalimumab (substance)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["17621005", "Normal (qualifier value)"], ["255386009", "Immune (qualifier value)"], ["18720000", "In (attribute)"], ["133933007", "Newborn (person)"], ["407317001", "Adalimumab (substance)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["410525008", "Needed (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["181455002", "Entire placenta (body structure)"], ["30507006", "Into (attribute)"], ["67922002", "Serum (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["28995006", "Treated with (attribute)"], ["407317001", "Adalimumab (substance)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["78648007", "At increased risk for infection (finding)|At risk for infection (finding)|At risk of infection (finding)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["396419007", "BCG vaccine (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["18720000", "In (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["86495002", "For (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["258706009", "month (qualifier value)"], ["255260001", "Following (attribute)"], ["394651000", "Mother (person)|Mother"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["407317001", "Adalimumab (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["226789007", "Breast milk (substance)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["260362008", "Very low (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["52101004", "Present (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["18720000", "In (attribute)"], ["226789007", "Breast milk (substance)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732332006", "0.1 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1269485005", "Maternal (qualifier value)"], ["67922002", "Serum (substance)"], ["276625007", "Level (attribute)"], ["26643006", "Oral route (qualifier value)"], ["165940001", "Immunoglobulin G (& [level]) (procedure)|Immunoglobulin G (& [level])"], ["88878007", "Protein (substance)"], ["1255345008", "Intestinal (intended site)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255351007", "Poor - grade (qualifier value)"], ["373067005", "No (qualifier value)"], ["420862001", "On (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["413712001", "Breastfeeding (mother) (observable entity)|Breast feeding (mother) (observable entity)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["420862001", "On (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["407317001", "Adalimumab (substance)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"]], "ncit.driving": [["C161316", "Female of Childbearing Potential"], ["C161316", "Female of Childbearing Potential"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C168111", "Adequate Daily Fluid Intake"], ["C37932", "Contraception"], ["C159124", "GDC Treatment Outcome Terminology"], ["C191656", "Pregnant Subject"], ["C16289", "Andorra"], ["C54064", "Continue"], ["C25340", "Use"], ["C64956", "For"], ["C158997", "GDC Analyte Type Terminology"], ["C66836", "Five"], ["C29846", "Month"], ["C38008", "Post"], ["C25551", "Last"], ["C65216", "Adalimumab"], ["C43442", "Biomaterial Treatment"], ["C191656", "Pregnant Subject"], ["C76246", "Blood Group A"], ["C49508", "Large"], ["C25463", "Count"], ["C45828", "Approximate"], ["C52874", "SPI1 wt Allele"], ["C170548", "Collected Value"], ["C159124", "GDC Treatment Outcome Terminology"], ["C65216", "Adalimumab"], ["C16727", "India"], ["C114091", "Live Birth"], ["C62355", "With"], ["C80137", "Known"], ["C166400", "Inclusive"], ["C61584", "Greater Than"], ["C25490", "During"], ["C92799", "First Trimester"], ["C86066", "Do"], ["C25594", "Negation"], ["C75889", "PAX6 wt Allele"], ["C25533", "Increase"], ["C16727", "India"], ["C77538", "Rating"], ["C52874", "SPI1 wt Allele"], ["C36287", "Congenital or Acquired Anatomic Abnormality"], ["C16727", "India"], ["C16731", "Newborn"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C53308", "Prospective Cohort Study"], ["C15753", "Cancer Registry"], ["C62355", "With"], ["C2884", "Rheumatoid Arthritis"], ["C2872", "Refractory Anemia"], ["C43508", "Oregon"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C78347", "Cluster of Differentiation"], ["C25705", "Treating"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C158997", "GDC Analyte Type Terminology"], ["C25490", "During"], ["C92799", "First Trimester"], ["C16289", "Andorra"], ["C192184", "One Hundred Twenty"], ["C62355", "With"], ["C2872", "Refractory Anemia"], ["C43508", "Oregon"], ["C78347", "Cluster of Differentiation"], ["C25594", "Negation"], ["C25705", "Treating"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C142715", "Study Subject Enrolled"], ["C94496", "Primary Endpoint"], ["C154196", "Washo Language"], ["C25155", "Birth"], ["C17010", "Prevalence"], ["C52874", "SPI1 wt Allele"], ["C45368", "Major"], ["C25155", "Birth"], ["C77538", "Rating"], ["C52874", "SPI1 wt Allele"], ["C25496", "End"], ["C62355", "With"], ["C158997", "GDC Analyte Type Terminology"], ["C66832", "One"], ["C114091", "Live Birth"], ["C27956", "Infant"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C45368", "Major"], ["C2849", "Congenital Abnormality"], ["C154196", "Washo Language"], ["C172979", "Fear Score 6"], ["C186755", "Human Papillomavirus-69"], ["C66839", "Eight"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C16727", "India"], ["C65216", "Adalimumab"], ["C25705", "Treating"], ["C62355", "With"], ["C2872", "Refractory Anemia"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C186780", "Human Papillomavirus-74"], ["C172979", "Fear Score 6"], ["C66839", "Eight"], ["C16727", "India"], ["C62355", "With"], ["C2872", "Refractory Anemia"], ["C43508", "Oregon"], ["C105723", "ECOG Performance Status 1"], ["C126863", "Thirty One"], ["C112239", "Coagulation Index Measurement"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C175628", "Thirty Eight"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C188320", "Fifty Two"], ["C16289", "Andorra"], ["C113430", "Sixteen"], ["C16427", "Chile"], ["C69122", "Ten"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16727", "India"], ["C65216", "Adalimumab"], ["C25705", "Treating"], ["C62355", "With"], ["C78347", "Cluster of Differentiation"], ["C16289", "Andorra"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C175622", "Thirty Two"], ["C120081", "Severity of Symptom Score 9"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16727", "India"], ["C62355", "With"], ["C78347", "Cluster of Differentiation"], ["C43508", "Oregon"], ["C105723", "ECOG Performance Status 1"], ["C113428", "Fourteen"], ["C112239", "Coagulation Index Measurement"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C126863", "Thirty One"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C113430", "Sixteen"], ["C49157", "Adjustment"], ["C43508", "Oregon"], ["C64956", "For"], ["C125938", "Baseline Epoch"], ["C154196", "Washo Language"], ["C105723", "ECOG Performance Status 1"], ["C69122", "Ten"], ["C112239", "Coagulation Index Measurement"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C175677", "Forty Five"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C188335", "Seventy Three"], ["C62355", "With"], ["C2872", "Refractory Anemia"], ["C16289", "Andorra"], ["C78347", "Cluster of Differentiation"], ["C25454", "Combined"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C94545", "Between"], ["C65216", "Adalimumab"], ["C25705", "Treating"], ["C16289", "Andorra"], ["C64956", "For"], ["C25666", "Second"], ["C48307", "Spontaneous"], ["C45367", "Minor"], ["C25155", "Birth"], ["C92861", "Preterm Birth"], ["C25155", "Birth"], ["C25681", "Size"], ["C16289", "Andorra"], ["C54035", "Serious"], ["C43508", "Oregon"], ["C16289", "Andorra"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43508", "Oregon"], ["C188308", "Reported Information"], ["C178948", "Interpretation of Laboratory Test"], ["C52874", "SPI1 wt Allele"], ["C25474", "Data"], ["C106184", "May"], ["C16329", "Belgium"], ["C82092", "Impaction"], ["C45263", "Due"], ["C159124", "GDC Treatment Outcome Terminology"], ["C52874", "SPI1 wt Allele"], ["C45319", "Study Object"], ["C166400", "Inclusive"], ["C25376", "Small"], ["C53190", "Sample Size"], ["C16289", "Andorra"], ["C93043", "Nonrandomized Clinical Trial"], ["C43358", "Design"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C168182", "Developmental Finding"], ["C27990", "Toxicity"], ["C45319", "Study Object"], ["C16727", "India"], ["C14243", "Monkey"], ["C154196", "Washo Language"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C41184", "Indication"], ["C52874", "SPI1 wt Allele"], ["C89336", "Maternal"], ["C27990", "Toxicity"], ["C43508", "Oregon"], ["C48674", "Preclinical"], ["C25474", "Data"], ["C92667", "SPARC wt Allele"], ["C81317", "Postnatal"], ["C27990", "Toxicity"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C68869", "Are"], ["C126101", "Not Available"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C89272", "Due To"], ["C42791", "Inhibition"], ["C52874", "SPI1 wt Allele"], ["C18368", "TNF Gene"], ["C65216", "Adalimumab"], ["C25382", "Administered"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C12801", "Tissue"], ["C17997", "Immune"], ["C16727", "India"], ["C16731", "Newborn"], ["C65216", "Adalimumab"], ["C48440", "Single"], ["C16329", "Belgium"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C198613", "CFI wt Allele"], ["C65216", "Adalimumab"], ["C106184", "May"], ["C81171", "Cross"], ["C13272", "Placenta"], ["C25544", "Into"], ["C13325", "Serum"], ["C52874", "SPI1 wt Allele"], ["C25155", "Birth"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25705", "Treating"], ["C62355", "With"], ["C65216", "Adalimumab"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C106184", "May"], ["C16329", "Belgium"], ["C158997", "GDC Analyte Type Terminology"], ["C164135", "Increased"], ["C17102", "Risk"], ["C64956", "For"], ["C128320", "Infection"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C89279", "Reside"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C298", "BCG Vaccine"], ["C159124", "GDC Treatment Outcome Terminology"], ["C159124", "GDC Treatment Outcome Terminology"], ["C65216", "Adalimumab"], ["C49641", "In Utero"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C64956", "For"], ["C163771", "Illness Intrusiveness Rating 5"], ["C29846", "Month"], ["C53286", "Next"], ["C25189", "Mother"], ["C42555", "Siemens"], ["C25551", "Last"], ["C65216", "Adalimumab"], ["C122632", "Injection Dosing Unit"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C142988", "Limited"], ["C48191", "Information"], ["C25516", "From"], ["C19026", "Scientific Publication"], ["C48471", "Publication"], ["C65216", "Adalimumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C13257", "Mammary Gland Milk"], ["C158997", "GDC Analyte Type Terminology"], ["C162680", "IPSS-R Risk Category Very Low"], ["C62355", "With"], ["C25626", "Present"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C16727", "India"], ["C14225", "Human"], ["C13257", "Mammary Gland Milk"], ["C158997", "GDC Analyte Type Terminology"], ["C52874", "SPI1 wt Allele"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C105723", "ECOG Performance Status 1"], ["C159124", "GDC Treatment Outcome Terminology"], ["C105723", "ECOG Performance Status 1"], ["C52874", "SPI1 wt Allele"], ["C89336", "Maternal"], ["C13325", "Serum"], ["C25554", "Level"], ["C64974", "Give"], ["C25311", "Oral"], ["C81971", "Immunoglobulin G Measurement"], ["C17021", "Protein"], ["C9157", "Gastric Intestinal-Type Adenocarcinoma"], ["C18105", "Proteolysis"], ["C16289", "Andorra"], ["C101282", "Have"], ["C177356", "Malignant Germ Cell International Collaborative Risk Classification, Poor"], ["C49664", "Bioavailability Study"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25492", "Effect"], ["C92667", "SPARC wt Allele"], ["C68869", "Are"], ["C25501", "Expected"], ["C65216", "Adalimumab"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C25490", "During"], ["C25596", "Breast Feeding"], ["C95089", "Fertility Domain"], ["C48674", "Preclinical"], ["C25474", "Data"], ["C92667", "SPARC wt Allele"], ["C95089", "Fertility Domain"], ["C25492", "Effect"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C68869", "Are"], ["C126101", "Not Available"]], "rxnorm.driving": [["353484", "Humira"], ["327361", "adalimumab"], ["327361", "adalimumab"], ["327361", "adalimumab"], ["327361", "adalimumab"], ["327361", "adalimumab"], ["327361", "adalimumab"], ["327361", "adalimumab"], ["327361", "adalimumab"], ["327361", "adalimumab"], ["327361", "adalimumab"], ["327361", "adalimumab"], ["327361", "adalimumab"], ["1656695", "adalimumab Injection"], ["327361", "adalimumab"], ["327361", "adalimumab"], ["T016", "Human"], ["5666", "immunoglobulin G"], ["353484", "Humira"], ["327361", "adalimumab"]], "loinc.driving": [["LA8913-1", "Adequate"], ["LP207970-7", "Pregnancy"], ["LA9507-0", "Continue"], ["LA21988-3", "AT"], ["MTHU068094", "Months"], ["LA16779-3", "Humira"], ["LP94823-9", "Treatment"], ["LP207970-7", "Pregnancy"], ["LP17763-1", "A"], ["LA8981-8", "Large"], ["LP18011-4", "Number"], ["LP73139-5", "Pregnancies"], ["LP173592-9", "Adalimumab"], ["LA22004-8", "IN"], ["LA14270-5", "Live birth"], ["LA16824-7", "More"], ["LP208035-8", "First trimester"], ["LA21291-2", "Not"], ["LA32048-3", "Increase"], ["LA22004-8", "IN"], ["MTHU027852", "Rate"], ["LA22004-8", "IN"], ["LP7744-8", "Newborn"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA15161-5", "Rheumatoid Arthritis"], ["LA22025-3", "OR"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LP173592-9", "Adalimumab"], ["LA21988-3", "AT"], ["LP208035-8", "First trimester"], ["LA32059-0", "120"], ["LA22025-3", "OR"], ["LA21291-2", "Not"], ["LP173592-9", "Adalimumab"], ["LA21208-6", "Primary"], ["LA29634-5", "Major"], ["LP192134-7", "Birth defects"], ["MTHU027852", "Rate"], ["LP73139-5", "Pregnancies"], ["LA21988-3", "AT"], ["LA6306-0", "One"], ["LA19747-7", "Infant"], ["LP17763-1", "A"], ["LA29634-5", "Major"], ["LP20594-5", "6"], ["LP36791-9", "8"], ["LP36790-1", "7"], ["LA22004-8", "IN"], ["LP173592-9", "Adalimumab"], ["LP20593-7", "5"], ["LP20594-5", "6"], ["LP36791-9", "8"], ["LA22004-8", "IN"], ["LP20187-8", "unadjusted"], ["LA22025-3", "OR"], ["LA6112-2", "1"], ["LA6111-4", "0"], ["LP20592-9", "4"], ["LA14562-5", "16"], ["LA13942-0", "10"], ["LP20593-7", "5"], ["LA22004-8", "IN"], ["LP173592-9", "Adalimumab"], ["LP20591-1", "3"], ["LA19317-9", "32"], ["LA10141-2", "9"], ["LP20592-9", "4"], ["LA22004-8", "IN"], ["LP20187-8", "unadjusted"], ["LA22025-3", "OR"], ["LA6112-2", "1"], ["LA14560-9", "14"], ["LA6111-4", "0"], ["LP20592-9", "4"], ["LA14562-5", "16"], ["LP20174-6", "adjusted"], ["LA22025-3", "OR"], ["LA16758-7", "Baseline"], ["LA6112-2", "1"], ["LA13942-0", "10"], ["LA24581-3", "0.45"], ["MTHU000002", "Clinical Class"], ["LA30596-3", "Combined"], ["LA32-8", "No"], ["LP173592-9", "Adalimumab"], ["LP263805-6", "Secondary"], ["MTHU002834", "Abortions"], ["LA29633-7", "Minor"], ["LP192134-7", "Birth defects"], ["LA7555-1", "Delivery"], ["LP18013-0", "Size"], ["LA30751-4", "Serious"], ["LA22025-3", "OR"], ["LP74970-2", "Infections"], ["LA32-8", "No"], ["LA22025-3", "OR"], ["LP6486-7", "Reported"], ["LA31393-4", "Interpretation"], ["LA14161-6", "May"], ["LA8952-9", "Impacted"], ["LP74341-6", "Study"], ["LA8983-4", "Small"], ["LP18013-0", "Size"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP74341-6", "Study"], ["LA22004-8", "IN"], ["LA32-8", "No"], ["LA26320-4", "Maternal"], ["LA22025-3", "OR"], ["LP173592-9", "Adalimumab"], ["LA7338-2", "Not available"], ["LP20593-7", "5"], ["LP20591-1", "3"], ["LP173592-9", "Adalimumab"], ["LP266032-4", "during pregnancy"], ["LA6626-1", "Normal"], ["LA27183-5", "Immune"], ["LA22004-8", "IN"], ["LP7744-8", "Newborn"], ["LP173592-9", "Adalimumab"], ["LP266032-4", "during pregnancy"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP173592-9", "Adalimumab"], ["LA14161-6", "May"], ["LP208379-0", "Placenta"], ["LP7567-3", "Serum"], ["LP173592-9", "Adalimumab"], ["LP266032-4", "during pregnancy"], ["LA14161-6", "May"], ["LA21988-3", "AT"], ["LA24544-1", "Increased risk"], ["LP266919-2", "Infection"], ["LA20283-0", "Vaccines"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP102323-5", "Bromocresol green (BCG) dye binding method"], ["LP30374-0", "Vaccine"], ["LP173592-9", "Adalimumab"], ["LA22004-8", "IN"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP20593-7", "5"], ["MTHU068094", "Months"], ["LP6983-3", "Mother"], ["LP15241-0", "S"], ["LP173592-9", "Adalimumab"], ["LA14542-7", "Injection"], ["LP266032-4", "during pregnancy"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LA6484-5", "Limited"], ["LP173592-9", "Adalimumab"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA16914-6", "Breast milk"], ["LA21988-3", "AT"], ["LA14643-3", "Very low"], ["LP149220-8", "Presence"], ["LP173592-9", "Adalimumab"], ["LA22004-8", "IN"], ["LA19711-3", "Human"], ["LP29290-1", "Milk"], ["LA21988-3", "AT"], ["LA24574-8", "0.1"], ["LA6112-2", "1"], ["LA26320-4", "Maternal"], ["LP7567-3", "Serum"], ["LP29256-2", "given"], ["MTHU005225", "IgG"], ["LA26027-5", "Intestinal"], ["LA8969-3", "Poor"], ["LA32-8", "No"], ["LA18412-9", "Anticipated"], ["LA16779-3", "Humira"], ["LP114922-0", "Breastfeeding"], ["MTHU000074", "Fertility"], ["MTHU000074", "Fertility"], ["LP173592-9", "Adalimumab"], ["LA7338-2", "Not available"]], "snomed.side_effects": [["422097006", "Upper case Roman letter A (qualifier value)"], ["410599005", "Minor (person)"], ["420862001", "On (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["247750002", "Drive (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["399153001", "Vertigo (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255374006", "Visual (qualifier value)"], ["40226000", "Impairment (finding)"], ["255260001", "Following (attribute)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732732008", "4.8 (qualifier value)"]], "ncit.side_effects": [["C65216", "Adalimumab"], ["C106184", "May"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C45367", "Minor"], ["C121660", "Influence"], ["C92667", "SPARC wt Allele"], ["C121232", "Ability to Drive"], ["C16289", "Andorra"], ["C25340", "Use"], ["C143935", "Vertigo, CTCAE"], ["C16289", "Andorra"], ["C38059", "Visual"], ["C21055", "Impairment"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C53286", "Next"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C65216", "Adalimumab"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"]], "rxnorm.side_effects": [["353484", "Humira"], ["353484", "Humira"]], "loinc.side_effects": [["LA16779-3", "Humira"], ["LA14161-6", "May"], ["LP17763-1", "A"], ["LA29633-7", "Minor"], ["LP145904-1", "Visual"], ["LA14161-6", "May"], ["LA16779-3", "Humira"], ["LP20592-9", "4"], ["LP36791-9", "8"]], "snomed.shelf_life": [["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"]], "ncit.shelf_life": [["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"]], "rxnorm.shelf_life": [], "loinc.shelf_life": [["LA31719-0", "2 years"]], "snomed.storage": [["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["21546008", "Refrigerator, device (physical object)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["18720000", "In (attribute)"], ["261074009", "External (qualifier value)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["371268001", "Light color (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["272113006", "Before values (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["86495002", "For (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222741009", "American Joint Committee on Cancer stage I:4 (qualifier value)"], ["258703001", "day (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["371268001", "Light color (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["262009000", "Not used (qualifier value)"], ["18720000", "In (attribute)"], ["1222741009", "American Joint Committee on Cancer stage I:4 (qualifier value)"], ["264721006", "day (qualifier value)|day"]], "ncit.storage": [["C60824", "Storage"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C178971", "Refrigerator"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67900", "Centi"], ["C66839", "Eight"], ["C67900", "Centi"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C48160", "Freezing"], ["C99569", "Retain"], ["C97716", "Pre-filled Syringe"], ["C16727", "India"], ["C187054", "Outer Surface"], ["C54702", "Carton Dosing Unit"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25516", "From"], ["C64650", "Light"], ["C76246", "Blood Group A"], ["C48440", "Single"], ["C65216", "Adalimumab"], ["C97716", "Pre-filled Syringe"], ["C106184", "May"], ["C16329", "Belgium"], ["C60824", "Storage"], ["C158997", "GDC Analyte Type Terminology"], ["C64643", "Up to"], ["C76246", "Blood Group A"], ["C82868", "Maximum Value Derivation Technique"], ["C52874", "SPI1 wt Allele"], ["C113663", "Twenty Five"], ["C67900", "Centi"], ["C64956", "For"], ["C76246", "Blood Group A"], ["C25616", "Period"], ["C52874", "SPI1 wt Allele"], ["C64643", "Up to"], ["C113428", "Fourteen"], ["C25301", "Day"], ["C50207", "Syringe Device"], ["C16329", "Belgium"], ["C25516", "From"], ["C64650", "Light"], ["C16289", "Andorra"], ["C198613", "CFI wt Allele"], ["C69062", "Not Used"], ["C25282", "Within"], ["C113428", "Fourteen"], ["C25301", "Day"], ["C25616", "Period"]], "rxnorm.storage": [["353484", "Humira"]], "loinc.storage": [["LA22004-8", "IN"], ["LP17763-1", "A"], ["MTHU000002", "Clinical Class"], ["LP17128-7", "C"], ["LP36791-9", "8"], ["LP17128-7", "C"], ["LA14426-3", "Do not"], ["LP32605-5", "pre"], ["LP188733-2", "Syringe"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LA15831-3", "Light"], ["LP17763-1", "A"], ["LA17717-2", "Single"], ["LA16779-3", "Humira"], ["LP32605-5", "pre"], ["LP188733-2", "Syringe"], ["LA14161-6", "May"], ["LA21988-3", "AT"], ["LP17763-1", "A"], ["LP6972-6", "maximum"], ["LA19281-7", "25"], ["LP17128-7", "C"], ["LP17763-1", "A"], ["LP203020-5", "14 days"], ["LP188733-2", "Syringe"], ["LA15831-3", "Light"], ["LA19707-1", "Discarded"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA157-0", "Not used"], ["LA14560-9", "14"], ["LP121628-4", "Day"]], "snomed.package": [["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["385219001", "Injection solution (qualifier value)|Conventional release solution for injection (dose form)|Injection solution (product)"], ["18720000", "In (attribute)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["258191002", "Type 1 (qualifier value)"], ["32039001", "Glass (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["43230003", "Rubber (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["79068005", "Needle, device (physical object)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["79068005", "Needle, device (physical object)"], ["30115002", "Shield, device (physical object)"], ["261777007", "Elastomer (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["75797008", "Syrinx (morphologic abnormality)"], ["732349004", "0.2 (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["261029002", "Sterile (qualifier value)"], ["739006009", "Solution (basic dose form)"], ["419473009", "Each (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["53041004", "Substance with alcohol structure (substance)|Alcohol (substance)"], ["733003008", "Pad (unit of presentation)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["732984005", "Blister (unit of presentation)"]], "ncit.package": [["C65216", "Adalimumab"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C16818", "Mammography"], ["C42945", "Injectable Solution Dosage Form"], ["C16727", "India"], ["C48440", "Single"], ["C25340", "Use"], ["C97716", "Pre-filled Syringe"], ["C181852", "Protocol Therapy Status"], ["C68254", "Dietary Iodine"], ["C45301", "Glass"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C50297", "Plunger Device"], ["C96139", "Stopper Container Closure"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C63846", "Needle Shape"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C63846", "Needle Shape"], ["C50171", "Shield Device"], ["C62653", "Pack Dosage Form"], ["C52874", "SPI1 wt Allele"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25629", "Prior"], ["C54093", "Fill"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16816", "Mali"], ["C3836", "Infertility"], ["C42986", "Solution Dosage Form"], ["C64933", "Each"], ["C62355", "With"], ["C105723", "ECOG Performance Status 1"], ["C74693", "Ethanol Measurement"], ["C114387", "PAD Regimen"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C43168", "Blister Pack"]], "rxnorm.package": [["353484", "Humira"], ["1649574", "Injection"]], "loinc.package": [["LA16779-3", "Humira"], ["LA19282-5", "20"], ["LP15217-0", "Mg"], ["LA14542-7", "Injection"], ["LA22004-8", "IN"], ["LA17717-2", "Single"], ["LP32605-5", "pre"], ["LP188733-2", "Syringe"], ["LA26022-6", "Type I"], ["LP17763-1", "A"], ["LP17763-1", "A"], ["LP208081-2", "Needle"], ["LP17763-1", "A"], ["LP208081-2", "Needle"], ["MTHU000002", "Clinical Class"], ["LP32605-5", "pre"], ["LA24577-1", "0.2"], ["LA6112-2", "1"], ["LA28139-6", "Alcohol"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA19024-1", "Blister"]], "snomed.marketing_authorization_numbers": [["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.marketing_authorization_numbers": [["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.marketing_authorization_numbers": [], "loinc.marketing_authorization_numbers": [["LA6112-2", "1"]]}, {"product_info": "Remsima 100 mg powder for concentrate for solution for infusion", "composition": "One vial contains 100 mg of infliximab*. After reconstitution each mL contains 10 mg of infliximab.  \n* Infliximab is a chimeric human-murine IgG1 monoclonal antibody produced in murine hybridoma \ncells by recombinant DNA technology. \nFor the full list of excipients, see section 6.1.", "indications": "Rheumatoid arthritis \nRemsima, in combination with methotrexate, is indicated for the reduction of signs and symptoms as \nwell as the improvement in physical function in: \nadult patients with active disease when the response to disease-modifying antirheumatic drugs \n(DMARDs), including methotrexate, has been inadequate. \nadult patients with severe, active and progressive disease not previously treated with \nmethotrexate or other DMARDs. \nIn these patient populations, a reduction in the rate of the progression of joint damage, as measured by \nX-ray, has been demonstrated (see section 5.1). \nAdult Crohn\u2019s disease \nRemsima is indicated for: \ntreatment of moderately to severely active Crohn\u2019s disease, in adult patients who have not \nresponded despite a full and adequate course of therapy with a corticosteroid and/or an \nimmunosuppressant; or who are intolerant to or have medical contraindications for such \ntherapies. \ntreatment of fistulising, active Crohn\u2019s disease, in adult patients who have not responded despite \na full and adequate course of therapy with conventional treatment (including antibiotics, \ndrainage and immunosuppressive therapy). \nPaediatric Crohn\u2019s disease \nRemsima is indicated for treatment of severe, active Crohn\u2019s disease in children and adolescents aged \n6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an \nimmunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for \nsuch therapies. Infliximab has been studied only in combination with conventional \nimmunosuppressive therapy. \nUlcerative colitis \nRemsima is indicated for treatment of moderately to severely active ulcerative colitis in adult patients \nwho have had an inadequate response to conventional therapy including corticosteroids and \n6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical \ncontraindications for such therapies. \nPaediatric ulcerative colitis \nRemsima is indicated for treatment of severely active ulcerative colitis in children and adolescents \naged 6 to 17 years, who have had an inadequate response to conventional therapy including \ncorticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such \ntherapies. \nAnkylosing spondylitis \nRemsima is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have \nresponded inadequately to conventional therapy. \nPsoriatic arthritis \nRemsima is indicated for treatment of active and progressive psoriatic arthritis in adult patients when \nthe response to previous DMARD therapy has been inadequate. \nRemsima should be administered: \nin combination with methotrexate \nor alone in patients who show intolerance to methotrexate or for whom methotrexate is \ncontraindicated. \nInfliximab has been shown to improve physical function in patients with psoriatic arthritis, and to \nreduce the rate of progression of peripheral joint damage as measured by X-ray in patients with \npolyarticular symmetrical subtypes of the disease (see section 5.1). \nPsoriasis \nRemsima is indicated for treatment of moderate to severe plaque psoriasis in adult patients who failed \nto respond to, or who have a contraindication to, or are intolerant to other systemic therapy including \nciclosporin, methotrexate or psoralen ultra-violet A (PUVA) (see section 5.1).", "posology": "Remsima treatment is to be initiated and supervised by qualified physicians experienced in the \ndiagnosis and treatment of rheumatoid arthritis, inflammatory bowel diseases, ankylosing spondylitis, \npsoriatic arthritis or psoriasis. Remsima should be administered intravenously. Remsima infusions \nshould be administered by qualified healthcare professionals trained to detect any infusion-related \nissues. Patients treated with Remsima should be given the package leaflet and the patient reminder \ncard. \nDuring Remsima treatment, other concomitant therapies, e.g. corticosteroids and immunosuppressants \nshould be optimised. \nIt is important to check the product labels to ensure that the correct formulation (intravenous or \nsubcutaneous) is being administered to the patient, as prescribed. Remsima subcutaneous formulation \nis not intended for intravenous administration and should be administered via a subcutaneous injection \nonly. \nPosology \nAdults (\u226518 years)  \nRheumatoid arthritis \n3 mg/kg given as an intravenous infusion followed by additional 3 mg/kg infusion doses at 2 and \n6 weeks after the first infusion, then every 8 weeks thereafter. \nRemsima must be given concomitantly with methotrexate.  \nAvailable data suggest that the clinical response is usually achieved within 12 weeks of treatment. If a \npatient has an inadequate response or loses response after this period, consideration may be given to \nincrease the dose step-wise by approximately 1.5 mg/kg, up to a maximum of 7.5 mg/kg every \n8 weeks. Alternatively, administration of 3 mg/kg as often as every 4 weeks may be considered. If \nadequate response is achieved, patients should be continued on the selected dose or dose frequency. \nContinued therapy should be carefully reconsidered in patients who show no evidence of therapeutic \nbenefit within the first 12 weeks of treatment or after dose adjustment. \nModerately to severely active Crohn\u2019s disease \n5 mg/kg given as an intravenous infusion followed by an additional 5 mg/kg infusion 2 weeks after the \nfirst infusion. If a patient does not respond after 2 doses, no additional treatment with infliximab \nshould be given. Available data do not support further infliximab treatment, in patients not responding \nwithin 6 weeks of the initial infusion. \nIn responding patients, the alternative strategies for continued treatment are: \nMaintenance: Additional infusion of 5 mg/kg at 6 weeks after the initial dose, followed by \ninfusions every 8 weeks or \nRe-administration: Infusion of 5 mg/kg if signs and symptoms of the disease recur (see \n\u2018Re-administration\u2019 below and section 4.4). \nAlthough comparative data are lacking, limited data in patients who initially responded to 5 mg/kg but \nwho lost response indicate that some patients may regain response with dose escalation (see \nsection 5.1). Continued therapy should be carefully reconsidered in patients who show no evidence of \ntherapeutic benefit after dose adjustment. \nFistulising, active Crohn\u2019s disease \n5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusions at 2 and 6 weeks \nafter the first infusion. If a patient does not respond after 3 doses, no additional treatment with \ninfliximab should be given. \nIn responding patients, the alternative strategies for continued treatment are: \nMaintenance: Additional infusions of 5 mg/kg every 8 weeks or \nRe-administration: Infusion of 5 mg/kg if signs and symptoms of the disease recur followed by \ninfusions of 5 mg/kg every 8 weeks (see \u2018Re-administration\u2019 below and section 4.4). \nAlthough comparative data are lacking, limited data in patients who initially responded to 5 mg/kg but \nwho lost response indicate that some patients may regain response with dose escalation (see \nsection 5.1). Continued therapy should be carefully reconsidered in patients who show no evidence of \ntherapeutic benefit after dose adjustment. \nIn Crohn\u2019s disease, experience with re-administration if signs and symptoms of disease recur is limited \nand comparative data on the benefit/risk of the alternative strategies for continued treatment are \nlacking. \nUlcerative colitis \n5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and \n6 weeks after the first infusion, then every 8 weeks thereafter. \nAvailable data suggest that the clinical response is usually achieved within 14 weeks of treatment, i.e. \nthree doses. Continued therapy should be carefully reconsidered in patients who show no evidence of \ntherapeutic benefit within this time period. \nAnkylosing spondylitis \n5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and \n6 weeks after the first infusion, then every 6 to 8 weeks. If a patient does not respond by 6 weeks (i.e. \nafter 2 doses), no additional treatment with infliximab should be given. \nPsoriatic arthritis \n5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and \n6 weeks after the first infusion, then every 8 weeks thereafter. \nPsoriasis \n5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and \n6 weeks after the first infusion, then every 8 weeks thereafter. If a patient shows no response after \n14 weeks (i.e. after 4 doses), no additional treatment with infliximab should be given. \nRe-administration for Crohn\u2019s disease and rheumatoid arthritis \nIf the signs and symptoms of disease recur, infliximab can be re-administered within 16 weeks \nfollowing the last infusion. In clinical studies, delayed hypersensitivity reactions have been uncommon \nand have occurred after infliximab-free intervals of less than 1 year (see sections 4.4 and 4.8). The \nsafety and efficacy of re-administration after an infliximab-free interval of more than 16 weeks has not \nbeen established. This applies to both Crohn\u2019s disease patients and rheumatoid arthritis patients. \nRe-administration for ulcerative colitis \nThe safety and efficacy of re-administration, other than every 8 weeks, has not been established (see \nsections 4.4 and 4.8). \nRe-administration for ankylosing spondylitis \nThe safety and efficacy of re-administration, other than every 6 to 8 weeks, has not been established \n(see sections 4.4 and 4.8). \nRe-administration for psoriatic arthritis \nThe safety and efficacy of re-administration, other than every 8 weeks, has not been established (see \nsections 4.4 and 4.8). \nRe-administration for psoriasis \nLimited experience from re-treatment with one single infliximab dose in psoriasis after an interval of \n20 weeks suggests reduced efficacy and a higher incidence of mild to moderate infusion reactions \nwhen compared to the initial induction regimen (see section 5.1). \nLimited experience from re-treatment following disease flare by a re-induction regimen suggests a \nhigher incidence of infusion reactions, including serious ones, when compared to 8-weekly \nmaintenance treatment (see section 4.8). \nRe-administration across indications \nIn case maintenance therapy is interrupted, and there is a need to restart treatment, use of a \nre-induction regimen is not recommended (see section 4.8). In this situation, infliximab should be \nre-initiated as a single dose followed by the maintenance dose recommendations described above. \nSpecial populations \nElderly \nSpecific studies of infliximab in elderly patients have not been conducted. No major age-related \ndifferences in clearance or volume of distribution were observed in clinical studies. No dose \nadjustment is required (see section 5.2). For more information about the safety of infliximab in elderly \npatients (see sections 4.4 and 4.8). \nRenal and/or hepatic impairment \nInfliximab has not been studied in these patient populations. No dose recommendations can be made \n(see section 5.2). \nPaediatric population \nCrohn\u2019s disease (6 to 17 years) \n5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and \n6 weeks after the first infusion, then every 8 weeks thereafter. Available data do not support further \ninfliximab treatment in children and adolescents not responding within the first 10 weeks of treatment \n(see section 5.1). \nSome patients may require a shorter dosing interval to maintain clinical benefit, while for others a \nlonger dosing interval may be sufficient. Patients who have had their dose interval shortened to less \nthan 8 weeks may be at greater risk for adverse reactions. Continued therapy with a shortened interval \nshould be carefully considered in those patients who show no evidence of additional therapeutic \nbenefit after a change in dosing interval. \nThe safety and efficacy of infliximab have not been studied in children with Crohn\u2019s disease below the \nage of 6 years. Currently available pharmacokinetic data are described in section 5.2 but no \nrecommendation on a posology can be made in children younger than 6 years. \nUlcerative colitis (6 to 17 years) \n5 mg/kg given as an intravenous infusion followed by additional 5 mg/kg infusion doses at 2 and \n6 weeks after the first infusion, then every 8 weeks thereafter. Available data do not support further \ninfliximab treatment in paediatric patients not responding within the first 8 weeks of treatment (see \nsection 5.1). \nThe safety and efficacy of infliximab have not been studied in children with ulcerative colitis below \nthe age of 6 years. Currently available pharmacokinetic data are described in section 5.2 but no \nrecommendation on a posology can be made in children younger than 6 years. \nPsoriasis \nThe safety and efficacy of infliximab in children and adolescents younger than 18 years for the \nindication of psoriasis have not been established. Currently available data are described in section 5.2 \nbut no recommendation on a posology can be made. \nJuvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis \nThe safety and efficacy of infliximab in children and adolescents younger than 18 years for the \nindications of juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis have not been \nestablished. Currently available data are described in section 5.2 but no recommendation on a \nposology can be made. \nJuvenile rheumatoid arthritis \nThe safety and efficacy of infliximab in children and adolescents younger than 18 years for the \nindication of juvenile rheumatoid arthritis have not been established. Currently available data are \ndescribed in sections 4.8 and 5.2 but no recommendation on a posology can be made. \nMethod of administration \nInfliximab should be administered intravenously over a 2 hour period. All patients administered \ninfliximab are to be observed for at least 1-2 hours post-infusion for acute infusion-related reactions. \nEmergency equipment, such as adrenaline, antihistamines, corticosteroids and an artificial airway must \nbe available. Patients may be pre-treated with e.g., an antihistamine, hydrocortisone and/or \nparacetamol and infusion rate may be slowed in order to decrease the risk of infusion-related reactions \nespecially if infusion-related reactions have occurred previously (see section 4.4). \nShortened infusions across adult indications \nIn carefully selected adult patients who have tolerated at least 3 initial 2-hour infusions of infliximab \n(induction phase) and are receiving maintenance therapy, consideration may be given to administering \nsubsequent infusions over a period of not less than 1 hour. If an infusion reaction occurs in association \nwith a shortened infusion, a slower infusion rate may be considered for future infusions if treatment is \nto be continued. Shortened infusions at doses >6 mg/kg have not been studied (see section 4.8). \nFor preparation and administration instructions, see section 6.6.", "contraindications": "Hypersensitivity to the active substance, to other murine proteins, or to any of the excipients listed in \nsection 6.1. \nPatients with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic \ninfections (see section 4.4). \nPatients with moderate or severe heart failure (NYHA class III/IV) (see sections 4.4 and 4.8).", "special_warnings": "Traceability \nIn order to improve the traceability of biological medicinal products, the tradename and the batch \nnumber of the administered product should be clearly recorded. \nInfusion reactions and hypersensitivity \nInfliximab has been associated with acute infusion-related reactions, including anaphylactic shock, \nand delayed hypersensitivity reactions (see section 4.8). \nAcute infusion reactions including anaphylactic reactions may develop during (within seconds) or \nwithin a few hours following infusion. If acute infusion reactions occur, the infusion must be \ninterrupted immediately. Emergency equipment, such as adrenaline, antihistamines, corticosteroids \nand an artificial airway must be available. Patients may be pre-treated with e.g., an antihistamine, \nhydrocortisone and/or paracetamol to prevent mild and transient effects. \nAntibodies to infliximab may develop and have been associated with an increased frequency of \ninfusion reactions. A low proportion of the infusion reactions was serious allergic reactions. An \nassociation between development of antibodies to infliximab and reduced duration of response has \nalso been observed. Concomitant administration of immunomodulators has been associated with lower \nincidence of antibodies to infliximab and a reduction in the frequency of infusion reactions. The effect \nof concomitant immunomodulator therapy was more profound in episodically-treated patients than in \npatients given maintenance therapy. Patients who discontinue immunosuppressants prior to or during \ninfliximab treatment are at greater risk of developing these antibodies. Antibodies to infliximab cannot \nalways be detected in serum samples. If serious reactions occur, symptomatic treatment must be given \nand further infliximab infusions must not be administered (see section 4.8). \nIn clinical studies, delayed hypersensitivity reactions have been reported. Available data suggest an \nincreased risk for delayed hypersensitivity with increasing infliximab-free interval. Patients should be \nadvised to seek immediate medical advice if they experience any delayed adverse reaction (see section \n4.8). If patients are re-treated after a prolonged period, they must be closely monitored for signs and \nsymptoms of delayed hypersensitivity. \nInfections \nPatients must be monitored closely for infections including tuberculosis before, during and after \ntreatment with infliximab. Because the elimination of infliximab may take up to six months, \nmonitoring should be continued throughout this period. Further treatment with infliximab must not be \ngiven if a patient develops a serious infection or sepsis. \nCaution should be exercised when considering the use of infliximab in patients with chronic infection \nor a history of recurrent infections, including concomitant immunosuppressive therapy. Patients \nshould be advised of and avoid exposure to potential risk factors for infection as appropriate. \nTumour necrosis factor alpha (TNF\u03b1) mediates inflammation and modulates cellular immune \nresponses. Experimental data show that TNF\u03b1 is essential for the clearing of intracellular infections. \nClinical experience shows that host defence against infection is compromised in some patients treated \nwith infliximab. \nIt should be noted that suppression of TNF\u03b1 may mask symptoms of infection such as fever. Early \nrecognition of atypical clinical presentations of serious infections and of typical clinical presentation \nof rare and unusual infections is critical in order to minimise delays in diagnosis and treatment.  \nPatients taking TNF-blockers are more susceptible to serious infections. \nTuberculosis, bacterial infections, including sepsis and pneumonia, invasive fungal, viral, and other \nopportunistic infections have been observed in patients treated with infliximab. Some of these \ninfections have been fatal; the most frequently reported opportunistic infections with a mortality rate \nof >5% include pneumocystosis, candidiasis, listeriosis and aspergillosis. \nPatients who develop a new infection while undergoing treatment with infliximab, should be \nmonitored closely and undergo a complete diagnostic evaluation. Administration of infliximab should \nbe discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial \nor antifungal therapy should be initiated until the infection is controlled. \nTuberculosis \nThere have been reports of active tuberculosis in patients receiving infliximab. It should be noted that \nin the majority of these reports tuberculosis was extrapulmonary, presenting as either local or \ndisseminated disease. \nBefore starting treatment with infliximab, all patients must be evaluated for both active and inactive \n(\u2018latent\u2019) tuberculosis. This evaluation should include a detailed medical history with personal history \nof tuberculosis or possible previous contact with tuberculosis and previous and/or current \nimmunosuppressive therapy. Appropriate screening tests, (e.g. tuberculin skin test, chest X-ray, and/or \nInterferon Gamma Release Assay), should be performed in all patients (local recommendations may \napply). It is recommended that the conduct of these tests should be recorded in the patient reminder \ncard. Prescribers are reminded of the risk of false negative tuberculin skin test results, especially in \npatients who are severely ill or immunocompromised. \nIf active tuberculosis is diagnosed, infliximab therapy must not be initiated (see section 4.3).  \nIf latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be \nconsulted. In all situations described below, the benefit/risk balance of infliximab therapy should be \nvery carefully considered. \nIf inactive (\u2018latent\u2019) tuberculosis is diagnosed, treatment for latent tuberculosis must be started with \nantituberculosis therapy before the initiation of infliximab, and in accordance with local \nrecommendations. \nIn patients who have several or significant risk factors for tuberculosis and have a negative test for \nlatent tuberculosis, antituberculosis therapy should be considered before the initiation of infliximab.  \nUse of antituberculosis therapy should also be considered before the initiation of infliximab in patients \nwith a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be \nconfirmed. \nSome cases of active tuberculosis have been reported in patients treated with infliximab during and \nafter treatment for latent tuberculosis. \nAll patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis \n(e.g. persistent cough, wasting/weight loss, low-grade fever) appear during or after infliximab \ntreatment. \nInvasive fungal infections \nIn patients treated with infliximab, an invasive fungal infection such as aspergillosis, candidiasis, \npneumocystosis, histoplasmosis, coccidioidomycosis or blastomycosis should be suspected if they \ndevelop a serious systemic illness, and a physician with expertise in the diagnosis and treatment of \ninvasive fungal infections should be consulted at an early stage when investigating these patients.  \nInvasive fungal infections may present as disseminated rather than localised disease, and antigen and \nantibody testing may be negative in some patients with active infection. Appropriate empiric \nantifungal therapy should be considered while a diagnostic workup is being performed taking into \naccount both the risk for severe fungal infection and the risks of antifungal therapy. \nFor patients who have resided in or travelled to regions where invasive fungal infections such as \nhistoplasmosis, coccidioidomycosis, or blastomycosis are endemic, the benefits and risks of infliximab \ntreatment should be carefully considered before initiation of infliximab therapy. \nFistulising Crohn\u2019s disease \nPatients with fistulising Crohn\u2019s disease with acute suppurative fistulas must not initiate infliximab \ntherapy until a source for possible infection, specifically abscess, has been excluded (see section 4.3). \nHepatitis B (HBV) reactivation \nReactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including infliximab, \nwho are chronic carriers of this virus. Some cases have had fatal outcome. \nPatients should be tested for HBV infection before initiating treatment with infliximab. For patients \nwho test positive for HBV infection, consultation with a physician with expertise in the treatment of \nhepatitis B is recommended. Carriers of HBV who require treatment with infliximab should be closely \nmonitored for signs and symptoms of active HBV infection throughout therapy and for several months \nfollowing termination of therapy. Adequate data of treating patients who are carriers of HBV with \nantiviral therapy in conjunction with TNF-antagonist therapy to prevent HBV reactivation are not \navailable. In patients who develop HBV reactivation, infliximab should be stopped and effective \nantiviral therapy with appropriate supportive treatment should be initiated. \n10 \nHepatobiliary events \nCases of jaundice and non-infectious hepatitis, some with features of autoimmune hepatitis, have been \nobserved in the post-marketing experience of infliximab. Isolated cases of liver failure resulting in \nliver transplantation or death have occurred. Patients with symptoms or signs of liver dysfunction \nshould be evaluated for evidence of liver injury. If jaundice and/or ALT elevations \n\u22655 times the upper \nlimit of normal develop(s), infliximab should be discontinued, and a thorough investigation of the \nabnormality should be undertaken. \nConcurrent administration of TNF-alpha inhibitor and anakinra \nSerious infections and neutropenia were seen in clinical studies with concurrent use of anakinra and \nanother TNF\u03b1-blocking agent, etanercept, with no added clinical benefit compared to etanercept alone. \nBecause of the nature of the adverse reactions seen with combination of etanercept and anakinra \ntherapy, similar toxicities may also result from the combination of anakinra and other TNF\u03b1-blocking \nagents. Therefore, the combination of infliximab and anakinra is not recommended. \nConcurrent administration of TNF-alpha inhibitor and abatacept \nIn clinical studies concurrent administration of TNF-antagonists and abatacept has been associated \nwith an increased risk of infections including serious infections compared to TNF-antagonists alone, \nwithout increased clinical benefit. The combination of infliximab and abatacept is not recommended. \nConcurrent administration with other biological therapeutics \nThere is insufficient information regarding the concomitant use of infliximab with other biological \ntherapeutics used to treat the same conditions as infliximab. The concomitant use of infliximab with \nthese biologics is not recommended because of the possibility of an increased risk of infection, and \nother potential pharmacological interactions. \nSwitching between biological DMARDs \nCare should be taken and patients should continue to be monitored when switching from one biologic \nto another, since overlapping biological activity may further increase the risk for adverse reactions, \nincluding infection. \nVaccinations \nIt is recommended that patients, if possible, be brought up to date with all vaccinations in agreement \nwith current vaccination guidelines prior to initiating Remsima therapy. Patients on infliximab may \nreceive concurrent vaccinations, except for live vaccines (see sections 4.5 and 4.6). \nIn a subset of 90 adult patients with rheumatoid arthritis from the ASPIRE study a similar proportion \nof patients in each treatment group (methotrexate plus: placebo [n = 17], 3 mg/kg [n = 27] or 6 mg/kg \ninfliximab [n = 46]) mounted an effective two-fold increase in titers to a polyvalent pneumococcal \nvaccine, indicating that infliximab did not interfere with T-cell independent humoral immune \nresponses. However, studies from the published literature in various indications (e.g. rheumatoid \narthritis, psoriasis, Crohn\u2019s disease) suggest that non-live vaccinations received during treatment with \nanti-TNF therapies, including infliximab may elicit a lower immune response than in patients not \nreceiving anti-TNF therapy. \nLive vaccines/therapeutic infectious agents \nIn patients receiving anti-TNF therapy, limited data are available on the response to vaccination with \nlive vaccines or on the secondary transmission of infection by live vaccines. Use of live vaccines can \nresult in clinical infections, including disseminated infections. The concurrent administration of live \nvaccines with infliximab is not recommended. \n11 \nInfant exposure \nin utero\nIn infants exposed \nin utero\n to infliximab, fatal outcome due to disseminated Bacillus Calmette-Gu\u00e9rin \n(BCG) infection has been reported following administration of BCG vaccine after birth. A twelve \nmonth waiting period following birth is recommended before the administration of live vaccines to \ninfants exposed \nin utero \nto infliximab. If infant infliximab serum levels are undetectable or infliximab \nadministration was limited to the first trimester of pregnancy, administration of a live vaccine might be \nconsidered at an earlier timepoint if there is a clear clinical benefit for the individual infant (see \nsection 4.6). \nInfant exposure via breast milk \nAdministration of a live vaccine to a breastfed infant while the mother is receiving infliximab is not \nrecommended unless infant infliximab serum levels are undetectable (see section 4.6). \nTherapeutic infectious agents \nOther uses of therapeutic infectious agents such as live attenuated bacteria (e.g., BCG bladder \ninstillation for the treatment of cancer) could result in clinical infections, including disseminated \ninfections. It is recommended that therapeutic infectious agents not be given concurrently with \ninfliximab. \nAutoimmune processes \nThe relative deficiency of TNF\u03b1 caused by anti-TNF therapy may result in the initiation of an \nautoimmune process. If a patient develops symptoms suggestive of a lupus-like syndrome following \ntreatment with infliximab and is positive for antibodies against double-stranded DNA, further \ntreatment with infliximab must not be given (see section 4.8). \nNeurological events \nUse of TNF-blocking agents, including infliximab, has been associated with cases of new onset or \nexacerbation of clinical symptoms and/or radiographic evidence of central nervous system \ndemyelinating disorders, including multiple sclerosis, and peripheral demyelinating disorders, \nincluding Guillain-Barr\u00e9 syndrome. In patients with pre-existing or recent onset of demyelinating \ndisorders, the benefits and risks of anti-TNF treatment should be carefully considered before initiation \nof infliximab therapy. Discontinuation of infliximab should be considered if these disorders develop. \nMalignancies and lymphoproliferative disorders \nIn the controlled portions of clinical studies of TNF-blocking agents, more cases of malignancies \nincluding lymphoma have been observed among patients receiving a TNF blocker compared with \ncontrol patients. During clinical studies of infliximab across all approved indications the incidence of \nlymphoma in infliximab-treated patients was higher than expected in the general population, but the \noccurrence of lymphoma was rare. In the post-marketing setting, cases of leukaemia have been \nreported in patients treated with a TNF-antagonist. There is an increased background risk for \nlymphoma and leukaemia in rheumatoid arthritis patients with long-standing, highly active, \ninflammatory disease, which complicates risk estimation. \nIn an exploratory clinical study evaluating the use of infliximab in patients with moderate to severe \nchronic obstructive pulmonary disease (COPD), more malignancies were reported in infliximab-\ntreated patients compared with control patients. All patients had a history of heavy smoking. Caution \nshould be exercised in considering treatment of patients with increased risk for malignancy due to \nheavy smoking. \nWith the current knowledge, a risk for the development of lymphomas or other malignancies in \npatients treated with a TNF-blocking agent cannot be excluded (see section 4.8). Caution should be \n12 \nexercised when considering TNF-blocking therapy for patients with a history of malignancy or when \nconsidering continuing treatment in patients who develop a malignancy. \nCaution should also be exercised in patients with psoriasis and a medical history of extensive \nimmunosuppressant therapy or prolonged PUVA treatment. \nMalignancies, some fatal, have been reported among children, adolescents and young adults (up to \n22 years of age) treated with TNF-\nblocking agents (initiation of therapy \u226418 years of age), including \ninfliximab in the post-marketing setting. Approximately half the cases were lymphomas. The other \ncases represented a variety of different malignancies and included rare malignancies usually associated \nwith immunosuppression. A risk for the development of malignancies in patients treated with \nTNF-blockers cannot be excluded. \nPost-marketing cases of hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients \ntreated with TNF-blocking agents including infliximab. This rare type of T-cell lymphoma has a very \naggressive disease course and is usually fatal. Almost all patients had received treatment with AZA or \n6-MP concomitantly with or immediately prior to a TNF-blocker. The vast majority of infliximab \ncases have occurred in patients with Crohn\u2019s disease or ulcerative colitis and most were reported in \nadolescent or young adult males. The potential risk with the combination of AZA or 6-MP and \ninfliximab should be carefully considered. A risk for the development for hepatosplenic T-cell \nlymphoma in patients treated with infliximab cannot be excluded (see section 4.8). \nMelanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker \ntherapy, including infliximab (see section 4.8). Periodic skin examination is recommended, \nparticularly for patients with risk factors for skin cancer. \nA population-based retrospective cohort study using data from Swedish national health registries \nfound an increased incidence of cervical cancer in women with rheumatoid arthritis treated with \ninfliximab compared to biologics-na\u00efve patients or the general population, including those over \n60 years of age. Periodic screening should continue in women treated with infliximab, including those \nover 60 years of age. \nAll patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma (for \nexample, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had a \nprior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals \nbefore therapy and throughout their disease course. This evaluation should include colonoscopy and \nbiopsies per local recommendations. Current data do not indicate that infliximab treatment influences \nthe risk for developing dysplasia or colon cancer. \nSince the possibility of increased risk of cancer development in patients with newly diagnosed \ndysplasia treated with infliximab is not established, the risk and benefits of continued therapy to the \nindividual patients should be carefully considered by the clinician. \nHeart failure \nInfliximab should be used with caution in patients with mild heart failure (NYHA class I/II). Patients \nshould be closely monitored and infliximab must not be continued in patients who develop new or \nworsening symptoms of heart failure (see sections 4.3 and 4.8). \nHaematologic reactions \nThere have been reports of pancytopenia, leukopenia, neutropenia, and thrombocytopenia in patients \nreceiving TNF-blockers, including infliximab. All patients should be advised to seek immediate \nmedical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent \nfever, bruising, bleeding, pallor). Discontinuation of infliximab therapy should be considered in \npatients with confirmed significant haematologic abnormalities. \n13 \nOthers \nThere is limited safety experience of infliximab treatment in patients who have undergone surgical \nprocedures, including arthroplasty. The long half-life of infliximab should be taken into consideration \nif a surgical procedure is planned. A patient who requires surgery while on infliximab should be \nclosely monitored for infections, and appropriate actions should be taken. \nFailure to respond to treatment for Crohn\u2019s disease may indicate the presence of a fixed fibrotic \nstricture that may require surgical treatment. There is no evidence to suggest that infliximab worsens \nor causes fibrotic strictures. \nSpecial populations  \nElderly \nThe incidence of serious infections in infliximab-treated patients 65 years and older was greater than \nin those under 65 years of age. Some of those had a fatal outcome. Particular attention regarding the \nrisk for infection should be paid when treating the elderly (see section 4.8). \nPaediatric population \nInfections \nIn clinical studies, infections have been reported in a higher proportion of paediatric patients compared \nto adult patients (see section 4.8). \nVaccinations \nIt is recommended that paediatric patients, if possible, be brought up to date with all vaccinations in \nagreement with current vaccination guidelines prior to initiating infliximab therapy. Paediatric patients \non infliximab may receive concurrent vaccinations, except for live vaccines (see sections 4.5 and 4.6). \nMalignancies and lymphoproliferative disorders \nMalignancies, some fatal, have been reported among children, adolescents and young adults (up to \n22 years of age) treated with TNF-\nblocking agents (initiation of therapy \u226418 years of age), including \ninfliximab in the post-marketing setting. Approximately half the cases were lymphomas. The other \ncases represented a variety of different malignancies and included rare malignancies usually associated \nwith immunosuppression. A risk for the development of malignancies in children and adolescents \ntreated with TNF-blockers cannot be excluded. \nPost-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with \nTNF-blocking agents including infliximab. This rare type of T-cell lymphoma has a very aggressive \ndisease course and is usually fatal. Almost all patients had received treatment with AZA or 6-MP \nconcomitantly with or immediately prior to a TNF-blocker. The vast majority of infliximab cases have \noccurred in patients with Crohn\u2019s disease or ulcerative colitis and most were reported in adolescent or \nyoung adult males. The potential risk with the combination of AZA or 6-MP and infliximab should be \ncarefully considered. A risk for the development for hepatosplenic T-cell lymphoma in patients treated \nwith infliximab cannot be excluded (see section 4.8). \nSodium content \nRemsima contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially \u2018sodium-free\u2019. Remsima \nis however, diluted in sodium chloride 9 mg/ml (0.9%) solution for infusion. This should be taken into \nconsideration for patients on a controlled sodium diet (see section 6.6).", "pregnancy": "No interaction studies have been performed. \n14 \nIn rheumatoid arthritis, psoriatic arthritis and Crohn's disease patients, there are indications that \nconcomitant use of methotrexate and other immunomodulators reduces the formation of antibodies \nagainst infliximab and increases the plasma concentrations of infliximab. However, the results are \nuncertain due to limitations in the methods used for serum analyses of infliximab and antibodies \nagainst infliximab. \nCorticosteroids do not appear to affect the pharmacokinetics of infliximab to a clinically relevant \nextent. \nThe combination of infliximab with other biological therapeutics used to treat the same conditions as \ninfliximab, including anakinra and abatacept, is not recommended (see section 4.4). \nIt is recommended that live vaccines not be given concurrently with infliximab. It is also \nrecommended that live vaccines not be given to infants after \nin utero\n exposure to infliximab for \n12 months following birth. If infant infliximab serum levels are undetectable or infliximab \nadministration was limited to the first trimester of pregnancy, administration of a live vaccine might be \nconsidered at an earlier timepoint if there is a clear clinical benefit for the individual infant (see \nsection 4.4). \nAdministration of a live vaccine to a breastfed infant while the mother is receiving infliximab is not \nrecommended unless infant infliximab serum levels are undetectable (see sections 4.4 and 4.6). \nIt is recommended that therapeutic infectious agents not be given concurrently with infliximab (see \nsection 4.4).", "driving": "Women of childbearing potential \nWomen of childbearing potential should consider the use of adequate contraception to prevent \npregnancy and continue its use for at least 6 months after the last infliximab treatment. \nPregnancy \nThe moderate number of prospectively collected pregnancies exposed to infliximab resulting in live \nbirth with known outcomes, including approximately 1,100 exposed during the first trimester, does not \nindicate an increase in the rate of malformation in the newborn.  \nBased on an observational study from Northern Europe, an increased risk (OR, 95% CI; p-value) for \nC-section (1.50, 1.14-1.96; p = 0.0032), preterm birth (1.48, 1.05-2.09; p = 0.024), small for \ngestational age (2.79, 1.54-5.04; p = 0.0007), and low birth weight (2.03, 1.41-2.94; p = 0.0002) was \nobserved in women exposed during pregnancy to infliximab (with or without \nimmunomodulators/corticosteroids, 270 pregnancies) as compared to women exposed to \nimmunomodulators and/or corticosteroids only (6,460 pregnancies). The potential contribution of \nexposure to infliximab and/or the severity of the underlying disease in these outcomes remains \nunclear. \nDue to its inhibition of TNF\u03b1, infliximab administered during pregnancy could affect normal immune \nresponses in the newborn. In a developmental toxicity study conducted in mice using an analogous \nantibody that selectively inhibits the functional activity of mouse TNF\u03b1, there was no indication of \nmaternal toxicity, embryotoxicity or teratogenicity (see section 5.3). \nThe available clinical experience is limited. Infliximab should only be used during pregnancy if \nclearly needed. \nInfliximab crosses the placenta and has been detected in the serum of infants up to 12 months \nfollowing birth. After \nin utero\n exposure to infliximab, infants may be at increased risk of infection, \n15 \nincluding serious disseminated infection that can become fatal. Administration of live vaccines \n(e.g., BCG vaccine) to infants exposed to infliximab \nin utero\n is not recommended for 12 months after \nbirth (see sections 4.4 and 4.5). If infant infliximab serum levels are undetectable or infliximab \nadministration was limited to the first trimester of pregnancy, administration of a live vaccine might be \nconsidered at an earlier timepoint if there is a clear clinical benefit for the individual infant. Cases of \nagranulocytosis have also been reported (see section 4.8). \nBreast-feeding \nLimited data from published literature indicate infliximab has been detected at low levels in human \nmilk at concentrations up to 5% of the maternal serum level. Infliximab has also been detected in \ninfant serum after exposure to infliximab via breast milk. While systemic exposure in a breastfed \ninfant is expected to be low because infliximab is largely degraded in the gastrointestinal tract, the \nadministration of live vaccines to a breastfed infant when the mother is receiving infliximab is not \nrecommended unless infant infliximab serum levels are undetectable. Infliximab could be considered \nfor use during breast-feeding. \nFertility \nThere are insufficient preclinical data to draw conclusions on the effects of infliximab on fertility and \ngeneral reproductive function (see section 5.3).", "side_effects": "Remsima may have a minor influence on the ability to drive and use machines. Dizziness may occur \nfollowing administration of infliximab (see section 4.8).", "shelf_life": "Before reconstitution: \n5 years at 2\u00b0C \u2013 8\u00b0C. \nRemsima may be stored at temperatures up to a maximum of 25\u00b0C for a single period of up to 6 \nmonths, but not exceeding the original expiry date. The new expiry date must be written on the carton. \nUpon removal from refrigerated storage, Remsima must not be returned to refrigerated storage. \nAfter reconstitution and dilution: \nChemical and physical in use stability of the diluted solution has been demonstrated for up to 60 days \nat 2 \u00b0C to 8 \u00b0C and for an additional 24 hours at 25\n\u00b0C after removal from refrigeration. From a \nmicrobiological point of view, the infusion solution should be administered immediately, in use \nstorage times and conditions prior to use are the responsibility of the user and would normally not be \nlonger than 24 hours at 2\u00b0C \u2013 8\u00b0C, unless reconstitution/dilution has been taken place in controlled \nand validated aseptic conditions.", "storage": "Store in a refrigerator (2\u00b0C \u2013 8\u00b0C). \nFor storage conditions up to 25\u00b0C before reconstitution of the medicinal product, see section 6.3. \n37 \nFor storage conditions after reconstitution of the medicinal product, see section 6.3", "package": "Type 1 glass vial with a (butyl) rubber stopper and an aluminium seal with a flip-off button. \nPack sizes of 1, 2, 3, 4, 5 vials. \nNot all pack sizes may be marketed.", "marketing_authorization_numbers": "EU/1/13/853/001 \nEU/1/13/853/002 \nEU/1/13/853/003 \nEU/1/13/853/004 \nEU/1/13/853/005", "filename": "remsima-epar-product-information_en.html", "snomed.product_info": [["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["739005008", "Powder (basic dose form)"], ["86495002", "For (qualifier value)"], ["1237267003", "Concentrate for conventional release solution for infusion (dose form)"]], "ncit.product_info": [["C1789", "Infliximab"], ["C105814", "One Hundred"], ["C16818", "Mammography"], ["C149813", "Powder for Concentrate for Solution for Infusion Dosage Form"]], "rxnorm.product_info": [], "loinc.product_info": [["LA19244-5", "100"], ["LP15217-0", "Mg"], ["LP263434-5", "Infusion"]], "snomed.composition": [["38112003", "One (qualifier value)|1 (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["255234002", "After (attribute)"], ["419473009", "Each (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["386891004", "Infliximab (substance)"], ["116680003", "Is a (attribute)"], ["338930006", "Human (organism)"], ["28406009", "Immunoglobulin IgG>1< (substance)|Immunoglobulin IgG1 (substance)"], ["312312006", "Monoclonal antibody (substance)|Monoclonal antibody"], ["18720000", "In (attribute)"], ["25326005", "Hybridoma (cell)"], ["788111003", "Recombinant deoxyribonucleic acid (substance)"], ["86495002", "For (qualifier value)"], ["261015003", "Full (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.composition": [["C66832", "One"], ["C41275", "Vial"], ["C79873", "Contain"], ["C105814", "One Hundred"], ["C16818", "Mammography"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C38008", "Post"], ["C64933", "Each"], ["C16816", "Mali"], ["C79873", "Contain"], ["C69122", "Ten"], ["C16818", "Mammography"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C1789", "Infliximab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C14194", "Chimera"], ["C14225", "Human"], ["C14238", "Mouse"], ["C201279", "IgG1"], ["C20401", "Monoclonal Antibody"], ["C16727", "India"], ["C14238", "Mouse"], ["C16700", "Hybridoma"], ["C48938", "Cell Count"], ["C158169", "Buyei Chinese"], ["C16621", "Genetic Engineering"], ["C64956", "For"], ["C25517", "Full"], ["C43432", "List"], ["C52874", "SPI1 wt Allele"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.composition": [["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["T016", "Human"]], "loinc.composition": [["LA6306-0", "One"], ["LA20376-2", "Vial"], ["LA19244-5", "100"], ["LP15217-0", "Mg"], ["MTHU060561", "inFLIXimab"], ["LA13942-0", "10"], ["LP15217-0", "Mg"], ["MTHU060561", "inFLIXimab"], ["LP6901-5", "*"], ["MTHU060561", "inFLIXimab"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LA19711-3", "Human"], ["LP32407-6", "IgG1"], ["LA22004-8", "IN"], ["MTHU001933", "Cells"], ["LA19712-1", "Recombinant"], ["MTHU003299", "DNA"], ["LA19682-6", "Full"], ["LP204165-7", "List"], ["LP20594-5", "6"], ["LA6112-2", "1"]], "snomed.indications": [["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["289928003", "Reduction plasty (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["20572008", "Good (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["19388002", "Physical (qualifier value)"], ["277064003", "Function (attribute)"], ["18720000", "In (attribute)"], ["255397009", "Adult (qualifier value)|Adult"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["64572001", "Disease (disorder)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["64572001", "Disease (disorder)"], ["55919000", "Including (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["255397009", "Adult (qualifier value)|Adult"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["55561003", "Active (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255314001", "Progressive (qualifier value)"], ["64572001", "Disease (disorder)"], ["28995006", "Treated with (attribute)"], ["387381009", "Methotrexate (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["18720000", "In (attribute)"], ["116154003", "Patient (person)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["289928003", "Reduction plasty (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["246450006", "Progression (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["302536002", "Entire joint (body structure)"], ["37782003", "Damage (morphologic abnormality)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["258104002", "Measured (qualifier value)"], ["363680008", "Radiographic imaging procedure (procedure)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["255397009", "Adult (qualifier value)|Adult"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["55561003", "Active (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["18720000", "In (attribute)"], ["255397009", "Adult (qualifier value)|Adult"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["261015003", "Full (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["88323005", "Adequate (qualifier value)"], ["260908002", "Course (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["372823004", "Immunosuppressant (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74188005", "Medical (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["55561003", "Active (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["18720000", "In (attribute)"], ["255397009", "Adult (qualifier value)|Adult"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["261015003", "Full (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["88323005", "Adequate (qualifier value)"], ["260908002", "Course (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255333006", "Conventional (qualifier value)"], ["55919000", "Including (qualifier value)"], ["122462000", "Drainage procedure (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["55561003", "Active (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["258707000", "year (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255333006", "Conventional (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["55919000", "Including (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["734544007", "Immunomodulator (disposition)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["261424001", "Primary operation (qualifier value)"], ["386373004", "Nutrition therapy (regime/therapy)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["386891004", "Infliximab (substance)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255333006", "Conventional (qualifier value)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["266447004", "Ulcerative colitis (disorder)|Ulcerative colitis"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["55561003", "Active (qualifier value)"], ["266447004", "Ulcerative colitis (disorder)|Ulcerative colitis"], ["18720000", "In (attribute)"], ["255397009", "Adult (qualifier value)|Adult"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255333006", "Conventional (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["55919000", "Including (qualifier value)"], ["79440004", "Product containing corticosteroid (product)|Product containing corticosteroid and/or corticosteroid derivative (product)|Corticoid preparation (product)|Product containing corticosteroid and corticosteroid derivative (product)|Corticoid preparation (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386835005", "Mercaptopurine (substance)"], ["386835005", "Mercaptopurine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["372574004", "Azathioprine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74188005", "Medical (qualifier value)"], ["86495002", "For (qualifier value)"], ["266447004", "Ulcerative colitis (disorder)|Ulcerative colitis"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["55561003", "Active (qualifier value)"], ["266447004", "Ulcerative colitis (disorder)|Ulcerative colitis"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["258707000", "year (qualifier value)"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255333006", "Conventional (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["55919000", "Including (qualifier value)"], ["79440004", "Product containing corticosteroid (product)|Product containing corticosteroid and/or corticosteroid derivative (product)|Corticoid preparation (product)|Product containing corticosteroid and corticosteroid derivative (product)|Corticoid preparation (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386835005", "Mercaptopurine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74188005", "Medical (qualifier value)"], ["86495002", "For (qualifier value)"], ["156619005", "Ankylosing spondylitis (disorder)|Ankylosing spondylitis"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["55561003", "Active (qualifier value)"], ["156619005", "Ankylosing spondylitis (disorder)|Ankylosing spondylitis"], ["18720000", "In (attribute)"], ["255397009", "Adult (qualifier value)|Adult"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255333006", "Conventional (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["55561003", "Active (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255314001", "Progressive (qualifier value)"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["18720000", "In (attribute)"], ["255397009", "Adult (qualifier value)|Adult"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["9130008", "Previous (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["29544009", "Intolerance, function (observable entity)|Intolerance (function)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410536001", "Contraindicated (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["19388002", "Physical (qualifier value)"], ["277064003", "Function (attribute)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["246450006", "Progression (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["14414005", "Peripheral (qualifier value)"], ["302536002", "Entire joint (body structure)"], ["37782003", "Damage (morphologic abnormality)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["258104002", "Measured (qualifier value)"], ["363680008", "Radiographic imaging procedure (procedure)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255205008", "Polyarticular (qualifier value)"], ["255473004", "Symmetrical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["64572001", "Disease (disorder)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["156369008", "Psoriasis|Psoriasis (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["371924009", "Moderate to severe (qualifier value)"], ["200965009", "Plaque psoriasis (disorder)"], ["18720000", "In (attribute)"], ["255397009", "Adult (qualifier value)|Adult"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["103306004", "Contraindication to (contextual qualifier) (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["31099001", "Systemic (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["55919000", "Including (qualifier value)"], ["387467008", "Ciclosporin (substance)|Cyclosporine (substance)"], ["387381009", "Methotrexate (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["419047007", "Psoralen (substance)"], ["415770004", "Ultra-violet color (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.indications": [["C2884", "Rheumatoid Arthritis"], ["C1789", "Infliximab"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C642", "Methotrexate"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C25640", "Reduced"], ["C52874", "SPI1 wt Allele"], ["C16289", "Andorra"], ["C168422", "Rheumatic Fever Symptom"], ["C71344", "Associate of Science"], ["C128793", "Microplate Well"], ["C71344", "Associate of Science"], ["C94226", "Improvement"], ["C16727", "India"], ["C150046", "Physical Function"], ["C16727", "India"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C62355", "With"], ["C154405", "Active State"], ["C2991", "Disease or Disorder"], ["C65140", "When"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C2991", "Disease or Disorder"], ["C166400", "Inclusive"], ["C642", "Methotrexate"], ["C101282", "Have"], ["C168268", "Inadequate Daily Salt Intake"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C154405", "Active State"], ["C16289", "Andorra"], ["C159955", "Global Progressive Disease in Skin"], ["C25594", "Negation"], ["C16124", "Prior Therapy"], ["C62355", "With"], ["C642", "Methotrexate"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C16727", "India"], ["C53691", "Veterinary Patient"], ["C76246", "Blood Group A"], ["C25640", "Reduced"], ["C16727", "India"], ["C77538", "Rating"], ["C52874", "SPI1 wt Allele"], ["C17747", "Disease Progression"], ["C52874", "SPI1 wt Allele"], ["C13044", "Joint"], ["C61555", "Damage"], ["C71344", "Associate of Science"], ["C44473", "Measured"], ["C158169", "Buyei Chinese"], ["C38101", "X-Ray Imaging"], ["C101282", "Have"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C52678", "Legal Adult"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C1789", "Infliximab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C125256", "Moderate Response"], ["C159124", "GDC Treatment Outcome Terminology"], ["C70667", "Severe"], ["C154405", "Active State"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C16727", "India"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C25594", "Negation"], ["C76246", "Blood Group A"], ["C25517", "Full"], ["C16289", "Andorra"], ["C168111", "Adequate Daily Fluid Intake"], ["C25379", "Course"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C211", "Therapeutic Corticosteroid"], ["C48928", "And/Or"], ["C75889", "PAX6 wt Allele"], ["C574", "Immunosuppressant"], ["C43508", "Oregon"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C101282", "Have"], ["C25261", "Medical"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C154405", "Active State"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C16727", "India"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C25594", "Negation"], ["C76246", "Blood Group A"], ["C25517", "Full"], ["C16289", "Andorra"], ["C168111", "Adequate Daily Fluid Intake"], ["C25379", "Course"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C62355", "With"], ["C97149", "Conventional Therapy"], ["C166400", "Inclusive"], ["C258", "Antibiotic"], ["C50434", "Drainage"], ["C16289", "Andorra"], ["C15261", "Immunosuppressive Therapy"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C1789", "Infliximab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C154405", "Active State"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C16727", "India"], ["C16423", "Child"], ["C16289", "Andorra"], ["C16266", "Adolescents"], ["C25150", "Age"], ["C172979", "Fear Score 6"], ["C159124", "GDC Treatment Outcome Terminology"], ["C113431", "Seventeen"], ["C29848", "Year"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C25594", "Negation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C97149", "Conventional Therapy"], ["C166400", "Inclusive"], ["C76246", "Blood Group A"], ["C211", "Therapeutic Corticosteroid"], ["C75889", "PAX6 wt Allele"], ["C16289", "Andorra"], ["C99531", "Primary Cause of Death"], ["C65017", "Nutritional Therapy"], ["C43508", "Oregon"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C101282", "Have"], ["C64956", "For"], ["C1789", "Infliximab"], ["C101282", "Have"], ["C48440", "Single"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C149409", "Conventional Release Mechanism of Action"], ["C15261", "Immunosuppressive Therapy"], ["C2952", "Ulcerative Colitis"], ["C1789", "Infliximab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C125256", "Moderate Response"], ["C159124", "GDC Treatment Outcome Terminology"], ["C70667", "Severe"], ["C154405", "Active State"], ["C2952", "Ulcerative Colitis"], ["C16727", "India"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C168268", "Inadequate Daily Salt Intake"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C97149", "Conventional Therapy"], ["C166400", "Inclusive"], ["C211", "Therapeutic Corticosteroid"], ["C16289", "Andorra"], ["C195", "Mercaptopurine"], ["C195", "Mercaptopurine"], ["C43508", "Oregon"], ["C290", "Azathioprine"], ["C290", "Azathioprine"], ["C43508", "Oregon"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C101282", "Have"], ["C25261", "Medical"], ["C64956", "For"], ["C2952", "Ulcerative Colitis"], ["C1789", "Infliximab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C70667", "Severe"], ["C154405", "Active State"], ["C2952", "Ulcerative Colitis"], ["C16727", "India"], ["C16423", "Child"], ["C16289", "Andorra"], ["C16266", "Adolescents"], ["C25150", "Age"], ["C172979", "Fear Score 6"], ["C159124", "GDC Treatment Outcome Terminology"], ["C113431", "Seventeen"], ["C29848", "Year"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C168268", "Inadequate Daily Salt Intake"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C97149", "Conventional Therapy"], ["C166400", "Inclusive"], ["C211", "Therapeutic Corticosteroid"], ["C16289", "Andorra"], ["C195", "Mercaptopurine"], ["C43508", "Oregon"], ["C290", "Azathioprine"], ["C43508", "Oregon"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C101282", "Have"], ["C25261", "Medical"], ["C64956", "For"], ["C84564", "Ankylosing Spondylitis"], ["C1789", "Infliximab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C154405", "Active State"], ["C84564", "Ankylosing Spondylitis"], ["C16727", "India"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C159124", "GDC Treatment Outcome Terminology"], ["C97149", "Conventional Therapy"], ["C61277", "Psoriatic Arthritis"], ["C1789", "Infliximab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C154405", "Active State"], ["C16289", "Andorra"], ["C25254", "Progressive"], ["C61277", "Psoriatic Arthritis"], ["C16727", "India"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C65140", "When"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25627", "Previous"], ["C121332", "Disease-Modifying Antirheumatic Drug"], ["C49236", "Therapeutic Procedure"], ["C101282", "Have"], ["C168268", "Inadequate Daily Salt Intake"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C642", "Methotrexate"], ["C43508", "Oregon"], ["C48440", "Single"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C71437", "Intolerance"], ["C159124", "GDC Treatment Outcome Terminology"], ["C642", "Methotrexate"], ["C43508", "Oregon"], ["C64956", "For"], ["C642", "Methotrexate"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C37933", "Contraindicated"], ["C1789", "Infliximab"], ["C101282", "Have"], ["C159124", "GDC Treatment Outcome Terminology"], ["C150046", "Physical Function"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C61277", "Psoriatic Arthritis"], ["C16289", "Andorra"], ["C159124", "GDC Treatment Outcome Terminology"], ["C77538", "Rating"], ["C52874", "SPI1 wt Allele"], ["C17747", "Disease Progression"], ["C52874", "SPI1 wt Allele"], ["C25233", "Peripheral"], ["C13044", "Joint"], ["C61555", "Damage"], ["C71344", "Associate of Science"], ["C44473", "Measured"], ["C158169", "Buyei Chinese"], ["C38101", "X-Ray Imaging"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C52874", "SPI1 wt Allele"], ["C2991", "Disease or Disorder"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C3346", "Psoriasis"], ["C1789", "Infliximab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C159124", "GDC Treatment Outcome Terminology"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C16727", "India"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C44281", "Failed"], ["C159124", "GDC Treatment Outcome Terminology"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C50646", "Medical Contraindication"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C118472", "Other License Status"], ["C15698", "Systemic Therapy"], ["C166400", "Inclusive"], ["C406", "Cyclosporine"], ["C642", "Methotrexate"], ["C43508", "Oregon"], ["C2586", "Psoralen"], ["C111019", "Violet"], ["C76246", "Blood Group A"], ["C29973", "PUVA Photochemotherapy"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.indications": [["6851", "methotrexate"], ["6851", "methotrexate"], ["6851", "methotrexate"], ["191831", "infliximab"], ["103", "mercaptopurine"], ["1256", "azathioprine"], ["6851", "methotrexate"], ["6851", "methotrexate"], ["6851", "methotrexate"], ["191831", "infliximab"], ["6851", "methotrexate"]], "loinc.indications": [["LA15161-5", "Rheumatoid Arthritis"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP16198-1", "Methotrexate"], ["LP200075-2", "IS"], ["LP267357-4", "Reduction"], ["LP75708-5", "Symptoms"], ["LA18365-9", "Well"], ["LA22004-8", "IN"], ["LP7799-2", "Physical function"], ["LA22004-8", "IN"], ["LA13524-6", "Adult"], ["LA16666-2", "Active"], ["LA18199-2", "Disease"], ["LA18199-2", "Disease"], ["LP18046-0", "Drugs"], ["LP16198-1", "Methotrexate"], ["LA8914-9", "Inadequate"], ["LA13524-6", "Adult"], ["LA6750-9", "Severe"], ["LA16666-2", "Active"], ["LA28370-7", "Progressive disease"], ["LA21291-2", "Not"], ["LP16198-1", "Methotrexate"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LA22004-8", "IN"], ["LP66710-2", "Patient"], ["LP17763-1", "A"], ["LP267357-4", "Reduction"], ["LA22004-8", "IN"], ["MTHU027852", "Rate"], ["MTHU048551", "Joint"], ["LP6378-6", "Measured"], ["LP21166-1", "X-ray"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LA13524-6", "Adult"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA13939-6", "Moderately"], ["LA28568-6", "Severely"], ["LA16666-2", "Active"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LA22004-8", "IN"], ["LA13524-6", "Adult"], ["LA21291-2", "Not"], ["LP17763-1", "A"], ["LA19682-6", "Full"], ["LA8913-1", "Adequate"], ["LP267221-2", "Therapy"], ["LP17763-1", "A"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LP75725-9", "Therapies"], ["LP94823-9", "Treatment"], ["LA16666-2", "Active"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LA22004-8", "IN"], ["LA13524-6", "Adult"], ["LA21291-2", "Not"], ["LP17763-1", "A"], ["LA19682-6", "Full"], ["LA8913-1", "Adequate"], ["LP267221-2", "Therapy"], ["LA32139-0", "Conventional"], ["LP94823-9", "Treatment"], ["LP31426-7", "Antibiotics"], ["LP200044-8", "Drainage"], ["LP267221-2", "Therapy"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA6750-9", "Severe"], ["LA16666-2", "Active"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LP20594-5", "6"], ["LA21291-2", "Not"], ["LA32139-0", "Conventional"], ["LP267221-2", "Therapy"], ["LP17763-1", "A"], ["LA21208-6", "Primary"], ["LP172860-1", "Nutrition"], ["LP267221-2", "Therapy"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LP75725-9", "Therapies"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LA32139-0", "Conventional"], ["LP267221-2", "Therapy"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA13939-6", "Moderately"], ["LA28568-6", "Severely"], ["LA16666-2", "Active"], ["LA22004-8", "IN"], ["LA13524-6", "Adult"], ["LA8914-9", "Inadequate"], ["LA32139-0", "Conventional"], ["LP267221-2", "Therapy"], ["LP20594-5", "6"], ["LP15173-5", "Mercaptopurine"], ["LP20594-5", "6"], ["LA22025-3", "OR"], ["LA31624-2", "Azathioprine"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LP75725-9", "Therapies"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA28568-6", "Severely"], ["LA16666-2", "Active"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LP20594-5", "6"], ["LA8914-9", "Inadequate"], ["LA32139-0", "Conventional"], ["LP267221-2", "Therapy"], ["LP20594-5", "6"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LP75725-9", "Therapies"], ["LA31822-2", "Spondylitis"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA6750-9", "Severe"], ["LA16666-2", "Active"], ["LA31822-2", "Spondylitis"], ["LA22004-8", "IN"], ["LA13524-6", "Adult"], ["LA32139-0", "Conventional"], ["LP267221-2", "Therapy"], ["MTHU020793", "Arthritis"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA16666-2", "Active"], ["LA25478-1", "Progressive"], ["MTHU020793", "Arthritis"], ["LA22004-8", "IN"], ["LA13524-6", "Adult"], ["LP267221-2", "Therapy"], ["LA8914-9", "Inadequate"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP16198-1", "Methotrexate"], ["LA22025-3", "OR"], ["LA27350-0", "Alone"], ["LA22004-8", "IN"], ["LP16198-1", "Methotrexate"], ["LA22025-3", "OR"], ["LP16198-1", "Methotrexate"], ["LP200075-2", "IS"], ["LA4216-3", "Contraindicated"], ["MTHU060561", "inFLIXimab"], ["LP7799-2", "Physical function"], ["LA22004-8", "IN"], ["MTHU020793", "Arthritis"], ["MTHU027852", "Rate"], ["LA24844-5", "Peripheral"], ["MTHU048551", "Joint"], ["LP6378-6", "Measured"], ["LP21166-1", "X-ray"], ["LA22004-8", "IN"], ["LA18199-2", "Disease"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LA15165-6", "Psoriasis"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA32820-5", "Moderate to severe"], ["LA15165-6", "Psoriasis"], ["LA22004-8", "IN"], ["LA13524-6", "Adult"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["MTHU038257", "Contraindication"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LP267221-2", "Therapy"], ["LP16198-1", "Methotrexate"], ["LA22025-3", "OR"], ["LA19062-1", "Violet"], ["LP17763-1", "A"], ["LA16783-5", "PUVA"], ["LP20593-7", "5"], ["LA6112-2", "1"]], "snomed.posology": [["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["439401001", "Diagnosis (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["255387000", "Inflammatory|Inflammatory (qualifier value)"], ["113276009", "Intestinal structure (body structure)"], ["64572001", "Disease (disorder)"], ["156619005", "Ankylosing spondylitis (disorder)|Ankylosing spondylitis"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["156369008", "Psoriasis|Psoriasis (disorder)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["36576007", "Infusion (procedure)"], ["262094002", "Related (finding)"], ["28995006", "Treated with (attribute)"], ["1681000175101", "Package - unit of product usage (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["116154003", "Patient (person)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["79440004", "Product containing corticosteroid (product)|Product containing corticosteroid and/or corticosteroid derivative (product)|Corticoid preparation (product)|Product containing corticosteroid and corticosteroid derivative (product)|Corticoid preparation (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["346414003", "Ensure (substance)|Ensure (product)"], ["255560000", "Intravenous (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["764295003", "Subcutaneous (intended site)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["116154003", "Patient (person)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["764295003", "Subcutaneous (intended site)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["86495002", "For (qualifier value)"], ["255560000", "Intravenous (qualifier value)"], ["416118004", "Administration (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["180251004", "Subcutaneous injection (& for local action) (procedure)|Subcutaneous injection (& for local action)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["258707000", "year (qualifier value)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["385228000", "Intravenous infusion (product)|Intravenous infusion (qualifier value)"], ["367409002", "Followed by (attribute)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["36576007", "Infusion (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["255216001", "First (qualifier value)"], ["36576007", "Infusion (procedure)"], ["421067001", "Then - dosing instruction fragment (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258705008", "week (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255234002", "After (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["398298007", "Step (qualifier value)"], ["26175008", "Approximate (qualifier value)"], ["732425003", "1.5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732850005", "7.5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["70232002", "Frequent (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["396134005", "Every four weeks (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["88323005", "Adequate (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420862001", "On (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["260864003", "Frequency (attribute)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["41647002", "No evidence of (contextual qualifier) (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["18720000", "In (attribute)"], ["255216001", "First (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258705008", "week (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255234002", "After (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["55561003", "Active (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["385228000", "Intravenous infusion (product)|Intravenous infusion (qualifier value)"], ["367409002", "Followed by (attribute)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["36576007", "Infusion (procedure)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["255216001", "First (qualifier value)"], ["36576007", "Infusion (procedure)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["717896003", "Does not (qualifier value)"], ["255234002", "After (attribute)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["373067005", "No (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["390683003", "Support|Support (regime/therapy)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["884001", "Initial (qualifier value)"], ["36576007", "Infusion (procedure)"], ["18720000", "In (attribute)"], ["86495002", "For (qualifier value)"], ["36576007", "Infusion (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["884001", "Initial (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["367409002", "Followed by (attribute)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["416118004", "Administration (procedure)"], ["36576007", "Infusion (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["64572001", "Disease (disorder)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["416118004", "Administration (procedure)"], ["351726001", "Below (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["41277001", "Lacking (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["18720000", "In (attribute)"], ["884001", "Initial (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["41647002", "No evidence of (contextual qualifier) (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["255234002", "After (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["55561003", "Active (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["385228000", "Intravenous infusion (product)|Intravenous infusion (qualifier value)"], ["367409002", "Followed by (attribute)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["255216001", "First (qualifier value)"], ["36576007", "Infusion (procedure)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["717896003", "Does not (qualifier value)"], ["255234002", "After (attribute)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["373067005", "No (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["416118004", "Administration (procedure)"], ["36576007", "Infusion (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["64572001", "Disease (disorder)"], ["367409002", "Followed by (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["416118004", "Administration (procedure)"], ["351726001", "Below (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["41277001", "Lacking (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["18720000", "In (attribute)"], ["884001", "Initial (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["41647002", "No evidence of (contextual qualifier) (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["255234002", "After (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["18720000", "In (attribute)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["416118004", "Administration (procedure)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["64572001", "Disease (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420862001", "On (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["86495002", "For (qualifier value)"], ["41277001", "Lacking (qualifier value)"], ["266447004", "Ulcerative colitis (disorder)|Ulcerative colitis"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["385228000", "Intravenous infusion (product)|Intravenous infusion (qualifier value)"], ["367409002", "Followed by (attribute)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["36576007", "Infusion (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["255216001", "First (qualifier value)"], ["36576007", "Infusion (procedure)"], ["421067001", "Then - dosing instruction fragment (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["1222741009", "American Joint Committee on Cancer stage I:4 (qualifier value)"], ["258705008", "week (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["41647002", "No evidence of (contextual qualifier) (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["18720000", "In (attribute)"], ["900000000000475002", "Time (foundation metadata concept)"], ["156619005", "Ankylosing spondylitis (disorder)|Ankylosing spondylitis"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["385228000", "Intravenous infusion (product)|Intravenous infusion (qualifier value)"], ["367409002", "Followed by (attribute)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["36576007", "Infusion (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["255216001", "First (qualifier value)"], ["36576007", "Infusion (procedure)"], ["421067001", "Then - dosing instruction fragment (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["717896003", "Does not (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["255234002", "After (attribute)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["373067005", "No (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["385228000", "Intravenous infusion (product)|Intravenous infusion (qualifier value)"], ["367409002", "Followed by (attribute)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["36576007", "Infusion (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["255216001", "First (qualifier value)"], ["36576007", "Infusion (procedure)"], ["421067001", "Then - dosing instruction fragment (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["156369008", "Psoriasis|Psoriasis (disorder)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["385228000", "Intravenous infusion (product)|Intravenous infusion (qualifier value)"], ["367409002", "Followed by (attribute)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["36576007", "Infusion (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["255216001", "First (qualifier value)"], ["36576007", "Infusion (procedure)"], ["421067001", "Then - dosing instruction fragment (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["373067005", "No (qualifier value)"], ["255234002", "After (attribute)"], ["1222741009", "American Joint Committee on Cancer stage I:4 (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["255234002", "After (attribute)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["373067005", "No (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["416118004", "Administration (procedure)"], ["86495002", "For (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["64572001", "Disease (disorder)"], ["386891004", "Infliximab (substance)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["1222743007", "American Joint Committee on Cancer stage I:6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255260001", "Following (attribute)"], ["36576007", "Infusion (procedure)"], ["18720000", "In (attribute)"], ["58147004", "Clinical (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["257550005", "Hypersensitivity (qualifier value)"], ["103356009", "Uncommon (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255234002", "After (attribute)"], ["386891004", "Infliximab (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258707000", "year (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["416118004", "Administration (procedure)"], ["255234002", "After (attribute)"], ["386891004", "Infliximab (substance)"], ["385673002", "Interval (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["242762006", "More (qualifier value)"], ["1222743007", "American Joint Committee on Cancer stage I:6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["263748003", "Established (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["51440002", "Right and left (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["416118004", "Administration (procedure)"], ["86495002", "For (qualifier value)"], ["266447004", "Ulcerative colitis (disorder)|Ulcerative colitis"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["416118004", "Administration (procedure)"], ["74964007", "Other (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["263748003", "Established (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["416118004", "Administration (procedure)"], ["86495002", "For (qualifier value)"], ["156619005", "Ankylosing spondylitis (disorder)|Ankylosing spondylitis"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["416118004", "Administration (procedure)"], ["74964007", "Other (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["263748003", "Established (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["416118004", "Administration (procedure)"], ["86495002", "For (qualifier value)"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["416118004", "Administration (procedure)"], ["74964007", "Other (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["263748003", "Established (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["416118004", "Administration (procedure)"], ["86495002", "For (qualifier value)"], ["156369008", "Psoriasis|Psoriasis (disorder)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["386891004", "Infliximab (substance)"], ["408102007", "Unit dose (qualifier value)"], ["18720000", "In (attribute)"], ["156369008", "Psoriasis|Psoriasis (disorder)"], ["255234002", "After (attribute)"], ["385673002", "Interval (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258705008", "week (qualifier value)"], ["260400001", "Reduced (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["371923003", "Mild to moderate (qualifier value)"], ["36576007", "Infusion (procedure)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["884001", "Initial (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["255260001", "Following (attribute)"], ["64572001", "Disease (disorder)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["36576007", "Infusion (procedure)"], ["55919000", "Including (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["732732008", "4.8 (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["416118004", "Administration (procedure)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["314122007", "Maintenance therapy (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["261017006", "Interrupted (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["116680003", "Is a (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["18720000", "In (attribute)"], ["386891004", "Infliximab (substance)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["408102007", "Unit dose (qualifier value)"], ["367409002", "Followed by (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["352730000", "Supra- (qualifier value)"], ["67995009", "Special (qualifier value)"], ["69658003", "Specific (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["373067005", "No (qualifier value)"], ["255603008", "Major (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["262094002", "Related (finding)"], ["18720000", "In (attribute)"], ["260695007", "Clearance (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["118565006", "Volume (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["246457009", "Distribution (attribute)"], ["18720000", "In (attribute)"], ["58147004", "Clinical (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["86495002", "For (qualifier value)"], ["242762006", "More (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["40226000", "Impairment (finding)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["116154003", "Patient (person)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["376171000221106", "Pediatric population (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["258707000", "year (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["385228000", "Intravenous infusion (product)|Intravenous infusion (qualifier value)"], ["367409002", "Followed by (attribute)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["36576007", "Infusion (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["255216001", "First (qualifier value)"], ["36576007", "Infusion (procedure)"], ["421067001", "Then - dosing instruction fragment (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["390683003", "Support|Support (regime/therapy)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["255216001", "First (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["258705008", "week (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["385673002", "Interval (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["86495002", "For (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["385673002", "Interval (qualifier value)"], ["51117008", "Sufficient (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["385673002", "Interval (qualifier value)"], ["359530003", "Shortened (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["263768009", "Greater (qualifier value)"], ["86495002", "For (qualifier value)"], ["281647001", "Adverse reaction (disorder)|Adverse reactions (disorder)|Adverse reactions (finding)"], ["277132007", "Therapeutic procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["359530003", "Shortened (qualifier value)"], ["385673002", "Interval (qualifier value)"], ["18720000", "In (attribute)"], ["41647002", "No evidence of (contextual qualifier) (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["255234002", "After (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263703002", "Changed status (qualifier value)"], ["385673002", "Interval (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["351726001", "Below (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258707000", "year (qualifier value)"], ["15240007", "Current (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["732766004", "5.2 (qualifier value)"], ["373067005", "No (qualifier value)"], ["420862001", "On (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258707000", "year (qualifier value)"], ["266447004", "Ulcerative colitis (disorder)|Ulcerative colitis"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["258707000", "year (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["385228000", "Intravenous infusion (product)|Intravenous infusion (qualifier value)"], ["367409002", "Followed by (attribute)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["36576007", "Infusion (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["255216001", "First (qualifier value)"], ["36576007", "Infusion (procedure)"], ["421067001", "Then - dosing instruction fragment (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["390683003", "Support|Support (regime/therapy)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["255216001", "First (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["266447004", "Ulcerative colitis (disorder)|Ulcerative colitis"], ["351726001", "Below (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258707000", "year (qualifier value)"], ["15240007", "Current (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["732766004", "5.2 (qualifier value)"], ["373067005", "No (qualifier value)"], ["420862001", "On (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258707000", "year (qualifier value)"], ["156369008", "Psoriasis|Psoriasis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["258707000", "year (qualifier value)"], ["86495002", "For (qualifier value)"], ["230165009", "Indication of (contextual qualifier) (qualifier value)"], ["156369008", "Psoriasis|Psoriasis (disorder)"], ["263748003", "Established (qualifier value)"], ["15240007", "Current (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["732766004", "5.2 (qualifier value)"], ["373067005", "No (qualifier value)"], ["420862001", "On (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["410502007", "Juvenile idiopathic arthritis (disorder)"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["156619005", "Ankylosing spondylitis (disorder)|Ankylosing spondylitis"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["258707000", "year (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["410502007", "Juvenile idiopathic arthritis (disorder)"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["156619005", "Ankylosing spondylitis (disorder)|Ankylosing spondylitis"], ["263748003", "Established (qualifier value)"], ["15240007", "Current (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["732766004", "5.2 (qualifier value)"], ["373067005", "No (qualifier value)"], ["420862001", "On (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["410795001", "Juvenile rheumatoid arthritis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["258707000", "year (qualifier value)"], ["86495002", "For (qualifier value)"], ["230165009", "Indication of (contextual qualifier) (qualifier value)"], ["410795001", "Juvenile rheumatoid arthritis (disorder)"], ["263748003", "Established (qualifier value)"], ["15240007", "Current (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["732732008", "4.8 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["373067005", "No (qualifier value)"], ["420862001", "On (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["260686004", "Method (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["386891004", "Infliximab (substance)"], ["21481007", "Over (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258702006", "hour (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["386891004", "Infliximab (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["123030002", "2 hours (qualifier value)"], ["288563008", "After values (qualifier value)"], ["36576007", "Infusion (procedure)"], ["86495002", "For (qualifier value)"], ["53737009", "Acute (qualifier value)"], ["36576007", "Infusion (procedure)"], ["262094002", "Related (finding)"], ["25876001", "Emergency (qualifier value)"], ["246137000", "Equipment (attribute)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["387362001", "Epinephrine (substance)|Epinephrine preparation (substance)"], ["320678002", "Antihistamines (product)|Antihistamines (substance)"], ["79440004", "Product containing corticosteroid (product)|Product containing corticosteroid and/or corticosteroid derivative (product)|Corticoid preparation (product)|Product containing corticosteroid and corticosteroid derivative (product)|Corticoid preparation (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["71967004", "Artificial (qualifier value)"], ["89187006", "Airway structure (body structure)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["28995006", "Treated with (attribute)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["372806008", "Substance with histamine receptor antagonist mechanism of action (substance)|Antihistamine (substance)"], ["396458002", "Hydrocortisone (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["387517004", "Paracetamol (substance)|Acetaminophen (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["36576007", "Infusion (procedure)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["260370003", "Decrease (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["36576007", "Infusion (procedure)"], ["262094002", "Related (finding)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["36576007", "Infusion (procedure)"], ["262094002", "Related (finding)"], ["732727007", "4.4 (qualifier value)"], ["359530003", "Shortened (qualifier value)"], ["255397009", "Adult (qualifier value)|Adult"], ["18720000", "In (attribute)"], ["255397009", "Adult (qualifier value)|Adult"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["884001", "Initial (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258702006", "hour (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["21191007", "Phase (attribute)|Phase (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["314122007", "Maintenance therapy (procedure)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["21481007", "Over (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258702006", "hour (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["441940003", "Adverse reaction caused by drug or medicament administered by infusion (disorder)|Adverse reaction to drug or medicament administered by infusion (disorder)"], ["18720000", "In (attribute)"], ["263534001", "Association (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["359530003", "Shortened (qualifier value)"], ["36576007", "Infusion (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["36576007", "Infusion (procedure)"], ["86495002", "For (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["359530003", "Shortened (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["86495002", "For (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["732810007", "6.6 (qualifier value)"]], "ncit.posology": [["C1789", "Infliximab"], ["C43442", "Biomaterial Treatment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C16289", "Andorra"], ["C158169", "Buyei Chinese"], ["C16727", "India"], ["C15220", "Diagnosis"], ["C16289", "Andorra"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C2884", "Rheumatoid Arthritis"], ["C25535", "Inflammatory"], ["C12736", "Intestine"], ["C2991", "Disease or Disorder"], ["C84564", "Ankylosing Spondylitis"], ["C61277", "Psoriatic Arthritis"], ["C43508", "Oregon"], ["C3346", "Psoriasis"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C38276", "Intravenous Route of Administration"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C158169", "Buyei Chinese"], ["C16205", "Healthcare Activity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C117041", "Dosing Days to Detection"], ["C81168", "Any"], ["C15388", "Infusion Procedure"], ["C53260", "Adverse Event Definitely Related to Intervention"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C64974", "Give"], ["C79887", "Package"], ["C97006", "Leaflet"], ["C16289", "Andorra"], ["C53691", "Veterinary Patient"], ["C54270", "Reminder"], ["C160555", "CaRD Regimen"], ["C25490", "During"], ["C1789", "Infliximab"], ["C43442", "Biomaterial Treatment"], ["C118472", "Other License Status"], ["C25730", "Concomitant"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C211", "Therapeutic Corticosteroid"], ["C16289", "Andorra"], ["C16329", "Belgium"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C125543", "Importance Rating Score 0"], ["C159124", "GDC Treatment Outcome Terminology"], ["C86058", "Check"], ["C40352", "Multiplicative Product"], ["C159124", "GDC Treatment Outcome Terminology"], ["C74452", "Nutritional Supplement Drink"], ["C68815", "Correct"], ["C15653", "Drug Formulation Process"], ["C38276", "Intravenous Route of Administration"], ["C43508", "Oregon"], ["C13353", "Subcutaneous"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C89327", "Be"], ["C25382", "Administered"], ["C159124", "GDC Treatment Outcome Terminology"], ["C53691", "Veterinary Patient"], ["C71344", "Associate of Science"], ["C1789", "Infliximab"], ["C13353", "Subcutaneous"], ["C15653", "Drug Formulation Process"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C118257", "Unintentional"], ["C64956", "For"], ["C38276", "Intravenous Route of Administration"], ["C70962", "Agent Administration"], ["C16289", "Andorra"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C113553", "SEMA6A wt Allele"], ["C76246", "Blood Group A"], ["C13353", "Subcutaneous"], ["C122632", "Injection Dosing Unit"], ["C48440", "Single"], ["C111798", "Eighteen"], ["C29848", "Year"], ["C2884", "Rheumatoid Arthritis"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C67401", "Milligram per Kilogram"], ["C64974", "Give"], ["C71344", "Associate of Science"], ["C75889", "PAX6 wt Allele"], ["C38275", "Intravenous Infusion"], ["C53286", "Next"], ["C25406", "Additional"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C67401", "Milligram per Kilogram"], ["C15388", "Infusion Procedure"], ["C25488", "Dose"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16289", "Andorra"], ["C172979", "Fear Score 6"], ["C29844", "Week"], ["C38008", "Post"], ["C25509", "First"], ["C15388", "Infusion Procedure"], ["C65106", "Then"], ["C103389", "Every Eight Weeks"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C64974", "Give"], ["C62355", "With"], ["C642", "Methotrexate"], ["C25429", "Availability"], ["C25474", "Data"], ["C48313", "Suggestion"], ["C123619", "Clinical Response"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C114711", "Usually"], ["C25282", "Within"], ["C113426", "Twelve"], ["C29844", "Week"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C168268", "Inadequate Daily Salt Intake"], ["C165206", "Responsive Disease"], ["C43508", "Oregon"], ["C165206", "Responsive Disease"], ["C38008", "Post"], ["C25616", "Period"], ["C113416", "Consideration"], ["C106184", "May"], ["C16329", "Belgium"], ["C64974", "Give"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25533", "Increase"], ["C25488", "Dose"], ["C16154", "Treatment Step"], ["C132098", "SOSTDC1 wt Allele"], ["C158169", "Buyei Chinese"], ["C45828", "Approximate"], ["C161429", "CDISC SDTM Model Version 1.5"], ["C67401", "Milligram per Kilogram"], ["C64643", "Up to"], ["C76246", "Blood Group A"], ["C82868", "Maximum Value Derivation Technique"], ["C52874", "SPI1 wt Allele"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C64651", "Every"], ["C66839", "Eight"], ["C29844", "Week"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C67401", "Milligram per Kilogram"], ["C71344", "Associate of Science"], ["C91247", "Often"], ["C71344", "Associate of Science"], ["C64529", "Every Four Weeks"], ["C106184", "May"], ["C16329", "Belgium"], ["C198613", "CFI wt Allele"], ["C168111", "Adequate Daily Fluid Intake"], ["C165206", "Responsive Disease"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C53279", "Continue"], ["C92667", "SPARC wt Allele"], ["C48912", "Choose"], ["C25488", "Dose"], ["C43508", "Oregon"], ["C89081", "Dose Frequency"], ["C53279", "Continue"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C25277", "Therapeutic"], ["C25387", "Benefit"], ["C25282", "Within"], ["C25509", "First"], ["C113426", "Twelve"], ["C29844", "Week"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C43508", "Oregon"], ["C38008", "Post"], ["C82495", "Dose Adjustment"], ["C125256", "Moderate Response"], ["C159124", "GDC Treatment Outcome Terminology"], ["C70667", "Severe"], ["C154405", "Active State"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C64974", "Give"], ["C71344", "Associate of Science"], ["C75889", "PAX6 wt Allele"], ["C38275", "Intravenous Infusion"], ["C53286", "Next"], ["C75889", "PAX6 wt Allele"], ["C25406", "Additional"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C15388", "Infusion Procedure"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29844", "Week"], ["C38008", "Post"], ["C25509", "First"], ["C15388", "Infusion Procedure"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C86066", "Do"], ["C25594", "Negation"], ["C38008", "Post"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25488", "Dose"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25406", "Additional"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C64974", "Give"], ["C25429", "Availability"], ["C25474", "Data"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C37902", "Support"], ["C25519", "Further"], ["C1789", "Infliximab"], ["C43442", "Biomaterial Treatment"], ["C16727", "India"], ["C16960", "Patient"], ["C25594", "Negation"], ["C25282", "Within"], ["C172979", "Fear Score 6"], ["C29844", "Week"], ["C52874", "SPI1 wt Allele"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C15388", "Infusion Procedure"], ["C16727", "India"], ["C16960", "Patient"], ["C97927", "Gene Variant"], ["C64956", "For"], ["C53279", "Continue"], ["C43442", "Biomaterial Treatment"], ["C68869", "Are"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25406", "Additional"], ["C15388", "Infusion Procedure"], ["C52874", "SPI1 wt Allele"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C158997", "GDC Analyte Type Terminology"], ["C172979", "Fear Score 6"], ["C29844", "Week"], ["C38008", "Post"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C25488", "Dose"], ["C53286", "Next"], ["C103389", "Every Eight Weeks"], ["C43508", "Oregon"], ["C17095", "Reunion"], ["C70962", "Agent Administration"], ["C15388", "Infusion Procedure"], ["C52874", "SPI1 wt Allele"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C198613", "CFI wt Allele"], ["C16289", "Andorra"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C2991", "Disease or Disorder"], ["C3352", "Recurrence"], ["C163702", "Staphylococcal Enterotoxin E"], ["C17095", "Reunion"], ["C70962", "Agent Administration"], ["C75330", "Below"], ["C16289", "Andorra"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25474", "Data"], ["C68869", "Are"], ["C142988", "Limited"], ["C25474", "Data"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C159124", "GDC Treatment Outcome Terminology"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C75419", "World Health Organization"], ["C165233", "Expression Negative"], ["C165206", "Responsive Disease"], ["C65099", "Some"], ["C16960", "Patient"], ["C106184", "May"], ["C165206", "Responsive Disease"], ["C62355", "With"], ["C90475", "Titration Study"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C53279", "Continue"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C25277", "Therapeutic"], ["C25387", "Benefit"], ["C38008", "Post"], ["C82495", "Dose Adjustment"], ["C154405", "Active State"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C64974", "Give"], ["C71344", "Associate of Science"], ["C75889", "PAX6 wt Allele"], ["C38275", "Intravenous Infusion"], ["C53286", "Next"], ["C25406", "Additional"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16289", "Andorra"], ["C172979", "Fear Score 6"], ["C29844", "Week"], ["C38008", "Post"], ["C25509", "First"], ["C15388", "Infusion Procedure"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C86066", "Do"], ["C25594", "Negation"], ["C38008", "Post"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C25488", "Dose"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25406", "Additional"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C64974", "Give"], ["C16727", "India"], ["C16960", "Patient"], ["C97927", "Gene Variant"], ["C64956", "For"], ["C53279", "Continue"], ["C43442", "Biomaterial Treatment"], ["C68869", "Are"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25406", "Additional"], ["C52874", "SPI1 wt Allele"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C103389", "Every Eight Weeks"], ["C43508", "Oregon"], ["C17095", "Reunion"], ["C70962", "Agent Administration"], ["C15388", "Infusion Procedure"], ["C52874", "SPI1 wt Allele"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C198613", "CFI wt Allele"], ["C16289", "Andorra"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C2991", "Disease or Disorder"], ["C3352", "Recurrence"], ["C53286", "Next"], ["C52874", "SPI1 wt Allele"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C103389", "Every Eight Weeks"], ["C163702", "Staphylococcal Enterotoxin E"], ["C17095", "Reunion"], ["C70962", "Agent Administration"], ["C75330", "Below"], ["C16289", "Andorra"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25474", "Data"], ["C68869", "Are"], ["C142988", "Limited"], ["C25474", "Data"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C159124", "GDC Treatment Outcome Terminology"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C75419", "World Health Organization"], ["C165233", "Expression Negative"], ["C165206", "Responsive Disease"], ["C65099", "Some"], ["C16960", "Patient"], ["C106184", "May"], ["C165206", "Responsive Disease"], ["C62355", "With"], ["C90475", "Titration Study"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C53279", "Continue"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C25277", "Therapeutic"], ["C25387", "Benefit"], ["C38008", "Post"], ["C82495", "Dose Adjustment"], ["C16727", "India"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C54627", "Experience"], ["C62355", "With"], ["C17095", "Reunion"], ["C70962", "Agent Administration"], ["C198613", "CFI wt Allele"], ["C16289", "Andorra"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C2991", "Disease or Disorder"], ["C3352", "Recurrence"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C142988", "Limited"], ["C16289", "Andorra"], ["C25474", "Data"], ["C92667", "SPARC wt Allele"], ["C25387", "Benefit"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C97927", "Gene Variant"], ["C64956", "For"], ["C53279", "Continue"], ["C43442", "Biomaterial Treatment"], ["C68869", "Are"], ["C2952", "Ulcerative Colitis"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C64974", "Give"], ["C71344", "Associate of Science"], ["C75889", "PAX6 wt Allele"], ["C38275", "Intravenous Infusion"], ["C53286", "Next"], ["C25406", "Additional"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C15388", "Infusion Procedure"], ["C25488", "Dose"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16289", "Andorra"], ["C172979", "Fear Score 6"], ["C29844", "Week"], ["C38008", "Post"], ["C25509", "First"], ["C15388", "Infusion Procedure"], ["C65106", "Then"], ["C103389", "Every Eight Weeks"], ["C25429", "Availability"], ["C25474", "Data"], ["C48313", "Suggestion"], ["C123619", "Clinical Response"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C114711", "Usually"], ["C25282", "Within"], ["C113428", "Fourteen"], ["C29844", "Week"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C68254", "Dietary Iodine"], ["C68800", "Elementary Charge"], ["C66834", "Three"], ["C25488", "Dose"], ["C53279", "Continue"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C25277", "Therapeutic"], ["C25387", "Benefit"], ["C25282", "Within"], ["C25616", "Period"], ["C84564", "Ankylosing Spondylitis"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C64974", "Give"], ["C71344", "Associate of Science"], ["C75889", "PAX6 wt Allele"], ["C38275", "Intravenous Infusion"], ["C53286", "Next"], ["C25406", "Additional"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C15388", "Infusion Procedure"], ["C25488", "Dose"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16289", "Andorra"], ["C172979", "Fear Score 6"], ["C29844", "Week"], ["C38008", "Post"], ["C25509", "First"], ["C15388", "Infusion Procedure"], ["C65106", "Then"], ["C64651", "Every"], ["C172979", "Fear Score 6"], ["C159124", "GDC Treatment Outcome Terminology"], ["C66839", "Eight"], ["C29844", "Week"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C86066", "Do"], ["C25594", "Negation"], ["C158169", "Buyei Chinese"], ["C172979", "Fear Score 6"], ["C29844", "Week"], ["C68254", "Dietary Iodine"], ["C68800", "Elementary Charge"], ["C38008", "Post"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25488", "Dose"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25406", "Additional"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C64974", "Give"], ["C61277", "Psoriatic Arthritis"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C64974", "Give"], ["C71344", "Associate of Science"], ["C75889", "PAX6 wt Allele"], ["C38275", "Intravenous Infusion"], ["C53286", "Next"], ["C25406", "Additional"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C15388", "Infusion Procedure"], ["C25488", "Dose"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16289", "Andorra"], ["C172979", "Fear Score 6"], ["C29844", "Week"], ["C38008", "Post"], ["C25509", "First"], ["C15388", "Infusion Procedure"], ["C65106", "Then"], ["C103389", "Every Eight Weeks"], ["C3346", "Psoriasis"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C64974", "Give"], ["C71344", "Associate of Science"], ["C75889", "PAX6 wt Allele"], ["C38275", "Intravenous Infusion"], ["C53286", "Next"], ["C25406", "Additional"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C15388", "Infusion Procedure"], ["C25488", "Dose"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16289", "Andorra"], ["C172979", "Fear Score 6"], ["C29844", "Week"], ["C38008", "Post"], ["C25509", "First"], ["C15388", "Infusion Procedure"], ["C65106", "Then"], ["C103389", "Every Eight Weeks"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C123600", "No Response"], ["C38008", "Post"], ["C113428", "Fourteen"], ["C29844", "Week"], ["C68254", "Dietary Iodine"], ["C68800", "Elementary Charge"], ["C38008", "Post"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25488", "Dose"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25406", "Additional"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C64974", "Give"], ["C17095", "Reunion"], ["C70962", "Agent Administration"], ["C64956", "For"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C16289", "Andorra"], ["C2884", "Rheumatoid Arthritis"], ["C198613", "CFI wt Allele"], ["C16289", "Andorra"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C2991", "Disease or Disorder"], ["C3352", "Recurrence"], ["C1789", "Infliximab"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C17095", "Reunion"], ["C25382", "Administered"], ["C25282", "Within"], ["C113430", "Sixteen"], ["C29844", "Week"], ["C53286", "Next"], ["C25551", "Last"], ["C15388", "Infusion Procedure"], ["C16727", "India"], ["C15206", "Clinical Study"], ["C168181", "Delayed Capillary Refill Time"], ["C3114", "Hypersensitivity"], ["C101282", "Have"], ["C16289", "Andorra"], ["C101282", "Have"], ["C54069", "Occur"], ["C38008", "Post"], ["C1789", "Infliximab"], ["C63628", "Empty"], ["C52874", "SPI1 wt Allele"], ["C127045", "Stayed Off Cigarettes Less than One Year Since Diagnosis"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C17095", "Reunion"], ["C70962", "Agent Administration"], ["C38008", "Post"], ["C75889", "PAX6 wt Allele"], ["C1789", "Infliximab"], ["C63628", "Empty"], ["C25543", "Interval"], ["C52874", "SPI1 wt Allele"], ["C61584", "Greater Than"], ["C113430", "Sixteen"], ["C29844", "Week"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49636", "Both"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C16960", "Patient"], ["C16289", "Andorra"], ["C2884", "Rheumatoid Arthritis"], ["C16960", "Patient"], ["C17095", "Reunion"], ["C70962", "Agent Administration"], ["C64956", "For"], ["C2952", "Ulcerative Colitis"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C17095", "Reunion"], ["C70962", "Agent Administration"], ["C151896", "Other Than"], ["C103389", "Every Eight Weeks"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C17095", "Reunion"], ["C70962", "Agent Administration"], ["C64956", "For"], ["C84564", "Ankylosing Spondylitis"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C17095", "Reunion"], ["C70962", "Agent Administration"], ["C151896", "Other Than"], ["C64651", "Every"], ["C172979", "Fear Score 6"], ["C159124", "GDC Treatment Outcome Terminology"], ["C66839", "Eight"], ["C29844", "Week"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C17095", "Reunion"], ["C70962", "Agent Administration"], ["C64956", "For"], ["C61277", "Psoriatic Arthritis"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C17095", "Reunion"], ["C70962", "Agent Administration"], ["C151896", "Other Than"], ["C103389", "Every Eight Weeks"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C17095", "Reunion"], ["C70962", "Agent Administration"], ["C64956", "For"], ["C3346", "Psoriasis"], ["C142988", "Limited"], ["C54627", "Experience"], ["C25516", "From"], ["C17095", "Reunion"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C66832", "One"], ["C48440", "Single"], ["C1789", "Infliximab"], ["C25488", "Dose"], ["C16727", "India"], ["C3346", "Psoriasis"], ["C38008", "Post"], ["C75889", "PAX6 wt Allele"], ["C25543", "Interval"], ["C52874", "SPI1 wt Allele"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C29844", "Week"], ["C25640", "Reduced"], ["C88183", "Efficacy"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C25227", "High"], ["C16726", "Incidence"], ["C52874", "SPI1 wt Allele"], ["C156242", "Mild Hallucination"], ["C159124", "GDC Treatment Outcome Terminology"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C15388", "Infusion Procedure"], ["C65140", "When"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C158876", "Induction Therapy"], ["C165496", "GDC Regimen Terminology"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C142988", "Limited"], ["C54627", "Experience"], ["C25516", "From"], ["C17095", "Reunion"], ["C43442", "Biomaterial Treatment"], ["C53286", "Next"], ["C2991", "Disease or Disorder"], ["C37953", "Flare"], ["C158169", "Buyei Chinese"], ["C76246", "Blood Group A"], ["C158877", "Reinduction Therapy"], ["C165496", "GDC Regimen Terminology"], ["C76246", "Blood Group A"], ["C25227", "High"], ["C16726", "Incidence"], ["C52874", "SPI1 wt Allele"], ["C15388", "Infusion Procedure"], ["C166400", "Inclusive"], ["C54035", "Serious"], ["C65140", "When"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C66839", "Eight"], ["C67069", "Weekly"], ["C156598", "Maintenance Clinical Trial Setting"], ["C43442", "Biomaterial Treatment"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C17095", "Reunion"], ["C70962", "Agent Administration"], ["C81171", "Cross"], ["C16727", "India"], ["C49152", "Case"], ["C15688", "Maintenance Therapy"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25542", "Interruption"], ["C16289", "Andorra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C41204", "Need"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25658", "Restart"], ["C43442", "Biomaterial Treatment"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C158877", "Reinduction Therapy"], ["C165496", "GDC Regimen Terminology"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C16727", "India"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C17095", "Reunion"], ["C71344", "Associate of Science"], ["C76246", "Blood Group A"], ["C48440", "Single"], ["C25488", "Dose"], ["C53286", "Next"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25488", "Dose"], ["C75329", "Above"], ["C18101", "Special Population"], ["C16268", "Elderly"], ["C38024", "Specified"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C16727", "India"], ["C16268", "Elderly"], ["C16960", "Patient"], ["C101282", "Have"], ["C25594", "Negation"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C45368", "Major"], ["C106312", "Advanced Glycation End Product"], ["C53260", "Adverse Event Definitely Related to Intervention"], ["C16727", "India"], ["C199688", "Drug Clearance"], ["C43508", "Oregon"], ["C70917", "Distribution Volume"], ["C25599", "Observed"], ["C16727", "India"], ["C15206", "Clinical Study"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25488", "Dose"], ["C49157", "Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C64956", "For"], ["C128667", "More"], ["C48191", "Information"], ["C45828", "Approximate"], ["C49667", "Safety Study"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C16727", "India"], ["C16268", "Elderly"], ["C16960", "Patient"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C25225", "Renal"], ["C48928", "And/Or"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C1789", "Infliximab"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C53691", "Veterinary Patient"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25488", "Dose"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C17005", "Population Group"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C172979", "Fear Score 6"], ["C159124", "GDC Treatment Outcome Terminology"], ["C113431", "Seventeen"], ["C29848", "Year"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C64974", "Give"], ["C71344", "Associate of Science"], ["C75889", "PAX6 wt Allele"], ["C38275", "Intravenous Infusion"], ["C53286", "Next"], ["C25406", "Additional"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C15388", "Infusion Procedure"], ["C25488", "Dose"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16289", "Andorra"], ["C172979", "Fear Score 6"], ["C29844", "Week"], ["C38008", "Post"], ["C25509", "First"], ["C15388", "Infusion Procedure"], ["C65106", "Then"], ["C103389", "Every Eight Weeks"], ["C25429", "Availability"], ["C25474", "Data"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C37902", "Support"], ["C25519", "Further"], ["C1789", "Infliximab"], ["C43442", "Biomaterial Treatment"], ["C16727", "India"], ["C16423", "Child"], ["C16289", "Andorra"], ["C16266", "Adolescents"], ["C25594", "Negation"], ["C25282", "Within"], ["C25509", "First"], ["C69122", "Ten"], ["C29844", "Week"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C65099", "Some"], ["C16960", "Patient"], ["C106184", "May"], ["C76246", "Blood Group A"], ["C176355", "Dosing Interval"], ["C159124", "GDC Treatment Outcome Terminology"], ["C53297", "Maintenance"], ["C142422", "Clinical Benefit"], ["C64956", "For"], ["C168369", "Other Chief Complaint"], ["C76246", "Blood Group A"], ["C176355", "Dosing Interval"], ["C106184", "May"], ["C16329", "Belgium"], ["C63351", "Sufficient"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C101282", "Have"], ["C25488", "Dose"], ["C25543", "Interval"], ["C159124", "GDC Treatment Outcome Terminology"], ["C61422", "Lesser"], ["C66839", "Eight"], ["C29844", "Week"], ["C106184", "May"], ["C16329", "Belgium"], ["C158997", "GDC Analyte Type Terminology"], ["C61421", "Greater"], ["C17102", "Risk"], ["C64956", "For"], ["C188368", "ELN Adverse-Risk Category"], ["C53279", "Continue"], ["C49236", "Therapeutic Procedure"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C25543", "Interval"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C25406", "Additional"], ["C25277", "Therapeutic"], ["C25387", "Benefit"], ["C38008", "Post"], ["C76246", "Blood Group A"], ["C54126", "Delta"], ["C16727", "India"], ["C176355", "Dosing Interval"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C16423", "Child"], ["C62355", "With"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C75330", "Below"], ["C106312", "Advanced Glycation End Product"], ["C52874", "SPI1 wt Allele"], ["C172979", "Fear Score 6"], ["C29848", "Year"], ["C25429", "Availability"], ["C49663", "Pharmacokinetic Study"], ["C25474", "Data"], ["C68869", "Are"], ["C16727", "India"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25197", "Recommendation"], ["C92667", "SPARC wt Allele"], ["C76246", "Blood Group A"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C16727", "India"], ["C16423", "Child"], ["C172979", "Fear Score 6"], ["C29848", "Year"], ["C2952", "Ulcerative Colitis"], ["C172979", "Fear Score 6"], ["C159124", "GDC Treatment Outcome Terminology"], ["C113431", "Seventeen"], ["C29848", "Year"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C64974", "Give"], ["C71344", "Associate of Science"], ["C75889", "PAX6 wt Allele"], ["C38275", "Intravenous Infusion"], ["C53286", "Next"], ["C25406", "Additional"], ["C163771", "Illness Intrusiveness Rating 5"], ["C67401", "Milligram per Kilogram"], ["C15388", "Infusion Procedure"], ["C25488", "Dose"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16289", "Andorra"], ["C172979", "Fear Score 6"], ["C29844", "Week"], ["C38008", "Post"], ["C25509", "First"], ["C15388", "Infusion Procedure"], ["C65106", "Then"], ["C103389", "Every Eight Weeks"], ["C25429", "Availability"], ["C25474", "Data"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C37902", "Support"], ["C25519", "Further"], ["C1789", "Infliximab"], ["C43442", "Biomaterial Treatment"], ["C16727", "India"], ["C16960", "Patient"], ["C25594", "Negation"], ["C25282", "Within"], ["C25509", "First"], ["C66839", "Eight"], ["C29844", "Week"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C16423", "Child"], ["C62355", "With"], ["C2952", "Ulcerative Colitis"], ["C75330", "Below"], ["C106312", "Advanced Glycation End Product"], ["C52874", "SPI1 wt Allele"], ["C172979", "Fear Score 6"], ["C29848", "Year"], ["C25429", "Availability"], ["C49663", "Pharmacokinetic Study"], ["C25474", "Data"], ["C68869", "Are"], ["C16727", "India"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25197", "Recommendation"], ["C92667", "SPARC wt Allele"], ["C76246", "Blood Group A"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C16727", "India"], ["C16423", "Child"], ["C172979", "Fear Score 6"], ["C29848", "Year"], ["C3346", "Psoriasis"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C16727", "India"], ["C16423", "Child"], ["C16289", "Andorra"], ["C16266", "Adolescents"], ["C111798", "Eighteen"], ["C29848", "Year"], ["C64956", "For"], ["C41184", "Indication"], ["C52874", "SPI1 wt Allele"], ["C3346", "Psoriasis"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C25429", "Availability"], ["C25474", "Data"], ["C68869", "Are"], ["C16727", "India"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25197", "Recommendation"], ["C92667", "SPARC wt Allele"], ["C76246", "Blood Group A"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C114357", "Juvenile Idiopathic Arthritis"], ["C61277", "Psoriatic Arthritis"], ["C16289", "Andorra"], ["C84564", "Ankylosing Spondylitis"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C16727", "India"], ["C16423", "Child"], ["C16289", "Andorra"], ["C16266", "Adolescents"], ["C111798", "Eighteen"], ["C29848", "Year"], ["C64956", "For"], ["C52874", "SPI1 wt Allele"], ["C114357", "Juvenile Idiopathic Arthritis"], ["C61277", "Psoriatic Arthritis"], ["C16289", "Andorra"], ["C84564", "Ankylosing Spondylitis"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C25429", "Availability"], ["C25474", "Data"], ["C68869", "Are"], ["C16727", "India"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25197", "Recommendation"], ["C92667", "SPARC wt Allele"], ["C76246", "Blood Group A"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C27179", "Juvenile Rheumatoid Arthritis"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C16727", "India"], ["C16423", "Child"], ["C16289", "Andorra"], ["C16266", "Adolescents"], ["C111798", "Eighteen"], ["C29848", "Year"], ["C64956", "For"], ["C41184", "Indication"], ["C52874", "SPI1 wt Allele"], ["C27179", "Juvenile Rheumatoid Arthritis"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C25429", "Availability"], ["C25474", "Data"], ["C68869", "Are"], ["C16727", "India"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25197", "Recommendation"], ["C92667", "SPARC wt Allele"], ["C76246", "Blood Group A"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C85492", "CDISC SDTM Method Terminology"], ["C52874", "SPI1 wt Allele"], ["C70962", "Agent Administration"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C38276", "Intravenous Route of Administration"], ["C25490", "During"], ["C76246", "Blood Group A"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25529", "Hour"], ["C25616", "Period"], ["C64916", "All"], ["C16960", "Patient"], ["C25382", "Administered"], ["C1789", "Infliximab"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C25599", "Observed"], ["C64956", "For"], ["C158997", "GDC Analyte Type Terminology"], ["C15693", "Phase I/II Trial"], ["C25529", "Hour"], ["C38008", "Post"], ["C15388", "Infusion Procedure"], ["C64956", "For"], ["C14140", "Acute"], ["C15388", "Infusion Procedure"], ["C53260", "Adverse Event Definitely Related to Intervention"], ["C53513", "Emergency Room"], ["C84337", "Scientific Equipment"], ["C71344", "Associate of Science"], ["C79445", "Epinephrine Measurement"], ["C211", "Therapeutic Corticosteroid"], ["C16289", "Andorra"], ["C75889", "PAX6 wt Allele"], ["C61464", "Artificial"], ["C89842", "Airway"], ["C16329", "Belgium"], ["C25429", "Availability"], ["C16960", "Patient"], ["C106184", "May"], ["C16329", "Belgium"], ["C25629", "Prior"], ["C25705", "Treating"], ["C62355", "With"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C75889", "PAX6 wt Allele"], ["C29716", "Antihistamine"], ["C2290", "Cortisol"], ["C48928", "And/Or"], ["C198", "Acetaminophen"], ["C16289", "Andorra"], ["C94916", "Infusion Rate"], ["C106184", "May"], ["C16329", "Belgium"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25640", "Reduced"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C15388", "Infusion Procedure"], ["C53260", "Adverse Event Definitely Related to Intervention"], ["C198613", "CFI wt Allele"], ["C15388", "Infusion Procedure"], ["C53260", "Adverse Event Definitely Related to Intervention"], ["C101282", "Have"], ["C54069", "Occur"], ["C25627", "Previous"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C81171", "Cross"], ["C52678", "Legal Adult"], ["C16727", "India"], ["C48912", "Choose"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C158997", "GDC Analyte Type Terminology"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25529", "Hour"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C123453", "Induction Therapy Epoch"], ["C16289", "Andorra"], ["C68869", "Are"], ["C25639", "Receive"], ["C15688", "Maintenance Therapy"], ["C113416", "Consideration"], ["C106184", "May"], ["C16329", "Belgium"], ["C64974", "Give"], ["C159124", "GDC Treatment Outcome Terminology"], ["C53286", "Next"], ["C25490", "During"], ["C76246", "Blood Group A"], ["C25616", "Period"], ["C52874", "SPI1 wt Allele"], ["C61583", "Greater Than or Equal To"], ["C105723", "ECOG Performance Status 1"], ["C25529", "Hour"], ["C198613", "CFI wt Allele"], ["C75889", "PAX6 wt Allele"], ["C15388", "Infusion Procedure"], ["C25637", "Reaction"], ["C16727", "India"], ["C73471", "Chemical Association"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C15388", "Infusion Procedure"], ["C76246", "Blood Group A"], ["C94916", "Infusion Rate"], ["C106184", "May"], ["C16329", "Belgium"], ["C64956", "For"], ["C67527", "Future"], ["C198613", "CFI wt Allele"], ["C43442", "Biomaterial Treatment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C53279", "Continue"], ["C158997", "GDC Analyte Type Terminology"], ["C25488", "Dose"], ["C172979", "Fear Score 6"], ["C67401", "Milligram per Kilogram"], ["C101282", "Have"], ["C25594", "Negation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C64956", "For"], ["C25625", "Preparation"], ["C16289", "Andorra"], ["C70962", "Agent Administration"], ["C42688", "Instruction"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C172979", "Fear Score 6"]], "rxnorm.posology": [["1649574", "Injection"], ["6851", "methotrexate"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["5492", "hydrocortisone"], ["191831", "infliximab"]], "loinc.posology": [["LP94823-9", "Treatment"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["MTHU008876", "Diagnosis"], ["LP94823-9", "Treatment"], ["LA15161-5", "Rheumatoid Arthritis"], ["MTHU002653", "Bowel"], ["LA31822-2", "Spondylitis"], ["MTHU020793", "Arthritis"], ["LA22025-3", "OR"], ["LA15165-6", "Psoriasis"], ["LA30302-6", "Healthcare"], ["LP263434-5", "Infusion"], ["LA31343-9", "Related"], ["LP29256-2", "given"], ["LP66710-2", "Patient"], ["LP29708-2", "Cardiology"], ["LP94823-9", "Treatment"], ["MTHU029809", "Other"], ["LP75725-9", "Therapies"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP251102-2", "Check"], ["LA9960-1", "Correct"], ["LA9437-0", "Intravenous"], ["LA22025-3", "OR"], ["LA9451-1", "Subcutaneous"], ["LP200075-2", "IS"], ["LP66710-2", "Patient"], ["LA9451-1", "Subcutaneous"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA9437-0", "Intravenous"], ["LP17763-1", "A"], ["LA9451-1", "Subcutaneous"], ["LA14542-7", "Injection"], ["LA15161-5", "Rheumatoid Arthritis"], ["LP20591-1", "3"], ["LP15217-0", "Mg"], ["LP29256-2", "given"], ["LA9437-0", "Intravenous"], ["LP263434-5", "Infusion"], ["LP263791-8", "Additional"], ["LP20591-1", "3"], ["LP15217-0", "Mg"], ["LP263434-5", "Infusion"], ["LA21988-3", "AT"], ["MTHU000002", "Clinical Class"], ["LA31713-3", "6 weeks"], ["LP6974-2", "first"], ["LP263434-5", "Infusion"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LP29256-2", "given"], ["LP16198-1", "Methotrexate"], ["LP7787-7", "Clinical"], ["LP200075-2", "IS"], ["LA14747-2", "Usually"], ["LA32245-5", "Achieved"], ["LA14558-3", "12"], ["LA9000-6", "Weeks"], ["LP94823-9", "Treatment"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LA8914-9", "Inadequate"], ["LA22025-3", "OR"], ["LA14161-6", "May"], ["LP29256-2", "given"], ["LA32048-3", "Increase"], ["MTHU065481", "Dose"], ["LA15765-3", "1.5"], ["LP15217-0", "Mg"], ["LP17763-1", "A"], ["LP6972-6", "maximum"], ["LA21653-3", "7.5"], ["LP15217-0", "Mg"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LP20591-1", "3"], ["LP15217-0", "Mg"], ["LA10044-8", "Often"], ["LP6941-1", "4 weeks"], ["LA14161-6", "May"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA8913-1", "Adequate"], ["LP200075-2", "IS"], ["LA32245-5", "Achieved"], ["MTHU065481", "Dose"], ["LA22025-3", "OR"], ["MTHU065481", "Dose"], ["MTHU029777", "Frequency"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LA32-8", "No"], ["LP263807-2", "Therapeutic"], ["LP6974-2", "first"], ["LA14558-3", "12"], ["LA9000-6", "Weeks"], ["LP94823-9", "Treatment"], ["LA22025-3", "OR"], ["MTHU065481", "Dose"], ["LA13939-6", "Moderately"], ["LA28568-6", "Severely"], ["LA16666-2", "Active"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP29256-2", "given"], ["LA9437-0", "Intravenous"], ["LP263434-5", "Infusion"], ["LP263791-8", "Additional"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP263434-5", "Infusion"], ["LP6931-2", "2 weeks"], ["LP6974-2", "first"], ["LP263434-5", "Infusion"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LA21291-2", "Not"], ["MTHU000002", "Clinical Class"], ["LA32-8", "No"], ["LP263791-8", "Additional"], ["LP94823-9", "Treatment"], ["MTHU060561", "inFLIXimab"], ["LP29256-2", "given"], ["LA14426-3", "Do not"], ["MTHU015279", "Support"], ["MTHU060561", "inFLIXimab"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LA21291-2", "Not"], ["LA31713-3", "6 weeks"], ["LA6662-6", "Initial"], ["LP263434-5", "Infusion"], ["LA22004-8", "IN"], ["LA30091-5", "Alternative"], ["LP94823-9", "Treatment"], ["LP263791-8", "Additional"], ["LP263434-5", "Infusion"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LA21988-3", "AT"], ["LA31713-3", "6 weeks"], ["LA6662-6", "Initial"], ["MTHU065481", "Dose"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LA22025-3", "OR"], ["LP263434-5", "Infusion"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP75708-5", "Symptoms"], ["LA18199-2", "Disease"], ["LA14987-4", "Below"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA6484-5", "Limited"], ["LA22004-8", "IN"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LA14803-3", "Lost"], ["LA14973-4", "Some"], ["LA14161-6", "May"], ["MTHU065481", "Dose"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LA32-8", "No"], ["LP263807-2", "Therapeutic"], ["MTHU065481", "Dose"], ["LA16666-2", "Active"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP29256-2", "given"], ["LA9437-0", "Intravenous"], ["LP263434-5", "Infusion"], ["LP263791-8", "Additional"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LA21988-3", "AT"], ["MTHU000002", "Clinical Class"], ["LA31713-3", "6 weeks"], ["LP6974-2", "first"], ["LP263434-5", "Infusion"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LA21291-2", "Not"], ["LP20591-1", "3"], ["LA32-8", "No"], ["LP263791-8", "Additional"], ["LP94823-9", "Treatment"], ["MTHU060561", "inFLIXimab"], ["LP29256-2", "given"], ["LA22004-8", "IN"], ["LA30091-5", "Alternative"], ["LP94823-9", "Treatment"], ["LP263791-8", "Additional"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LA22025-3", "OR"], ["LP263434-5", "Infusion"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP75708-5", "Symptoms"], ["LA18199-2", "Disease"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LA14987-4", "Below"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA6484-5", "Limited"], ["LA22004-8", "IN"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LA14803-3", "Lost"], ["LA14973-4", "Some"], ["LA14161-6", "May"], ["MTHU065481", "Dose"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LA32-8", "No"], ["LP263807-2", "Therapeutic"], ["MTHU065481", "Dose"], ["LA22004-8", "IN"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP75708-5", "Symptoms"], ["LA18199-2", "Disease"], ["LP200075-2", "IS"], ["LA6484-5", "Limited"], ["LA30091-5", "Alternative"], ["LP94823-9", "Treatment"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP29256-2", "given"], ["LA9437-0", "Intravenous"], ["LP263434-5", "Infusion"], ["LP263791-8", "Additional"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP263434-5", "Infusion"], ["LA21988-3", "AT"], ["MTHU000002", "Clinical Class"], ["LA31713-3", "6 weeks"], ["LP6974-2", "first"], ["LP263434-5", "Infusion"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LP7787-7", "Clinical"], ["LP200075-2", "IS"], ["LA14747-2", "Usually"], ["LA32245-5", "Achieved"], ["LA14560-9", "14"], ["LA9000-6", "Weeks"], ["LP94823-9", "Treatment"], ["LA15457-7", "I"], ["LA13503-0", "E"], ["LA6395-3", "Three"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LA32-8", "No"], ["LP263807-2", "Therapeutic"], ["LP125120-8", "Time period"], ["LA31822-2", "Spondylitis"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP29256-2", "given"], ["LA9437-0", "Intravenous"], ["LP263434-5", "Infusion"], ["LP263791-8", "Additional"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP263434-5", "Infusion"], ["LA21988-3", "AT"], ["MTHU000002", "Clinical Class"], ["LA31713-3", "6 weeks"], ["LP6974-2", "first"], ["LP263434-5", "Infusion"], ["LP20594-5", "6"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LA21291-2", "Not"], ["LA31713-3", "6 weeks"], ["LA15457-7", "I"], ["LA13503-0", "E"], ["MTHU000002", "Clinical Class"], ["LA32-8", "No"], ["LP263791-8", "Additional"], ["LP94823-9", "Treatment"], ["MTHU060561", "inFLIXimab"], ["LP29256-2", "given"], ["MTHU020793", "Arthritis"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP29256-2", "given"], ["LA9437-0", "Intravenous"], ["LP263434-5", "Infusion"], ["LP263791-8", "Additional"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP263434-5", "Infusion"], ["LA21988-3", "AT"], ["MTHU000002", "Clinical Class"], ["LA31713-3", "6 weeks"], ["LP6974-2", "first"], ["LP263434-5", "Infusion"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LA15165-6", "Psoriasis"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP29256-2", "given"], ["LA9437-0", "Intravenous"], ["LP263434-5", "Infusion"], ["LP263791-8", "Additional"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP263434-5", "Infusion"], ["LA21988-3", "AT"], ["MTHU000002", "Clinical Class"], ["LA31713-3", "6 weeks"], ["LP6974-2", "first"], ["LP263434-5", "Infusion"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LA10996-9", "No response"], ["LA14560-9", "14"], ["LA9000-6", "Weeks"], ["LA15457-7", "I"], ["LA13503-0", "E"], ["LP20592-9", "4"], ["LA32-8", "No"], ["LP263791-8", "Additional"], ["LP94823-9", "Treatment"], ["MTHU060561", "inFLIXimab"], ["LP29256-2", "given"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LA15161-5", "Rheumatoid Arthritis"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP75708-5", "Symptoms"], ["LA18199-2", "Disease"], ["MTHU060561", "inFLIXimab"], ["LA14562-5", "16"], ["LA9000-6", "Weeks"], ["LP263434-5", "Infusion"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LP266901-0", "Delayed"], ["MTHU060561", "inFLIXimab"], ["LA14220-0", "Less than 1 year"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["MTHU060561", "inFLIXimab"], ["LA16824-7", "More"], ["LA14562-5", "16"], ["LA9000-6", "Weeks"], ["LA21291-2", "Not"], ["LA14331-5", "Both"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LA15161-5", "Rheumatoid Arthritis"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["MTHU029809", "Other"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LA21291-2", "Not"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA31822-2", "Spondylitis"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["MTHU029809", "Other"], ["LP20594-5", "6"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LA21291-2", "Not"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["MTHU020793", "Arthritis"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["MTHU029809", "Other"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LA21291-2", "Not"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA15165-6", "Psoriasis"], ["LA6484-5", "Limited"], ["LP94823-9", "Treatment"], ["LA6306-0", "One"], ["LA17717-2", "Single"], ["MTHU060561", "inFLIXimab"], ["MTHU065481", "Dose"], ["LA22004-8", "IN"], ["LA15165-6", "Psoriasis"], ["LA19282-5", "20"], ["LA9000-6", "Weeks"], ["LA32619-1", "Reduced"], ["LA26687-6", "Efficacy"], ["LP17763-1", "A"], ["LA15008-8", "Mild to moderate"], ["LP263434-5", "Infusion"], ["LA6662-6", "Initial"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LA6484-5", "Limited"], ["LP94823-9", "Treatment"], ["LA18199-2", "Disease"], ["LP201262-5", "Flare"], ["LP17763-1", "A"], ["LP17763-1", "A"], ["LP263434-5", "Infusion"], ["LA30751-4", "Serious"], ["LP36791-9", "8"], ["LA18891-4", "Weekly"], ["LP94823-9", "Treatment"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["MTHU008862", "Indications"], ["LA22004-8", "IN"], ["LP267221-2", "Therapy"], ["LP200075-2", "IS"], ["LA19654-5", "Interrupted"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LP94823-9", "Treatment"], ["LP17763-1", "A"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LP17763-1", "A"], ["LA17717-2", "Single"], ["MTHU065481", "Dose"], ["MTHU065481", "Dose"], ["LA14991-6", "Above"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["LA21291-2", "Not"], ["LA32-8", "No"], ["LA29634-5", "Major"], ["MTHU010047", "Age"], ["LA31343-9", "Related"], ["LA22004-8", "IN"], ["LP267658-5", "Clearance"], ["LA22025-3", "OR"], ["MTHU003070", "Volume"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA16824-7", "More"], ["LA17589-5", "Safety"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["MTHU065909", "Renal"], ["LA22025-3", "OR"], ["MTHU060561", "inFLIXimab"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP66710-2", "Patient"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LP62263-6", "Population"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LP20594-5", "6"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP29256-2", "given"], ["LA9437-0", "Intravenous"], ["LP263434-5", "Infusion"], ["LP263791-8", "Additional"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP263434-5", "Infusion"], ["LA21988-3", "AT"], ["MTHU000002", "Clinical Class"], ["LA31713-3", "6 weeks"], ["LP6974-2", "first"], ["LP263434-5", "Infusion"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LA14426-3", "Do not"], ["MTHU015279", "Support"], ["MTHU060561", "inFLIXimab"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LA21291-2", "Not"], ["LP6974-2", "first"], ["LA13942-0", "10"], ["LA9000-6", "Weeks"], ["LP94823-9", "Treatment"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LA14973-4", "Some"], ["LA14161-6", "May"], ["LP17763-1", "A"], ["LP7787-7", "Clinical"], ["LP32758-2", "Others"], ["LP17763-1", "A"], ["LA14161-6", "May"], ["LA28126-3", "Sufficient"], ["MTHU065481", "Dose"], ["LA16823-9", "Less"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LA14161-6", "May"], ["LA21988-3", "AT"], ["LP267221-2", "Therapy"], ["LP17763-1", "A"], ["LA22004-8", "IN"], ["LA32-8", "No"], ["LP263791-8", "Additional"], ["LP263807-2", "Therapeutic"], ["LP17763-1", "A"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["MTHU060561", "inFLIXimab"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LA14987-4", "Below"], ["MTHU010047", "Age"], ["LP20594-5", "6"], ["LA22004-8", "IN"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA32-8", "No"], ["LP111410-9", "Recommendation"], ["LP17763-1", "A"], ["LA22004-8", "IN"], ["LP20594-5", "6"], ["LP20594-5", "6"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP29256-2", "given"], ["LA9437-0", "Intravenous"], ["LP263434-5", "Infusion"], ["LP263791-8", "Additional"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP263434-5", "Infusion"], ["LA21988-3", "AT"], ["MTHU000002", "Clinical Class"], ["LA31713-3", "6 weeks"], ["LP6974-2", "first"], ["LP263434-5", "Infusion"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LA14426-3", "Do not"], ["MTHU015279", "Support"], ["MTHU060561", "inFLIXimab"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LA21291-2", "Not"], ["LP6974-2", "first"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LP94823-9", "Treatment"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["MTHU060561", "inFLIXimab"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA14987-4", "Below"], ["MTHU010047", "Age"], ["LP20594-5", "6"], ["LA22004-8", "IN"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA32-8", "No"], ["LP111410-9", "Recommendation"], ["LP17763-1", "A"], ["LA22004-8", "IN"], ["LP20594-5", "6"], ["LA15165-6", "Psoriasis"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["LA15165-6", "Psoriasis"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA32-8", "No"], ["LP111410-9", "Recommendation"], ["LP17763-1", "A"], ["LA31871-9", "Idiopathic"], ["MTHU020793", "Arthritis"], ["MTHU020793", "Arthritis"], ["LA31822-2", "Spondylitis"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["MTHU008862", "Indications"], ["LA31871-9", "Idiopathic"], ["MTHU020793", "Arthritis"], ["MTHU020793", "Arthritis"], ["LA31822-2", "Spondylitis"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA32-8", "No"], ["LP111410-9", "Recommendation"], ["LP17763-1", "A"], ["LA29644-4", "Juvenile rheumatoid arthritis"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["LA29644-4", "Juvenile rheumatoid arthritis"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA32-8", "No"], ["LP111410-9", "Recommendation"], ["LP17763-1", "A"], ["LP72939-9", "Method"], ["MTHU060561", "inFLIXimab"], ["LP17763-1", "A"], ["MTHU000002", "Clinical Class"], ["LA18187-7", "All"], ["MTHU060561", "inFLIXimab"], ["LP6425-5", "Observed"], ["LA21988-3", "AT"], ["LA32149-9", "1-2 hours"], ["LP32606-3", "post"], ["LP263434-5", "Infusion"], ["LA18821-1", "Acute"], ["LP263434-5", "Infusion"], ["LA31343-9", "Related"], ["MTHU056908", "Equipment"], ["MTHU003328", "Antihistamines"], ["MTHU042294", "Artificial airway"], ["LA14161-6", "May"], ["LP32605-5", "pre"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP97871-5", "Hydrocortisone"], ["LA22025-3", "OR"], ["LP263434-5", "Infusion"], ["MTHU027852", "Rate"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LA32049-1", "Decrease"], ["LP263434-5", "Infusion"], ["LA31343-9", "Related"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP263434-5", "Infusion"], ["LA31343-9", "Related"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA13524-6", "Adult"], ["MTHU008862", "Indications"], ["LA22004-8", "IN"], ["LA13524-6", "Adult"], ["LA21988-3", "AT"], ["LP20591-1", "3"], ["LA6662-6", "Initial"], ["MTHU000002", "Clinical Class"], ["MTHU060561", "inFLIXimab"], ["LP267221-2", "Therapy"], ["LA14161-6", "May"], ["LP29256-2", "given"], ["LA20296-2", "Administering"], ["LP17763-1", "A"], ["LA21291-2", "Not"], ["LA12717-7", "Less than 1 hour"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP263434-5", "Infusion"], ["LP73228-6", "Reaction"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP263434-5", "Infusion"], ["LP17763-1", "A"], ["LP263434-5", "Infusion"], ["MTHU027852", "Rate"], ["LA14161-6", "May"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP94823-9", "Treatment"], ["LP200075-2", "IS"], ["LA21988-3", "AT"], ["LP20594-5", "6"], ["LP15217-0", "Mg"], ["LA21291-2", "Not"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP6820-7", "Instructions"], ["LP20594-5", "6"], ["LP20594-5", "6"]], "snomed.contraindications": [["257550005", "Hypersensitivity (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["261217004", "Substance (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["88878007", "Protein (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["186392004", "(Septicaemia NOS) or (sepsis)|(Septicaemia NOS) or (sepsis) (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1255665007", "Moderate (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["155374007", "Heart failure (disorder)|Heart failure"], ["258394001", "Class 3 (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"]], "ncit.contraindications": [["C3114", "Hypersensitivity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C154405", "Active State"], ["C45306", "Substance"], ["C159124", "GDC Treatment Outcome Terminology"], ["C118472", "Other License Status"], ["C14238", "Mouse"], ["C17021", "Protein"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"], ["C16960", "Patient"], ["C62355", "With"], ["C3423", "Tuberculosis"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C71344", "Associate of Science"], ["C3364", "Septicemia"], ["C16289", "Andorra"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16960", "Patient"], ["C62355", "With"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C43508", "Oregon"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C143529", "Heart Failure, CTCAE"], ["C7922", "New York Heart Association Class III/IV"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"]], "rxnorm.contraindications": [["T167", "Substance"]], "loinc.contraindications": [["LA16666-2", "Active"], ["T167", "Substance"], ["MTHU029809", "Other"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP20594-5", "6"], ["LA6112-2", "1"], ["MTHU020835", "Tuberculosis"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LA6750-9", "Severe"], ["LP74970-2", "Infections"], ["LP74970-2", "Infections"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA6751-7", "Moderate"], ["LA22025-3", "OR"], ["LA6750-9", "Severe"], ["LP269421-6", "Heart failure"], ["LP264302-3", "NYHA"], ["LA28406-9", "Class III"], ["LP200078-6", "IV"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP36791-9", "8"]], "snomed.special_warnings": [["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["410681005", "Count of entities (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["36576007", "Infusion (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["257550005", "Hypersensitivity (qualifier value)"], ["386891004", "Infliximab (substance)"], ["47429007", "Associated with (attribute)"], ["53737009", "Acute (qualifier value)"], ["36576007", "Infusion (procedure)"], ["262094002", "Related (finding)"], ["55919000", "Including (qualifier value)"], ["735173007", "Shock due to anaphylaxis (disorder)|Shock co-occurrent and due to anaphylaxis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["257550005", "Hypersensitivity (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["53737009", "Acute (qualifier value)"], ["36576007", "Infusion (procedure)"], ["55919000", "Including (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["257997001", "s (qualifier value)|seconds (qualifier value)|Seconds (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["57176003", "Few (qualifier value)"], ["258702006", "hour (qualifier value)"], ["255260001", "Following (attribute)"], ["36576007", "Infusion (procedure)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["53737009", "Acute (qualifier value)"], ["36576007", "Infusion (procedure)"], ["36576007", "Infusion (procedure)"], ["261017006", "Interrupted (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["25876001", "Emergency (qualifier value)"], ["246137000", "Equipment (attribute)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["387362001", "Epinephrine (substance)|Epinephrine preparation (substance)"], ["320678002", "Antihistamines (product)|Antihistamines (substance)"], ["79440004", "Product containing corticosteroid (product)|Product containing corticosteroid and/or corticosteroid derivative (product)|Corticoid preparation (product)|Product containing corticosteroid and corticosteroid derivative (product)|Corticoid preparation (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["71967004", "Artificial (qualifier value)"], ["89187006", "Airway structure (body structure)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["28995006", "Treated with (attribute)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["372806008", "Substance with histamine receptor antagonist mechanism of action (substance)|Antihistamine (substance)"], ["396458002", "Hydrocortisone (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["387517004", "Paracetamol (substance)|Acetaminophen (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["101445003", "PREVENT (substance)|PREVENT (product)"], ["255604002", "Mild (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255276005", "Transient (disorder)|Transient"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["47429007", "Associated with (attribute)"], ["35105006", "Increased (qualifier value)"], ["260864003", "Frequency (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["36576007", "Infusion (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["62482003", "Low (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["36576007", "Infusion (procedure)"], ["42745003", "Serious (qualifier value)"], ["263534001", "Association (attribute)"], ["11896004", "Intermediate (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260400001", "Reduced (qualifier value)"], ["762636008", "Duration (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["47429007", "Associated with (attribute)"], ["261122009", "Lower (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["289928003", "Reduction plasty (qualifier value)"], ["18720000", "In (attribute)"], ["260864003", "Frequency (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["36576007", "Infusion (procedure)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["734544007", "Immunomodulator (disposition)"], ["277132007", "Therapeutic procedure (procedure)"], ["242762006", "More (qualifier value)"], ["255611003", "Profound (qualifier value)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["314122007", "Maintenance therapy (procedure)"], ["421286000", "Discontinue - dosing instruction imperative (qualifier value)"], ["288556008", "Before (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["263768009", "Greater (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["260373001", "Detected (qualifier value)"], ["18720000", "In (attribute)"], ["67922002", "Serum (substance)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["264931009", "Symptomatic (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["732732008", "4.8 (qualifier value)"], ["18720000", "In (attribute)"], ["58147004", "Clinical (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["257550005", "Hypersensitivity (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["86495002", "For (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["257550005", "Hypersensitivity (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["260369004", "Increasing (qualifier value)"], ["386891004", "Infliximab (substance)"], ["385673002", "Interval (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["394433005", "Immediate (qualifier value)|Immediate"], ["74188005", "Medical (qualifier value)"], ["243073001", "Advice (regime/therapy)|Advice (regime/therapy)(procedure)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["281647001", "Adverse reaction (disorder)|Adverse reactions (disorder)|Adverse reactions (finding)"], ["732732008", "4.8 (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["255234002", "After (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255224006", "Prolonged (qualifier value)"], ["86495002", "For (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["257550005", "Hypersensitivity (qualifier value)"], ["86495002", "For (qualifier value)"], ["55919000", "Including (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255234002", "After (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["63911002", "Excretory function (observable entity)|Excretory function (function)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["419652001", "Take (qualifier value)|Take - dosing instruction imperative (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["68244004", "Six (qualifier value)|6 (qualifier value)"], ["258706009", "month (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["186392004", "(Septicaemia NOS) or (sepsis)|(Septicaemia NOS) or (sepsis) (disorder)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["176130006", "Chronic infection (disorder)|Chronic infection"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["255227004", "Recurrent (qualifier value)"], ["55919000", "Including (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["86495002", "For (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["39525005", "Tumor necrosis factor alpha (substance)"], ["8612007", "Tumor necrosis factor (substance)"], ["257552002", "Inflammation (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255386009", "Immune (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["34325006", "Essential (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["83167003", "Intracellular (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["5418000", "Host defense (function)|Host defense, function (observable entity)"], ["65897001", "Against (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["80633008", "Suppression (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["261382003", "Mask (physical object)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["386661006", "Fever (finding)"], ["264499004", "Early (qualifier value)"], ["312020002", "Recognition (qualifier value)|Recognition, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["112231000", "Atypical (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["246105001", "Presentation (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["439401001", "Diagnosis (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["242762006", "More (qualifier value)"], ["263890004", "Susceptible [dup] (qualifier value)|Susceptible (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["55919000", "Including (qualifier value)"], ["186392004", "(Septicaemia NOS) or (sepsis)|(Septicaemia NOS) or (sepsis) (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["266391003", "Pneumonia and influenza &/or pneumonia|Pneumonia and influenza &/or pneumonia (disorder)"], ["10179008", "Invasive (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["386891004", "Infliximab (substance)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["399166001", "Fatal (qualifier value)"], ["4757001", "Most (qualifier value)"], ["70232002", "Frequent (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["409651001", "Mortality rate (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["264706000", ">5 (qualifier value)"], ["88860002", "Pneumocystosis (disorder)"], ["187005005", "Candidiasis|Candidiasis (disorder)"], ["186315001", "Listeriosis|Listeriosis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["266218008", "Other mycoses (& [aspergillosis] or [coccidioidomycosis] or [histoplasmosis] or [piedra] or [sporotrichosis])|Other mycoses (& [aspergillosis] or [coccidioidomycosis] or [histoplasmosis] or [piedra] or [sporotrichosis]) (disorder)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255219008", "New infection (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255594003", "Complete (qualifier value)"], ["261004008", "Diagnostic - procedure intent (qualifier value)|Diagnostic intent (qualifier value)"], ["129265001", "Evaluation - action (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["410546004", "Discontinued (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["261021004", "New (qualifier value)|New [dup] (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["186392004", "(Septicaemia NOS) or (sepsis)|(Septicaemia NOS) or (sepsis) (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["768680004", "Antimicrobial (disposition)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["718526003", "Antifungal therapy (procedure)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["427099000", "Active tuberculosis (disorder)"], ["18720000", "In (attribute)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["255470001", "Local (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["65709003", "Disseminated (qualifier value)"], ["64572001", "Disease (disorder)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["86495002", "For (qualifier value)"], ["51440002", "Right and left (qualifier value)"], ["55561003", "Active (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["73425007", "Inactive (qualifier value)"], ["44104002", "Latent (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["129265001", "Evaluation - action (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["74188005", "Medical (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["160476009", "Social / personal history observable (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["9130008", "Previous (qualifier value)"], ["11723008", "Contact with (contextual qualifier) (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["9130008", "Previous (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["15240007", "Current (qualifier value)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["360156006", "Screening - procedure intent (qualifier value)"], ["272393004", "Tests (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["164976005", "Tuberculin test - Mantoux (& [Heaf] or [Mantoux])|Tuberculin test - Mantoux (& [Heaf] or [Mantoux]) (procedure)"], ["399208008", "Plain chest X-ray (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420303002", "Interferon gamma (substance)"], ["115956009", "Release (procedure)"], ["272392009", "Assay technique (qualifier value)|Assay (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["18720000", "In (attribute)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["255470001", "Local (qualifier value)"], ["738991002", "Apply (administration method)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["844005", "Behavior finding (finding)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["272393004", "Tests (qualifier value)"], ["18720000", "In (attribute)"], ["116154003", "Patient (person)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["61707005", "False negative (qualifier value)"], ["164976005", "Tuberculin test - Mantoux (& [Heaf] or [Mantoux])|Tuberculin test - Mantoux (& [Heaf] or [Mantoux]) (procedure)"], ["18720000", "In (attribute)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["161900002", "Feels unwell (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["427099000", "Active tuberculosis (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["713517003", "Infliximab therapy (procedure)"], ["732725004", "4.3 (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["44104002", "Latent (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["415684004", "Suspected (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["309343006", "Physician (occupation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["18720000", "In (attribute)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["351726001", "Below (qualifier value)"], ["705235004", "Balance (physical object)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["713517003", "Infliximab therapy (procedure)"], ["260358002", "Very (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["73425007", "Inactive (qualifier value)"], ["44104002", "Latent (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["86495002", "For (qualifier value)"], ["44104002", "Latent (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["385652002", "Started (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255470001", "Local (qualifier value)"], ["18720000", "In (attribute)"], ["261028005", "Several (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["394653002", "Significant|Significant (qualifier value)"], ["86495002", "For (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["394426005", "Negative|Negative (qualifier value)"], ["86495002", "For (qualifier value)"], ["44104002", "Latent (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["277132007", "Therapeutic procedure (procedure)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["260676000", "Use of (attribute)"], ["277132007", "Therapeutic procedure (procedure)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["127452003", "Past medical history of (contextual qualifier) (context-dependent category)"], ["44104002", "Latent (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["427099000", "Active tuberculosis (disorder)"], ["18720000", "In (attribute)"], ["88323005", "Adequate (qualifier value)"], ["260908002", "Course (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["427099000", "Active tuberculosis (disorder)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["386891004", "Infliximab (substance)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255234002", "After (attribute)"], ["86495002", "For (qualifier value)"], ["44104002", "Latent (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["74188005", "Medical (qualifier value)"], ["243073001", "Advice (regime/therapy)|Advice (regime/therapy)(procedure)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["7196007", "Suggestive of (attribute)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["284523002", "Persistent cough (finding)"], ["816160009", "Measured weight loss (observable entity)"], ["62482003", "Low (qualifier value)"], ["277420004", "Grade|Grade (qualifier value)"], ["386661006", "Fever (finding)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255234002", "After (attribute)"], ["386891004", "Infliximab (substance)"], ["10179008", "Invasive (qualifier value)"], ["266214005", "(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses) (disorder)|(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["386891004", "Infliximab (substance)"], ["12391000132109", "Invasive fungal infection (disorder)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["266218008", "Other mycoses (& [aspergillosis] or [coccidioidomycosis] or [histoplasmosis] or [piedra] or [sporotrichosis])|Other mycoses (& [aspergillosis] or [coccidioidomycosis] or [histoplasmosis] or [piedra] or [sporotrichosis]) (disorder)"], ["187005005", "Candidiasis|Candidiasis (disorder)"], ["88860002", "Pneumocystosis (disorder)"], ["266218008", "Other mycoses (& [aspergillosis] or [coccidioidomycosis] or [histoplasmosis] or [piedra] or [sporotrichosis])|Other mycoses (& [aspergillosis] or [coccidioidomycosis] or [histoplasmosis] or [piedra] or [sporotrichosis]) (disorder)"], ["266218008", "Other mycoses (& [aspergillosis] or [coccidioidomycosis] or [histoplasmosis] or [piedra] or [sporotrichosis])|Other mycoses (& [aspergillosis] or [coccidioidomycosis] or [histoplasmosis] or [piedra] or [sporotrichosis]) (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["266217003", "(Other dermatophytosis) or (blastomycosis)|(Other dermatophytosis) or (blastomycosis) (disorder)"], ["415684004", "Suspected (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["264578000", "Systemic illness (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["309343006", "Physician (occupation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["439401001", "Diagnosis (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["10179008", "Invasive (qualifier value)"], ["266214005", "(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses) (disorder)|(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["234438000", "Early stage (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["10179008", "Invasive (qualifier value)"], ["266214005", "(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses) (disorder)|(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses)"], ["52101004", "Present (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["65709003", "Disseminated (qualifier value)"], ["74217003", "Local disease (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["7120007", "Antigen (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["68498002", "Antibody (substance)"], ["394426005", "Negative|Negative (qualifier value)"], ["18720000", "In (attribute)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["718526003", "Antifungal therapy (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["261004008", "Diagnostic - procedure intent (qualifier value)|Diagnostic intent (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["30507006", "Into (attribute)"], ["51440002", "Right and left (qualifier value)"], ["86495002", "For (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["266214005", "(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses) (disorder)|(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["718526003", "Antifungal therapy (procedure)"], ["86495002", "For (qualifier value)"], ["18720000", "In (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["10179008", "Invasive (qualifier value)"], ["266214005", "(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses) (disorder)|(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["266218008", "Other mycoses (& [aspergillosis] or [coccidioidomycosis] or [histoplasmosis] or [piedra] or [sporotrichosis])|Other mycoses (& [aspergillosis] or [coccidioidomycosis] or [histoplasmosis] or [piedra] or [sporotrichosis]) (disorder)"], ["266218008", "Other mycoses (& [aspergillosis] or [coccidioidomycosis] or [histoplasmosis] or [piedra] or [sporotrichosis])|Other mycoses (& [aspergillosis] or [coccidioidomycosis] or [histoplasmosis] or [piedra] or [sporotrichosis]) (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["266217003", "(Other dermatophytosis) or (blastomycosis)|(Other dermatophytosis) or (blastomycosis) (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["713517003", "Infliximab therapy (procedure)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["53737009", "Acute (qualifier value)"], ["255320000", "Infection - suppurative (disorder)"], ["386891004", "Infliximab (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["734842000", "Source (property) (qualifier value)"], ["86495002", "For (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["128477000", "Abscess (disorder)"], ["732725004", "4.3 (qualifier value)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["55919000", "Including (qualifier value)"], ["386891004", "Infliximab (substance)"], ["90734009", "Chronic (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["49872002", "Virus (organism)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["399166001", "Fatal (qualifier value)"], ["86495002", "For (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["86495002", "For (qualifier value)"], ["10828004", "Positive (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["11429006", "Consultation (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["309343006", "Physician (occupation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["86495002", "For (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["55561003", "Active (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["277132007", "Therapeutic procedure (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["261028005", "Several (qualifier value)"], ["258706009", "month (qualifier value)"], ["255260001", "Following (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["88323005", "Adequate (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["427314002", "Antiviral therapy (procedure)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["101445003", "PREVENT (substance)|PREVENT (product)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["386891004", "Infliximab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["254648000", "Effective (qualifier value)"], ["427314002", "Antiviral therapy (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["263780001", "Jaundice|Jaundice (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["154347003", "Infectious hepatitis (disorder)|Infectious hepatitis"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["408335007", "Autoimmune hepatitis (disorder)"], ["18720000", "In (attribute)"], ["288563008", "After values (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["46651001", "Isolated (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["59927004", "Hepatic failure (disorder)"], ["79409006", "Resulting in (attribute)"], ["181268008", "Entire liver (body structure)"], ["77465005", "Transplantation (procedure)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["419620001", "Death (event)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["181268008", "Entire liver (body structure)"], ["88846004", "Functional disorder (finding)"], ["86495002", "For (qualifier value)"], ["18669006", "Evidence of (contextual qualifier) (qualifier value)"], ["181268008", "Entire liver (body structure)"], ["417746004", "Traumatic injury (disorder)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["263780001", "Jaundice|Jaundice (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["417929005", "Times (qualifier value)"], ["261183002", "Upper (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["17621005", "Normal (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["386891004", "Infliximab (substance)"], ["410546004", "Discontinued (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["263660008", "Greek letter alpha (qualifier value)|Alpha (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["42745003", "Serious (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["303011007", "Neutropenic disorder (disorder)"], ["30190008", "Seen (qualifier value)"], ["18720000", "In (attribute)"], ["58147004", "Clinical (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["260676000", "Use of (attribute)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["112232007", "Blocking (qualifier value)"], ["260872001", "Agent (attribute)"], ["387045004", "Etanercept (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["387045004", "Etanercept (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["246425008", "Nature (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["281647001", "Adverse reaction (disorder)|Adverse reactions (disorder)|Adverse reactions (finding)"], ["30190008", "Seen (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387045004", "Etanercept (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["277132007", "Therapeutic procedure (procedure)"], ["394617004", "Result (navigational concept)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["112232007", "Blocking (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["263660008", "Greek letter alpha (qualifier value)|Alpha (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421777009", "Abatacept (substance)"], ["18720000", "In (attribute)"], ["58147004", "Clinical (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421777009", "Abatacept (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["55919000", "Including (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["45169001", "Without (attribute)"], ["35105006", "Increased (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421777009", "Abatacept (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["423437008", "Insufficient (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["260676000", "Use of (attribute)"], ["386891004", "Infliximab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["262126009", "Same (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["79970003", "Simultaneous (qualifier value)"], ["260676000", "Use of (attribute)"], ["386891004", "Infliximab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["56183000", "Pharmacologic (qualifier value)"], ["11896004", "Intermediate (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["24846002", "Imbrication (procedure)"], ["12893009", "Biologic (qualifier value)"], ["257733005", "Activity (observable entity)|Activities (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["86495002", "For (qualifier value)"], ["281647001", "Adverse reaction (disorder)|Adverse reactions (disorder)|Adverse reactions (finding)"], ["55919000", "Including (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["170310008", "Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)]) (procedure)|Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)])"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["410672004", "Date property (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["170310008", "Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)]) (procedure)|Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)])"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["15240007", "Current (qualifier value)"], ["33879002", "Administration of vaccine to produce active immunity (procedure)"], ["288556008", "Before (attribute)"], ["277132007", "Therapeutic procedure (procedure)"], ["420862001", "On (qualifier value)"], ["386891004", "Infliximab (substance)"], ["68405009", "Concurrent (qualifier value)"], ["170310008", "Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)]) (procedure)|Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)])"], ["5185003", "Except for (attribute)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["732729005", "4.5 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732731001", "4.6 (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732899009", "90 (qualifier value)"], ["255397009", "Adult (qualifier value)|Adult"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["224699009", "Study (environment)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["419473009", "Each (qualifier value)"], ["389109008", "Group (social concept)"], ["387381009", "Methotrexate (substance)"], ["20401003", "With (attribute)"], ["257992007", "n (qualifier value)|Lower case Roman letter n (qualifier value)"], ["276136004", "Equal symbol = (qualifier value)|= (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["257992007", "n (qualifier value)|Lower case Roman letter n (qualifier value)"], ["276136004", "Equal symbol = (qualifier value)|= (qualifier value)"], ["1222780001", "American Joint Committee on Cancer stage II:7 (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["386891004", "Infliximab (substance)"], ["257992007", "n (qualifier value)|Lower case Roman letter n (qualifier value)"], ["276136004", "Equal symbol = (qualifier value)|= (qualifier value)"], ["1222849002", "American Joint Committee on Cancer stage IV:6 (qualifier value)"], ["254648000", "Effective (qualifier value)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["26310004", "Folded structure (morphologic abnormality)"], ["260366006", "Increase (qualifier value)"], ["18720000", "In (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["398827000", "Vaccine (substance)"], ["386891004", "Infliximab (substance)"], ["59067001", "Does not interfere with (contextual qualifier) (qualifier value)"], ["57184004", "T lymphocyte (cell)"], ["371153006", "Independent (qualifier value)|Independently able (qualifier value)"], ["255386009", "Immune (qualifier value)"], ["18720000", "In (attribute)"], ["256220008", "Various (substance)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["372091005", "Arthritis (finding)"], ["156369008", "Psoriasis|Psoriasis (disorder)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["170310008", "Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)]) (procedure)|Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)])"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["55919000", "Including (qualifier value)"], ["386891004", "Infliximab (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["261122009", "Lower (qualifier value)"], ["35024006", "Immune response (function)|Immune response, function (observable entity)"], ["18720000", "In (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["18720000", "In (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["420862001", "On (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["33879002", "Administration of vaccine to produce active immunity (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420862001", "On (qualifier value)"], ["2603003", "Secondary (qualifier value)"], ["258150004", "Transmission (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["260676000", "Use of (attribute)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["58147004", "Clinical (qualifier value)"], ["55919000", "Including (qualifier value)"], ["65709003", "Disseminated (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["1222737005", "American Joint Committee on Cancer stage I:1 (qualifier value)"], ["133931009", "Infant (person)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["399166001", "Fatal (qualifier value)"], ["42752001", "Due to (attribute)"], ["65709003", "Disseminated (qualifier value)"], ["44762009", "Genus Bacillus (organism)|Bacillus (organism)"], ["257551009", "Infection (disorder)|Infection"], ["733985002", "Reported (qualifier value)"], ["255260001", "Following (attribute)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["396419007", "BCG vaccine (substance)"], ["255234002", "After (attribute)"], ["3950001", "Birth (finding)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["82809009", "12 (qualifier value)|Twelve (qualifier value)"], ["258706009", "month (qualifier value)"], ["255260001", "Following (attribute)"], ["3950001", "Birth (finding)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["133931009", "Infant (person)"], ["386891004", "Infliximab (substance)"], ["67922002", "Serum (substance)"], ["258395000", "Levels (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["416118004", "Administration (procedure)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255246003", "First trimester (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["398827000", "Vaccine (substance)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["116680003", "Is a (attribute)"], ["263707001", "Clear (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["86495002", "For (qualifier value)"], ["385435006", "Individual (person)"], ["133931009", "Infant (person)"], ["732731001", "4.6 (qualifier value)"], ["133931009", "Infant (person)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["226789007", "Breast milk (substance)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["398827000", "Vaccine (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["133931009", "Infant (person)"], ["394651000", "Mother (person)|Mother"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["386891004", "Infliximab (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["133931009", "Infant (person)"], ["386891004", "Infliximab (substance)"], ["67922002", "Serum (substance)"], ["258395000", "Levels (qualifier value)"], ["732731001", "4.6 (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["24588000", "Attenuated by (contextual qualifier) (qualifier value)"], ["413624004", "Bacteria (organism)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["302512001", "Entire urinary bladder (body structure)|Entire bladder (body structure)"], ["55870005", "Instillation (procedure)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["58147004", "Clinical (qualifier value)"], ["55919000", "Including (qualifier value)"], ["65709003", "Disseminated (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["263680009", "Autoimmune (qualifier value)|Autoimmune process (qualifier value)"], ["394439009", "Relative|Relative (person)"], ["129453003", "Deficiency of (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["42752001", "Due to (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["263680009", "Autoimmune (qualifier value)|Autoimmune process (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["7196007", "Suggestive of (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["80258006", "Drug-induced lupus erythematosus (disorder)"], ["255260001", "Following (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["10828004", "Positive (qualifier value)"], ["65897001", "Against (qualifier value)"], ["1305003", "Double (qualifier value)"], ["24851008", "Deoxyribonucleic acid (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["732732008", "4.8 (qualifier value)"], ["1199008", "Neurologic (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["260676000", "Use of (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["112232007", "Blocking (qualifier value)"], ["55919000", "Including (qualifier value)"], ["386891004", "Infliximab (substance)"], ["47429007", "Associated with (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["261021004", "New (qualifier value)|New [dup] (qualifier value)"], ["246100006", "Onset (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258106000", "Radiographic (qualifier value)"], ["18669006", "Evidence of (contextual qualifier) (qualifier value)"], ["278199004", "Entire central nervous system (body structure)"], ["64572001", "Disease (disorder)"], ["55919000", "Including (qualifier value)"], ["155023009", "Multiple sclerosis (disorder)|Multiple sclerosis"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["14414005", "Peripheral (qualifier value)"], ["64572001", "Disease (disorder)"], ["55919000", "Including (qualifier value)"], ["40956001", "Guillain-Barr\u00e9 syndrome (disorder)|Guillain-Barre syndrome (disorder)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["263852005", "Recent episode (qualifier value)"], ["77374008", "Onset of (contextual qualifier) (qualifier value)"], ["64572001", "Disease (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["713517003", "Infliximab therapy (procedure)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["64572001", "Disease (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["64572001", "Disease (disorder)"], ["18720000", "In (attribute)"], ["31509003", "Controlled (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["112232007", "Blocking (qualifier value)"], ["242762006", "More (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["55919000", "Including (qualifier value)"], ["1163043007", "Malignant lymphoma (morphologic abnormality)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["246106000", "Control (attribute)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["9571008", "Approved (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1163043007", "Malignant lymphoma (morphologic abnormality)"], ["18720000", "In (attribute)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["60132005", "Generalized (qualifier value)"], ["385436007", "Population (social concept)"], ["246454002", "Occurrence (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1163043007", "Malignant lymphoma (morphologic abnormality)"], ["89292003", "Rare (qualifier value)"], ["18720000", "In (attribute)"], ["288563008", "After values (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1162768007", "Leukemia (morphologic abnormality)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["86495002", "For (qualifier value)"], ["1163043007", "Malignant lymphoma (morphologic abnormality)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1162768007", "Leukemia (morphologic abnormality)"], ["18720000", "In (attribute)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255511005", "Long (qualifier value)"], ["10904000", "Orthostatic body position (finding)"], ["55561003", "Active (qualifier value)"], ["128139000", "Inflammatory disorder (disorder)"], ["18720000", "In (attribute)"], ["58147004", "Clinical (qualifier value)"], ["224699009", "Study (environment)"], ["260676000", "Use of (attribute)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["371924009", "Moderate to severe (qualifier value)"], ["13645005", "Chronic obstructive lung disease (disorder)|Chronic obstructive pulmonary disease (disorder)"], ["13645005", "Chronic obstructive lung disease (disorder)|Chronic obstructive pulmonary disease (disorder)"], ["242762006", "More (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["386891004", "Infliximab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["246106000", "Control (attribute)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["410712002", "Heavy sensation quality (qualifier value)"], ["365981007", "Finding of tobacco smoking behavior (finding)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["86495002", "For (qualifier value)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["42752001", "Due to (attribute)"], ["410712002", "Heavy sensation quality (qualifier value)"], ["365981007", "Finding of tobacco smoking behavior (finding)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["15240007", "Current (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["112232007", "Blocking (qualifier value)"], ["260872001", "Agent (attribute)"], ["732732008", "4.8 (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["112232007", "Blocking (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["156369008", "Psoriasis|Psoriasis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["74188005", "Medical (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["41118005", "Extensive (qualifier value)"], ["372823004", "Immunosuppressant (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255224006", "Prolonged (qualifier value)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["399166001", "Fatal (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["84422007", "Young (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222775005", "American Joint Committee on Cancer stage II:2 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["28995006", "Treated with (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["112232007", "Blocking (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["55919000", "Including (qualifier value)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["288563008", "After values (qualifier value)"], ["26175008", "Approximate (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["74964007", "Other (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["288563008", "After values (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["445406001", "Hepatosplenic T-cell lymphoma (disorder)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["112232007", "Blocking (qualifier value)"], ["55919000", "Including (qualifier value)"], ["386891004", "Infliximab (substance)"], ["89292003", "Rare (qualifier value)"], ["410657003", "Type (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1163404000", "Peripheral T-cell lymphoma (morphologic abnormality)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260358002", "Very (qualifier value)"], ["255325005", "Aggressive course (qualifier value)"], ["64572001", "Disease (disorder)"], ["260908002", "Course (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["399166001", "Fatal (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386835005", "Mercaptopurine (substance)"], ["79970003", "Simultaneous (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["288556008", "Before (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["266447004", "Ulcerative colitis (disorder)|Ulcerative colitis"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["4757001", "Most (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["133937008", "Adolescent (person)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["84422007", "Young (qualifier value)"], ["255397009", "Adult (qualifier value)|Adult"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386835005", "Mercaptopurine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["86495002", "For (qualifier value)"], ["86495002", "For (qualifier value)"], ["57184004", "T lymphocyte (cell)"], ["1163043007", "Malignant lymphoma (morphologic abnormality)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["386891004", "Infliximab (substance)"], ["732732008", "4.8 (qualifier value)"], ["2092003", "Malignant melanoma, no ICD-O subtype (morphologic abnormality)|Malignant melanoma, morphology (morphologic abnormality)|Malignant melanoma, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|Malignant melanoma (morphologic abnormality)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["253001006", "Merkel cell carcinoma (disorder)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["55919000", "Including (qualifier value)"], ["386891004", "Infliximab (substance)"], ["732732008", "4.8 (qualifier value)"], ["123115008", "Periodic (qualifier value)|Periodic -RETIRED-"], ["181469002", "Entire skin (body structure)"], ["302199004", "Examination - action (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["372130007", "Malignant neoplasm of skin (disorder)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["385436007", "Population (social concept)"], ["224699009", "Study (environment)"], ["261583007", "Using (attribute)"], ["263775005", "Health (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["363354003", "Malignant tumor of cervix (disorder)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["28995006", "Treated with (attribute)"], ["386891004", "Infliximab (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["60132005", "Generalized (qualifier value)"], ["385436007", "Population (social concept)"], ["55919000", "Including (qualifier value)"], ["21481007", "Over (qualifier value)"], ["732814003", "60 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["123115008", "Periodic (qualifier value)|Periodic -RETIRED-"], ["360156006", "Screening - procedure intent (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["386891004", "Infliximab (substance)"], ["55919000", "Including (qualifier value)"], ["21481007", "Over (qualifier value)"], ["732814003", "60 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["266447004", "Ulcerative colitis (disorder)|Ulcerative colitis"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["86495002", "For (qualifier value)"], ["25723000", "Dysplasia (morphologic abnormality)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["302508007", "Entire colon (body structure)"], ["1187425009", "Carcinoma (morphologic abnormality)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255511005", "Long (qualifier value)"], ["10904000", "Orthostatic body position (finding)"], ["266447004", "Ulcerative colitis (disorder)|Ulcerative colitis"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["197441003", "Primary sclerosing cholangitis (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["25723000", "Dysplasia (morphologic abnormality)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["302508007", "Entire colon (body structure)"], ["1187425009", "Carcinoma (morphologic abnormality)"], ["86495002", "For (qualifier value)"], ["25723000", "Dysplasia (morphologic abnormality)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["17854005", "Regular (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["64572001", "Disease (disorder)"], ["260908002", "Course (attribute)"], ["129265001", "Evaluation - action (qualifier value)"], ["271997005", "Colonoscopy [Ambiguous]|Colonoscopy (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["255470001", "Local (qualifier value)"], ["15240007", "Current (qualifier value)"], ["386891004", "Infliximab (substance)"], ["86495002", "For (qualifier value)"], ["25723000", "Dysplasia (morphologic abnormality)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["302508007", "Entire colon (body structure)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["25723000", "Dysplasia (morphologic abnormality)"], ["28995006", "Treated with (attribute)"], ["386891004", "Infliximab (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["263748003", "Established (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["385435006", "Individual (person)"], ["155374007", "Heart failure (disorder)|Heart failure"], ["386891004", "Infliximab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255604002", "Mild (qualifier value)"], ["155374007", "Heart failure (disorder)|Heart failure"], ["258392002", "Class 1 (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["261021004", "New (qualifier value)|New [dup] (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["230993007", "Worsening (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["155374007", "Heart failure (disorder)|Heart failure"], ["732725004", "4.3 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["57407000", "Hematologic (qualifier value)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["127034005", "Pancytopenia (disorder)"], ["419188005", "Decreased blood leukocyte number (finding)|Blood leukocyte number below reference range (finding)"], ["303011007", "Neutropenic disorder (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["415116008", "Platelet count below reference range (finding)"], ["18720000", "In (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["55919000", "Including (qualifier value)"], ["386891004", "Infliximab (substance)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["394433005", "Immediate (qualifier value)|Immediate"], ["74188005", "Medical (qualifier value)"], ["247759001", "Attention [Ambiguous]|Attention (finding)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["7196007", "Suggestive of (attribute)"], ["87612001", "Blood (substance)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["255222005", "Persistent (qualifier value)"], ["386661006", "Fever (finding)"], ["308492005", "Contusion - lesion (morphologic abnormality)|Bruise - lesion (morphologic abnormality)"], ["303123004", "Bleeding (disorder)|Bleeding"], ["398979000", "Pale complexion (finding)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["713517003", "Infliximab therapy (procedure)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["394653002", "Significant|Significant (qualifier value)"], ["57407000", "Hematologic (qualifier value)"], ["1222740005", "American Joint Committee on Cancer stage I:3 (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["83578000", "Surgical (qualifier value)"], ["55919000", "Including (qualifier value)"], ["442095009", "Repair of joint (procedure)"], ["255511005", "Long (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["30507006", "Into (attribute)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["387713003", "Surgical procedure (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["397943006", "Planned (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["387713003", "Surgical procedure (procedure)"], ["420862001", "On (qualifier value)"], ["386891004", "Infliximab (substance)"], ["86495002", "For (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["76797004", "Failure (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["52101004", "Present (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["261010008", "Fixed (qualifier value)"], ["27551008", "Stricture (morphologic abnormality)"], ["83578000", "Surgical (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["67995009", "Special (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["18720000", "In (attribute)"], ["386891004", "Infliximab (substance)"], ["264695004", "65 (qualifier value)|Arabic numeral 65 (qualifier value)"], ["258707000", "year (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["263768009", "Greater (qualifier value)"], ["18720000", "In (attribute)"], ["351726001", "Below (qualifier value)"], ["264695004", "65 (qualifier value)|Arabic numeral 65 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["399166001", "Fatal (qualifier value)"], ["247759001", "Attention [Ambiguous]|Attention (finding)"], ["86495002", "For (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["376171000221106", "Pediatric population (qualifier value)"], ["18720000", "In (attribute)"], ["58147004", "Clinical (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255397009", "Adult (qualifier value)|Adult"], ["732732008", "4.8 (qualifier value)"], ["170310008", "Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)]) (procedure)|Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)])"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["410672004", "Date property (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["170310008", "Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)]) (procedure)|Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)])"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["15240007", "Current (qualifier value)"], ["33879002", "Administration of vaccine to produce active immunity (procedure)"], ["288556008", "Before (attribute)"], ["713517003", "Infliximab therapy (procedure)"], ["420862001", "On (qualifier value)"], ["386891004", "Infliximab (substance)"], ["68405009", "Concurrent (qualifier value)"], ["170310008", "Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)]) (procedure)|Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)])"], ["5185003", "Except for (attribute)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["732729005", "4.5 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732731001", "4.6 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["64572001", "Disease (disorder)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["399166001", "Fatal (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["84422007", "Young (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222775005", "American Joint Committee on Cancer stage II:2 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["28995006", "Treated with (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["112232007", "Blocking (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["55919000", "Including (qualifier value)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["288563008", "After values (qualifier value)"], ["26175008", "Approximate (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["74964007", "Other (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["28995006", "Treated with (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["288563008", "After values (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["445406001", "Hepatosplenic T-cell lymphoma (disorder)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["112232007", "Blocking (qualifier value)"], ["55919000", "Including (qualifier value)"], ["386891004", "Infliximab (substance)"], ["89292003", "Rare (qualifier value)"], ["410657003", "Type (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1163404000", "Peripheral T-cell lymphoma (morphologic abnormality)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260358002", "Very (qualifier value)"], ["255325005", "Aggressive course (qualifier value)"], ["64572001", "Disease (disorder)"], ["260908002", "Course (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["399166001", "Fatal (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386835005", "Mercaptopurine (substance)"], ["79970003", "Simultaneous (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["288556008", "Before (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["64572001", "Disease (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["266447004", "Ulcerative colitis (disorder)|Ulcerative colitis"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["4757001", "Most (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["133937008", "Adolescent (person)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["84422007", "Young (qualifier value)"], ["255397009", "Adult (qualifier value)|Adult"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386835005", "Mercaptopurine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["86495002", "For (qualifier value)"], ["86495002", "For (qualifier value)"], ["445406001", "Hepatosplenic T-cell lymphoma (disorder)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["732732008", "4.8 (qualifier value)"], ["39972003", "Sodium (substance)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258718000", "mmol (qualifier value)|millimole (qualifier value)"], ["39972003", "Sodium (substance)"], ["1222776006", "American Joint Committee on Cancer stage II:3 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["39972003", "Sodium (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["387390002", "Sodium chloride (substance)"], ["422113007", "Arabic numeral 9 (qualifier value)"], ["258798001", "Milligram/milliliter (qualifier value)|mg/mL (qualifier value)"], ["732402004", "0.9 (qualifier value)"], ["385229008", "Infusion solution (product)|Conventional release solution for infusion (dose form)|Infusion solution (qualifier value)"], ["30507006", "Into (attribute)"], ["86495002", "For (qualifier value)"], ["420862001", "On (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["20676001", "Sodium diet (finding)"], ["732810007", "6.6 (qualifier value)"]], "ncit.special_warnings": [["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C52874", "SPI1 wt Allele"], ["C28226", "Biological"], ["C16289", "Andorra"], ["C104504", "Batch Number"], ["C25463", "Count"], ["C52874", "SPI1 wt Allele"], ["C25382", "Administered"], ["C40352", "Multiplicative Product"], ["C16329", "Belgium"], ["C15388", "Infusion Procedure"], ["C16289", "Andorra"], ["C3114", "Hypersensitivity"], ["C1789", "Infliximab"], ["C101282", "Have"], ["C25281", "Associated"], ["C62355", "With"], ["C14140", "Acute"], ["C15388", "Infusion Procedure"], ["C53260", "Adverse Event Definitely Related to Intervention"], ["C166400", "Inclusive"], ["C50460", "Anaphylactic Shock"], ["C16289", "Andorra"], ["C168181", "Delayed Capillary Refill Time"], ["C3114", "Hypersensitivity"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C14140", "Acute"], ["C15388", "Infusion Procedure"], ["C166400", "Inclusive"], ["C106184", "May"], ["C25490", "During"], ["C25282", "Within"], ["C42535", "Second"], ["C43508", "Oregon"], ["C25282", "Within"], ["C76246", "Blood Group A"], ["C64942", "Few"], ["C25529", "Hour"], ["C53286", "Next"], ["C15388", "Infusion Procedure"], ["C198613", "CFI wt Allele"], ["C14140", "Acute"], ["C15388", "Infusion Procedure"], ["C127786", "Occurrence Indicator"], ["C15388", "Infusion Procedure"], ["C16329", "Belgium"], ["C25542", "Interruption"], ["C64597", "Immediately"], ["C53513", "Emergency Room"], ["C84337", "Scientific Equipment"], ["C71344", "Associate of Science"], ["C79445", "Epinephrine Measurement"], ["C211", "Therapeutic Corticosteroid"], ["C16289", "Andorra"], ["C75889", "PAX6 wt Allele"], ["C61464", "Artificial"], ["C89842", "Airway"], ["C16329", "Belgium"], ["C25429", "Availability"], ["C16960", "Patient"], ["C106184", "May"], ["C16329", "Belgium"], ["C25629", "Prior"], ["C25705", "Treating"], ["C62355", "With"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C75889", "PAX6 wt Allele"], ["C29716", "Antihistamine"], ["C2290", "Cortisol"], ["C48928", "And/Or"], ["C198", "Acetaminophen"], ["C159124", "GDC Treatment Outcome Terminology"], ["C156242", "Mild Hallucination"], ["C16289", "Andorra"], ["C53288", "Temporary"], ["C25492", "Effect"], ["C16295", "Antibody"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1789", "Infliximab"], ["C106184", "May"], ["C16289", "Andorra"], ["C101282", "Have"], ["C25281", "Associated"], ["C62355", "With"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C71113", "CDISC SDTM Frequency Terminology"], ["C52874", "SPI1 wt Allele"], ["C15388", "Infusion Procedure"], ["C76246", "Blood Group A"], ["C139301", "IPSS Risk Category Low"], ["C49159", "Proportion"], ["C52874", "SPI1 wt Allele"], ["C15388", "Infusion Procedure"], ["C154196", "Washo Language"], ["C54035", "Serious"], ["C37910", "Allergic"], ["C75889", "PAX6 wt Allele"], ["C73471", "Chemical Association"], ["C94545", "Between"], ["C18732", "Development"], ["C52874", "SPI1 wt Allele"], ["C16295", "Antibody"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1789", "Infliximab"], ["C16289", "Andorra"], ["C25640", "Reduced"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C165206", "Responsive Disease"], ["C101282", "Have"], ["C25599", "Observed"], ["C25730", "Concomitant"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C308", "Immunotherapeutic Agent"], ["C101282", "Have"], ["C25281", "Associated"], ["C62355", "With"], ["C25309", "Lower"], ["C16726", "Incidence"], ["C52874", "SPI1 wt Allele"], ["C16295", "Antibody"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1789", "Infliximab"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C25640", "Reduced"], ["C16727", "India"], ["C71113", "CDISC SDTM Frequency Terminology"], ["C52874", "SPI1 wt Allele"], ["C15388", "Infusion Procedure"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C25730", "Concomitant"], ["C49236", "Therapeutic Procedure"], ["C154196", "Washo Language"], ["C128667", "More"], ["C16727", "India"], ["C25705", "Treating"], ["C16960", "Patient"], ["C16727", "India"], ["C16960", "Patient"], ["C64974", "Give"], ["C15688", "Maintenance Therapy"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C25484", "Discontinue"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C25490", "During"], ["C1789", "Infliximab"], ["C43442", "Biomaterial Treatment"], ["C68869", "Are"], ["C158997", "GDC Analyte Type Terminology"], ["C61421", "Greater"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C16295", "Antibody"], ["C16295", "Antibody"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1789", "Infliximab"], ["C110990", "All of the Time"], ["C16329", "Belgium"], ["C16210", "Detection"], ["C16727", "India"], ["C13325", "Serum"], ["C198613", "CFI wt Allele"], ["C54035", "Serious"], ["C127786", "Occurrence Indicator"], ["C170740", "Symptomatic Therapy"], ["C16329", "Belgium"], ["C64974", "Give"], ["C16289", "Andorra"], ["C25519", "Further"], ["C1789", "Infliximab"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C16727", "India"], ["C15206", "Clinical Study"], ["C168181", "Delayed Capillary Refill Time"], ["C3114", "Hypersensitivity"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C25429", "Availability"], ["C25474", "Data"], ["C48313", "Suggestion"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C17102", "Risk"], ["C64956", "For"], ["C168181", "Delayed Capillary Refill Time"], ["C3114", "Hypersensitivity"], ["C62355", "With"], ["C1789", "Infliximab"], ["C63628", "Empty"], ["C25543", "Interval"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C64597", "Immediately"], ["C25261", "Medical"], ["C198613", "CFI wt Allele"], ["C54627", "Experience"], ["C81168", "Any"], ["C168181", "Delayed Capillary Refill Time"], ["C41332", "Adverse Reaction"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C198613", "CFI wt Allele"], ["C16960", "Patient"], ["C68869", "Are"], ["C17095", "Reunion"], ["C25705", "Treating"], ["C38008", "Post"], ["C76246", "Blood Group A"], ["C149870", "Prolonged Release Mechanism of Action"], ["C25616", "Period"], ["C16329", "Belgium"], ["C64956", "For"], ["C16289", "Andorra"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C168181", "Delayed Capillary Refill Time"], ["C3114", "Hypersensitivity"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C64956", "For"], ["C166400", "Inclusive"], ["C3423", "Tuberculosis"], ["C201357", "Before Timing Type"], ["C25490", "During"], ["C16289", "Andorra"], ["C38008", "Post"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C1789", "Infliximab"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C106184", "May"], ["C65105", "Take"], ["C64643", "Up to"], ["C66837", "Six"], ["C29846", "Month"], ["C61256", "Monitoring"], ["C16329", "Belgium"], ["C53279", "Continue"], ["C25616", "Period"], ["C25519", "Further"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C1789", "Infliximab"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C64974", "Give"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C76246", "Blood Group A"], ["C54035", "Serious"], ["C128320", "Infection"], ["C43508", "Oregon"], ["C3364", "Septicemia"], ["C16329", "Belgium"], ["C65140", "When"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C4981", "Chronic Graft Versus Host Disease"], ["C128320", "Infection"], ["C43508", "Oregon"], ["C76246", "Blood Group A"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C14173", "Recurrent"], ["C166400", "Inclusive"], ["C25730", "Concomitant"], ["C15261", "Immunosuppressive Therapy"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C52874", "SPI1 wt Allele"], ["C16289", "Andorra"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C62230", "Potential"], ["C17103", "Risk Factor"], ["C64956", "For"], ["C128320", "Infection"], ["C71344", "Associate of Science"], ["C36184", "Necrotic Change"], ["C174133", "Feelings about Genomic Testing Results"], ["C86942", "Alpha"], ["C18368", "TNF Gene"], ["C3137", "Inflammation"], ["C16289", "Andorra"], ["C12508", "Cell"], ["C17997", "Immune"], ["C28296", "Experimental"], ["C25474", "Data"], ["C18368", "TNF Gene"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C71578", "Essential"], ["C64956", "For"], ["C52874", "SPI1 wt Allele"], ["C28217", "Intracellular"], ["C123619", "Clinical Response"], ["C54627", "Experience"], ["C66819", "Host"], ["C64937", "Against"], ["C128320", "Infection"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C65099", "Some"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C1789", "Infliximab"], ["C38267", "Intrathecal Route of Administration"], ["C16329", "Belgium"], ["C126374", "Notable"], ["C52874", "SPI1 wt Allele"], ["C18368", "TNF Gene"], ["C106184", "May"], ["C173747", "Protective Face Mask"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C128320", "Infection"], ["C71344", "Associate of Science"], ["C143485", "Fever, CTCAE"], ["C61589", "Early"], ["C86585", "Recognition"], ["C52874", "SPI1 wt Allele"], ["C25428", "Atypical"], ["C123619", "Clinical Response"], ["C52874", "SPI1 wt Allele"], ["C54035", "Serious"], ["C16289", "Andorra"], ["C52874", "SPI1 wt Allele"], ["C102843", "Usual"], ["C123619", "Clinical Response"], ["C61388", "Presentation"], ["C52874", "SPI1 wt Allele"], ["C13634", "Retinoic Acid Response Element"], ["C16289", "Andorra"], ["C77967", "Unusual"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25467", "Critical"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16727", "India"], ["C15220", "Diagnosis"], ["C16289", "Andorra"], ["C43442", "Biomaterial Treatment"], ["C16960", "Patient"], ["C18368", "TNF Gene"], ["C68869", "Are"], ["C128667", "More"], ["C16505", "Susceptibility"], ["C159124", "GDC Treatment Outcome Terminology"], ["C54035", "Serious"], ["C3423", "Tuberculosis"], ["C166400", "Inclusive"], ["C3364", "Septicemia"], ["C16289", "Andorra"], ["C3333", "Pneumonia"], ["C93159", "Invasive Procedure"], ["C27985", "Viral"], ["C16289", "Andorra"], ["C118472", "Other License Status"], ["C101282", "Have"], ["C25599", "Observed"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C1789", "Infliximab"], ["C65099", "Some"], ["C52874", "SPI1 wt Allele"], ["C101282", "Have"], ["C48275", "Death Related to Adverse Event"], ["C25258", "Most"], ["C64649", "Frequently"], ["C188308", "Reported Information"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C53358", "Mortality Rate"], ["C52874", "SPI1 wt Allele"], ["C163771", "Illness Intrusiveness Rating 5"], ["C74521", "Include"], ["C26711", "Candidiasis"], ["C82994", "Listeriosis"], ["C16289", "Andorra"], ["C2886", "Aspergillosis"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C76246", "Blood Group A"], ["C94522", "New Lesion Identification"], ["C128320", "Infection"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C127315", "Complete Pharyngeal Contraction"], ["C25482", "Diagnostic"], ["C25214", "Evaluation"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C76246", "Blood Group A"], ["C94522", "New Lesion Identification"], ["C54035", "Serious"], ["C128320", "Infection"], ["C43508", "Oregon"], ["C3364", "Septicemia"], ["C16289", "Andorra"], ["C258", "Antibiotic"], ["C43508", "Oregon"], ["C15704", "Antifungal Therapy"], ["C16329", "Belgium"], ["C65136", "Until"], ["C128320", "Infection"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C82500", "Disease Controlled"], ["C3423", "Tuberculosis"], ["C101282", "Have"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C3423", "Tuberculosis"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C1789", "Infliximab"], ["C38267", "Intrathecal Route of Administration"], ["C16329", "Belgium"], ["C126374", "Notable"], ["C16727", "India"], ["C52874", "SPI1 wt Allele"], ["C115575", "Clinical Trial Final Report"], ["C3423", "Tuberculosis"], ["C154196", "Washo Language"], ["C190829", "Extrapulmonary"], ["C61388", "Presentation"], ["C71344", "Associate of Science"], ["C25388", "Local-Regional"], ["C43508", "Oregon"], ["C28222", "Disseminate"], ["C2991", "Disease or Disorder"], ["C201357", "Before Timing Type"], ["C171584", "Since Starting Treatment"], ["C62355", "With"], ["C1789", "Infliximab"], ["C64916", "All"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C25214", "Evaluation"], ["C64956", "For"], ["C49636", "Both"], ["C154405", "Active State"], ["C16289", "Andorra"], ["C45422", "Absence of Biochemical Activity"], ["C28225", "Latent"], ["C3423", "Tuberculosis"], ["C25214", "Evaluation"], ["C74521", "Include"], ["C76246", "Blood Group A"], ["C25480", "Details"], ["C18772", "Personal Medical History"], ["C62355", "With"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C3423", "Tuberculosis"], ["C43508", "Oregon"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C25627", "Previous"], ["C49147", "Physical Contact"], ["C62355", "With"], ["C3423", "Tuberculosis"], ["C16289", "Andorra"], ["C25627", "Previous"], ["C48928", "And/Or"], ["C48434", "Electrical Current"], ["C15261", "Immunosuppressive Therapy"], ["C48261", "Screening"], ["C25294", "Laboratory Procedure"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C85994", "Tuberculin Skin Test"], ["C38103", "Chest Radiography"], ["C48928", "And/Or"], ["C81996", "Interferon Gamma Measurement"], ["C134029", "Release Determination"], ["C16341", "Bioassay"], ["C16329", "Belgium"], ["C38000", "Performed"], ["C16727", "India"], ["C64916", "All"], ["C16960", "Patient"], ["C25388", "Local-Regional"], ["C106184", "May"], ["C64915", "Apply"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C16326", "Behavior"], ["C52874", "SPI1 wt Allele"], ["C25294", "Laboratory Procedure"], ["C16329", "Belgium"], ["C16727", "India"], ["C53691", "Veterinary Patient"], ["C54270", "Reminder"], ["C160555", "CaRD Regimen"], ["C68869", "Are"], ["C52874", "SPI1 wt Allele"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C93283", "False Negative"], ["C85994", "Tuberculin Skin Test"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C70667", "Severe"], ["C43508", "Oregon"], ["C14139", "Immunocompromised"], ["C198613", "CFI wt Allele"], ["C3423", "Tuberculosis"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C15220", "Diagnosis"], ["C1789", "Infliximab"], ["C49236", "Therapeutic Procedure"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C198613", "CFI wt Allele"], ["C28225", "Latent"], ["C3423", "Tuberculosis"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C71458", "Suspected"], ["C76246", "Blood Group A"], ["C25741", "Physician"], ["C62355", "With"], ["C16727", "India"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C3423", "Tuberculosis"], ["C16329", "Belgium"], ["C16727", "India"], ["C64916", "All"], ["C75330", "Below"], ["C25387", "Benefit"], ["C17102", "Risk"], ["C73497", "Balance"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C116076", "Very"], ["C198613", "CFI wt Allele"], ["C45422", "Absence of Biochemical Activity"], ["C28225", "Latent"], ["C3423", "Tuberculosis"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C15220", "Diagnosis"], ["C43442", "Biomaterial Treatment"], ["C64956", "For"], ["C28225", "Latent"], ["C3423", "Tuberculosis"], ["C16329", "Belgium"], ["C62355", "With"], ["C280", "Antitubercular Agent"], ["C49236", "Therapeutic Procedure"], ["C201357", "Before Timing Type"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C16289", "Andorra"], ["C64950", "Follow"], ["C25388", "Local-Regional"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C107221", "Several"], ["C43508", "Oregon"], ["C41130", "Significant"], ["C17103", "Risk Factor"], ["C64956", "For"], ["C3423", "Tuberculosis"], ["C16289", "Andorra"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C160366", "FGFR3 Gene Rearrangement Negative"], ["C82541", "Test Name"], ["C64956", "For"], ["C28225", "Latent"], ["C3423", "Tuberculosis"], ["C280", "Antitubercular Agent"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C201357", "Before Timing Type"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C280", "Antitubercular Agent"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C201357", "Before Timing Type"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C126474", "EHD1 wt Allele"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C28225", "Latent"], ["C43508", "Oregon"], ["C3423", "Tuberculosis"], ["C16727", "India"], ["C75889", "PAX6 wt Allele"], ["C168111", "Adequate Daily Fluid Intake"], ["C25379", "Course"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C25458", "Confirmation"], ["C65099", "Some"], ["C52874", "SPI1 wt Allele"], ["C3423", "Tuberculosis"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C1789", "Infliximab"], ["C25490", "During"], ["C16289", "Andorra"], ["C54735", "Post-Therapy"], ["C64956", "For"], ["C28225", "Latent"], ["C3423", "Tuberculosis"], ["C64916", "All"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C37896", "Informed"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25261", "Medical"], ["C198613", "CFI wt Allele"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C3423", "Tuberculosis"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C43623", "Persistent"], ["C124215", "Cough Frequency"], ["C125292", "How Often Weight Loss"], ["C139301", "IPSS Risk Category Low"], ["C48309", "Grade"], ["C143485", "Fever, CTCAE"], ["C179695", "Specimen Appearance Assessment"], ["C49640", "During or After"], ["C1789", "Infliximab"], ["C43442", "Biomaterial Treatment"], ["C93159", "Invasive Procedure"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C1789", "Infliximab"], ["C75889", "PAX6 wt Allele"], ["C93159", "Invasive Procedure"], ["C3245", "Fungal Infection"], ["C71344", "Associate of Science"], ["C2886", "Aspergillosis"], ["C26711", "Candidiasis"], ["C77201", "Histoplasmosis"], ["C84642", "Coccidioidomycosis"], ["C43508", "Oregon"], ["C34428", "Blastomycosis"], ["C16329", "Belgium"], ["C71458", "Suspected"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C54035", "Serious"], ["C13310", "Systemic"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C25741", "Physician"], ["C62355", "With"], ["C16727", "India"], ["C15220", "Diagnosis"], ["C16289", "Andorra"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C93159", "Invasive Procedure"], ["C16329", "Belgium"], ["C158997", "GDC Analyte Type Terminology"], ["C75889", "PAX6 wt Allele"], ["C28065", "Limited Stage"], ["C65140", "When"], ["C16960", "Patient"], ["C93159", "Invasive Procedure"], ["C106184", "May"], ["C160703", "Tumor Necrosis Present"], ["C71344", "Associate of Science"], ["C28222", "Disseminate"], ["C14146", "Localized"], ["C2991", "Disease or Disorder"], ["C16289", "Andorra"], ["C268", "Antigen"], ["C16289", "Andorra"], ["C16295", "Antibody"], ["C15336", "Testing"], ["C106184", "May"], ["C16329", "Belgium"], ["C160366", "FGFR3 Gene Rearrangement Negative"], ["C16727", "India"], ["C65099", "Some"], ["C16960", "Patient"], ["C62355", "With"], ["C154405", "Active State"], ["C128320", "Infection"], ["C54726", "Empiric"], ["C15704", "Antifungal Therapy"], ["C16329", "Belgium"], ["C76246", "Blood Group A"], ["C25482", "Diagnostic"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C89327", "Be"], ["C38000", "Performed"], ["C25544", "Into"], ["C88186", "Financial Account"], ["C49636", "Both"], ["C17102", "Risk"], ["C64956", "For"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C3245", "Fungal Infection"], ["C16289", "Andorra"], ["C52874", "SPI1 wt Allele"], ["C15704", "Antifungal Therapy"], ["C64956", "For"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C16727", "India"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C93159", "Invasive Procedure"], ["C71344", "Associate of Science"], ["C77201", "Histoplasmosis"], ["C84642", "Coccidioidomycosis"], ["C43508", "Oregon"], ["C34428", "Blastomycosis"], ["C68869", "Are"], ["C27122", "Endemic Burkitt Lymphoma"], ["C25387", "Benefit"], ["C16289", "Andorra"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C201357", "Before Timing Type"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C49236", "Therapeutic Procedure"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C16960", "Patient"], ["C62355", "With"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C62355", "With"], ["C14140", "Acute"], ["C25594", "Negation"], ["C47938", "Initiation"], ["C1789", "Infliximab"], ["C49236", "Therapeutic Procedure"], ["C65136", "Until"], ["C76246", "Blood Group A"], ["C43822", "Term Source"], ["C64956", "For"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C128320", "Infection"], ["C26686", "Abscess"], ["C101282", "Have"], ["C82931", "Exclusion"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C3097", "Hepatitis B Infection"], ["C189553", "Hepatitis B Virus Measurement"], ["C124063", "Reactivation"], ["C124063", "Reactivation"], ["C52874", "SPI1 wt Allele"], ["C3097", "Hepatitis B Infection"], ["C101282", "Have"], ["C54069", "Occur"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C76246", "Blood Group A"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C166400", "Inclusive"], ["C1789", "Infliximab"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C4981", "Chronic Graft Versus Host Disease"], ["C52874", "SPI1 wt Allele"], ["C14283", "Virus"], ["C65099", "Some"], ["C101282", "Have"], ["C101282", "Have"], ["C48275", "Death Related to Adverse Event"], ["C20200", "Outcome"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C64956", "For"], ["C189553", "Hepatitis B Virus Measurement"], ["C128320", "Infection"], ["C201357", "Before Timing Type"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C1789", "Infliximab"], ["C64956", "For"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C82541", "Test Name"], ["C36659", "CTNNB1 Gene Mutation"], ["C64956", "For"], ["C189553", "Hepatitis B Virus Measurement"], ["C128320", "Infection"], ["C41188", "Consultation"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C25741", "Physician"], ["C62355", "With"], ["C16727", "India"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C3097", "Hepatitis B Infection"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C52874", "SPI1 wt Allele"], ["C189553", "Hepatitis B Virus Measurement"], ["C75419", "World Health Organization"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C64956", "For"], ["C16289", "Andorra"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C154405", "Active State"], ["C189553", "Hepatitis B Virus Measurement"], ["C128320", "Infection"], ["C49236", "Therapeutic Procedure"], ["C16289", "Andorra"], ["C64956", "For"], ["C107221", "Several"], ["C29846", "Month"], ["C53286", "Next"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C168111", "Adequate Daily Fluid Intake"], ["C25474", "Data"], ["C52874", "SPI1 wt Allele"], ["C25705", "Treating"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C52874", "SPI1 wt Allele"], ["C189553", "Hepatitis B Virus Measurement"], ["C62355", "With"], ["C16119", "Antiviral Therapy"], ["C16727", "India"], ["C79874", "Conjunction"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C49236", "Therapeutic Procedure"], ["C159124", "GDC Treatment Outcome Terminology"], ["C189553", "Hepatitis B Virus Measurement"], ["C124063", "Reactivation"], ["C68869", "Are"], ["C25594", "Negation"], ["C25429", "Availability"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C189553", "Hepatitis B Virus Measurement"], ["C124063", "Reactivation"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C16289", "Andorra"], ["C49287", "Effective"], ["C16119", "Antiviral Therapy"], ["C62355", "With"], ["C37902", "Support"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C69122", "Ten"], ["C43612", "Hepatobiliary System"], ["C150901", "Event Unit"], ["C52874", "SPI1 wt Allele"], ["C3143", "Jaundice"], ["C16289", "Andorra"], ["C14460", "NON Mouse"], ["C26726", "Infectious Disorder"], ["C3095", "Hepatitis"], ["C65099", "Some"], ["C62355", "With"], ["C25447", "Characteristic"], ["C52874", "SPI1 wt Allele"], ["C27029", "Autoimmune Hepatitis"], ["C101282", "Have"], ["C25599", "Observed"], ["C16727", "India"], ["C38008", "Post"], ["C53292", "Marketing"], ["C54627", "Experience"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C25549", "Isolation"], ["C52874", "SPI1 wt Allele"], ["C26922", "Liver Failure"], ["C16727", "India"], ["C15271", "Liver Transplantation"], ["C43508", "Oregon"], ["C171353", "Clinical Status Ordinal Scale Outcome 7"], ["C101282", "Have"], ["C54069", "Occur"], ["C16960", "Patient"], ["C62355", "With"], ["C168422", "Rheumatic Fever Symptom"], ["C43508", "Oregon"], ["C52874", "SPI1 wt Allele"], ["C50634", "Liver Dysfunction"], ["C16329", "Belgium"], ["C25214", "Evaluation"], ["C64956", "For"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C23327", "Murine Liver"], ["C3671", "Injury"], ["C198613", "CFI wt Allele"], ["C3143", "Jaundice"], ["C48928", "And/Or"], ["C153832", "Southern Altai Language"], ["C163771", "Illness Intrusiveness Rating 5"], ["C187053", "Upper Surface"], ["C70987", "Bound"], ["C52874", "SPI1 wt Allele"], ["C12801", "Tissue"], ["C42555", "Siemens"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C41198", "Investigation"], ["C52874", "SPI1 wt Allele"], ["C9440", "Abnormality"], ["C16329", "Belgium"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C51526", "TNF wt Allele"], ["C154898", "Inhibitor"], ["C16289", "Andorra"], ["C38717", "Anakinra"], ["C54035", "Serious"], ["C16289", "Andorra"], ["C80520", "Neutropenia"], ["C16727", "India"], ["C15206", "Clinical Study"], ["C62355", "With"], ["C25456", "Concurrent"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C38717", "Anakinra"], ["C16289", "Andorra"], ["C18368", "TNF Gene"], ["C86946", "Mental Blocking"], ["C41161", "Protocol Agent"], ["C2381", "Etanercept"], ["C62355", "With"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C45330", "Added"], ["C142422", "Clinical Benefit"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C2381", "Etanercept"], ["C48440", "Single"], ["C52874", "SPI1 wt Allele"], ["C25447", "Characteristic"], ["C52874", "SPI1 wt Allele"], ["C188368", "ELN Adverse-Risk Category"], ["C62355", "With"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16289", "Andorra"], ["C38717", "Anakinra"], ["C49236", "Therapeutic Procedure"], ["C72665", "Similarity"], ["C106184", "May"], ["C20200", "Outcome"], ["C25516", "From"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C38717", "Anakinra"], ["C16289", "Andorra"], ["C118472", "Other License Status"], ["C18368", "TNF Gene"], ["C86946", "Mental Blocking"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C16289", "Andorra"], ["C38717", "Anakinra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C51526", "TNF wt Allele"], ["C154898", "Inhibitor"], ["C16289", "Andorra"], ["C28898", "Abatacept"], ["C16727", "India"], ["C15206", "Clinical Study"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C18368", "TNF Gene"], ["C16289", "Andorra"], ["C28898", "Abatacept"], ["C101282", "Have"], ["C25281", "Associated"], ["C62355", "With"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C166400", "Inclusive"], ["C54035", "Serious"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C18368", "TNF Gene"], ["C48440", "Single"], ["C25718", "Without"], ["C164135", "Increased"], ["C142422", "Clinical Benefit"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C16289", "Andorra"], ["C28898", "Abatacept"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C62355", "With"], ["C118472", "Other License Status"], ["C28226", "Biological"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C172138", "Insufficient Information to Classify Health Impact"], ["C25730", "Concomitant"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C62355", "With"], ["C118472", "Other License Status"], ["C28226", "Biological"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49236", "Therapeutic Procedure"], ["C172515", "S-Adenosylmethionine Measurement"], ["C25457", "Condition"], ["C71344", "Associate of Science"], ["C1789", "Infliximab"], ["C25730", "Concomitant"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C62355", "With"], ["C307", "Biological Agent"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C52874", "SPI1 wt Allele"], ["C52874", "SPI1 wt Allele"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C128320", "Infection"], ["C16289", "Andorra"], ["C118472", "Other License Status"], ["C62230", "Potential"], ["C16974", "Pharmacology"], ["C94545", "Between"], ["C28226", "Biological"], ["C61488", "Care"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C16289", "Andorra"], ["C16960", "Patient"], ["C54064", "Continue"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C65140", "When"], ["C25516", "From"], ["C66832", "One"], ["C28226", "Biological"], ["C159124", "GDC Treatment Outcome Terminology"], ["C45325", "Since"], ["C54669", "Overlap"], ["C28226", "Biological"], ["C120914", "Physical Activity Measurement"], ["C106184", "May"], ["C25519", "Further"], ["C25533", "Increase"], ["C17102", "Risk"], ["C64956", "For"], ["C188368", "ELN Adverse-Risk Category"], ["C166400", "Inclusive"], ["C128320", "Infection"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C16960", "Patient"], ["C198613", "CFI wt Allele"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C16329", "Belgium"], ["C64643", "Up to"], ["C48871", "Date Data Type"], ["C62355", "With"], ["C64916", "All"], ["C16727", "India"], ["C25369", "Agreement"], ["C62355", "With"], ["C48434", "Electrical Current"], ["C15346", "Vaccination"], ["C17564", "Guideline"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1789", "Infliximab"], ["C49236", "Therapeutic Procedure"], ["C16960", "Patient"], ["C92667", "SPARC wt Allele"], ["C1789", "Infliximab"], ["C106184", "May"], ["C25639", "Receive"], ["C25456", "Concurrent"], ["C151896", "Other Than"], ["C64956", "For"], ["C89279", "Reside"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C172979", "Fear Score 6"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C25693", "Subgroup"], ["C52874", "SPI1 wt Allele"], ["C182728", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 90"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C62355", "With"], ["C2884", "Rheumatoid Arthritis"], ["C25516", "From"], ["C45319", "Study Object"], ["C76246", "Blood Group A"], ["C72665", "Similarity"], ["C49159", "Proportion"], ["C52874", "SPI1 wt Allele"], ["C16960", "Patient"], ["C16727", "India"], ["C64933", "Each"], ["C161322", "Treatment Group"], ["C642", "Methotrexate"], ["C49648", "Placebo Control"], ["C25580", "N Category"], ["C113431", "Seventeen"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C67401", "Milligram per Kilogram"], ["C25580", "N Category"], ["C126887", "Twenty Seven"], ["C43508", "Oregon"], ["C172979", "Fear Score 6"], ["C67401", "Milligram per Kilogram"], ["C1789", "Infliximab"], ["C25580", "N Category"], ["C178275", "Forty Six"], ["C75889", "PAX6 wt Allele"], ["C49287", "Effective"], ["C66833", "Two"], ["C25533", "Increase"], ["C16727", "India"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C923", "Vaccine"], ["C1789", "Infliximab"], ["C163546", "Double Immunodiffusion"], ["C25594", "Negation"], ["C72886", "Interference"], ["C62355", "With"], ["C12476", "T-Lymphocyte"], ["C131943", "Independent for Transfer"], ["C17997", "Immune"], ["C25516", "From"], ["C19026", "Scientific Publication"], ["C48471", "Publication"], ["C16727", "India"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C2883", "Arthritis"], ["C3346", "Psoriasis"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C48313", "Suggestion"], ["C14460", "NON Mouse"], ["C89279", "Reside"], ["C25639", "Receive"], ["C175242", "During Treatment"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C166400", "Inclusive"], ["C1789", "Infliximab"], ["C106184", "May"], ["C76246", "Blood Group A"], ["C25309", "Lower"], ["C17930", "Immune Response Process"], ["C16727", "India"], ["C16960", "Patient"], ["C25594", "Negation"], ["C25639", "Receive"], ["C15577", "Anti-Tumor Necrosis Factor Therapy"], ["C89279", "Reside"], ["C25277", "Therapeutic"], ["C14316", "Infectious Agent"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C15577", "Anti-Tumor Necrosis Factor Therapy"], ["C142988", "Limited"], ["C25474", "Data"], ["C68869", "Are"], ["C25429", "Availability"], ["C92667", "SPARC wt Allele"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C15346", "Vaccination"], ["C62355", "With"], ["C89279", "Reside"], ["C43508", "Oregon"], ["C92667", "SPARC wt Allele"], ["C25666", "Second"], ["C17214", "Disease Transmission"], ["C52874", "SPI1 wt Allele"], ["C128320", "Infection"], ["C158169", "Buyei Chinese"], ["C89279", "Reside"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C89279", "Reside"], ["C52288", "NUP214 wt Allele"], ["C20200", "Outcome"], ["C16727", "India"], ["C123619", "Clinical Response"], ["C166400", "Inclusive"], ["C28222", "Disseminate"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C89279", "Reside"], ["C62355", "With"], ["C1789", "Infliximab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C113425", "Eleven"], ["C27956", "Infant"], ["C49587", "Exposure Domain"], ["C49641", "In Utero"], ["C16727", "India"], ["C49641", "In Utero"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1789", "Infliximab"], ["C48275", "Death Related to Adverse Event"], ["C20200", "Outcome"], ["C89272", "Due To"], ["C28222", "Disseminate"], ["C76202", "Bacillus"], ["C16652", "Guam"], ["C63637", "RNA Integrity Number"], ["C1328", "BCG"], ["C128320", "Infection"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C53286", "Next"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C298", "BCG Vaccine"], ["C38008", "Post"], ["C25155", "Birth"], ["C76246", "Blood Group A"], ["C113426", "Twelve"], ["C29846", "Month"], ["C25616", "Period"], ["C53286", "Next"], ["C25155", "Birth"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C201357", "Before Timing Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C89279", "Reside"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49641", "In Utero"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1789", "Infliximab"], ["C198613", "CFI wt Allele"], ["C27956", "Infant"], ["C1789", "Infliximab"], ["C13325", "Serum"], ["C68869", "Are"], ["C111568", "Undetectable"], ["C43508", "Oregon"], ["C1789", "Infliximab"], ["C70962", "Agent Administration"], ["C154196", "Washo Language"], ["C142988", "Limited"], ["C159124", "GDC Treatment Outcome Terminology"], ["C92799", "First Trimester"], ["C52874", "SPI1 wt Allele"], ["C191656", "Pregnant Subject"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C89279", "Reside"], ["C923", "Vaccine"], ["C16329", "Belgium"], ["C158997", "GDC Analyte Type Terminology"], ["C75889", "PAX6 wt Allele"], ["C68568", "Timepoint"], ["C198613", "CFI wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C48621", "Negative Surgical Margin"], ["C142422", "Clinical Benefit"], ["C64956", "For"], ["C25190", "Person"], ["C27956", "Infant"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C172979", "Fear Score 6"], ["C27956", "Infant"], ["C49587", "Exposure Domain"], ["C113553", "SEMA6A wt Allele"], ["C13257", "Mammary Gland Milk"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C89279", "Reside"], ["C923", "Vaccine"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C27956", "Infant"], ["C25189", "Mother"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25639", "Receive"], ["C1789", "Infliximab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C27956", "Infant"], ["C1789", "Infliximab"], ["C13325", "Serum"], ["C68869", "Are"], ["C111568", "Undetectable"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C172979", "Fear Score 6"], ["C25277", "Therapeutic"], ["C14316", "Infectious Agent"], ["C118472", "Other License Status"], ["C52874", "SPI1 wt Allele"], ["C25277", "Therapeutic"], ["C14316", "Infectious Agent"], ["C71344", "Associate of Science"], ["C89279", "Reside"], ["C62761", "Attenuated Bacteria Vaccine"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C1328", "BCG"], ["C131917", "Bladder Continence"], ["C64981", "Drop Instillation Route of Administration"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C9305", "Malignant Neoplasm"], ["C20200", "Outcome"], ["C16727", "India"], ["C123619", "Clinical Response"], ["C166400", "Inclusive"], ["C28222", "Disseminate"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C25277", "Therapeutic"], ["C14316", "Infectious Agent"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C64974", "Give"], ["C62355", "With"], ["C1789", "Infliximab"], ["C37916", "Autoimmune"], ["C45830", "Relative Value"], ["C94372", "Deficiency"], ["C52874", "SPI1 wt Allele"], ["C18368", "TNF Gene"], ["C158169", "Buyei Chinese"], ["C15577", "Anti-Tumor Necrosis Factor Therapy"], ["C106184", "May"], ["C20200", "Outcome"], ["C16727", "India"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C75889", "PAX6 wt Allele"], ["C16313", "Autoimmune Reaction"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C27153", "Lupus Erythematosus"], ["C72665", "Similarity"], ["C168217", "Genetic Syndrome Associated with Congenital Heart Defect"], ["C53286", "Next"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C1789", "Infliximab"], ["C16289", "Andorra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C36659", "CTNNB1 Gene Mutation"], ["C64956", "For"], ["C16295", "Antibody"], ["C64937", "Against"], ["C449", "DNA"], ["C25519", "Further"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C1789", "Infliximab"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C64974", "Give"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C25262", "Neurologic"], ["C150901", "Event Unit"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C18368", "TNF Gene"], ["C86946", "Mental Blocking"], ["C166400", "Inclusive"], ["C1789", "Infliximab"], ["C101282", "Have"], ["C25281", "Associated"], ["C62355", "With"], ["C52874", "SPI1 wt Allele"], ["C94522", "New Lesion Identification"], ["C25279", "Onset"], ["C43508", "Oregon"], ["C124138", "Exacerbation"], ["C52874", "SPI1 wt Allele"], ["C123619", "Clinical Response"], ["C168422", "Rheumatic Fever Symptom"], ["C48928", "And/Or"], ["C192332", "Radiographic Staging"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C12438", "Central Nervous System"], ["C2991", "Disease or Disorder"], ["C166400", "Inclusive"], ["C3243", "Multiple Sclerosis"], ["C16289", "Andorra"], ["C25233", "Peripheral"], ["C2991", "Disease or Disorder"], ["C166400", "Inclusive"], ["C116345", "Guillain-Barre Syndrome"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C73621", "Pre-existing"], ["C43508", "Oregon"], ["C25280", "Recent"], ["C25279", "Onset"], ["C52874", "SPI1 wt Allele"], ["C2991", "Disease or Disorder"], ["C25387", "Benefit"], ["C16289", "Andorra"], ["C52874", "SPI1 wt Allele"], ["C18368", "TNF Gene"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C201357", "Before Timing Type"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C49236", "Therapeutic Procedure"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C198613", "CFI wt Allele"], ["C2991", "Disease or Disorder"], ["C16289", "Andorra"], ["C2991", "Disease or Disorder"], ["C16727", "India"], ["C82500", "Disease Controlled"], ["C52874", "SPI1 wt Allele"], ["C15206", "Clinical Study"], ["C52874", "SPI1 wt Allele"], ["C18368", "TNF Gene"], ["C86946", "Mental Blocking"], ["C128667", "More"], ["C52874", "SPI1 wt Allele"], ["C166400", "Inclusive"], ["C7587", "Adult Lymphoma"], ["C101282", "Have"], ["C25599", "Observed"], ["C16960", "Patient"], ["C25639", "Receive"], ["C76246", "Blood Group A"], ["C18368", "TNF Gene"], ["C49156", "Comparison"], ["C62355", "With"], ["C64355", "Scientific Control"], ["C16960", "Patient"], ["C25490", "During"], ["C15206", "Clinical Study"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C81171", "Cross"], ["C64916", "All"], ["C179009", "Approved for Emergency Use Authorization"], ["C16726", "Incidence"], ["C52874", "SPI1 wt Allele"], ["C7587", "Adult Lymphoma"], ["C16727", "India"], ["C1789", "Infliximab"], ["C25705", "Treating"], ["C16960", "Patient"], ["C154196", "Washo Language"], ["C25227", "High"], ["C41333", "Expected Adverse Event"], ["C16727", "India"], ["C18241", "General Population"], ["C25275", "Occurrence"], ["C52874", "SPI1 wt Allele"], ["C7587", "Adult Lymphoma"], ["C154196", "Washo Language"], ["C13634", "Retinoic Acid Response Element"], ["C16727", "India"], ["C38008", "Post"], ["C53292", "Marketing"], ["C127262", "CDISC SDTM Environmental Setting Terminology"], ["C52874", "SPI1 wt Allele"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C45782", "Background"], ["C17102", "Risk"], ["C64956", "For"], ["C7587", "Adult Lymphoma"], ["C16289", "Andorra"], ["C16727", "India"], ["C2884", "Rheumatoid Arthritis"], ["C16960", "Patient"], ["C62355", "With"], ["C25248", "Long"], ["C62166", "Standing"], ["C25227", "High"], ["C154405", "Active State"], ["C93210", "Inflammatory Disorder"], ["C17102", "Risk"], ["C25498", "Estimate"], ["C16727", "India"], ["C75889", "PAX6 wt Allele"], ["C15206", "Clinical Study"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C159124", "GDC Treatment Outcome Terminology"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C3199", "Chronic Obstructive Pulmonary Disease"], ["C128667", "More"], ["C188308", "Reported Information"], ["C16727", "India"], ["C1789", "Infliximab"], ["C25705", "Treating"], ["C16960", "Patient"], ["C49156", "Comparison"], ["C62355", "With"], ["C64355", "Scientific Control"], ["C16960", "Patient"], ["C64916", "All"], ["C16960", "Patient"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C68807", "Heavy"], ["C17934", "Tobacco Smoking"], ["C16329", "Belgium"], ["C16727", "India"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C16960", "Patient"], ["C62355", "With"], ["C164135", "Increased"], ["C17102", "Risk"], ["C64956", "For"], ["C9305", "Malignant Neoplasm"], ["C89272", "Due To"], ["C68807", "Heavy"], ["C17934", "Tobacco Smoking"], ["C62355", "With"], ["C48434", "Electrical Current"], ["C76246", "Blood Group A"], ["C17102", "Risk"], ["C64956", "For"], ["C18732", "Development"], ["C52874", "SPI1 wt Allele"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C18368", "TNF Gene"], ["C86946", "Mental Blocking"], ["C41161", "Protocol Agent"], ["C16329", "Belgium"], ["C82931", "Exclusion"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C16329", "Belgium"], ["C113426", "Twelve"], ["C65140", "When"], ["C18368", "TNF Gene"], ["C86946", "Mental Blocking"], ["C49236", "Therapeutic Procedure"], ["C64956", "For"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C9305", "Malignant Neoplasm"], ["C43508", "Oregon"], ["C65140", "When"], ["C54064", "Continue"], ["C43442", "Biomaterial Treatment"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C76246", "Blood Group A"], ["C9305", "Malignant Neoplasm"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C3346", "Psoriasis"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C198967", "Extensive Extracapsular Extention"], ["C574", "Immunosuppressant"], ["C49236", "Therapeutic Procedure"], ["C43508", "Oregon"], ["C149870", "Prolonged Release Mechanism of Action"], ["C29973", "PUVA Photochemotherapy"], ["C43442", "Biomaterial Treatment"], ["C65099", "Some"], ["C48275", "Death Related to Adverse Event"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16423", "Child"], ["C16266", "Adolescents"], ["C16289", "Andorra"], ["C64643", "Up to"], ["C126884", "Twenty Two"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C25705", "Treating"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C86946", "Mental Blocking"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C111798", "Eighteen"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C166400", "Inclusive"], ["C1789", "Infliximab"], ["C16727", "India"], ["C38008", "Post"], ["C53292", "Marketing"], ["C127262", "CDISC SDTM Environmental Setting Terminology"], ["C45828", "Approximate"], ["C81009", "Half"], ["C118472", "Other License Status"], ["C76246", "Blood Group A"], ["C69085", "Assortment"], ["C52874", "SPI1 wt Allele"], ["C46003", "Difference"], ["C16289", "Andorra"], ["C13634", "Retinoic Acid Response Element"], ["C114711", "Usually"], ["C25281", "Associated"], ["C62355", "With"], ["C15261", "Immunosuppressive Therapy"], ["C76246", "Blood Group A"], ["C17102", "Risk"], ["C64956", "For"], ["C18732", "Development"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C16329", "Belgium"], ["C82931", "Exclusion"], ["C38008", "Post"], ["C53292", "Marketing"], ["C52874", "SPI1 wt Allele"], ["C8459", "Hepatosplenic T-Cell Lymphoma"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C86946", "Mental Blocking"], ["C166400", "Inclusive"], ["C1789", "Infliximab"], ["C13634", "Retinoic Acid Response Element"], ["C181852", "Protocol Therapy Status"], ["C52874", "SPI1 wt Allele"], ["C3466", "T-Cell Non-Hodgkin Lymphoma"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C116076", "Very"], ["C14138", "Aggressive"], ["C2991", "Disease or Disorder"], ["C25379", "Course"], ["C16289", "Andorra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C114711", "Usually"], ["C48275", "Death Related to Adverse Event"], ["C119986", "Almost All of the Time"], ["C16960", "Patient"], ["C101282", "Have"], ["C25639", "Receive"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C290", "Azathioprine"], ["C43508", "Oregon"], ["C195", "Mercaptopurine"], ["C62355", "With"], ["C43508", "Oregon"], ["C64597", "Immediately"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C18368", "TNF Gene"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C101282", "Have"], ["C54069", "Occur"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C43508", "Oregon"], ["C2952", "Ulcerative Colitis"], ["C16289", "Andorra"], ["C25258", "Most"], ["C188308", "Reported Information"], ["C16727", "India"], ["C27954", "Adolescent"], ["C43508", "Oregon"], ["C91107", "Young Adult"], ["C62230", "Potential"], ["C17102", "Risk"], ["C62355", "With"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C290", "Azathioprine"], ["C43508", "Oregon"], ["C195", "Mercaptopurine"], ["C16289", "Andorra"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C76246", "Blood Group A"], ["C17102", "Risk"], ["C64956", "For"], ["C18732", "Development"], ["C64956", "For"], ["C12476", "T-Lymphocyte"], ["C7587", "Adult Lymphoma"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C82931", "Exclusion"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C103113", "NCI CTEP SDC Melanoma Sub-Category Terminology"], ["C16289", "Andorra"], ["C9231", "Merkel Cell Carcinoma"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C49236", "Therapeutic Procedure"], ["C166400", "Inclusive"], ["C1789", "Infliximab"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C53578", "Periodic Report"], ["C168436", "Skin Examination"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C64956", "For"], ["C16960", "Patient"], ["C62355", "With"], ["C17103", "Risk Factor"], ["C64956", "For"], ["C2920", "Malignant Skin Neoplasm"], ["C76246", "Blood Group A"], ["C17005", "Population Group"], ["C48055", "Base"], ["C93228", "Retrospective Cohort Study"], ["C25474", "Data"], ["C25516", "From"], ["C154146", "Swedish Language"], ["C61423", "National"], ["C25178", "Health"], ["C25626", "Present"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C16726", "Incidence"], ["C52874", "SPI1 wt Allele"], ["C9039", "Cervical Carcinoma"], ["C16727", "India"], ["C62355", "With"], ["C2884", "Rheumatoid Arthritis"], ["C25705", "Treating"], ["C62355", "With"], ["C1789", "Infliximab"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C307", "Biological Agent"], ["C123723", "Package Type Not Applicable"], ["C17250", "Venezuela, Bolivarian Republic of"], ["C16960", "Patient"], ["C43508", "Oregon"], ["C18241", "General Population"], ["C166400", "Inclusive"], ["C25490", "During"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C53578", "Periodic Report"], ["C48261", "Screening"], ["C54064", "Continue"], ["C16727", "India"], ["C25705", "Treating"], ["C62355", "With"], ["C1789", "Infliximab"], ["C166400", "Inclusive"], ["C25490", "During"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C64916", "All"], ["C16960", "Patient"], ["C62355", "With"], ["C2952", "Ulcerative Colitis"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C158997", "GDC Analyte Type Terminology"], ["C164135", "Increased"], ["C17102", "Risk"], ["C64956", "For"], ["C4086", "Dysplasia"], ["C43508", "Oregon"], ["C4910", "Colon Carcinoma"], ["C64956", "For"], ["C48175", "Example"], ["C16960", "Patient"], ["C62355", "With"], ["C25248", "Long"], ["C62166", "Standing"], ["C2952", "Ulcerative Colitis"], ["C43508", "Oregon"], ["C4828", "Primary Sclerosing Cholangitis"], ["C43508", "Oregon"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C25629", "Prior"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C4086", "Dysplasia"], ["C43508", "Oregon"], ["C4910", "Colon Carcinoma"], ["C16329", "Belgium"], ["C64956", "For"], ["C4086", "Dysplasia"], ["C158997", "GDC Analyte Type Terminology"], ["C25647", "Regular"], ["C201357", "Before Timing Type"], ["C49236", "Therapeutic Procedure"], ["C16289", "Andorra"], ["C2991", "Disease or Disorder"], ["C25379", "Course"], ["C25214", "Evaluation"], ["C74521", "Include"], ["C16450", "Colonoscopy"], ["C16289", "Andorra"], ["C97722", "PER1 wt Allele"], ["C25388", "Local-Regional"], ["C48434", "Electrical Current"], ["C25474", "Data"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C1789", "Infliximab"], ["C43442", "Biomaterial Treatment"], ["C17102", "Risk"], ["C64956", "For"], ["C4086", "Dysplasia"], ["C43508", "Oregon"], ["C4910", "Colon Carcinoma"], ["C45325", "Since"], ["C52874", "SPI1 wt Allele"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C9305", "Malignant Neoplasm"], ["C18732", "Development"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C25587", "Newly Diagnosed"], ["C4086", "Dysplasia"], ["C25705", "Treating"], ["C62355", "With"], ["C1789", "Infliximab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C71155", "Established"], ["C17102", "Risk"], ["C16289", "Andorra"], ["C25387", "Benefit"], ["C52874", "SPI1 wt Allele"], ["C53279", "Continue"], ["C49236", "Therapeutic Procedure"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25190", "Person"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C158169", "Buyei Chinese"], ["C85499", "Clinician"], ["C143529", "Heart Failure, CTCAE"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C62355", "With"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C156242", "Mild Hallucination"], ["C143529", "Heart Failure, CTCAE"], ["C66904", "New York Heart Association Class I"], ["C62395", "WHO Central Nervous System Grade 2"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C16289", "Andorra"], ["C1789", "Infliximab"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C53279", "Continue"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C94522", "New Lesion Identification"], ["C43508", "Oregon"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C143529", "Heart Failure, CTCAE"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C101282", "Have"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C34889", "Pancytopenia"], ["C26816", "Leukopenia"], ["C80520", "Neutropenia"], ["C16289", "Andorra"], ["C3408", "Thrombocytopenia"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C18368", "TNF Gene"], ["C166400", "Inclusive"], ["C1789", "Infliximab"], ["C64916", "All"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C64597", "Immediately"], ["C25261", "Medical"], ["C41209", "Attention Concentration"], ["C198613", "CFI wt Allele"], ["C16289", "Andorra"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C17610", "Blood Sample"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C43623", "Persistent"], ["C143485", "Fever, CTCAE"], ["C37921", "Bruise"], ["C26791", "Hemorrhage"], ["C50685", "Pallor"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C25458", "Confirmation"], ["C41130", "Significant"], ["C113427", "Thirteen"], ["C168369", "Other Chief Complaint"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C142988", "Limited"], ["C49667", "Safety Study"], ["C54627", "Experience"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C43442", "Biomaterial Treatment"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C15329", "Surgical Procedure"], ["C102700", "Procedure Domain"], ["C166400", "Inclusive"], ["C51691", "Arthroplasty"], ["C25248", "Long"], ["C70916", "Half Life"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C25544", "Into"], ["C113416", "Consideration"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C15329", "Surgical Procedure"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25619", "Plan"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C75419", "World Health Organization"], ["C160609", "Surgical Procedure was Curative Therapy"], ["C92667", "SPARC wt Allele"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C64956", "For"], ["C16289", "Andorra"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C25745", "Failure"], ["C159124", "GDC Treatment Outcome Terminology"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43442", "Biomaterial Treatment"], ["C64956", "For"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C106184", "May"], ["C25626", "Present"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C192305", "Fixed Basis Relative Biological Effectiveness"], ["C50754", "Stenosis"], ["C106184", "May"], ["C15329", "Surgical Procedure"], ["C43442", "Biomaterial Treatment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43583", "Evidence"], ["C159124", "GDC Treatment Outcome Terminology"], ["C48313", "Suggestion"], ["C1789", "Infliximab"], ["C43508", "Oregon"], ["C18101", "Special Population"], ["C16268", "Elderly"], ["C16726", "Incidence"], ["C52874", "SPI1 wt Allele"], ["C54035", "Serious"], ["C16727", "India"], ["C1789", "Infliximab"], ["C25705", "Treating"], ["C16960", "Patient"], ["C188329", "Sixty Five"], ["C29848", "Year"], ["C16289", "Andorra"], ["C154196", "Washo Language"], ["C61584", "Greater Than"], ["C16727", "India"], ["C188329", "Sixty Five"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C65099", "Some"], ["C52874", "SPI1 wt Allele"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C48275", "Death Related to Adverse Event"], ["C20200", "Outcome"], ["C41209", "Attention Concentration"], ["C17102", "Risk"], ["C64956", "For"], ["C128320", "Infection"], ["C16329", "Belgium"], ["C173947", "Paid Hours"], ["C65140", "When"], ["C25705", "Treating"], ["C16268", "Elderly"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C17005", "Population Group"], ["C16727", "India"], ["C15206", "Clinical Study"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C25227", "High"], ["C49159", "Proportion"], ["C52874", "SPI1 wt Allele"], ["C16960", "Patient"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C16960", "Patient"], ["C198613", "CFI wt Allele"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C16329", "Belgium"], ["C64643", "Up to"], ["C48871", "Date Data Type"], ["C62355", "With"], ["C64916", "All"], ["C16727", "India"], ["C25369", "Agreement"], ["C62355", "With"], ["C48434", "Electrical Current"], ["C15346", "Vaccination"], ["C17564", "Guideline"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1789", "Infliximab"], ["C49236", "Therapeutic Procedure"], ["C16960", "Patient"], ["C92667", "SPARC wt Allele"], ["C1789", "Infliximab"], ["C106184", "May"], ["C25639", "Receive"], ["C25456", "Concurrent"], ["C151896", "Other Than"], ["C64956", "For"], ["C89279", "Reside"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C172979", "Fear Score 6"], ["C16289", "Andorra"], ["C2991", "Disease or Disorder"], ["C65099", "Some"], ["C48275", "Death Related to Adverse Event"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16423", "Child"], ["C16266", "Adolescents"], ["C16289", "Andorra"], ["C64643", "Up to"], ["C126884", "Twenty Two"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C25705", "Treating"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C86946", "Mental Blocking"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C111798", "Eighteen"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C166400", "Inclusive"], ["C1789", "Infliximab"], ["C16727", "India"], ["C38008", "Post"], ["C53292", "Marketing"], ["C127262", "CDISC SDTM Environmental Setting Terminology"], ["C45828", "Approximate"], ["C81009", "Half"], ["C118472", "Other License Status"], ["C76246", "Blood Group A"], ["C69085", "Assortment"], ["C52874", "SPI1 wt Allele"], ["C46003", "Difference"], ["C16289", "Andorra"], ["C13634", "Retinoic Acid Response Element"], ["C114711", "Usually"], ["C25281", "Associated"], ["C62355", "With"], ["C15261", "Immunosuppressive Therapy"], ["C76246", "Blood Group A"], ["C17102", "Risk"], ["C64956", "For"], ["C18732", "Development"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C16423", "Child"], ["C16289", "Andorra"], ["C16266", "Adolescents"], ["C25705", "Treating"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C16329", "Belgium"], ["C82931", "Exclusion"], ["C38008", "Post"], ["C53292", "Marketing"], ["C52874", "SPI1 wt Allele"], ["C8459", "Hepatosplenic T-Cell Lymphoma"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C86946", "Mental Blocking"], ["C166400", "Inclusive"], ["C1789", "Infliximab"], ["C13634", "Retinoic Acid Response Element"], ["C181852", "Protocol Therapy Status"], ["C52874", "SPI1 wt Allele"], ["C3466", "T-Cell Non-Hodgkin Lymphoma"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C116076", "Very"], ["C14138", "Aggressive"], ["C2991", "Disease or Disorder"], ["C25379", "Course"], ["C16289", "Andorra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C114711", "Usually"], ["C48275", "Death Related to Adverse Event"], ["C119986", "Almost All of the Time"], ["C16960", "Patient"], ["C101282", "Have"], ["C25639", "Receive"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C290", "Azathioprine"], ["C43508", "Oregon"], ["C195", "Mercaptopurine"], ["C62355", "With"], ["C43508", "Oregon"], ["C64597", "Immediately"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C18368", "TNF Gene"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C101282", "Have"], ["C54069", "Occur"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C42555", "Siemens"], ["C2991", "Disease or Disorder"], ["C43508", "Oregon"], ["C2952", "Ulcerative Colitis"], ["C16289", "Andorra"], ["C25258", "Most"], ["C188308", "Reported Information"], ["C16727", "India"], ["C27954", "Adolescent"], ["C43508", "Oregon"], ["C91107", "Young Adult"], ["C62230", "Potential"], ["C17102", "Risk"], ["C62355", "With"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C290", "Azathioprine"], ["C43508", "Oregon"], ["C195", "Mercaptopurine"], ["C16289", "Andorra"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C76246", "Blood Group A"], ["C17102", "Risk"], ["C64956", "For"], ["C18732", "Development"], ["C64956", "For"], ["C8459", "Hepatosplenic T-Cell Lymphoma"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C82931", "Exclusion"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C830", "Sodium"], ["C95494", "Content"], ["C1789", "Infliximab"], ["C79873", "Contain"], ["C61585", "Less Than"], ["C105723", "ECOG Performance Status 1"], ["C48513", "Millimole"], ["C830", "Sodium"], ["C126885", "Twenty Three"], ["C16818", "Mammography"], ["C97722", "PER1 wt Allele"], ["C25488", "Dose"], ["C68254", "Dietary Iodine"], ["C68800", "Elementary Charge"], ["C830", "Sodium"], ["C63628", "Empty"], ["C1789", "Infliximab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C29974", "Sodium Chloride"], ["C120081", "Severity of Symptom Score 9"], ["C42576", "Kilogram per Cubic Meter"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C120081", "Severity of Symptom Score 9"], ["C149910", "Solution for Infusion Dosage Form"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C25544", "Into"], ["C113416", "Consideration"], ["C64956", "For"], ["C16960", "Patient"], ["C92667", "SPARC wt Allele"], ["C76246", "Blood Group A"], ["C82500", "Disease Controlled"], ["C830", "Sodium"], ["C90364", "Basal Diet"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C172979", "Fear Score 6"]], "rxnorm.special_warnings": [["191831", "infliximab"], ["5492", "hydrocortisone"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["10908", "tuberculin"], ["10908", "tuberculin"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["T005", "Virus"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["72435", "anakinra"], ["72435", "anakinra"], ["214555", "etanercept"], ["214555", "etanercept"], ["214555", "etanercept"], ["72435", "anakinra"], ["72435", "anakinra"], ["191831", "infliximab"], ["72435", "anakinra"], ["614391", "abatacept"], ["614391", "abatacept"], ["191831", "infliximab"], ["614391", "abatacept"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["T052", "Activity"], ["191831", "infliximab"], ["T096", "Group"], ["6851", "methotrexate"], ["8375", "placebo"], ["191831", "infliximab"], ["191831", "infliximab"], ["T025", "Cell"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["T025", "Cell"], ["191831", "infliximab"], ["T025", "Cell"], ["191831", "infliximab"], ["191831", "infliximab"], ["T025", "Cell"], ["191831", "infliximab"], ["T025", "Cell"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["T025", "Cell"], ["191831", "infliximab"], ["T025", "Cell"], ["191831", "infliximab"], ["191831", "infliximab"], ["T025", "Cell"], ["191831", "infliximab"], ["9853", "sodium"], ["9853", "sodium"], ["9853", "sodium"], ["1661411", "sodium chloride 9 MG/ML"], ["9853", "sodium"]], "loinc.special_warnings": [["LA22004-8", "IN"], ["LA25433-6", "Biological"], ["LP18011-4", "Number"], ["LP263434-5", "Infusion"], ["MTHU060561", "inFLIXimab"], ["LA18821-1", "Acute"], ["LP263434-5", "Infusion"], ["LA31343-9", "Related"], ["LA7473-7", "Shock"], ["LP266901-0", "Delayed"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA18821-1", "Acute"], ["LP263434-5", "Infusion"], ["LA14161-6", "May"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LA17820-4", "Few hours"], ["LP263434-5", "Infusion"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA18821-1", "Acute"], ["LP263434-5", "Infusion"], ["LP263434-5", "Infusion"], ["LA19654-5", "Interrupted"], ["MTHU056908", "Equipment"], ["MTHU003328", "Antihistamines"], ["MTHU042294", "Artificial airway"], ["LA14161-6", "May"], ["LP32605-5", "pre"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP97871-5", "Hydrocortisone"], ["LA22025-3", "OR"], ["LA6752-5", "Mild"], ["LP17807-6", "Antibodies"], ["MTHU060561", "inFLIXimab"], ["LA14161-6", "May"], ["LA24377-6", "Increased"], ["MTHU029777", "Frequency"], ["LP263434-5", "Infusion"], ["LP17763-1", "A"], ["LA9194-7", "Low"], ["LP263434-5", "Infusion"], ["LA30751-4", "Serious"], ["LP17807-6", "Antibodies"], ["MTHU060561", "inFLIXimab"], ["LA32619-1", "Reduced"], ["LP14744-4", "Duration"], ["LP6425-5", "Observed"], ["LP17807-6", "Antibodies"], ["MTHU060561", "inFLIXimab"], ["LP17763-1", "A"], ["LP267357-4", "Reduction"], ["LA22004-8", "IN"], ["MTHU029777", "Frequency"], ["LP263434-5", "Infusion"], ["LP267221-2", "Therapy"], ["LA16824-7", "More"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LP29256-2", "given"], ["LP267221-2", "Therapy"], ["LA9508-8", "Discontinue"], ["LA33028-4", "Prior"], ["LA22025-3", "OR"], ["MTHU060561", "inFLIXimab"], ["LP94823-9", "Treatment"], ["LA21988-3", "AT"], ["LP17807-6", "Antibodies"], ["LP17807-6", "Antibodies"], ["MTHU060561", "inFLIXimab"], ["LA9933-8", "Always"], ["LA11882-0", "Detected"], ["LA22004-8", "IN"], ["LP7567-3", "Serum"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA30751-4", "Serious"], ["LA17766-9", "Symptomatic"], ["LP94823-9", "Treatment"], ["LP29256-2", "given"], ["MTHU060561", "inFLIXimab"], ["LA21291-2", "Not"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LP266901-0", "Delayed"], ["LP6486-7", "Reported"], ["LA24544-1", "Increased risk"], ["LP266901-0", "Delayed"], ["MTHU060561", "inFLIXimab"], ["LP417559-4", "Safe Environment for Every Kid"], ["LP32637-8", "Immediate"], ["LA14523-7", "Advice"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP266901-0", "Delayed"], ["LP73228-6", "Reaction"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP75708-5", "Symptoms"], ["LP266901-0", "Delayed"], ["LP74970-2", "Infections"], ["LP74970-2", "Infections"], ["MTHU020835", "Tuberculosis"], ["LP94823-9", "Treatment"], ["MTHU060561", "inFLIXimab"], ["MTHU060561", "inFLIXimab"], ["LA14161-6", "May"], ["MTHU068094", "Months"], ["LA20297-0", "Monitoring"], ["LP94823-9", "Treatment"], ["MTHU060561", "inFLIXimab"], ["LA21291-2", "Not"], ["LP29256-2", "given"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LP17763-1", "A"], ["LA30751-4", "Serious"], ["LP266919-2", "Infection"], ["LA22025-3", "OR"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["LA28752-6", "Chronic"], ["LP266919-2", "Infection"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LP7800-8", "History"], ["LA28751-8", "Recurrent"], ["LP74970-2", "Infections"], ["LP267221-2", "Therapy"], ["46467-7", "Risk factors:Find:Pt:^Patient:Nom"], ["LP266919-2", "Infection"], ["LA7456-2", "Necrosis"], ["LA7447-1", "Inflammation"], ["LA27183-5", "Immune"], ["LP200075-2", "IS"], ["LP74970-2", "Infections"], ["LP7787-7", "Clinical"], ["LP266919-2", "Infection"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA14973-4", "Some"], ["MTHU060561", "inFLIXimab"], ["LP200077-8", "IT"], ["LA14161-6", "May"], ["LP75708-5", "Symptoms"], ["LP266919-2", "Infection"], ["LP74849-8", "Fever"], ["LA12111-3", "Early"], ["LA13702-8", "Atypical"], ["LP7787-7", "Clinical"], ["LA30751-4", "Serious"], ["LP74970-2", "Infections"], ["LP91518-8", "Clinical presentation"], ["LA15679-6", "Rare"], ["LP74970-2", "Infections"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["MTHU008876", "Diagnosis"], ["LP94823-9", "Treatment"], ["LA16824-7", "More"], ["LA24225-7", "Susceptible"], ["LA30751-4", "Serious"], ["LP74970-2", "Infections"], ["MTHU020835", "Tuberculosis"], ["LP74970-2", "Infections"], ["MTHU020831", "Pneumonia"], ["LP102225-2", "Invasive"], ["MTHU029809", "Other"], ["LP74970-2", "Infections"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LA14973-4", "Some"], ["LP74970-2", "Infections"], ["LA32822-1", "Fatal"], ["LA6482-9", "Frequently"], ["LP6486-7", "Reported"], ["LP74970-2", "Infections"], ["LP17763-1", "A"], ["MTHU027852", "Rate"], ["LP20593-7", "5"], ["LA10485-3", "Listeriosis"], ["LP17763-1", "A"], ["LA9039-4", "New"], ["LP266919-2", "Infection"], ["LP94823-9", "Treatment"], ["MTHU060561", "inFLIXimab"], ["LP17763-1", "A"], ["LP267470-5", "Complete"], ["LP249287-6", "Diagnostic"], ["LA27332-8", "Evaluation"], ["MTHU060561", "inFLIXimab"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LP17763-1", "A"], ["LA9039-4", "New"], ["LA30751-4", "Serious"], ["LP266919-2", "Infection"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LP267221-2", "Therapy"], ["LP266919-2", "Infection"], ["LP200075-2", "IS"], ["MTHU020835", "Tuberculosis"], ["LA16666-2", "Active"], ["MTHU020835", "Tuberculosis"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LP200077-8", "IT"], ["LA22004-8", "IN"], ["MTHU020835", "Tuberculosis"], ["LA11930-7", "Either"], ["LA4583-6", "Local"], ["LA22025-3", "OR"], ["LA18199-2", "Disease"], ["LP94823-9", "Treatment"], ["MTHU060561", "inFLIXimab"], ["LA18187-7", "All"], ["LA14331-5", "Both"], ["LA16666-2", "Active"], ["LA18632-2", "Inactive"], ["LA24776-9", "Latent"], ["MTHU020835", "Tuberculosis"], ["LA27332-8", "Evaluation"], ["LP17763-1", "A"], ["LP128548-7", "Medical history"], ["LP7800-8", "History"], ["MTHU020835", "Tuberculosis"], ["LA22025-3", "OR"], ["LA15097-1", "Possible"], ["LP248328-9", "Contact"], ["MTHU020835", "Tuberculosis"], ["LA22025-3", "OR"], ["LP267221-2", "Therapy"], ["LP200187-5", "Screening"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP32625-3", "Tuberculin"], ["LP130014-6", "Skin"], ["LA7556-9", "Test"], ["LA16043-4", "Chest x-ray"], ["LA22025-3", "OR"], ["LP18171-6", "Interferon gamma"], ["LA19974-7", "Performed"], ["LA22004-8", "IN"], ["LA18187-7", "All"], ["LA4583-6", "Local"], ["LA14161-6", "May"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP66710-2", "Patient"], ["LP29708-2", "Cardiology"], ["LA14496-6", "False"], ["LA6577-6", "Negative"], ["LP32625-3", "Tuberculin"], ["LP130014-6", "Skin"], ["LA7556-9", "Test"], ["LA22004-8", "IN"], ["98971-5", "Severely ill:Find:Pt:^Patient:Ord"], ["LA22025-3", "OR"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA16666-2", "Active"], ["MTHU020835", "Tuberculosis"], ["LP200075-2", "IS"], ["MTHU060561", "inFLIXimab"], ["LP267221-2", "Therapy"], ["LA21291-2", "Not"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA24776-9", "Latent"], ["MTHU020835", "Tuberculosis"], ["LP200075-2", "IS"], ["LA15291-0", "Suspected"], ["LP17763-1", "A"], ["MTHU010489", "Physician"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["MTHU020835", "Tuberculosis"], ["LA22004-8", "IN"], ["LA18187-7", "All"], ["LA14987-4", "Below"], ["MTHU060561", "inFLIXimab"], ["LP267221-2", "Therapy"], ["LA29696-4", "Very"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA18632-2", "Inactive"], ["LA24776-9", "Latent"], ["MTHU020835", "Tuberculosis"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA24776-9", "Latent"], ["MTHU020835", "Tuberculosis"], ["LP267221-2", "Therapy"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["LA4583-6", "Local"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LA28474-7", "Significant"], ["46467-7", "Risk factors:Find:Pt:^Patient:Nom"], ["MTHU020835", "Tuberculosis"], ["LP17763-1", "A"], ["LA6577-6", "Negative"], ["LA7556-9", "Test"], ["LA24776-9", "Latent"], ["MTHU020835", "Tuberculosis"], ["LP267221-2", "Therapy"], ["MTHU060561", "inFLIXimab"], ["LP267221-2", "Therapy"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP7800-8", "History"], ["LA24776-9", "Latent"], ["LA22025-3", "OR"], ["LA16666-2", "Active"], ["MTHU020835", "Tuberculosis"], ["LA22004-8", "IN"], ["LA8913-1", "Adequate"], ["LP94823-9", "Treatment"], ["LA15290-2", "Confirmed"], ["LA14973-4", "Some"], ["LP270144-1", "Cases"], ["LA16666-2", "Active"], ["MTHU020835", "Tuberculosis"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LP94823-9", "Treatment"], ["LA24776-9", "Latent"], ["MTHU020835", "Tuberculosis"], ["LA18187-7", "All"], ["LP417559-4", "Safe Environment for Every Kid"], ["LA14523-7", "Advice"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP75708-5", "Symptoms"], ["MTHU020835", "Tuberculosis"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LA30866-0", "Persistent cough"], ["MTHU020881", "Weight loss"], ["LA9194-7", "Low"], ["MTHU003112", "Grade"], ["LP74849-8", "Fever"], ["LA22025-3", "OR"], ["MTHU060561", "inFLIXimab"], ["LP94823-9", "Treatment"], ["LP102225-2", "Invasive"], ["LP74970-2", "Infections"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LP102225-2", "Invasive"], ["LP266919-2", "Infection"], ["LA10477-0", "Histoplasmosis"], ["LA10444-0", "Coccidioidomycosis"], ["LA22025-3", "OR"], ["LA10436-6", "Blastomycosis"], ["LA15291-0", "Suspected"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LA30751-4", "Serious"], ["LP17763-1", "A"], ["MTHU010489", "Physician"], ["LA22004-8", "IN"], ["MTHU008876", "Diagnosis"], ["LP94823-9", "Treatment"], ["LP102225-2", "Invasive"], ["LP74970-2", "Infections"], ["LA21988-3", "AT"], ["LA12111-3", "Early"], ["LP73395-3", "Stage"], ["LP102225-2", "Invasive"], ["LP74970-2", "Infections"], ["LA14161-6", "May"], ["LA9633-4", "Present"], ["LA28439-0", "Rather"], ["LA18199-2", "Disease"], ["LA14161-6", "May"], ["LA6577-6", "Negative"], ["LA22004-8", "IN"], ["LA14973-4", "Some"], ["LA16666-2", "Active"], ["LP266919-2", "Infection"], ["LP267221-2", "Therapy"], ["LP17763-1", "A"], ["LP249287-6", "Diagnostic"], ["LP200075-2", "IS"], ["LA19974-7", "Performed"], ["LA14331-5", "Both"], ["LA6750-9", "Severe"], ["LP266919-2", "Infection"], ["MTHU043138", "Risks"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LP102225-2", "Invasive"], ["LP74970-2", "Infections"], ["LA10477-0", "Histoplasmosis"], ["LA10444-0", "Coccidioidomycosis"], ["LA22025-3", "OR"], ["LA10436-6", "Blastomycosis"], ["MTHU043138", "Risks"], ["MTHU060561", "inFLIXimab"], ["LP94823-9", "Treatment"], ["MTHU060561", "inFLIXimab"], ["LP267221-2", "Therapy"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LA18821-1", "Acute"], ["LA21291-2", "Not"], ["LA20934-8", "initiate"], ["MTHU060561", "inFLIXimab"], ["LP267221-2", "Therapy"], ["LP17763-1", "A"], ["LA15097-1", "Possible"], ["LP266919-2", "Infection"], ["MTHU022414", "Abscess"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LA18126-5", "Hepatitis B"], ["LA18126-5", "Hepatitis B"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["MTHU060561", "inFLIXimab"], ["LA28752-6", "Chronic"], ["LP14855-8", "Virus"], ["LA14973-4", "Some"], ["LP270144-1", "Cases"], ["LA32822-1", "Fatal"], ["LP32426-6", "tested"], ["LP266919-2", "Infection"], ["LP94823-9", "Treatment"], ["MTHU060561", "inFLIXimab"], ["LA7556-9", "Test"], ["LA6576-8", "Positive"], ["LP266919-2", "Infection"], ["LA7553-6", "Consultation"], ["LP17763-1", "A"], ["MTHU010489", "Physician"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA18126-5", "Hepatitis B"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["MTHU060561", "inFLIXimab"], ["LP75708-5", "Symptoms"], ["LA16666-2", "Active"], ["LP266919-2", "Infection"], ["LP267221-2", "Therapy"], ["MTHU068094", "Months"], ["LP267221-2", "Therapy"], ["LA8913-1", "Adequate"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LP267221-2", "Therapy"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LP267221-2", "Therapy"], ["LP94823-9", "Treatment"], ["LA13942-0", "10"], ["MTHU058708", "Events"], ["LP270144-1", "Cases"], ["LA7450-5", "Jaundice"], ["LA7442-2", "Hepatitis"], ["LA14973-4", "Some"], ["LA7442-2", "Hepatitis"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LP32606-3", "post"], ["MTHU060561", "inFLIXimab"], ["LA24949-2", "Isolated"], ["LP270144-1", "Cases"], ["MTHU002039", "Liver"], ["LA9664-9", "Failure"], ["LA22004-8", "IN"], ["MTHU002039", "Liver"], ["LA18638-9", "Transplantation"], ["LA22025-3", "OR"], ["LA7424-0", "Death"], ["LP75708-5", "Symptoms"], ["LA22025-3", "OR"], ["MTHU002039", "Liver"], ["MTHU002039", "Liver"], ["LA17713-1", "Injury"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA7450-5", "Jaundice"], ["LA22025-3", "OR"], ["LP20593-7", "5"], ["LA6626-1", "Normal"], ["LP15241-0", "S"], ["MTHU060561", "inFLIXimab"], ["LP17763-1", "A"], ["LP36377-7", "Investigation"], ["LP191906-9", "Anakinra"], ["LA30751-4", "Serious"], ["LP74970-2", "Infections"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LP191906-9", "Anakinra"], ["MTHU054569", "Etanercept"], ["LA32-8", "No"], ["LP7787-7", "Clinical"], ["MTHU054569", "Etanercept"], ["LA27350-0", "Alone"], ["LA12701-1", "Combination"], ["MTHU054569", "Etanercept"], ["LP191906-9", "Anakinra"], ["LP267221-2", "Therapy"], ["LA14161-6", "May"], ["LA12701-1", "Combination"], ["LP191906-9", "Anakinra"], ["MTHU029809", "Other"], ["LA12701-1", "Combination"], ["MTHU060561", "inFLIXimab"], ["LP191906-9", "Anakinra"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LA24544-1", "Increased risk"], ["LP74970-2", "Infections"], ["LA30751-4", "Serious"], ["LP74970-2", "Infections"], ["LA27350-0", "Alone"], ["LA24377-6", "Increased"], ["LP7787-7", "Clinical"], ["LA12701-1", "Combination"], ["MTHU060561", "inFLIXimab"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["MTHU029809", "Other"], ["LA25433-6", "Biological"], ["LP200075-2", "IS"], ["LA28127-1", "Insufficient"], ["MTHU060561", "inFLIXimab"], ["MTHU029809", "Other"], ["LA25433-6", "Biological"], ["LA11009-0", "Same"], ["MTHU060561", "inFLIXimab"], ["MTHU060561", "inFLIXimab"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA24544-1", "Increased risk"], ["LP266919-2", "Infection"], ["MTHU029809", "Other"], ["LA25433-6", "Biological"], ["LP68340-6", "Continuity assessment record and evaluation"], ["LA9507-0", "Continue"], ["LA6306-0", "One"], ["LA31430-4", "Biologic"], ["LA25433-6", "Biological"], ["LP72045-5", "Activity"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["LP266919-2", "Infection"], ["MTHU000146", "Vaccinations"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA15097-1", "Possible"], ["LP182451-7", "Date"], ["LA18187-7", "All"], ["MTHU000146", "Vaccinations"], ["LA22004-8", "IN"], ["MTHU052654", "Agreement"], ["LA33028-4", "Prior"], ["LP267221-2", "Therapy"], ["MTHU060561", "inFLIXimab"], ["LA14161-6", "May"], ["MTHU000146", "Vaccinations"], ["LA20283-0", "Vaccines"], ["LA15768-7", "4.5"], ["LP20592-9", "4"], ["LP20594-5", "6"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA28891-2", "90"], ["LA13524-6", "Adult"], ["LA15161-5", "Rheumatoid Arthritis"], ["LP74341-6", "Study"], ["LP17763-1", "A"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["T096", "Group"], ["LP16198-1", "Methotrexate"], ["LA15167-2", "N"], ["LP20591-1", "3"], ["LP15217-0", "Mg"], ["LA15167-2", "N"], ["LA22025-3", "OR"], ["LP20594-5", "6"], ["LP15217-0", "Mg"], ["MTHU060561", "inFLIXimab"], ["LA15167-2", "N"], ["LA6404-3", "Two"], ["LA32048-3", "Increase"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP30374-0", "Vaccine"], ["MTHU060561", "inFLIXimab"], ["LA21291-2", "Not"], ["LP14634-7", "T-cell"], ["LA12302-8", "Independent"], ["LA27183-5", "Immune"], ["LA22004-8", "IN"], ["MTHU008862", "Indications"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["MTHU020793", "Arthritis"], ["LA15165-6", "Psoriasis"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["MTHU000146", "Vaccinations"], ["LA32660-5", "Received"], ["LP93408-0", "during treatment"], ["LP75725-9", "Therapies"], ["MTHU060561", "inFLIXimab"], ["LA14161-6", "May"], ["LP17763-1", "A"], ["LA27183-5", "Immune"], ["LA22004-8", "IN"], ["LA21291-2", "Not"], ["LP267221-2", "Therapy"], ["LA20283-0", "Vaccines"], ["LP263807-2", "Therapeutic"], ["LA22004-8", "IN"], ["LP267221-2", "Therapy"], ["LA6484-5", "Limited"], ["LA20283-0", "Vaccines"], ["LA22025-3", "OR"], ["LP263805-6", "Secondary"], ["MTHU050362", "Transmission"], ["LP266919-2", "Infection"], ["LA20283-0", "Vaccines"], ["LA20283-0", "Vaccines"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LP74970-2", "Infections"], ["LP74970-2", "Infections"], ["LA20283-0", "Vaccines"], ["MTHU060561", "inFLIXimab"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA14557-5", "11"], ["LA19747-7", "Infant"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LA32822-1", "Fatal"], ["LP102323-5", "Bromocresol green (BCG) dye binding method"], ["LP266919-2", "Infection"], ["LP6486-7", "Reported"], ["LP102323-5", "Bromocresol green (BCG) dye binding method"], ["LP30374-0", "Vaccine"], ["LP17763-1", "A"], ["LA14217-6", "Month"], ["LP200075-2", "IS"], ["LA20283-0", "Vaccines"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA19747-7", "Infant"], ["MTHU060561", "inFLIXimab"], ["LP7567-3", "Serum"], ["LA22025-3", "OR"], ["MTHU060561", "inFLIXimab"], ["LA6484-5", "Limited"], ["LP208035-8", "First trimester"], ["LP207970-7", "Pregnancy"], ["LP17763-1", "A"], ["LP30374-0", "Vaccine"], ["LA21988-3", "AT"], ["LA14566-6", "Earlier"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LA19732-9", "Clear"], ["LP7787-7", "Clinical"], ["LA12070-1", "Individual"], ["LA19747-7", "Infant"], ["LP20592-9", "4"], ["LP20594-5", "6"], ["LA19747-7", "Infant"], ["LA16914-6", "Breast milk"], ["LP17763-1", "A"], ["LP30374-0", "Vaccine"], ["LP17763-1", "A"], ["LA19747-7", "Infant"], ["LP6983-3", "Mother"], ["LP200075-2", "IS"], ["MTHU060561", "inFLIXimab"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA19747-7", "Infant"], ["MTHU060561", "inFLIXimab"], ["LP7567-3", "Serum"], ["LP20592-9", "4"], ["LP20594-5", "6"], ["LP263807-2", "Therapeutic"], ["MTHU029809", "Other"], ["LP263807-2", "Therapeutic"], ["LA12886-0", "Bacteria"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP102323-5", "Bromocresol green (BCG) dye binding method"], ["LP7056-7", "Bladder"], ["LP94823-9", "Treatment"], ["54532-7", "Cancer:-:Pt:^Patient:-"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LP74970-2", "Infections"], ["LP74970-2", "Infections"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP263807-2", "Therapeutic"], ["LA21291-2", "Not"], ["LP29256-2", "given"], ["MTHU060561", "inFLIXimab"], ["63897-3", "Relative:Find:Pt:^Patient:Nom:California Teachers Study"], ["LP267221-2", "Therapy"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LP75708-5", "Symptoms"], ["LP17763-1", "A"], ["LP94823-9", "Treatment"], ["MTHU060561", "inFLIXimab"], ["LP200075-2", "IS"], ["LA6576-8", "Positive"], ["LP17807-6", "Antibodies"], ["MTHU003299", "DNA"], ["LP94823-9", "Treatment"], ["MTHU060561", "inFLIXimab"], ["LA21291-2", "Not"], ["LP29256-2", "given"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP89782-4", "Neurological"], ["MTHU058708", "Events"], ["MTHU060561", "inFLIXimab"], ["LP270144-1", "Cases"], ["LA9039-4", "New"], ["LA22025-3", "OR"], ["LP7787-7", "Clinical"], ["LP75708-5", "Symptoms"], ["LA22025-3", "OR"], ["LA4174-4", "Central Nervous System"], ["LP75152-6", "Multiple sclerosis"], ["LA24844-5", "Peripheral"], ["LA22004-8", "IN"], ["LP32605-5", "pre"], ["LA22025-3", "OR"], ["MTHU043138", "Risks"], ["LP94823-9", "Treatment"], ["MTHU060561", "inFLIXimab"], ["LP267221-2", "Therapy"], ["MTHU060561", "inFLIXimab"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LA16824-7", "More"], ["LP270144-1", "Cases"], ["LA15685-3", "Lymphoma"], ["LP6425-5", "Observed"], ["LP17763-1", "A"], ["LP7741-4", "Control"], ["LP7787-7", "Clinical"], ["MTHU060561", "inFLIXimab"], ["LA18187-7", "All"], ["MTHU008862", "Indications"], ["LA15685-3", "Lymphoma"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["LA29505-7", "General population"], ["LA15685-3", "Lymphoma"], ["LA15679-6", "Rare"], ["LA22004-8", "IN"], ["LP32606-3", "post"], ["MTHU047625", "Setting"], ["LP270144-1", "Cases"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP200075-2", "IS"], ["LA24377-6", "Increased"], ["LA15685-3", "Lymphoma"], ["LA22004-8", "IN"], ["LA15161-5", "Rheumatoid Arthritis"], ["MTHU046607", "Standing"], ["LA16666-2", "Active"], ["LA18199-2", "Disease"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LP74341-6", "Study"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["LA32820-5", "Moderate to severe"], ["LA28200-6", "Chronic obstructive pulmonary disease"], ["LA10559-5", "COPD"], ["LA16824-7", "More"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LP7741-4", "Control"], ["LA18187-7", "All"], ["LP17763-1", "A"], ["LP7800-8", "History"], ["LA6213-8", "Heavy smoking"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA24544-1", "Increased risk"], ["LP128794-7", "Malignancy"], ["LA6213-8", "Heavy smoking"], ["LP17763-1", "A"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA14558-3", "12"], ["LP267221-2", "Therapy"], ["LP17763-1", "A"], ["LP7800-8", "History"], ["LP128794-7", "Malignancy"], ["LA22025-3", "OR"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP128794-7", "Malignancy"], ["LA22004-8", "IN"], ["LA15165-6", "Psoriasis"], ["LP17763-1", "A"], ["LP128548-7", "Medical history"], ["LP267221-2", "Therapy"], ["LA22025-3", "OR"], ["LA16783-5", "PUVA"], ["LP94823-9", "Treatment"], ["LA14973-4", "Some"], ["LA32822-1", "Fatal"], ["LP6486-7", "Reported"], ["MTHU010047", "Age"], ["LP267221-2", "Therapy"], ["MTHU010047", "Age"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["LP32606-3", "post"], ["MTHU047625", "Setting"], ["LP270144-1", "Cases"], ["MTHU029809", "Other"], ["LP270144-1", "Cases"], ["LP17763-1", "A"], ["LA15679-6", "Rare"], ["LA14747-2", "Usually"], ["LP17763-1", "A"], ["LA22004-8", "IN"], ["LP32606-3", "post"], ["LP270144-1", "Cases"], ["LP14634-7", "T-cell"], ["LA15685-3", "Lymphoma"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LA15679-6", "Rare"], ["LP6886-8", "Type"], ["LP14634-7", "T-cell"], ["LA15685-3", "Lymphoma"], ["LP17763-1", "A"], ["LA29696-4", "Very"], ["LA18199-2", "Disease"], ["LP200075-2", "IS"], ["LA14747-2", "Usually"], ["LA32822-1", "Fatal"], ["LA18187-7", "All"], ["LA32660-5", "Received"], ["LP94823-9", "Treatment"], ["LA22025-3", "OR"], ["LP20594-5", "6"], ["LA22025-3", "OR"], ["LA33028-4", "Prior"], ["LP17763-1", "A"], ["MTHU060561", "inFLIXimab"], ["LP270144-1", "Cases"], ["LA22004-8", "IN"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LA22025-3", "OR"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LA19749-3", "Adolescent"], ["LA22025-3", "OR"], ["LA13524-6", "Adult"], ["LA12701-1", "Combination"], ["LA22025-3", "OR"], ["LP20594-5", "6"], ["MTHU060561", "inFLIXimab"], ["LP17763-1", "A"], ["LP14634-7", "T-cell"], ["LA15685-3", "Lymphoma"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA14279-6", "Melanoma"], ["T025", "Cell"], ["LA15448-6", "Carcinoma"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LP267221-2", "Therapy"], ["MTHU060561", "inFLIXimab"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA6663-4", "Periodic"], ["LP130014-6", "Skin"], ["LP200075-2", "IS"], ["46467-7", "Risk factors:Find:Pt:^Patient:Nom"], ["LA10543-9", "Skin Cancer"], ["LP17763-1", "A"], ["LP62263-6", "Population"], ["LP74341-6", "Study"], ["LA17983-0", "Health"], ["LA24377-6", "Increased"], ["54532-7", "Cancer:-:Pt:^Patient:-"], ["LA22004-8", "IN"], ["LA15161-5", "Rheumatoid Arthritis"], ["MTHU060561", "inFLIXimab"], ["LA22025-3", "OR"], ["LA29505-7", "General population"], ["LA28853-2", "60"], ["MTHU010047", "Age"], ["LA6663-4", "Periodic"], ["LP200187-5", "Screening"], ["LA9507-0", "Continue"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LA10400-2", "OVER 60"], ["MTHU010047", "Age"], ["LA18187-7", "All"], ["LA21988-3", "AT"], ["LA24544-1", "Increased risk"], ["LA22025-3", "OR"], ["LP199922-8", "Colon"], ["LA15448-6", "Carcinoma"], ["MTHU046607", "Standing"], ["LA22025-3", "OR"], ["LA21208-6", "Primary"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LA33028-4", "Prior"], ["LP7800-8", "History"], ["LA22025-3", "OR"], ["LP199922-8", "Colon"], ["LA15448-6", "Carcinoma"], ["LA21988-3", "AT"], ["LA15487-4", "Regular"], ["LP267221-2", "Therapy"], ["LA18199-2", "Disease"], ["LA27332-8", "Evaluation"], ["LA15380-1", "Colonoscopy"], ["LA4583-6", "Local"], ["LA14426-3", "Do not"], ["MTHU060561", "inFLIXimab"], ["LP94823-9", "Treatment"], ["LA22025-3", "OR"], ["LA10537-1", "Colon Cancer"], ["LA24544-1", "Increased risk"], ["54532-7", "Cancer:-:Pt:^Patient:-"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LP267221-2", "Therapy"], ["LA12070-1", "Individual"], ["LP269421-6", "Heart failure"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["LA6752-5", "Mild"], ["LP269421-6", "Heart failure"], ["LP264302-3", "NYHA"], ["LA28404-4", "Class I"], ["LA15458-5", "II"], ["MTHU060561", "inFLIXimab"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA9039-4", "New"], ["LA22025-3", "OR"], ["LP75708-5", "Symptoms"], ["LP269421-6", "Heart failure"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LA18187-7", "All"], ["LP417559-4", "Safe Environment for Every Kid"], ["LP32637-8", "Immediate"], ["LA22668-0", "Attention"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP75708-5", "Symptoms"], ["MTHU029981", "Blood"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP74849-8", "Fever"], ["LA7418-2", "Bleeding"], ["MTHU060561", "inFLIXimab"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LA15290-2", "Confirmed"], ["LA28474-7", "Significant"], ["LA14559-1", "13"], ["LP32758-2", "Others"], ["LP200075-2", "IS"], ["LA6484-5", "Limited"], ["LA17589-5", "Safety"], ["MTHU060561", "inFLIXimab"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LA31426-2", "Surgical"], ["MTHU060561", "inFLIXimab"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP7616-8", "Surgery"], ["LP200075-2", "IS"], ["LA20099-0", "Planned"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LP7616-8", "Surgery"], ["MTHU060561", "inFLIXimab"], ["LP74970-2", "Infections"], ["LA9664-9", "Failure"], ["LP94823-9", "Treatment"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LA14161-6", "May"], ["LP149220-8", "Presence"], ["LP17763-1", "A"], ["LA14109-5", "Fibrotic"], ["LP263828-8", "Stricture"], ["LA14161-6", "May"], ["LA31426-2", "Surgical"], ["LP94823-9", "Treatment"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["MTHU060561", "inFLIXimab"], ["LA14960-1", "Worsens"], ["LA22025-3", "OR"], ["LA14109-5", "Fibrotic"], ["LA30751-4", "Serious"], ["LP74970-2", "Infections"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["MTHU010047", "Age"], ["LA14973-4", "Some"], ["LP17763-1", "A"], ["LA32822-1", "Fatal"], ["LA22668-0", "Attention"], ["LP266919-2", "Infection"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP62263-6", "Population"], ["LP74970-2", "Infections"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LP74970-2", "Infections"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA13524-6", "Adult"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["MTHU000146", "Vaccinations"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA15097-1", "Possible"], ["LP182451-7", "Date"], ["LA18187-7", "All"], ["MTHU000146", "Vaccinations"], ["LA22004-8", "IN"], ["MTHU052654", "Agreement"], ["LA33028-4", "Prior"], ["MTHU060561", "inFLIXimab"], ["LP267221-2", "Therapy"], ["MTHU060561", "inFLIXimab"], ["LA14161-6", "May"], ["MTHU000146", "Vaccinations"], ["LA20283-0", "Vaccines"], ["LA15768-7", "4.5"], ["LP20592-9", "4"], ["LP20594-5", "6"], ["LA14973-4", "Some"], ["LA32822-1", "Fatal"], ["LP6486-7", "Reported"], ["MTHU010047", "Age"], ["LP267221-2", "Therapy"], ["MTHU010047", "Age"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["LP32606-3", "post"], ["MTHU047625", "Setting"], ["LP270144-1", "Cases"], ["MTHU029809", "Other"], ["LP270144-1", "Cases"], ["LP17763-1", "A"], ["LA15679-6", "Rare"], ["LA14747-2", "Usually"], ["LP17763-1", "A"], ["LA22004-8", "IN"], ["LP32606-3", "post"], ["LP270144-1", "Cases"], ["LP14634-7", "T-cell"], ["LA15685-3", "Lymphoma"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LA15679-6", "Rare"], ["LP6886-8", "Type"], ["LP14634-7", "T-cell"], ["LA15685-3", "Lymphoma"], ["LP17763-1", "A"], ["LA29696-4", "Very"], ["LA18199-2", "Disease"], ["LP200075-2", "IS"], ["LA14747-2", "Usually"], ["LA32822-1", "Fatal"], ["LA18187-7", "All"], ["LA32660-5", "Received"], ["LP94823-9", "Treatment"], ["LA22025-3", "OR"], ["LP20594-5", "6"], ["LA22025-3", "OR"], ["LA33028-4", "Prior"], ["LP17763-1", "A"], ["MTHU060561", "inFLIXimab"], ["LP270144-1", "Cases"], ["LA22004-8", "IN"], ["LP15241-0", "S"], ["LA18199-2", "Disease"], ["LA22025-3", "OR"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LA19749-3", "Adolescent"], ["LA22025-3", "OR"], ["LA13524-6", "Adult"], ["LA12701-1", "Combination"], ["LA22025-3", "OR"], ["LP20594-5", "6"], ["MTHU060561", "inFLIXimab"], ["LP17763-1", "A"], ["LP14634-7", "T-cell"], ["LA15685-3", "Lymphoma"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP15099-2", "Sodium"], ["LA16823-9", "Less"], ["LA6112-2", "1"], ["LP15099-2", "Sodium"], ["LP15217-0", "Mg"], ["MTHU065481", "Dose"], ["LA15457-7", "I"], ["LA13503-0", "E"], ["LP15099-2", "Sodium"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP15099-2", "Sodium"], ["LP15483-8", "Chloride"], ["LA10141-2", "9"], ["LP15217-0", "Mg"], ["LA24587-0", "0.9"], ["LP263434-5", "Infusion"], ["LP17763-1", "A"], ["LP15099-2", "Sodium"], ["MTHU053295", "Diet"], ["LP20594-5", "6"], ["LP20594-5", "6"]], "snomed.pregnancy": [["373067005", "No (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["1222741009", "American Joint Committee on Cancer stage I:4 (qualifier value)"], ["18720000", "In (attribute)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["266517004", "Crohn's disease (& [regional enteritis]) (disorder)|Crohn's disease (& [regional enteritis])"], ["79970003", "Simultaneous (qualifier value)"], ["260676000", "Use of (attribute)"], ["387381009", "Methotrexate (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["65897001", "Against (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["50863008", "Plasma (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["394425009", "Uncertain|Uncertain (qualifier value)"], ["42752001", "Due to (attribute)"], ["18720000", "In (attribute)"], ["86495002", "For (qualifier value)"], ["67922002", "Serum (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["65897001", "Against (qualifier value)"], ["386891004", "Infliximab (substance)"], ["79440004", "Product containing corticosteroid (product)|Product containing corticosteroid and/or corticosteroid derivative (product)|Corticoid preparation (product)|Product containing corticosteroid and corticosteroid derivative (product)|Corticoid preparation (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260858005", "Extent (attribute)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["262126009", "Same (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["55919000", "Including (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421777009", "Abatacept (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255234002", "After (attribute)"], ["18720000", "In (attribute)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["386891004", "Infliximab (substance)"], ["86495002", "For (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258706009", "month (qualifier value)"], ["255260001", "Following (attribute)"], ["3950001", "Birth (finding)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["133931009", "Infant (person)"], ["386891004", "Infliximab (substance)"], ["67922002", "Serum (substance)"], ["258395000", "Levels (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["416118004", "Administration (procedure)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255246003", "First trimester (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["398827000", "Vaccine (substance)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["116680003", "Is a (attribute)"], ["263707001", "Clear (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["86495002", "For (qualifier value)"], ["385435006", "Individual (person)"], ["133931009", "Infant (person)"], ["732727007", "4.4 (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["398827000", "Vaccine (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["133931009", "Infant (person)"], ["394651000", "Mother (person)|Mother"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["386891004", "Infliximab (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["133931009", "Infant (person)"], ["386891004", "Infliximab (substance)"], ["67922002", "Serum (substance)"], ["258395000", "Levels (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732731001", "4.6 (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["732727007", "4.4 (qualifier value)"]], "ncit.pregnancy": [["C159586", "Preoperative IV Sedation was Not Administered"], ["C54216", "Interaction"], ["C101282", "Have"], ["C38000", "Performed"], ["C113428", "Fourteen"], ["C16727", "India"], ["C2884", "Rheumatoid Arthritis"], ["C61277", "Psoriatic Arthritis"], ["C16289", "Andorra"], ["C2965", "Crohn Disease"], ["C16960", "Patient"], ["C68869", "Are"], ["C25730", "Concomitant"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C642", "Methotrexate"], ["C16289", "Andorra"], ["C118472", "Other License Status"], ["C308", "Immunotherapeutic Agent"], ["C25513", "Formation"], ["C52874", "SPI1 wt Allele"], ["C16295", "Antibody"], ["C64937", "Against"], ["C1789", "Infliximab"], ["C16289", "Andorra"], ["C13356", "Plasma"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C68869", "Are"], ["C125071", "Uncertain if Satisfied or Dissatisfied"], ["C89272", "Due To"], ["C16727", "India"], ["C16847", "Technique"], ["C64956", "For"], ["C13325", "Serum"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C16289", "Andorra"], ["C16295", "Antibody"], ["C64937", "Against"], ["C1789", "Infliximab"], ["C211", "Therapeutic Corticosteroid"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C179695", "Specimen Appearance Assessment"], ["C159124", "GDC Treatment Outcome Terminology"], ["C15299", "Pharmacokinetics"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C70664", "Relevance"], ["C25332", "Extent"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C62355", "With"], ["C118472", "Other License Status"], ["C28226", "Biological"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49236", "Therapeutic Procedure"], ["C172515", "S-Adenosylmethionine Measurement"], ["C25457", "Condition"], ["C71344", "Associate of Science"], ["C1789", "Infliximab"], ["C166400", "Inclusive"], ["C38717", "Anakinra"], ["C16289", "Andorra"], ["C28898", "Abatacept"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C89279", "Reside"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C64974", "Give"], ["C62355", "With"], ["C1789", "Infliximab"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C89279", "Reside"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C64974", "Give"], ["C159124", "GDC Treatment Outcome Terminology"], ["C38008", "Post"], ["C49641", "In Utero"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1789", "Infliximab"], ["C64956", "For"], ["C156842", "12 Months"], ["C53286", "Next"], ["C25155", "Birth"], ["C198613", "CFI wt Allele"], ["C27956", "Infant"], ["C1789", "Infliximab"], ["C13325", "Serum"], ["C68869", "Are"], ["C111568", "Undetectable"], ["C43508", "Oregon"], ["C1789", "Infliximab"], ["C70962", "Agent Administration"], ["C154196", "Washo Language"], ["C142988", "Limited"], ["C159124", "GDC Treatment Outcome Terminology"], ["C92799", "First Trimester"], ["C52874", "SPI1 wt Allele"], ["C191656", "Pregnant Subject"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C89279", "Reside"], ["C923", "Vaccine"], ["C16329", "Belgium"], ["C158997", "GDC Analyte Type Terminology"], ["C75889", "PAX6 wt Allele"], ["C68568", "Timepoint"], ["C198613", "CFI wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C48621", "Negative Surgical Margin"], ["C142422", "Clinical Benefit"], ["C64956", "For"], ["C25190", "Person"], ["C27956", "Infant"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C89279", "Reside"], ["C923", "Vaccine"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C27956", "Infant"], ["C25189", "Mother"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25639", "Receive"], ["C1789", "Infliximab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C27956", "Infant"], ["C1789", "Infliximab"], ["C13325", "Serum"], ["C68869", "Are"], ["C111568", "Undetectable"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C172979", "Fear Score 6"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C25277", "Therapeutic"], ["C14316", "Infectious Agent"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C64974", "Give"], ["C62355", "With"], ["C1789", "Infliximab"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"]], "rxnorm.pregnancy": [["6851", "methotrexate"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["72435", "anakinra"], ["614391", "abatacept"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"]], "loinc.pregnancy": [["LA32-8", "No"], ["LA19974-7", "Performed"], ["LA14560-9", "14"], ["LA22004-8", "IN"], ["LA15161-5", "Rheumatoid Arthritis"], ["MTHU020793", "Arthritis"], ["LA10554-6", "Crohn's Disease"], ["MTHU008862", "Indications"], ["LP16198-1", "Methotrexate"], ["MTHU029809", "Other"], ["LP17807-6", "Antibodies"], ["MTHU060561", "inFLIXimab"], ["LA14961-9", "Increases"], ["LP7479-1", "Plasma"], ["MTHU060561", "inFLIXimab"], ["LA12719-3", "Uncertain"], ["LA22004-8", "IN"], ["LP7567-3", "Serum"], ["MTHU060561", "inFLIXimab"], ["LP17807-6", "Antibodies"], ["MTHU060561", "inFLIXimab"], ["LA14426-3", "Do not"], ["MTHU060561", "inFLIXimab"], ["LP17763-1", "A"], ["LA12701-1", "Combination"], ["MTHU060561", "inFLIXimab"], ["MTHU029809", "Other"], ["LA25433-6", "Biological"], ["LA11009-0", "Same"], ["MTHU060561", "inFLIXimab"], ["LP191906-9", "Anakinra"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA20283-0", "Vaccines"], ["LA21291-2", "Not"], ["LP29256-2", "given"], ["MTHU060561", "inFLIXimab"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA20283-0", "Vaccines"], ["LA21291-2", "Not"], ["LP29256-2", "given"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LP189870-1", "12 months"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA19747-7", "Infant"], ["MTHU060561", "inFLIXimab"], ["LP7567-3", "Serum"], ["LA22025-3", "OR"], ["MTHU060561", "inFLIXimab"], ["LA6484-5", "Limited"], ["LP208035-8", "First trimester"], ["LP207970-7", "Pregnancy"], ["LP17763-1", "A"], ["LP30374-0", "Vaccine"], ["LA21988-3", "AT"], ["LA14566-6", "Earlier"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LA19732-9", "Clear"], ["LP7787-7", "Clinical"], ["LA12070-1", "Individual"], ["LA19747-7", "Infant"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP17763-1", "A"], ["LP30374-0", "Vaccine"], ["LP17763-1", "A"], ["LA19747-7", "Infant"], ["LP6983-3", "Mother"], ["LP200075-2", "IS"], ["MTHU060561", "inFLIXimab"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA19747-7", "Infant"], ["MTHU060561", "inFLIXimab"], ["LP7567-3", "Serum"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20594-5", "6"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP263807-2", "Therapeutic"], ["LA21291-2", "Not"], ["LP29256-2", "given"], ["MTHU060561", "inFLIXimab"], ["LP20592-9", "4"], ["LP20592-9", "4"]], "snomed.driving": [["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["260676000", "Use of (attribute)"], ["88323005", "Adequate (qualifier value)"], ["146680009", "Contraception|Contraception (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["101445003", "PREVENT (substance)|PREVENT (product)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["86495002", "For (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258706009", "month (qualifier value)"], ["255234002", "After (attribute)"], ["386891004", "Infliximab (substance)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["260354000", "Moderate number (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["386891004", "Infliximab (substance)"], ["79409006", "Resulting in (attribute)"], ["3950001", "Birth (finding)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["36692007", "Known (qualifier value)"], ["55919000", "Including (qualifier value)"], ["26175008", "Approximate (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["255246003", "First trimester (qualifier value)"], ["717896003", "Does not (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["21390004", "Developmental anomaly (morphologic abnormality)"], ["18720000", "In (attribute)"], ["133933007", "Newborn (person)"], ["420862001", "On (qualifier value)"], ["224699009", "Study (environment)"], ["223502009", "Europe (geographic location)"], ["35105006", "Increased (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["732906005", "95 (qualifier value)"], ["282109005", "Curie (qualifier value)|Ci (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["86495002", "For (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732774003", "50 (qualifier value)"], ["732410003", "1.14 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732907001", "96 (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["276136004", "Equal symbol = (qualifier value)|= (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["3950001", "Birth (finding)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222851003", "American Joint Committee on Cancer stage IV:8 (qualifier value)"], ["783761000", "1.05 (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["276136004", "Equal symbol = (qualifier value)|= (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["255507004", "Small (qualifier value)"], ["86495002", "For (qualifier value)"], ["255402008", "Gestational (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732789007", "54 (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["276136004", "Equal symbol = (qualifier value)|= (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["276610007", "Low birth weight infant (disorder)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222844007", "American Joint Committee on Cancer stage IV:1 (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["276136004", "Equal symbol = (qualifier value)|= (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["18720000", "In (attribute)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["45169001", "Without (attribute)"], ["79440004", "Product containing corticosteroid (product)|Product containing corticosteroid and/or corticosteroid derivative (product)|Corticoid preparation (product)|Product containing corticosteroid and corticosteroid derivative (product)|Corticoid preparation (substance)"], ["732631008", "270 (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["79440004", "Product containing corticosteroid (product)|Product containing corticosteroid and/or corticosteroid derivative (product)|Corticoid preparation (product)|Product containing corticosteroid and corticosteroid derivative (product)|Corticoid preparation (substance)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["871793007", "460 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["386891004", "Infliximab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["246112005", "Severity (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["64572001", "Disease (disorder)"], ["18720000", "In (attribute)"], ["42752001", "Due to (attribute)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["386891004", "Infliximab (substance)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["17621005", "Normal (qualifier value)"], ["255386009", "Immune (qualifier value)"], ["18720000", "In (attribute)"], ["133933007", "Newborn (person)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["278923009", "Developmental (qualifier value)"], ["75478009", "Poisoning (disorder)"], ["224699009", "Study (environment)"], ["18720000", "In (attribute)"], ["261583007", "Using (attribute)"], ["68498002", "Antibody (substance)"], ["40143009", "Functional (qualifier value)"], ["257733005", "Activity (observable entity)|Activities (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["82968002", "Mouse (organism)"], ["8612007", "Tumor necrosis factor (substance)"], ["71653005", "No indication of (contextual qualifier) (qualifier value)"], ["1269485005", "Maternal (qualifier value)"], ["75478009", "Poisoning (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["58694006", "Teratogenesis (finding)"], ["769082003", "5.3 (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["386891004", "Infliximab (substance)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["410525008", "Needed (qualifier value)"], ["386891004", "Infliximab (substance)"], ["181455002", "Entire placenta (body structure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260373001", "Detected (qualifier value)"], ["18720000", "In (attribute)"], ["67922002", "Serum (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258706009", "month (qualifier value)"], ["255260001", "Following (attribute)"], ["3950001", "Birth (finding)"], ["255234002", "After (attribute)"], ["18720000", "In (attribute)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["386891004", "Infliximab (substance)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["55919000", "Including (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["65709003", "Disseminated (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["429308001", "Can - unit of product usage (qualifier value)"], ["399166001", "Fatal (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["396419007", "BCG vaccine (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["386891004", "Infliximab (substance)"], ["18720000", "In (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["86495002", "For (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258706009", "month (qualifier value)"], ["255234002", "After (attribute)"], ["3950001", "Birth (finding)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["133931009", "Infant (person)"], ["386891004", "Infliximab (substance)"], ["67922002", "Serum (substance)"], ["258395000", "Levels (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386891004", "Infliximab (substance)"], ["416118004", "Administration (procedure)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255246003", "First trimester (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["398827000", "Vaccine (substance)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["116680003", "Is a (attribute)"], ["263707001", "Clear (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["86495002", "For (qualifier value)"], ["385435006", "Individual (person)"], ["133931009", "Infant (person)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["191336001", "(Agranulocytosis) or (Kostmann's syndrome) or (neutropenia)|(Agranulocytosis) or (Kostmann's syndrome) or (neutropenia) (disorder)"], ["733985002", "Reported (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["386891004", "Infliximab (substance)"], ["260373001", "Detected (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["62482003", "Low (qualifier value)"], ["258395000", "Levels (qualifier value)"], ["18720000", "In (attribute)"], ["338930006", "Human (organism)"], ["70813002", "Milk (substance)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1269485005", "Maternal (qualifier value)"], ["67922002", "Serum (substance)"], ["276625007", "Level (attribute)"], ["386891004", "Infliximab (substance)"], ["260373001", "Detected (qualifier value)"], ["18720000", "In (attribute)"], ["133931009", "Infant (person)"], ["67922002", "Serum (substance)"], ["255234002", "After (attribute)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["386891004", "Infliximab (substance)"], ["226789007", "Breast milk (substance)"], ["31099001", "Systemic (qualifier value)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["133931009", "Infant (person)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["62482003", "Low (qualifier value)"], ["386891004", "Infliximab (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["279972009", "Entire gastrointestinal tract (body structure)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["133931009", "Infant (person)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["394651000", "Mother (person)|Mother"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["386891004", "Infliximab (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["133931009", "Infant (person)"], ["386891004", "Infliximab (substance)"], ["67922002", "Serum (substance)"], ["258395000", "Levels (qualifier value)"], ["386891004", "Infliximab (substance)"], ["86495002", "For (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["423437008", "Insufficient (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["420862001", "On (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["60132005", "Generalized (qualifier value)"], ["118255001", "Reproductive function (function)|Reproductive function (observable entity)"], ["769082003", "5.3 (qualifier value)"]], "ncit.driving": [["C161316", "Female of Childbearing Potential"], ["C161316", "Female of Childbearing Potential"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C168111", "Adequate Daily Fluid Intake"], ["C37932", "Contraception"], ["C159124", "GDC Treatment Outcome Terminology"], ["C191656", "Pregnant Subject"], ["C16289", "Andorra"], ["C54064", "Continue"], ["C25340", "Use"], ["C64956", "For"], ["C158997", "GDC Analyte Type Terminology"], ["C172979", "Fear Score 6"], ["C29846", "Month"], ["C38008", "Post"], ["C25551", "Last"], ["C1789", "Infliximab"], ["C43442", "Biomaterial Treatment"], ["C191656", "Pregnant Subject"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C25463", "Count"], ["C52874", "SPI1 wt Allele"], ["C170548", "Collected Value"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1789", "Infliximab"], ["C16727", "India"], ["C89279", "Reside"], ["C25155", "Birth"], ["C62355", "With"], ["C80137", "Known"], ["C166400", "Inclusive"], ["C45828", "Approximate"], ["C105723", "ECOG Performance Status 1"], ["C105814", "One Hundred"], ["C25490", "During"], ["C92799", "First Trimester"], ["C86066", "Do"], ["C25594", "Negation"], ["C75889", "PAX6 wt Allele"], ["C25533", "Increase"], ["C16727", "India"], ["C77538", "Rating"], ["C52874", "SPI1 wt Allele"], ["C36287", "Congenital or Acquired Anatomic Abnormality"], ["C16727", "India"], ["C16731", "Newborn"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C75889", "PAX6 wt Allele"], ["C16084", "Observational Study"], ["C25516", "From"], ["C45849", "North"], ["C26274", "Europe"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C17102", "Risk"], ["C43508", "Oregon"], ["C112239", "Coagulation Index Measurement"], ["C44185", "P-Value"], ["C64956", "For"], ["C46088", "Cesarean Section"], ["C105723", "ECOG Performance Status 1"], ["C105785", "Fifty"], ["C105723", "ECOG Performance Status 1"], ["C113428", "Fourteen"], ["C105723", "ECOG Performance Status 1"], ["C192182", "Ninety Six"], ["C68277", "Dietary Phosphorus"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C92861", "Preterm Birth"], ["C105723", "ECOG Performance Status 1"], ["C175678", "Forty Eight"], ["C105723", "ECOG Performance Status 1"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C68277", "Dietary Phosphorus"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C16292", "Angola"], ["C25376", "Small"], ["C64956", "For"], ["C81253", "Gestational Weeks Assessment"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C105791", "Seventy Nine"], ["C105723", "ECOG Performance Status 1"], ["C186754", "Human Papillomavirus-54"], ["C163771", "Illness Intrusiveness Rating 5"], ["C68277", "Dietary Phosphorus"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C16289", "Andorra"], ["C34724", "Low Birth Weight"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C105723", "ECOG Performance Status 1"], ["C178273", "Forty One"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C68277", "Dietary Phosphorus"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C154196", "Washo Language"], ["C25599", "Observed"], ["C16727", "India"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1789", "Infliximab"], ["C62355", "With"], ["C43508", "Oregon"], ["C25718", "Without"], ["C308", "Immunotherapeutic Agent"], ["C211", "Therapeutic Corticosteroid"], ["C16598", "The Gambia"], ["C71344", "Associate of Science"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C159124", "GDC Treatment Outcome Terminology"], ["C308", "Immunotherapeutic Agent"], ["C48928", "And/Or"], ["C211", "Therapeutic Corticosteroid"], ["C48440", "Single"], ["C172979", "Fear Score 6"], ["C62230", "Potential"], ["C61412", "Contribution"], ["C52874", "SPI1 wt Allele"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1789", "Infliximab"], ["C48928", "And/Or"], ["C25676", "Severity"], ["C52874", "SPI1 wt Allele"], ["C154417", "Underlying"], ["C2991", "Disease or Disorder"], ["C16727", "India"], ["C150000", "Unclear State of Matter"], ["C89272", "Due To"], ["C42791", "Inhibition"], ["C52874", "SPI1 wt Allele"], ["C18368", "TNF Gene"], ["C1789", "Infliximab"], ["C25382", "Administered"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C12801", "Tissue"], ["C17997", "Immune"], ["C16727", "India"], ["C16731", "Newborn"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C168182", "Developmental Finding"], ["C27990", "Toxicity"], ["C45319", "Study Object"], ["C16727", "India"], ["C14238", "Mouse"], ["C75889", "PAX6 wt Allele"], ["C16295", "Antibody"], ["C75924", "Functional Relationship"], ["C120914", "Physical Activity Measurement"], ["C52874", "SPI1 wt Allele"], ["C14238", "Mouse"], ["C18368", "TNF Gene"], ["C154196", "Washo Language"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C41184", "Indication"], ["C52874", "SPI1 wt Allele"], ["C89336", "Maternal"], ["C27990", "Toxicity"], ["C43508", "Oregon"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C25429", "Availability"], ["C123619", "Clinical Response"], ["C54627", "Experience"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C142988", "Limited"], ["C1789", "Infliximab"], ["C48440", "Single"], ["C16329", "Belgium"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C198613", "CFI wt Allele"], ["C1789", "Infliximab"], ["C13272", "Placenta"], ["C16289", "Andorra"], ["C101282", "Have"], ["C16210", "Detection"], ["C16727", "India"], ["C13325", "Serum"], ["C52874", "SPI1 wt Allele"], ["C64643", "Up to"], ["C156842", "12 Months"], ["C53286", "Next"], ["C25155", "Birth"], ["C38008", "Post"], ["C49641", "In Utero"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1789", "Infliximab"], ["C106184", "May"], ["C16329", "Belgium"], ["C158997", "GDC Analyte Type Terminology"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C128320", "Infection"], ["C113429", "Fifteen"], ["C166400", "Inclusive"], ["C54035", "Serious"], ["C28222", "Disseminate"], ["C128320", "Infection"], ["C52288", "NUP214 wt Allele"], ["C48275", "Death Related to Adverse Event"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C89279", "Reside"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C298", "BCG Vaccine"], ["C159124", "GDC Treatment Outcome Terminology"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1789", "Infliximab"], ["C49641", "In Utero"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C64956", "For"], ["C156842", "12 Months"], ["C38008", "Post"], ["C25155", "Birth"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C198613", "CFI wt Allele"], ["C27956", "Infant"], ["C1789", "Infliximab"], ["C13325", "Serum"], ["C68869", "Are"], ["C111568", "Undetectable"], ["C43508", "Oregon"], ["C1789", "Infliximab"], ["C70962", "Agent Administration"], ["C154196", "Washo Language"], ["C142988", "Limited"], ["C159124", "GDC Treatment Outcome Terminology"], ["C92799", "First Trimester"], ["C52874", "SPI1 wt Allele"], ["C191656", "Pregnant Subject"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C89279", "Reside"], ["C923", "Vaccine"], ["C16329", "Belgium"], ["C158997", "GDC Analyte Type Terminology"], ["C75889", "PAX6 wt Allele"], ["C68568", "Timepoint"], ["C198613", "CFI wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C48621", "Negative Surgical Margin"], ["C142422", "Clinical Benefit"], ["C64956", "For"], ["C25190", "Person"], ["C27956", "Infant"], ["C52874", "SPI1 wt Allele"], ["C107102", "Agranulocytosis"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C142988", "Limited"], ["C25474", "Data"], ["C25516", "From"], ["C19026", "Scientific Publication"], ["C48471", "Publication"], ["C1789", "Infliximab"], ["C101282", "Have"], ["C16210", "Detection"], ["C158997", "GDC Analyte Type Terminology"], ["C139301", "IPSS Risk Category Low"], ["C16727", "India"], ["C14225", "Human"], ["C13257", "Mammary Gland Milk"], ["C158997", "GDC Analyte Type Terminology"], ["C64643", "Up to"], ["C163771", "Illness Intrusiveness Rating 5"], ["C52874", "SPI1 wt Allele"], ["C89336", "Maternal"], ["C13325", "Serum"], ["C25554", "Level"], ["C1789", "Infliximab"], ["C101282", "Have"], ["C16210", "Detection"], ["C16727", "India"], ["C27956", "Infant"], ["C13325", "Serum"], ["C38008", "Post"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1789", "Infliximab"], ["C113553", "SEMA6A wt Allele"], ["C13257", "Mammary Gland Milk"], ["C13310", "Systemic"], ["C49587", "Exposure Domain"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C27956", "Infant"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C41333", "Expected Adverse Event"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C139301", "IPSS Risk Category Low"], ["C1789", "Infliximab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C62970", "Degradation"], ["C16727", "India"], ["C34082", "Gastrointestinal Tract"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C89279", "Reside"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C27956", "Infant"], ["C65140", "When"], ["C25189", "Mother"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25639", "Receive"], ["C1789", "Infliximab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C27956", "Infant"], ["C1789", "Infliximab"], ["C13325", "Serum"], ["C68869", "Are"], ["C111568", "Undetectable"], ["C1789", "Infliximab"], ["C16329", "Belgium"], ["C64956", "For"], ["C25340", "Use"], ["C25490", "During"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C95089", "Fertility Domain"], ["C68869", "Are"], ["C126862", "Unsatisfactory"], ["C48674", "Preclinical"], ["C25474", "Data"], ["C159124", "GDC Treatment Outcome Terminology"], ["C54353", "Draw"], ["C92667", "SPARC wt Allele"], ["C25492", "Effect"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C92667", "SPARC wt Allele"], ["C95089", "Fertility Domain"], ["C16289", "Andorra"], ["C115727", "Safety Reporting Documentation"], ["C17087", "Reproduction"], ["C25518", "Function"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"]], "rxnorm.driving": [["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["T052", "Activity"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["T016", "Human"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"], ["191831", "infliximab"]], "loinc.driving": [["LA8913-1", "Adequate"], ["LP207970-7", "Pregnancy"], ["LA9507-0", "Continue"], ["LA21988-3", "AT"], ["LP203021-3", "6 months"], ["MTHU060561", "inFLIXimab"], ["LP94823-9", "Treatment"], ["LP207970-7", "Pregnancy"], ["LA6751-7", "Moderate"], ["LP18011-4", "Number"], ["LP73139-5", "Pregnancies"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["LA6112-2", "1"], ["LA19244-5", "100"], ["LP208035-8", "First trimester"], ["LA21291-2", "Not"], ["LA32048-3", "Increase"], ["LA22004-8", "IN"], ["MTHU027852", "Rate"], ["LA22004-8", "IN"], ["LP7744-8", "Newborn"], ["LP74341-6", "Study"], ["LA31575-6", "Europe"], ["LA24544-1", "Increased risk"], ["LA22025-3", "OR"], ["LP15232-9", "P"], ["LP17128-7", "C"], ["LA6112-2", "1"], ["LA28854-0", "50"], ["LA6112-2", "1"], ["LA14560-9", "14"], ["LA6112-2", "1"], ["LP15232-9", "P"], ["LA6111-4", "0"], ["LA6112-2", "1"], ["LA24588-8", "1.05"], ["MTHU000002", "Clinical Class"], ["LP15232-9", "P"], ["LA6111-4", "0"], ["LA8983-4", "Small"], ["18185-9", "Gestational age:Time:Pt:^Fetus:Qn"], ["MTHU000002", "Clinical Class"], ["LA6112-2", "1"], ["LP20593-7", "5"], ["LP15232-9", "P"], ["LA6111-4", "0"], ["LA9194-7", "Low"], ["LP221195-3", "Weight"], ["MTHU000002", "Clinical Class"], ["LA6112-2", "1"], ["MTHU000002", "Clinical Class"], ["LP15232-9", "P"], ["LA6111-4", "0"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LP266032-4", "during pregnancy"], ["MTHU060561", "inFLIXimab"], ["LA22025-3", "OR"], ["LP73139-5", "Pregnancies"], ["LA22025-3", "OR"], ["LP20594-5", "6"], ["LP73139-5", "Pregnancies"], ["MTHU060561", "inFLIXimab"], ["LA22025-3", "OR"], ["LA26681-9", "Underlying"], ["LA18199-2", "Disease"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LP266032-4", "during pregnancy"], ["LA6626-1", "Normal"], ["LA27183-5", "Immune"], ["LA22004-8", "IN"], ["LP7744-8", "Newborn"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP74341-6", "Study"], ["LA22004-8", "IN"], ["LA12069-3", "Functional"], ["LP72045-5", "Activity"], ["LP14470-6", "Mouse"], ["LA32-8", "No"], ["LA26320-4", "Maternal"], ["LA22025-3", "OR"], ["LP20593-7", "5"], ["LP20591-1", "3"], ["LP7787-7", "Clinical"], ["LP200075-2", "IS"], ["LA6484-5", "Limited"], ["MTHU060561", "inFLIXimab"], ["LP266032-4", "during pregnancy"], ["LP6323-2", "Immunofluorescence (IF)"], ["MTHU060561", "inFLIXimab"], ["LP208379-0", "Placenta"], ["LA11882-0", "Detected"], ["LA22004-8", "IN"], ["LP7567-3", "Serum"], ["LP189870-1", "12 months"], ["LA22004-8", "IN"], ["MTHU060561", "inFLIXimab"], ["LA14161-6", "May"], ["LA21988-3", "AT"], ["LA24544-1", "Increased risk"], ["LP266919-2", "Infection"], ["LA14561-7", "15"], ["LA30751-4", "Serious"], ["LP266919-2", "Infection"], ["LA32822-1", "Fatal"], ["LA20283-0", "Vaccines"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP102323-5", "Bromocresol green (BCG) dye binding method"], ["LP30374-0", "Vaccine"], ["MTHU060561", "inFLIXimab"], ["LA22004-8", "IN"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP189870-1", "12 months"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA15768-7", "4.5"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA19747-7", "Infant"], ["MTHU060561", "inFLIXimab"], ["LP7567-3", "Serum"], ["LA22025-3", "OR"], ["MTHU060561", "inFLIXimab"], ["LA6484-5", "Limited"], ["LP208035-8", "First trimester"], ["LP207970-7", "Pregnancy"], ["LP17763-1", "A"], ["LP30374-0", "Vaccine"], ["LA21988-3", "AT"], ["LA14566-6", "Earlier"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LA19732-9", "Clear"], ["LP7787-7", "Clinical"], ["LA12070-1", "Individual"], ["LA19747-7", "Infant"], ["LP270144-1", "Cases"], ["LP6486-7", "Reported"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LA6484-5", "Limited"], ["MTHU060561", "inFLIXimab"], ["LA11882-0", "Detected"], ["LA21988-3", "AT"], ["LA9194-7", "Low"], ["LA22004-8", "IN"], ["LA19711-3", "Human"], ["LP29290-1", "Milk"], ["LA21988-3", "AT"], ["LP20593-7", "5"], ["LA26320-4", "Maternal"], ["LP7567-3", "Serum"], ["MTHU060561", "inFLIXimab"], ["LA11882-0", "Detected"], ["LA22004-8", "IN"], ["LA19747-7", "Infant"], ["LP7567-3", "Serum"], ["MTHU060561", "inFLIXimab"], ["LA16914-6", "Breast milk"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA19747-7", "Infant"], ["LP200075-2", "IS"], ["LA9194-7", "Low"], ["MTHU060561", "inFLIXimab"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP76054-3", "Gastrointestinal tract"], ["LA20283-0", "Vaccines"], ["LP17763-1", "A"], ["LA19747-7", "Infant"], ["LP6983-3", "Mother"], ["LP200075-2", "IS"], ["MTHU060561", "inFLIXimab"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA19747-7", "Infant"], ["MTHU060561", "inFLIXimab"], ["LP7567-3", "Serum"], ["MTHU060561", "inFLIXimab"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["MTHU000074", "Fertility"], ["LA28127-1", "Insufficient"], ["MTHU032359", "Conclusions"], ["MTHU060561", "inFLIXimab"], ["MTHU000074", "Fertility"], ["LA17571-3", "General"], ["LA28307-9", "Reproductive function"], ["LP20593-7", "5"], ["LP20591-1", "3"]], "snomed.side_effects": [["422097006", "Upper case Roman letter A (qualifier value)"], ["410599005", "Minor (person)"], ["420862001", "On (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["247750002", "Drive (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["404640003", "Dizziness (finding)"], ["255260001", "Following (attribute)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386891004", "Infliximab (substance)"], ["732732008", "4.8 (qualifier value)"]], "ncit.side_effects": [["C1789", "Infliximab"], ["C106184", "May"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C45367", "Minor"], ["C121660", "Influence"], ["C92667", "SPARC wt Allele"], ["C121232", "Ability to Drive"], ["C16289", "Andorra"], ["C25340", "Use"], ["C125409", "Have Dizziness"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C53286", "Next"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C1789", "Infliximab"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"]], "rxnorm.side_effects": [["191831", "infliximab"]], "loinc.side_effects": [["LA14161-6", "May"], ["LP17763-1", "A"], ["LA29633-7", "Minor"], ["LA7428-1", "Dizziness"], ["LA14161-6", "May"], ["MTHU060561", "inFLIXimab"], ["LP20592-9", "4"], ["LP36791-9", "8"]], "snomed.shelf_life": [["421718005", "Before - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["258707000", "year (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["86495002", "For (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258706009", "month (qualifier value)"], ["19535007", "Original (qualifier value)"], ["410672004", "Date property (qualifier value)"], ["261021004", "New (qualifier value)|New [dup] (qualifier value)"], ["410672004", "Date property (qualifier value)"], ["420862001", "On (qualifier value)"], ["420771004", "Upon - dosing instruction fragment (qualifier value)"], ["315350008", "Removal - procedure|Removal - procedure (procedure)"], ["440276004", "Storage (procedure)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["440276004", "Storage (procedure)"], ["255234002", "After (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["272390001", "Dilution (qualifier value)"], ["441900009", "Chemical (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["19388002", "Physical (qualifier value)"], ["18720000", "In (attribute)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["739006009", "Solution (basic dose form)"], ["86495002", "For (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["732814003", "60 (qualifier value)"], ["258703001", "day (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["123027009", "24 hours (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["255234002", "After (attribute)"], ["315350008", "Removal - procedure|Removal - procedure (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["246516004", "View (attribute)"], ["385229008", "Infusion solution (product)|Conventional release solution for infusion (dose form)|Infusion solution (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["18720000", "In (attribute)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["440276004", "Storage (procedure)"], ["417929005", "Times (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["288556008", "Before (attribute)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["123027009", "24 hours (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["272390001", "Dilution (qualifier value)"], ["421066005", "Place - dosing instruction imperative (qualifier value)"], ["18720000", "In (attribute)"], ["31509003", "Controlled (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260984003", "Aseptic (qualifier value)"]], "ncit.shelf_life": [["C201357", "Before Timing Type"], ["C163771", "Illness Intrusiveness Rating 5"], ["C29848", "Year"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67900", "Centi"], ["C66839", "Eight"], ["C67900", "Centi"], ["C1789", "Infliximab"], ["C106184", "May"], ["C16329", "Belgium"], ["C60824", "Storage"], ["C158997", "GDC Analyte Type Terminology"], ["C64643", "Up to"], ["C76246", "Blood Group A"], ["C82868", "Maximum Value Derivation Technique"], ["C52874", "SPI1 wt Allele"], ["C113663", "Twenty Five"], ["C67900", "Centi"], ["C64956", "For"], ["C76246", "Blood Group A"], ["C48440", "Single"], ["C25616", "Period"], ["C52874", "SPI1 wt Allele"], ["C64643", "Up to"], ["C172979", "Fear Score 6"], ["C29846", "Month"], ["C25594", "Negation"], ["C175323", "Exceed"], ["C25604", "Original"], ["C48871", "Date Data Type"], ["C94522", "New Lesion Identification"], ["C48871", "Date Data Type"], ["C16329", "Belgium"], ["C92667", "SPARC wt Allele"], ["C54702", "Carton Dosing Unit"], ["C65137", "Upon"], ["C61575", "Extraction"], ["C25516", "From"], ["C70718", "Refrigerated Specimen"], ["C60824", "Storage"], ["C1789", "Infliximab"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C106328", "Quantity Final Containers Returned"], ["C159124", "GDC Treatment Outcome Terminology"], ["C70718", "Refrigerated Specimen"], ["C60824", "Storage"], ["C38008", "Post"], ["C16289", "Andorra"], ["C64657", "Dilute"], ["C158345", "Chemical and Physical Restraint"], ["C16727", "India"], ["C25340", "Use"], ["C134030", "Stability Determination"], ["C52874", "SPI1 wt Allele"], ["C42986", "Solution Dosage Form"], ["C101282", "Have"], ["C64956", "For"], ["C64643", "Up to"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C25301", "Day"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67900", "Centi"], ["C159124", "GDC Treatment Outcome Terminology"], ["C66839", "Eight"], ["C67900", "Centi"], ["C16289", "Andorra"], ["C64956", "For"], ["C75889", "PAX6 wt Allele"], ["C25406", "Additional"], ["C113753", "Twenty Four"], ["C25529", "Hour"], ["C158997", "GDC Analyte Type Terminology"], ["C113663", "Twenty Five"], ["C67900", "Centi"], ["C38008", "Post"], ["C61575", "Extraction"], ["C25516", "From"], ["C25516", "From"], ["C76246", "Blood Group A"], ["C92081", "Microbial Contamination"], ["C70656", "Point"], ["C52874", "SPI1 wt Allele"], ["C80271", "View"], ["C15388", "Infusion Procedure"], ["C42986", "Solution Dosage Form"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C64597", "Immediately"], ["C16727", "India"], ["C25340", "Use"], ["C60824", "Storage"], ["C16289", "Andorra"], ["C25457", "Condition"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25340", "Use"], ["C68869", "Are"], ["C90023", "Responsibility"], ["C52874", "SPI1 wt Allele"], ["C42745", "System User"], ["C16289", "Andorra"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C113753", "Twenty Four"], ["C25529", "Hour"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67900", "Centi"], ["C66839", "Eight"], ["C67900", "Centi"], ["C64657", "Dilute"], ["C101282", "Have"], ["C25701", "Taken"], ["C126366", "Placement"], ["C16727", "India"], ["C82500", "Disease Controlled"], ["C16289", "Andorra"], ["C172871", "File Validated"], ["C63385", "Sterile"], ["C25457", "Condition"]], "rxnorm.shelf_life": [["T103", "Chemical"]], "loinc.shelf_life": [["LA31722-4", "5 years"], ["LA21988-3", "AT"], ["MTHU000002", "Clinical Class"], ["LP17128-7", "C"], ["LP36791-9", "8"], ["LP17128-7", "C"], ["LA14161-6", "May"], ["LA21988-3", "AT"], ["LP17763-1", "A"], ["LP6972-6", "maximum"], ["LA19281-7", "25"], ["LP17128-7", "C"], ["LP17763-1", "A"], ["LA17717-2", "Single"], ["LP20594-5", "6"], ["MTHU068094", "Months"], ["LA21291-2", "Not"], ["LA9505-4", "Original"], ["LP182451-7", "Date"], ["LA9039-4", "New"], ["LP182451-7", "Date"], ["LP263431-1", "Removal"], ["LA21291-2", "Not"], ["LP6228-3", "Dilution"], ["LA18356-8", "Chemical"], ["MTHU000078", "Physical"], ["LA22004-8", "IN"], ["MTHU015276", "Stability"], ["LA28853-2", "60"], ["LA8999-0", "Days"], ["LA21988-3", "AT"], ["MTHU000002", "Clinical Class"], ["LP17128-7", "C"], ["LP36791-9", "8"], ["LP17128-7", "C"], ["LP263791-8", "Additional"], ["LP6924-7", "24 hours"], ["LA21988-3", "AT"], ["LA19281-7", "25"], ["LP17128-7", "C"], ["LP263431-1", "Removal"], ["LP17763-1", "A"], ["LP28725-7", "Single view"], ["LP263434-5", "Infusion"], ["LA22004-8", "IN"], ["LA33028-4", "Prior"], ["LA21291-2", "Not"], ["LP6924-7", "24 hours"], ["LA21988-3", "AT"], ["MTHU000002", "Clinical Class"], ["LP17128-7", "C"], ["LP36791-9", "8"], ["LP17128-7", "C"], ["LP6228-3", "Dilution"], ["LA22004-8", "IN"]], "snomed.storage": [["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["21546008", "Refrigerator, device (physical object)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["86495002", "For (qualifier value)"], ["440276004", "Storage (procedure)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["763158003", "Medicinal product (product)"], ["732807000", "6.3 (qualifier value)"], ["1222818007", "American Joint Committee on Cancer stage III:7 (qualifier value)"], ["86495002", "For (qualifier value)"], ["440276004", "Storage (procedure)"], ["255234002", "After (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["763158003", "Medicinal product (product)"], ["732807000", "6.3 (qualifier value)"]], "ncit.storage": [["C60824", "Storage"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C178971", "Refrigerator"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67900", "Centi"], ["C66839", "Eight"], ["C67900", "Centi"], ["C64956", "For"], ["C60824", "Storage"], ["C25457", "Condition"], ["C64643", "Up to"], ["C113663", "Twenty Five"], ["C67900", "Centi"], ["C201357", "Before Timing Type"], ["C52874", "SPI1 wt Allele"], ["C142605", "Medicinal Product"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C175627", "Thirty Seven"], ["C64956", "For"], ["C60824", "Storage"], ["C25457", "Condition"], ["C38008", "Post"], ["C52874", "SPI1 wt Allele"], ["C142605", "Medicinal Product"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"]], "rxnorm.storage": [], "loinc.storage": [["LA22004-8", "IN"], ["LP17763-1", "A"], ["MTHU000002", "Clinical Class"], ["LP17128-7", "C"], ["LP36791-9", "8"], ["LP17128-7", "C"], ["LA19281-7", "25"], ["LP17128-7", "C"], ["LP20594-5", "6"], ["LP20591-1", "3"], ["LP20594-5", "6"], ["LP20591-1", "3"]], "snomed.package": [["258191002", "Type 1 (qualifier value)"], ["32039001", "Glass (substance)"], ["733026001", "Vial (unit of presentation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["43230003", "Rubber (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255977005", "Aluminum material (substance)"], ["19314006", "Seal (organism)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["420680007", "Off (qualifier value)"], ["228263000", "Button|Button (physical object)"], ["257260002", "Pack (physical object)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["415818006", "Vial (qualifier value)|Vial - unit of product usage (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["257260002", "Pack (physical object)"]], "ncit.package": [["C125394", "Bristol Stool Type 1"], ["C43209", "Glass Vial"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C96139", "Stopper Container Closure"], ["C16289", "Andorra"], ["C75889", "PAX6 wt Allele"], ["C50163", "Seal Device"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C96017", "CFLAR wt Allele"], ["C40450", "Off"], ["C84731", "Packing"], ["C52874", "SPI1 wt Allele"], ["C105723", "ECOG Performance Status 1"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C25594", "Negation"], ["C64916", "All"], ["C84731", "Packing"], ["C106184", "May"], ["C16329", "Belgium"]], "rxnorm.package": [["746839", "Pack"], ["746839", "Pack"]], "loinc.package": [["LP6886-8", "Type"], ["LA6112-2", "1"], ["LA20376-2", "Vial"], ["LP17763-1", "A"], ["LP17763-1", "A"], ["LA26227-1", "Off"], ["LA6112-2", "1"], ["MTHU000002", "Clinical Class"], ["LP20591-1", "3"], ["LP20592-9", "4"], ["LP20593-7", "5"], ["LA21291-2", "Not"], ["LA18187-7", "All"], ["LA14161-6", "May"]], "snomed.marketing_authorization_numbers": [["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222740005", "American Joint Committee on Cancer stage I:3 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222740005", "American Joint Committee on Cancer stage I:3 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222740005", "American Joint Committee on Cancer stage I:3 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222740005", "American Joint Committee on Cancer stage I:3 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222740005", "American Joint Committee on Cancer stage I:3 (qualifier value)"]], "ncit.marketing_authorization_numbers": [["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113427", "Thirteen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113427", "Thirteen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113427", "Thirteen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113427", "Thirteen"], ["C16267", "Afghanistan"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113427", "Thirteen"]], "rxnorm.marketing_authorization_numbers": [], "loinc.marketing_authorization_numbers": [["LA6112-2", "1"], ["LA14559-1", "13"], ["LA6112-2", "1"], ["LA14559-1", "13"], ["LA6112-2", "1"], ["LA14559-1", "13"], ["LA6112-2", "1"], ["LA14559-1", "13"], ["LA6112-2", "1"], ["LA14559-1", "13"]]}, {"product_info": "Humalog 100 units/ml solution for injection in vial \nHumalog 100 units/ml solution for injection in cartridge \nHumalog 100 units/ml KwikPen solution for injection in a pre-filled pen \nHumalog 100 units/ml Junior KwikPen solution for injection in a pre-filled pen \nHumalog 100 units/ml Tempo Pen solution for injection in a pre-filled pen", "composition": "Each ml contains 100 units of insulin lispro* (equivalent to 3.5mg).   \nVial \nEach vial contains 1000 units insulin lispro in 10 ml solution. \nCartridge \nEach cartridge contains 300 units of insulin lispro in 3 ml solution. \nKwikPen and Tempo Pen \nEach pre-filled pen contains 300 units of insulin lispro in 3 ml solution. \nEach pre-filled pen delivers 1-60 units in steps of 1 unit. \nJunior KwikPen \nEach pre-filled pen contains 300 units of insulin lispro in 3 ml solution. \nEach Junior KwikPen delivers 0.5 \u2013 30 units in steps of 0.5 units. \n*produced in \nE.coli\n by recombinant DNA technology. \nFor a full list of excipients, see section 6.1.", "indications": "For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance \nof normal glucose homeostasis. Humalog is also indicated for the initial stabilisation of diabetes \nmellitus.", "posology": "Posology \nThe dose should be determined by the physician, according to the requirement of the patient.  \nJunior KwikPen \nHumalog 100 units/ml Junior KwikPen is suitable for patients who may benefit from finer insulin dose \nadjustments. \nHumalog may be given shortly before meals. When necessary Humalog can be given soon after meals.  \nHumalog takes effect rapidly and has a shorter duration of activity (2 to 5 hours) given subcutaneously \nas compared with soluble insulin. This rapid onset of activity allows a Humalog injection (or, in the \ncase of administration by continuous subcutaneous infusion, a Humalog bolus) to be given very close \nto mealtime. The time course of action of any insulin may vary considerably in different individuals or \nat different times in the same individual. The faster onset of action compared to soluble human insulin \nis maintained regardless of injection site. As with all insulin preparations, the duration of action of \nHumalog is dependent on dose, site of injection, blood supply, temperature, and physical activity. \nHumalog can be used in conjunction with a longer-acting insulin or oral sulphonylurea agents, on the \nadvice of a physician.  \nSpecial populations \nRenal impairment \nInsulin requirements may be reduced in the presence of renal impairment. \nHepatic impairment \nInsulin requirements may be reduced in patients with hepatic impairment due to reduced capacity for \ngluconeogenesis and reduced insulin breakdown; however, in patients with chronic hepatic \nimpairment, an increase in insulin resistance may lead to increased insulin requirements. \nPaediatric population \nHumalog can be used in adolescents and children (see section 5.1). \nMethod of administration \nSubcutaneous use \nHumalog preparations should be given by subcutaneous injection.  \nThe KwikPen,Junior KwikPen and Tempo Pen are only suitable for subcutaneous injections. Humalog \nin cartridges is only suitable for subcutaneous injections from a Lilly reusable pen or compatible pump \nsystems for continuous subcutaneous insulin infusion (CSII).  \nSubcutaneous administration should be in the upper arms, thighs, buttocks, or abdomen. Use of \ninjection sites should be rotated so that the same site is not used more than approximately once a \nmonth, in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see section 4.4 and \n4.8). \nWhen administered subcutaneously care should be taken when injecting Humalog to ensure that a \nblood vessel has not been entered. After injection, the site of injection should not be massaged. \nPatients must be educated to use the proper injection techniques. \nHumalog KwikPens \nHumalog KwikPen is available in two strengths. The Humalog 100 units/ml KwikPen (and Humalog \n200 units/ml KwikPen, \nsee separate SmPC)\n delivers 1 \u2013 60 units in steps of 1 unit in a single injection. \nThe Humalog 100 units/ml Junior KwikPen delivers 0.5 \u2013 30 units in steps of 0.5 units in a single \ninjection.\n The number of insulin units is shown in the dose window of the pen regardless of \nstrength and no \ndose conversion should be done when transferring a patient to a new strength or to a \npen with a different dose step.  \nHumalog\nTempo Pen\nThe Humalog 100 units/ml Tempo Pen delivers 1 \u2013 60 units in steps of 1 unit in a single injection. The \nnumber of insulin units is shown in the dose window of the pen regardless of strength and no dose \nconversion should be done when transferring a patient to a new strength or to a pen with a different \ndose step. The Tempo Pen can be used with the optional transfer module Tempo Smart Button (see \nsection 6.6). \nAs with any insulin injection, when using the Tempo Pen, Smart Button and the mobile application, \nthe patient should be instructed to check their blood sugar levels when considering or making \ndecisions about another injection if they are unsure how much they have injected. \nUse of Humalog in an insulin infusion pump \nFor subcutaneous injection of Humalog using a continuous infusion pump, you may fill the pump \nreservoir from a Humalog 100 units/ml vial. Some pumps are compatible with cartridges that can be \ninserted intact into the pump. \nOnly certain CE-marked insulin infusion pumps may be used to infuse insulin lispro. Before infusing \ninsulin lispro, the pump manufacturer\u2019s instructions should be studied to ascertain the suitability for \nthe particular pump. Use the correct reservoir and catheter for the pump. When filling the pump \nreservoir avoid damaging it by using the correct needle length on the filling system. The infusion set \n(tubing and cannula) should be changed in accordance with the instructions in the product information \nsupplied with the infusion set. In the event of a hypoglycaemic episode, the infusion should be stopped \nuntil the episode is resolved. If repeated or severe low blood glucose levels occur consider the need to \nreduce or stop an insulin infusion. A pump malfunction or obstruction of the infusion set can result in \na rapid rise in glucose levels. If an interruption to insulin flow is suspected, follow the instructions in \nthe pump product literature. When used with an insulin infusion pump, Humalog should not be mixed \nwith any other insulin.\nIntravenous administration of insulin \nIf necessary, Humalog may also be administered intravenously, for example: for the control of blood \nglucose levels during ketoacidosis, acute illnesses or during intra and post operative periods. \nHumalog 100 units /ml is available in vials if administration of intravenous injection is necessary.   \nIntravenous injection of insulin lispro should be carried out following normal clinical practise for \nintravenous injections, for example by an intravenous bolus or by an infusion system. Frequent \nmonitoring of the blood glucose levels is required. \nInfusion systems at concentrations from 0.1 units/ml to 1.0 units/ml insulin lispro in 0.9% sodium \nchloride or 5% dextrose are stable at room temperature for 48 hours. It is recommended that the \nsystem is primed before starting the infusion to the patient.", "contraindications": "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. \nHypoglycaemia.", "special_warnings": "Traceability \nIn order to improve the traceability of biological medicinal products, the name and the batch number \nof the administered medicinal product should be clearly recorded. \nTransferring a patient to another type or brand of insulin  \nTransferring a patient to another type or brand of insulin should be done under strict medical \nsupervision. Changes in strength, brand (manufacturer), type (regular/soluble, NPH/isophane,  etc.), \nspecies (animal, human, human insulin analogue), and/or method of manufacture (recombinant DNA \nversus animal-source insulin) may result in the need for a change in dosage. For fast-acting insulins, \nany patient also on basal insulin must optimise dosage of both insulins to obtain glucose control across \nthe whole day, particularly nocturnal/fasting glucose control. \nVial \nWhen mixing Humalog with a longer acting insulin, the shorter-acting Humalog should be drawn into \nthe syringe first, to prevent contamination of the vial by the longer-acting insulin. Mixing of the \ninsulins ahead of time or just before the injection should be on advice of the physician. However, a \nconsistent routine must be followed. \nHypoglycaemia and hyperglycaemia \nConditions which may make the early warning symptoms of hypoglycaemia different or less \npronounced include long duration of diabetes, intensified insulin therapy, diabetic nerve disease or \nmedications such as beta-blockers. \nA few patients who have experienced hypoglycaemic reactions after transfer from animal-source \ninsulin to human insulin have reported that the early warning symptoms of hypoglycaemia were less \npronounced or different from those experienced with their previous insulin. Uncorrected \nhypoglycaemic or hyperglycaemic reactions can cause loss of consciousness, coma, or death. \nThe use of dosages which are inadequate or discontinuation of treatment, especially in insulin-\ndependent diabetics, may lead to hyperglycaemia and diabetic ketoacidosis; conditions which are \npotentially lethal. \nInjection technique \nPatients must be instructed to perform continuous rotation of the injection site to reduce the risk of \ndeveloping lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin \nabsorption and worsened glycaemic control following insulin injections at sites with these reactions. A \nsudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. \nBlood glucose monitoring is recommended after the change in the injection site, and dose adjustment \nof antidiabetic medications may be considered. \nInsulin requirements and dosage adjustment \nInsulin requirements may be increased during illness or emotional disturbances. \nAdjustment of dosage may also be necessary if patients undertake increased physical activity or \nchange their usual diet. Exercise taken immediately after a meal may increase the risk of \nhypoglycaemia. A consequence of the pharmacodynamics of rapid-acting insulin analogues is that if \nhypoglycaemia occurs, it may occur earlier after an injection when compared with soluble human \ninsulin. \nCombination of Humalog with pioglitazone \nCases of cardiac failure have been reported when pioglitazone was used in combination with insulin, \nespecially in patients with risk factors for development of cardiac heart failure. This should be kept in \nmind, if treatment with the combination of pioglitazone and Humalog is considered. If the \ncombination is used, patients should be observed for signs and symptoms of heart failure, weight gain \nand oedema. Pioglitazone should be discontinued, if any deterioration in cardiac symptoms occurs. \nAvoidance of medication errors \nPatients must be instructed to always check the insulin label before each injection to avoid accidental \nmix-ups between the two different strengths of Humalog KwikPen as well as other insulin products. \nPatients must visually verify the dialled units on the dose counter of the pen. Therefore, the \nrequirement for patients to self-inject is that they can read the dose counter on the pen. Patients who \nare blind or have poor vision must be instructed to always get help/assistance from another person who \nhas good vision and is trained in using the insulin device. \nTempo Pen  \nThe Tempo Pen contains a magnet (see section 6.5) that may interfere with the functions of an \nimplantable electronic medical device, such as a pacemaker. The magnetic field extends to \napproximately 1.5 cm. \nExcipients \nThis medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e., essentially \n\u201csodium-free\u201d.", "pregnancy": "Insulin requirements may be increased by medicinal products with hyperglycaemic activity, such as \noral contraceptives, corticosteroids, or thyroid replacement therapy, danazol, beta2 stimulants (such as \nritodrine, salbutamol, terbutaline).  \nInsulin requirements may be reduced in the presence of medicinal products with hypoglycaemic \nactivity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha \nantibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake \ninhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II \nreceptor blockers, beta-blockers, octreotide or alcohol.  \nThe physician should be consulted when using other medications in addition to Humalog (see section \n4.4).", "driving": "Pregnancy \nData on a large number of exposed pregnancies do not indicate any adverse effect of insulin lispro on \npregnancy or on the health of the foetus/newborn.    \nIt is essential to maintain good control of the insulin-treated (insulin-dependent or gestational \ndiabetes) patient throughout pregnancy. Insulin requirements usually fall during the first trimester and \nincrease during the second and third trimesters. Patients with diabetes should be advised to inform \ntheir doctor if they are pregnant or are contemplating pregnancy. Careful monitoring of glucose \ncontrol, as well as general health, is essential in pregnant patients with diabetes.  \nBreast-feeding \nPatients with diabetes who are breast-feeding may require adjustments in insulin dose, diet or both.  \nFertility \nInsulin lispro did not induce fertility impairment in animal studies (see section 5.3).", "side_effects": "The patient\u2019s ability to concentrate and react may be impaired as a result of hypoglycaemia. This may \nconstitute a risk in situations where these abilities are of special importance (e.g. driving a car or \noperating machinery). \nPatients should be advised to take precautions to avoid hypoglycaemia whilst driving, this is \nparticularly important in those who have reduced or absent awareness of the warning signs of \nhypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be \nconsidered in these circumstances.", "shelf_life": "Before use \n3 years.  \nAfter first use / after cartridge insertion \n28 days.", "storage": "Do not freeze. Do not expose to excessive heat or direct sunlight.  \nBefore use \nStore in a refrigerator (2\u00b0C - 8\u00b0C). \nAfter first use / after cartridge insertion \nVial \nStore in a refrigerator (2\u00b0C - 8\u00b0C) or below 30\u00b0C. \nCartridge \nStore below 30\u00b0C. Do not refrigerate. The pen with the inserted cartridge should not be stored with the \nneedle attached. \nKwikPen,Junior KwikPen and Tempo Pen \nStore below 30\u00b0C. Do not refrigerate. The pre-filled pen should not be stored with the needle attached.", "package": "Vial \nThe solution is contained in type I flint glass vials, sealed with butyl or halobutyl stoppers and secured \nwith aluminium seals. Dimeticone or silicone emulsion may be used to treat the vial stoppers. \n10 ml vial: Packs of 1 or 2 or a multipack of 5 (5 packs of 1). Not all packs may be marketed. \nCartridge \nThe solution is contained in type I flint glass cartridges, sealed with butyl or halobutyl disc seals and \nplunger heads, and are secured with aluminium seals. Dimeticone or silicone emulsion may be used to \ntreat the cartridge plungers, and/or the glass cartridges. \n3 ml cartridge: Packs of 5 or 10. Not all packs may be marketed. \nKwikPen \nThe solution is contained in type I flint glass cartridges, sealed with butyl or halobutyl disc seals and \nplunger heads and are secured with aluminium seals. Dimeticone or silicone emulsion may be used to \n  12 \ntreat the cartridge plunger, and/or the glass cartridge. The 3 ml cartridges are sealed in a disposable \npen injector, called the \u201cKwikPen\u201d. Needles are not included. \n3 ml KwikPen: Packs of 5 or a multipack of 10 (2 packs of 5). Not all packs may be marketed. \nJunior KwikPen \nType I glass cartridges, sealed with halobutyl disc seals secured with aluminium seals and bromobutyl \nplunger heads. Dimeticone or silicone emulsion may be used to treat the cartridge plunger. The 3 ml \ncartridges are sealed in a disposable pen injector, called the \u201cJunior KwikPen\u201d. Needles are not \nincluded. \n3 ml Junior KwikPen: Packs of 1 prefilled pen, 5 prefilled pens or a multipack of 10 (2 packs of 5) \nprefilled pens. Not all packs may be marketed. \nTempo Pen \nType I glass cartridges, sealed with halobutyl disc seals secured with aluminium seals and bromobutyl \nplunger heads. Dimeticone or silicone emulsion may be used to treat the cartridge plunger. The 3 ml \ncartridges are sealed in a disposable pen injector, called the \u201cTempo Pen\u201d. The Tempo Pen contains a \nmagnet (see section 4.4). Needles are not included. \n3 ml Tempo Pen: Packs of 5 prefilled pens or a multipack of 10 (2 packs of 5) prefilled pens. Not all \npacks may be marketed.", "marketing_authorization_numbers": "touch anything. \nii) \nMixing Humalog with longer-acting Human Insulins (see section 6.2) \n1. \nHumalog should be mixed with longer-acting human insulins only on the advice of a \ndoctor. \n2. \nDraw air into the syringe equal to the amount of longer-acting insulin being taken. Insert \nthe needle into the longer-acting insulin vial and inject the air. Withdraw the needle.  \n3. \nNow inject air into the Humalog vial in the same manner, but do not withdraw the needle.  \n4. \nTurn the vial and syringe upside down.  \n5. \nMaking sure the tip of the needle is in the Humalog, withdraw the correct dose of \nHumalog into the syringe.  \n6. \nBefore removing the needle from the vial, check the syringe for air bubbles that reduce \nthe amount of Humalog in it. If bubbles are present, hold the syringe straight up and tap \nits side until the bubbles float to the top. Push them out with the plunger and withdraw \nthe correct dose.  \n7. \nRemove the needle from the vial of Humalog and insert it into the vial of the longer-\nacting insulin. Turn the vial and syringe upside down. Hold the vial and syringe firmly in \none hand and shake gently. Making sure the tip of the needle is in the insulin, withdraw \nthe dose of longer-acting insulin. \n8. \nWithdraw the needle and lay the syringe down so that the needle does not touch anything. \n  14 \nCartridge \nHumalog cartridges are to be used with a Lilly reusable insulin pen and should not be used with any \nother reusable pen as the dosing accuracy has not been established with other pens. \nThe instructions with each individual pen must be followed for loading the cartridge, attaching the \nneedle and administering the insulin injection. \nKwikPen, Junior KwikPen and Tempo Pen \nBefore using the pre-filled pen the user manual included in the package leaflet must be read carefully.  \nThe pre-filled pen has to be used as recommended in the user manual.  \nPens should not be used if any part looks broken or damaged. \nInjecting a dose \nIf using a pre-filled or reusable pen refer to the detailed instructions for preparing the pen and injecting \nthe dose, the following is a general description. \n1. \nWash your hands \n2. \nChoose a site for injection. \n3. \nClean the skin as instructed. \n4. \nStabilise the skin by spreading it or pinching up a large area. Insert the needle and inject \nas instructed. \n5. \nPull the needle out and apply gentle pressure over the injection site for several seconds. \nDo not rub the area. \n6. \nDispose of the syringe and needle safely. For an injection device use the outer needle cap, \nunscrew the needle and dispose of it safely. \n7. \nUse of the injection sites should be rotated so that the same is not used more than \napproximately once a month. \nHumalog\nTempo Pen\nThe Tempo Pen is designed to work with the Tempo Smart Button. The Tempo Smart Button is an \noptional product that can be attached to the Tempo Pen dose knob and aids in transmitting Humalog \ndose information from the Tempo Pen to a compatible mobile application. The Tempo Pen injects \ninsulin with or without the Tempo Smart Button attached. To transmit data to the mobile application, \nfollow the instructions provided with the Tempo Smart Button and the instructions with the mobile \napplication \nAny unused product or waste material should be disposed of in accordance with local requirements. \n7. \nMARKETING AUTHORISATION HOLDER \nEli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands. \n  15 \n8. \nMARKETING AUTHORISATION NUMBERS \nEU/1/96/007/002 \nEU/1/96/007/004 \nEU/1/96/007/020 \nEU/1/96/007/021 \nEU/1/96/007/023 \nEU/1/96/007/031 \nEU/1/96/007/032 \nEU/1/96/007/043 \nEU/1/96/007/044 \nEU/1/96/007/045 \nEU/1/96/007/046 \nEU/1/96/007/047", "filename": "humalog-epar-product-information_en.html", "snomed.product_info": [["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["385219001", "Injection solution (qualifier value)|Conventional release solution for injection (dose form)|Injection solution (product)"], ["18720000", "In (attribute)"], ["733026001", "Vial (unit of presentation)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["385219001", "Injection solution (qualifier value)|Conventional release solution for injection (dose form)|Injection solution (product)"], ["18720000", "In (attribute)"], ["732988008", "Cartridge (unit of presentation)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["385219001", "Injection solution (qualifier value)|Conventional release solution for injection (dose form)|Injection solution (product)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["385219001", "Injection solution (qualifier value)|Conventional release solution for injection (dose form)|Injection solution (product)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["385219001", "Injection solution (qualifier value)|Conventional release solution for injection (dose form)|Injection solution (product)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"]], "ncit.product_info": [["C29123", "Insulin Lispro"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C42945", "Injectable Solution Dosage Form"], ["C16727", "India"], ["C41275", "Vial"], ["C29123", "Insulin Lispro"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C149914", "Solution for Injection in Cartridge Dosage Form"], ["C29123", "Insulin Lispro"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C42945", "Injectable Solution Dosage Form"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C97717", "Pre-filled Pen Syringe"], ["C29123", "Insulin Lispro"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C49466", "Junior"], ["C42945", "Injectable Solution Dosage Form"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C97717", "Pre-filled Pen Syringe"], ["C29123", "Insulin Lispro"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C157049", "Pen Device"], ["C42945", "Injectable Solution Dosage Form"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C97717", "Pre-filled Pen Syringe"]], "rxnorm.product_info": [["135805", "Humalog"], ["1649574", "Injection"], ["135805", "Humalog"], ["1649574", "Injection"], ["1649572", "Cartridge"], ["135805", "Humalog"], ["1649574", "Injection"], ["135805", "Humalog"], ["1649574", "Injection"], ["135805", "Humalog"], ["1649574", "Injection"]], "loinc.product_info": [["LA19244-5", "100"], ["LP32708-7", "Units"], ["LA14542-7", "Injection"], ["LA22004-8", "IN"], ["LA20376-2", "Vial"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LA14542-7", "Injection"], ["LA22004-8", "IN"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LA14542-7", "Injection"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP32605-5", "pre"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LA14542-7", "Injection"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP32605-5", "pre"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LA14542-7", "Injection"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP32605-5", "pre"]], "snomed.composition": [["419473009", "Each (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["412210000", "Insulin lispro (substance)|Lispro insulin (substance)"], ["258726008", "Eq (qualifier value)|equivalent - unit (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["419473009", "Each (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["732445006", "1000 (qualifier value)"], ["246514001", "Units (attribute)"], ["412210000", "Insulin lispro (substance)|Lispro insulin (substance)"], ["18720000", "In (attribute)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["739006009", "Solution (basic dose form)"], ["732988008", "Cartridge (unit of presentation)"], ["419473009", "Each (qualifier value)"], ["732988008", "Cartridge (unit of presentation)"], ["725125005", "300 (qualifier value)"], ["246514001", "Units (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["412210000", "Insulin lispro (substance)|Lispro insulin (substance)"], ["18720000", "In (attribute)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["739006009", "Solution (basic dose form)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["419473009", "Each (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["725125005", "300 (qualifier value)"], ["246514001", "Units (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["412210000", "Insulin lispro (substance)|Lispro insulin (substance)"], ["18720000", "In (attribute)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["739006009", "Solution (basic dose form)"], ["419473009", "Each (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732814003", "60 (qualifier value)"], ["246514001", "Units (attribute)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["767525000", "Unit (qualifier value)"], ["419473009", "Each (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["725125005", "300 (qualifier value)"], ["246514001", "Units (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["412210000", "Insulin lispro (substance)|Lispro insulin (substance)"], ["18720000", "In (attribute)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["739006009", "Solution (basic dose form)"], ["419473009", "Each (qualifier value)"], ["260304006", "0.5 (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["246514001", "Units (attribute)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["260304006", "0.5 (qualifier value)"], ["246514001", "Units (attribute)"], ["18720000", "In (attribute)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["788111003", "Recombinant deoxyribonucleic acid (substance)"], ["86495002", "For (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["261015003", "Full (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.composition": [["C64933", "Each"], ["C16816", "Mali"], ["C79873", "Contain"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C52874", "SPI1 wt Allele"], ["C29123", "Insulin Lispro"], ["C48793", "Equivalent"], ["C159124", "GDC Treatment Outcome Terminology"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C41275", "Vial"], ["C64933", "Each"], ["C41275", "Vial"], ["C79873", "Contain"], ["C67234", "Thousand"], ["C68553", "Unit"], ["C29123", "Insulin Lispro"], ["C16727", "India"], ["C69122", "Ten"], ["C16816", "Mali"], ["C42986", "Solution Dosage Form"], ["C48481", "Cartridge Dosing Unit"], ["C64933", "Each"], ["C48481", "Cartridge Dosing Unit"], ["C79873", "Contain"], ["C16645", "Greece"], ["C68553", "Unit"], ["C52874", "SPI1 wt Allele"], ["C29123", "Insulin Lispro"], ["C16727", "India"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16816", "Mali"], ["C42986", "Solution Dosage Form"], ["C16289", "Andorra"], ["C157049", "Pen Device"], ["C64933", "Each"], ["C97717", "Pre-filled Pen Syringe"], ["C79873", "Contain"], ["C16645", "Greece"], ["C68553", "Unit"], ["C52874", "SPI1 wt Allele"], ["C29123", "Insulin Lispro"], ["C16727", "India"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16816", "Mali"], ["C42986", "Solution Dosage Form"], ["C64933", "Each"], ["C97717", "Pre-filled Pen Syringe"], ["C105723", "ECOG Performance Status 1"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C68553", "Unit"], ["C16727", "India"], ["C156404", "STEPS to Enhance Physical Activity"], ["C52874", "SPI1 wt Allele"], ["C105723", "ECOG Performance Status 1"], ["C68553", "Unit"], ["C49466", "Junior"], ["C64933", "Each"], ["C97717", "Pre-filled Pen Syringe"], ["C79873", "Contain"], ["C16645", "Greece"], ["C68553", "Unit"], ["C52874", "SPI1 wt Allele"], ["C29123", "Insulin Lispro"], ["C16727", "India"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16816", "Mali"], ["C42986", "Solution Dosage Form"], ["C64933", "Each"], ["C49466", "Junior"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C163771", "Illness Intrusiveness Rating 5"], ["C70541", "Lansky Performance Status 30"], ["C68553", "Unit"], ["C16727", "India"], ["C156404", "STEPS to Enhance Physical Activity"], ["C52874", "SPI1 wt Allele"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C163771", "Illness Intrusiveness Rating 5"], ["C68553", "Unit"], ["C16727", "India"], ["C68800", "Elementary Charge"], ["C158169", "Buyei Chinese"], ["C16621", "Genetic Engineering"], ["C64956", "For"], ["C76246", "Blood Group A"], ["C25517", "Full"], ["C43432", "List"], ["C52874", "SPI1 wt Allele"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.composition": [["86009", "insulin lispro"], ["86009", "insulin lispro"], ["1649572", "Cartridge"], ["1649572", "Cartridge"], ["86009", "insulin lispro"], ["86009", "insulin lispro"], ["86009", "insulin lispro"]], "loinc.composition": [["LA19244-5", "100"], ["LP32708-7", "Units"], ["LP32542-0", "insulin"], ["LA31680-4", "Lispro"], ["LP20591-1", "3"], ["LA20376-2", "Vial"], ["LA20376-2", "Vial"], ["LP32708-7", "Units"], ["LP32542-0", "insulin"], ["LA31680-4", "Lispro"], ["LA22004-8", "IN"], ["LA13942-0", "10"], ["LP32708-7", "Units"], ["LP32542-0", "insulin"], ["LA31680-4", "Lispro"], ["LA22004-8", "IN"], ["LP20591-1", "3"], ["LP32605-5", "pre"], ["LP32708-7", "Units"], ["LP32542-0", "insulin"], ["LA31680-4", "Lispro"], ["LA22004-8", "IN"], ["LP20591-1", "3"], ["LP32605-5", "pre"], ["LA6112-2", "1"], ["LA28853-2", "60"], ["LP32708-7", "Units"], ["LA22004-8", "IN"], ["LA6112-2", "1"], ["LP32605-5", "pre"], ["LP32708-7", "Units"], ["LP32542-0", "insulin"], ["LA31680-4", "Lispro"], ["LA22004-8", "IN"], ["LP20591-1", "3"], ["LA16632-4", "0.5"], ["LA28855-7", "30"], ["LP32708-7", "Units"], ["LA22004-8", "IN"], ["LA16632-4", "0.5"], ["LP32708-7", "Units"], ["LA22004-8", "IN"], ["LA13503-0", "E"], ["LA19712-1", "Recombinant"], ["MTHU003299", "DNA"], ["LP17763-1", "A"], ["LA19682-6", "Full"], ["LP204165-7", "List"], ["LP20594-5", "6"], ["LA6112-2", "1"]], "snomed.indications": [["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["267467004", "Diabetes mellitus (& [ketoacidosis]) (disorder)|Diabetes mellitus (& [ketoacidosis])"], ["67866001", "Insulin (substance)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["17621005", "Normal (qualifier value)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["21979002", "Homeostasis, function (observable entity)|Homeostasis (function)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["884001", "Initial (qualifier value)"], ["115979005", "Stabilization (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"]], "ncit.indications": [["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C16289", "Andorra"], ["C16423", "Child"], ["C62355", "With"], ["C2985", "Diabetes Mellitus"], ["C75419", "World Health Organization"], ["C2271", "Insulin"], ["C64956", "For"], ["C156598", "Maintenance Clinical Trial Setting"], ["C52874", "SPI1 wt Allele"], ["C12801", "Tissue"], ["C2831", "Glucose"], ["C25989", "Homeostatic Process"], ["C29123", "Insulin Lispro"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C52874", "SPI1 wt Allele"], ["C2985", "Diabetes Mellitus"]], "rxnorm.indications": [["4850", "glucose"], ["135805", "Humalog"]], "loinc.indications": [["LP94823-9", "Treatment"], ["LP74722-7", "Diabetes mellitus"], ["LP32542-0", "insulin"], ["LA6626-1", "Normal"], ["MTHU001675", "Glucose"], ["LP200075-2", "IS"], ["LA6662-6", "Initial"], ["LP128793-9", "Diabetes"]], "snomed.posology": [["408102007", "Unit dose (qualifier value)"], ["436000", "Determined by (contextual qualifier) (qualifier value)"], ["309343006", "Physician (occupation)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["116154003", "Patient (person)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["86495002", "For (qualifier value)"], ["789480007", "Insulin dose (observable entity)"], ["257738001", "Adjustments (procedure)|Adjustments"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["769557005", "With meals (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["255234002", "After (attribute)"], ["769557005", "With meals (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["418694008", "Rapidly (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["762636008", "Duration (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["257733005", "Activity (observable entity)|Activities (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["123032005", "5 hours (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["325014006", "Soluble insulin (substance)"], ["255358001", "Rapid (qualifier value)"], ["77374008", "Onset of (contextual qualifier) (qualifier value)"], ["257733005", "Activity (observable entity)|Activities (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["255238004", "Continuous (qualifier value)"], ["300036000", "Subcutaneous infusion (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["260358002", "Very (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["263510006", "Time course (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["273248003", "Action (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67866001", "Insulin (substance)"], ["18720000", "In (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["417929005", "Times (qualifier value)"], ["18720000", "In (attribute)"], ["262126009", "Same (qualifier value)"], ["385435006", "Individual (person)"], ["77374008", "Onset of (contextual qualifier) (qualifier value)"], ["273248003", "Action (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["96367001", "Human insulin (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["385630006", "Maintained (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["13136005", "Injection site (morphologic abnormality)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["67866001", "Insulin (substance)"], ["762636008", "Duration (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["273248003", "Action (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["371154000", "Dependent (qualifier value)"], ["420862001", "On (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["272737002", "Site of (attribute)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["87612001", "Blood (substance)"], ["722490005", "Temperature (property) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["390736008", "Physical activity (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["67866001", "Insulin (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["738956005", "Oral (intended site)"], ["372711004", "Sulfonylurea (substance)"], ["420862001", "On (qualifier value)"], ["243073001", "Advice (regime/therapy)|Advice (regime/therapy)(procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["309343006", "Physician (occupation)"], ["67995009", "Special (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["67866001", "Insulin (substance)"], ["260400001", "Reduced (qualifier value)"], ["18720000", "In (attribute)"], ["52101004", "Present (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["40226000", "Impairment (finding)"], ["67866001", "Insulin (substance)"], ["260400001", "Reduced (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["40226000", "Impairment (finding)"], ["42752001", "Due to (attribute)"], ["260400001", "Reduced (qualifier value)"], ["86495002", "For (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260400001", "Reduced (qualifier value)"], ["67866001", "Insulin (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["40226000", "Impairment (finding)"], ["260366006", "Increase (qualifier value)"], ["18720000", "In (attribute)"], ["763325000", "Insulin resistance (disorder)"], ["88488004", "Lead (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["67866001", "Insulin (substance)"], ["376171000221106", "Pediatric population (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["260686004", "Method (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["34206005", "Subcutaneous route (qualifier value)"], ["180251004", "Subcutaneous injection (& for local action) (procedure)|Subcutaneous injection (& for local action)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["764295003", "Subcutaneous (intended site)"], ["18720000", "In (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["764295003", "Subcutaneous (intended site)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["44668000", "Pump, device (physical object)"], ["86495002", "For (qualifier value)"], ["255238004", "Continuous (qualifier value)"], ["764295003", "Subcutaneous (intended site)"], ["67866001", "Insulin (substance)"], ["36576007", "Infusion (procedure)"], ["764295003", "Subcutaneous (intended site)"], ["416118004", "Administration (procedure)"], ["18720000", "In (attribute)"], ["261183002", "Upper (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["818983003", "Structure of abdominopelvic cavity and/or content of abdominopelvic cavity and/or anterior abdominal wall (body structure)"], ["260676000", "Use of (attribute)"], ["268517006", "Diabetic monitoring - injection sites (finding)"], ["263861005", "Rotated (qualifier value)"], ["262126009", "Same (qualifier value)"], ["10546003", "Site (qualifier value)|Site (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["262009000", "Not used (qualifier value)"], ["242762006", "More (qualifier value)"], ["26175008", "Approximate (qualifier value)"], ["422114001", "Once - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258706009", "month (qualifier value)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["190789006", "(Lipodystrophy) or (Barraquer - Simons disease)|(Lipodystrophy) or (Barraquer - Simons disease) (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["282834007", "Cutaneous amyloidosis (disorder)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["346414003", "Ensure (substance)|Ensure (product)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["361097006", "Entire blood vessel (body structure)"], ["255234002", "After (attribute)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["272737002", "Site of (attribute)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["272394005", "Techniques values (qualifier value)|Technique (qualifier value)|Techniques (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["725123003", "200 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["263869007", "Separate (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732814003", "60 (qualifier value)"], ["246514001", "Units (attribute)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["767525000", "Unit (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["260304006", "0.5 (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["246514001", "Units (attribute)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["260304006", "0.5 (qualifier value)"], ["246514001", "Units (attribute)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["410681005", "Count of entities (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67866001", "Insulin (substance)"], ["246514001", "Units (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["224755008", "Window (physical object)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["385658003", "Done (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["129005007", "Transferring, function (observable entity)|Transferring (function)|Transferring (observable entity)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["261021004", "New (qualifier value)|New [dup] (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["398298007", "Step (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732814003", "60 (qualifier value)"], ["246514001", "Units (attribute)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["767525000", "Unit (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["410681005", "Count of entities (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67866001", "Insulin (substance)"], ["246514001", "Units (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["224755008", "Window (physical object)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["385658003", "Done (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["129005007", "Transferring, function (observable entity)|Transferring (function)|Transferring (observable entity)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["261021004", "New (qualifier value)|New [dup] (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["398298007", "Step (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["129347002", "Surgical transfer - action (qualifier value)"], ["900000000000443000", "Module (core metadata concept)"], ["228263000", "Button|Button (physical object)"], ["732810007", "6.6 (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["325017004", "Soluble neutral insulin (substance)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["261583007", "Using (attribute)"], ["733006000", "Pen (unit of presentation)"], ["228263000", "Button|Button (physical object)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["413568008", "Application (qualifier value)|Application - unit of product usage (qualifier value)"], ["116154003", "Patient (person)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["87612001", "Blood (substance)"], ["74801000", "Simple carbohydrate (substance)|Sugar (substance)"], ["258395000", "Levels (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["18720000", "In (attribute)"], ["67866001", "Insulin (substance)"], ["430033006", "Infusion pump (physical object)"], ["86495002", "For (qualifier value)"], ["180251004", "Subcutaneous injection (& for local action) (procedure)|Subcutaneous injection (& for local action)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["261583007", "Using (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["261754007", "Continuous infusion (qualifier value)"], ["44668000", "Pump, device (physical object)"], ["44668000", "Pump, device (physical object)"], ["257687008", "Reservoir (environment)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["7883008", "Compatible with (attribute)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["11163003", "Intact (qualifier value)"], ["30507006", "Into (attribute)"], ["44668000", "Pump, device (physical object)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["17162000", "Certain (qualifier value)"], ["46998006", "Massive (qualifier value)"], ["67866001", "Insulin (substance)"], ["36576007", "Infusion (procedure)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["764794000", "Infuse (administration method)"], ["412210000", "Insulin lispro (substance)|Lispro insulin (substance)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["412210000", "Insulin lispro (substance)|Lispro insulin (substance)"], ["44668000", "Pump, device (physical object)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["44668000", "Pump, device (physical object)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["257687008", "Reservoir (environment)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["19923001", "Catheter, device (physical object)"], ["86495002", "For (qualifier value)"], ["44668000", "Pump, device (physical object)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["44668000", "Pump, device (physical object)"], ["257687008", "Reservoir (environment)"], ["261583007", "Using (attribute)"], ["79068005", "Needle, device (physical object)"], ["410668003", "Length property (qualifier value)"], ["420862001", "On (qualifier value)"], ["1231568003", "System (basic dose form)"], ["36576007", "Infusion (procedure)"], ["706842002", "Tubing (physical object)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["12150006", "Cannula, device (physical object)"], ["263703002", "Changed status (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["36576007", "Infusion (procedure)"], ["18720000", "In (attribute)"], ["272379006", "Events (event)|Event (event)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["373299009", "Hypoglycemic agent (substance)"], ["263503000", "Episode (attribute)"], ["36576007", "Infusion (procedure)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["263503000", "Episode (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["723506003", "Resolved (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["27582007", "Repeat (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["62482003", "Low (qualifier value)"], ["87612001", "Blood (substance)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["258395000", "Levels (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422117008", "Stop (qualifier value)"], ["67866001", "Insulin (substance)"], ["36576007", "Infusion (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["44668000", "Pump, device (physical object)"], ["88846004", "Functional disorder (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["26036001", "Obstruction (morphologic abnormality)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["36576007", "Infusion (procedure)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255358001", "Rapid (qualifier value)"], ["18720000", "In (attribute)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["258395000", "Levels (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["67866001", "Insulin (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["415684004", "Suspected (qualifier value)"], ["421939007", "Follow - dosing instruction imperative (qualifier value)"], ["18720000", "In (attribute)"], ["44668000", "Pump, device (physical object)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["67866001", "Insulin (substance)"], ["430033006", "Infusion pump (physical object)"], ["26242008", "Mixed (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["67866001", "Insulin (substance)"], ["255560000", "Intravenous (qualifier value)"], ["39543009", "Administration of insulin (procedure)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["86495002", "For (qualifier value)"], ["246106000", "Control (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["87612001", "Blood (substance)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["258395000", "Levels (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["56051008", "Ketoacidosis (disorder)"], ["53737009", "Acute (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["272114000", "During values (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["288563008", "After values (qualifier value)"], ["248957007", "Menstruation, function (observable entity)|Menstruation (qualifier value)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["259035002", "/mL (qualifier value)|per milliliter (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["415818006", "Vial (qualifier value)|Vial - unit of product usage (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["151042000", "Intravenous injection|Intravenous injection (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["151042000", "Intravenous injection|Intravenous injection (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["412210000", "Insulin lispro (substance)|Lispro insulin (substance)"], ["255529000", "Out (qualifier value)"], ["255260001", "Following (attribute)"], ["17621005", "Normal (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["86495002", "For (qualifier value)"], ["255560000", "Intravenous (qualifier value)"], ["86495002", "For (qualifier value)"], ["255560000", "Intravenous (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["36576007", "Infusion (procedure)"], ["1231568003", "System (basic dose form)"], ["70232002", "Frequent (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["87612001", "Blood (substance)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["258395000", "Levels (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["36576007", "Infusion (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["732332006", "0.1 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["412210000", "Insulin lispro (substance)|Lispro insulin (substance)"], ["18720000", "In (attribute)"], ["732402004", "0.9 (qualifier value)"], ["39972003", "Sodium (substance)"], ["278429001", "Chloride (substance)|Chloride"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["387370006", "Dextrose (substance)|Dextrose preparation (substance)"], ["58158008", "Stable (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["722490005", "Temperature (property) (qualifier value)"], ["86495002", "For (qualifier value)"], ["255249005", "48 hours (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["1231568003", "System (basic dose form)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["36576007", "Infusion (procedure)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["116154003", "Patient (person)"]], "ncit.posology": [["C25488", "Dose"], ["C16329", "Belgium"], ["C136827", "Determine"], ["C158169", "Buyei Chinese"], ["C25741", "Physician"], ["C159124", "GDC Treatment Outcome Terminology"], ["C115762", "Content Type Requirement"], ["C52874", "SPI1 wt Allele"], ["C53691", "Veterinary Patient"], ["C49466", "Junior"], ["C29123", "Insulin Lispro"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C49466", "Junior"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C116358", "Amenable"], ["C64956", "For"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C106184", "May"], ["C25387", "Benefit"], ["C25516", "From"], ["C2271", "Insulin"], ["C25488", "Dose"], ["C29123", "Insulin Lispro"], ["C106184", "May"], ["C16329", "Belgium"], ["C64974", "Give"], ["C64592", "Before Meals"], ["C65140", "When"], ["C29123", "Insulin Lispro"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C64974", "Give"], ["C65106", "Then"], ["C29123", "Insulin Lispro"], ["C71600", "Effect, Appearance"], ["C65069", "Rapidly"], ["C16289", "Andorra"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C120914", "Physical Activity Measurement"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C159124", "GDC Treatment Outcome Terminology"], ["C163771", "Illness Intrusiveness Rating 5"], ["C25529", "Hour"], ["C64974", "Give"], ["C71344", "Associate of Science"], ["C49156", "Comparison"], ["C62355", "With"], ["C64364", "Soluble"], ["C2271", "Insulin"], ["C65069", "Rapidly"], ["C25279", "Onset"], ["C52874", "SPI1 wt Allele"], ["C120914", "Physical Activity Measurement"], ["C76246", "Blood Group A"], ["C29123", "Insulin Lispro"], ["C122632", "Injection Dosing Unit"], ["C43508", "Oregon"], ["C16727", "India"], ["C49152", "Case"], ["C52874", "SPI1 wt Allele"], ["C70962", "Agent Administration"], ["C158169", "Buyei Chinese"], ["C167446", "Continuous Heart Murmur"], ["C13353", "Subcutaneous"], ["C15388", "Infusion Procedure"], ["C76246", "Blood Group A"], ["C29123", "Insulin Lispro"], ["C15678", "Bolus Infusion Procedure"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C64974", "Give"], ["C116076", "Very"], ["C49070", "Closed"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25330", "Duration"], ["C25379", "Course"], ["C52874", "SPI1 wt Allele"], ["C25404", "Action"], ["C52874", "SPI1 wt Allele"], ["C81168", "Any"], ["C2271", "Insulin"], ["C106184", "May"], ["C16727", "India"], ["C46003", "Difference"], ["C43508", "Oregon"], ["C158997", "GDC Analyte Type Terminology"], ["C46003", "Difference"], ["C16727", "India"], ["C172515", "S-Adenosylmethionine Measurement"], ["C25190", "Person"], ["C94495", "Onset of Action"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C64364", "Soluble"], ["C14225", "Human"], ["C2271", "Insulin"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C103851", "Regardless"], ["C52874", "SPI1 wt Allele"], ["C77680", "Injection Site"], ["C71344", "Associate of Science"], ["C62355", "With"], ["C64916", "All"], ["C2271", "Insulin"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C25404", "Action"], ["C52874", "SPI1 wt Allele"], ["C29123", "Insulin Lispro"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C63905", "Conditional"], ["C92667", "SPARC wt Allele"], ["C25488", "Dose"], ["C37901", "Site"], ["C52874", "SPI1 wt Allele"], ["C122632", "Injection Dosing Unit"], ["C17610", "Blood Sample"], ["C80514", "Provide"], ["C174446", "Body Temperature"], ["C16289", "Andorra"], ["C17708", "Physical Activity"], ["C29123", "Insulin Lispro"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C16727", "India"], ["C79874", "Conjunction"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C2271", "Insulin"], ["C43508", "Oregon"], ["C25311", "Oral"], ["C92667", "SPARC wt Allele"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C25741", "Physician"], ["C18101", "Special Population"], ["C114592", "Renal Impairment"], ["C2271", "Insulin"], ["C106184", "May"], ["C16329", "Belgium"], ["C25640", "Reduced"], ["C16727", "India"], ["C25626", "Present"], ["C52874", "SPI1 wt Allele"], ["C114592", "Renal Impairment"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C2271", "Insulin"], ["C106184", "May"], ["C16329", "Belgium"], ["C25640", "Reduced"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C89272", "Due To"], ["C25640", "Reduced"], ["C25443", "Capacity"], ["C64956", "For"], ["C28151", "Gluconeogenic Process"], ["C16289", "Andorra"], ["C25640", "Reduced"], ["C2271", "Insulin"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C4981", "Chronic Graft Versus Host Disease"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C75889", "PAX6 wt Allele"], ["C25533", "Increase"], ["C16727", "India"], ["C113101", "Insulin Resistance"], ["C106184", "May"], ["C25552", "Lead"], ["C159124", "GDC Treatment Outcome Terminology"], ["C164135", "Increased"], ["C2271", "Insulin"], ["C17005", "Population Group"], ["C29123", "Insulin Lispro"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C16727", "India"], ["C16266", "Adolescents"], ["C16289", "Andorra"], ["C16423", "Child"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C85492", "CDISC SDTM Method Terminology"], ["C52874", "SPI1 wt Allele"], ["C70962", "Agent Administration"], ["C38299", "Subcutaneous Route of Administration"], ["C29123", "Insulin Lispro"], ["C16329", "Belgium"], ["C64974", "Give"], ["C158169", "Buyei Chinese"], ["C13353", "Subcutaneous"], ["C122632", "Injection Dosing Unit"], ["C49466", "Junior"], ["C16289", "Andorra"], ["C157049", "Pen Device"], ["C68869", "Are"], ["C48440", "Single"], ["C116358", "Amenable"], ["C64956", "For"], ["C13353", "Subcutaneous"], ["C29123", "Insulin Lispro"], ["C16727", "India"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C48440", "Single"], ["C116358", "Amenable"], ["C64956", "For"], ["C13353", "Subcutaneous"], ["C25516", "From"], ["C76246", "Blood Group A"], ["C157049", "Pen Device"], ["C43508", "Oregon"], ["C40414", "Compatible"], ["C111984", "Pump Dosing Unit"], ["C64956", "For"], ["C167446", "Continuous Heart Murmur"], ["C13353", "Subcutaneous"], ["C2271", "Insulin"], ["C15388", "Infusion Procedure"], ["C13353", "Subcutaneous"], ["C70962", "Agent Administration"], ["C16329", "Belgium"], ["C16727", "India"], ["C187053", "Upper Surface"], ["C185374", "Adherence to Refills and Medications Scale"], ["C43508", "Oregon"], ["C12664", "Abdomen"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C122632", "Injection Dosing Unit"], ["C37901", "Site"], ["C16329", "Belgium"], ["C17149", "Somalia"], ["C172515", "S-Adenosylmethionine Measurement"], ["C37901", "Site"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C69062", "Not Used"], ["C61584", "Greater Than"], ["C45828", "Approximate"], ["C64576", "Once"], ["C76246", "Blood Group A"], ["C29846", "Month"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C97093", "Lipodystrophy"], ["C16289", "Andorra"], ["C13316", "Cutaneous"], ["C2868", "Amyloidosis"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C65140", "When"], ["C25382", "Administered"], ["C61488", "Care"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C65140", "When"], ["C29123", "Insulin Lispro"], ["C159124", "GDC Treatment Outcome Terminology"], ["C74452", "Nutritional Supplement Drink"], ["C76246", "Blood Group A"], ["C12679", "Blood Vessel"], ["C101282", "Have"], ["C25594", "Negation"], ["C37949", "Entered"], ["C38008", "Post"], ["C122632", "Injection Dosing Unit"], ["C37901", "Site"], ["C52874", "SPI1 wt Allele"], ["C122632", "Injection Dosing Unit"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25340", "Use"], ["C122632", "Injection Dosing Unit"], ["C16847", "Technique"], ["C29123", "Insulin Lispro"], ["C29123", "Insulin Lispro"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25429", "Availability"], ["C16727", "India"], ["C66833", "Two"], ["C29123", "Insulin Lispro"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C16289", "Andorra"], ["C29123", "Insulin Lispro"], ["C159711", "Two Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C163702", "Staphylococcal Enterotoxin E"], ["C63803", "Separate"], ["C105723", "ECOG Performance Status 1"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C68553", "Unit"], ["C16727", "India"], ["C156404", "STEPS to Enhance Physical Activity"], ["C52874", "SPI1 wt Allele"], ["C105723", "ECOG Performance Status 1"], ["C68553", "Unit"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C48440", "Single"], ["C122632", "Injection Dosing Unit"], ["C29123", "Insulin Lispro"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C49466", "Junior"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C163771", "Illness Intrusiveness Rating 5"], ["C70541", "Lansky Performance Status 30"], ["C68553", "Unit"], ["C16727", "India"], ["C156404", "STEPS to Enhance Physical Activity"], ["C52874", "SPI1 wt Allele"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C163771", "Illness Intrusiveness Rating 5"], ["C68553", "Unit"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C48440", "Single"], ["C122632", "Injection Dosing Unit"], ["C25463", "Count"], ["C52874", "SPI1 wt Allele"], ["C2271", "Insulin"], ["C68553", "Unit"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C25488", "Dose"], ["C48051", "Window"], ["C52874", "SPI1 wt Allele"], ["C157049", "Pen Device"], ["C103851", "Regardless"], ["C52874", "SPI1 wt Allele"], ["C53294", "Pharmaceutical Strength"], ["C16289", "Andorra"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25488", "Dose"], ["C165230", "Conversion Mutation"], ["C16329", "Belgium"], ["C111784", "Done"], ["C65140", "When"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C94522", "New Lesion Identification"], ["C53294", "Pharmaceutical Strength"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C157049", "Pen Device"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C46003", "Difference"], ["C25488", "Dose"], ["C16154", "Treatment Step"], ["C29123", "Insulin Lispro"], ["C157049", "Pen Device"], ["C29123", "Insulin Lispro"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C157049", "Pen Device"], ["C105723", "ECOG Performance Status 1"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C68553", "Unit"], ["C16727", "India"], ["C156404", "STEPS to Enhance Physical Activity"], ["C52874", "SPI1 wt Allele"], ["C105723", "ECOG Performance Status 1"], ["C68553", "Unit"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C48440", "Single"], ["C122632", "Injection Dosing Unit"], ["C25463", "Count"], ["C52874", "SPI1 wt Allele"], ["C2271", "Insulin"], ["C68553", "Unit"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C25488", "Dose"], ["C48051", "Window"], ["C52874", "SPI1 wt Allele"], ["C157049", "Pen Device"], ["C103851", "Regardless"], ["C52874", "SPI1 wt Allele"], ["C53294", "Pharmaceutical Strength"], ["C16289", "Andorra"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25488", "Dose"], ["C165230", "Conversion Mutation"], ["C16329", "Belgium"], ["C111784", "Done"], ["C65140", "When"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C94522", "New Lesion Identification"], ["C53294", "Pharmaceutical Strength"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C157049", "Pen Device"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C46003", "Difference"], ["C25488", "Dose"], ["C16154", "Treatment Step"], ["C157049", "Pen Device"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C62355", "With"], ["C25603", "Optional"], ["C48167", "Transfer"], ["C42721", "Module"], ["C180379", "Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C172979", "Fear Score 6"], ["C71344", "Associate of Science"], ["C62355", "With"], ["C81168", "Any"], ["C179441", "Injected Insulin Diabetes Therapy"], ["C65140", "When"], ["C157049", "Pen Device"], ["C180379", "Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy"], ["C16289", "Andorra"], ["C25295", "Mobile"], ["C42608", "Computer Application"], ["C53691", "Veterinary Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C86058", "Check"], ["C94312", "Blood Glucose"], ["C65140", "When"], ["C43508", "Oregon"], ["C45828", "Approximate"], ["C122632", "Injection Dosing Unit"], ["C198613", "CFI wt Allele"], ["C68869", "Are"], ["C47944", "Uncertain"], ["C25256", "Quantity"], ["C101282", "Have"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C29123", "Insulin Lispro"], ["C16727", "India"], ["C75889", "PAX6 wt Allele"], ["C2271", "Insulin"], ["C15388", "Infusion Procedure"], ["C111984", "Pump Dosing Unit"], ["C64956", "For"], ["C13353", "Subcutaneous"], ["C122632", "Injection Dosing Unit"], ["C52874", "SPI1 wt Allele"], ["C29123", "Insulin Lispro"], ["C76246", "Blood Group A"], ["C15648", "Continuous Infusion Procedure"], ["C111984", "Pump Dosing Unit"], ["C106184", "May"], ["C54093", "Fill"], ["C111984", "Pump Dosing Unit"], ["C50140", "Reservoir Device"], ["C25516", "From"], ["C76246", "Blood Group A"], ["C29123", "Insulin Lispro"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C41275", "Vial"], ["C65099", "Some"], ["C68869", "Are"], ["C40414", "Compatible"], ["C62355", "With"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C48685", "Insertion"], ["C62399", "Intact"], ["C25544", "Into"], ["C111984", "Pump Dosing Unit"], ["C48440", "Single"], ["C107561", "Certain"], ["C85441", "Clinical Events Domain"], ["C182282", "Marked Heterogeneity Morphology"], ["C2271", "Insulin"], ["C15388", "Infusion Procedure"], ["C106184", "May"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C29123", "Insulin Lispro"], ["C201357", "Before Timing Type"], ["C29123", "Insulin Lispro"], ["C111984", "Pump Dosing Unit"], ["C25392", "Manufacturer"], ["C42555", "Siemens"], ["C42688", "Instruction"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C64956", "For"], ["C111984", "Pump Dosing Unit"], ["C25340", "Use"], ["C68815", "Correct"], ["C50140", "Reservoir Device"], ["C16289", "Andorra"], ["C17446", "Catheter"], ["C64956", "For"], ["C111984", "Pump Dosing Unit"], ["C65140", "When"], ["C111984", "Pump Dosing Unit"], ["C50140", "Reservoir Device"], ["C38267", "Intrathecal Route of Administration"], ["C158169", "Buyei Chinese"], ["C68815", "Correct"], ["C63846", "Needle Shape"], ["C25334", "Length"], ["C92667", "SPARC wt Allele"], ["C149975", "System Dosing Unit"], ["C15388", "Infusion Procedure"], ["C29939", "Protein SET"], ["C16289", "Andorra"], ["C50343", "Cannula Device"], ["C16329", "Belgium"], ["C25572", "Modification"], ["C64950", "Follow"], ["C42688", "Instruction"], ["C16727", "India"], ["C40352", "Multiplicative Product"], ["C48191", "Information"], ["C80514", "Provide"], ["C62355", "With"], ["C15388", "Infusion Procedure"], ["C29939", "Protein SET"], ["C16727", "India"], ["C74589", "Protocol Event"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C75539", "Episode"], ["C15388", "Infusion Procedure"], ["C16329", "Belgium"], ["C65136", "Until"], ["C75539", "Episode"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C118471", "Resolved License"], ["C198613", "CFI wt Allele"], ["C43508", "Oregon"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C139301", "IPSS Risk Category Low"], ["C94312", "Blood Glucose"], ["C127786", "Occurrence Indicator"], ["C41204", "Need"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C68617", "End Date"], ["C75889", "PAX6 wt Allele"], ["C2271", "Insulin"], ["C15388", "Infusion Procedure"], ["C76246", "Blood Group A"], ["C111984", "Pump Dosing Unit"], ["C25745", "Failure"], ["C43508", "Oregon"], ["C3284", "Obstruction"], ["C52874", "SPI1 wt Allele"], ["C15388", "Infusion Procedure"], ["C29939", "Protein SET"], ["C52288", "NUP214 wt Allele"], ["C20200", "Outcome"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C65069", "Rapidly"], ["C131877", "Relational and Item-Specific Encoding Task"], ["C16727", "India"], ["C2831", "Glucose"], ["C198613", "CFI wt Allele"], ["C75889", "PAX6 wt Allele"], ["C25542", "Interruption"], ["C159124", "GDC Treatment Outcome Terminology"], ["C2271", "Insulin"], ["C41141", "Flow"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C71458", "Suspected"], ["C64950", "Follow"], ["C42688", "Instruction"], ["C16727", "India"], ["C111984", "Pump Dosing Unit"], ["C40352", "Multiplicative Product"], ["C48471", "Publication"], ["C65140", "When"], ["C62355", "With"], ["C75889", "PAX6 wt Allele"], ["C2271", "Insulin"], ["C15388", "Infusion Procedure"], ["C111984", "Pump Dosing Unit"], ["C29123", "Insulin Lispro"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C26457", "Mixed (Normal and Tumor)"], ["C62355", "With"], ["C81168", "Any"], ["C118472", "Other License Status"], ["C2271", "Insulin"], ["C38276", "Intravenous Route of Administration"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C2271", "Insulin"], ["C198613", "CFI wt Allele"], ["C29123", "Insulin Lispro"], ["C106184", "May"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C38276", "Intravenous Route of Administration"], ["C64956", "For"], ["C48175", "Example"], ["C64956", "For"], ["C64355", "Scientific Control"], ["C52874", "SPI1 wt Allele"], ["C17610", "Blood Sample"], ["C2831", "Glucose"], ["C25490", "During"], ["C14140", "Acute"], ["C43508", "Oregon"], ["C25490", "During"], ["C25282", "Within"], ["C16289", "Andorra"], ["C38008", "Post"], ["C54733", "Operative"], ["C29123", "Insulin Lispro"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C105519", "Thousand Per Liter"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25429", "Availability"], ["C16727", "India"], ["C198613", "CFI wt Allele"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C28162", "Intravenous Injection"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C28162", "Intravenous Injection"], ["C52874", "SPI1 wt Allele"], ["C29123", "Insulin Lispro"], ["C16329", "Belgium"], ["C66768", "CDISC SDTM Adverse Event Outcome Terminology"], ["C53286", "Next"], ["C12801", "Tissue"], ["C123619", "Clinical Response"], ["C64956", "For"], ["C38276", "Intravenous Route of Administration"], ["C64956", "For"], ["C48175", "Example"], ["C158169", "Buyei Chinese"], ["C75889", "PAX6 wt Allele"], ["C38274", "Intravenous Bolus"], ["C43508", "Oregon"], ["C158169", "Buyei Chinese"], ["C75889", "PAX6 wt Allele"], ["C15388", "Infusion Procedure"], ["C149975", "System Dosing Unit"], ["C64649", "Frequently"], ["C61256", "Monitoring"], ["C52874", "SPI1 wt Allele"], ["C94312", "Blood Glucose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C15388", "Infusion Procedure"], ["C158997", "GDC Analyte Type Terminology"], ["C25516", "From"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C105723", "ECOG Performance Status 1"], ["C68553", "Unit"], ["C16816", "Mali"], ["C159124", "GDC Treatment Outcome Terminology"], ["C189636", "CDISC SDTM Implementation Guide Medical Device Version 1.0"], ["C68553", "Unit"], ["C16816", "Mali"], ["C29123", "Insulin Lispro"], ["C16727", "India"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C120081", "Severity of Symptom Score 9"], ["C830", "Sodium"], ["C25824", "Chloride"], ["C43508", "Oregon"], ["C163771", "Illness Intrusiveness Rating 5"], ["C68869", "Are"], ["C131459", "Microsatellite Stable"], ["C158997", "GDC Analyte Type Terminology"], ["C70719", "Specimen at Room Temperature"], ["C64956", "For"], ["C175678", "Forty Eight"], ["C25529", "Hour"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C149975", "System Dosing Unit"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C201357", "Before Timing Type"], ["C15388", "Infusion Procedure"], ["C159124", "GDC Treatment Outcome Terminology"], ["C53691", "Veterinary Patient"]], "rxnorm.posology": [["135805", "Humalog"], ["135805", "Humalog"], ["135805", "Humalog"], ["135805", "Humalog"], ["T052", "Activity"], ["T052", "Activity"], ["135805", "Humalog"], ["1649574", "Injection"], ["135805", "Humalog"], ["T016", "Human"], ["1649574", "Injection"], ["135805", "Humalog"], ["1649574", "Injection"], ["T052", "Activity"], ["135805", "Humalog"], ["6260", "lead"], ["135805", "Humalog"], ["135805", "Humalog"], ["1649574", "Injection"], ["135805", "Humalog"], ["1649574", "Injection"], ["135805", "Humalog"], ["1649574", "Injection"], ["1649574", "Injection"], ["1649574", "Injection"], ["135805", "Humalog"], ["135805", "Humalog"], ["135805", "Humalog"], ["135805", "Humalog"], ["1649574", "Injection"], ["135805", "Humalog"], ["1649574", "Injection"], ["135805", "Humalog"], ["135805", "Humalog"], ["1649574", "Injection"], ["1649574", "Injection"], ["1649574", "Injection"], ["135805", "Humalog"], ["1649574", "Injection"], ["135805", "Humalog"], ["135805", "Humalog"], ["86009", "insulin lispro"], ["86009", "insulin lispro"], ["T051", "Event"], ["4850", "glucose"], ["4850", "glucose"], ["135805", "Humalog"], ["135805", "Humalog"], ["4850", "glucose"], ["135805", "Humalog"], ["1649574", "Injection"], ["1649574", "Injection"], ["86009", "insulin lispro"], ["4850", "glucose"], ["86009", "insulin lispro"], ["9853", "sodium"]], "loinc.posology": [["MTHU065481", "Dose"], ["MTHU010489", "Physician"], ["LP66710-2", "Patient"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LP200075-2", "IS"], ["LA14161-6", "May"], ["LP32542-0", "insulin"], ["MTHU065481", "Dose"], ["LA14161-6", "May"], ["LP29256-2", "given"], ["LP202940-5", "Meals"], ["LP29256-2", "given"], ["LP202940-5", "Meals"], ["LP17763-1", "A"], ["LP14744-4", "Duration"], ["LP72045-5", "Activity"], ["MTHU000002", "Clinical Class"], ["LP6943-7", "5 hours"], ["LP29256-2", "given"], ["LP32542-0", "insulin"], ["LA24868-4", "Rapid"], ["LP72045-5", "Activity"], ["LP17763-1", "A"], ["LA14542-7", "Injection"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LA16902-1", "Continuous"], ["LA9451-1", "Subcutaneous"], ["LP263434-5", "Infusion"], ["LP17763-1", "A"], ["LP29256-2", "given"], ["LA15595-4", "Very close"], ["LP73517-2", "Time"], ["LP32542-0", "insulin"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LA21988-3", "AT"], ["LA22004-8", "IN"], ["LA11009-0", "Same"], ["LA12070-1", "Individual"], ["LA31677-0", "Human insulin"], ["LP200075-2", "IS"], ["LA14542-7", "Injection"], ["LP73352-4", "Site"], ["LA18187-7", "All"], ["LP32542-0", "insulin"], ["LP14744-4", "Duration"], ["LP200075-2", "IS"], ["LA12304-4", "Dependent"], ["MTHU065481", "Dose"], ["LP73352-4", "Site"], ["LA14542-7", "Injection"], ["MTHU029981", "Blood"], ["LP309988-6", "Supply"], ["LP36617-6", "Temperature"], ["MTHU017278", "Physical activity"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP32542-0", "insulin"], ["LA22025-3", "OR"], ["LA9367-9", "Oral"], ["LA14523-7", "Advice"], ["LP17763-1", "A"], ["MTHU010489", "Physician"], ["MTHU065909", "Renal"], ["LP32542-0", "insulin"], ["LA14161-6", "May"], ["LA32619-1", "Reduced"], ["LA22004-8", "IN"], ["LP149220-8", "Presence"], ["MTHU065909", "Renal"], ["LP32542-0", "insulin"], ["LA14161-6", "May"], ["LA32619-1", "Reduced"], ["LA22004-8", "IN"], ["LA32619-1", "Reduced"], ["LP72218-8", "Capacity"], ["LA32619-1", "Reduced"], ["LP32542-0", "insulin"], ["LA22004-8", "IN"], ["LA28752-6", "Chronic"], ["LA32048-3", "Increase"], ["LA22004-8", "IN"], ["LP32542-0", "insulin"], ["LP6857-9", "Resistance"], ["LA14161-6", "May"], ["LP14259-3", "Lead"], ["LA24377-6", "Increased"], ["LP32542-0", "insulin"], ["LP62263-6", "Population"], ["LA22004-8", "IN"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LP72939-9", "Method"], ["LA9451-1", "Subcutaneous"], ["LP29256-2", "given"], ["LA9451-1", "Subcutaneous"], ["LA14542-7", "Injection"], ["LA9451-1", "Subcutaneous"], ["LA22004-8", "IN"], ["LP200075-2", "IS"], ["LA9451-1", "Subcutaneous"], ["LP17763-1", "A"], ["LA19811-1", "Reusable"], ["LA22025-3", "OR"], ["LA19695-8", "Compatible"], ["LA16902-1", "Continuous"], ["LA9451-1", "Subcutaneous"], ["LP32542-0", "insulin"], ["LP263434-5", "Infusion"], ["LA9451-1", "Subcutaneous"], ["LA22004-8", "IN"], ["LP7095-5", "Buttocks"], ["LA22025-3", "OR"], ["LP6990-8", "Abdomen"], ["LA14542-7", "Injection"], ["LA11009-0", "Same"], ["LP73352-4", "Site"], ["LP200075-2", "IS"], ["LA157-0", "Not used"], ["LA16824-7", "More"], ["LA14312-5", "Once"], ["LP17763-1", "A"], ["LA14217-6", "Month"], ["LA22004-8", "IN"], ["LP209029-0", "Amyloidosis"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP68340-6", "Continuity assessment record and evaluation"], ["LP17763-1", "A"], ["LA28734-4", "Blood vessel"], ["LA21291-2", "Not"], ["LA14542-7", "Injection"], ["LP73352-4", "Site"], ["LA14542-7", "Injection"], ["LA21291-2", "Not"], ["LA14542-7", "Injection"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA6404-3", "Two"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LP32708-7", "Units"], ["LA6112-2", "1"], ["LA28853-2", "60"], ["LP32708-7", "Units"], ["LA22004-8", "IN"], ["LA6112-2", "1"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA17717-2", "Single"], ["LA14542-7", "Injection"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LA16632-4", "0.5"], ["LA28855-7", "30"], ["LP32708-7", "Units"], ["LA22004-8", "IN"], ["LA16632-4", "0.5"], ["LP32708-7", "Units"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA17717-2", "Single"], ["LA14542-7", "Injection"], ["LP18011-4", "Number"], ["LP32542-0", "insulin"], ["LP32708-7", "Units"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["MTHU065481", "Dose"], ["MTHU001445", "Strength"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["MTHU021345", "Transferring"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LP17763-1", "A"], ["LA9039-4", "New"], ["MTHU001445", "Strength"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LA6112-2", "1"], ["LA28853-2", "60"], ["LP32708-7", "Units"], ["LA22004-8", "IN"], ["LA6112-2", "1"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA17717-2", "Single"], ["LA14542-7", "Injection"], ["LP18011-4", "Number"], ["LP32542-0", "insulin"], ["LP32708-7", "Units"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["MTHU065481", "Dose"], ["MTHU001445", "Strength"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["MTHU021345", "Transferring"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LP17763-1", "A"], ["LA9039-4", "New"], ["MTHU001445", "Strength"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP97172-8", "Transfer"], ["LP20594-5", "6"], ["LP20594-5", "6"], ["LP32542-0", "insulin"], ["LA14542-7", "Injection"], ["LA33035-9", "Mobile"], ["LP66710-2", "Patient"], ["LP251102-2", "Check"], ["MTHU029981", "Blood"], ["MTHU026696", "Sugar"], ["LA22025-3", "OR"], ["LA14542-7", "Injection"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA14072-5", "Unsure"], ["LA15550-9", "Much"], ["LA22004-8", "IN"], ["LP32542-0", "insulin"], ["MTHU050275", "Infusion pump"], ["LA9451-1", "Subcutaneous"], ["LA14542-7", "Injection"], ["LP17763-1", "A"], ["LA16902-1", "Continuous"], ["MTHU050275", "Infusion pump"], ["LA33220-7", "You"], ["LA14161-6", "May"], ["LP17763-1", "A"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LA20376-2", "Vial"], ["LA14973-4", "Some"], ["LA19695-8", "Compatible"], ["LA18951-6", "Intact"], ["LP412022-8", "CE"], ["LA17968-1", "Marked"], ["LP32542-0", "insulin"], ["LP263434-5", "Infusion"], ["LA14161-6", "May"], ["LP32542-0", "insulin"], ["LA31680-4", "Lispro"], ["LP32542-0", "insulin"], ["LA31680-4", "Lispro"], ["LP15241-0", "S"], ["LP6820-7", "Instructions"], ["LA9960-1", "Correct"], ["LP249200-9", "Catheter"], ["LP200077-8", "IT"], ["LA9960-1", "Correct"], ["LP208081-2", "Needle"], ["MTHU003498", "Length"], ["LP263434-5", "Infusion"], ["LP7754-7", "Set"], ["MTHU022488", "Cannula"], ["LA22004-8", "IN"], ["LP6820-7", "Instructions"], ["LA22004-8", "IN"], ["LP263434-5", "Infusion"], ["LP7754-7", "Set"], ["LA22004-8", "IN"], ["MTHU019184", "Event"], ["LP17763-1", "A"], ["LP266734-5", "Episode"], ["LP263434-5", "Infusion"], ["LP266734-5", "Episode"], ["LP200075-2", "IS"], ["LA9041-0", "Resolved"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA22025-3", "OR"], ["LA6750-9", "Severe"], ["LA9194-7", "Low"], ["MTHU029981", "Blood"], ["MTHU001675", "Glucose"], ["LA22025-3", "OR"], ["LP32542-0", "insulin"], ["LP263434-5", "Infusion"], ["LP17763-1", "A"], ["LA22025-3", "OR"], ["LP222112-7", "Obstruction"], ["LP263434-5", "Infusion"], ["LP7754-7", "Set"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA24868-4", "Rapid"], ["LA22004-8", "IN"], ["MTHU001675", "Glucose"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP32542-0", "insulin"], ["MTHU009126", "Flow"], ["LP200075-2", "IS"], ["LA15291-0", "Suspected"], ["LP6820-7", "Instructions"], ["LA22004-8", "IN"], ["LP32542-0", "insulin"], ["MTHU050275", "Infusion pump"], ["LA21291-2", "Not"], ["LA11840-8", "Mixed"], ["MTHU029809", "Other"], ["LP32542-0", "insulin"], ["LA9437-0", "Intravenous"], ["LP32542-0", "insulin"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA14161-6", "May"], ["LP7741-4", "Control"], ["MTHU029981", "Blood"], ["MTHU001675", "Glucose"], ["LA18821-1", "Acute"], ["LA22025-3", "OR"], ["LP32606-3", "post"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA9437-0", "Intravenous"], ["LA14542-7", "Injection"], ["LP200075-2", "IS"], ["LA9437-0", "Intravenous"], ["LA14542-7", "Injection"], ["LP32542-0", "insulin"], ["LA31680-4", "Lispro"], ["LA6626-1", "Normal"], ["LP7787-7", "Clinical"], ["LA9437-0", "Intravenous"], ["LA9437-0", "Intravenous"], ["LA22025-3", "OR"], ["LP263434-5", "Infusion"], ["LA20297-0", "Monitoring"], ["MTHU029981", "Blood"], ["MTHU001675", "Glucose"], ["LP200075-2", "IS"], ["LP263434-5", "Infusion"], ["LA21988-3", "AT"], ["LA24574-8", "0.1"], ["LP32708-7", "Units"], ["LA6112-2", "1"], ["LA6111-4", "0"], ["LP32708-7", "Units"], ["LP32542-0", "insulin"], ["LA31680-4", "Lispro"], ["LA22004-8", "IN"], ["LA24587-0", "0.9"], ["LP15099-2", "Sodium"], ["LP15483-8", "Chloride"], ["LA22025-3", "OR"], ["LP20593-7", "5"], ["LA14122-8", "Stable"], ["LA21988-3", "AT"], ["60832-3", "Temperature.ambient:Temp:Pt:Room:Qn"], ["LP6938-7", "48 hours"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP200075-2", "IS"], ["LP263434-5", "Infusion"], ["LP66710-2", "Patient"]], "snomed.contraindications": [["257550005", "Hypersensitivity (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["261217004", "Substance (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"]], "ncit.contraindications": [["C3114", "Hypersensitivity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C154405", "Active State"], ["C45306", "Substance"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.contraindications": [["T167", "Substance"]], "loinc.contraindications": [["LA16666-2", "Active"], ["T167", "Substance"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP20594-5", "6"], ["LA6112-2", "1"]], "snomed.special_warnings": [["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["734841007", "Name (property) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["410681005", "Count of entities (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["763158003", "Medicinal product (product)"], ["129005007", "Transferring, function (observable entity)|Transferring (function)|Transferring (observable entity)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["410657003", "Type (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67866001", "Insulin (substance)"], ["129005007", "Transferring, function (observable entity)|Transferring (function)|Transferring (observable entity)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["410657003", "Type (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67866001", "Insulin (substance)"], ["385658003", "Done (qualifier value)"], ["351726001", "Below (qualifier value)"], ["74188005", "Medical (qualifier value)"], ["225313009", "Supervision (regime/therapy)|Supervision (procedure)"], ["18720000", "In (attribute)"], ["410657003", "Type (attribute)"], ["17854005", "Regular (qualifier value)"], ["387961004", "Kingdom Animalia (organism)"], ["338930006", "Human (organism)"], ["96367001", "Human insulin (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["260686004", "Method (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["788111003", "Recombinant deoxyribonucleic acid (substance)"], ["387961004", "Kingdom Animalia (organism)"], ["734842000", "Source (property) (qualifier value)"], ["67866001", "Insulin (substance)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["103325001", "Patient need for (contextual qualifier) (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263703002", "Changed status (qualifier value)"], ["260911001", "Dosage (attribute)"], ["86495002", "For (qualifier value)"], ["277748003", "Fast (qualifier value)"], ["116154003", "Patient (person)"], ["420862001", "On (qualifier value)"], ["416303005", "Basal insulin (product)"], ["260911001", "Dosage (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["51440002", "Right and left (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["246106000", "Control (attribute)"], ["260232004", "Whole (qualifier value)"], ["264721006", "day (qualifier value)|day"], ["2546009", "Night time (qualifier value)"], ["792805006", "Fasting (regime/therapy)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["246106000", "Control (attribute)"], ["733026001", "Vial (unit of presentation)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["67866001", "Insulin (substance)"], ["30507006", "Into (attribute)"], ["733020007", "Syringe (unit of presentation)"], ["255216001", "First (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["101445003", "PREVENT (substance)|PREVENT (product)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["67866001", "Insulin (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["420862001", "On (qualifier value)"], ["243073001", "Advice (regime/therapy)|Advice (regime/therapy)(procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["309343006", "Physician (occupation)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["50811001", "Routine (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["270004003", "(Blood sugar result [& glucose]) or (plasma glucose level) or (hyperglycaemia)|(Blood sugar result [& glucose]) or (plasma glucose level) or (hyperglycaemia) (procedure)"], ["264499004", "Early (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["260384008", "Long duration (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67866001", "Insulin (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["256864008", "Entire nerve (body structure)"], ["64572001", "Disease (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["260989008", "Beta - Greek letter (qualifier value)|Greek letter beta (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["57176003", "Few (qualifier value)"], ["373299009", "Hypoglycemic agent (substance)"], ["255234002", "After (attribute)"], ["129347002", "Surgical transfer - action (qualifier value)"], ["387961004", "Kingdom Animalia (organism)"], ["734842000", "Source (property) (qualifier value)"], ["67866001", "Insulin (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["96367001", "Human insulin (substance)"], ["733985002", "Reported (qualifier value)"], ["264499004", "Early (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["9130008", "Previous (qualifier value)"], ["67866001", "Insulin (substance)"], ["373299009", "Hypoglycemic agent (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["419045004", "Loss of consciousness (finding)"], ["371632003", "Coma (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["419620001", "Death (event)"], ["260676000", "Use of (attribute)"], ["277406006", "Dosages (qualifier value)"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["67866001", "Insulin (substance)"], ["371154000", "Dependent (qualifier value)"], ["88488004", "Lead (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["270004003", "(Blood sugar result [& glucose]) or (plasma glucose level) or (hyperglycaemia)|(Blood sugar result [& glucose]) or (plasma glucose level) or (hyperglycaemia) (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420422005", "Ketoacidosis due to diabetes mellitus (disorder)|Ketoacidosis in diabetes mellitus (disorder)"], ["447120003", "Injection technique (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255238004", "Continuous (qualifier value)"], ["257912008", "Rotation - action (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["13136005", "Injection site (morphologic abnormality)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["190789006", "(Lipodystrophy) or (Barraquer - Simons disease)|(Lipodystrophy) or (Barraquer - Simons disease) (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["282834007", "Cutaneous amyloidosis (disorder)"], ["116680003", "Is a (attribute)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["67866001", "Insulin (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["231877006", "Worse (qualifier value)"], ["246106000", "Control (attribute)"], ["255260001", "Following (attribute)"], ["67866001", "Insulin (substance)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255363002", "Sudden (qualifier value)"], ["263703002", "Changed status (qualifier value)"], ["13136005", "Injection site (morphologic abnormality)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["42798000", "Area (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["302866003", "Hypoglycemia (disorder)"], ["698472009", "Blood glucose monitoring (regime/therapy)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["255234002", "After (attribute)"], ["161712005", "Menopause (qualifier value)|Menopause, function (observable entity)"], ["18720000", "In (attribute)"], ["13136005", "Injection site (morphologic abnormality)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67866001", "Insulin (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260911001", "Dosage (attribute)"], ["410617001", "Adjustment (procedure)"], ["67866001", "Insulin (substance)"], ["35105006", "Increased (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["39104002", "Illness (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["408453002", "Emotional (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["260911001", "Dosage (attribute)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["1171000175109", "Increased physical activity (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["41829006", "Dietary finding (finding)"], ["256235009", "Exercise (observable entity)|Exercise (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["255234002", "After (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["103332005", "Consequence of (contextual qualifier) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["8780003", "Rapid-acting insulin (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["255234002", "After (attribute)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["338930006", "Human (organism)"], ["67866001", "Insulin (substance)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["395828009", "Pioglitazone (substance)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["84114007", "Heart failure (disorder)"], ["733985002", "Reported (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["395828009", "Pioglitazone (substance)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["67866001", "Insulin (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["155374007", "Heart failure (disorder)|Heart failure"], ["18720000", "In (attribute)"], ["89970005", "Psyche structure (body structure)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["395828009", "Pioglitazone (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["86495002", "For (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["155374007", "Heart failure (disorder)|Heart failure"], ["816159004", "Measured weight gain (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["423666004", "Edema (observable entity)"], ["395828009", "Pioglitazone (substance)"], ["410546004", "Discontinued (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["2533004", "Drug (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["67866001", "Insulin (substance)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["419473009", "Each (qualifier value)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["53348004", "Accidental (qualifier value)"], ["764462006", "Mix (transformation)"], ["11896004", "Intermediate (qualifier value)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["20572008", "Good (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["67866001", "Insulin (substance)"], ["246514001", "Units (attribute)"], ["420862001", "On (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["303502004", "Counter (physical object)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["86495002", "For (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["740685003", "Inject (administration method)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["303502004", "Counter (physical object)"], ["420862001", "On (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["277675000", "Blind (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["40031005", "Vision problem (disorder)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["125676002", "Person (person)"], ["20572008", "Good (qualifier value)"], ["61402003", "Vision (qualifier value)|Vision, function (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["261583007", "Using (attribute)"], ["67866001", "Insulin (substance)"], ["49062001", "Device (physical object)"], ["733006000", "Pen (unit of presentation)"], ["733006000", "Pen (unit of presentation)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["706591002", "Magnet (physical object)"], ["732809002", "6.5 (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["246464006", "Function (observable entity)|Functions (qualifier value)|Functions (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258097001", "Electronic (qualifier value)"], ["63653004", "Biomedical device (physical object)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["285651005", "Magnetic field (physical force)"], ["66211004", "Extending (qualifier value)"], ["26175008", "Approximate (qualifier value)"], ["732425003", "1.5 (qualifier value)"], ["258672001", "cm (qualifier value)|centimeter (qualifier value)|Centimeter (qualifier value)"], ["763158003", "Medicinal product (product)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258718000", "mmol (qualifier value)|millimole (qualifier value)"], ["39972003", "Sodium (substance)"], ["1222776006", "American Joint Committee on Cancer stage II:3 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["39972003", "Sodium (substance)"]], "ncit.special_warnings": [["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C52874", "SPI1 wt Allele"], ["C28226", "Biological"], ["C42614", "Name"], ["C16289", "Andorra"], ["C104504", "Batch Number"], ["C52874", "SPI1 wt Allele"], ["C25382", "Administered"], ["C142605", "Medicinal Product"], ["C16329", "Belgium"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C159124", "GDC Treatment Outcome Terminology"], ["C181852", "Protocol Therapy Status"], ["C43508", "Oregon"], ["C71898", "Proprietary Name"], ["C52874", "SPI1 wt Allele"], ["C2271", "Insulin"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C159124", "GDC Treatment Outcome Terminology"], ["C181852", "Protocol Therapy Status"], ["C43508", "Oregon"], ["C71898", "Proprietary Name"], ["C52874", "SPI1 wt Allele"], ["C2271", "Insulin"], ["C16329", "Belgium"], ["C111784", "Done"], ["C25261", "Medical"], ["C61372", "Management"], ["C16727", "India"], ["C53294", "Pharmaceutical Strength"], ["C71898", "Proprietary Name"], ["C25392", "Manufacturer"], ["C181852", "Protocol Therapy Status"], ["C25647", "Regular"], ["C64364", "Soluble"], ["C155831", "Nasopharyngeal Swab Specimen"], ["C45293", "Species"], ["C14182", "Animal"], ["C14225", "Human"], ["C14225", "Human"], ["C2271", "Insulin"], ["C1513", "Analog"], ["C48928", "And/Or"], ["C85492", "CDISC SDTM Method Terminology"], ["C52874", "SPI1 wt Allele"], ["C43360", "Manufacture"], ["C453", "Recombinant DNA"], ["C49156", "Comparison"], ["C14182", "Animal"], ["C43822", "Term Source"], ["C2271", "Insulin"], ["C106184", "May"], ["C20200", "Outcome"], ["C16727", "India"], ["C41204", "Need"], ["C64956", "For"], ["C76246", "Blood Group A"], ["C54126", "Delta"], ["C16727", "India"], ["C94394", "Cumulative Dose"], ["C64956", "For"], ["C63663", "Fasting"], ["C123459", "Insulin Sensitivity Measurement"], ["C81168", "Any"], ["C53691", "Veterinary Patient"], ["C92667", "SPARC wt Allele"], ["C23409", "Murine Basal Cells"], ["C2271", "Insulin"], ["C94394", "Cumulative Dose"], ["C52874", "SPI1 wt Allele"], ["C49636", "Both"], ["C123459", "Insulin Sensitivity Measurement"], ["C159124", "GDC Treatment Outcome Terminology"], ["C52349", "Obtain"], ["C2831", "Glucose"], ["C64355", "Scientific Control"], ["C81171", "Cross"], ["C25326", "Whole"], ["C25301", "Day"], ["C63663", "Fasting"], ["C2831", "Glucose"], ["C64355", "Scientific Control"], ["C41275", "Vial"], ["C65140", "When"], ["C64925", "Mix"], ["C29123", "Insulin Lispro"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C2271", "Insulin"], ["C29123", "Insulin Lispro"], ["C16329", "Belgium"], ["C25544", "Into"], ["C50207", "Syringe Device"], ["C25509", "First"], ["C159124", "GDC Treatment Outcome Terminology"], ["C63018", "Contamination during Use"], ["C52874", "SPI1 wt Allele"], ["C41275", "Vial"], ["C158169", "Buyei Chinese"], ["C2271", "Insulin"], ["C64925", "Mix"], ["C52874", "SPI1 wt Allele"], ["C123459", "Insulin Sensitivity Measurement"], ["C52874", "SPI1 wt Allele"], ["C25330", "Duration"], ["C43508", "Oregon"], ["C201357", "Before Timing Type"], ["C122632", "Injection Dosing Unit"], ["C16329", "Belgium"], ["C92667", "SPARC wt Allele"], ["C52874", "SPI1 wt Allele"], ["C25741", "Physician"], ["C76246", "Blood Group A"], ["C85901", "Consistent"], ["C47893", "Routine"], ["C16329", "Belgium"], ["C16033", "Follow-Up"], ["C16289", "Andorra"], ["C25457", "Condition"], ["C106184", "May"], ["C25392", "Manufacturer"], ["C61589", "Early"], ["C47896", "Warning"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C46003", "Difference"], ["C43508", "Oregon"], ["C61422", "Lesser"], ["C190998", "Modified Van Assche Index MVAI102 Original Result - Pronounced"], ["C74521", "Include"], ["C25248", "Long"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C2985", "Diabetes Mellitus"], ["C2271", "Insulin"], ["C49236", "Therapeutic Procedure"], ["C23400", "Murine Nerve"], ["C2991", "Disease or Disorder"], ["C43508", "Oregon"], ["C459", "Medication"], ["C71344", "Associate of Science"], ["C29576", "Beta-Adrenergic Antagonist"], ["C76246", "Blood Group A"], ["C64942", "Few"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C38008", "Post"], ["C48167", "Transfer"], ["C25516", "From"], ["C14182", "Animal"], ["C43822", "Term Source"], ["C2271", "Insulin"], ["C159124", "GDC Treatment Outcome Terminology"], ["C14225", "Human"], ["C2271", "Insulin"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C61589", "Early"], ["C47896", "Warning"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C61422", "Lesser"], ["C190998", "Modified Van Assche Index MVAI102 Original Result - Pronounced"], ["C43508", "Oregon"], ["C46003", "Difference"], ["C25516", "From"], ["C62355", "With"], ["C25627", "Previous"], ["C2271", "Insulin"], ["C43508", "Oregon"], ["C52288", "NUP214 wt Allele"], ["C16390", "Etiology"], ["C50635", "Loss of Consciousness"], ["C34497", "Coma"], ["C43508", "Oregon"], ["C171353", "Clinical Status Ordinal Scale Outcome 7"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C68869", "Are"], ["C168268", "Inadequate Daily Salt Intake"], ["C43508", "Oregon"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C16727", "India"], ["C2271", "Insulin"], ["C63905", "Conditional"], ["C106184", "May"], ["C25552", "Lead"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16289", "Andorra"], ["C50530", "Diabetic Ketoacidosis"], ["C25457", "Condition"], ["C68869", "Are"], ["C122632", "Injection Dosing Unit"], ["C16847", "Technique"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C38000", "Performed"], ["C167446", "Continuous Heart Murmur"], ["C48439", "Revolution"], ["C52874", "SPI1 wt Allele"], ["C77680", "Injection Site"], ["C159124", "GDC Treatment Outcome Terminology"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C97093", "Lipodystrophy"], ["C16289", "Andorra"], ["C13316", "Cutaneous"], ["C2868", "Amyloidosis"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C62230", "Potential"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C168181", "Delayed Capillary Refill Time"], ["C2271", "Insulin"], ["C71731", "Material Absorption"], ["C16289", "Andorra"], ["C125461", "Got Worse"], ["C64355", "Scientific Control"], ["C53286", "Next"], ["C2271", "Insulin"], ["C158997", "GDC Analyte Type Terminology"], ["C37901", "Site"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C113683", "Abrupt"], ["C54126", "Delta"], ["C16727", "India"], ["C77680", "Injection Site"], ["C159124", "GDC Treatment Outcome Terminology"], ["C75889", "PAX6 wt Allele"], ["C94232", "Unaffected"], ["C25244", "Area"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C159124", "GDC Treatment Outcome Terminology"], ["C20200", "Outcome"], ["C16727", "India"], ["C92744", "Blood Glucose Measurement"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C38008", "Post"], ["C54126", "Delta"], ["C16727", "India"], ["C77680", "Injection Site"], ["C16289", "Andorra"], ["C82495", "Dose Adjustment"], ["C52874", "SPI1 wt Allele"], ["C459", "Medication"], ["C106184", "May"], ["C16329", "Belgium"], ["C2271", "Insulin"], ["C16289", "Andorra"], ["C94394", "Cumulative Dose"], ["C49157", "Adjustment"], ["C2271", "Insulin"], ["C106184", "May"], ["C16329", "Belgium"], ["C164135", "Increased"], ["C25490", "During"], ["C43508", "Oregon"], ["C54266", "Emotion"], ["C49157", "Adjustment"], ["C52874", "SPI1 wt Allele"], ["C94394", "Cumulative Dose"], ["C106184", "May"], ["C16329", "Belgium"], ["C198613", "CFI wt Allele"], ["C16960", "Patient"], ["C164135", "Increased"], ["C17708", "Physical Activity"], ["C43508", "Oregon"], ["C54126", "Delta"], ["C102843", "Usual"], ["C90364", "Basal Diet"], ["C16567", "Exercise"], ["C25701", "Taken"], ["C64597", "Immediately"], ["C124898", "Refrain from Smoking After a Meal"], ["C106184", "May"], ["C25533", "Increase"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C74555", "Consequence"], ["C52874", "SPI1 wt Allele"], ["C15720", "Pharmacodynamics"], ["C52874", "SPI1 wt Allele"], ["C65069", "Rapidly"], ["C2271", "Insulin"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C198613", "CFI wt Allele"], ["C38267", "Intrathecal Route of Administration"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C38008", "Post"], ["C75889", "PAX6 wt Allele"], ["C122632", "Injection Dosing Unit"], ["C65140", "When"], ["C49156", "Comparison"], ["C62355", "With"], ["C64364", "Soluble"], ["C14225", "Human"], ["C2271", "Insulin"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C29123", "Insulin Lispro"], ["C62355", "With"], ["C71633", "Pioglitazone"], ["C52874", "SPI1 wt Allele"], ["C50577", "Heart Failure"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C65140", "When"], ["C71633", "Pioglitazone"], ["C154196", "Washo Language"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C2271", "Insulin"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C17103", "Risk Factor"], ["C64956", "For"], ["C18732", "Development"], ["C52874", "SPI1 wt Allele"], ["C12727", "Heart"], ["C143529", "Heart Failure, CTCAE"], ["C16329", "Belgium"], ["C16727", "India"], ["C198613", "CFI wt Allele"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C71633", "Pioglitazone"], ["C16289", "Andorra"], ["C29123", "Insulin Lispro"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C198613", "CFI wt Allele"], ["C61517", "Combination"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C25599", "Observed"], ["C64956", "For"], ["C16289", "Andorra"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C143529", "Heart Failure, CTCAE"], ["C113453", "Have Gained Weight"], ["C16289", "Andorra"], ["C71633", "Pioglitazone"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C198613", "CFI wt Allele"], ["C81168", "Any"], ["C25751", "Deterioration"], ["C16727", "India"], ["C12727", "Heart"], ["C168422", "Rheumatic Fever Symptom"], ["C54264", "Avoidance"], ["C52874", "SPI1 wt Allele"], ["C459", "Medication"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C110990", "All of the Time"], ["C86058", "Check"], ["C2271", "Insulin"], ["C41203", "Medical Product Label"], ["C201357", "Before Timing Type"], ["C64933", "Each"], ["C122632", "Injection Dosing Unit"], ["C159124", "GDC Treatment Outcome Terminology"], ["C34340", "Accident"], ["C64925", "Mix"], ["C187066", "United Parcel Service"], ["C94545", "Between"], ["C66833", "Two"], ["C46003", "Difference"], ["C52874", "SPI1 wt Allele"], ["C29123", "Insulin Lispro"], ["C71344", "Associate of Science"], ["C128793", "Microplate Well"], ["C71344", "Associate of Science"], ["C118472", "Other License Status"], ["C2271", "Insulin"], ["C16960", "Patient"], ["C45513", "Verification"], ["C68553", "Unit"], ["C92667", "SPARC wt Allele"], ["C25488", "Dose"], ["C49894", "Counter Device"], ["C52874", "SPI1 wt Allele"], ["C157049", "Pen Device"], ["C115762", "Content Type Requirement"], ["C64956", "For"], ["C16960", "Patient"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25200", "Self"], ["C64978", "Inject"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C52288", "NUP214 wt Allele"], ["C156982", "Do Reading"], ["C25488", "Dose"], ["C49894", "Counter Device"], ["C92667", "SPARC wt Allele"], ["C157049", "Pen Device"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C49068", "Blinded"], ["C43508", "Oregon"], ["C101282", "Have"], ["C177356", "Malignant Germ Cell International Collaborative Risk Classification, Poor"], ["C38533", "Sight"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C110990", "All of the Time"], ["C89271", "Assistance"], ["C89271", "Assistance"], ["C25516", "From"], ["C25190", "Person"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C64975", "Good"], ["C38533", "Sight"], ["C16289", "Andorra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C2271", "Insulin"], ["C62103", "Device"], ["C157049", "Pen Device"], ["C157049", "Pen Device"], ["C79873", "Contain"], ["C76246", "Blood Group A"], ["C50040", "Magnet Device"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C163771", "Illness Intrusiveness Rating 5"], ["C106184", "May"], ["C72886", "Interference"], ["C62355", "With"], ["C142468", "Daily Living"], ["C52874", "SPI1 wt Allele"], ["C75889", "PAX6 wt Allele"], ["C41075", "Implant"], ["C16830", "Medical Device"], ["C71344", "Associate of Science"], ["C76246", "Blood Group A"], ["C99998", "Pacemaker Procedure"], ["C151962", "Magnetic Field"], ["C159124", "GDC Treatment Outcome Terminology"], ["C45828", "Approximate"], ["C161429", "CDISC SDTM Model Version 1.5"], ["C7137", "Cutaneous Mastocytosis"], ["C142605", "Medicinal Product"], ["C79873", "Contain"], ["C61585", "Less Than"], ["C105723", "ECOG Performance Status 1"], ["C48513", "Millimole"], ["C830", "Sodium"], ["C126885", "Twenty Three"], ["C16818", "Mammography"], ["C97722", "PER1 wt Allele"], ["C25488", "Dose"], ["C68254", "Dietary Iodine"], ["C68800", "Elementary Charge"], ["C830", "Sodium"], ["C63628", "Empty"]], "rxnorm.special_warnings": [["T008", "Animal"], ["T016", "Human"], ["T016", "Human"], ["T008", "Animal"], ["4850", "glucose"], ["4850", "glucose"], ["135805", "Humalog"], ["135805", "Humalog"], ["1649574", "Injection"], ["T008", "Animal"], ["T016", "Human"], ["6260", "lead"], ["1649574", "Injection"], ["1043225", "Perform"], ["1649574", "Injection"], ["1649574", "Injection"], ["4850", "glucose"], ["1649574", "Injection"], ["T052", "Activity"], ["1649574", "Injection"], ["T016", "Human"], ["135805", "Humalog"], ["33738", "pioglitazone"], ["33738", "pioglitazone"], ["33738", "pioglitazone"], ["135805", "Humalog"], ["33738", "pioglitazone"], ["1649574", "Injection"], ["135805", "Humalog"], ["T074", "Medical Device"], ["9853", "sodium"], ["9853", "sodium"]], "loinc.special_warnings": [["LA22004-8", "IN"], ["LA25433-6", "Biological"], ["MTHU008539", "Name"], ["LP18011-4", "Number"], ["MTHU021345", "Transferring"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LP6886-8", "Type"], ["LA22025-3", "OR"], ["LP32542-0", "insulin"], ["MTHU021345", "Transferring"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LP6886-8", "Type"], ["LA22025-3", "OR"], ["LP32542-0", "insulin"], ["LA22004-8", "IN"], ["MTHU001445", "Strength"], ["LP6886-8", "Type"], ["LA15487-4", "Regular"], ["LP30875-6", "Nasopharynx"], ["LA8920-6", "Etc."], ["LA30681-3", "Animal"], ["LA19711-3", "Human"], ["LA31677-0", "Human insulin"], ["LA22025-3", "OR"], ["LP72939-9", "Method"], ["LA19712-1", "Recombinant"], ["MTHU003299", "DNA"], ["LA30681-3", "Animal"], ["LP32542-0", "insulin"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["LP6801-7", "Dosage"], ["LP66710-2", "Patient"], ["LP32542-0", "insulin"], ["LP6801-7", "Dosage"], ["LA14331-5", "Both"], ["MTHU001675", "Glucose"], ["LP7741-4", "Control"], ["LP121628-4", "Day"], ["LA18069-7", "Nocturnal"], ["LA11831-7", "Fasting"], ["MTHU001675", "Glucose"], ["LP7741-4", "Control"], ["LA20376-2", "Vial"], ["LP17763-1", "A"], ["LP32542-0", "insulin"], ["LP188733-2", "Syringe"], ["LP6974-2", "first"], ["LA20376-2", "Vial"], ["LP32542-0", "insulin"], ["LP73517-2", "Time"], ["LA22025-3", "OR"], ["LA14542-7", "Injection"], ["LA14523-7", "Advice"], ["MTHU010489", "Physician"], ["LP17763-1", "A"], ["LA9035-2", "Routine"], ["LA14161-6", "May"], ["LA12111-3", "Early"], ["LP75708-5", "Symptoms"], ["LA22025-3", "OR"], ["LA16823-9", "Less"], ["LP14744-4", "Duration"], ["LP128793-9", "Diabetes"], ["LP32542-0", "insulin"], ["LP267221-2", "Therapy"], ["LA26134-9", "Diabetic"], ["LP262855-2", "Nerve"], ["LA18199-2", "Disease"], ["LA22025-3", "OR"], ["LP230280-2", "Medications"], ["LP17763-1", "A"], ["LA15680-4", "Few"], ["LP97172-8", "Transfer"], ["LA30681-3", "Animal"], ["LP32542-0", "insulin"], ["LA31677-0", "Human insulin"], ["LP6486-7", "Reported"], ["LA12111-3", "Early"], ["LP75708-5", "Symptoms"], ["LA16823-9", "Less"], ["LA22025-3", "OR"], ["LP32542-0", "insulin"], ["LP200592-6", "uncorrected"], ["LA22025-3", "OR"], ["LA7453-9", "Loss of consciousness"], ["LA22025-3", "OR"], ["LA7424-0", "Death"], ["LA8914-9", "Inadequate"], ["LA22025-3", "OR"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LP32542-0", "insulin"], ["LA12304-4", "Dependent"], ["LA14161-6", "May"], ["LP14259-3", "Lead"], ["LA26134-9", "Diabetic"], ["LA14542-7", "Injection"], ["LA16902-1", "Continuous"], ["LA14542-7", "Injection"], ["LP73352-4", "Site"], ["LP209029-0", "Amyloidosis"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LP266901-0", "Delayed"], ["LP32542-0", "insulin"], ["LA32282-8", "Worsened"], ["LP7741-4", "Control"], ["LP32542-0", "insulin"], ["LA21988-3", "AT"], ["LP17763-1", "A"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["LA14542-7", "Injection"], ["LP73352-4", "Site"], ["LP6782-9", "Area"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["MTHU029981", "Blood"], ["MTHU001675", "Glucose"], ["LA20297-0", "Monitoring"], ["LP200075-2", "IS"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["LA14542-7", "Injection"], ["LP73352-4", "Site"], ["MTHU065481", "Dose"], ["LP230280-2", "Medications"], ["LA14161-6", "May"], ["LP32542-0", "insulin"], ["LP6801-7", "Dosage"], ["LP32542-0", "insulin"], ["LA14161-6", "May"], ["LA24377-6", "Increased"], ["LA22025-3", "OR"], ["LA7431-5", "Emotional"], ["LP6801-7", "Dosage"], ["LA14161-6", "May"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA24377-6", "Increased"], ["MTHU017278", "Physical activity"], ["LA22025-3", "OR"], ["LP249806-3", "Change"], ["LP183687-5", "usual"], ["MTHU053295", "Diet"], ["LP207667-9", "Exercise"], ["LP17763-1", "A"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["LP17763-1", "A"], ["LA24868-4", "Rapid"], ["LP32542-0", "insulin"], ["LP200075-2", "IS"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP200077-8", "IT"], ["LA14161-6", "May"], ["LA14566-6", "Earlier"], ["LA14542-7", "Injection"], ["LA19711-3", "Human"], ["LP32542-0", "insulin"], ["LA12701-1", "Combination"], ["LP171629-1", "Pioglitazone"], ["LP270144-1", "Cases"], ["LP29659-7", "Cardiac"], ["LA9664-9", "Failure"], ["LP6486-7", "Reported"], ["LP171629-1", "Pioglitazone"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP32542-0", "insulin"], ["LA22004-8", "IN"], ["46467-7", "Risk factors:Find:Pt:^Patient:Nom"], ["LP29659-7", "Cardiac"], ["LP269421-6", "Heart failure"], ["LA22004-8", "IN"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP94823-9", "Treatment"], ["LA12701-1", "Combination"], ["LP171629-1", "Pioglitazone"], ["LP200075-2", "IS"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA12701-1", "Combination"], ["LP200075-2", "IS"], ["LP6425-5", "Observed"], ["LP75708-5", "Symptoms"], ["LP269421-6", "Heart failure"], ["MTHU020882", "Weight gain"], ["LP171629-1", "Pioglitazone"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA22004-8", "IN"], ["LP29659-7", "Cardiac"], ["LP75708-5", "Symptoms"], ["MTHU038481", "Medication"], ["LA9933-8", "Always"], ["LP251102-2", "Check"], ["LP32542-0", "insulin"], ["LA14542-7", "Injection"], ["LA6404-3", "Two"], ["LA18365-9", "Well"], ["MTHU029809", "Other"], ["LP32542-0", "insulin"], ["LP32708-7", "Units"], ["MTHU065481", "Dose"], ["LA15312-4", "Self"], ["LP200075-2", "IS"], ["LA18152-1", "Read"], ["MTHU065481", "Dose"], ["LA17710-7", "Blind"], ["LA22025-3", "OR"], ["LA8969-3", "Poor"], ["MTHU014733", "Vision"], ["LA9933-8", "Always"], ["MTHU066373", "Person"], ["LA8967-7", "Good"], ["MTHU014733", "Vision"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP32542-0", "insulin"], ["LP17763-1", "A"], ["LA15770-3", "6.5"], ["LA14161-6", "May"], ["LA26663-7", "Electronic"], ["LP94757-9", "Medical device"], ["LP17763-1", "A"], ["LP431007-6", "Pacemaker"], ["LA15765-3", "1.5"], ["LA16823-9", "Less"], ["LA6112-2", "1"], ["LP15099-2", "Sodium"], ["LP15217-0", "Mg"], ["MTHU065481", "Dose"], ["LA15457-7", "I"], ["LA13503-0", "E"], ["LP15099-2", "Sodium"]], "snomed.pregnancy": [["67866001", "Insulin (substance)"], ["35105006", "Increased (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["257733005", "Activity (observable entity)|Activities (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["738956005", "Oral (intended site)"], ["108899006", "Contraceptives (product)|Medicinal product acting as contraceptive (product)|Contraceptives (substance)"], ["79440004", "Product containing corticosteroid (product)|Product containing corticosteroid and/or corticosteroid derivative (product)|Corticoid preparation (product)|Product containing corticosteroid and corticosteroid derivative (product)|Corticoid preparation (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["69748006", "Thyroid structure (body structure)"], ["182819002", "Replacement therapy (situation)|Replacement therapy (context-dependent category)"], ["126124009", "Danazol (substance)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["372893009", "Ritodrine (substance)"], ["372897005", "Salbutamol (substance)|Albuterol (substance)"], ["372745006", "Terbutaline (substance)"], ["67866001", "Insulin (substance)"], ["260400001", "Reduced (qualifier value)"], ["18720000", "In (attribute)"], ["52101004", "Present (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["373299009", "Hypoglycemic agent (substance)"], ["257733005", "Activity (observable entity)|Activities (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["738956005", "Oral (intended site)"], ["9203006", "Salicylate (substance)|Salicylate (product)"], ["86495002", "For (qualifier value)"], ["387458008", "Aspirin (substance)"], ["17162000", "Certain (qualifier value)"], ["4824009", "Amine oxidase (flavin-containing) (substance)"], ["33635003", "Serotonin (substance)"], ["17162000", "Certain (qualifier value)"], ["112049007", "Dipeptidyl carboxypeptidase I (substance)"], ["387160004", "Captopril (substance)"], ["372658000", "Enalapril (substance)"], ["85267009", "Angiotensin II (substance)"], ["116647005", "Receptor (substance)"], ["260989008", "Beta - Greek letter (qualifier value)|Greek letter beta (qualifier value)"], ["126155003", "Octreotide preparation (product)|Octreotide preparation (substance)|Product containing octreotide (medicinal product)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["53041004", "Substance with alcohol structure (substance)|Alcohol (substance)"], ["309343006", "Physician (occupation)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["261583007", "Using (attribute)"], ["74964007", "Other (qualifier value)"], ["20401003", "With (attribute)"], ["732727007", "4.4 (qualifier value)"]], "ncit.pregnancy": [["C2271", "Insulin"], ["C106184", "May"], ["C16329", "Belgium"], ["C164135", "Increased"], ["C158169", "Buyei Chinese"], ["C62355", "With"], ["C120914", "Physical Activity Measurement"], ["C71344", "Associate of Science"], ["C389", "Oral Contraceptive"], ["C211", "Therapeutic Corticosteroid"], ["C43508", "Oregon"], ["C23335", "Murine Thyroid"], ["C15471", "Replacement Therapy"], ["C414", "Danazol"], ["C98201", "NEUROD1 wt Allele"], ["C71344", "Associate of Science"], ["C61929", "Ritodrine"], ["C61965", "Terbutaline"], ["C2271", "Insulin"], ["C106184", "May"], ["C16329", "Belgium"], ["C25640", "Reduced"], ["C16727", "India"], ["C25626", "Present"], ["C52874", "SPI1 wt Allele"], ["C62355", "With"], ["C120914", "Physical Activity Measurement"], ["C71344", "Associate of Science"], ["C25311", "Oral"], ["C147431", "Salicylates Measurement"], ["C64956", "For"], ["C48175", "Example"], ["C287", "Aspirin"], ["C258", "Antibiotic"], ["C107561", "Certain"], ["C74691", "Antidepressant Measurement"], ["C74872", "Serotonin Measurement"], ["C107561", "Certain"], ["C80169", "Angiotensin Converting Enzyme Measurement"], ["C340", "Captopril"], ["C62027", "Enalapril"], ["C107562", "Angiotensin-2"], ["C18106", "Receptor"], ["C29576", "Beta-Adrenergic Antagonist"], ["C711", "Octreotide"], ["C43508", "Oregon"], ["C74693", "Ethanol Measurement"], ["C25741", "Physician"], ["C16329", "Belgium"], ["C65140", "When"], ["C118472", "Other License Status"], ["C459", "Medication"], ["C16727", "India"], ["C64911", "Add"], ["C159124", "GDC Treatment Outcome Terminology"], ["C29123", "Insulin Lispro"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"]], "rxnorm.pregnancy": [["T052", "Activity"], ["3102", "danazol"], ["9392", "ritodrine"], ["10368", "terbutaline"], ["T052", "Activity"], ["1311214", "serotonin"], ["T126", "Enzyme"], ["1998", "captopril"], ["3827", "enalapril"], ["1999003", "angiotensin II"], ["T192", "Receptor"], ["7617", "octreotide"], ["135805", "Humalog"]], "loinc.pregnancy": [["LP32542-0", "insulin"], ["LA14161-6", "May"], ["LA24377-6", "Increased"], ["LP72045-5", "Activity"], ["LA9367-9", "Oral"], ["LA22025-3", "OR"], ["LP32941-4", "Thyroid"], ["LP200053-9", "Replacement"], ["LP267221-2", "Therapy"], ["MTHU046384", "Danazol"], ["LP18148-4", "Stimulants"], ["MTHU013595", "Terbutaline"], ["LP32542-0", "insulin"], ["LA14161-6", "May"], ["LA32619-1", "Reduced"], ["LA22004-8", "IN"], ["LP149220-8", "Presence"], ["LP72045-5", "Activity"], ["LA9367-9", "Oral"], ["LP16276-5", "Salicylates"], ["LP31426-7", "Antibiotics"], ["MTHU006782", "Antidepressants"], ["LP31494-5", "Monoamine oxidase inhibitors"], ["MTHU005043", "Serotonin"], ["LP15387-1", "Angiotensin converting enzyme"], ["LP18914-9", "Captopril"], ["LP171394-2", "Enalapril"], ["LP15389-7", "Angiotensin II"], ["T192", "Receptor"], ["MTHU035158", "Octreotide"], ["LA22025-3", "OR"], ["LA28139-6", "Alcohol"], ["MTHU010489", "Physician"], ["MTHU014534", "Other medications"], ["LA22004-8", "IN"], ["LA11132-0", "Addition"], ["LP20592-9", "4"], ["LP20592-9", "4"]], "snomed.driving": [["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["420862001", "On (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255509001", "Large (qualifier value)"], ["410681005", "Count of entities (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["412210000", "Insulin lispro (substance)|Lispro insulin (substance)"], ["420862001", "On (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420862001", "On (qualifier value)"], ["263775005", "Health (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["394447009", "Fetus (person)|Fetus"], ["133933007", "Newborn (person)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["34325006", "Essential (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["20572008", "Good (qualifier value)"], ["246106000", "Control (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67866001", "Insulin (substance)"], ["67866001", "Insulin (substance)"], ["371154000", "Dependent (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255402008", "Gestational (qualifier value)"], ["116154003", "Patient (person)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["67866001", "Insulin (substance)"], ["1912002", "Fall (event)|Fall (finding)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["255246003", "First trimester (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["81170007", "Second (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["70905002", "Third (qualifier value)"], ["272107002", "Trimesters (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["158965000", "Medical practitioner (occupation)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["246106000", "Control (attribute)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["20572008", "Good (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["60132005", "Generalized (qualifier value)"], ["263775005", "Health (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["34325006", "Essential (qualifier value)"], ["18720000", "In (attribute)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["257738001", "Adjustments (procedure)|Adjustments"], ["18720000", "In (attribute)"], ["789480007", "Insulin dose (observable entity)"], ["41829006", "Dietary finding (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["51440002", "Right and left (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["412210000", "Insulin lispro (substance)|Lispro insulin (substance)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["40226000", "Impairment (finding)"], ["18720000", "In (attribute)"], ["387961004", "Kingdom Animalia (organism)"], ["769082003", "5.3 (qualifier value)"]], "ncit.driving": [["C191656", "Pregnant Subject"], ["C25474", "Data"], ["C92667", "SPARC wt Allele"], ["C76246", "Blood Group A"], ["C49508", "Large"], ["C25463", "Count"], ["C52874", "SPI1 wt Allele"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C81168", "Any"], ["C41332", "Adverse Reaction"], ["C52874", "SPI1 wt Allele"], ["C29123", "Insulin Lispro"], ["C92667", "SPARC wt Allele"], ["C191656", "Pregnant Subject"], ["C43508", "Oregon"], ["C92667", "SPARC wt Allele"], ["C25178", "Health"], ["C52874", "SPI1 wt Allele"], ["C16731", "Newborn"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C71578", "Essential"], ["C159124", "GDC Treatment Outcome Terminology"], ["C53297", "Maintenance"], ["C64975", "Good"], ["C64355", "Scientific Control"], ["C52874", "SPI1 wt Allele"], ["C2271", "Insulin"], ["C25705", "Treating"], ["C2271", "Insulin"], ["C63905", "Conditional"], ["C43508", "Oregon"], ["C92804", "Gestation"], ["C2985", "Diabetes Mellitus"], ["C53691", "Veterinary Patient"], ["C191656", "Pregnant Subject"], ["C2271", "Insulin"], ["C114711", "Usually"], ["C50558", "Fall"], ["C25490", "During"], ["C92799", "First Trimester"], ["C16289", "Andorra"], ["C25533", "Increase"], ["C25490", "During"], ["C25666", "Second"], ["C16289", "Andorra"], ["C25260", "Third"], ["C16960", "Patient"], ["C62355", "With"], ["C2985", "Diabetes Mellitus"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1722", "Oprelvekin"], ["C69164", "Doctor"], ["C198613", "CFI wt Allele"], ["C68869", "Are"], ["C73435", "Gravida"], ["C43508", "Oregon"], ["C68869", "Are"], ["C191656", "Pregnant Subject"], ["C61256", "Monitoring"], ["C52874", "SPI1 wt Allele"], ["C2831", "Glucose"], ["C64355", "Scientific Control"], ["C71344", "Associate of Science"], ["C128793", "Microplate Well"], ["C71344", "Associate of Science"], ["C115727", "Safety Reporting Documentation"], ["C25178", "Health"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C71578", "Essential"], ["C16727", "India"], ["C73435", "Gravida"], ["C16960", "Patient"], ["C62355", "With"], ["C2985", "Diabetes Mellitus"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C16960", "Patient"], ["C62355", "With"], ["C2985", "Diabetes Mellitus"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C106184", "May"], ["C16727", "India"], ["C2271", "Insulin"], ["C25488", "Dose"], ["C90364", "Basal Diet"], ["C43508", "Oregon"], ["C49636", "Both"], ["C95089", "Fertility Domain"], ["C29123", "Insulin Lispro"], ["C163546", "Double Immunodiffusion"], ["C25594", "Negation"], ["C61367", "Induction"], ["C95089", "Fertility Domain"], ["C21055", "Impairment"], ["C16727", "India"], ["C14182", "Animal"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"]], "rxnorm.driving": [["86009", "insulin lispro"], ["4850", "glucose"], ["86009", "insulin lispro"], ["T008", "Animal"]], "loinc.driving": [["LP207970-7", "Pregnancy"], ["LP17763-1", "A"], ["LA8981-8", "Large"], ["LP18011-4", "Number"], ["LP73139-5", "Pregnancies"], ["LA14426-3", "Do not"], ["LP32542-0", "insulin"], ["LA31680-4", "Lispro"], ["LP207970-7", "Pregnancy"], ["LA22025-3", "OR"], ["LA17983-0", "Health"], ["LP7744-8", "Newborn"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA8967-7", "Good"], ["LP7741-4", "Control"], ["LP32542-0", "insulin"], ["LP32542-0", "insulin"], ["LA12304-4", "Dependent"], ["LA22025-3", "OR"], ["LP128793-9", "Diabetes"], ["LP66710-2", "Patient"], ["LP207970-7", "Pregnancy"], ["LP32542-0", "insulin"], ["LA14747-2", "Usually"], ["LA7238-4", "Fall"], ["LP208035-8", "First trimester"], ["LA32048-3", "Increase"], ["LP128793-9", "Diabetes"], ["LA18968-0", "Doctor"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA15173-0", "Pregnant"], ["LA22025-3", "OR"], ["LP207970-7", "Pregnancy"], ["LA20297-0", "Monitoring"], ["MTHU001675", "Glucose"], ["LP7741-4", "Control"], ["LA18365-9", "Well"], ["MTHU048728", "General Health"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA15173-0", "Pregnant"], ["LP128793-9", "Diabetes"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LP128793-9", "Diabetes"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LP32542-0", "insulin"], ["MTHU065481", "Dose"], ["MTHU053295", "Diet"], ["LA22025-3", "OR"], ["LA14331-5", "Both"], ["MTHU000074", "Fertility"], ["LP32542-0", "insulin"], ["LA31680-4", "Lispro"], ["LA21291-2", "Not"], ["MTHU000074", "Fertility"], ["LA22004-8", "IN"], ["LA30681-3", "Animal"], ["LP20593-7", "5"], ["LP20591-1", "3"]], "snomed.side_effects": [["116154003", "Patient (person)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["247760006", "Ability to concentrate (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260379002", "Impaired (qualifier value)"], ["19531003", "Following (qualifier value)|Following [Ambiguous]"], ["302866003", "Hypoglycemia (disorder)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67995009", "Special (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["129060000", "Driving, function (observable entity)|Driving (function)|Driving (observable entity)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["71783008", "Automobile, device (physical object)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["419652001", "Take (qualifier value)|Take - dosing instruction imperative (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["129060000", "Driving, function (observable entity)|Driving (function)|Driving (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["260400001", "Reduced (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["2667000", "Absent (qualifier value)"], ["312012004", "Cognitive function: awareness (observable entity)|Cognitive function: awareness (function)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["70232002", "Frequent (qualifier value)"], ["272128006", "Episodes (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["129060000", "Driving, function (observable entity)|Driving (function)|Driving (observable entity)"], ["18720000", "In (attribute)"]], "ncit.side_effects": [["C53691", "Veterinary Patient"], ["C42555", "Siemens"], ["C173045", "Ability Question"], ["C85856", "Concentrate"], ["C16289", "Andorra"], ["C106184", "May"], ["C16329", "Belgium"], ["C21055", "Impairment"], ["C71344", "Associate of Science"], ["C76246", "Blood Group A"], ["C20200", "Outcome"], ["C52874", "SPI1 wt Allele"], ["C106184", "May"], ["C76246", "Blood Group A"], ["C17102", "Risk"], ["C16727", "India"], ["C68869", "Are"], ["C52874", "SPI1 wt Allele"], ["C25684", "Special"], ["C115916", "Important"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C121232", "Ability to Drive"], ["C76246", "Blood Group A"], ["C201831", "CASR wt Allele"], ["C43508", "Oregon"], ["C168221", "Machinery Heart Murmur"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C65105", "Take"], ["C60827", "Precaution"], ["C159124", "GDC Treatment Outcome Terminology"], ["C121232", "Ability to Drive"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C125543", "Importance Rating Score 0"], ["C16727", "India"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C25640", "Reduced"], ["C43508", "Oregon"], ["C190988", "Modified Van Assche Index MVAI101 Original Result - Absent"], ["C54070", "Awareness"], ["C52874", "SPI1 wt Allele"], ["C47896", "Warning"], ["C52874", "SPI1 wt Allele"], ["C43508", "Oregon"], ["C101282", "Have"], ["C64649", "Frequently"], ["C52874", "SPI1 wt Allele"], ["C52874", "SPI1 wt Allele"], ["C121232", "Ability to Drive"], ["C16329", "Belgium"], ["C16727", "India"]], "rxnorm.side_effects": [["1788859", "React"]], "loinc.side_effects": [["LP66710-2", "Patient"], ["LP15241-0", "S"], ["MTHU051452", "Ability to concentrate"], ["LA14161-6", "May"], ["LA13035-3", "Impaired"], ["LP17763-1", "A"], ["LA14161-6", "May"], ["LP17763-1", "A"], ["LA22004-8", "IN"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["MTHU053653", "Driving"], ["LP17763-1", "A"], ["LA22025-3", "OR"], ["MTHU059423", "Operating"], ["MTHU053653", "Driving"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA32619-1", "Reduced"], ["LA22025-3", "OR"], ["LA9634-2", "Absent"], ["LA22025-3", "OR"], ["MTHU053653", "Driving"], ["LA22004-8", "IN"]], "snomed.shelf_life": [["421718005", "Before - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258707000", "year (qualifier value)"], ["255234002", "After (attribute)"], ["255216001", "First (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["255234002", "After (attribute)"], ["732988008", "Cartridge (unit of presentation)"], ["257867005", "Insertion (qualifier value)|Insertion - action (qualifier value)"], ["1222781002", "American Joint Committee on Cancer stage II:8 (qualifier value)"], ["258703001", "day (qualifier value)"]], "ncit.shelf_life": [["C201357", "Before Timing Type"], ["C25340", "Use"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C29848", "Year"], ["C38008", "Post"], ["C25509", "First"], ["C25340", "Use"], ["C38008", "Post"], ["C48481", "Cartridge Dosing Unit"], ["C149594", "Insertion Method of Administration"], ["C126888", "Twenty Eight"], ["C25301", "Day"]], "rxnorm.shelf_life": [["1649572", "Cartridge"]], "loinc.shelf_life": [["LA31720-8", "3 years"], ["LP6974-2", "first"], ["LA6687-3", "Insertion"], ["LA8999-0", "Days"]], "snomed.storage": [["421035004", "To - dosing instruction fragment (qualifier value)"], ["260378005", "Excessive (qualifier value)"], ["88999006", "Heat (physical force)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255589003", "Direct (qualifier value)"], ["279045004", "Sunlight (substance)|Sunlight"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["21546008", "Refrigerator, device (physical object)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["255234002", "After (attribute)"], ["255216001", "First (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["255234002", "After (attribute)"], ["732988008", "Cartridge (unit of presentation)"], ["257867005", "Insertion (qualifier value)|Insertion - action (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["21546008", "Refrigerator, device (physical object)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["351726001", "Below (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["732988008", "Cartridge (unit of presentation)"], ["351726001", "Below (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["732988008", "Cartridge (unit of presentation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["79068005", "Needle, device (physical object)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["351726001", "Below (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["79068005", "Needle, device (physical object)"]], "ncit.storage": [["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C48160", "Freezing"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C168191", "Excessive Daily Salt Intake"], ["C186249", "Estrus"], ["C43508", "Oregon"], ["C62254", "Direct"], ["C201357", "Before Timing Type"], ["C25340", "Use"], ["C60824", "Storage"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C178971", "Refrigerator"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67900", "Centi"], ["C66839", "Eight"], ["C67900", "Centi"], ["C38008", "Post"], ["C25509", "First"], ["C25340", "Use"], ["C38008", "Post"], ["C48481", "Cartridge Dosing Unit"], ["C149594", "Insertion Method of Administration"], ["C41275", "Vial"], ["C60824", "Storage"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C178971", "Refrigerator"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67900", "Centi"], ["C66839", "Eight"], ["C67900", "Centi"], ["C43508", "Oregon"], ["C75330", "Below"], ["C70541", "Lansky Performance Status 30"], ["C67900", "Centi"], ["C48481", "Cartridge Dosing Unit"], ["C60824", "Storage"], ["C75330", "Below"], ["C70541", "Lansky Performance Status 30"], ["C67900", "Centi"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C157049", "Pen Device"], ["C62355", "With"], ["C48685", "Insertion"], ["C48481", "Cartridge Dosing Unit"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C60824", "Storage"], ["C62355", "With"], ["C63846", "Needle Shape"], ["C52253", "Fix"], ["C49466", "Junior"], ["C16289", "Andorra"], ["C157049", "Pen Device"], ["C60824", "Storage"], ["C75330", "Below"], ["C70541", "Lansky Performance Status 30"], ["C67900", "Centi"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C97717", "Pre-filled Pen Syringe"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C60824", "Storage"], ["C62355", "With"], ["C63846", "Needle Shape"], ["C52253", "Fix"]], "rxnorm.storage": [["1649572", "Cartridge"], ["1649572", "Cartridge"], ["1649572", "Cartridge"]], "loinc.storage": [["LA14426-3", "Do not"], ["LA14426-3", "Do not"], ["LA21195-5", "Excessive"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["MTHU000002", "Clinical Class"], ["LP17128-7", "C"], ["LP70420-2", "-"], ["LP36791-9", "8"], ["LP17128-7", "C"], ["LP6974-2", "first"], ["LA6687-3", "Insertion"], ["LA20376-2", "Vial"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["MTHU000002", "Clinical Class"], ["LP17128-7", "C"], ["LP70420-2", "-"], ["LP36791-9", "8"], ["LP17128-7", "C"], ["LA22025-3", "OR"], ["LA14987-4", "Below"], ["LA28855-7", "30"], ["LP17128-7", "C"], ["LA14987-4", "Below"], ["LA28855-7", "30"], ["LP17128-7", "C"], ["LA14426-3", "Do not"], ["LA21291-2", "Not"], ["LP208081-2", "Needle"], ["LA19094-4", "Attached"], ["LA14987-4", "Below"], ["LA28855-7", "30"], ["LP17128-7", "C"], ["LA14426-3", "Do not"], ["LP32605-5", "pre"], ["LA21291-2", "Not"], ["LP208081-2", "Needle"], ["LA19094-4", "Attached"]], "snomed.package": [["733026001", "Vial (unit of presentation)"], ["739006009", "Solution (basic dose form)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["734136001", "Contained in (attribute)"], ["258191002", "Type 1 (qualifier value)"], ["46810001", "Flint (substance)"], ["32039001", "Glass (substance)"], ["415818006", "Vial (qualifier value)|Vial - unit of product usage (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255977005", "Aluminum material (substance)"], ["420874002", "Dimeticone (product)|Product containing dimeticone (medicinal product)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["350103006", "Silicone product (product)|Silicone product (substance)|Product containing silicone (medicinal product)"], ["738998008", "Emulsion (basic dose form)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["732988008", "Cartridge (unit of presentation)"], ["739006009", "Solution (basic dose form)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["734136001", "Contained in (attribute)"], ["258191002", "Type 1 (qualifier value)"], ["46810001", "Flint (substance)"], ["32039001", "Glass (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["427678004", "Disc - unit of product usage (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255977005", "Aluminum material (substance)"], ["420874002", "Dimeticone (product)|Product containing dimeticone (medicinal product)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["350103006", "Silicone product (product)|Silicone product (substance)|Product containing silicone (medicinal product)"], ["738998008", "Emulsion (basic dose form)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["732988008", "Cartridge (unit of presentation)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["32039001", "Glass (substance)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["732988008", "Cartridge (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["739006009", "Solution (basic dose form)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["734136001", "Contained in (attribute)"], ["258191002", "Type 1 (qualifier value)"], ["46810001", "Flint (substance)"], ["32039001", "Glass (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["427678004", "Disc - unit of product usage (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255977005", "Aluminum material (substance)"], ["420874002", "Dimeticone (product)|Product containing dimeticone (medicinal product)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["350103006", "Silicone product (product)|Silicone product (substance)|Product containing silicone (medicinal product)"], ["738998008", "Emulsion (basic dose form)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["732988008", "Cartridge (unit of presentation)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["32039001", "Glass (substance)"], ["732988008", "Cartridge (unit of presentation)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["60773001", "Injector, device (physical object)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["258191002", "Type 1 (qualifier value)"], ["32039001", "Glass (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["427678004", "Disc - unit of product usage (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255977005", "Aluminum material (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420874002", "Dimeticone (product)|Product containing dimeticone (medicinal product)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["350103006", "Silicone product (product)|Silicone product (substance)|Product containing silicone (medicinal product)"], ["738998008", "Emulsion (basic dose form)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["732988008", "Cartridge (unit of presentation)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["60773001", "Injector, device (physical object)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["733006000", "Pen (unit of presentation)"], ["258191002", "Type 1 (qualifier value)"], ["32039001", "Glass (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["427678004", "Disc - unit of product usage (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255977005", "Aluminum material (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420874002", "Dimeticone (product)|Product containing dimeticone (medicinal product)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["350103006", "Silicone product (product)|Silicone product (substance)|Product containing silicone (medicinal product)"], ["738998008", "Emulsion (basic dose form)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["732988008", "Cartridge (unit of presentation)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["60773001", "Injector, device (physical object)"], ["733006000", "Pen (unit of presentation)"], ["733006000", "Pen (unit of presentation)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["706591002", "Magnet (physical object)"], ["732727007", "4.4 (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"]], "ncit.package": [["C41275", "Vial"], ["C42986", "Solution Dosage Form"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C182398", "Contained Diffuse Intrinsic Pontine Glioma Morphology Imaging Finding"], ["C16727", "India"], ["C181852", "Protocol Therapy Status"], ["C68254", "Dietary Iodine"], ["C45301", "Glass"], ["C62355", "With"], ["C43508", "Oregon"], ["C16289", "Andorra"], ["C62355", "With"], ["C43508", "Oregon"], ["C28189", "Silicone"], ["C154466", "Emulsion Dosage Form Category"], ["C106184", "May"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49236", "Therapeutic Procedure"], ["C41275", "Vial"], ["C69122", "Ten"], ["C16816", "Mali"], ["C41275", "Vial"], ["C62653", "Pack Dosage Form"], ["C52874", "SPI1 wt Allele"], ["C105723", "ECOG Performance Status 1"], ["C43508", "Oregon"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C43508", "Oregon"], ["C76246", "Blood Group A"], ["C52874", "SPI1 wt Allele"], ["C163771", "Illness Intrusiveness Rating 5"], ["C163771", "Illness Intrusiveness Rating 5"], ["C62653", "Pack Dosage Form"], ["C52874", "SPI1 wt Allele"], ["C105723", "ECOG Performance Status 1"], ["C25594", "Negation"], ["C64916", "All"], ["C62653", "Pack Dosage Form"], ["C106184", "May"], ["C16329", "Belgium"], ["C48481", "Cartridge Dosing Unit"], ["C42986", "Solution Dosage Form"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C182398", "Contained Diffuse Intrinsic Pontine Glioma Morphology Imaging Finding"], ["C16727", "India"], ["C181852", "Protocol Therapy Status"], ["C68254", "Dietary Iodine"], ["C45301", "Glass"], ["C62355", "With"], ["C43508", "Oregon"], ["C25484", "Discontinue"], ["C16289", "Andorra"], ["C50297", "Plunger Device"], ["C16289", "Andorra"], ["C68869", "Are"], ["C62355", "With"], ["C43508", "Oregon"], ["C28189", "Silicone"], ["C154466", "Emulsion Dosage Form Category"], ["C106184", "May"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49236", "Therapeutic Procedure"], ["C48481", "Cartridge Dosing Unit"], ["C48928", "And/Or"], ["C45301", "Glass"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16816", "Mali"], ["C48481", "Cartridge Dosing Unit"], ["C62653", "Pack Dosage Form"], ["C52874", "SPI1 wt Allele"], ["C163771", "Illness Intrusiveness Rating 5"], ["C43508", "Oregon"], ["C69122", "Ten"], ["C25594", "Negation"], ["C64916", "All"], ["C62653", "Pack Dosage Form"], ["C106184", "May"], ["C16329", "Belgium"], ["C42986", "Solution Dosage Form"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C182398", "Contained Diffuse Intrinsic Pontine Glioma Morphology Imaging Finding"], ["C16727", "India"], ["C181852", "Protocol Therapy Status"], ["C68254", "Dietary Iodine"], ["C45301", "Glass"], ["C62355", "With"], ["C43508", "Oregon"], ["C25484", "Discontinue"], ["C16289", "Andorra"], ["C50297", "Plunger Device"], ["C16289", "Andorra"], ["C68869", "Are"], ["C62355", "With"], ["C43508", "Oregon"], ["C28189", "Silicone"], ["C154466", "Emulsion Dosage Form Category"], ["C106184", "May"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C113426", "Twelve"], ["C49236", "Therapeutic Procedure"], ["C48481", "Cartridge Dosing Unit"], ["C50297", "Plunger Device"], ["C48928", "And/Or"], ["C45301", "Glass"], ["C48481", "Cartridge Dosing Unit"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16816", "Mali"], ["C68869", "Are"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C157049", "Pen Device"], ["C68869", "Are"], ["C25594", "Negation"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16816", "Mali"], ["C62653", "Pack Dosage Form"], ["C52874", "SPI1 wt Allele"], ["C163771", "Illness Intrusiveness Rating 5"], ["C43508", "Oregon"], ["C76246", "Blood Group A"], ["C52874", "SPI1 wt Allele"], ["C69122", "Ten"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C62653", "Pack Dosage Form"], ["C52874", "SPI1 wt Allele"], ["C163771", "Illness Intrusiveness Rating 5"], ["C25594", "Negation"], ["C64916", "All"], ["C62653", "Pack Dosage Form"], ["C106184", "May"], ["C16329", "Belgium"], ["C49466", "Junior"], ["C181852", "Protocol Therapy Status"], ["C68254", "Dietary Iodine"], ["C45301", "Glass"], ["C62355", "With"], ["C25484", "Discontinue"], ["C62355", "With"], ["C16289", "Andorra"], ["C50297", "Plunger Device"], ["C43508", "Oregon"], ["C28189", "Silicone"], ["C154466", "Emulsion Dosage Form Category"], ["C106184", "May"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49236", "Therapeutic Procedure"], ["C48481", "Cartridge Dosing Unit"], ["C50297", "Plunger Device"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16816", "Mali"], ["C68869", "Are"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C157049", "Pen Device"], ["C49466", "Junior"], ["C68869", "Are"], ["C25594", "Negation"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16816", "Mali"], ["C49466", "Junior"], ["C62653", "Pack Dosage Form"], ["C52874", "SPI1 wt Allele"], ["C105723", "ECOG Performance Status 1"], ["C157049", "Pen Device"], ["C163771", "Illness Intrusiveness Rating 5"], ["C21026", "Peripheral Electronic Nerve Stimulation"], ["C43508", "Oregon"], ["C76246", "Blood Group A"], ["C52874", "SPI1 wt Allele"], ["C69122", "Ten"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C62653", "Pack Dosage Form"], ["C52874", "SPI1 wt Allele"], ["C163771", "Illness Intrusiveness Rating 5"], ["C21026", "Peripheral Electronic Nerve Stimulation"], ["C25594", "Negation"], ["C64916", "All"], ["C62653", "Pack Dosage Form"], ["C106184", "May"], ["C16329", "Belgium"], ["C157049", "Pen Device"], ["C181852", "Protocol Therapy Status"], ["C68254", "Dietary Iodine"], ["C45301", "Glass"], ["C62355", "With"], ["C25484", "Discontinue"], ["C62355", "With"], ["C16289", "Andorra"], ["C50297", "Plunger Device"], ["C43508", "Oregon"], ["C28189", "Silicone"], ["C154466", "Emulsion Dosage Form Category"], ["C106184", "May"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49236", "Therapeutic Procedure"], ["C48481", "Cartridge Dosing Unit"], ["C50297", "Plunger Device"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16816", "Mali"], ["C68869", "Are"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C157049", "Pen Device"], ["C157049", "Pen Device"], ["C157049", "Pen Device"], ["C79873", "Contain"], ["C76246", "Blood Group A"], ["C50040", "Magnet Device"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C68869", "Are"], ["C25594", "Negation"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16816", "Mali"], ["C157049", "Pen Device"], ["C62653", "Pack Dosage Form"], ["C52874", "SPI1 wt Allele"], ["C163771", "Illness Intrusiveness Rating 5"], ["C21026", "Peripheral Electronic Nerve Stimulation"], ["C43508", "Oregon"], ["C76246", "Blood Group A"], ["C52874", "SPI1 wt Allele"], ["C69122", "Ten"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C62653", "Pack Dosage Form"], ["C52874", "SPI1 wt Allele"], ["C163771", "Illness Intrusiveness Rating 5"], ["C21026", "Peripheral Electronic Nerve Stimulation"], ["C25594", "Negation"], ["C64916", "All"], ["C62653", "Pack Dosage Form"], ["C106184", "May"], ["C16329", "Belgium"]], "rxnorm.package": [["1649572", "Cartridge"], ["1649572", "Cartridge"], ["1649572", "Cartridge"], ["1649572", "Cartridge"], ["1649572", "Cartridge"], ["1649571", "Pen Injector"], ["1649572", "Cartridge"], ["1649571", "Pen Injector"], ["1649572", "Cartridge"], ["1649571", "Pen Injector"]], "loinc.package": [["LA20376-2", "Vial"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA26022-6", "Type I"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LP17967-8", "Silicone"], ["LA14161-6", "May"], ["LA20376-2", "Vial"], ["LA13942-0", "10"], ["LA20376-2", "Vial"], ["LA15694-5", "1 or 2"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LP20593-7", "5"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LA21291-2", "Not"], ["LA18187-7", "All"], ["LA14161-6", "May"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA26022-6", "Type I"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LP17967-8", "Silicone"], ["LA14161-6", "May"], ["LA22025-3", "OR"], ["LP20591-1", "3"], ["LP20593-7", "5"], ["LA22025-3", "OR"], ["LA13942-0", "10"], ["LA21291-2", "Not"], ["LA18187-7", "All"], ["LA14161-6", "May"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA26022-6", "Type I"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LP17967-8", "Silicone"], ["LA14161-6", "May"], ["LA14558-3", "12"], ["LA22025-3", "OR"], ["LP20591-1", "3"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA19810-3", "Disposable"], ["LA21291-2", "Not"], ["LP20591-1", "3"], ["LP20593-7", "5"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LA13942-0", "10"], ["MTHU000002", "Clinical Class"], ["LP20593-7", "5"], ["LA21291-2", "Not"], ["LA18187-7", "All"], ["LA14161-6", "May"], ["LA26022-6", "Type I"], ["LA22025-3", "OR"], ["LP17967-8", "Silicone"], ["LA14161-6", "May"], ["LP20591-1", "3"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA19810-3", "Disposable"], ["LA21291-2", "Not"], ["LP20591-1", "3"], ["LA6112-2", "1"], ["LP20593-7", "5"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LA13942-0", "10"], ["MTHU000002", "Clinical Class"], ["LP20593-7", "5"], ["LA21291-2", "Not"], ["LA18187-7", "All"], ["LA14161-6", "May"], ["LA26022-6", "Type I"], ["LA22025-3", "OR"], ["LP17967-8", "Silicone"], ["LA14161-6", "May"], ["LP20591-1", "3"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA19810-3", "Disposable"], ["LP17763-1", "A"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA21291-2", "Not"], ["LP20591-1", "3"], ["LP20593-7", "5"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LA13942-0", "10"], ["MTHU000002", "Clinical Class"], ["LP20593-7", "5"], ["LA21291-2", "Not"], ["LA18187-7", "All"], ["LA14161-6", "May"]], "snomed.marketing_authorization_numbers": [["397624008", "Touch sensation, function (observable entity)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["338930006", "Human (organism)"], ["732805008", "6.2 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["26242008", "Mixed (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["338930006", "Human (organism)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["420862001", "On (qualifier value)"], ["243073001", "Advice (regime/therapy)|Advice (regime/therapy)(procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["158965000", "Medical practitioner (occupation)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["417696007", "Medical air (medicinal product)|Medical air (product)"], ["30507006", "Into (attribute)"], ["733020007", "Syringe (unit of presentation)"], ["9726003", "Equal (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["246205007", "Quantity (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67866001", "Insulin (substance)"], ["738993004", "Insert (administration method)"], ["79068005", "Needle, device (physical object)"], ["30507006", "Into (attribute)"], ["67866001", "Insulin (substance)"], ["733026001", "Vial (unit of presentation)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["740685003", "Inject (administration method)"], ["417696007", "Medical air (medicinal product)|Medical air (product)"], ["79068005", "Needle, device (physical object)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["421723005", "Now - dosing instruction fragment (qualifier value)"], ["740685003", "Inject (administration method)"], ["417696007", "Medical air (medicinal product)|Medical air (product)"], ["30507006", "Into (attribute)"], ["733026001", "Vial (unit of presentation)"], ["18720000", "In (attribute)"], ["262126009", "Same (qualifier value)"], ["79068005", "Needle, device (physical object)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["255518004", "Down (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["706491004", "Device tip (physical object)|Tip (physical object)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["79068005", "Needle, device (physical object)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["30507006", "Into (attribute)"], ["733020007", "Syringe (unit of presentation)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["79068005", "Needle, device (physical object)"], ["733026001", "Vial (unit of presentation)"], ["733020007", "Syringe (unit of presentation)"], ["86495002", "For (qualifier value)"], ["417696007", "Medical air (medicinal product)|Medical air (product)"], ["246205007", "Quantity (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["52101004", "Present (qualifier value)"], ["421139008", "Hold - dosing instruction fragment (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["262185006", "Straight (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86088003", "Centesis (procedure)"], ["182353008", "Side (qualifier value)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421812003", "Top (qualifier value)"], ["420620005", "Push - dosing instruction imperative (qualifier value)"], ["255529000", "Out (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["79068005", "Needle, device (physical object)"], ["733026001", "Vial (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["738993004", "Insert (administration method)"], ["30507006", "Into (attribute)"], ["733026001", "Vial (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67866001", "Insulin (substance)"], ["733026001", "Vial (unit of presentation)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["255518004", "Down (qualifier value)"], ["421139008", "Hold - dosing instruction fragment (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["18720000", "In (attribute)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["302539009", "Entire hand (body structure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["418449005", "Gently (qualifier value)"], ["706491004", "Device tip (physical object)|Tip (physical object)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["79068005", "Needle, device (physical object)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["67866001", "Insulin (substance)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67866001", "Insulin (substance)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["79068005", "Needle, device (physical object)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["255518004", "Down (qualifier value)"], ["79068005", "Needle, device (physical object)"], ["717896003", "Does not (qualifier value)"], ["397624008", "Touch sensation, function (observable entity)"], ["1222741009", "American Joint Committee on Cancer stage I:4 (qualifier value)"], ["732988008", "Cartridge (unit of presentation)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["67866001", "Insulin (substance)"], ["733006000", "Pen (unit of presentation)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["263748003", "Established (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["419473009", "Each (qualifier value)"], ["385435006", "Individual (person)"], ["733006000", "Pen (unit of presentation)"], ["86495002", "For (qualifier value)"], ["732988008", "Cartridge (unit of presentation)"], ["79068005", "Needle, device (physical object)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["325017004", "Soluble neutral insulin (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["261583007", "Using (attribute)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["87982008", "Manual (qualifier value)"], ["18720000", "In (attribute)"], ["1681000175101", "Package - unit of product usage (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["18720000", "In (attribute)"], ["87982008", "Manual (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["260726005", "Part (attribute)"], ["386548000", "Personal appearance, function (observable entity)"], ["1156075003", "Broken (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["261583007", "Using (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["255260001", "Following (attribute)"], ["116680003", "Is a (attribute)"], ["60132005", "Generalized (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["422152000", "Wash - dosing instruction imperative (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["10546003", "Site (qualifier value)|Site (attribute)"], ["86495002", "For (qualifier value)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["181469002", "Entire skin (body structure)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["181469002", "Entire skin (body structure)"], ["410676001", "Spreading (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255509001", "Large (qualifier value)"], ["42798000", "Area (qualifier value)"], ["738993004", "Insert (administration method)"], ["79068005", "Needle, device (physical object)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["740685003", "Inject (administration method)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["79068005", "Needle, device (physical object)"], ["255529000", "Out (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["738991002", "Apply (administration method)"], ["722243006", "Pressure (property) (qualifier value)"], ["21481007", "Over (qualifier value)"], ["13136005", "Injection site (morphologic abnormality)"], ["86495002", "For (qualifier value)"], ["261028005", "Several (qualifier value)"], ["257997001", "s (qualifier value)|seconds (qualifier value)|Seconds (qualifier value)"], ["42798000", "Area (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["79068005", "Needle, device (physical object)"], ["86495002", "For (qualifier value)"], ["337026009", "Injection device|Injection device (physical object)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["261074009", "External (qualifier value)"], ["79068005", "Needle, device (physical object)"], ["228254002", "Cap (physical object)"], ["79068005", "Needle, device (physical object)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["260676000", "Use of (attribute)"], ["268517006", "Diabetic monitoring - injection sites (finding)"], ["263861005", "Rotated (qualifier value)"], ["262126009", "Same (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["262009000", "Not used (qualifier value)"], ["242762006", "More (qualifier value)"], ["26175008", "Approximate (qualifier value)"], ["422114001", "Once - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258706009", "month (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["733006000", "Pen (unit of presentation)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["228263000", "Button|Button (physical object)"], ["228263000", "Button|Button (physical object)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["408102007", "Unit dose (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["62479008", "Acquired immune deficiency syndrome (AIDS) (disorder)|AIDS (disorder)|Acquired immune deficiency syndrome (disorder)"], ["18720000", "In (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["413568008", "Application (qualifier value)|Application - unit of product usage (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["67866001", "Insulin (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["45169001", "Without (attribute)"], ["228263000", "Button|Button (physical object)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["413568008", "Application (qualifier value)|Application - unit of product usage (qualifier value)"], ["421939007", "Follow - dosing instruction imperative (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["228263000", "Button|Button (physical object)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["413568008", "Application (qualifier value)|Application - unit of product usage (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["289925000", "Waste material (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255470001", "Local (qualifier value)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["706864006", "Holder (physical object)"], ["421211000", "Lymphoma staging symptom status B (tumor staging)"], ["422276003", "Roman numeral V (qualifier value)"], ["732885005", "83 (qualifier value)"], ["223672001", "Netherlands (geographic location)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["260299005", "Number (qualifier value)|Numbers (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732907001", "96 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732907001", "96 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732907001", "96 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732907001", "96 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732907001", "96 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732907001", "96 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732907001", "96 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732907001", "96 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732907001", "96 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732907001", "96 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732907001", "96 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732907001", "96 (qualifier value)"]], "ncit.marketing_authorization_numbers": [["C38535", "Touch"], ["C62395", "WHO Central Nervous System Grade 2"], ["C64925", "Mix"], ["C29123", "Insulin Lispro"], ["C62355", "With"], ["C14225", "Human"], ["C123459", "Insulin Sensitivity Measurement"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C105723", "ECOG Performance Status 1"], ["C29123", "Insulin Lispro"], ["C16329", "Belgium"], ["C26457", "Mixed (Normal and Tumor)"], ["C62355", "With"], ["C14225", "Human"], ["C123459", "Insulin Sensitivity Measurement"], ["C48440", "Single"], ["C92667", "SPARC wt Allele"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C69164", "Doctor"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C54353", "Draw"], ["C73434", "Air"], ["C25544", "Into"], ["C50207", "Syringe Device"], ["C61582", "Equality"], ["C25256", "Quantity"], ["C52874", "SPI1 wt Allele"], ["C2271", "Insulin"], ["C89327", "Be"], ["C25701", "Taken"], ["C62276", "Insert Dosing Unit"], ["C63846", "Needle Shape"], ["C25544", "Into"], ["C2271", "Insulin"], ["C41275", "Vial"], ["C16289", "Andorra"], ["C64978", "Inject"], ["C73434", "Air"], ["C38061", "Withdraw"], ["C63846", "Needle Shape"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C65002", "Now"], ["C64978", "Inject"], ["C73434", "Air"], ["C25544", "Into"], ["C29123", "Insulin Lispro"], ["C41275", "Vial"], ["C16727", "India"], ["C172515", "S-Adenosylmethionine Measurement"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C38061", "Withdraw"], ["C63846", "Needle Shape"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C47946", "Protein Turn"], ["C41275", "Vial"], ["C16289", "Andorra"], ["C50207", "Syringe Device"], ["C163771", "Illness Intrusiveness Rating 5"], ["C107561", "Certain"], ["C51043", "KAT5 wt Allele"], ["C52874", "SPI1 wt Allele"], ["C63846", "Needle Shape"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C29123", "Insulin Lispro"], ["C38061", "Withdraw"], ["C68815", "Correct"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C29123", "Insulin Lispro"], ["C25544", "Into"], ["C50207", "Syringe Device"], ["C172979", "Fear Score 6"], ["C201357", "Before Timing Type"], ["C63846", "Needle Shape"], ["C25516", "From"], ["C41275", "Vial"], ["C86058", "Check"], ["C50207", "Syringe Device"], ["C64956", "For"], ["C73434", "Air"], ["C25256", "Quantity"], ["C52874", "SPI1 wt Allele"], ["C29123", "Insulin Lispro"], ["C16727", "India"], ["C38267", "Intrathecal Route of Administration"], ["C198613", "CFI wt Allele"], ["C68869", "Are"], ["C160703", "Tumor Necrosis Present"], ["C62290", "Hold"], ["C50207", "Syringe Device"], ["C84362", "Heterosexuality"], ["C16289", "Andorra"], ["C168396", "Precordial Palpation Finding of Tap"], ["C25306", "Side"], ["C65136", "Until"], ["C48150", "Float"], ["C159124", "GDC Treatment Outcome Terminology"], ["C62637", "Top"], ["C65061", "Push"], ["C66768", "CDISC SDTM Adverse Event Outcome Terminology"], ["C62355", "With"], ["C50297", "Plunger Device"], ["C16289", "Andorra"], ["C38061", "Withdraw"], ["C68815", "Correct"], ["C25488", "Dose"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C64914", "Remove"], ["C63846", "Needle Shape"], ["C25516", "From"], ["C41275", "Vial"], ["C52874", "SPI1 wt Allele"], ["C29123", "Insulin Lispro"], ["C16289", "Andorra"], ["C62276", "Insert Dosing Unit"], ["C38267", "Intrathecal Route of Administration"], ["C25544", "Into"], ["C41275", "Vial"], ["C52874", "SPI1 wt Allele"], ["C2271", "Insulin"], ["C47946", "Protein Turn"], ["C41275", "Vial"], ["C16289", "Andorra"], ["C50207", "Syringe Device"], ["C62290", "Hold"], ["C41275", "Vial"], ["C16289", "Andorra"], ["C50207", "Syringe Device"], ["C64654", "Firmly"], ["C16727", "India"], ["C66832", "One"], ["C71216", "Hand Unit of Length"], ["C16289", "Andorra"], ["C64646", "Shake"], ["C64653", "Gently"], ["C107561", "Certain"], ["C51043", "KAT5 wt Allele"], ["C52874", "SPI1 wt Allele"], ["C63846", "Needle Shape"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C2271", "Insulin"], ["C38061", "Withdraw"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C2271", "Insulin"], ["C66839", "Eight"], ["C38061", "Withdraw"], ["C63846", "Needle Shape"], ["C16289", "Andorra"], ["C50207", "Syringe Device"], ["C17149", "Somalia"], ["C63846", "Needle Shape"], ["C86066", "Do"], ["C25594", "Negation"], ["C38535", "Touch"], ["C113428", "Fourteen"], ["C48481", "Cartridge Dosing Unit"], ["C29123", "Insulin Lispro"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C2271", "Insulin"], ["C157049", "Pen Device"], ["C16289", "Andorra"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C62355", "With"], ["C81168", "Any"], ["C118472", "Other License Status"], ["C157049", "Pen Device"], ["C71344", "Associate of Science"], ["C49145", "Accuracy"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C62355", "With"], ["C118472", "Other License Status"], ["C21026", "Peripheral Electronic Nerve Stimulation"], ["C42688", "Instruction"], ["C62355", "With"], ["C64933", "Each"], ["C25190", "Person"], ["C157049", "Pen Device"], ["C16329", "Belgium"], ["C16033", "Follow-Up"], ["C64956", "For"], ["C71584", "Load"], ["C48481", "Cartridge Dosing Unit"], ["C63846", "Needle Shape"], ["C16289", "Andorra"], ["C179441", "Injected Insulin Diabetes Therapy"], ["C49466", "Junior"], ["C16289", "Andorra"], ["C157049", "Pen Device"], ["C201357", "Before Timing Type"], ["C97717", "Pre-filled Pen Syringe"], ["C115541", "Laboratory Sample Manual"], ["C16727", "India"], ["C79887", "Package"], ["C97006", "Leaflet"], ["C16329", "Belgium"], ["C156982", "Do Reading"], ["C97717", "Pre-filled Pen Syringe"], ["C101282", "Have"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C71344", "Associate of Science"], ["C25197", "Recommendation"], ["C16727", "India"], ["C115541", "Laboratory Sample Manual"], ["C21026", "Peripheral Electronic Nerve Stimulation"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C198613", "CFI wt Allele"], ["C81168", "Any"], ["C45313", "Part"], ["C43508", "Oregon"], ["C76246", "Blood Group A"], ["C25488", "Dose"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C25629", "Prior"], ["C54093", "Fill"], ["C43508", "Oregon"], ["C157049", "Pen Device"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25480", "Details"], ["C42688", "Instruction"], ["C64956", "For"], ["C157049", "Pen Device"], ["C16289", "Andorra"], ["C25488", "Dose"], ["C53286", "Next"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C115727", "Safety Reporting Documentation"], ["C25365", "Description"], ["C105723", "ECOG Performance Status 1"], ["C65077", "Wash"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C48912", "Choose"], ["C76246", "Blood Group A"], ["C37901", "Site"], ["C64956", "For"], ["C122632", "Injection Dosing Unit"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C65076", "Clean"], ["C12470", "Skin"], ["C71344", "Associate of Science"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C12470", "Skin"], ["C158169", "Buyei Chinese"], ["C61404", "Spread"], ["C38267", "Intrathecal Route of Administration"], ["C43508", "Oregon"], ["C76246", "Blood Group A"], ["C49508", "Large"], ["C25244", "Area"], ["C62276", "Insert Dosing Unit"], ["C63846", "Needle Shape"], ["C16289", "Andorra"], ["C64978", "Inject"], ["C71344", "Associate of Science"], ["C163771", "Illness Intrusiveness Rating 5"], ["C63846", "Needle Shape"], ["C66768", "CDISC SDTM Adverse Event Outcome Terminology"], ["C16289", "Andorra"], ["C64915", "Apply"], ["C25195", "Pressure"], ["C25490", "During"], ["C77680", "Injection Site"], ["C64956", "For"], ["C107221", "Several"], ["C42535", "Second"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C168025", "Pericardial Rub"], ["C25244", "Area"], ["C172979", "Fear Score 6"], ["C48166", "Disposal"], ["C52874", "SPI1 wt Allele"], ["C50207", "Syringe Device"], ["C16289", "Andorra"], ["C63846", "Needle Shape"], ["C64956", "For"], ["C75889", "PAX6 wt Allele"], ["C122632", "Injection Dosing Unit"], ["C62103", "Device"], ["C25340", "Use"], ["C187054", "Outer Surface"], ["C63846", "Needle Shape"], ["C157719", "College of American Pathologists"], ["C63846", "Needle Shape"], ["C16289", "Andorra"], ["C48166", "Disposal"], ["C52874", "SPI1 wt Allele"], ["C38267", "Intrathecal Route of Administration"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C122632", "Injection Dosing Unit"], ["C37901", "Site"], ["C16329", "Belgium"], ["C17149", "Somalia"], ["C172515", "S-Adenosylmethionine Measurement"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C69062", "Not Used"], ["C61584", "Greater Than"], ["C45828", "Approximate"], ["C64576", "Once"], ["C76246", "Blood Group A"], ["C29846", "Month"], ["C29123", "Insulin Lispro"], ["C157049", "Pen Device"], ["C157049", "Pen Device"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C74299", "Work"], ["C62355", "With"], ["C180379", "Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy"], ["C180379", "Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C75889", "PAX6 wt Allele"], ["C25603", "Optional"], ["C40352", "Multiplicative Product"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C52253", "Fix"], ["C159124", "GDC Treatment Outcome Terminology"], ["C157049", "Pen Device"], ["C25488", "Dose"], ["C50022", "Knob Device"], ["C16289", "Andorra"], ["C2851", "Acquired Immunodeficiency Syndrome"], ["C16727", "India"], ["C29123", "Insulin Lispro"], ["C25488", "Dose"], ["C48191", "Information"], ["C25516", "From"], ["C157049", "Pen Device"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C40414", "Compatible"], ["C25295", "Mobile"], ["C42608", "Computer Application"], ["C157049", "Pen Device"], ["C2271", "Insulin"], ["C62355", "With"], ["C43508", "Oregon"], ["C25718", "Without"], ["C180379", "Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy"], ["C52253", "Fix"], ["C159124", "GDC Treatment Outcome Terminology"], ["C142499", "Data Transmission"], ["C25474", "Data"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25295", "Mobile"], ["C42608", "Computer Application"], ["C64950", "Follow"], ["C42688", "Instruction"], ["C80514", "Provide"], ["C62355", "With"], ["C180379", "Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy"], ["C16289", "Andorra"], ["C42688", "Instruction"], ["C62355", "With"], ["C25295", "Mobile"], ["C42608", "Computer Application"], ["C81168", "Any"], ["C69062", "Not Used"], ["C40352", "Multiplicative Product"], ["C43508", "Oregon"], ["C48187", "Material"], ["C16329", "Belgium"], ["C52874", "SPI1 wt Allele"], ["C64950", "Follow"], ["C25388", "Local-Regional"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C53292", "Marketing"], ["C49989", "Holder Device"], ["C113692", "Child-Pugh Class B"], ["C14533", "V Mouse"], ["C188342", "Eighty Three"], ["C16333", "Benin"], ["C15134", "Utrecht"], ["C16903", "Netherlands"], ["C113429", "Fifteen"], ["C66839", "Eight"], ["C53292", "Marketing"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C192182", "Ninety Six"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C192182", "Ninety Six"], ["C16267", "Afghanistan"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C192182", "Ninety Six"], ["C16289", "Andorra"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C192182", "Ninety Six"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C192182", "Ninety Six"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C192182", "Ninety Six"], ["C16316", "Azerbaijan"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C192182", "Ninety Six"], ["C16305", "Argentina"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C192182", "Ninety Six"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C192182", "Ninety Six"], ["C16321", "Bahamas"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C192182", "Ninety Six"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C192182", "Ninety Six"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C192182", "Ninety Six"]], "rxnorm.marketing_authorization_numbers": [["135805", "Humalog"], ["T016", "Human"], ["135805", "Humalog"], ["T016", "Human"], ["411", "air"], ["411", "air"], ["411", "air"], ["135805", "Humalog"], ["135805", "Humalog"], ["135805", "Humalog"], ["411", "air"], ["135805", "Humalog"], ["135805", "Humalog"], ["1649572", "Cartridge"], ["135805", "Humalog"], ["1649572", "Cartridge"], ["1649574", "Injection"], ["1649574", "Injection"], ["1649574", "Injection"], ["1649574", "Injection"], ["1649574", "Injection"], ["135805", "Humalog"], ["135805", "Humalog"]], "loinc.marketing_authorization_numbers": [["LA33545-7", "Touch"], ["LA15458-5", "II"], ["LA19711-3", "Human"], ["LP20594-5", "6"], ["MTHU000002", "Clinical Class"], ["LA6112-2", "1"], ["LA11840-8", "Mixed"], ["LA19711-3", "Human"], ["LA14523-7", "Advice"], ["LP17763-1", "A"], ["LA18968-0", "Doctor"], ["MTHU000002", "Clinical Class"], ["LP34750-7", "Air"], ["LP188733-2", "Syringe"], ["MTHU051337", "Amount"], ["LP32542-0", "insulin"], ["LA15488-2", "Insert"], ["LP208081-2", "Needle"], ["LP32542-0", "insulin"], ["LA20376-2", "Vial"], ["LP34750-7", "Air"], ["LP208081-2", "Needle"], ["LP20591-1", "3"], ["LA30002-2", "Now"], ["LP34750-7", "Air"], ["LA20376-2", "Vial"], ["LA22004-8", "IN"], ["LA11009-0", "Same"], ["LA14426-3", "Do not"], ["LP208081-2", "Needle"], ["LP20592-9", "4"], ["LA20376-2", "Vial"], ["LP188733-2", "Syringe"], ["LP20593-7", "5"], ["LP208081-2", "Needle"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA9960-1", "Correct"], ["MTHU065481", "Dose"], ["LP188733-2", "Syringe"], ["LP20594-5", "6"], ["LP208081-2", "Needle"], ["LA20376-2", "Vial"], ["LP251102-2", "Check"], ["LP188733-2", "Syringe"], ["LP34750-7", "Air"], ["MTHU051337", "Amount"], ["LA22004-8", "IN"], ["LP200077-8", "IT"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA9633-4", "Present"], ["LP188733-2", "Syringe"], ["LP73349-0", "Side"], ["LP270117-7", "Pressure Ulcer Scale for Healing"], ["LA9960-1", "Correct"], ["MTHU065481", "Dose"], ["LP36790-1", "7"], ["LP208081-2", "Needle"], ["LA20376-2", "Vial"], ["LA15488-2", "Insert"], ["LP200077-8", "IT"], ["LA20376-2", "Vial"], ["LP32542-0", "insulin"], ["LA20376-2", "Vial"], ["LP188733-2", "Syringe"], ["LA20376-2", "Vial"], ["LP188733-2", "Syringe"], ["LA22004-8", "IN"], ["LA6306-0", "One"], ["LP221491-6", "Hand"], ["LP208081-2", "Needle"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP32542-0", "insulin"], ["MTHU065481", "Dose"], ["LP32542-0", "insulin"], ["LP36791-9", "8"], ["LP208081-2", "Needle"], ["LP188733-2", "Syringe"], ["LP208081-2", "Needle"], ["LA21291-2", "Not"], ["LA33545-7", "Touch"], ["LA14560-9", "14"], ["LP17763-1", "A"], ["LA19811-1", "Reusable"], ["LP32542-0", "insulin"], ["LA21291-2", "Not"], ["MTHU029809", "Other"], ["LA19811-1", "Reusable"], ["LA21291-2", "Not"], ["MTHU029809", "Other"], ["LP6820-7", "Instructions"], ["LA12070-1", "Individual"], ["LP208081-2", "Needle"], ["LA20296-2", "Administering"], ["LP32542-0", "insulin"], ["LA14542-7", "Injection"], ["LP32605-5", "pre"], ["LP6376-0", "Manual"], ["LA22004-8", "IN"], ["LA18152-1", "Read"], ["LP32605-5", "pre"], ["LA22004-8", "IN"], ["LP6376-0", "Manual"], ["LA21291-2", "Not"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP32605-5", "pre"], ["LA22025-3", "OR"], ["LA19811-1", "Reusable"], ["LA10393-9", "Refer"], ["LP6820-7", "Instructions"], ["LA20294-7", "Preparing"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LA17571-3", "General"], ["LP6800-9", "Description"], ["LA6112-2", "1"], ["MTHU000002", "Clinical Class"], ["LP17763-1", "A"], ["LP73352-4", "Site"], ["LA14542-7", "Injection"], ["LP20591-1", "3"], ["LP130014-6", "Skin"], ["LP20592-9", "4"], ["LP130014-6", "Skin"], ["LP200077-8", "IT"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LA8981-8", "Large"], ["LP6782-9", "Area"], ["LA15488-2", "Insert"], ["LP208081-2", "Needle"], ["LP20593-7", "5"], ["LP208081-2", "Needle"], ["LP73147-8", "Pressure"], ["LA14542-7", "Injection"], ["LP73352-4", "Site"], ["LA14426-3", "Do not"], ["LP6782-9", "Area"], ["LP20594-5", "6"], ["LP188733-2", "Syringe"], ["LP208081-2", "Needle"], ["LA14542-7", "Injection"], ["LP208081-2", "Needle"], ["LP208081-2", "Needle"], ["LP200077-8", "IT"], ["LP36790-1", "7"], ["LA14542-7", "Injection"], ["LA11009-0", "Same"], ["LP200075-2", "IS"], ["LA157-0", "Not used"], ["LA16824-7", "More"], ["LA6304-5", "Once a month"], ["LP200075-2", "IS"], ["LA16501-1", "Work"], ["LP200075-2", "IS"], ["LA19094-4", "Attached"], ["MTHU065481", "Dose"], ["LA10430-9", "AIDS"], ["LA22004-8", "IN"], ["MTHU065481", "Dose"], ["LP17763-1", "A"], ["LA19695-8", "Compatible"], ["LA33035-9", "Mobile"], ["LP32542-0", "insulin"], ["LA22025-3", "OR"], ["LA19094-4", "Attached"], ["LA33035-9", "Mobile"], ["MTHU058803", "Instructions provided"], ["LP6820-7", "Instructions"], ["LA33035-9", "Mobile"], ["LA22025-3", "OR"], ["LP72916-7", "Material"], ["LA22004-8", "IN"], ["LA4583-6", "Local"], ["LP36790-1", "7"], ["LA14518-7", "B"], ["LP149833-8", "V"], ["LA3754-4", "Netherlands"], ["LA14561-7", "15"], ["LP36791-9", "8"], ["LA25497-1", "Numbers"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"]]}, {"product_info": "Karvea 75 mg tablets.", "composition": "Each tablet contains 75 mg of irbesartan. \nExcipient with known effect: 15.37 mg of lactose monohydrate per tablet. \nFor the full list of excipients, see section 6.1.", "indications": "Karvea is indicated in adults for the treatment of essential hypertension. \nIt is also indicated for the treatment of renal disease in adult patients with hypertension and type 2 \ndiabetes mellitus as part of an antihypertensive medicinal product regimen (see sections 4.3, 4.4, 4.5 \nand 5.1).", "posology": "Posology \nThe usual recommended initial and maintenance dose is 150 mg once daily, with or without food. \nKarvea at a dose of 150 mg once daily generally provides a better 24-hour blood pressure control than \n75 mg. However, initiation of therapy with 75 mg could be considered, particularly in haemodialyzed \npatients and in the elderly over 75 years. \nIn patients insufficiently controlled with 150 mg once daily, the dose of Karvea can be increased to \n300 mg, or other antihypertensive agents can be added (see sections 4.3, 4.4, 4.5 and 5.1). In \nparticular, the addition of a diuretic such as hydrochlorothiazide has been shown to have an additive \neffect with Karvea (see section 4.5). \nIn hypertensive type 2 diabetic patients, therapy should be initiated at 150 mg irbesartan once daily \nand titrated up to 300 mg once daily as the preferred maintenance dose for treatment of renal disease. \nThe demonstration of renal benefit of Karvea in hypertensive type 2 diabetic patients is based on \nstudies where irbesartan was used in addition to other antihypertensive agents, as needed, to reach \ntarget blood pressure (see sections 4.3, 4.4, 4.5 and 5.1). \nSpecial Populations \nRenal impairment\nNo dosage adjustment is necessary in patients with impaired renal function. A lower starting dose \n(75 mg) should be considered for patients undergoing haemodialysis (see section 4.4). \nHepatic impairment\nNo dosage adjustment is necessary in patients with mild to moderate hepatic impairment. There is no \nclinical experience in patients with severe hepatic impairment. \nOlder people\nAlthough consideration should be given to initiating therapy with 75 mg in patients over 75 years of \nage, dosage adjustment is not usually necessary for the older people. \nPaediatric population\nThe safety and efficacy of Karvea in children aged 0 to 18 has not been established. Currently \navailable data are described in sections 4.8, 5.1, and 5.2 but no recommendation on a posology can be \nmade. \nMethod of Administration \nFor oral use.", "contraindications": "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. \nSecond and third trimesters of pregnancy (see sections 4.4 and 4.6). \n The concomitant use of Karvea with aliskiren-containing products is contraindicated in patients with \ndiabetes mellitus or renal impairment (glomerular filtration rate (GFR) <60 ml/min/1.73m2) (see \nsections 4.5 and 5.1).", "special_warnings": "Intravascular volume depletion: symptomatic hypotension, especially after the first dose, may occur in \npatients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, \ndiarrhoea or vomiting. Such conditions should be corrected before the administration of Karvea. \nRenovascular hypertension: there is an increased risk of severe hypotension and renal insufficiency \nwhen patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney \nare treated with medicinal products that affect the renin-angiotensin-aldosterone system. While this is \nnot documented with Karvea, a similar effect should be anticipated with angiotensin-II receptor \nantagonists. \nRenal impairment and kidney transplantation: when Karvea is used in patients with impaired renal \nfunction, a periodic monitoring of potassium and creatinine serum levels is recommended. There is no \nexperience regarding the administration of Karvea in patients with a recent kidney transplantation. \nHypertensive patients with type 2 diabetes and renal disease: the effects of irbesartan both on renal and \ncardiovascular events were not uniform across all subgroups, in an analysis carried out in the study \nwith patients with advanced renal disease. In particular, they appeared less favourable in women and \nnon-white subjects (see section 5.1). \nDual blockade of the renin-angiotensin-aldosterone system (RAAS): \nThere is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or \naliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including \nacute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin \nII receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).  If dual \nblockade therapy is considered absolutely necessary, this should only occur under specialist \nsupervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure. \nACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with \ndiabetic nephropathy. \nHyperkalaemia: as with other medicinal products that affect the renin-angiotensin-aldosterone system, \nhyperkalaemia may occur during the treatment with Karvea, especially in the presence of renal \nimpairment, overt proteinuria due to diabetic renal disease, and/or heart failure. Close monitoring of \nserum potassium in patients at risk is recommended (see section 4.5). \nHypoglycaemia: Karvea may induce hypoglycaemia, particularly in diabetic patients. In patients \ntreated with insulin or antidiabetics an appropriate blood glucose monitoring should be considered; a \ndose adjustment of insulin or antidiabetics may be required when indicated (see section 4.5). \nLithium: the combination of lithium and Karvea is not recommended (see section 4.5). \nAortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators, \nspecial caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive \nhypertrophic cardiomyopathy. \nPrimary aldosteronism: patients with primary aldosteronism generally will not respond to \nantihypertensive medicinal products acting through inhibition of the renin-angiotensin system. \nTherefore, the use of Karvea is not recommended. \nGeneral: in patients whose vascular tone and renal function depend predominantly on the activity of \nthe renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or \nunderlying renal disease, including renal artery stenosis), treatment with angiotensin\nconverting \nenzyme inhibitors or angiotensin-II receptor antagonists that affect this system has been associated \nwith acute hypotension, azotaemia, oliguria, or rarely acute renal failure (see section 4.5). As with any \nantihypertensive agent, excessive blood pressure decrease in patients with ischaemic cardiopathy or \nischaemic cardiovascular disease could result in a myocardial infarction or stroke. \nAs observed for angiotensin converting enzyme inhibitors, irbesartan and the other angiotensin \nantagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, \npossibly because of higher prevalence of low-renin states in the black hypertensive population (see \nsection 5.1). \nPregnancy: angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. \nUnless continued AIIRA therapy is considered essential, patients planning pregnancy should be \nchanged to alternative antihypertensive treatments which have an established safety profile for use in \npregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, \nand, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6). \nPaediatric population: irbesartan has been studied in paediatric populations aged 6 to 16 years old but \nthe current data are insufficient to support an extension of the use in children until further data become \navailable (see sections 4.8, 5.1 and 5.2). \nExcipients: \nKarvea 75 mg tablet contains lactose. Patients with rare hereditary problems of galactose intolerance, \ntotal lactase deficiency or glucose-galactose malabsorption should not take this medicine. \nKarvea 75 mg tablet contains sodium. This medicine contains less than 1 mmol sodium (23 mg) per \ntablet, that is to say essentially \u2018sodium-free\u2019.", "pregnancy": "Diuretics and other antihypertensive agents: other antihypertensive agents may increase the \nhypotensive effects of irbesartan; however Karvea has been safely administered with other \nantihypertensive agents, such as beta-blockers, long-acting calcium channel blockers, and thiazide \ndiuretics. Prior treatment with high dose diuretics may result in volume depletion and a risk of \nhypotension when initiating therapy with Karvea (see section 4.4). \nAliskiren-containing products or ACE-inhibitors: clinical trial data has shown that dual blockade of \nthe renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, \nangiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events \nsuch as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) \ncompared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1). \nPotassium supplements and potassium-sparing diuretics:\nbased on experience with the use of other \nmedicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing \ndiuretics, potassium supplements, salt substitutes containing potassium or other medicinal products \nthat may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium and \nis, therefore, not recommended (see section 4.4). \nLithium:\nreversible increases in serum lithium concentrations and toxicity have been reported during \nconcomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects \nhave been very rarely reported with irbesartan so far. Therefore, this combination is not recommended \n(see section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is \nrecommended.\nNon-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered \nsimultaneously with non-steroidal anti-inflammatory drugs (i.e. selective COX-2 inhibitors, \nacetylsalicylic acid (> 3 g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect \nmay occur. \nAs with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an \nincreased risk of worsening of renal function, including possible acute renal failure, and an increase in \nserum potassium, especially in patients with poor pre-existing renal function. The combination should \nbe administered with caution, especially in the elderly. Patients should be adequately hydrated and \nconsideration should be given to monitoring renal function after initiation of concomitant therapy, and \nperiodically thereafter. \nRepaglinide: irbesartan has the potential to inhibit OATP1B1. In a clinical study, it was reported that \nirbesartan increased the Cmax and AUC of repaglinide (substrate of OATP1B1) by 1.8-fold and \n1.3-fold, respectively, when administered 1 hour before repaglinide. In another study, no relevant \npharmacokinetic interaction was reported, when the two drugs were co-administered. Therefore, dose \nadjustment of antidiabetic treatment such as repaglinide may be required (see section 4.4). \nAdditional information on irbesartan interactions: in clinical studies, the pharmacokinetic of irbesartan \nis not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser \nextent by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were \nobserved when irbesartan was coadministered with warfarin, a medicinal product metabolised by \nCYP2C9. The effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of irbesartan \nhave not been evaluated. The pharmacokinetic of digoxin was not altered by coadministration of \nirbesartan.", "driving": "Pregnancy \nThe use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The \nuse of AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 \nand 4.4). \nEpidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors \nduring the first trimester of pregnancy has not been conclusive; however a small increase in risk \ncannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II \nReceptor Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued \nAIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative \nantihypertensive treatments which have an established safety profile for use in pregnancy. When \npregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, \nalternative therapy should be started. \nExposure to AIIRA therapy during the second and third trimesters is known to induce human \nfetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal \ntoxicity (renal failure, hypotension, hyperkalaemia). (See section 5.3). \nShould exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check \nof renal function and skull is recommended. \nInfants whose mothers have taken AIIRAs should be closely observed for hypotension (see \nsections 4.3 and 4.4). \nBreast-feeding \nBecause no information is available regarding the use of Karvea during breast-feeding, Karvea is not \nrecommended and alternative treatments with better established safety profiles during breast-feeding \nare preferable, especially while nursing a newborn or preterm infant. \nIt is unknown whether irbesartan or its metabolites are excreted in human milk.  \nAvailable pharmacodynamic/toxicological data in rats have shown excretion of irbesartan or its \nmetabolites in milk (for details see 5.3). \nFertility \nIrbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing \nthe first signs of parental toxicity (see section 5.3).", "side_effects": "Based on its pharmacodynamic properties, irbesartan is unlikely to affect the ability to drive and use \nmachine. When driving vehicles or operating machines, it should be taken into account that dizziness \nor weariness may occur during treatment.", "shelf_life": "3 years.", "storage": "Do not store above 30\u00b0C.", "package": "Cartons of 14 tablets in PVC/PVDC/Aluminium blisters. \nCartons of 28 tablets in PVC/PVDC/Aluminium blisters. \nCartons of 56 tablets in PVC/PVDC/Aluminium blisters. \nCartons of 98 tablets in PVC/PVDC/Aluminium blisters. \nCartons of 56 x 1 tablet in PVC/PVDC/Aluminium perforated unit dose blisters. \nNot all pack sizes may be marketed.", "marketing_authorization_numbers": "EU/1/97/049/001-003 \nEU/1/97/049/010 \nEU/1/97/049/013", "filename": "karvea-epar-product-information_en.html", "snomed.product_info": [["732861002", "75 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"]], "ncit.product_info": [["C160687", "Seventy Five"], ["C16818", "Mammography"]], "rxnorm.product_info": [], "loinc.product_info": [["LP15217-0", "Mg"]], "snomed.composition": [["419473009", "Each (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["732861002", "75 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386877005", "Irbesartan (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["36692007", "Known (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["1222818007", "American Joint Committee on Cancer stage III:7 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["423291009", "Product containing lactose (medicinal product)|Lactose (product)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["86495002", "For (qualifier value)"], ["261015003", "Full (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.composition": [["C64933", "Each"], ["C154605", "Tablet Dosage Form Category"], ["C79873", "Contain"], ["C160687", "Seventy Five"], ["C16818", "Mammography"], ["C52874", "SPI1 wt Allele"], ["C29130", "Irbesartan"], ["C42637", "Pharmaceutical Excipient"], ["C62355", "With"], ["C80137", "Known"], ["C71600", "Effect, Appearance"], ["C113429", "Fifteen"], ["C175627", "Thirty Seven"], ["C16818", "Mammography"], ["C52874", "SPI1 wt Allele"], ["C76719", "Lactose Monohydrate"], ["C97722", "PER1 wt Allele"], ["C154605", "Tablet Dosage Form Category"], ["C64956", "For"], ["C25517", "Full"], ["C43432", "List"], ["C52874", "SPI1 wt Allele"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.composition": [["83818", "irbesartan"], ["1305527", "lactose monohydrate"]], "loinc.composition": [["LP136501-6", "Tablet"], ["LP15217-0", "Mg"], ["LP171611-9", "Irbesartan"], ["LA14561-7", "15"], ["LP15217-0", "Mg"], ["LP32533-9", "Lactose"], ["LP136501-6", "Tablet"], ["LA19682-6", "Full"], ["LP204165-7", "List"], ["LP20594-5", "6"], ["LA6112-2", "1"]], "snomed.indications": [["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["18720000", "In (attribute)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["194757006", "High blood pressure (& [essential hypertension]) (disorder)|High blood pressure (& [essential hypertension])"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["90708001", "Kidney disease (disorder)"], ["18720000", "In (attribute)"], ["255397009", "Adult (qualifier value)|Adult"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["266287006", "(Hypertensive disease) or (hypertension)|(Hypertensive disease) or (hypertension) (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258195006", "Type 2 (qualifier value)"], ["267467004", "Diabetes mellitus (& [ketoacidosis]) (disorder)|Diabetes mellitus (& [ketoacidosis])"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["123005000", "Part of (attribute)"], ["1182007", "Hypotensive agent (substance)|Hypotensive agent (product)"], ["763158003", "Medicinal product (product)"], ["732725004", "4.3 (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.indications": [["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C3478", "Essential Hypertension"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C3149", "Kidney Disorder"], ["C16727", "India"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C62355", "With"], ["C168203", "Family History of Hypertension"], ["C16289", "Andorra"], ["C125395", "Bristol Stool Type 2"], ["C2985", "Diabetes Mellitus"], ["C71344", "Associate of Science"], ["C45313", "Part"], ["C52874", "SPI1 wt Allele"], ["C75889", "PAX6 wt Allele"], ["C142605", "Medicinal Product"], ["C165496", "GDC Regimen Terminology"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.indications": [], "loinc.indications": [["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA7444-8", "Hypertension"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["MTHU065909", "Renal"], ["LA18199-2", "Disease"], ["LA22004-8", "IN"], ["LA13524-6", "Adult"], ["LA7444-8", "Hypertension"], ["LP6886-8", "Type"], ["MTHU000002", "Clinical Class"], ["LP74722-7", "Diabetes mellitus"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA15768-7", "4.5"], ["LP20593-7", "5"], ["LA6112-2", "1"]], "snomed.posology": [["897015005", "Recommended (qualifier value)"], ["884001", "Initial (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["732515006", "150 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["45169001", "Without (attribute)"], ["255620007", "Food (substance)|Foods (substance)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732515006", "150 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["3442003", "Better (qualifier value)"], ["1222777002", "American Joint Committee on Cancer stage II:4 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["250765005", "Blood pressure (observable entity)|Blood pressure [dup] (observable entity)"], ["246106000", "Control (attribute)"], ["732861002", "75 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["732861002", "75 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["21481007", "Over (qualifier value)"], ["732861002", "75 (qualifier value)"], ["258707000", "year (qualifier value)"], ["18720000", "In (attribute)"], ["31509003", "Controlled (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["732515006", "150 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["725125005", "300 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["1182007", "Hypotensive agent (substance)|Hypotensive agent (product)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["732725004", "4.3 (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["372695000", "Diuretic (substance)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["387525002", "Hydrochlorothiazide (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["260364009", "Additive (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["18720000", "In (attribute)"], ["258195006", "Type 2 (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["732515006", "150 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["386877005", "Irbesartan (substance)"], ["229797004", "Once daily (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["725125005", "300 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["900000000000548007", "Preferred (foundation metadata concept)"], ["408102007", "Unit dose (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["90708001", "Kidney disease (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["258195006", "Type 2 (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420862001", "On (qualifier value)"], ["386877005", "Irbesartan (substance)"], ["20401003", "With (attribute)"], ["74964007", "Other (qualifier value)"], ["1182007", "Hypotensive agent (substance)|Hypotensive agent (product)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["410525008", "Needed (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["250765005", "Blood pressure (observable entity)|Blood pressure [dup] (observable entity)"], ["732725004", "4.3 (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["67995009", "Special (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["373067005", "No (qualifier value)"], ["260911001", "Dosage (attribute)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["261122009", "Lower (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["732861002", "75 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["86495002", "For (qualifier value)"], ["421503006", "Haemodialysis route (qualifier value)|Hemodialysis route (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["40226000", "Impairment (finding)"], ["373067005", "No (qualifier value)"], ["260911001", "Dosage (attribute)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["371923003", "Mild to moderate (qualifier value)"], ["40226000", "Impairment (finding)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["40226000", "Impairment (finding)"], ["257496000", "Person [dup] (person)|Person (person)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["732861002", "75 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["18720000", "In (attribute)"], ["21481007", "Over (qualifier value)"], ["732861002", "75 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["260911001", "Dosage (attribute)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["86495002", "For (qualifier value)"], ["257496000", "Person [dup] (person)|Person (person)"], ["376171000221106", "Pediatric population (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["263748003", "Established (qualifier value)"], ["15240007", "Current (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["732732008", "4.8 (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["373067005", "No (qualifier value)"], ["420862001", "On (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["260686004", "Method (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["86495002", "For (qualifier value)"], ["26643006", "Oral route (qualifier value)"]], "ncit.posology": [["C102843", "Usual"], ["C25197", "Recommendation"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C16289", "Andorra"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C129532", "One Hundred Fifty"], ["C16818", "Mammography"], ["C125004", "Once Daily"], ["C62355", "With"], ["C43508", "Oregon"], ["C25718", "Without"], ["C62695", "Food"], ["C158997", "GDC Analyte Type Terminology"], ["C76246", "Blood Group A"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C129532", "One Hundred Fifty"], ["C16818", "Mammography"], ["C125004", "Once Daily"], ["C76246", "Blood Group A"], ["C125459", "Improved"], ["C113753", "Twenty Four"], ["C25529", "Hour"], ["C54707", "Blood Pressure Finding"], ["C64355", "Scientific Control"], ["C160687", "Seventy Five"], ["C16818", "Mammography"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C62355", "With"], ["C160687", "Seventy Five"], ["C16818", "Mammography"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C16289", "Andorra"], ["C16727", "India"], ["C16268", "Elderly"], ["C25490", "During"], ["C160687", "Seventy Five"], ["C29848", "Year"], ["C16727", "India"], ["C16960", "Patient"], ["C82500", "Disease Controlled"], ["C62355", "With"], ["C129532", "One Hundred Fifty"], ["C16818", "Mammography"], ["C125004", "Once Daily"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C164135", "Increased"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16645", "Greece"], ["C16818", "Mammography"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C45330", "Added"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C16727", "India"], ["C64911", "Add"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C448", "Diuretic"], ["C71344", "Associate of Science"], ["C29098", "Hydrochlorothiazide"], ["C101282", "Have"], ["C159124", "GDC Treatment Outcome Terminology"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C63495", "Additive"], ["C71600", "Effect, Appearance"], ["C62355", "With"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16727", "India"], ["C125395", "Bristol Stool Type 2"], ["C16960", "Patient"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C158997", "GDC Analyte Type Terminology"], ["C129532", "One Hundred Fifty"], ["C16818", "Mammography"], ["C29130", "Irbesartan"], ["C125004", "Once Daily"], ["C16289", "Andorra"], ["C64643", "Up to"], ["C16645", "Greece"], ["C16818", "Mammography"], ["C125004", "Once Daily"], ["C71344", "Associate of Science"], ["C42711", "Preferred"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25488", "Dose"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C3149", "Kidney Disorder"], ["C52874", "SPI1 wt Allele"], ["C25225", "Renal"], ["C25387", "Benefit"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C125395", "Bristol Stool Type 2"], ["C16960", "Patient"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C29130", "Irbesartan"], ["C154196", "Washo Language"], ["C16727", "India"], ["C64911", "Add"], ["C159124", "GDC Treatment Outcome Terminology"], ["C118472", "Other License Status"], ["C64622", "As Needed"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81004", "Reaching"], ["C184748", "Therapeutically Applicable Research to Generate Effective Treatments"], ["C54707", "Blood Pressure Finding"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C18101", "Special Population"], ["C114592", "Renal Impairment"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C94394", "Cumulative Dose"], ["C49157", "Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C21055", "Impairment"], ["C164220", "Renal Function"], ["C76246", "Blood Group A"], ["C25309", "Lower"], ["C25488", "Dose"], ["C160687", "Seventy Five"], ["C16818", "Mammography"], ["C16329", "Belgium"], ["C64956", "For"], ["C16960", "Patient"], ["C38200", "Administration via Hemodialysis"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C94394", "Cumulative Dose"], ["C49157", "Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C156242", "Mild Hallucination"], ["C159124", "GDC Treatment Outcome Terminology"], ["C148420", "Moderate Hepatic Insufficiency"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C123619", "Clinical Response"], ["C54627", "Experience"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C95553", "People"], ["C113416", "Consideration"], ["C16329", "Belgium"], ["C64974", "Give"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49236", "Therapeutic Procedure"], ["C62355", "With"], ["C160687", "Seventy Five"], ["C16818", "Mammography"], ["C16727", "India"], ["C16960", "Patient"], ["C25490", "During"], ["C160687", "Seventy Five"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C94394", "Cumulative Dose"], ["C49157", "Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C114711", "Usually"], ["C64956", "For"], ["C95553", "People"], ["C17005", "Population Group"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C16423", "Child"], ["C25150", "Age"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C159124", "GDC Treatment Outcome Terminology"], ["C111798", "Eighteen"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C25429", "Availability"], ["C25474", "Data"], ["C68869", "Are"], ["C16727", "India"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25197", "Recommendation"], ["C92667", "SPARC wt Allele"], ["C76246", "Blood Group A"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C85492", "CDISC SDTM Method Terminology"], ["C52874", "SPI1 wt Allele"], ["C70962", "Agent Administration"], ["C64956", "For"], ["C38288", "Oral Route of Administration"]], "rxnorm.posology": [["T168", "Food"], ["5487", "hydrochlorothiazide"], ["83818", "irbesartan"], ["83818", "irbesartan"]], "loinc.posology": [["LP183687-5", "usual"], ["LA6662-6", "Initial"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP15217-0", "Mg"], ["LA6305-2", "Once daily"], ["LA22025-3", "OR"], ["MTHU065486", "Food"], ["LA21988-3", "AT"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP15217-0", "Mg"], ["LA6305-2", "Once daily"], ["LP17763-1", "A"], ["MTHU008342", "Blood pressure"], ["LP7741-4", "Control"], ["LP15217-0", "Mg"], ["LP267221-2", "Therapy"], ["LP15217-0", "Mg"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LP15217-0", "Mg"], ["LA6305-2", "Once daily"], ["MTHU065481", "Dose"], ["LA24377-6", "Increased"], ["LP15217-0", "Mg"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA15768-7", "4.5"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LA22004-8", "IN"], ["LA11132-0", "Addition"], ["LP17763-1", "A"], ["LA30461-0", "Diuretic"], ["MTHU060558", "hydroCHLOROthiazide"], ["LA15768-7", "4.5"], ["LA22004-8", "IN"], ["LP6886-8", "Type"], ["MTHU000002", "Clinical Class"], ["LA26134-9", "Diabetic"], ["LP267221-2", "Therapy"], ["LA21988-3", "AT"], ["LP15217-0", "Mg"], ["LP171611-9", "Irbesartan"], ["LA6305-2", "Once daily"], ["LP15217-0", "Mg"], ["LA6305-2", "Once daily"], ["MTHU065481", "Dose"], ["LP94823-9", "Treatment"], ["MTHU065909", "Renal"], ["LA18199-2", "Disease"], ["MTHU065909", "Renal"], ["LA22004-8", "IN"], ["LP6886-8", "Type"], ["MTHU000002", "Clinical Class"], ["LA26134-9", "Diabetic"], ["LP200075-2", "IS"], ["LP171611-9", "Irbesartan"], ["LA22004-8", "IN"], ["LA11132-0", "Addition"], ["MTHU029809", "Other"], ["LA14060-0", "As needed"], ["LA21676-4", "Reach"], ["MTHU008342", "Blood pressure"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA15768-7", "4.5"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["MTHU065909", "Renal"], ["LA32-8", "No"], ["LP6801-7", "Dosage"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA13035-3", "Impaired"], ["LP31398-8", "Renal function"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP15217-0", "Mg"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA32-8", "No"], ["LP6801-7", "Dosage"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA15008-8", "Mild to moderate"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LP7787-7", "Clinical"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["LP29256-2", "given"], ["LP267221-2", "Therapy"], ["LP15217-0", "Mg"], ["LA22004-8", "IN"], ["MTHU010047", "Age"], ["LP6801-7", "Dosage"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA14747-2", "Usually"], ["LP62263-6", "Population"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LA6111-4", "0"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA32-8", "No"], ["LP111410-9", "Recommendation"], ["LP17763-1", "A"], ["LP72939-9", "Method"], ["LA9367-9", "Oral"]], "snomed.contraindications": [["257550005", "Hypersensitivity (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["261217004", "Substance (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["81170007", "Second (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["70905002", "Third (qualifier value)"], ["272107002", "Trimesters (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732731001", "4.6 (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["260676000", "Use of (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["427002003", "Aliskiren (product)|Product containing aliskiren (medicinal product)"], ["42504009", "Containing (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410536001", "Contraindicated (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["267467004", "Diabetes mellitus (& [ketoacidosis]) (disorder)|Diabetes mellitus (& [ketoacidosis])"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["80274001", "Glomerular filtration rate (observable entity)|Glomerular filtration rate (function)|Glomerular filtration rate, function (observable entity)"], ["732814003", "60 (qualifier value)"], ["258859000", "Milliliter/minute (qualifier value)|mL/min (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.contraindications": [["C3114", "Hypersensitivity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C154405", "Active State"], ["C45306", "Substance"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"], ["C25666", "Second"], ["C16289", "Andorra"], ["C25260", "Third"], ["C52874", "SPI1 wt Allele"], ["C191656", "Pregnant Subject"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C172979", "Fear Score 6"], ["C25730", "Concomitant"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C62355", "With"], ["C65222", "Aliskiren"], ["C79873", "Contain"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C37933", "Contraindicated"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C2985", "Diabetes Mellitus"], ["C43508", "Oregon"], ["C114592", "Renal Impairment"], ["C90505", "Glomerular Filtration Rate"], ["C90505", "Glomerular Filtration Rate"], ["C182738", "ATLAS Score ATLAS101 Original Result - <60"], ["C67412", "Milliliter per Minute per 1.73 m2 of Body Surface Area"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.contraindications": [["T167", "Substance"], ["325646", "aliskiren"]], "loinc.contraindications": [["LA16666-2", "Active"], ["T167", "Substance"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP20594-5", "6"], ["LA6112-2", "1"], ["LP207970-7", "Pregnancy"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20594-5", "6"], ["LP200075-2", "IS"], ["LA4216-3", "Contraindicated"], ["LA22004-8", "IN"], ["LP74722-7", "Diabetes mellitus"], ["LA22025-3", "OR"], ["MTHU065909", "Renal"], ["LP266917-6", "Glomerular filtration rate"], ["LA28853-2", "60"], ["LP6970-0", "minimum"], ["LA6112-2", "1"], ["LA15768-7", "4.5"], ["LP20593-7", "5"], ["LA6112-2", "1"]], "snomed.special_warnings": [["261101003", "Intravascular (qualifier value)"], ["28560003", "Hypovolemia (disorder)"], ["264931009", "Symptomatic (qualifier value)"], ["155487000", "Hypotension (disorder)|Hypotension"], ["255234002", "After (attribute)"], ["255216001", "First (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["18720000", "In (attribute)"], ["118565006", "Volume (property) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["39972003", "Sodium (substance)"], ["722048006", "Diuretic therapy (procedure)"], ["387390002", "Sodium chloride (substance)"], ["162105005", "Diarrhoea (disorder)|Diarrhoea"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422400008", "Vomiting (disorder)"], ["33714007", "Corrected (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["123799005", "Renovascular hypertension (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["155487000", "Hypotension (disorder)|Hypotension"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["723188008", "Renal insufficiency (disorder)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["425414000", "Bilateral renal artery stenosis (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["415582006", "Stenosis (morphologic abnormality)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["51114001", "Arterial structure (body structure)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["181414000", "Entire kidney (body structure)"], ["28995006", "Treated with (attribute)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["112052004", "Renin (substance)"], ["304274007", "Angiotensin (substance)|Angiotensin"], ["42605004", "Aldosterone (substance)"], ["1231568003", "System (basic dose form)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["397934002", "Documented (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["304274007", "Angiotensin (substance)|Angiotensin"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["116647005", "Receptor (substance)"], ["236423003", "Renal impairment (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["70536003", "Transplant of kidney (procedure)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["260379002", "Impaired (qualifier value)"], ["277064003", "Function (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["123115008", "Periodic (qualifier value)|Periodic -RETIRED-"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["88480006", "Potassium (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["15373003", "Creatinine (substance)"], ["67922002", "Serum (substance)"], ["258395000", "Levels (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263852005", "Recent episode (qualifier value)"], ["70536003", "Transplant of kidney (procedure)"], ["35362001", "With type (attribute)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["90708001", "Kidney disease (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386877005", "Irbesartan (substance)"], ["51440002", "Right and left (qualifier value)"], ["420862001", "On (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["27617004", "Uniform (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["18720000", "In (attribute)"], ["272389005", "Analysis (qualifier value)"], ["255529000", "Out (qualifier value)"], ["18720000", "In (attribute)"], ["224699009", "Study (environment)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86005002", "Advanced (qualifier value)"], ["90708001", "Kidney disease (disorder)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["371251000", "White color (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["112052004", "Renin (substance)"], ["304274007", "Angiotensin (substance)|Angiotensin"], ["42605004", "Aldosterone (substance)"], ["1231568003", "System (basic dose form)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["260676000", "Use of (attribute)"], ["85267009", "Angiotensin II (substance)"], ["116647005", "Receptor (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["427002003", "Aliskiren (product)|Product containing aliskiren (medicinal product)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["155487000", "Hypotension (disorder)|Hypotension"], ["154764002", "Hyperkalaemia (disorder)|Hyperkalaemia"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["76114004", "Decreased renal function (finding)"], ["55919000", "Including (qualifier value)"], ["129561000119108", "Pre-renal acute kidney injury (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["112235009", "Through (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["260676000", "Use of (attribute)"], ["304274007", "Angiotensin (substance)|Angiotensin"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["116647005", "Receptor (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["427002003", "Aliskiren (product)|Product containing aliskiren (medicinal product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["351726001", "Below (qualifier value)"], ["309395003", "Hospital specialist (occupation)"], ["225313009", "Supervision (regime/therapy)|Supervision (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["70232002", "Frequent (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["50741009", "Urinary tract function (observable entity)|Urinary tract function (function)"], ["269999005", "Electrolytes (& level (& serum)) (procedure)|Electrolytes (& level (& serum))"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["250765005", "Blood pressure (observable entity)|Blood pressure [dup] (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["85267009", "Angiotensin II (substance)"], ["116647005", "Receptor (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["267470000", "Diabetes + nephropathy (& [Kimmelstiel-Wilson syndrome])|Diabetes + nephropathy (& [Kimmelstiel-Wilson syndrome]) (disorder)"], ["154764002", "Hyperkalaemia (disorder)|Hyperkalaemia"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["112052004", "Renin (substance)"], ["304274007", "Angiotensin (substance)|Angiotensin"], ["42605004", "Aldosterone (substance)"], ["1231568003", "System (basic dose form)"], ["154764002", "Hyperkalaemia (disorder)|Hyperkalaemia"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["52101004", "Present (qualifier value)"], ["40226000", "Impairment (finding)"], ["236719005", "Proteinuria [Ambiguous]|Proteinuria (disorder)"], ["42752001", "Due to (attribute)"], ["127013003", "Disorder of kidney due to diabetes mellitus (disorder)|Diabetic renal disease (disorder)|Disorder of kidney co-occurrent and due to diabetes mellitus (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["155374007", "Heart failure (disorder)|Heart failure"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["166687002", "Serum potassium (& level) (procedure)|Serum potassium (& level)"], ["18720000", "In (attribute)"], ["410519009", "At risk context (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["302866003", "Hypoglycemia (disorder)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["67866001", "Insulin (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["698472009", "Blood glucose monitoring (regime/therapy)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67866001", "Insulin (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["321719003", "Lithium (product)|Lithium product (product)|Lithium product (substance)|Product containing lithium (medicinal product)|Product containing lithium (product)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["321719003", "Lithium (product)|Lithium product (product)|Lithium product (substance)|Product containing lithium (medicinal product)|Product containing lithium (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["261051005", "Aortic (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["79619009", "Mitral valve stenosis (disorder)"], ["389998005", "Hypertrophic cardiomyopathy|Hypertrophic cardiomyopathy (disorder)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["67995009", "Special (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["18720000", "In (attribute)"], ["706873003", "Suffering (finding)"], ["261051005", "Aortic (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["194725005", "Mitral stenosis (& [rheumatic])|Mitral stenosis (& [rheumatic]) (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["389998005", "Hypertrophic cardiomyopathy|Hypertrophic cardiomyopathy (disorder)"], ["190507007", "Primary hyperaldosteronism (disorder)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["190507007", "Primary hyperaldosteronism (disorder)"], ["17884002", "Volition, function (observable entity)|Volition (function)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1182007", "Hypotensive agent (substance)|Hypotensive agent (product)"], ["112235009", "Through (qualifier value)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["112052004", "Renin (substance)"], ["304274007", "Angiotensin (substance)|Angiotensin"], ["1231568003", "System (basic dose form)"], ["260676000", "Use of (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["60132005", "Generalized (qualifier value)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["50741009", "Urinary tract function (observable entity)|Urinary tract function (function)"], ["420862001", "On (qualifier value)"], ["257733005", "Activity (observable entity)|Activities (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["112052004", "Renin (substance)"], ["304274007", "Angiotensin (substance)|Angiotensin"], ["42605004", "Aldosterone (substance)"], ["1231568003", "System (basic dose form)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["195108009", "Heart failure: [right] or [congestive]|Heart failure: [right] or [congestive] (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["90708001", "Kidney disease (disorder)"], ["55919000", "Including (qualifier value)"], ["302233006", "Renal artery stenosis (disorder)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["304274007", "Angiotensin (substance)|Angiotensin"], ["734543001", "Enzyme (disposition)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["304274007", "Angiotensin (substance)|Angiotensin"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["116647005", "Receptor (substance)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["1231568003", "System (basic dose form)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["53737009", "Acute (qualifier value)"], ["155487000", "Hypotension (disorder)|Hypotension"], ["445009001", "Azotemia (disorder)"], ["139461002", "Oliguria|Oliguria (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["129561000119108", "Pre-renal acute kidney injury (disorder)"], ["732729005", "4.5 (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["372586001", "Hypotensive agent (substance)"], ["260378005", "Excessive (qualifier value)"], ["250765005", "Blood pressure (observable entity)|Blood pressure [dup] (observable entity)"], ["260370003", "Decrease (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255426005", "Ischemic (qualifier value)"], ["56265001", "Heart disease (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255426005", "Ischemic (qualifier value)"], ["266275004", "Cardiovascular disease (& [circulatory] or [heart]) (disorder)|Cardiovascular disease (& [circulatory] or [heart])"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["233824008", "Myocardial infarction|Myocardial infarction (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["230690007", "Cerebrovascular accident (disorder)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["112049007", "Dipeptidyl carboxypeptidase I (substance)"], ["386877005", "Irbesartan (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["304274007", "Angiotensin (substance)|Angiotensin"], ["254648000", "Effective (qualifier value)"], ["18720000", "In (attribute)"], ["250765005", "Blood pressure (observable entity)|Blood pressure [dup] (observable entity)"], ["18720000", "In (attribute)"], ["413464008", "African race (racial group)"], ["257496000", "Person [dup] (person)|Person (person)"], ["18720000", "In (attribute)"], ["60022001", "Possible diagnosis (contextual qualifier) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["62482003", "Low (qualifier value)"], ["112052004", "Renin (substance)"], ["18720000", "In (attribute)"], ["413464008", "African race (racial group)"], ["385436007", "Population (social concept)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["85267009", "Angiotensin II (substance)"], ["116647005", "Receptor (substance)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["277132007", "Therapeutic procedure (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["34325006", "Essential (qualifier value)"], ["312011006", "Cognitive function: planning (observable entity)|Cognitive function: planning (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["263703002", "Changed status (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1182007", "Hypotensive agent (substance)|Hypotensive agent (product)"], ["263748003", "Established (qualifier value)"], ["86495002", "For (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["18720000", "In (attribute)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["385652002", "Started (qualifier value)"], ["732725004", "4.3 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732731001", "4.6 (qualifier value)"], ["376171000221106", "Pediatric population (qualifier value)"], ["386877005", "Irbesartan (substance)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222743007", "American Joint Committee on Cancer stage I:6 (qualifier value)"], ["258707000", "year (qualifier value)"], ["272131007", "Old episode (qualifier value)"], ["15240007", "Current (qualifier value)"], ["423437008", "Insufficient (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["390683003", "Support|Support (regime/therapy)"], ["66211004", "Extending (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["18720000", "In (attribute)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["732861002", "75 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["423291009", "Product containing lactose (medicinal product)|Lactose (product)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["255404009", "Hereditary (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["190749000", "Glucose-galactose malabsorption (disorder)"], ["255619001", "Total (qualifier value)"], ["237975008", "Lactase deficiency (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["190749000", "Glucose-galactose malabsorption (disorder)"], ["419652001", "Take (qualifier value)|Take - dosing instruction imperative (qualifier value)"], ["2533004", "Drug (substance)"], ["732861002", "75 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["39972003", "Sodium (substance)"], ["2533004", "Drug (substance)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258718000", "mmol (qualifier value)|millimole (qualifier value)"], ["39972003", "Sodium (substance)"], ["1222776006", "American Joint Committee on Cancer stage II:3 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["39972003", "Sodium (substance)"]], "ncit.special_warnings": [["C38273", "Intravascular Route of Administration"], ["C74720", "Volume Measurement"], ["C168447", "Symptomatic Presentation"], ["C55061", "Hypotension, CTCAE"], ["C38008", "Post"], ["C25509", "First"], ["C25488", "Dose"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C74720", "Volume Measurement"], ["C48928", "And/Or"], ["C830", "Sodium"], ["C158169", "Buyei Chinese"], ["C125253", "How True Feel Vigorous Right Now"], ["C448", "Diuretic"], ["C49236", "Therapeutic Procedure"], ["C78373", "Dietary Route of Administration"], ["C29974", "Sodium Chloride"], ["C53452", "Restriction"], ["C43508", "Oregon"], ["C125278", "How Often Vomiting"], ["C25457", "Condition"], ["C16329", "Belgium"], ["C37934", "Corrected"], ["C201357", "Before Timing Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C85044", "Renovascular Hypertension"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C55061", "Hypotension, CTCAE"], ["C16289", "Andorra"], ["C4376", "Renal Failure"], ["C65140", "When"], ["C16960", "Patient"], ["C62355", "With"], ["C160201", "Tumor Laterality Bilateral"], ["C123221", "Renal Artery Stenosis"], ["C43508", "Oregon"], ["C50754", "Stenosis"], ["C52874", "SPI1 wt Allele"], ["C23307", "Murine Artery"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C48440", "Single"], ["C142468", "Daily Living"], ["C23349", "Murine Kidney"], ["C68869", "Are"], ["C25705", "Treating"], ["C62355", "With"], ["C74893", "Renin Measurement"], ["C248", "Angiotensin-1"], ["C219", "Aldosterone"], ["C149975", "System Dosing Unit"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25356", "Documented"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C72665", "Similarity"], ["C71600", "Effect, Appearance"], ["C16329", "Belgium"], ["C25501", "Expected"], ["C62355", "With"], ["C248", "Angiotensin-1"], ["C62395", "WHO Central Nervous System Grade 2"], ["C18106", "Receptor"], ["C114592", "Renal Impairment"], ["C16289", "Andorra"], ["C15265", "Kidney Transplantation"], ["C65140", "When"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C21055", "Impairment"], ["C25225", "Renal"], ["C25518", "Function"], ["C76246", "Blood Group A"], ["C53578", "Periodic Report"], ["C61256", "Monitoring"], ["C52874", "SPI1 wt Allele"], ["C68279", "Dietary Potassium"], ["C16289", "Andorra"], ["C399", "Creatinine"], ["C13325", "Serum"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C54627", "Experience"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C25280", "Recent"], ["C15265", "Kidney Transplantation"], ["C16960", "Patient"], ["C62355", "With"], ["C26747", "Type 2 Diabetes Mellitus"], ["C16289", "Andorra"], ["C3149", "Kidney Disorder"], ["C25492", "Effect"], ["C52874", "SPI1 wt Allele"], ["C29130", "Irbesartan"], ["C49636", "Both"], ["C92667", "SPARC wt Allele"], ["C25225", "Renal"], ["C16289", "Andorra"], ["C12686", "Cardiovascular System"], ["C150901", "Event Unit"], ["C25594", "Negation"], ["C73944", "Uniform"], ["C81171", "Cross"], ["C64916", "All"], ["C16727", "India"], ["C75889", "PAX6 wt Allele"], ["C25391", "Analysis"], ["C66768", "CDISC SDTM Adverse Event Outcome Terminology"], ["C16727", "India"], ["C45319", "Study Object"], ["C62355", "With"], ["C16960", "Patient"], ["C62355", "With"], ["C25411", "Advanced"], ["C3149", "Kidney Disorder"], ["C16727", "India"], ["C61422", "Lesser"], ["C16727", "India"], ["C16289", "Andorra"], ["C14460", "NON Mouse"], ["C48325", "White"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C62265", "Double"], ["C61286", "Block"], ["C52874", "SPI1 wt Allele"], ["C74893", "Renin Measurement"], ["C248", "Angiotensin-1"], ["C219", "Aldosterone"], ["C149975", "System Dosing Unit"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C43583", "Evidence"], ["C25730", "Concomitant"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C91295", "ACE Gene"], ["C107562", "Angiotensin-2"], ["C18106", "Receptor"], ["C43508", "Oregon"], ["C65222", "Aliskiren"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C55061", "Hypotension, CTCAE"], ["C16289", "Andorra"], ["C25640", "Reduced"], ["C164220", "Renal Function"], ["C166400", "Inclusive"], ["C26808", "Acute Renal Failure"], ["C62265", "Double"], ["C61286", "Block"], ["C52874", "SPI1 wt Allele"], ["C25454", "Combined"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C91295", "ACE Gene"], ["C248", "Angiotensin-1"], ["C62395", "WHO Central Nervous System Grade 2"], ["C18106", "Receptor"], ["C43508", "Oregon"], ["C65222", "Aliskiren"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C198613", "CFI wt Allele"], ["C62265", "Double"], ["C61286", "Block"], ["C49236", "Therapeutic Procedure"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C48440", "Single"], ["C127786", "Occurrence Indicator"], ["C73456", "Specialist Physician"], ["C61372", "Management"], ["C16289", "Andorra"], ["C79916", "Investigative Subject"], ["C159124", "GDC Treatment Outcome Terminology"], ["C64649", "Frequently"], ["C49070", "Closed"], ["C61256", "Monitoring"], ["C52874", "SPI1 wt Allele"], ["C164220", "Renal Function"], ["C464", "Electrolytes"], ["C16289", "Andorra"], ["C54707", "Blood Pressure Finding"], ["C91295", "ACE Gene"], ["C16289", "Andorra"], ["C107562", "Angiotensin-2"], ["C18106", "Receptor"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C84417", "Diabetic Nephropathy"], ["C71344", "Associate of Science"], ["C62355", "With"], ["C118472", "Other License Status"], ["C74893", "Renin Measurement"], ["C248", "Angiotensin-1"], ["C219", "Aldosterone"], ["C149975", "System Dosing Unit"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C25490", "During"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C16727", "India"], ["C25626", "Present"], ["C52874", "SPI1 wt Allele"], ["C25225", "Renal"], ["C21055", "Impairment"], ["C38012", "Proteinuria"], ["C89272", "Due To"], ["C3149", "Kidney Disorder"], ["C48928", "And/Or"], ["C143529", "Heart Failure, CTCAE"], ["C49070", "Closed"], ["C61256", "Monitoring"], ["C52874", "SPI1 wt Allele"], ["C13325", "Serum"], ["C68279", "Dietary Potassium"], ["C16727", "India"], ["C16960", "Patient"], ["C158997", "GDC Analyte Type Terminology"], ["C17102", "Risk"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C106184", "May"], ["C61367", "Induction"], ["C16727", "India"], ["C16960", "Patient"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C2271", "Insulin"], ["C43508", "Oregon"], ["C75889", "PAX6 wt Allele"], ["C92744", "Blood Glucose Measurement"], ["C16329", "Belgium"], ["C76246", "Blood Group A"], ["C82495", "Dose Adjustment"], ["C52874", "SPI1 wt Allele"], ["C2271", "Insulin"], ["C43508", "Oregon"], ["C106184", "May"], ["C16329", "Belgium"], ["C25652", "Requirement"], ["C65140", "When"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C1318", "Lithium Carbonate"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C1318", "Lithium Carbonate"], ["C16289", "Andorra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C12669", "Aorta"], ["C16289", "Andorra"], ["C50654", "Mitral Valve Stenosis"], ["C34449", "Hypertrophic Cardiomyopathy"], ["C71344", "Associate of Science"], ["C62355", "With"], ["C118472", "Other License Status"], ["C25684", "Special"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C16960", "Patient"], ["C25516", "From"], ["C12669", "Aorta"], ["C43508", "Oregon"], ["C50754", "Stenosis"], ["C43508", "Oregon"], ["C34449", "Hypertrophic Cardiomyopathy"], ["C99531", "Primary Cause of Death"], ["C113213", "Hyperaldosteronism"], ["C16960", "Patient"], ["C62355", "With"], ["C99531", "Primary Cause of Death"], ["C113213", "Hyperaldosteronism"], ["C25594", "Negation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C42791", "Inhibition"], ["C52874", "SPI1 wt Allele"], ["C91434", "Renin-Angiotensin Pathway"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C115727", "Safety Reporting Documentation"], ["C16727", "India"], ["C16960", "Patient"], ["C53809", "Adverse Event Associated with the Vascular System"], ["C16289", "Andorra"], ["C164220", "Renal Function"], ["C92667", "SPARC wt Allele"], ["C120914", "Physical Activity Measurement"], ["C52874", "SPI1 wt Allele"], ["C74893", "Renin Measurement"], ["C248", "Angiotensin-1"], ["C219", "Aldosterone"], ["C149975", "System Dosing Unit"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C3080", "Congestive Heart Failure"], ["C43508", "Oregon"], ["C154417", "Underlying"], ["C3149", "Kidney Disorder"], ["C166400", "Inclusive"], ["C123221", "Renal Artery Stenosis"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C248", "Angiotensin-1"], ["C16554", "Enzyme"], ["C43508", "Oregon"], ["C248", "Angiotensin-1"], ["C62395", "WHO Central Nervous System Grade 2"], ["C18106", "Receptor"], ["C149975", "System Dosing Unit"], ["C101282", "Have"], ["C25281", "Associated"], ["C62355", "With"], ["C14140", "Acute"], ["C55061", "Hypotension, CTCAE"], ["C114698", "Oliguria"], ["C43508", "Oregon"], ["C73116", "Rarely"], ["C26808", "Acute Renal Failure"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C71344", "Associate of Science"], ["C62355", "With"], ["C81168", "Any"], ["C270", "Antihypertensive Agent"], ["C168191", "Excessive Daily Salt Intake"], ["C54707", "Blood Pressure Finding"], ["C25640", "Reduced"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C43508", "Oregon"], ["C2931", "Cardiovascular Disorder"], ["C20200", "Outcome"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C27996", "Myocardial Infarction"], ["C43508", "Oregon"], ["C143862", "Stroke, CTCAE"], ["C71344", "Associate of Science"], ["C25599", "Observed"], ["C64956", "For"], ["C80169", "Angiotensin Converting Enzyme Measurement"], ["C29130", "Irbesartan"], ["C16289", "Andorra"], ["C118472", "Other License Status"], ["C248", "Angiotensin-1"], ["C68869", "Are"], ["C61422", "Lesser"], ["C49287", "Effective"], ["C16727", "India"], ["C86568", "Lower"], ["C54707", "Blood Pressure Finding"], ["C16727", "India"], ["C128938", "Black"], ["C95553", "People"], ["C16727", "India"], ["C14460", "NON Mouse"], ["C52874", "SPI1 wt Allele"], ["C25227", "High"], ["C17010", "Prevalence"], ["C52874", "SPI1 wt Allele"], ["C139301", "IPSS Risk Category Low"], ["C74893", "Renin Measurement"], ["C16727", "India"], ["C128938", "Black"], ["C17005", "Population Group"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C191656", "Pregnant Subject"], ["C66930", "Angiotensin II Receptor Antagonist"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C53279", "Continue"], ["C49236", "Therapeutic Procedure"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C71578", "Essential"], ["C16960", "Patient"], ["C25619", "Plan"], ["C191656", "Pregnant Subject"], ["C16329", "Belgium"], ["C25572", "Modification"], ["C159124", "GDC Treatment Outcome Terminology"], ["C97927", "Gene Variant"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C71155", "Established"], ["C49667", "Safety Study"], ["C84385", "Profile"], ["C64956", "For"], ["C25340", "Use"], ["C16727", "India"], ["C191656", "Pregnant Subject"], ["C65140", "When"], ["C191656", "Pregnant Subject"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C15220", "Diagnosis"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C16329", "Belgium"], ["C64597", "Immediately"], ["C16289", "Andorra"], ["C198613", "CFI wt Allele"], ["C15178", "Complementary and Alternative Medicine"], ["C16329", "Belgium"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C172979", "Fear Score 6"], ["C17005", "Population Group"], ["C29130", "Irbesartan"], ["C101282", "Have"], ["C16727", "India"], ["C25150", "Age"], ["C172979", "Fear Score 6"], ["C159124", "GDC Treatment Outcome Terminology"], ["C113430", "Sixteen"], ["C29848", "Year"], ["C65010", "Old"], ["C48434", "Electrical Current"], ["C25474", "Data"], ["C68869", "Are"], ["C126862", "Unsatisfactory"], ["C159124", "GDC Treatment Outcome Terminology"], ["C37902", "Support"], ["C75889", "PAX6 wt Allele"], ["C25270", "Extend"], ["C52874", "SPI1 wt Allele"], ["C25340", "Use"], ["C16727", "India"], ["C16423", "Child"], ["C65136", "Until"], ["C25519", "Further"], ["C25474", "Data"], ["C25429", "Availability"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C160687", "Seventy Five"], ["C16818", "Mammography"], ["C154605", "Tablet Dosage Form Category"], ["C79873", "Contain"], ["C28166", "Lactose"], ["C16960", "Patient"], ["C62355", "With"], ["C13634", "Retinoic Acid Response Element"], ["C27998", "Hereditary"], ["C52874", "SPI1 wt Allele"], ["C68482", "Galactose"], ["C71437", "Intolerance"], ["C25304", "Total"], ["C107438", "Beta-Galactosidase"], ["C94372", "Deficiency"], ["C43508", "Oregon"], ["C2831", "Glucose"], ["C68482", "Galactose"], ["C3214", "Malabsorption Syndrome"], ["C25594", "Negation"], ["C65105", "Take"], ["C459", "Medication"], ["C160687", "Seventy Five"], ["C16818", "Mammography"], ["C154605", "Tablet Dosage Form Category"], ["C79873", "Contain"], ["C830", "Sodium"], ["C459", "Medication"], ["C79873", "Contain"], ["C61585", "Less Than"], ["C105723", "ECOG Performance Status 1"], ["C48513", "Millimole"], ["C830", "Sodium"], ["C126885", "Twenty Three"], ["C16818", "Mammography"], ["C97722", "PER1 wt Allele"], ["C154605", "Tablet Dosage Form Category"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C830", "Sodium"], ["C63628", "Empty"]], "rxnorm.special_warnings": [["9853", "sodium"], ["1312358", "aldosterone"], ["T192", "Receptor"], ["8588", "potassium"], ["2913", "creatinine"], ["83818", "irbesartan"], ["1312358", "aldosterone"], ["1999003", "angiotensin II"], ["T192", "Receptor"], ["325646", "aliskiren"], ["T192", "Receptor"], ["325646", "aliskiren"], ["1999003", "angiotensin II"], ["T192", "Receptor"], ["1312358", "aldosterone"], ["8588", "potassium"], ["4850", "glucose"], ["6448", "lithium"], ["6448", "lithium"], ["T052", "Activity"], ["1312358", "aldosterone"], ["T126", "Enzyme"], ["T192", "Receptor"], ["T126", "Enzyme"], ["83818", "irbesartan"], ["1999003", "angiotensin II"], ["T192", "Receptor"], ["83818", "irbesartan"], ["6211", "lactose"], ["4626", "galactose"], ["41397", "lactase"], ["4850", "glucose"], ["4626", "galactose"], ["9853", "sodium"], ["9853", "sodium"], ["9853", "sodium"]], "loinc.special_warnings": [["MTHU050166", "Intravascular"], ["MTHU003070", "Volume"], ["LA17766-9", "Symptomatic"], ["MTHU020790", "Hypotension"], ["LP6974-2", "first"], ["MTHU065481", "Dose"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["MTHU003070", "Volume"], ["LA22025-3", "OR"], ["LP15099-2", "Sodium"], ["LA30461-0", "Diuretic"], ["LP267221-2", "Therapy"], ["LA22025-3", "OR"], ["LA15099-7", "Vomiting"], ["LP417729-3", "corrected"], ["LA7444-8", "Hypertension"], ["LP200075-2", "IS"], ["LA24544-1", "Increased risk"], ["LA6750-9", "Severe"], ["MTHU020790", "Hypotension"], ["MTHU065909", "Renal"], ["LA25377-5", "Bilateral"], ["LP29817-1", "Renal artery"], ["LP200256-8", "Stenosis"], ["LA22025-3", "OR"], ["LP200256-8", "Stenosis"], ["LP208397-2", "Artery"], ["LP17763-1", "A"], ["LA17717-2", "Single"], ["LA17816-2", "Functioning"], ["LP200461-4", "Kidney"], ["MTHU003186", "Renin"], ["MTHU004471", "Aldosterone"], ["LP200075-2", "IS"], ["LA32226-5", "Not documented"], ["LP17763-1", "A"], ["LA18412-9", "Anticipated"], ["LA15458-5", "II"], ["T192", "Receptor"], ["MTHU065909", "Renal"], ["LP200461-4", "Kidney"], ["LA18638-9", "Transplantation"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA13035-3", "Impaired"], ["MTHU065909", "Renal"], ["LA8916-4", "Function"], ["LP17763-1", "A"], ["LA6663-4", "Periodic"], ["LA20297-0", "Monitoring"], ["LP15098-4", "Potassium"], ["MTHU002337", "Creatinine"], ["LP7567-3", "Serum"], ["LP200075-2", "IS"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP200461-4", "Kidney"], ["LA18638-9", "Transplantation"], ["LP6886-8", "Type"], ["MTHU000002", "Clinical Class"], ["LP128793-9", "Diabetes"], ["MTHU065909", "Renal"], ["LA18199-2", "Disease"], ["LP171611-9", "Irbesartan"], ["LA14331-5", "Both"], ["MTHU065909", "Renal"], ["MTHU065907", "Cardiovascular"], ["MTHU058708", "Events"], ["LA21291-2", "Not"], ["LA18187-7", "All"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LP74341-6", "Study"], ["MTHU065909", "Renal"], ["LA18199-2", "Disease"], ["LA22004-8", "IN"], ["LA16823-9", "Less"], ["LA22004-8", "IN"], ["LA4457-3", "White"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["MTHU003186", "Renin"], ["MTHU004471", "Aldosterone"], ["LP200075-2", "IS"], ["LP230189-5", "Adverse Childhood Experiences"], ["LP15389-7", "Angiotensin II"], ["T192", "Receptor"], ["LA22025-3", "OR"], ["LA14961-9", "Increases"], ["MTHU020790", "Hypotension"], ["LA24378-4", "Decreased"], ["LP31398-8", "Renal function"], ["LA27519-0", "Acute renal failure"], ["LA30596-3", "Combined"], ["LP230189-5", "Adverse Childhood Experiences"], ["LA15458-5", "II"], ["T192", "Receptor"], ["LA22025-3", "OR"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA15768-7", "4.5"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP267221-2", "Therapy"], ["LP200075-2", "IS"], ["LA28116-4", "Specialist"], ["LP427044-5", "Subject"], ["LA16797-5", "Close"], ["LA20297-0", "Monitoring"], ["LP31398-8", "Renal function"], ["LP19403-2", "Electrolytes - single valence"], ["MTHU008342", "Blood pressure"], ["LP230189-5", "Adverse Childhood Experiences"], ["LP15389-7", "Angiotensin II"], ["T192", "Receptor"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA26134-9", "Diabetic"], ["MTHU029809", "Other"], ["MTHU003186", "Renin"], ["MTHU004471", "Aldosterone"], ["LA14161-6", "May"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LP149220-8", "Presence"], ["MTHU065909", "Renal"], ["LA18970-6", "Proteinuria"], ["LA26134-9", "Diabetic"], ["MTHU065909", "Renal"], ["LA18199-2", "Disease"], ["LA22025-3", "OR"], ["LP269421-6", "Heart failure"], ["LA16797-5", "Close"], ["LA20297-0", "Monitoring"], ["LP7567-3", "Serum"], ["LP15098-4", "Potassium"], ["LA22004-8", "IN"], ["LA19952-3", "At risk"], ["LP200075-2", "IS"], ["LA15768-7", "4.5"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LA26134-9", "Diabetic"], ["LA22004-8", "IN"], ["LP32542-0", "insulin"], ["LA22025-3", "OR"], ["MTHU029981", "Blood"], ["MTHU001675", "Glucose"], ["LA20297-0", "Monitoring"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP32542-0", "insulin"], ["LA22025-3", "OR"], ["LA14161-6", "May"], ["LA15768-7", "4.5"], ["MTHU004197", "Lithium"], ["LA12701-1", "Combination"], ["MTHU004197", "Lithium"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA15768-7", "4.5"], ["MTHU002664", "Mitral valve"], ["LP200256-8", "Stenosis"], ["LP128708-7", "Cardiomyopathy"], ["MTHU029809", "Other"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LP200256-8", "Stenosis"], ["LA22025-3", "OR"], ["LP128708-7", "Cardiomyopathy"], ["LA21208-6", "Primary"], ["LA21208-6", "Primary"], ["LA21291-2", "Not"], ["MTHU003186", "Renin"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA17571-3", "General"], ["LA22004-8", "IN"], ["LP31398-8", "Renal function"], ["LP72045-5", "Activity"], ["MTHU003186", "Renin"], ["MTHU004471", "Aldosterone"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LA6750-9", "Severe"], ["LP74648-4", "Congestive heart failure"], ["LA22025-3", "OR"], ["LA26681-9", "Underlying"], ["MTHU065909", "Renal"], ["LA18199-2", "Disease"], ["LP29817-1", "Renal artery"], ["LP200256-8", "Stenosis"], ["LP94823-9", "Treatment"], ["LA31429-6", "Enzyme"], ["LA22025-3", "OR"], ["LA15458-5", "II"], ["T192", "Receptor"], ["LA18821-1", "Acute"], ["MTHU020790", "Hypotension"], ["LA25321-3", "Oliguria"], ["LA22025-3", "OR"], ["LA10066-1", "Rarely"], ["LA27519-0", "Acute renal failure"], ["LA15768-7", "4.5"], ["LA21195-5", "Excessive"], ["MTHU008342", "Blood pressure"], ["LA32049-1", "Decrease"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LA32627-4", "Cardiovascular disease"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA14274-7", "Myocardial infarction"], ["LA22025-3", "OR"], ["LA22099-8", "Stroke"], ["LP6425-5", "Observed"], ["LP15387-1", "Angiotensin converting enzyme"], ["LP171611-9", "Irbesartan"], ["MTHU029809", "Other"], ["LA16823-9", "Less"], ["LA22004-8", "IN"], ["MTHU008342", "Blood pressure"], ["LA22004-8", "IN"], ["MTHU041634", "Black"], ["LA22004-8", "IN"], ["LA9194-7", "Low"], ["MTHU003186", "Renin"], ["LA22004-8", "IN"], ["MTHU041634", "Black"], ["LP62263-6", "Population"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LP207970-7", "Pregnancy"], ["LP15389-7", "Angiotensin II"], ["T192", "Receptor"], ["LA21291-2", "Not"], ["LP266032-4", "during pregnancy"], ["LP267221-2", "Therapy"], ["LP200075-2", "IS"], ["MTHU061379", "Planning"], ["LP207970-7", "Pregnancy"], ["LA30091-5", "Alternative"], ["MTHU021207", "Treatments"], ["LA17589-5", "Safety"], ["LA22004-8", "IN"], ["LP207970-7", "Pregnancy"], ["LP207970-7", "Pregnancy"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA30091-5", "Alternative"], ["LP267221-2", "Therapy"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LP20592-9", "4"], ["LP20594-5", "6"], ["LP62263-6", "Population"], ["LP171611-9", "Irbesartan"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LP20594-5", "6"], ["LA14562-5", "16"], ["LA28127-1", "Insufficient"], ["MTHU015279", "Support"], ["LP72568-6", "Extension"], ["LA22004-8", "IN"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["LP32533-9", "Lactose"], ["LA15679-6", "Rare"], ["MTHU015041", "Hereditary"], ["LP15263-4", "Galactose"], ["LA6661-8", "Total"], ["LP207986-3", "Lactase"], ["LA22025-3", "OR"], ["MTHU001675", "Glucose"], ["LP15263-4", "Galactose"], ["LA21291-2", "Not"], ["LA16120-0", "Medicine"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["LP15099-2", "Sodium"], ["LA16120-0", "Medicine"], ["LA16823-9", "Less"], ["LA6112-2", "1"], ["LP15099-2", "Sodium"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["LP200075-2", "IS"], ["LP15099-2", "Sodium"]], "snomed.pregnancy": [["421829000", "And - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["1182007", "Hypotensive agent (substance)|Hypotensive agent (product)"], ["74964007", "Other (qualifier value)"], ["1182007", "Hypotensive agent (substance)|Hypotensive agent (product)"], ["260366006", "Increase (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386877005", "Irbesartan (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["1182007", "Hypotensive agent (substance)|Hypotensive agent (product)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["260989008", "Beta - Greek letter (qualifier value)|Greek letter beta (qualifier value)"], ["255511005", "Long (qualifier value)"], ["115568009", "Calcium channel (function)|Calcium channel, function (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["860766002", "Thiazide (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["261829003", "High dose (qualifier value)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["28560003", "Hypovolemia (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["155487000", "Hypotension (disorder)|Hypotension"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["427002003", "Aliskiren (product)|Product containing aliskiren (medicinal product)"], ["42504009", "Containing (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["112052004", "Renin (substance)"], ["304274007", "Angiotensin (substance)|Angiotensin"], ["42605004", "Aldosterone (substance)"], ["1231568003", "System (basic dose form)"], ["112235009", "Through (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["260676000", "Use of (attribute)"], ["85267009", "Angiotensin II (substance)"], ["116647005", "Receptor (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["427002003", "Aliskiren (product)|Product containing aliskiren (medicinal product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["47429007", "Associated with (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260864003", "Frequency (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["155487000", "Hypotension (disorder)|Hypotension"], ["154764002", "Hyperkalaemia (disorder)|Hyperkalaemia"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["76114004", "Decreased renal function (finding)"], ["55919000", "Including (qualifier value)"], ["129561000119108", "Pre-renal acute kidney injury (disorder)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["260872001", "Agent (attribute)"], ["732725004", "4.3 (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["88480006", "Potassium (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["88480006", "Potassium (substance)"], ["420862001", "On (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["74964007", "Other (qualifier value)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["112052004", "Renin (substance)"], ["304274007", "Angiotensin (substance)|Angiotensin"], ["1231568003", "System (basic dose form)"], ["79970003", "Simultaneous (qualifier value)"], ["260676000", "Use of (attribute)"], ["88480006", "Potassium (substance)"], ["88480006", "Potassium (substance)"], ["387390002", "Sodium chloride (substance)"], ["42504009", "Containing (qualifier value)"], ["88480006", "Potassium (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["166687002", "Serum potassium (& level) (procedure)|Serum potassium (& level)"], ["258395000", "Levels (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["372877000", "Heparin (substance)"], ["88488004", "Lead (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["166687002", "Serum potassium (& level) (procedure)|Serum potassium (& level)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["321719003", "Lithium (product)|Lithium product (product)|Lithium product (substance)|Product containing lithium (medicinal product)|Product containing lithium (product)"], ["35174006", "Reversible (qualifier value)"], ["18720000", "In (attribute)"], ["67922002", "Serum (substance)"], ["321719003", "Lithium (product)|Lithium product (product)|Lithium product (substance)|Product containing lithium (medicinal product)|Product containing lithium (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["75478009", "Poisoning (disorder)"], ["733985002", "Reported (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["321719003", "Lithium (product)|Lithium product (product)|Lithium product (substance)|Product containing lithium (medicinal product)|Product containing lithium (product)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["112049007", "Dipeptidyl carboxypeptidase I (substance)"], ["260358002", "Very (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386877005", "Irbesartan (substance)"], ["89780004", "Combined (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67922002", "Serum (substance)"], ["321719003", "Lithium (product)|Lithium product (product)|Lithium product (substance)|Product containing lithium (medicinal product)|Product containing lithium (product)"], ["258395000", "Levels (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["255387000", "Inflammatory|Inflammatory (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["85267009", "Angiotensin II (substance)"], ["79970003", "Simultaneous (qualifier value)"], ["255387000", "Inflammatory|Inflammatory (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["261287007", "Cox (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["387458008", "Aspirin (substance)"], ["276140008", "Greater-than symbol > (qualifier value)|> (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258829005", "g/day (qualifier value)|Gram/day (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1182007", "Hypotensive agent (substance)|Hypotensive agent (product)"], ["253861007", "Effect (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["260676000", "Use of (attribute)"], ["85267009", "Angiotensin II (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["88488004", "Lead (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["230993007", "Worsening (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["50741009", "Urinary tract function (observable entity)|Urinary tract function (function)"], ["55919000", "Including (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["129561000119108", "Pre-renal acute kidney injury (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["18720000", "In (attribute)"], ["166687002", "Serum potassium (& level) (procedure)|Serum potassium (& level)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255351007", "Poor - grade (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["50741009", "Urinary tract function (observable entity)|Urinary tract function (function)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["1144674006", "Adequately hydrated (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["50741009", "Urinary tract function (observable entity)|Urinary tract function (function)"], ["255234002", "After (attribute)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["81591007", "Periodic (qualifier value)"], ["386964000", "Repaglinide (substance)"], ["386877005", "Irbesartan (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["224699009", "Study (environment)"], ["733985002", "Reported (qualifier value)"], ["386877005", "Irbesartan (substance)"], ["35105006", "Increased (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["413573002", "Area under the curve (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386964000", "Repaglinide (substance)"], ["1119456000", "Substrate (foundation metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732435009", "1.8 (qualifier value)"], ["26310004", "Folded structure (morphologic abnormality)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732418005", "1.3 (qualifier value)"], ["26310004", "Folded structure (morphologic abnormality)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258702006", "hour (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["386964000", "Repaglinide (substance)"], ["18720000", "In (attribute)"], ["224699009", "Study (environment)"], ["373067005", "No (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["386964000", "Repaglinide (substance)"], ["732727007", "4.4 (qualifier value)"], ["420862001", "On (qualifier value)"], ["386877005", "Irbesartan (substance)"], ["18720000", "In (attribute)"], ["58147004", "Clinical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386877005", "Irbesartan (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["247591002", "Affecting (qualifier value)"], ["387525002", "Hydrochlorothiazide (substance)"], ["386877005", "Irbesartan (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["422602005", "Cytochrome p450 CYP2C9 enzyme (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263796003", "Lesser (qualifier value)"], ["260858005", "Extent (attribute)"], ["373067005", "No (qualifier value)"], ["394653002", "Significant|Significant (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["386877005", "Irbesartan (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["372756006", "Warfarin (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["763158003", "Medicinal product (product)"], ["422602005", "Cytochrome p450 CYP2C9 enzyme (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422602005", "Cytochrome p450 CYP2C9 enzyme (substance)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["387159009", "Rifampin (substance)|Rifampicin (substance)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386877005", "Irbesartan (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387461009", "Digoxin (substance)"], ["18307000", "Altered (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386877005", "Irbesartan (substance)"]], "ncit.pregnancy": [["C448", "Diuretic"], ["C16289", "Andorra"], ["C118472", "Other License Status"], ["C118472", "Other License Status"], ["C106184", "May"], ["C25533", "Increase"], ["C25492", "Effect"], ["C52874", "SPI1 wt Allele"], ["C29130", "Irbesartan"], ["C101282", "Have"], ["C25382", "Administered"], ["C62355", "With"], ["C118472", "Other License Status"], ["C71344", "Associate of Science"], ["C29576", "Beta-Adrenergic Antagonist"], ["C25248", "Long"], ["C333", "Calcium Channel Blocker"], ["C16289", "Andorra"], ["C448", "Diuretic"], ["C16124", "Prior Therapy"], ["C62355", "With"], ["C139304", "IPSS Risk Category High"], ["C25488", "Dose"], ["C448", "Diuretic"], ["C106184", "May"], ["C20200", "Outcome"], ["C16727", "India"], ["C74720", "Volume Measurement"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C55061", "Hypotension, CTCAE"], ["C65140", "When"], ["C49236", "Therapeutic Procedure"], ["C62355", "With"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C65222", "Aliskiren"], ["C79873", "Contain"], ["C43508", "Oregon"], ["C91295", "ACE Gene"], ["C142441", "Clinical Trial Data"], ["C101282", "Have"], ["C62265", "Double"], ["C61286", "Block"], ["C52874", "SPI1 wt Allele"], ["C74893", "Renin Measurement"], ["C248", "Angiotensin-1"], ["C219", "Aldosterone"], ["C149975", "System Dosing Unit"], ["C25454", "Combined"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C91295", "ACE Gene"], ["C107562", "Angiotensin-2"], ["C18106", "Receptor"], ["C43508", "Oregon"], ["C65222", "Aliskiren"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25281", "Associated"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C25227", "High"], ["C71113", "CDISC SDTM Frequency Terminology"], ["C52874", "SPI1 wt Allele"], ["C49562", "Adverse Event Domain"], ["C71344", "Associate of Science"], ["C55061", "Hypotension, CTCAE"], ["C16289", "Andorra"], ["C25640", "Reduced"], ["C164220", "Renal Function"], ["C166400", "Inclusive"], ["C26808", "Acute Renal Failure"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C48440", "Single"], ["C41161", "Protocol Agent"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C68279", "Dietary Potassium"], ["C1505", "Dietary Supplement"], ["C16289", "Andorra"], ["C68279", "Dietary Potassium"], ["C448", "Diuretic"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C54627", "Experience"], ["C62355", "With"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C118472", "Other License Status"], ["C91434", "Renin-Angiotensin Pathway"], ["C25730", "Concomitant"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C68279", "Dietary Potassium"], ["C448", "Diuretic"], ["C68279", "Dietary Potassium"], ["C1505", "Dietary Supplement"], ["C29974", "Sodium Chloride"], ["C79873", "Contain"], ["C68279", "Dietary Potassium"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C106184", "May"], ["C25533", "Increase"], ["C13325", "Serum"], ["C68279", "Dietary Potassium"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C539", "Heparin"], ["C106184", "May"], ["C25552", "Lead"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16727", "India"], ["C13325", "Serum"], ["C68279", "Dietary Potassium"], ["C16289", "Andorra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C1318", "Lithium Carbonate"], ["C16727", "India"], ["C13325", "Serum"], ["C1318", "Lithium Carbonate"], ["C16289", "Andorra"], ["C27990", "Toxicity"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C25490", "During"], ["C25730", "Concomitant"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C1318", "Lithium Carbonate"], ["C62355", "With"], ["C80169", "Angiotensin Converting Enzyme Measurement"], ["C72665", "Similarity"], ["C25492", "Effect"], ["C101282", "Have"], ["C116076", "Very"], ["C73116", "Rarely"], ["C188308", "Reported Information"], ["C62355", "With"], ["C29130", "Irbesartan"], ["C17149", "Somalia"], ["C174434", "Fibrinogen to Albumin Ratio Measurement"], ["C61517", "Combination"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C198613", "CFI wt Allele"], ["C61517", "Combination"], ["C61256", "Monitoring"], ["C52874", "SPI1 wt Allele"], ["C13325", "Serum"], ["C1318", "Lithium Carbonate"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C14460", "NON Mouse"], ["C256", "Anti-Inflammatory Agent"], ["C65140", "When"], ["C107562", "Angiotensin-2"], ["C68869", "Are"], ["C25382", "Administered"], ["C62355", "With"], ["C14460", "NON Mouse"], ["C256", "Anti-Inflammatory Agent"], ["C68254", "Dietary Iodine"], ["C68800", "Elementary Charge"], ["C17984", "Prostaglandin G/H Synthase 2"], ["C287", "Aspirin"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C67372", "Gram per 24 Hours"], ["C16289", "Andorra"], ["C14460", "NON Mouse"], ["C257", "Nonsteroidal Antiinflammatory Drug"], ["C61471", "Attenuation"], ["C52874", "SPI1 wt Allele"], ["C71600", "Effect, Appearance"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C71344", "Associate of Science"], ["C62355", "With"], ["C91295", "ACE Gene"], ["C25730", "Concomitant"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C107562", "Angiotensin-2"], ["C16289", "Andorra"], ["C257", "Nonsteroidal Antiinflammatory Drug"], ["C106184", "May"], ["C25552", "Lead"], ["C159124", "GDC Treatment Outcome Terminology"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C52874", "SPI1 wt Allele"], ["C164220", "Renal Function"], ["C166400", "Inclusive"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C26808", "Acute Renal Failure"], ["C16289", "Andorra"], ["C75889", "PAX6 wt Allele"], ["C25533", "Increase"], ["C16727", "India"], ["C13325", "Serum"], ["C68279", "Dietary Potassium"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C177356", "Malignant Germ Cell International Collaborative Risk Classification, Poor"], ["C73621", "Pre-existing"], ["C164220", "Renal Function"], ["C61517", "Combination"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C62355", "With"], ["C16727", "India"], ["C16268", "Elderly"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C16289", "Andorra"], ["C113416", "Consideration"], ["C16329", "Belgium"], ["C64974", "Give"], ["C159124", "GDC Treatment Outcome Terminology"], ["C61256", "Monitoring"], ["C164220", "Renal Function"], ["C38008", "Post"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C53630", "Concomitant Therapy"], ["C16289", "Andorra"], ["C47703", "Repaglinide"], ["C29130", "Irbesartan"], ["C101282", "Have"], ["C62230", "Potential"], ["C159124", "GDC Treatment Outcome Terminology"], ["C106615", "SLCO1B1 wt Allele"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C15206", "Clinical Study"], ["C38267", "Intrathecal Route of Administration"], ["C154196", "Washo Language"], ["C188308", "Reported Information"], ["C29130", "Irbesartan"], ["C164135", "Increased"], ["C70918", "Cmax"], ["C16289", "Andorra"], ["C64774", "Area Under Curve"], ["C52874", "SPI1 wt Allele"], ["C47703", "Repaglinide"], ["C50196", "Substrate Device"], ["C52874", "SPI1 wt Allele"], ["C106615", "SLCO1B1 wt Allele"], ["C158169", "Buyei Chinese"], ["C105723", "ECOG Performance Status 1"], ["C66839", "Eight"], ["C16289", "Andorra"], ["C161427", "CDISC SDTM Model Version 1.3"], ["C65140", "When"], ["C25382", "Administered"], ["C105723", "ECOG Performance Status 1"], ["C25529", "Hour"], ["C201357", "Before Timing Type"], ["C47703", "Repaglinide"], ["C16727", "India"], ["C45319", "Study Object"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C70664", "Relevance"], ["C49663", "Pharmacokinetic Study"], ["C54216", "Interaction"], ["C154196", "Washo Language"], ["C188308", "Reported Information"], ["C65140", "When"], ["C66833", "Two"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C25488", "Dose"], ["C49157", "Adjustment"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C71344", "Associate of Science"], ["C47703", "Repaglinide"], ["C106184", "May"], ["C16329", "Belgium"], ["C25652", "Requirement"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C53586", "Additional Information Report"], ["C92667", "SPARC wt Allele"], ["C29130", "Irbesartan"], ["C16727", "India"], ["C15206", "Clinical Study"], ["C49663", "Pharmacokinetic Study"], ["C52874", "SPI1 wt Allele"], ["C29130", "Irbesartan"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C64917", "Affected"], ["C158169", "Buyei Chinese"], ["C29098", "Hydrochlorothiazide"], ["C29130", "Irbesartan"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C158169", "Buyei Chinese"], ["C161355", "Cytochrome P450 2C9 Measurement"], ["C16289", "Andorra"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C61422", "Lesser"], ["C25332", "Extent"], ["C158169", "Buyei Chinese"], ["C63811", "Glucuronidation Pathway"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C41130", "Significant"], ["C49663", "Pharmacokinetic Study"], ["C43508", "Oregon"], ["C49662", "Pharmacodynamic Study"], ["C25599", "Observed"], ["C65140", "When"], ["C29130", "Irbesartan"], ["C154196", "Washo Language"], ["C62355", "With"], ["C945", "Warfarin"], ["C76246", "Blood Group A"], ["C142605", "Medicinal Product"], ["C158169", "Buyei Chinese"], ["C161355", "Cytochrome P450 2C9 Measurement"], ["C25492", "Effect"], ["C52874", "SPI1 wt Allele"], ["C161355", "Cytochrome P450 2C9 Measurement"], ["C71344", "Associate of Science"], ["C811", "Rifampin"], ["C92667", "SPARC wt Allele"], ["C49663", "Pharmacokinetic Study"], ["C52874", "SPI1 wt Allele"], ["C29130", "Irbesartan"], ["C101282", "Have"], ["C25594", "Negation"], ["C25214", "Evaluation"], ["C49663", "Pharmacokinetic Study"], ["C52874", "SPI1 wt Allele"], ["C28990", "Digoxin"], ["C154196", "Washo Language"], ["C25594", "Negation"], ["C158169", "Buyei Chinese"], ["C52874", "SPI1 wt Allele"], ["C29130", "Irbesartan"]], "rxnorm.pregnancy": [["83818", "irbesartan"], ["1895", "calcium"], ["325646", "aliskiren"], ["1312358", "aldosterone"], ["1999003", "angiotensin II"], ["T192", "Receptor"], ["325646", "aliskiren"], ["8588", "potassium"], ["8588", "potassium"], ["8588", "potassium"], ["8588", "potassium"], ["8588", "potassium"], ["8588", "potassium"], ["5224", "heparin"], ["6260", "lead"], ["8588", "potassium"], ["6448", "lithium"], ["6448", "lithium"], ["6448", "lithium"], ["T126", "Enzyme"], ["83818", "irbesartan"], ["6448", "lithium"], ["1999003", "angiotensin II"], ["1999003", "angiotensin II"], ["6260", "lead"], ["8588", "potassium"], ["73044", "repaglinide"], ["83818", "irbesartan"], ["83818", "irbesartan"], ["73044", "repaglinide"], ["73044", "repaglinide"], ["73044", "repaglinide"], ["83818", "irbesartan"], ["83818", "irbesartan"], ["5487", "hydrochlorothiazide"], ["83818", "irbesartan"], ["83818", "irbesartan"], ["11289", "warfarin"], ["9384", "rifampin"], ["83818", "irbesartan"], ["3407", "digoxin"], ["83818", "irbesartan"]], "loinc.pregnancy": [["MTHU003217", "Diuretics"], ["MTHU029809", "Other"], ["MTHU029809", "Other"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["LP171611-9", "Irbesartan"], ["MTHU029809", "Other"], ["LP31438-2", "Calcium channel blockers"], ["MTHU003217", "Diuretics"], ["LA33028-4", "Prior"], ["LP94823-9", "Treatment"], ["LP30871-5", "High dose"], ["MTHU003217", "Diuretics"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["MTHU003070", "Volume"], ["LP17763-1", "A"], ["MTHU020790", "Hypotension"], ["LP267221-2", "Therapy"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA22025-3", "OR"], ["LP230189-5", "Adverse Childhood Experiences"], ["LP7787-7", "Clinical"], ["MTHU003186", "Renin"], ["MTHU004471", "Aldosterone"], ["LA30596-3", "Combined"], ["LP230189-5", "Adverse Childhood Experiences"], ["LP15389-7", "Angiotensin II"], ["T192", "Receptor"], ["LA22025-3", "OR"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["MTHU029777", "Frequency"], ["MTHU058708", "Events"], ["MTHU020790", "Hypotension"], ["LA24378-4", "Decreased"], ["LP31398-8", "Renal function"], ["LA27519-0", "Acute renal failure"], ["LP17763-1", "A"], ["LA17717-2", "Single"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LP15098-4", "Potassium"], ["LP15098-4", "Potassium"], ["MTHU003217", "Diuretics"], ["MTHU029809", "Other"], ["MTHU003186", "Renin"], ["LP15098-4", "Potassium"], ["MTHU003217", "Diuretics"], ["LP15098-4", "Potassium"], ["LP15098-4", "Potassium"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["LP7567-3", "Serum"], ["LP15098-4", "Potassium"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP15998-5", "Heparin"], ["LA14161-6", "May"], ["LP14259-3", "Lead"], ["LA14961-9", "Increases"], ["LA22004-8", "IN"], ["LP7567-3", "Serum"], ["LP15098-4", "Potassium"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["MTHU004197", "Lithium"], ["LA14961-9", "Increases"], ["LA22004-8", "IN"], ["LP7567-3", "Serum"], ["MTHU004197", "Lithium"], ["LP6486-7", "Reported"], ["MTHU004197", "Lithium"], ["LP15387-1", "Angiotensin converting enzyme"], ["LA29696-4", "Very"], ["LA10066-1", "Rarely"], ["LP6486-7", "Reported"], ["LP171611-9", "Irbesartan"], ["LA32577-1", "Far"], ["LA12701-1", "Combination"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA12701-1", "Combination"], ["LA20297-0", "Monitoring"], ["LP7567-3", "Serum"], ["MTHU004197", "Lithium"], ["LP200075-2", "IS"], ["LP18046-0", "Drugs"], ["LP15389-7", "Angiotensin II"], ["LP18046-0", "Drugs"], ["LA15457-7", "I"], ["LA13503-0", "E"], ["MTHU000002", "Clinical Class"], ["LP20591-1", "3"], ["LP14561-2", "G"], ["LP121628-4", "Day"], ["LP31430-9", "NSAIDS"], ["LA25485-6", "Attenuation"], ["LA14161-6", "May"], ["LP31444-0", "Ace inhibitors"], ["LP15389-7", "Angiotensin II"], ["LP31430-9", "NSAIDS"], ["LA14161-6", "May"], ["LP14259-3", "Lead"], ["LA24544-1", "Increased risk"], ["LP31398-8", "Renal function"], ["LA15097-1", "Possible"], ["LA27519-0", "Acute renal failure"], ["LA32048-3", "Increase"], ["LA22004-8", "IN"], ["LP7567-3", "Serum"], ["LP15098-4", "Potassium"], ["LA22004-8", "IN"], ["LA8969-3", "Poor"], ["LP32605-5", "pre"], ["LP31398-8", "Renal function"], ["LA12701-1", "Combination"], ["LA22004-8", "IN"], ["LP29256-2", "given"], ["LA20297-0", "Monitoring"], ["LP31398-8", "Renal function"], ["LP267221-2", "Therapy"], ["MTHU017515", "Repaglinide"], ["LP171611-9", "Irbesartan"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP7787-7", "Clinical"], ["LP74341-6", "Study"], ["LP200077-8", "IT"], ["LP6486-7", "Reported"], ["LP171611-9", "Irbesartan"], ["LA24377-6", "Increased"], ["MTHU017515", "Repaglinide"], ["LA24592-0", "1.8"], ["LA6112-2", "1"], ["LP20591-1", "3"], ["LP6915-5", "1 hour"], ["MTHU017515", "Repaglinide"], ["LA22004-8", "IN"], ["LP74341-6", "Study"], ["LA32-8", "No"], ["LP6486-7", "Reported"], ["LA6404-3", "Two"], ["LP18046-0", "Drugs"], ["LA21996-6", "CO"], ["MTHU065481", "Dose"], ["LP94823-9", "Treatment"], ["MTHU017515", "Repaglinide"], ["LA14161-6", "May"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP263791-8", "Additional"], ["LP171611-9", "Irbesartan"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LP171611-9", "Irbesartan"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["MTHU060558", "hydroCHLOROthiazide"], ["LP171611-9", "Irbesartan"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LA32-8", "No"], ["LA28474-7", "Significant"], ["LA22025-3", "OR"], ["LP6425-5", "Observed"], ["LP171611-9", "Irbesartan"], ["LA28654-4", "Warfarin"], ["LP17763-1", "A"], ["LP171611-9", "Irbesartan"], ["LA21291-2", "Not"], ["MTHU001808", "Digoxin"], ["LA21291-2", "Not"], ["LP171611-9", "Irbesartan"]], "snomed.driving": [["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["260676000", "Use of (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["255246003", "First trimester (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["732727007", "4.4 (qualifier value)"], ["260676000", "Use of (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410536001", "Contraindicated (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["81170007", "Second (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["70905002", "Third (qualifier value)"], ["272107002", "Trimesters (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["732725004", "4.3 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["58694006", "Teratogenesis (finding)"], ["255260001", "Following (attribute)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["255246003", "First trimester (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255507004", "Small (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["18720000", "In (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["420862001", "On (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["85267009", "Angiotensin II (substance)"], ["116647005", "Receptor (substance)"], ["86495002", "For (qualifier value)"], ["277046005", "Class (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["34325006", "Essential (qualifier value)"], ["312011006", "Cognitive function: planning (observable entity)|Cognitive function: planning (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["263703002", "Changed status (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1182007", "Hypotensive agent (substance)|Hypotensive agent (product)"], ["263748003", "Established (qualifier value)"], ["86495002", "For (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["18720000", "In (attribute)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["385652002", "Started (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["81170007", "Second (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["70905002", "Third (qualifier value)"], ["272107002", "Trimesters (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["36692007", "Known (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["338930006", "Human (organism)"], ["76114004", "Decreased renal function (finding)"], ["157051001", "Oligohydramnios (disorder)|Oligohydramnios"], ["89546000", "Bone structure of cranium (body structure)"], ["83323007", "Bone formation, function (observable entity)|Bone formation (function)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255407002", "Neonatal (qualifier value)"], ["75478009", "Poisoning (disorder)"], ["198524000", "Renal failure (disorder)|Renal failure"], ["155487000", "Hypotension (disorder)|Hypotension"], ["154764002", "Hyperkalaemia (disorder)|Hyperkalaemia"], ["769082003", "5.3 (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["255247007", "Second trimester (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["371573008", "Ultrasonography (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["50741009", "Urinary tract function (observable entity)|Urinary tract function (function)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["89546000", "Bone structure of cranium (body structure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["86495002", "For (qualifier value)"], ["155487000", "Hypotension (disorder)|Hypotension"], ["732725004", "4.3 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["373067005", "No (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["260676000", "Use of (attribute)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["3442003", "Better (qualifier value)"], ["263748003", "Established (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["722165004", "Nursing (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["133933007", "Newborn (person)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["157080005", "Preterm infant|Preterm infant (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["261665006", "Unknown (qualifier value)"], ["386877005", "Irbesartan (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["226789007", "Breast milk (substance)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["64427006", "Toxicologic (qualifier value)"], ["18720000", "In (attribute)"], ["718500008", "Excretory process (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386877005", "Irbesartan (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["70813002", "Milk (substance)"], ["86495002", "For (qualifier value)"], ["769082003", "5.3 (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["386877005", "Irbesartan (substance)"], ["397971000", "No effect (qualifier value)"], ["420771004", "Upon - dosing instruction fragment (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258395000", "Levels (qualifier value)"], ["255216001", "First (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["75478009", "Poisoning (disorder)"], ["769082003", "5.3 (qualifier value)"]], "ncit.driving": [["C191656", "Pregnant Subject"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C25490", "During"], ["C92799", "First Trimester"], ["C52874", "SPI1 wt Allele"], ["C191656", "Pregnant Subject"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C37933", "Contraindicated"], ["C25490", "During"], ["C25666", "Second"], ["C16289", "Andorra"], ["C25260", "Third"], ["C52874", "SPI1 wt Allele"], ["C191656", "Pregnant Subject"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16556", "Epidemiology"], ["C43583", "Evidence"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C53286", "Next"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C91295", "ACE Gene"], ["C25490", "During"], ["C92799", "First Trimester"], ["C52874", "SPI1 wt Allele"], ["C191656", "Pregnant Subject"], ["C101282", "Have"], ["C25594", "Negation"], ["C87050", "Conclusive"], ["C76246", "Blood Group A"], ["C25376", "Small"], ["C25533", "Increase"], ["C16727", "India"], ["C17102", "Risk"], ["C16329", "Belgium"], ["C82931", "Exclusion"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82500", "Disease Controlled"], ["C16556", "Epidemiology"], ["C25474", "Data"], ["C92667", "SPARC wt Allele"], ["C17102", "Risk"], ["C62355", "With"], ["C107562", "Angiotensin-2"], ["C18106", "Receptor"], ["C72665", "Similarity"], ["C106184", "May"], ["C89327", "Be"], ["C64956", "For"], ["C41106", "Object Class"], ["C52874", "SPI1 wt Allele"], ["C53279", "Continue"], ["C49236", "Therapeutic Procedure"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C71578", "Essential"], ["C16960", "Patient"], ["C25619", "Plan"], ["C191656", "Pregnant Subject"], ["C16329", "Belgium"], ["C25572", "Modification"], ["C159124", "GDC Treatment Outcome Terminology"], ["C97927", "Gene Variant"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C71155", "Established"], ["C49667", "Safety Study"], ["C84385", "Profile"], ["C64956", "For"], ["C25340", "Use"], ["C16727", "India"], ["C191656", "Pregnant Subject"], ["C65140", "When"], ["C191656", "Pregnant Subject"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C15220", "Diagnosis"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C16329", "Belgium"], ["C64597", "Immediately"], ["C16289", "Andorra"], ["C198613", "CFI wt Allele"], ["C15178", "Complementary and Alternative Medicine"], ["C16329", "Belgium"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49236", "Therapeutic Procedure"], ["C25490", "During"], ["C25666", "Second"], ["C16289", "Andorra"], ["C25260", "Third"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C80137", "Known"], ["C159124", "GDC Treatment Outcome Terminology"], ["C61367", "Induction"], ["C14225", "Human"], ["C25640", "Reduced"], ["C164220", "Renal Function"], ["C92839", "Oligohydramnios"], ["C23720", "Murine Skull"], ["C124594", "Ossification Abnormality"], ["C16289", "Andorra"], ["C16731", "Newborn"], ["C27990", "Toxicity"], ["C4376", "Renal Failure"], ["C55061", "Hypotension, CTCAE"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C101282", "Have"], ["C54069", "Occur"], ["C25516", "From"], ["C92876", "Second Trimester"], ["C52874", "SPI1 wt Allele"], ["C191656", "Pregnant Subject"], ["C19337", "Diagnostic Ultrasound"], ["C86058", "Check"], ["C52874", "SPI1 wt Allele"], ["C164220", "Renal Function"], ["C16289", "Andorra"], ["C23720", "Murine Skull"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C101282", "Have"], ["C25701", "Taken"], ["C16329", "Belgium"], ["C25599", "Observed"], ["C64956", "For"], ["C55061", "Hypotension, CTCAE"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C53269", "No Information Available"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25429", "Availability"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C25490", "During"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C16289", "Andorra"], ["C97927", "Gene Variant"], ["C62355", "With"], ["C125459", "Improved"], ["C71155", "Established"], ["C49667", "Safety Study"], ["C25490", "During"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C68869", "Are"], ["C25596", "Breast Feeding"], ["C76246", "Blood Group A"], ["C16731", "Newborn"], ["C43508", "Oregon"], ["C49642", "Preterm Infant"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C160764", "Unknown Molecular Analysis"], ["C29130", "Irbesartan"], ["C43508", "Oregon"], ["C79395", "Other Toxicity Studies: Metabolites"], ["C68869", "Are"], ["C16727", "India"], ["C14225", "Human"], ["C13257", "Mammary Gland Milk"], ["C25429", "Availability"], ["C49662", "Pharmacodynamic Study"], ["C25474", "Data"], ["C16727", "India"], ["C101282", "Have"], ["C94618", "Excretion"], ["C52874", "SPI1 wt Allele"], ["C29130", "Irbesartan"], ["C43508", "Oregon"], ["C79395", "Other Toxicity Studies: Metabolites"], ["C16727", "India"], ["C13257", "Mammary Gland Milk"], ["C64956", "For"], ["C25480", "Details"], ["C163702", "Staphylococcal Enterotoxin E"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C95089", "Fertility Domain"], ["C29130", "Irbesartan"], ["C101282", "Have"], ["C164134", "No Effect"], ["C65137", "Upon"], ["C95089", "Fertility Domain"], ["C52874", "SPI1 wt Allele"], ["C25705", "Treating"], ["C16289", "Andorra"], ["C42708", "Offspring"], ["C64643", "Up to"], ["C25488", "Dose"], ["C61367", "Induction"], ["C25509", "First"], ["C52874", "SPI1 wt Allele"], ["C42709", "Parent"], ["C27990", "Toxicity"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"]], "rxnorm.driving": [["1999003", "angiotensin II"], ["T192", "Receptor"], ["T016", "Human"], ["83818", "irbesartan"], ["T016", "Human"], ["83818", "irbesartan"], ["83818", "irbesartan"]], "loinc.driving": [["LP207970-7", "Pregnancy"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP208035-8", "First trimester"], ["LP207970-7", "Pregnancy"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP200075-2", "IS"], ["LA4216-3", "Contraindicated"], ["LP207970-7", "Pregnancy"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP31444-0", "Ace inhibitors"], ["LP208035-8", "First trimester"], ["LP207970-7", "Pregnancy"], ["LA21291-2", "Not"], ["LP17763-1", "A"], ["LA8983-4", "Small"], ["LA32048-3", "Increase"], ["LA22004-8", "IN"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LP15389-7", "Angiotensin II"], ["T192", "Receptor"], ["MTHU043138", "Risks"], ["LA14161-6", "May"], ["LP6795-1", "Class"], ["LP18046-0", "Drugs"], ["LP267221-2", "Therapy"], ["LP200075-2", "IS"], ["MTHU061379", "Planning"], ["LP207970-7", "Pregnancy"], ["LA30091-5", "Alternative"], ["MTHU021207", "Treatments"], ["LA17589-5", "Safety"], ["LA22004-8", "IN"], ["LP207970-7", "Pregnancy"], ["LP207970-7", "Pregnancy"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA30091-5", "Alternative"], ["LP267221-2", "Therapy"], ["LP267221-2", "Therapy"], ["LP200075-2", "IS"], ["LA19711-3", "Human"], ["LA24378-4", "Decreased"], ["LP31398-8", "Renal function"], ["LP30281-7", "Skull"], ["MTHU020824", "Renal failure"], ["MTHU020790", "Hypotension"], ["LP20593-7", "5"], ["LP20591-1", "3"], ["LP207970-7", "Pregnancy"], ["LP7853-7", "Ultrasound"], ["LP251102-2", "Check"], ["LP31398-8", "Renal function"], ["LP30281-7", "Skull"], ["LP200075-2", "IS"], ["LP6425-5", "Observed"], ["MTHU020790", "Hypotension"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LA21413-2", "No information"], ["LP200075-2", "IS"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA30091-5", "Alternative"], ["MTHU021207", "Treatments"], ["LA17589-5", "Safety"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LP6423-0", "Nursing"], ["LP17763-1", "A"], ["LP7744-8", "Newborn"], ["LA22025-3", "OR"], ["LA19747-7", "Infant"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA4489-6", "Unknown"], ["LP171611-9", "Irbesartan"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LA19711-3", "Human"], ["LP29290-1", "Milk"], ["LA22004-8", "IN"], ["LP171611-9", "Irbesartan"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP29290-1", "Milk"], ["LP72435-8", "Details"], ["LP20593-7", "5"], ["LP20591-1", "3"], ["MTHU000074", "Fertility"], ["LP171611-9", "Irbesartan"], ["LA32-8", "No"], ["MTHU000074", "Fertility"], ["MTHU065481", "Dose"], ["LP6974-2", "first"], ["LA30680-5", "Parental"], ["LP20593-7", "5"], ["LP20591-1", "3"]], "snomed.side_effects": [["420862001", "On (qualifier value)"], ["386877005", "Irbesartan (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["247750002", "Drive (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["61284002", "Machine, device (physical object)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["129060000", "Driving, function (observable entity)|Driving (function)|Driving (observable entity)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["30507006", "Into (attribute)"], ["404640003", "Dizziness (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["84229001", "Fatigue (finding)"], ["421994004", "During - dosing instruction fragment (qualifier value)"]], "ncit.side_effects": [["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C49662", "Pharmacodynamic Study"], ["C29130", "Irbesartan"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C85549", "Unlikely"], ["C159124", "GDC Treatment Outcome Terminology"], ["C121232", "Ability to Drive"], ["C16289", "Andorra"], ["C25340", "Use"], ["C65140", "When"], ["C121232", "Ability to Drive"], ["C43508", "Oregon"], ["C38267", "Intrathecal Route of Administration"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C25544", "Into"], ["C88186", "Financial Account"], ["C125409", "Have Dizziness"], ["C43508", "Oregon"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C175242", "During Treatment"]], "rxnorm.side_effects": [["83818", "irbesartan"]], "loinc.side_effects": [["LP171611-9", "Irbesartan"], ["LP200075-2", "IS"], ["LA15588-9", "Unlikely"], ["MTHU053653", "Driving"], ["LA22025-3", "OR"], ["MTHU059423", "Operating"], ["LP200077-8", "IT"], ["LA7428-1", "Dizziness"], ["LA22025-3", "OR"], ["LA14161-6", "May"], ["LP93408-0", "during treatment"]], "snomed.shelf_life": [["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258707000", "year (qualifier value)"]], "ncit.shelf_life": [["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C29848", "Year"]], "rxnorm.shelf_life": [], "loinc.shelf_life": [["LA31720-8", "3 years"]], "snomed.storage": [["352730000", "Supra- (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"]], "ncit.storage": [["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C60824", "Storage"], ["C75329", "Above"], ["C70541", "Lansky Performance Status 30"], ["C67900", "Centi"]], "rxnorm.storage": [], "loinc.storage": [["LA14426-3", "Do not"], ["LA14991-6", "Above"], ["LA28855-7", "30"], ["LP17128-7", "C"]], "snomed.package": [["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222741009", "American Joint Committee on Cancer stage I:4 (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["18720000", "In (attribute)"], ["35233000", "Polyvinyl chloride (substance)"], ["255977005", "Aluminum material (substance)"], ["210984001", "(Superficial injury) or (abrasions) or (blisters) or (friction burns) or (splinters) or (sting (& without reaction): [bee] or [wasp]) or (bites: [insect - non venomous] or [flea]) (disorder)|(Superficial injury) or (abrasions) or (blisters) or (friction burns) or (splinters) or (sting (& without reaction): [bee] or [wasp]) or (bites: [insect - non venomous] or [flea])"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222781002", "American Joint Committee on Cancer stage II:8 (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["18720000", "In (attribute)"], ["35233000", "Polyvinyl chloride (substance)"], ["255977005", "Aluminum material (substance)"], ["210984001", "(Superficial injury) or (abrasions) or (blisters) or (friction burns) or (splinters) or (sting (& without reaction): [bee] or [wasp]) or (bites: [insect - non venomous] or [flea]) (disorder)|(Superficial injury) or (abrasions) or (blisters) or (friction burns) or (splinters) or (sting (& without reaction): [bee] or [wasp]) or (bites: [insect - non venomous] or [flea])"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["18720000", "In (attribute)"], ["35233000", "Polyvinyl chloride (substance)"], ["255977005", "Aluminum material (substance)"], ["210984001", "(Superficial injury) or (abrasions) or (blisters) or (friction burns) or (splinters) or (sting (& without reaction): [bee] or [wasp]) or (bites: [insect - non venomous] or [flea]) (disorder)|(Superficial injury) or (abrasions) or (blisters) or (friction burns) or (splinters) or (sting (& without reaction): [bee] or [wasp]) or (bites: [insect - non venomous] or [flea])"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732913005", "98 (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["18720000", "In (attribute)"], ["35233000", "Polyvinyl chloride (substance)"], ["255977005", "Aluminum material (substance)"], ["210984001", "(Superficial injury) or (abrasions) or (blisters) or (friction burns) or (splinters) or (sting (& without reaction): [bee] or [wasp]) or (bites: [insect - non venomous] or [flea]) (disorder)|(Superficial injury) or (abrasions) or (blisters) or (friction burns) or (splinters) or (sting (& without reaction): [bee] or [wasp]) or (bites: [insect - non venomous] or [flea])"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422045004", "Roman numeral X (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["18720000", "In (attribute)"], ["35233000", "Polyvinyl chloride (substance)"], ["255977005", "Aluminum material (substance)"], ["263837003", "Perforated (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["210984001", "(Superficial injury) or (abrasions) or (blisters) or (friction burns) or (splinters) or (sting (& without reaction): [bee] or [wasp]) or (bites: [insect - non venomous] or [flea]) (disorder)|(Superficial injury) or (abrasions) or (blisters) or (friction burns) or (splinters) or (sting (& without reaction): [bee] or [wasp]) or (bites: [insect - non venomous] or [flea])"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["257260002", "Pack (physical object)"]], "ncit.package": [["C52874", "SPI1 wt Allele"], ["C113428", "Fourteen"], ["C16727", "India"], ["C10268", "Cisplatin/Cyclophosphamide/Etoposide"], ["C52874", "SPI1 wt Allele"], ["C126888", "Twenty Eight"], ["C16727", "India"], ["C10268", "Cisplatin/Cyclophosphamide/Etoposide"], ["C52874", "SPI1 wt Allele"], ["C188323", "Fifty Six"], ["C16727", "India"], ["C10268", "Cisplatin/Cyclophosphamide/Etoposide"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C10268", "Cisplatin/Cyclophosphamide/Etoposide"], ["C52874", "SPI1 wt Allele"], ["C188323", "Fifty Six"], ["C173030", "MATCH Arm EAY131-X"], ["C105723", "ECOG Performance Status 1"], ["C154605", "Tablet Dosage Form Category"], ["C16727", "India"], ["C10268", "Cisplatin/Cyclophosphamide/Etoposide"], ["C4080", "Perforation"], ["C65135", "Unit Dose"], ["C25594", "Negation"], ["C64916", "All"], ["C84731", "Packing"], ["C106184", "May"], ["C16329", "Belgium"]], "rxnorm.package": [["746839", "Pack"]], "loinc.package": [["LA14560-9", "14"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LA32969-0", "X"], ["LA6112-2", "1"], ["LP136501-6", "Tablet"], ["LA22004-8", "IN"], ["MTHU065481", "Dose"], ["LA21291-2", "Not"], ["LA18187-7", "All"], ["LA14161-6", "May"]], "snomed.marketing_authorization_numbers": [["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["260309001", "97 (qualifier value)|Arabic numeral 97 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["260309001", "97 (qualifier value)|Arabic numeral 97 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["260309001", "97 (qualifier value)|Arabic numeral 97 (qualifier value)"]], "ncit.marketing_authorization_numbers": [["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C18007", "Antarctica"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.marketing_authorization_numbers": [], "loinc.marketing_authorization_numbers": [["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"]]}, {"product_info": "Dovato 50 mg/300 mg film-coated tablets", "composition": "Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir and 300 mg \nlamivudine. \nFor the full list of excipients, see section 6.1.", "indications": "Dovato is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults \nand adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the \nintegrase inhibitor class, or lamivudine (see section 5.1).", "posology": "Dovato should be prescribed by physicians experienced in the management of HIV infection. \nPosology \nAdults and adolescents (above 12 years of age weighing at least 40\nkg). \nThe recommended dose of Dovato in adults and adolescents is one 50 mg/300 mg tablet once daily. \nDose adjustments \nA separate preparation of dolutegravir is available where a dose adjustment is indicated due to drug-drug \ninteractions (e.g. rifampicin, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, St. John\u2019s wort, \netravirine (without boosted protease inhibitors), efavirenz, nevirapine, or tipranavir/ritonavir, see sections 4.4 \nand 4.5). In these cases the physician should refer to the individual product information for dolutegravir. \nMissed doses \nIf the patient misses a dose of Dovato, the patient should take Dovato as soon as possible, providing the next \ndose is not due within 4 hours. If the next dose is due within 4 hours, the patient should not take the missed \ndose and simply resume the usual dosing schedule. \nElderly \nThere are limited data available on the use of Dovato in patients aged 65 years and over. No dose adjustment \nis necessary (see section 5.2). \nRenal impairment \nDovato is not recommended for use in patients with a creatinine clearance < 30 mL/min (see section 5.2). No \ndose adjustment is required in patients with mild or moderate renal impairment. However, the lamivudine \nexposure is significantly increased in patients with a creatinine clearance < 50 mL/min (see section 4.4). \nHepatic impairment \nNo dosage adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh grade A \nor B). No data are available in patients with severe hepatic impairment (Child-Pugh grade C); therefore \nDovato should be used with caution in these patients (see section 5.2). \nPaediatric population\nThe safety and efficacy of Dovato in children aged less than 12 years or weighing less than 40 kg have not \nbeen established. No data are available. \nMethod of administration \nOral use.  \nDovato can be taken with or without food (see section 5.2).", "contraindications": "Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. \nCo-administration with medicinal products with narrow therapeutic windows, that are substrates of organic \ncation transporter (OCT) 2, including but not limited to fampridine (also known as dalfampridine; see section \n4.5).", "special_warnings": "Hypersensitivity reactions \nHypersensitivity reactions have been reported with dolutegravir, and were characterized by rash, \nconstitutional findings, and sometimes, organ dysfunction, including severe liver reactions. Dovato and other \nsuspect medicinal products should be discontinued immediately if signs or symptoms of hypersensitivity \nreactions develop (including, but not limited to, severe rash or rash accompanied by raised liver enzymes, \nfever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, facial oedema, \neosinophilia, angioedema). Clinical status including liver aminotransferases and bilirubin should be \nmonitored. Delay in stopping treatment with Dovato or other suspect active substances after the onset of \nhypersensitivity may result in a life-threatening allergic reaction.\nWeight and metabolic parameters \nAn increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. Such \nchanges may in part be linked to disease control and lifestyle. For lipids and weight, there is in some cases \nevidence for a treatment effect. For monitoring of blood lipids and glucose reference is made to established \nHIV treatment guidelines. Lipid disorders should be managed as clinically appropriate.\nLiver disease \nPatients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased \nrisk of severe and potentially fatal hepatic adverse reactions. In case of concomitant antiviral therapy for \nhepatitis B or C, please refer also to the relevant product information for these medicinal products. \nDovato includes lamivudine, which is active against hepatitis B. Dolutegravir lacks such activity. \nLamivudine monotherapy is generally not considered an adequate treatment for hepatitis B, since the risk for \nhepatitis B resistance development is high. If Dovato is used in patients co-infected with hepatitis B an \nadditional antiviral is therefore generally needed. Reference should be made to treatment guidelines. \nIf Dovato is discontinued in patients co-infected with hepatitis B virus, periodic monitoring of both liver \nfunction tests and markers of HBV replication is recommended, as withdrawal of lamivudine may result in \nan acute exacerbation of hepatitis.\nPatients with pre-existing liver dysfunction, including chronic active hepatitis have an increased frequency of \nliver function abnormalities during combination antiretroviral therapy, and should be monitored according to \nstandard practice. If there is evidence of worsening liver disease in such patients, interruption or \ndiscontinuation of treatment must be considered.\nImmune Reactivation Syndrome \nIn HIV-infected patients with severe immune deficiency at the time of institution of combination \nantiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic \npathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such \nreactions have been observed within the first few weeks or months of initiation of CART. Relevant examples \nare \nCytomegalovirus retinitis\n, generalised and/or focal mycobacterial infections, and \nPneumocystis jirovecii\npneumonia (often referred to as PCP). Any inflammatory symptoms should be evaluated and treatment \ninstituted when necessary. Autoimmune disorders (such as Graves\u2019 disease and autoimmune hepatitis) have \nalso been reported to occur in the setting of immune reactivation; however, the reported time to onset is more \nvariable and these events can occur many months after initiation of treatment. \nLiver chemistry elevations consistent with immune reconstitution syndrome were observed in some hepatitis \nB and/or C co-infected patients at the start of dolutegravir therapy. Monitoring of liver chemistries is \nrecommended in patients with hepatitis B and/or C co-infection. (See \u2018Liver disease\u2019 earlier in this section \nand also see section 4.8).\nMitochondrial dysfunction following exposure \nin utero \nNucleoside and nucleotide analogues may impact mitochondrial function to a variable degree, which is most \npronounced with stavudine, didanosine and zidovudine. There have been reports of mitochondrial \ndysfunction in HIV-negative infants exposed \nin utero\n and/or post-natally to nucleoside analogues, these have \npredominantly concerned treatment with regimens containing zidovudine. The main adverse reactions \nreported are haematological disorders (anaemia, neutropenia), and metabolic disorders (hyperlactatemia, \nhyperlipasemia). These reactions have often been transitory. Some late-onset neurological disorders have \nbeen reported rarely (hypertonia, convulsion, abnormal behaviour). Whether such neurological disorders are \ntransient or permanent is currently unknown. These findings should be considered for any child exposed \nin \nutero\n to nucleoside and nucleotide analogues, who presents with severe clinical findings of unknown \naetiology, particularly neurologic findings. These findings do not affect current national recommendations to \nuse antiretroviral therapy in pregnant women to prevent vertical transmission of HIV. \nOsteonecrosis \nAlthough the aetiology is considered to be multifactorial (including corticosteroid use, biphosphonates, \nalcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been \nreported in patients with advanced HIV-disease and/or long-term exposure to CART. Patients should be \nadvised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in \nmovement. \nOpportunistic infections \nPatients should be advised that dolutegravir, lamivudine or any other antiretroviral therapy does not cure \nHIV infection and that they may still develop opportunistic infections and other complications of HIV \ninfection. Therefore, patients should remain under close clinical observation by physicians experienced in the \ntreatment of these associated HIV diseases. \nAdministration in subjects with moderate renal impairment \nPatients with a creatinine clearance between 30 and 49 mL/min receiving Dovato may experience a 1.6-to \n3.3-fold higher lamivudine exposure (AUC) than patients with a creatinine clearance \u226550 mL/min. There are \nno safety data from randomized, controlled trials comparing Dovato to the individual components in patients \nwith a creatinine clearance between 30 and 49 mL/min who received dose-adjusted lamivudine. In the \noriginal lamivudine registrational trials in combination with zidovudine, higher lamivudine exposures were \nassociated with higher rates of haematologic toxicities (neutropenia and anaemia), although discontinuations \ndue to neutropenia or anaemia each occurred in <1% of subjects. Other lamivudine-related adverse events \n(such as gastro-intestinal and hepatic disorders) may occur. \nPatients with a sustained creatinine clearance between 30 and 49 mL/min who receive Dovato should be \nmonitored for lamivudine-related adverse events, notably haematologic toxicities. If new or worsening \nneutropenia or anaemia develop, a dose adjustment of lamivudine, per lamivudine prescribing information, is \nindicated, which cannot be achieved with Dovato. Dovato should be discontinued and the individual \ncomponents should be used to construct the treatment regimen. \nDrug interactions \nThe recommended dose of dolutegravir is 50 mg twice daily when co-administered with rifampicin, \ncarbamazepine, oxcarbazepine, phenytoin, phenobarbital, St. John\u2019s wort, etravirine (without boosted \nprotease inhibitors), efavirenz, nevirapine, or tipranavir/ritonavir (see section 4.5). \nDovato should not be co-administered with polyvalent cation-containing antacids. Polyvalent cation-\ncontaining antacids are recommended to be taken 2 hours after or 6 hours before Dovato (see section 4.5). \nWhen taken with food, Dovato and supplements or multivitamins containing calcium, iron or magnesium can \nbe taken at the same time. If Dovato is administered under fasting conditions, supplements or multivitamins \ncontaining calcium, iron or magnesium are recommended to be taken 2 hours after or 6 hours before Dovato \n(see section 4.5). \nDolutegravir increased metformin concentrations. A dose adjustment of metformin should be considered \nwhen starting and stopping coadministration of Dovato with metformin, to maintain glycaemic control (see \nsection 4.5). Metformin is eliminated renally and, therefore, it is of importance to monitor renal function \nwhen co-treated with Dovato. This combination may increase the risk for lactic acidosis in patients with \nmoderate renal impairment (stage 3a creatinine clearance 45\u2013 59 mL/min) and a cautious approach is \nrecommended. Reduction of the metformin dose should be highly considered. \nThe combination of Dovato with cladribine is not recommended (see section 4.5). \nDovato should not be taken with any other medicinal product containing dolutegravir, lamivudine or \nemtricitabine, except where a dose adjustment of dolutegravir is indicated due to drug-drug interactions (see \nsection 4.5).", "pregnancy": "No drug interaction studies have been conducted using Dovato. Dovato contains dolutegravir and \nlamivudine, therefore any interactions identified for these individually are relevant to Dovato. No clinically \nsignificant drug interactions are expected between dolutegravir and lamivudine. \nEffect of other medicinal products on the pharmacokinetics of dolutegravir and lamivudine \nDolutegravir is eliminated mainly through metabolism by uridine diphosphate glucuronosyl transferase \n(UGT) 1A1. Dolutegravir is also a substrate of UGT1A3, UGT1A9, CYP3A4, P-glycoprotein (P-gp), and \nbreast cancer resistance protein\n(BCRP). Co-administration of Dovato and other medicinal products that \ninhibit UGT1A1, UGT1A3, UGT1A9, CYP3A4, and/or P-gp may, therefore, increase dolutegravir plasma \nconcentration. Medicinal products that induce those enzymes or transporters may decrease dolutegravir \nplasma concentration and reduce the therapeutic effect of dolutegravir. \nThe absorption of dolutegravir is reduced by certain metal cation-containing anti-acid substances and \nsupplements (see Table 1). \nLamivudine is cleared renally. Active renal secretion of lamivudine in the urine is mediated through the \nOCT2 and multidrug and toxin extrusion transporters (MATE1 and MATE2-K). Trimethoprim (an inhibitor \nof these transporters) has been shown to increase lamivudine plasma concentrations, however the resulting \nincrease was not clinically significant (see Table 1). Dolutegravir is an OCT2 and MATE1 inhibitor; \nhowever, lamivudine concentrations were similar with or without co-administration of dolutegravir based on \na cross study analysis, indicating that dolutegravir has no relevant effect on lamivudine exposure \nin vivo\nLamivudine is also substrate of the hepatic uptake transporter OCT1. As hepatic elimination plays a minor \nrole in the clearance of lamivudine, drug interactions due to inhibition of OCT1 are unlikely to be of clinical \nsignificance. \nAlthough lamivudine is a substrate of BCRP and P-gp \nin vitro\n, given its high absolute bioavailability, (see \nsection 5.2), inhibitors of these efflux transporters are unlikely to result in a clinically relevant impact on \nlamivudine concentrations. \nEffect of dolutegravir and lamivudine on the pharmacokinetics of other medicinal products \nIn vivo\n, dolutegravir did not have an effect on midazolam, a CYP3A4 probe. Based on \nin vivo\n and/or \nin vitro\ndata, dolutegravir is not expected to affect the pharmacokinetics of medicinal products that are substrates of \nany major enzyme or transporter such as CYP3A4, CYP2C9 and P-gp (for more information see section 5.2). \nIn vitro\n, dolutegravir inhibited the renal transporters OCT2 and MATE1. \nIn vivo\n, a 10-14% decrease of \ncreatinine clearance (secretory fraction is dependent on OCT2 and MATE1 transport) was observed in \npatients. \nIn vivo\n, dolutegravir may increase plasma concentrations of medicinal products in which excretion \nis dependent upon OCT2 and/or MATE1 (e.g. fampridine [also known as dalfampridine], metformin) (see \nTable 1 and section 4.3). \nIn vitro\n, dolutegravir inhibited the renal uptake organic anion transporters (OAT)1 and OAT3. Based on the \nlack of effect on the \nin vivo\n pharmacokinetics of the OAT substrate tenofovir, \nin vivo\n inhibition of OAT1 is \nunlikely. Inhibition of OAT3 has not been studied \nin vivo\n. Dolutegravir may increase plasma concentrations \nof medicinal products in which excretion is dependent upon OAT3. \nIn vitro,\n lamivudine was an inhibitor of OCT1 and OCT2; the clinical consequences are not known. \nEstablished and theoretical interactions with selected antiretrovirals and non-antiretroviral medicinal \nproducts are listed in Table 1. \nInteraction table \nInteractions between dolutegravir, lamivudine and co-administered medical products are listed in Table 1 \n(increase is indicated as \u201c\u2191\u201d, decrease as \u201c\u2193\u201d, no change as \u201c\u2194\u201d, area under the concentration versus time \ncurve as \u201cAUC\u201d, maximum observed concentration as \u201cCmax\u201d, concentration at end of dosing interval as \n\u201cC\u03c4\u201d). The table should not be considered exhaustive but is representative of the classes studied. \nTable 1: \nDrug Interactions \nMedicinal products by \ntherapeutic areas\nInteraction geometric \nmean change (%)  \nRecommendations concerning co-\nadministration\nAntiretroviral medicinal products\nNon-nucleoside reverse transcriptase inhibitors \nEtravirine without boosted \nprotease inhibitors / \nDolutegravir\nDolutegravir \u2193 \n   AUC \u2193 71% \n   Cmax \u2193 52% \n   C\u03c4 \u2193 88% \nEtravirine \u2194 \n(induction of UGT1A1 \nand CYP3A enzymes) \nEtravirine without boosted protease \ninhibitors decreased plasma dolutegravir \nconcentration. The recommended dose \nof dolutegravir is 50 mg twice daily for \npatients taking etravirine without \nboosted protease inhibitors. As Dovato \nis a fixed-dose tablet, an additional \n50 mg tablet of dolutegravir should be \nadministered, approximately 12 hours \nafter Dovato for the duration of the \netravirine without boosted protease \ninhibitor co-administration (a separate \nformulation of dolutegravir is available \nfor this dose adjustment, see section \n4.2).  \nLopinavir+ritonavir+etravirine/ \nDolutegravir \nDolutegravir \u2194 \n   AUC \u2191 11% \n   Cmax \u2191 7% \n   C\u03c4 \u2191 28% \nLopinavir \u2194 \nRitonavir \u2194 \nEtravirine \u2194 \nNo dose adjustment is necessary. \nDarunavir+ritonavir+etravirine/ \nDolutegravir \nDolutegravir \u2193 \n   AUC \u2193 25% \n   Cmax \u2193 12% \n   C\u03c4 \u2193 36% \nDarunavir \u2194 \nRitonavir \u2194 \nEtravirine \u2194 \nNo dose adjustment is necessary. \nEfavirenz/Dolutegravir \nDolutegravir \u2193 \n   AUC \u2193 57% \n   Cmax \u2193 39% \n   C\u03c4 \u2193 75% \nEfavirenz \u2194 (historical \ncontrols) \n(induction of UGT1A1 \nand CYP3A enzymes) \nThe recommended dose of dolutegravir \nis 50 mg twice daily when \nco-administered with efavirenz. As \nDovato is a fixed-dose tablet, an \nadditional 50 mg tablet of dolutegravir \nshould be administered, approximately \n12 hours after Dovato for the duration of \nthe efavirenz co-administration (a \nseparate formulation of dolutegravir is \navailable for this dose adjustment, see \nsection 4.2).  \nNevirapine/Dolutegravir \nDolutegravir \u2193 \n(Not studied, a similar \nreduction in exposure as \nobserved with efavirenz is \nexpected, due to \ninduction) \nThe recommended dose of dolutegravir \nis 50 mg twice daily when \nco-administered with nevirapine. As \nDovato is a fixed-dose tablet, an \nadditional 50 mg tablet of dolutegravir \nshould be administered, approximately \n12 hours after Dovato for the duration of \nthe nevirapine co-administration (a \nseparate formulation of dolutegravir is \navailable for this dose adjustment, see \nsection 4.2).  \nRilpivirine/Dolutegravir \nDolutegravir \u2194 \n   AUC \u2191 12% \n   Cmax \u2191 13% \n   C\u03c4 \u2191 22% \nRilpivirine \u2194 \nNo dose adjustment is necessary. \nNucleoside reverse transcriptase inhibitors (NRTIs) \nTenofovir disoproxil  \nEmtricitabine, didanosine, \nstavudine, tenofovir \nalafenamide, zidovudine \nDolutegravir \u2194 \n   AUC \u2191 1% \n   Cmax \u2193 3% \n   C\u03c4 \u2193 8% \nTenofovir \u2194 \nInteraction not studied \nNo dose adjustment is necessary when \nDovato is combined with tenofovir, \ndidanosine, stavudine or zidovudine. \nDovato is not recommended for use in \ncombination with emtricitabine \ncontaining products, since both \nlamivudine (in Dovato) and \nemtricitabine are cytidine analogues (i.e. \nrisk for intracellular interactions), see \nsection 4.4. \nProtease inhibitors \nAtazanavir/Dolutegravir \nDolutegravir \u2191 \n   AUC \u2191 91% \n   Cmax \u2191 50% \n   C\u03c4 \u2191 180% \nAtazanavir \u2194 (historical \ncontrols) \n(inhibition of UGT1A1 \nand CYP3A enzymes) \nNo dose adjustment is necessary. \nAtazanavir+ ritonavir/ \nDolutegravir \nDolutegravir \u2191 \n   AUC \u2191 62% \n   Cmax \u2191 34% \n   C\u03c4 \u2191 121% \nAtazanavir \u2194 \nRitonavir \u2194 \nNo dose adjustment is necessary. \nTipranavir+ritonavir/ \nDolutegravir \nDolutegravir \u2193 \n   AUC \u2193 59% \n   Cmax \u2193 47% \n   C\u03c4 \u2193 76% \nTipranavir \u2194 \nRitonavir \u2194 \n(induction of UGT1A1 \nand CYP3A enzymes) \nThe recommended dose of dolutegravir \nis 50 mg twice daily when \nco administered with \ntipranavir/ritonavir. As Dovato is a \nfixed-dose tablet, an additional 50 mg \ntablet of dolutegravir should be \nadministered, approximately 12 hours \nafter Dovato for the duration of the \ntipranavir/ritonavir co-administration (a \nseparate formulation of dolutegravir is \navailable for this dose adjustment, see \nsection 4.2).  \nFosamprenavir+ritonavir/ \nDolutegravir \nDolutegravir\u2193 \n   AUC \u2193 35% \n   Cmax \u2193 24% \n   C\u03c4 \u2193 49% \nFosamprenavir\u2194 \nFosamprenavir/ritonavir decreases \ndolutegravir concentrations, but based \non limited data, did not result in \ndecreased efficacy in Phase III studies. \nNo dose adjustment is necessary.  \nRitonavir \u2194 \n(induction of UGT1A1 \nand CYP3A enzymes) \nLopinavir+ritonavir/ \nDolutegravir \nDolutegravir \u2194 \n   AUC \u2193 4% \n   Cmax \u2194 0% \n   C24 \u2193 6% \nLopinavir \u2194 \nRitonavir \u2194 \nNo dose adjustment is necessary. \nDarunavir+ritonavir/ \nDolutegravir \nDolutegravir \u2193 \n   AUC \u2193 22%  \n   Cmax \u2193 11% \n   C\u03c4 \u2193 38% \nDarunavir \u2194 \nRitonavir \u2194 \n(induction of UGT1A1 \nand CYP3A enzymes) \nNo dose adjustment is necessary. \nOther antiviral active substances \nDaclatasvir/Dolutegravir \nDolutegravir \u2194 \n   AUC \u2191 33%  \n   Cmax \u2191 29% \n   C\u03c4 \u2191 45% \nDaclatasvir \u2194 \nDaclatasvir did not change dolutegravir \nplasma concentration to a clinically \nrelevant extent. Dolutegravir did not \nchange daclatasvir plasma concentration. \nNo dose adjustment is necessary. \nLedipasvir/Sofosbuvir/ \nLamivudine (with abacavir) \nLamivudine \u2194 \nLedipasvir \u2194 \nSofosbuvir \u2194 \nNo dosage adjustment necessary. \nSofosbuvir/ \nVelpatasvir/Dolutegravir \nDolutegravir \u2194 \nSofosbuvir \u2194 \nVelpatasvir\u2194 \nNo dosage adjustment necessary. \nRibavirin \nInteraction not studied. \nClinically significant \ninteraction unlikely. \nNo dosage adjustment necessary. \nAnti-infective products\nTrimethoprim/sulfamethoxazole \n(Co-trimoxazole)/Lamivudine \n(160 mg/800 mg once daily for \n5 days/300 mg single dose) \nLamivudine:  \n   AUC \u2191 43% \n   Cmax \u2191 7% \nTrimethoprim:  \n   AUC \u2194 \nSulfamethoxazole:  \n   AUC \u2194 \n(organic cation transporter \ninhibition) \nNo dosage adjustment necessary. \nAntimycobacterials\nRifampicin/Dolutegravir \nDolutegravir \u2193 \n   AUC \u2193 54% \n   Cmax \u2193 43% \n   C\u03c4 \u2193 72% \nThe recommended dose of dolutegravir \nis 50 mg twice daily when \nco-administered with rifampicin. As \nDovato is a fixed-dose tablet, an \nadditional 50 mg tablet of dolutegravir \n10 \n(induction of UGT1A1 \nand CYP3A enzymes) \nshould be administered, approximately \n12 hours after Dovato for the duration of \nthe rifampicin co-administration (a \nseparate formulation of dolutegravir is \navailable for this dose adjustment, see \nsection 4.2).  \nRifabutin/Dolutegravir \nDolutegravir \u2194 \n   AUC \u2193 5% \n   Cmax \u2191 16% \n   C\u03c4 \u2193 30% \n(induction of UGT1A1 \nand CYP3A enzymes) \nNo dose adjustment is necessary. \nAnticonvulsants\nCarbamazepine/Dolutegravir \nDolutegravir \u2193 \n   AUC \u2193 49% \n   Cmax \u2193 33% \n   C\u03c4 \u2193 73% \nThe recommended dose of dolutegravir \nis 50 mg twice daily when \nco-administered with these metabolic \ninducers. As Dovato is a fixed-dose \ntablet, an additional 50 mg tablet of \ndolutegravir should be administered, \napproximately 12 hours after Dovato for \nthe duration of the co-administration \nwith these metabolic inducers (a separate \nformulation of dolutegravir is available \nfor this dose adjustment, see section \n4.2).  \nPhenobarbital/Dolutegravir \nPhenytoin/Dolutegravir \nOxcarbazepine/Dolutegravir \nDolutegravir \u2193 \n(Not studied, decrease \nexpected due to induction \nof UGT1A1 and CYP3A \nenzymes, a similar \nreduction in exposure as \nobserved with \ncarbamazepine is \nexpected). \nAntihistamines (histamine H2 receptor antagonists)\nRanitidine \nInteraction not studied. \nClinically significant \ninteraction unlikely. \nNo dosage adjustment necessary. \nCimetidine \nInteraction not studied. \nClinically significant \ninteraction unlikely. \nNo dosage adjustment necessary. \nCytotoxics\nCladribine/Lamivudine \nInteraction not studied.  \nIn vitro\n lamivudine \ninhibits the intracellular \nphosphorylation of \ncladribine leading to a \npotential risk of cladribine \nloss of efficacy in case of \ncombination in the \nclinical setting. Some \nclinical findings also \nsupport a possible \ninteraction between \nlamivudine and \ncladribine. \nConcomitant use of Dovato with \ncladribine is not recommended (see \nsection 4.4). \nMiscellaneous\nSorbitol \n11 \nSorbitol solution (3.2\n g, 10.2 g, \n13.4\n g)/Lamivudine \nSingle dose lamivudine \noral solution 300 mg.  \nLamivudine: \nAUC \u2193 14%; 32%; 36%  \nCmax \u2193 28%; 52%, 55%. \nWhen possible, avoid chronic \ncoadministration of Dovato with \nmedicinal products containing sorbitol \nor other osmotic acting poly-alcohols or \nmonosaccharide alcohols (eg: xylitol, \nmannitol, lactitol, maltitol). Consider \nmore frequent monitoring of HIV-1 viral \nload when chronic coadministration \ncannot be avoided. \nPotassium channel blockers\nFampridine (also known as \ndalfampridine)/Dolutegravir \nFampridine \u2191 \nCo-administration of dolutegravir has \nthe potential to cause seizures due to \nincreased fampridine plasma \nconcentration via inhibition of OCT2 \ntransporter; co-administration has not \nbeen studied. Fampridine co-\nadministration with Dovato is \ncontraindicated (see section 4.3).  \nAntacids and supplements \nMagnesium/ \naluminium-containing \nantacids/Dolutegravir \nDolutegravir \u2193 \nAUC \u2193 74%  \nCmax \u2193 72% \n(Complex binding to \npolyvalent ions) \nMagnesium/ aluminium-containing \nantacids should be taken well separated \nin time from the administration of \nDovato (minimum 2 hours after or \n6 hours before). \nCalcium \nsupplements/Dolutegravir \n(fasted intake) \nDolutegravir \u2193 \n   AUC \u2193 39%  \n   Cmax \u2193 37% \n   C24 \u2193 39% \n(Complex binding to \npolyvalent ions) \n- When taken with food, Dovato and \nsupplements or multivitamins containing \ncalcium, iron or magnesium can be taken \nat the same time.  \n- If Dovato is taken in a fasted state, \nsuch supplements should be taken a \nminimum 2 hours after or 6 hours before \nthe intake of Dovato. \nThe stated reductions in dolutegravir \nexposure were observed with the intake \nof dolutegravir and these supplements \nduring fasted conditions. In fed state, the \nchanges in exposure following intake \ntogether with calcium or iron \nsupplements were modified by the food \neffect, resulting in an exposure similar to \nthat obtained with dolutegravir \nadministered in the fasted state. \nIron supplements/Dolutegravir \n(fasted intake) \nDolutegravir \u2193 \n   AUC \u2193 54%  \n   Cmax \u2193 57% \n   C24 \u2193 56% \n(Complex binding to \npolyvalent ions) \nMultivitamins (containing \ncalcium, iron and magnesium) \n/Dolutegravir \n(fasted intake) \nDolutegravir \u2193 \n   AUC \u2193 33%  \n   Cmax \u2193 35% \n   C24 \u2193 32% \n(Complex binding to \npolyvalent ions) \nProton pump inhibitors \nOmeprazole \nDolutegravir \u2194 \nNo dosage adjustment necessary. \nCorticosteroids \nPrednisone/Dolutegravir \nDolutegravir \u2194 \n   AUC \u2191 11% \n   Cmax \u2191 6% \n   C\u03c4 \u2191 17% \nNo dose adjustment is necessary. \nAntidiabetics \nMetformin/Dolutegravir \nMetformin \u2191 \nDolutegravir \u2194 \nA dose adjustment of metformin should \nbe considered when starting and \nstopping coadministration of Dovato \n12 \nWhen co-administered \nwith dolutegravir 50 mg \nQD: \nMetformin \n   AUC \u2191 79%  \n   Cmax \u2191 66% \nWhen co-administered \nwith dolutegravir 50 mg \nBID:  \n   Metformin \n   AUC \u2191 145 %  \n   Cmax \u2191 111% \nwith metformin, to maintain glycaemic \ncontrol. In patients with moderate renal \nimpairment a dose adjustment of \nmetformin should be considered when \ncoadministered with Dovato, because of \nthe increased risk for lactic acidosis in \npatients with moderate renal impairment \ndue to increased metformin \nconcentration (section 4.4). \nHerbal products \nSt. John\u2019s wort/Dolutegravir \nDolutegravir \u2193 \n(Not studied, decrease \nexpected due to induction \nof UGT1A1 and CYP3A \nenzymes, a similar \nreduction in exposure as \nobserved with \ncarbamazepine is \nexpected). \nThe recommended dose of dolutegravir \nis 50 mg twice daily when co-\nadministered with St. John\u2019s wort. As \nDovato is a fixed-dose tablet, an \nadditional 50 mg tablet of dolutegravir \nshould be administered, approximately \n12 hours after Dovato for the duration of \nthe St. John\u2019s wort co-administration (a \nseparate formulation of dolutegravir is \navailable for this dose adjustment, see \nsection 4.2).  \nOral contraceptives \nEthinyl estradiol (EE) and \nNorgestromin \n(NGMN)/Dolutegravir \nEffect of dolutegravir: \nEE \u2194 \n   AUC \u2191 3%  \n   Cmax \u2193 1% \nEffect of dolutegravir: \nNGMN \u2194 \n   AUC \u2193 2%  \n   Cmax \u2193 11% \nDolutegravir had no pharmacodynamic \neffect on Luteinizing Hormone (LH), \nFollicle Stimulating Hormone (FSH) and \nprogesterone. No dose adjustment of \noral contraceptives is necessary when \nco-administered with Dovato. \nPaediatric population \nInteraction studies have only been performed in adults.", "driving": "Women of childbearing potential \nWomen of childbearing potential (WOCBP) should be counselled about the potential risk of neural tube \ndefects with dolutegravir (a component of Dovato, see below), including consideration of effective \ncontraceptive measures. \nIf a woman plans pregnancy, the benefits and the risks of continuing treatment with Dovato should be \ndiscussed with the patient. \nPregnancy \nThe safety and efficacy of a dual regimen has not been studied in pregnancy. \n13 \nHuman experience from a birth outcome surveillance study in Botswana shows a small increase of neural \ntube defects; 7 cases in 3,591 deliveries (0.19%; 95% CI 0.09%, 0.40%) to mothers taking dolutegravir-\ncontaining regimens at the time of conception compared to 21 cases in 19,361 deliveries (0.11%: 95% CI \n0.07%, 0.17%) to women exposed to non-dolutegravir regimens at the time of conception. \nThe incidence of neural tube defects in the general population ranges from 0.5-1 case per 1,000 live births \n(0.05-0.1%). Most neural tube defects occur within the first 4 weeks of embryonic development after \nconception (approximately 6 weeks after the last menstrual period). If a pregnancy is confirmed in the first \ntrimester while on Dovato, the benefits and risks of continuing Dovato versus switching to another \nantiretroviral regimen should be discussed with the patient taking the gestational age and the critical time \nperiod of neural tube defect development into account. \nData analysed from the Antiretroviral Pregnancy Registry do not indicate an increased risk of major birth \ndefects in over 600 women exposed to dolutegravir during pregnancy but are currently insufficient to address \nthe risk of neural tube defects.  \nIn animal reproductive toxicology studies with dolutegravir, no adverse development outcomes, including \nneural tube defects, were identified (see section 5.3).  \nMore than 1000 outcomes from exposure to dolutegravir during second and third trimester pregnancy \nindicate no evidence of increased risk of foetal/neonatal toxicity. Dovato may be used during the second and \nthird trimester of pregnancy when the expected benefit justifies the potential risk to the foetus. \nDolutegravir crosses the placenta in humans. In pregnant women living with HIV, the median foetal \numbilical cord concentration of dolutegravir was approximately 1.3-fold greater compared with the maternal \nperipheral plasma concentration. \nThere is insufficient information on the effects of dolutegravir on neonates. \nA large amount of data on the use of lamivudine in pregnant women (more than 5200 outcomes from first \ntrimester) indicates no malformative toxicity.  \nAnimal studies showed lamivudine may inhibit cellular DNA replication (see section 5.3). The clinical \nrelevance of these findings is unknown. \nMitochondrial dysfunction\nNucleoside and nucleotide analogues have been demonstrated \nin vitro\n and \nin vivo\n to cause a variable degree \nof mitochondrial damage. There have been reports of mitochondrial dysfunction in HIV-negative infants \nexposed \nin utero\n and/or post-natally to nucleoside analogues (see section 4.4). \nBreast-feeding  \nDolutegravir is excreted in human milk in small amounts (a median dolutegravir breast milk to maternal \nplasma ratio of 0.033 has been shown). There is insufficient information on the effects of dolutegravir in \nneonates/infants.  \nBased on more than 200 mother/child pairs treated for HIV, serum concentrations of lamivudine in breastfed \ninfants of mothers treated for HIV are very low (< 4% of maternal serum concentrations) and progressively \ndecrease to undetectable levels when breastfed infants reach 24 weeks of age. There are no data available on \nthe safety of lamivudine when administered to babies less than three months old. \nIt is recommended that women living with HIV do not breast-feed their infants in order to avoid transmission \nof HIV. \nFertility  \n14 \nThere are no data on the effects of dolutegravir or lamivudine on human male or female fertility. Animal \nstudies indicate no effects of dolutegravir or lamivudine on male or female fertility (see section 5.3).", "side_effects": "Dovato has no or negligible influence on the ability to drive and use machines. Patients should be informed \nthat dizziness and somnolence has been reported during treatment with dolutegravir. The clinical status of \nthe patient and the adverse reaction profile of Dovato should be borne in mind when considering the patient\u2019s \nability to drive or operate machinery.", "shelf_life": "3 years.", "storage": "This medicinal product does not require any special storage conditions.", "package": "Opaque, white HDPE (high density polyethylene) bottles closed with child resistant polypropylene closures, \nwith a polyethylene faced induction heat seal liner. Each pack consists of one bottle containing 30 film-\ncoated tablets. \nMultipacks containing 90 (3 packs of 30) film-coated tablets.", "marketing_authorization_numbers": "EU/1/19/1370/001 \nEU/1/19/1370/002 \n27", "filename": "dovato-epar-product-information_en.html", "snomed.product_info": [["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["725125005", "300 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"]], "ncit.product_info": [["C199581", "Dolutegravir Sodium/Lamivudine"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C16645", "Greece"], ["C16818", "Mammography"], ["C154467", "Film Dosage Form Category"], ["C25450", "Coat"]], "rxnorm.product_info": [["2122521", "Dovato"]], "loinc.product_info": [["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LP15217-0", "Mg"]], "snomed.composition": [["419473009", "Each (qualifier value)"], ["385057009", "Film-coated tablet (product)|Film-coated tablet (basic dose form)|Film-coated tablet (qualifier value)"], ["713465004", "Dolutegravir sodium (substance)"], ["258726008", "Eq (qualifier value)|equivalent - unit (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["725125005", "300 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["86495002", "For (qualifier value)"], ["261015003", "Full (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.composition": [["C64933", "Each"], ["C42931", "Film Coated Tablet Dosage Form"], ["C79873", "Contain"], ["C148408", "Dolutegravir Sodium"], ["C48793", "Equivalent"], ["C159124", "GDC Treatment Outcome Terminology"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C121543", "Dolutegravir"], ["C16289", "Andorra"], ["C16645", "Greece"], ["C16818", "Mammography"], ["C1471", "Lamivudine"], ["C64956", "For"], ["C25517", "Full"], ["C43432", "List"], ["C52874", "SPI1 wt Allele"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.composition": [["1433867", "dolutegravir sodium"], ["1433868", "dolutegravir"], ["68244", "lamivudine"]], "loinc.composition": [["LP136501-6", "Tablet"], ["LP157327-0", "Dolutegravir"], ["LP15099-2", "Sodium"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LP157327-0", "Dolutegravir"], ["LP15217-0", "Mg"], ["MTHU060537", "lamiVUDine"], ["LA19682-6", "Full"], ["LP204165-7", "List"], ["LP20594-5", "6"], ["LA6112-2", "1"]], "snomed.indications": [["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["243598007", "Human immunodeficiency virus type 1 [Ambiguous]|Human immunodeficiency virus type 1 (organism)"], ["89293008", "Human immunodeficiency virus type I (organism)"], ["257551009", "Infection (disorder)|Infection"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["352730000", "Supra- (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["39857003", "Weighing patient (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["36692007", "Known (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["415684004", "Suspected (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["428617003", "Integrase strand transfer inhibitor (product)|Product containing integrase strand transfer inhibitor (product)"], ["277046005", "Class (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.indications": [["C199581", "Dolutegravir Sodium/Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C125394", "Bristol Stool Type 1"], ["C14220", "Human Immunodeficiency Virus 1"], ["C128320", "Infection"], ["C16727", "India"], ["C16289", "Andorra"], ["C16266", "Adolescents"], ["C75329", "Above"], ["C113426", "Twelve"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C158997", "GDC Analyte Type Terminology"], ["C105795", "Forty"], ["C16771", "Kyrgyzstan"], ["C62355", "With"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C80137", "Known"], ["C43508", "Oregon"], ["C71458", "Suspected"], ["C41546", "Resistance Process"], ["C159124", "GDC Treatment Outcome Terminology"], ["C157401", "HIV Integrase Inhibitor"], ["C41106", "Object Class"], ["C43508", "Oregon"], ["C1471", "Lamivudine"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.indications": [["2122521", "Dovato"], ["T016", "Human"], ["T005", "Virus"], ["68244", "lamivudine"]], "loinc.indications": [["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA19711-3", "Human"], ["LP231628-1", "Immunodeficiency"], ["LP14855-8", "Virus"], ["LP6886-8", "Type"], ["LA6112-2", "1"], ["LP183501-8", "HIV"], ["LA6112-2", "1"], ["LP266919-2", "Infection"], ["LA22004-8", "IN"], ["LA14991-6", "Above"], ["LA14558-3", "12"], ["MTHU010047", "Age"], ["LA21988-3", "AT"], ["LA28858-1", "40"], ["LA32-8", "No"], ["LA22025-3", "OR"], ["LA15291-0", "Suspected"], ["LP6857-9", "Resistance"], ["LP6795-1", "Class"], ["LA22025-3", "OR"], ["MTHU060537", "lamiVUDine"], ["LP20593-7", "5"], ["LA6112-2", "1"]], "snomed.posology": [["18720000", "In (attribute)"], ["394834005", "Management|Management (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86406008", "Human immunodeficiency virus infection (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["352730000", "Supra- (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["39857003", "Weighing patient (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["725125005", "300 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["229797004", "Once daily (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["257738001", "Adjustments (procedure)|Adjustments"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263869007", "Separate (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["42752001", "Due to (attribute)"], ["410942007", "Drug or medicament (substance)"], ["410942007", "Drug or medicament (substance)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["387159009", "Rifampin (substance)|Rifampicin (substance)"], ["387222003", "Carbamazepine (substance)"], ["387025007", "Oxcarbazepine (substance)"], ["387220006", "Phenytoin (substance)"], ["373505007", "Phenobarbital (substance)"], ["224006005", "St. John (geographic location)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["432221004", "Etravirine (product)|Product containing etravirine (medicinal product)"], ["45169001", "Without (attribute)"], ["736207009", "Protease (disposition)"], ["387001004", "Efavirenz (substance)"], ["386898005", "Nevirapine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["419409009", "Tipranavir (substance)"], ["386896009", "Ritonavir (substance)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["309343006", "Physician (occupation)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["385435006", "Individual (person)"], ["86495002", "For (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["116154003", "Patient (person)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["116154003", "Patient (person)"], ["419652001", "Take (qualifier value)|Take - dosing instruction imperative (qualifier value)"], ["709122007", "As soon as possible (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["123031003", "4 hours (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["123031003", "4 hours (qualifier value)"], ["116154003", "Patient (person)"], ["419652001", "Take (qualifier value)|Take - dosing instruction imperative (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["420862001", "On (qualifier value)"], ["260676000", "Use of (attribute)"], ["18720000", "In (attribute)"], ["264695004", "65 (qualifier value)|Arabic numeral 65 (qualifier value)"], ["258707000", "year (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["21481007", "Over (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["86495002", "For (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["270011004", "Creatinine clearance (& level (& glom filt))|Creatinine clearance (& level (& glom filt)) (procedure)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258859000", "Milliliter/minute (qualifier value)|mL/min (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255604002", "Mild (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1255665007", "Moderate (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["386897000", "Lamivudine (substance)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["270011004", "Creatinine clearance (& level (& glom filt))|Creatinine clearance (& level (& glom filt)) (procedure)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258859000", "Milliliter/minute (qualifier value)|mL/min (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["40226000", "Impairment (finding)"], ["373067005", "No (qualifier value)"], ["260911001", "Dosage (attribute)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255604002", "Mild (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1255665007", "Moderate (qualifier value)"], ["40226000", "Impairment (finding)"], ["410601007", "Childhood age person (person)"], ["258356001", "Grade A (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421211000", "Lymphoma staging symptom status B (tumor staging)"], ["373067005", "No (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["40226000", "Impairment (finding)"], ["410601007", "Childhood age person (person)"], ["258358000", "Grade C (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["732766004", "5.2 (qualifier value)"], ["376171000221106", "Pediatric population (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258707000", "year (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["39857003", "Weighing patient (procedure)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["263748003", "Established (qualifier value)"], ["373067005", "No (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["260686004", "Method (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["26643006", "Oral route (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["45169001", "Without (attribute)"], ["255620007", "Food (substance)|Foods (substance)"], ["732766004", "5.2 (qualifier value)"]], "ncit.posology": [["C199581", "Dolutegravir Sodium/Lamivudine"], ["C16329", "Belgium"], ["C158169", "Buyei Chinese"], ["C16727", "India"], ["C97639", "Management Occupations"], ["C52874", "SPI1 wt Allele"], ["C3108", "HIV Infection"], ["C16289", "Andorra"], ["C16266", "Adolescents"], ["C75329", "Above"], ["C113426", "Twelve"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C158997", "GDC Analyte Type Terminology"], ["C105795", "Forty"], ["C16771", "Kyrgyzstan"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C16727", "India"], ["C16289", "Andorra"], ["C16266", "Adolescents"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C66832", "One"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C16645", "Greece"], ["C16818", "Mammography"], ["C154605", "Tablet Dosage Form Category"], ["C125004", "Once Daily"], ["C25488", "Dose"], ["C76246", "Blood Group A"], ["C63803", "Separate"], ["C25625", "Preparation"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25429", "Availability"], ["C76246", "Blood Group A"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C89272", "Due To"], ["C459", "Medication"], ["C459", "Medication"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C811", "Rifampin"], ["C341", "Carbamazepine"], ["C47643", "Oxcarbazepine"], ["C741", "Phenytoin"], ["C75368", "Phenobarbital Measurement"], ["C159109", "GDC Sample Type Terminology"], ["C42555", "Siemens"], ["C73195", "Etravirine"], ["C25718", "Without"], ["C783", "Protease Inhibitor"], ["C29027", "Efavirenz"], ["C29277", "Nevirapine"], ["C43508", "Oregon"], ["C66603", "Tipranavir"], ["C1609", "Ritonavir"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16727", "India"], ["C25741", "Physician"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25190", "Person"], ["C40352", "Multiplicative Product"], ["C48191", "Information"], ["C64956", "For"], ["C121543", "Dolutegravir"], ["C54031", "Missing"], ["C25488", "Dose"], ["C198613", "CFI wt Allele"], ["C53691", "Veterinary Patient"], ["C76246", "Blood Group A"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C53691", "Veterinary Patient"], ["C65105", "Take"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C71344", "Associate of Science"], ["C71344", "Associate of Science"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C82511", "Subsequent Trial Activity"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C45263", "Due"], ["C25282", "Within"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25529", "Hour"], ["C198613", "CFI wt Allele"], ["C82511", "Subsequent Trial Activity"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C45263", "Due"], ["C25282", "Within"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25529", "Hour"], ["C53691", "Veterinary Patient"], ["C25594", "Negation"], ["C65105", "Take"], ["C54031", "Missing"], ["C25488", "Dose"], ["C16289", "Andorra"], ["C54631", "Curriculum Vitae"], ["C102843", "Usual"], ["C25211", "Schedule"], ["C16268", "Elderly"], ["C68869", "Are"], ["C142988", "Limited"], ["C25474", "Data"], ["C25429", "Availability"], ["C92667", "SPARC wt Allele"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C16727", "India"], ["C16960", "Patient"], ["C25150", "Age"], ["C188329", "Sixty Five"], ["C29848", "Year"], ["C16289", "Andorra"], ["C25490", "During"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C114592", "Renal Impairment"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C64956", "For"], ["C25340", "Use"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C25747", "Creatinine Clearance"], ["C70541", "Lansky Performance Status 30"], ["C64777", "Milliliter per Minute"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C156242", "Mild Hallucination"], ["C43508", "Oregon"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C114592", "Renal Impairment"], ["C1471", "Lamivudine"], ["C49587", "Exposure Domain"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C164135", "Increased"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C25747", "Creatinine Clearance"], ["C105785", "Fifty"], ["C64777", "Milliliter per Minute"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C94394", "Cumulative Dose"], ["C49157", "Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C156242", "Mild Hallucination"], ["C43508", "Oregon"], ["C148420", "Moderate Hepatic Insufficiency"], ["C121007", "Child-Pugh Clinical Classification"], ["C48309", "Grade"], ["C76246", "Blood Group A"], ["C43508", "Oregon"], ["C113692", "Child-Pugh Class B"], ["C53269", "No Information Available"], ["C68869", "Are"], ["C25429", "Availability"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C121007", "Child-Pugh Clinical Classification"], ["C48309", "Grade"], ["C67900", "Centi"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C16329", "Belgium"], ["C62355", "With"], ["C16727", "India"], ["C16960", "Patient"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C17005", "Population Group"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C16727", "India"], ["C16423", "Child"], ["C25150", "Age"], ["C61585", "Less Than"], ["C113426", "Twelve"], ["C29848", "Year"], ["C43508", "Oregon"], ["C61585", "Less Than"], ["C105795", "Forty"], ["C16771", "Kyrgyzstan"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C53269", "No Information Available"], ["C68869", "Are"], ["C25429", "Availability"], ["C85492", "CDISC SDTM Method Terminology"], ["C52874", "SPI1 wt Allele"], ["C70962", "Agent Administration"], ["C38288", "Oral Route of Administration"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C62355", "With"], ["C43508", "Oregon"], ["C25718", "Without"], ["C62695", "Food"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"]], "rxnorm.posology": [["2122521", "Dovato"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["9384", "rifampin"], ["2002", "carbamazepine"], ["32624", "oxcarbazepine"], ["8183", "phenytoin"], ["8134", "phenobarbital"], ["475969", "etravirine"], ["8031", "protease"], ["195085", "efavirenz"], ["53654", "nevirapine"], ["190548", "tipranavir"], ["85762", "ritonavir"], ["1433868", "dolutegravir"], ["2122521", "Dovato"], ["2122521", "Dovato"], ["2122521", "Dovato"], ["2122521", "Dovato"], ["2913", "creatinine"], ["68244", "lamivudine"], ["2913", "creatinine"], ["2122521", "Dovato"], ["2122521", "Dovato"], ["2122521", "Dovato"], ["T168", "Food"]], "loinc.posology": [["LA22004-8", "IN"], ["LA20391-1", "Management"], ["MTHU020829", "HIV infection"], ["LA14991-6", "Above"], ["LA14558-3", "12"], ["MTHU010047", "Age"], ["LA21988-3", "AT"], ["LA28858-1", "40"], ["MTHU065481", "Dose"], ["LA22004-8", "IN"], ["LP200075-2", "IS"], ["LA6306-0", "One"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["LA6305-2", "Once daily"], ["MTHU065481", "Dose"], ["LP17763-1", "A"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA20274-9", "Drug-drug"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP16061-1", "carBAMazepine"], ["MTHU060529", "OXcarbazepine"], ["LP14732-9", "Phenytoin"], ["MTHU060452", "PHENobarbital"], ["LP15241-0", "S"], ["LP68431-3", "Etravirine"], ["LP21310-5", "Efavirenz"], ["MTHU013861", "Nevirapine"], ["LA22025-3", "OR"], ["LP36120-1", "Tipranavir"], ["MTHU013855", "Ritonavir"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA15768-7", "4.5"], ["LA22004-8", "IN"], ["LP270144-1", "Cases"], ["MTHU010489", "Physician"], ["LA10393-9", "Refer"], ["LA12070-1", "Individual"], ["LP157327-0", "Dolutegravir"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP66710-2", "Patient"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP66710-2", "Patient"], ["LA15097-1", "Possible"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LP6940-3", "4 hours"], ["LP6323-2", "Immunofluorescence (IF)"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP6940-3", "4 hours"], ["LP66710-2", "Patient"], ["LA21291-2", "Not"], ["MTHU065481", "Dose"], ["LP183687-5", "usual"], ["LA6484-5", "Limited"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["MTHU065909", "Renal"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP29651-4", "Creatinine clearance"], ["LA32970-8", "<"], ["LA28855-7", "30"], ["LP6970-0", "minimum"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA6752-5", "Mild"], ["LA22025-3", "OR"], ["LA6751-7", "Moderate"], ["MTHU065909", "Renal"], ["MTHU060537", "lamiVUDine"], ["LP200075-2", "IS"], ["LA24377-6", "Increased"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP29651-4", "Creatinine clearance"], ["LA32970-8", "<"], ["LA28854-0", "50"], ["LP6970-0", "minimum"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA32-8", "No"], ["LP6801-7", "Dosage"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA6752-5", "Mild"], ["LA22025-3", "OR"], ["LA6751-7", "Moderate"], ["LP428313-3", "Child-Pugh"], ["MTHU003112", "Grade"], ["LP17763-1", "A"], ["LA22025-3", "OR"], ["LA14518-7", "B"], ["LA32-8", "No"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["LP428313-3", "Child-Pugh"], ["MTHU003112", "Grade"], ["LP17128-7", "C"], ["LA22004-8", "IN"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LP62263-6", "Population"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LA16823-9", "Less"], ["LA14558-3", "12"], ["LA22025-3", "OR"], ["LA16823-9", "Less"], ["LA28858-1", "40"], ["LA21291-2", "Not"], ["LA32-8", "No"], ["LP72939-9", "Method"], ["LA9367-9", "Oral"], ["LA22025-3", "OR"], ["MTHU065486", "Food"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"]], "snomed.contraindications": [["257550005", "Hypersensitivity (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["105590001", "Substance (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["134223000", "Narrow (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["31046007", "Cation (substance)"], ["705591009", "Transporter (physical object)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["55919000", "Including (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["413355004", "4-Aminopyridine (product)|Product containing 4-Aminopyridine (medicinal product)|Product containing fampridine (medicinal product)"], ["36692007", "Known (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["80994002", "Fampridine (substance)|4-Aminopyridine (substance)"], ["732729005", "4.5 (qualifier value)"]], "ncit.contraindications": [["C3114", "Hypersensitivity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C154405", "Active State"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C62355", "With"], ["C62355", "With"], ["C124564", "Narrow"], ["C25277", "Therapeutic"], ["C68869", "Are"], ["C52874", "SPI1 wt Allele"], ["C63848", "Organic"], ["C63523", "Optimal Cutting Temperature Compound"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C166400", "Inclusive"], ["C25594", "Negation"], ["C142988", "Limited"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76777", "Dalfampridine"], ["C80137", "Known"], ["C71344", "Associate of Science"], ["C76777", "Dalfampridine"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"]], "rxnorm.contraindications": [["897018", "dalfampridine"], ["897018", "dalfampridine"]], "loinc.contraindications": [["LA16666-2", "Active"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP20594-5", "6"], ["LA6112-2", "1"], ["LA21996-6", "CO"], ["LA9191-3", "Narrow"], ["LP263807-2", "Therapeutic"], ["LP97035-7", "by OCT"], ["MTHU000002", "Clinical Class"], ["LA21291-2", "Not"], ["LA6484-5", "Limited"], ["LA15768-7", "4.5"]], "snomed.special_warnings": [["257550005", "Hypersensitivity (qualifier value)"], ["257550005", "Hypersensitivity (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["271807003", "Eruption of skin (disorder)|Eruption (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["88846004", "Functional disorder (finding)"], ["55919000", "Including (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["181268008", "Entire liver (body structure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["410546004", "Discontinued (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["257550005", "Hypersensitivity (qualifier value)"], ["55919000", "Including (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["271807003", "Eruption of skin (disorder)|Eruption (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["271807003", "Eruption of skin (disorder)|Eruption (disorder)"], ["260399008", "Raised (qualifier value)"], ["166641008", "Liver enzymes (& blood level [ALT] or [SGPT])|Liver enzymes (& blood level [ALT] or [SGPT]) (procedure)"], ["386661006", "Fever (finding)"], ["60132005", "Generalized (qualifier value)"], ["367391008", "Malaise (finding)"], ["139126000", "Fatigue (finding)|Fatigue"], ["71616004", "Skeletal and/or smooth muscle structure (body structure)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["302536002", "Entire joint (body structure)"], ["210984001", "(Superficial injury) or (abrasions) or (blisters) or (friction burns) or (splinters) or (sting (& without reaction): [bee] or [wasp]) or (bites: [insect - non venomous] or [flea]) (disorder)|(Superficial injury) or (abrasions) or (blisters) or (friction burns) or (splinters) or (sting (& without reaction): [bee] or [wasp]) or (bites: [insect - non venomous] or [flea])"], ["738956005", "Oral (intended site)"], ["193858003", "Conjunctivitis &/or unspecified acute conjunctivitis|Conjunctivitis &/or unspecified acute conjunctivitis (disorder)"], ["423666004", "Edema (observable entity)"], ["419769007", "Increased blood eosinophil number (finding)"], ["846575004", "Angioedema (morphologic abnormality)"], ["263493007", "Clinical status (attribute)"], ["55919000", "Including (qualifier value)"], ["181268008", "Entire liver (body structure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["79706000", "Bilirubin (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["55561003", "Active (qualifier value)"], ["105590001", "Substance (substance)"], ["255234002", "After (attribute)"], ["77374008", "Onset of (contextual qualifier) (qualifier value)"], ["257550005", "Hypersensitivity (qualifier value)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["419076005", "Allergic reaction (disorder)"], ["726527001", "Weight (property) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["252116004", "Observation parameter (observable entity)"], ["260366006", "Increase (qualifier value)"], ["18720000", "In (attribute)"], ["726527001", "Weight (property) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["258395000", "Levels (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["87612001", "Blood (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["768685009", "Antiretroviral (disposition)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["260726005", "Part (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["64572001", "Disease (disorder)"], ["246106000", "Control (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["367150003", "Lifestyle|Lifestyle (finding)"], ["86495002", "For (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["726527001", "Weight (property) (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["18669006", "Evidence of (contextual qualifier) (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["87612001", "Blood (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["263748003", "Established (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["70106000", "Lipid (substance)"], ["64572001", "Disease (disorder)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["266535008", "(Liver/biliary/pancreas+GIT NOS) or (biliary disease) or (gallbladder disease) or (liver disease)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["266539002", "Chronic hepatitis (& [NOS] or [active B] or [active] or [persistent]) (disorder)|Chronic hepatitis (& [NOS] or [active B] or [active] or [persistent])"], ["421211000", "Lymphoma staging symptom status B (tumor staging)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["28995006", "Treated with (attribute)"], ["89780004", "Combined (qualifier value)"], ["768685009", "Antiretroviral (disposition)"], ["277132007", "Therapeutic procedure (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["399166001", "Fatal (qualifier value)"], ["281647001", "Adverse reaction (disorder)|Adverse reactions (disorder)|Adverse reactions (finding)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["427314002", "Antiviral therapy (procedure)"], ["86495002", "For (qualifier value)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["55919000", "Including (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["55561003", "Active (qualifier value)"], ["65897001", "Against (qualifier value)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["257733005", "Activity (observable entity)|Activities (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["88323005", "Adequate (qualifier value)"], ["86495002", "For (qualifier value)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["86495002", "For (qualifier value)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["75540009", "High (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["73154007", "Infected (morphologic abnormality)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["768683002", "Antiviral (disposition)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410525008", "Needed (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410546004", "Discontinued (qualifier value)"], ["18720000", "In (attribute)"], ["73154007", "Infected (morphologic abnormality)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["81665004", "Hepatitis B virus (organism)"], ["123115008", "Periodic (qualifier value)|Periodic -RETIRED-"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["51440002", "Right and left (qualifier value)"], ["181268008", "Entire liver (body structure)"], ["277064003", "Function (attribute)"], ["272393004", "Tests (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["53737009", "Acute (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["128241005", "Inflammatory disease of liver (disorder)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["181268008", "Entire liver (body structure)"], ["88846004", "Functional disorder (finding)"], ["55919000", "Including (qualifier value)"], ["266539002", "Chronic hepatitis (& [NOS] or [active B] or [active] or [persistent]) (disorder)|Chronic hepatitis (& [NOS] or [active B] or [active] or [persistent])"], ["35105006", "Increased (qualifier value)"], ["260864003", "Frequency (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["79036002", "Liver function (function)|Liver function (observable entity)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["768685009", "Antiretroviral (disposition)"], ["277132007", "Therapeutic procedure (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18669006", "Evidence of (contextual qualifier) (qualifier value)"], ["230993007", "Worsening (qualifier value)"], ["266535008", "(Liver/biliary/pancreas+GIT NOS) or (biliary disease) or (gallbladder disease) or (liver disease)"], ["18720000", "In (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255386009", "Immune (qualifier value)"], ["64572001", "Disease (disorder)"], ["18720000", "In (attribute)"], ["19030005", "Human immunodeficiency virus (organism)"], ["73154007", "Infected (morphologic abnormality)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["255386009", "Immune (qualifier value)"], ["246199000", "Deficiency (attribute)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["385437003", "Institution (social concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["768685009", "Antiretroviral (disposition)"], ["277132007", "Therapeutic procedure (procedure)"], ["85455005", "Cart, device (physical object)"], ["23583003", "Inflammation (morphologic abnormality)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["84387000", "Asymptomatic (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["362977000", "Sequela (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["255216001", "First (qualifier value)"], ["57176003", "Few (qualifier value)"], ["258705008", "week (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258706009", "month (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["85455005", "Cart, device (physical object)"], ["22455005", "Cytomegaloviral retinitis (disorder)"], ["60132005", "Generalized (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["87017008", "Focal (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["79909001", "Pneumocystis jiroveci (organism)|Pneumocystis jirovecii (organism)"], ["266391003", "Pneumonia and influenza &/or pneumonia|Pneumonia and influenza &/or pneumonia (disorder)"], ["70232002", "Frequent (qualifier value)"], ["85241004", "Referred (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["9721008", "Phencyclidine (substance)"], ["255387000", "Inflammatory|Inflammatory (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["263680009", "Autoimmune (qualifier value)|Autoimmune process (qualifier value)"], ["64572001", "Disease (disorder)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["64572001", "Disease (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["408335007", "Autoimmune hepatitis (disorder)"], ["733985002", "Reported (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255386009", "Immune (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["246100006", "Onset (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["242762006", "More (qualifier value)"], ["255372005", "Variable (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["260396001", "Numerous (qualifier value)"], ["258706009", "month (qualifier value)"], ["255234002", "After (attribute)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["181268008", "Entire liver (body structure)"], ["385433004", "Consistent with (qualifier value)"], ["426202004", "Immune reconstitution syndrome (disorder)"], ["18720000", "In (attribute)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["128241005", "Inflammatory disease of liver (disorder)"], ["421211000", "Lymphoma staging symptom status B (tumor staging)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["73154007", "Infected (morphologic abnormality)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["226630009", "Start (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["277132007", "Therapeutic procedure (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["181268008", "Entire liver (body structure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["266535008", "(Liver/biliary/pancreas+GIT NOS) or (biliary disease) or (gallbladder disease) or (liver disease)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["88846004", "Functional disorder (finding)"], ["255260001", "Following (attribute)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["18720000", "In (attribute)"], ["47368004", "Nucleoside (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["71211001", "Nucleotide (substance)"], ["277064003", "Function (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255372005", "Variable (qualifier value)"], ["246173007", "Degree (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["4757001", "Most (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386895008", "Stavudine (substance)"], ["387105006", "Didanosine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387151007", "Zidovudine (substance)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["88846004", "Functional disorder (finding)"], ["18720000", "In (attribute)"], ["19030005", "Human immunodeficiency virus (organism)"], ["394426005", "Negative|Negative (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["288563008", "After values (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["47368004", "Nucleoside (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["42504009", "Containing (qualifier value)"], ["387151007", "Zidovudine (substance)"], ["63161005", "Principal (qualifier value)"], ["281647001", "Adverse reaction (disorder)|Adverse reactions (disorder)|Adverse reactions (finding)"], ["733985002", "Reported (qualifier value)"], ["64572001", "Disease (disorder)"], ["271737000", "Anemia (disorder)"], ["303011007", "Neutropenic disorder (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["154733004", "Metabolic disorders (disorder)|Metabolic disorders"], ["70232002", "Frequent (qualifier value)"], ["14803004", "Transitory (qualifier value)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["260383002", "Late (qualifier value)"], ["246100006", "Onset (attribute)"], ["267679005", "Neurological disorder (& [nervous system disease] or [CNS diseases] or [sense organ disease])|Neurological disorder (& [nervous system disease] or [CNS diseases] or [sense organ disease]) (disorder)"], ["733985002", "Reported (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["56731001", "Increased muscle tone (finding)"], ["271788002", "Fit: [Convulsion) &/or (fit and well]|Fit: [Convulsion) &/or (fit and well] (disorder)"], ["25786006", "Abnormal behavior (finding)"], ["267679005", "Neurological disorder (& [nervous system disease] or [CNS diseases] or [sense organ disease])|Neurological disorder (& [nervous system disease] or [CNS diseases] or [sense organ disease]) (disorder)"], ["255276005", "Transient (disorder)|Transient"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["6934004", "Permanent (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["15240007", "Current (qualifier value)"], ["261665006", "Unknown (qualifier value)"], ["86495002", "For (qualifier value)"], ["410601007", "Childhood age person (person)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["47368004", "Nucleoside (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["71211001", "Nucleotide (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["105589005", "Finding, conclusion AND/OR assessment|Finding, conclusion AND/OR assessment (finding)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["261665006", "Unknown (qualifier value)"], ["134198009", "Etiology (attribute)"], ["1199008", "Neurologic (qualifier value)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["15240007", "Current (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["768685009", "Antiretroviral (disposition)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["101445003", "PREVENT (substance)|PREVENT (product)"], ["1290740005", "Vertical transmission (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["398199007", "Aseptic necrosis of bone (disorder)"], ["134198009", "Etiology (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["55919000", "Including (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["96281001", "Product containing bisphosphonate (product)|Diphosphonate (product)|Diphosphonate (substance)"], ["160573003", "Alcohol intake (observable entity)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["363807006", "Body mass index|Body mass index (observable entity)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["398199007", "Aseptic necrosis of bone (disorder)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86005002", "Advanced (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["64572001", "Disease (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["263803006", "Long-term (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["85455005", "Cart, device (physical object)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["74188005", "Medical (qualifier value)"], ["243073001", "Advice (regime/therapy)|Advice (regime/therapy)(procedure)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["302536002", "Entire joint (body structure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["367206007", "Pain|Pain (finding)"], ["84445001", "Joint stiffness (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["371157007", "Has difficulty doing (qualifier value)|Able with difficulty (qualifier value)"], ["18720000", "In (attribute)"], ["255324009", "Movement (observable entity)|Movement, function (observable entity)|Movement (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["386897000", "Lamivudine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["768685009", "Antiretroviral (disposition)"], ["277132007", "Therapeutic procedure (procedure)"], ["717896003", "Does not (qualifier value)"], ["86406008", "Human immunodeficiency virus infection (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["257551009", "Infection (disorder)|Infection"], ["351726001", "Below (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["122544007", "Observation procedure (procedure)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["64572001", "Disease (disorder)"], ["416118004", "Administration (procedure)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1255665007", "Moderate (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["270011004", "Creatinine clearance (& level (& glom filt))|Creatinine clearance (& level (& glom filt)) (procedure)"], ["11896004", "Intermediate (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222852005", "American Joint Committee on Cancer stage IV:9 (qualifier value)"], ["258859000", "Milliliter/minute (qualifier value)|mL/min (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["732428001", "1.6 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["732646001", "3.3 (qualifier value)"], ["26310004", "Folded structure (morphologic abnormality)"], ["386897000", "Lamivudine (substance)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["413573002", "Area under the curve (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["270011004", "Creatinine clearance (& level (& glom filt))|Creatinine clearance (& level (& glom filt)) (procedure)"], ["732774003", "50 (qualifier value)"], ["258859000", "Milliliter/minute (qualifier value)|mL/min (qualifier value)"], ["373067005", "No (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["385435006", "Individual (person)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["270011004", "Creatinine clearance (& level (& glom filt))|Creatinine clearance (& level (& glom filt)) (procedure)"], ["11896004", "Intermediate (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222852005", "American Joint Committee on Cancer stage IV:9 (qualifier value)"], ["258859000", "Milliliter/minute (qualifier value)|mL/min (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["18720000", "In (attribute)"], ["19535007", "Original (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387151007", "Zidovudine (substance)"], ["386897000", "Lamivudine (substance)"], ["47429007", "Associated with (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["57407000", "Hematologic (qualifier value)"], ["303011007", "Neutropenic disorder (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["271737000", "Anemia (disorder)"], ["42752001", "Due to (attribute)"], ["303011007", "Neutropenic disorder (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["271737000", "Anemia (disorder)"], ["419473009", "Each (qualifier value)"], ["18720000", "In (attribute)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["74964007", "Other (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["262094002", "Related (finding)"], ["272379006", "Events (event)|Event (event)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["1255345008", "Intestinal (intended site)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["64572001", "Disease (disorder)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263892007", "Sustained (qualifier value)"], ["270011004", "Creatinine clearance (& level (& glom filt))|Creatinine clearance (& level (& glom filt)) (procedure)"], ["11896004", "Intermediate (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222852005", "American Joint Committee on Cancer stage IV:9 (qualifier value)"], ["258859000", "Milliliter/minute (qualifier value)|mL/min (qualifier value)"], ["86495002", "For (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["262094002", "Related (finding)"], ["272379006", "Events (event)|Event (event)"], ["57407000", "Hematologic (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["261021004", "New (qualifier value)|New [dup] (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["230993007", "Worsening (qualifier value)"], ["303011007", "Neutropenic disorder (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["271737000", "Anemia (disorder)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["410546004", "Discontinued (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["385435006", "Individual (person)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["410942007", "Drug or medicament (substance)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229799001", "Twice a day (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387159009", "Rifampin (substance)|Rifampicin (substance)"], ["387222003", "Carbamazepine (substance)"], ["387025007", "Oxcarbazepine (substance)"], ["387220006", "Phenytoin (substance)"], ["373505007", "Phenobarbital (substance)"], ["224006005", "St. John (geographic location)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["432221004", "Etravirine (product)|Product containing etravirine (medicinal product)"], ["45169001", "Without (attribute)"], ["736207009", "Protease (disposition)"], ["387001004", "Efavirenz (substance)"], ["386898005", "Nevirapine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["419409009", "Tipranavir (substance)"], ["386896009", "Ritonavir (substance)"], ["732729005", "4.5 (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["31046007", "Cation (substance)"], ["42504009", "Containing (qualifier value)"], ["31046007", "Cation (substance)"], ["42504009", "Containing (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["123030002", "2 hours (qualifier value)"], ["255234002", "After (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["123033000", "6 hours (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255620007", "Food (substance)|Foods (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["329413004", "Multivitamins (substance)"], ["42504009", "Containing (qualifier value)"], ["5540006", "Calcium (substance)"], ["3829006", "Iron (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["72717003", "Magnesium (substance)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["262126009", "Same (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["351726001", "Below (qualifier value)"], ["792805006", "Fasting (regime/therapy)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["329413004", "Multivitamins (substance)"], ["42504009", "Containing (qualifier value)"], ["5540006", "Calcium (substance)"], ["3829006", "Iron (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["72717003", "Magnesium (substance)"], ["897015005", "Recommended (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["123030002", "2 hours (qualifier value)"], ["255234002", "After (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["123033000", "6 hours (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["35105006", "Increased (qualifier value)"], ["372567009", "Metformin (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["372567009", "Metformin (substance)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["372567009", "Metformin (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["246106000", "Control (attribute)"], ["732729005", "4.5 (qualifier value)"], ["372567009", "Metformin (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["13288007", "Monitor, device (physical object)"], ["50741009", "Urinary tract function (observable entity)|Urinary tract function (function)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["28995006", "Treated with (attribute)"], ["89780004", "Combined (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["86495002", "For (qualifier value)"], ["91273001", "Lactic acidosis (disorder)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1255665007", "Moderate (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["261638004", "Stage 3A (qualifier value)"], ["270011004", "Creatinine clearance (& level (& glom filt))|Creatinine clearance (& level (& glom filt)) (procedure)"], ["1222848005", "American Joint Committee on Cancer stage IV:5 (qualifier value)"], ["732804007", "59 (qualifier value)"], ["258859000", "Milliliter/minute (qualifier value)|mL/min (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260669005", "Approach (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["289928003", "Reduction plasty (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["372567009", "Metformin (substance)"], ["408102007", "Unit dose (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386916009", "Cladribine (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["763158003", "Medicinal product (product)"], ["42504009", "Containing (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["386897000", "Lamivudine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["42752001", "Due to (attribute)"], ["410942007", "Drug or medicament (substance)"], ["410942007", "Drug or medicament (substance)"], ["732729005", "4.5 (qualifier value)"]], "ncit.special_warnings": [["C3114", "Hypersensitivity"], ["C3114", "Hypersensitivity"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C62355", "With"], ["C121543", "Dolutegravir"], ["C16289", "Andorra"], ["C62606", "Characterization"], ["C158169", "Buyei Chinese"], ["C39594", "Skin Rash"], ["C37931", "Constitutional"], ["C103373", "CDISC Findings Class"], ["C16289", "Andorra"], ["C90025", "Sometimes"], ["C13018", "Organ"], ["C20632", "Pathophysiology"], ["C166400", "Inclusive"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C23327", "Murine Liver"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C16289", "Andorra"], ["C118472", "Other License Status"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C64597", "Immediately"], ["C198613", "CFI wt Allele"], ["C100104", "Sign or Symptom"], ["C52874", "SPI1 wt Allele"], ["C3114", "Hypersensitivity"], ["C166400", "Inclusive"], ["C25594", "Negation"], ["C142988", "Limited"], ["C159124", "GDC Treatment Outcome Terminology"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C39594", "Skin Rash"], ["C43508", "Oregon"], ["C39594", "Skin Rash"], ["C158169", "Buyei Chinese"], ["C23327", "Murine Liver"], ["C16554", "Enzyme"], ["C143485", "Fever, CTCAE"], ["C115727", "Safety Reporting Documentation"], ["C143665", "Malaise, CTCAE"], ["C122347", "Fatigue Subordinate Domain"], ["C13056", "Muscle"], ["C43508", "Oregon"], ["C13044", "Joint"], ["C25311", "Oral"], ["C143384", "Conjunctivitis, CTCAE"], ["C161327", "Facial"], ["C3015", "Eosinophilia"], ["C112175", "Angioedema"], ["C123619", "Clinical Response"], ["C25688", "Status"], ["C166400", "Inclusive"], ["C23327", "Murine Liver"], ["C16289", "Andorra"], ["C38037", "Total Bilirubin Measurement"], ["C16329", "Belgium"], ["C25476", "Delay"], ["C16727", "India"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C154405", "Active State"], ["C38008", "Post"], ["C25279", "Onset"], ["C52874", "SPI1 wt Allele"], ["C3114", "Hypersensitivity"], ["C106184", "May"], ["C20200", "Outcome"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C20203", "Laser-Induced Fluorescence Endoscopy"], ["C168250", "History of Allergic Reaction"], ["C48192", "Importance Weight"], ["C16289", "Andorra"], ["C28240", "Metabolic"], ["C75889", "PAX6 wt Allele"], ["C25533", "Increase"], ["C16727", "India"], ["C48192", "Importance Weight"], ["C16289", "Andorra"], ["C16727", "India"], ["C52874", "SPI1 wt Allele"], ["C17610", "Blood Sample"], ["C616", "Lipid"], ["C16289", "Andorra"], ["C2831", "Glucose"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C25490", "During"], ["C94631", "Antiretroviral Therapy"], ["C106184", "May"], ["C16727", "India"], ["C45313", "Part"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C2991", "Disease or Disorder"], ["C64355", "Scientific Control"], ["C16289", "Andorra"], ["C16795", "Lifestyle"], ["C64956", "For"], ["C616", "Lipid"], ["C16289", "Andorra"], ["C48192", "Importance Weight"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C65099", "Some"], ["C43583", "Evidence"], ["C64956", "For"], ["C76246", "Blood Group A"], ["C38032", "Therapeutic Effect"], ["C64956", "For"], ["C61256", "Monitoring"], ["C52874", "SPI1 wt Allele"], ["C17610", "Blood Sample"], ["C616", "Lipid"], ["C16289", "Andorra"], ["C2831", "Glucose"], ["C25641", "Reference"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C71155", "Established"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C43442", "Biomaterial Treatment"], ["C17564", "Guideline"], ["C616", "Lipid"], ["C2991", "Disease or Disorder"], ["C16329", "Belgium"], ["C61372", "Management"], ["C71344", "Associate of Science"], ["C3959", "Hepatobiliary Disorder"], ["C16960", "Patient"], ["C62355", "With"], ["C82978", "Chronic Hepatitis"], ["C113692", "Child-Pugh Class B"], ["C43508", "Oregon"], ["C67900", "Centi"], ["C16289", "Andorra"], ["C25705", "Treating"], ["C62355", "With"], ["C61517", "Combination"], ["C94631", "Antiretroviral Therapy"], ["C68869", "Are"], ["C158997", "GDC Analyte Type Terminology"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C16289", "Andorra"], ["C48275", "Death Related to Adverse Event"], ["C13308", "Hepatic"], ["C188368", "ELN Adverse-Risk Category"], ["C16727", "India"], ["C49152", "Case"], ["C52874", "SPI1 wt Allele"], ["C25730", "Concomitant"], ["C16119", "Antiviral Therapy"], ["C64956", "For"], ["C3097", "Hepatitis B Infection"], ["C43508", "Oregon"], ["C67900", "Centi"], ["C159124", "GDC Treatment Outcome Terminology"], ["C70664", "Relevance"], ["C40352", "Multiplicative Product"], ["C48191", "Information"], ["C64956", "For"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C1471", "Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C154405", "Active State"], ["C64937", "Against"], ["C3097", "Hepatitis B Infection"], ["C121543", "Dolutegravir"], ["C120914", "Physical Activity Measurement"], ["C1471", "Lamivudine"], ["C157514", "Single Agent Therapy"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C75889", "PAX6 wt Allele"], ["C168111", "Adequate Daily Fluid Intake"], ["C43442", "Biomaterial Treatment"], ["C64956", "For"], ["C3097", "Hepatitis B Infection"], ["C45325", "Since"], ["C17102", "Risk"], ["C64956", "For"], ["C3097", "Hepatitis B Infection"], ["C41546", "Resistance Process"], ["C18732", "Development"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C139304", "IPSS Risk Category High"], ["C198613", "CFI wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C16960", "Patient"], ["C95633", "Coded Ordinal Data Type"], ["C189188", "Infected with SARS-CoV-2"], ["C62355", "With"], ["C3097", "Hepatitis B Infection"], ["C75889", "PAX6 wt Allele"], ["C25406", "Additional"], ["C281", "Antiviral Agent"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25641", "Reference"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43442", "Biomaterial Treatment"], ["C17564", "Guideline"], ["C198613", "CFI wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25484", "Discontinue"], ["C16727", "India"], ["C16960", "Patient"], ["C95633", "Coded Ordinal Data Type"], ["C189188", "Infected with SARS-CoV-2"], ["C62355", "With"], ["C189553", "Hepatitis B Virus Measurement"], ["C53578", "Periodic Report"], ["C61256", "Monitoring"], ["C52874", "SPI1 wt Allele"], ["C49636", "Both"], ["C23327", "Murine Liver"], ["C25518", "Function"], ["C25294", "Laboratory Procedure"], ["C16289", "Andorra"], ["C52874", "SPI1 wt Allele"], ["C189553", "Hepatitis B Virus Measurement"], ["C16514", "DNA Replication"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C71344", "Associate of Science"], ["C121294", "Withdrawal Scale"], ["C52874", "SPI1 wt Allele"], ["C1471", "Lamivudine"], ["C106184", "May"], ["C20200", "Outcome"], ["C16727", "India"], ["C75889", "PAX6 wt Allele"], ["C14140", "Acute"], ["C124138", "Exacerbation"], ["C52874", "SPI1 wt Allele"], ["C3095", "Hepatitis"], ["C16960", "Patient"], ["C62355", "With"], ["C73621", "Pre-existing"], ["C50634", "Liver Dysfunction"], ["C166400", "Inclusive"], ["C120853", "Chronic Active"], ["C3095", "Hepatitis"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C71113", "CDISC SDTM Frequency Terminology"], ["C52874", "SPI1 wt Allele"], ["C23327", "Murine Liver"], ["C25518", "Function"], ["C25490", "During"], ["C61517", "Combination"], ["C94631", "Antiretroviral Therapy"], ["C16289", "Andorra"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81893", "Standard"], ["C198613", "CFI wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C3959", "Hepatobiliary Disorder"], ["C16727", "India"], ["C16960", "Patient"], ["C25542", "Interruption"], ["C43508", "Oregon"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C17997", "Immune"], ["C124063", "Reactivation"], ["C168217", "Genetic Syndrome Associated with Congenital Heart Defect"], ["C16727", "India"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C189188", "Infected with SARS-CoV-2"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C17997", "Immune"], ["C94372", "Deficiency"], ["C158997", "GDC Analyte Type Terminology"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C41206", "Institution"], ["C52874", "SPI1 wt Allele"], ["C61517", "Combination"], ["C94631", "Antiretroviral Therapy"], ["C147930", "Cocaine- and Amphetamine-Regulated Transcript Protein"], ["C75889", "PAX6 wt Allele"], ["C25535", "Inflammatory"], ["C25637", "Reaction"], ["C159124", "GDC Treatment Outcome Terminology"], ["C168121", "Asymptomatic Presentation"], ["C43508", "Oregon"], ["C37895", "Residual"], ["C106184", "May"], ["C16289", "Andorra"], ["C16390", "Etiology"], ["C54035", "Serious"], ["C123619", "Clinical Response"], ["C25457", "Condition"], ["C43508", "Oregon"], ["C52874", "SPI1 wt Allele"], ["C168422", "Rheumatic Fever Symptom"], ["C101282", "Have"], ["C25599", "Observed"], ["C25282", "Within"], ["C25509", "First"], ["C64942", "Few"], ["C29844", "Week"], ["C43508", "Oregon"], ["C29846", "Month"], ["C52874", "SPI1 wt Allele"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C147930", "Cocaine- and Amphetamine-Regulated Transcript Protein"], ["C70664", "Relevance"], ["C68869", "Are"], ["C50521", "Cytomegaloviral Retinitis"], ["C48928", "And/Or"], ["C191010", "Modified Van Assche Index MVAI104 Original Result - Focal"], ["C16289", "Andorra"], ["C117361", "Pneumocystis jirovecii"], ["C3333", "Pneumonia"], ["C91247", "Often"], ["C52582", "Referral"], ["C159124", "GDC Treatment Outcome Terminology"], ["C71344", "Associate of Science"], ["C4725", "Papillary Craniopharyngioma"], ["C81168", "Any"], ["C25535", "Inflammatory"], ["C168422", "Rheumatic Fever Symptom"], ["C16329", "Belgium"], ["C25214", "Evaluation"], ["C16289", "Andorra"], ["C43442", "Biomaterial Treatment"], ["C65140", "When"], ["C37916", "Autoimmune"], ["C2991", "Disease or Disorder"], ["C71344", "Associate of Science"], ["C2991", "Disease or Disorder"], ["C16289", "Andorra"], ["C27029", "Autoimmune Hepatitis"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C159124", "GDC Treatment Outcome Terminology"], ["C127786", "Occurrence Indicator"], ["C16727", "India"], ["C127262", "CDISC SDTM Environmental Setting Terminology"], ["C52874", "SPI1 wt Allele"], ["C17997", "Immune"], ["C124063", "Reactivation"], ["C188308", "Reported Information"], ["C25330", "Duration"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25279", "Onset"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C128667", "More"], ["C142192", "Study Variable"], ["C16289", "Andorra"], ["C150901", "Event Unit"], ["C52288", "NUP214 wt Allele"], ["C127786", "Occurrence Indicator"], ["C160235", "Many Tumor Infiltrating Lymphocytes"], ["C29846", "Month"], ["C38008", "Post"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C23327", "Murine Liver"], ["C16414", "Chemistry"], ["C85901", "Consistent"], ["C17997", "Immune"], ["C168217", "Genetic Syndrome Associated with Congenital Heart Defect"], ["C25599", "Observed"], ["C16727", "India"], ["C65099", "Some"], ["C3095", "Hepatitis"], ["C113692", "Child-Pugh Class B"], ["C48928", "And/Or"], ["C67900", "Centi"], ["C95633", "Coded Ordinal Data Type"], ["C189188", "Infected with SARS-CoV-2"], ["C16960", "Patient"], ["C158997", "GDC Analyte Type Terminology"], ["C68616", "Start Date"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C49236", "Therapeutic Procedure"], ["C61256", "Monitoring"], ["C52874", "SPI1 wt Allele"], ["C23327", "Murine Liver"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C3097", "Hepatitis B Infection"], ["C48928", "And/Or"], ["C67900", "Centi"], ["C173511", "Co-infection"], ["C163702", "Staphylococcal Enterotoxin E"], ["C3959", "Hepatobiliary Disorder"], ["C16727", "India"], ["C68872", "Square Mile"], ["C16289", "Andorra"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C168331", "Muscular Dystrophy Secondary to Mitochondrial Disorder"], ["C20632", "Pathophysiology"], ["C53286", "Next"], ["C49587", "Exposure Domain"], ["C49641", "In Utero"], ["C707", "Nucleoside"], ["C16289", "Andorra"], ["C709", "Nucleotide"], ["C106184", "May"], ["C62534", "Arginine/Omega-3 Fatty Acids/Nucleotides Oral Supplement"], ["C168331", "Muscular Dystrophy Secondary to Mitochondrial Disorder"], ["C25518", "Function"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C142192", "Study Variable"], ["C25554", "Level"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25258", "Most"], ["C190998", "Modified Van Assche Index MVAI102 Original Result - Pronounced"], ["C62355", "With"], ["C1428", "Stavudine"], ["C431", "Didanosine"], ["C16289", "Andorra"], ["C947", "Zidovudine"], ["C101282", "Have"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C168331", "Muscular Dystrophy Secondary to Mitochondrial Disorder"], ["C20632", "Pathophysiology"], ["C16727", "India"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C160366", "FGFR3 Gene Rearrangement Negative"], ["C49641", "In Utero"], ["C48928", "And/Or"], ["C38008", "Post"], ["C159124", "GDC Treatment Outcome Terminology"], ["C707", "Nucleoside"], ["C101282", "Have"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C79873", "Contain"], ["C947", "Zidovudine"], ["C25562", "Main"], ["C188368", "ELN Adverse-Risk Category"], ["C188308", "Reported Information"], ["C68869", "Are"], ["C2991", "Disease or Disorder"], ["C80520", "Neutropenia"], ["C16289", "Andorra"], ["C28240", "Metabolic"], ["C2991", "Disease or Disorder"], ["C78435", "Hyperlipasemia"], ["C101282", "Have"], ["C91247", "Often"], ["C53288", "Temporary"], ["C65099", "Some"], ["C64998", "Late"], ["C25279", "Onset"], ["C25262", "Neurologic"], ["C2991", "Disease or Disorder"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C73116", "Rarely"], ["C87085", "Hypertonia"], ["C2962", "Seizure"], ["C25401", "Abnormal"], ["C25262", "Neurologic"], ["C2991", "Disease or Disorder"], ["C68869", "Are"], ["C53288", "Temporary"], ["C43508", "Oregon"], ["C160628", "Permanent"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C160764", "Unknown Molecular Analysis"], ["C103373", "CDISC Findings Class"], ["C16329", "Belgium"], ["C64956", "For"], ["C81168", "Any"], ["C150886", "Child Relation"], ["C16727", "India"], ["C12405", "Uterus"], ["C159124", "GDC Treatment Outcome Terminology"], ["C707", "Nucleoside"], ["C16289", "Andorra"], ["C709", "Nucleotide"], ["C75419", "World Health Organization"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C123619", "Clinical Response"], ["C103373", "CDISC Findings Class"], ["C52874", "SPI1 wt Allele"], ["C160764", "Unknown Molecular Analysis"], ["C12755", "Nervous System"], ["C103373", "CDISC Findings Class"], ["C103373", "CDISC Findings Class"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C48434", "Electrical Current"], ["C61423", "National"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25340", "Use"], ["C94631", "Antiretroviral Therapy"], ["C16727", "India"], ["C73435", "Gravida"], ["C159124", "GDC Treatment Outcome Terminology"], ["C98977", "Maternal Transmission"], ["C52874", "SPI1 wt Allele"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C143225", "Osteonecrosis, CTCAE"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C166400", "Inclusive"], ["C211", "Therapeutic Corticosteroid"], ["C25340", "Use"], ["C16273", "Alcohol Consumption"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C15261", "Immunosuppressive Therapy"], ["C25227", "High"], ["C138901", "Body Mass Index Finding"], ["C52874", "SPI1 wt Allele"], ["C143225", "Osteonecrosis, CTCAE"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C25411", "Advanced"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C2991", "Disease or Disorder"], ["C48928", "And/Or"], ["C25322", "Long-Term"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C147930", "Cocaine- and Amphetamine-Regulated Transcript Protein"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25261", "Medical"], ["C198613", "CFI wt Allele"], ["C54627", "Experience"], ["C13044", "Joint"], ["C16289", "Andorra"], ["C143725", "Pain, CTCAE"], ["C79603", "Joint Stiffness"], ["C43508", "Oregon"], ["C62189", "Difficulty"], ["C16727", "India"], ["C37994", "Movement"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C121543", "Dolutegravir"], ["C1471", "Lamivudine"], ["C43508", "Oregon"], ["C81168", "Any"], ["C118472", "Other License Status"], ["C94631", "Antiretroviral Therapy"], ["C86066", "Do"], ["C25594", "Negation"], ["C19732", "Continuing Umbrella of Research Experience for Underserved Minorities (CURE) Program"], ["C3108", "HIV Infection"], ["C16289", "Andorra"], ["C106184", "May"], ["C16289", "Andorra"], ["C118472", "Other License Status"], ["C2959", "Complication"], ["C52874", "SPI1 wt Allele"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C128320", "Infection"], ["C16960", "Patient"], ["C49070", "Closed"], ["C95086", "Clinical Observation Domain"], ["C158169", "Buyei Chinese"], ["C16727", "India"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C25281", "Associated"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C2991", "Disease or Disorder"], ["C70962", "Agent Administration"], ["C16727", "India"], ["C62355", "With"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C114592", "Renal Impairment"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C25747", "Creatinine Clearance"], ["C94545", "Between"], ["C70541", "Lansky Performance Status 30"], ["C16289", "Andorra"], ["C105796", "Forty Nine"], ["C64777", "Milliliter per Minute"], ["C25639", "Receive"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C106184", "May"], ["C54627", "Experience"], ["C76246", "Blood Group A"], ["C161430", "CDISC SDTM Model Version 1.6"], ["C159124", "GDC Treatment Outcome Terminology"], ["C161437", "CDISC SDTM Implementation Guide Version 3.3"], ["C25227", "High"], ["C1471", "Lamivudine"], ["C49587", "Exposure Domain"], ["C64774", "Area Under Curve"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C25747", "Creatinine Clearance"], ["C105785", "Fifty"], ["C64777", "Milliliter per Minute"], ["C68869", "Are"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C49667", "Safety Study"], ["C25474", "Data"], ["C25516", "From"], ["C15417", "Randomized Clinical Trial"], ["C82500", "Disease Controlled"], ["C71104", "Clinical Trial"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25190", "Person"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C25747", "Creatinine Clearance"], ["C94545", "Between"], ["C70541", "Lansky Performance Status 30"], ["C16289", "Andorra"], ["C105796", "Forty Nine"], ["C64777", "Milliliter per Minute"], ["C75419", "World Health Organization"], ["C25639", "Receive"], ["C25488", "Dose"], ["C49157", "Adjustment"], ["C1471", "Lamivudine"], ["C16727", "India"], ["C25604", "Original"], ["C1471", "Lamivudine"], ["C71104", "Clinical Trial"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C947", "Zidovudine"], ["C25227", "High"], ["C1471", "Lamivudine"], ["C25281", "Associated"], ["C62355", "With"], ["C25227", "High"], ["C52874", "SPI1 wt Allele"], ["C80520", "Neutropenia"], ["C16289", "Andorra"], ["C89272", "Due To"], ["C80520", "Neutropenia"], ["C43508", "Oregon"], ["C64933", "Each"], ["C54069", "Occur"], ["C16727", "India"], ["C183022", "Acute Physiology and Chronic Health Evaluation II APCH111 Original Result - <1"], ["C52874", "SPI1 wt Allele"], ["C118472", "Other License Status"], ["C1471", "Lamivudine"], ["C53260", "Adverse Event Definitely Related to Intervention"], ["C49562", "Adverse Event Domain"], ["C71344", "Associate of Science"], ["C128681", "CDISC SDTM Gastrointestinal Test Name Terminology"], ["C9157", "Gastric Intestinal-Type Adenocarcinoma"], ["C16289", "Andorra"], ["C13308", "Hepatic"], ["C2991", "Disease or Disorder"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C25747", "Creatinine Clearance"], ["C94545", "Between"], ["C70541", "Lansky Performance Status 30"], ["C16289", "Andorra"], ["C105796", "Forty Nine"], ["C64777", "Milliliter per Minute"], ["C75419", "World Health Organization"], ["C25639", "Receive"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C16329", "Belgium"], ["C64956", "For"], ["C1471", "Lamivudine"], ["C53260", "Adverse Event Definitely Related to Intervention"], ["C49562", "Adverse Event Domain"], ["C198613", "CFI wt Allele"], ["C94522", "New Lesion Identification"], ["C43508", "Oregon"], ["C80520", "Neutropenia"], ["C43508", "Oregon"], ["C76246", "Blood Group A"], ["C82495", "Dose Adjustment"], ["C52874", "SPI1 wt Allele"], ["C1471", "Lamivudine"], ["C97722", "PER1 wt Allele"], ["C1471", "Lamivudine"], ["C154633", "Prescribing Domain"], ["C48191", "Information"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16329", "Belgium"], ["C62355", "With"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C16289", "Andorra"], ["C25190", "Person"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C453", "Recombinant DNA"], ["C15697", "Treatment Regimen"], ["C459", "Medication"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C64496", "Twice Daily"], ["C65140", "When"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C811", "Rifampin"], ["C341", "Carbamazepine"], ["C47643", "Oxcarbazepine"], ["C741", "Phenytoin"], ["C75368", "Phenobarbital Measurement"], ["C159109", "GDC Sample Type Terminology"], ["C42555", "Siemens"], ["C73195", "Etravirine"], ["C25718", "Without"], ["C783", "Protease Inhibitor"], ["C29027", "Efavirenz"], ["C29277", "Nevirapine"], ["C43508", "Oregon"], ["C66603", "Tipranavir"], ["C1609", "Ritonavir"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C79873", "Contain"], ["C29633", "Antacid Preparation"], ["C79873", "Contain"], ["C29633", "Antacid Preparation"], ["C68869", "Are"], ["C25197", "Recommendation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25529", "Hour"], ["C38008", "Post"], ["C43508", "Oregon"], ["C172979", "Fear Score 6"], ["C25529", "Hour"], ["C201357", "Before Timing Type"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C65140", "When"], ["C25701", "Taken"], ["C67010", "With Food"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C16289", "Andorra"], ["C1505", "Dietary Supplement"], ["C43508", "Oregon"], ["C79873", "Contain"], ["C64488", "Calcium Measurement"], ["C68256", "Dietary Iron"], ["C43508", "Oregon"], ["C29239", "Magnesium"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C158997", "GDC Analyte Type Terminology"], ["C172515", "S-Adenosylmethionine Measurement"], ["C25330", "Duration"], ["C198613", "CFI wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25382", "Administered"], ["C63663", "Fasting"], ["C25457", "Condition"], ["C1505", "Dietary Supplement"], ["C43508", "Oregon"], ["C79873", "Contain"], ["C64488", "Calcium Measurement"], ["C68256", "Dietary Iron"], ["C43508", "Oregon"], ["C29239", "Magnesium"], ["C68869", "Are"], ["C25197", "Recommendation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25529", "Hour"], ["C38008", "Post"], ["C43508", "Oregon"], ["C172979", "Fear Score 6"], ["C25529", "Hour"], ["C201357", "Before Timing Type"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C121543", "Dolutegravir"], ["C164135", "Increased"], ["C61612", "Metformin"], ["C76246", "Blood Group A"], ["C82495", "Dose Adjustment"], ["C52874", "SPI1 wt Allele"], ["C61612", "Metformin"], ["C16329", "Belgium"], ["C65140", "When"], ["C16289", "Andorra"], ["C52874", "SPI1 wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C62355", "With"], ["C61612", "Metformin"], ["C159124", "GDC Treatment Outcome Terminology"], ["C53297", "Maintenance"], ["C64355", "Scientific Control"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C61612", "Metformin"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25650", "Removed"], ["C16289", "Andorra"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C52874", "SPI1 wt Allele"], ["C115916", "Important"], ["C159124", "GDC Treatment Outcome Terminology"], ["C41201", "Study Monitor"], ["C164220", "Renal Function"], ["C65140", "When"], ["C95633", "Coded Ordinal Data Type"], ["C25705", "Treating"], ["C62355", "With"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C61517", "Combination"], ["C106184", "May"], ["C25533", "Increase"], ["C17102", "Risk"], ["C64956", "For"], ["C98969", "Lactic Acidosis"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C114592", "Renal Impairment"], ["C16899", "Neoplasm Stage"], ["C49687", "Phase IIIa Trial"], ["C25747", "Creatinine Clearance"], ["C175677", "Forty Five"], ["C105794", "Fifty Nine"], ["C64777", "Milliliter per Minute"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C25424", "Approach"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C25640", "Reduced"], ["C52874", "SPI1 wt Allele"], ["C61612", "Metformin"], ["C25488", "Dose"], ["C16329", "Belgium"], ["C25227", "High"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C62355", "With"], ["C1336", "Cladribine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C62355", "With"], ["C81168", "Any"], ["C118472", "Other License Status"], ["C142605", "Medicinal Product"], ["C79873", "Contain"], ["C121543", "Dolutegravir"], ["C1471", "Lamivudine"], ["C43508", "Oregon"], ["C47509", "Emtricitabine"], ["C151896", "Other Than"], ["C76246", "Blood Group A"], ["C82495", "Dose Adjustment"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C89272", "Due To"], ["C459", "Medication"], ["C459", "Medication"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"]], "rxnorm.special_warnings": [["1433868", "dolutegravir"], ["2122521", "Dovato"], ["2122521", "Dovato"], ["4850", "glucose"], ["4850", "glucose"], ["2122521", "Dovato"], ["68244", "lamivudine"], ["1433868", "dolutegravir"], ["T052", "Activity"], ["68244", "lamivudine"], ["2122521", "Dovato"], ["2122521", "Dovato"], ["1427211", "hepatitis B virus"], ["68244", "lamivudine"], ["1433868", "dolutegravir"], ["59763", "stavudine"], ["3364", "didanosine"], ["11413", "zidovudine"], ["11413", "zidovudine"], ["1433868", "dolutegravir"], ["68244", "lamivudine"], ["2913", "creatinine"], ["2122521", "Dovato"], ["68244", "lamivudine"], ["2913", "creatinine"], ["2122521", "Dovato"], ["2913", "creatinine"], ["68244", "lamivudine"], ["68244", "lamivudine"], ["11413", "zidovudine"], ["68244", "lamivudine"], ["68244", "lamivudine"], ["2913", "creatinine"], ["2122521", "Dovato"], ["68244", "lamivudine"], ["68244", "lamivudine"], ["68244", "lamivudine"], ["2122521", "Dovato"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["9384", "rifampin"], ["2002", "carbamazepine"], ["32624", "oxcarbazepine"], ["8183", "phenytoin"], ["8134", "phenobarbital"], ["475969", "etravirine"], ["8031", "protease"], ["195085", "efavirenz"], ["53654", "nevirapine"], ["190548", "tipranavir"], ["85762", "ritonavir"], ["2122521", "Dovato"], ["2122521", "Dovato"], ["T168", "Food"], ["2122521", "Dovato"], ["1895", "calcium"], ["90176", "iron"], ["6574", "magnesium"], ["2122521", "Dovato"], ["1895", "calcium"], ["90176", "iron"], ["6574", "magnesium"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["6809", "metformin"], ["6809", "metformin"], ["2122521", "Dovato"], ["6809", "metformin"], ["6809", "metformin"], ["2122521", "Dovato"], ["2913", "creatinine"], ["6809", "metformin"], ["2122521", "Dovato"], ["44157", "cladribine"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["68244", "lamivudine"], ["276237", "emtricitabine"], ["1433868", "dolutegravir"]], "loinc.special_warnings": [["LP6486-7", "Reported"], ["LP157327-0", "Dolutegravir"], ["MTHU015064", "Rash"], ["59776-5", "Procedure findings:Find:Pt:^Patient:Nar"], ["LA10082-8", "Sometimes"], ["LA6750-9", "Severe"], ["MTHU002039", "Liver"], ["MTHU029809", "Other"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA22025-3", "OR"], ["LP75708-5", "Symptoms"], ["LA21291-2", "Not"], ["LA6484-5", "Limited"], ["LA6750-9", "Severe"], ["MTHU015064", "Rash"], ["LA22025-3", "OR"], ["MTHU015064", "Rash"], ["MTHU002039", "Liver"], ["LP31392-1", "Enzymes (see also Inborn errors metabolism lysosomal)"], ["LP74849-8", "Fever"], ["LA17571-3", "General"], ["MTHU013358", "Fatigue"], ["LP234848-2", "Muscle"], ["LA22025-3", "OR"], ["MTHU048551", "Joint"], ["LA9367-9", "Oral"], ["LP74649-2", "Conjunctivitis"], ["LA9269-7", "Facial"], ["LP7787-7", "Clinical"], ["LP73412-6", "Status"], ["MTHU002039", "Liver"], ["MTHU002437", "Bilirubin"], ["LA7343-2", "Delay"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LA16666-2", "Active"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA9532-8", "Allergic reaction"], ["LP221195-3", "Weight"], ["LP212101-2", "Metabolic"], ["LA32048-3", "Increase"], ["LA22004-8", "IN"], ["LP221195-3", "Weight"], ["LA22004-8", "IN"], ["MTHU029981", "Blood"], ["LA12903-3", "Lipids"], ["MTHU001675", "Glucose"], ["LA14161-6", "May"], ["LP66375-4", "Antiretroviral therapy"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LA18199-2", "Disease"], ["LP7741-4", "Control"], ["LA32823-9", "Lifestyle"], ["LA12903-3", "Lipids"], ["LP221195-3", "Weight"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA14973-4", "Some"], ["LP270144-1", "Cases"], ["LP17763-1", "A"], ["LP94823-9", "Treatment"], ["LA20297-0", "Monitoring"], ["MTHU029981", "Blood"], ["LA12903-3", "Lipids"], ["MTHU001675", "Glucose"], ["LP212405-7", "Reference"], ["LP200075-2", "IS"], ["LP183501-8", "HIV"], ["LP94823-9", "Treatment"], ["LA25810-5", "Liver disease"], ["LA28752-6", "Chronic"], ["LA18126-5", "Hepatitis B"], ["LA22025-3", "OR"], ["LP17128-7", "C"], ["LA12701-1", "Combination"], ["LP66375-4", "Antiretroviral therapy"], ["LA21988-3", "AT"], ["LA24377-6", "Increased"], ["LA6750-9", "Severe"], ["LA32822-1", "Fatal"], ["LA22004-8", "IN"], ["LP267221-2", "Therapy"], ["LA18126-5", "Hepatitis B"], ["LA22025-3", "OR"], ["LP17128-7", "C"], ["LA10393-9", "Refer"], ["MTHU060537", "lamiVUDine"], ["LP200075-2", "IS"], ["LA16666-2", "Active"], ["LA18126-5", "Hepatitis B"], ["LP157327-0", "Dolutegravir"], ["LP72045-5", "Activity"], ["MTHU060537", "lamiVUDine"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA8913-1", "Adequate"], ["LP94823-9", "Treatment"], ["LA18126-5", "Hepatitis B"], ["LA18126-5", "Hepatitis B"], ["LP6857-9", "Resistance"], ["LP200075-2", "IS"], ["LA9193-9", "High"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA21996-6", "CO"], ["LA18126-5", "Hepatitis B"], ["LP263791-8", "Additional"], ["LP200075-2", "IS"], ["LP212405-7", "Reference"], ["LP94823-9", "Treatment"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA21996-6", "CO"], ["LG32752-4", "Hepatitis B virus"], ["LA6663-4", "Periodic"], ["LA20297-0", "Monitoring"], ["LA14331-5", "Both"], ["MTHU002039", "Liver"], ["LA8916-4", "Function"], ["LP200075-2", "IS"], ["LA14549-2", "Withdrawal"], ["MTHU060537", "lamiVUDine"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LA18821-1", "Acute"], ["LA7442-2", "Hepatitis"], ["LP32605-5", "pre"], ["MTHU002039", "Liver"], ["LA28752-6", "Chronic"], ["LA16666-2", "Active"], ["LA7442-2", "Hepatitis"], ["LA24377-6", "Increased"], ["MTHU029777", "Frequency"], ["LP31397-0", "Liver function (excluding enzymes)"], ["LA12701-1", "Combination"], ["LP66375-4", "Antiretroviral therapy"], ["LP20607-5", "standard"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP200075-2", "IS"], ["LA25810-5", "Liver disease"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LP94823-9", "Treatment"], ["LA27183-5", "Immune"], ["LA22004-8", "IN"], ["LP183501-8", "HIV"], ["LA6750-9", "Severe"], ["LA27183-5", "Immune"], ["LA21988-3", "AT"], ["LP73517-2", "Time"], ["LA12701-1", "Combination"], ["LP66375-4", "Antiretroviral therapy"], ["LP73228-6", "Reaction"], ["LA6737-6", "Asymptomatic"], ["LA22025-3", "OR"], ["LA14161-6", "May"], ["LA30751-4", "Serious"], ["LP7787-7", "Clinical"], ["LA22025-3", "OR"], ["LP75708-5", "Symptoms"], ["LP6425-5", "Observed"], ["LP6974-2", "first"], ["LA15680-4", "Few"], ["LA9000-6", "Weeks"], ["LA22025-3", "OR"], ["MTHU068094", "Months"], ["LP14255-1", "Cytomegalovirus"], ["LA22025-3", "OR"], ["LA26555-5", "Focal"], ["LP74970-2", "Infections"], ["MTHU020831", "Pneumonia"], ["LA10044-8", "Often"], ["LA6624-6", "Referred"], ["LA15874-3", "PCP"], ["LP75708-5", "Symptoms"], ["LP94823-9", "Treatment"], ["LA18199-2", "Disease"], ["LA7442-2", "Hepatitis"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["MTHU047625", "Setting"], ["LA27183-5", "Immune"], ["LP6486-7", "Reported"], ["LP73517-2", "Time"], ["LP200075-2", "IS"], ["LA16824-7", "More"], ["LA18409-5", "Variable"], ["MTHU058708", "Events"], ["LA15681-2", "Many"], ["MTHU068094", "Months"], ["LP94823-9", "Treatment"], ["MTHU002039", "Liver"], ["LP31388-9", "Chemistry"], ["LA27183-5", "Immune"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LA14973-4", "Some"], ["LA7442-2", "Hepatitis"], ["LA14518-7", "B"], ["LA22025-3", "OR"], ["LP17128-7", "C"], ["LA21996-6", "CO"], ["LA21988-3", "AT"], ["LP190656-1", "start"], ["LP157327-0", "Dolutegravir"], ["LP267221-2", "Therapy"], ["LA20297-0", "Monitoring"], ["MTHU002039", "Liver"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA18126-5", "Hepatitis B"], ["LA22025-3", "OR"], ["LP17128-7", "C"], ["LA21996-6", "CO"], ["LP266919-2", "Infection"], ["LA25810-5", "Liver disease"], ["LA14566-6", "Earlier"], ["LA22004-8", "IN"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA24789-2", "Mitochondrial"], ["LA22004-8", "IN"], ["LA14161-6", "May"], ["LA24789-2", "Mitochondrial"], ["LA8916-4", "Function"], ["LP17763-1", "A"], ["LA18409-5", "Variable"], ["LP200075-2", "IS"], ["MTHU013858", "Stavudine"], ["LP21309-7", "Didanosine"], ["LP16744-2", "Zidovudine"], ["LA24789-2", "Mitochondrial"], ["LA22004-8", "IN"], ["LP183501-8", "HIV"], ["LA6577-6", "Negative"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LP32606-3", "post"], ["LP94823-9", "Treatment"], ["LP16744-2", "Zidovudine"], ["LP6486-7", "Reported"], ["LP212101-2", "Metabolic"], ["LA10044-8", "Often"], ["LA14973-4", "Some"], ["LA10590-0", "Neurological Disorders"], ["LP6486-7", "Reported"], ["LA10066-1", "Rarely"], ["LA12748-2", "Abnormal"], ["LA10590-0", "Neurological Disorders"], ["LA22025-3", "OR"], ["LP200075-2", "IS"], ["LA4489-6", "Unknown"], ["59776-5", "Procedure findings:Find:Pt:^Patient:Nar"], ["LA9949-4", "Child"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["LP7787-7", "Clinical"], ["59776-5", "Procedure findings:Find:Pt:^Patient:Nar"], ["LA4489-6", "Unknown"], ["LA16973-2", "Neurologic"], ["59776-5", "Procedure findings:Find:Pt:^Patient:Nar"], ["59776-5", "Procedure findings:Find:Pt:^Patient:Nar"], ["LA14426-3", "Do not"], ["LP66375-4", "Antiretroviral therapy"], ["LA22004-8", "IN"], ["LA29507-3", "Pregnant women"], ["LA8994-1", "Vertical"], ["MTHU050362", "Transmission"], ["LP183501-8", "HIV"], ["LP200075-2", "IS"], ["LA28139-6", "Alcohol"], ["LA6750-9", "Severe"], ["LP35925-4", "Body mass index (BMI)"], ["LP270144-1", "Cases"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LP183501-8", "HIV"], ["LA18199-2", "Disease"], ["LA22025-3", "OR"], ["LA18950-8", "Term"], ["LP417559-4", "Safe Environment for Every Kid"], ["LA14523-7", "Advice"], ["LP6323-2", "Immunofluorescence (IF)"], ["MTHU048551", "Joint"], ["MTHU029813", "Pain"], ["MTHU048551", "Joint"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP96286-7", "Movement"], ["LP74970-2", "Infections"], ["LP157327-0", "Dolutegravir"], ["MTHU060537", "lamiVUDine"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LP66375-4", "Antiretroviral therapy"], ["LA21291-2", "Not"], ["MTHU020829", "HIV infection"], ["LA14161-6", "May"], ["LP74970-2", "Infections"], ["MTHU029809", "Other"], ["19817-6", "Complications:Type:Stdy:^Patient:Nom"], ["LP183501-8", "HIV"], ["LP266919-2", "Infection"], ["LA16797-5", "Close"], ["LP7787-7", "Clinical"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LP183501-8", "HIV"], ["LA22004-8", "IN"], ["LA6751-7", "Moderate"], ["MTHU065909", "Renal"], ["LP17763-1", "A"], ["LP29651-4", "Creatinine clearance"], ["LA28855-7", "30"], ["LP6970-0", "minimum"], ["LA14161-6", "May"], ["LP17763-1", "A"], ["LA6112-2", "1"], ["LP20594-5", "6"], ["LP20591-1", "3"], ["LP20591-1", "3"], ["MTHU060537", "lamiVUDine"], ["LP17763-1", "A"], ["LP29651-4", "Creatinine clearance"], ["LA28854-0", "50"], ["LP6970-0", "minimum"], ["LA32-8", "No"], ["LA17589-5", "Safety"], ["LA12070-1", "Individual"], ["MTHU036318", "Components"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP29651-4", "Creatinine clearance"], ["LA28855-7", "30"], ["LP6970-0", "minimum"], ["LA32660-5", "Received"], ["MTHU065481", "Dose"], ["LP20174-6", "adjusted"], ["MTHU060537", "lamiVUDine"], ["LA22004-8", "IN"], ["LA9505-4", "Original"], ["MTHU060537", "lamiVUDine"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP16744-2", "Zidovudine"], ["MTHU060537", "lamiVUDine"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LA6112-2", "1"], ["MTHU029809", "Other"], ["MTHU060537", "lamiVUDine"], ["LA31343-9", "Related"], ["MTHU058708", "Events"], ["LA26027-5", "Intestinal"], ["LA14161-6", "May"], ["LP17763-1", "A"], ["LP29651-4", "Creatinine clearance"], ["LA28855-7", "30"], ["LP6970-0", "minimum"], ["MTHU060537", "lamiVUDine"], ["LA31343-9", "Related"], ["MTHU058708", "Events"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA9039-4", "New"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["MTHU060537", "lamiVUDine"], ["MTHU060537", "lamiVUDine"], ["LP200075-2", "IS"], ["LA32245-5", "Achieved"], ["LA12070-1", "Individual"], ["MTHU036318", "Components"], ["LP94823-9", "Treatment"], ["LA18200-8", "Drug"], ["MTHU065481", "Dose"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LA14664-9", "Twice"], ["LA14435-4", "Daily"], ["LA21996-6", "CO"], ["LP16061-1", "carBAMazepine"], ["MTHU060529", "OXcarbazepine"], ["LP14732-9", "Phenytoin"], ["MTHU060452", "PHENobarbital"], ["LP15241-0", "S"], ["LP68431-3", "Etravirine"], ["LP21310-5", "Efavirenz"], ["MTHU013861", "Nevirapine"], ["LA22025-3", "OR"], ["LP36120-1", "Tipranavir"], ["MTHU013855", "Ritonavir"], ["LA15768-7", "4.5"], ["LA21291-2", "Not"], ["LA21996-6", "CO"], ["LA11829-1", "2 hours"], ["LA22025-3", "OR"], ["LP6946-0", "6 hours"], ["LA15768-7", "4.5"], ["MTHU065486", "Food"], ["LA22025-3", "OR"], ["LP32547-9", "Calcium"], ["MTHU004837", "Iron"], ["LA22025-3", "OR"], ["MTHU002163", "Magnesium"], ["LA21988-3", "AT"], ["LA11009-0", "Same"], ["LP73517-2", "Time"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP200075-2", "IS"], ["LA11831-7", "Fasting"], ["LA22025-3", "OR"], ["LP32547-9", "Calcium"], ["MTHU004837", "Iron"], ["LA22025-3", "OR"], ["MTHU002163", "Magnesium"], ["LA11829-1", "2 hours"], ["LA22025-3", "OR"], ["LP6946-0", "6 hours"], ["LA15768-7", "4.5"], ["LP157327-0", "Dolutegravir"], ["LA24377-6", "Increased"], ["MTHU060554", "metFORMIN"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["MTHU060554", "metFORMIN"], ["MTHU060554", "metFORMIN"], ["LP7741-4", "Control"], ["LA15768-7", "4.5"], ["MTHU060554", "metFORMIN"], ["LP200075-2", "IS"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP31398-8", "Renal function"], ["LA21996-6", "CO"], ["LA12701-1", "Combination"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["LA22004-8", "IN"], ["LA6751-7", "Moderate"], ["MTHU065909", "Renal"], ["LP73395-3", "Stage"], ["LP29651-4", "Creatinine clearance"], ["LP6970-0", "minimum"], ["LP17763-1", "A"], ["LP200075-2", "IS"], ["LP267357-4", "Reduction"], ["MTHU060554", "metFORMIN"], ["MTHU065481", "Dose"], ["LA12701-1", "Combination"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA15768-7", "4.5"], ["LA21291-2", "Not"], ["MTHU029809", "Other"], ["LP157327-0", "Dolutegravir"], ["MTHU060537", "lamiVUDine"], ["LA22025-3", "OR"], ["MTHU018643", "Emtricitabine"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["LA20274-9", "Drug-drug"], ["LA15768-7", "4.5"]], "snomed.pregnancy": [["373067005", "No (qualifier value)"], ["277359009", "Drug interaction (finding)"], ["261583007", "Using (attribute)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["7882003", "Identified (qualifier value)"], ["86495002", "For (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["394653002", "Significant|Significant (qualifier value)"], ["410942007", "Drug or medicament (substance)"], ["11896004", "Intermediate (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["74964007", "Other (qualifier value)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["112235009", "Through (qualifier value)"], ["47722004", "General metabolic function (function)|General metabolic function (observable entity)"], ["65639002", "Uridine diphosphate (substance)"], ["736203008", "Transferase (disposition)"], ["1222725008", "American Joint Committee on Cancer stage IA1 (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1119456000", "Substrate (foundation metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422741004", "Cytochrome p450 CYP3A4 enzyme (substance)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["59804006", "Glycoprotein (substance)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["254837009", "Malignant tumor of breast (disorder)|Malignant neoplasm of breast (disorder)"], ["88878007", "Protein (substance)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["422741004", "Cytochrome p450 CYP3A4 enzyme (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["260366006", "Increase (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["50863008", "Plasma (substance)"], ["702942001", "Concentration (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["260370003", "Decrease (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["50863008", "Plasma (substance)"], ["702942001", "Concentration (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["260400001", "Reduced (qualifier value)"], ["17162000", "Certain (qualifier value)"], ["425620007", "Metal (substance)"], ["31046007", "Cation (substance)"], ["42504009", "Containing (qualifier value)"], ["34957004", "Acid (substance)"], ["105590001", "Substance (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86407004", "Table, device (physical object)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["55561003", "Active (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["18720000", "In (attribute)"], ["78014005", "Urine (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["112235009", "Through (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["734818004", "Toxin (disposition)"], ["263751005", "Extrusion (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["257991000", "k (qualifier value)|Lower case Roman letter k (qualifier value)"], ["387179001", "Trimethoprim (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["50863008", "Plasma (substance)"], ["260366006", "Increase (qualifier value)"], ["394653002", "Significant|Significant (qualifier value)"], ["86407004", "Table, device (physical object)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["45169001", "Without (attribute)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["420862001", "On (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["224699009", "Study (environment)"], ["272389005", "Analysis (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["373067005", "No (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["420862001", "On (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["18720000", "In (attribute)"], ["386897000", "Lamivudine (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["1119456000", "Substrate (foundation metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["705591009", "Transporter (physical object)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["63911002", "Excretory function (observable entity)|Excretory function (function)"], ["300776002", "Does play (finding)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["410599005", "Minor (person)"], ["766940004", "Role (role)"], ["18720000", "In (attribute)"], ["260695007", "Clearance (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["410942007", "Drug or medicament (substance)"], ["42752001", "Due to (attribute)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["116680003", "Is a (attribute)"], ["1119456000", "Substrate (foundation metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["18720000", "In (attribute)"], ["75540009", "High (qualifier value)"], ["56136002", "Absolute (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["420862001", "On (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["74964007", "Other (qualifier value)"], ["18720000", "In (attribute)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["253861007", "Effect (qualifier value)"], ["420862001", "On (qualifier value)"], ["373476007", "Midazolam (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["422741004", "Cytochrome p450 CYP3A4 enzyme (substance)"], ["7402007", "Probe, device (physical object)"], ["420862001", "On (qualifier value)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255603008", "Major (qualifier value)"], ["734543001", "Enzyme (disposition)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["705591009", "Transporter (physical object)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["422741004", "Cytochrome p450 CYP3A4 enzyme (substance)"], ["422602005", "Cytochrome p450 CYP2C9 enzyme (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["86495002", "For (qualifier value)"], ["242762006", "More (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["18720000", "In (attribute)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["1222741009", "American Joint Committee on Cancer stage I:4 (qualifier value)"], ["260370003", "Decrease (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["270011004", "Creatinine clearance (& level (& glom filt))|Creatinine clearance (& level (& glom filt)) (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["371154000", "Dependent (qualifier value)"], ["420862001", "On (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["360300001", "Transport (physical object)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["260366006", "Increase (qualifier value)"], ["50863008", "Plasma (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["718500008", "Excretory process (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["371154000", "Dependent (qualifier value)"], ["420771004", "Upon - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["413355004", "4-Aminopyridine (product)|Product containing 4-Aminopyridine (medicinal product)|Product containing fampridine (medicinal product)"], ["36692007", "Known (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["80994002", "Fampridine (substance)|4-Aminopyridine (substance)"], ["372567009", "Metformin (substance)"], ["86407004", "Table, device (physical object)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732725004", "4.3 (qualifier value)"], ["18720000", "In (attribute)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["47707009", "Anion (substance)"], ["418504009", "Oats (substance)|Oat (substance)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["420862001", "On (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["418504009", "Oats (substance)|Oat (substance)"], ["1119456000", "Substrate (foundation metadata concept)"], ["422091007", "Tenofovir (substance)"], ["18720000", "In (attribute)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["260366006", "Increase (qualifier value)"], ["50863008", "Plasma (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["718500008", "Excretory process (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["371154000", "Dependent (qualifier value)"], ["420771004", "Upon - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["386897000", "Lamivudine (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["36692007", "Known (qualifier value)"], ["263748003", "Established (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["768685009", "Antiretroviral (disposition)"], ["18720000", "In (attribute)"], ["86407004", "Table, device (physical object)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["86407004", "Table, device (physical object)"], ["11896004", "Intermediate (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["386897000", "Lamivudine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["74188005", "Medical (qualifier value)"], ["18720000", "In (attribute)"], ["86407004", "Table, device (physical object)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["260370003", "Decrease (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["260388006", "No status change (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["42798000", "Area (qualifier value)"], ["351726001", "Below (qualifier value)"], ["702942001", "Concentration (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["413573002", "Area under the curve (qualifier value)"], ["702942001", "Concentration (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["702942001", "Concentration (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["261782000", "End (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["385673002", "Interval (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["86407004", "Table, device (physical object)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258391009", "Classes (qualifier value)"], ["86407004", "Table, device (physical object)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["410942007", "Drug or medicament (substance)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["255586005", "Mean (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["416118004", "Administration (procedure)"], ["768685009", "Antiretroviral (disposition)"], ["47368004", "Nucleoside (substance)"], ["8313009", "RNA-directed DNA polymerase (substance)|Ribonucleic acid-directed deoxyribonucleic acid polymerase (substance)"], ["432221004", "Etravirine (product)|Product containing etravirine (medicinal product)"], ["45169001", "Without (attribute)"], ["736207009", "Protease (disposition)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["264699005", "71 (qualifier value)|Arabic numeral 71 (qualifier value)"], ["732782003", "52 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["732897006", "88 (qualifier value)"], ["432221004", "Etravirine (product)|Product containing etravirine (medicinal product)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["432221004", "Etravirine (product)|Product containing etravirine (medicinal product)"], ["45169001", "Without (attribute)"], ["736207009", "Protease (disposition)"], ["1250004", "Decreased (qualifier value)"], ["50863008", "Plasma (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["702942001", "Concentration (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229799001", "Twice a day (qualifier value)"], ["86495002", "For (qualifier value)"], ["432221004", "Etravirine (product)|Product containing etravirine (medicinal product)"], ["45169001", "Without (attribute)"], ["736207009", "Protease (disposition)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["116680003", "Is a (attribute)"], ["261010008", "Fixed (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["26175008", "Approximate (qualifier value)"], ["123035007", "12 hours (qualifier value)"], ["255234002", "After (attribute)"], ["86495002", "For (qualifier value)"], ["762636008", "Duration (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["432221004", "Etravirine (product)|Product containing etravirine (medicinal product)"], ["45169001", "Without (attribute)"], ["736207009", "Protease (disposition)"], ["416118004", "Administration (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263869007", "Separate (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["86495002", "For (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["732724000", "4.2 (qualifier value)"], ["134573001", "Product containing lopinavir and ritonavir (medicinal product)|Lopinavir+ritonavir (product)|Lopinavir+ritonavir (substance)"], ["432221004", "Etravirine (product)|Product containing etravirine (medicinal product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["1222737005", "American Joint Committee on Cancer stage I:1 (qualifier value)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["1222781002", "American Joint Committee on Cancer stage II:8 (qualifier value)"], ["387067003", "Lopinavir (substance)"], ["386896009", "Ritonavir (substance)"], ["432221004", "Etravirine (product)|Product containing etravirine (medicinal product)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["424096001", "Darunavir (product)|Product containing darunavir (medicinal product)"], ["386896009", "Ritonavir (substance)"], ["432221004", "Etravirine (product)|Product containing etravirine (medicinal product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["1222817002", "American Joint Committee on Cancer stage III:6 (qualifier value)"], ["424096001", "Darunavir (product)|Product containing darunavir (medicinal product)"], ["386896009", "Ritonavir (substance)"], ["432221004", "Etravirine (product)|Product containing etravirine (medicinal product)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["387001004", "Efavirenz (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["732798005", "57 (qualifier value)"], ["1222820005", "American Joint Committee on Cancer stage III:9 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["732861002", "75 (qualifier value)"], ["387001004", "Efavirenz (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229799001", "Twice a day (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387001004", "Efavirenz (substance)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["116680003", "Is a (attribute)"], ["261010008", "Fixed (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["26175008", "Approximate (qualifier value)"], ["123035007", "12 hours (qualifier value)"], ["255234002", "After (attribute)"], ["86495002", "For (qualifier value)"], ["762636008", "Duration (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387001004", "Efavirenz (substance)"], ["416118004", "Administration (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263869007", "Separate (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["86495002", "For (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["732724000", "4.2 (qualifier value)"], ["386898005", "Nevirapine (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["289928003", "Reduction plasty (qualifier value)"], ["18720000", "In (attribute)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387001004", "Efavirenz (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["42752001", "Due to (attribute)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229799001", "Twice a day (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386898005", "Nevirapine (substance)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["116680003", "Is a (attribute)"], ["261010008", "Fixed (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["26175008", "Approximate (qualifier value)"], ["123035007", "12 hours (qualifier value)"], ["255234002", "After (attribute)"], ["86495002", "For (qualifier value)"], ["762636008", "Duration (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386898005", "Nevirapine (substance)"], ["416118004", "Administration (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263869007", "Separate (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["86495002", "For (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["732724000", "4.2 (qualifier value)"], ["703777002", "Rilpivirine (product)|Product containing rilpivirine (medicinal product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["1222740005", "American Joint Committee on Cancer stage I:3 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["1222775005", "American Joint Committee on Cancer stage II:2 (qualifier value)"], ["703777002", "Rilpivirine (product)|Product containing rilpivirine (medicinal product)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["47368004", "Nucleoside (substance)"], ["8313009", "RNA-directed DNA polymerase (substance)|Ribonucleic acid-directed deoxyribonucleic acid polymerase (substance)"], ["421203005", "Tenofovir disoproxil (substance)"], ["404856006", "Emtricitabine (substance)"], ["387105006", "Didanosine (substance)"], ["386895008", "Stavudine (substance)"], ["422091007", "Tenofovir (substance)"], ["387151007", "Zidovudine (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["422091007", "Tenofovir (substance)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422091007", "Tenofovir (substance)"], ["387105006", "Didanosine (substance)"], ["386895008", "Stavudine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["387151007", "Zidovudine (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["86495002", "For (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["42504009", "Containing (qualifier value)"], ["51440002", "Right and left (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["75265007", "Cytidine (substance)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["86495002", "For (qualifier value)"], ["83167003", "Intracellular (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["736207009", "Protease (disposition)"], ["413592000", "Atazanavir (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["732774003", "50 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["732554007", "180 (qualifier value)"], ["413592000", "Atazanavir (substance)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["413592000", "Atazanavir (substance)"], ["386896009", "Ritonavir (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["732824006", "62 (qualifier value)"], ["1222815005", "American Joint Committee on Cancer stage III:4 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["1222760002", "American Joint Committee on Cancer stage I:21 (qualifier value)"], ["413592000", "Atazanavir (substance)"], ["386896009", "Ritonavir (substance)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["419409009", "Tipranavir (substance)"], ["386896009", "Ritonavir (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["732804007", "59 (qualifier value)"], ["1222850002", "American Joint Committee on Cancer stage IV:7 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["732867003", "76 (qualifier value)"], ["419409009", "Tipranavir (substance)"], ["386896009", "Ritonavir (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229799001", "Twice a day (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["419409009", "Tipranavir (substance)"], ["386896009", "Ritonavir (substance)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["116680003", "Is a (attribute)"], ["261010008", "Fixed (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["26175008", "Approximate (qualifier value)"], ["123035007", "12 hours (qualifier value)"], ["255234002", "After (attribute)"], ["86495002", "For (qualifier value)"], ["762636008", "Duration (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["419409009", "Tipranavir (substance)"], ["386896009", "Ritonavir (substance)"], ["416118004", "Administration (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263869007", "Separate (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["86495002", "For (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["732724000", "4.2 (qualifier value)"], ["407018001", "Product containing fosamprenavir (medicinal product)|Fosamprenavir (product)"], ["386896009", "Ritonavir (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["1222816006", "American Joint Committee on Cancer stage III:5 (qualifier value)"], ["1222777002", "American Joint Committee on Cancer stage II:4 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["1222852005", "American Joint Committee on Cancer stage IV:9 (qualifier value)"], ["407018001", "Product containing fosamprenavir (medicinal product)|Fosamprenavir (product)"], ["407018001", "Product containing fosamprenavir (medicinal product)|Fosamprenavir (product)"], ["386896009", "Ritonavir (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["420862001", "On (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["1250004", "Decreased (qualifier value)"], ["18720000", "In (attribute)"], ["21191007", "Phase (attribute)|Phase (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["386896009", "Ritonavir (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["134573001", "Product containing lopinavir and ritonavir (medicinal product)|Lopinavir+ritonavir (product)|Lopinavir+ritonavir (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["387067003", "Lopinavir (substance)"], ["386896009", "Ritonavir (substance)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["424096001", "Darunavir (product)|Product containing darunavir (medicinal product)"], ["386896009", "Ritonavir (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["1222775005", "American Joint Committee on Cancer stage II:2 (qualifier value)"], ["1222737005", "American Joint Committee on Cancer stage I:1 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["1222819004", "American Joint Committee on Cancer stage III:8 (qualifier value)"], ["424096001", "Darunavir (product)|Product containing darunavir (medicinal product)"], ["386896009", "Ritonavir (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["74964007", "Other (qualifier value)"], ["768683002", "Antiviral (disposition)"], ["55561003", "Active (qualifier value)"], ["105590001", "Substance (substance)"], ["714014007", "Daclatasvir (product)|Product containing daclatasvir (medicinal product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["1222814009", "American Joint Committee on Cancer stage III:3 (qualifier value)"], ["1222782009", "American Joint Committee on Cancer stage II:9 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["1222848005", "American Joint Committee on Cancer stage IV:5 (qualifier value)"], ["714014007", "Daclatasvir (product)|Product containing daclatasvir (medicinal product)"], ["714014007", "Daclatasvir (product)|Product containing daclatasvir (medicinal product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["50863008", "Plasma (substance)"], ["702942001", "Concentration (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260858005", "Extent (attribute)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714014007", "Daclatasvir (product)|Product containing daclatasvir (medicinal product)"], ["50863008", "Plasma (substance)"], ["702942001", "Concentration (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["714387002", "Product containing ledipasvir (medicinal product)|Ledipasvir (product)"], ["713645002", "Sofosbuvir (product)|Product containing sofosbuvir (medicinal product)"], ["386897000", "Lamivudine (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387005008", "Abacavir (substance)"], ["386897000", "Lamivudine (substance)"], ["714387002", "Product containing ledipasvir (medicinal product)|Ledipasvir (product)"], ["713645002", "Sofosbuvir (product)|Product containing sofosbuvir (medicinal product)"], ["373067005", "No (qualifier value)"], ["260911001", "Dosage (attribute)"], ["410617001", "Adjustment (procedure)"], ["713645002", "Sofosbuvir (product)|Product containing sofosbuvir (medicinal product)"], ["719641001", "Velpatasvir (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["713645002", "Sofosbuvir (product)|Product containing sofosbuvir (medicinal product)"], ["719641001", "Velpatasvir (substance)"], ["373067005", "No (qualifier value)"], ["260911001", "Dosage (attribute)"], ["410617001", "Adjustment (procedure)"], ["387188005", "Ribavirin (substance)"], ["394653002", "Significant|Significant (qualifier value)"], ["373067005", "No (qualifier value)"], ["260911001", "Dosage (attribute)"], ["410617001", "Adjustment (procedure)"], ["387179001", "Trimethoprim (substance)"], ["387388003", "Sulfamethoxazole (substance)"], ["398731002", "Product containing sulfamethoxazole and trimethoprim (medicinal product)|Sulfamethoxazole + trimethoprim (product)"], ["386897000", "Lamivudine (substance)"], ["732529007", "160 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732878006", "800 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["86495002", "For (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["258703001", "day (qualifier value)"], ["725125005", "300 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["408102007", "Unit dose (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["1222846009", "American Joint Committee on Cancer stage IV:3 (qualifier value)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["387179001", "Trimethoprim (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["387388003", "Sulfamethoxazole (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["31046007", "Cation (substance)"], ["705591009", "Transporter (physical object)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["373067005", "No (qualifier value)"], ["260911001", "Dosage (attribute)"], ["410617001", "Adjustment (procedure)"], ["387159009", "Rifampin (substance)|Rifampicin (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["732789007", "54 (qualifier value)"], ["1222846009", "American Joint Committee on Cancer stage IV:3 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["732857008", "72 (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229799001", "Twice a day (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387159009", "Rifampin (substance)|Rifampicin (substance)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["116680003", "Is a (attribute)"], ["261010008", "Fixed (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["26175008", "Approximate (qualifier value)"], ["123035007", "12 hours (qualifier value)"], ["255234002", "After (attribute)"], ["86495002", "For (qualifier value)"], ["762636008", "Duration (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387159009", "Rifampin (substance)|Rifampicin (substance)"], ["416118004", "Administration (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263869007", "Separate (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["86495002", "For (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["732724000", "4.2 (qualifier value)"], ["386893001", "Rifabutin (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222743007", "American Joint Committee on Cancer stage I:6 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["387222003", "Carbamazepine (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["1222852005", "American Joint Committee on Cancer stage IV:9 (qualifier value)"], ["1222814009", "American Joint Committee on Cancer stage III:3 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229799001", "Twice a day (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["116680003", "Is a (attribute)"], ["261010008", "Fixed (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["26175008", "Approximate (qualifier value)"], ["123035007", "12 hours (qualifier value)"], ["255234002", "After (attribute)"], ["86495002", "For (qualifier value)"], ["762636008", "Duration (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263869007", "Separate (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["86495002", "For (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["732724000", "4.2 (qualifier value)"], ["373505007", "Phenobarbital (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["387220006", "Phenytoin (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["387025007", "Oxcarbazepine (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["260370003", "Decrease (qualifier value)"], ["42752001", "Due to (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["289928003", "Reduction plasty (qualifier value)"], ["18720000", "In (attribute)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387222003", "Carbamazepine (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["320678002", "Antihistamines (product)|Antihistamines (substance)"], ["59822009", "Histamine H2 receptor (substance)"], ["372755005", "Ranitidine (substance)"], ["394653002", "Significant|Significant (qualifier value)"], ["373067005", "No (qualifier value)"], ["260911001", "Dosage (attribute)"], ["410617001", "Adjustment (procedure)"], ["373541007", "Cimetidine (substance)"], ["394653002", "Significant|Significant (qualifier value)"], ["373067005", "No (qualifier value)"], ["260911001", "Dosage (attribute)"], ["410617001", "Adjustment (procedure)"], ["386916009", "Cladribine (substance)"], ["386897000", "Lamivudine (substance)"], ["18720000", "In (attribute)"], ["386897000", "Lamivudine (substance)"], ["83167003", "Intracellular (qualifier value)"], ["363262008", "Phosphorylation, function (observable entity)|Phosphorylation (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386916009", "Cladribine (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["386916009", "Cladribine (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["18720000", "In (attribute)"], ["58147004", "Clinical (qualifier value)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["105589005", "Finding, conclusion AND/OR assessment|Finding, conclusion AND/OR assessment (finding)"], ["390683003", "Support|Support (regime/therapy)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["11896004", "Intermediate (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386916009", "Cladribine (substance)"], ["79970003", "Simultaneous (qualifier value)"], ["260676000", "Use of (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386916009", "Cladribine (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["49634009", "Miscellaneous (qualifier value)"], ["412513004", "Sorbitol (product)|Product containing sorbitol (medicinal product)"], ["1222737005", "American Joint Committee on Cancer stage I:1 (qualifier value)"], ["412513004", "Sorbitol (product)|Product containing sorbitol (medicinal product)"], ["739006009", "Solution (basic dose form)"], ["732645002", "3.2 (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["732487008", "13.4 (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["408102007", "Unit dose (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["385023001", "Conventional release oral solution (dose form)|Oral solution (qualifier value)|Oral solution (product)"], ["725125005", "300 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["1222741009", "American Joint Committee on Cancer stage I:4 (qualifier value)"], ["1222813003", "American Joint Committee on Cancer stage III:2 (qualifier value)"], ["1222817002", "American Joint Committee on Cancer stage III:6 (qualifier value)"], ["1222781002", "American Joint Committee on Cancer stage II:8 (qualifier value)"], ["732782003", "52 (qualifier value)"], ["264691008", "Arabic numeral 55 (qualifier value)|55 (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["42504009", "Containing (qualifier value)"], ["412513004", "Sorbitol (product)|Product containing sorbitol (medicinal product)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["116257004", "Monosaccharide (substance)"], ["398986008", "Xylitol (product)|Product containing xylitol (medicinal product)"], ["387168006", "Mannitol (substance)"], ["418929008", "Lactitol (substance)"], ["116269007", "Maltitol (substance)"], ["242762006", "More (qualifier value)"], ["70232002", "Frequent (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["89293008", "Human immunodeficiency virus type I (organism)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["88480006", "Potassium (substance)"], ["255592004", "Channel (qualifier value)"], ["413355004", "4-Aminopyridine (product)|Product containing 4-Aminopyridine (medicinal product)|Product containing fampridine (medicinal product)"], ["36692007", "Known (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["80994002", "Fampridine (substance)|4-Aminopyridine (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413355004", "4-Aminopyridine (product)|Product containing 4-Aminopyridine (medicinal product)|Product containing fampridine (medicinal product)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["42752001", "Due to (attribute)"], ["35105006", "Increased (qualifier value)"], ["413355004", "4-Aminopyridine (product)|Product containing 4-Aminopyridine (medicinal product)|Product containing fampridine (medicinal product)"], ["50863008", "Plasma (substance)"], ["702942001", "Concentration (qualifier value)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["705591009", "Transporter (physical object)"], ["416118004", "Administration (procedure)"], ["413355004", "4-Aminopyridine (product)|Product containing 4-Aminopyridine (medicinal product)|Product containing fampridine (medicinal product)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410536001", "Contraindicated (qualifier value)"], ["732725004", "4.3 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["72717003", "Magnesium (substance)"], ["255977005", "Aluminum material (substance)"], ["42504009", "Containing (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["732860001", "74 (qualifier value)"], ["732857008", "72 (qualifier value)"], ["103360007", "Complex (qualifier value)"], ["257768005", "Binding - action (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["48006008", "Ion (substance)"], ["72717003", "Magnesium (substance)"], ["255977005", "Aluminum material (substance)"], ["42504009", "Containing (qualifier value)"], ["20572008", "Good (qualifier value)"], ["160494003", "(Separated (& [from cohabitee]) or (left home: [husband] or [wife] or [cohabitee]))|(Separated (& [from cohabitee]) or (left home: [husband] or [wife] or [cohabitee])) (finding)"], ["18720000", "In (attribute)"], ["900000000000475002", "Time (foundation metadata concept)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["123030002", "2 hours (qualifier value)"], ["255234002", "After (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["123033000", "6 hours (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["5540006", "Calcium (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["1222820005", "American Joint Committee on Cancer stage III:9 (qualifier value)"], ["1222818007", "American Joint Committee on Cancer stage III:7 (qualifier value)"], ["1222820005", "American Joint Committee on Cancer stage III:9 (qualifier value)"], ["103360007", "Complex (qualifier value)"], ["257768005", "Binding - action (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["48006008", "Ion (substance)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255620007", "Food (substance)|Foods (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["329413004", "Multivitamins (substance)"], ["42504009", "Containing (qualifier value)"], ["5540006", "Calcium (substance)"], ["3829006", "Iron (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["72717003", "Magnesium (substance)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["262126009", "Same (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["398070004", "State (environment)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["123030002", "2 hours (qualifier value)"], ["255234002", "After (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["123033000", "6 hours (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["398070004", "State (environment)"], ["18720000", "In (attribute)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["255260001", "Following (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["5540006", "Calcium (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["3829006", "Iron (substance)"], ["18307000", "Altered (qualifier value)"], ["255620007", "Food (substance)|Foods (substance)"], ["253861007", "Effect (qualifier value)"], ["79409006", "Resulting in (attribute)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["398092000", "Obtained (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["18720000", "In (attribute)"], ["398070004", "State (environment)"], ["3829006", "Iron (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["732789007", "54 (qualifier value)"], ["732798005", "57 (qualifier value)"], ["103360007", "Complex (qualifier value)"], ["257768005", "Binding - action (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["48006008", "Ion (substance)"], ["329413004", "Multivitamins (substance)"], ["42504009", "Containing (qualifier value)"], ["5540006", "Calcium (substance)"], ["3829006", "Iron (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["72717003", "Magnesium (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["1222814009", "American Joint Committee on Cancer stage III:3 (qualifier value)"], ["1222816006", "American Joint Committee on Cancer stage III:5 (qualifier value)"], ["1222813003", "American Joint Committee on Cancer stage III:2 (qualifier value)"], ["103360007", "Complex (qualifier value)"], ["257768005", "Binding - action (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["48006008", "Ion (substance)"], ["108665006", "Proton pump inhibitor (product)|Product containing hydrogen/potassium adenosine triphosphatase enzyme system inhibitor (product)|Product containing H+/K+-exchanging ATPase inhibitor (product)|Proton pump inhibitor (substance)"], ["387137007", "Omeprazole (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["373067005", "No (qualifier value)"], ["260911001", "Dosage (attribute)"], ["410617001", "Adjustment (procedure)"], ["79440004", "Product containing corticosteroid (product)|Product containing corticosteroid and/or corticosteroid derivative (product)|Corticoid preparation (product)|Product containing corticosteroid and corticosteroid derivative (product)|Corticoid preparation (substance)"], ["116602009", "Prednisone (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["1222737005", "American Joint Committee on Cancer stage I:1 (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["1222746004", "American Joint Committee on Cancer stage I:7 (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["372567009", "Metformin (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["372567009", "Metformin (substance)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["372567009", "Metformin (substance)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["372567009", "Metformin (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["732832003", "66 (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["372567009", "Metformin (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["732509006", "145 (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["1222750006", "American Joint Committee on Cancer stage I:11 (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["372567009", "Metformin (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["246106000", "Control (attribute)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1255665007", "Moderate (qualifier value)"], ["40226000", "Impairment (finding)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["372567009", "Metformin (substance)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["86495002", "For (qualifier value)"], ["91273001", "Lactic acidosis (disorder)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1255665007", "Moderate (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["42752001", "Due to (attribute)"], ["35105006", "Increased (qualifier value)"], ["372567009", "Metformin (substance)"], ["702942001", "Concentration (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["224006005", "St. John (geographic location)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["260370003", "Decrease (qualifier value)"], ["42752001", "Due to (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["289928003", "Reduction plasty (qualifier value)"], ["18720000", "In (attribute)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387222003", "Carbamazepine (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229799001", "Twice a day (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["224006005", "St. John (geographic location)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["116680003", "Is a (attribute)"], ["261010008", "Fixed (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["26175008", "Approximate (qualifier value)"], ["123035007", "12 hours (qualifier value)"], ["255234002", "After (attribute)"], ["86495002", "For (qualifier value)"], ["762636008", "Duration (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["224006005", "St. John (geographic location)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["416118004", "Administration (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263869007", "Separate (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["86495002", "For (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["732724000", "4.2 (qualifier value)"], ["738956005", "Oral (intended site)"], ["108899006", "Contraceptives (product)|Medicinal product acting as contraceptive (product)|Contraceptives (substance)"], ["126097006", "Ethinyl estradiol (substance)|Ethinylestradiol (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["1222737005", "American Joint Committee on Cancer stage I:1 (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["373067005", "No (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["420862001", "On (qualifier value)"], ["259348009", "Luteinizing hormone (substance)"], ["64182005", "Pituitary luteinizing hormone (substance)"], ["25217009", "Pituitary follicle stimulating hormone (substance)"], ["25217009", "Pituitary follicle stimulating hormone (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["50318003", "Progesterone preparation (substance)|Product containing progesterone (medicinal product)|Progesterone preparation (product)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["738956005", "Oral (intended site)"], ["108899006", "Contraceptives (product)|Medicinal product acting as contraceptive (product)|Contraceptives (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["376171000221106", "Pediatric population (qualifier value)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["18720000", "In (attribute)"]], "ncit.pregnancy": [["C159586", "Preoperative IV Sedation was Not Administered"], ["C54708", "Drug Interaction"], ["C101282", "Have"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C79873", "Contain"], ["C121543", "Dolutegravir"], ["C16289", "Andorra"], ["C1471", "Lamivudine"], ["C81168", "Any"], ["C25737", "Identification"], ["C64956", "For"], ["C68869", "Are"], ["C70664", "Relevance"], ["C159124", "GDC Treatment Outcome Terminology"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C41130", "Significant"], ["C459", "Medication"], ["C68869", "Are"], ["C41333", "Expected Adverse Event"], ["C94545", "Between"], ["C121543", "Dolutegravir"], ["C16289", "Andorra"], ["C1471", "Lamivudine"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C118472", "Other License Status"], ["C92667", "SPARC wt Allele"], ["C15299", "Pharmacokinetics"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C16289", "Andorra"], ["C1471", "Lamivudine"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25650", "Removed"], ["C16842", "Metabolism, Organismal"], ["C158169", "Buyei Chinese"], ["C922", "Uridine"], ["C17210", "Transferase"], ["C127927", "UGT1A Locus"], ["C124235", "SLC45A2 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C50196", "Substrate Device"], ["C52874", "SPI1 wt Allele"], ["C105862", "UGT1A9 Gene"], ["C17573", "Cytochrome P450 3A4"], ["C17746", "Multidrug Resistance Protein 1"], ["C52273", "ABCB1 wt Allele"], ["C16289", "Andorra"], ["C21253", "Broad Substrate Specificity ATP-Binding Cassette Transporter ABCG2"], ["C52276", "ABCG2 wt Allele"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C16289", "Andorra"], ["C118472", "Other License Status"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C105862", "UGT1A9 Gene"], ["C17573", "Cytochrome P450 3A4"], ["C48928", "And/Or"], ["C52273", "ABCB1 wt Allele"], ["C106184", "May"], ["C25533", "Increase"], ["C121543", "Dolutegravir"], ["C13356", "Plasma"], ["C105891", "Able to Concentrate"], ["C61367", "Induction"], ["C16554", "Enzyme"], ["C43508", "Oregon"], ["C106184", "May"], ["C25640", "Reduced"], ["C121543", "Dolutegravir"], ["C13356", "Plasma"], ["C105891", "Able to Concentrate"], ["C16289", "Andorra"], ["C38032", "Therapeutic Effect"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C71731", "Material Absorption"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25640", "Reduced"], ["C158169", "Buyei Chinese"], ["C107561", "Certain"], ["C637", "Metal"], ["C79873", "Contain"], ["C75354", "Lysergide Measurement"], ["C16289", "Andorra"], ["C1505", "Dietary Supplement"], ["C163702", "Staphylococcal Enterotoxin E"], ["C48441", "Table"], ["C105723", "ECOG Performance Status 1"], ["C1471", "Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C154405", "Active State"], ["C25225", "Renal"], ["C17119", "Cellular Secretion"], ["C52874", "SPI1 wt Allele"], ["C1471", "Lamivudine"], ["C16727", "India"], ["C13283", "Urine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C61426", "Mediator"], ["C53112", "POU2F2 wt Allele"], ["C16289", "Andorra"], ["C16289", "Andorra"], ["C894", "Toxin"], ["C50557", "Extrusion"], ["C113565", "SLC47A1 wt Allele"], ["C16289", "Andorra"], ["C113568", "SLC47A2 wt Allele"], ["C908", "Trimethoprim"], ["C75889", "PAX6 wt Allele"], ["C154898", "Inhibitor"], ["C52874", "SPI1 wt Allele"], ["C101282", "Have"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25533", "Increase"], ["C1471", "Lamivudine"], ["C13356", "Plasma"], ["C25533", "Increase"], ["C154196", "Washo Language"], ["C25594", "Negation"], ["C41130", "Significant"], ["C163702", "Staphylococcal Enterotoxin E"], ["C48441", "Table"], ["C105723", "ECOG Performance Status 1"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C75889", "PAX6 wt Allele"], ["C53112", "POU2F2 wt Allele"], ["C16289", "Andorra"], ["C113565", "SLC47A1 wt Allele"], ["C154898", "Inhibitor"], ["C1471", "Lamivudine"], ["C72665", "Similarity"], ["C62355", "With"], ["C43508", "Oregon"], ["C25718", "Without"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C76246", "Blood Group A"], ["C81171", "Cross"], ["C45319", "Study Object"], ["C25391", "Analysis"], ["C121543", "Dolutegravir"], ["C101282", "Have"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C70664", "Relevance"], ["C71600", "Effect, Appearance"], ["C92667", "SPARC wt Allele"], ["C1471", "Lamivudine"], ["C49587", "Exposure Domain"], ["C15744", "In Vivo"], ["C1471", "Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C50196", "Substrate Device"], ["C52874", "SPI1 wt Allele"], ["C13308", "Hepatic"], ["C71688", "Uptake"], ["C105074", "SLC22A1 wt Allele"], ["C71344", "Associate of Science"], ["C13308", "Hepatic"], ["C76246", "Blood Group A"], ["C45367", "Minor"], ["C48835", "Role"], ["C16727", "India"], ["C199688", "Drug Clearance"], ["C52874", "SPI1 wt Allele"], ["C1471", "Lamivudine"], ["C459", "Medication"], ["C89272", "Due To"], ["C42791", "Inhibition"], ["C52874", "SPI1 wt Allele"], ["C105074", "SLC22A1 wt Allele"], ["C68869", "Are"], ["C85549", "Unlikely"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C52874", "SPI1 wt Allele"], ["C123619", "Clinical Response"], ["C41130", "Significant"], ["C1471", "Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C50196", "Substrate Device"], ["C52874", "SPI1 wt Allele"], ["C52276", "ABCG2 wt Allele"], ["C16289", "Andorra"], ["C52273", "ABCB1 wt Allele"], ["C15263", "In Vitro"], ["C64974", "Give"], ["C139304", "IPSS Risk Category High"], ["C154838", "Absolute Bioavailability"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C52874", "SPI1 wt Allele"], ["C68869", "Are"], ["C85549", "Unlikely"], ["C159124", "GDC Treatment Outcome Terminology"], ["C20200", "Outcome"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C70664", "Relevance"], ["C62534", "Arginine/Omega-3 Fatty Acids/Nucleotides Oral Supplement"], ["C92667", "SPARC wt Allele"], ["C1471", "Lamivudine"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C16289", "Andorra"], ["C1471", "Lamivudine"], ["C92667", "SPARC wt Allele"], ["C15299", "Pharmacokinetics"], ["C52874", "SPI1 wt Allele"], ["C118472", "Other License Status"], ["C15744", "In Vivo"], ["C121543", "Dolutegravir"], ["C192133", "Did Not Have"], ["C75889", "PAX6 wt Allele"], ["C71600", "Effect, Appearance"], ["C92667", "SPARC wt Allele"], ["C139083", "Midazolam Measurement"], ["C76246", "Blood Group A"], ["C17573", "Cytochrome P450 3A4"], ["C73628", "Chemical Probe"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C15744", "In Vivo"], ["C48928", "And/Or"], ["C15263", "In Vitro"], ["C25474", "Data"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C41333", "Expected Adverse Event"], ["C159124", "GDC Treatment Outcome Terminology"], ["C15299", "Pharmacokinetics"], ["C52874", "SPI1 wt Allele"], ["C68869", "Are"], ["C52874", "SPI1 wt Allele"], ["C81168", "Any"], ["C45368", "Major"], ["C16554", "Enzyme"], ["C43508", "Oregon"], ["C71344", "Associate of Science"], ["C17573", "Cytochrome P450 3A4"], ["C161355", "Cytochrome P450 2C9 Measurement"], ["C16289", "Andorra"], ["C52273", "ABCB1 wt Allele"], ["C64956", "For"], ["C128667", "More"], ["C48191", "Information"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C15263", "In Vitro"], ["C121543", "Dolutegravir"], ["C25225", "Renal"], ["C53112", "POU2F2 wt Allele"], ["C16289", "Andorra"], ["C113565", "SLC47A1 wt Allele"], ["C15744", "In Vivo"], ["C76246", "Blood Group A"], ["C69122", "Ten"], ["C113428", "Fourteen"], ["C25640", "Reduced"], ["C52874", "SPI1 wt Allele"], ["C25747", "Creatinine Clearance"], ["C17119", "Cellular Secretion"], ["C25514", "Fraction"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C63905", "Conditional"], ["C92667", "SPARC wt Allele"], ["C53112", "POU2F2 wt Allele"], ["C16289", "Andorra"], ["C113565", "SLC47A1 wt Allele"], ["C21079", "Transport Process"], ["C154196", "Washo Language"], ["C25599", "Observed"], ["C16727", "India"], ["C16960", "Patient"], ["C15744", "In Vivo"], ["C121543", "Dolutegravir"], ["C106184", "May"], ["C25533", "Increase"], ["C13356", "Plasma"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C94618", "Excretion"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C63905", "Conditional"], ["C65137", "Upon"], ["C53112", "POU2F2 wt Allele"], ["C48928", "And/Or"], ["C113565", "SLC47A1 wt Allele"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C76777", "Dalfampridine"], ["C80137", "Known"], ["C71344", "Associate of Science"], ["C76777", "Dalfampridine"], ["C61612", "Metformin"], ["C163702", "Staphylococcal Enterotoxin E"], ["C48441", "Table"], ["C105723", "ECOG Performance Status 1"], ["C16289", "Andorra"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C15263", "In Vitro"], ["C121543", "Dolutegravir"], ["C25225", "Renal"], ["C71688", "Uptake"], ["C63848", "Organic"], ["C116443", "Thermoacoustic Computed Tomography"], ["C105723", "ECOG Performance Status 1"], ["C16289", "Andorra"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C187247", "Lack of Effect"], ["C92667", "SPARC wt Allele"], ["C15744", "In Vivo"], ["C15299", "Pharmacokinetics"], ["C52874", "SPI1 wt Allele"], ["C116443", "Thermoacoustic Computed Tomography"], ["C50196", "Substrate Device"], ["C29490", "Tenofovir"], ["C15744", "In Vivo"], ["C42791", "Inhibition"], ["C52874", "SPI1 wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C85549", "Unlikely"], ["C42791", "Inhibition"], ["C52874", "SPI1 wt Allele"], ["C101282", "Have"], ["C25594", "Negation"], ["C15744", "In Vivo"], ["C121543", "Dolutegravir"], ["C106184", "May"], ["C25533", "Increase"], ["C13356", "Plasma"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C94618", "Excretion"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C63905", "Conditional"], ["C65137", "Upon"], ["C15263", "In Vitro"], ["C1471", "Lamivudine"], ["C154196", "Washo Language"], ["C75889", "PAX6 wt Allele"], ["C154898", "Inhibitor"], ["C52874", "SPI1 wt Allele"], ["C105074", "SLC22A1 wt Allele"], ["C16289", "Andorra"], ["C53112", "POU2F2 wt Allele"], ["C123619", "Clinical Response"], ["C68869", "Are"], ["C17998", "Unknown"], ["C71155", "Established"], ["C16289", "Andorra"], ["C84379", "Theory"], ["C62355", "With"], ["C48912", "Choose"], ["C16289", "Andorra"], ["C14460", "NON Mouse"], ["C68869", "Are"], ["C16727", "India"], ["C48441", "Table"], ["C105723", "ECOG Performance Status 1"], ["C54216", "Interaction"], ["C48441", "Table"], ["C94545", "Between"], ["C121543", "Dolutegravir"], ["C1471", "Lamivudine"], ["C16289", "Andorra"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C25261", "Medical"], ["C68869", "Are"], ["C16727", "India"], ["C48441", "Table"], ["C105723", "ECOG Performance Status 1"], ["C25533", "Increase"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C71344", "Associate of Science"], ["C25640", "Reduced"], ["C71344", "Associate of Science"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C54126", "Delta"], ["C71344", "Associate of Science"], ["C25244", "Area"], ["C105891", "Able to Concentrate"], ["C49156", "Comparison"], ["C25330", "Duration"], ["C70828", "Curve"], ["C71344", "Associate of Science"], ["C64774", "Area Under Curve"], ["C82868", "Maximum Value Derivation Technique"], ["C25599", "Observed"], ["C105891", "Able to Concentrate"], ["C71344", "Associate of Science"], ["C70918", "Cmax"], ["C105891", "Able to Concentrate"], ["C158997", "GDC Analyte Type Terminology"], ["C25496", "End"], ["C52874", "SPI1 wt Allele"], ["C176355", "Dosing Interval"], ["C71344", "Associate of Science"], ["C67900", "Centi"], ["C48441", "Table"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C67045", "Representation"], ["C52874", "SPI1 wt Allele"], ["C48441", "Table"], ["C105723", "ECOG Performance Status 1"], ["C459", "Medication"], ["C158169", "Buyei Chinese"], ["C101302", "Therapeutic Area"], ["C54216", "Interaction"], ["C181249", "Mean Based on Unspecified Calculation"], ["C54126", "Delta"], ["C48570", "Percent Unit"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C14460", "NON Mouse"], ["C707", "Nucleoside"], ["C17096", "Reverse Transcriptase"], ["C73195", "Etravirine"], ["C25718", "Without"], ["C783", "Protease Inhibitor"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C188333", "Seventy One"], ["C70918", "Cmax"], ["C188320", "Fifty Two"], ["C67900", "Centi"], ["C188347", "Eighty Eight"], ["C73195", "Etravirine"], ["C158876", "Induction Therapy"], ["C52874", "SPI1 wt Allele"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C16289", "Andorra"], ["C107557", "CYP3A Gene Locus"], ["C16554", "Enzyme"], ["C73195", "Etravirine"], ["C25718", "Without"], ["C16965", "Peptidase"], ["C25640", "Reduced"], ["C13356", "Plasma"], ["C121543", "Dolutegravir"], ["C105891", "Able to Concentrate"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C64496", "Twice Daily"], ["C64956", "For"], ["C16960", "Patient"], ["C73195", "Etravirine"], ["C25718", "Without"], ["C783", "Protease Inhibitor"], ["C71344", "Associate of Science"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C192102", "Fixed Dose"], ["C154605", "Tablet Dosage Form Category"], ["C75889", "PAX6 wt Allele"], ["C25406", "Additional"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C154605", "Tablet Dosage Form Category"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C45828", "Approximate"], ["C113426", "Twelve"], ["C25529", "Hour"], ["C38008", "Post"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C64956", "For"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C73195", "Etravirine"], ["C25718", "Without"], ["C16965", "Peptidase"], ["C154898", "Inhibitor"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C76246", "Blood Group A"], ["C63803", "Separate"], ["C15653", "Drug Formulation Process"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25429", "Availability"], ["C64956", "For"], ["C82495", "Dose Adjustment"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C2095", "Lopinavir"], ["C1609", "Ritonavir"], ["C73195", "Etravirine"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C113425", "Eleven"], ["C70918", "Cmax"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C67900", "Centi"], ["C126888", "Twenty Eight"], ["C2095", "Lopinavir"], ["C1609", "Ritonavir"], ["C73195", "Etravirine"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C65364", "Darunavir"], ["C1609", "Ritonavir"], ["C73195", "Etravirine"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C113663", "Twenty Five"], ["C70918", "Cmax"], ["C113426", "Twelve"], ["C67900", "Centi"], ["C175626", "Thirty Six"], ["C65364", "Darunavir"], ["C1609", "Ritonavir"], ["C73195", "Etravirine"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C29027", "Efavirenz"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C175681", "Fifty Seven"], ["C70918", "Cmax"], ["C105798", "Thirty Nine"], ["C67900", "Centi"], ["C160687", "Seventy Five"], ["C29027", "Efavirenz"], ["C54625", "History"], ["C158876", "Induction Therapy"], ["C52874", "SPI1 wt Allele"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C16289", "Andorra"], ["C107557", "CYP3A Gene Locus"], ["C16554", "Enzyme"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C64496", "Twice Daily"], ["C65140", "When"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C29027", "Efavirenz"], ["C71344", "Associate of Science"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C192102", "Fixed Dose"], ["C154605", "Tablet Dosage Form Category"], ["C75889", "PAX6 wt Allele"], ["C25406", "Additional"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C154605", "Tablet Dosage Form Category"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C45828", "Approximate"], ["C113426", "Twelve"], ["C25529", "Hour"], ["C38008", "Post"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C64956", "For"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C29027", "Efavirenz"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C76246", "Blood Group A"], ["C63803", "Separate"], ["C15653", "Drug Formulation Process"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25429", "Availability"], ["C64956", "For"], ["C82495", "Dose Adjustment"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29277", "Nevirapine"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C25594", "Negation"], ["C76246", "Blood Group A"], ["C72665", "Similarity"], ["C25640", "Reduced"], ["C16727", "India"], ["C49587", "Exposure Domain"], ["C71344", "Associate of Science"], ["C25599", "Observed"], ["C62355", "With"], ["C29027", "Efavirenz"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C41333", "Expected Adverse Event"], ["C89272", "Due To"], ["C158876", "Induction Therapy"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C64496", "Twice Daily"], ["C65140", "When"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C29277", "Nevirapine"], ["C71344", "Associate of Science"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C192102", "Fixed Dose"], ["C154605", "Tablet Dosage Form Category"], ["C75889", "PAX6 wt Allele"], ["C25406", "Additional"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C154605", "Tablet Dosage Form Category"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C45828", "Approximate"], ["C113426", "Twelve"], ["C25529", "Hour"], ["C38008", "Post"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C64956", "For"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C29277", "Nevirapine"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C76246", "Blood Group A"], ["C63803", "Separate"], ["C15653", "Drug Formulation Process"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25429", "Availability"], ["C64956", "For"], ["C82495", "Dose Adjustment"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C189974", "Dolutegravir Sodium/Rilpivirine Hydrochloride"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C113426", "Twelve"], ["C70918", "Cmax"], ["C113427", "Thirteen"], ["C67900", "Centi"], ["C126884", "Twenty Two"], ["C76929", "Rilpivirine"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C707", "Nucleoside"], ["C17096", "Reverse Transcriptase"], ["C29490", "Tenofovir"], ["C47509", "Emtricitabine"], ["C431", "Didanosine"], ["C1428", "Stavudine"], ["C29490", "Tenofovir"], ["C947", "Zidovudine"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C105723", "ECOG Performance Status 1"], ["C70918", "Cmax"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C67900", "Centi"], ["C66839", "Eight"], ["C29490", "Tenofovir"], ["C54216", "Interaction"], ["C25594", "Negation"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C65140", "When"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25454", "Combined"], ["C62355", "With"], ["C29490", "Tenofovir"], ["C431", "Didanosine"], ["C1428", "Stavudine"], ["C43508", "Oregon"], ["C947", "Zidovudine"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C64956", "For"], ["C25340", "Use"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C47509", "Emtricitabine"], ["C79873", "Contain"], ["C45325", "Since"], ["C49636", "Both"], ["C1471", "Lamivudine"], ["C16727", "India"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C16289", "Andorra"], ["C47509", "Emtricitabine"], ["C68869", "Are"], ["C409", "Cytidine"], ["C68254", "Dietary Iodine"], ["C68800", "Elementary Charge"], ["C17102", "Risk"], ["C64956", "For"], ["C28217", "Intracellular"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C783", "Protease Inhibitor"], ["C66872", "Atazanavir"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C105785", "Fifty"], ["C67900", "Centi"], ["C17266", "Congo, the Democratic Republic of the"], ["C66872", "Atazanavir"], ["C54625", "History"], ["C42791", "Inhibition"], ["C52874", "SPI1 wt Allele"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C16289", "Andorra"], ["C107557", "CYP3A Gene Locus"], ["C16554", "Enzyme"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C66872", "Atazanavir"], ["C1609", "Ritonavir"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C188326", "Sixty Two"], ["C70918", "Cmax"], ["C186749", "Human Papillomavirus-34"], ["C67900", "Centi"], ["C66872", "Atazanavir"], ["C1609", "Ritonavir"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C66603", "Tipranavir"], ["C1609", "Ritonavir"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C105794", "Fifty Nine"], ["C70918", "Cmax"], ["C178277", "Forty Seven"], ["C67900", "Centi"], ["C188337", "Seventy Six"], ["C66603", "Tipranavir"], ["C1609", "Ritonavir"], ["C158876", "Induction Therapy"], ["C52874", "SPI1 wt Allele"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C16289", "Andorra"], ["C107557", "CYP3A Gene Locus"], ["C16554", "Enzyme"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C64496", "Twice Daily"], ["C65140", "When"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C66603", "Tipranavir"], ["C1609", "Ritonavir"], ["C71344", "Associate of Science"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C192102", "Fixed Dose"], ["C154605", "Tablet Dosage Form Category"], ["C75889", "PAX6 wt Allele"], ["C25406", "Additional"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C154605", "Tablet Dosage Form Category"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C45828", "Approximate"], ["C113426", "Twelve"], ["C25529", "Hour"], ["C38008", "Post"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C64956", "For"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C66603", "Tipranavir"], ["C1609", "Ritonavir"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C76246", "Blood Group A"], ["C63803", "Separate"], ["C15653", "Drug Formulation Process"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25429", "Availability"], ["C64956", "For"], ["C82495", "Dose Adjustment"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C83720", "Fosamprenavir"], ["C1609", "Ritonavir"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C102997", "Human Papillomavirus-35"], ["C70918", "Cmax"], ["C113753", "Twenty Four"], ["C67900", "Centi"], ["C105796", "Forty Nine"], ["C83720", "Fosamprenavir"], ["C83720", "Fosamprenavir"], ["C1609", "Ritonavir"], ["C121543", "Dolutegravir"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C142988", "Limited"], ["C25474", "Data"], ["C163546", "Double Immunodiffusion"], ["C25594", "Negation"], ["C20200", "Outcome"], ["C16727", "India"], ["C25640", "Reduced"], ["C88183", "Efficacy"], ["C16727", "India"], ["C48281", "Trial Phase"], ["C133421", "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C1609", "Ritonavir"], ["C158876", "Induction Therapy"], ["C52874", "SPI1 wt Allele"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C16289", "Andorra"], ["C107557", "CYP3A Gene Locus"], ["C16554", "Enzyme"], ["C2095", "Lopinavir"], ["C1609", "Ritonavir"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C70918", "Cmax"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C172979", "Fear Score 6"], ["C2095", "Lopinavir"], ["C1609", "Ritonavir"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C65364", "Darunavir"], ["C1609", "Ritonavir"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C126884", "Twenty Two"], ["C70918", "Cmax"], ["C113425", "Eleven"], ["C67900", "Centi"], ["C175628", "Thirty Eight"], ["C65364", "Darunavir"], ["C1609", "Ritonavir"], ["C158876", "Induction Therapy"], ["C52874", "SPI1 wt Allele"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C16289", "Andorra"], ["C107557", "CYP3A Gene Locus"], ["C16554", "Enzyme"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C118472", "Other License Status"], ["C281", "Antiviral Agent"], ["C154405", "Active State"], ["C114981", "Daclatasvir"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C102996", "Human Papillomavirus-33"], ["C70918", "Cmax"], ["C105800", "Twenty Nine"], ["C67900", "Centi"], ["C175677", "Forty Five"], ["C114981", "Daclatasvir"], ["C114981", "Daclatasvir"], ["C163546", "Double Immunodiffusion"], ["C25594", "Negation"], ["C54126", "Delta"], ["C121543", "Dolutegravir"], ["C13356", "Plasma"], ["C105891", "Able to Concentrate"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C70664", "Relevance"], ["C25332", "Extent"], ["C121543", "Dolutegravir"], ["C163546", "Double Immunodiffusion"], ["C25594", "Negation"], ["C54126", "Delta"], ["C114981", "Daclatasvir"], ["C13356", "Plasma"], ["C105891", "Able to Concentrate"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C153378", "Ledipasvir/Sofosbuvir"], ["C1471", "Lamivudine"], ["C62355", "With"], ["C61523", "Abacavir"], ["C1471", "Lamivudine"], ["C129019", "Ledipasvir"], ["C101263", "Sofosbuvir"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C94394", "Cumulative Dose"], ["C49157", "Adjustment"], ["C101263", "Sofosbuvir"], ["C152851", "Velpatasvir"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C101263", "Sofosbuvir"], ["C152851", "Velpatasvir"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C94394", "Cumulative Dose"], ["C49157", "Adjustment"], ["C807", "Ribavirin"], ["C54216", "Interaction"], ["C25594", "Negation"], ["C41130", "Significant"], ["C54216", "Interaction"], ["C85549", "Unlikely"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C94394", "Cumulative Dose"], ["C49157", "Adjustment"], ["C909", "Trimethoprim-Sulfamethoxazole"], ["C909", "Trimethoprim-Sulfamethoxazole"], ["C1471", "Lamivudine"], ["C16818", "Mammography"], ["C17228", "Uganda"], ["C16818", "Mammography"], ["C125004", "Once Daily"], ["C64956", "For"], ["C163771", "Illness Intrusiveness Rating 5"], ["C25301", "Day"], ["C16645", "Greece"], ["C16818", "Mammography"], ["C48440", "Single"], ["C25488", "Dose"], ["C1471", "Lamivudine"], ["C64774", "Area Under Curve"], ["C186752", "Human Papillomavirus-43"], ["C70918", "Cmax"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C908", "Trimethoprim"], ["C64774", "Area Under Curve"], ["C47737", "Sulfamethoxazole"], ["C64774", "Area Under Curve"], ["C21204", "Organic Cation Transporter"], ["C42791", "Inhibition"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C94394", "Cumulative Dose"], ["C49157", "Adjustment"], ["C811", "Rifampin"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C186754", "Human Papillomavirus-54"], ["C70918", "Cmax"], ["C186752", "Human Papillomavirus-43"], ["C67900", "Centi"], ["C188334", "Seventy Two"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C64496", "Twice Daily"], ["C65140", "When"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C811", "Rifampin"], ["C71344", "Associate of Science"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C192102", "Fixed Dose"], ["C154605", "Tablet Dosage Form Category"], ["C75889", "PAX6 wt Allele"], ["C25406", "Additional"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C154605", "Tablet Dosage Form Category"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C69122", "Ten"], ["C158876", "Induction Therapy"], ["C52874", "SPI1 wt Allele"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C16289", "Andorra"], ["C107557", "CYP3A Gene Locus"], ["C16554", "Enzyme"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C45828", "Approximate"], ["C113426", "Twelve"], ["C25529", "Hour"], ["C38008", "Post"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C64956", "For"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C811", "Rifampin"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C76246", "Blood Group A"], ["C63803", "Separate"], ["C15653", "Drug Formulation Process"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25429", "Availability"], ["C64956", "For"], ["C82495", "Dose Adjustment"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C1408", "Rifabutin"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C163771", "Illness Intrusiveness Rating 5"], ["C70918", "Cmax"], ["C113430", "Sixteen"], ["C67900", "Centi"], ["C70541", "Lansky Performance Status 30"], ["C158876", "Induction Therapy"], ["C52874", "SPI1 wt Allele"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C16289", "Andorra"], ["C107557", "CYP3A Gene Locus"], ["C16554", "Enzyme"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C264", "Anticonvulsant Agent"], ["C341", "Carbamazepine"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C105796", "Forty Nine"], ["C70918", "Cmax"], ["C102996", "Human Papillomavirus-33"], ["C67900", "Centi"], ["C188335", "Seventy Three"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C64496", "Twice Daily"], ["C65140", "When"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C28240", "Metabolic"], ["C71344", "Associate of Science"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C192102", "Fixed Dose"], ["C154605", "Tablet Dosage Form Category"], ["C75889", "PAX6 wt Allele"], ["C25406", "Additional"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C154605", "Tablet Dosage Form Category"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C45828", "Approximate"], ["C113426", "Twelve"], ["C25529", "Hour"], ["C38008", "Post"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C64956", "For"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C62355", "With"], ["C28240", "Metabolic"], ["C76246", "Blood Group A"], ["C63803", "Separate"], ["C15653", "Drug Formulation Process"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25429", "Availability"], ["C64956", "For"], ["C82495", "Dose Adjustment"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C75368", "Phenobarbital Measurement"], ["C121543", "Dolutegravir"], ["C741", "Phenytoin"], ["C121543", "Dolutegravir"], ["C47643", "Oxcarbazepine"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C25594", "Negation"], ["C25640", "Reduced"], ["C41333", "Expected Adverse Event"], ["C89272", "Due To"], ["C158876", "Induction Therapy"], ["C52874", "SPI1 wt Allele"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C16289", "Andorra"], ["C107557", "CYP3A Gene Locus"], ["C16554", "Enzyme"], ["C76246", "Blood Group A"], ["C72665", "Similarity"], ["C25640", "Reduced"], ["C16727", "India"], ["C49587", "Exposure Domain"], ["C71344", "Associate of Science"], ["C25599", "Observed"], ["C62355", "With"], ["C341", "Carbamazepine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C41333", "Expected Adverse Event"], ["C41020", "Histamine H2 Receptor"], ["C66506", "Ranitidine Hydrochloride"], ["C54216", "Interaction"], ["C25594", "Negation"], ["C41130", "Significant"], ["C54216", "Interaction"], ["C85549", "Unlikely"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C94394", "Cumulative Dose"], ["C49157", "Adjustment"], ["C374", "Cimetidine"], ["C54216", "Interaction"], ["C25594", "Negation"], ["C41130", "Significant"], ["C54216", "Interaction"], ["C85549", "Unlikely"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C94394", "Cumulative Dose"], ["C49157", "Adjustment"], ["C1336", "Cladribine"], ["C1471", "Lamivudine"], ["C54216", "Interaction"], ["C25594", "Negation"], ["C15263", "In Vitro"], ["C1471", "Lamivudine"], ["C28217", "Intracellular"], ["C18496", "Protein Phosphorylation Process"], ["C52874", "SPI1 wt Allele"], ["C1336", "Cladribine"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C62230", "Potential"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C1336", "Cladribine"], ["C25559", "Loss"], ["C52874", "SPI1 wt Allele"], ["C88183", "Efficacy"], ["C16727", "India"], ["C49152", "Case"], ["C52874", "SPI1 wt Allele"], ["C61517", "Combination"], ["C16727", "India"], ["C123619", "Clinical Response"], ["C127262", "CDISC SDTM Environmental Setting Terminology"], ["C65099", "Some"], ["C123619", "Clinical Response"], ["C103373", "CDISC Findings Class"], ["C37902", "Support"], ["C76246", "Blood Group A"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C54216", "Interaction"], ["C94545", "Between"], ["C1471", "Lamivudine"], ["C16289", "Andorra"], ["C1336", "Cladribine"], ["C25730", "Concomitant"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C62355", "With"], ["C1336", "Cladribine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C69023", "Miscellaneous"], ["C29462", "Sorbitol"], ["C113425", "Eleven"], ["C29462", "Sorbitol"], ["C42986", "Solution Dosage Form"], ["C161436", "CDISC SDTM Implementation Guide Version 3.2"], ["C68915", "Gauss"], ["C69122", "Ten"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C68915", "Gauss"], ["C113427", "Thirteen"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C68915", "Gauss"], ["C1471", "Lamivudine"], ["C48440", "Single"], ["C25488", "Dose"], ["C1471", "Lamivudine"], ["C68996", "Oral Solution Dosage Form"], ["C16645", "Greece"], ["C16818", "Mammography"], ["C1471", "Lamivudine"], ["C64774", "Area Under Curve"], ["C113428", "Fourteen"], ["C175622", "Thirty Two"], ["C175626", "Thirty Six"], ["C70918", "Cmax"], ["C126888", "Twenty Eight"], ["C188320", "Fifty Two"], ["C188322", "Fifty Five"], ["C65140", "When"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C4981", "Chronic Graft Versus Host Disease"], ["C52874", "SPI1 wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C62355", "With"], ["C79873", "Contain"], ["C29462", "Sorbitol"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C61379", "Osmosis"], ["C180989", "Polysexuality"], ["C218", "Alcohol [Chemical Class]"], ["C43508", "Oregon"], ["C68471", "Monosaccharide"], ["C218", "Alcohol [Chemical Class]"], ["C16530", "Egypt"], ["C76517", "Xylitol"], ["C625", "Mannitol"], ["C81025", "Lactitol"], ["C77138", "Maltitol"], ["C128667", "More"], ["C64649", "Frequently"], ["C61256", "Monitoring"], ["C52874", "SPI1 wt Allele"], ["C14220", "Human Immunodeficiency Virus 1"], ["C27985", "Viral"], ["C71584", "Load"], ["C65140", "When"], ["C4981", "Chronic Graft Versus Host Disease"], ["C16329", "Belgium"], ["C17008", "Potassium Channel"], ["C76777", "Dalfampridine"], ["C80137", "Known"], ["C71344", "Associate of Science"], ["C76777", "Dalfampridine"], ["C121543", "Dolutegravir"], ["C76777", "Dalfampridine"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C101282", "Have"], ["C62230", "Potential"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16390", "Etiology"], ["C191619", "Seizure Related to COVID-19"], ["C89272", "Due To"], ["C164135", "Increased"], ["C76777", "Dalfampridine"], ["C13356", "Plasma"], ["C105891", "Able to Concentrate"], ["C113553", "SEMA6A wt Allele"], ["C42791", "Inhibition"], ["C52874", "SPI1 wt Allele"], ["C53112", "POU2F2 wt Allele"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C101282", "Have"], ["C25594", "Negation"], ["C76777", "Dalfampridine"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C62355", "With"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C37933", "Contraindicated"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C29633", "Antacid Preparation"], ["C16289", "Andorra"], ["C1505", "Dietary Supplement"], ["C29239", "Magnesium"], ["C79873", "Contain"], ["C29633", "Antacid Preparation"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C186780", "Human Papillomavirus-74"], ["C70918", "Cmax"], ["C188334", "Seventy Two"], ["C19398", "Complex"], ["C18219", "Molecular Interaction Process"], ["C159124", "GDC Treatment Outcome Terminology"], ["C597", "Ion"], ["C29239", "Magnesium"], ["C79873", "Contain"], ["C29633", "Antacid Preparation"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C128793", "Microplate Well"], ["C51777", "Legally Separated"], ["C16727", "India"], ["C25330", "Duration"], ["C25516", "From"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C25570", "Minimum"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25529", "Hour"], ["C38008", "Post"], ["C43508", "Oregon"], ["C172979", "Fear Score 6"], ["C25529", "Hour"], ["C201357", "Before Timing Type"], ["C64488", "Calcium Measurement"], ["C1505", "Dietary Supplement"], ["C121543", "Dolutegravir"], ["C25538", "Intake"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C105798", "Thirty Nine"], ["C70918", "Cmax"], ["C175627", "Thirty Seven"], ["C105798", "Thirty Nine"], ["C19398", "Complex"], ["C18219", "Molecular Interaction Process"], ["C159124", "GDC Treatment Outcome Terminology"], ["C597", "Ion"], ["C65140", "When"], ["C25701", "Taken"], ["C67010", "With Food"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C16289", "Andorra"], ["C1505", "Dietary Supplement"], ["C43508", "Oregon"], ["C79873", "Contain"], ["C64488", "Calcium Measurement"], ["C68256", "Dietary Iron"], ["C43508", "Oregon"], ["C29239", "Magnesium"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C158997", "GDC Analyte Type Terminology"], ["C172515", "S-Adenosylmethionine Measurement"], ["C25330", "Duration"], ["C198613", "CFI wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25701", "Taken"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C133313", "State Ownership"], ["C1505", "Dietary Supplement"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C76246", "Blood Group A"], ["C25570", "Minimum"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25529", "Hour"], ["C38008", "Post"], ["C43508", "Oregon"], ["C172979", "Fear Score 6"], ["C25529", "Hour"], ["C201357", "Before Timing Type"], ["C25538", "Intake"], ["C52874", "SPI1 wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C16727", "India"], ["C121543", "Dolutegravir"], ["C49587", "Exposure Domain"], ["C25599", "Observed"], ["C62355", "With"], ["C25538", "Intake"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C16289", "Andorra"], ["C1505", "Dietary Supplement"], ["C25490", "During"], ["C25457", "Condition"], ["C16727", "India"], ["C133313", "State Ownership"], ["C16727", "India"], ["C49587", "Exposure Domain"], ["C53286", "Next"], ["C25538", "Intake"], ["C63802", "Together"], ["C62355", "With"], ["C64488", "Calcium Measurement"], ["C43508", "Oregon"], ["C68256", "Dietary Iron"], ["C1505", "Dietary Supplement"], ["C42629", "Modified By"], ["C62695", "Food"], ["C71600", "Effect, Appearance"], ["C16727", "India"], ["C75889", "PAX6 wt Allele"], ["C49587", "Exposure Domain"], ["C72665", "Similarity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C52349", "Obtain"], ["C62355", "With"], ["C121543", "Dolutegravir"], ["C25382", "Administered"], ["C16727", "India"], ["C133313", "State Ownership"], ["C68256", "Dietary Iron"], ["C1505", "Dietary Supplement"], ["C121543", "Dolutegravir"], ["C25538", "Intake"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C186754", "Human Papillomavirus-54"], ["C70918", "Cmax"], ["C175681", "Fifty Seven"], ["C188323", "Fifty Six"], ["C19398", "Complex"], ["C18219", "Molecular Interaction Process"], ["C159124", "GDC Treatment Outcome Terminology"], ["C597", "Ion"], ["C79873", "Contain"], ["C64488", "Calcium Measurement"], ["C68256", "Dietary Iron"], ["C16289", "Andorra"], ["C29239", "Magnesium"], ["C121543", "Dolutegravir"], ["C25538", "Intake"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C102996", "Human Papillomavirus-33"], ["C70918", "Cmax"], ["C102997", "Human Papillomavirus-35"], ["C175622", "Thirty Two"], ["C19398", "Complex"], ["C18219", "Molecular Interaction Process"], ["C159124", "GDC Treatment Outcome Terminology"], ["C597", "Ion"], ["C29723", "Proton Pump Inhibitor"], ["C74598", "Omeprazole Sodium"], ["C121543", "Dolutegravir"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C94394", "Cumulative Dose"], ["C49157", "Adjustment"], ["C211", "Therapeutic Corticosteroid"], ["C770", "Prednisone"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C113425", "Eleven"], ["C70918", "Cmax"], ["C172979", "Fear Score 6"], ["C67900", "Centi"], ["C113431", "Seventeen"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C61612", "Metformin"], ["C121543", "Dolutegravir"], ["C61612", "Metformin"], ["C121543", "Dolutegravir"], ["C76246", "Blood Group A"], ["C82495", "Dose Adjustment"], ["C52874", "SPI1 wt Allele"], ["C61612", "Metformin"], ["C16329", "Belgium"], ["C65140", "When"], ["C16289", "Andorra"], ["C52874", "SPI1 wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C113426", "Twelve"], ["C65140", "When"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C121543", "Dolutegravir"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C25473", "Daily"], ["C61612", "Metformin"], ["C64774", "Area Under Curve"], ["C105791", "Seventy Nine"], ["C70918", "Cmax"], ["C188330", "Sixty Six"], ["C65140", "When"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C121543", "Dolutegravir"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C20419", "BID Gene"], ["C61612", "Metformin"], ["C64774", "Area Under Curve"], ["C48570", "Percent Unit"], ["C70918", "Cmax"], ["C62355", "With"], ["C61612", "Metformin"], ["C159124", "GDC Treatment Outcome Terminology"], ["C53297", "Maintenance"], ["C64355", "Scientific Control"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C25225", "Renal"], ["C21055", "Impairment"], ["C76246", "Blood Group A"], ["C82495", "Dose Adjustment"], ["C52874", "SPI1 wt Allele"], ["C61612", "Metformin"], ["C16329", "Belgium"], ["C65140", "When"], ["C62355", "With"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C52874", "SPI1 wt Allele"], ["C164135", "Increased"], ["C17102", "Risk"], ["C64956", "For"], ["C98969", "Lactic Acidosis"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C114592", "Renal Impairment"], ["C89272", "Due To"], ["C164135", "Increased"], ["C61612", "Metformin"], ["C105891", "Able to Concentrate"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C94319", "Herbal"], ["C159109", "GDC Sample Type Terminology"], ["C42555", "Siemens"], ["C121543", "Dolutegravir"], ["C121543", "Dolutegravir"], ["C25594", "Negation"], ["C25640", "Reduced"], ["C41333", "Expected Adverse Event"], ["C89272", "Due To"], ["C158876", "Induction Therapy"], ["C52874", "SPI1 wt Allele"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C16289", "Andorra"], ["C107557", "CYP3A Gene Locus"], ["C16554", "Enzyme"], ["C76246", "Blood Group A"], ["C72665", "Similarity"], ["C25640", "Reduced"], ["C16727", "India"], ["C49587", "Exposure Domain"], ["C71344", "Associate of Science"], ["C25599", "Observed"], ["C62355", "With"], ["C341", "Carbamazepine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C41333", "Expected Adverse Event"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C64496", "Twice Daily"], ["C65140", "When"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C159109", "GDC Sample Type Terminology"], ["C42555", "Siemens"], ["C71344", "Associate of Science"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C192102", "Fixed Dose"], ["C154605", "Tablet Dosage Form Category"], ["C75889", "PAX6 wt Allele"], ["C25406", "Additional"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C154605", "Tablet Dosage Form Category"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C45828", "Approximate"], ["C113426", "Twelve"], ["C25529", "Hour"], ["C38008", "Post"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C64956", "For"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C159109", "GDC Sample Type Terminology"], ["C42555", "Siemens"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C76246", "Blood Group A"], ["C63803", "Separate"], ["C15653", "Drug Formulation Process"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25429", "Availability"], ["C64956", "For"], ["C82495", "Dose Adjustment"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C389", "Oral Contraceptive"], ["C486", "Ethinyl Estradiol"], ["C16562", "Estonia"], ["C16289", "Andorra"], ["C121543", "Dolutegravir"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C16562", "Estonia"], ["C64774", "Area Under Curve"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C70918", "Cmax"], ["C105723", "ECOG Performance Status 1"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C64774", "Area Under Curve"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C70918", "Cmax"], ["C113425", "Eleven"], ["C121543", "Dolutegravir"], ["C101282", "Have"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C49662", "Pharmacodynamic Study"], ["C71600", "Effect, Appearance"], ["C92667", "SPARC wt Allele"], ["C190789", "Luteinizing Hormone"], ["C158181", "Lahu Chinese"], ["C2286", "Follicle Stimulating Hormone"], ["C2286", "Follicle Stimulating Hormone"], ["C16289", "Andorra"], ["C74791", "Progesterone Measurement"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C52874", "SPI1 wt Allele"], ["C389", "Oral Contraceptive"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C65140", "When"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C17005", "Population Group"], ["C54216", "Interaction"], ["C101282", "Have"], ["C48440", "Single"], ["C38000", "Performed"], ["C16727", "India"]], "rxnorm.pregnancy": [["2122521", "Dovato"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["68244", "lamivudine"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["68244", "lamivudine"], ["1433868", "dolutegravir"], ["68244", "lamivudine"], ["1433868", "dolutegravir"], ["11017", "uridine"], ["1433868", "dolutegravir"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["68244", "lamivudine"], ["68244", "lamivudine"], ["10829", "trimethoprim"], ["68244", "lamivudine"], ["1433868", "dolutegravir"], ["68244", "lamivudine"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["68244", "lamivudine"], ["68244", "lamivudine"], ["68244", "lamivudine"], ["68244", "lamivudine"], ["68244", "lamivudine"], ["1433868", "dolutegravir"], ["68244", "lamivudine"], ["1433868", "dolutegravir"], ["6960", "midazolam"], ["1433868", "dolutegravir"], ["T126", "Enzyme"], ["1433868", "dolutegravir"], ["2913", "creatinine"], ["1433868", "dolutegravir"], ["897018", "dalfampridine"], ["897018", "dalfampridine"], ["6809", "metformin"], ["1433868", "dolutegravir"], ["117466", "tenofovir"], ["1433868", "dolutegravir"], ["68244", "lamivudine"], ["1433868", "dolutegravir"], ["68244", "lamivudine"], ["475969", "etravirine"], ["8031", "protease"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["475969", "etravirine"], ["475969", "etravirine"], ["8031", "protease"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["475969", "etravirine"], ["8031", "protease"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["2122521", "Dovato"], ["475969", "etravirine"], ["8031", "protease"], ["1433868", "dolutegravir"], ["195088", "lopinavir"], ["85762", "ritonavir"], ["475969", "etravirine"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["195088", "lopinavir"], ["85762", "ritonavir"], ["475969", "etravirine"], ["460132", "darunavir"], ["85762", "ritonavir"], ["475969", "etravirine"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["460132", "darunavir"], ["85762", "ritonavir"], ["475969", "etravirine"], ["195085", "efavirenz"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["195085", "efavirenz"], ["1433868", "dolutegravir"], ["195085", "efavirenz"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["2122521", "Dovato"], ["195085", "efavirenz"], ["1433868", "dolutegravir"], ["53654", "nevirapine"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["195085", "efavirenz"], ["1433868", "dolutegravir"], ["53654", "nevirapine"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["2122521", "Dovato"], ["53654", "nevirapine"], ["1433868", "dolutegravir"], ["1102270", "rilpivirine"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["1102270", "rilpivirine"], ["300195", "tenofovir disoproxil"], ["276237", "emtricitabine"], ["3364", "didanosine"], ["59763", "stavudine"], ["117466", "tenofovir"], ["11413", "zidovudine"], ["1433868", "dolutegravir"], ["117466", "tenofovir"], ["2122521", "Dovato"], ["117466", "tenofovir"], ["3364", "didanosine"], ["59763", "stavudine"], ["11413", "zidovudine"], ["2122521", "Dovato"], ["276237", "emtricitabine"], ["68244", "lamivudine"], ["2122521", "Dovato"], ["276237", "emtricitabine"], ["8031", "protease"], ["343047", "atazanavir"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["343047", "atazanavir"], ["343047", "atazanavir"], ["85762", "ritonavir"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["343047", "atazanavir"], ["85762", "ritonavir"], ["190548", "tipranavir"], ["85762", "ritonavir"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["190548", "tipranavir"], ["85762", "ritonavir"], ["1433868", "dolutegravir"], ["190548", "tipranavir"], ["85762", "ritonavir"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["2122521", "Dovato"], ["190548", "tipranavir"], ["85762", "ritonavir"], ["1433868", "dolutegravir"], ["358262", "fosamprenavir"], ["85762", "ritonavir"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["358262", "fosamprenavir"], ["358262", "fosamprenavir"], ["85762", "ritonavir"], ["1433868", "dolutegravir"], ["85762", "ritonavir"], ["195088", "lopinavir"], ["85762", "ritonavir"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["195088", "lopinavir"], ["85762", "ritonavir"], ["460132", "darunavir"], ["85762", "ritonavir"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["460132", "darunavir"], ["85762", "ritonavir"], ["1606218", "daclatasvir"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["1606218", "daclatasvir"], ["1606218", "daclatasvir"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["1606218", "daclatasvir"], ["1591922", "ledipasvir"], ["1484911", "sofosbuvir"], ["68244", "lamivudine"], ["190521", "abacavir"], ["68244", "lamivudine"], ["1591922", "ledipasvir"], ["1484911", "sofosbuvir"], ["1484911", "sofosbuvir"], ["1799206", "velpatasvir"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["1484911", "sofosbuvir"], ["1799206", "velpatasvir"], ["9344", "ribavirin"], ["10829", "trimethoprim"], ["10180", "sulfamethoxazole"], ["68244", "lamivudine"], ["68244", "lamivudine"], ["10829", "trimethoprim"], ["10180", "sulfamethoxazole"], ["9384", "rifampin"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["9384", "rifampin"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["2122521", "Dovato"], ["9384", "rifampin"], ["1433868", "dolutegravir"], ["55672", "rifabutin"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["2002", "carbamazepine"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["8134", "phenobarbital"], ["1433868", "dolutegravir"], ["8183", "phenytoin"], ["1433868", "dolutegravir"], ["32624", "oxcarbazepine"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["2002", "carbamazepine"], ["5333", "histamine"], ["T192", "Receptor"], ["9143", "ranitidine"], ["2541", "cimetidine"], ["44157", "cladribine"], ["68244", "lamivudine"], ["68244", "lamivudine"], ["44157", "cladribine"], ["44157", "cladribine"], ["68244", "lamivudine"], ["44157", "cladribine"], ["2122521", "Dovato"], ["44157", "cladribine"], ["9945", "sorbitol"], ["9945", "sorbitol"], ["68244", "lamivudine"], ["68244", "lamivudine"], ["316968", "Oral Solution"], ["68244", "lamivudine"], ["2122521", "Dovato"], ["9945", "sorbitol"], ["11377", "xylitol"], ["6628", "mannitol"], ["28395", "lactitol"], ["1363049", "maltitol"], ["8588", "potassium"], ["897018", "dalfampridine"], ["897018", "dalfampridine"], ["1433868", "dolutegravir"], ["897018", "dalfampridine"], ["1433868", "dolutegravir"], ["897018", "dalfampridine"], ["897018", "dalfampridine"], ["2122521", "Dovato"], ["6574", "magnesium"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["6574", "magnesium"], ["2122521", "Dovato"], ["1895", "calcium"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["T168", "Food"], ["2122521", "Dovato"], ["1895", "calcium"], ["90176", "iron"], ["6574", "magnesium"], ["2122521", "Dovato"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["1895", "calcium"], ["90176", "iron"], ["T168", "Food"], ["1433868", "dolutegravir"], ["90176", "iron"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["1895", "calcium"], ["90176", "iron"], ["6574", "magnesium"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["7646", "omeprazole"], ["1433868", "dolutegravir"], ["8640", "prednisone"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["6809", "metformin"], ["1433868", "dolutegravir"], ["6809", "metformin"], ["1433868", "dolutegravir"], ["6809", "metformin"], ["2122521", "Dovato"], ["1433869", "dolutegravir 50 MG"], ["6809", "metformin"], ["1433869", "dolutegravir 50 MG"], ["6809", "metformin"], ["6809", "metformin"], ["6809", "metformin"], ["2122521", "Dovato"], ["6809", "metformin"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["2002", "carbamazepine"], ["1433868", "dolutegravir"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["4124", "ethinyl estradiol"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["6383", "luteinizing hormone"], ["227518", "follicle stimulating hormone"], ["8727", "progesterone"], ["2122521", "Dovato"]], "loinc.pregnancy": [["LA32-8", "No"], ["LA18848-4", "Drug interaction"], ["LP157327-0", "Dolutegravir"], ["MTHU060537", "lamiVUDine"], ["LP40035-5", "Identified"], ["LA32-8", "No"], ["LA28474-7", "Significant"], ["LA18200-8", "Drug"], ["LP157327-0", "Dolutegravir"], ["MTHU060537", "lamiVUDine"], ["MTHU029809", "Other"], ["LP157327-0", "Dolutegravir"], ["MTHU060537", "lamiVUDine"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["LP99932-3", "Uridine"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LP15232-9", "P"], ["LP15232-9", "P"], ["LA14283-8", "Breast cancer"], ["LP6857-9", "Resistance"], ["LP15838-3", "Protein"], ["LA21996-6", "CO"], ["MTHU029809", "Other"], ["LA22025-3", "OR"], ["LP15232-9", "P"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["LP157327-0", "Dolutegravir"], ["LP7479-1", "Plasma"], ["LP6194-7", "Concentration"], ["LP31392-1", "Enzymes (see also Inborn errors metabolism lysosomal)"], ["LA22025-3", "OR"], ["LA14161-6", "May"], ["LA32049-1", "Decrease"], ["LP157327-0", "Dolutegravir"], ["LP7479-1", "Plasma"], ["LP6194-7", "Concentration"], ["LP263807-2", "Therapeutic"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["LA32619-1", "Reduced"], ["LA6112-2", "1"], ["MTHU060537", "lamiVUDine"], ["LP200075-2", "IS"], ["LA16666-2", "Active"], ["MTHU065909", "Renal"], ["MTHU060537", "lamiVUDine"], ["LA22004-8", "IN"], ["LP7681-2", "Urine"], ["LP200075-2", "IS"], ["LP71001-9", "OCT2"], ["LP14926-7", "K"], ["MTHU002305", "Trimethoprim"], ["LA32048-3", "Increase"], ["MTHU060537", "lamiVUDine"], ["LP7479-1", "Plasma"], ["LA32048-3", "Increase"], ["LA21291-2", "Not"], ["LA28474-7", "Significant"], ["LA6112-2", "1"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["LP71001-9", "OCT2"], ["MTHU060537", "lamiVUDine"], ["LA22025-3", "OR"], ["LA21996-6", "CO"], ["LP157327-0", "Dolutegravir"], ["LP17763-1", "A"], ["LP74341-6", "Study"], ["LP157327-0", "Dolutegravir"], ["LA32-8", "No"], ["MTHU060537", "lamiVUDine"], ["LA22004-8", "IN"], ["MTHU060537", "lamiVUDine"], ["LP200075-2", "IS"], ["LP209065-4", "Uptake"], ["LP17763-1", "A"], ["LA29633-7", "Minor"], ["MTHU047628", "Role"], ["LA22004-8", "IN"], ["LP267658-5", "Clearance"], ["MTHU060537", "lamiVUDine"], ["LA18200-8", "Drug"], ["LA15588-9", "Unlikely"], ["LP7787-7", "Clinical"], ["MTHU060537", "lamiVUDine"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LP15232-9", "P"], ["LA22004-8", "IN"], ["LP29256-2", "given"], ["LA9193-9", "High"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA15588-9", "Unlikely"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["MTHU060537", "lamiVUDine"], ["LP157327-0", "Dolutegravir"], ["MTHU060537", "lamiVUDine"], ["MTHU029809", "Other"], ["LA22004-8", "IN"], ["LP157327-0", "Dolutegravir"], ["LA21291-2", "Not"], ["LP16207-0", "Midazolam"], ["LP17763-1", "A"], ["LP6459-4", "Probe"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA29634-5", "Major"], ["LA31429-6", "Enzyme"], ["LA22025-3", "OR"], ["LP15232-9", "P"], ["LA16824-7", "More"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA22004-8", "IN"], ["LP157327-0", "Dolutegravir"], ["MTHU065909", "Renal"], ["LP71001-9", "OCT2"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA14574-0", "10-14"], ["LA32049-1", "Decrease"], ["LP29651-4", "Creatinine clearance"], ["LP200075-2", "IS"], ["LA12304-4", "Dependent"], ["LP71001-9", "OCT2"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LP157327-0", "Dolutegravir"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["LP7479-1", "Plasma"], ["LA22004-8", "IN"], ["LP200075-2", "IS"], ["LA12304-4", "Dependent"], ["LP71001-9", "OCT2"], ["LA22025-3", "OR"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["MTHU060554", "metFORMIN"], ["LA6112-2", "1"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LA22004-8", "IN"], ["LP157327-0", "Dolutegravir"], ["MTHU065909", "Renal"], ["LP209065-4", "Uptake"], ["LA6112-2", "1"], ["LA22004-8", "IN"], ["MTHU015506", "Tenofovir"], ["LA22004-8", "IN"], ["LP200075-2", "IS"], ["LA15588-9", "Unlikely"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP157327-0", "Dolutegravir"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["LP7479-1", "Plasma"], ["LA22004-8", "IN"], ["LP200075-2", "IS"], ["LA12304-4", "Dependent"], ["LA22004-8", "IN"], ["MTHU060537", "lamiVUDine"], ["LP71001-9", "OCT2"], ["LP7787-7", "Clinical"], ["LA14748-0", "Not known"], ["LA22004-8", "IN"], ["LA6112-2", "1"], ["LP157327-0", "Dolutegravir"], ["MTHU060537", "lamiVUDine"], ["LA21996-6", "CO"], ["LA22004-8", "IN"], ["LA6112-2", "1"], ["LA32048-3", "Increase"], ["LP200075-2", "IS"], ["LA32049-1", "Decrease"], ["LA64-1", "No change"], ["LP6782-9", "Area"], ["LP6194-7", "Concentration"], ["LP73517-2", "Time"], ["LP6972-6", "maximum"], ["LP6425-5", "Observed"], ["LP6194-7", "Concentration"], ["LP6194-7", "Concentration"], ["LA21988-3", "AT"], ["LP190655-3", "end"], ["LP17128-7", "C"], ["LA21291-2", "Not"], ["LP200075-2", "IS"], ["LA12065-1", "Classes"], ["LA6112-2", "1"], ["LA18200-8", "Drug"], ["LP263807-2", "Therapeutic"], ["LP6971-8", "mean"], ["LP249806-3", "Change"], ["LA21996-6", "CO"], ["LP68431-3", "Etravirine"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LP17128-7", "C"], ["LP68431-3", "Etravirine"], ["LP31392-1", "Enzymes (see also Inborn errors metabolism lysosomal)"], ["LP68431-3", "Etravirine"], ["LA24378-4", "Decreased"], ["LP7479-1", "Plasma"], ["LP157327-0", "Dolutegravir"], ["LP6194-7", "Concentration"], ["MTHU065481", "Dose"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LA14664-9", "Twice"], ["LA14435-4", "Daily"], ["LP68431-3", "Etravirine"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP136501-6", "Tablet"], ["LP263791-8", "Additional"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["LP157327-0", "Dolutegravir"], ["LP6908-0", "12 hours"], ["LP14744-4", "Duration"], ["LP68431-3", "Etravirine"], ["LA21996-6", "CO"], ["LP17763-1", "A"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["MTHU065481", "Dose"], ["LP20592-9", "4"], ["MTHU000002", "Clinical Class"], ["LP28548-3", "Lopinavir+Ritonavir"], ["LP68431-3", "Etravirine"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LA14557-5", "11"], ["LP36790-1", "7"], ["LP17128-7", "C"], ["MTHU014678", "Lopinavir"], ["MTHU013855", "Ritonavir"], ["LP68431-3", "Etravirine"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["MTHU026279", "Darunavir+Ritonavir"], ["LP68431-3", "Etravirine"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LA19281-7", "25"], ["LA14558-3", "12"], ["LP17128-7", "C"], ["MTHU026540", "Darunavir"], ["MTHU013855", "Ritonavir"], ["LP68431-3", "Etravirine"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP21310-5", "Efavirenz"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LP17128-7", "C"], ["LP21310-5", "Efavirenz"], ["LP31392-1", "Enzymes (see also Inborn errors metabolism lysosomal)"], ["MTHU065481", "Dose"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LA14664-9", "Twice"], ["LA14435-4", "Daily"], ["LA21996-6", "CO"], ["LP21310-5", "Efavirenz"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP136501-6", "Tablet"], ["LP263791-8", "Additional"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["LP157327-0", "Dolutegravir"], ["LP6908-0", "12 hours"], ["LP14744-4", "Duration"], ["LP21310-5", "Efavirenz"], ["LA21996-6", "CO"], ["LP17763-1", "A"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["MTHU065481", "Dose"], ["LP20592-9", "4"], ["MTHU000002", "Clinical Class"], ["MTHU013861", "Nevirapine"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LA21291-2", "Not"], ["LP17763-1", "A"], ["LP267357-4", "Reduction"], ["LA22004-8", "IN"], ["LP6425-5", "Observed"], ["LP21310-5", "Efavirenz"], ["LP200075-2", "IS"], ["MTHU065481", "Dose"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LA14664-9", "Twice"], ["LA14435-4", "Daily"], ["LA21996-6", "CO"], ["MTHU013861", "Nevirapine"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP136501-6", "Tablet"], ["LP263791-8", "Additional"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["LP157327-0", "Dolutegravir"], ["LP6908-0", "12 hours"], ["LP14744-4", "Duration"], ["MTHU013861", "Nevirapine"], ["LA21996-6", "CO"], ["LP17763-1", "A"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["MTHU065481", "Dose"], ["LP20592-9", "4"], ["MTHU000002", "Clinical Class"], ["LP135443-2", "Rilpivirine"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LA14558-3", "12"], ["LA14559-1", "13"], ["LP17128-7", "C"], ["LP135443-2", "Rilpivirine"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["MTHU015506", "Tenofovir"], ["MTHU018643", "Emtricitabine"], ["LP21309-7", "Didanosine"], ["MTHU013858", "Stavudine"], ["MTHU015506", "Tenofovir"], ["LP16744-2", "Zidovudine"], ["LP157327-0", "Dolutegravir"], ["LA6112-2", "1"], ["LP20591-1", "3"], ["LP17128-7", "C"], ["LP36791-9", "8"], ["MTHU015506", "Tenofovir"], ["LA21291-2", "Not"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP200075-2", "IS"], ["LA30596-3", "Combined"], ["MTHU015506", "Tenofovir"], ["LP21309-7", "Didanosine"], ["MTHU013858", "Stavudine"], ["LA22025-3", "OR"], ["LP16744-2", "Zidovudine"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["MTHU018643", "Emtricitabine"], ["LA14331-5", "Both"], ["MTHU060537", "lamiVUDine"], ["LA22004-8", "IN"], ["MTHU018643", "Emtricitabine"], ["LP201693-1", "Cytidine"], ["LA15457-7", "I"], ["LA13503-0", "E"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP35785-2", "Atazanavir"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LA15248-0", "50%"], ["LP17128-7", "C"], ["LP35785-2", "Atazanavir"], ["LP31392-1", "Enzymes (see also Inborn errors metabolism lysosomal)"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP35785-2", "Atazanavir"], ["MTHU013855", "Ritonavir"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LA19315-3", "34"], ["LP17128-7", "C"], ["LP35785-2", "Atazanavir"], ["MTHU013855", "Ritonavir"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP64719-5", "Tipranavir+Ritonavir"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LP17128-7", "C"], ["LP36120-1", "Tipranavir"], ["MTHU013855", "Ritonavir"], ["LP31392-1", "Enzymes (see also Inborn errors metabolism lysosomal)"], ["MTHU065481", "Dose"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LA14664-9", "Twice"], ["LA14435-4", "Daily"], ["LA21996-6", "CO"], ["LP36120-1", "Tipranavir"], ["MTHU013855", "Ritonavir"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP136501-6", "Tablet"], ["LP263791-8", "Additional"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["LP157327-0", "Dolutegravir"], ["LP6908-0", "12 hours"], ["LP14744-4", "Duration"], ["LP36120-1", "Tipranavir"], ["MTHU013855", "Ritonavir"], ["LA21996-6", "CO"], ["LP17763-1", "A"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["MTHU065481", "Dose"], ["LP20592-9", "4"], ["MTHU000002", "Clinical Class"], ["MTHU027099", "Fosamprenavir+Ritonavir"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LP17128-7", "C"], ["LP36119-3", "Fosamprenavir"], ["LP36119-3", "Fosamprenavir"], ["MTHU013855", "Ritonavir"], ["LA14962-7", "Decreases"], ["LP157327-0", "Dolutegravir"], ["LA6484-5", "Limited"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA24378-4", "Decreased"], ["LA26687-6", "Efficacy"], ["LA22004-8", "IN"], ["LA15459-3", "III"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["MTHU013855", "Ritonavir"], ["LP31392-1", "Enzymes (see also Inborn errors metabolism lysosomal)"], ["LP28548-3", "Lopinavir+Ritonavir"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LP20592-9", "4"], ["LA15243-1", "0%"], ["LP20594-5", "6"], ["MTHU014678", "Lopinavir"], ["MTHU013855", "Ritonavir"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["MTHU026279", "Darunavir+Ritonavir"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LA14557-5", "11"], ["LP17128-7", "C"], ["MTHU026540", "Darunavir"], ["MTHU013855", "Ritonavir"], ["LP31392-1", "Enzymes (see also Inborn errors metabolism lysosomal)"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["MTHU029809", "Other"], ["LA16666-2", "Active"], ["MTHU054533", "Daclatasvir"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LA19316-1", "33"], ["LA19243-7", "29"], ["LP17128-7", "C"], ["MTHU054533", "Daclatasvir"], ["MTHU054533", "Daclatasvir"], ["LA31195-3", "Not change"], ["LP157327-0", "Dolutegravir"], ["LP7479-1", "Plasma"], ["LP6194-7", "Concentration"], ["LP17763-1", "A"], ["LP157327-0", "Dolutegravir"], ["LA21291-2", "Not"], ["LP249806-3", "Change"], ["MTHU054533", "Daclatasvir"], ["LP7479-1", "Plasma"], ["LP6194-7", "Concentration"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP220249-9", "Ledipasvir"], ["MTHU054459", "Sofosbuvir"], ["MTHU060537", "lamiVUDine"], ["MTHU013841", "Abacavir"], ["MTHU060537", "lamiVUDine"], ["LP220249-9", "Ledipasvir"], ["MTHU054459", "Sofosbuvir"], ["LA32-8", "No"], ["LP6801-7", "Dosage"], ["MTHU054459", "Sofosbuvir"], ["MTHU054608", "Velpatasvir"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["MTHU054459", "Sofosbuvir"], ["MTHU054608", "Velpatasvir"], ["LA32-8", "No"], ["LP6801-7", "Dosage"], ["MTHU018696", "Ribavirin"], ["LA21291-2", "Not"], ["LA28474-7", "Significant"], ["LA15588-9", "Unlikely"], ["LA32-8", "No"], ["LP6801-7", "Dosage"], ["MTHU002305", "Trimethoprim"], ["MTHU001572", "Sulfamethoxazole"], ["LA21996-6", "CO"], ["MTHU060537", "lamiVUDine"], ["LP15217-0", "Mg"], ["LA14011-3", "800"], ["LP15217-0", "Mg"], ["LA6305-2", "Once daily"], ["LP6942-9", "5 days"], ["LP15217-0", "Mg"], ["LA17717-2", "Single"], ["MTHU065481", "Dose"], ["MTHU060537", "lamiVUDine"], ["LP36790-1", "7"], ["MTHU002305", "Trimethoprim"], ["MTHU001572", "Sulfamethoxazole"], ["LA32-8", "No"], ["LP6801-7", "Dosage"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LP17128-7", "C"], ["MTHU065481", "Dose"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LA14664-9", "Twice"], ["LA14435-4", "Daily"], ["LA21996-6", "CO"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP136501-6", "Tablet"], ["LP263791-8", "Additional"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["LP157327-0", "Dolutegravir"], ["LA13942-0", "10"], ["LP31392-1", "Enzymes (see also Inborn errors metabolism lysosomal)"], ["LP6908-0", "12 hours"], ["LP14744-4", "Duration"], ["LA21996-6", "CO"], ["LP17763-1", "A"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["MTHU065481", "Dose"], ["LP20592-9", "4"], ["MTHU000002", "Clinical Class"], ["MTHU006676", "Rifabutin"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LP20593-7", "5"], ["LA14562-5", "16"], ["LP17128-7", "C"], ["LA15246-4", "30%"], ["LP31392-1", "Enzymes (see also Inborn errors metabolism lysosomal)"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["MTHU006781", "Anticonvulsants"], ["LP16061-1", "carBAMazepine"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LA19316-1", "33"], ["LP17128-7", "C"], ["MTHU065481", "Dose"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LA14664-9", "Twice"], ["LA14435-4", "Daily"], ["LA21996-6", "CO"], ["LP212101-2", "Metabolic"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP136501-6", "Tablet"], ["LP263791-8", "Additional"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["LP157327-0", "Dolutegravir"], ["LP6908-0", "12 hours"], ["LP14744-4", "Duration"], ["LA21996-6", "CO"], ["LP212101-2", "Metabolic"], ["LP17763-1", "A"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["MTHU065481", "Dose"], ["LP20592-9", "4"], ["MTHU000002", "Clinical Class"], ["MTHU060452", "PHENobarbital"], ["LP157327-0", "Dolutegravir"], ["LP14732-9", "Phenytoin"], ["LP157327-0", "Dolutegravir"], ["MTHU060529", "OXcarbazepine"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LA21291-2", "Not"], ["LA32049-1", "Decrease"], ["LP31392-1", "Enzymes (see also Inborn errors metabolism lysosomal)"], ["LP17763-1", "A"], ["LP267357-4", "Reduction"], ["LA22004-8", "IN"], ["LP6425-5", "Observed"], ["LP16061-1", "carBAMazepine"], ["LP200075-2", "IS"], ["MTHU003328", "Antihistamines"], ["LP15636-1", "Histamine"], ["LA13509-7", "H2"], ["T192", "Receptor"], ["LP17253-3", "raNITIdine"], ["LA21291-2", "Not"], ["LA28474-7", "Significant"], ["LA15588-9", "Unlikely"], ["LA32-8", "No"], ["LP6801-7", "Dosage"], ["LP16078-5", "Cimetidine"], ["LA21291-2", "Not"], ["LA28474-7", "Significant"], ["LA15588-9", "Unlikely"], ["LA32-8", "No"], ["LP6801-7", "Dosage"], ["MTHU060537", "lamiVUDine"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["MTHU060537", "lamiVUDine"], ["LP17763-1", "A"], ["LA26687-6", "Efficacy"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LA22004-8", "IN"], ["LP128240-1", "Clinical setting"], ["LA14973-4", "Some"], ["LP7787-7", "Clinical"], ["59776-5", "Procedure findings:Find:Pt:^Patient:Nar"], ["MTHU015279", "Support"], ["LP17763-1", "A"], ["LA15097-1", "Possible"], ["MTHU060537", "lamiVUDine"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["MTHU000097", "Miscellaneous"], ["LP62208-1", "Sorbitol"], ["LA14557-5", "11"], ["LP62208-1", "Sorbitol"], ["LP20591-1", "3"], ["MTHU000002", "Clinical Class"], ["LP14561-2", "G"], ["LA13942-0", "10"], ["MTHU000002", "Clinical Class"], ["LP14561-2", "G"], ["LA14559-1", "13"], ["LP20592-9", "4"], ["LP14561-2", "G"], ["MTHU060537", "lamiVUDine"], ["LA17717-2", "Single"], ["MTHU065481", "Dose"], ["MTHU060537", "lamiVUDine"], ["LA9367-9", "Oral"], ["LP15217-0", "Mg"], ["MTHU060537", "lamiVUDine"], ["LA14560-9", "14"], ["LA19317-9", "32"], ["LA15097-1", "Possible"], ["LA28752-6", "Chronic"], ["LP62208-1", "Sorbitol"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LA22025-3", "OR"], ["LP62192-7", "Xylitol"], ["LP15722-9", "Mannitol"], ["LA16824-7", "More"], ["LA20297-0", "Monitoring"], ["LP183501-8", "HIV"], ["LA6112-2", "1"], ["LA28752-6", "Chronic"], ["LP15098-4", "Potassium"], ["LP157327-0", "Dolutegravir"], ["LA21996-6", "CO"], ["LP157327-0", "Dolutegravir"], ["LA15899-0", "Seizures"], ["LA24377-6", "Increased"], ["LP7479-1", "Plasma"], ["LP6194-7", "Concentration"], ["LP71001-9", "OCT2"], ["LA21996-6", "CO"], ["LA21291-2", "Not"], ["LA21996-6", "CO"], ["LP200075-2", "IS"], ["LA4216-3", "Contraindicated"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["MTHU002163", "Magnesium"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LP6796-9", "Complex"], ["MTHU002163", "Magnesium"], ["LA18365-9", "Well"], ["LA4288-2", "Separated"], ["LA22004-8", "IN"], ["LP73517-2", "Time"], ["LP6970-0", "minimum"], ["LA11829-1", "2 hours"], ["LA22025-3", "OR"], ["LP6946-0", "6 hours"], ["LP32547-9", "Calcium"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LP6796-9", "Complex"], ["LP70420-2", "-"], ["MTHU065486", "Food"], ["LA22025-3", "OR"], ["LP32547-9", "Calcium"], ["MTHU004837", "Iron"], ["LA22025-3", "OR"], ["MTHU002163", "Magnesium"], ["LA21988-3", "AT"], ["LA11009-0", "Same"], ["LP73517-2", "Time"], ["LP70420-2", "-"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP135457-2", "State"], ["LP17763-1", "A"], ["LP6970-0", "minimum"], ["LA11829-1", "2 hours"], ["LA22025-3", "OR"], ["LP6946-0", "6 hours"], ["LP6530-2", "Stated"], ["LA22004-8", "IN"], ["LP157327-0", "Dolutegravir"], ["LP6425-5", "Observed"], ["LP157327-0", "Dolutegravir"], ["LA22004-8", "IN"], ["LP135457-2", "State"], ["LA22004-8", "IN"], ["LP32547-9", "Calcium"], ["LA22025-3", "OR"], ["MTHU004837", "Iron"], ["MTHU065486", "Food"], ["LA22004-8", "IN"], ["LP157327-0", "Dolutegravir"], ["LA22004-8", "IN"], ["LP135457-2", "State"], ["MTHU004837", "Iron"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LP6796-9", "Complex"], ["LP32547-9", "Calcium"], ["MTHU004837", "Iron"], ["MTHU002163", "Magnesium"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LA19316-1", "33"], ["LA19317-9", "32"], ["LP6796-9", "Complex"], ["LP18586-5", "Omeprazole"], ["LP157327-0", "Dolutegravir"], ["LA32-8", "No"], ["LP6801-7", "Dosage"], ["LP18109-6", "predniSONE"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LA14557-5", "11"], ["LP20594-5", "6"], ["LP17128-7", "C"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["MTHU060554", "metFORMIN"], ["LP157327-0", "Dolutegravir"], ["MTHU060554", "metFORMIN"], ["LP157327-0", "Dolutegravir"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["MTHU060554", "metFORMIN"], ["LA14558-3", "12"], ["LA21996-6", "CO"], ["LP157327-0", "Dolutegravir"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["MTHU060554", "metFORMIN"], ["LA21996-6", "CO"], ["LP157327-0", "Dolutegravir"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["MTHU060554", "metFORMIN"], ["MTHU060554", "metFORMIN"], ["LP7741-4", "Control"], ["LA22004-8", "IN"], ["LA6751-7", "Moderate"], ["MTHU065909", "Renal"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["MTHU060554", "metFORMIN"], ["LA24544-1", "Increased risk"], ["LA22004-8", "IN"], ["LA6751-7", "Moderate"], ["MTHU065909", "Renal"], ["LA24377-6", "Increased"], ["MTHU060554", "metFORMIN"], ["LP6194-7", "Concentration"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP15241-0", "S"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LA21291-2", "Not"], ["LA32049-1", "Decrease"], ["LP31392-1", "Enzymes (see also Inborn errors metabolism lysosomal)"], ["LP17763-1", "A"], ["LP267357-4", "Reduction"], ["LA22004-8", "IN"], ["LP6425-5", "Observed"], ["LP16061-1", "carBAMazepine"], ["LP200075-2", "IS"], ["MTHU065481", "Dose"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LA14664-9", "Twice"], ["LA14435-4", "Daily"], ["LA21996-6", "CO"], ["LP15241-0", "S"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP136501-6", "Tablet"], ["LP263791-8", "Additional"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["LP157327-0", "Dolutegravir"], ["LP6908-0", "12 hours"], ["LP14744-4", "Duration"], ["LP15241-0", "S"], ["LA21996-6", "CO"], ["LP17763-1", "A"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["MTHU065481", "Dose"], ["LP20592-9", "4"], ["MTHU000002", "Clinical Class"], ["LA9367-9", "Oral"], ["MTHU003161", "Estradiol"], ["LP157327-0", "Dolutegravir"], ["LP157327-0", "Dolutegravir"], ["LP20591-1", "3"], ["LA6112-2", "1"], ["LP157327-0", "Dolutegravir"], ["MTHU000002", "Clinical Class"], ["LA14557-5", "11"], ["LP157327-0", "Dolutegravir"], ["LA32-8", "No"], ["T125", "Hormone"], ["LP7243-1", "Follicle"], ["T125", "Hormone"], ["MTHU003615", "Progesterone"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LA9367-9", "Oral"], ["LP200075-2", "IS"], ["LA21996-6", "CO"], ["LP62263-6", "Population"], ["LA19974-7", "Performed"], ["LA22004-8", "IN"]], "snomed.driving": [["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["60271003", "Neural tube structure (body structure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["246093002", "Component (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["351726001", "Below (qualifier value)"], ["55919000", "Including (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["254648000", "Effective (qualifier value)"], ["367346004", "Measures (attribute)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["224526002", "Woman (person)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["116154003", "Patient (person)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["18720000", "In (attribute)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["1222740005", "American Joint Committee on Cancer stage I:3 (qualifier value)"], ["338930006", "Human (organism)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["364587008", "Birth outcome (observable entity)"], ["225419007", "Surveillance (procedure)|Surveillance (regime/therapy)"], ["224699009", "Study (environment)"], ["18720000", "In (attribute)"], ["223547005", "Botswana (geographic location)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255507004", "Small (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["733024003", "Tube (unit of presentation)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["18720000", "In (attribute)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["732348007", "0.19 (qualifier value)"], ["732906005", "95 (qualifier value)"], ["282109005", "Curie (qualifier value)|Ci (qualifier value)"], ["732331004", "0.09 (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["42504009", "Containing (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["13693004", "Conception, function (observable entity)|Conception (function)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222774009", "American Joint Committee on Cancer stage II:1 (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["18720000", "In (attribute)"], ["1222748003", "American Joint Committee on Cancer stage I:9 (qualifier value)"], ["732337000", "0.11 (qualifier value)"], ["732906005", "95 (qualifier value)"], ["282109005", "Curie (qualifier value)|Ci (qualifier value)"], ["733910000", "0.07 (qualifier value)"], ["732345005", "0.17 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["13693004", "Conception, function (observable entity)|Conception (function)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["60271003", "Neural tube structure (body structure)"], ["18720000", "In (attribute)"], ["60132005", "Generalized (qualifier value)"], ["385436007", "Population (social concept)"], ["260304006", "0.5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732323009", "0.05 (qualifier value)"], ["732332006", "0.1 (qualifier value)"], ["4757001", "Most (qualifier value)"], ["60271003", "Neural tube structure (body structure)"], ["18720000", "In (attribute)"], ["255216001", "First (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["258705008", "week (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255234002", "After (attribute)"], ["13693004", "Conception, function (observable entity)|Conception (function)"], ["26175008", "Approximate (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["255216001", "First (qualifier value)"], ["420862001", "On (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["768685009", "Antiretroviral (disposition)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["116154003", "Patient (person)"], ["255402008", "Gestational (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["253098009", "Neural tube defect (disorder)"], ["30507006", "Into (attribute)"], ["768685009", "Antiretroviral (disposition)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["255603008", "Major (qualifier value)"], ["3950001", "Birth (finding)"], ["18720000", "In (attribute)"], ["21481007", "Over (qualifier value)"], ["725127002", "600 (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["15240007", "Current (qualifier value)"], ["423437008", "Insufficient (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["734004005", "Address (property) (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["60271003", "Neural tube structure (body structure)"], ["18720000", "In (attribute)"], ["387961004", "Kingdom Animalia (organism)"], ["409967009", "Toxicology (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["373067005", "No (qualifier value)"], ["55919000", "Including (qualifier value)"], ["60271003", "Neural tube structure (body structure)"], ["7882003", "Identified (qualifier value)"], ["769082003", "5.3 (qualifier value)"], ["242762006", "More (qualifier value)"], ["732445006", "1000 (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["81170007", "Second (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["41587001", "Third trimester pregnancy (finding)"], ["41647002", "No evidence of (contextual qualifier) (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["255407002", "Neonatal (qualifier value)"], ["75478009", "Poisoning (disorder)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["81170007", "Second (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255248002", "Third trimester (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["394447009", "Fetus (person)|Fetus"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["181455002", "Entire placenta (body structure)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["260528009", "Median (qualifier value)"], ["280644003", "Entire umbilical cord (body structure)"], ["702942001", "Concentration (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["26175008", "Approximate (qualifier value)"], ["732418005", "1.3 (qualifier value)"], ["26310004", "Folded structure (morphologic abnormality)"], ["263768009", "Greater (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1269485005", "Maternal (qualifier value)"], ["14414005", "Peripheral (qualifier value)"], ["50863008", "Plasma (substance)"], ["702942001", "Concentration (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["423437008", "Insufficient (qualifier value)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["420862001", "On (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255509001", "Large (qualifier value)"], ["246205007", "Quantity (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420862001", "On (qualifier value)"], ["260676000", "Use of (attribute)"], ["386897000", "Lamivudine (substance)"], ["18720000", "In (attribute)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["242762006", "More (qualifier value)"], ["255216001", "First (qualifier value)"], ["373067005", "No (qualifier value)"], ["75478009", "Poisoning (disorder)"], ["387961004", "Kingdom Animalia (organism)"], ["386897000", "Lamivudine (substance)"], ["74256009", "DNA replication (finding)|Deoxyribonucleic acid replication (finding)"], ["769082003", "5.3 (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["261665006", "Unknown (qualifier value)"], ["88846004", "Functional disorder (finding)"], ["47368004", "Nucleoside (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["71211001", "Nucleotide (substance)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255372005", "Variable (qualifier value)"], ["246173007", "Degree (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["37782003", "Damage (morphologic abnormality)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["88846004", "Functional disorder (finding)"], ["18720000", "In (attribute)"], ["19030005", "Human immunodeficiency virus (organism)"], ["394426005", "Negative|Negative (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["288563008", "After values (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["47368004", "Nucleoside (substance)"], ["732727007", "4.4 (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["226789007", "Breast milk (substance)"], ["18720000", "In (attribute)"], ["255507004", "Small (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260528009", "Median (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["226789007", "Breast milk (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1269485005", "Maternal (qualifier value)"], ["50863008", "Plasma (substance)"], ["118586006", "Ratio (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["423437008", "Insufficient (qualifier value)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["18720000", "In (attribute)"], ["420862001", "On (qualifier value)"], ["242762006", "More (qualifier value)"], ["725123003", "200 (qualifier value)"], ["394651000", "Mother (person)|Mother"], ["410601007", "Childhood age person (person)"], ["69845001", "Received therapy or drug for (contextual qualifier) (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["67922002", "Serum (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["69845001", "Received therapy or drug for (contextual qualifier) (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["260362008", "Very low (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1269485005", "Maternal (qualifier value)"], ["67922002", "Serum (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260370003", "Decrease (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258395000", "Levels (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["1222777002", "American Joint Committee on Cancer stage II:4 (qualifier value)"], ["258705008", "week (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["373067005", "No (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["258706009", "month (qualifier value)"], ["272131007", "Old episode (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["181131000", "Entire breast (body structure)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258150004", "Transmission (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["1222741009", "American Joint Committee on Cancer stage I:4 (qualifier value)"], ["373067005", "No (qualifier value)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["420862001", "On (qualifier value)"], ["338930006", "Human (organism)"], ["248153007", "Male (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["248152002", "Female (finding)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["387961004", "Kingdom Animalia (organism)"], ["373067005", "No (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386897000", "Lamivudine (substance)"], ["420862001", "On (qualifier value)"], ["248153007", "Male (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["248152002", "Female (finding)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["769082003", "5.3 (qualifier value)"]], "ncit.driving": [["C161316", "Female of Childbearing Potential"], ["C161316", "Female of Childbearing Potential"], ["C161316", "Female of Childbearing Potential"], ["C16329", "Belgium"], ["C45828", "Approximate"], ["C62230", "Potential"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C34226", "Neural Tube"], ["C62355", "With"], ["C121543", "Dolutegravir"], ["C76246", "Blood Group A"], ["C40565", "Component, LOINC Axis 1"], ["C52874", "SPI1 wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C163702", "Staphylococcal Enterotoxin E"], ["C75330", "Below"], ["C166400", "Inclusive"], ["C113416", "Consideration"], ["C52874", "SPI1 wt Allele"], ["C49287", "Effective"], ["C42734", "Contraceptive Device"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C14284", "Woman"], ["C191656", "Pregnant Subject"], ["C25387", "Benefit"], ["C16289", "Andorra"], ["C52874", "SPI1 wt Allele"], ["C54064", "Continue"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C16329", "Belgium"], ["C62355", "With"], ["C53691", "Veterinary Patient"], ["C191656", "Pregnant Subject"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C62265", "Double"], ["C165496", "GDC Regimen Terminology"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C191656", "Pregnant Subject"], ["C113427", "Thirteen"], ["C14225", "Human"], ["C54627", "Experience"], ["C25516", "From"], ["C76246", "Blood Group A"], ["C25155", "Birth"], ["C20200", "Outcome"], ["C15719", "Surveillance"], ["C45319", "Study Object"], ["C16727", "India"], ["C16363", "Botswana"], ["C76246", "Blood Group A"], ["C25376", "Small"], ["C25533", "Increase"], ["C52874", "SPI1 wt Allele"], ["C25363", "Neural"], ["C41277", "Tube"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C16727", "India"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16951", "Panama"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C105801", "Nineteen"], ["C112239", "Coagulation Index Measurement"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C105795", "Forty"], ["C159124", "GDC Treatment Outcome Terminology"], ["C121543", "Dolutegravir"], ["C79873", "Contain"], ["C158997", "GDC Analyte Type Terminology"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C16465", "Conception"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C107434", "Twenty One"], ["C16727", "India"], ["C105801", "Nineteen"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C113425", "Eleven"], ["C112239", "Coagulation Index Measurement"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C113431", "Seventeen"], ["C159124", "GDC Treatment Outcome Terminology"], ["C159124", "GDC Treatment Outcome Terminology"], ["C14460", "NON Mouse"], ["C121543", "Dolutegravir"], ["C158997", "GDC Analyte Type Terminology"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C16465", "Conception"], ["C16726", "Incidence"], ["C52874", "SPI1 wt Allele"], ["C34226", "Neural Tube"], ["C16727", "India"], ["C18241", "General Population"], ["C25516", "From"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C49152", "Case"], ["C97722", "PER1 wt Allele"], ["C105723", "ECOG Performance Status 1"], ["C89279", "Reside"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C105723", "ECOG Performance Status 1"], ["C25258", "Most"], ["C34226", "Neural Tube"], ["C127786", "Occurrence Indicator"], ["C25282", "Within"], ["C25509", "First"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C29844", "Week"], ["C52874", "SPI1 wt Allele"], ["C16649", "Embryogenesis"], ["C38008", "Post"], ["C16465", "Conception"], ["C45828", "Approximate"], ["C172979", "Fear Score 6"], ["C29844", "Week"], ["C38008", "Post"], ["C81257", "Last Menstrual Period"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C191656", "Pregnant Subject"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25458", "Confirmation"], ["C16727", "India"], ["C25509", "First"], ["C69121", "Trimester"], ["C92667", "SPARC wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C25387", "Benefit"], ["C16289", "Andorra"], ["C52874", "SPI1 wt Allele"], ["C54064", "Continue"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C165496", "GDC Regimen Terminology"], ["C16329", "Belgium"], ["C62355", "With"], ["C53691", "Veterinary Patient"], ["C81253", "Gestational Weeks Assessment"], ["C16289", "Andorra"], ["C25467", "Critical"], ["C25330", "Duration"], ["C25616", "Period"], ["C52874", "SPI1 wt Allele"], ["C84923", "Neural Tube Defect"], ["C18732", "Development"], ["C25544", "Into"], ["C88186", "Financial Account"], ["C25474", "Data"], ["C25516", "From"], ["C191656", "Pregnant Subject"], ["C15753", "Cancer Registry"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C45368", "Major"], ["C25155", "Birth"], ["C16727", "India"], ["C25490", "During"], ["C16953", "Paraguay"], ["C159124", "GDC Treatment Outcome Terminology"], ["C121543", "Dolutegravir"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C68869", "Are"], ["C126862", "Unsatisfactory"], ["C159124", "GDC Treatment Outcome Terminology"], ["C86945", "Address"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C34226", "Neural Tube"], ["C16727", "India"], ["C14182", "Animal"], ["C17087", "Reproduction"], ["C17206", "Toxicology"], ["C62355", "With"], ["C121543", "Dolutegravir"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C188368", "ELN Adverse-Risk Category"], ["C18732", "Development"], ["C166400", "Inclusive"], ["C34226", "Neural Tube"], ["C25737", "Identification"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C61584", "Greater Than"], ["C67234", "Thousand"], ["C25516", "From"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C121543", "Dolutegravir"], ["C25490", "During"], ["C25666", "Second"], ["C16289", "Andorra"], ["C92896", "Third Trimester"], ["C191656", "Pregnant Subject"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C16731", "Newborn"], ["C27990", "Toxicity"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C106184", "May"], ["C16329", "Belgium"], ["C25490", "During"], ["C25666", "Second"], ["C16289", "Andorra"], ["C92896", "Third Trimester"], ["C52874", "SPI1 wt Allele"], ["C191656", "Pregnant Subject"], ["C65140", "When"], ["C41333", "Expected Adverse Event"], ["C25387", "Benefit"], ["C62230", "Potential"], ["C17102", "Risk"], ["C159124", "GDC Treatment Outcome Terminology"], ["C121543", "Dolutegravir"], ["C13272", "Placenta"], ["C16727", "India"], ["C16727", "India"], ["C73435", "Gravida"], ["C37987", "Alive"], ["C62355", "With"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C28007", "Median"], ["C34320", "Umbilical Cord"], ["C105891", "Able to Concentrate"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C154196", "Washo Language"], ["C45828", "Approximate"], ["C161427", "CDISC SDTM Model Version 1.3"], ["C61421", "Greater"], ["C49156", "Comparison"], ["C62355", "With"], ["C89336", "Maternal"], ["C25233", "Peripheral"], ["C13356", "Plasma"], ["C105891", "Able to Concentrate"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C172138", "Insufficient Information to Classify Health Impact"], ["C92667", "SPARC wt Allele"], ["C25492", "Effect"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C92667", "SPARC wt Allele"], ["C76246", "Blood Group A"], ["C49508", "Large"], ["C25256", "Quantity"], ["C52874", "SPI1 wt Allele"], ["C25474", "Data"], ["C92667", "SPARC wt Allele"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C1471", "Lamivudine"], ["C16727", "India"], ["C73435", "Gravida"], ["C61584", "Greater Than"], ["C25516", "From"], ["C25509", "First"], ["C69121", "Trimester"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C27990", "Toxicity"], ["C14182", "Animal"], ["C1471", "Lamivudine"], ["C106184", "May"], ["C12508", "Cell"], ["C16514", "DNA Replication"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C123619", "Clinical Response"], ["C70664", "Relevance"], ["C52874", "SPI1 wt Allele"], ["C103373", "CDISC Findings Class"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C160764", "Unknown Molecular Analysis"], ["C168331", "Muscular Dystrophy Secondary to Mitochondrial Disorder"], ["C20632", "Pathophysiology"], ["C707", "Nucleoside"], ["C16289", "Andorra"], ["C709", "Nucleotide"], ["C101282", "Have"], ["C15263", "In Vitro"], ["C16289", "Andorra"], ["C15744", "In Vivo"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16390", "Etiology"], ["C76246", "Blood Group A"], ["C142192", "Study Variable"], ["C25554", "Level"], ["C52874", "SPI1 wt Allele"], ["C45524", "Mitochondrial Damage"], ["C101282", "Have"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C168331", "Muscular Dystrophy Secondary to Mitochondrial Disorder"], ["C20632", "Pathophysiology"], ["C16727", "India"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C160366", "FGFR3 Gene Rearrangement Negative"], ["C49641", "In Utero"], ["C48928", "And/Or"], ["C38008", "Post"], ["C159124", "GDC Treatment Outcome Terminology"], ["C707", "Nucleoside"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C121543", "Dolutegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C14225", "Human"], ["C13257", "Mammary Gland Milk"], ["C16727", "India"], ["C25376", "Small"], ["C76246", "Blood Group A"], ["C28007", "Median"], ["C121543", "Dolutegravir"], ["C13257", "Mammary Gland Milk"], ["C159124", "GDC Treatment Outcome Terminology"], ["C89336", "Maternal"], ["C13356", "Plasma"], ["C179809", "Ratio Result Type"], ["C52874", "SPI1 wt Allele"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C101282", "Have"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C172138", "Insufficient Information to Classify Health Impact"], ["C92667", "SPARC wt Allele"], ["C25492", "Effect"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C16727", "India"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C61584", "Greater Than"], ["C159711", "Two Hundred"], ["C25189", "Mother"], ["C150886", "Child Relation"], ["C25705", "Treating"], ["C64956", "For"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C13325", "Serum"], ["C52874", "SPI1 wt Allele"], ["C1471", "Lamivudine"], ["C16727", "India"], ["C52874", "SPI1 wt Allele"], ["C25705", "Treating"], ["C64956", "For"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C68869", "Are"], ["C162680", "IPSS-R Risk Category Very Low"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C52874", "SPI1 wt Allele"], ["C89336", "Maternal"], ["C13325", "Serum"], ["C16289", "Andorra"], ["C25640", "Reduced"], ["C159124", "GDC Treatment Outcome Terminology"], ["C111568", "Undetectable"], ["C65140", "When"], ["C81004", "Reaching"], ["C113753", "Twenty Four"], ["C29844", "Week"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C68869", "Are"], ["C53269", "No Information Available"], ["C92667", "SPARC wt Allele"], ["C49667", "Safety Study"], ["C52874", "SPI1 wt Allele"], ["C1471", "Lamivudine"], ["C65140", "When"], ["C25382", "Administered"], ["C159124", "GDC Treatment Outcome Terminology"], ["C61585", "Less Than"], ["C66834", "Three"], ["C29846", "Month"], ["C65010", "Old"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C37987", "Alive"], ["C62355", "With"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C25389", "Chest"], ["C69427", "Feed"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C17214", "Disease Transmission"], ["C52874", "SPI1 wt Allele"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C95089", "Fertility Domain"], ["C113428", "Fourteen"], ["C68869", "Are"], ["C53269", "No Information Available"], ["C92667", "SPARC wt Allele"], ["C25492", "Effect"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C43508", "Oregon"], ["C1471", "Lamivudine"], ["C92667", "SPARC wt Allele"], ["C14225", "Human"], ["C46107", "Male, Self-Report"], ["C43508", "Oregon"], ["C46110", "Female Gender"], ["C95089", "Fertility Domain"], ["C14182", "Animal"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25492", "Effect"], ["C52874", "SPI1 wt Allele"], ["C121543", "Dolutegravir"], ["C43508", "Oregon"], ["C1471", "Lamivudine"], ["C92667", "SPARC wt Allele"], ["C46107", "Male, Self-Report"], ["C43508", "Oregon"], ["C46110", "Female Gender"], ["C95089", "Fertility Domain"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"]], "rxnorm.driving": [["1433868", "dolutegravir"], ["2122521", "Dovato"], ["2122521", "Dovato"], ["T016", "Human"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["2122521", "Dovato"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["T008", "Animal"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["2122521", "Dovato"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["68244", "lamivudine"], ["T008", "Animal"], ["68244", "lamivudine"], ["1433868", "dolutegravir"], ["T016", "Human"], ["1433868", "dolutegravir"], ["1433868", "dolutegravir"], ["68244", "lamivudine"], ["68244", "lamivudine"], ["1433868", "dolutegravir"], ["68244", "lamivudine"], ["T016", "Human"], ["T008", "Animal"], ["1433868", "dolutegravir"], ["68244", "lamivudine"]], "loinc.driving": [["LP249176-1", "Tube"], ["LP157327-0", "Dolutegravir"], ["LP17763-1", "A"], ["LA14987-4", "Below"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP207970-7", "Pregnancy"], ["MTHU043138", "Risks"], ["LP94823-9", "Treatment"], ["LP66710-2", "Patient"], ["LP207970-7", "Pregnancy"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["LP17763-1", "A"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP207970-7", "Pregnancy"], ["LA14559-1", "13"], ["LA19711-3", "Human"], ["LP17763-1", "A"], ["LP74341-6", "Study"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA8983-4", "Small"], ["LA32048-3", "Increase"], ["LP249176-1", "Tube"], ["LP36790-1", "7"], ["LP270144-1", "Cases"], ["LA22004-8", "IN"], ["LP20591-1", "3"], ["LA6111-4", "0"], ["LA6111-4", "0"], ["LA6111-4", "0"], ["LA15247-2", "40%"], ["LP157327-0", "Dolutegravir"], ["LA21988-3", "AT"], ["LP73517-2", "Time"], ["LP270144-1", "Cases"], ["LA22004-8", "IN"], ["LA6111-4", "0"], ["LA14557-5", "11"], ["LA6111-4", "0"], ["LA6111-4", "0"], ["LP157327-0", "Dolutegravir"], ["LA21988-3", "AT"], ["LP73517-2", "Time"], ["LP249176-1", "Tube"], ["LA22004-8", "IN"], ["LA29505-7", "General population"], ["LA16632-4", "0.5"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6111-4", "0"], ["LA24574-8", "0.1"], ["LP249176-1", "Tube"], ["LP6974-2", "first"], ["LP6941-1", "4 weeks"], ["LA31713-3", "6 weeks"], ["MTHU003120", "Last menstrual period"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP207970-7", "Pregnancy"], ["LP200075-2", "IS"], ["LA15290-2", "Confirmed"], ["LA22004-8", "IN"], ["LP6974-2", "first"], ["MTHU043138", "Risks"], ["LP66710-2", "Patient"], ["18185-9", "Gestational age:Time:Pt:^Fetus:Qn"], ["LP73517-2", "Time"], ["MTHU052259", "Neural tube defect"], ["LP207970-7", "Pregnancy"], ["LA14426-3", "Do not"], ["LA24544-1", "Increased risk"], ["LA29634-5", "Major"], ["LA22004-8", "IN"], ["LA14010-5", "600"], ["LP157327-0", "Dolutegravir"], ["LP266032-4", "during pregnancy"], ["LA28127-1", "Insufficient"], ["LP96251-1", "Address"], ["LP249176-1", "Tube"], ["LA22004-8", "IN"], ["LA30681-3", "Animal"], ["LA18285-9", "Reproductive"], ["LP74364-8", "Toxicology studies"], ["LP157327-0", "Dolutegravir"], ["LA32-8", "No"], ["LP249176-1", "Tube"], ["LP40035-5", "Identified"], ["LP20593-7", "5"], ["LP20591-1", "3"], ["LA16824-7", "More"], ["LP157327-0", "Dolutegravir"], ["LP207970-7", "Pregnancy"], ["LA32-8", "No"], ["LA24544-1", "Increased risk"], ["LA14161-6", "May"], ["LP207970-7", "Pregnancy"], ["LP157327-0", "Dolutegravir"], ["LP208379-0", "Placenta"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LA29507-3", "Pregnant women"], ["LP29689-4", "Living with HIV"], ["LA25381-7", "Median"], ["LP7676-2", "Umbilical cord"], ["LP6194-7", "Concentration"], ["LP157327-0", "Dolutegravir"], ["LA6112-2", "1"], ["LP20591-1", "3"], ["LA26320-4", "Maternal"], ["LA24844-5", "Peripheral"], ["LP7479-1", "Plasma"], ["LP6194-7", "Concentration"], ["LP200075-2", "IS"], ["LA28127-1", "Insufficient"], ["LP157327-0", "Dolutegravir"], ["LP17763-1", "A"], ["LA20975-1", "Large amount"], ["MTHU060537", "lamiVUDine"], ["LA22004-8", "IN"], ["LA29507-3", "Pregnant women"], ["LA16824-7", "More"], ["LP6974-2", "first"], ["LA32-8", "No"], ["LA30681-3", "Animal"], ["MTHU060537", "lamiVUDine"], ["LA14161-6", "May"], ["MTHU003299", "DNA"], ["LP20593-7", "5"], ["LP20591-1", "3"], ["LP7787-7", "Clinical"], ["59776-5", "Procedure findings:Find:Pt:^Patient:Nar"], ["LP200075-2", "IS"], ["LA4489-6", "Unknown"], ["LA24789-2", "Mitochondrial"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA18409-5", "Variable"], ["LA24789-2", "Mitochondrial"], ["LA24789-2", "Mitochondrial"], ["LA22004-8", "IN"], ["LP183501-8", "HIV"], ["LA6577-6", "Negative"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LP32606-3", "post"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LP157327-0", "Dolutegravir"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA19711-3", "Human"], ["LP29290-1", "Milk"], ["LA22004-8", "IN"], ["LA8983-4", "Small"], ["LP17763-1", "A"], ["LA25381-7", "Median"], ["LP157327-0", "Dolutegravir"], ["LA16914-6", "Breast milk"], ["LA26320-4", "Maternal"], ["LP7479-1", "Plasma"], ["LP6852-0", "Ratio"], ["LA6111-4", "0"], ["LP200075-2", "IS"], ["LA28127-1", "Insufficient"], ["LP157327-0", "Dolutegravir"], ["LA22004-8", "IN"], ["LA16824-7", "More"], ["LP6983-3", "Mother"], ["LA9949-4", "Child"], ["LP183501-8", "HIV"], ["LP7567-3", "Serum"], ["MTHU060537", "lamiVUDine"], ["LA22004-8", "IN"], ["LP183501-8", "HIV"], ["LA14643-3", "Very low"], ["LA32970-8", "<"], ["LP20592-9", "4"], ["LA26320-4", "Maternal"], ["LP7567-3", "Serum"], ["LA32049-1", "Decrease"], ["LA21676-4", "Reach"], ["LA9000-6", "Weeks"], ["MTHU010047", "Age"], ["LA32-8", "No"], ["LA17589-5", "Safety"], ["MTHU060537", "lamiVUDine"], ["LA16823-9", "Less"], ["LA6395-3", "Three"], ["MTHU068094", "Months"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP29689-4", "Living with HIV"], ["LA14426-3", "Do not"], ["LP199961-6", "Breast"], ["LP7228-2", "Feed"], ["LA22004-8", "IN"], ["MTHU050362", "Transmission"], ["LP183501-8", "HIV"], ["MTHU000074", "Fertility"], ["LA14560-9", "14"], ["LA32-8", "No"], ["LP157327-0", "Dolutegravir"], ["LA22025-3", "OR"], ["MTHU060537", "lamiVUDine"], ["LA19711-3", "Human"], ["LA2-8", "Male"], ["LA22025-3", "OR"], ["LP32818-4", "Female fertility"], ["LA30681-3", "Animal"], ["LA32-8", "No"], ["LP157327-0", "Dolutegravir"], ["LA22025-3", "OR"], ["MTHU060537", "lamiVUDine"], ["LA2-8", "Male"], ["LA22025-3", "OR"], ["LP32818-4", "Female fertility"], ["LP20593-7", "5"], ["LP20591-1", "3"]], "snomed.side_effects": [["373067005", "No (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["86137003", "Negligible (qualifier value)"], ["420862001", "On (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["247750002", "Drive (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["404640003", "Dizziness (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["271782001", "Drowsy (finding)"], ["733985002", "Reported (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["714767001", "Product containing dolutegravir (medicinal product)|Dolutegravir (product)"], ["263493007", "Clinical status (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["116154003", "Patient (person)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["281647001", "Adverse reaction (disorder)|Adverse reactions (disorder)|Adverse reactions (finding)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["89970005", "Psyche structure (body structure)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["116154003", "Patient (person)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["247750002", "Drive (observable entity)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"]], "ncit.side_effects": [["C199581", "Dolutegravir Sodium/Lamivudine"], ["C101282", "Have"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43508", "Oregon"], ["C121660", "Influence"], ["C92667", "SPARC wt Allele"], ["C121232", "Ability to Drive"], ["C16289", "Andorra"], ["C25340", "Use"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C37896", "Informed"], ["C125409", "Have Dizziness"], ["C16289", "Andorra"], ["C26754", "Somnolence"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C175242", "During Treatment"], ["C62355", "With"], ["C121543", "Dolutegravir"], ["C123619", "Clinical Response"], ["C25688", "Status"], ["C52874", "SPI1 wt Allele"], ["C53691", "Veterinary Patient"], ["C16289", "Andorra"], ["C41332", "Adverse Reaction"], ["C84385", "Profile"], ["C52874", "SPI1 wt Allele"], ["C199581", "Dolutegravir Sodium/Lamivudine"], ["C16329", "Belgium"], ["C16727", "India"], ["C65140", "When"], ["C53691", "Veterinary Patient"], ["C42555", "Siemens"], ["C121232", "Ability to Drive"], ["C43508", "Oregon"], ["C168221", "Machinery Heart Murmur"]], "rxnorm.side_effects": [["2122521", "Dovato"], ["1433868", "dolutegravir"], ["2122521", "Dovato"]], "loinc.side_effects": [["LA32-8", "No"], ["LA22025-3", "OR"], ["LA7428-1", "Dizziness"], ["LP6486-7", "Reported"], ["LP93408-0", "during treatment"], ["LP157327-0", "Dolutegravir"], ["LP7787-7", "Clinical"], ["LP73412-6", "Status"], ["LP66710-2", "Patient"], ["LP73228-6", "Reaction"], ["LA22004-8", "IN"], ["LP66710-2", "Patient"], ["LP15241-0", "S"], ["LA22025-3", "OR"]], "snomed.shelf_life": [["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258707000", "year (qualifier value)"]], "ncit.shelf_life": [["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C29848", "Year"]], "rxnorm.shelf_life": [], "loinc.shelf_life": [["LA31720-8", "3 years"]], "snomed.storage": [["763158003", "Medicinal product (product)"], ["717896003", "Does not (qualifier value)"], ["67995009", "Special (qualifier value)"], ["440276004", "Storage (procedure)"]], "ncit.storage": [["C142605", "Medicinal Product"], ["C86066", "Do"], ["C25594", "Negation"], ["C81168", "Any"], ["C101704", "Special Storage Condition"]], "rxnorm.storage": [], "loinc.storage": [["LA21291-2", "Not"]], "snomed.package": [["134295003", "Opaque (qualifier value)"], ["371251000", "White color (qualifier value)"], ["75540009", "High (qualifier value)"], ["125146005", "Density (qualifier value)"], ["71463006", "Polyethylene (substance)"], ["419672006", "Bottle (qualifier value)|Bottle - unit of product usage (qualifier value)"], ["29179001", "Closed (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["410601007", "Childhood age person (person)"], ["30714006", "Resistant (qualifier value)"], ["256633009", "Polypropylene (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["71463006", "Polyethylene (substance)"], ["88999006", "Heat (physical force)"], ["19314006", "Seal (organism)"], ["706608009", "Liner (physical object)"], ["419473009", "Each (qualifier value)"], ["257260002", "Pack (physical object)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["732986007", "Bottle (unit of presentation)"], ["42504009", "Containing (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["42504009", "Containing (qualifier value)"], ["732899009", "90 (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"]], "ncit.package": [["C82125", "Opaque"], ["C48325", "White"], ["C83759", "High Density Polyethylene"], ["C83759", "High Density Polyethylene"], ["C49070", "Closed"], ["C62355", "With"], ["C150886", "Child Relation"], ["C41546", "Resistance Process"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C83759", "High Density Polyethylene"], ["C158876", "Induction Therapy"], ["C186249", "Estrus"], ["C50163", "Seal Device"], ["C62126", "Cavity Liner"], ["C64933", "Each"], ["C84731", "Packing"], ["C52874", "SPI1 wt Allele"], ["C66832", "One"], ["C43169", "Bottle"], ["C79873", "Contain"], ["C70541", "Lansky Performance Status 30"], ["C154467", "Film Dosage Form Category"], ["C25450", "Coat"], ["C79873", "Contain"], ["C182728", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 90"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C62653", "Pack Dosage Form"], ["C52874", "SPI1 wt Allele"], ["C70541", "Lansky Performance Status 30"], ["C154467", "Film Dosage Form Category"], ["C25450", "Coat"]], "rxnorm.package": [["746839", "Pack"]], "loinc.package": [["LA4457-3", "White"], ["LA9193-9", "High"], ["LA9228-3", "Closed"], ["LA9949-4", "Child"], ["LA6676-6", "Resistant"], ["LP17763-1", "A"], ["LA6306-0", "One"], ["LA28855-7", "30"], ["LA28891-2", "90"], ["LP20591-1", "3"], ["LA28855-7", "30"]], "snomed.marketing_authorization_numbers": [["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222748003", "American Joint Committee on Cancer stage I:9 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222748003", "American Joint Committee on Cancer stage I:9 (qualifier value)"], ["1222780001", "American Joint Committee on Cancer stage II:7 (qualifier value)"]], "ncit.marketing_authorization_numbers": [["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C105801", "Nineteen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C105801", "Nineteen"], ["C126887", "Twenty Seven"]], "rxnorm.marketing_authorization_numbers": [], "loinc.marketing_authorization_numbers": [["LA6112-2", "1"], ["LA6112-2", "1"]]}, {"product_info": "Ogivri 150 mg powder for concentrate for solution for infusion \nOgivri 420 mg powder for concentrate for solution for infusion", "composition": "Ogivri 150 mg powder for concentrate for solution for infusion \nOne vial contains 150 mg of trastuzumab, a humanised IgG1 monoclonal antibody produced by \nmammalian (Chinese hamster ovary) cell suspension culture and purified by affinity and ion exchange \nchromatography including specific viral inactivation and removal procedures. \nOgivri 420 mg powder for concentrate for solution for infusion \nOne vial contains 420 mg of trastuzumab, a humanised IgG1 monoclonal antibody produced by \nmammalian (Chinese hamster ovary) cell suspension culture and purified by affinity and ion exchange \nchromatography including specific viral inactivation and removal procedures. \nThe reconstituted Ogivri solution contains 21 mg/mL of trastuzumab. \nExcipient with known effect \nEach 150 mg vial contains 115.2 mg sorbitol (E420).  \nEach 420 mg vial contains 322.6 mg sorbitol (E420).  \nFor the full list of excipients, see section 6.1.", "indications": "Breast cancer \nMetastatic breast cancer \nOgivri is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer \n(MBC): \nas monotherapy for the treatment of those patients who have received at least two chemotherapy \nregimens for their metastatic disease. Prior chemotherapy must have included at least an \nanthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor \npositive patients must also have failed hormonal therapy, unless patients are unsuitable for these \ntreatments \nin combination with paclitaxel for the treatment of those patients who have not received \nchemotherapy for their metastatic disease and for whom an anthracycline is not suitable \nin combination with docetaxel for the treatment of those patients who have not received \nchemotherapy for their metastatic disease \nin combination with an aromatase inhibitor for the treatment of postmenopausal patients with \nhormone-receptor positive MBC, not previously treated with trastuzumab. \nEarly breast cancer \nOgivri is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC): \nfollowing surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see \nsection 5.1) \nfollowing adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with \npaclitaxel or docetaxel \nin combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. \nin combination with neoadjuvant chemotherapy followed by adjuvant Ogivri therapy, for locally \nadvanced (including inflammatory) disease or tumours > 2 cm in diameter (see sections 4.4 and \n5.1). \nOgivri should only be used in patients with metastatic or EBC whose tumours have either HER2 \noverexpression or HER2 gene amplification as determined by an accurate and validated assay (see \nsections 4.4 and 5.1). \nMetastatic gastric cancer \nOgivri in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of \nadult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal \njunction who have not received prior anti-cancer treatment for their metastatic disease. \nOgivri should only be used in patients with metastatic gastric cancer (MGC) whose tumours have \nHER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ \nresult. Accurate and validated assay methods should be used (see sections 4.4 and 5.1).", "posology": "HER2 testing is mandatory prior to initiation of therapy (see sections 4.4 and 5.1). Trastuzumab \ntreatment should only be initiated by a physician experienced in the administration of cytotoxic \nchemotherapy (see section 4.4), and should be administered by a healthcare professional only. \nOgivri intravenous formulation is not intended for subcutaneous administration and should be \nadministered via an intravenous infusion only. \nIf an alternate route of administration is required, other trastuzumab products offering such an option \nshould be used. \nIn order to prevent medication errors it is important to check the vial labels to ensure that the \nmedicinal product being prepared and administered is Ogivri (trastuzumab) and not another \ntrastuzumab-containing product (e.g. trastuzumab emtansine or trastuzumab deruxtecan). \nPosology \nMetastatic breast cancer \nThree-weekly schedule \nThe recommended initial loading dose is 8 mg/kg body weight. The recommended maintenance dose \nat three-weekly intervals is 6 mg/kg body weight, beginning three weeks after the loading dose. \nWeekly schedule \nThe recommended initial loading dose of trastuzumab is 4 mg/kg body weight. The recommended \nweekly maintenance dose of trastuzumab is 2 mg/kg body weight, beginning one week after the \nloading dose. \nAdministration in combination with paclitaxel or docetaxel \nIn the pivotal trials (H0648g, M77001), paclitaxel or docetaxel was administered the day following the \nfirst dose of trastuzumab (for dose, see the Summary of Product Characteristics (SmPC) for paclitaxel \nor docetaxel) and immediately after the subsequent doses of trastuzumab if the preceding dose of \ntrastuzumab was well tolerated. \nAdministration in combination with an aromatase inhibitor \nIn the pivotal trial (BO16216) trastuzumab and anastrozole were administered from day 1. There were \nno restrictions on the relative timing of trastuzumab and anastrozole at administration (for dose, see \nthe SmPC for anastrozole or other aromatase inhibitors). \nEarly breast cancer \nThree-weekly and weekly schedule \nAs a three-weekly regimen the recommended initial loading dose of trastuzumab is 8 mg/kg body \nweight. The recommended maintenance dose of trastuzumab at three-weekly intervals is 6 mg/kg body \nweight, beginning three weeks after the loading dose. \nAs a weekly regimen (initial loading dose of 4 mg/kg followed by 2 mg/kg every week) concomitantly \nwith paclitaxel following chemotherapy with doxorubicin and cyclophosphamide. \nSee section 5.1 for chemotherapy combination dosing. \nMetastatic gastric cancer \nThree-weekly schedule \nThe recommended initial loading dose is 8 mg/kg body weight. The recommended maintenance dose \nat three-weekly intervals is 6 mg/kg body weight, beginning three weeks after the loading dose. \nBreast cancer and gastric cancer \nDuration of treatment \nPatients with MBC or MGC should be treated with trastuzumab until progression of disease. \nPatients with EBC should be treated with trastuzumab for 1 year or until disease recurrence, whichever \noccurs first; extending treatment in EBC beyond one year is not recommended (see section 5.1). \nDose reduction \nNo reductions in the dose of trastuzumab were made during clinical trials. Patients may continue \ntherapy during periods of reversible, chemotherapy-induced myelosuppression but they should be \nmonitored carefully for complications of neutropenia during this time. Refer to the SmPC for \npaclitaxel, docetaxel or aromatase inhibitor for information on dose reduction or delays. \nIf left ventricular ejection fraction (LVEF) percentage drops \u2265 10 points from baseline AND to below \n50 %, treatment should be suspended and a repeat LVEF assessment performed within approximately \n3 weeks. If LVEF has not improved, or has declined further, or if symptomatic congestive heart failure \n(CHF) has developed, discontinuation of trastuzumab should be strongly considered, unless the \nbenefits for the individual patient are deemed to outweigh the risks. All such patients should be \nreferred for assessment by a cardiologist and followed up.\nMissed doses \nIf the patient has missed a dose of trastuzumab by one week or less, then the usual maintenance dose \n(weekly regimen: 2 mg/kg; three-weekly regimen: 6 mg/kg) should be administered as soon as \npossible. Do not wait until the next planned cycle. Subsequent maintenance doses should be \nadministered 7 days or 21 days later according to the weekly or three-weekly schedules, respectively. \nIf the patient has missed a dose of trastuzumab by more than one week, a re-loading dose of \ntrastuzumab should be administered over approximately 90 minutes (weekly regimen: 4 mg/kg; three-\nweekly regimen: 8 mg/kg) as soon as possible. Subsequent trastuzumab maintenance doses (weekly \nregimen: 2 mg/kg; three-weekly regimen 6 mg/kg respectively) should be administered 7 days or 21 \ndays later according to the weekly or three-weekly schedules respectively.\nSpecial populations \nDedicated pharmacokinetic studies in the elderly and those with renal or hepatic impairment have not \nbeen carried out. In a population pharmacokinetic analysis, age and renal impairment were not shown \nto affect trastuzumab disposition. \nPaediatric population \nThere is no relevant use of trastuzumab in the paediatric population. \nMethod of administration \nTrastuzumab loading dose should be administered as a 90-minute intravenous infusion. Do not \nadminister as an intravenous push or bolus. Trastuzumab intravenous infusion should be administered \nby a healthcare provider prepared to manage anaphylaxis and an emergency kit should be available. \nPatients should be observed for at least six hours after the start of the first infusion and for two hours \nafter the start of the subsequent infusions for symptoms like fever and chills or other infusion-related \nsymptoms (see sections 4.4 and 4.8). Interruption or slowing the rate of the infusion may help control \nsuch symptoms. The infusion may be resumed when symptoms abate. \nIf the initial loading dose was well tolerated, the subsequent doses can be administered as a 30-minute \ninfusion. \nFor instructions on reconstitution of the medicinal product before administration, see section 6.6.", "contraindications": "Hypersensitivity to the active substance, murine proteins, or to any of the excipients listed \nin section 6.1. \nSevere dyspnoea at rest due to complications of advanced malignancy or requiring \nsupplementary oxygen therapy.", "special_warnings": "Traceability \nIn order to improve the traceability of biological medicinal products, the name and the batch number \nof the administered product should be clearly recorded. \nHER2 testing must be performed in a specialised laboratory which can ensure adequate validation of \nthe testing procedures (see section 5.1). \nCurrently no data from clinical trials are available on re-treatment of patients with previous exposure \nto trastuzumab in the adjuvant setting\nCardiac dysfunction \nGeneral considerations \nPatients treated with trastuzumab are at increased risk for developing CHF (New York Heart \nAssociation [NYHA] Class II-IV) or asymptomatic cardiac dysfunction. These events have been \nobserved in patients receiving trastuzumab therapy alone or in combination with paclitaxel or \ndocetaxel, particularly following anthracycline (doxorubicin or epirubicin) containing chemotherapy. \nThese may be moderate to severe and have been associated with death (see section 4.8). In addition, \ncaution should be exercised in treating patients with increased cardiac risk, e.g. hypertension, \ndocumented coronary artery disease, CHF, LVEF of < 55%, older age. \nAll candidates for treatment with trastuzumab, but especially those with prior anthracycline and \ncyclophosphamide (AC) exposure, should undergo baseline cardiac assessment including history and \nphysical examination, electrocardiogram (ECG), echocardiogram, and/or multigated acquisition \n(MUGA) scan or magnetic resonance imaging. Monitoring may help to identify patients who develop \ncardiac dysfunction. Cardiac assessments, as performed at baseline, should be repeated every 3 months \nduring treatment and every 6 months following discontinuation of treatment until 24 months from the \nlast administration of trastuzumab. A careful risk-benefit assessment should be made before deciding \nto treat with trastuzumab. \nTrastuzumab may persist in the circulation for up to 7 months after stopping Ogivri treatment based on \npopulation pharmacokinetic analysis of all available data (see section 5.2). Patients who receive \nanthracyclines after stopping trastuzumab may possibly be at increased risk of cardiac dysfunction. If \npossible, physicians should avoid anthracycline-based therapy for up to 7 months after stopping \ntrastuzumab. If anthracyclines are used, the patient\u2019s cardiac function should be monitored carefully. \nFormal cardiological assessment should be considered in patients in whom there are cardiovascular \nconcerns following baseline screening. In all patients cardiac function should be monitored during \ntreatment (e.g. every 12 weeks). Monitoring may help to identify patients who develop cardiac \ndysfunction. Patients who develop asymptomatic cardiac dysfunction may benefit from more frequent \nmonitoring (e.g. every 6 - 8 weeks). If patients have a continued decrease in left ventricular function, \nbut remain asymptomatic, the physician should consider discontinuing therapy if no clinical benefit of \ntrastuzumab therapy has been seen. \nThe safety of continuation or resumption of trastuzumab in patients who experience cardiac \ndysfunction has not been prospectively studied. If LVEF percentage drops \u2265 10 points from baseline \nAND to below 50%, treatment should be suspended and a repeat LVEF assessment performed within \napproximately 3 weeks. If LVEF has not improved, or declined further, or symptomatic CHF has \ndeveloped, discontinuation of trastuzumab should be strongly considered, unless the benefits for the \nindividual patient are deemed to outweigh the risks. All such patients should be referred for \nassessment by a cardiologist and followed up. \nIf symptomatic cardiac failure develops during trastuzumab therapy, it should be treated with standard \nmedicinal products for CHF. Most patients who developed CHF or asymptomatic cardiac dysfunction \nin pivotal trials improved with standard CHF treatment consisting of an angiotensin-converting \nenzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) and a beta-blocker. The majority of \npatients with cardiac symptoms and evidence of a clinical benefit of trastuzumab treatment continued \non therapy without additional clinical cardiac events. \nMetastatic breast cancer \nTrastuzumab and anthracyclines should not be given concurrently in combination in the MBC setting. \nPatients with MBC who have previously received anthracyclines are also at risk of cardiac dysfunction \nwith trastuzumab treatment, although the risk is lower than with concurrent use of trastuzumab and \nanthracyclines. \nEarly breast cancer \nFor patients with EBC, cardiac assessments, as performed at baseline, should be repeated every 3 \nmonths during treatment and every 6 months following discontinuation of treatment until 24 months \nfrom the last administration of trastuzumab. In patients who receive anthracycline-containing \nchemotherapy further monitoring is recommended, and should occur yearly up to 5 years from the last \nadministration of trastuzumab, or longer if a continuous decrease of LVEF is observed. \nPatients with history of myocardial infarction (MI), angina pectoris requiring medical treatment, \nhistory of or existing CHF (NYHA Class II \u2013IV), LVEF of < 55%, other cardiomyopathy, cardiac \narrhythmia requiring medical treatment, clinically significant cardiac valvular disease, poorly \ncontrolled hypertension (hypertension controlled by standard medical treatment eligible), and \nhemodynamic effective pericardial effusion were excluded from adjuvant and neoadjuvant EBC \npivotal trials with trastuzumab and therefore treatment cannot be recommended in such patients. \nAdjuvant treatment \nTrastuzumab and anthracyclines should not be given concurrently in combination in the adjuvant \ntreatment setting. \nIn patients with EBC an increase in the incidence of symptomatic and asymptomatic cardiac events \nwas observed when trastuzumab was administered after anthracycline-containing chemotherapy \ncompared to administration with a non-anthracycline regimen of docetaxel and carboplatin and was \nmore marked when trastuzumab was administered concurrently with taxanes than when administered \nsequentially to taxanes. Regardless of the regimen used, most symptomatic cardiac events occurred \nwithin the first 18 months. In one of the 3 pivotal studies conducted in which a median follow-up of \n5.5 years was available (BCIRG006) a continuous increase in the cumulative rate of symptomatic \ncardiac or LVEF events was observed in patients who were administered trastuzumab concurrently \nwith a taxane following anthracycline therapy up to 2.37 % compared to approximately 1 % in the two \ncomparator arms (anthracycline plus cyclophosphamide followed by taxane and taxane, carboplatin \nand trastuzumab). \nRisk factors for a cardiac event identified in four large adjuvant studies included advanced age \n(> 50 years), low LVEF (< 55 %) at baseline, prior to or following the initiation of paclitaxel \ntreatment, decline in LVEF by 10-15 points, and prior or concurrent use of anti-hypertensive \nmedicinal products. \nIn patients receiving trastuzumab after completion of adjuvant chemotherapy, the risk of cardiac \ndysfunction was associated with a higher cumulative dose of anthracycline given prior to initiation of \ntrastuzumab and a body mass index (BMI) > 25 kg/m2. \nNeoadjuvant-adjuvant treatment \nIn patients with EBC eligible for neoadjuvant-adjuvant treatment, trastuzumab should be used \nconcurrently with anthracyclines only in chemotherapy-naive patients and only with low-dose \nanthracycline regimens i.e. maximum cumulative doses of doxorubicin 180 mg/m2 or epirubicin \n360 mg/m2. \nIf patients have been treated concurrently with a full course of low-dose anthracyclines and \ntrastuzumab in the neoadjuvant setting, no additional cytotoxic chemotherapy should be given after \nsurgery. In other situations, the decision on the need for additional cytotoxic chemotherapy is \ndetermined based on individual factors. \nExperience of concurrent administration of trastuzumab with low dose anthracycline regimens is \ncurrently limited to the trial MO16432. \nIn the pivotal trial MO16432, trastuzumab was administered concurrently with neoadjuvant \nchemotherapy containing three cycles of doxorubicin (cumulative dose 180 mg/m2). \nThe incidence of symptomatic cardiac dysfunction was 1.7 % in the trastuzumab arm. \nClinical experience is limited in patients above 65 years of age. \nInfusion-related reactions (IRRs) and hypersensitivity \nSerious IRRs to trastuzumab infusion including dyspnoea, hypotension, wheezing, hypertension, \nbronchospasm, supraventricular tachyarrhythmia, reduced oxygen saturation, anaphylaxis, respiratory \ndistress, urticaria and angioedema have been reported (see section 4.8). Pre-medication may be used to \nreduce risk of occurrence of these events. The majority of these events occur during or within 2.5 \nhours of the start of the first infusion. Should an infusion reaction occur the infusion should be \ndiscontinued or the rate of infusion slowed and the patient should be monitored until resolution of all \nobserved symptoms (see section 4.2). These symptoms can be treated with an analgesic/antipyretic \nsuch as meperidine or paracetamol, or an antihistamine such as diphenhydramine. The majority of \npatients experienced resolution of symptoms and subsequently received further infusions of \ntrastuzumab. Serious reactions have been treated successfully with supportive therapy such as oxygen, \nbeta agonists, and corticosteroids. In rare cases, these reactions are associated with a clinical course \nculminating in a fatal outcome. Patients experiencing dyspnoea at rest due to complications of \nadvanced malignancy and comorbidities may be at increased risk of a fatal infusion reaction. \nTherefore, these patients should not be treated with trastuzumab (see section 4.3). \nInitial improvement followed by clinical deterioration and delayed reactions with rapid clinical \ndeterioration have also been reported. Fatalities have occurred within hours and up to one week \nfollowing infusion. On very rare occasions, patients have experienced the onset of infusion symptoms \nand pulmonary symptoms more than six hours after the start of the trastuzumab infusion. Patients \nshould be warned of the possibility of such a late onset and should be instructed to contact their \nphysician if these symptoms occur. \nPulmonary events \nSevere pulmonary events have been reported with the use of trastuzumab in the post-marketing setting \n(see section 4.8). These events have occasionally been fatal. In addition, cases of interstitial lung \ndisease including lung infiltrates, acute respiratory distress syndrome, pneumonia, pneumonitis, \npleural effusion, respiratory distress, acute pulmonary oedema and respiratory insufficiency have been \nreported. Risk factors associated with interstitial lung disease include prior or concomitant therapy \nwith other anti-neoplastic therapies known to be associated with it such as taxanes, gemcitabine, \nvinorelbine and radiation therapy. These events may occur as part of an infusion-related reaction or \nwith a delayed onset. Patients experiencing dyspnoea at rest due to complications of advanced \nmalignancy and comorbidities may be at increased risk of pulmonary events. Therefore, these patients \nshould not be treated with trastuzumab (see section 4.3). Caution should be exercised for pneumonitis, \nespecially in patients being treated concomitantly with taxanes. \nExcipients \nSorbitol content \nOgivri 150 mg contains 115.2 mg sorbitol in each vial.  \nOgivri 420 mg contains 322.6 mg sorbitol in each vial. \nPatients with hereditary fructose intolerance (HFI) must not be given this medicine unless strictly \nnecessary. \nA detailed history with regards to HFI symptoms has to be taken of each patient prior to being given \nthis medicinal product. \nSodium \nThis medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say, essentially \n\u2018sodium-free\u2019.", "pregnancy": "No interaction studies have been performed. Clinically significant interactions between trastuzumab \nand the concomitant medicinal products used in clinical trials have not been observed. \nEffect of trastuzumab on the pharmacokinetics of other antineoplastic agents \nPharmacokinetic data from studies BO15935 and M77004 in women with HER2-positive MBC \nsuggested that exposure to paclitaxel and doxorubicin (and their major metabolites 6-\u03b1 hydroxyl-\npaclitaxel, POH, and doxorubicinol, DOL) was not altered in the presence of trastuzumab (8 mg/kg or \n4 mg/kg intravenous loading dose followed by 6 mg/kg q3w or 2 mg/kg q1w intravenous, \nrespectively). \nHowever, trastuzumab may elevate the overall exposure of one doxorubicin metabolite, (7-deoxy-13 \ndihydro-doxorubicinone, D7D). The bioactivity of D7D and the clinical impact of the elevation of this \nmetabolite were unclear. \nData from study JP16003, a single-arm study of trastuzumab (4 mg/kg intravenous loading dose and \n2 mg/kg intravenous weekly) and docetaxel (60 mg/m2 intravenous) in Japanese women with HER2- \npositive MBC, suggested that concomitant administration of trastuzumab had no effect on the single \ndose pharmacokinetics of docetaxel. Study JP19959 was a sub study of BO18255 (ToGA) performed \nin male and female Japanese patients with advanced gastric cancer (AGC) to study the \npharmacokinetics of capecitabine and cisplatin when used with or without trastuzumab. The results of \nthis sub study suggested that the exposure to the bioactive metabolites (e.g. 5-FU) of capecitabine was \nnot affected by concurrent use of cisplatin or by concurrent use of cisplatin plus trastuzumab. \nHowever, capecitabine itself showed higher concentrations and a longer half-life when combined with \ntrastuzumab. The data also suggested that the pharmacokinetics of cisplatin were not affected by \nconcurrent use of capecitabine or by concurrent use of capecitabine plus trastuzumab. \n10 \nPharmacokinetic data from Study H4613g/GO01305 in patients with metastatic or locally advanced \ninoperable HER2-positive cancer suggested that trastuzumab had no impact on the PK of carboplatin. \nEffect of antineoplastic agents on trastuzumab pharmacokinetics  \nBy comparison of simulated serum trastuzumab concentrations after trastuzumab monotherapy \n(4 mg/kg loading/2 mg/kg q1w intravenous) and observed serum concentrations in Japanese women \nwith HER2- positive MBC (study JP16003) no evidence of a PK effect of concurrent administration of \ndocetaxel on the pharmacokinetics of trastuzumab was found. \nComparison of PK results from two phase II studies (BO15935 and M77004) and one phase III study \n(H0648g) in which patients were treated concomitantly with trastuzumab and paclitaxel and two phase \nII studies in which trastuzumab was administered as monotherapy (W016229 and MO16982), in \nwomen with HER2-positive MBC indicates that individual and mean trastuzumab trough serum \nconcentrations varied within and across studies but there was no clear effect of the concomitant \nadministration of paclitaxel on the pharmacokinetics of trastuzumab. Comparison of trastuzumab PK \ndata from Study M77004 in which women with HER2-positive MBC were treated concomitantly with \ntrastuzumab, paclitaxel and doxorubicin to trastuzumab PK data in studies where trastuzumab was \nadministered as monotherapy (H0649g) or in combination with anthracycline plus cyclophosphamide \nor paclitaxel (Study H0648g), suggested no effect of doxorubicin and paclitaxel on the \npharmacokinetics of trastuzumab. \nPharmacokinetic data from Study H4613g/GO01305 suggested that carboplatin had no impact on the \nPK of trastuzumab. \nThe administration of concomitant anastrozole did not appear to influence the pharmacokinetics of \ntrastuzumab.", "driving": "Women of childbearing potential \nWomen of childbearing potential should be advised to use effective contraception during treatment \nwith trastuzumab and for 7 months after treatment has concluded (see section 5.2). \nPregnancy \nReproduction studies have been conducted in Cynomolgus monkeys at doses up to 25 times that of the \nweekly human maintenance dose of 2 mg/kg trastuzumab intravenous formulation and have revealed \nno evidence of impaired fertility or harm to the foetus. Placental transfer of trastuzumab during the \nearly (days 20\u201350 of gestation) and late (days 120\u2013150 of gestation) foetal development period was \nobserved. It is not known whether trastuzumab can affect reproductive capacity. As animal \nreproduction studies are not always predictive of human response, trastuzumab should be avoided \nduring pregnancy unless the potential benefit for the mother outweighs the potential risk to the foetus. \nIn the post-marketing setting, cases of foetal renal growth and/or function impairment in association \nwith oligohydramnios, some associated with fatal pulmonary hypoplasia of the foetus, have been \nreported in pregnant women receiving trastuzumab. Women who become pregnant should be advised \nof the possibility of harm to the foetus. If a pregnant woman is treated with trastuzumab, or if a patient \nbecomes pregnant while receiving trastuzumab or within 7 months following the last dose of \ntrastuzumab, close monitoring by a multidisciplinary team is desirable. \n11 \nBreast-feeding \nA study conducted in Cynomolgus monkeys at doses 25 times that of the weekly human maintenance \ndose of 2 mg/kg trastuzumab intravenous formulation from days 120 to 150 of pregnancy \ndemonstrated that trastuzumab is secreted in the milk postpartum. The exposure to trastuzumab in \nutero and presence of trastuzumab in the serum of infant monkeys was not associated with any adverse \neffects on their growth or development from birth to 1 month of age. It is not known whether \ntrastuzumab is secreted in human milk. As human IgG1 is secreted into human milk, and the potential \nfor harm to the infant is unknown, women should not breast-feed during trastuzumab therapy and for 7 \nmonths after the last dose. \nFertility \nThere is no fertility data available.", "side_effects": "Ogivri has a minor influence on the ability to drive and use machines (see section 4.8). Dizziness and \nsomnolence may occur during treatment with Ogivri (see section 4.8). Patients experiencing infusion-\nrelated symptoms (see section 4.4) should be advised not to drive and use machines until symptoms \nabate.", "shelf_life": "4 years. \nAfter reconstitution with sterile water for injections, the reconstituted solution is physically and \nchemically stable for 10 days at 2\u00b0C \u2013 8\u00b0C. Any remaining reconstituted solution should be discarded. \nSolutions of Ogivri for intravenous infusion are physically and chemically stable in polyvinylchloride, \npolyethylene or polypropylene bags containing sodium chloride 9 mg/mL (0.9 %) solution for \ninjection for up to 90 days at 2\u00b0C \u2013 8\u00b0C and 24 hours at temperatures not exceeding 30\u00b0C. \nFrom a microbiological point of view, the reconstituted solution and Ogivri infusion solution should \nbe used immediately. The product is not intended to be stored after reconstitution and dilution unless \nthis has taken place under controlled and validated aseptic conditions. If not used immediately, in-use \nstorage times and conditions are the responsibility of the user.", "storage": "Store in a refrigerator (2\u00b0C \u2013 8\u00b0C). \nFor storage conditions after reconstitution of the medicinal product, see sections 6.3 and 6.6. \n32", "package": "Ogivri 150 mg powder for concentrate for solution for infusion \n15 mL clear glass type I vial with butyl rubber stopper laminated with a fluoro-resin film containing \n150 mg of trastuzumab. \nEach carton contains one vial. \nOgivri 420 mg powder for concentrate for solution for infusion \n50 mL clear glass type I vial with butyl rubber stopper laminated with a fluoro-resin film containing \n420 mg of trastuzumab. \nEach carton contains one vial.", "marketing_authorization_numbers": "EU/1/18/1341/001 \nEU/1/18/1341/002", "filename": "ogivri-epar-product-information_en.html", "snomed.product_info": [["732515006", "150 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["739005008", "Powder (basic dose form)"], ["86495002", "For (qualifier value)"], ["1237267003", "Concentrate for conventional release solution for infusion (dose form)"], ["1222865001", "American Joint Committee on Cancer stage IV:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["739005008", "Powder (basic dose form)"], ["86495002", "For (qualifier value)"], ["1237267003", "Concentrate for conventional release solution for infusion (dose form)"]], "ncit.product_info": [["C1647", "Trastuzumab"], ["C129532", "One Hundred Fifty"], ["C16818", "Mammography"], ["C149813", "Powder for Concentrate for Solution for Infusion Dosage Form"], ["C1647", "Trastuzumab"], ["C16818", "Mammography"], ["C149813", "Powder for Concentrate for Solution for Infusion Dosage Form"]], "rxnorm.product_info": [["2179754", "Ogivri"], ["2179754", "Ogivri"]], "loinc.product_info": [["LP15217-0", "Mg"], ["LP263434-5", "Infusion"], ["LP15217-0", "Mg"], ["LP263434-5", "Infusion"]], "snomed.composition": [["732515006", "150 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["739005008", "Powder (basic dose form)"], ["86495002", "For (qualifier value)"], ["1237267003", "Concentrate for conventional release solution for infusion (dose form)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["732515006", "150 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["28406009", "Immunoglobulin IgG>1< (substance)|Immunoglobulin IgG1 (substance)"], ["312312006", "Monoclonal antibody (substance)|Monoclonal antibody"], ["392392002", "Cricetulus griseus (organism)"], ["181464007", "Entire ovary (body structure)"], ["362837007", "Entire cell (body structure)|Entire cell (cell)"], ["739008005", "Suspension (basic dose form)"], ["703725008", "Culture technique (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["35840005", "Ion exchange, function (observable entity)|Ion exchange (function)"], ["55919000", "Including (qualifier value)"], ["69658003", "Specific (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["315350008", "Removal - procedure|Removal - procedure (procedure)"], ["1222865001", "American Joint Committee on Cancer stage IV:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["739005008", "Powder (basic dose form)"], ["86495002", "For (qualifier value)"], ["1237267003", "Concentrate for conventional release solution for infusion (dose form)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["1222865001", "American Joint Committee on Cancer stage IV:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["28406009", "Immunoglobulin IgG>1< (substance)|Immunoglobulin IgG1 (substance)"], ["312312006", "Monoclonal antibody (substance)|Monoclonal antibody"], ["392392002", "Cricetulus griseus (organism)"], ["181464007", "Entire ovary (body structure)"], ["362837007", "Entire cell (body structure)|Entire cell (cell)"], ["739008005", "Suspension (basic dose form)"], ["703725008", "Culture technique (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["35840005", "Ion exchange, function (observable entity)|Ion exchange (function)"], ["55919000", "Including (qualifier value)"], ["69658003", "Specific (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["315350008", "Removal - procedure|Removal - procedure (procedure)"], ["739006009", "Solution (basic dose form)"], ["1222774009", "American Joint Committee on Cancer stage II:1 (qualifier value)"], ["258798001", "Milligram/milliliter (qualifier value)|mg/mL (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["36692007", "Known (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["419473009", "Each (qualifier value)"], ["732515006", "150 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["1222754002", "American Joint Committee on Cancer stage I:15 (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["412513004", "Sorbitol (product)|Product containing sorbitol (medicinal product)"], ["419473009", "Each (qualifier value)"], ["1222865001", "American Joint Committee on Cancer stage IV:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["1222833004", "American Joint Committee on Cancer stage III:22 (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["412513004", "Sorbitol (product)|Product containing sorbitol (medicinal product)"], ["86495002", "For (qualifier value)"], ["261015003", "Full (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.composition": [["C1647", "Trastuzumab"], ["C129532", "One Hundred Fifty"], ["C16818", "Mammography"], ["C149813", "Powder for Concentrate for Solution for Infusion Dosage Form"], ["C66832", "One"], ["C41275", "Vial"], ["C79873", "Contain"], ["C129532", "One Hundred Fifty"], ["C16818", "Mammography"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C76246", "Blood Group A"], ["C201279", "IgG1"], ["C20401", "Monoclonal Antibody"], ["C158169", "Buyei Chinese"], ["C14234", "Mammalia"], ["C77091", "Chinese Hamster"], ["C12404", "Ovary"], ["C48694", "Cell"], ["C20217", "Suspension Culture"], ["C16289", "Andorra"], ["C68780", "Purification"], ["C158169", "Buyei Chinese"], ["C20604", "Affinity"], ["C16289", "Andorra"], ["C38203", "Iontophoresis Route of Administration"], ["C16431", "Chromatography"], ["C166400", "Inclusive"], ["C38024", "Specified"], ["C27985", "Viral"], ["C175900", "Inactivation"], ["C16289", "Andorra"], ["C61575", "Extraction"], ["C102700", "Procedure Domain"], ["C1647", "Trastuzumab"], ["C16818", "Mammography"], ["C149813", "Powder for Concentrate for Solution for Infusion Dosage Form"], ["C66832", "One"], ["C41275", "Vial"], ["C79873", "Contain"], ["C16818", "Mammography"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C76246", "Blood Group A"], ["C201279", "IgG1"], ["C20401", "Monoclonal Antibody"], ["C158169", "Buyei Chinese"], ["C14234", "Mammalia"], ["C77091", "Chinese Hamster"], ["C12404", "Ovary"], ["C48694", "Cell"], ["C20217", "Suspension Culture"], ["C16289", "Andorra"], ["C68780", "Purification"], ["C158169", "Buyei Chinese"], ["C20604", "Affinity"], ["C16289", "Andorra"], ["C38203", "Iontophoresis Route of Administration"], ["C16431", "Chromatography"], ["C166400", "Inclusive"], ["C38024", "Specified"], ["C27985", "Viral"], ["C175900", "Inactivation"], ["C16289", "Andorra"], ["C61575", "Extraction"], ["C102700", "Procedure Domain"], ["C1647", "Trastuzumab"], ["C42986", "Solution Dosage Form"], ["C79873", "Contain"], ["C107434", "Twenty One"], ["C42576", "Kilogram per Cubic Meter"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C42637", "Pharmaceutical Excipient"], ["C62355", "With"], ["C80137", "Known"], ["C71600", "Effect, Appearance"], ["C64933", "Each"], ["C129532", "One Hundred Fifty"], ["C16818", "Mammography"], ["C41275", "Vial"], ["C79873", "Contain"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16818", "Mammography"], ["C29462", "Sorbitol"], ["C64933", "Each"], ["C16818", "Mammography"], ["C41275", "Vial"], ["C79873", "Contain"], ["C172979", "Fear Score 6"], ["C16818", "Mammography"], ["C29462", "Sorbitol"], ["C64956", "For"], ["C25517", "Full"], ["C43432", "List"], ["C52874", "SPI1 wt Allele"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.composition": [["2179754", "Ogivri"], ["224905", "trastuzumab"], ["T025", "Cell"], ["2179754", "Ogivri"], ["224905", "trastuzumab"], ["T025", "Cell"], ["2179754", "Ogivri"], ["224905", "trastuzumab"], ["9945", "sorbitol"], ["9945", "sorbitol"]], "loinc.composition": [["LP15217-0", "Mg"], ["LP263434-5", "Infusion"], ["LA6306-0", "One"], ["LA20376-2", "Vial"], ["LP15217-0", "Mg"], ["LP17763-1", "A"], ["LP32407-6", "IgG1"], ["LA4168-6", "Chinese"], ["LP206706-6", "Ovary"], ["MTHU064138", "Cell suspension"], ["LA7508-0", "Culture"], ["LP200045-5", "Exchange"], ["LA11134-6", "Inactivation"], ["LP263431-1", "Removal"], ["LP15217-0", "Mg"], ["LP263434-5", "Infusion"], ["LA6306-0", "One"], ["LA20376-2", "Vial"], ["LP15217-0", "Mg"], ["LP17763-1", "A"], ["LP32407-6", "IgG1"], ["LA4168-6", "Chinese"], ["LP206706-6", "Ovary"], ["MTHU064138", "Cell suspension"], ["LA7508-0", "Culture"], ["LP200045-5", "Exchange"], ["LA11134-6", "Inactivation"], ["LP263431-1", "Removal"], ["LA19717-0", "Reconstituted"], ["LP15217-0", "Mg"], ["LP15217-0", "Mg"], ["LA20376-2", "Vial"], ["MTHU000002", "Clinical Class"], ["LP15217-0", "Mg"], ["LP62208-1", "Sorbitol"], ["LP15217-0", "Mg"], ["LA20376-2", "Vial"], ["LP20594-5", "6"], ["LP15217-0", "Mg"], ["LP62208-1", "Sorbitol"], ["LA19682-6", "Full"], ["LP204165-7", "List"], ["LP20594-5", "6"], ["LA6112-2", "1"]], "snomed.indications": [["254837009", "Malignant tumor of breast (disorder)|Malignant neoplasm of breast (disorder)"], ["254837009", "Malignant tumor of breast (disorder)|Malignant neoplasm of breast (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255397009", "Adult (qualifier value)|Adult"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["394424008", "Positive|Positive (qualifier value)"], ["254837009", "Malignant tumor of breast (disorder)|Malignant neoplasm of breast (disorder)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["367336001", "Chemotherapy (procedure)"], ["86495002", "For (qualifier value)"], ["64572001", "Disease (disorder)"], ["367336001", "Chemotherapy (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["372540003", "Anthracycline (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["86495002", "For (qualifier value)"], ["734617007", "Hormone (disposition)"], ["116647005", "Receptor (substance)"], ["394424008", "Positive|Positive (qualifier value)"], ["278994005", "Hormonal (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["86495002", "For (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387374002", "Paclitaxel (substance)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["367336001", "Chemotherapy (procedure)"], ["86495002", "For (qualifier value)"], ["64572001", "Disease (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["372540003", "Anthracycline (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386918005", "Docetaxel (substance)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["367336001", "Chemotherapy (procedure)"], ["86495002", "For (qualifier value)"], ["64572001", "Disease (disorder)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["734580007", "Aromatase inhibitor (disposition)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["76498008", "Postmenopausal state (finding)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["734617007", "Hormone (disposition)"], ["116647005", "Receptor (substance)"], ["394424008", "Positive|Positive (qualifier value)"], ["28995006", "Treated with (attribute)"], ["387003001", "Trastuzumab (substance)"], ["264499004", "Early (qualifier value)"], ["254837009", "Malignant tumor of breast (disorder)|Malignant neoplasm of breast (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255397009", "Adult (qualifier value)|Adult"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["394424008", "Positive|Positive (qualifier value)"], ["264499004", "Early (qualifier value)"], ["254837009", "Malignant tumor of breast (disorder)|Malignant neoplasm of breast (disorder)"], ["255260001", "Following (attribute)"], ["387713003", "Surgical procedure (procedure)"], ["367336001", "Chemotherapy (procedure)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["10926004", "Adjuvant (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419815003", "Radiation oncology (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["255260001", "Following (attribute)"], ["10926004", "Adjuvant (substance)"], ["367336001", "Chemotherapy (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["372817009", "Doxorubicin (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387420009", "Cyclophosphamide (substance)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387374002", "Paclitaxel (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386918005", "Docetaxel (substance)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["10926004", "Adjuvant (substance)"], ["367336001", "Chemotherapy (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386918005", "Docetaxel (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386905002", "Carboplatin (substance)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["367336001", "Chemotherapy (procedure)"], ["367409002", "Followed by (attribute)"], ["10926004", "Adjuvant (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["86495002", "For (qualifier value)"], ["86005002", "Advanced (qualifier value)"], ["55919000", "Including (qualifier value)"], ["255387000", "Inflammatory|Inflammatory (qualifier value)"], ["64572001", "Disease (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["276140008", "Greater-than symbol > (qualifier value)|> (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258672001", "cm (qualifier value)|centimeter (qualifier value)|Centimeter (qualifier value)"], ["18720000", "In (attribute)"], ["81827009", "Diameter (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["12645001", "Gene amplification (finding)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["436000", "Determined by (contextual qualifier) (qualifier value)"], ["263656005", "Accurate (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["272392009", "Assay technique (qualifier value)|Assay (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["363349007", "Malignant tumor of stomach (disorder)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386906001", "Capecitabine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["387172005", "Fluorouracil (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387318005", "Cisplatin (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255397009", "Adult (qualifier value)|Adult"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["394424008", "Positive|Positive (qualifier value)"], ["354081000119101", "Metastatic adenocarcinoma (disorder)|Secondary adenocarcinoma (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["181246003", "Entire stomach (body structure)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["50974003", "Junctional (qualifier value)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["86495002", "For (qualifier value)"], ["64572001", "Disease (disorder)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["363349007", "Malignant tumor of stomach (disorder)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["900000000000073002", "Sufficiently defined by necessary conditions definition status (core metadata concept)|Sufficiently defined concept definition status (core metadata concept)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["735971005", "Fish (substance)"], ["394617004", "Result (navigational concept)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["394617004", "Result (navigational concept)"], ["263656005", "Accurate (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["272392009", "Assay technique (qualifier value)|Assay (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.indications": [["C4872", "Breast Carcinoma"], ["C3261", "Metastatic Neoplasm"], ["C4872", "Breast Carcinoma"], ["C1647", "Trastuzumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C62355", "With"], ["C68748", "HER2/Neu Positive"], ["C3261", "Metastatic Neoplasm"], ["C4872", "Breast Carcinoma"], ["C9609", "Bleomycin/Cisplatin/Methotrexate Regimen"], ["C71344", "Associate of Science"], ["C157514", "Single Agent Therapy"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C25639", "Receive"], ["C158997", "GDC Analyte Type Terminology"], ["C66833", "Two"], ["C15632", "Chemotherapy"], ["C64956", "For"], ["C40557", "Metastatic Lesion"], ["C16171", "Prior Chemotherapy"], ["C101282", "Have"], ["C158997", "GDC Analyte Type Terminology"], ["C75889", "PAX6 wt Allele"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C1490", "Taxane Compound"], ["C16960", "Patient"], ["C68869", "Are"], ["C64956", "For"], ["C28154", "Hormone Receptor"], ["C36659", "CTNNB1 Gene Mutation"], ["C16960", "Patient"], ["C101282", "Have"], ["C44281", "Failed"], ["C15445", "Hormone Therapy"], ["C16960", "Patient"], ["C68869", "Are"], ["C64956", "For"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C1411", "Paclitaxel"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C25594", "Negation"], ["C25639", "Receive"], ["C15632", "Chemotherapy"], ["C64956", "For"], ["C40557", "Metastatic Lesion"], ["C16289", "Andorra"], ["C64956", "For"], ["C75889", "PAX6 wt Allele"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C116358", "Amenable"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C1526", "Docetaxel"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C25594", "Negation"], ["C25639", "Receive"], ["C15632", "Chemotherapy"], ["C64956", "For"], ["C40557", "Metastatic Lesion"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C75889", "PAX6 wt Allele"], ["C1740", "Aromatase Inhibitor"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C15421", "Postmenopausal"], ["C16960", "Patient"], ["C62355", "With"], ["C2315", "Hormone"], ["C18106", "Receptor"], ["C36659", "CTNNB1 Gene Mutation"], ["C9609", "Bleomycin/Cisplatin/Methotrexate Regimen"], ["C25594", "Negation"], ["C16124", "Prior Therapy"], ["C62355", "With"], ["C1647", "Trastuzumab"], ["C61589", "Early"], ["C4872", "Breast Carcinoma"], ["C1647", "Trastuzumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C62355", "With"], ["C68748", "HER2/Neu Positive"], ["C61589", "Early"], ["C4872", "Breast Carcinoma"], ["C53286", "Next"], ["C160609", "Surgical Procedure was Curative Therapy"], ["C15632", "Chemotherapy"], ["C15665", "Neoadjuvant Therapy"], ["C43508", "Oregon"], ["C124450", "Adjuvant Therapy Clinical Trial Setting"], ["C16289", "Andorra"], ["C15313", "Radiation Therapy"], ["C198613", "CFI wt Allele"], ["C44483", "Applicable"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C53286", "Next"], ["C15360", "Adjuvant Chemotherapy"], ["C62355", "With"], ["C456", "Doxorubicin"], ["C16289", "Andorra"], ["C405", "Cyclophosphamide"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C1411", "Paclitaxel"], ["C43508", "Oregon"], ["C1526", "Docetaxel"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C15360", "Adjuvant Chemotherapy"], ["C52874", "SPI1 wt Allele"], ["C1526", "Docetaxel"], ["C16289", "Andorra"], ["C1282", "Carboplatin"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C15665", "Neoadjuvant Therapy"], ["C15632", "Chemotherapy"], ["C53286", "Next"], ["C124450", "Adjuvant Therapy Clinical Trial Setting"], ["C1647", "Trastuzumab"], ["C49236", "Therapeutic Procedure"], ["C64956", "For"], ["C41065", "Locally"], ["C25411", "Advanced"], ["C166400", "Inclusive"], ["C25535", "Inflammatory"], ["C2991", "Disease or Disorder"], ["C43508", "Oregon"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C7137", "Cutaneous Mastocytosis"], ["C16727", "India"], ["C25285", "Diameter"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C1647", "Trastuzumab"], ["C48440", "Single"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C3261", "Metastatic Neoplasm"], ["C43508", "Oregon"], ["C101282", "Have"], ["C17756", "ERBB2 Gene"], ["C18211", "Protein Overexpression"], ["C43508", "Oregon"], ["C36638", "ERBB2 Gene Amplification"], ["C71344", "Associate of Science"], ["C136827", "Determine"], ["C158169", "Buyei Chinese"], ["C75889", "PAX6 wt Allele"], ["C49145", "Accuracy"], ["C16289", "Andorra"], ["C172871", "File Validated"], ["C16341", "Bioassay"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C3261", "Metastatic Neoplasm"], ["C4911", "Gastric Carcinoma"], ["C1647", "Trastuzumab"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C1794", "Capecitabine"], ["C43508", "Oregon"], ["C505", "Fluorouracil"], ["C16289", "Andorra"], ["C376", "Cisplatin"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C62355", "With"], ["C68748", "HER2/Neu Positive"], ["C4124", "Metastatic Adenocarcinoma"], ["C52874", "SPI1 wt Allele"], ["C12391", "Stomach"], ["C43508", "Oregon"], ["C50017", "Junction Device"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C25594", "Negation"], ["C25639", "Receive"], ["C25629", "Prior"], ["C16212", "Cancer Therapeutic Procedure"], ["C64956", "For"], ["C40557", "Metastatic Lesion"], ["C1647", "Trastuzumab"], ["C48440", "Single"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C3261", "Metastatic Neoplasm"], ["C4911", "Gastric Carcinoma"], ["C101282", "Have"], ["C150634", "ERBB2 Overexpression"], ["C71344", "Associate of Science"], ["C151401", "Definable"], ["C158169", "Buyei Chinese"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C25458", "Confirmation"], ["C142344", "Silver-Enhanced in Situ Hybridization"], ["C43508", "Oregon"], ["C14207", "Fish"], ["C20200", "Outcome"], ["C43508", "Oregon"], ["C158169", "Buyei Chinese"], ["C75889", "PAX6 wt Allele"], ["C174249", "EWS Immunohistochemistry Table"], ["C88130", "3+ Score, WHO"], ["C20200", "Outcome"], ["C49145", "Accuracy"], ["C16289", "Andorra"], ["C172871", "File Validated"], ["C16341", "Bioassay"], ["C16847", "Technique"], ["C16329", "Belgium"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.indications": [["2179754", "Ogivri"], ["T125", "Hormone"], ["T192", "Receptor"], ["56946", "paclitaxel"], ["72962", "docetaxel"], ["T125", "Hormone"], ["T192", "Receptor"], ["224905", "trastuzumab"], ["2179754", "Ogivri"], ["3639", "doxorubicin"], ["3002", "cyclophosphamide"], ["56946", "paclitaxel"], ["72962", "docetaxel"], ["72962", "docetaxel"], ["40048", "carboplatin"], ["2179754", "Ogivri"], ["2179754", "Ogivri"], ["2179754", "Ogivri"], ["194000", "capecitabine"], ["4492", "fluorouracil"], ["2555", "cisplatin"], ["2179754", "Ogivri"], ["T013", "Fish"]], "loinc.indications": [["LA14283-8", "Breast cancer"], ["LA14283-8", "Breast cancer"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA13524-6", "Adult"], ["LP28442-9", "HER2"], ["LA6576-8", "Positive"], ["LA14283-8", "Breast cancer"], ["LP94823-9", "Treatment"], ["LA32660-5", "Received"], ["LA21988-3", "AT"], ["LA6404-3", "Two"], ["MTHU010425", "Chemotherapy"], ["LA18199-2", "Disease"], ["LA33028-4", "Prior"], ["MTHU010425", "Chemotherapy"], ["LA21988-3", "AT"], ["LP17763-1", "A"], ["MTHU021207", "Treatments"], ["T125", "Hormone"], ["T192", "Receptor"], ["LA6576-8", "Positive"], ["LP267221-2", "Therapy"], ["MTHU021207", "Treatments"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["MTHU060612", "PACLitaxel"], ["LP94823-9", "Treatment"], ["LA21291-2", "Not"], ["LA32660-5", "Received"], ["MTHU010425", "Chemotherapy"], ["LA18199-2", "Disease"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP94823-9", "Treatment"], ["LA21291-2", "Not"], ["LA32660-5", "Received"], ["MTHU010425", "Chemotherapy"], ["LA18199-2", "Disease"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP94823-9", "Treatment"], ["LP140232-2", "postmenopausal"], ["T125", "Hormone"], ["T192", "Receptor"], ["LA6576-8", "Positive"], ["LA21291-2", "Not"], ["LA12111-3", "Early"], ["LA14283-8", "Breast cancer"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA13524-6", "Adult"], ["LP28442-9", "HER2"], ["LA6576-8", "Positive"], ["LA12111-3", "Early"], ["LA14283-8", "Breast cancer"], ["LP7616-8", "Surgery"], ["MTHU010425", "Chemotherapy"], ["LA22025-3", "OR"], ["LA26009-3", "Radiotherapy"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["MTHU010425", "Chemotherapy"], ["LP18382-9", "DOXOrubicin"], ["LP70366-7", "Cyclophosphamide"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["MTHU060612", "PACLitaxel"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["MTHU010425", "Chemotherapy"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["MTHU010425", "Chemotherapy"], ["LP267221-2", "Therapy"], ["LA18199-2", "Disease"], ["LA22025-3", "OR"], ["MTHU000002", "Clinical Class"], ["LA22004-8", "IN"], ["MTHU002654", "Diameter"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LA11930-7", "Either"], ["LP28442-9", "HER2"], ["LA22025-3", "OR"], ["LP28442-9", "HER2"], ["LA18201-6", "Gene"], ["LA9926-2", "Accurate"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LA10547-0", "Gastric Cancer"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LA22025-3", "OR"], ["LP20593-7", "5"], ["MTHU016749", "Fluorouracil"], ["MTHU060553", "CISplatin"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA13524-6", "Adult"], ["LP28442-9", "HER2"], ["LA6576-8", "Positive"], ["LA11900-0", "Adenocarcinoma"], ["MTHU003059", "Stomach"], ["LA22025-3", "OR"], ["LA21291-2", "Not"], ["LA32660-5", "Received"], ["LA33028-4", "Prior"], ["MTHU038130", "Cancer treatment"], ["LA18199-2", "Disease"], ["LA22004-8", "IN"], ["LA10547-0", "Gastric Cancer"], ["LP28442-9", "HER2"], ["LP17763-1", "A"], ["LA22025-3", "OR"], ["LP62864-1", "Fluorescent in situ hybridization (FISH)"], ["LA22025-3", "OR"], ["LA11843-2", "3+"], ["LA9926-2", "Accurate"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20593-7", "5"], ["LA6112-2", "1"]], "snomed.posology": [["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["288556008", "Before (attribute)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["309343006", "Physician (occupation)"], ["18720000", "In (attribute)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["734873001", "Cytotoxic (disposition)"], ["367336001", "Chemotherapy (procedure)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["223366009", "Healthcare professional (occupation)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["255560000", "Intravenous (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["86495002", "For (qualifier value)"], ["764295003", "Subcutaneous (intended site)"], ["416118004", "Administration (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["385228000", "Intravenous infusion (product)|Intravenous infusion (qualifier value)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["410675002", "Route of administration (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["74964007", "Other (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["101445003", "PREVENT (substance)|PREVENT (product)"], ["2533004", "Drug (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["346414003", "Ensure (substance)|Ensure (product)"], ["763158003", "Medicinal product (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["327397006", "Trastuzumab (product)|Product containing trastuzumab (medicinal product)|Trastuzumab (substance)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["702836004", "Trastuzumab emtansine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["838469001", "Trastuzumab deruxtecan (substance)"], ["254837009", "Malignant tumor of breast (disorder)|Malignant neoplasm of breast (disorder)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["897015005", "Recommended (qualifier value)"], ["884001", "Initial (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["228920005", "Milligram/kilogram body weight (qualifier value)|mg/kg body weight (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["228920005", "Milligram/kilogram body weight (qualifier value)|mg/kg body weight (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["897015005", "Recommended (qualifier value)"], ["884001", "Initial (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["228920005", "Milligram/kilogram body weight (qualifier value)|mg/kg body weight (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["228920005", "Milligram/kilogram body weight (qualifier value)|mg/kg body weight (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["416118004", "Administration (procedure)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387374002", "Paclitaxel (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386918005", "Docetaxel (substance)"], ["18720000", "In (attribute)"], ["387374002", "Paclitaxel (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386918005", "Docetaxel (substance)"], ["264721006", "day (qualifier value)|day"], ["255260001", "Following (attribute)"], ["255216001", "First (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["86495002", "For (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86495002", "For (qualifier value)"], ["387374002", "Paclitaxel (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386918005", "Docetaxel (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["255234002", "After (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["288556008", "Before (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["20572008", "Good (qualifier value)"], ["416118004", "Administration (procedure)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["734580007", "Aromatase inhibitor (disposition)"], ["18720000", "In (attribute)"], ["387003001", "Trastuzumab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386910003", "Anastrozole (substance)"], ["264721006", "day (qualifier value)|day"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["373067005", "No (qualifier value)"], ["420862001", "On (qualifier value)"], ["394439009", "Relative|Relative (person)"], ["246512002", "Timing (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386910003", "Anastrozole (substance)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["86495002", "For (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["86495002", "For (qualifier value)"], ["386910003", "Anastrozole (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["264499004", "Early (qualifier value)"], ["254837009", "Malignant tumor of breast (disorder)|Malignant neoplasm of breast (disorder)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["897015005", "Recommended (qualifier value)"], ["884001", "Initial (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["726527001", "Weight (property) (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["726527001", "Weight (property) (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["884001", "Initial (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["367409002", "Followed by (attribute)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["14497002", "Weekly (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387374002", "Paclitaxel (substance)"], ["255260001", "Following (attribute)"], ["367336001", "Chemotherapy (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["372817009", "Doxorubicin (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387420009", "Cyclophosphamide (substance)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["86495002", "For (qualifier value)"], ["367336001", "Chemotherapy (procedure)"], ["89780004", "Combined (qualifier value)"], ["363349007", "Malignant tumor of stomach (disorder)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["897015005", "Recommended (qualifier value)"], ["884001", "Initial (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["228920005", "Milligram/kilogram body weight (qualifier value)|mg/kg body weight (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["228920005", "Milligram/kilogram body weight (qualifier value)|mg/kg body weight (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["254837009", "Malignant tumor of breast (disorder)|Malignant neoplasm of breast (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["363349007", "Malignant tumor of stomach (disorder)"], ["261774000", "Duration of treatment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["28995006", "Treated with (attribute)"], ["387003001", "Trastuzumab (substance)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["246450006", "Progression (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["64572001", "Disease (disorder)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["28995006", "Treated with (attribute)"], ["387003001", "Trastuzumab (substance)"], ["86495002", "For (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258707000", "year (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["64572001", "Disease (disorder)"], ["246455001", "Recurrence (qualifier value)"], ["255216001", "First (qualifier value)"], ["66211004", "Extending (qualifier value)"], ["18720000", "In (attribute)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["258707000", "year (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["289928003", "Reduction plasty (qualifier value)"], ["373067005", "No (qualifier value)"], ["18720000", "In (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["277132007", "Therapeutic procedure (procedure)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["248957007", "Menstruation, function (observable entity)|Menstruation (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["35174006", "Reversible (qualifier value)"], ["1177084005", "Myelosuppression due to chemotherapy (finding)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["303011007", "Neutropenic disorder (disorder)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["387374002", "Paclitaxel (substance)"], ["386918005", "Docetaxel (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["734580007", "Aromatase inhibitor (disposition)"], ["86495002", "For (qualifier value)"], ["420862001", "On (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["289928003", "Reduction plasty (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["390116000", "Left ventricular ejection fraction|Left ventricular ejection fraction (finding)"], ["426684005", "Drops dose form (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["351726001", "Below (qualifier value)"], ["732774003", "50 (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["385655000", "Suspended (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["27582007", "Repeat (qualifier value)"], ["386053000", "Evaluation procedure (procedure)|Patient evaluation procedure (procedure)"], ["398166005", "Performed (qualifier value)"], ["18720000", "In (attribute)"], ["26175008", "Approximate (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258705008", "week (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["385425000", "Improved (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["443390004", "Refused (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["698594003", "Symptomatic congestive heart failure (disorder)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["86495002", "For (qualifier value)"], ["385435006", "Individual (person)"], ["116154003", "Patient (person)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["439980006", "Referred (situation)|Referral placed (situation)"], ["86495002", "For (qualifier value)"], ["386053000", "Evaluation procedure (procedure)|Patient evaluation procedure (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["17561000", "Cardiologist (occupation)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["116154003", "Patient (person)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["258705008", "week (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421067001", "Then - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["397943006", "Planned (qualifier value)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["258703001", "day (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1222774009", "American Joint Committee on Cancer stage II:1 (qualifier value)"], ["258703001", "day (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["116154003", "Patient (person)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["242762006", "More (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["258705008", "week (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["21481007", "Over (qualifier value)"], ["26175008", "Approximate (qualifier value)"], ["732899009", "90 (qualifier value)"], ["1156209001", "minute (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["709122007", "As soon as possible (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["258703001", "day (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1222774009", "American Joint Committee on Cancer stage II:1 (qualifier value)"], ["258703001", "day (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["67995009", "Special (qualifier value)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["40226000", "Impairment (finding)"], ["255529000", "Out (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["385436007", "Population (social concept)"], ["272389005", "Analysis (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["387003001", "Trastuzumab (substance)"], ["726711005", "Disposition (disposition)"], ["376171000221106", "Pediatric population (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["260676000", "Use of (attribute)"], ["387003001", "Trastuzumab (substance)"], ["18720000", "In (attribute)"], ["376171000221106", "Pediatric population (qualifier value)"], ["260686004", "Method (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["387003001", "Trastuzumab (substance)"], ["408102007", "Unit dose (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["732899009", "90 (qualifier value)"], ["1156210006", "Minuscule (qualifier value)"], ["385228000", "Intravenous infusion (product)|Intravenous infusion (qualifier value)"], ["738990001", "Administer (administration method)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["404816009", "Intravenous push route (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["385228000", "Intravenous infusion (product)|Intravenous infusion (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["39579001", "Anaphylaxis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["25876001", "Emergency (qualifier value)"], ["419179001", "Kit - unit of product usage (qualifier value)|Kit (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["86495002", "For (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["68244004", "Six (qualifier value)|6 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["255234002", "After (attribute)"], ["226630009", "Start (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255216001", "First (qualifier value)"], ["36576007", "Infusion (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["258702006", "hour (qualifier value)"], ["255234002", "After (attribute)"], ["226630009", "Start (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86495002", "For (qualifier value)"], ["386661006", "Fever (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["36576007", "Infusion (procedure)"], ["262094002", "Related (finding)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["36576007", "Infusion (procedure)"], ["246106000", "Control (attribute)"], ["36576007", "Infusion (procedure)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["884001", "Initial (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["20572008", "Good (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["1156210006", "Minuscule (qualifier value)"], ["36576007", "Infusion (procedure)"], ["86495002", "For (qualifier value)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["763158003", "Medicinal product (product)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["732810007", "6.6 (qualifier value)"]], "ncit.posology": [["C17756", "ERBB2 Gene"], ["C15336", "Testing"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C1647", "Trastuzumab"], ["C43442", "Biomaterial Treatment"], ["C48440", "Single"], ["C16329", "Belgium"], ["C158169", "Buyei Chinese"], ["C76246", "Blood Group A"], ["C25741", "Physician"], ["C16727", "India"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C15681", "Cytotoxic Chemotherapy"], ["C15632", "Chemotherapy"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C158169", "Buyei Chinese"], ["C76246", "Blood Group A"], ["C16205", "Healthcare Activity"], ["C97016", "Health Care Professional Promotional Material"], ["C48440", "Single"], ["C1647", "Trastuzumab"], ["C38276", "Intravenous Route of Administration"], ["C15653", "Drug Formulation Process"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C118257", "Unintentional"], ["C64956", "For"], ["C13353", "Subcutaneous"], ["C70962", "Agent Administration"], ["C16289", "Andorra"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C113553", "SEMA6A wt Allele"], ["C75889", "PAX6 wt Allele"], ["C38275", "Intravenous Infusion"], ["C48440", "Single"], ["C198613", "CFI wt Allele"], ["C75889", "PAX6 wt Allele"], ["C25415", "Alternative"], ["C38114", "Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C118472", "Other License Status"], ["C1647", "Trastuzumab"], ["C166358", "Offer"], ["C75889", "PAX6 wt Allele"], ["C25374", "Options"], ["C16329", "Belgium"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C459", "Medication"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C125543", "Importance Rating Score 0"], ["C159124", "GDC Treatment Outcome Terminology"], ["C86058", "Check"], ["C41275", "Vial"], ["C159124", "GDC Treatment Outcome Terminology"], ["C74452", "Nutritional Supplement Drink"], ["C142605", "Medicinal Product"], ["C89327", "Be"], ["C25625", "Preparation"], ["C16289", "Andorra"], ["C25382", "Administered"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C1647", "Trastuzumab"], ["C1647", "Trastuzumab"], ["C16289", "Andorra"], ["C25594", "Negation"], ["C1647", "Trastuzumab"], ["C79873", "Contain"], ["C40352", "Multiplicative Product"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C82492", "Trastuzumab Emtansine"], ["C43508", "Oregon"], ["C128799", "Trastuzumab Deruxtecan"], ["C3261", "Metastatic Neoplasm"], ["C4872", "Breast Carcinoma"], ["C66834", "Three"], ["C67069", "Weekly"], ["C25211", "Schedule"], ["C25197", "Recommendation"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C71584", "Load"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C66839", "Eight"], ["C67401", "Milligram per Kilogram"], ["C95085", "Body Weight Domain"], ["C25197", "Recommendation"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25488", "Dose"], ["C158997", "GDC Analyte Type Terminology"], ["C66834", "Three"], ["C67069", "Weekly"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C172979", "Fear Score 6"], ["C67401", "Milligram per Kilogram"], ["C95085", "Body Weight Domain"], ["C66834", "Three"], ["C29844", "Week"], ["C38008", "Post"], ["C71584", "Load"], ["C25488", "Dose"], ["C67069", "Weekly"], ["C25211", "Schedule"], ["C25197", "Recommendation"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C71584", "Load"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C67401", "Milligram per Kilogram"], ["C95085", "Body Weight Domain"], ["C25197", "Recommendation"], ["C67069", "Weekly"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67401", "Milligram per Kilogram"], ["C95085", "Body Weight Domain"], ["C66832", "One"], ["C29844", "Week"], ["C38008", "Post"], ["C71584", "Load"], ["C25488", "Dose"], ["C70962", "Agent Administration"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C1411", "Paclitaxel"], ["C43508", "Oregon"], ["C1526", "Docetaxel"], ["C16727", "India"], ["C71104", "Clinical Trial"], ["C1411", "Paclitaxel"], ["C43508", "Oregon"], ["C1526", "Docetaxel"], ["C154196", "Washo Language"], ["C25382", "Administered"], ["C25301", "Day"], ["C53286", "Next"], ["C25509", "First"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C64956", "For"], ["C25488", "Dose"], ["C163702", "Staphylococcal Enterotoxin E"], ["C42581", "Summary"], ["C52874", "SPI1 wt Allele"], ["C40352", "Multiplicative Product"], ["C25447", "Characteristic"], ["C64956", "For"], ["C1411", "Paclitaxel"], ["C43508", "Oregon"], ["C1526", "Docetaxel"], ["C16289", "Andorra"], ["C64597", "Immediately"], ["C38008", "Post"], ["C53286", "Next"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C198613", "CFI wt Allele"], ["C25629", "Prior"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C154196", "Washo Language"], ["C128793", "Microplate Well"], ["C70962", "Agent Administration"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C75889", "PAX6 wt Allele"], ["C1740", "Aromatase Inhibitor"], ["C16727", "India"], ["C71104", "Clinical Trial"], ["C1647", "Trastuzumab"], ["C16289", "Andorra"], ["C1607", "Anastrozole"], ["C25382", "Administered"], ["C25516", "From"], ["C25301", "Day"], ["C105723", "ECOG Performance Status 1"], ["C121396", "No Extremity Functional Restrictions"], ["C92667", "SPARC wt Allele"], ["C45830", "Relative Value"], ["C40567", "Timing, LOINC Axis 3"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C16289", "Andorra"], ["C1607", "Anastrozole"], ["C158997", "GDC Analyte Type Terminology"], ["C70962", "Agent Administration"], ["C64956", "For"], ["C25488", "Dose"], ["C163702", "Staphylococcal Enterotoxin E"], ["C64956", "For"], ["C1607", "Anastrozole"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C17956", "Cytochrome P450 19A1"], ["C61589", "Early"], ["C4872", "Breast Carcinoma"], ["C66834", "Three"], ["C67069", "Weekly"], ["C16289", "Andorra"], ["C67069", "Weekly"], ["C25211", "Schedule"], ["C71344", "Associate of Science"], ["C76246", "Blood Group A"], ["C66834", "Three"], ["C67069", "Weekly"], ["C165496", "GDC Regimen Terminology"], ["C25197", "Recommendation"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C71584", "Load"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C66839", "Eight"], ["C67401", "Milligram per Kilogram"], ["C12258", "Body of Stomach"], ["C48192", "Importance Weight"], ["C25197", "Recommendation"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C158997", "GDC Analyte Type Terminology"], ["C66834", "Three"], ["C67069", "Weekly"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C172979", "Fear Score 6"], ["C67401", "Milligram per Kilogram"], ["C12258", "Body of Stomach"], ["C48192", "Importance Weight"], ["C66834", "Three"], ["C29844", "Week"], ["C38008", "Post"], ["C71584", "Load"], ["C25488", "Dose"], ["C71344", "Associate of Science"], ["C76246", "Blood Group A"], ["C67069", "Weekly"], ["C165496", "GDC Regimen Terminology"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C71584", "Load"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C67401", "Milligram per Kilogram"], ["C53286", "Next"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67401", "Milligram per Kilogram"], ["C67069", "Weekly"], ["C62355", "With"], ["C1411", "Paclitaxel"], ["C53286", "Next"], ["C15632", "Chemotherapy"], ["C62355", "With"], ["C456", "Doxorubicin"], ["C16289", "Andorra"], ["C405", "Cyclophosphamide"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C64956", "For"], ["C15632", "Chemotherapy"], ["C61517", "Combination"], ["C3261", "Metastatic Neoplasm"], ["C4911", "Gastric Carcinoma"], ["C66834", "Three"], ["C67069", "Weekly"], ["C25211", "Schedule"], ["C25197", "Recommendation"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C71584", "Load"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C66839", "Eight"], ["C67401", "Milligram per Kilogram"], ["C95085", "Body Weight Domain"], ["C25197", "Recommendation"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25488", "Dose"], ["C158997", "GDC Analyte Type Terminology"], ["C66834", "Three"], ["C67069", "Weekly"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C172979", "Fear Score 6"], ["C67401", "Milligram per Kilogram"], ["C95085", "Body Weight Domain"], ["C66834", "Three"], ["C29844", "Week"], ["C38008", "Post"], ["C71584", "Load"], ["C25488", "Dose"], ["C4872", "Breast Carcinoma"], ["C16289", "Andorra"], ["C4911", "Gastric Carcinoma"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C16960", "Patient"], ["C62355", "With"], ["C9609", "Bleomycin/Cisplatin/Methotrexate Regimen"], ["C43508", "Oregon"], ["C16329", "Belgium"], ["C25705", "Treating"], ["C62355", "With"], ["C1647", "Trastuzumab"], ["C65136", "Until"], ["C17747", "Disease Progression"], ["C52874", "SPI1 wt Allele"], ["C2991", "Disease or Disorder"], ["C16960", "Patient"], ["C62355", "With"], ["C16329", "Belgium"], ["C25705", "Treating"], ["C62355", "With"], ["C1647", "Trastuzumab"], ["C64956", "For"], ["C105723", "ECOG Performance Status 1"], ["C29848", "Year"], ["C43508", "Oregon"], ["C65136", "Until"], ["C2991", "Disease or Disorder"], ["C3352", "Recurrence"], ["C25509", "First"], ["C43442", "Biomaterial Treatment"], ["C16727", "India"], ["C151408", "Beyond"], ["C66832", "One"], ["C29848", "Year"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C49505", "Dose Reduced"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C16727", "India"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C25490", "During"], ["C71104", "Clinical Trial"], ["C16960", "Patient"], ["C106184", "May"], ["C54064", "Continue"], ["C49236", "Therapeutic Procedure"], ["C25490", "During"], ["C52874", "SPI1 wt Allele"], ["C15632", "Chemotherapy"], ["C61367", "Induction"], ["C74440", "Bone Marrow Suppression"], ["C16329", "Belgium"], ["C64956", "For"], ["C2959", "Complication"], ["C52874", "SPI1 wt Allele"], ["C80520", "Neutropenia"], ["C25490", "During"], ["C25330", "Duration"], ["C159124", "GDC Treatment Outcome Terminology"], ["C64956", "For"], ["C1411", "Paclitaxel"], ["C1526", "Docetaxel"], ["C43508", "Oregon"], ["C1740", "Aromatase Inhibitor"], ["C64956", "For"], ["C48191", "Information"], ["C92667", "SPARC wt Allele"], ["C49505", "Dose Reduced"], ["C43508", "Oregon"], ["C198613", "CFI wt Allele"], ["C99524", "Left Ventricular Ejection Fraction"], ["C99524", "Left Ventricular Ejection Fraction"], ["C48570", "Percent Unit"], ["C69442", "Medical Drop"], ["C69122", "Ten"], ["C25516", "From"], ["C125938", "Baseline Epoch"], ["C16289", "Andorra"], ["C159124", "GDC Treatment Outcome Terminology"], ["C75330", "Below"], ["C105785", "Fifty"], ["C48570", "Percent Unit"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C118406", "Suspended License"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C48804", "Repeat Object"], ["C99524", "Left Ventricular Ejection Fraction"], ["C25367", "Assessment"], ["C38000", "Performed"], ["C25282", "Within"], ["C45828", "Approximate"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C29844", "Week"], ["C198613", "CFI wt Allele"], ["C99524", "Left Ventricular Ejection Fraction"], ["C101282", "Have"], ["C25594", "Negation"], ["C125459", "Improved"], ["C43508", "Oregon"], ["C101282", "Have"], ["C51024", "Response Declined"], ["C25519", "Further"], ["C43508", "Oregon"], ["C198613", "CFI wt Allele"], ["C168447", "Symptomatic Presentation"], ["C3080", "Congestive Heart Failure"], ["C3080", "Congestive Heart Failure"], ["C101282", "Have"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C16329", "Belgium"], ["C25387", "Benefit"], ["C64956", "For"], ["C25190", "Person"], ["C53691", "Veterinary Patient"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C64916", "All"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C52582", "Referral"], ["C64956", "For"], ["C25367", "Assessment"], ["C158169", "Buyei Chinese"], ["C76246", "Blood Group A"], ["C125951", "Cardiologist"], ["C16289", "Andorra"], ["C16033", "Follow-Up"], ["C54031", "Missing"], ["C25488", "Dose"], ["C198613", "CFI wt Allele"], ["C53691", "Veterinary Patient"], ["C101282", "Have"], ["C54031", "Missing"], ["C76246", "Blood Group A"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C158169", "Buyei Chinese"], ["C66832", "One"], ["C29844", "Week"], ["C43508", "Oregon"], ["C61422", "Lesser"], ["C65106", "Then"], ["C102843", "Usual"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25488", "Dose"], ["C67069", "Weekly"], ["C165496", "GDC Regimen Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67401", "Milligram per Kilogram"], ["C66834", "Three"], ["C67069", "Weekly"], ["C165496", "GDC Regimen Terminology"], ["C172979", "Fear Score 6"], ["C67401", "Milligram per Kilogram"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C71344", "Associate of Science"], ["C71344", "Associate of Science"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C65136", "Until"], ["C82511", "Subsequent Trial Activity"], ["C25619", "Plan"], ["C25472", "Cycle"], ["C53286", "Next"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25488", "Dose"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C25301", "Day"], ["C43508", "Oregon"], ["C107434", "Twenty One"], ["C25301", "Day"], ["C159124", "GDC Treatment Outcome Terminology"], ["C67069", "Weekly"], ["C43508", "Oregon"], ["C66834", "Three"], ["C67069", "Weekly"], ["C198613", "CFI wt Allele"], ["C53691", "Veterinary Patient"], ["C101282", "Have"], ["C54031", "Missing"], ["C76246", "Blood Group A"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C158169", "Buyei Chinese"], ["C61584", "Greater Than"], ["C66832", "One"], ["C29844", "Week"], ["C76246", "Blood Group A"], ["C17095", "Reunion"], ["C71584", "Load"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C25490", "During"], ["C45828", "Approximate"], ["C182728", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 90"], ["C67069", "Weekly"], ["C165496", "GDC Regimen Terminology"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C67401", "Milligram per Kilogram"], ["C66834", "Three"], ["C67069", "Weekly"], ["C165496", "GDC Regimen Terminology"], ["C66839", "Eight"], ["C67401", "Milligram per Kilogram"], ["C71344", "Associate of Science"], ["C71344", "Associate of Science"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C53286", "Next"], ["C1647", "Trastuzumab"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25488", "Dose"], ["C67069", "Weekly"], ["C165496", "GDC Regimen Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67401", "Milligram per Kilogram"], ["C66834", "Three"], ["C67069", "Weekly"], ["C165496", "GDC Regimen Terminology"], ["C172979", "Fear Score 6"], ["C67401", "Milligram per Kilogram"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C25301", "Day"], ["C43508", "Oregon"], ["C107434", "Twenty One"], ["C25301", "Day"], ["C159124", "GDC Treatment Outcome Terminology"], ["C67069", "Weekly"], ["C43508", "Oregon"], ["C66834", "Three"], ["C67069", "Weekly"], ["C18101", "Special Population"], ["C133269", "Dedicated Blood Product Donation"], ["C49663", "Pharmacokinetic Study"], ["C16727", "India"], ["C16268", "Elderly"], ["C16289", "Andorra"], ["C62355", "With"], ["C25225", "Renal"], ["C43508", "Oregon"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C101282", "Have"], ["C25594", "Negation"], ["C66768", "CDISC SDTM Adverse Event Outcome Terminology"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C189348", "Population Pharmacokinetic Analysis Dataset"], ["C106312", "Advanced Glycation End Product"], ["C16289", "Andorra"], ["C114592", "Renal Impairment"], ["C25594", "Negation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1647", "Trastuzumab"], ["C41205", "Disposition"], ["C17005", "Population Group"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C70664", "Relevance"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C16727", "India"], ["C17005", "Population Group"], ["C85492", "CDISC SDTM Method Terminology"], ["C52874", "SPI1 wt Allele"], ["C70962", "Agent Administration"], ["C1647", "Trastuzumab"], ["C71584", "Load"], ["C25488", "Dose"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C71344", "Associate of Science"], ["C76246", "Blood Group A"], ["C182728", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 90"], ["C48154", "Minute"], ["C38275", "Intravenous Infusion"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C64912", "Administer"], ["C71344", "Associate of Science"], ["C75889", "PAX6 wt Allele"], ["C64995", "Intravenous Push"], ["C43508", "Oregon"], ["C15678", "Bolus Infusion Procedure"], ["C1647", "Trastuzumab"], ["C38275", "Intravenous Infusion"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C158169", "Buyei Chinese"], ["C76246", "Blood Group A"], ["C16666", "Health Care Provider"], ["C25625", "Preparation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C143282", "Anaphylaxis, CTCAE"], ["C16289", "Andorra"], ["C75889", "PAX6 wt Allele"], ["C53513", "Emergency Room"], ["C48504", "Kit Dosing Unit"], ["C16329", "Belgium"], ["C25429", "Availability"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C25599", "Observed"], ["C64956", "For"], ["C158997", "GDC Analyte Type Terminology"], ["C66837", "Six"], ["C25529", "Hour"], ["C38008", "Post"], ["C68616", "Start Date"], ["C52874", "SPI1 wt Allele"], ["C25509", "First"], ["C15388", "Infusion Procedure"], ["C16289", "Andorra"], ["C64956", "For"], ["C66833", "Two"], ["C25529", "Hour"], ["C38008", "Post"], ["C68616", "Start Date"], ["C52874", "SPI1 wt Allele"], ["C53286", "Next"], ["C64956", "For"], ["C168422", "Rheumatic Fever Symptom"], ["C72665", "Similarity"], ["C143485", "Fever, CTCAE"], ["C16289", "Andorra"], ["C35143", "Chills"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C15388", "Infusion Procedure"], ["C53260", "Adverse Event Definitely Related to Intervention"], ["C168422", "Rheumatic Fever Symptom"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C25542", "Interruption"], ["C43508", "Oregon"], ["C77538", "Rating"], ["C52874", "SPI1 wt Allele"], ["C15388", "Infusion Procedure"], ["C106184", "May"], ["C89271", "Assistance"], ["C64355", "Scientific Control"], ["C168422", "Rheumatic Fever Symptom"], ["C15388", "Infusion Procedure"], ["C106184", "May"], ["C16329", "Belgium"], ["C65140", "When"], ["C168422", "Rheumatic Fever Symptom"], ["C86045", "Abate"], ["C198613", "CFI wt Allele"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C71584", "Load"], ["C25488", "Dose"], ["C154196", "Washo Language"], ["C128793", "Microplate Well"], ["C53286", "Next"], ["C25488", "Dose"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C71344", "Associate of Science"], ["C76246", "Blood Group A"], ["C70541", "Lansky Performance Status 30"], ["C48154", "Minute"], ["C15388", "Infusion Procedure"], ["C64956", "For"], ["C42688", "Instruction"], ["C92667", "SPARC wt Allele"], ["C52874", "SPI1 wt Allele"], ["C142605", "Medicinal Product"], ["C201357", "Before Timing Type"], ["C70962", "Agent Administration"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C172979", "Fear Score 6"]], "rxnorm.posology": [["224905", "trastuzumab"], ["2179754", "Ogivri"], ["224905", "trastuzumab"], ["2179754", "Ogivri"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["1371041", "ado-trastuzumab emtansine"], ["2267582", "trastuzumab deruxtecan"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["56946", "paclitaxel"], ["72962", "docetaxel"], ["56946", "paclitaxel"], ["72962", "docetaxel"], ["224905", "trastuzumab"], ["56946", "paclitaxel"], ["72962", "docetaxel"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["84857", "anastrozole"], ["224905", "trastuzumab"], ["84857", "anastrozole"], ["84857", "anastrozole"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["56946", "paclitaxel"], ["3639", "doxorubicin"], ["3002", "cyclophosphamide"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["56946", "paclitaxel"], ["72962", "docetaxel"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"]], "loinc.posology": [["LP28442-9", "HER2"], ["LP200075-2", "IS"], ["LA33028-4", "Prior"], ["LP267221-2", "Therapy"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LP94823-9", "Treatment"], ["LP17763-1", "A"], ["MTHU010489", "Physician"], ["LA22004-8", "IN"], ["MTHU010425", "Chemotherapy"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP17763-1", "A"], ["LP182445-9", "Healthcare professional"], ["LA9437-0", "Intravenous"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA9451-1", "Subcutaneous"], ["LA9437-0", "Intravenous"], ["LP263434-5", "Infusion"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP35951-0", "Route"], ["LP200075-2", "IS"], ["MTHU029809", "Other"], ["LA22004-8", "IN"], ["MTHU038481", "Medication"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP251102-2", "Check"], ["LA20376-2", "Vial"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LA22025-3", "OR"], ["LA14283-8", "Breast cancer"], ["LA6395-3", "Three"], ["LA18891-4", "Weekly"], ["LA6662-6", "Initial"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP36791-9", "8"], ["LP15217-0", "Mg"], ["MTHU001885", "Body weight"], ["MTHU065481", "Dose"], ["LA21988-3", "AT"], ["LA6395-3", "Three"], ["LA18891-4", "Weekly"], ["LP200075-2", "IS"], ["LP20594-5", "6"], ["LP15217-0", "Mg"], ["MTHU001885", "Body weight"], ["LA6395-3", "Three"], ["LA9000-6", "Weeks"], ["MTHU065481", "Dose"], ["LA18891-4", "Weekly"], ["LA6662-6", "Initial"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP20592-9", "4"], ["LP15217-0", "Mg"], ["MTHU001885", "Body weight"], ["LA18891-4", "Weekly"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["MTHU000002", "Clinical Class"], ["LP15217-0", "Mg"], ["MTHU001885", "Body weight"], ["LA6306-0", "One"], ["LA14216-8", "Week"], ["MTHU065481", "Dose"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["MTHU060612", "PACLitaxel"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["MTHU060612", "PACLitaxel"], ["LA22025-3", "OR"], ["LP121628-4", "Day"], ["LP6974-2", "first"], ["MTHU065481", "Dose"], ["MTHU065481", "Dose"], ["LP182278-4", "Summary"], ["MTHU060612", "PACLitaxel"], ["LA22025-3", "OR"], ["LP6323-2", "Immunofluorescence (IF)"], ["MTHU065481", "Dose"], ["LA18365-9", "Well"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LA22004-8", "IN"], ["LA16584-7", "Day 1"], ["LA32-8", "No"], ["63897-3", "Relative:Find:Pt:^Patient:Nom:California Teachers Study"], ["LP74359-8", "Timing"], ["LA21988-3", "AT"], ["MTHU065481", "Dose"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LA12111-3", "Early"], ["LA14283-8", "Breast cancer"], ["LA6395-3", "Three"], ["LA18891-4", "Weekly"], ["LA18891-4", "Weekly"], ["LP17763-1", "A"], ["LA6395-3", "Three"], ["LA18891-4", "Weekly"], ["LA6662-6", "Initial"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP36791-9", "8"], ["LP15217-0", "Mg"], ["LP221195-3", "Weight"], ["MTHU065481", "Dose"], ["LA21988-3", "AT"], ["LA6395-3", "Three"], ["LA18891-4", "Weekly"], ["LP200075-2", "IS"], ["LP20594-5", "6"], ["LP15217-0", "Mg"], ["LP221195-3", "Weight"], ["LA6395-3", "Three"], ["LA9000-6", "Weeks"], ["MTHU065481", "Dose"], ["LP17763-1", "A"], ["LA18891-4", "Weekly"], ["LA6662-6", "Initial"], ["MTHU065481", "Dose"], ["LP20592-9", "4"], ["LP15217-0", "Mg"], ["MTHU000002", "Clinical Class"], ["LP15217-0", "Mg"], ["LA14216-8", "Week"], ["MTHU060612", "PACLitaxel"], ["MTHU010425", "Chemotherapy"], ["LP18382-9", "DOXOrubicin"], ["LP70366-7", "Cyclophosphamide"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["MTHU010425", "Chemotherapy"], ["LA12701-1", "Combination"], ["LA10547-0", "Gastric Cancer"], ["LA6395-3", "Three"], ["LA18891-4", "Weekly"], ["LA6662-6", "Initial"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP36791-9", "8"], ["LP15217-0", "Mg"], ["MTHU001885", "Body weight"], ["MTHU065481", "Dose"], ["LA21988-3", "AT"], ["LA6395-3", "Three"], ["LA18891-4", "Weekly"], ["LP200075-2", "IS"], ["LP20594-5", "6"], ["LP15217-0", "Mg"], ["MTHU001885", "Body weight"], ["LA6395-3", "Three"], ["LA9000-6", "Weeks"], ["MTHU065481", "Dose"], ["LA14283-8", "Breast cancer"], ["LA10547-0", "Gastric Cancer"], ["LP14744-4", "Duration"], ["LP94823-9", "Treatment"], ["LA22025-3", "OR"], ["LA18199-2", "Disease"], ["LA31718-2", "1 year"], ["LA22025-3", "OR"], ["LA18199-2", "Disease"], ["LP6974-2", "first"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LA6306-0", "One"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["MTHU065481", "Dose"], ["LP267357-4", "Reduction"], ["LA32-8", "No"], ["LA22004-8", "IN"], ["MTHU065481", "Dose"], ["MTHU854704", "Clinical trials"], ["LA14161-6", "May"], ["LA9507-0", "Continue"], ["LP267221-2", "Therapy"], ["MTHU010425", "Chemotherapy"], ["19817-6", "Complications:Type:Stdy:^Patient:Nom"], ["LP73517-2", "Time"], ["LA10393-9", "Refer"], ["MTHU060612", "PACLitaxel"], ["LA22025-3", "OR"], ["MTHU065481", "Dose"], ["LP267357-4", "Reduction"], ["LA22025-3", "OR"], ["LP6323-2", "Immunofluorescence (IF)"], ["10230-1", "Ejection fraction:VFr:Pt:Heart.ventricle.left:Qn"], ["LA13942-0", "10"], ["LA16758-7", "Baseline"], ["LA14987-4", "Below"], ["LA28854-0", "50"], ["LP94823-9", "Treatment"], ["LP17763-1", "A"], ["LP73913-3", "Assessment"], ["LA19974-7", "Performed"], ["LP20591-1", "3"], ["LA9000-6", "Weeks"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA21291-2", "Not"], ["LA65-8", "Improved"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA17766-9", "Symptomatic"], ["LP74648-4", "Congestive heart failure"], ["LA12070-1", "Individual"], ["LP66710-2", "Patient"], ["MTHU043138", "Risks"], ["LA18187-7", "All"], ["LA6624-6", "Referred"], ["LP73913-3", "Assessment"], ["LP17763-1", "A"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP66710-2", "Patient"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LA6306-0", "One"], ["LA14216-8", "Week"], ["LA22025-3", "OR"], ["LA16823-9", "Less"], ["LP183687-5", "usual"], ["MTHU065481", "Dose"], ["LA18891-4", "Weekly"], ["MTHU000002", "Clinical Class"], ["LP15217-0", "Mg"], ["LA6395-3", "Three"], ["LA18891-4", "Weekly"], ["LP20594-5", "6"], ["LP15217-0", "Mg"], ["LA15097-1", "Possible"], ["LA14426-3", "Do not"], ["LA20099-0", "Planned"], ["LP204183-0", "7 days"], ["LA22025-3", "OR"], ["LA8999-0", "Days"], ["LA12112-1", "Later"], ["LA18891-4", "Weekly"], ["LA22025-3", "OR"], ["LA6395-3", "Three"], ["LA18891-4", "Weekly"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP66710-2", "Patient"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LA30123-6", "More than one"], ["LA14216-8", "Week"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP6953-6", "90 minutes"], ["LA18891-4", "Weekly"], ["LP20592-9", "4"], ["LP15217-0", "Mg"], ["LA6395-3", "Three"], ["LA18891-4", "Weekly"], ["LP36791-9", "8"], ["LP15217-0", "Mg"], ["LA15097-1", "Possible"], ["LA18891-4", "Weekly"], ["MTHU000002", "Clinical Class"], ["LP15217-0", "Mg"], ["LA6395-3", "Three"], ["LA18891-4", "Weekly"], ["LP20594-5", "6"], ["LP15217-0", "Mg"], ["LP204183-0", "7 days"], ["LA22025-3", "OR"], ["LA8999-0", "Days"], ["LA12112-1", "Later"], ["LA18891-4", "Weekly"], ["LA22025-3", "OR"], ["LA6395-3", "Three"], ["LA18891-4", "Weekly"], ["LA22004-8", "IN"], ["MTHU065909", "Renal"], ["LA22025-3", "OR"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP62263-6", "Population"], ["MTHU010047", "Age"], ["MTHU065909", "Renal"], ["LA21291-2", "Not"], ["59775-7", "Procedure disposition:Find:Pt:^Patient:Nar"], ["LP62263-6", "Population"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LA22004-8", "IN"], ["LP62263-6", "Population"], ["LP72939-9", "Method"], ["MTHU065481", "Dose"], ["LP17763-1", "A"], ["LA28891-2", "90"], ["LA9437-0", "Intravenous"], ["LP263434-5", "Infusion"], ["LA14426-3", "Do not"], ["LA18623-1", "Intravenous push"], ["LA22025-3", "OR"], ["LA9437-0", "Intravenous"], ["LP263434-5", "Infusion"], ["LP17763-1", "A"], ["LA30302-6", "Healthcare"], ["MTHU001352", "Provider"], ["LA7413-3", "Anaphylaxis"], ["LP6425-5", "Observed"], ["LA21988-3", "AT"], ["LP190656-1", "start"], ["LP6974-2", "first"], ["LP263434-5", "Infusion"], ["LA6404-3", "Two"], ["LP190656-1", "start"], ["LP75708-5", "Symptoms"], ["LP74849-8", "Fever"], ["MTHU013512", "Chills"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LP263434-5", "Infusion"], ["LA31343-9", "Related"], ["LP75708-5", "Symptoms"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA22025-3", "OR"], ["MTHU027852", "Rate"], ["LP263434-5", "Infusion"], ["LA14161-6", "May"], ["LP7741-4", "Control"], ["LP75708-5", "Symptoms"], ["LP263434-5", "Infusion"], ["LA14161-6", "May"], ["LP75708-5", "Symptoms"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA6662-6", "Initial"], ["MTHU065481", "Dose"], ["LA18365-9", "Well"], ["LP17763-1", "A"], ["LA28855-7", "30"], ["LP263434-5", "Infusion"], ["LP6820-7", "Instructions"], ["LP20594-5", "6"], ["LP20594-5", "6"]], "snomed.contraindications": [["257550005", "Hypersensitivity (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["261217004", "Substance (attribute)"], ["88878007", "Protein (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["161941007", "Dyspnea at rest (finding)"], ["42752001", "Due to (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86005002", "Advanced (qualifier value)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["182712003", "Oxygen therapy (& enrichment)|Oxygen therapy (& enrichment) (procedure)"]], "ncit.contraindications": [["C3114", "Hypersensitivity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C154405", "Active State"], ["C45306", "Substance"], ["C14238", "Mouse"], ["C17021", "Protein"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C168162", "Chief Complaint Occurs at Rest"], ["C89272", "Due To"], ["C2959", "Complication"], ["C52874", "SPI1 wt Allele"], ["C25411", "Advanced"], ["C9305", "Malignant Neoplasm"], ["C43508", "Oregon"], ["C29545", "Warburg Therapy"]], "rxnorm.contraindications": [["T167", "Substance"], ["7806", "oxygen"]], "loinc.contraindications": [["LA16666-2", "Active"], ["T167", "Substance"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP20594-5", "6"], ["LA6112-2", "1"], ["LA6750-9", "Severe"], ["LP230193-7", "at rest"], ["19817-6", "Complications:Type:Stdy:^Patient:Nom"], ["LP128794-7", "Malignancy"], ["LA22025-3", "OR"], ["LA27962-2", "Oxygen therapy"]], "snomed.special_warnings": [["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["734841007", "Name (property) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["410681005", "Count of entities (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["67995009", "Special (qualifier value)"], ["261904005", "Laboratory (environment)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["346414003", "Ensure (substance)|Ensure (product)"], ["88323005", "Adequate (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["15240007", "Current (qualifier value)"], ["373067005", "No (qualifier value)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["420862001", "On (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["9130008", "Previous (qualifier value)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["18720000", "In (attribute)"], ["10926004", "Adjuvant (substance)"], ["88846004", "Functional disorder (finding)"], ["60132005", "Generalized (qualifier value)"], ["28995006", "Treated with (attribute)"], ["387003001", "Trastuzumab (substance)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["86495002", "For (qualifier value)"], ["420278009", "New York (geographic location)"], ["302509004", "Entire heart (body structure)"], ["263534001", "Association (attribute)"], ["258393007", "Class 2 (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["84387000", "Asymptomatic (finding)"], ["88846004", "Functional disorder (finding)"], ["272379006", "Events (event)|Event (event)"], ["18720000", "In (attribute)"], ["387003001", "Trastuzumab (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387374002", "Paclitaxel (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["386918005", "Docetaxel (substance)"], ["255260001", "Following (attribute)"], ["372540003", "Anthracycline (substance)"], ["372817009", "Doxorubicin (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["417916005", "Epirubicin (substance)"], ["42504009", "Containing (qualifier value)"], ["367336001", "Chemotherapy (procedure)"], ["371924009", "Moderate to severe (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["47429007", "Associated with (attribute)"], ["419620001", "Death (event)"], ["732732008", "4.8 (qualifier value)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["266287006", "(Hypertensive disease) or (hypertension)|(Hypertensive disease) or (hypertension) (disorder)"], ["397934002", "Documented (qualifier value)"], ["194841001", "Coronary (atherosclerosis or artery disease) or triple vessel disease of the heart|Coronary (atherosclerosis or artery disease) or triple vessel disease of the heart (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["264691008", "Arabic numeral 55 (qualifier value)|55 (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["372540003", "Anthracycline (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387420009", "Cyclophosphamide (substance)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["425315000", "Cardiac assessment (regime/therapy)|Cardiac assessment (procedure)"], ["55919000", "Including (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["5880005", "Physical examination procedure (procedure)"], ["271334005", "ECG - electrocardiogram (& general)|ECG - electrocardiogram (& general) (procedure)"], ["46825001", "Electrocardiographic monitoring (procedure)|Electrocardiographic monitoring (regime/therapy)"], ["40701008", "Echocardiography (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["312250003", "Magnetic resonance imaging - action (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["88846004", "Functional disorder (finding)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["27582007", "Repeat (qualifier value)"], ["396129006", "Every three months (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["396149002", "Every six months (qualifier value)"], ["255260001", "Following (attribute)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["1222777002", "American Joint Committee on Cancer stage II:4 (qualifier value)"], ["258706009", "month (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["386053000", "Evaluation procedure (procedure)|Patient evaluation procedure (procedure)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["387003001", "Trastuzumab (substance)"], ["18720000", "In (attribute)"], ["86495002", "For (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["258706009", "month (qualifier value)"], ["255234002", "After (attribute)"], ["420862001", "On (qualifier value)"], ["385436007", "Population (social concept)"], ["272389005", "Analysis (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["255234002", "After (attribute)"], ["387003001", "Trastuzumab (substance)"], ["60022001", "Possible diagnosis (contextual qualifier) (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["88846004", "Functional disorder (finding)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["372540003", "Anthracycline (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["86495002", "For (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["258706009", "month (qualifier value)"], ["255234002", "After (attribute)"], ["387003001", "Trastuzumab (substance)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["116154003", "Patient (person)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["86185002", "Cardiac function (observable entity)|Cardiac function (function)"], ["386053000", "Evaluation procedure (procedure)|Patient evaluation procedure (procedure)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["255260001", "Following (attribute)"], ["360156006", "Screening - procedure intent (qualifier value)"], ["18720000", "In (attribute)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["86185002", "Cardiac function (observable entity)|Cardiac function (function)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258705008", "week (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["88846004", "Functional disorder (finding)"], ["84387000", "Asymptomatic (finding)"], ["88846004", "Functional disorder (finding)"], ["242762006", "More (qualifier value)"], ["70232002", "Frequent (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260370003", "Decrease (qualifier value)"], ["18720000", "In (attribute)"], ["250907009", "Left ventricular function (observable entity)"], ["84387000", "Asymptomatic (finding)"], ["309343006", "Physician (occupation)"], ["277132007", "Therapeutic procedure (procedure)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["30190008", "Seen (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["18720000", "In (attribute)"], ["88846004", "Functional disorder (finding)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["426684005", "Drops dose form (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["351726001", "Below (qualifier value)"], ["732774003", "50 (qualifier value)"], ["385655000", "Suspended (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["27582007", "Repeat (qualifier value)"], ["386053000", "Evaluation procedure (procedure)|Patient evaluation procedure (procedure)"], ["398166005", "Performed (qualifier value)"], ["18720000", "In (attribute)"], ["26175008", "Approximate (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258705008", "week (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["385425000", "Improved (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["443390004", "Refused (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["264931009", "Symptomatic (qualifier value)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["86495002", "For (qualifier value)"], ["385435006", "Individual (person)"], ["116154003", "Patient (person)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["439980006", "Referred (situation)|Referral placed (situation)"], ["86495002", "For (qualifier value)"], ["386053000", "Evaluation procedure (procedure)|Patient evaluation procedure (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["17561000", "Cardiologist (occupation)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["264931009", "Symptomatic (qualifier value)"], ["84114007", "Heart failure (disorder)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["28995006", "Treated with (attribute)"], ["86495002", "For (qualifier value)"], ["4757001", "Most (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["84387000", "Asymptomatic (finding)"], ["88846004", "Functional disorder (finding)"], ["18720000", "In (attribute)"], ["385425000", "Improved (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["304274007", "Angiotensin (substance)|Angiotensin"], ["734543001", "Enzyme (disposition)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["45648004", "Angiotensin receptor (substance)"], ["118521003", "Arbitrary (property) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["33252009", "beta-Blocking agent (product)|beta-Blocking agent (substance)|Product containing beta adrenergic receptor antagonist (product)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18669006", "Evidence of (contextual qualifier) (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["420862001", "On (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["45169001", "Without (attribute)"], ["58147004", "Clinical (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["254837009", "Malignant tumor of breast (disorder)|Malignant neoplasm of breast (disorder)"], ["387003001", "Trastuzumab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["410519009", "At risk context (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["88846004", "Functional disorder (finding)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["261122009", "Lower (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["260676000", "Use of (attribute)"], ["387003001", "Trastuzumab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["264499004", "Early (qualifier value)"], ["254837009", "Malignant tumor of breast (disorder)|Malignant neoplasm of breast (disorder)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["27582007", "Repeat (qualifier value)"], ["421612001", "Every - dosing instruction fragment (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258706009", "month (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["396149002", "Every six months (qualifier value)"], ["255260001", "Following (attribute)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["1222777002", "American Joint Committee on Cancer stage II:4 (qualifier value)"], ["258706009", "month (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["18720000", "In (attribute)"], ["372540003", "Anthracycline (substance)"], ["42504009", "Containing (qualifier value)"], ["367336001", "Chemotherapy (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["53281000", "Annual (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["258707000", "year (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255238004", "Continuous (qualifier value)"], ["260370003", "Decrease (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["399211009", "History of myocardial infarction (situation)|History of - myocardial infarction (context-dependent category)|History of - myocardial infarction (situation)"], ["45169001", "Without (attribute)"], ["367416001", "Angina pectoris (disorder)"], ["74188005", "Medical (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258393007", "Class 2 (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["264691008", "Arabic numeral 55 (qualifier value)|55 (qualifier value)"], ["74964007", "Other (qualifier value)"], ["266301006", "Cardiomyopathy (& [congest. obst.] or [hyper. obst.]) or endomyocardial fibrosis|Cardiomyopathy (& [congest. obst.] or [hyper. obst.]) or endomyocardial fibrosis (disorder)"], ["698247007", "Cardiac arrhythmia (disorder)"], ["74188005", "Medical (qualifier value)"], ["394653002", "Significant|Significant (qualifier value)"], ["64572001", "Disease (disorder)"], ["556001", "Bad (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["266287006", "(Hypertensive disease) or (hypertension)|(Hypertensive disease) or (hypertension) (disorder)"], ["266287006", "(Hypertensive disease) or (hypertension)|(Hypertensive disease) or (hypertension) (disorder)"], ["54776003", "Controlled by (attribute)"], ["74188005", "Medical (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["254648000", "Effective (qualifier value)"], ["373945007", "Pericardial effusion (disorder)"], ["10926004", "Adjuvant (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["18720000", "In (attribute)"], ["10926004", "Adjuvant (substance)"], ["387003001", "Trastuzumab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["18720000", "In (attribute)"], ["10926004", "Adjuvant (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["264931009", "Symptomatic (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["84387000", "Asymptomatic (finding)"], ["272379006", "Events (event)|Event (event)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["255234002", "After (attribute)"], ["372540003", "Anthracycline (substance)"], ["42504009", "Containing (qualifier value)"], ["367336001", "Chemotherapy (procedure)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["372540003", "Anthracycline (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386918005", "Docetaxel (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386905002", "Carboplatin (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["242762006", "More (qualifier value)"], ["46998006", "Massive (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["4757001", "Most (qualifier value)"], ["264931009", "Symptomatic (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["18720000", "In (attribute)"], ["255216001", "First (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["258706009", "month (qualifier value)"], ["18720000", "In (attribute)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260528009", "Median (qualifier value)"], ["308273005", "Follow-up status (finding)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732769006", "5.5 (qualifier value)"], ["258707000", "year (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255238004", "Continuous (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["264931009", "Symptomatic (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["18720000", "In (attribute)"], ["387003001", "Trastuzumab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255260001", "Following (attribute)"], ["50050141000188100", "Anthracycline therapy (procedure)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["1222818007", "American Joint Committee on Cancer stage III:7 (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["26175008", "Approximate (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["18720000", "In (attribute)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["372540003", "Anthracycline (substance)"], ["20401003", "With (attribute)"], ["387420009", "Cyclophosphamide (substance)"], ["367409002", "Followed by (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386905002", "Carboplatin (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["86495002", "For (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["7882003", "Identified (qualifier value)"], ["18720000", "In (attribute)"], ["9362000", "Four (qualifier value)|4 (qualifier value)"], ["255509001", "Large (qualifier value)"], ["10926004", "Adjuvant (substance)"], ["49808004", "Old-age (function)|Old-age (finding)|Old-age, function (observable entity)"], ["276140008", "Greater-than symbol > (qualifier value)|> (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258707000", "year (qualifier value)"], ["62482003", "Low (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["264691008", "Arabic numeral 55 (qualifier value)|55 (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["288556008", "Before (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255260001", "Following (attribute)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387374002", "Paclitaxel (substance)"], ["18720000", "In (attribute)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["260676000", "Use of (attribute)"], ["18720000", "In (attribute)"], ["387003001", "Trastuzumab (substance)"], ["255234002", "After (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["10926004", "Adjuvant (substance)"], ["367336001", "Chemotherapy (procedure)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["88846004", "Functional disorder (finding)"], ["47429007", "Associated with (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["372540003", "Anthracycline (substance)"], ["288556008", "Before (attribute)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["363807006", "Body mass index|Body mass index (observable entity)"], ["276140008", "Greater-than symbol > (qualifier value)|> (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258896009", "kg/sq.m (qualifier value)|kg/sq. m (qualifier value)|Kilogram/square meter (qualifier value)"], ["10926004", "Adjuvant (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["10926004", "Adjuvant (substance)"], ["387003001", "Trastuzumab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["367336001", "Chemotherapy (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["62482003", "Low (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["372540003", "Anthracycline (substance)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["372817009", "Doxorubicin (substance)"], ["732554007", "180 (qualifier value)"], ["404216004", "Milligram/square meter (qualifier value)|mg/sq.m (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["417916005", "Epirubicin (substance)"], ["732700008", "360 (qualifier value)"], ["404216004", "Milligram/square meter (qualifier value)|mg/sq.m (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["261015003", "Full (qualifier value)"], ["260908002", "Course (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["62482003", "Low (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["18720000", "In (attribute)"], ["373067005", "No (qualifier value)"], ["734873001", "Cytotoxic (disposition)"], ["367336001", "Chemotherapy (procedure)"], ["255234002", "After (attribute)"], ["387713003", "Surgical procedure (procedure)"], ["18720000", "In (attribute)"], ["74964007", "Other (qualifier value)"], ["420862001", "On (qualifier value)"], ["103325001", "Patient need for (contextual qualifier) (qualifier value)"], ["734873001", "Cytotoxic (disposition)"], ["367336001", "Chemotherapy (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420862001", "On (qualifier value)"], ["385435006", "Individual (person)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["262459003", "Low dose (qualifier value)"], ["372540003", "Anthracycline (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["15240007", "Current (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["387003001", "Trastuzumab (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["367336001", "Chemotherapy (procedure)"], ["42504009", "Containing (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["372817009", "Doxorubicin (substance)"], ["408102007", "Unit dose (qualifier value)"], ["732554007", "180 (qualifier value)"], ["404216004", "Milligram/square meter (qualifier value)|mg/sq.m (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["264931009", "Symptomatic (qualifier value)"], ["88846004", "Functional disorder (finding)"], ["732432007", "1.7 (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["18720000", "In (attribute)"], ["387003001", "Trastuzumab (substance)"], ["302538001", "Entire upper arm (body structure)"], ["58147004", "Clinical (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["18720000", "In (attribute)"], ["352730000", "Supra- (qualifier value)"], ["264695004", "65 (qualifier value)|Arabic numeral 65 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["36576007", "Infusion (procedure)"], ["262094002", "Related (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["257550005", "Hypersensitivity (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["36576007", "Infusion (procedure)"], ["55919000", "Including (qualifier value)"], ["267036007", "Dyspnea (finding)"], ["155487000", "Hypotension (disorder)|Hypotension"], ["161944004", "Wheezing (& [symptom])|Wheezing (& [symptom]) (finding)"], ["266287006", "(Hypertensive disease) or (hypertension)|(Hypertensive disease) or (hypertension) (disorder)"], ["269012003", "(Bronchospasm) or (O/E - rhonchi (& present))|(Bronchospasm) or (O/E - rhonchi (& present)) (finding)"], ["6285003", "Tachyarrhythmia (disorder)"], ["260400001", "Reduced (qualifier value)"], ["24099007", "Oxygen (substance)"], ["39579001", "Anaphylaxis (disorder)"], ["69328002", "Distress (finding)"], ["269433002", "(Angioneurotic oedema) or (urticaria) (disorder)|(Angioneurotic oedema) or (urticaria)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["846575004", "Angioedema (morphologic abnormality)"], ["733985002", "Reported (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["2533004", "Drug (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["246454002", "Occurrence (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["732576003", "2.5 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["226630009", "Start (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255216001", "First (qualifier value)"], ["36576007", "Infusion (procedure)"], ["441940003", "Adverse reaction caused by drug or medicament administered by infusion (disorder)|Adverse reaction to drug or medicament administered by infusion (disorder)"], ["36576007", "Infusion (procedure)"], ["410546004", "Discontinued (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["36576007", "Infusion (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["116154003", "Patient (person)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["732724000", "4.2 (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["28995006", "Treated with (attribute)"], ["373265006", "Analgesic (substance)"], ["76644002", "Antipyretic (substance)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["387298007", "Meperidine (substance)|Pethidine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["387517004", "Paracetamol (substance)|Acetaminophen (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["372806008", "Substance with histamine receptor antagonist mechanism of action (substance)|Antihistamine (substance)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["372682005", "Diphenhydramine (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["42745003", "Serious (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["38678006", "Client-centered psychotherapy (procedure)|Client-centered psychotherapy (regime/therapy)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["24099007", "Oxygen (substance)"], ["260989008", "Beta - Greek letter (qualifier value)|Greek letter beta (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["79440004", "Product containing corticosteroid (product)|Product containing corticosteroid and/or corticosteroid derivative (product)|Corticoid preparation (product)|Product containing corticosteroid and corticosteroid derivative (product)|Corticoid preparation (substance)"], ["18720000", "In (attribute)"], ["89292003", "Rare (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["47429007", "Associated with (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263502005", "Clinical course (attribute)"], ["90571008", "Culminating (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["399166001", "Fatal (qualifier value)"], ["161941007", "Dyspnea at rest (finding)"], ["42752001", "Due to (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86005002", "Advanced (qualifier value)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["399166001", "Fatal (qualifier value)"], ["441940003", "Adverse reaction caused by drug or medicament administered by infusion (disorder)|Adverse reaction to drug or medicament administered by infusion (disorder)"], ["28995006", "Treated with (attribute)"], ["387003001", "Trastuzumab (substance)"], ["732725004", "4.3 (qualifier value)"], ["884001", "Initial (qualifier value)"], ["367409002", "Followed by (attribute)"], ["58147004", "Clinical (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255358001", "Rapid (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["258702006", "hour (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255260001", "Following (attribute)"], ["36576007", "Infusion (procedure)"], ["420862001", "On (qualifier value)"], ["260358002", "Very (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["77374008", "Onset of (contextual qualifier) (qualifier value)"], ["36576007", "Infusion (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["738985004", "Pulmonary (intended site)"], ["242762006", "More (qualifier value)"], ["68244004", "Six (qualifier value)|6 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["255234002", "After (attribute)"], ["226630009", "Start (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["36576007", "Infusion (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260383002", "Late (qualifier value)"], ["246100006", "Onset (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["309343006", "Physician (occupation)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["738985004", "Pulmonary (intended site)"], ["272379006", "Events (event)|Event (event)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["738985004", "Pulmonary (intended site)"], ["272379006", "Events (event)|Event (event)"], ["733985002", "Reported (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["387003001", "Trastuzumab (substance)"], ["18720000", "In (attribute)"], ["288563008", "After values (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["399166001", "Fatal (qualifier value)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["181216001", "Entire lung (body structure)"], ["64572001", "Disease (disorder)"], ["55919000", "Including (qualifier value)"], ["181216001", "Entire lung (body structure)"], ["67782005", "Adult respiratory distress syndrome (disorder)|Acute respiratory distress syndrome (disorder)"], ["266391003", "Pneumonia and influenza &/or pneumonia|Pneumonia and influenza &/or pneumonia (disorder)"], ["205237003", "Pneumonitis (disorder)"], ["155606001", "Pleural effusion|Pleural effusion (disorder)"], ["271825005", "Respiratory distress (finding)"], ["123262009", "Acute pulmonary edema (disorder)|Acute pulmonary edema -RETIRED-"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["409623005", "Respiratory insufficiency (disorder)"], ["733985002", "Reported (qualifier value)"], ["47429007", "Associated with (attribute)"], ["233703007", "Interstitial lung disease (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["36692007", "Known (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["47429007", "Associated with (attribute)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["386920008", "Gemcitabine (substance)"], ["372541004", "Vinorelbine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["182666000", "Phototherapy &/or radiation therapy|Phototherapy &/or radiation therapy (procedure)"], ["272379006", "Events (event)|Event (event)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["123005000", "Part of (attribute)"], ["36576007", "Infusion (procedure)"], ["262094002", "Related (finding)"], ["263851003", "Reaction (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["788800008", "Delayed onset (qualifier value)"], ["161941007", "Dyspnea at rest (finding)"], ["42752001", "Due to (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86005002", "Advanced (qualifier value)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["738985004", "Pulmonary (intended site)"], ["272379006", "Events (event)|Event (event)"], ["28995006", "Treated with (attribute)"], ["387003001", "Trastuzumab (substance)"], ["732725004", "4.3 (qualifier value)"], ["86495002", "For (qualifier value)"], ["205237003", "Pneumonitis (disorder)"], ["18720000", "In (attribute)"], ["79970003", "Simultaneous (qualifier value)"], ["412513004", "Sorbitol (product)|Product containing sorbitol (medicinal product)"], ["732515006", "150 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222754002", "American Joint Committee on Cancer stage I:15 (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["412513004", "Sorbitol (product)|Product containing sorbitol (medicinal product)"], ["18720000", "In (attribute)"], ["419473009", "Each (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["1222865001", "American Joint Committee on Cancer stage IV:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222833004", "American Joint Committee on Cancer stage III:22 (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["412513004", "Sorbitol (product)|Product containing sorbitol (medicinal product)"], ["18720000", "In (attribute)"], ["419473009", "Each (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["20052008", "Hereditary fructosuria (disorder)|Fructose-1,6-bisphosphate aldolase B deficiency (disorder)"], ["2533004", "Drug (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["419473009", "Each (qualifier value)"], ["116154003", "Patient (person)"], ["288556008", "Before (attribute)"], ["763158003", "Medicinal product (product)"], ["39972003", "Sodium (substance)"], ["763158003", "Medicinal product (product)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258718000", "mmol (qualifier value)|millimole (qualifier value)"], ["39972003", "Sodium (substance)"], ["1222776006", "American Joint Committee on Cancer stage II:3 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["39972003", "Sodium (substance)"]], "ncit.special_warnings": [["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C52874", "SPI1 wt Allele"], ["C28226", "Biological"], ["C42614", "Name"], ["C16289", "Andorra"], ["C104504", "Batch Number"], ["C52874", "SPI1 wt Allele"], ["C25382", "Administered"], ["C40352", "Multiplicative Product"], ["C16329", "Belgium"], ["C17756", "ERBB2 Gene"], ["C15336", "Testing"], ["C16329", "Belgium"], ["C38000", "Performed"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C37984", "Laboratory"], ["C52288", "NUP214 wt Allele"], ["C74452", "Nutritional Supplement Drink"], ["C168111", "Adequate Daily Fluid Intake"], ["C133993", "Validation Batch"], ["C52874", "SPI1 wt Allele"], ["C15336", "Testing"], ["C102700", "Procedure Domain"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C53269", "No Information Available"], ["C25516", "From"], ["C71104", "Clinical Trial"], ["C68869", "Are"], ["C25429", "Availability"], ["C92667", "SPARC wt Allele"], ["C17095", "Reunion"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C16960", "Patient"], ["C62355", "With"], ["C25627", "Previous"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1647", "Trastuzumab"], ["C16727", "India"], ["C124450", "Adjuvant Therapy Clinical Trial Setting"], ["C127262", "CDISC SDTM Environmental Setting Terminology"], ["C12727", "Heart"], ["C20632", "Pathophysiology"], ["C115727", "Safety Reporting Documentation"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C1647", "Trastuzumab"], ["C68869", "Are"], ["C158997", "GDC Analyte Type Terminology"], ["C164135", "Increased"], ["C17102", "Risk"], ["C64956", "For"], ["C3080", "Congestive Heart Failure"], ["C43468", "New York"], ["C12727", "Heart"], ["C73471", "Chemical Association"], ["C77266", "Canadian Cardiovascular Society Grading of Angina Pectoris CCSGA101 Standardized Character Result Grade II"], ["C38276", "Intravenous Route of Administration"], ["C43508", "Oregon"], ["C168121", "Asymptomatic Presentation"], ["C12727", "Heart"], ["C20632", "Pathophysiology"], ["C150901", "Event Unit"], ["C101282", "Have"], ["C25599", "Observed"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C1647", "Trastuzumab"], ["C49236", "Therapeutic Procedure"], ["C48440", "Single"], ["C43508", "Oregon"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C1411", "Paclitaxel"], ["C43508", "Oregon"], ["C1526", "Docetaxel"], ["C53286", "Next"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C456", "Doxorubicin"], ["C43508", "Oregon"], ["C62028", "Epirubicin"], ["C79873", "Contain"], ["C15632", "Chemotherapy"], ["C106184", "May"], ["C16329", "Belgium"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C159124", "GDC Treatment Outcome Terminology"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C16289", "Andorra"], ["C101282", "Have"], ["C25281", "Associated"], ["C62355", "With"], ["C171353", "Clinical Status Ordinal Scale Outcome 7"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C16727", "India"], ["C64911", "Add"], ["C16329", "Belgium"], ["C16727", "India"], ["C25705", "Treating"], ["C16960", "Patient"], ["C62355", "With"], ["C164135", "Increased"], ["C12727", "Heart"], ["C17102", "Risk"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C168203", "Family History of Hypertension"], ["C25356", "Documented"], ["C26732", "Coronary Artery Disease"], ["C3080", "Congestive Heart Failure"], ["C99524", "Left Ventricular Ejection Fraction"], ["C52874", "SPI1 wt Allele"], ["C188322", "Fifty Five"], ["C106312", "Advanced Glycation End Product"], ["C64916", "All"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C1647", "Trastuzumab"], ["C62355", "With"], ["C15451", "Prior Anthracycline Therapy"], ["C16289", "Andorra"], ["C405", "Cyclophosphamide"], ["C158197", "Achang Chinese"], ["C49587", "Exposure Domain"], ["C125938", "Baseline Epoch"], ["C12727", "Heart"], ["C25367", "Assessment"], ["C166400", "Inclusive"], ["C18772", "Personal Medical History"], ["C16289", "Andorra"], ["C20989", "Physical Examination"], ["C168553", "EKG"], ["C29773", "Pregnant Mare Serum Gonadotropin"], ["C37945", "Echocardiogram Recording"], ["C48928", "And/Or"], ["C43384", "Acquisition"], ["C38073", "Multigated Acquisition Scan"], ["C82561", "Related to Cancer"], ["C43508", "Oregon"], ["C16809", "Magnetic Resonance Imaging"], ["C61256", "Monitoring"], ["C106184", "May"], ["C89271", "Assistance"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C12727", "Heart"], ["C20632", "Pathophysiology"], ["C12727", "Heart"], ["C71344", "Associate of Science"], ["C38000", "Performed"], ["C158997", "GDC Analyte Type Terminology"], ["C125938", "Baseline Epoch"], ["C16329", "Belgium"], ["C64537", "Every Three Months"], ["C175242", "During Treatment"], ["C16289", "Andorra"], ["C89789", "Every Six Months"], ["C53286", "Next"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C65136", "Until"], ["C156843", "24 Months"], ["C25516", "From"], ["C25551", "Last"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C76246", "Blood Group A"], ["C17102", "Risk"], ["C25387", "Benefit"], ["C25367", "Assessment"], ["C16329", "Belgium"], ["C201357", "Before Timing Type"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49236", "Therapeutic Procedure"], ["C62355", "With"], ["C1647", "Trastuzumab"], ["C1647", "Trastuzumab"], ["C106184", "May"], ["C16727", "India"], ["C41510", "Circulatory Process"], ["C64956", "For"], ["C64643", "Up to"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C29846", "Month"], ["C38008", "Post"], ["C1647", "Trastuzumab"], ["C43442", "Biomaterial Treatment"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C189348", "Population Pharmacokinetic Analysis Dataset"], ["C52874", "SPI1 wt Allele"], ["C64916", "All"], ["C25429", "Availability"], ["C25474", "Data"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C25639", "Receive"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C38008", "Post"], ["C1647", "Trastuzumab"], ["C106184", "May"], ["C16329", "Belgium"], ["C158997", "GDC Analyte Type Terminology"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C12727", "Heart"], ["C20632", "Pathophysiology"], ["C198613", "CFI wt Allele"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C48055", "Base"], ["C49236", "Therapeutic Procedure"], ["C64956", "For"], ["C64643", "Up to"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C29846", "Month"], ["C38008", "Post"], ["C1647", "Trastuzumab"], ["C198613", "CFI wt Allele"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C68869", "Are"], ["C53691", "Veterinary Patient"], ["C42555", "Siemens"], ["C12727", "Heart"], ["C25518", "Function"], ["C16329", "Belgium"], ["C25367", "Assessment"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C16727", "India"], ["C68869", "Are"], ["C12686", "Cardiovascular System"], ["C79892", "Concern"], ["C53286", "Next"], ["C125938", "Baseline Epoch"], ["C48261", "Screening"], ["C16727", "India"], ["C64916", "All"], ["C16960", "Patient"], ["C12727", "Heart"], ["C25518", "Function"], ["C16329", "Belgium"], ["C25490", "During"], ["C43442", "Biomaterial Treatment"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C161332", "Every Twelve Weeks"], ["C61256", "Monitoring"], ["C106184", "May"], ["C89271", "Assistance"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C12727", "Heart"], ["C20632", "Pathophysiology"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C168121", "Asymptomatic Presentation"], ["C12727", "Heart"], ["C20632", "Pathophysiology"], ["C106184", "May"], ["C25387", "Benefit"], ["C25516", "From"], ["C128667", "More"], ["C64649", "Frequently"], ["C61256", "Monitoring"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C64651", "Every"], ["C172979", "Fear Score 6"], ["C66839", "Eight"], ["C29844", "Week"], ["C198613", "CFI wt Allele"], ["C16960", "Patient"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C53279", "Continue"], ["C25640", "Reduced"], ["C16727", "India"], ["C25229", "Left"], ["C38055", "Ventricular"], ["C25518", "Function"], ["C168121", "Asymptomatic Presentation"], ["C25741", "Physician"], ["C49236", "Therapeutic Procedure"], ["C198613", "CFI wt Allele"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C142422", "Clinical Benefit"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C49236", "Therapeutic Procedure"], ["C101282", "Have"], ["C49667", "Safety Study"], ["C52874", "SPI1 wt Allele"], ["C123452", "Continuation Therapy Epoch"], ["C43508", "Oregon"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C54627", "Experience"], ["C12727", "Heart"], ["C20632", "Pathophysiology"], ["C101282", "Have"], ["C25594", "Negation"], ["C198613", "CFI wt Allele"], ["C99524", "Left Ventricular Ejection Fraction"], ["C48570", "Percent Unit"], ["C69442", "Medical Drop"], ["C69122", "Ten"], ["C25516", "From"], ["C125938", "Baseline Epoch"], ["C16289", "Andorra"], ["C159124", "GDC Treatment Outcome Terminology"], ["C75330", "Below"], ["C105785", "Fifty"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C118406", "Suspended License"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C48804", "Repeat Object"], ["C99524", "Left Ventricular Ejection Fraction"], ["C25367", "Assessment"], ["C38000", "Performed"], ["C25282", "Within"], ["C45828", "Approximate"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C29844", "Week"], ["C198613", "CFI wt Allele"], ["C99524", "Left Ventricular Ejection Fraction"], ["C101282", "Have"], ["C25594", "Negation"], ["C125459", "Improved"], ["C43508", "Oregon"], ["C51024", "Response Declined"], ["C25519", "Further"], ["C43508", "Oregon"], ["C168447", "Symptomatic Presentation"], ["C3080", "Congestive Heart Failure"], ["C101282", "Have"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C16329", "Belgium"], ["C25387", "Benefit"], ["C64956", "For"], ["C25190", "Person"], ["C53691", "Veterinary Patient"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C64916", "All"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C52582", "Referral"], ["C64956", "For"], ["C25367", "Assessment"], ["C158169", "Buyei Chinese"], ["C76246", "Blood Group A"], ["C125951", "Cardiologist"], ["C16289", "Andorra"], ["C16033", "Follow-Up"], ["C198613", "CFI wt Allele"], ["C168447", "Symptomatic Presentation"], ["C50577", "Heart Failure"], ["C25490", "During"], ["C1647", "Trastuzumab"], ["C49236", "Therapeutic Procedure"], ["C38267", "Intrathecal Route of Administration"], ["C16329", "Belgium"], ["C25705", "Treating"], ["C62355", "With"], ["C81893", "Standard"], ["C64956", "For"], ["C3080", "Congestive Heart Failure"], ["C25258", "Most"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C3080", "Congestive Heart Failure"], ["C43508", "Oregon"], ["C168121", "Asymptomatic Presentation"], ["C12727", "Heart"], ["C20632", "Pathophysiology"], ["C16727", "India"], ["C71104", "Clinical Trial"], ["C125459", "Improved"], ["C62355", "With"], ["C81893", "Standard"], ["C3080", "Congestive Heart Failure"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C75889", "PAX6 wt Allele"], ["C248", "Angiotensin-1"], ["C16554", "Enzyme"], ["C91295", "ACE Gene"], ["C154898", "Inhibitor"], ["C43508", "Oregon"], ["C17064", "Proto-Oncogene Mas"], ["C192722", "BEST1 wt Allele"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C179575", "SARS Coronavirus 2 B.1.351"], ["C52874", "SPI1 wt Allele"], ["C16960", "Patient"], ["C62355", "With"], ["C12727", "Heart"], ["C168422", "Rheumatic Fever Symptom"], ["C16289", "Andorra"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C142422", "Clinical Benefit"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C43442", "Biomaterial Treatment"], ["C53279", "Continue"], ["C92667", "SPARC wt Allele"], ["C49236", "Therapeutic Procedure"], ["C25718", "Without"], ["C25406", "Additional"], ["C123619", "Clinical Response"], ["C12727", "Heart"], ["C150901", "Event Unit"], ["C3261", "Metastatic Neoplasm"], ["C4872", "Breast Carcinoma"], ["C1647", "Trastuzumab"], ["C16289", "Andorra"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C64974", "Give"], ["C16727", "India"], ["C61517", "Combination"], ["C16727", "India"], ["C9609", "Bleomycin/Cisplatin/Methotrexate Regimen"], ["C127262", "CDISC SDTM Environmental Setting Terminology"], ["C16960", "Patient"], ["C62355", "With"], ["C9609", "Bleomycin/Cisplatin/Methotrexate Regimen"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C25627", "Previous"], ["C25639", "Receive"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C68869", "Are"], ["C158997", "GDC Analyte Type Terminology"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C12727", "Heart"], ["C20632", "Pathophysiology"], ["C62355", "With"], ["C1647", "Trastuzumab"], ["C43442", "Biomaterial Treatment"], ["C17102", "Risk"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25309", "Lower"], ["C62355", "With"], ["C25456", "Concurrent"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C16289", "Andorra"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C61589", "Early"], ["C4872", "Breast Carcinoma"], ["C64956", "For"], ["C16960", "Patient"], ["C62355", "With"], ["C12727", "Heart"], ["C71344", "Associate of Science"], ["C38000", "Performed"], ["C158997", "GDC Analyte Type Terminology"], ["C125938", "Baseline Epoch"], ["C16329", "Belgium"], ["C64651", "Every"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C29846", "Month"], ["C175242", "During Treatment"], ["C16289", "Andorra"], ["C89789", "Every Six Months"], ["C53286", "Next"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C65136", "Until"], ["C156843", "24 Months"], ["C25516", "From"], ["C25551", "Last"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C25639", "Receive"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C79873", "Contain"], ["C15632", "Chemotherapy"], ["C25519", "Further"], ["C61256", "Monitoring"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C16289", "Andorra"], ["C127786", "Occurrence Indicator"], ["C74924", "Per Year"], ["C64643", "Up to"], ["C163771", "Illness Intrusiveness Rating 5"], ["C29848", "Year"], ["C25516", "From"], ["C25551", "Last"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C43508", "Oregon"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C167446", "Continuous Heart Murmur"], ["C25640", "Reduced"], ["C52874", "SPI1 wt Allele"], ["C99524", "Left Ventricular Ejection Fraction"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25599", "Observed"], ["C16960", "Patient"], ["C62355", "With"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C27996", "Myocardial Infarction"], ["C27996", "Myocardial Infarction"], ["C51221", "Angina"], ["C25261", "Medical"], ["C43442", "Biomaterial Treatment"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C43508", "Oregon"], ["C3080", "Congestive Heart Failure"], ["C66905", "New York Heart Association Class II"], ["C38276", "Intravenous Route of Administration"], ["C99524", "Left Ventricular Ejection Fraction"], ["C52874", "SPI1 wt Allele"], ["C188322", "Fifty Five"], ["C118472", "Other License Status"], ["C34830", "Cardiomyopathy"], ["C12727", "Heart"], ["C2881", "Arrhythmia"], ["C25261", "Medical"], ["C43442", "Biomaterial Treatment"], ["C41130", "Significant"], ["C12727", "Heart"], ["C45525", "Valvular Heart Disorder"], ["C157664", "Poorly Marginated Nodule"], ["C82500", "Disease Controlled"], ["C168203", "Family History of Hypertension"], ["C168203", "Family History of Hypertension"], ["C82500", "Disease Controlled"], ["C158169", "Buyei Chinese"], ["C81893", "Standard"], ["C25261", "Medical"], ["C43442", "Biomaterial Treatment"], ["C126586", "Eligible"], ["C16289", "Andorra"], ["C49287", "Effective"], ["C3319", "Pericardial Effusion"], ["C82931", "Exclusion"], ["C25516", "From"], ["C124450", "Adjuvant Therapy Clinical Trial Setting"], ["C16289", "Andorra"], ["C15665", "Neoadjuvant Therapy"], ["C71104", "Clinical Trial"], ["C62355", "With"], ["C1647", "Trastuzumab"], ["C16289", "Andorra"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C25197", "Recommendation"], ["C16727", "India"], ["C16960", "Patient"], ["C124450", "Adjuvant Therapy Clinical Trial Setting"], ["C43442", "Biomaterial Treatment"], ["C1647", "Trastuzumab"], ["C16289", "Andorra"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C64974", "Give"], ["C16727", "India"], ["C61517", "Combination"], ["C16727", "India"], ["C124450", "Adjuvant Therapy Clinical Trial Setting"], ["C124308", "CDISC SDTM Treatment Setting Terminology"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C75889", "PAX6 wt Allele"], ["C25533", "Increase"], ["C16727", "India"], ["C16726", "Incidence"], ["C52874", "SPI1 wt Allele"], ["C168447", "Symptomatic Presentation"], ["C16289", "Andorra"], ["C168121", "Asymptomatic Presentation"], ["C12727", "Heart"], ["C150901", "Event Unit"], ["C154196", "Washo Language"], ["C25599", "Observed"], ["C65140", "When"], ["C1647", "Trastuzumab"], ["C154196", "Washo Language"], ["C25382", "Administered"], ["C38008", "Post"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C79873", "Contain"], ["C15632", "Chemotherapy"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C70962", "Agent Administration"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C14460", "NON Mouse"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C165496", "GDC Regimen Terminology"], ["C52874", "SPI1 wt Allele"], ["C1526", "Docetaxel"], ["C16289", "Andorra"], ["C1282", "Carboplatin"], ["C16289", "Andorra"], ["C154196", "Washo Language"], ["C128667", "More"], ["C182282", "Marked Heterogeneity Morphology"], ["C65140", "When"], ["C1647", "Trastuzumab"], ["C154196", "Washo Language"], ["C25382", "Administered"], ["C62355", "With"], ["C1490", "Taxane Compound"], ["C65140", "When"], ["C25382", "Administered"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1490", "Taxane Compound"], ["C103851", "Regardless"], ["C52874", "SPI1 wt Allele"], ["C165496", "GDC Regimen Terminology"], ["C25258", "Most"], ["C168447", "Symptomatic Presentation"], ["C12727", "Heart"], ["C150901", "Event Unit"], ["C54069", "Occur"], ["C25282", "Within"], ["C25509", "First"], ["C111798", "Eighteen"], ["C29846", "Month"], ["C16727", "India"], ["C66832", "One"], ["C52874", "SPI1 wt Allele"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C28007", "Median"], ["C99158", "Clinical Study Follow-up"], ["C52874", "SPI1 wt Allele"], ["C163771", "Illness Intrusiveness Rating 5"], ["C163771", "Illness Intrusiveness Rating 5"], ["C29848", "Year"], ["C154196", "Washo Language"], ["C25429", "Availability"], ["C76246", "Blood Group A"], ["C167446", "Continuous Heart Murmur"], ["C25533", "Increase"], ["C16727", "India"], ["C25470", "Cumulative"], ["C77538", "Rating"], ["C52874", "SPI1 wt Allele"], ["C168447", "Symptomatic Presentation"], ["C12727", "Heart"], ["C43508", "Oregon"], ["C99524", "Left Ventricular Ejection Fraction"], ["C150901", "Event Unit"], ["C154196", "Washo Language"], ["C25599", "Observed"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C25382", "Administered"], ["C1647", "Trastuzumab"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C1490", "Taxane Compound"], ["C53286", "Next"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C49236", "Therapeutic Procedure"], ["C64643", "Up to"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C175627", "Thirty Seven"], ["C48570", "Percent Unit"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C45828", "Approximate"], ["C105723", "ECOG Performance Status 1"], ["C48570", "Percent Unit"], ["C16727", "India"], ["C66833", "Two"], ["C49882", "Comparator Device"], ["C185374", "Adherence to Refills and Medications Scale"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C405", "Cyclophosphamide"], ["C53286", "Next"], ["C1490", "Taxane Compound"], ["C16289", "Andorra"], ["C1490", "Taxane Compound"], ["C1282", "Carboplatin"], ["C16289", "Andorra"], ["C1647", "Trastuzumab"], ["C17103", "Risk Factor"], ["C64956", "For"], ["C76246", "Blood Group A"], ["C12727", "Heart"], ["C74589", "Protocol Event"], ["C25737", "Identification"], ["C16727", "India"], ["C66835", "Four"], ["C49508", "Large"], ["C124450", "Adjuvant Therapy Clinical Trial Setting"], ["C25411", "Advanced"], ["C106312", "Advanced Glycation End Product"], ["C105785", "Fifty"], ["C29848", "Year"], ["C139301", "IPSS Risk Category Low"], ["C99524", "Left Ventricular Ejection Fraction"], ["C188322", "Fifty Five"], ["C48570", "Percent Unit"], ["C158997", "GDC Analyte Type Terminology"], ["C125938", "Baseline Epoch"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C53286", "Next"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C1411", "Paclitaxel"], ["C43442", "Biomaterial Treatment"], ["C16727", "India"], ["C99524", "Left Ventricular Ejection Fraction"], ["C158169", "Buyei Chinese"], ["C69122", "Ten"], ["C113429", "Fifteen"], ["C16289", "Andorra"], ["C25629", "Prior"], ["C43508", "Oregon"], ["C25456", "Concurrent"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C1647", "Trastuzumab"], ["C38008", "Post"], ["C25250", "Complete"], ["C52874", "SPI1 wt Allele"], ["C15360", "Adjuvant Chemotherapy"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C12727", "Heart"], ["C20632", "Pathophysiology"], ["C154196", "Washo Language"], ["C25281", "Associated"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C25227", "High"], ["C94394", "Cumulative Dose"], ["C52874", "SPI1 wt Allele"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C64974", "Give"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C138901", "Body Mass Index Finding"], ["C138901", "Body Mass Index Finding"], ["C113663", "Twenty Five"], ["C49671", "Kilogram per Square Meter"], ["C15665", "Neoadjuvant Therapy"], ["C124450", "Adjuvant Therapy Clinical Trial Setting"], ["C43442", "Biomaterial Treatment"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C126586", "Eligible"], ["C64956", "For"], ["C15665", "Neoadjuvant Therapy"], ["C124450", "Adjuvant Therapy Clinical Trial Setting"], ["C43442", "Biomaterial Treatment"], ["C1647", "Trastuzumab"], ["C16329", "Belgium"], ["C62355", "With"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C48440", "Single"], ["C16727", "India"], ["C15632", "Chemotherapy"], ["C189136", "SARS-CoV-2 Naive Specimen"], ["C16960", "Patient"], ["C16289", "Andorra"], ["C48440", "Single"], ["C62355", "With"], ["C49341", "Low-Dose Treatment"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C68254", "Dietary Iodine"], ["C68800", "Elementary Charge"], ["C82868", "Maximum Value Derivation Technique"], ["C25470", "Cumulative"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C456", "Doxorubicin"], ["C17266", "Congo, the Democratic Republic of the"], ["C67402", "Milligram per Square Meter"], ["C43508", "Oregon"], ["C62028", "Epirubicin"], ["C16728", "Indonesia"], ["C67402", "Milligram per Square Meter"], ["C198613", "CFI wt Allele"], ["C16960", "Patient"], ["C101282", "Have"], ["C25705", "Treating"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C25517", "Full"], ["C25379", "Course"], ["C52874", "SPI1 wt Allele"], ["C49341", "Low-Dose Treatment"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C16289", "Andorra"], ["C1647", "Trastuzumab"], ["C16727", "India"], ["C15665", "Neoadjuvant Therapy"], ["C127262", "CDISC SDTM Environmental Setting Terminology"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25406", "Additional"], ["C15681", "Cytotoxic Chemotherapy"], ["C16329", "Belgium"], ["C64974", "Give"], ["C38008", "Post"], ["C160609", "Surgical Procedure was Curative Therapy"], ["C16727", "India"], ["C118472", "Other License Status"], ["C53285", "Decision"], ["C92667", "SPARC wt Allele"], ["C41204", "Need"], ["C64956", "For"], ["C25406", "Additional"], ["C15681", "Cytotoxic Chemotherapy"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C136827", "Determine"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C25190", "Person"], ["C54627", "Experience"], ["C52874", "SPI1 wt Allele"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C62355", "With"], ["C139301", "IPSS Risk Category Low"], ["C25488", "Dose"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C142988", "Limited"], ["C159124", "GDC Treatment Outcome Terminology"], ["C71104", "Clinical Trial"], ["C16727", "India"], ["C71104", "Clinical Trial"], ["C1647", "Trastuzumab"], ["C154196", "Washo Language"], ["C25382", "Administered"], ["C62355", "With"], ["C15665", "Neoadjuvant Therapy"], ["C15632", "Chemotherapy"], ["C79873", "Contain"], ["C66834", "Three"], ["C25472", "Cycle"], ["C52874", "SPI1 wt Allele"], ["C456", "Doxorubicin"], ["C94394", "Cumulative Dose"], ["C17266", "Congo, the Democratic Republic of the"], ["C67402", "Milligram per Square Meter"], ["C16726", "Incidence"], ["C52874", "SPI1 wt Allele"], ["C168447", "Symptomatic Presentation"], ["C12727", "Heart"], ["C20632", "Pathophysiology"], ["C154196", "Washo Language"], ["C161431", "CDISC SDTM Model Version 1.7"], ["C48570", "Percent Unit"], ["C16727", "India"], ["C1647", "Trastuzumab"], ["C12671", "Upper Extremity"], ["C123619", "Clinical Response"], ["C54627", "Experience"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C142988", "Limited"], ["C16727", "India"], ["C16960", "Patient"], ["C75329", "Above"], ["C188329", "Sixty Five"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C15388", "Infusion Procedure"], ["C53260", "Adverse Event Definitely Related to Intervention"], ["C16289", "Andorra"], ["C3114", "Hypersensitivity"], ["C54035", "Serious"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1647", "Trastuzumab"], ["C15388", "Infusion Procedure"], ["C166400", "Inclusive"], ["C55061", "Hypotension, CTCAE"], ["C143947", "Wheezing, CTCAE"], ["C168203", "Family History of Hypertension"], ["C34439", "Bronchospasm"], ["C110938", "Tachyarrhythmia"], ["C25640", "Reduced"], ["C60832", "Oxygen Saturation Measurement"], ["C143282", "Anaphylaxis, CTCAE"], ["C12779", "Respiratory System"], ["C37942", "Distress"], ["C3432", "Urticaria"], ["C16289", "Andorra"], ["C112175", "Angioedema"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C69295", "Pre-Medication"], ["C106184", "May"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C25275", "Occurrence"], ["C52874", "SPI1 wt Allele"], ["C150901", "Event Unit"], ["C52874", "SPI1 wt Allele"], ["C150901", "Event Unit"], ["C127786", "Occurrence Indicator"], ["C25490", "During"], ["C43508", "Oregon"], ["C25282", "Within"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C163771", "Illness Intrusiveness Rating 5"], ["C25529", "Hour"], ["C52874", "SPI1 wt Allele"], ["C68616", "Start Date"], ["C52874", "SPI1 wt Allele"], ["C25509", "First"], ["C15388", "Infusion Procedure"], ["C75889", "PAX6 wt Allele"], ["C15388", "Infusion Procedure"], ["C25637", "Reaction"], ["C127786", "Occurrence Indicator"], ["C15388", "Infusion Procedure"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C43508", "Oregon"], ["C77538", "Rating"], ["C52874", "SPI1 wt Allele"], ["C15388", "Infusion Procedure"], ["C16289", "Andorra"], ["C53691", "Veterinary Patient"], ["C16329", "Belgium"], ["C65136", "Until"], ["C25655", "Physiologic Resolution"], ["C52874", "SPI1 wt Allele"], ["C64916", "All"], ["C25599", "Observed"], ["C168422", "Rheumatic Fever Symptom"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C168422", "Rheumatic Fever Symptom"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C25705", "Treating"], ["C62355", "With"], ["C75889", "PAX6 wt Allele"], ["C241", "Analgesic Agent"], ["C71344", "Associate of Science"], ["C635", "Meperidine Hydrochloride"], ["C43508", "Oregon"], ["C198", "Acetaminophen"], ["C43508", "Oregon"], ["C75889", "PAX6 wt Allele"], ["C29716", "Antihistamine"], ["C71344", "Associate of Science"], ["C61728", "Diphenhydramine"], ["C52874", "SPI1 wt Allele"], ["C16960", "Patient"], ["C25655", "Physiologic Resolution"], ["C52874", "SPI1 wt Allele"], ["C168422", "Rheumatic Fever Symptom"], ["C16289", "Andorra"], ["C25639", "Receive"], ["C25519", "Further"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C54035", "Serious"], ["C101282", "Have"], ["C25705", "Treating"], ["C62355", "With"], ["C15747", "Supportive Care"], ["C71344", "Associate of Science"], ["C722", "Oxygen"], ["C179575", "SARS Coronavirus 2 B.1.351"], ["C16289", "Andorra"], ["C211", "Therapeutic Corticosteroid"], ["C16727", "India"], ["C13634", "Retinoic Acid Response Element"], ["C68869", "Are"], ["C25281", "Associated"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C35461", "Clinical Course of Disease"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C48275", "Death Related to Adverse Event"], ["C20200", "Outcome"], ["C16960", "Patient"], ["C168162", "Chief Complaint Occurs at Rest"], ["C89272", "Due To"], ["C2959", "Complication"], ["C52874", "SPI1 wt Allele"], ["C25411", "Advanced"], ["C9305", "Malignant Neoplasm"], ["C16289", "Andorra"], ["C16457", "Comorbidity"], ["C106184", "May"], ["C16329", "Belgium"], ["C158997", "GDC Analyte Type Terminology"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C48275", "Death Related to Adverse Event"], ["C15388", "Infusion Procedure"], ["C25637", "Reaction"], ["C16960", "Patient"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C25705", "Treating"], ["C62355", "With"], ["C1647", "Trastuzumab"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C53620", "Initial Adverse Event and Product Problem Report"], ["C94226", "Improvement"], ["C53286", "Next"], ["C123619", "Clinical Response"], ["C25751", "Deterioration"], ["C16289", "Andorra"], ["C168181", "Delayed Capillary Refill Time"], ["C62355", "With"], ["C65069", "Rapidly"], ["C123619", "Clinical Response"], ["C25751", "Deterioration"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C101282", "Have"], ["C54069", "Occur"], ["C25282", "Within"], ["C25529", "Hour"], ["C16289", "Andorra"], ["C64643", "Up to"], ["C66832", "One"], ["C29844", "Week"], ["C53286", "Next"], ["C15388", "Infusion Procedure"], ["C92667", "SPARC wt Allele"], ["C116076", "Very"], ["C13634", "Retinoic Acid Response Element"], ["C16960", "Patient"], ["C101282", "Have"], ["C25279", "Onset"], ["C52874", "SPI1 wt Allele"], ["C15388", "Infusion Procedure"], ["C168422", "Rheumatic Fever Symptom"], ["C16289", "Andorra"], ["C105692", "Pulmonary Medicine"], ["C168422", "Rheumatic Fever Symptom"], ["C61584", "Greater Than"], ["C66837", "Six"], ["C25529", "Hour"], ["C38008", "Post"], ["C68616", "Start Date"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C15388", "Infusion Procedure"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C52874", "SPI1 wt Allele"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C64998", "Late"], ["C25279", "Onset"], ["C16289", "Andorra"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49147", "Physical Contact"], ["C25741", "Physician"], ["C198613", "CFI wt Allele"], ["C168422", "Rheumatic Fever Symptom"], ["C127786", "Occurrence Indicator"], ["C105692", "Pulmonary Medicine"], ["C150901", "Event Unit"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C105692", "Pulmonary Medicine"], ["C150901", "Event Unit"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C62355", "With"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C16727", "India"], ["C38008", "Post"], ["C53292", "Marketing"], ["C127262", "CDISC SDTM Environmental Setting Terminology"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C150901", "Event Unit"], ["C101282", "Have"], ["C151974", "Occasionally"], ["C48275", "Death Related to Adverse Event"], ["C16727", "India"], ["C64911", "Add"], ["C52874", "SPI1 wt Allele"], ["C38219", "Interstitial Route of Administration"], ["C23402", "Murine Lung"], ["C2991", "Disease or Disorder"], ["C166400", "Inclusive"], ["C23402", "Murine Lung"], ["C4928", "Acute Respiratory Distress Syndrome"], ["C3333", "Pneumonia"], ["C143767", "Pneumonitis, CTCAE"], ["C3331", "Pleural Effusion"], ["C27165", "Respiratory Distress"], ["C14140", "Acute"], ["C105692", "Pulmonary Medicine"], ["C16289", "Andorra"], ["C51447", "Pulmonary Insufficiency"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C17103", "Risk Factor"], ["C25281", "Associated"], ["C62355", "With"], ["C164315", "Interstitial Lung Disease"], ["C74521", "Include"], ["C25629", "Prior"], ["C43508", "Oregon"], ["C53630", "Concomitant Therapy"], ["C62355", "With"], ["C118472", "Other License Status"], ["C45315", "Neoplastic"], ["C80137", "Known"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C25281", "Associated"], ["C62355", "With"], ["C38267", "Intrathecal Route of Administration"], ["C71344", "Associate of Science"], ["C1490", "Taxane Compound"], ["C66876", "Gemcitabine"], ["C1275", "Vinorelbine"], ["C16289", "Andorra"], ["C15313", "Radiation Therapy"], ["C150901", "Event Unit"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C71344", "Associate of Science"], ["C45313", "Part"], ["C52874", "SPI1 wt Allele"], ["C75889", "PAX6 wt Allele"], ["C78361", "Infusion-Related Reaction"], ["C43508", "Oregon"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C161521", "Delayed Onset"], ["C16960", "Patient"], ["C168162", "Chief Complaint Occurs at Rest"], ["C89272", "Due To"], ["C2959", "Complication"], ["C52874", "SPI1 wt Allele"], ["C25411", "Advanced"], ["C9305", "Malignant Neoplasm"], ["C16289", "Andorra"], ["C16457", "Comorbidity"], ["C106184", "May"], ["C16329", "Belgium"], ["C158997", "GDC Analyte Type Terminology"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C105692", "Pulmonary Medicine"], ["C150901", "Event Unit"], ["C16960", "Patient"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C25705", "Treating"], ["C62355", "With"], ["C1647", "Trastuzumab"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16329", "Belgium"], ["C64956", "For"], ["C143767", "Pneumonitis, CTCAE"], ["C16727", "India"], ["C16960", "Patient"], ["C89327", "Be"], ["C25705", "Treating"], ["C62355", "With"], ["C1490", "Taxane Compound"], ["C29462", "Sorbitol"], ["C95494", "Content"], ["C1647", "Trastuzumab"], ["C129532", "One Hundred Fifty"], ["C16818", "Mammography"], ["C79873", "Contain"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16818", "Mammography"], ["C29462", "Sorbitol"], ["C16727", "India"], ["C64933", "Each"], ["C41275", "Vial"], ["C1647", "Trastuzumab"], ["C16818", "Mammography"], ["C79873", "Contain"], ["C172979", "Fear Score 6"], ["C16818", "Mammography"], ["C29462", "Sorbitol"], ["C16727", "India"], ["C64933", "Each"], ["C41275", "Vial"], ["C16960", "Patient"], ["C62355", "With"], ["C84720", "Hereditary Fructose Intolerance"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C64974", "Give"], ["C459", "Medication"], ["C76246", "Blood Group A"], ["C25480", "Details"], ["C18772", "Personal Medical History"], ["C62355", "With"], ["C159124", "GDC Treatment Outcome Terminology"], ["C168422", "Rheumatic Fever Symptom"], ["C101282", "Have"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C64642", "Of Each"], ["C53691", "Veterinary Patient"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C89327", "Be"], ["C64974", "Give"], ["C142605", "Medicinal Product"], ["C830", "Sodium"], ["C142605", "Medicinal Product"], ["C79873", "Contain"], ["C61585", "Less Than"], ["C105723", "ECOG Performance Status 1"], ["C48513", "Millimole"], ["C830", "Sodium"], ["C126885", "Twenty Three"], ["C16818", "Mammography"], ["C97722", "PER1 wt Allele"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C830", "Sodium"], ["C63628", "Empty"]], "rxnorm.special_warnings": [["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["56946", "paclitaxel"], ["72962", "docetaxel"], ["3639", "doxorubicin"], ["3995", "epirubicin"], ["224905", "trastuzumab"], ["3002", "cyclophosphamide"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["2179754", "Ogivri"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["T126", "Enzyme"], ["T192", "Receptor"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["72962", "docetaxel"], ["40048", "carboplatin"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["3002", "cyclophosphamide"], ["40048", "carboplatin"], ["224905", "trastuzumab"], ["T051", "Event"], ["56946", "paclitaxel"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["3639", "doxorubicin"], ["3995", "epirubicin"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["3639", "doxorubicin"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["7806", "oxygen"], ["6754", "meperidine"], ["3498", "diphenhydramine"], ["224905", "trastuzumab"], ["7806", "oxygen"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["12574", "gemcitabine"], ["39541", "vinorelbine"], ["224905", "trastuzumab"], ["9945", "sorbitol"], ["2179754", "Ogivri"], ["9945", "sorbitol"], ["2179754", "Ogivri"], ["9945", "sorbitol"], ["4570", "fructose"], ["9853", "sodium"], ["9853", "sodium"], ["9853", "sodium"]], "loinc.special_warnings": [["LA22004-8", "IN"], ["LA25433-6", "Biological"], ["MTHU008539", "Name"], ["LP18011-4", "Number"], ["LP28442-9", "HER2"], ["LA19974-7", "Performed"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["MTHU029808", "Laboratory"], ["LA8913-1", "Adequate"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LA32-8", "No"], ["MTHU854704", "Clinical trials"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["MTHU047625", "Setting"], ["LP29659-7", "Cardiac"], ["LA17571-3", "General"], ["LA21988-3", "AT"], ["LA24544-1", "Increased risk"], ["LA3748-6", "New York"], ["MTHU001067", "Heart"], ["LP264302-3", "NYHA"], ["LA28405-1", "Class II"], ["LP200078-6", "IV"], ["LA22025-3", "OR"], ["LA6737-6", "Asymptomatic"], ["LP29659-7", "Cardiac"], ["MTHU058708", "Events"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LP267221-2", "Therapy"], ["LA27350-0", "Alone"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["MTHU060612", "PACLitaxel"], ["LA22025-3", "OR"], ["LP18382-9", "DOXOrubicin"], ["LA22025-3", "OR"], ["MTHU010425", "Chemotherapy"], ["LA14161-6", "May"], ["LA32820-5", "Moderate to severe"], ["LA7424-0", "Death"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA22004-8", "IN"], ["LA11132-0", "Addition"], ["LA22004-8", "IN"], ["LA24377-6", "Increased"], ["LP121306-7", "Cardiac risk"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LA7444-8", "Hypertension"], ["LP208397-2", "Artery"], ["LA18199-2", "Disease"], ["LA32970-8", "<"], ["MTHU010047", "Age"], ["LA18187-7", "All"], ["LP94823-9", "Treatment"], ["LA33028-4", "Prior"], ["LP70366-7", "Cyclophosphamide"], ["LA16758-7", "Baseline"], ["LP29659-7", "Cardiac"], ["LP73913-3", "Assessment"], ["LP7800-8", "History"], ["MTHU000078", "Physical"], ["LA24331-3", "Electrocardiogram"], ["MTHU044181", "ECG"], ["LA24330-5", "Echocardiogram"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LP206574-8", "Magnetic resonance"], ["LP6328-1", "Imaging"], ["LA20297-0", "Monitoring"], ["LA14161-6", "May"], ["LP29659-7", "Cardiac"], ["LP29659-7", "Cardiac"], ["LA19974-7", "Performed"], ["LA21988-3", "AT"], ["LA16758-7", "Baseline"], ["LA18435-0", "3 months"], ["LP93408-0", "during treatment"], ["LP203021-3", "6 months"], ["LP94823-9", "Treatment"], ["MTHU068094", "Months"], ["LP17763-1", "A"], ["LP73913-3", "Assessment"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LP36790-1", "7"], ["MTHU068094", "Months"], ["LP94823-9", "Treatment"], ["LP62263-6", "Population"], ["LA18187-7", "All"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA14161-6", "May"], ["LA21988-3", "AT"], ["LA24544-1", "Increased risk"], ["LP29659-7", "Cardiac"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA15097-1", "Possible"], ["LP267221-2", "Therapy"], ["LP36790-1", "7"], ["MTHU068094", "Months"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP66710-2", "Patient"], ["LP15241-0", "S"], ["LP29659-7", "Cardiac"], ["LA8916-4", "Function"], ["LP73913-3", "Assessment"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["MTHU065907", "Cardiovascular"], ["LA16758-7", "Baseline"], ["LP200187-5", "Screening"], ["LA22004-8", "IN"], ["LA18187-7", "All"], ["LP29659-7", "Cardiac"], ["LA8916-4", "Function"], ["LP94823-9", "Treatment"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LA14558-3", "12"], ["LA9000-6", "Weeks"], ["LA20297-0", "Monitoring"], ["LA14161-6", "May"], ["LP29659-7", "Cardiac"], ["LA6737-6", "Asymptomatic"], ["LP29659-7", "Cardiac"], ["LA14161-6", "May"], ["LA16824-7", "More"], ["LA20297-0", "Monitoring"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP20594-5", "6"], ["LP70420-2", "-"], ["LP36791-9", "8"], ["LA9000-6", "Weeks"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LA32049-1", "Decrease"], ["LA22004-8", "IN"], ["LP267223-8", "Left ventricular function"], ["LA6737-6", "Asymptomatic"], ["MTHU010489", "Physician"], ["LP267221-2", "Therapy"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA32-8", "No"], ["LP7787-7", "Clinical"], ["LP267221-2", "Therapy"], ["LA17589-5", "Safety"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP29659-7", "Cardiac"], ["LA21291-2", "Not"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA13942-0", "10"], ["LA16758-7", "Baseline"], ["LA14987-4", "Below"], ["LA15248-0", "50%"], ["LP94823-9", "Treatment"], ["LP17763-1", "A"], ["LP73913-3", "Assessment"], ["LA19974-7", "Performed"], ["LP20591-1", "3"], ["LA9000-6", "Weeks"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA21291-2", "Not"], ["LA65-8", "Improved"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LA17766-9", "Symptomatic"], ["LA12070-1", "Individual"], ["LP66710-2", "Patient"], ["MTHU043138", "Risks"], ["LA18187-7", "All"], ["LA6624-6", "Referred"], ["LP73913-3", "Assessment"], ["LP17763-1", "A"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA17766-9", "Symptomatic"], ["LP29659-7", "Cardiac"], ["LA9664-9", "Failure"], ["LP267221-2", "Therapy"], ["LP200077-8", "IT"], ["LP20607-5", "standard"], ["LA22025-3", "OR"], ["LA6737-6", "Asymptomatic"], ["LP29659-7", "Cardiac"], ["LA22004-8", "IN"], ["LA65-8", "Improved"], ["LP20607-5", "standard"], ["LP94823-9", "Treatment"], ["LA31429-6", "Enzyme"], ["LP230189-5", "Adverse Childhood Experiences"], ["LA22025-3", "OR"], ["T192", "Receptor"], ["LP6781-1", "Arbitrary"], ["LP17763-1", "A"], ["LP29659-7", "Cardiac"], ["LP75708-5", "Symptoms"], ["LP17763-1", "A"], ["LP7787-7", "Clinical"], ["LP94823-9", "Treatment"], ["LP267221-2", "Therapy"], ["LP263791-8", "Additional"], ["LP7787-7", "Clinical"], ["LP29659-7", "Cardiac"], ["MTHU058708", "Events"], ["LA14283-8", "Breast cancer"], ["LA21291-2", "Not"], ["LP29256-2", "given"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LA22004-8", "IN"], ["MTHU047625", "Setting"], ["LA32660-5", "Received"], ["LA19952-3", "At risk"], ["LP29659-7", "Cardiac"], ["LP94823-9", "Treatment"], ["LP200075-2", "IS"], ["LA12111-3", "Early"], ["LA14283-8", "Breast cancer"], ["LP29659-7", "Cardiac"], ["LA19974-7", "Performed"], ["LA21988-3", "AT"], ["LA16758-7", "Baseline"], ["LP20591-1", "3"], ["MTHU068094", "Months"], ["LP93408-0", "during treatment"], ["LP203021-3", "6 months"], ["LP94823-9", "Treatment"], ["MTHU068094", "Months"], ["LA22004-8", "IN"], ["MTHU010425", "Chemotherapy"], ["LA20297-0", "Monitoring"], ["LP200075-2", "IS"], ["LA31722-4", "5 years"], ["LA22025-3", "OR"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LA16902-1", "Continuous"], ["LA32049-1", "Decrease"], ["LP200075-2", "IS"], ["LP6425-5", "Observed"], ["LA20365-5", "History of myocardial infarction"], ["LA22011-3", "MI"], ["LA14275-4", "Angina pectoris"], ["LP94823-9", "Treatment"], ["LP7800-8", "History"], ["LA22025-3", "OR"], ["LP264302-3", "NYHA"], ["LA28405-1", "Class II"], ["LP200078-6", "IV"], ["LA32970-8", "<"], ["MTHU029809", "Other"], ["LP128708-7", "Cardiomyopathy"], ["LP29659-7", "Cardiac"], ["MTHU050325", "Arrhythmia"], ["LP94823-9", "Treatment"], ["LA28474-7", "Significant"], ["LP29659-7", "Cardiac"], ["MTHU040650", "Valvular disease"], ["LA7444-8", "Hypertension"], ["LA7444-8", "Hypertension"], ["LP20607-5", "standard"], ["LP94823-9", "Treatment"], ["MTHU063500", "Pericardial effusion"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA21291-2", "Not"], ["LP29256-2", "given"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["MTHU047625", "Setting"], ["LA22004-8", "IN"], ["LA32048-3", "Increase"], ["LA22004-8", "IN"], ["LA17766-9", "Symptomatic"], ["LA6737-6", "Asymptomatic"], ["LP29659-7", "Cardiac"], ["MTHU058708", "Events"], ["LP6425-5", "Observed"], ["MTHU010425", "Chemotherapy"], ["LP17763-1", "A"], ["LA16824-7", "More"], ["LA17968-1", "Marked"], ["LA17766-9", "Symptomatic"], ["LP29659-7", "Cardiac"], ["MTHU058708", "Events"], ["LP6974-2", "first"], ["MTHU068094", "Months"], ["LA22004-8", "IN"], ["LA6306-0", "One"], ["LP20591-1", "3"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA25381-7", "Median"], ["LP422890-6", "Follow-up"], ["LA15769-5", "5.5"], ["LP17763-1", "A"], ["LA16902-1", "Continuous"], ["LA32048-3", "Increase"], ["LA22004-8", "IN"], ["MTHU027852", "Rate"], ["LA17766-9", "Symptomatic"], ["LP29659-7", "Cardiac"], ["LA22025-3", "OR"], ["MTHU058708", "Events"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP267221-2", "Therapy"], ["MTHU000002", "Clinical Class"], ["LA6112-2", "1"], ["LA22004-8", "IN"], ["LA6404-3", "Two"], ["LP70366-7", "Cyclophosphamide"], ["46467-7", "Risk factors:Find:Pt:^Patient:Nom"], ["LP17763-1", "A"], ["LP29659-7", "Cardiac"], ["MTHU019184", "Event"], ["LP40035-5", "Identified"], ["LA22004-8", "IN"], ["LA33103-5", "Four"], ["LA8981-8", "Large"], ["MTHU010047", "Age"], ["LA28854-0", "50"], ["LA9194-7", "Low"], ["LA32970-8", "<"], ["LA21988-3", "AT"], ["LA16758-7", "Baseline"], ["LA33028-4", "Prior"], ["LA22025-3", "OR"], ["MTHU060612", "PACLitaxel"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LA13942-0", "10"], ["LA14561-7", "15"], ["LA33028-4", "Prior"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["MTHU010425", "Chemotherapy"], ["LP29659-7", "Cardiac"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP29256-2", "given"], ["LA33028-4", "Prior"], ["LP17763-1", "A"], ["LP35925-4", "Body mass index (BMI)"], ["LA19281-7", "25"], ["LA32062-4", "M2"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["MTHU010425", "Chemotherapy"], ["LA9194-7", "Low"], ["MTHU065481", "Dose"], ["LA15457-7", "I"], ["LA13503-0", "E"], ["LP6972-6", "maximum"], ["LP18382-9", "DOXOrubicin"], ["LP15217-0", "Mg"], ["LA32062-4", "M2"], ["LA22025-3", "OR"], ["LP15217-0", "Mg"], ["LA32062-4", "M2"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LA19682-6", "Full"], ["LA9194-7", "Low"], ["MTHU065481", "Dose"], ["LA22004-8", "IN"], ["MTHU047625", "Setting"], ["LA32-8", "No"], ["LP263791-8", "Additional"], ["MTHU010425", "Chemotherapy"], ["LP29256-2", "given"], ["LP7616-8", "Surgery"], ["LA22004-8", "IN"], ["MTHU029809", "Other"], ["LP263791-8", "Additional"], ["MTHU010425", "Chemotherapy"], ["LP200075-2", "IS"], ["LA12070-1", "Individual"], ["LP30872-3", "Low dose"], ["LP200075-2", "IS"], ["LA6484-5", "Limited"], ["LA22004-8", "IN"], ["MTHU010425", "Chemotherapy"], ["LA6395-3", "Three"], ["LP18382-9", "DOXOrubicin"], ["MTHU065481", "Dose"], ["LP15217-0", "Mg"], ["LA32062-4", "M2"], ["LA17766-9", "Symptomatic"], ["LP29659-7", "Cardiac"], ["LA6112-2", "1"], ["LP36790-1", "7"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LP200075-2", "IS"], ["LA6484-5", "Limited"], ["LA22004-8", "IN"], ["LA14991-6", "Above"], ["MTHU010047", "Age"], ["LP263434-5", "Infusion"], ["LA31343-9", "Related"], ["LA30751-4", "Serious"], ["LP263434-5", "Infusion"], ["MTHU020790", "Hypotension"], ["MTHU013532", "Wheezing"], ["LA7444-8", "Hypertension"], ["LA32619-1", "Reduced"], ["LP21258-6", "Oxygen saturation"], ["LA7413-3", "Anaphylaxis"], ["LP29718-1", "Respiratory"], ["LA31437-9", "Distress"], ["LA20642-7", "Urticaria"], ["LP6486-7", "Reported"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP32605-5", "pre"], ["MTHU038481", "Medication"], ["LA14161-6", "May"], ["MTHU058708", "Events"], ["MTHU058708", "Events"], ["LA22025-3", "OR"], ["LA15766-1", "2.5"], ["LP190656-1", "start"], ["LP6974-2", "first"], ["LP263434-5", "Infusion"], ["LP263434-5", "Infusion"], ["LP73228-6", "Reaction"], ["LP263434-5", "Infusion"], ["LA22025-3", "OR"], ["MTHU027852", "Rate"], ["LP263434-5", "Infusion"], ["LP66710-2", "Patient"], ["LA18187-7", "All"], ["LP6425-5", "Observed"], ["LP75708-5", "Symptoms"], ["LP20592-9", "4"], ["MTHU000002", "Clinical Class"], ["LP75708-5", "Symptoms"], ["LA28608-0", "Meperidine"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["MTHU063001", "diphenhydrAMINE"], ["LP75708-5", "Symptoms"], ["LA32660-5", "Received"], ["LA30751-4", "Serious"], ["LP267221-2", "Therapy"], ["MTHU002757", "Oxygen"], ["LA22004-8", "IN"], ["LA15679-6", "Rare"], ["LP270144-1", "Cases"], ["LP17763-1", "A"], ["MTHU058835", "Clinical course"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA32822-1", "Fatal"], ["LP230193-7", "at rest"], ["19817-6", "Complications:Type:Stdy:^Patient:Nom"], ["LP128794-7", "Malignancy"], ["LA14161-6", "May"], ["LA21988-3", "AT"], ["LA24544-1", "Increased risk"], ["LP17763-1", "A"], ["LA32822-1", "Fatal"], ["LP263434-5", "Infusion"], ["LP73228-6", "Reaction"], ["LA21291-2", "Not"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LA6662-6", "Initial"], ["LP7787-7", "Clinical"], ["LP266901-0", "Delayed"], ["LA24868-4", "Rapid"], ["LP7787-7", "Clinical"], ["LP6486-7", "Reported"], ["LA6306-0", "One"], ["LA14216-8", "Week"], ["LP263434-5", "Infusion"], ["LA29696-4", "Very"], ["LA15679-6", "Rare"], ["LP263434-5", "Infusion"], ["LP75708-5", "Symptoms"], ["54542-6", "Pulmonary:-:Pt:^Patient:-"], ["LP75708-5", "Symptoms"], ["LA16824-7", "More"], ["LP190656-1", "start"], ["LP263434-5", "Infusion"], ["LP17763-1", "A"], ["LP248328-9", "Contact"], ["MTHU010489", "Physician"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP75708-5", "Symptoms"], ["54542-6", "Pulmonary:-:Pt:^Patient:-"], ["MTHU058708", "Events"], ["LA6750-9", "Severe"], ["54542-6", "Pulmonary:-:Pt:^Patient:-"], ["MTHU058708", "Events"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LP32606-3", "post"], ["MTHU047625", "Setting"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["MTHU058708", "Events"], ["LA6483-7", "Occasionally"], ["LA32822-1", "Fatal"], ["LA22004-8", "IN"], ["LA11132-0", "Addition"], ["LP270144-1", "Cases"], ["LP199934-3", "Lung"], ["LA18199-2", "Disease"], ["LP199934-3", "Lung"], ["LA28203-0", "Acute respiratory distress syndrome"], ["MTHU020831", "Pneumonia"], ["LA9548-4", "Respiratory distress"], ["LA18821-1", "Acute"], ["54542-6", "Pulmonary:-:Pt:^Patient:-"], ["MTHU054873", "Respiratory insufficiency"], ["LP6486-7", "Reported"], ["46467-7", "Risk factors:Find:Pt:^Patient:Nom"], ["LA10531-4", "Lung Disease"], ["LA33028-4", "Prior"], ["LA22025-3", "OR"], ["LP267221-2", "Therapy"], ["MTHU029809", "Other"], ["LP75725-9", "Therapies"], ["LP200077-8", "IT"], ["MTHU026213", "Radiation"], ["LP267221-2", "Therapy"], ["MTHU058708", "Events"], ["LA14161-6", "May"], ["LP263434-5", "Infusion"], ["LA31343-9", "Related"], ["LP73228-6", "Reaction"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LP266901-0", "Delayed"], ["LP230193-7", "at rest"], ["19817-6", "Complications:Type:Stdy:^Patient:Nom"], ["LP128794-7", "Malignancy"], ["LA14161-6", "May"], ["LA21988-3", "AT"], ["LA24544-1", "Increased risk"], ["54542-6", "Pulmonary:-:Pt:^Patient:-"], ["MTHU058708", "Events"], ["LA21291-2", "Not"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LA22004-8", "IN"], ["LP62208-1", "Sorbitol"], ["LP15217-0", "Mg"], ["MTHU000002", "Clinical Class"], ["LP15217-0", "Mg"], ["LP62208-1", "Sorbitol"], ["LA22004-8", "IN"], ["LA20376-2", "Vial"], ["LP15217-0", "Mg"], ["LP20594-5", "6"], ["LP15217-0", "Mg"], ["LP62208-1", "Sorbitol"], ["LA22004-8", "IN"], ["LA20376-2", "Vial"], ["MTHU015041", "Hereditary"], ["LP62996-1", "Fructose"], ["LA21291-2", "Not"], ["LP29256-2", "given"], ["LA16120-0", "Medicine"], ["LP17763-1", "A"], ["LP7800-8", "History"], ["LP75708-5", "Symptoms"], ["LP66710-2", "Patient"], ["LA33028-4", "Prior"], ["LP29256-2", "given"], ["LP15099-2", "Sodium"], ["LA16823-9", "Less"], ["LA6112-2", "1"], ["LP15099-2", "Sodium"], ["LP15217-0", "Mg"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP15099-2", "Sodium"]], "snomed.pregnancy": [["373067005", "No (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["394653002", "Significant|Significant (qualifier value)"], ["11896004", "Intermediate (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["18720000", "In (attribute)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["327392000", "Other antineoplastic agents (substance)|Other antineoplastic agents (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["394424008", "Positive|Positive (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["387374002", "Paclitaxel (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["372817009", "Doxorubicin (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255603008", "Major (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["387374002", "Paclitaxel (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18307000", "Altered (qualifier value)"], ["18720000", "In (attribute)"], ["52101004", "Present (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["255560000", "Intravenous (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["367409002", "Followed by (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["255560000", "Intravenous (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["372817009", "Doxorubicin (substance)"], ["767279008", "Metabolite (substance)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["1222740005", "American Joint Committee on Cancer stage I:3 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255456001", "Elevation - value (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["767279008", "Metabolite (substance)"], ["224699009", "Study (environment)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["302538001", "Entire upper arm (body structure)"], ["224699009", "Study (environment)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["255560000", "Intravenous (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["255560000", "Intravenous (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386918005", "Docetaxel (substance)"], ["732814003", "60 (qualifier value)"], ["404216004", "Milligram/square meter (qualifier value)|mg/sq.m (qualifier value)"], ["255560000", "Intravenous (qualifier value)"], ["18720000", "In (attribute)"], ["414551003", "Japanese (ethnic group)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["394424008", "Positive|Positive (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["397971000", "No effect (qualifier value)"], ["420862001", "On (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386918005", "Docetaxel (substance)"], ["224699009", "Study (environment)"], ["159083000", "WAS A (attribute)"], ["118555000", "Substance amount (property) (qualifier value)"], ["224699009", "Study (environment)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["18720000", "In (attribute)"], ["248153007", "Male (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["248152002", "Female (finding)"], ["414551003", "Japanese (ethnic group)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86005002", "Advanced (qualifier value)"], ["363349007", "Malignant tumor of stomach (disorder)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["224699009", "Study (environment)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386906001", "Capecitabine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387318005", "Cisplatin (substance)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["45169001", "Without (attribute)"], ["387003001", "Trastuzumab (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["118555000", "Substance amount (property) (qualifier value)"], ["224699009", "Study (environment)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["387172005", "Fluorouracil (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386906001", "Capecitabine (substance)"], ["247591002", "Affecting (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["260676000", "Use of (attribute)"], ["387318005", "Cisplatin (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["260676000", "Use of (attribute)"], ["387318005", "Cisplatin (substance)"], ["20401003", "With (attribute)"], ["387003001", "Trastuzumab (substance)"], ["386906001", "Capecitabine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387318005", "Cisplatin (substance)"], ["247591002", "Affecting (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["260676000", "Use of (attribute)"], ["386906001", "Capecitabine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["260676000", "Use of (attribute)"], ["386906001", "Capecitabine (substance)"], ["20401003", "With (attribute)"], ["387003001", "Trastuzumab (substance)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["224699009", "Study (environment)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["86005002", "Advanced (qualifier value)"], ["74778001", "Inoperable (qualifier value)"], ["394424008", "Positive|Positive (qualifier value)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["387003001", "Trastuzumab (substance)"], ["373067005", "No (qualifier value)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386905002", "Carboplatin (substance)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["27867009", "Antineoplastic agent (product)|Medicinal product acting as antineoplastic agent (product)|Antineoplastic agent (substance)"], ["420862001", "On (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67922002", "Serum (substance)"], ["387003001", "Trastuzumab (substance)"], ["255234002", "After (attribute)"], ["387003001", "Trastuzumab (substance)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["255560000", "Intravenous (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["67922002", "Serum (substance)"], ["18720000", "In (attribute)"], ["414551003", "Japanese (ethnic group)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["394424008", "Positive|Positive (qualifier value)"], ["224699009", "Study (environment)"], ["41647002", "No evidence of (contextual qualifier) (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386918005", "Docetaxel (substance)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["21191007", "Phase (attribute)|Phase (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["21191007", "Phase (attribute)|Phase (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["224699009", "Study (environment)"], ["18720000", "In (attribute)"], ["79970003", "Simultaneous (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387374002", "Paclitaxel (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["21191007", "Phase (attribute)|Phase (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["18720000", "In (attribute)"], ["387003001", "Trastuzumab (substance)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["394424008", "Positive|Positive (qualifier value)"], ["385435006", "Individual (person)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255586005", "Mean (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["255588006", "Trough (qualifier value)"], ["67922002", "Serum (substance)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["263707001", "Clear (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387374002", "Paclitaxel (substance)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["224699009", "Study (environment)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["394424008", "Positive|Positive (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["387374002", "Paclitaxel (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["372817009", "Doxorubicin (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["18720000", "In (attribute)"], ["387003001", "Trastuzumab (substance)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["372540003", "Anthracycline (substance)"], ["20401003", "With (attribute)"], ["387420009", "Cyclophosphamide (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["387374002", "Paclitaxel (substance)"], ["224699009", "Study (environment)"], ["397971000", "No effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["372817009", "Doxorubicin (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387374002", "Paclitaxel (substance)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["224699009", "Study (environment)"], ["386905002", "Carboplatin (substance)"], ["373067005", "No (qualifier value)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["386910003", "Anastrozole (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"]], "ncit.pregnancy": [["C159586", "Preoperative IV Sedation was Not Administered"], ["C54216", "Interaction"], ["C101282", "Have"], ["C38000", "Performed"], ["C41130", "Significant"], ["C94545", "Between"], ["C1647", "Trastuzumab"], ["C16289", "Andorra"], ["C25730", "Concomitant"], ["C16727", "India"], ["C71104", "Clinical Trial"], ["C101282", "Have"], ["C25594", "Negation"], ["C25599", "Observed"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C92667", "SPARC wt Allele"], ["C15299", "Pharmacokinetics"], ["C52874", "SPI1 wt Allele"], ["C118472", "Other License Status"], ["C274", "Antineoplastic Agent"], ["C49663", "Pharmacokinetic Study"], ["C25474", "Data"], ["C25516", "From"], ["C16289", "Andorra"], ["C16727", "India"], ["C62355", "With"], ["C17756", "ERBB2 Gene"], ["C36659", "CTNNB1 Gene Mutation"], ["C9609", "Bleomycin/Cisplatin/Methotrexate Regimen"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1411", "Paclitaxel"], ["C16289", "Andorra"], ["C456", "Doxorubicin"], ["C16289", "Andorra"], ["C45368", "Major"], ["C79395", "Other Toxicity Studies: Metabolites"], ["C172979", "Fear Score 6"], ["C64370", "Hydroxyl Group"], ["C1411", "Paclitaxel"], ["C1461", "Perillyl Alcohol"], ["C16289", "Andorra"], ["C154196", "Washo Language"], ["C25594", "Negation"], ["C16727", "India"], ["C25626", "Present"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C66839", "Eight"], ["C67401", "Milligram per Kilogram"], ["C43508", "Oregon"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C67401", "Milligram per Kilogram"], ["C38276", "Intravenous Route of Administration"], ["C71584", "Load"], ["C25488", "Dose"], ["C53286", "Next"], ["C172979", "Fear Score 6"], ["C67401", "Milligram per Kilogram"], ["C43508", "Oregon"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67401", "Milligram per Kilogram"], ["C38276", "Intravenous Route of Administration"], ["C1647", "Trastuzumab"], ["C106184", "May"], ["C25605", "Overall"], ["C49587", "Exposure Domain"], ["C52874", "SPI1 wt Allele"], ["C66832", "One"], ["C456", "Doxorubicin"], ["C61154", "Metabolite"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C113427", "Thirteen"], ["C52874", "SPI1 wt Allele"], ["C16289", "Andorra"], ["C123619", "Clinical Response"], ["C62534", "Arginine/Omega-3 Fatty Acids/Nucleotides Oral Supplement"], ["C52874", "SPI1 wt Allele"], ["C25494", "Elevation"], ["C52874", "SPI1 wt Allele"], ["C61154", "Metabolite"], ["C150000", "Unclear State of Matter"], ["C25474", "Data"], ["C25516", "From"], ["C45319", "Study Object"], ["C76246", "Blood Group A"], ["C48440", "Single"], ["C12671", "Upper Extremity"], ["C45319", "Study Object"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C67401", "Milligram per Kilogram"], ["C38276", "Intravenous Route of Administration"], ["C71584", "Load"], ["C25488", "Dose"], ["C16289", "Andorra"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67401", "Milligram per Kilogram"], ["C38276", "Intravenous Route of Administration"], ["C67069", "Weekly"], ["C16289", "Andorra"], ["C1526", "Docetaxel"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C67402", "Milligram per Square Meter"], ["C38276", "Intravenous Route of Administration"], ["C16727", "India"], ["C43392", "Japanese"], ["C62355", "With"], ["C17756", "ERBB2 Gene"], ["C36659", "CTNNB1 Gene Mutation"], ["C9609", "Bleomycin/Cisplatin/Methotrexate Regimen"], ["C25730", "Concomitant"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C101282", "Have"], ["C164134", "No Effect"], ["C92667", "SPARC wt Allele"], ["C48440", "Single"], ["C25488", "Dose"], ["C15299", "Pharmacokinetics"], ["C52874", "SPI1 wt Allele"], ["C1526", "Docetaxel"], ["C45319", "Study Object"], ["C154196", "Washo Language"], ["C76246", "Blood Group A"], ["C45319", "Study Object"], ["C52874", "SPI1 wt Allele"], ["C38000", "Performed"], ["C16727", "India"], ["C46107", "Male, Self-Report"], ["C16289", "Andorra"], ["C46110", "Female Gender"], ["C43392", "Japanese"], ["C16960", "Patient"], ["C62355", "With"], ["C25411", "Advanced"], ["C4911", "Gastric Carcinoma"], ["C36912", "Atypical Glandular Cell"], ["C159124", "GDC Treatment Outcome Terminology"], ["C45319", "Study Object"], ["C15299", "Pharmacokinetics"], ["C52874", "SPI1 wt Allele"], ["C1794", "Capecitabine"], ["C16289", "Andorra"], ["C376", "Cisplatin"], ["C65140", "When"], ["C62355", "With"], ["C43508", "Oregon"], ["C25718", "Without"], ["C1647", "Trastuzumab"], ["C52874", "SPI1 wt Allele"], ["C45319", "Study Object"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C79395", "Other Toxicity Studies: Metabolites"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C505", "Fluorouracil"], ["C52874", "SPI1 wt Allele"], ["C1794", "Capecitabine"], ["C154196", "Washo Language"], ["C25594", "Negation"], ["C64917", "Affected"], ["C158169", "Buyei Chinese"], ["C25456", "Concurrent"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C376", "Cisplatin"], ["C43508", "Oregon"], ["C158169", "Buyei Chinese"], ["C25456", "Concurrent"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C376", "Cisplatin"], ["C1647", "Trastuzumab"], ["C1794", "Capecitabine"], ["C25227", "High"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C70916", "Half Life"], ["C65140", "When"], ["C25454", "Combined"], ["C62355", "With"], ["C1647", "Trastuzumab"], ["C25474", "Data"], ["C15299", "Pharmacokinetics"], ["C52874", "SPI1 wt Allele"], ["C376", "Cisplatin"], ["C25594", "Negation"], ["C64917", "Affected"], ["C158169", "Buyei Chinese"], ["C25456", "Concurrent"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C1794", "Capecitabine"], ["C43508", "Oregon"], ["C158169", "Buyei Chinese"], ["C25456", "Concurrent"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C138033", "Capecitabine/Trastuzumab Regimen"], ["C69122", "Ten"], ["C49663", "Pharmacokinetic Study"], ["C25474", "Data"], ["C25516", "From"], ["C45319", "Study Object"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C3261", "Metastatic Neoplasm"], ["C43508", "Oregon"], ["C124451", "Locally Advanced Disease Clinical Trial Setting"], ["C64247", "Inoperable"], ["C17756", "ERBB2 Gene"], ["C36659", "CTNNB1 Gene Mutation"], ["C9305", "Malignant Neoplasm"], ["C1647", "Trastuzumab"], ["C101282", "Have"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C62534", "Arginine/Omega-3 Fatty Acids/Nucleotides Oral Supplement"], ["C92667", "SPARC wt Allele"], ["C15299", "Pharmacokinetics"], ["C52874", "SPI1 wt Allele"], ["C1282", "Carboplatin"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C274", "Antineoplastic Agent"], ["C92667", "SPARC wt Allele"], ["C1647", "Trastuzumab"], ["C15299", "Pharmacokinetics"], ["C158169", "Buyei Chinese"], ["C49156", "Comparison"], ["C52874", "SPI1 wt Allele"], ["C13325", "Serum"], ["C1647", "Trastuzumab"], ["C38008", "Post"], ["C160135", "Trastuzumab Regimen"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C67401", "Milligram per Kilogram"], ["C71584", "Load"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67401", "Milligram per Kilogram"], ["C38276", "Intravenous Route of Administration"], ["C16289", "Andorra"], ["C25599", "Observed"], ["C13325", "Serum"], ["C16727", "India"], ["C43392", "Japanese"], ["C62355", "With"], ["C17756", "ERBB2 Gene"], ["C36659", "CTNNB1 Gene Mutation"], ["C9609", "Bleomycin/Cisplatin/Methotrexate Regimen"], ["C45319", "Study Object"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C15299", "Pharmacokinetics"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C1526", "Docetaxel"], ["C92667", "SPARC wt Allele"], ["C15299", "Pharmacokinetics"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C154196", "Washo Language"], ["C25626", "Present"], ["C49156", "Comparison"], ["C52874", "SPI1 wt Allele"], ["C15299", "Pharmacokinetics"], ["C25516", "From"], ["C66833", "Two"], ["C48281", "Trial Phase"], ["C62395", "WHO Central Nervous System Grade 2"], ["C16289", "Andorra"], ["C16289", "Andorra"], ["C66832", "One"], ["C15602", "Phase III Trial"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C1647", "Trastuzumab"], ["C16289", "Andorra"], ["C1411", "Paclitaxel"], ["C16289", "Andorra"], ["C66833", "Two"], ["C48281", "Trial Phase"], ["C62395", "WHO Central Nervous System Grade 2"], ["C16727", "India"], ["C1647", "Trastuzumab"], ["C154196", "Washo Language"], ["C25382", "Administered"], ["C71344", "Associate of Science"], ["C157514", "Single Agent Therapy"], ["C16289", "Andorra"], ["C16727", "India"], ["C62355", "With"], ["C17756", "ERBB2 Gene"], ["C36659", "CTNNB1 Gene Mutation"], ["C9609", "Bleomycin/Cisplatin/Methotrexate Regimen"], ["C25190", "Person"], ["C16289", "Andorra"], ["C181249", "Mean Based on Unspecified Calculation"], ["C1647", "Trastuzumab"], ["C13325", "Serum"], ["C25282", "Within"], ["C16289", "Andorra"], ["C81171", "Cross"], ["C154196", "Washo Language"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C48621", "Negative Surgical Margin"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C25730", "Concomitant"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C1411", "Paclitaxel"], ["C92667", "SPARC wt Allele"], ["C15299", "Pharmacokinetics"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C49156", "Comparison"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C15299", "Pharmacokinetics"], ["C25474", "Data"], ["C25516", "From"], ["C45319", "Study Object"], ["C16727", "India"], ["C62355", "With"], ["C17756", "ERBB2 Gene"], ["C36659", "CTNNB1 Gene Mutation"], ["C9609", "Bleomycin/Cisplatin/Methotrexate Regimen"], ["C25705", "Treating"], ["C62355", "With"], ["C1647", "Trastuzumab"], ["C1411", "Paclitaxel"], ["C16289", "Andorra"], ["C456", "Doxorubicin"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1647", "Trastuzumab"], ["C15299", "Pharmacokinetics"], ["C25474", "Data"], ["C16727", "India"], ["C1647", "Trastuzumab"], ["C154196", "Washo Language"], ["C25382", "Administered"], ["C71344", "Associate of Science"], ["C157514", "Single Agent Therapy"], ["C43508", "Oregon"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C1594", "Anthracycline Antineoplastic Antibiotic"], ["C405", "Cyclophosphamide"], ["C43508", "Oregon"], ["C1411", "Paclitaxel"], ["C45319", "Study Object"], ["C164134", "No Effect"], ["C52874", "SPI1 wt Allele"], ["C63416", "Doxorubicin/Paclitaxel Regimen"], ["C92667", "SPARC wt Allele"], ["C15299", "Pharmacokinetics"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C49663", "Pharmacokinetic Study"], ["C25474", "Data"], ["C25516", "From"], ["C45319", "Study Object"], ["C1282", "Carboplatin"], ["C101282", "Have"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C62534", "Arginine/Omega-3 Fatty Acids/Nucleotides Oral Supplement"], ["C92667", "SPARC wt Allele"], ["C15299", "Pharmacokinetics"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C25730", "Concomitant"], ["C1607", "Anastrozole"], ["C163546", "Double Immunodiffusion"], ["C25594", "Negation"], ["C179695", "Specimen Appearance Assessment"], ["C159124", "GDC Treatment Outcome Terminology"], ["C121660", "Influence"], ["C15299", "Pharmacokinetics"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"]], "rxnorm.pregnancy": [["224905", "trastuzumab"], ["224905", "trastuzumab"], ["56946", "paclitaxel"], ["3639", "doxorubicin"], ["56946", "paclitaxel"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["3639", "doxorubicin"], ["224905", "trastuzumab"], ["72962", "docetaxel"], ["224905", "trastuzumab"], ["72962", "docetaxel"], ["194000", "capecitabine"], ["2555", "cisplatin"], ["224905", "trastuzumab"], ["194000", "capecitabine"], ["2555", "cisplatin"], ["2555", "cisplatin"], ["224905", "trastuzumab"], ["194000", "capecitabine"], ["224905", "trastuzumab"], ["2555", "cisplatin"], ["194000", "capecitabine"], ["194000", "capecitabine"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["40048", "carboplatin"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["72962", "docetaxel"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["56946", "paclitaxel"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["56946", "paclitaxel"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["56946", "paclitaxel"], ["3639", "doxorubicin"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["3002", "cyclophosphamide"], ["56946", "paclitaxel"], ["3639", "doxorubicin"], ["56946", "paclitaxel"], ["224905", "trastuzumab"], ["40048", "carboplatin"], ["224905", "trastuzumab"], ["84857", "anastrozole"], ["224905", "trastuzumab"]], "loinc.pregnancy": [["LA32-8", "No"], ["LA19974-7", "Performed"], ["LA28474-7", "Significant"], ["LA22004-8", "IN"], ["MTHU854704", "Clinical trials"], ["LA21291-2", "Not"], ["LP6425-5", "Observed"], ["MTHU029809", "Other"], ["LA22004-8", "IN"], ["LP28442-9", "HER2"], ["LA6576-8", "Positive"], ["MTHU060612", "PACLitaxel"], ["LP18382-9", "DOXOrubicin"], ["LA29634-5", "Major"], ["LP20594-5", "6"], ["MTHU060612", "PACLitaxel"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP149220-8", "Presence"], ["LP36791-9", "8"], ["LP15217-0", "Mg"], ["LA22025-3", "OR"], ["LP20592-9", "4"], ["LP15217-0", "Mg"], ["LA9437-0", "Intravenous"], ["MTHU065481", "Dose"], ["LP20594-5", "6"], ["LP15217-0", "Mg"], ["LA22025-3", "OR"], ["MTHU000002", "Clinical Class"], ["LP15217-0", "Mg"], ["LA9437-0", "Intravenous"], ["LA14161-6", "May"], ["MTHU044104", "Overall"], ["LA6306-0", "One"], ["LP18382-9", "DOXOrubicin"], ["LP36790-1", "7"], ["LA14559-1", "13"], ["LP7787-7", "Clinical"], ["LA25349-4", "Elevation"], ["LP74341-6", "Study"], ["LP17763-1", "A"], ["LA17717-2", "Single"], ["LP74341-6", "Study"], ["LP20592-9", "4"], ["LP15217-0", "Mg"], ["LA9437-0", "Intravenous"], ["MTHU065481", "Dose"], ["MTHU000002", "Clinical Class"], ["LP15217-0", "Mg"], ["LA9437-0", "Intravenous"], ["LA18891-4", "Weekly"], ["LA28853-2", "60"], ["LP15217-0", "Mg"], ["LA32062-4", "M2"], ["LA9437-0", "Intravenous"], ["LA22004-8", "IN"], ["LA4595-0", "Japanese"], ["LP28442-9", "HER2"], ["LA6576-8", "Positive"], ["LA32-8", "No"], ["LA17717-2", "Single"], ["MTHU065481", "Dose"], ["LP74341-6", "Study"], ["LP17763-1", "A"], ["LP6869-4", "Substance Amount"], ["LP74341-6", "Study"], ["LA19974-7", "Performed"], ["LA22004-8", "IN"], ["LA2-8", "Male"], ["LA3-6", "Female"], ["LA4595-0", "Japanese"], ["LA10547-0", "Gastric Cancer"], ["LP74341-6", "Study"], ["MTHU060553", "CISplatin"], ["LA22025-3", "OR"], ["LP6869-4", "Substance Amount"], ["LP74341-6", "Study"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP20593-7", "5"], ["LA21291-2", "Not"], ["MTHU060553", "CISplatin"], ["LA22025-3", "OR"], ["MTHU060553", "CISplatin"], ["LP17763-1", "A"], ["LA30596-3", "Combined"], ["MTHU060553", "CISplatin"], ["LA21291-2", "Not"], ["LA22025-3", "OR"], ["LA13942-0", "10"], ["LP74341-6", "Study"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LP28442-9", "HER2"], ["LA6576-8", "Positive"], ["54532-7", "Cancer:-:Pt:^Patient:-"], ["LA32-8", "No"], ["LP15213-9", "pk"], ["LP266973-9", "Comparison"], ["LP7567-3", "Serum"], ["LP20592-9", "4"], ["LP15217-0", "Mg"], ["MTHU000002", "Clinical Class"], ["LP15217-0", "Mg"], ["LA9437-0", "Intravenous"], ["LP6425-5", "Observed"], ["LP7567-3", "Serum"], ["LA22004-8", "IN"], ["LA4595-0", "Japanese"], ["LP28442-9", "HER2"], ["LA6576-8", "Positive"], ["LP74341-6", "Study"], ["LA32-8", "No"], ["LP17763-1", "A"], ["LP15213-9", "pk"], ["LP266973-9", "Comparison"], ["LP15213-9", "pk"], ["LA6404-3", "Two"], ["LA15458-5", "II"], ["LA6306-0", "One"], ["LA15459-3", "III"], ["LP74341-6", "Study"], ["LA22004-8", "IN"], ["MTHU060612", "PACLitaxel"], ["LA6404-3", "Two"], ["LA15458-5", "II"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LP28442-9", "HER2"], ["LA6576-8", "Positive"], ["LA12070-1", "Individual"], ["LP6971-8", "mean"], ["LA29503-2", "Trough"], ["LP7567-3", "Serum"], ["LA32-8", "No"], ["LA19732-9", "Clear"], ["MTHU060612", "PACLitaxel"], ["LP266973-9", "Comparison"], ["LP15213-9", "pk"], ["LP74341-6", "Study"], ["LA22004-8", "IN"], ["LP28442-9", "HER2"], ["LA6576-8", "Positive"], ["MTHU060612", "PACLitaxel"], ["LP18382-9", "DOXOrubicin"], ["LP15213-9", "pk"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP70366-7", "Cyclophosphamide"], ["LA22025-3", "OR"], ["MTHU060612", "PACLitaxel"], ["LP74341-6", "Study"], ["LA32-8", "No"], ["LP18382-9", "DOXOrubicin"], ["MTHU060612", "PACLitaxel"], ["LP74341-6", "Study"], ["LA32-8", "No"], ["LP15213-9", "pk"], ["LA21291-2", "Not"]], "snomed.driving": [["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["254648000", "Effective (qualifier value)"], ["146680009", "Contraception|Contraception (finding)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["258706009", "month (qualifier value)"], ["255234002", "After (attribute)"], ["732766004", "5.2 (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["18720000", "In (attribute)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["417929005", "Times (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["338930006", "Human (organism)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["255560000", "Intravenous (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["263857004", "Revealed (qualifier value)"], ["41647002", "No evidence of (contextual qualifier) (qualifier value)"], ["260379002", "Impaired (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["394447009", "Fetus (person)|Fetus"], ["129347002", "Surgical transfer - action (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["264499004", "Early (qualifier value)"], ["258703001", "day (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260383002", "Late (qualifier value)"], ["258703001", "day (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["732515006", "150 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["36692007", "Known (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["387961004", "Kingdom Animalia (organism)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["338930006", "Human (organism)"], ["387003001", "Trastuzumab (substance)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["86495002", "For (qualifier value)"], ["394651000", "Mother (person)|Mother"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["394447009", "Fetus (person)|Fetus"], ["18720000", "In (attribute)"], ["288563008", "After values (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["277064003", "Function (attribute)"], ["40226000", "Impairment (finding)"], ["18720000", "In (attribute)"], ["263534001", "Association (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["157051001", "Oligohydramnios (disorder)|Oligohydramnios"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["47429007", "Associated with (attribute)"], ["399166001", "Fatal (qualifier value)"], ["204574007", "Pulmonary hypoplasia (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["394447009", "Fetus (person)|Fetus"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["387003001", "Trastuzumab (substance)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["394447009", "Fetus (person)|Fetus"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255409004", "Pregnant woman (person)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["28995006", "Treated with (attribute)"], ["387003001", "Trastuzumab (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["387003001", "Trastuzumab (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["258706009", "month (qualifier value)"], ["255260001", "Following (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["1222737005", "American Joint Committee on Cancer stage I:1 (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["224699009", "Study (environment)"], ["18720000", "In (attribute)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["417929005", "Times (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["338930006", "Human (organism)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["255560000", "Intravenous (qualifier value)"], ["258703001", "day (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["732515006", "150 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["387003001", "Trastuzumab (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["70813002", "Milk (substance)"], ["255410009", "Maternal postpartum (qualifier value)|Postpartum (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["52101004", "Present (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["18720000", "In (attribute)"], ["67922002", "Serum (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["133931009", "Infant (person)"], ["47429007", "Associated with (attribute)"], ["420862001", "On (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["3950001", "Birth (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258706009", "month (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["36692007", "Known (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["226789007", "Breast milk (substance)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["338930006", "Human (organism)"], ["28406009", "Immunoglobulin IgG>1< (substance)|Immunoglobulin IgG1 (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["30507006", "Into (attribute)"], ["226789007", "Breast milk (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["133931009", "Infant (person)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["261665006", "Unknown (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["258706009", "month (qualifier value)"], ["255234002", "After (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"]], "ncit.driving": [["C161316", "Female of Childbearing Potential"], ["C161316", "Female of Childbearing Potential"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25340", "Use"], ["C49287", "Effective"], ["C37932", "Contraception"], ["C175242", "During Treatment"], ["C62355", "With"], ["C1647", "Trastuzumab"], ["C16289", "Andorra"], ["C64956", "For"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C29846", "Month"], ["C54735", "Post-Therapy"], ["C101282", "Have"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C191656", "Pregnant Subject"], ["C17087", "Reproduction"], ["C101282", "Have"], ["C16727", "India"], ["C14232", "Cynomolgus Monkey"], ["C14243", "Monkey"], ["C158997", "GDC Analyte Type Terminology"], ["C25488", "Dose"], ["C64643", "Up to"], ["C113663", "Twenty Five"], ["C52874", "SPI1 wt Allele"], ["C67069", "Weekly"], ["C14225", "Human"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67401", "Milligram per Kilogram"], ["C1647", "Trastuzumab"], ["C38276", "Intravenous Route of Administration"], ["C15653", "Drug Formulation Process"], ["C16289", "Andorra"], ["C101282", "Have"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C21055", "Impairment"], ["C95089", "Fertility Domain"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C13272", "Placenta"], ["C48167", "Transfer"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C25490", "During"], ["C61589", "Early"], ["C25301", "Day"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C105785", "Fifty"], ["C52874", "SPI1 wt Allele"], ["C25742", "Pregnancy"], ["C16289", "Andorra"], ["C64998", "Late"], ["C25301", "Day"], ["C192184", "One Hundred Twenty"], ["C129532", "One Hundred Fifty"], ["C52874", "SPI1 wt Allele"], ["C25742", "Pregnancy"], ["C18732", "Development"], ["C25616", "Period"], ["C154196", "Washo Language"], ["C25599", "Observed"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C17998", "Unknown"], ["C1647", "Trastuzumab"], ["C52288", "NUP214 wt Allele"], ["C17087", "Reproduction"], ["C25443", "Capacity"], ["C71344", "Associate of Science"], ["C14182", "Animal"], ["C17087", "Reproduction"], ["C68869", "Are"], ["C25594", "Negation"], ["C110990", "All of the Time"], ["C52874", "SPI1 wt Allele"], ["C14225", "Human"], ["C165206", "Responsive Disease"], ["C1647", "Trastuzumab"], ["C16329", "Belgium"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C62230", "Potential"], ["C25387", "Benefit"], ["C64956", "For"], ["C25189", "Mother"], ["C62230", "Potential"], ["C17102", "Risk"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16727", "India"], ["C38008", "Post"], ["C53292", "Marketing"], ["C127262", "CDISC SDTM Environmental Setting Terminology"], ["C52874", "SPI1 wt Allele"], ["C25225", "Renal"], ["C16648", "Tissue Growth"], ["C48928", "And/Or"], ["C25518", "Function"], ["C21055", "Impairment"], ["C16727", "India"], ["C73471", "Chemical Association"], ["C62355", "With"], ["C92839", "Oligohydramnios"], ["C65099", "Some"], ["C25281", "Associated"], ["C62355", "With"], ["C48275", "Death Related to Adverse Event"], ["C99035", "Pulmonary Hypoplasia"], ["C52874", "SPI1 wt Allele"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C73435", "Gravida"], ["C25639", "Receive"], ["C1647", "Trastuzumab"], ["C75419", "World Health Organization"], ["C73435", "Gravida"], ["C16329", "Belgium"], ["C52874", "SPI1 wt Allele"], ["C52874", "SPI1 wt Allele"], ["C159124", "GDC Treatment Outcome Terminology"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C73435", "Gravida"], ["C14284", "Woman"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25705", "Treating"], ["C62355", "With"], ["C1647", "Trastuzumab"], ["C43508", "Oregon"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C73435", "Gravida"], ["C25639", "Receive"], ["C1647", "Trastuzumab"], ["C43508", "Oregon"], ["C25282", "Within"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C29846", "Month"], ["C53286", "Next"], ["C25551", "Last"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C49070", "Closed"], ["C61256", "Monitoring"], ["C158169", "Buyei Chinese"], ["C76246", "Blood Group A"], ["C94845", "Multidisciplinary"], ["C86041", "Team"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C192497", "Desirable"], ["C113425", "Eleven"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C76246", "Blood Group A"], ["C45319", "Study Object"], ["C16727", "India"], ["C14232", "Cynomolgus Monkey"], ["C14243", "Monkey"], ["C158997", "GDC Analyte Type Terminology"], ["C25488", "Dose"], ["C113663", "Twenty Five"], ["C52874", "SPI1 wt Allele"], ["C67069", "Weekly"], ["C14225", "Human"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67401", "Milligram per Kilogram"], ["C1647", "Trastuzumab"], ["C38276", "Intravenous Route of Administration"], ["C15653", "Drug Formulation Process"], ["C25516", "From"], ["C25301", "Day"], ["C192184", "One Hundred Twenty"], ["C159124", "GDC Treatment Outcome Terminology"], ["C129532", "One Hundred Fifty"], ["C52874", "SPI1 wt Allele"], ["C191656", "Pregnant Subject"], ["C1647", "Trastuzumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C17119", "Cellular Secretion"], ["C16727", "India"], ["C13257", "Mammary Gland Milk"], ["C92851", "Postpartum"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1647", "Trastuzumab"], ["C16727", "India"], ["C12405", "Uterus"], ["C16289", "Andorra"], ["C25626", "Present"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C16727", "India"], ["C13325", "Serum"], ["C52874", "SPI1 wt Allele"], ["C27956", "Infant"], ["C14243", "Monkey"], ["C154196", "Washo Language"], ["C25594", "Negation"], ["C25281", "Associated"], ["C62355", "With"], ["C81168", "Any"], ["C188368", "ELN Adverse-Risk Category"], ["C25492", "Effect"], ["C92667", "SPARC wt Allele"], ["C16648", "Tissue Growth"], ["C43508", "Oregon"], ["C18732", "Development"], ["C25516", "From"], ["C25155", "Birth"], ["C159124", "GDC Treatment Outcome Terminology"], ["C105723", "ECOG Performance Status 1"], ["C29846", "Month"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C17998", "Unknown"], ["C1647", "Trastuzumab"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C17119", "Cellular Secretion"], ["C16727", "India"], ["C14225", "Human"], ["C13257", "Mammary Gland Milk"], ["C71344", "Associate of Science"], ["C14225", "Human"], ["C201279", "IgG1"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C17119", "Cellular Secretion"], ["C25544", "Into"], ["C14225", "Human"], ["C13257", "Mammary Gland Milk"], ["C16289", "Andorra"], ["C62230", "Potential"], ["C64956", "For"], ["C159124", "GDC Treatment Outcome Terminology"], ["C27956", "Infant"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C160764", "Unknown Molecular Analysis"], ["C25594", "Negation"], ["C25389", "Chest"], ["C69427", "Feed"], ["C25490", "During"], ["C1647", "Trastuzumab"], ["C49236", "Therapeutic Procedure"], ["C16289", "Andorra"], ["C64956", "For"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C29846", "Month"], ["C38008", "Post"], ["C25551", "Last"], ["C25488", "Dose"], ["C95089", "Fertility Domain"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C95089", "Fertility Domain"], ["C25474", "Data"], ["C25429", "Availability"]], "rxnorm.driving": [["224905", "trastuzumab"], ["T016", "Human"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["T008", "Animal"], ["T016", "Human"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["T016", "Human"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["224905", "trastuzumab"], ["T016", "Human"], ["T016", "Human"], ["T016", "Human"], ["224905", "trastuzumab"]], "loinc.driving": [["LP93408-0", "during treatment"], ["LP36790-1", "7"], ["MTHU068094", "Months"], ["LP94823-9", "Treatment"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LP207970-7", "Pregnancy"], ["LA22004-8", "IN"], ["LA21988-3", "AT"], ["LA19281-7", "25"], ["LA18891-4", "Weekly"], ["LA19711-3", "Human"], ["MTHU065481", "Dose"], ["MTHU000002", "Clinical Class"], ["LP15217-0", "Mg"], ["LA9437-0", "Intravenous"], ["LA32-8", "No"], ["LA13035-3", "Impaired"], ["MTHU000074", "Fertility"], ["LA22025-3", "OR"], ["LP97172-8", "Transfer"], ["LA12111-3", "Early"], ["LA8999-0", "Days"], ["LA19282-5", "20"], ["LA28854-0", "50"], ["LA8999-0", "Days"], ["LA32059-0", "120"], ["LP6425-5", "Observed"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA14748-0", "Not known"], ["LA18285-9", "Reproductive"], ["LP72218-8", "Capacity"], ["LA30681-3", "Animal"], ["LA21291-2", "Not"], ["LA9933-8", "Always"], ["LA19711-3", "Human"], ["LP266032-4", "during pregnancy"], ["LP6983-3", "Mother"], ["LA22004-8", "IN"], ["LP32606-3", "post"], ["MTHU047625", "Setting"], ["LP270144-1", "Cases"], ["MTHU065909", "Renal"], ["LA31297-7", "Growth"], ["LA22025-3", "OR"], ["LA8916-4", "Function"], ["LA22004-8", "IN"], ["LA14973-4", "Some"], ["LA32822-1", "Fatal"], ["54542-6", "Pulmonary:-:Pt:^Patient:-"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LA29507-3", "Pregnant women"], ["LA15173-0", "Pregnant"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LA15173-0", "Pregnant"], ["LP200075-2", "IS"], ["LA22025-3", "OR"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LA15173-0", "Pregnant"], ["LA22025-3", "OR"], ["LP36790-1", "7"], ["MTHU068094", "Months"], ["MTHU065481", "Dose"], ["LA16797-5", "Close"], ["LA20297-0", "Monitoring"], ["LP17763-1", "A"], ["LP433613-9", "Multidisciplinary"], ["LP185852-3", "Team"], ["LP200075-2", "IS"], ["LA14557-5", "11"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LP17763-1", "A"], ["LP74341-6", "Study"], ["LA22004-8", "IN"], ["LA21988-3", "AT"], ["LA19281-7", "25"], ["LA18891-4", "Weekly"], ["LA19711-3", "Human"], ["MTHU065481", "Dose"], ["MTHU000002", "Clinical Class"], ["LP15217-0", "Mg"], ["LA9437-0", "Intravenous"], ["LA8999-0", "Days"], ["LA32059-0", "120"], ["LP207970-7", "Pregnancy"], ["LP200075-2", "IS"], ["LA19762-6", "Secreted"], ["LA22004-8", "IN"], ["LP29290-1", "Milk"], ["LA22004-8", "IN"], ["LP149220-8", "Presence"], ["LA22004-8", "IN"], ["LP7567-3", "Serum"], ["LA19747-7", "Infant"], ["LA21291-2", "Not"], ["LA31297-7", "Growth"], ["LA22025-3", "OR"], ["LP6920-5", "1 month"], ["MTHU010047", "Age"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA14748-0", "Not known"], ["LP200075-2", "IS"], ["LA19762-6", "Secreted"], ["LA22004-8", "IN"], ["LA19711-3", "Human"], ["LP29290-1", "Milk"], ["LA19711-3", "Human"], ["LP32407-6", "IgG1"], ["LP200075-2", "IS"], ["LA19762-6", "Secreted"], ["LA19711-3", "Human"], ["LP29290-1", "Milk"], ["LA19747-7", "Infant"], ["LP200075-2", "IS"], ["LA4489-6", "Unknown"], ["LA21291-2", "Not"], ["LP199961-6", "Breast"], ["LP7228-2", "Feed"], ["LP267221-2", "Therapy"], ["LP36790-1", "7"], ["MTHU068094", "Months"], ["MTHU065481", "Dose"], ["MTHU000074", "Fertility"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["MTHU000074", "Fertility"]], "snomed.side_effects": [["422097006", "Upper case Roman letter A (qualifier value)"], ["410599005", "Minor (person)"], ["420862001", "On (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["247750002", "Drive (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["404640003", "Dizziness (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["271782001", "Drowsy (finding)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["36576007", "Infusion (procedure)"], ["262094002", "Related (finding)"], ["732727007", "4.4 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["247750002", "Drive (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"]], "ncit.side_effects": [["C1647", "Trastuzumab"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C45367", "Minor"], ["C121660", "Influence"], ["C92667", "SPARC wt Allele"], ["C121232", "Ability to Drive"], ["C16289", "Andorra"], ["C25340", "Use"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C125409", "Have Dizziness"], ["C16289", "Andorra"], ["C26754", "Somnolence"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C175242", "During Treatment"], ["C62355", "With"], ["C1647", "Trastuzumab"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C16960", "Patient"], ["C15388", "Infusion Procedure"], ["C53260", "Adverse Event Definitely Related to Intervention"], ["C168422", "Rheumatic Fever Symptom"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16329", "Belgium"], ["C25594", "Negation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16289", "Andorra"], ["C25340", "Use"], ["C65136", "Until"], ["C168422", "Rheumatic Fever Symptom"], ["C86045", "Abate"]], "rxnorm.side_effects": [["2179754", "Ogivri"], ["2179754", "Ogivri"]], "loinc.side_effects": [["LP17763-1", "A"], ["LA29633-7", "Minor"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA7428-1", "Dizziness"], ["LA14161-6", "May"], ["LP93408-0", "during treatment"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP263434-5", "Infusion"], ["LA31343-9", "Related"], ["LP75708-5", "Symptoms"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA21291-2", "Not"], ["LP75708-5", "Symptoms"]], "snomed.shelf_life": [["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["258707000", "year (qualifier value)"], ["255234002", "After (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["101782006", "STERILE WATER (product)|STERILE WATER (substance)"], ["86495002", "For (qualifier value)"], ["739006009", "Solution (basic dose form)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["58158008", "Stable (qualifier value)"], ["86495002", "For (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["258703001", "day (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["739006009", "Solution (basic dose form)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86495002", "For (qualifier value)"], ["385228000", "Intravenous infusion (product)|Intravenous infusion (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["58158008", "Stable (qualifier value)"], ["18720000", "In (attribute)"], ["71463006", "Polyethylene (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["256633009", "Polypropylene (substance)"], ["42504009", "Containing (qualifier value)"], ["387390002", "Sodium chloride (substance)"], ["422113007", "Arabic numeral 9 (qualifier value)"], ["258798001", "Milligram/milliliter (qualifier value)|mg/mL (qualifier value)"], ["732402004", "0.9 (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["739006009", "Solution (basic dose form)"], ["86495002", "For (qualifier value)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["86495002", "For (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["732899009", "90 (qualifier value)"], ["258703001", "day (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["123027009", "24 hours (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["246516004", "View (attribute)"], ["739006009", "Solution (basic dose form)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["385229008", "Infusion solution (product)|Conventional release solution for infusion (dose form)|Infusion solution (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255234002", "After (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["272390001", "Dilution (qualifier value)"], ["421066005", "Place - dosing instruction imperative (qualifier value)"], ["351726001", "Below (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260984003", "Aseptic (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["262009000", "Not used (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["18720000", "In (attribute)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["440276004", "Storage (procedure)"], ["417929005", "Times (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"]], "ncit.shelf_life": [["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C29848", "Year"], ["C38008", "Post"], ["C62355", "With"], ["C3836", "Infertility"], ["C65147", "Water"], ["C64956", "For"], ["C42986", "Solution Dosage Form"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16289", "Andorra"], ["C48807", "Chemical"], ["C131459", "Microsatellite Stable"], ["C64956", "For"], ["C69122", "Ten"], ["C25301", "Day"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67900", "Centi"], ["C66839", "Eight"], ["C67900", "Centi"], ["C81168", "Any"], ["C25649", "Remaining"], ["C42986", "Solution Dosage Form"], ["C16329", "Belgium"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C64956", "For"], ["C38275", "Intravenous Infusion"], ["C68869", "Are"], ["C16289", "Andorra"], ["C48807", "Chemical"], ["C131459", "Microsatellite Stable"], ["C16727", "India"], ["C83759", "High Density Polyethylene"], ["C43508", "Oregon"], ["C79873", "Contain"], ["C29974", "Sodium Chloride"], ["C120081", "Severity of Symptom Score 9"], ["C42576", "Kilogram per Cubic Meter"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C120081", "Severity of Symptom Score 9"], ["C48570", "Percent Unit"], ["C42986", "Solution Dosage Form"], ["C64956", "For"], ["C122632", "Injection Dosing Unit"], ["C64956", "For"], ["C64643", "Up to"], ["C182728", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 90"], ["C25301", "Day"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67900", "Centi"], ["C66839", "Eight"], ["C67900", "Centi"], ["C16289", "Andorra"], ["C113753", "Twenty Four"], ["C25529", "Hour"], ["C158997", "GDC Analyte Type Terminology"], ["C25594", "Negation"], ["C175323", "Exceed"], ["C70541", "Lansky Performance Status 30"], ["C67900", "Centi"], ["C25516", "From"], ["C76246", "Blood Group A"], ["C92081", "Microbial Contamination"], ["C70656", "Point"], ["C52874", "SPI1 wt Allele"], ["C80271", "View"], ["C42986", "Solution Dosage Form"], ["C16289", "Andorra"], ["C1647", "Trastuzumab"], ["C15388", "Infusion Procedure"], ["C42986", "Solution Dosage Form"], ["C16329", "Belgium"], ["C64597", "Immediately"], ["C40352", "Multiplicative Product"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C118257", "Unintentional"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C60824", "Storage"], ["C38008", "Post"], ["C16289", "Andorra"], ["C64657", "Dilute"], ["C101282", "Have"], ["C25701", "Taken"], ["C126366", "Placement"], ["C82500", "Disease Controlled"], ["C16289", "Andorra"], ["C172871", "File Validated"], ["C63385", "Sterile"], ["C25457", "Condition"], ["C198613", "CFI wt Allele"], ["C69062", "Not Used"], ["C64597", "Immediately"], ["C16727", "India"], ["C25340", "Use"], ["C60824", "Storage"], ["C16289", "Andorra"], ["C25457", "Condition"], ["C68869", "Are"], ["C90023", "Responsibility"], ["C52874", "SPI1 wt Allele"], ["C42745", "System User"]], "rxnorm.shelf_life": [["107129", "sterile water"], ["2179754", "Ogivri"], ["1661411", "sodium chloride 9 MG/ML"], ["1649574", "Injection"], ["2179754", "Ogivri"]], "loinc.shelf_life": [["LA31721-6", "4 years"], ["LP99666-7", "Water"], ["LA19717-0", "Reconstituted"], ["LP200075-2", "IS"], ["LA14122-8", "Stable"], ["LA13942-0", "10"], ["LA8999-0", "Days"], ["LA21988-3", "AT"], ["MTHU000002", "Clinical Class"], ["LP17128-7", "C"], ["LP36791-9", "8"], ["LP17128-7", "C"], ["LA19717-0", "Reconstituted"], ["LA19707-1", "Discarded"], ["LA9437-0", "Intravenous"], ["LP263434-5", "Infusion"], ["LA14122-8", "Stable"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LP15099-2", "Sodium"], ["LP15483-8", "Chloride"], ["LA10141-2", "9"], ["LP15217-0", "Mg"], ["LA24587-0", "0.9"], ["LA14542-7", "Injection"], ["LP203019-7", "90 days"], ["LA21988-3", "AT"], ["MTHU000002", "Clinical Class"], ["LP17128-7", "C"], ["LP36791-9", "8"], ["LP17128-7", "C"], ["LP6924-7", "24 hours"], ["LA21988-3", "AT"], ["LA21291-2", "Not"], ["LA28855-7", "30"], ["LP17128-7", "C"], ["LP17763-1", "A"], ["LP28725-7", "Single view"], ["LA19717-0", "Reconstituted"], ["LP263434-5", "Infusion"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LP6228-3", "Dilution"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA157-0", "Not used"], ["LA22004-8", "IN"]], "snomed.storage": [["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["21546008", "Refrigerator, device (physical object)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["86495002", "For (qualifier value)"], ["440276004", "Storage (procedure)"], ["255234002", "After (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["763158003", "Medicinal product (product)"], ["732807000", "6.3 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732810007", "6.6 (qualifier value)"], ["1222813003", "American Joint Committee on Cancer stage III:2 (qualifier value)"]], "ncit.storage": [["C60824", "Storage"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C178971", "Refrigerator"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67900", "Centi"], ["C66839", "Eight"], ["C67900", "Centi"], ["C64956", "For"], ["C60824", "Storage"], ["C25457", "Condition"], ["C38008", "Post"], ["C52874", "SPI1 wt Allele"], ["C142605", "Medicinal Product"], ["C163702", "Staphylococcal Enterotoxin E"], ["C172979", "Fear Score 6"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16289", "Andorra"], ["C172979", "Fear Score 6"], ["C172979", "Fear Score 6"], ["C175622", "Thirty Two"]], "rxnorm.storage": [], "loinc.storage": [["LA22004-8", "IN"], ["LP17763-1", "A"], ["MTHU000002", "Clinical Class"], ["LP17128-7", "C"], ["LP36791-9", "8"], ["LP17128-7", "C"], ["LP20594-5", "6"], ["LP20591-1", "3"], ["LP20594-5", "6"], ["LP20594-5", "6"], ["LA19317-9", "32"]], "snomed.package": [["732515006", "150 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["739005008", "Powder (basic dose form)"], ["86495002", "For (qualifier value)"], ["1237267003", "Concentrate for conventional release solution for infusion (dose form)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["263707001", "Clear (qualifier value)"], ["32039001", "Glass (substance)"], ["258191002", "Type 1 (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["43230003", "Rubber (substance)"], ["88446008", "Laminar (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["42504009", "Containing (qualifier value)"], ["732515006", "150 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["419473009", "Each (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["1222865001", "American Joint Committee on Cancer stage IV:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["739005008", "Powder (basic dose form)"], ["86495002", "For (qualifier value)"], ["1237267003", "Concentrate for conventional release solution for infusion (dose form)"], ["732774003", "50 (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["263707001", "Clear (qualifier value)"], ["32039001", "Glass (substance)"], ["258191002", "Type 1 (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["43230003", "Rubber (substance)"], ["88446008", "Laminar (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["42504009", "Containing (qualifier value)"], ["1222865001", "American Joint Committee on Cancer stage IV:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387003001", "Trastuzumab (substance)"], ["419473009", "Each (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["733026001", "Vial (unit of presentation)"]], "ncit.package": [["C1647", "Trastuzumab"], ["C129532", "One Hundred Fifty"], ["C16818", "Mammography"], ["C149813", "Powder for Concentrate for Solution for Infusion Dosage Form"], ["C113429", "Fifteen"], ["C16816", "Mali"], ["C48621", "Negative Surgical Margin"], ["C45301", "Glass"], ["C181852", "Protocol Therapy Status"], ["C68254", "Dietary Iodine"], ["C41275", "Vial"], ["C62355", "With"], ["C96139", "Stopper Container Closure"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C79662", "Resin"], ["C154467", "Film Dosage Form Category"], ["C79873", "Contain"], ["C129532", "One Hundred Fifty"], ["C16818", "Mammography"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C64933", "Each"], ["C54702", "Carton Dosing Unit"], ["C79873", "Contain"], ["C66832", "One"], ["C41275", "Vial"], ["C1647", "Trastuzumab"], ["C16818", "Mammography"], ["C149813", "Powder for Concentrate for Solution for Infusion Dosage Form"], ["C105785", "Fifty"], ["C16816", "Mali"], ["C48621", "Negative Surgical Margin"], ["C45301", "Glass"], ["C181852", "Protocol Therapy Status"], ["C68254", "Dietary Iodine"], ["C41275", "Vial"], ["C62355", "With"], ["C96139", "Stopper Container Closure"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C79662", "Resin"], ["C154467", "Film Dosage Form Category"], ["C79873", "Contain"], ["C16818", "Mammography"], ["C52874", "SPI1 wt Allele"], ["C1647", "Trastuzumab"], ["C64933", "Each"], ["C54702", "Carton Dosing Unit"], ["C79873", "Contain"], ["C66832", "One"], ["C41275", "Vial"]], "rxnorm.package": [["2179754", "Ogivri"], ["224905", "trastuzumab"], ["2179754", "Ogivri"], ["224905", "trastuzumab"]], "loinc.package": [["LP15217-0", "Mg"], ["LP263434-5", "Infusion"], ["LA14561-7", "15"], ["LA19732-9", "Clear"], ["LA26022-6", "Type I"], ["LA20376-2", "Vial"], ["LP17763-1", "A"], ["LP15217-0", "Mg"], ["LA6306-0", "One"], ["LA20376-2", "Vial"], ["LP15217-0", "Mg"], ["LP263434-5", "Infusion"], ["LA28854-0", "50"], ["LA19732-9", "Clear"], ["LA26022-6", "Type I"], ["LA20376-2", "Vial"], ["LP17763-1", "A"], ["LP15217-0", "Mg"], ["LA6306-0", "One"], ["LA20376-2", "Vial"]], "snomed.marketing_authorization_numbers": [["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"]], "ncit.marketing_authorization_numbers": [["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C111798", "Eighteen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C111798", "Eighteen"]], "rxnorm.marketing_authorization_numbers": [], "loinc.marketing_authorization_numbers": [["LA6112-2", "1"], ["LA6112-2", "1"]]}, {"product_info": "Biktarvy 30 mg/120 mg/15 mg film-coated tablets  \nBiktarvy 50 mg/200 mg/25 mg film-coated tablets", "composition": "Biktarvy 30 mg/120 mg/15 mg film-coated tablets \nEach film-coated tablet contains bictegravir sodium equivalent to 30 mg of bictegravir, 120 mg of \nemtricitabine, and tenofovir alafenamide fumarate equivalent to 15 mg of tenofovir alafenamide. \nBiktarvy 50 mg/200 mg/25 mg film-coated tablets \nEach film-coated tablet contains bictegravir sodium equivalent to 50 mg of bictegravir, 200 mg of \nemtricitabine, and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide. \nFor the full list of excipients, see section 6.1.", "indications": "Biktarvy is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults \nand paediatric patients at least 2 years of age and weighing at least 14 kg without present or past \nevidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir (see section 5.1).", "posology": "Therapy should be initiated by a physician experienced in the management of HIV infection. \nPosology \nPaediatric patients at least 2 years of age and weighing at least 14\nkg to less than 25 kg \nOne 30 mg/120 mg/15 mg tablet to be taken once daily. \nAdults and paediatric patients weighing at least 25 kg \nOne 50 mg/200 mg/25 mg tablet to be taken once daily. \nMissed doses \nIf the patient misses a dose of Biktarvy within 18 hours of the time it is usually taken, the patient \nshould take Biktarvy as soon as possible and resume the normal dosing schedule.  If a patient misses a \ndose of Biktarvy by more than 18 hours, the patient should not take the missed dose and simply \nresume the usual dosing schedule. \nIf the patient vomits within 1 hour of taking Biktarvy another tablet should be taken.  If a patient \nvomits more than 1 hour after taking Biktarvy they do not need to take another dose of Biktarvy until \nthe next regularly scheduled dose. \nSpecial populations \nElderly\nNo dose adjustment of Biktarvy is required in patients aged \u2265 65 years (see sections 4.8 and 5.2). \nHepatic impairment \nNo dose adjustment of Biktarvy is required in patients with mild (Child-Pugh Class A) or moderate \n(Child-Pugh Class B) hepatic impairment.  Biktarvy has not been studied in patients with severe \nhepatic impairment (Child-Pugh Class C), therefore Biktarvy is not recommended for use in patients \nwith severe hepatic impairment (see sections 4.4 and 5.2). \nRenal impairment \nNo dose adjustment of Biktarvy is required in patients weighing \u2265 35 kg with estimated creatinine \nclearance (CrCl) \u2265 30 mL/min. \nNo dose adjustment of Biktarvy is required in adult patients with end stage renal disease (estimated \ncreatinine clearance < 15 mL/minute) who are receiving chronic haemodialysis.  However, Biktarvy \nshould generally be avoided and only be used in these patients if the potential benefits are considered \nto outweigh the potential risks (see sections 4.4 and 5.2).  On days of haemodialysis, Biktarvy should \nbe administered after completion of haemodialysis treatment. \nInitiation of Biktarvy should be avoided in patients with estimated creatinine clearance \u226515 mL/min \nand < 30 mL/min, or < 15 mL/min who are not receiving chronic haemodialysis, as the safety of \nBiktarvy has not been established in these populations (see section 5.2). \nNo data are available to make dose recommendations in patients weighing < 35 kg with renal \nimpairment or in paediatric patients less than 18 years with end stage renal disease. \nPaediatric population \nThe safety and efficacy of Biktarvy in children less than 2 years of age or weighing less than 14 kg \nhave not yet been established.  No data are available. \nMethod of administration \nOral use. \nBiktarvy can be taken with or without food (see section 5.2). \nDue to the bitter taste, it is recommended that the film-coated tablets should not be chewed or crushed.  \nFor patients who are unable to swallow the tablet whole, the tablet may be split in half and both halves \ntaken one after the other, ensuring that the full dose is taken immediately.", "contraindications": "Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. \nCo-administration with rifampicin and St. John\u2019s wort (\nHypericum perforatum\n) (see section 4.5).", "special_warnings": "Patients co-infected with HIV and hepatitis B or C virus \nPatients with chronic hepatitis B or C treated with antiretroviral therapy are at an increased risk for \nsevere and potentially fatal hepatic adverse reactions. \nThere are limited safety and efficacy data for Biktarvy in patients co-infected with HIV-1 and \nhepatitis C virus (HCV).  \nBiktarvy contains tenofovir alafenamide, which is active against hepatitis B virus (HBV). \nDiscontinuation of Biktarvy therapy in patients co-infected with HIV and HBV may be associated \nwith severe acute exacerbations of hepatitis.  Patients co-infected with HIV and HBV who discontinue \nBiktarvy should be closely monitored with both clinical and laboratory follow-up for at least several \nmonths after stopping treatment. \nLiver disease \nThe safety and efficacy of Biktarvy in patients with significant underlying liver disorders have not \nbeen established. \nPatients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased \nfrequency of liver function abnormalities during combination antiretroviral therapy (CART) and \nshould be monitored according to standard practice.  If there is evidence of worsening liver disease in \nsuch patients, interruption or discontinuation of treatment must be considered. \nWeight and metabolic parameters \nAn increase in weight and in levels of blood lipids and glucose may occur during antiretroviral \ntherapy.  Such changes may in part be linked to disease control and lifestyle.  For lipids, there is in \nsome cases evidence for a treatment effect, while for weight gain there is no strong evidence relating \nthis to any particular treatment.  For monitoring of blood lipids and glucose, reference is made to \nestablished HIV treatment guidelines.  Lipid disorders should be managed as clinically appropriate. \nMitochondrial dysfunction following exposure \nin utero\nNucleos(t)ide analogues may impact mitochondrial function to a variable degree, which is most \npronounced with stavudine, didanosine and zidovudine.  There have been reports of mitochondrial \ndysfunction in HIV negative infants exposed \nin utero\n and/or postnatally to nucleoside analogues; these \nhave predominantly concerned treatment with regimens containing zidovudine.  The main adverse \nreactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders \n(hyperlactatemia, hyperlipasemia).  These events have often been transitory.  Late onset neurological \ndisorders have been reported rarely (hypertonia, convulsion, abnormal behaviour).  Whether such \nneurological disorders are transient or permanent is currently unknown.  These findings should be \nconsidered for any child exposed \nin utero\n to nucleos(t)ide analogues, who present with severe clinical \nfindings of unknown aetiology, particularly neurologic findings.  These findings do not affect current \nnational recommendations to use antiretroviral therapy in pregnant women to prevent vertical \ntransmission of HIV. \nImmune Reactivation Syndrome \nIn HIV infected patients with severe immune deficiency at the time of institution of CART, an \ninflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause \nserious clinical conditions, or aggravation of symptoms.  Typically, such reactions have been observed \nwithin the first few weeks or months of initiation of CART.  Relevant examples include \ncytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and \nPneumocystis \njirovecii\n pneumonia.  Any inflammatory symptoms should be evaluated and treatment instituted when \nnecessary. \nAutoimmune disorders (such as Graves\u2019 disease and autoimmune hepatitis) have also been reported to \noccur in the setting of immune reactivation; however, the reported time to onset is more variable and \nthese events can occur many months after initiation of treatment. \nOpportunistic infections \nPatients should be advised that Biktarvy or any other antiretroviral therapy does not cure \nHIV infection and that they may still develop opportunistic infections and other complications of \nHIV infection.  Therefore, patients should remain under close clinical observation by physicians \nexperienced in the treatment of patients with HIV associated diseases. \nOsteonecrosis \nAlthough the aetiology is considered to be multifactorial (including corticosteroid use, alcohol \nconsumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been \nreported particularly in patients with advanced HIV disease and/or long-term exposure to CART.  \nPatients should be advised to seek medical advice if they experience joint aches and pain, joint \nstiffness or difficulty in movement. \nNephrotoxicity \nPost-marketing cases of renal impairment, including acute renal failure and proximal renal \ntubulopathy have been reported with tenofovir alafenamide-containing products.  A potential risk of \nnephrotoxicity resulting from chronic exposure to low levels of tenofovir due to dosing with tenofovir \nalafenamide cannot be excluded (see section 5.3). \nIt is recommended that renal function is assessed in all patients prior to, or when initiating, therapy \nwith Biktarvy and that it is also monitored during therapy in all patients as clinically appropriate.  In \npatients who develop clinically significant decreases in renal function, or evidence of proximal renal \ntubulopathy, discontinuation of Biktarvy should be considered. \nPatients with end stage renal disease on chronic haemodialysis \nBiktarvy should generally be avoided but may be used in adults with end stage renal disease \n(estimated CrCl < 15 mL/min) on chronic haemodialysis if the potential benefits outweigh the \npotential risks (see section 4.2).  In a study of emtricitabine + tenofovir alafenamide in combination \nwith elvitegravir + cobicistat as a fixed-dose combination tablet (E/C/F/TAF) in HIV-1 infected adults \nwith end stage renal disease (estimated CrCl < 15 mL/min) on chronic haemodialysis, efficacy was \nmaintained through 96 weeks but emtricitabine exposure was significantly higher than in patients with \nnormal renal function.  Efficacy was also maintained in the extension phase of the study in which 10 \npatients switched to Biktarvy for 48 weeks.  Although no additional adverse reactions were identified, \nthe implications of increased emtricitabine exposure remain uncertain (see sections 4.8 and 5.2). \nCo-administration of other medicinal products \nBiktarvy should not be co-administered simultaneously with magnesium/aluminium-containing \nantacids or iron supplements under fasted conditions.  Biktarvy should be administered at least 2 hours \nbefore, or with food 2 hours after antacids containing magnesium and/or aluminium.  Biktarvy should \nbe administered at least 2 hours before iron supplements, or taken together with food (see section 4.5). \nSome medicinal products are not recommended for co-administration with Biktarvy: atazanavir, \ncarbamazepine, ciclosporin (IV or oral use), oxcarbazepine, phenobarbital, phenytoin, rifabutin, \nrifapentine, or sucralfate. \nBiktarvy should not be co-administered with other antiretroviral medicinal products. \nPaediatric population \nReductions in bone mineral density (BMD \u2265 4%) of the spine and total body less head (TBLH) have \nbeen reported in patients aged between 3 to < 12 years who received tenofovir alafenamide-containing \nproducts for 48 weeks (see section 4.8).  The long-term effects of changes in BMD on the growing \nbone, including the risk of fracture, are uncertain.  A multidisciplinary approach is recommended to \ndecide the appropriate monitoring during treatment. \nExcipients\nThis medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially \n\u2018sodium-free\u2019.", "pregnancy": "Interaction studies have only been performed in adults. \nBiktarvy should not be administered concomitantly with medicinal products containing tenofovir \nalafenamide, tenofovir disoproxil, lamivudine or adefovir dipivoxil used for the treatment of \nHBV infection. \nBictegravir \nBictegravir\nis a substrate of CYP3A and UGT1A1.  Co-administration of bictegravir and medicinal \nproducts that potently induce both CYP3A and UGT1A1, such as rifampicin or St. John\u2019s wort, may \nsignificantly decrease plasma concentrations of bictegravir, which may result in a loss of therapeutic \neffect of Biktarvy and development of resistance, therefore co-administration is contraindicated (see \nsection 4.3).  Co-administration of bictegravir with medicinal products that potently inhibit both \nCYP3A and UGT1A1, such as atazanavir, may significantly increase plasma concentrations of \nbictegravir, therefore co-administration is not recommended.  \nBictegravir is both a P-gp and a BCRP substrate.  The clinical relevance of this feature is not \nestablished.  Therefore, caution is recommended when bictegravir is combined with medicinal \nproducts known to inhibit P-gp and/or BCRP (e.g. macrolides, ciclosporin, verapamil, dronedarone, \nglecaprevir/pibrentasvir) (see also table below). \nBictegravir\ninhibits organic cation transporter 2 (OCT2) and multidrug and toxin extrusion \ntransporter 1 (MATE1) \nin vitro\n.  Co-administration of Biktarvy with the OCT2 and MATE1 substrate \nmetformin did not result in a clinically significant increase in metformin exposure.  Biktarvy may be \nco-administered with substrates of OCT2 and MATE1.  \nBictegravir\nis not an inhibitor or inducer of CYP \nin vivo\nEmtricitabine \nIn vitro\n and clinical pharmacokinetic drug-drug interaction studies have shown that the potential for \nCYP-mediated interactions involving emtricitabine with other medicinal products is low.  \nCo-administration of emtricitabine with medicinal products that are eliminated by active tubular \nsecretion may increase concentrations of emtricitabine, and/or the co-administered medicinal product.  \nMedicinal products that decrease renal function may increase concentrations of emtricitabine. \nTenofovir alafenamide \nTenofovir alafenamide is transported by P-glycoprotein (P-gp) and breast cancer resistance protein \n(BCRP).  Co-administration of Biktarvy with medicinal products that strongly affect P-gp and BCRP \nactivity may lead to changes in tenofovir alafenamide absorption.  Medicinal products that induce \nP-gp activity (e.g. rifabutin, carbamazepine, phenobarbital) are expected to decrease the absorption of \ntenofovir alafenamide, resulting in decreased plasma concentration of tenofovir alafenamide, which \nmay lead to loss of therapeutic effect of Biktarvy and development of resistance.  Co-administration of \nBiktarvy with other medicinal products that inhibit P-gp and BCRP may increase the absorption and \nplasma concentration of tenofovir alafenamide. \nTenofovir alafenamide is not an inhibitor or inducer of CYP3A\n in vivo\nOther interactions \nInteractions between Biktarvy or its individual component(s) and co-administered medicinal products \nare listed in Table 1 below (increase is indicated as \u201c\u2191\u201d, decrease as \u201c\u2193\u201d and no change as \u201c\u2194\u201d; all No \nEffect Boundaries are 70%-143%).  \nTable 1: Interactions between Biktarvy or its individual component(s) and other medicinal \nproducts \nMedicinal product by \ntherapeutic areas/possible \nmechanism of interaction \nEffects on medicinal product \nlevels. \nMean percent change in AUC, \nCmax, Cmin \nRecommendation concerning \nco-administration with Biktarvy \nHERBAL PRODUCTS\nSt. John\u2019s wort (\nHypericum \nperforatum\n(Induction of CYP3A, UGT1A1, \nand P-gp)\nInteraction not studied with any of \nthe components of Biktarvy. \nCo-administration may decrease \nbictegravir and tenofovir \nalafenamide plasma \nconcentrations.\nCo-administration with St. John\u2019s \nwort is contraindicated, due to the \neffect of St. John\u2019s wort on the \nbictegravir component of \nBiktarvy.\nANTI-INFECTIVES \nAntimycobacterials \nRifampicin (600 mg once daily),  \nBictegravir1 \n(Induction of CYP3A, UGT1A1, \nand P-gp) \nBictegravir: \nAUC: \u2193 75% \nCmax: \u2193 28% \nInteraction not studied with \ntenofovir alafenamide.   \nCo-administration of rifampicin \nmay decrease tenofovir \nalafenamide plasma \nconcentrations. \nCo-administration is \ncontraindicated due to the effect \nof rifampicin on the bictegravir \ncomponent of Biktarvy. \nRifabutin (300 mg once daily),  \nBictegravir1 \n(Induction of CYP3A and P-gp) \nBictegravir: \nAUC: \u2193 38% \nCmin: \u2193 56% \nCmax: \u2193 20% \nInteraction not studied with \ntenofovir alafenamide. \nCo-administration of rifabutin may \ndecrease tenofovir alafenamide \nplasma concentrations. \nCo-administration is not \nrecommended due to the expected \ndecrease of tenofovir alafenamide. \nMedicinal product by \ntherapeutic areas/possible \nmechanism of interaction \nEffects on medicinal product \nlevels. \nMean percent change in AUC, \nCmax, Cmin \nRecommendation concerning \nco-administration with Biktarvy \nRifapentine \n(Induction of CYP3A and P-gp)\nInteraction not studied with any of \nthe components of Biktarvy. \nCo-administration of rifapentine \nmay decrease bictegravir and \ntenofovir alafenamide plasma \nconcentrations. \nCo-administration is not \nrecommended. \nHIV-1 antiviral agents \nAtazanavir (300 mg once daily), \nCobicistat (150 mg once daily), \nBictegravir1 \n(Inhibition of CYP3A, UGT1A1, \nand P-gp/BCRP) \nBictegravir: \nAUC: \u2191 306% \nCmax: \u2194 \nCo-administration is not \nrecommended. \nAtazanavir (400 mg once daily), \nBictegravir1 \n(Inhibition of CYP3A and \nUGT1A1)\nBictegravir: \nAUC: \u2191 315% \nCmax: \u2194\nHepatitis C virus antiviral agents \nLedipasvir/Sofosbuvir \n(90 mg/400 mg once daily), \nBictegravir/Emtricitabine/ \nTenofovir alafenamide2 \nBictegravir: \nAUC: \u2194 \nCmin: \u2194 \nCmax: \u2194 \nEmtricitabine: \nAUC: \u2194 \nCmin: \u2194 \nCmax: \u2194 \nTenofovir alafenamide: \nAUC: \u2194 \nCmax: \u2194 \nLedipasvir: \nAUC: \u2194 \nCmin: \u2194 \nCmax: \u2194 \nSofosbuvir: \nAUC: \u2194 \nCmax: \u2194 \nSofosbuvir metabolite GS-331007: \nAUC: \u2194 \nCmin: \u2194 \nCmax: \u2194 \nNo dose adjustment is required \nupon co-administration. \nMedicinal product by \ntherapeutic areas/possible \nmechanism of interaction \nEffects on medicinal product \nlevels. \nMean percent change in AUC, \nCmax, Cmin \nRecommendation concerning \nco-administration with Biktarvy \nSofosbuvir/Velpatasvir/ \nVoxilaprevir \n(400/100/100 + 100 mg3 once \ndaily), Bictegravir/Emtricitabine/ \nTenofovir alafenamide \n(Inhibition of P-gp/BCRP) \nBictegravir: \nAUC: \u2194 \nCmin: \u2194 \nCmax: \u2194 \nEmtricitabine: \nAUC: \u2194 \nCmin: \u2194 \nCmax: \u2194 \nTenofovir alafenamide: \nAUC: \u2191 57% \nCmax: \u2191 28% \nSofosbuvir: \nAUC: \u2194 \nCmax: \u2194 \nSofosbuvir metabolite GS-331007: \nAUC: \u2194 \nCmin: \u2194 \nCmax: \u2194 \nVelpatasvir: \nAUC: \u2194 \nCmin: \u2194 \nCmax: \u2194 \nVoxilaprevir: \nAUC: \u2194 \nCmin: \u2194 \nCmax: \u2194 \nNo dose adjustment is required \nupon co-administration. \nAntifungals\nVoriconazole (300 mg twice \ndaily), Bictegravir1 \n(Inhibition of CYP3A) \nBictegravir: \nAUC: \u2191 61% \nCmax: \u2194\nNo dose adjustment is required \nupon co-administration.\nItraconazole \nPosaconazole  \n(Inhibition of P-gp/BCRP) \nInteraction not studied with any of \nthe components of Biktarvy.  \nCo-administration of itraconazole \nor posaconazole may increase \nbictegravir\nplasma concentrations. \nMacrolides\nAzithromycin \nClarithromycin \n(Inhibition of P-gp) \nInteraction not studied.  \nCo-administration of azithromycin \nor clarithromycin may increase \nbictegravir plasma concentrations. \nCaution is recommended due to \nthe potential effect of these \nmedicinal products on the \nbictegravir component of \nBiktarvy. \n10 \nMedicinal product by \ntherapeutic areas/possible \nmechanism of interaction \nEffects on medicinal product \nlevels. \nMean percent change in AUC, \nCmax, Cmin \nRecommendation concerning \nco-administration with Biktarvy \nANTICONVULSANTS \nCarbamazepine (titrated from \n100 mg to 300 mg twice a day), \nEmtricitabine/Tenofovir \nalafenamide4 \n(Induction of CYP3A, UGT1A1, \nand P-gp) \nTenofovir alafenamide: \nAUC: \u2193 54% \nCmax: \u2193 57% \nInteraction not studied with \nbictegravir.  \nCo-administration of \ncarbamazepine may decrease \nbictegravir\nplasma concentrations. \nCo-administration is not \nrecommended. \nOxcarbazepine \nPhenobarbital \nPhenytoin \n(Induction of CYP3A, UGT1A1, \nand P-gp) \nInteraction not studied with any of \nthe components of Biktarvy. \nCo-administration of \noxcarbazepine, phenobarbital, or \nphenytoin may decrease \nbictegravir\nand tenofovir \nalafenamide plasma \nconcentrations. \nCo-administration is not \nrecommended. \nANTACIDS, SUPPLEMENTS AND BUFFERED MEDICINES \nMagnesium/aluminium-containing \nantacid suspension (20 mL single \ndose5), Bictegravir \n(Chelation with polyvalent \ncations) \nBictegravir (antacid suspension \n2 hours prior, fasted): \nAUC: \u2193 52% \nCmax: \u2193 58% \nBictegravir (antacid suspension \nafter 2 hours, fasted): \nAUC: \u2194 \nCmax: \u2194 \nBictegravir (simultaneous \nadministration, fasted): \nAUC: \u2193 79% \nCmax: \u2193 80% \nBictegravir (simultaneous \nadministration with food): \nAUC: \u2193 47% \nCmax: \u2193 49% \nBiktarvy should not be taken \nsimultaneously with supplements \ncontaining magnesium and/or \naluminium due to the expected \nsubstantial decrease of bictegravir \nexposure (see section 4.4). \nBiktarvy should be administered \nat least 2 hours before, or with \nfood 2 hours after antacids \ncontaining magnesium and/or \naluminium. \nFerrous fumarate (324 mg single \ndose), Bictegravir \n(Chelation with polyvalent \ncations) \nBictegravir (simultaneous \nadministration, fasted): \nAUC: \u2193 63% \nCmax: \u2193 71% \nBictegravir (simultaneous \nadministration with food): \nAUC: \u2194 \nCmax: \u2193 25% \nBiktarvy should be administered \nat least 2 hours before iron \nsupplements, or taken together \nwith food. \nCalcium carbonate (1,200 mg \nsingle dose), Bictegravir \n(Chelation with polyvalent \ncations) \nBictegravir (simultaneous \nadministration, fasted): \nAUC: \u2193 33% \nCmax: \u2193 42% \nBictegravir (simultaneous \nadministration with food): \nAUC: \u2194 \nCmax: \u2194 \nBiktarvy and calcium-containing \nsupplements can be taken \ntogether, without regard to food. \n11 \nMedicinal product by \ntherapeutic areas/possible \nmechanism of interaction \nEffects on medicinal product \nlevels. \nMean percent change in AUC, \nCmax, Cmin \nRecommendation concerning \nco-administration with Biktarvy \nSucralfate \n(Chelation with polyvalent \ncations) \nInteraction not studied with any of \nthe components of Biktarvy. \nCo-administration may decrease \nbictegravir plasma concentrations. \nCo-administration not \nrecommended. \nANTIDEPRESSANTS\nSertraline (50 mg single dose), \nTenofovir alafenamide6 \nTenofovir alafenamide: \nAUC: \u2194 \nCmax: \u2194 \nSertraline: \nAUC: \u2194 \nCmax: \u2194 \nNo interaction is expected with \nbictegravir and emtricitabine. \nNo dose adjustment is required \nupon co-administration. \nIMMUNOSUPPRESSANTS\nCiclosporin (IV or oral use) \n(P-gp inhibition) \nInteraction not studied with any of \nthe components of Biktarvy.  \nCo-administration of ciclosporin \n(IV or oral use) is expected to \nincrease plasma concentrations of \nboth bictegravir and tenofovir \nalafenamide. \nCo-administration of ciclosporin \n(IV or oral use) is not \nrecommended.  If the combination \nis needed, clinical and biological \nmonitoring, notably renal \nfunction, is recommended. \nORAL ANTI-DIABETICS \nMetformin (500 mg twice daily), \nBictegravir/Emtricitabine/ \nTenofovir alafenamide \n(Inhibition of OCT2/MATE1)\nMetformin: \nAUC: \u2191 39% \nCmin: \u2191 36% \nCmax: \u2194 \nNo dose adjustment is required \nupon co-administration\nin patients \nwith normal renal function. \nIn patients with moderate renal \nimpairment, close monitoring \nshould be considered when \nstarting co-administration of \nbictegravir with metformin, due to \nthe increased risk for lactic \nacidosis in these patients.\n  A dose \nadjustment of metformin should \nbe considered if required.\nORAL CONTRACEPTIVES \nNorgestimate \n(0.180/0.215/0.250 mg once \ndaily)/ Ethinylestradiol (0.025 mg \nonce daily), Bictegravir1 \nNorelgestromin: \nAUC: \u2194 \nCmin: \u2194 \nCmax: \u2194 \nNorgestrel: \nAUC: \u2194 \nCmin: \u2194 \nCmax: \u2194 \nEthinylestradiol: \nAUC: \u2194 \nCmin: \u2194 \nCmax: \u2194 \nNo dose adjustment is required \nupon co-administration. \nNorgestimate \n(0.180/0.215/0.250 mg once \ndaily), Ethinylestradiol (0.025 mg \nonce daily), \nEmtricitabine/Tenofovir \nalafenamide4 \n12 \nMedicinal product by \ntherapeutic areas/possible \nmechanism of interaction \nEffects on medicinal product \nlevels. \nMean percent change in AUC, \nCmax, Cmin \nRecommendation concerning \nco-administration with Biktarvy \nSEDATIVES/HYPNOTICS\nMidazolam (2 mg, oral syrup, \nsingle dose), \nBictegravir/Emtricitabine/ \nTenofovir alafenamide \nMidazolam: \nAUC: \u2194 \nCmax: \u2194 \nNo dose adjustment is required \nupon co-administration. \n1  This study was conducted using\nbictegravir 75 mg single dose. \n2  This study was conducted using bictegravir/emtricitabine/tenofovir alafenamide 75/200/25 mg once daily. \n3  Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in HCV infected \npatients. \n4  This study was conducted using emtricitabine/tenofovir alafenamide 200/25 mg once daily. \n5  Maximum strength antacid contained 80 mg aluminium hydroxide, 80 mg magnesium hydroxide, and 8 mg \nsimethicone per mL. \n6  This study was conducted using elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide 150/150/200/10 mg once \ndaily. \nBased on drug interaction studies conducted with Biktarvy or the components of Biktarvy, no \nclinically significant drug interactions are expected with: amlodipine, atorvastatin, buprenorphine, \ndrospirenone, famciclovir, famotidine, fluticasone, methadone, naloxone, norbuprenorphine, \nomeprazole or rosuvastatin.", "driving": "Pregnancy \nThere are no or limited data (less than 300 pregnancy outcomes) from the use of bictegravir or \ntenofovir alafenamide in pregnant women.  A large amount of data on pregnant women (more than \n1,000 exposed outcomes) indicate no malformative nor foetal/neonatal toxicity associated with \nemtricitabine. \nAnimal studies do not indicate direct or indirect harmful effects of emtricitabine with respect to \nfertility parameters, pregnancy, foetal development, parturition or postnatal development.  Studies of \nbictegravir and tenofovir alafenamide, administered separately, in animals have shown no evidence of \nharmful effects on fertility parameters, pregnancy, or foetal development (see section 5.3). \nBiktarvy should be used during pregnancy only if the potential benefit justifies the potential risk to \nthe foetus. \nBreast-feeding \nIt is not known whether bictegravir or tenofovir alafenamide is excreted in human milk.  Emtricitabine \nis excreted in human milk.  In animal studies, bictegravir was detected in the plasma of nursing rat \npups likely due to the presence of bictegravir in milk, without effects on nursing pups.  In animal \nstudies it has been shown that tenofovir is excreted in milk.   \nThere is insufficient information on the effects of all the components of Biktarvy in newborns/infants, \ntherefore Biktarvy should not be used during breast-feeding. \nIn order to avoid transmission of HIV to the infant it is recommended that women living with HIV do \nnot breast-feed their infants. \nFertility \nNo human data on the effect of Biktarvy on fertility are available.  Animal studies indicate no effects \nof bictegravir, emtricitabine or tenofovir alafenamide on mating or fertility (see section 5.3). \n13", "side_effects": "Biktarvy may have minor influence on the ability to drive and use machines.  Patients should be \ninformed that dizziness has been reported during treatment with the components of Biktarvy (see \nsection 4.8).", "shelf_life": "Bottle \n3 years \nBlister \n2 years", "storage": "Bottle \nStore in the original package in order to protect from moisture.  Keep the bottle tightly closed.  Do not \nuse if seal over bottle opening is broken or missing. \nBlister \nStore in the original package in order to protect from moisture.  Do not use if foil over blister is broken \nor pierced.", "package": "The following pack configurations are available: \nBottle \nBiktarvy 30 mg/120 mg/15 mg tablets and 50 mg/200 mg/25 mg tablets are packaged in white, high \ndensity polyethylene (HDPE) bottle with a polypropylene continuous-thread, child-resistant cap, lined \nwith an induction activated aluminium foil liner containing 30 film-coated tablets.  Each bottle \ncontains silica gel desiccant and polyester coil. \nOuter carton containing 1 bottle of 30 film-coated tablets \nOuter carton containing 90 (3 bottles of 30) film-coated tablets. \nBlister \nBiktarvy 50 mg/200 mg/25 mg blister packs consisting of polyvinyl \nchloride/polyethylene/polychlorotrifluoroethylene (PVC/PE/PCTFE) film, sealed to aluminium foil \nlidding material fitted with a molecular sieve desiccant within each blister cavity.  \n27 \nOuter carton containing 30 film-coated tablets (4 x blister strips containing 7 film-coated \ntablets and 1 x blister strip containing 2 film-coated tablets). \nOuter carton containing 90 (3 blister packs of 30) film-coated tablets. \nNot all pack sizes may be marketed.", "marketing_authorization_numbers": "EU/1/18/1289/001 \nEU/1/18/1289/002 \nEU/1/18/1289/003 \nEU/1/18/1289/004 \nEU/1/18/1289/005 \nEU/1/18/1289/006", "filename": "biktarvy-epar-product-information_en.html", "snomed.product_info": [["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["725123003", "200 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"]], "ncit.product_info": [["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C70541", "Lansky Performance Status 30"], ["C16818", "Mammography"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C113429", "Fifteen"], ["C16818", "Mammography"], ["C154467", "Film Dosage Form Category"], ["C25450", "Coat"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C159711", "Two Hundred"], ["C16818", "Mammography"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C154467", "Film Dosage Form Category"], ["C25450", "Coat"]], "rxnorm.product_info": [["1999668", "Biktarvy"], ["1999668", "Biktarvy"]], "loinc.product_info": [["LA28855-7", "30"], ["LP15217-0", "Mg"], ["LA32059-0", "120"], ["LP15217-0", "Mg"], ["LA14561-7", "15"], ["LP15217-0", "Mg"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LP15217-0", "Mg"], ["LA19281-7", "25"], ["LP15217-0", "Mg"]], "snomed.composition": [["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["419473009", "Each (qualifier value)"], ["385057009", "Film-coated tablet (product)|Film-coated tablet (basic dose form)|Film-coated tablet (qualifier value)"], ["772194009", "Bictegravir sodium (substance)"], ["258726008", "Eq (qualifier value)|equivalent - unit (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["734973002", "Tenofovir alafenamide fumarate (substance)"], ["258726008", "Eq (qualifier value)|equivalent - unit (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["725123003", "200 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["419473009", "Each (qualifier value)"], ["385057009", "Film-coated tablet (product)|Film-coated tablet (basic dose form)|Film-coated tablet (qualifier value)"], ["772194009", "Bictegravir sodium (substance)"], ["258726008", "Eq (qualifier value)|equivalent - unit (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["725123003", "200 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["734973002", "Tenofovir alafenamide fumarate (substance)"], ["258726008", "Eq (qualifier value)|equivalent - unit (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["86495002", "For (qualifier value)"], ["261015003", "Full (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.composition": [["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C70541", "Lansky Performance Status 30"], ["C16818", "Mammography"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C113429", "Fifteen"], ["C16818", "Mammography"], ["C154467", "Film Dosage Form Category"], ["C25450", "Coat"], ["C64933", "Each"], ["C42931", "Film Coated Tablet Dosage Form"], ["C79873", "Contain"], ["C142955", "Bictegravir Sodium"], ["C48793", "Equivalent"], ["C159124", "GDC Treatment Outcome Terminology"], ["C70541", "Lansky Performance Status 30"], ["C16818", "Mammography"], ["C52874", "SPI1 wt Allele"], ["C171719", "Bictegravir"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C52874", "SPI1 wt Allele"], ["C47509", "Emtricitabine"], ["C16289", "Andorra"], ["C152559", "Tenofovir Alafenamide Fumarate"], ["C48793", "Equivalent"], ["C159124", "GDC Treatment Outcome Terminology"], ["C113429", "Fifteen"], ["C16818", "Mammography"], ["C52874", "SPI1 wt Allele"], ["C148276", "Tenofovir Alafenamide"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C159711", "Two Hundred"], ["C16818", "Mammography"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C154467", "Film Dosage Form Category"], ["C25450", "Coat"], ["C64933", "Each"], ["C42931", "Film Coated Tablet Dosage Form"], ["C79873", "Contain"], ["C142955", "Bictegravir Sodium"], ["C48793", "Equivalent"], ["C159124", "GDC Treatment Outcome Terminology"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C52874", "SPI1 wt Allele"], ["C171719", "Bictegravir"], ["C159711", "Two Hundred"], ["C16818", "Mammography"], ["C52874", "SPI1 wt Allele"], ["C47509", "Emtricitabine"], ["C16289", "Andorra"], ["C152559", "Tenofovir Alafenamide Fumarate"], ["C48793", "Equivalent"], ["C159124", "GDC Treatment Outcome Terminology"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C52874", "SPI1 wt Allele"], ["C148276", "Tenofovir Alafenamide"], ["C64956", "For"], ["C25517", "Full"], ["C43432", "List"], ["C52874", "SPI1 wt Allele"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.composition": [["1999668", "Biktarvy"], ["1999661", "bictegravir sodium"], ["1999660", "bictegravir"], ["276237", "emtricitabine"], ["1721604", "tenofovir alafenamide fumarate"], ["1721603", "tenofovir alafenamide"], ["1999668", "Biktarvy"], ["1999661", "bictegravir sodium"], ["1999660", "bictegravir"], ["276237", "emtricitabine"], ["1721604", "tenofovir alafenamide fumarate"], ["1721603", "tenofovir alafenamide"]], "loinc.composition": [["LA28855-7", "30"], ["LP15217-0", "Mg"], ["LA32059-0", "120"], ["LP15217-0", "Mg"], ["LA14561-7", "15"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["MTHU059747", "Bictegravir"], ["LP15099-2", "Sodium"], ["LA28855-7", "30"], ["LP15217-0", "Mg"], ["MTHU059747", "Bictegravir"], ["LA32059-0", "120"], ["LP15217-0", "Mg"], ["MTHU018643", "Emtricitabine"], ["MTHU015506", "Tenofovir"], ["LP15583-5", "Fumarate"], ["LA14561-7", "15"], ["LP15217-0", "Mg"], ["MTHU015506", "Tenofovir"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LP15217-0", "Mg"], ["LA19281-7", "25"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["MTHU059747", "Bictegravir"], ["LP15099-2", "Sodium"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["MTHU059747", "Bictegravir"], ["LP15217-0", "Mg"], ["MTHU018643", "Emtricitabine"], ["MTHU015506", "Tenofovir"], ["LP15583-5", "Fumarate"], ["LA19281-7", "25"], ["LP15217-0", "Mg"], ["MTHU015506", "Tenofovir"], ["LA19682-6", "Full"], ["LP204165-7", "List"], ["LP20594-5", "6"], ["LA6112-2", "1"]], "snomed.indications": [["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["72621000119104", "Human immunodeficiency virus (HIV) II infection category B1 (disorder)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["89293008", "Human immunodeficiency virus type I (organism)"], ["257551009", "Infection (disorder)|Infection"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["39857003", "Weighing patient (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222741009", "American Joint Committee on Cancer stage I:4 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["45169001", "Without (attribute)"], ["52101004", "Present (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["410513005", "In the past (qualifier value)"], ["18669006", "Evidence of (contextual qualifier) (qualifier value)"], ["56285002", "Viral resistance (function)|Viral resistance, function (observable entity)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["428617003", "Integrase strand transfer inhibitor (product)|Product containing integrase strand transfer inhibitor (product)"], ["277046005", "Class (attribute)"], ["404856006", "Emtricitabine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422091007", "Tenofovir (substance)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.indications": [["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C105723", "ECOG Performance Status 1"], ["C14220", "Human Immunodeficiency Virus 1"], ["C128320", "Infection"], ["C16727", "India"], ["C16289", "Andorra"], ["C16960", "Patient"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C16289", "Andorra"], ["C158997", "GDC Analyte Type Terminology"], ["C113428", "Fourteen"], ["C16771", "Kyrgyzstan"], ["C25718", "Without"], ["C160703", "Tumor Necrosis Present"], ["C43508", "Oregon"], ["C126474", "EHD1 wt Allele"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C27985", "Viral"], ["C41546", "Resistance Process"], ["C159124", "GDC Treatment Outcome Terminology"], ["C157401", "HIV Integrase Inhibitor"], ["C41106", "Object Class"], ["C47509", "Emtricitabine"], ["C43508", "Oregon"], ["C29490", "Tenofovir"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.indications": [["1999668", "Biktarvy"], ["T016", "Human"], ["T005", "Virus"], ["276237", "emtricitabine"], ["117466", "tenofovir"]], "loinc.indications": [["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA19711-3", "Human"], ["LP231628-1", "Immunodeficiency"], ["LP14855-8", "Virus"], ["LA6112-2", "1"], ["LP183501-8", "HIV"], ["LA6112-2", "1"], ["LP266919-2", "Infection"], ["LA22004-8", "IN"], ["LA21988-3", "AT"], ["LA31719-0", "2 years"], ["MTHU010047", "Age"], ["LA21988-3", "AT"], ["LA14560-9", "14"], ["LA9633-4", "Present"], ["LA22025-3", "OR"], ["LP6857-9", "Resistance"], ["LP6795-1", "Class"], ["MTHU018643", "Emtricitabine"], ["LA22025-3", "OR"], ["MTHU015506", "Tenofovir"], ["LP20593-7", "5"], ["LA6112-2", "1"]], "snomed.posology": [["277132007", "Therapeutic procedure (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["309343006", "Physician (occupation)"], ["18720000", "In (attribute)"], ["394834005", "Management|Management (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86406008", "Human immunodeficiency virus infection (disorder)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["39857003", "Weighing patient (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222741009", "American Joint Committee on Cancer stage I:4 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["39857003", "Weighing patient (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["725123003", "200 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["116154003", "Patient (person)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["116154003", "Patient (person)"], ["419652001", "Take (qualifier value)|Take - dosing instruction imperative (qualifier value)"], ["709122007", "As soon as possible (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["17621005", "Normal (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["242762006", "More (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["116154003", "Patient (person)"], ["419652001", "Take (qualifier value)|Take - dosing instruction imperative (qualifier value)"], ["1269470004", "Individual dose of drug or medicament not taken (situation)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["116154003", "Patient (person)"], ["18720000", "In (attribute)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258702006", "hour (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["242762006", "More (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258702006", "hour (qualifier value)"], ["255234002", "After (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["419652001", "Take (qualifier value)|Take - dosing instruction imperative (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["416774000", "Scheduled - priority (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["67995009", "Special (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["264695004", "65 (qualifier value)|Arabic numeral 65 (qualifier value)"], ["258707000", "year (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["40226000", "Impairment (finding)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255604002", "Mild (qualifier value)"], ["410601007", "Childhood age person (person)"], ["277046005", "Class (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1255665007", "Moderate (qualifier value)"], ["410601007", "Childhood age person (person)"], ["277046005", "Class (attribute)"], ["421211000", "Lymphoma staging symptom status B (tumor staging)"], ["40226000", "Impairment (finding)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["40226000", "Impairment (finding)"], ["410601007", "Childhood age person (person)"], ["277046005", "Class (attribute)"], ["420453007", "Roman numeral C (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["86495002", "For (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["40226000", "Impairment (finding)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["39857003", "Weighing patient (procedure)"], ["1222816006", "American Joint Committee on Cancer stage III:5 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["414135002", "Estimated (qualifier value)"], ["15373003", "Creatinine (substance)"], ["260695007", "Clearance (attribute)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258859000", "Milliliter/minute (qualifier value)|mL/min (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["255397009", "Adult (qualifier value)|Adult"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["46177005", "End-stage renal disease (disorder)|End stage renal disease (disorder)"], ["414135002", "Estimated (qualifier value)"], ["270011004", "Creatinine clearance (& level (& glom filt))|Creatinine clearance (& level (& glom filt)) (procedure)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["1156210006", "Minuscule (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["421503006", "Haemodialysis route (qualifier value)|Hemodialysis route (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["420862001", "On (qualifier value)"], ["258703001", "day (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421503006", "Haemodialysis route (qualifier value)|Hemodialysis route (qualifier value)"], ["255234002", "After (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421503006", "Haemodialysis route (qualifier value)|Hemodialysis route (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["784580008", "Estimation of creatinine clearance (procedure)|Estimated creatinine clearance (procedure)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["258859000", "Milliliter/minute (qualifier value)|mL/min (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258859000", "Milliliter/minute (qualifier value)|mL/min (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["258859000", "Milliliter/minute (qualifier value)|mL/min (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["421503006", "Haemodialysis route (qualifier value)|Hemodialysis route (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["263748003", "Established (qualifier value)"], ["18720000", "In (attribute)"], ["732766004", "5.2 (qualifier value)"], ["373067005", "No (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["18720000", "In (attribute)"], ["39857003", "Weighing patient (procedure)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["1222816006", "American Joint Committee on Cancer stage III:5 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["40226000", "Impairment (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["258707000", "year (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["46177005", "End-stage renal disease (disorder)|End stage renal disease (disorder)"], ["376171000221106", "Pediatric population (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["39857003", "Weighing patient (procedure)"], ["1222741009", "American Joint Committee on Cancer stage I:4 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["263748003", "Established (qualifier value)"], ["373067005", "No (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["260686004", "Method (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["26643006", "Oral route (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["45169001", "Without (attribute)"], ["255620007", "Food (substance)|Foods (substance)"], ["732766004", "5.2 (qualifier value)"], ["42752001", "Due to (attribute)"], ["397627001", "Taste, function (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["249486008", "Unable to swallow (finding)"], ["732936001", "Tablet (unit of presentation)"], ["260232004", "Whole (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["51440002", "Right and left (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["255234002", "After (attribute)"], ["74964007", "Other (qualifier value)"], ["261015003", "Full (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["311498008", "Immediately (qualifier value)"]], "ncit.posology": [["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C158169", "Buyei Chinese"], ["C76246", "Blood Group A"], ["C25741", "Physician"], ["C16727", "India"], ["C97639", "Management Occupations"], ["C52874", "SPI1 wt Allele"], ["C3108", "HIV Infection"], ["C16960", "Patient"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C16289", "Andorra"], ["C158997", "GDC Analyte Type Terminology"], ["C113428", "Fourteen"], ["C16771", "Kyrgyzstan"], ["C159124", "GDC Treatment Outcome Terminology"], ["C61585", "Less Than"], ["C113663", "Twenty Five"], ["C16771", "Kyrgyzstan"], ["C66832", "One"], ["C70541", "Lansky Performance Status 30"], ["C16818", "Mammography"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C113429", "Fifteen"], ["C16818", "Mammography"], ["C154605", "Tablet Dosage Form Category"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C125004", "Once Daily"], ["C16289", "Andorra"], ["C16960", "Patient"], ["C158997", "GDC Analyte Type Terminology"], ["C113663", "Twenty Five"], ["C16771", "Kyrgyzstan"], ["C66832", "One"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C159711", "Two Hundred"], ["C16818", "Mammography"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C154605", "Tablet Dosage Form Category"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C125004", "Once Daily"], ["C54031", "Missing"], ["C25488", "Dose"], ["C198613", "CFI wt Allele"], ["C53691", "Veterinary Patient"], ["C76246", "Blood Group A"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C25282", "Within"], ["C111798", "Eighteen"], ["C25529", "Hour"], ["C52874", "SPI1 wt Allele"], ["C25330", "Duration"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C114711", "Usually"], ["C25701", "Taken"], ["C53691", "Veterinary Patient"], ["C65105", "Take"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C71344", "Associate of Science"], ["C71344", "Associate of Science"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C16289", "Andorra"], ["C54631", "Curriculum Vitae"], ["C12801", "Tissue"], ["C25211", "Schedule"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C76246", "Blood Group A"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C158169", "Buyei Chinese"], ["C61584", "Greater Than"], ["C111798", "Eighteen"], ["C25529", "Hour"], ["C53691", "Veterinary Patient"], ["C25594", "Negation"], ["C65105", "Take"], ["C50429", "Missed Dose"], ["C16289", "Andorra"], ["C54631", "Curriculum Vitae"], ["C102843", "Usual"], ["C25211", "Schedule"], ["C198613", "CFI wt Allele"], ["C53691", "Veterinary Patient"], ["C167404", "Pet Acts Nauseous or Vomits"], ["C25282", "Within"], ["C105723", "ECOG Performance Status 1"], ["C25529", "Hour"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C154605", "Tablet Dosage Form Category"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C167404", "Pet Acts Nauseous or Vomits"], ["C61584", "Greater Than"], ["C105723", "ECOG Performance Status 1"], ["C25529", "Hour"], ["C38008", "Post"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C41204", "Need"], ["C159124", "GDC Treatment Outcome Terminology"], ["C65105", "Take"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C65136", "Until"], ["C82511", "Subsequent Trial Activity"], ["C25211", "Schedule"], ["C25488", "Dose"], ["C18101", "Special Population"], ["C16268", "Elderly"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C16727", "India"], ["C16960", "Patient"], ["C25150", "Age"], ["C188329", "Sixty Five"], ["C29848", "Year"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C156242", "Mild Hallucination"], ["C113691", "Child-Pugh Class A"], ["C43508", "Oregon"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C113692", "Child-Pugh Class B"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C113694", "Child-Pugh Class C"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C64956", "For"], ["C25340", "Use"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C114592", "Renal Impairment"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C16727", "India"], ["C16960", "Patient"], ["C102997", "Human Papillomavirus-35"], ["C16771", "Kyrgyzstan"], ["C62355", "With"], ["C25498", "Estimate"], ["C399", "Creatinine"], ["C199688", "Drug Clearance"], ["C70541", "Lansky Performance Status 30"], ["C64777", "Milliliter per Minute"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C16727", "India"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C62355", "With"], ["C9439", "Chronic Kidney Disease, Stage 5"], ["C25498", "Estimate"], ["C25747", "Creatinine Clearance"], ["C113429", "Fifteen"], ["C16816", "Mali"], ["C48154", "Minute"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C25639", "Receive"], ["C4981", "Chronic Graft Versus Host Disease"], ["C38200", "Administration via Hemodialysis"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16329", "Belgium"], ["C16289", "Andorra"], ["C48440", "Single"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C198613", "CFI wt Allele"], ["C62230", "Potential"], ["C25387", "Benefit"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C62230", "Potential"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C92667", "SPARC wt Allele"], ["C25301", "Day"], ["C52874", "SPI1 wt Allele"], ["C38200", "Administration via Hemodialysis"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C38008", "Post"], ["C25250", "Complete"], ["C52874", "SPI1 wt Allele"], ["C38200", "Administration via Hemodialysis"], ["C43442", "Biomaterial Treatment"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C150847", "Estimated Creatinine Clearance"], ["C113429", "Fifteen"], ["C64777", "Milliliter per Minute"], ["C16289", "Andorra"], ["C70541", "Lansky Performance Status 30"], ["C64777", "Milliliter per Minute"], ["C43508", "Oregon"], ["C113429", "Fifteen"], ["C64777", "Milliliter per Minute"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C25594", "Negation"], ["C25639", "Receive"], ["C4981", "Chronic Graft Versus Host Disease"], ["C38200", "Administration via Hemodialysis"], ["C71344", "Associate of Science"], ["C49667", "Safety Study"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C16727", "India"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C53269", "No Information Available"], ["C68869", "Are"], ["C25429", "Availability"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25392", "Manufacturer"], ["C25488", "Dose"], ["C16727", "India"], ["C16960", "Patient"], ["C102997", "Human Papillomavirus-35"], ["C16771", "Kyrgyzstan"], ["C62355", "With"], ["C25225", "Renal"], ["C21055", "Impairment"], ["C43508", "Oregon"], ["C16727", "India"], ["C16960", "Patient"], ["C61585", "Less Than"], ["C111798", "Eighteen"], ["C29848", "Year"], ["C62355", "With"], ["C9439", "Chronic Kidney Disease, Stage 5"], ["C17005", "Population Group"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16727", "India"], ["C16423", "Child"], ["C61585", "Less Than"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C43508", "Oregon"], ["C61585", "Less Than"], ["C113428", "Fourteen"], ["C16771", "Kyrgyzstan"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C53269", "No Information Available"], ["C68869", "Are"], ["C25429", "Availability"], ["C85492", "CDISC SDTM Method Terminology"], ["C52874", "SPI1 wt Allele"], ["C70962", "Agent Administration"], ["C38288", "Oral Route of Administration"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C62355", "With"], ["C43508", "Oregon"], ["C25718", "Without"], ["C62695", "Food"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C89272", "Due To"], ["C150481", "Bitter"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C154467", "Film Dosage Form Category"], ["C25450", "Coat"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C43508", "Oregon"], ["C64956", "For"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C121742", "Unable to Do"], ["C64927", "Swallow"], ["C154605", "Tablet Dosage Form Category"], ["C25326", "Whole"], ["C154605", "Tablet Dosage Form Category"], ["C106184", "May"], ["C16329", "Belgium"], ["C54572", "Split"], ["C16727", "India"], ["C81009", "Half"], ["C16289", "Andorra"], ["C49636", "Both"], ["C25701", "Taken"], ["C66832", "One"], ["C38008", "Post"], ["C118472", "Other License Status"], ["C191521", "COVID-19-specific Full Anticoagulation Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25701", "Taken"], ["C64597", "Immediately"]], "rxnorm.posology": [["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["2913", "creatinine"], ["1999668", "Biktarvy"], ["2913", "creatinine"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["2913", "creatinine"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["T168", "Food"]], "loinc.posology": [["LP267221-2", "Therapy"], ["LP17763-1", "A"], ["MTHU010489", "Physician"], ["LA22004-8", "IN"], ["LA20391-1", "Management"], ["MTHU020829", "HIV infection"], ["LA21988-3", "AT"], ["LA31719-0", "2 years"], ["MTHU010047", "Age"], ["LA21988-3", "AT"], ["LA14560-9", "14"], ["LA16823-9", "Less"], ["LA19281-7", "25"], ["LA6306-0", "One"], ["LA28855-7", "30"], ["LP15217-0", "Mg"], ["LA32059-0", "120"], ["LP15217-0", "Mg"], ["LA14561-7", "15"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["LA6305-2", "Once daily"], ["LA21988-3", "AT"], ["LA19281-7", "25"], ["LA6306-0", "One"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LP15217-0", "Mg"], ["LA19281-7", "25"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["LA6305-2", "Once daily"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP66710-2", "Patient"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP6913-0", "18 hours"], ["LP73517-2", "Time"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA14747-2", "Usually"], ["LP66710-2", "Patient"], ["LA15097-1", "Possible"], ["LA6626-1", "Normal"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LA16824-7", "More"], ["LP6913-0", "18 hours"], ["LP66710-2", "Patient"], ["LA21291-2", "Not"], ["MTHU065481", "Dose"], ["LP183687-5", "usual"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP66710-2", "Patient"], ["LP6915-5", "1 hour"], ["LP136501-6", "Tablet"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LA16824-7", "More"], ["LP6915-5", "1 hour"], ["LA14426-3", "Do not"], ["MTHU065481", "Dose"], ["LA22866-0", "Scheduled"], ["MTHU065481", "Dose"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA6752-5", "Mild"], ["LP428313-3", "Child-Pugh"], ["LP6795-1", "Class"], ["LP17763-1", "A"], ["LA22025-3", "OR"], ["LA6751-7", "Moderate"], ["LP428313-3", "Child-Pugh"], ["LP6795-1", "Class"], ["LA14518-7", "B"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["LP428313-3", "Child-Pugh"], ["LP6795-1", "Class"], ["LP17128-7", "C"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["MTHU065909", "Renal"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP6260-6", "Estimated"], ["MTHU002337", "Creatinine"], ["LP267658-5", "Clearance"], ["LA28855-7", "30"], ["LP6970-0", "minimum"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA13524-6", "Adult"], ["LP146090-8", "End Stage Renal Disease"], ["LP6260-6", "Estimated"], ["LP29651-4", "Creatinine clearance"], ["LA32970-8", "<"], ["LA14561-7", "15"], ["LA28752-6", "Chronic"], ["LA22004-8", "IN"], ["LP6323-2", "Immunofluorescence (IF)"], ["MTHU043138", "Risks"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA8999-0", "Days"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LP6260-6", "Estimated"], ["LP29651-4", "Creatinine clearance"], ["LA14561-7", "15"], ["LP6970-0", "minimum"], ["LA32970-8", "<"], ["LA28855-7", "30"], ["LP6970-0", "minimum"], ["LA22025-3", "OR"], ["LA32970-8", "<"], ["LA14561-7", "15"], ["LP6970-0", "minimum"], ["LA21291-2", "Not"], ["LA28752-6", "Chronic"], ["LA17589-5", "Safety"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LA22004-8", "IN"], ["LA32970-8", "<"], ["MTHU065909", "Renal"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LA16823-9", "Less"], ["LP146090-8", "End Stage Renal Disease"], ["LP62263-6", "Population"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["LA22004-8", "IN"], ["LA16823-9", "Less"], ["LA31719-0", "2 years"], ["MTHU010047", "Age"], ["LA22025-3", "OR"], ["LA16823-9", "Less"], ["LA14560-9", "14"], ["LA21291-2", "Not"], ["LA32-8", "No"], ["LP72939-9", "Method"], ["LA9367-9", "Oral"], ["LA22025-3", "OR"], ["MTHU065486", "Food"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA22025-3", "OR"], ["LA24937-7", "Unable"], ["LP136501-6", "Tablet"], ["LP136501-6", "Tablet"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LA14331-5", "Both"], ["LA6306-0", "One"], ["MTHU029809", "Other"], ["LA19682-6", "Full"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"]], "snomed.contraindications": [["257550005", "Hypersensitivity (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["105590001", "Substance (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387159009", "Rifampin (substance)|Rifampicin (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["224006005", "St. John (geographic location)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["51621002", "Hypericum perforatum (organism)"], ["732729005", "4.5 (qualifier value)"]], "ncit.contraindications": [["C3114", "Hypersensitivity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C154405", "Active State"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C62355", "With"], ["C811", "Rifampin"], ["C16289", "Andorra"], ["C159109", "GDC Sample Type Terminology"], ["C42555", "Siemens"], ["C2589", "St. John's Wort"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"]], "rxnorm.contraindications": [["9384", "rifampin"]], "loinc.contraindications": [["LA16666-2", "Active"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP20594-5", "6"], ["LA6112-2", "1"], ["LA21996-6", "CO"], ["LP15241-0", "S"], ["LP428044-4", "St. John's wort"], ["LA15768-7", "4.5"]], "snomed.special_warnings": [["73154007", "Infected (morphologic abnormality)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["49872002", "Virus (organism)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["266539002", "Chronic hepatitis (& [NOS] or [active B] or [active] or [persistent]) (disorder)|Chronic hepatitis (& [NOS] or [active B] or [active] or [persistent])"], ["421211000", "Lymphoma staging symptom status B (tumor staging)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["28995006", "Treated with (attribute)"], ["768685009", "Antiretroviral (disposition)"], ["277132007", "Therapeutic procedure (procedure)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["86495002", "For (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["399166001", "Fatal (qualifier value)"], ["281647001", "Adverse reaction (disorder)|Adverse reactions (disorder)|Adverse reactions (finding)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["18720000", "In (attribute)"], ["73154007", "Infected (morphologic abnormality)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["89293008", "Human immunodeficiency virus type I (organism)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["62944002", "Hepatitis C virus (organism)"], ["715220007", "Tenofovir alafenamide (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["55561003", "Active (qualifier value)"], ["65897001", "Against (qualifier value)"], ["81665004", "Hepatitis B virus (organism)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["73154007", "Infected (morphologic abnormality)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["53737009", "Acute (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["128241005", "Inflammatory disease of liver (disorder)"], ["73154007", "Infected (morphologic abnormality)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421286000", "Discontinue - dosing instruction imperative (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["51440002", "Right and left (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["261904005", "Laboratory (environment)"], ["308273005", "Follow-up status (finding)"], ["86495002", "For (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["261028005", "Several (qualifier value)"], ["258706009", "month (qualifier value)"], ["255234002", "After (attribute)"], ["266535008", "(Liver/biliary/pancreas+GIT NOS) or (biliary disease) or (gallbladder disease) or (liver disease)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["394653002", "Significant|Significant (qualifier value)"], ["181268008", "Entire liver (body structure)"], ["64572001", "Disease (disorder)"], ["263748003", "Established (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["181268008", "Entire liver (body structure)"], ["88846004", "Functional disorder (finding)"], ["55919000", "Including (qualifier value)"], ["266539002", "Chronic hepatitis (& [NOS] or [active B] or [active] or [persistent]) (disorder)|Chronic hepatitis (& [NOS] or [active B] or [active] or [persistent])"], ["35105006", "Increased (qualifier value)"], ["260864003", "Frequency (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["79036002", "Liver function (function)|Liver function (observable entity)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["768685009", "Antiretroviral (disposition)"], ["277132007", "Therapeutic procedure (procedure)"], ["85455005", "Cart, device (physical object)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18669006", "Evidence of (contextual qualifier) (qualifier value)"], ["230993007", "Worsening (qualifier value)"], ["266535008", "(Liver/biliary/pancreas+GIT NOS) or (biliary disease) or (gallbladder disease) or (liver disease)"], ["18720000", "In (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["726527001", "Weight (property) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["252116004", "Observation parameter (observable entity)"], ["260366006", "Increase (qualifier value)"], ["18720000", "In (attribute)"], ["726527001", "Weight (property) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["258395000", "Levels (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["87612001", "Blood (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["768685009", "Antiretroviral (disposition)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["260726005", "Part (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["64572001", "Disease (disorder)"], ["246106000", "Control (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["367150003", "Lifestyle|Lifestyle (finding)"], ["86495002", "For (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["18669006", "Evidence of (contextual qualifier) (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["86495002", "For (qualifier value)"], ["816159004", "Measured weight gain (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["260404005", "Strong (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["87612001", "Blood (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["263748003", "Established (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["70106000", "Lipid (substance)"], ["64572001", "Disease (disorder)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["88846004", "Functional disorder (finding)"], ["255260001", "Following (attribute)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["18720000", "In (attribute)"], ["257998006", "Lower case Roman letter t (qualifier value)|t (qualifier value)"], ["84440006", "Leuciscus idus (organism)"], ["277064003", "Function (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255372005", "Variable (qualifier value)"], ["246173007", "Degree (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["4757001", "Most (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386895008", "Stavudine (substance)"], ["387105006", "Didanosine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387151007", "Zidovudine (substance)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["88846004", "Functional disorder (finding)"], ["18720000", "In (attribute)"], ["165815009", "Human immunodeficiency virus (HIV) negative (finding)|Human immunodeficiency virus negative (finding)|HIV negative (finding)|Human immunodeficiency virus not detected (finding)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["47368004", "Nucleoside (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["42504009", "Containing (qualifier value)"], ["387151007", "Zidovudine (substance)"], ["63161005", "Principal (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["64572001", "Disease (disorder)"], ["271737000", "Anemia (disorder)"], ["303011007", "Neutropenic disorder (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["154733004", "Metabolic disorders (disorder)|Metabolic disorders"], ["272379006", "Events (event)|Event (event)"], ["70232002", "Frequent (qualifier value)"], ["14803004", "Transitory (qualifier value)"], ["260383002", "Late (qualifier value)"], ["246100006", "Onset (attribute)"], ["1199008", "Neurologic (qualifier value)"], ["64572001", "Disease (disorder)"], ["733985002", "Reported (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["56731001", "Increased muscle tone (finding)"], ["271788002", "Fit: [Convulsion) &/or (fit and well]|Fit: [Convulsion) &/or (fit and well] (disorder)"], ["25786006", "Abnormal behavior (finding)"], ["267679005", "Neurological disorder (& [nervous system disease] or [CNS diseases] or [sense organ disease])|Neurological disorder (& [nervous system disease] or [CNS diseases] or [sense organ disease]) (disorder)"], ["255276005", "Transient (disorder)|Transient"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["6934004", "Permanent (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["15240007", "Current (qualifier value)"], ["261665006", "Unknown (qualifier value)"], ["86495002", "For (qualifier value)"], ["410601007", "Childhood age person (person)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["257998006", "Lower case Roman letter t (qualifier value)|t (qualifier value)"], ["84440006", "Leuciscus idus (organism)"], ["52101004", "Present (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["261665006", "Unknown (qualifier value)"], ["134198009", "Etiology (attribute)"], ["1199008", "Neurologic (qualifier value)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["15240007", "Current (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["768685009", "Antiretroviral (disposition)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["101445003", "PREVENT (substance)|PREVENT (product)"], ["33096000", "Vertical (qualifier value)"], ["258150004", "Transmission (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["255386009", "Immune (qualifier value)"], ["64572001", "Disease (disorder)"], ["18720000", "In (attribute)"], ["19030005", "Human immunodeficiency virus (organism)"], ["73154007", "Infected (morphologic abnormality)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["255386009", "Immune (qualifier value)"], ["246199000", "Deficiency (attribute)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["385437003", "Institution (social concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["85455005", "Cart, device (physical object)"], ["23583003", "Inflammation (morphologic abnormality)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["84387000", "Asymptomatic (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["362977000", "Sequela (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["255216001", "First (qualifier value)"], ["57176003", "Few (qualifier value)"], ["258705008", "week (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258706009", "month (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["85455005", "Cart, device (physical object)"], ["22455005", "Cytomegaloviral retinitis (disorder)"], ["60132005", "Generalized (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["87017008", "Focal (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["115987006", "Pneumocystis (organism)"], ["266391003", "Pneumonia and influenza &/or pneumonia|Pneumonia and influenza &/or pneumonia (disorder)"], ["255387000", "Inflammatory|Inflammatory (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["263680009", "Autoimmune (qualifier value)|Autoimmune process (qualifier value)"], ["64572001", "Disease (disorder)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["64572001", "Disease (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["408335007", "Autoimmune hepatitis (disorder)"], ["733985002", "Reported (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255386009", "Immune (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["246100006", "Onset (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["242762006", "More (qualifier value)"], ["255372005", "Variable (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["260396001", "Numerous (qualifier value)"], ["258706009", "month (qualifier value)"], ["255234002", "After (attribute)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["768685009", "Antiretroviral (disposition)"], ["277132007", "Therapeutic procedure (procedure)"], ["717896003", "Does not (qualifier value)"], ["86406008", "Human immunodeficiency virus infection (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86406008", "Human immunodeficiency virus infection (disorder)"], ["351726001", "Below (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["122544007", "Observation procedure (procedure)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["64572001", "Disease (disorder)"], ["398199007", "Aseptic necrosis of bone (disorder)"], ["134198009", "Etiology (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["55919000", "Including (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["53041004", "Substance with alcohol structure (substance)|Alcohol (substance)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["363807006", "Body mass index|Body mass index (observable entity)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["398199007", "Aseptic necrosis of bone (disorder)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86005002", "Advanced (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["64572001", "Disease (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["263803006", "Long-term (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["85455005", "Cart, device (physical object)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["74188005", "Medical (qualifier value)"], ["243073001", "Advice (regime/therapy)|Advice (regime/therapy)(procedure)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["302536002", "Entire joint (body structure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["367206007", "Pain|Pain (finding)"], ["302536002", "Entire joint (body structure)"], ["271587009", "Stiffness (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["371157007", "Has difficulty doing (qualifier value)|Able with difficulty (qualifier value)"], ["18720000", "In (attribute)"], ["255324009", "Movement (observable entity)|Movement, function (observable entity)|Movement (qualifier value)"], ["288563008", "After values (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["55919000", "Including (qualifier value)"], ["129561000119108", "Pre-renal acute kidney injury (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["40415009", "Proximal (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["42504009", "Containing (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["13064003", "Followed by [Ambiguous]|Followed by (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["62482003", "Low (qualifier value)"], ["258395000", "Levels (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422091007", "Tenofovir (substance)"], ["42752001", "Due to (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422091007", "Tenofovir (substance)"], ["769082003", "5.3 (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["50741009", "Urinary tract function (observable entity)|Urinary tract function (function)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["288556008", "Before (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["394653002", "Significant|Significant (qualifier value)"], ["18720000", "In (attribute)"], ["50741009", "Urinary tract function (observable entity)|Urinary tract function (function)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18669006", "Evidence of (contextual qualifier) (qualifier value)"], ["40415009", "Proximal (qualifier value)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["46177005", "End-stage renal disease (disorder)|End stage renal disease (disorder)"], ["420862001", "On (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["421503006", "Haemodialysis route (qualifier value)|Hemodialysis route (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["46177005", "End-stage renal disease (disorder)|End stage renal disease (disorder)"], ["414135002", "Estimated (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["258859000", "Milliliter/minute (qualifier value)|mL/min (qualifier value)"], ["420862001", "On (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["421503006", "Haemodialysis route (qualifier value)|Hemodialysis route (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["732724000", "4.2 (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["224699009", "Study (environment)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["414090006", "Product containing emtricitabine and tenofovir (medicinal product)|Emtricitabine + tenofovir (product)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["714795001", "Elvitegravir (product)|Product containing elvitegravir (medicinal product)"], ["260347006", "Present + out of ++++ (qualifier value)|+ (qualifier value)"], ["714771003", "Cobicistat (product)|Product containing cobicistat (medicinal product)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["261010008", "Fixed (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["257987005", "Lower case Roman letter f (qualifier value)|f (qualifier value)"], ["18720000", "In (attribute)"], ["89293008", "Human immunodeficiency virus type I (organism)"], ["73154007", "Infected (morphologic abnormality)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["46177005", "End-stage renal disease (disorder)|End stage renal disease (disorder)"], ["414135002", "Estimated (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["258859000", "Milliliter/minute (qualifier value)|mL/min (qualifier value)"], ["420862001", "On (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["421503006", "Haemodialysis route (qualifier value)|Hemodialysis route (qualifier value)"], ["385630006", "Maintained (qualifier value)"], ["112235009", "Through (qualifier value)"], ["732907001", "96 (qualifier value)"], ["258705008", "week (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["81141003", "Normal renal function (finding)"], ["385630006", "Maintained (qualifier value)"], ["18720000", "In (attribute)"], ["706422001", "Extension (physical object)"], ["21191007", "Phase (attribute)|Phase (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["224699009", "Study (environment)"], ["18720000", "In (attribute)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["1222851003", "American Joint Committee on Cancer stage IV:8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["373067005", "No (qualifier value)"], ["281647001", "Adverse reaction (disorder)|Adverse reactions (disorder)|Adverse reactions (finding)"], ["7882003", "Identified (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["394425009", "Uncertain|Uncertain (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["74964007", "Other (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["72717003", "Magnesium (substance)"], ["255977005", "Aluminum material (substance)"], ["42504009", "Containing (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["3829006", "Iron (substance)"], ["351726001", "Below (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["123030002", "2 hours (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255620007", "Food (substance)|Foods (substance)"], ["123030002", "2 hours (qualifier value)"], ["255234002", "After (attribute)"], ["42504009", "Containing (qualifier value)"], ["72717003", "Magnesium (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255977005", "Aluminum material (substance)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["123030002", "2 hours (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["3829006", "Iron (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255620007", "Food (substance)|Foods (substance)"], ["732729005", "4.5 (qualifier value)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["897016006", "Not recommended (qualifier value)"], ["86495002", "For (qualifier value)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["413592000", "Atazanavir (substance)"], ["387222003", "Carbamazepine (substance)"], ["387467008", "Ciclosporin (substance)|Cyclosporine (substance)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["26643006", "Oral route (qualifier value)"], ["387025007", "Oxcarbazepine (substance)"], ["373505007", "Phenobarbital (substance)"], ["387220006", "Phenytoin (substance)"], ["386893001", "Rifabutin (substance)"], ["410831004", "Product containing rifapentine (medicinal product)|Rifapentine (product)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["387387008", "Sucralfate (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["768685009", "Antiretroviral (disposition)"], ["376171000221106", "Pediatric population (qualifier value)"], ["18720000", "In (attribute)"], ["128530007", "Entire bony skeleton (body structure)"], ["87918000", "Mineral (substance)"], ["125146005", "Density (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421060004", "Structure of vertebral column (body structure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["38266002", "Entire body as a whole (body structure)"], ["302548004", "Entire head (body structure)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["11896004", "Intermediate (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258707000", "year (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["42504009", "Containing (qualifier value)"], ["86495002", "For (qualifier value)"], ["1222851003", "American Joint Committee on Cancer stage IV:8 (qualifier value)"], ["258705008", "week (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["263803006", "Long-term (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["420862001", "On (qualifier value)"], ["128530007", "Entire bony skeleton (body structure)"], ["55919000", "Including (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["157169007", "Fracture (disorder)|Fracture"], ["394425009", "Uncertain|Uncertain (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260669005", "Approach (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["2533004", "Drug (substance)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258718000", "mmol (qualifier value)|millimole (qualifier value)"], ["39972003", "Sodium (substance)"], ["1222776006", "American Joint Committee on Cancer stage II:3 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["732936001", "Tablet (unit of presentation)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["39972003", "Sodium (substance)"]], "ncit.special_warnings": [["C16960", "Patient"], ["C95633", "Coded Ordinal Data Type"], ["C189188", "Infected with SARS-CoV-2"], ["C62355", "With"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C16289", "Andorra"], ["C3097", "Hepatitis B Infection"], ["C43508", "Oregon"], ["C67900", "Centi"], ["C14283", "Virus"], ["C16960", "Patient"], ["C62355", "With"], ["C82978", "Chronic Hepatitis"], ["C113692", "Child-Pugh Class B"], ["C43508", "Oregon"], ["C67900", "Centi"], ["C25705", "Treating"], ["C62355", "With"], ["C94631", "Antiretroviral Therapy"], ["C68869", "Are"], ["C158997", "GDC Analyte Type Terminology"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C17102", "Risk"], ["C64956", "For"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C16289", "Andorra"], ["C48275", "Death Related to Adverse Event"], ["C13308", "Hepatic"], ["C188368", "ELN Adverse-Risk Category"], ["C68869", "Are"], ["C142988", "Limited"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C25474", "Data"], ["C64956", "For"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16727", "India"], ["C16960", "Patient"], ["C95633", "Coded Ordinal Data Type"], ["C189188", "Infected with SARS-CoV-2"], ["C62355", "With"], ["C14220", "Human Immunodeficiency Virus 1"], ["C16289", "Andorra"], ["C189554", "Hepatitis C Virus Measurement"], ["C189554", "Hepatitis C Virus Measurement"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C79873", "Contain"], ["C148276", "Tenofovir Alafenamide"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C154405", "Active State"], ["C64937", "Against"], ["C189553", "Hepatitis B Virus Measurement"], ["C189553", "Hepatitis B Virus Measurement"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C49236", "Therapeutic Procedure"], ["C16727", "India"], ["C16960", "Patient"], ["C95633", "Coded Ordinal Data Type"], ["C189188", "Infected with SARS-CoV-2"], ["C62355", "With"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C16289", "Andorra"], ["C189553", "Hepatitis B Virus Measurement"], ["C106184", "May"], ["C16329", "Belgium"], ["C25281", "Associated"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C14140", "Acute"], ["C52874", "SPI1 wt Allele"], ["C3095", "Hepatitis"], ["C16960", "Patient"], ["C95633", "Coded Ordinal Data Type"], ["C189188", "Infected with SARS-CoV-2"], ["C62355", "With"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C16289", "Andorra"], ["C189553", "Hepatitis B Virus Measurement"], ["C75419", "World Health Organization"], ["C25484", "Discontinue"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16329", "Belgium"], ["C62355", "With"], ["C49636", "Both"], ["C123619", "Clinical Response"], ["C16289", "Andorra"], ["C37984", "Laboratory"], ["C99158", "Clinical Study Follow-up"], ["C64956", "For"], ["C158997", "GDC Analyte Type Terminology"], ["C107221", "Several"], ["C29846", "Month"], ["C38008", "Post"], ["C43442", "Biomaterial Treatment"], ["C3959", "Hepatobiliary Disorder"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C41130", "Significant"], ["C154417", "Underlying"], ["C23327", "Murine Liver"], ["C2991", "Disease or Disorder"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C16960", "Patient"], ["C62355", "With"], ["C73621", "Pre-existing"], ["C50634", "Liver Dysfunction"], ["C166400", "Inclusive"], ["C120853", "Chronic Active"], ["C3095", "Hepatitis"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C71113", "CDISC SDTM Frequency Terminology"], ["C52874", "SPI1 wt Allele"], ["C23327", "Murine Liver"], ["C25518", "Function"], ["C25490", "During"], ["C61517", "Combination"], ["C94631", "Antiretroviral Therapy"], ["C147930", "Cocaine- and Amphetamine-Regulated Transcript Protein"], ["C16289", "Andorra"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81893", "Standard"], ["C198613", "CFI wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C3959", "Hepatobiliary Disorder"], ["C16727", "India"], ["C16960", "Patient"], ["C25542", "Interruption"], ["C43508", "Oregon"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C48192", "Importance Weight"], ["C16289", "Andorra"], ["C28240", "Metabolic"], ["C75889", "PAX6 wt Allele"], ["C25533", "Increase"], ["C16727", "India"], ["C48192", "Importance Weight"], ["C16289", "Andorra"], ["C16727", "India"], ["C52874", "SPI1 wt Allele"], ["C17610", "Blood Sample"], ["C616", "Lipid"], ["C16289", "Andorra"], ["C2831", "Glucose"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C25490", "During"], ["C49236", "Therapeutic Procedure"], ["C106184", "May"], ["C16727", "India"], ["C45313", "Part"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C2991", "Disease or Disorder"], ["C64355", "Scientific Control"], ["C16289", "Andorra"], ["C16795", "Lifestyle"], ["C64956", "For"], ["C616", "Lipid"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C65099", "Some"], ["C43583", "Evidence"], ["C64956", "For"], ["C76246", "Blood Group A"], ["C38032", "Therapeutic Effect"], ["C64956", "For"], ["C113453", "Have Gained Weight"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C62223", "Strong"], ["C43583", "Evidence"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81168", "Any"], ["C43442", "Biomaterial Treatment"], ["C64956", "For"], ["C61256", "Monitoring"], ["C52874", "SPI1 wt Allele"], ["C17610", "Blood Sample"], ["C616", "Lipid"], ["C16289", "Andorra"], ["C2831", "Glucose"], ["C25641", "Reference"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C71155", "Established"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C43442", "Biomaterial Treatment"], ["C17564", "Guideline"], ["C616", "Lipid"], ["C2991", "Disease or Disorder"], ["C16329", "Belgium"], ["C61372", "Management"], ["C71344", "Associate of Science"], ["C168331", "Muscular Dystrophy Secondary to Mitochondrial Disorder"], ["C20632", "Pathophysiology"], ["C53286", "Next"], ["C49587", "Exposure Domain"], ["C49641", "In Utero"], ["C25728", "T Category"], ["C112878", "Insulin-Degrading Enzyme"], ["C106184", "May"], ["C62534", "Arginine/Omega-3 Fatty Acids/Nucleotides Oral Supplement"], ["C168331", "Muscular Dystrophy Secondary to Mitochondrial Disorder"], ["C25518", "Function"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C142192", "Study Variable"], ["C25554", "Level"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25258", "Most"], ["C190998", "Modified Van Assche Index MVAI102 Original Result - Pronounced"], ["C62355", "With"], ["C1428", "Stavudine"], ["C431", "Didanosine"], ["C16289", "Andorra"], ["C947", "Zidovudine"], ["C101282", "Have"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C168331", "Muscular Dystrophy Secondary to Mitochondrial Disorder"], ["C20632", "Pathophysiology"], ["C16727", "India"], ["C137693", "Human Immunodeficiency Virus Negative"], ["C49641", "In Utero"], ["C48928", "And/Or"], ["C159124", "GDC Treatment Outcome Terminology"], ["C707", "Nucleoside"], ["C101282", "Have"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C79873", "Contain"], ["C947", "Zidovudine"], ["C25562", "Main"], ["C188368", "ELN Adverse-Risk Category"], ["C188308", "Reported Information"], ["C68869", "Are"], ["C2991", "Disease or Disorder"], ["C80520", "Neutropenia"], ["C16289", "Andorra"], ["C28240", "Metabolic"], ["C2991", "Disease or Disorder"], ["C78435", "Hyperlipasemia"], ["C150901", "Event Unit"], ["C101282", "Have"], ["C91247", "Often"], ["C53288", "Temporary"], ["C64998", "Late"], ["C25279", "Onset"], ["C25262", "Neurologic"], ["C2991", "Disease or Disorder"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C73116", "Rarely"], ["C87085", "Hypertonia"], ["C2962", "Seizure"], ["C25401", "Abnormal"], ["C25262", "Neurologic"], ["C2991", "Disease or Disorder"], ["C68869", "Are"], ["C53288", "Temporary"], ["C43508", "Oregon"], ["C160628", "Permanent"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C160764", "Unknown Molecular Analysis"], ["C103373", "CDISC Findings Class"], ["C16329", "Belgium"], ["C64956", "For"], ["C81168", "Any"], ["C150886", "Child Relation"], ["C49641", "In Utero"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25728", "T Category"], ["C112878", "Insulin-Degrading Enzyme"], ["C75419", "World Health Organization"], ["C160703", "Tumor Necrosis Present"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C123619", "Clinical Response"], ["C103373", "CDISC Findings Class"], ["C52874", "SPI1 wt Allele"], ["C160764", "Unknown Molecular Analysis"], ["C12755", "Nervous System"], ["C103373", "CDISC Findings Class"], ["C103373", "CDISC Findings Class"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C48434", "Electrical Current"], ["C61423", "National"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25340", "Use"], ["C94631", "Antiretroviral Therapy"], ["C16727", "India"], ["C73435", "Gravida"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25243", "Vertical"], ["C17214", "Disease Transmission"], ["C52874", "SPI1 wt Allele"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C17997", "Immune"], ["C124063", "Reactivation"], ["C168217", "Genetic Syndrome Associated with Congenital Heart Defect"], ["C16727", "India"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C189188", "Infected with SARS-CoV-2"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C17997", "Immune"], ["C94372", "Deficiency"], ["C158997", "GDC Analyte Type Terminology"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C41206", "Institution"], ["C52874", "SPI1 wt Allele"], ["C147930", "Cocaine- and Amphetamine-Regulated Transcript Protein"], ["C75889", "PAX6 wt Allele"], ["C25535", "Inflammatory"], ["C25637", "Reaction"], ["C159124", "GDC Treatment Outcome Terminology"], ["C168121", "Asymptomatic Presentation"], ["C43508", "Oregon"], ["C37895", "Residual"], ["C106184", "May"], ["C16289", "Andorra"], ["C16390", "Etiology"], ["C54035", "Serious"], ["C123619", "Clinical Response"], ["C25457", "Condition"], ["C43508", "Oregon"], ["C52874", "SPI1 wt Allele"], ["C168422", "Rheumatic Fever Symptom"], ["C101282", "Have"], ["C25599", "Observed"], ["C25282", "Within"], ["C25509", "First"], ["C64942", "Few"], ["C29844", "Week"], ["C43508", "Oregon"], ["C29846", "Month"], ["C52874", "SPI1 wt Allele"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C147930", "Cocaine- and Amphetamine-Regulated Transcript Protein"], ["C70664", "Relevance"], ["C74521", "Include"], ["C50521", "Cytomegaloviral Retinitis"], ["C48928", "And/Or"], ["C191010", "Modified Van Assche Index MVAI104 Original Result - Focal"], ["C16289", "Andorra"], ["C124358", "Pneumocystis"], ["C3333", "Pneumonia"], ["C81168", "Any"], ["C25535", "Inflammatory"], ["C168422", "Rheumatic Fever Symptom"], ["C16329", "Belgium"], ["C25214", "Evaluation"], ["C16289", "Andorra"], ["C43442", "Biomaterial Treatment"], ["C65140", "When"], ["C37916", "Autoimmune"], ["C2991", "Disease or Disorder"], ["C71344", "Associate of Science"], ["C2991", "Disease or Disorder"], ["C16289", "Andorra"], ["C27029", "Autoimmune Hepatitis"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C159124", "GDC Treatment Outcome Terminology"], ["C127786", "Occurrence Indicator"], ["C16727", "India"], ["C127262", "CDISC SDTM Environmental Setting Terminology"], ["C52874", "SPI1 wt Allele"], ["C17997", "Immune"], ["C124063", "Reactivation"], ["C188308", "Reported Information"], ["C25330", "Duration"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25279", "Onset"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C128667", "More"], ["C142192", "Study Variable"], ["C16289", "Andorra"], ["C150901", "Event Unit"], ["C52288", "NUP214 wt Allele"], ["C127786", "Occurrence Indicator"], ["C160235", "Many Tumor Infiltrating Lymphocytes"], ["C29846", "Month"], ["C38008", "Post"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C43508", "Oregon"], ["C81168", "Any"], ["C118472", "Other License Status"], ["C94631", "Antiretroviral Therapy"], ["C86066", "Do"], ["C25594", "Negation"], ["C19732", "Continuing Umbrella of Research Experience for Underserved Minorities (CURE) Program"], ["C3108", "HIV Infection"], ["C16289", "Andorra"], ["C106184", "May"], ["C16289", "Andorra"], ["C118472", "Other License Status"], ["C2959", "Complication"], ["C52874", "SPI1 wt Allele"], ["C3108", "HIV Infection"], ["C16960", "Patient"], ["C49070", "Closed"], ["C95086", "Clinical Observation Domain"], ["C158169", "Buyei Chinese"], ["C16727", "India"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C16960", "Patient"], ["C62355", "With"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C25281", "Associated"], ["C2991", "Disease or Disorder"], ["C143225", "Osteonecrosis, CTCAE"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C166400", "Inclusive"], ["C211", "Therapeutic Corticosteroid"], ["C25340", "Use"], ["C74693", "Ethanol Measurement"], ["C66716", "Consumption of Goods"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C15261", "Immunosuppressive Therapy"], ["C25227", "High"], ["C138901", "Body Mass Index Finding"], ["C52874", "SPI1 wt Allele"], ["C143225", "Osteonecrosis, CTCAE"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C25411", "Advanced"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C2991", "Disease or Disorder"], ["C48928", "And/Or"], ["C25322", "Long-Term"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C147930", "Cocaine- and Amphetamine-Regulated Transcript Protein"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25261", "Medical"], ["C198613", "CFI wt Allele"], ["C54627", "Experience"], ["C13044", "Joint"], ["C16289", "Andorra"], ["C143725", "Pain, CTCAE"], ["C13044", "Joint"], ["C43508", "Oregon"], ["C62189", "Difficulty"], ["C16727", "India"], ["C37994", "Movement"], ["C38008", "Post"], ["C53292", "Marketing"], ["C52874", "SPI1 wt Allele"], ["C114592", "Renal Impairment"], ["C166400", "Inclusive"], ["C26808", "Acute Renal Failure"], ["C16289", "Andorra"], ["C25236", "Proximal"], ["C25225", "Renal"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C62355", "With"], ["C148276", "Tenofovir Alafenamide"], ["C79873", "Contain"], ["C76246", "Blood Group A"], ["C62230", "Potential"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C25516", "From"], ["C4981", "Chronic Graft Versus Host Disease"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C139301", "IPSS Risk Category Low"], ["C52874", "SPI1 wt Allele"], ["C29490", "Tenofovir"], ["C89272", "Due To"], ["C62355", "With"], ["C29490", "Tenofovir"], ["C16329", "Belgium"], ["C82931", "Exclusion"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C164220", "Renal Function"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25217", "Assessment"], ["C16727", "India"], ["C64916", "All"], ["C16960", "Patient"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C65140", "When"], ["C49236", "Therapeutic Procedure"], ["C62355", "With"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16289", "Andorra"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C175242", "During Treatment"], ["C16727", "India"], ["C64916", "All"], ["C16960", "Patient"], ["C71344", "Associate of Science"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C41130", "Significant"], ["C16727", "India"], ["C164220", "Renal Function"], ["C43508", "Oregon"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C25236", "Proximal"], ["C25225", "Renal"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16329", "Belgium"], ["C16960", "Patient"], ["C62355", "With"], ["C9439", "Chronic Kidney Disease, Stage 5"], ["C92667", "SPARC wt Allele"], ["C4981", "Chronic Graft Versus Host Disease"], ["C38200", "Administration via Hemodialysis"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16329", "Belgium"], ["C106184", "May"], ["C16329", "Belgium"], ["C16727", "India"], ["C62355", "With"], ["C9439", "Chronic Kidney Disease, Stage 5"], ["C25498", "Estimate"], ["C113429", "Fifteen"], ["C64777", "Milliliter per Minute"], ["C92667", "SPARC wt Allele"], ["C4981", "Chronic Graft Versus Host Disease"], ["C38200", "Administration via Hemodialysis"], ["C198613", "CFI wt Allele"], ["C62230", "Potential"], ["C25387", "Benefit"], ["C62230", "Potential"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C45319", "Study Object"], ["C52874", "SPI1 wt Allele"], ["C47509", "Emtricitabine"], ["C148276", "Tenofovir Alafenamide"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C76493", "Elvitegravir"], ["C97360", "Cobicistat"], ["C71344", "Associate of Science"], ["C76246", "Blood Group A"], ["C192102", "Fixed Dose"], ["C61517", "Combination"], ["C154605", "Tablet Dosage Form Category"], ["C68800", "Elementary Charge"], ["C67900", "Centi"], ["C14560", "F"], ["C73534", "Insulin-Like Growth Factor-Binding Protein 7"], ["C16727", "India"], ["C14220", "Human Immunodeficiency Virus 1"], ["C189188", "Infected with SARS-CoV-2"], ["C62355", "With"], ["C9439", "Chronic Kidney Disease, Stage 5"], ["C25498", "Estimate"], ["C113429", "Fifteen"], ["C64777", "Milliliter per Minute"], ["C92667", "SPARC wt Allele"], ["C4981", "Chronic Graft Versus Host Disease"], ["C38200", "Administration via Hemodialysis"], ["C88183", "Efficacy"], ["C154196", "Washo Language"], ["C192182", "Ninety Six"], ["C29844", "Week"], ["C47509", "Emtricitabine"], ["C49587", "Exposure Domain"], ["C154196", "Washo Language"], ["C25227", "High"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C12801", "Tissue"], ["C164220", "Renal Function"], ["C88183", "Efficacy"], ["C154196", "Washo Language"], ["C16727", "India"], ["C25270", "Extend"], ["C48281", "Trial Phase"], ["C52874", "SPI1 wt Allele"], ["C45319", "Study Object"], ["C16727", "India"], ["C69122", "Ten"], ["C16960", "Patient"], ["C159124", "GDC Treatment Outcome Terminology"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C64956", "For"], ["C175678", "Forty Eight"], ["C29844", "Week"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25406", "Additional"], ["C188368", "ELN Adverse-Risk Category"], ["C25737", "Identification"], ["C52874", "SPI1 wt Allele"], ["C164135", "Increased"], ["C47509", "Emtricitabine"], ["C49587", "Exposure Domain"], ["C125071", "Uncertain if Satisfied or Dissatisfied"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C118472", "Other License Status"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C29239", "Magnesium"], ["C79873", "Contain"], ["C29633", "Antacid Preparation"], ["C43508", "Oregon"], ["C68256", "Dietary Iron"], ["C1505", "Dietary Supplement"], ["C25457", "Condition"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25529", "Hour"], ["C201357", "Before Timing Type"], ["C43508", "Oregon"], ["C67010", "With Food"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25529", "Hour"], ["C38008", "Post"], ["C29633", "Antacid Preparation"], ["C79873", "Contain"], ["C29239", "Magnesium"], ["C48928", "And/Or"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25529", "Hour"], ["C201357", "Before Timing Type"], ["C68256", "Dietary Iron"], ["C1505", "Dietary Supplement"], ["C43508", "Oregon"], ["C25701", "Taken"], ["C63802", "Together"], ["C67010", "With Food"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C65099", "Some"], ["C68869", "Are"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C64956", "For"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C62355", "With"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C66872", "Atazanavir"], ["C341", "Carbamazepine"], ["C406", "Cyclosporine"], ["C38276", "Intravenous Route of Administration"], ["C43508", "Oregon"], ["C38288", "Oral Route of Administration"], ["C47643", "Oxcarbazepine"], ["C75368", "Phenobarbital Measurement"], ["C741", "Phenytoin"], ["C1408", "Rifabutin"], ["C66516", "Rifapentine"], ["C43508", "Oregon"], ["C848", "Sucralfate"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C118472", "Other License Status"], ["C17005", "Population Group"], ["C16727", "India"], ["C96950", "Bone Mineral Density"], ["C96950", "Bone Mineral Density"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C52874", "SPI1 wt Allele"], ["C12998", "Vertebral Column"], ["C16289", "Andorra"], ["C25304", "Total"], ["C12258", "Body of Stomach"], ["C61422", "Lesser"], ["C23353", "Murine Head"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C25150", "Age"], ["C94545", "Between"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C159124", "GDC Treatment Outcome Terminology"], ["C113426", "Twelve"], ["C29848", "Year"], ["C75419", "World Health Organization"], ["C25639", "Receive"], ["C148276", "Tenofovir Alafenamide"], ["C79873", "Contain"], ["C64956", "For"], ["C175678", "Forty Eight"], ["C29844", "Week"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C25322", "Long-Term"], ["C25492", "Effect"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C96950", "Bone Mineral Density"], ["C92667", "SPARC wt Allele"], ["C12366", "Bone"], ["C166400", "Inclusive"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C58382", "Fracture, CTCAE"], ["C68869", "Are"], ["C125071", "Uncertain if Satisfied or Dissatisfied"], ["C76246", "Blood Group A"], ["C94845", "Multidisciplinary"], ["C25424", "Approach"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C61256", "Monitoring"], ["C175242", "During Treatment"], ["C459", "Medication"], ["C79873", "Contain"], ["C61585", "Less Than"], ["C105723", "ECOG Performance Status 1"], ["C48513", "Millimole"], ["C830", "Sodium"], ["C126885", "Twenty Three"], ["C16818", "Mammography"], ["C97722", "PER1 wt Allele"], ["C154605", "Tablet Dosage Form Category"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C830", "Sodium"], ["C63628", "Empty"]], "rxnorm.special_warnings": [["T005", "Virus"], ["1999668", "Biktarvy"], ["1491863", "hepatitis C virus"], ["1999668", "Biktarvy"], ["1721603", "tenofovir alafenamide"], ["1427211", "hepatitis B virus"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["4850", "glucose"], ["4850", "glucose"], ["59763", "stavudine"], ["3364", "didanosine"], ["11413", "zidovudine"], ["11413", "zidovudine"], ["1999668", "Biktarvy"], ["1721603", "tenofovir alafenamide"], ["117466", "tenofovir"], ["117466", "tenofovir"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["276237", "emtricitabine"], ["1721603", "tenofovir alafenamide"], ["1306286", "elvitegravir"], ["1306284", "cobicistat"], ["276237", "emtricitabine"], ["1999668", "Biktarvy"], ["276237", "emtricitabine"], ["1999668", "Biktarvy"], ["6574", "magnesium"], ["90176", "iron"], ["1999668", "Biktarvy"], ["T168", "Food"], ["6574", "magnesium"], ["1999668", "Biktarvy"], ["90176", "iron"], ["T168", "Food"], ["1999668", "Biktarvy"], ["343047", "atazanavir"], ["2002", "carbamazepine"], ["32624", "oxcarbazepine"], ["8134", "phenobarbital"], ["8183", "phenytoin"], ["55672", "rifabutin"], ["35617", "rifapentine"], ["10156", "sucralfate"], ["1999668", "Biktarvy"], ["1721603", "tenofovir alafenamide"], ["9853", "sodium"], ["9853", "sodium"]], "loinc.special_warnings": [["LA21996-6", "CO"], ["LP183501-8", "HIV"], ["LA18126-5", "Hepatitis B"], ["LA22025-3", "OR"], ["LP17128-7", "C"], ["LP14855-8", "Virus"], ["LA28752-6", "Chronic"], ["LA18126-5", "Hepatitis B"], ["LA22025-3", "OR"], ["LP17128-7", "C"], ["LP66375-4", "Antiretroviral therapy"], ["LA21988-3", "AT"], ["LA24544-1", "Increased risk"], ["LA6750-9", "Severe"], ["LA32822-1", "Fatal"], ["LA6484-5", "Limited"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["LA22004-8", "IN"], ["LA21996-6", "CO"], ["LP183501-8", "HIV"], ["LA6112-2", "1"], ["LA32624-1", "Hepatitis C virus (HCV)"], ["MTHU015506", "Tenofovir"], ["LP200075-2", "IS"], ["LA16666-2", "Active"], ["LA32623-3", "Hepatitis B virus (HBV)"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LA21996-6", "CO"], ["LP183501-8", "HIV"], ["LA14161-6", "May"], ["LA6750-9", "Severe"], ["LA18821-1", "Acute"], ["LA7442-2", "Hepatitis"], ["LA21996-6", "CO"], ["LP183501-8", "HIV"], ["LA9508-8", "Discontinue"], ["LA14331-5", "Both"], ["LP7787-7", "Clinical"], ["MTHU029808", "Laboratory"], ["LP422890-6", "Follow-up"], ["LA21988-3", "AT"], ["MTHU068094", "Months"], ["LP94823-9", "Treatment"], ["LA25810-5", "Liver disease"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["LA22004-8", "IN"], ["LA28474-7", "Significant"], ["LA26681-9", "Underlying"], ["MTHU002039", "Liver"], ["LA21291-2", "Not"], ["LP32605-5", "pre"], ["MTHU002039", "Liver"], ["LA28752-6", "Chronic"], ["LA16666-2", "Active"], ["LA7442-2", "Hepatitis"], ["LA24377-6", "Increased"], ["MTHU029777", "Frequency"], ["LP31397-0", "Liver function (excluding enzymes)"], ["LA12701-1", "Combination"], ["LP66375-4", "Antiretroviral therapy"], ["LP20607-5", "standard"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP200075-2", "IS"], ["LA25810-5", "Liver disease"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LP94823-9", "Treatment"], ["LP221195-3", "Weight"], ["LP212101-2", "Metabolic"], ["LA32048-3", "Increase"], ["LA22004-8", "IN"], ["LP221195-3", "Weight"], ["LA22004-8", "IN"], ["MTHU029981", "Blood"], ["LA12903-3", "Lipids"], ["MTHU001675", "Glucose"], ["LA14161-6", "May"], ["LP267221-2", "Therapy"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LA18199-2", "Disease"], ["LP7741-4", "Control"], ["LA32823-9", "Lifestyle"], ["LA12903-3", "Lipids"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA14973-4", "Some"], ["LP270144-1", "Cases"], ["LP17763-1", "A"], ["LP94823-9", "Treatment"], ["MTHU020882", "Weight gain"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LA14974-2", "Strong"], ["LP94823-9", "Treatment"], ["LA20297-0", "Monitoring"], ["MTHU029981", "Blood"], ["LA12903-3", "Lipids"], ["MTHU001675", "Glucose"], ["LP212405-7", "Reference"], ["LP200075-2", "IS"], ["LP183501-8", "HIV"], ["LP94823-9", "Treatment"], ["LA24789-2", "Mitochondrial"], ["LA22004-8", "IN"], ["LA14161-6", "May"], ["LA24789-2", "Mitochondrial"], ["LA8916-4", "Function"], ["LP17763-1", "A"], ["LA18409-5", "Variable"], ["LP200075-2", "IS"], ["MTHU013858", "Stavudine"], ["LP21309-7", "Didanosine"], ["LP16744-2", "Zidovudine"], ["LA24789-2", "Mitochondrial"], ["LA22004-8", "IN"], ["LA24959-1", "HIV Negative"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["LP94823-9", "Treatment"], ["LP16744-2", "Zidovudine"], ["LP6486-7", "Reported"], ["LP212101-2", "Metabolic"], ["MTHU058708", "Events"], ["LA10044-8", "Often"], ["LP89782-4", "Neurological"], ["LP6486-7", "Reported"], ["LA10066-1", "Rarely"], ["LA12748-2", "Abnormal"], ["LA10590-0", "Neurological Disorders"], ["LA22025-3", "OR"], ["LP200075-2", "IS"], ["LA4489-6", "Unknown"], ["59776-5", "Procedure findings:Find:Pt:^Patient:Nar"], ["LA9949-4", "Child"], ["LA22004-8", "IN"], ["LA9633-4", "Present"], ["LA6750-9", "Severe"], ["LP7787-7", "Clinical"], ["59776-5", "Procedure findings:Find:Pt:^Patient:Nar"], ["LA4489-6", "Unknown"], ["LA16973-2", "Neurologic"], ["59776-5", "Procedure findings:Find:Pt:^Patient:Nar"], ["59776-5", "Procedure findings:Find:Pt:^Patient:Nar"], ["LA14426-3", "Do not"], ["LP66375-4", "Antiretroviral therapy"], ["LA22004-8", "IN"], ["LA29507-3", "Pregnant women"], ["LA8994-1", "Vertical"], ["MTHU050362", "Transmission"], ["LP183501-8", "HIV"], ["LA27183-5", "Immune"], ["LA22004-8", "IN"], ["LP183501-8", "HIV"], ["LA6750-9", "Severe"], ["LA27183-5", "Immune"], ["LA21988-3", "AT"], ["LP73517-2", "Time"], ["LP73228-6", "Reaction"], ["LA6737-6", "Asymptomatic"], ["LA22025-3", "OR"], ["LA14161-6", "May"], ["LA30751-4", "Serious"], ["LP7787-7", "Clinical"], ["LA22025-3", "OR"], ["LP75708-5", "Symptoms"], ["LP6425-5", "Observed"], ["LP6974-2", "first"], ["LA15680-4", "Few"], ["LA9000-6", "Weeks"], ["LA22025-3", "OR"], ["MTHU068094", "Months"], ["LP14255-1", "Cytomegalovirus"], ["LA22025-3", "OR"], ["LA26555-5", "Focal"], ["LP74970-2", "Infections"], ["MTHU020831", "Pneumonia"], ["LP75708-5", "Symptoms"], ["LP94823-9", "Treatment"], ["LA18199-2", "Disease"], ["LA7442-2", "Hepatitis"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["MTHU047625", "Setting"], ["LA27183-5", "Immune"], ["LP6486-7", "Reported"], ["LP73517-2", "Time"], ["LP200075-2", "IS"], ["LA16824-7", "More"], ["LA18409-5", "Variable"], ["MTHU058708", "Events"], ["LA15681-2", "Many"], ["MTHU068094", "Months"], ["LP94823-9", "Treatment"], ["LP74970-2", "Infections"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LP66375-4", "Antiretroviral therapy"], ["LA21291-2", "Not"], ["MTHU020829", "HIV infection"], ["LA14161-6", "May"], ["LP74970-2", "Infections"], ["MTHU029809", "Other"], ["19817-6", "Complications:Type:Stdy:^Patient:Nom"], ["MTHU020829", "HIV infection"], ["LA16797-5", "Close"], ["LP7787-7", "Clinical"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LP183501-8", "HIV"], ["LP200075-2", "IS"], ["LA28139-6", "Alcohol"], ["LA6750-9", "Severe"], ["LP35925-4", "Body mass index (BMI)"], ["LP270144-1", "Cases"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LP183501-8", "HIV"], ["LA18199-2", "Disease"], ["LA22025-3", "OR"], ["LA18950-8", "Term"], ["LP417559-4", "Safe Environment for Every Kid"], ["LA14523-7", "Advice"], ["LP6323-2", "Immunofluorescence (IF)"], ["MTHU048551", "Joint"], ["MTHU029813", "Pain"], ["MTHU048551", "Joint"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP96286-7", "Movement"], ["LP32606-3", "post"], ["LP270144-1", "Cases"], ["MTHU065909", "Renal"], ["LA27519-0", "Acute renal failure"], ["MTHU065909", "Renal"], ["LP6486-7", "Reported"], ["MTHU015506", "Tenofovir"], ["LP17763-1", "A"], ["LA28752-6", "Chronic"], ["LA9194-7", "Low"], ["MTHU015506", "Tenofovir"], ["MTHU015506", "Tenofovir"], ["LP20593-7", "5"], ["LP20591-1", "3"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP31398-8", "Renal function"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA18187-7", "All"], ["LA33028-4", "Prior"], ["LA22025-3", "OR"], ["LP267221-2", "Therapy"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LA18187-7", "All"], ["LA22004-8", "IN"], ["LA28474-7", "Significant"], ["LA14962-7", "Decreases"], ["LA22004-8", "IN"], ["LP31398-8", "Renal function"], ["LA22025-3", "OR"], ["MTHU065909", "Renal"], ["LP146090-8", "End Stage Renal Disease"], ["LA28752-6", "Chronic"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LP146090-8", "End Stage Renal Disease"], ["LP6260-6", "Estimated"], ["LA32970-8", "<"], ["LA14561-7", "15"], ["LP6970-0", "minimum"], ["LA28752-6", "Chronic"], ["LP6323-2", "Immunofluorescence (IF)"], ["MTHU043138", "Risks"], ["LP20592-9", "4"], ["MTHU000002", "Clinical Class"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP74341-6", "Study"], ["MTHU018643", "Emtricitabine"], ["LA30923-9", "+"], ["MTHU015506", "Tenofovir"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP157318-9", "Elvitegravir"], ["LA30923-9", "+"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LA12701-1", "Combination"], ["LP136501-6", "Tablet"], ["LA13503-0", "E"], ["LP17128-7", "C"], ["LA13504-8", "F"], ["LA22004-8", "IN"], ["LP183501-8", "HIV"], ["LA6112-2", "1"], ["LP146090-8", "End Stage Renal Disease"], ["LP6260-6", "Estimated"], ["LA32970-8", "<"], ["LA14561-7", "15"], ["LP6970-0", "minimum"], ["LA28752-6", "Chronic"], ["LA26687-6", "Efficacy"], ["LA9000-6", "Weeks"], ["MTHU018643", "Emtricitabine"], ["LA22004-8", "IN"], ["LA6626-1", "Normal"], ["LP31398-8", "Renal function"], ["LA26687-6", "Efficacy"], ["LA22004-8", "IN"], ["LP72568-6", "Extension"], ["LP74341-6", "Study"], ["LA22004-8", "IN"], ["LA13942-0", "10"], ["LA9000-6", "Weeks"], ["LA32-8", "No"], ["LP263791-8", "Additional"], ["LP40035-5", "Identified"], ["LA24377-6", "Increased"], ["MTHU018643", "Emtricitabine"], ["LA12719-3", "Uncertain"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA21996-6", "CO"], ["MTHU029809", "Other"], ["LA21291-2", "Not"], ["LA21996-6", "CO"], ["MTHU002163", "Magnesium"], ["LA22025-3", "OR"], ["MTHU004837", "Iron"], ["LA21988-3", "AT"], ["LA11829-1", "2 hours"], ["LA22025-3", "OR"], ["MTHU065486", "Food"], ["LA11829-1", "2 hours"], ["MTHU002163", "Magnesium"], ["LA22025-3", "OR"], ["LA21988-3", "AT"], ["LA11829-1", "2 hours"], ["MTHU004837", "Iron"], ["LA22025-3", "OR"], ["MTHU065486", "Food"], ["LA15768-7", "4.5"], ["LA14973-4", "Some"], ["LA4695-8", "Not Recommended"], ["LA21996-6", "CO"], ["LP35785-2", "Atazanavir"], ["LP16061-1", "carBAMazepine"], ["LP200078-6", "IV"], ["LA22025-3", "OR"], ["LA9367-9", "Oral"], ["MTHU060529", "OXcarbazepine"], ["MTHU060452", "PHENobarbital"], ["LP14732-9", "Phenytoin"], ["MTHU006676", "Rifabutin"], ["LP189348-8", "Rifapentine"], ["LA22025-3", "OR"], ["LP171641-6", "Sucralfate"], ["LA21291-2", "Not"], ["LA21996-6", "CO"], ["MTHU029809", "Other"], ["LP62263-6", "Population"], ["LA22004-8", "IN"], ["LP209032-4", "Bone"], ["LP20592-9", "4"], ["LP234806-0", "Spine"], ["LA6661-8", "Total"], ["LA16823-9", "Less"], ["LP7281-1", "Head"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LP20591-1", "3"], ["LA32970-8", "<"], ["LA14558-3", "12"], ["LA32660-5", "Received"], ["MTHU015506", "Tenofovir"], ["LA9000-6", "Weeks"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA18950-8", "Term"], ["LA22004-8", "IN"], ["LP209032-4", "Bone"], ["LA7437-2", "Fracture"], ["LA12719-3", "Uncertain"], ["LP17763-1", "A"], ["LP433613-9", "Multidisciplinary"], ["LP200075-2", "IS"], ["LA20297-0", "Monitoring"], ["LP93408-0", "during treatment"], ["LA16120-0", "Medicine"], ["LA16823-9", "Less"], ["LA6112-2", "1"], ["LP15099-2", "Sodium"], ["LP15217-0", "Mg"], ["LP136501-6", "Tablet"], ["LP200075-2", "IS"], ["LP15099-2", "Sodium"]], "snomed.pregnancy": [["420295001", "Only - dosing instruction fragment (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["18720000", "In (attribute)"], ["79970003", "Simultaneous (qualifier value)"], ["42504009", "Containing (qualifier value)"], ["422091007", "Tenofovir (substance)"], ["421203005", "Tenofovir disoproxil (substance)"], ["386897000", "Lamivudine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["409114008", "Adefovir dipivoxil (substance)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["772193003", "Bictegravir (substance)"], ["772193003", "Bictegravir (substance)"], ["116680003", "Is a (attribute)"], ["1119456000", "Substrate (foundation metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["51440002", "Right and left (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["387159009", "Rifampin (substance)|Rifampicin (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["224006005", "St. John (geographic location)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["260370003", "Decrease (qualifier value)"], ["50863008", "Plasma (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410536001", "Contraindicated (qualifier value)"], ["732725004", "4.3 (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["51440002", "Right and left (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["413592000", "Atazanavir (substance)"], ["260366006", "Increase (qualifier value)"], ["50863008", "Plasma (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["416118004", "Administration (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["51440002", "Right and left (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1119456000", "Substrate (foundation metadata concept)"], ["58147004", "Clinical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["263748003", "Established (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["36692007", "Known (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["105908007", "Macrolide (class of antibiotic) (product)|Macrolide (class of antibiotic, substance) (substance)|Macrolide (class of antibiotic, substance) (product)|Product containing macrolide and antibiotic (product)|Medicinal product containing macrolide and acting as antibacterial agent (product)"], ["387467008", "Ciclosporin (substance)|Cyclosporine (substance)"], ["372754009", "Verapamil (substance)"], ["443310000", "Dronedarone (product)|Product containing dronedarone (medicinal product)"], ["736837006", "Glecaprevir (substance)"], ["736836002", "Pibrentasvir (substance)"], ["86407004", "Table, device (physical object)"], ["351726001", "Below (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["31046007", "Cation (substance)"], ["705591009", "Transporter (physical object)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["734818004", "Toxin (disposition)"], ["263751005", "Extrusion (qualifier value)"], ["705591009", "Transporter (physical object)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["18720000", "In (attribute)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1119456000", "Substrate (foundation metadata concept)"], ["372567009", "Metformin (substance)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["394653002", "Significant|Significant (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["18720000", "In (attribute)"], ["372567009", "Metformin (substance)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["404856006", "Emtricitabine (substance)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["410942007", "Drug or medicament (substance)"], ["277359009", "Drug interaction (finding)"], ["86495002", "For (qualifier value)"], ["248448006", "Involved (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["62482003", "Low (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["13336003", "Tubular (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["763158003", "Medicinal product (product)"], ["260370003", "Decrease (qualifier value)"], ["50741009", "Urinary tract function (observable entity)|Urinary tract function (function)"], ["260366006", "Increase (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["715220007", "Tenofovir alafenamide (substance)"], ["715220007", "Tenofovir alafenamide (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["59804006", "Glycoprotein (substance)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["254837009", "Malignant tumor of breast (disorder)|Malignant neoplasm of breast (disorder)"], ["88878007", "Protein (substance)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["257733005", "Activity (observable entity)|Activities (qualifier value)"], ["88488004", "Lead (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["715220007", "Tenofovir alafenamide (substance)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["257733005", "Activity (observable entity)|Activities (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["386893001", "Rifabutin (substance)"], ["387222003", "Carbamazepine (substance)"], ["373505007", "Phenobarbital (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["260370003", "Decrease (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["79409006", "Resulting in (attribute)"], ["1250004", "Decreased (qualifier value)"], ["50863008", "Plasma (substance)"], ["702942001", "Concentration (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["88488004", "Lead (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["50863008", "Plasma (substance)"], ["702942001", "Concentration (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["715220007", "Tenofovir alafenamide (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["18720000", "In (attribute)"], ["74964007", "Other (qualifier value)"], ["11896004", "Intermediate (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["385435006", "Individual (person)"], ["246093002", "Component (attribute)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["86407004", "Table, device (physical object)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["351726001", "Below (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["260370003", "Decrease (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260388006", "No status change (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["373067005", "No (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["732853007", "70 (qualifier value)"], ["732505000", "143 (qualifier value)"], ["86407004", "Table, device (physical object)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["11896004", "Intermediate (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["385435006", "Individual (person)"], ["246093002", "Component (attribute)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["763158003", "Medicinal product (product)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["278109006", "Mechanism (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420862001", "On (qualifier value)"], ["763158003", "Medicinal product (product)"], ["258395000", "Levels (qualifier value)"], ["255586005", "Mean (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["263703002", "Changed status (qualifier value)"], ["413573002", "Area under the curve (qualifier value)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["224006005", "St. John (geographic location)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["420467003", "Hypericum (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["260370003", "Decrease (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422091007", "Tenofovir (substance)"], ["50863008", "Plasma (substance)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["224006005", "St. John (geographic location)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410536001", "Contraindicated (qualifier value)"], ["42752001", "Due to (attribute)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["224006005", "St. John (geographic location)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["420862001", "On (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["246093002", "Component (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["373249005", "Anti-infective agent (substance)"], ["387159009", "Rifampin (substance)|Rifampicin (substance)"], ["725127002", "600 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["772193003", "Bictegravir (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["732861002", "75 (qualifier value)"], ["1222781002", "American Joint Committee on Cancer stage II:8 (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387159009", "Rifampin (substance)|Rifampicin (substance)"], ["260370003", "Decrease (qualifier value)"], ["422091007", "Tenofovir (substance)"], ["50863008", "Plasma (substance)"], ["416118004", "Administration (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410536001", "Contraindicated (qualifier value)"], ["42752001", "Due to (attribute)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387159009", "Rifampin (substance)|Rifampicin (substance)"], ["420862001", "On (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["246093002", "Component (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386893001", "Rifabutin (substance)"], ["725125005", "300 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["772193003", "Bictegravir (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["1222819004", "American Joint Committee on Cancer stage III:8 (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386893001", "Rifabutin (substance)"], ["260370003", "Decrease (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["50863008", "Plasma (substance)"], ["416118004", "Administration (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["42752001", "Due to (attribute)"], ["260370003", "Decrease (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["763158003", "Medicinal product (product)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["278109006", "Mechanism (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420862001", "On (qualifier value)"], ["763158003", "Medicinal product (product)"], ["258395000", "Levels (qualifier value)"], ["255586005", "Mean (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["263703002", "Changed status (qualifier value)"], ["413573002", "Area under the curve (qualifier value)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["410831004", "Product containing rifapentine (medicinal product)|Rifapentine (product)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["410831004", "Product containing rifapentine (medicinal product)|Rifapentine (product)"], ["260370003", "Decrease (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["50863008", "Plasma (substance)"], ["416118004", "Administration (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["89293008", "Human immunodeficiency virus type I (organism)"], ["768683002", "Antiviral (disposition)"], ["413592000", "Atazanavir (substance)"], ["725125005", "300 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["714771003", "Cobicistat (product)|Product containing cobicistat (medicinal product)"], ["732515006", "150 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["772193003", "Bictegravir (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["416118004", "Administration (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["413592000", "Atazanavir (substance)"], ["732733003", "400 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["1222826004", "American Joint Committee on Cancer stage III:15 (qualifier value)"], ["62944002", "Hepatitis C virus (organism)"], ["768683002", "Antiviral (disposition)"], ["714387002", "Product containing ledipasvir (medicinal product)|Ledipasvir (product)"], ["713645002", "Sofosbuvir (product)|Product containing sofosbuvir (medicinal product)"], ["732899009", "90 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732733003", "400 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["404856006", "Emtricitabine (substance)"], ["422091007", "Tenofovir (substance)"], ["772193003", "Bictegravir (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["714387002", "Product containing ledipasvir (medicinal product)|Ledipasvir (product)"], ["413573002", "Area under the curve (qualifier value)"], ["713645002", "Sofosbuvir (product)|Product containing sofosbuvir (medicinal product)"], ["413573002", "Area under the curve (qualifier value)"], ["713645002", "Sofosbuvir (product)|Product containing sofosbuvir (medicinal product)"], ["767279008", "Metabolite (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420771004", "Upon - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["763158003", "Medicinal product (product)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["278109006", "Mechanism (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420862001", "On (qualifier value)"], ["763158003", "Medicinal product (product)"], ["258395000", "Levels (qualifier value)"], ["255586005", "Mean (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["263703002", "Changed status (qualifier value)"], ["413573002", "Area under the curve (qualifier value)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["713645002", "Sofosbuvir (product)|Product containing sofosbuvir (medicinal product)"], ["719641001", "Velpatasvir (substance)"], ["736536005", "Voxilaprevir (substance)"], ["732733003", "400 (qualifier value)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["260347006", "Present + out of ++++ (qualifier value)|+ (qualifier value)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["422114001", "Once - dosing instruction fragment (qualifier value)"], ["123128001", "Daily -RETIRED-|Daily (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["404856006", "Emtricitabine (substance)"], ["715220007", "Tenofovir alafenamide (substance)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["772193003", "Bictegravir (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["732798005", "57 (qualifier value)"], ["1222781002", "American Joint Committee on Cancer stage II:8 (qualifier value)"], ["713645002", "Sofosbuvir (product)|Product containing sofosbuvir (medicinal product)"], ["413573002", "Area under the curve (qualifier value)"], ["713645002", "Sofosbuvir (product)|Product containing sofosbuvir (medicinal product)"], ["767279008", "Metabolite (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["719641001", "Velpatasvir (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["736536005", "Voxilaprevir (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420771004", "Upon - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["386116008", "Product containing voriconazole (medicinal product)|Voriconazole (product)"], ["725125005", "300 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["421832002", "Twice - dosing instruction fragment (qualifier value)"], ["123128001", "Daily -RETIRED-|Daily (qualifier value)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["772193003", "Bictegravir (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["732821003", "61 (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420771004", "Upon - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["387532006", "Itraconazole (substance)"], ["421747003", "Posaconazole (substance)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387532006", "Itraconazole (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421747003", "Posaconazole (substance)"], ["260366006", "Increase (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["50863008", "Plasma (substance)"], ["105908007", "Macrolide (class of antibiotic) (product)|Macrolide (class of antibiotic, substance) (substance)|Macrolide (class of antibiotic, substance) (product)|Product containing macrolide and antibiotic (product)|Medicinal product containing macrolide and acting as antibacterial agent (product)"], ["387531004", "Azithromycin (substance)"], ["387487009", "Clarithromycin (substance)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387531004", "Azithromycin (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["387487009", "Clarithromycin (substance)"], ["260366006", "Increase (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["50863008", "Plasma (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["42752001", "Due to (attribute)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420862001", "On (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["246093002", "Component (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["763158003", "Medicinal product (product)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["278109006", "Mechanism (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420862001", "On (qualifier value)"], ["763158003", "Medicinal product (product)"], ["258395000", "Levels (qualifier value)"], ["255586005", "Mean (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["263703002", "Changed status (qualifier value)"], ["413573002", "Area under the curve (qualifier value)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387222003", "Carbamazepine (substance)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["725125005", "300 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229799001", "Twice a day (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["422091007", "Tenofovir (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["715220007", "Tenofovir alafenamide (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["732789007", "54 (qualifier value)"], ["732798005", "57 (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387222003", "Carbamazepine (substance)"], ["260370003", "Decrease (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["50863008", "Plasma (substance)"], ["416118004", "Administration (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["387025007", "Oxcarbazepine (substance)"], ["373505007", "Phenobarbital (substance)"], ["387220006", "Phenytoin (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424790003", "Cytochrome p450 CYP3A enzyme (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387025007", "Oxcarbazepine (substance)"], ["373505007", "Phenobarbital (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["387220006", "Phenytoin (substance)"], ["260370003", "Decrease (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422091007", "Tenofovir (substance)"], ["50863008", "Plasma (substance)"], ["416118004", "Administration (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["72717003", "Magnesium (substance)"], ["255977005", "Aluminum material (substance)"], ["42504009", "Containing (qualifier value)"], ["372794006", "Antacid (substance)"], ["739008005", "Suspension (basic dose form)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["772193003", "Bictegravir (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["372794006", "Antacid (substance)"], ["739008005", "Suspension (basic dose form)"], ["123030002", "2 hours (qualifier value)"], ["413573002", "Area under the curve (qualifier value)"], ["732782003", "52 (qualifier value)"], ["732801004", "58 (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["372794006", "Antacid (substance)"], ["739008005", "Suspension (basic dose form)"], ["255234002", "After (attribute)"], ["123030002", "2 hours (qualifier value)"], ["413573002", "Area under the curve (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["79970003", "Simultaneous (qualifier value)"], ["416118004", "Administration (procedure)"], ["413573002", "Area under the curve (qualifier value)"], ["725128007", "80 (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["79970003", "Simultaneous (qualifier value)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255620007", "Food (substance)|Foods (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["1222850002", "American Joint Committee on Cancer stage IV:7 (qualifier value)"], ["1222852005", "American Joint Committee on Cancer stage IV:9 (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["42504009", "Containing (qualifier value)"], ["72717003", "Magnesium (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255977005", "Aluminum material (substance)"], ["42752001", "Due to (attribute)"], ["260370003", "Decrease (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["732727007", "4.4 (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["123030002", "2 hours (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255620007", "Food (substance)|Foods (substance)"], ["123030002", "2 hours (qualifier value)"], ["255234002", "After (attribute)"], ["42504009", "Containing (qualifier value)"], ["72717003", "Magnesium (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255977005", "Aluminum material (substance)"], ["387289009", "Ferrous fumarate (substance)"], ["1222835006", "American Joint Committee on Cancer stage III:24 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["408102007", "Unit dose (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["79970003", "Simultaneous (qualifier value)"], ["416118004", "Administration (procedure)"], ["413573002", "Area under the curve (qualifier value)"], ["732828009", "63 (qualifier value)"], ["264699005", "71 (qualifier value)|Arabic numeral 71 (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["79970003", "Simultaneous (qualifier value)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255620007", "Food (substance)|Foods (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["123030002", "2 hours (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["3829006", "Iron (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255620007", "Food (substance)|Foods (substance)"], ["387307005", "Calcium carbonate (substance)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["725123003", "200 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["408102007", "Unit dose (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["79970003", "Simultaneous (qualifier value)"], ["416118004", "Administration (procedure)"], ["413573002", "Area under the curve (qualifier value)"], ["1222814009", "American Joint Committee on Cancer stage III:3 (qualifier value)"], ["1222845008", "American Joint Committee on Cancer stage IV:2 (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["79970003", "Simultaneous (qualifier value)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255620007", "Food (substance)|Foods (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["5540006", "Calcium (substance)"], ["42504009", "Containing (qualifier value)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["45169001", "Without (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255620007", "Food (substance)|Foods (substance)"], ["1222737005", "American Joint Committee on Cancer stage I:1 (qualifier value)"], ["763158003", "Medicinal product (product)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["278109006", "Mechanism (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420862001", "On (qualifier value)"], ["763158003", "Medicinal product (product)"], ["258395000", "Levels (qualifier value)"], ["255586005", "Mean (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["263703002", "Changed status (qualifier value)"], ["413573002", "Area under the curve (qualifier value)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387387008", "Sucralfate (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["260370003", "Decrease (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["50863008", "Plasma (substance)"], ["416118004", "Administration (procedure)"], ["897015005", "Recommended (qualifier value)"], ["372594008", "Sertraline (substance)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["408102007", "Unit dose (qualifier value)"], ["422091007", "Tenofovir (substance)"], ["715220007", "Tenofovir alafenamide (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["372594008", "Sertraline (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["373067005", "No (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420771004", "Upon - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["387467008", "Ciclosporin (substance)|Cyclosporine (substance)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["26643006", "Oral route (qualifier value)"], ["421824005", "Tumor staging descriptor p (tumor staging)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387467008", "Ciclosporin (substance)|Cyclosporine (substance)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["26643006", "Oral route (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["50863008", "Plasma (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["51440002", "Right and left (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422091007", "Tenofovir (substance)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387467008", "Ciclosporin (substance)|Cyclosporine (substance)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["26643006", "Oral route (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410525008", "Needed (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["277064003", "Function (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["738956005", "Oral (intended site)"], ["372567009", "Metformin (substance)"], ["732775002", "500 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229799001", "Twice a day (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["404856006", "Emtricitabine (substance)"], ["715220007", "Tenofovir alafenamide (substance)"], ["61511001", "Inhibition (function)|Inhibition, function (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["372567009", "Metformin (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["1222820005", "American Joint Committee on Cancer stage III:9 (qualifier value)"], ["1222817002", "American Joint Committee on Cancer stage III:6 (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420771004", "Upon - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["81141003", "Normal renal function (finding)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1255665007", "Moderate (qualifier value)"], ["40226000", "Impairment (finding)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["372567009", "Metformin (substance)"], ["42752001", "Due to (attribute)"], ["35105006", "Increased (qualifier value)"], ["86495002", "For (qualifier value)"], ["154757004", "Acidosis|Acidosis (disorder)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["372567009", "Metformin (substance)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["738956005", "Oral (intended site)"], ["108899006", "Contraceptives (product)|Medicinal product acting as contraceptive (product)|Contraceptives (substance)"], ["126115000", "Norgestimate (substance)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["732554007", "180 (qualifier value)"], ["732351000", "0.215 (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["732617008", "250 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["422114001", "Once - dosing instruction fragment (qualifier value)"], ["123128001", "Daily -RETIRED-|Daily (qualifier value)"], ["126097006", "Ethinyl estradiol (substance)|Ethinylestradiol (substance)"], ["732312005", "0.025 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["404867007", "Product containing norelgestromin (medicinal product)|Norelgestromin (product)"], ["413573002", "Area under the curve (qualifier value)"], ["126106007", "Norgestrel (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["126097006", "Ethinyl estradiol (substance)|Ethinylestradiol (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420771004", "Upon - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["126115000", "Norgestimate (substance)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["732554007", "180 (qualifier value)"], ["732351000", "0.215 (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["732617008", "250 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["422114001", "Once - dosing instruction fragment (qualifier value)"], ["123128001", "Daily -RETIRED-|Daily (qualifier value)"], ["126097006", "Ethinyl estradiol (substance)|Ethinylestradiol (substance)"], ["732312005", "0.025 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["422091007", "Tenofovir (substance)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["763158003", "Medicinal product (product)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["278109006", "Mechanism (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420862001", "On (qualifier value)"], ["763158003", "Medicinal product (product)"], ["258395000", "Levels (qualifier value)"], ["255586005", "Mean (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["263703002", "Changed status (qualifier value)"], ["413573002", "Area under the curve (qualifier value)"], ["416118004", "Administration (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["321088006", "Medicinal product acting as hypnotic (product)|Hypnotics (substance)|Hypnotics (product)"], ["373476007", "Midazolam (substance)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["385032004", "Conventional release oral syrup (dose form)|Syrup (product)|Syrup (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["408102007", "Unit dose (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["404856006", "Emtricitabine (substance)"], ["715220007", "Tenofovir alafenamide (substance)"], ["373476007", "Midazolam (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420771004", "Upon - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["224699009", "Study (environment)"], ["261583007", "Using (attribute)"], ["772193003", "Bictegravir (substance)"], ["732861002", "75 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["408102007", "Unit dose (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["224699009", "Study (environment)"], ["261583007", "Using (attribute)"], ["772193003", "Bictegravir (substance)"], ["404856006", "Emtricitabine (substance)"], ["715220007", "Tenofovir alafenamide (substance)"], ["732861002", "75 (qualifier value)"], ["725123003", "200 (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["224699009", "Study (environment)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["736536005", "Voxilaprevir (substance)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["736536005", "Voxilaprevir (substance)"], ["18720000", "In (attribute)"], ["73154007", "Infected (morphologic abnormality)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["224699009", "Study (environment)"], ["261583007", "Using (attribute)"], ["404856006", "Emtricitabine (substance)"], ["715220007", "Tenofovir alafenamide (substance)"], ["725123003", "200 (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229797004", "Once daily (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["372794006", "Antacid (substance)"], ["725128007", "80 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["273944007", "Aluminum hydroxide - chemical (substance)|Aluminium hydroxide (substance)|Aluminum hydroxide (substance)"], ["725128007", "80 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["387337001", "Magnesium hydroxide (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["387442005", "Simeticone (substance)|Simethicone (substance)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["224699009", "Study (environment)"], ["261583007", "Using (attribute)"], ["714795001", "Elvitegravir (product)|Product containing elvitegravir (medicinal product)"], ["714771003", "Cobicistat (product)|Product containing cobicistat (medicinal product)"], ["404856006", "Emtricitabine (substance)"], ["715220007", "Tenofovir alafenamide (substance)"], ["732515006", "150 (qualifier value)"], ["732515006", "150 (qualifier value)"], ["725123003", "200 (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["422114001", "Once - dosing instruction fragment (qualifier value)"], ["123128001", "Daily -RETIRED-|Daily (qualifier value)"], ["420862001", "On (qualifier value)"], ["277359009", "Drug interaction (finding)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["373067005", "No (qualifier value)"], ["394653002", "Significant|Significant (qualifier value)"], ["410942007", "Drug or medicament (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386864001", "Amlodipine (substance)"], ["373444002", "Atorvastatin (substance)"], ["387173000", "Buprenorphine (substance)"], ["410919000", "Drospirenone (substance)"], ["387557001", "Famciclovir (substance)"], ["387211002", "Famotidine (substance)"], ["397192001", "Fluticasone (substance)"], ["387286002", "Methadone (substance)"], ["372890007", "Naloxone (substance)"], ["447029004", "Norbuprenorphine (substance)"], ["387137007", "Omeprazole (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["700067006", "Rosuvastatin (substance)"]], "ncit.pregnancy": [["C54216", "Interaction"], ["C101282", "Have"], ["C48440", "Single"], ["C38000", "Performed"], ["C16727", "India"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C62355", "With"], ["C79873", "Contain"], ["C29490", "Tenofovir"], ["C29490", "Tenofovir"], ["C1471", "Lamivudine"], ["C43508", "Oregon"], ["C28811", "Adefovir Dipivoxil"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C189553", "Hepatitis B Virus Measurement"], ["C128320", "Infection"], ["C171719", "Bictegravir"], ["C171719", "Bictegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C50196", "Substrate Device"], ["C52874", "SPI1 wt Allele"], ["C107557", "CYP3A Gene Locus"], ["C16289", "Andorra"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C171719", "Bictegravir"], ["C16289", "Andorra"], ["C61367", "Induction"], ["C49636", "Both"], ["C107557", "CYP3A Gene Locus"], ["C16289", "Andorra"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C71344", "Associate of Science"], ["C811", "Rifampin"], ["C43508", "Oregon"], ["C159109", "GDC Sample Type Terminology"], ["C42555", "Siemens"], ["C106184", "May"], ["C25640", "Reduced"], ["C13356", "Plasma"], ["C52874", "SPI1 wt Allele"], ["C171719", "Bictegravir"], ["C106184", "May"], ["C20200", "Outcome"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C25559", "Loss"], ["C52874", "SPI1 wt Allele"], ["C25277", "Therapeutic"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16289", "Andorra"], ["C18732", "Development"], ["C52874", "SPI1 wt Allele"], ["C41546", "Resistance Process"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C37933", "Contraindicated"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C171719", "Bictegravir"], ["C62355", "With"], ["C49636", "Both"], ["C107557", "CYP3A Gene Locus"], ["C16289", "Andorra"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C71344", "Associate of Science"], ["C66872", "Atazanavir"], ["C106184", "May"], ["C25533", "Increase"], ["C13356", "Plasma"], ["C52874", "SPI1 wt Allele"], ["C171719", "Bictegravir"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C171719", "Bictegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C49636", "Both"], ["C76246", "Blood Group A"], ["C52273", "ABCB1 wt Allele"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C191817", "ABCG2 Substrate"], ["C123619", "Clinical Response"], ["C70664", "Relevance"], ["C52874", "SPI1 wt Allele"], ["C70838", "Image Feature"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C71155", "Established"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C65140", "When"], ["C171719", "Bictegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25454", "Combined"], ["C62355", "With"], ["C80137", "Known"], ["C159124", "GDC Treatment Outcome Terminology"], ["C52273", "ABCB1 wt Allele"], ["C48928", "And/Or"], ["C52276", "ABCG2 wt Allele"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C261", "Macrolide Antibiotic"], ["C406", "Cyclosporine"], ["C928", "Verapamil"], ["C65485", "Dronedarone"], ["C160484", "Glecaprevir/Pibrentasvir"], ["C163702", "Staphylococcal Enterotoxin E"], ["C48441", "Table"], ["C75330", "Below"], ["C171719", "Bictegravir"], ["C107576", "Solute Carrier Family 22 Member 2"], ["C53112", "POU2F2 wt Allele"], ["C16289", "Andorra"], ["C16289", "Andorra"], ["C894", "Toxin"], ["C50557", "Extrusion"], ["C105723", "ECOG Performance Status 1"], ["C113565", "SLC47A1 wt Allele"], ["C15263", "In Vitro"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C62355", "With"], ["C53112", "POU2F2 wt Allele"], ["C16289", "Andorra"], ["C113565", "SLC47A1 wt Allele"], ["C50196", "Substrate Device"], ["C61612", "Metformin"], ["C163546", "Double Immunodiffusion"], ["C25594", "Negation"], ["C20200", "Outcome"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C41130", "Significant"], ["C25533", "Increase"], ["C16727", "India"], ["C61612", "Metformin"], ["C49587", "Exposure Domain"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C106184", "May"], ["C16329", "Belgium"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C52874", "SPI1 wt Allele"], ["C53112", "POU2F2 wt Allele"], ["C16289", "Andorra"], ["C113565", "SLC47A1 wt Allele"], ["C171719", "Bictegravir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C75889", "PAX6 wt Allele"], ["C154898", "Inhibitor"], ["C43508", "Oregon"], ["C120268", "Inducer"], ["C52874", "SPI1 wt Allele"], ["C16480", "Cyprus"], ["C15744", "In Vivo"], ["C47509", "Emtricitabine"], ["C15263", "In Vitro"], ["C16289", "Andorra"], ["C123619", "Clinical Response"], ["C49663", "Pharmacokinetic Study"], ["C158286", "Drug-Drug Interaction Study"], ["C101282", "Have"], ["C62230", "Potential"], ["C64956", "For"], ["C16480", "Cyprus"], ["C61426", "Mediator"], ["C47509", "Emtricitabine"], ["C62355", "With"], ["C118472", "Other License Status"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C139301", "IPSS Risk Category Low"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C47509", "Emtricitabine"], ["C62355", "With"], ["C68869", "Are"], ["C25650", "Removed"], ["C158169", "Buyei Chinese"], ["C154405", "Active State"], ["C61294", "Tubular Structures Present"], ["C17119", "Cellular Secretion"], ["C106184", "May"], ["C25533", "Increase"], ["C52874", "SPI1 wt Allele"], ["C47509", "Emtricitabine"], ["C48928", "And/Or"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C142605", "Medicinal Product"], ["C25640", "Reduced"], ["C164220", "Renal Function"], ["C106184", "May"], ["C25533", "Increase"], ["C52874", "SPI1 wt Allele"], ["C47509", "Emtricitabine"], ["C148276", "Tenofovir Alafenamide"], ["C148276", "Tenofovir Alafenamide"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C158169", "Buyei Chinese"], ["C17746", "Multidrug Resistance Protein 1"], ["C52273", "ABCB1 wt Allele"], ["C16289", "Andorra"], ["C21253", "Broad Substrate Specificity ATP-Binding Cassette Transporter ABCG2"], ["C52276", "ABCG2 wt Allele"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C62355", "With"], ["C52273", "ABCB1 wt Allele"], ["C16289", "Andorra"], ["C52276", "ABCG2 wt Allele"], ["C120914", "Physical Activity Measurement"], ["C106184", "May"], ["C25552", "Lead"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16727", "India"], ["C148276", "Tenofovir Alafenamide"], ["C71731", "Material Absorption"], ["C61367", "Induction"], ["C52273", "ABCB1 wt Allele"], ["C120914", "Physical Activity Measurement"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C1408", "Rifabutin"], ["C341", "Carbamazepine"], ["C75368", "Phenobarbital Measurement"], ["C68869", "Are"], ["C41333", "Expected Adverse Event"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25640", "Reduced"], ["C71731", "Material Absorption"], ["C52874", "SPI1 wt Allele"], ["C148276", "Tenofovir Alafenamide"], ["C16727", "India"], ["C25640", "Reduced"], ["C13356", "Plasma"], ["C105891", "Able to Concentrate"], ["C52874", "SPI1 wt Allele"], ["C148276", "Tenofovir Alafenamide"], ["C106184", "May"], ["C25552", "Lead"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25559", "Loss"], ["C52874", "SPI1 wt Allele"], ["C38032", "Therapeutic Effect"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16289", "Andorra"], ["C18732", "Development"], ["C52874", "SPI1 wt Allele"], ["C41546", "Resistance Process"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C62355", "With"], ["C118472", "Other License Status"], ["C52273", "ABCB1 wt Allele"], ["C16289", "Andorra"], ["C52276", "ABCG2 wt Allele"], ["C106184", "May"], ["C25533", "Increase"], ["C71731", "Material Absorption"], ["C16289", "Andorra"], ["C13356", "Plasma"], ["C105891", "Able to Concentrate"], ["C52874", "SPI1 wt Allele"], ["C148276", "Tenofovir Alafenamide"], ["C148276", "Tenofovir Alafenamide"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C75889", "PAX6 wt Allele"], ["C154898", "Inhibitor"], ["C43508", "Oregon"], ["C120268", "Inducer"], ["C52874", "SPI1 wt Allele"], ["C107557", "CYP3A Gene Locus"], ["C15744", "In Vivo"], ["C118472", "Other License Status"], ["C94545", "Between"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C43508", "Oregon"], ["C25190", "Person"], ["C40565", "Component, LOINC Axis 1"], ["C42555", "Siemens"], ["C16289", "Andorra"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C68869", "Are"], ["C16727", "India"], ["C48441", "Table"], ["C105723", "ECOG Performance Status 1"], ["C75330", "Below"], ["C25533", "Increase"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C71344", "Associate of Science"], ["C25640", "Reduced"], ["C71344", "Associate of Science"], ["C16289", "Andorra"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C54126", "Delta"], ["C71344", "Associate of Science"], ["C64916", "All"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C71600", "Effect, Appearance"], ["C68869", "Are"], ["C105790", "Seventy"], ["C48441", "Table"], ["C105723", "ECOG Performance Status 1"], ["C94545", "Between"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C43508", "Oregon"], ["C25190", "Person"], ["C40565", "Component, LOINC Axis 1"], ["C42555", "Siemens"], ["C16289", "Andorra"], ["C118472", "Other License Status"], ["C142605", "Medicinal Product"], ["C158169", "Buyei Chinese"], ["C101302", "Therapeutic Area"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C50285", "Mechanism Device"], ["C52874", "SPI1 wt Allele"], ["C54216", "Interaction"], ["C25492", "Effect"], ["C92667", "SPARC wt Allele"], ["C142605", "Medicinal Product"], ["C181249", "Mean Based on Unspecified Calculation"], ["C48570", "Percent Unit"], ["C54126", "Delta"], ["C16727", "India"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C85579", "Cmin"], ["C25197", "Recommendation"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C62355", "With"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C94319", "Herbal"], ["C159109", "GDC Sample Type Terminology"], ["C42555", "Siemens"], ["C72523", "Hypericum erectum"], ["C158876", "Induction Therapy"], ["C52874", "SPI1 wt Allele"], ["C107557", "CYP3A Gene Locus"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C16289", "Andorra"], ["C52273", "ABCB1 wt Allele"], ["C54216", "Interaction"], ["C25594", "Negation"], ["C62355", "With"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C106184", "May"], ["C25640", "Reduced"], ["C171719", "Bictegravir"], ["C16289", "Andorra"], ["C29490", "Tenofovir"], ["C13356", "Plasma"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C62355", "With"], ["C159109", "GDC Sample Type Terminology"], ["C42555", "Siemens"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C37933", "Contraindicated"], ["C89272", "Due To"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C159109", "GDC Sample Type Terminology"], ["C42555", "Siemens"], ["C92667", "SPARC wt Allele"], ["C171719", "Bictegravir"], ["C40565", "Component, LOINC Axis 1"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C254", "Anti-Infective Agent"], ["C811", "Rifampin"], ["C16953", "Paraguay"], ["C16818", "Mammography"], ["C125004", "Once Daily"], ["C158876", "Induction Therapy"], ["C52874", "SPI1 wt Allele"], ["C107557", "CYP3A Gene Locus"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C16289", "Andorra"], ["C52273", "ABCB1 wt Allele"], ["C171719", "Bictegravir"], ["C64774", "Area Under Curve"], ["C160687", "Seventy Five"], ["C70918", "Cmax"], ["C126888", "Twenty Eight"], ["C54216", "Interaction"], ["C25594", "Negation"], ["C62355", "With"], ["C148276", "Tenofovir Alafenamide"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C811", "Rifampin"], ["C106184", "May"], ["C25640", "Reduced"], ["C29490", "Tenofovir"], ["C13356", "Plasma"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C37933", "Contraindicated"], ["C89272", "Due To"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C811", "Rifampin"], ["C92667", "SPARC wt Allele"], ["C171719", "Bictegravir"], ["C40565", "Component, LOINC Axis 1"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C1408", "Rifabutin"], ["C16645", "Greece"], ["C16818", "Mammography"], ["C125004", "Once Daily"], ["C158876", "Induction Therapy"], ["C52874", "SPI1 wt Allele"], ["C107557", "CYP3A Gene Locus"], ["C16289", "Andorra"], ["C52273", "ABCB1 wt Allele"], ["C171719", "Bictegravir"], ["C64774", "Area Under Curve"], ["C175628", "Thirty Eight"], ["C85579", "Cmin"], ["C188323", "Fifty Six"], ["C70918", "Cmax"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C54216", "Interaction"], ["C25594", "Negation"], ["C62355", "With"], ["C148276", "Tenofovir Alafenamide"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C1408", "Rifabutin"], ["C106184", "May"], ["C25640", "Reduced"], ["C148276", "Tenofovir Alafenamide"], ["C13356", "Plasma"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C89272", "Due To"], ["C41333", "Expected Adverse Event"], ["C25640", "Reduced"], ["C52874", "SPI1 wt Allele"], ["C148276", "Tenofovir Alafenamide"], ["C142605", "Medicinal Product"], ["C158169", "Buyei Chinese"], ["C101302", "Therapeutic Area"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C50285", "Mechanism Device"], ["C52874", "SPI1 wt Allele"], ["C54216", "Interaction"], ["C25492", "Effect"], ["C92667", "SPARC wt Allele"], ["C142605", "Medicinal Product"], ["C181249", "Mean Based on Unspecified Calculation"], ["C48570", "Percent Unit"], ["C54126", "Delta"], ["C16727", "India"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C85579", "Cmin"], ["C25197", "Recommendation"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C62355", "With"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C66516", "Rifapentine"], ["C158876", "Induction Therapy"], ["C52874", "SPI1 wt Allele"], ["C107557", "CYP3A Gene Locus"], ["C16289", "Andorra"], ["C52273", "ABCB1 wt Allele"], ["C54216", "Interaction"], ["C25594", "Negation"], ["C62355", "With"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C66516", "Rifapentine"], ["C106184", "May"], ["C25640", "Reduced"], ["C171719", "Bictegravir"], ["C16289", "Andorra"], ["C148276", "Tenofovir Alafenamide"], ["C13356", "Plasma"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C14220", "Human Immunodeficiency Virus 1"], ["C281", "Antiviral Agent"], ["C66872", "Atazanavir"], ["C16645", "Greece"], ["C16818", "Mammography"], ["C125004", "Once Daily"], ["C97360", "Cobicistat"], ["C129532", "One Hundred Fifty"], ["C16818", "Mammography"], ["C125004", "Once Daily"], ["C42791", "Inhibition"], ["C52874", "SPI1 wt Allele"], ["C107557", "CYP3A Gene Locus"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C16289", "Andorra"], ["C52273", "ABCB1 wt Allele"], ["C52276", "ABCG2 wt Allele"], ["C171719", "Bictegravir"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C66872", "Atazanavir"], ["C16765", "Jordan"], ["C16818", "Mammography"], ["C125004", "Once Daily"], ["C42791", "Inhibition"], ["C52874", "SPI1 wt Allele"], ["C107557", "CYP3A Gene Locus"], ["C16289", "Andorra"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C171719", "Bictegravir"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C189554", "Hepatitis C Virus Measurement"], ["C281", "Antiviral Agent"], ["C153378", "Ledipasvir/Sofosbuvir"], ["C182728", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 90"], ["C16818", "Mammography"], ["C16765", "Jordan"], ["C16818", "Mammography"], ["C125004", "Once Daily"], ["C171719", "Bictegravir"], ["C47509", "Emtricitabine"], ["C29490", "Tenofovir"], ["C171719", "Bictegravir"], ["C64774", "Area Under Curve"], ["C85579", "Cmin"], ["C70918", "Cmax"], ["C47509", "Emtricitabine"], ["C64774", "Area Under Curve"], ["C85579", "Cmin"], ["C70918", "Cmax"], ["C148276", "Tenofovir Alafenamide"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C129019", "Ledipasvir"], ["C64774", "Area Under Curve"], ["C85579", "Cmin"], ["C70918", "Cmax"], ["C101263", "Sofosbuvir"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C101263", "Sofosbuvir"], ["C61154", "Metabolite"], ["C20111", "South Georgia and the South Sandwich Islands"], ["C64774", "Area Under Curve"], ["C85579", "Cmin"], ["C70918", "Cmax"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C65137", "Upon"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C142605", "Medicinal Product"], ["C158169", "Buyei Chinese"], ["C101302", "Therapeutic Area"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C50285", "Mechanism Device"], ["C52874", "SPI1 wt Allele"], ["C54216", "Interaction"], ["C25492", "Effect"], ["C92667", "SPARC wt Allele"], ["C142605", "Medicinal Product"], ["C181249", "Mean Based on Unspecified Calculation"], ["C48570", "Percent Unit"], ["C54126", "Delta"], ["C16727", "India"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C85579", "Cmin"], ["C25197", "Recommendation"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C62355", "With"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C101263", "Sofosbuvir"], ["C152851", "Velpatasvir"], ["C152922", "Voxilaprevir"], ["C16765", "Jordan"], ["C105814", "One Hundred"], ["C105814", "One Hundred"], ["C105814", "One Hundred"], ["C64576", "Once"], ["C168156", "Chief Complaint is Present Daily"], ["C171719", "Bictegravir"], ["C47509", "Emtricitabine"], ["C148276", "Tenofovir Alafenamide"], ["C42791", "Inhibition"], ["C52874", "SPI1 wt Allele"], ["C52273", "ABCB1 wt Allele"], ["C52276", "ABCG2 wt Allele"], ["C171719", "Bictegravir"], ["C64774", "Area Under Curve"], ["C85579", "Cmin"], ["C70918", "Cmax"], ["C47509", "Emtricitabine"], ["C64774", "Area Under Curve"], ["C85579", "Cmin"], ["C70918", "Cmax"], ["C148276", "Tenofovir Alafenamide"], ["C64774", "Area Under Curve"], ["C175681", "Fifty Seven"], ["C70918", "Cmax"], ["C126888", "Twenty Eight"], ["C101263", "Sofosbuvir"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C101263", "Sofosbuvir"], ["C61154", "Metabolite"], ["C20111", "South Georgia and the South Sandwich Islands"], ["C64774", "Area Under Curve"], ["C85579", "Cmin"], ["C70918", "Cmax"], ["C152851", "Velpatasvir"], ["C64774", "Area Under Curve"], ["C85579", "Cmin"], ["C70918", "Cmax"], ["C152922", "Voxilaprevir"], ["C64774", "Area Under Curve"], ["C85579", "Cmin"], ["C70918", "Cmax"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C65137", "Upon"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C514", "Antifungal Agent"], ["C1707", "Voriconazole"], ["C16645", "Greece"], ["C16818", "Mammography"], ["C65134", "Twice"], ["C168156", "Chief Complaint is Present Daily"], ["C42791", "Inhibition"], ["C52874", "SPI1 wt Allele"], ["C107557", "CYP3A Gene Locus"], ["C171719", "Bictegravir"], ["C64774", "Area Under Curve"], ["C188325", "Sixty One"], ["C70918", "Cmax"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C65137", "Upon"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C1138", "Itraconazole"], ["C61500", "Posaconazole"], ["C42791", "Inhibition"], ["C52874", "SPI1 wt Allele"], ["C52273", "ABCB1 wt Allele"], ["C52276", "ABCG2 wt Allele"], ["C54216", "Interaction"], ["C25594", "Negation"], ["C62355", "With"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C1138", "Itraconazole"], ["C43508", "Oregon"], ["C61500", "Posaconazole"], ["C106184", "May"], ["C25533", "Increase"], ["C171719", "Bictegravir"], ["C13356", "Plasma"], ["C261", "Macrolide Antibiotic"], ["C28844", "Azithromycin"], ["C1054", "Clarithromycin"], ["C42791", "Inhibition"], ["C52874", "SPI1 wt Allele"], ["C52273", "ABCB1 wt Allele"], ["C54216", "Interaction"], ["C25594", "Negation"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C28844", "Azithromycin"], ["C43508", "Oregon"], ["C1054", "Clarithromycin"], ["C106184", "May"], ["C25533", "Increase"], ["C171719", "Bictegravir"], ["C13356", "Plasma"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C89272", "Due To"], ["C62230", "Potential"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C92667", "SPARC wt Allele"], ["C171719", "Bictegravir"], ["C40565", "Component, LOINC Axis 1"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C69122", "Ten"], ["C142605", "Medicinal Product"], ["C158169", "Buyei Chinese"], ["C101302", "Therapeutic Area"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C50285", "Mechanism Device"], ["C52874", "SPI1 wt Allele"], ["C54216", "Interaction"], ["C25492", "Effect"], ["C92667", "SPARC wt Allele"], ["C142605", "Medicinal Product"], ["C181249", "Mean Based on Unspecified Calculation"], ["C48570", "Percent Unit"], ["C54126", "Delta"], ["C16727", "India"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C85579", "Cmin"], ["C25197", "Recommendation"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C62355", "With"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C264", "Anticonvulsant Agent"], ["C341", "Carbamazepine"], ["C25516", "From"], ["C105814", "One Hundred"], ["C16818", "Mammography"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16645", "Greece"], ["C16818", "Mammography"], ["C64496", "Twice Daily"], ["C47509", "Emtricitabine"], ["C29490", "Tenofovir"], ["C158876", "Induction Therapy"], ["C52874", "SPI1 wt Allele"], ["C107557", "CYP3A Gene Locus"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C16289", "Andorra"], ["C52273", "ABCB1 wt Allele"], ["C148276", "Tenofovir Alafenamide"], ["C64774", "Area Under Curve"], ["C186754", "Human Papillomavirus-54"], ["C70918", "Cmax"], ["C175681", "Fifty Seven"], ["C54216", "Interaction"], ["C25594", "Negation"], ["C62355", "With"], ["C171719", "Bictegravir"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C341", "Carbamazepine"], ["C106184", "May"], ["C25640", "Reduced"], ["C171719", "Bictegravir"], ["C13356", "Plasma"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C47643", "Oxcarbazepine"], ["C75368", "Phenobarbital Measurement"], ["C741", "Phenytoin"], ["C158876", "Induction Therapy"], ["C52874", "SPI1 wt Allele"], ["C107557", "CYP3A Gene Locus"], ["C28288", "UDP-Glucuronosyltransferase 1-1"], ["C16289", "Andorra"], ["C52273", "ABCB1 wt Allele"], ["C54216", "Interaction"], ["C25594", "Negation"], ["C62355", "With"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C47643", "Oxcarbazepine"], ["C75368", "Phenobarbital Measurement"], ["C43508", "Oregon"], ["C741", "Phenytoin"], ["C106184", "May"], ["C25640", "Reduced"], ["C171719", "Bictegravir"], ["C16289", "Andorra"], ["C29490", "Tenofovir"], ["C13356", "Plasma"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C29633", "Antacid Preparation"], ["C1505", "Dietary Supplement"], ["C16289", "Andorra"], ["C70815", "Buffer"], ["C29239", "Magnesium"], ["C79873", "Contain"], ["C29701", "Anti-ulcer Agent"], ["C42994", "Suspension Dosage Form"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C16816", "Mali"], ["C48440", "Single"], ["C171719", "Bictegravir"], ["C40483", "Chelating Activity"], ["C62355", "With"], ["C171719", "Bictegravir"], ["C29701", "Anti-ulcer Agent"], ["C42994", "Suspension Dosage Form"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25529", "Hour"], ["C25629", "Prior"], ["C64774", "Area Under Curve"], ["C188320", "Fifty Two"], ["C70918", "Cmax"], ["C103004", "Human Papillomavirus-58"], ["C171719", "Bictegravir"], ["C29701", "Anti-ulcer Agent"], ["C42994", "Suspension Dosage Form"], ["C38008", "Post"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25529", "Hour"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C171719", "Bictegravir"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C64774", "Area Under Curve"], ["C105791", "Seventy Nine"], ["C70918", "Cmax"], ["C105710", "Karnofsky Performance Status 80"], ["C171719", "Bictegravir"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C67010", "With Food"], ["C64774", "Area Under Curve"], ["C178277", "Forty Seven"], ["C70918", "Cmax"], ["C105796", "Forty Nine"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C62355", "With"], ["C1505", "Dietary Supplement"], ["C79873", "Contain"], ["C29239", "Magnesium"], ["C48928", "And/Or"], ["C89272", "Due To"], ["C41333", "Expected Adverse Event"], ["C25640", "Reduced"], ["C52874", "SPI1 wt Allele"], ["C171719", "Bictegravir"], ["C49587", "Exposure Domain"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25529", "Hour"], ["C201357", "Before Timing Type"], ["C43508", "Oregon"], ["C62355", "With"], ["C62695", "Food"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25529", "Hour"], ["C38008", "Post"], ["C29633", "Antacid Preparation"], ["C79873", "Contain"], ["C29239", "Magnesium"], ["C48928", "And/Or"], ["C61763", "Ferrous Fumarate"], ["C16655", "Guinea"], ["C16818", "Mammography"], ["C48440", "Single"], ["C25488", "Dose"], ["C171719", "Bictegravir"], ["C40483", "Chelating Activity"], ["C62355", "With"], ["C171719", "Bictegravir"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C64774", "Area Under Curve"], ["C188327", "Sixty Three"], ["C70918", "Cmax"], ["C188333", "Seventy One"], ["C171719", "Bictegravir"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C67010", "With Food"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C113663", "Twenty Five"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C158997", "GDC Analyte Type Terminology"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25529", "Hour"], ["C201357", "Before Timing Type"], ["C68256", "Dietary Iron"], ["C1505", "Dietary Supplement"], ["C43508", "Oregon"], ["C25701", "Taken"], ["C63802", "Together"], ["C67010", "With Food"], ["C332", "Calcium Carbonate"], ["C105723", "ECOG Performance Status 1"], ["C159711", "Two Hundred"], ["C16818", "Mammography"], ["C48440", "Single"], ["C25488", "Dose"], ["C171719", "Bictegravir"], ["C40483", "Chelating Activity"], ["C62355", "With"], ["C171719", "Bictegravir"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C64774", "Area Under Curve"], ["C102996", "Human Papillomavirus-33"], ["C70918", "Cmax"], ["C175676", "Forty Two"], ["C171719", "Bictegravir"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C67010", "With Food"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16289", "Andorra"], ["C64488", "Calcium Measurement"], ["C79873", "Contain"], ["C1505", "Dietary Supplement"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C63802", "Together"], ["C25718", "Without"], ["C159124", "GDC Treatment Outcome Terminology"], ["C62695", "Food"], ["C113425", "Eleven"], ["C142605", "Medicinal Product"], ["C158169", "Buyei Chinese"], ["C101302", "Therapeutic Area"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C50285", "Mechanism Device"], ["C52874", "SPI1 wt Allele"], ["C54216", "Interaction"], ["C25492", "Effect"], ["C92667", "SPARC wt Allele"], ["C142605", "Medicinal Product"], ["C181249", "Mean Based on Unspecified Calculation"], ["C48570", "Percent Unit"], ["C54126", "Delta"], ["C16727", "India"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C85579", "Cmin"], ["C25197", "Recommendation"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C62355", "With"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C848", "Sucralfate"], ["C40483", "Chelating Activity"], ["C62355", "With"], ["C54216", "Interaction"], ["C25594", "Negation"], ["C62355", "With"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C106184", "May"], ["C25640", "Reduced"], ["C171719", "Bictegravir"], ["C13356", "Plasma"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C74691", "Antidepressant Measurement"], ["C61939", "Sertraline"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C48440", "Single"], ["C25488", "Dose"], ["C29490", "Tenofovir"], ["C148276", "Tenofovir Alafenamide"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C61939", "Sertraline"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C54216", "Interaction"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C41333", "Expected Adverse Event"], ["C62355", "With"], ["C171719", "Bictegravir"], ["C16289", "Andorra"], ["C47509", "Emtricitabine"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C65137", "Upon"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C406", "Cyclosporine"], ["C38276", "Intravenous Route of Administration"], ["C43508", "Oregon"], ["C38288", "Oral Route of Administration"], ["C52273", "ABCB1 wt Allele"], ["C42791", "Inhibition"], ["C54216", "Interaction"], ["C25594", "Negation"], ["C62355", "With"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C406", "Cyclosporine"], ["C38276", "Intravenous Route of Administration"], ["C43508", "Oregon"], ["C38288", "Oral Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C41333", "Expected Adverse Event"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25533", "Increase"], ["C13356", "Plasma"], ["C52874", "SPI1 wt Allele"], ["C49636", "Both"], ["C171719", "Bictegravir"], ["C16289", "Andorra"], ["C29490", "Tenofovir"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C406", "Cyclosporine"], ["C38276", "Intravenous Route of Administration"], ["C43508", "Oregon"], ["C38288", "Oral Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C198613", "CFI wt Allele"], ["C61517", "Combination"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C123619", "Clinical Response"], ["C16289", "Andorra"], ["C28226", "Biological"], ["C61256", "Monitoring"], ["C25225", "Renal"], ["C25518", "Function"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C25311", "Oral"], ["C29711", "Anti-diabetic Agent"], ["C61612", "Metformin"], ["C16876", "Montserrat"], ["C16818", "Mammography"], ["C64496", "Twice Daily"], ["C171719", "Bictegravir"], ["C47509", "Emtricitabine"], ["C148276", "Tenofovir Alafenamide"], ["C42791", "Inhibition"], ["C52874", "SPI1 wt Allele"], ["C53112", "POU2F2 wt Allele"], ["C113565", "SLC47A1 wt Allele"], ["C61612", "Metformin"], ["C64774", "Area Under Curve"], ["C105798", "Thirty Nine"], ["C85579", "Cmin"], ["C175626", "Thirty Six"], ["C70918", "Cmax"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C65137", "Upon"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C12801", "Tissue"], ["C164220", "Renal Function"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C25225", "Renal"], ["C21055", "Impairment"], ["C49070", "Closed"], ["C61256", "Monitoring"], ["C16329", "Belgium"], ["C65140", "When"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C171719", "Bictegravir"], ["C62355", "With"], ["C61612", "Metformin"], ["C89272", "Due To"], ["C164135", "Increased"], ["C17102", "Risk"], ["C64956", "For"], ["C37906", "Acidosis"], ["C16727", "India"], ["C16960", "Patient"], ["C76246", "Blood Group A"], ["C25488", "Dose"], ["C49157", "Adjustment"], ["C52874", "SPI1 wt Allele"], ["C61612", "Metformin"], ["C16329", "Belgium"], ["C198613", "CFI wt Allele"], ["C25652", "Requirement"], ["C389", "Oral Contraceptive"], ["C66245", "Norgestimate"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C17266", "Congo, the Democratic Republic of the"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C69123", "Two Hundred Fifty"], ["C16818", "Mammography"], ["C64576", "Once"], ["C168156", "Chief Complaint is Present Daily"], ["C486", "Ethinyl Estradiol"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C16818", "Mammography"], ["C125004", "Once Daily"], ["C66243", "Norelgestromin"], ["C64774", "Area Under Curve"], ["C85579", "Cmin"], ["C70918", "Cmax"], ["C703", "Norgestrel"], ["C64774", "Area Under Curve"], ["C85579", "Cmin"], ["C70918", "Cmax"], ["C486", "Ethinyl Estradiol"], ["C64774", "Area Under Curve"], ["C85579", "Cmin"], ["C70918", "Cmax"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C65137", "Upon"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C66245", "Norgestimate"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C17266", "Congo, the Democratic Republic of the"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C69123", "Two Hundred Fifty"], ["C16818", "Mammography"], ["C64576", "Once"], ["C168156", "Chief Complaint is Present Daily"], ["C486", "Ethinyl Estradiol"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C16818", "Mammography"], ["C125004", "Once Daily"], ["C47509", "Emtricitabine"], ["C29490", "Tenofovir"], ["C113426", "Twelve"], ["C142605", "Medicinal Product"], ["C158169", "Buyei Chinese"], ["C101302", "Therapeutic Area"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C50285", "Mechanism Device"], ["C52874", "SPI1 wt Allele"], ["C54216", "Interaction"], ["C25492", "Effect"], ["C92667", "SPARC wt Allele"], ["C142605", "Medicinal Product"], ["C181249", "Mean Based on Unspecified Calculation"], ["C48570", "Percent Unit"], ["C54126", "Delta"], ["C16727", "India"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C85579", "Cmin"], ["C25197", "Recommendation"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C62355", "With"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C139083", "Midazolam Measurement"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16818", "Mammography"], ["C25311", "Oral"], ["C154604", "Syrup Dosage Form Category"], ["C48440", "Single"], ["C25488", "Dose"], ["C171719", "Bictegravir"], ["C47509", "Emtricitabine"], ["C148276", "Tenofovir Alafenamide"], ["C139083", "Midazolam Measurement"], ["C64774", "Area Under Curve"], ["C70918", "Cmax"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C65137", "Upon"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C105723", "ECOG Performance Status 1"], ["C45319", "Study Object"], ["C154196", "Washo Language"], ["C171719", "Bictegravir"], ["C160687", "Seventy Five"], ["C16818", "Mammography"], ["C48440", "Single"], ["C25488", "Dose"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C45319", "Study Object"], ["C154196", "Washo Language"], ["C171719", "Bictegravir"], ["C157538", "Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C160687", "Seventy Five"], ["C159711", "Two Hundred"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C125004", "Once Daily"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C45319", "Study Object"], ["C62355", "With"], ["C25406", "Additional"], ["C152922", "Voxilaprevir"], ["C105814", "One Hundred"], ["C16818", "Mammography"], ["C159124", "GDC Treatment Outcome Terminology"], ["C152922", "Voxilaprevir"], ["C41333", "Expected Adverse Event"], ["C16727", "India"], ["C189554", "Hepatitis C Virus Measurement"], ["C189188", "Infected with SARS-CoV-2"], ["C16960", "Patient"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C45319", "Study Object"], ["C154196", "Washo Language"], ["C157538", "Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C159711", "Two Hundred"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C125004", "Once Daily"], ["C163771", "Illness Intrusiveness Rating 5"], ["C82868", "Maximum Value Derivation Technique"], ["C53294", "Pharmaceutical Strength"], ["C29701", "Anti-ulcer Agent"], ["C182398", "Contained Diffuse Intrinsic Pontine Glioma Morphology Imaging Finding"], ["C105710", "Karnofsky Performance Status 80"], ["C16818", "Mammography"], ["C105710", "Karnofsky Performance Status 80"], ["C16818", "Mammography"], ["C29262", "Magnesium Hydroxide"], ["C16289", "Andorra"], ["C66839", "Eight"], ["C16818", "Mammography"], ["C29453", "Simethicone"], ["C103452", "Per Milliliter"], ["C172979", "Fear Score 6"], ["C45319", "Study Object"], ["C154196", "Washo Language"], ["C157537", "Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C129532", "One Hundred Fifty"], ["C129532", "One Hundred Fifty"], ["C159711", "Two Hundred"], ["C69122", "Ten"], ["C16818", "Mammography"], ["C64576", "Once"], ["C168156", "Chief Complaint is Present Daily"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C54708", "Drug Interaction"], ["C62355", "With"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C43508", "Oregon"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C41130", "Significant"], ["C459", "Medication"], ["C68869", "Are"], ["C41333", "Expected Adverse Event"], ["C62355", "With"], ["C61635", "Amlodipine"], ["C61527", "Atorvastatin"], ["C61656", "Buprenorphine"], ["C47502", "Drospirenone"], ["C29044", "Famciclovir"], ["C29045", "Famotidine"], ["C61767", "Fluticasone"], ["C62044", "Methadone"], ["C62054", "Naloxone"], ["C74598", "Omeprazole Sodium"], ["C43508", "Oregon"], ["C66523", "Rosuvastatin"]], "rxnorm.pregnancy": [["1999668", "Biktarvy"], ["117466", "tenofovir"], ["300195", "tenofovir disoproxil"], ["68244", "lamivudine"], ["141400", "adefovir dipivoxil"], ["1999660", "bictegravir"], ["1999660", "bictegravir"], ["1999660", "bictegravir"], ["9384", "rifampin"], ["1999660", "bictegravir"], ["1999668", "Biktarvy"], ["1999660", "bictegravir"], ["343047", "atazanavir"], ["1999660", "bictegravir"], ["1999660", "bictegravir"], ["1999660", "bictegravir"], ["11170", "verapamil"], ["233698", "dronedarone"], ["1940635", "glecaprevir"], ["1940636", "pibrentasvir"], ["1999660", "bictegravir"], ["1999668", "Biktarvy"], ["6809", "metformin"], ["6809", "metformin"], ["1999668", "Biktarvy"], ["1999660", "bictegravir"], ["276237", "emtricitabine"], ["276237", "emtricitabine"], ["276237", "emtricitabine"], ["276237", "emtricitabine"], ["276237", "emtricitabine"], ["1721603", "tenofovir alafenamide"], ["1721603", "tenofovir alafenamide"], ["1999668", "Biktarvy"], ["T052", "Activity"], ["6260", "lead"], ["1721603", "tenofovir alafenamide"], ["T052", "Activity"], ["55672", "rifabutin"], ["2002", "carbamazepine"], ["8134", "phenobarbital"], ["1721603", "tenofovir alafenamide"], ["1721603", "tenofovir alafenamide"], ["6260", "lead"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1721603", "tenofovir alafenamide"], ["1721603", "tenofovir alafenamide"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["1999660", "bictegravir"], ["117466", "tenofovir"], ["1999660", "bictegravir"], ["1999668", "Biktarvy"], ["9384", "rifampin"], ["1999660", "bictegravir"], ["1721603", "tenofovir alafenamide"], ["9384", "rifampin"], ["117466", "tenofovir"], ["9384", "rifampin"], ["1999660", "bictegravir"], ["1999668", "Biktarvy"], ["55672", "rifabutin"], ["1999660", "bictegravir"], ["1721603", "tenofovir alafenamide"], ["55672", "rifabutin"], ["1721603", "tenofovir alafenamide"], ["1721603", "tenofovir alafenamide"], ["1999668", "Biktarvy"], ["35617", "rifapentine"], ["1999668", "Biktarvy"], ["35617", "rifapentine"], ["1999660", "bictegravir"], ["1721603", "tenofovir alafenamide"], ["343047", "atazanavir"], ["1306284", "cobicistat"], ["1999660", "bictegravir"], ["343047", "atazanavir"], ["1999660", "bictegravir"], ["1491863", "hepatitis C virus"], ["1591922", "ledipasvir"], ["1484911", "sofosbuvir"], ["1999660", "bictegravir"], ["276237", "emtricitabine"], ["117466", "tenofovir"], ["1999660", "bictegravir"], ["276237", "emtricitabine"], ["1721603", "tenofovir alafenamide"], ["1591922", "ledipasvir"], ["1484911", "sofosbuvir"], ["1484911", "sofosbuvir"], ["1999668", "Biktarvy"], ["1484911", "sofosbuvir"], ["1799206", "velpatasvir"], ["1939323", "voxilaprevir"], ["1999660", "bictegravir"], ["276237", "emtricitabine"], ["1721603", "tenofovir alafenamide"], ["1999660", "bictegravir"], ["276237", "emtricitabine"], ["1721603", "tenofovir alafenamide"], ["1484911", "sofosbuvir"], ["1484911", "sofosbuvir"], ["1799206", "velpatasvir"], ["1939323", "voxilaprevir"], ["121243", "voriconazole"], ["1999660", "bictegravir"], ["28031", "itraconazole"], ["282446", "posaconazole"], ["1999668", "Biktarvy"], ["28031", "itraconazole"], ["282446", "posaconazole"], ["1999660", "bictegravir"], ["18631", "azithromycin"], ["21212", "clarithromycin"], ["18631", "azithromycin"], ["21212", "clarithromycin"], ["1999660", "bictegravir"], ["1999660", "bictegravir"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["2002", "carbamazepine"], ["276237", "emtricitabine"], ["117466", "tenofovir"], ["1721603", "tenofovir alafenamide"], ["1999660", "bictegravir"], ["2002", "carbamazepine"], ["1999660", "bictegravir"], ["32624", "oxcarbazepine"], ["8134", "phenobarbital"], ["8183", "phenytoin"], ["1999668", "Biktarvy"], ["32624", "oxcarbazepine"], ["8134", "phenobarbital"], ["8183", "phenytoin"], ["1999660", "bictegravir"], ["117466", "tenofovir"], ["6574", "magnesium"], ["1999660", "bictegravir"], ["1999660", "bictegravir"], ["1999660", "bictegravir"], ["1999660", "bictegravir"], ["1999660", "bictegravir"], ["T168", "Food"], ["1999668", "Biktarvy"], ["6574", "magnesium"], ["1999660", "bictegravir"], ["1999668", "Biktarvy"], ["T168", "Food"], ["6574", "magnesium"], ["24941", "ferrous fumarate"], ["1999660", "bictegravir"], ["1999660", "bictegravir"], ["1999660", "bictegravir"], ["T168", "Food"], ["1999668", "Biktarvy"], ["90176", "iron"], ["T168", "Food"], ["1897", "calcium carbonate"], ["1999660", "bictegravir"], ["1999660", "bictegravir"], ["1999660", "bictegravir"], ["T168", "Food"], ["1999668", "Biktarvy"], ["1895", "calcium"], ["T168", "Food"], ["1999668", "Biktarvy"], ["10156", "sucralfate"], ["1999668", "Biktarvy"], ["1999660", "bictegravir"], ["36437", "sertraline"], ["117466", "tenofovir"], ["1721603", "tenofovir alafenamide"], ["36437", "sertraline"], ["1999660", "bictegravir"], ["276237", "emtricitabine"], ["1999668", "Biktarvy"], ["1999660", "bictegravir"], ["117466", "tenofovir"], ["6809", "metformin"], ["1999660", "bictegravir"], ["276237", "emtricitabine"], ["1721603", "tenofovir alafenamide"], ["6809", "metformin"], ["1999660", "bictegravir"], ["6809", "metformin"], ["6809", "metformin"], ["31994", "norgestimate"], ["326374", "norelgestromin"], ["7518", "norgestrel"], ["31994", "norgestimate"], ["276237", "emtricitabine"], ["117466", "tenofovir"], ["1999668", "Biktarvy"], ["6960", "midazolam"], ["1999660", "bictegravir"], ["276237", "emtricitabine"], ["1721603", "tenofovir alafenamide"], ["6960", "midazolam"], ["1999660", "bictegravir"], ["1999660", "bictegravir"], ["276237", "emtricitabine"], ["1721603", "tenofovir alafenamide"], ["1939324", "voxilaprevir 100 MG"], ["1939323", "voxilaprevir"], ["276237", "emtricitabine"], ["1721603", "tenofovir alafenamide"], ["612", "aluminum hydroxide"], ["6581", "magnesium hydroxide"], ["9796", "simethicone"], ["1306286", "elvitegravir"], ["1306284", "cobicistat"], ["276237", "emtricitabine"], ["1721603", "tenofovir alafenamide"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["17767", "amlodipine"], ["83367", "atorvastatin"], ["1819", "buprenorphine"], ["11636", "drospirenone"], ["68099", "famciclovir"], ["4278", "famotidine"], ["41126", "fluticasone"], ["6813", "methadone"], ["7242", "naloxone"], ["7646", "omeprazole"], ["301542", "rosuvastatin"]], "loinc.pregnancy": [["LA19974-7", "Performed"], ["LA22004-8", "IN"], ["LA21291-2", "Not"], ["MTHU015506", "Tenofovir"], ["MTHU015506", "Tenofovir"], ["MTHU060537", "lamiVUDine"], ["LA22025-3", "OR"], ["MTHU013860", "Adefovir"], ["LP94823-9", "Treatment"], ["LP266919-2", "Infection"], ["MTHU059747", "Bictegravir"], ["MTHU059747", "Bictegravir"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LA21996-6", "CO"], ["MTHU059747", "Bictegravir"], ["LA14331-5", "Both"], ["LA22025-3", "OR"], ["LP15241-0", "S"], ["LA14161-6", "May"], ["LA32049-1", "Decrease"], ["LP7479-1", "Plasma"], ["MTHU059747", "Bictegravir"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP263807-2", "Therapeutic"], ["LP6857-9", "Resistance"], ["LA21996-6", "CO"], ["LP200075-2", "IS"], ["LA4216-3", "Contraindicated"], ["LP20592-9", "4"], ["LP20591-1", "3"], ["LA21996-6", "CO"], ["MTHU059747", "Bictegravir"], ["LA14331-5", "Both"], ["LP35785-2", "Atazanavir"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["LP7479-1", "Plasma"], ["MTHU059747", "Bictegravir"], ["LA21996-6", "CO"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["MTHU059747", "Bictegravir"], ["LP200075-2", "IS"], ["LA14331-5", "Both"], ["LP17763-1", "A"], ["LP15232-9", "P"], ["LP17763-1", "A"], ["LP7787-7", "Clinical"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LP200075-2", "IS"], ["MTHU059747", "Bictegravir"], ["LP200075-2", "IS"], ["LA30596-3", "Combined"], ["LP15232-9", "P"], ["LA22025-3", "OR"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP16307-8", "Verapamil"], ["LP343292-1", "Glecaprevir"], ["LP343295-4", "Pibrentasvir"], ["LA14987-4", "Below"], ["MTHU059747", "Bictegravir"], ["MTHU000002", "Clinical Class"], ["LP71001-9", "OCT2"], ["LA6112-2", "1"], ["LA22004-8", "IN"], ["LA21996-6", "CO"], ["LP71001-9", "OCT2"], ["MTHU060554", "metFORMIN"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA28474-7", "Significant"], ["LA32048-3", "Increase"], ["LA22004-8", "IN"], ["MTHU060554", "metFORMIN"], ["LA14161-6", "May"], ["LA21996-6", "CO"], ["LP71001-9", "OCT2"], ["MTHU059747", "Bictegravir"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["MTHU018643", "Emtricitabine"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LA20274-9", "Drug-drug"], ["MTHU018643", "Emtricitabine"], ["MTHU029809", "Other"], ["LP200075-2", "IS"], ["LA9194-7", "Low"], ["LA21996-6", "CO"], ["MTHU018643", "Emtricitabine"], ["LA16666-2", "Active"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["MTHU018643", "Emtricitabine"], ["LA22025-3", "OR"], ["LA21996-6", "CO"], ["LA32049-1", "Decrease"], ["LP31398-8", "Renal function"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["MTHU018643", "Emtricitabine"], ["MTHU015506", "Tenofovir"], ["MTHU015506", "Tenofovir"], ["LP200075-2", "IS"], ["LP15232-9", "P"], ["LP15232-9", "P"], ["LA14283-8", "Breast cancer"], ["LP6857-9", "Resistance"], ["LP15838-3", "Protein"], ["LA21996-6", "CO"], ["LP15232-9", "P"], ["LP72045-5", "Activity"], ["LA14161-6", "May"], ["LP14259-3", "Lead"], ["LA22004-8", "IN"], ["MTHU015506", "Tenofovir"], ["LP15232-9", "P"], ["LP72045-5", "Activity"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["MTHU006676", "Rifabutin"], ["LP16061-1", "carBAMazepine"], ["MTHU060452", "PHENobarbital"], ["LA32049-1", "Decrease"], ["MTHU015506", "Tenofovir"], ["LA22004-8", "IN"], ["LA24378-4", "Decreased"], ["LP7479-1", "Plasma"], ["LP6194-7", "Concentration"], ["MTHU015506", "Tenofovir"], ["LA14161-6", "May"], ["LP14259-3", "Lead"], ["LP263807-2", "Therapeutic"], ["LP6857-9", "Resistance"], ["LA21996-6", "CO"], ["MTHU029809", "Other"], ["LP15232-9", "P"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["LP7479-1", "Plasma"], ["LP6194-7", "Concentration"], ["MTHU015506", "Tenofovir"], ["MTHU015506", "Tenofovir"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["MTHU029809", "Other"], ["LA22025-3", "OR"], ["LA12070-1", "Individual"], ["LP15241-0", "S"], ["LA21996-6", "CO"], ["LA22004-8", "IN"], ["LA6112-2", "1"], ["LA14987-4", "Below"], ["LA32048-3", "Increase"], ["LP200075-2", "IS"], ["LA32049-1", "Decrease"], ["LA64-1", "No change"], ["LA18187-7", "All"], ["LA32-8", "No"], ["LA15250-6", "70%"], ["LA6112-2", "1"], ["LA22025-3", "OR"], ["LA12070-1", "Individual"], ["LP15241-0", "S"], ["MTHU029809", "Other"], ["LP263807-2", "Therapeutic"], ["LA15097-1", "Possible"], ["LP6971-8", "mean"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["LP111410-9", "Recommendation"], ["LA21996-6", "CO"], ["LP15241-0", "S"], ["LP15232-9", "P"], ["LA21291-2", "Not"], ["MTHU036318", "Components"], ["LA21996-6", "CO"], ["LA14161-6", "May"], ["LA32049-1", "Decrease"], ["MTHU059747", "Bictegravir"], ["MTHU015506", "Tenofovir"], ["LP7479-1", "Plasma"], ["LA21996-6", "CO"], ["LP15241-0", "S"], ["LP200075-2", "IS"], ["LA4216-3", "Contraindicated"], ["LP15241-0", "S"], ["MTHU059747", "Bictegravir"], ["LA14010-5", "600"], ["LP15217-0", "Mg"], ["LA6305-2", "Once daily"], ["LP15232-9", "P"], ["MTHU059747", "Bictegravir"], ["LA21291-2", "Not"], ["MTHU015506", "Tenofovir"], ["LA21996-6", "CO"], ["LA14161-6", "May"], ["LA32049-1", "Decrease"], ["MTHU015506", "Tenofovir"], ["LP7479-1", "Plasma"], ["LA21996-6", "CO"], ["LP200075-2", "IS"], ["LA4216-3", "Contraindicated"], ["MTHU059747", "Bictegravir"], ["MTHU006676", "Rifabutin"], ["LP15217-0", "Mg"], ["LA6305-2", "Once daily"], ["LP15232-9", "P"], ["MTHU059747", "Bictegravir"], ["LA15245-6", "20%"], ["LA21291-2", "Not"], ["MTHU015506", "Tenofovir"], ["LA21996-6", "CO"], ["MTHU006676", "Rifabutin"], ["LA14161-6", "May"], ["LA32049-1", "Decrease"], ["MTHU015506", "Tenofovir"], ["LP7479-1", "Plasma"], ["LA21996-6", "CO"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA32049-1", "Decrease"], ["MTHU015506", "Tenofovir"], ["LP263807-2", "Therapeutic"], ["LA15097-1", "Possible"], ["LP6971-8", "mean"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["LP111410-9", "Recommendation"], ["LA21996-6", "CO"], ["LP189348-8", "Rifapentine"], ["LP15232-9", "P"], ["LA21291-2", "Not"], ["MTHU036318", "Components"], ["LA21996-6", "CO"], ["LP189348-8", "Rifapentine"], ["LA14161-6", "May"], ["LA32049-1", "Decrease"], ["MTHU059747", "Bictegravir"], ["MTHU015506", "Tenofovir"], ["LP7479-1", "Plasma"], ["LA21996-6", "CO"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LP183501-8", "HIV"], ["LA6112-2", "1"], ["LP35785-2", "Atazanavir"], ["LP15217-0", "Mg"], ["LA6305-2", "Once daily"], ["LP15217-0", "Mg"], ["LA6305-2", "Once daily"], ["LP15232-9", "P"], ["MTHU059747", "Bictegravir"], ["LA21996-6", "CO"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LP35785-2", "Atazanavir"], ["LA14008-9", "400"], ["LP15217-0", "Mg"], ["LA6305-2", "Once daily"], ["MTHU059747", "Bictegravir"], ["LG32754-0", "Hepatitis C virus"], ["LP220249-9", "Ledipasvir"], ["MTHU054459", "Sofosbuvir"], ["LA28891-2", "90"], ["LP15217-0", "Mg"], ["LA14008-9", "400"], ["LP15217-0", "Mg"], ["LA6305-2", "Once daily"], ["MTHU059747", "Bictegravir"], ["MTHU018643", "Emtricitabine"], ["MTHU015506", "Tenofovir"], ["MTHU059747", "Bictegravir"], ["MTHU018643", "Emtricitabine"], ["MTHU015506", "Tenofovir"], ["LP220249-9", "Ledipasvir"], ["MTHU054459", "Sofosbuvir"], ["MTHU054459", "Sofosbuvir"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA21996-6", "CO"], ["LP263807-2", "Therapeutic"], ["LA15097-1", "Possible"], ["LP6971-8", "mean"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["LP111410-9", "Recommendation"], ["LA21996-6", "CO"], ["MTHU054459", "Sofosbuvir"], ["MTHU054608", "Velpatasvir"], ["LP343299-6", "Voxilaprevir"], ["LA14008-9", "400"], ["LA19244-5", "100"], ["LA19244-5", "100"], ["LA30923-9", "+"], ["LA19244-5", "100"], ["LA14312-5", "Once"], ["LA14435-4", "Daily"], ["MTHU059747", "Bictegravir"], ["MTHU018643", "Emtricitabine"], ["MTHU015506", "Tenofovir"], ["LP15232-9", "P"], ["MTHU059747", "Bictegravir"], ["MTHU018643", "Emtricitabine"], ["MTHU015506", "Tenofovir"], ["MTHU054459", "Sofosbuvir"], ["MTHU054459", "Sofosbuvir"], ["MTHU054608", "Velpatasvir"], ["LP343299-6", "Voxilaprevir"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA21996-6", "CO"], ["LP31435-8", "Antifungals"], ["LP30491-2", "Voriconazole"], ["LP15217-0", "Mg"], ["LA14664-9", "Twice"], ["LA14435-4", "Daily"], ["MTHU059747", "Bictegravir"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA21996-6", "CO"], ["MTHU002298", "Itraconazole"], ["LP71165-2", "Posaconazole"], ["LP15232-9", "P"], ["LA21291-2", "Not"], ["MTHU036318", "Components"], ["LA21996-6", "CO"], ["MTHU002298", "Itraconazole"], ["LA22025-3", "OR"], ["LP71165-2", "Posaconazole"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["MTHU059747", "Bictegravir"], ["LP7479-1", "Plasma"], ["LP16090-0", "Azithromycin"], ["LP15406-9", "Clarithromycin"], ["LP15232-9", "P"], ["LA21291-2", "Not"], ["LA21996-6", "CO"], ["LP16090-0", "Azithromycin"], ["LA22025-3", "OR"], ["LP15406-9", "Clarithromycin"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["MTHU059747", "Bictegravir"], ["LP7479-1", "Plasma"], ["LP200075-2", "IS"], ["MTHU059747", "Bictegravir"], ["LA13942-0", "10"], ["LP263807-2", "Therapeutic"], ["LA15097-1", "Possible"], ["LP6971-8", "mean"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["LP111410-9", "Recommendation"], ["LA21996-6", "CO"], ["MTHU006781", "Anticonvulsants"], ["LP16061-1", "carBAMazepine"], ["LA19244-5", "100"], ["LP15217-0", "Mg"], ["LP15217-0", "Mg"], ["LA14664-9", "Twice"], ["LP17763-1", "A"], ["LP121628-4", "Day"], ["MTHU018643", "Emtricitabine"], ["MTHU015506", "Tenofovir"], ["LP15232-9", "P"], ["MTHU015506", "Tenofovir"], ["LA21291-2", "Not"], ["MTHU059747", "Bictegravir"], ["LA21996-6", "CO"], ["LP16061-1", "carBAMazepine"], ["LA14161-6", "May"], ["LA32049-1", "Decrease"], ["MTHU059747", "Bictegravir"], ["LP7479-1", "Plasma"], ["LA21996-6", "CO"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["MTHU060529", "OXcarbazepine"], ["MTHU060452", "PHENobarbital"], ["LP14732-9", "Phenytoin"], ["LP15232-9", "P"], ["LA21291-2", "Not"], ["MTHU036318", "Components"], ["LA21996-6", "CO"], ["MTHU060529", "OXcarbazepine"], ["MTHU060452", "PHENobarbital"], ["LA22025-3", "OR"], ["LP14732-9", "Phenytoin"], ["LA14161-6", "May"], ["LA32049-1", "Decrease"], ["MTHU059747", "Bictegravir"], ["MTHU015506", "Tenofovir"], ["LP7479-1", "Plasma"], ["LA21996-6", "CO"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["MTHU002163", "Magnesium"], ["LA21913-1", "Suspension"], ["LA19282-5", "20"], ["LA17717-2", "Single"], ["MTHU059747", "Bictegravir"], ["MTHU059747", "Bictegravir"], ["LA21913-1", "Suspension"], ["LA11829-1", "2 hours"], ["LA33028-4", "Prior"], ["MTHU059747", "Bictegravir"], ["LA21913-1", "Suspension"], ["LA11829-1", "2 hours"], ["MTHU059747", "Bictegravir"], ["LA15251-4", "80%"], ["MTHU059747", "Bictegravir"], ["MTHU065486", "Food"], ["LA21291-2", "Not"], ["MTHU002163", "Magnesium"], ["LA22025-3", "OR"], ["LA32049-1", "Decrease"], ["MTHU059747", "Bictegravir"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA21988-3", "AT"], ["LA11829-1", "2 hours"], ["LA22025-3", "OR"], ["MTHU065486", "Food"], ["LA11829-1", "2 hours"], ["MTHU002163", "Magnesium"], ["LA22025-3", "OR"], ["LP15583-5", "Fumarate"], ["LP15217-0", "Mg"], ["LA17717-2", "Single"], ["MTHU065481", "Dose"], ["MTHU059747", "Bictegravir"], ["MTHU059747", "Bictegravir"], ["MTHU059747", "Bictegravir"], ["MTHU065486", "Food"], ["LA19281-7", "25"], ["LA21988-3", "AT"], ["LA11829-1", "2 hours"], ["MTHU004837", "Iron"], ["LA22025-3", "OR"], ["MTHU065486", "Food"], ["LP16845-7", "Calcium carbonate"], ["LA6112-2", "1"], ["LP15217-0", "Mg"], ["LA17717-2", "Single"], ["MTHU065481", "Dose"], ["MTHU059747", "Bictegravir"], ["MTHU059747", "Bictegravir"], ["LA19316-1", "33"], ["MTHU059747", "Bictegravir"], ["MTHU065486", "Food"], ["LP32547-9", "Calcium"], ["MTHU065486", "Food"], ["LA14557-5", "11"], ["LP263807-2", "Therapeutic"], ["LA15097-1", "Possible"], ["LP6971-8", "mean"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["LP111410-9", "Recommendation"], ["LA21996-6", "CO"], ["LP171641-6", "Sucralfate"], ["LA21291-2", "Not"], ["MTHU036318", "Components"], ["LA21996-6", "CO"], ["LA14161-6", "May"], ["LA32049-1", "Decrease"], ["MTHU059747", "Bictegravir"], ["LP7479-1", "Plasma"], ["LA21996-6", "CO"], ["LA21291-2", "Not"], ["MTHU006782", "Antidepressants"], ["LP17242-6", "Sertraline"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LA17717-2", "Single"], ["MTHU065481", "Dose"], ["MTHU015506", "Tenofovir"], ["MTHU015506", "Tenofovir"], ["LP17242-6", "Sertraline"], ["LA32-8", "No"], ["LP200075-2", "IS"], ["MTHU059747", "Bictegravir"], ["MTHU018643", "Emtricitabine"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA21996-6", "CO"], ["LP200078-6", "IV"], ["LA22025-3", "OR"], ["LA9367-9", "Oral"], ["LP15232-9", "P"], ["LA21291-2", "Not"], ["MTHU036318", "Components"], ["LA21996-6", "CO"], ["LP200078-6", "IV"], ["LA22025-3", "OR"], ["LA9367-9", "Oral"], ["LP200075-2", "IS"], ["LA32048-3", "Increase"], ["LP7479-1", "Plasma"], ["LA14331-5", "Both"], ["MTHU059747", "Bictegravir"], ["MTHU015506", "Tenofovir"], ["LA21996-6", "CO"], ["LP200078-6", "IV"], ["LA22025-3", "OR"], ["LA9367-9", "Oral"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA12701-1", "Combination"], ["LP200075-2", "IS"], ["LP7787-7", "Clinical"], ["LA25433-6", "Biological"], ["LA20297-0", "Monitoring"], ["MTHU065909", "Renal"], ["LA8916-4", "Function"], ["LP200075-2", "IS"], ["LA9367-9", "Oral"], ["MTHU060554", "metFORMIN"], ["LA14009-7", "500"], ["LP15217-0", "Mg"], ["LA14664-9", "Twice"], ["LA14435-4", "Daily"], ["MTHU059747", "Bictegravir"], ["MTHU018643", "Emtricitabine"], ["MTHU015506", "Tenofovir"], ["LP71001-9", "OCT2"], ["MTHU060554", "metFORMIN"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA21996-6", "CO"], ["LA22004-8", "IN"], ["LA6626-1", "Normal"], ["LP31398-8", "Renal function"], ["LA22004-8", "IN"], ["LA6751-7", "Moderate"], ["MTHU065909", "Renal"], ["LA16797-5", "Close"], ["LA20297-0", "Monitoring"], ["LA21996-6", "CO"], ["MTHU059747", "Bictegravir"], ["MTHU060554", "metFORMIN"], ["LA24544-1", "Increased risk"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["MTHU060554", "metFORMIN"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA9367-9", "Oral"], ["LA6111-4", "0"], ["LA6111-4", "0"], ["LA6111-4", "0"], ["LP15217-0", "Mg"], ["LA14312-5", "Once"], ["LA14435-4", "Daily"], ["LA6111-4", "0"], ["LP15217-0", "Mg"], ["LA6305-2", "Once daily"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA21996-6", "CO"], ["LA6111-4", "0"], ["LA6111-4", "0"], ["LA6111-4", "0"], ["LP15217-0", "Mg"], ["LA14312-5", "Once"], ["LA14435-4", "Daily"], ["LA6111-4", "0"], ["LP15217-0", "Mg"], ["LA6305-2", "Once daily"], ["MTHU018643", "Emtricitabine"], ["MTHU015506", "Tenofovir"], ["LA14558-3", "12"], ["LP263807-2", "Therapeutic"], ["LA15097-1", "Possible"], ["LP6971-8", "mean"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["LP111410-9", "Recommendation"], ["LA21996-6", "CO"], ["LP30810-3", "Hypnotics"], ["LP16207-0", "Midazolam"], ["MTHU000002", "Clinical Class"], ["LP15217-0", "Mg"], ["LA9367-9", "Oral"], ["LA17717-2", "Single"], ["MTHU065481", "Dose"], ["MTHU059747", "Bictegravir"], ["MTHU018643", "Emtricitabine"], ["MTHU015506", "Tenofovir"], ["LP16207-0", "Midazolam"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA21996-6", "CO"], ["LA6112-2", "1"], ["LP74341-6", "Study"], ["MTHU059747", "Bictegravir"], ["LP15217-0", "Mg"], ["LA17717-2", "Single"], ["MTHU065481", "Dose"], ["MTHU000002", "Clinical Class"], ["LP74341-6", "Study"], ["MTHU059747", "Bictegravir"], ["MTHU018643", "Emtricitabine"], ["MTHU015506", "Tenofovir"], ["LA19281-7", "25"], ["LP15217-0", "Mg"], ["LA6305-2", "Once daily"], ["LP20591-1", "3"], ["LP74341-6", "Study"], ["LP263791-8", "Additional"], ["LP343299-6", "Voxilaprevir"], ["LA19244-5", "100"], ["LP15217-0", "Mg"], ["LP343299-6", "Voxilaprevir"], ["LA22004-8", "IN"], ["LP20592-9", "4"], ["LP74341-6", "Study"], ["MTHU018643", "Emtricitabine"], ["MTHU015506", "Tenofovir"], ["LA19281-7", "25"], ["LP15217-0", "Mg"], ["LA6305-2", "Once daily"], ["LP20593-7", "5"], ["LP6972-6", "maximum"], ["MTHU001445", "Strength"], ["LP15217-0", "Mg"], ["LP15217-0", "Mg"], ["MTHU002163", "Magnesium"], ["LP36791-9", "8"], ["LP15217-0", "Mg"], ["LP171639-0", "Simethicone"], ["LP20594-5", "6"], ["LP74341-6", "Study"], ["LP157318-9", "Elvitegravir"], ["MTHU018643", "Emtricitabine"], ["MTHU015506", "Tenofovir"], ["LA13942-0", "10"], ["LP15217-0", "Mg"], ["LA14312-5", "Once"], ["LA14435-4", "Daily"], ["LA18848-4", "Drug interaction"], ["LA22025-3", "OR"], ["MTHU036318", "Components"], ["LA32-8", "No"], ["LA28474-7", "Significant"], ["LA18200-8", "Drug"], ["MTHU060535", "amLODIPine"], ["LP171386-8", "Atorvastatin"], ["MTHU006723", "Buprenorphine"], ["MTHU045606", "Famciclovir"], ["LP14346-8", "Famotidine"], ["LP15015-8", "Methadone"], ["LP28525-1", "Naloxone"], ["MTHU026562", "Norbuprenorphine"], ["LP18586-5", "Omeprazole"], ["LA22025-3", "OR"], ["LP171638-2", "Rosuvastatin"]], "snomed.driving": [["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["373067005", "No (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["725125005", "300 (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["260676000", "Use of (attribute)"], ["772193003", "Bictegravir (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["18720000", "In (attribute)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255509001", "Large (qualifier value)"], ["246205007", "Quantity (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420862001", "On (qualifier value)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["242762006", "More (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["373067005", "No (qualifier value)"], ["255407002", "Neonatal (qualifier value)"], ["75478009", "Poisoning (disorder)"], ["47429007", "Associated with (attribute)"], ["404856006", "Emtricitabine (substance)"], ["387961004", "Kingdom Animalia (organism)"], ["255589003", "Direct (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255541007", "Indirect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["404856006", "Emtricitabine (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["252116004", "Observation parameter (observable entity)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["386217009", "Non-human parturition, function (observable entity)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["263844007", "Maternal postnatal period (qualifier value)|Postnatal (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["18720000", "In (attribute)"], ["387961004", "Kingdom Animalia (organism)"], ["41647002", "No evidence of (contextual qualifier) (qualifier value)"], ["420862001", "On (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["252116004", "Observation parameter (observable entity)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["769082003", "5.3 (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["394447009", "Fetus (person)|Fetus"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["36692007", "Known (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["226789007", "Breast milk (substance)"], ["404856006", "Emtricitabine (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["226789007", "Breast milk (substance)"], ["18720000", "In (attribute)"], ["387961004", "Kingdom Animalia (organism)"], ["772193003", "Bictegravir (substance)"], ["260373001", "Detected (qualifier value)"], ["18720000", "In (attribute)"], ["50863008", "Plasma (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["722165004", "Nursing (qualifier value)"], ["371565004", "Rattus norvegicus (organism)"], ["2931005", "Probable diagnosis (contextual qualifier) (qualifier value)"], ["42752001", "Due to (attribute)"], ["52101004", "Present (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["18720000", "In (attribute)"], ["70813002", "Milk (substance)"], ["45169001", "Without (attribute)"], ["420862001", "On (qualifier value)"], ["722165004", "Nursing (qualifier value)"], ["18720000", "In (attribute)"], ["387961004", "Kingdom Animalia (organism)"], ["422091007", "Tenofovir (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["70813002", "Milk (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["423437008", "Insufficient (qualifier value)"], ["420862001", "On (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258150004", "Transmission (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["133931009", "Infant (person)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["181131000", "Entire breast (body structure)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["373067005", "No (qualifier value)"], ["338930006", "Human (organism)"], ["420862001", "On (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420862001", "On (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["387961004", "Kingdom Animalia (organism)"], ["373067005", "No (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["772193003", "Bictegravir (substance)"], ["404856006", "Emtricitabine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["715220007", "Tenofovir alafenamide (substance)"], ["420862001", "On (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["769082003", "5.3 (qualifier value)"], ["1222740005", "American Joint Committee on Cancer stage I:3 (qualifier value)"]], "ncit.driving": [["C191656", "Pregnant Subject"], ["C68869", "Are"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43508", "Oregon"], ["C142988", "Limited"], ["C25474", "Data"], ["C61585", "Less Than"], ["C16645", "Greece"], ["C191656", "Pregnant Subject"], ["C25516", "From"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C171719", "Bictegravir"], ["C43508", "Oregon"], ["C148276", "Tenofovir Alafenamide"], ["C16727", "India"], ["C73435", "Gravida"], ["C76246", "Blood Group A"], ["C49508", "Large"], ["C25256", "Quantity"], ["C52874", "SPI1 wt Allele"], ["C25474", "Data"], ["C92667", "SPARC wt Allele"], ["C73435", "Gravida"], ["C61584", "Greater Than"], ["C105723", "ECOG Performance Status 1"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C154059", "Norwegian Language"], ["C16731", "Newborn"], ["C27990", "Toxicity"], ["C25281", "Associated"], ["C62355", "With"], ["C47509", "Emtricitabine"], ["C14182", "Animal"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C62254", "Direct"], ["C43508", "Oregon"], ["C62255", "Indirect"], ["C25492", "Effect"], ["C52874", "SPI1 wt Allele"], ["C47509", "Emtricitabine"], ["C62355", "With"], ["C159124", "GDC Treatment Outcome Terminology"], ["C95089", "Fertility Domain"], ["C191656", "Pregnant Subject"], ["C18732", "Development"], ["C92934", "Labor and Delivery Process"], ["C43508", "Oregon"], ["C81317", "Postnatal"], ["C18732", "Development"], ["C52874", "SPI1 wt Allele"], ["C171719", "Bictegravir"], ["C16289", "Andorra"], ["C148276", "Tenofovir Alafenamide"], ["C25382", "Administered"], ["C16727", "India"], ["C14182", "Animal"], ["C101282", "Have"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C25492", "Effect"], ["C92667", "SPARC wt Allele"], ["C95089", "Fertility Domain"], ["C191656", "Pregnant Subject"], ["C43508", "Oregon"], ["C18732", "Development"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16329", "Belgium"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C48440", "Single"], ["C198613", "CFI wt Allele"], ["C62230", "Potential"], ["C25387", "Benefit"], ["C62230", "Potential"], ["C17102", "Risk"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C17998", "Unknown"], ["C171719", "Bictegravir"], ["C43508", "Oregon"], ["C148276", "Tenofovir Alafenamide"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C14225", "Human"], ["C13257", "Mammary Gland Milk"], ["C47509", "Emtricitabine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C14225", "Human"], ["C13257", "Mammary Gland Milk"], ["C16727", "India"], ["C14182", "Animal"], ["C171719", "Bictegravir"], ["C154196", "Washo Language"], ["C16210", "Detection"], ["C16727", "India"], ["C13356", "Plasma"], ["C52874", "SPI1 wt Allele"], ["C25596", "Breast Feeding"], ["C160998", "Rat"], ["C85550", "Likely"], ["C89272", "Due To"], ["C25626", "Present"], ["C52874", "SPI1 wt Allele"], ["C171719", "Bictegravir"], ["C16727", "India"], ["C13257", "Mammary Gland Milk"], ["C25718", "Without"], ["C25492", "Effect"], ["C92667", "SPARC wt Allele"], ["C25596", "Breast Feeding"], ["C16727", "India"], ["C14182", "Animal"], ["C38267", "Intrathecal Route of Administration"], ["C101282", "Have"], ["C29490", "Tenofovir"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C13257", "Mammary Gland Milk"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C172138", "Insufficient Information to Classify Health Impact"], ["C92667", "SPARC wt Allele"], ["C25492", "Effect"], ["C52874", "SPI1 wt Allele"], ["C64916", "All"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C16727", "India"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C25490", "During"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C17214", "Disease Transmission"], ["C52874", "SPI1 wt Allele"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C159124", "GDC Treatment Outcome Terminology"], ["C27956", "Infant"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C37987", "Alive"], ["C62355", "With"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C25389", "Chest"], ["C69427", "Feed"], ["C95089", "Fertility Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C14225", "Human"], ["C25474", "Data"], ["C92667", "SPARC wt Allele"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C92667", "SPARC wt Allele"], ["C95089", "Fertility Domain"], ["C68869", "Are"], ["C25429", "Availability"], ["C14182", "Animal"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25492", "Effect"], ["C52874", "SPI1 wt Allele"], ["C171719", "Bictegravir"], ["C47509", "Emtricitabine"], ["C43508", "Oregon"], ["C148276", "Tenofovir Alafenamide"], ["C92667", "SPARC wt Allele"], ["C88194", "Mating"], ["C43508", "Oregon"], ["C95089", "Fertility Domain"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C113427", "Thirteen"]], "rxnorm.driving": [["1999660", "bictegravir"], ["1721603", "tenofovir alafenamide"], ["276237", "emtricitabine"], ["T008", "Animal"], ["276237", "emtricitabine"], ["1999660", "bictegravir"], ["1721603", "tenofovir alafenamide"], ["1999668", "Biktarvy"], ["1999660", "bictegravir"], ["1721603", "tenofovir alafenamide"], ["T016", "Human"], ["276237", "emtricitabine"], ["T016", "Human"], ["T008", "Animal"], ["1999660", "bictegravir"], ["1999660", "bictegravir"], ["T008", "Animal"], ["117466", "tenofovir"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["T016", "Human"], ["1999668", "Biktarvy"], ["T008", "Animal"], ["1999660", "bictegravir"], ["276237", "emtricitabine"], ["1721603", "tenofovir alafenamide"]], "loinc.driving": [["LP207970-7", "Pregnancy"], ["LA32-8", "No"], ["LA22025-3", "OR"], ["LA6484-5", "Limited"], ["LA16823-9", "Less"], ["LP207970-7", "Pregnancy"], ["MTHU059747", "Bictegravir"], ["LA22025-3", "OR"], ["MTHU015506", "Tenofovir"], ["LA22004-8", "IN"], ["LA29507-3", "Pregnant women"], ["LP17763-1", "A"], ["LA20975-1", "Large amount"], ["LA29507-3", "Pregnant women"], ["LA16824-7", "More"], ["LA6112-2", "1"], ["LA32-8", "No"], ["MTHU018643", "Emtricitabine"], ["LA30681-3", "Animal"], ["LA14426-3", "Do not"], ["LA22025-3", "OR"], ["MTHU018643", "Emtricitabine"], ["MTHU000074", "Fertility"], ["LP207970-7", "Pregnancy"], ["LA22025-3", "OR"], ["MTHU059747", "Bictegravir"], ["MTHU015506", "Tenofovir"], ["LA22004-8", "IN"], ["LA32-8", "No"], ["MTHU000074", "Fertility"], ["LP207970-7", "Pregnancy"], ["LA22025-3", "OR"], ["LP20593-7", "5"], ["LP20591-1", "3"], ["LP266032-4", "during pregnancy"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA14748-0", "Not known"], ["MTHU059747", "Bictegravir"], ["LA22025-3", "OR"], ["MTHU015506", "Tenofovir"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA19711-3", "Human"], ["LP29290-1", "Milk"], ["MTHU018643", "Emtricitabine"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA19711-3", "Human"], ["LP29290-1", "Milk"], ["LA22004-8", "IN"], ["LA30681-3", "Animal"], ["MTHU059747", "Bictegravir"], ["LA11882-0", "Detected"], ["LA22004-8", "IN"], ["LP7479-1", "Plasma"], ["LP6423-0", "Nursing"], ["LP14225-4", "Rat"], ["LA15587-1", "Likely"], ["LP149220-8", "Presence"], ["MTHU059747", "Bictegravir"], ["LA22004-8", "IN"], ["LP29290-1", "Milk"], ["LP6423-0", "Nursing"], ["LA22004-8", "IN"], ["LA30681-3", "Animal"], ["LP200077-8", "IT"], ["MTHU015506", "Tenofovir"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP29290-1", "Milk"], ["LP200075-2", "IS"], ["LA28127-1", "Insufficient"], ["LA18187-7", "All"], ["MTHU036318", "Components"], ["LA22004-8", "IN"], ["LA21291-2", "Not"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LA22004-8", "IN"], ["MTHU050362", "Transmission"], ["LP183501-8", "HIV"], ["LA19747-7", "Infant"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP29689-4", "Living with HIV"], ["LA20037-0", "DO"], ["LA21291-2", "Not"], ["LP199961-6", "Breast"], ["LP7228-2", "Feed"], ["MTHU000074", "Fertility"], ["LA32-8", "No"], ["LA19711-3", "Human"], ["MTHU000074", "Fertility"], ["LA30681-3", "Animal"], ["LA32-8", "No"], ["MTHU059747", "Bictegravir"], ["MTHU018643", "Emtricitabine"], ["LA22025-3", "OR"], ["MTHU015506", "Tenofovir"], ["LA22025-3", "OR"], ["MTHU000074", "Fertility"], ["LP20593-7", "5"], ["LP20591-1", "3"], ["LA14559-1", "13"]], "snomed.side_effects": [["410599005", "Minor (person)"], ["420862001", "On (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["247750002", "Drive (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["404640003", "Dizziness (finding)"], ["733985002", "Reported (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732732008", "4.8 (qualifier value)"]], "ncit.side_effects": [["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C106184", "May"], ["C101282", "Have"], ["C45367", "Minor"], ["C121660", "Influence"], ["C92667", "SPARC wt Allele"], ["C121232", "Ability to Drive"], ["C16289", "Andorra"], ["C25340", "Use"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C37896", "Informed"], ["C125409", "Have Dizziness"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C175242", "During Treatment"], ["C62355", "With"], ["C52874", "SPI1 wt Allele"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"]], "rxnorm.side_effects": [["1999668", "Biktarvy"], ["1999668", "Biktarvy"]], "loinc.side_effects": [["LA14161-6", "May"], ["LA29633-7", "Minor"], ["LA7428-1", "Dizziness"], ["LP6486-7", "Reported"], ["LP93408-0", "during treatment"], ["MTHU036318", "Components"], ["LP20592-9", "4"], ["LP36791-9", "8"]], "snomed.shelf_life": [["732986007", "Bottle (unit of presentation)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258707000", "year (qualifier value)"], ["732984005", "Blister (unit of presentation)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"]], "ncit.shelf_life": [["C43169", "Bottle"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C29848", "Year"], ["C43168", "Blister Pack"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"]], "rxnorm.shelf_life": [], "loinc.shelf_life": [["LA31720-8", "3 years"], ["LA19024-1", "Blister"], ["LA31719-0", "2 years"]], "snomed.storage": [["732986007", "Bottle (unit of presentation)"], ["18720000", "In (attribute)"], ["19535007", "Original (qualifier value)"], ["1681000175101", "Package - unit of product usage (qualifier value)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["732986007", "Bottle (unit of presentation)"], ["29179001", "Closed (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["19314006", "Seal (organism)"], ["21481007", "Over (qualifier value)"], ["732986007", "Bottle (unit of presentation)"], ["56116003", "Patent (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["1156075003", "Broken (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["732984005", "Blister (unit of presentation)"], ["18720000", "In (attribute)"], ["19535007", "Original (qualifier value)"], ["1681000175101", "Package - unit of product usage (qualifier value)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["21481007", "Over (qualifier value)"], ["732984005", "Blister (unit of presentation)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["1156075003", "Broken (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"]], "ncit.storage": [["C43169", "Bottle"], ["C60824", "Storage"], ["C16727", "India"], ["C25604", "Original"], ["C79887", "Package"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25516", "From"], ["C99569", "Retain"], ["C43169", "Bottle"], ["C49070", "Closed"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C25340", "Use"], ["C198613", "CFI wt Allele"], ["C50163", "Seal Device"], ["C25490", "During"], ["C43169", "Bottle"], ["C61378", "Opening"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C43508", "Oregon"], ["C96372", "Missing Study Animal"], ["C43168", "Blister Pack"], ["C60824", "Storage"], ["C16727", "India"], ["C25604", "Original"], ["C79887", "Package"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25516", "From"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C25340", "Use"], ["C198613", "CFI wt Allele"], ["C49961", "Foil Device"], ["C25490", "During"], ["C43168", "Blister Pack"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C43508", "Oregon"]], "rxnorm.storage": [], "loinc.storage": [["LA22004-8", "IN"], ["LA9505-4", "Original"], ["LA22004-8", "IN"], ["MTHU017843", "Moisture"], ["LA9228-3", "Closed"], ["LA14426-3", "Do not"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP200075-2", "IS"], ["LA22025-3", "OR"], ["LA14698-7", "Missing"], ["LA19024-1", "Blister"], ["LA22004-8", "IN"], ["LA9505-4", "Original"], ["LA22004-8", "IN"], ["MTHU017843", "Moisture"], ["LA14426-3", "Do not"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA19024-1", "Blister"], ["LP200075-2", "IS"], ["LA22025-3", "OR"]], "snomed.package": [["255260001", "Following (attribute)"], ["257260002", "Pack (physical object)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["732986007", "Bottle (unit of presentation)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222742002", "American Joint Committee on Cancer stage I:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["725123003", "200 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["18720000", "In (attribute)"], ["371251000", "White color (qualifier value)"], ["75540009", "High (qualifier value)"], ["125146005", "Density (qualifier value)"], ["71463006", "Polyethylene (substance)"], ["732986007", "Bottle (unit of presentation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["256633009", "Polypropylene (substance)"], ["255238004", "Continuous (qualifier value)"], ["733023009", "Thread (unit of presentation)"], ["410601007", "Childhood age person (person)"], ["30714006", "Resistant (qualifier value)"], ["228254002", "Cap (physical object)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255977005", "Aluminum material (substance)"], ["706608009", "Liner (physical object)"], ["42504009", "Containing (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["419473009", "Each (qualifier value)"], ["732986007", "Bottle (unit of presentation)"], ["83581005", "Silicon dioxide (substance)"], ["385100002", "Gel (basic dose form)|Gel (product)|Gel (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["8204009", "Polyester (substance)"], ["261074009", "External (qualifier value)"], ["42504009", "Containing (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732986007", "Bottle (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["261074009", "External (qualifier value)"], ["42504009", "Containing (qualifier value)"], ["732899009", "90 (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["419672006", "Bottle (qualifier value)|Bottle - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["732984005", "Blister (unit of presentation)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["725123003", "200 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732984005", "Blister (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["278429001", "Chloride (substance)|Chloride"], ["71463006", "Polyethylene (substance)"], ["35233000", "Polyvinyl chloride (substance)"], ["732995004", "Film (unit of presentation)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255977005", "Aluminum material (substance)"], ["276731003", "Material (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["18720000", "In (attribute)"], ["419473009", "Each (qualifier value)"], ["732984005", "Blister (unit of presentation)"], ["2483006", "Cavity (morphologic abnormality)"], ["1222780001", "American Joint Committee on Cancer stage II:7 (qualifier value)"], ["261074009", "External (qualifier value)"], ["42504009", "Containing (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["422045004", "Roman numeral X (qualifier value)"], ["732984005", "Blister (unit of presentation)"], ["42504009", "Containing (qualifier value)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["422045004", "Roman numeral X (qualifier value)"], ["732984005", "Blister (unit of presentation)"], ["1671000175104", "Strip - unit of product usage (qualifier value)"], ["42504009", "Containing (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["261074009", "External (qualifier value)"], ["42504009", "Containing (qualifier value)"], ["732899009", "90 (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["732984005", "Blister (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["732995004", "Film (unit of presentation)"], ["385055001", "Tablet (product)|Tablet dose form (product)|Tablet dose form (qualifier value)|Tablet (basic dose form)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["257260002", "Pack (physical object)"]], "ncit.package": [["C53286", "Next"], ["C84731", "Packing"], ["C68869", "Are"], ["C25429", "Availability"], ["C43169", "Bottle"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C70541", "Lansky Performance Status 30"], ["C16818", "Mammography"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C113429", "Fifteen"], ["C16818", "Mammography"], ["C16289", "Andorra"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C159711", "Two Hundred"], ["C16818", "Mammography"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C68869", "Are"], ["C16727", "India"], ["C48325", "White"], ["C139304", "IPSS Risk Category High"], ["C45781", "Density"], ["C83759", "High Density Polyethylene"], ["C83759", "High Density Polyethylene"], ["C43169", "Bottle"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C167446", "Continuous Heart Murmur"], ["C149992", "Thread Dosing Unit"], ["C150886", "Child Relation"], ["C41546", "Resistance Process"], ["C157719", "College of American Pathologists"], ["C62355", "With"], ["C75889", "PAX6 wt Allele"], ["C158876", "Induction Therapy"], ["C64382", "Activation"], ["C49961", "Foil Device"], ["C62126", "Cavity Liner"], ["C79873", "Contain"], ["C70541", "Lansky Performance Status 30"], ["C154467", "Film Dosage Form Category"], ["C25450", "Coat"], ["C64933", "Each"], ["C43169", "Bottle"], ["C79873", "Contain"], ["C29853", "Silicon Dioxide"], ["C45307", "Electrophoresis Gel"], ["C16289", "Andorra"], ["C49877", "Coil Device"], ["C187054", "Outer Surface"], ["C54702", "Carton Dosing Unit"], ["C79873", "Contain"], ["C105723", "ECOG Performance Status 1"], ["C43169", "Bottle"], ["C52874", "SPI1 wt Allele"], ["C70541", "Lansky Performance Status 30"], ["C154467", "Film Dosage Form Category"], ["C25450", "Coat"], ["C187054", "Outer Surface"], ["C54702", "Carton Dosing Unit"], ["C79873", "Contain"], ["C182728", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 90"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C52874", "SPI1 wt Allele"], ["C70541", "Lansky Performance Status 30"], ["C154467", "Film Dosage Form Category"], ["C25450", "Coat"], ["C43168", "Blister Pack"], ["C199579", "Bictegravir Sodium/Emtricitabine/Tenofovir Alafenamide Fumarate"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C159711", "Two Hundred"], ["C16818", "Mammography"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C43168", "Blister Pack"], ["C62653", "Pack Dosage Form"], ["C52874", "SPI1 wt Allele"], ["C25824", "Chloride"], ["C83759", "High Density Polyethylene"], ["C10268", "Cisplatin/Cyclophosphamide/Etoposide"], ["C201760", "AP3B1 wt Allele"], ["C154467", "Film Dosage Form Category"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49961", "Foil Device"], ["C48187", "Material"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C25574", "Molecular"], ["C25282", "Within"], ["C64933", "Each"], ["C43168", "Blister Pack"], ["C25444", "Body Cavity"], ["C126887", "Twenty Seven"], ["C187054", "Outer Surface"], ["C54702", "Carton Dosing Unit"], ["C79873", "Contain"], ["C70541", "Lansky Performance Status 30"], ["C154467", "Film Dosage Form Category"], ["C25450", "Coat"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C173030", "MATCH Arm EAY131-X"], ["C43168", "Blister Pack"], ["C79873", "Contain"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C154467", "Film Dosage Form Category"], ["C25450", "Coat"], ["C16289", "Andorra"], ["C105723", "ECOG Performance Status 1"], ["C173030", "MATCH Arm EAY131-X"], ["C43168", "Blister Pack"], ["C47914", "Strip Dosage Form"], ["C79873", "Contain"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C154467", "Film Dosage Form Category"], ["C25450", "Coat"], ["C187054", "Outer Surface"], ["C54702", "Carton Dosing Unit"], ["C79873", "Contain"], ["C182728", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 90"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C43168", "Blister Pack"], ["C62653", "Pack Dosage Form"], ["C52874", "SPI1 wt Allele"], ["C70541", "Lansky Performance Status 30"], ["C154467", "Film Dosage Form Category"], ["C25450", "Coat"], ["C25594", "Negation"], ["C64916", "All"], ["C84731", "Packing"], ["C106184", "May"], ["C16329", "Belgium"]], "rxnorm.package": [["746839", "Pack"], ["1999668", "Biktarvy"], ["1999668", "Biktarvy"], ["746839", "Pack"]], "loinc.package": [["LA28855-7", "30"], ["LP15217-0", "Mg"], ["LA32059-0", "120"], ["LP15217-0", "Mg"], ["LA14561-7", "15"], ["LP15217-0", "Mg"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LP15217-0", "Mg"], ["LA19281-7", "25"], ["LP15217-0", "Mg"], ["LA22004-8", "IN"], ["LA4457-3", "White"], ["LA9193-9", "High"], ["LP17763-1", "A"], ["LA16902-1", "Continuous"], ["LA9949-4", "Child"], ["LA6676-6", "Resistant"], ["LA28855-7", "30"], ["LP36406-4", "Silica"], ["LP183635-4", "GEL"], ["LA6112-2", "1"], ["LA28855-7", "30"], ["LA28891-2", "90"], ["LP20591-1", "3"], ["LA28855-7", "30"], ["LA19024-1", "Blister"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LP15217-0", "Mg"], ["LA19281-7", "25"], ["LP15217-0", "Mg"], ["LA19024-1", "Blister"], ["LP15483-8", "Chloride"], ["58282-5", "Ever told by doctor that you had pulmonary embolus:Find:Pt:^Patient:Ord"], ["LP72916-7", "Material"], ["LP17763-1", "A"], ["LA19024-1", "Blister"], ["LP30448-2", "Cavity"], ["LA28855-7", "30"], ["LP20592-9", "4"], ["LA32969-0", "X"], ["LA19024-1", "Blister"], ["LP36790-1", "7"], ["LA6112-2", "1"], ["LA32969-0", "X"], ["LA19024-1", "Blister"], ["MTHU000002", "Clinical Class"], ["LA28891-2", "90"], ["LP20591-1", "3"], ["LA19024-1", "Blister"], ["LA28855-7", "30"], ["LA21291-2", "Not"], ["LA18187-7", "All"], ["LA14161-6", "May"]], "snomed.marketing_authorization_numbers": [["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"]], "ncit.marketing_authorization_numbers": [["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C111798", "Eighteen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C111798", "Eighteen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C111798", "Eighteen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C111798", "Eighteen"], ["C16267", "Afghanistan"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C111798", "Eighteen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C111798", "Eighteen"]], "rxnorm.marketing_authorization_numbers": [], "loinc.marketing_authorization_numbers": [["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["LA6112-2", "1"]]}, {"product_info": "Enbrel 25 mg powder for solution for injection", "composition": "Each vial contains 25 mg of etanercept.\nEtanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant \nDNA technology in a Chinese hamster ovary (CHO) mammalian expression system.\nFor the full list of excipients, see section 6.1.", "indications": "Rheumatoid arthritis\nEnbrel in combination with methotrexate is indicated for the treatment of moderate to severe active \nrheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including \nmethotrexate (unless contraindicated), has been inadequate.\nEnbrel can be given as monotherapy in case of intolerance to methotrexate or when continued \ntreatment with methotrexate is inappropriate.\nEnbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults \nnot previously treated with methotrexate.\nEnbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression \nof joint damage as measured by X-ray and to improve physical function.\nJuvenile idiopathic arthritis\nTreatment of polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in \nchildren and adolescents from the age of 2 years who have had an inadequate response to, or who have \nproved intolerant of, methotrexate. \nTreatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate \nresponse to, or who have proved intolerant of, methotrexate.\nTreatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an \ninadequate response to, or who have proved intolerant of, conventional therapy.\nPsoriatic arthritis\nTreatment of active and progressive psoriatic arthritis in adults when the response to previous disease-\nmodifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve \nphysical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral\njoint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease.\nAxial spondyloarthritis\nAnkylosing spondylitis (AS)\nTreatment of adults with severe active ankylosing spondylitis who have had an inadequate response to \nconventional therapy.\nNon-radiographic axial spondyloarthritis\nTreatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of \ninflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging \n(MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs\n(NSAIDs).\nPlaque psoriasis\nTreatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a \ncontraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or \npsoralen and ultraviolet-A light (PUVA) (see section 5.1).\nPaediatric plaque psoriasis\nTreatment of chronic severe plaque psoriasis in children and adolescents from the age of 6 years who \nare inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.", "posology": "Enbrel treatment should be initiated and supervised by specialist physicians experienced in the \ndiagnosis and treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, \nankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis or paediatric plaque \npsoriasis. Patients treated with Enbrel should be given the Patient Card.\nEnbrel is available in strengths of 10, 25 and 50 mg. \nPosology\nRheumatoid arthritis\n25 mg Enbrel administered twice weekly is the recommended dose. Alternatively, 50 mg administered \nonce weekly has been shown to be safe and effective (see section 5.1).\nPsoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis\nThe recommended dose is 25 mg Enbrel administered twice weekly, or 50 mg administered once \nweekly.  \nFor all of the above indications, available data suggest that a clinical response is usually achieved \nwithin 12 weeks of treatment. Continued therapy should be carefully reconsidered in a patient not \nresponding within this time period.\nPlaque psoriasis\nThe recommended dose of Enbrel is 25 mg administered twice weekly or 50 mg administered once \nweekly. Alternatively, 50 mg given twice weekly may be used for up to 12 weeks followed, if \nnecessary, by a dose of 25 mg twice weekly or 50 mg once weekly. Treatment with Enbrel should \ncontinue until remission is achieved, for up to 24 weeks. Continuous therapy beyond 24 weeks may be \nappropriate for some adult patients (see section 5.1). Treatment should be discontinued in patients who \nshow no response after 12 weeks. If re-treatment with Enbrel is indicated, the same guidance on \ntreatment duration should be followed. The dose should be 25 mg twice weekly or 50 mg once \nweekly. \nSpecial populations\nRenal and hepatic impairment\nNo dose adjustment is required.\nElderly\nNo dose adjustment is required. Posology and administration are the same as for adults 18-64 years of \nage.\nPaediatric population\nThe safety and efficacy of Enbrel in children aged less than 2 years has not been established.\nNo data are available.\nJuvenile idiopathic arthritis \nThe recommended dose is 0.4 mg/kg (up to a maximum of 25 mg per dose), given twice weekly as a \nsubcutaneous injection with an interval of 3-4 days between doses or 0.8 mg/kg (up to a maximum of \n50 mg per dose) given once weekly. Discontinuation of treatment should be considered in patients \nwho show no response after 4 months.\nThe 10 mg vial strength may be more appropriate for administration to children with JIA below the \nweight of 25 kg.\nNo formal clinical trials have been conducted in children aged 2 to 3 years. However, limited safety \ndata from a patient registry suggest that the safety profile in children from 2 to 3 years of age is similar \nto that seen in adults and children aged 4 years and older, when dosed every week with 0.8 mg/kg \nsubcutaneously (see section 5.1).\nThere is generally no applicable use of Enbrel in children aged below 2 years in the indication juvenile \nidiopathic arthritis.\nPaediatric plaque psoriasis (age 6 years and above)\nThe recommended dose is 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly for up to \n24 weeks. Treatment should be discontinued in patients who show no response after 12 weeks.\nIf re-treatment with Enbrel is indicated, the above guidance on treatment duration should be followed. \nThe dose should be 0.8 mg/kg (up to a maximum of 50 mg per dose) once weekly.\nThere is generally no applicable use of Enbrel in children aged below 6 years in the indication plaque \npsoriasis.\nMethod of administration\nEnbrel is administered by subcutaneous injection. Enbrel powder for solution must be reconstituted in \n1 ml of solvent before use (see section 6.6).\nComprehensive instructions for the preparation and administration of the reconstituted Enbrel vial are \ngiven in the package leaflet, section 7, \"Instructions for preparation and giving an injection of Enbrel.\"\nDetailed instructions on unintentional dosing or scheduling variations, including missed doses, are \nprovided in section 3 of the package leaflet.", "contraindications": "Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.\nSepsis or risk of sepsis.\nTreatment with Enbrel should not be initiated in patients with active infections, including chronic or \nlocalised infections.", "special_warnings": "In order to improve the traceability of biological medicinal products, the brand name and batch \nnumber of the administered product should be clearly recorded (or stated) in the patient file.\nInfections\nPatients should be evaluated for infections before, during, and after treatment with Enbrel, taking into \nconsideration that the mean elimination half-life of etanercept is approximately 70 hours (range 7 to \n300 hours).\nSerious infections, sepsis, tuberculosis, and opportunistic infections, including invasive fungal \ninfections, listeriosis and legionellosis, have been reported with the use of Enbrel (see section 4.8). \nThese infections were due to bacteria, mycobacteria, fungi, viruses and parasites (including protozoa). \nIn some cases, particular fungal and other opportunistic infections have not been recognised, resulting \nin delay of appropriate treatment and sometimes death. In evaluating patients for infections, the \npatient\u2019s risk for relevant opportunistic infections (e.g., exposure to endemic mycoses) should be \nconsidered. \nPatients who develop a new infection while undergoing treatment with Enbrel should be monitored \nclosely. Administration of Enbrel should be discontinued if a patient develops a serious infection. The \nsafety and efficacy of Enbrel in patients with chronic infections have not been evaluated. Physicians \nshould exercise caution when considering the use of Enbrel in patients with a history of recurring or \nchronic infections or with underlying conditions that may predispose patients to infections, such as \nadvanced or poorly controlled diabetes.\nTuberculosis\nCases of active tuberculosis, including miliary tuberculosis and tuberculosis with extra-pulmonary \nlocation, have been reported in patients treated with Enbrel.\nBefore starting treatment with Enbrel, all patients must be evaluated for both active and inactive \n(\u2018latent\u2019) tuberculosis. This evaluation should include a detailed medical history with personal history \nof tuberculosis or possible previous contact with tuberculosis and previous and/or current \nimmunosuppressive therapy. Appropriate screening tests, i.e., tuberculin skin test and chest X-ray, \nshould be performed in all patients (local recommendations may apply). It is recommended that the \nconduct of these tests should be recorded in the Patient Card. Prescribers are reminded of the risk of \nfalse negative tuberculin skin test results, especially in patients who are severely ill or \nimmunocompromised.\nIf active tuberculosis is diagnosed, Enbrel therapy must not be initiated. If inactive (\u2018latent\u2019) \ntuberculosis is diagnosed, treatment for latent tuberculosis must be started with anti-tuberculosis \ntherapy before the initiation of Enbrel, and in accordance with local recommendations. In this \nsituation, the benefit/risk balance of Enbrel therapy should be very carefully considered.\nAll patients should be informed to seek medical advice if signs/symptoms suggestive of tuberculosis \n(e.g., persistent cough, wasting/weight loss, low-grade fever) appear during or after Enbrel treatment.\nHepatitis B reactivation\nReactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) \nand had received concomitant TNF-antagonists, including Enbrel, has been reported. This includes \nreports of reactivation of hepatitis B in patients who were anti-HBc positive but HBsAg negative.\nPatients should be tested for HBV infection before initiating treatment with Enbrel. For patients who \ntest positive for HBV infection, consultation with a physician with expertise in the treatment of \nhepatitis B is recommended. Caution should be exercised when administering Enbrel in patients \npreviously infected with HBV. These patients should be monitored for signs and symptoms of active \nHBV infection throughout therapy and for several weeks following termination of therapy. Adequate \ndata from treating patients infected with HBV with anti-viral therapy in conjunction with \nTNF-antagonist therapy are not available. In patients who develop HBV infection, Enbrel should be \nstopped and effective anti-viral therapy with appropriate supportive treatment should be initiated.\nWorsening of hepatitis C\nThere have been reports of worsening of hepatitis C in patients receiving Enbrel. Enbrel should be \nused with caution in patients with a history of hepatitis C.\nConcurrent treatment with anakinra \nConcurrent administration of Enbrel and anakinra has been associated with an increased risk of serious \ninfections and neutropenia compared to Enbrel alone. This combination has not demonstrated \nincreased clinical benefit. Thus, the combined use of Enbrel and anakinra is not recommended (see \nsections 4.5 and 4.8).\nConcurrent treatment with abatacept \nIn clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences \nof serious adverse events. This combination has not demonstrated increased clinical benefit; such use \nis not recommended (see section 4.5).\nAllergic reactions\nAllergic reactions associated with Enbrel administration have been reported commonly. Allergic \nreactions have included angioedema and urticaria; serious reactions have occurred. If any serious \nallergic or anaphylactic reaction occurs, Enbrel therapy should be discontinued immediately and\nappropriate therapy initiated.\nImmunosuppression\nThe possibility exists for TNF-antagonists, including Enbrel, to affect host defences against infections \nand malignancies since TNF mediates inflammation and modulates cellular immune responses. In a \nstudy of 49 adult patients with rheumatoid arthritis treated with Enbrel, there was no evidence of \ndepression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in \nenumeration of effector cell populations.\nTwo juvenile idiopathic arthritis patients developed varicella infection and signs and symptoms of \naseptic meningitis, which resolved without sequelae. Patients with a significant exposure to varicella \nvirus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with \nVaricella Zoster Immune Globulin.\nThe safety and efficacy of Enbrel in patients with immunosuppression have not been evaluated.\nMalignancies and lymphoproliferative disorders\nSolid and haematopoietic malignancies (excluding skin cancers)\nReports of various malignancies (including breast and lung carcinoma and lymphoma) have been \nreceived in the postmarketing period (see section 4.8). \nIn the controlled portions of clinical trials of TNF-antagonists, more cases of lymphoma have been \nobserved among patients receiving a TNF-antagonist compared with control patients. However, the \noccurrence was rare, and the follow-up period of placebo patients was shorter than for patients \nreceiving TNF-antagonist therapy. In the postmarketing setting, cases of leukaemia have been reported \nin patients treated with TNF-antagonists. There is an increased background risk for lymphoma and \nleukaemia in rheumatoid arthritis patients with long-standing, highly active, inflammatory disease, \nwhich complicates risk estimation.\nBased on current knowledge, a possible risk for the development of lymphomas, leukaemia or other \nhaematopoietic or solid malignancies in patients treated with a TNF-antagonist cannot be excluded. \nCaution should be exercised when considering TNF-antagonist therapy for patients with a history of \nmalignancy or when considering continuing treatment in patients who develop a malignancy.\nMalignancies, some fatal, have been reported among children, adolescents and young adults (up to \n22 years of age) treated with TNF-antagonists (initiation of therapy \u2264 18 years of age), including \nEnbrel, in the postmarketing setting. Approximately half the cases were lymphomas. The other cases \nrepresented a variety of different malignancies and included rare malignancies typically associated \nwith immunosuppression. A risk for the development of malignancies in children and adolescents \ntreated with TNF-antagonists cannot be excluded.\nSkin cancers\nMelanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with \nTNF-antagonists, including Enbrel. Postmarketing cases of Merkel cell carcinoma have been reported \nvery infrequently in patients treated with Enbrel. Periodic skin examination is recommended for all \npatients, particularly those with risk factors for skin cancer.\nCombining the results of controlled clinical trials, more cases of NMSC were observed in patients \nreceiving Enbrel compared with control patients, particularly in patients with psoriasis.\nVaccinations\nLive vaccines should not be given concurrently with Enbrel. No data are available on the secondary \ntransmission of infection by live vaccines in patients receiving Enbrel. In a double-blind, \nplacebo-controlled, randomised clinical study in adult patients with psoriatic arthritis, 184 patients also \nreceived a multivalent pneumococcal polysaccharide vaccine at week 4. In this study, most psoriatic \narthritis patients receiving Enbrel were able to mount effective B-cell immune response to \npneumococcal polysaccharide vaccine, but titres in aggregate were moderately lower, and few patients \nhad two-fold rises in titres compared to patients not receiving Enbrel. The clinical significance of this \nis unknown.\nAutoantibody formation\nTreatment with Enbrel may result in the formation of autoimmune antibodies (see section 4.8).\nHaematologic reactions\nRare cases of pancytopenia and very rare cases of aplastic anaemia, some with fatal outcome, have \nbeen reported in patients treated with Enbrel. Caution should be exercised in patients being treated \nwith Enbrel who have a previous history of blood dyscrasias. All patients and parents/caregivers \nshould be advised that if the patient develops signs and symptoms suggestive of blood dyscrasias or \ninfections (e.g., persistent fever, sore throat, bruising, bleeding, paleness) whilst on Enbrel, they \nshould seek immediate medical advice. Such patients should be investigated urgently, including full \nblood count; if blood dyscrasias are confirmed, Enbrel should be discontinued.\nNeurological disorders\nThere have been rare reports of CNS demyelinating disorders in patients treated with Enbrel (see \nsection 4.8). Additionally, there have been rare reports of peripheral demyelinating polyneuropathies \n(including Guillain-Barr\u00e9 syndrome, chronic inflammatory demyelinating polyneuropathy, \ndemyelinating polyneuropathy, and multifocal motor neuropathy). Although no clinical trials have \nbeen performed evaluating Enbrel therapy in patients with multiple sclerosis, clinical trials of other \nTNF antagonists in patients with multiple sclerosis have shown increases in disease activity. A careful \nrisk/benefit evaluation, including a neurologic assessment, is recommended when prescribing Enbrel \nto patients with pre-existing or recent onset of demyelinating disease, or to those who are considered \nto have an increased risk of developing demyelinating disease.\nCombination therapy\nIn a controlled clinical trial of two years duration in rheumatoid arthritis patients, the combination of \nEnbrel and methotrexate did not result in unexpected safety findings, and the safety profile of Enbrel \nwhen given in combination with methotrexate was similar to the profiles reported in studies of Enbrel \nand methotrexate alone. Long-term studies to assess the safety of the combination are ongoing. The \nlong-term safety of Enbrel in combination with other disease-modifying antirheumatic drugs \n(DMARD) has not been established.\nThe use of Enbrel in combination with other systemic therapies or phototherapy for the treatment of \npsoriasis has not been studied.\nRenal and hepatic impairment\nBased on pharmacokinetic data (see section 5.2), no dose adjustment is needed in patients with renal \nor hepatic impairment; clinical experience in such patients is limited.\nCongestive heart failure (Cardiac failure congestive)\nPhysicians should use caution when using Enbrel in patients who have congestive heart failure (CHF). \nThere have been postmarketing reports of worsening of CHF, with and without identifiable \nprecipitating factors, in patients taking Enbrel. There have also been rare (< 0.1%) reports of new \nonset CHF, including CHF in patients without known pre-existing cardiovascular disease. Some of \nthese patients have been under 50 years of age. Two large clinical trials evaluating the use of Enbrel in \nthe treatment of CHF were terminated early due to lack of efficacy. Although not conclusive, data \nfrom one of these trials suggest a possible tendency toward worsening CHF in those patients assigned \nto Enbrel treatment. \nAlcoholic hepatitis\nIn a phase II randomised placebo-controlled study of 48 hospitalised patients treated with Enbrel or \nplacebo for moderate to severe alcoholic hepatitis, Enbrel was not efficacious, and the mortality rate in \npatients treated with Enbrel was significantly higher after 6 months. Consequently, Enbrel should not \nbe used in patients for the treatment of alcoholic hepatitis. Physicians should use caution when using \nEnbrel in patients who also have moderate to severe alcoholic hepatitis.\nWegener's granulomatosis\nA placebo-controlled trial, in which 89 adult patients were treated with Enbrel in addition to standard \ntherapy (including cyclophosphamide or methotrexate, and glucocorticoids) for a median duration of \n25 months, has not shown Enbrel to be an effective treatment for Wegener\u2019s granulomatosis. The \nincidence of non-cutaneous malignancies of various types was significantly higher in patients treated \nwith Enbrel than in the control group. Enbrel is not recommended for the treatment of Wegener\u2019s \ngranulomatosis.\nHypoglycaemia in patients treated for diabetes\nThere have been reports of hypoglycaemia following initiation of Enbrel in patients receiving \nmedication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.\nSpecial populations\nElderly\nIn the Phase 3 studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, no overall \ndifferences in adverse events, serious adverse events, and serious infections in patients age 65 or older \nwho received Enbrel were observed compared with younger patients. However, caution should be \nexercised when treating the elderly and particular attention paid with respect to occurrence of \ninfections.\nPaediatric population\nVaccinations\nIt is recommended that paediatric patients, if possible, be brought up to date with all immunisations in \nagreement with current immunisation guidelines prior to initiating Enbrel therapy (see Vaccinations, \nabove).", "pregnancy": "Concurrent treatment with anakinra \nAdult patients treated with Enbrel and anakinra were observed to have a higher rate of serious \ninfection when compared with patients treated with either Enbrel or anakinra alone (historical data).\nIn addition, in a double-blind, placebo-controlled trial in adult patients receiving background \nmethotrexate, patients treated with Enbrel and anakinra were observed to have a higher rate of serious \ninfections (7%) and neutropenia than patients treated with Enbrel (see sections 4.4 and 4.8). The \ncombination Enbrel and anakinra has not demonstrated increased clinical benefit, and is therefore not \nrecommended.\nConcurrent treatment with abatacept \nIn clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences \nof serious adverse events. This combination has not demonstrated increased clinical benefit; such use \nis not recommended (see section 4.4). \nConcurrent treatment with sulfasalazine \nIn a clinical study of adult patients who were receiving established doses of sulfasalazine, to which \nEnbrel was added, patients in the combination group experienced a statistically significant decrease in \nmean white blood cell counts in comparison to groups treated with Enbrel or sulfasalazine alone. The \nclinical significance of this interaction is unknown. Physicians should use caution when considering \ncombination therapy with sulfasalazine.\nNon-interactions\nIn clinical trials, no interactions have been observed when Enbrel was administered with \nglucocorticoids, salicylates (except sulfasalazine), nonsteroidal anti-inflammatory drugs (NSAIDs), \nanalgesics, or methotrexate. See section 4.4 for vaccination advice.\nNo clinically significant pharmacokinetic drug-drug interactions were observed in studies with \nmethotrexate, digoxin or warfarin.", "driving": "Women of childbearing potential\nWomen of childbearing potential should consider the use of appropriate contraception to avoid \nbecoming pregnant during Enbrel therapy and for three weeks after discontinuation of therapy.\nPregnancy \nDevelopmental toxicity studies performed in rats and rabbits have revealed no evidence of harm to the \nfoetus or neonatal rat due to etanercept. The effects of etanercept on pregnancy outcomes have been \ninvestigated in two observational cohort studies. A higher rate of major birth defects was observed in \none observational study comparing pregnancies exposed to etanercept (n=370) during the first \ntrimester with pregnancies not exposed to etanercept or other TNF-antagonists (n=164) (adjusted odds \nratio 2.4, 95% CI: 1.0-5.5). The types of major birth defects were consistent with those most \ncommonly reported in the general population and no particular pattern of abnormalities was identified. \nNo change in the rate of spontaneous abortion, stillbirth, or minor malformations was observed. In \nanother observational multi-country registry study comparing the risk of adverse pregnancy outcomes \nin women exposed to etanercept during the first 90 days of pregnancy (n=425) to those exposed to \nnon-biologic drugs (n=3497), there was no observed increased risk of major birth defects (crude odds \nratio [OR]= 1.22, 95% CI: 0.79-1.90; adjusted OR = 0.96, 95% CI: 0.58-1.60 after adjusting for \ncountry, maternal disease, parity, maternal age and smoking in early pregnancy). This study also \nshowed no increased risks of minor birth defects, preterm birth, stillbirth, or infections in the first year \nof life for infants born to women exposed to etanercept during pregnancy. Enbrel should only be used \nduring pregnancy if clearly needed.\nEtanercept crosses the placenta and has been detected in the serum of infants born to female patients \ntreated with Enbrel during pregnancy. The clinical impact of this is unknown, however, infants may be \nat increased risk of infection. Administration of live vaccines to infants for 16 weeks after the \nmother\u2019s last dose of Enbrel is generally not recommended.\nBreast-feeding\nIn lactating rats following subcutaneous administration, etanercept was excreted in the milk and \ndetected in the serum of pups. Limited information from the published literature indicates etanercept \nhas been detected at low levels in human milk. Etanercept could be considered for use during \nbreast-feeding taking into account the benefit of breast-feeding for the child and the benefit of therapy \nfor the woman.\nWhile systemic exposure in a breastfed infant is expected to be low because etanercept is largely \ndegraded in the gastrointestinal tract, limited data regarding systemic exposure in the breastfed infant \nare available. Therefore, the administration of live vaccines (e.g., BCG) to a breastfed infant when the \nmother is receiving etanercept could be considered 16 weeks after stopping breast-feeding (or at an \nearlier timepoint if the infant etanercept serum levels are undetectable). \nFertility\nPreclinical data about peri- and postnatal toxicity of etanercept and of effects of etanercept on fertility \nand general reproductive performance are not available.", "side_effects": "Enbrel has no or negligible influence on the ability to drive and use machines.", "shelf_life": "4 years.\nChemical and physical in-use stability has been demonstrated for 6 hours at temperatures of up to \n\uf0b0C after reconstitution. From a microbiological point of view, the reconstituted medicinal product \nshould be used immediately. If not used immediately, storage times and conditions prior to use are the \nresponsibility of the user and would normally not be longer than 6 hours at temperatures of up to \n\uf0b0C, unless reconstitution has taken place in controlled and validated aseptic conditions.", "storage": "Store in a refrigerator (2\n\uf0b0C \u2013 8\uf0b0C). Do not freeze.\nEnbrel may be stored at temperatures up to a maximum of 25\n\uf0b0C for a single period of up to four \nweeks; after which, it should not be refrigerated again. Enbrel should be discarded if not used within \nfour weeks of removal from refrigeration.\nFor storage conditions of the reconstituted medicinal product, see section 6.3.", "package": "Clear glass vial (2 ml, type I glass) with rubber stoppers, aluminium seals, and flip-off plastic caps. \nCartons contain 4 vials of Enbrel with 8 alcohol swabs.", "marketing_authorization_numbers": "EU/1/99/126/002", "filename": "enbrel-epar-product-information_en.html", "snomed.product_info": [["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["385223009", "Powder for injection solution (qualifier value)|Powder for injection solution (product)|Powder for conventional release solution for injection (dose form)"]], "ncit.product_info": [["C2381", "Etanercept"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C42974", "Powder for Injectable Solution Dosage Form"]], "rxnorm.product_info": [["216891", "Enbrel"], ["1649574", "Injection"]], "loinc.product_info": [["LA19281-7", "25"], ["LP15217-0", "Mg"], ["LA14542-7", "Injection"]], "snomed.composition": [["419473009", "Each (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387045004", "Etanercept (substance)"], ["387045004", "Etanercept (substance)"], ["116680003", "Is a (attribute)"], ["338930006", "Human (organism)"], ["8612007", "Tumor necrosis factor (substance)"], ["116647005", "Receptor (substance)"], ["422055000", "Fusion protein (substance)"], ["24851008", "Deoxyribonucleic acid (substance)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["392392002", "Cricetulus griseus (organism)"], ["181464007", "Entire ovary (body structure)"], ["706999006", "Expression (foundation metadata concept)"], ["1231568003", "System (basic dose form)"], ["86495002", "For (qualifier value)"], ["261015003", "Full (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.composition": [["C64933", "Each"], ["C41275", "Vial"], ["C79873", "Contain"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C2381", "Etanercept"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C14225", "Human"], ["C36184", "Necrotic Change"], ["C174133", "Feelings about Genomic Testing Results"], ["C18106", "Receptor"], ["C18487", "Tumor Necrosis Factor Receptor Superfamily Member 1B"], ["C90384", "Food Consumption"], ["C17561", "Fusion Protein"], ["C158169", "Buyei Chinese"], ["C14353", "Recombinants"], ["C449", "DNA"], ["C17187", "Technology"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C77091", "Chinese Hamster"], ["C12404", "Ovary"], ["C9540", "Cyclophosphamide/Doxorubicin/Vincristine"], ["C14234", "Mammalia"], ["C80488", "Expression"], ["C149975", "System Dosing Unit"], ["C64956", "For"], ["C25517", "Full"], ["C43432", "List"], ["C52874", "SPI1 wt Allele"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.composition": [["214555", "etanercept"], ["214555", "etanercept"], ["T016", "Human"], ["T192", "Receptor"]], "loinc.composition": [["LA20376-2", "Vial"], ["LA19281-7", "25"], ["LP15217-0", "Mg"], ["MTHU054569", "Etanercept"], ["MTHU054569", "Etanercept"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LA19711-3", "Human"], ["LA7456-2", "Necrosis"], ["T192", "Receptor"], ["LP15838-3", "Protein"], ["LA19712-1", "Recombinant"], ["MTHU003299", "DNA"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA4168-6", "Chinese"], ["LP206706-6", "Ovary"], ["LA19682-6", "Full"], ["LP204165-7", "List"], ["LP20594-5", "6"], ["LA6112-2", "1"]], "snomed.indications": [["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["371924009", "Moderate to severe (qualifier value)"], ["55561003", "Active (qualifier value)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["18720000", "In (attribute)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["64572001", "Disease (disorder)"], ["55919000", "Including (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["410536001", "Contraindicated (qualifier value)"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["29544009", "Intolerance, function (observable entity)|Intolerance (function)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["900000000000494007", "Inappropriate component (foundation metadata concept)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["55561003", "Active (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255314001", "Progressive (qualifier value)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["387381009", "Methotrexate (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["246450006", "Progression (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["302536002", "Entire joint (body structure)"], ["37782003", "Damage (morphologic abnormality)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["258104002", "Measured (qualifier value)"], ["363680008", "Radiographic imaging procedure (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["19388002", "Physical (qualifier value)"], ["277064003", "Function (attribute)"], ["410502007", "Juvenile idiopathic arthritis (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416956002", "Undifferentiated inflammatory polyarthritis (disorder)"], ["165839004", "Rheumatoid factor positive (finding)|Rheumatoid factor detected (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["394426005", "Negative|Negative (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["288467006", "Extended (qualifier value)"], ["239819001", "Undifferentiated inflammatory oligoarthritis (disorder)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["18720000", "In (attribute)"], ["424144002", "Current chronological age (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258707000", "year (qualifier value)"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["359643005", "Enthesitis (disorder)"], ["262094002", "Related (finding)"], ["372091005", "Arthritis (finding)"], ["18720000", "In (attribute)"], ["424144002", "Current chronological age (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258707000", "year (qualifier value)"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255333006", "Conventional (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["55561003", "Active (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255314001", "Progressive (qualifier value)"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["18720000", "In (attribute)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["9130008", "Previous (qualifier value)"], ["64572001", "Disease (disorder)"], ["416608005", "Drug therapy (procedure)"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["19388002", "Physical (qualifier value)"], ["277064003", "Function (attribute)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["246450006", "Progression (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["14414005", "Peripheral (qualifier value)"], ["302536002", "Entire joint (body structure)"], ["37782003", "Damage (morphologic abnormality)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["258104002", "Measured (qualifier value)"], ["363680008", "Radiographic imaging procedure (procedure)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255205008", "Polyarticular (qualifier value)"], ["255473004", "Symmetrical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["64572001", "Disease (disorder)"], ["723116002", "Axial spondyloarthritis (disorder)"], ["156619005", "Ankylosing spondylitis (disorder)|Ankylosing spondylitis"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["55561003", "Active (qualifier value)"], ["156619005", "Ankylosing spondylitis (disorder)|Ankylosing spondylitis"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255333006", "Conventional (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["713777005", "Non-radiographic axial spondyloarthritis (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["713777005", "Non-radiographic axial spondyloarthritis (disorder)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["260224007", "Objective observation (qualifier value)|Objective (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["257552002", "Inflammation (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["119971000119104", "C-reactive protein above reference range (finding)|Elevated C-reactive protein (finding)"], ["61425002", "C reactive protein (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["312250003", "Magnetic resonance imaging - action (qualifier value)"], ["113091000", "Magnetic resonance imaging (procedure)"], ["162197008", "Inadequate (& symptom)|Inadequate (& symptom) (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255387000", "Inflammatory|Inflammatory (qualifier value)"], ["200965009", "Plaque psoriasis (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["371924009", "Moderate to severe (qualifier value)"], ["200965009", "Plaque psoriasis (disorder)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["103306004", "Contraindication to (contextual qualifier) (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["31099001", "Systemic (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["55919000", "Including (qualifier value)"], ["387467008", "Ciclosporin (substance)|Cyclosporine (substance)"], ["387381009", "Methotrexate (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["419047007", "Psoralen (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["415770004", "Ultra-violet color (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["371268001", "Light color (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["200965009", "Plaque psoriasis (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["200965009", "Plaque psoriasis (disorder)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258707000", "year (qualifier value)"], ["54776003", "Controlled by (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["31099001", "Systemic (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"]], "ncit.indications": [["C2884", "Rheumatoid Arthritis"], ["C2381", "Etanercept"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C642", "Methotrexate"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C159124", "GDC Treatment Outcome Terminology"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C154405", "Active State"], ["C2884", "Rheumatoid Arthritis"], ["C16727", "India"], ["C65140", "When"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C2991", "Disease or Disorder"], ["C166400", "Inclusive"], ["C642", "Methotrexate"], ["C37933", "Contraindicated"], ["C101282", "Have"], ["C168268", "Inadequate Daily Salt Intake"], ["C2381", "Etanercept"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C64974", "Give"], ["C71344", "Associate of Science"], ["C157514", "Single Agent Therapy"], ["C16727", "India"], ["C49152", "Case"], ["C52874", "SPI1 wt Allele"], ["C71437", "Intolerance"], ["C159124", "GDC Treatment Outcome Terminology"], ["C642", "Methotrexate"], ["C43508", "Oregon"], ["C65140", "When"], ["C53279", "Continue"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C642", "Methotrexate"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C74958", "Inappropriate"], ["C2381", "Etanercept"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C154405", "Active State"], ["C16289", "Andorra"], ["C25254", "Progressive"], ["C2884", "Rheumatoid Arthritis"], ["C16727", "India"], ["C25594", "Negation"], ["C16124", "Prior Therapy"], ["C62355", "With"], ["C642", "Methotrexate"], ["C2381", "Etanercept"], ["C48440", "Single"], ["C43508", "Oregon"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C642", "Methotrexate"], ["C101282", "Have"], ["C159124", "GDC Treatment Outcome Terminology"], ["C77538", "Rating"], ["C52874", "SPI1 wt Allele"], ["C17747", "Disease Progression"], ["C52874", "SPI1 wt Allele"], ["C13044", "Joint"], ["C61555", "Damage"], ["C71344", "Associate of Science"], ["C44473", "Measured"], ["C158169", "Buyei Chinese"], ["C38101", "X-Ray Imaging"], ["C16289", "Andorra"], ["C159124", "GDC Treatment Outcome Terminology"], ["C150046", "Physical Function"], ["C114357", "Juvenile Idiopathic Arthritis"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C26996", "Polyarticular Arthritis"], ["C74717", "Rheumatoid Factor Measurement"], ["C36659", "CTNNB1 Gene Mutation"], ["C43508", "Oregon"], ["C160366", "FGFR3 Gene Rearrangement Negative"], ["C16289", "Andorra"], ["C25270", "Extend"], ["C119021", "Oligoarticular Arthritis"], ["C16727", "India"], ["C16423", "Child"], ["C16289", "Andorra"], ["C16266", "Adolescents"], ["C25516", "From"], ["C106312", "Advanced Glycation End Product"], ["C52874", "SPI1 wt Allele"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C168268", "Inadequate Daily Salt Intake"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C52874", "SPI1 wt Allele"], ["C642", "Methotrexate"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C61277", "Psoriatic Arthritis"], ["C16727", "India"], ["C16266", "Adolescents"], ["C25516", "From"], ["C106312", "Advanced Glycation End Product"], ["C52874", "SPI1 wt Allele"], ["C113426", "Twelve"], ["C29848", "Year"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C168268", "Inadequate Daily Salt Intake"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C52874", "SPI1 wt Allele"], ["C642", "Methotrexate"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C119024", "Enthesitis-Related Arthritis"], ["C16727", "India"], ["C16266", "Adolescents"], ["C25516", "From"], ["C106312", "Advanced Glycation End Product"], ["C52874", "SPI1 wt Allele"], ["C113426", "Twelve"], ["C29848", "Year"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C168268", "Inadequate Daily Salt Intake"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C52874", "SPI1 wt Allele"], ["C97149", "Conventional Therapy"], ["C61277", "Psoriatic Arthritis"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C154405", "Active State"], ["C16289", "Andorra"], ["C25254", "Progressive"], ["C61277", "Psoriatic Arthritis"], ["C16727", "India"], ["C65140", "When"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25627", "Previous"], ["C2991", "Disease or Disorder"], ["C95761", "Drug Therapy"], ["C101282", "Have"], ["C168268", "Inadequate Daily Salt Intake"], ["C2381", "Etanercept"], ["C101282", "Have"], ["C159124", "GDC Treatment Outcome Terminology"], ["C150046", "Physical Function"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C61277", "Psoriatic Arthritis"], ["C16289", "Andorra"], ["C159124", "GDC Treatment Outcome Terminology"], ["C77538", "Rating"], ["C52874", "SPI1 wt Allele"], ["C17747", "Disease Progression"], ["C52874", "SPI1 wt Allele"], ["C25233", "Peripheral"], ["C13044", "Joint"], ["C61555", "Damage"], ["C71344", "Associate of Science"], ["C44473", "Measured"], ["C158169", "Buyei Chinese"], ["C38101", "X-Ray Imaging"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C52874", "SPI1 wt Allele"], ["C2991", "Disease or Disorder"], ["C73439", "Axial"], ["C116778", "Spondyloarthritis"], ["C84564", "Ankylosing Spondylitis"], ["C71344", "Associate of Science"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C154405", "Active State"], ["C84564", "Ankylosing Spondylitis"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C168268", "Inadequate Daily Salt Intake"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C97149", "Conventional Therapy"], ["C14460", "NON Mouse"], ["C192332", "Radiographic Staging"], ["C73439", "Axial"], ["C116778", "Spondyloarthritis"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C14460", "NON Mouse"], ["C192332", "Radiographic Staging"], ["C73439", "Axial"], ["C116778", "Spondyloarthritis"], ["C62355", "With"], ["C88181", "Objective"], ["C52874", "SPI1 wt Allele"], ["C3137", "Inflammation"], ["C71344", "Associate of Science"], ["C158169", "Buyei Chinese"], ["C162107", "High Platelet Count"], ["C60651", "C-Reactive Protein"], ["C60649", "CRP Gene"], ["C48928", "And/Or"], ["C16809", "Magnetic Resonance Imaging"], ["C154036", "Maori Language"], ["C43583", "Evidence"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C168268", "Inadequate Daily Salt Intake"], ["C165206", "Responsive Disease"], ["C159124", "GDC Treatment Outcome Terminology"], ["C256", "Anti-Inflammatory Agent"], ["C257", "Nonsteroidal Antiinflammatory Drug"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C62355", "With"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C159124", "GDC Treatment Outcome Terminology"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C75419", "World Health Organization"], ["C44281", "Failed"], ["C159124", "GDC Treatment Outcome Terminology"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C50646", "Medical Contraindication"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C118472", "Other License Status"], ["C15698", "Systemic Therapy"], ["C166400", "Inclusive"], ["C406", "Cyclosporine"], ["C642", "Methotrexate"], ["C43508", "Oregon"], ["C2586", "Psoralen"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C64650", "Light"], ["C29973", "PUVA Photochemotherapy"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C4981", "Chronic Graft Versus Host Disease"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C16727", "India"], ["C16423", "Child"], ["C16289", "Andorra"], ["C16266", "Adolescents"], ["C25516", "From"], ["C106312", "Advanced Glycation End Product"], ["C52874", "SPI1 wt Allele"], ["C172979", "Fear Score 6"], ["C29848", "Year"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C82500", "Disease Controlled"], ["C158169", "Buyei Chinese"], ["C43508", "Oregon"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C118472", "Other License Status"], ["C13310", "Systemic"], ["C43508", "Oregon"]], "rxnorm.indications": [["216891", "Enbrel"], ["6851", "methotrexate"], ["6851", "methotrexate"], ["216891", "Enbrel"], ["6851", "methotrexate"], ["6851", "methotrexate"], ["216891", "Enbrel"], ["6851", "methotrexate"], ["216891", "Enbrel"], ["6851", "methotrexate"], ["6851", "methotrexate"], ["6851", "methotrexate"], ["216891", "Enbrel"], ["6851", "methotrexate"]], "loinc.indications": [["LA15161-5", "Rheumatoid Arthritis"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP16198-1", "Methotrexate"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA32820-5", "Moderate to severe"], ["LA16666-2", "Active"], ["LA15161-5", "Rheumatoid Arthritis"], ["LA22004-8", "IN"], ["LA18199-2", "Disease"], ["LP18046-0", "Drugs"], ["LP16198-1", "Methotrexate"], ["LA4216-3", "Contraindicated"], ["LA8914-9", "Inadequate"], ["LP29256-2", "given"], ["LA22004-8", "IN"], ["LP16198-1", "Methotrexate"], ["LA22025-3", "OR"], ["LP94823-9", "Treatment"], ["LP16198-1", "Methotrexate"], ["LP200075-2", "IS"], ["LP31488-7", "Inappropriate"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA6750-9", "Severe"], ["LA16666-2", "Active"], ["LA25478-1", "Progressive"], ["LA15161-5", "Rheumatoid Arthritis"], ["LA22004-8", "IN"], ["LA21291-2", "Not"], ["LP16198-1", "Methotrexate"], ["LA27350-0", "Alone"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP16198-1", "Methotrexate"], ["MTHU027852", "Rate"], ["MTHU048551", "Joint"], ["LP6378-6", "Measured"], ["LP21166-1", "X-ray"], ["LP7799-2", "Physical function"], ["LA31871-9", "Idiopathic"], ["MTHU020793", "Arthritis"], ["LP94823-9", "Treatment"], ["LP16738-4", "Rheumatoid factor"], ["LA6576-8", "Positive"], ["LA22025-3", "OR"], ["LA6577-6", "Negative"], ["LA22004-8", "IN"], ["MTHU010047", "Age"], ["LA31719-0", "2 years"], ["LA8914-9", "Inadequate"], ["LA22025-3", "OR"], ["LP16198-1", "Methotrexate"], ["LP94823-9", "Treatment"], ["MTHU020793", "Arthritis"], ["LA22004-8", "IN"], ["MTHU010047", "Age"], ["LA14558-3", "12"], ["LA8914-9", "Inadequate"], ["LA22025-3", "OR"], ["LP16198-1", "Methotrexate"], ["LP94823-9", "Treatment"], ["LA31343-9", "Related"], ["MTHU020793", "Arthritis"], ["LA22004-8", "IN"], ["MTHU010047", "Age"], ["LA14558-3", "12"], ["LA8914-9", "Inadequate"], ["LA22025-3", "OR"], ["LA32139-0", "Conventional"], ["LP267221-2", "Therapy"], ["MTHU020793", "Arthritis"], ["LP94823-9", "Treatment"], ["LA16666-2", "Active"], ["LA25478-1", "Progressive"], ["MTHU020793", "Arthritis"], ["LA22004-8", "IN"], ["LA18199-2", "Disease"], ["LA18200-8", "Drug"], ["LP267221-2", "Therapy"], ["LA8914-9", "Inadequate"], ["LP7799-2", "Physical function"], ["LA22004-8", "IN"], ["MTHU020793", "Arthritis"], ["MTHU027852", "Rate"], ["LA24844-5", "Peripheral"], ["MTHU048551", "Joint"], ["LP6378-6", "Measured"], ["LP21166-1", "X-ray"], ["LA22004-8", "IN"], ["LA18199-2", "Disease"], ["LP266843-4", "Axial"], ["LA31822-2", "Spondylitis"], ["LP94823-9", "Treatment"], ["LA6750-9", "Severe"], ["LA16666-2", "Active"], ["LA31822-2", "Spondylitis"], ["LA8914-9", "Inadequate"], ["LA32139-0", "Conventional"], ["LP267221-2", "Therapy"], ["LP266843-4", "Axial"], ["LP94823-9", "Treatment"], ["LA6750-9", "Severe"], ["LP266843-4", "Axial"], ["MTHU036448", "Objective"], ["LA7447-1", "Inflammation"], ["LA32146-5", "Elevated"], ["LP17128-7", "C"], ["LA15255-5", "Reactive"], ["LP15838-3", "Protein"], ["LA22025-3", "OR"], ["LP206574-8", "Magnetic resonance"], ["LP6328-1", "Imaging"], ["LP6406-5", "Magnetic resonance imaging (MRI)"], ["LA8914-9", "Inadequate"], ["LP18046-0", "Drugs"], ["LP31430-9", "NSAIDS"], ["LA15165-6", "Psoriasis"], ["LP94823-9", "Treatment"], ["LA32820-5", "Moderate to severe"], ["LA15165-6", "Psoriasis"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["MTHU038257", "Contraindication"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LP267221-2", "Therapy"], ["LP16198-1", "Methotrexate"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LA15831-3", "Light"], ["LA16783-5", "PUVA"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LA15165-6", "Psoriasis"], ["LP94823-9", "Treatment"], ["LA28752-6", "Chronic"], ["LA6750-9", "Severe"], ["LA15165-6", "Psoriasis"], ["LA22004-8", "IN"], ["MTHU010047", "Age"], ["LP20594-5", "6"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LP75725-9", "Therapies"], ["LA22025-3", "OR"]], "snomed.posology": [["421829000", "And - dosing instruction fragment (qualifier value)"], ["309395003", "Hospital specialist (occupation)"], ["18720000", "In (attribute)"], ["439401001", "Diagnosis (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["410502007", "Juvenile idiopathic arthritis (disorder)"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["156619005", "Ankylosing spondylitis (disorder)|Ankylosing spondylitis"], ["713777005", "Non-radiographic axial spondyloarthritis (disorder)"], ["200965009", "Plaque psoriasis (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1522000", "Plaque (morphologic abnormality)"], ["156369008", "Psoriasis|Psoriasis (disorder)"], ["28995006", "Treated with (attribute)"], ["116154003", "Patient (person)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229800002", "Twice weekly (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["225769003", "Once a week (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["254648000", "Effective (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["156619005", "Ankylosing spondylitis (disorder)|Ankylosing spondylitis"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["713777005", "Non-radiographic axial spondyloarthritis (disorder)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229800002", "Twice weekly (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["422114001", "Once - dosing instruction fragment (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["86495002", "For (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["352730000", "Supra- (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258705008", "week (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["18720000", "In (attribute)"], ["900000000000475002", "Time (foundation metadata concept)"], ["200965009", "Plaque psoriasis (disorder)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229800002", "Twice weekly (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["422114001", "Once - dosing instruction fragment (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229800002", "Twice weekly (qualifier value)"], ["86495002", "For (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258705008", "week (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229800002", "Twice weekly (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["225769003", "Once a week (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["277022003", "Remission phase (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["86495002", "For (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222777002", "American Joint Committee on Cancer stage II:4 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255238004", "Continuous (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["1222777002", "American Joint Committee on Cancer stage II:4 (qualifier value)"], ["258705008", "week (qualifier value)"], ["86495002", "For (qualifier value)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["255397009", "Adult (qualifier value)|Adult"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["410546004", "Discontinued (qualifier value)"], ["18720000", "In (attribute)"], ["373067005", "No (qualifier value)"], ["255234002", "After (attribute)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258705008", "week (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["262126009", "Same (qualifier value)"], ["243073001", "Advice (regime/therapy)|Advice (regime/therapy)(procedure)"], ["420862001", "On (qualifier value)"], ["762636008", "Duration (property) (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229800002", "Twice weekly (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["422114001", "Once - dosing instruction fragment (qualifier value)"], ["123176000", "Weekly (qualifier value)|Weekly -RETIRED-"], ["67995009", "Special (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["40226000", "Impairment (finding)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["168666000", "SAME AS (attribute)"], ["86495002", "For (qualifier value)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["732829001", "64 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["376171000221106", "Pediatric population (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["263748003", "Established (qualifier value)"], ["373067005", "No (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["410502007", "Juvenile idiopathic arthritis (disorder)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["732371009", "0.4 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["229800002", "Twice weekly (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["180251004", "Subcutaneous injection (& for local action) (procedure)|Subcutaneous injection (& for local action)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["385673002", "Interval (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["258703001", "day (qualifier value)"], ["11896004", "Intermediate (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["732398008", "0.8 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["225769003", "Once a week (qualifier value)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["373067005", "No (qualifier value)"], ["255234002", "After (attribute)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["258706009", "month (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["242762006", "More (qualifier value)"], ["86495002", "For (qualifier value)"], ["416118004", "Administration (procedure)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["351726001", "Below (qualifier value)"], ["726527001", "Weight (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["373067005", "No (qualifier value)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["18720000", "In (attribute)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258707000", "year (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["18720000", "In (attribute)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["30190008", "Seen (qualifier value)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["258707000", "year (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["14497002", "Weekly (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["732398008", "0.8 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["260676000", "Use of (attribute)"], ["18720000", "In (attribute)"], ["351726001", "Below (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"], ["18720000", "In (attribute)"], ["282035009", "Juvenile|Juvenile (qualifier value)"], ["54690008", "Unknown (origin) (qualifier value)"], ["372091005", "Arthritis (finding)"], ["200965009", "Plaque psoriasis (disorder)"], ["424144002", "Current chronological age (observable entity)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258707000", "year (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["352730000", "Supra- (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["732398008", "0.8 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["225769003", "Once a week (qualifier value)"], ["86495002", "For (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222777002", "American Joint Committee on Cancer stage II:4 (qualifier value)"], ["258705008", "week (qualifier value)"], ["410546004", "Discontinued (qualifier value)"], ["18720000", "In (attribute)"], ["373067005", "No (qualifier value)"], ["255234002", "After (attribute)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258705008", "week (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["352730000", "Supra- (qualifier value)"], ["243073001", "Advice (regime/therapy)|Advice (regime/therapy)(procedure)"], ["420862001", "On (qualifier value)"], ["762636008", "Duration (property) (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["732398008", "0.8 (qualifier value)"], ["396163008", "Milligram/kilogram (qualifier value)|mg/kg (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["225769003", "Once a week (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["260676000", "Use of (attribute)"], ["18720000", "In (attribute)"], ["351726001", "Below (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258707000", "year (qualifier value)"], ["18720000", "In (attribute)"], ["1522000", "Plaque (morphologic abnormality)"], ["156369008", "Psoriasis|Psoriasis (disorder)"], ["260686004", "Method (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["180251004", "Subcutaneous injection (& for local action) (procedure)|Subcutaneous injection (& for local action)"], ["420955009", "Powder for solution (product)|Powder for solution (qualifier value)"], ["18720000", "In (attribute)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["61010005", "Solvent (substance)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["732810007", "6.6 (qualifier value)"], ["86495002", "For (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["733026001", "Vial (unit of presentation)"], ["18720000", "In (attribute)"], ["1681000175101", "Package - unit of product usage (qualifier value)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["86495002", "For (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420862001", "On (qualifier value)"], ["361390002", "Unintentional (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["410538000", "Scheduling (procedure)"], ["55919000", "Including (qualifier value)"], ["18720000", "In (attribute)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1681000175101", "Package - unit of product usage (qualifier value)"]], "ncit.posology": [["C2381", "Etanercept"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C16289", "Andorra"], ["C158169", "Buyei Chinese"], ["C73456", "Specialist Physician"], ["C16727", "India"], ["C15220", "Diagnosis"], ["C16289", "Andorra"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C2884", "Rheumatoid Arthritis"], ["C114357", "Juvenile Idiopathic Arthritis"], ["C61277", "Psoriatic Arthritis"], ["C84564", "Ankylosing Spondylitis"], ["C14460", "NON Mouse"], ["C192332", "Radiographic Staging"], ["C73439", "Axial"], ["C116778", "Spondyloarthritis"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C43508", "Oregon"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C16329", "Belgium"], ["C64974", "Give"], ["C53691", "Veterinary Patient"], ["C160555", "CaRD Regimen"], ["C2381", "Etanercept"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25429", "Availability"], ["C16727", "India"], ["C52874", "SPI1 wt Allele"], ["C69122", "Ten"], ["C113663", "Twenty Five"], ["C16289", "Andorra"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C2884", "Rheumatoid Arthritis"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C2381", "Etanercept"], ["C25382", "Administered"], ["C64497", "Twice Weekly"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C25382", "Administered"], ["C64526", "Once Weekly"], ["C101282", "Have"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C142675", "SAFE-Biopharma Standard"], ["C16289", "Andorra"], ["C49287", "Effective"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C61277", "Psoriatic Arthritis"], ["C84564", "Ankylosing Spondylitis"], ["C16289", "Andorra"], ["C14460", "NON Mouse"], ["C192332", "Radiographic Staging"], ["C73439", "Axial"], ["C116778", "Spondyloarthritis"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C2381", "Etanercept"], ["C25382", "Administered"], ["C64497", "Twice Weekly"], ["C43508", "Oregon"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C25382", "Administered"], ["C64576", "Once"], ["C67069", "Weekly"], ["C64956", "For"], ["C64916", "All"], ["C52874", "SPI1 wt Allele"], ["C75329", "Above"], ["C25429", "Availability"], ["C25474", "Data"], ["C48313", "Suggestion"], ["C76246", "Blood Group A"], ["C123619", "Clinical Response"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C114711", "Usually"], ["C25282", "Within"], ["C113426", "Twelve"], ["C29844", "Week"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C53279", "Continue"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C25594", "Negation"], ["C25282", "Within"], ["C25616", "Period"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C25382", "Administered"], ["C64497", "Twice Weekly"], ["C43508", "Oregon"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C25382", "Administered"], ["C64576", "Once"], ["C67069", "Weekly"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C64974", "Give"], ["C64497", "Twice Weekly"], ["C106184", "May"], ["C16329", "Belgium"], ["C64956", "For"], ["C64643", "Up to"], ["C113426", "Twelve"], ["C29844", "Week"], ["C16033", "Follow-Up"], ["C198613", "CFI wt Allele"], ["C158169", "Buyei Chinese"], ["C76246", "Blood Group A"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C64497", "Twice Weekly"], ["C43508", "Oregon"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C64526", "Once Weekly"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C2381", "Etanercept"], ["C54064", "Continue"], ["C65136", "Until"], ["C18246", "Remission"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C64643", "Up to"], ["C113753", "Twenty Four"], ["C29844", "Week"], ["C167446", "Continuous Heart Murmur"], ["C49236", "Therapeutic Procedure"], ["C151408", "Beyond"], ["C113753", "Twenty Four"], ["C29844", "Week"], ["C106184", "May"], ["C16329", "Belgium"], ["C64956", "For"], ["C65099", "Some"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C123600", "No Response"], ["C38008", "Post"], ["C113426", "Twelve"], ["C29844", "Week"], ["C198613", "CFI wt Allele"], ["C17095", "Reunion"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C2381", "Etanercept"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C172515", "S-Adenosylmethionine Measurement"], ["C192973", "Guidance"], ["C92667", "SPARC wt Allele"], ["C198202", "Treatment Duration in Days"], ["C16329", "Belgium"], ["C16033", "Follow-Up"], ["C25488", "Dose"], ["C16329", "Belgium"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C64497", "Twice Weekly"], ["C43508", "Oregon"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C64576", "Once"], ["C67069", "Weekly"], ["C18101", "Special Population"], ["C25225", "Renal"], ["C16289", "Andorra"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C16268", "Elderly"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C16289", "Andorra"], ["C70962", "Agent Administration"], ["C68869", "Are"], ["C172515", "S-Adenosylmethionine Measurement"], ["C71344", "Associate of Science"], ["C64956", "For"], ["C111798", "Eighteen"], ["C188328", "Sixty Four"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C17005", "Population Group"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16727", "India"], ["C16423", "Child"], ["C25150", "Age"], ["C61585", "Less Than"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C53269", "No Information Available"], ["C68869", "Are"], ["C25429", "Availability"], ["C114357", "Juvenile Idiopathic Arthritis"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C67401", "Milligram per Kilogram"], ["C64643", "Up to"], ["C76246", "Blood Group A"], ["C82868", "Maximum Value Derivation Technique"], ["C52874", "SPI1 wt Allele"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C97722", "PER1 wt Allele"], ["C25488", "Dose"], ["C64974", "Give"], ["C64497", "Twice Weekly"], ["C71344", "Associate of Science"], ["C76246", "Blood Group A"], ["C13353", "Subcutaneous"], ["C122632", "Injection Dosing Unit"], ["C62355", "With"], ["C75889", "PAX6 wt Allele"], ["C25543", "Interval"], ["C52874", "SPI1 wt Allele"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25301", "Day"], ["C94545", "Between"], ["C25488", "Dose"], ["C43508", "Oregon"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C66839", "Eight"], ["C67401", "Milligram per Kilogram"], ["C64643", "Up to"], ["C76246", "Blood Group A"], ["C82868", "Maximum Value Derivation Technique"], ["C52874", "SPI1 wt Allele"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C97722", "PER1 wt Allele"], ["C25488", "Dose"], ["C64974", "Give"], ["C64526", "Once Weekly"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C123600", "No Response"], ["C38008", "Post"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C29846", "Month"], ["C69122", "Ten"], ["C16818", "Mammography"], ["C41275", "Vial"], ["C53294", "Pharmaceutical Strength"], ["C106184", "May"], ["C16329", "Belgium"], ["C128667", "More"], ["C64956", "For"], ["C70962", "Agent Administration"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16423", "Child"], ["C62355", "With"], ["C114357", "Juvenile Idiopathic Arthritis"], ["C75330", "Below"], ["C48192", "Importance Weight"], ["C52874", "SPI1 wt Allele"], ["C113663", "Twenty Five"], ["C16771", "Kyrgyzstan"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C71104", "Clinical Trial"], ["C101282", "Have"], ["C16727", "India"], ["C16423", "Child"], ["C25150", "Age"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C159124", "GDC Treatment Outcome Terminology"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C29848", "Year"], ["C142988", "Limited"], ["C49667", "Safety Study"], ["C25474", "Data"], ["C25516", "From"], ["C76246", "Blood Group A"], ["C129000", "Patient Registry Study"], ["C48313", "Suggestion"], ["C49667", "Safety Study"], ["C84385", "Profile"], ["C16727", "India"], ["C16423", "Child"], ["C25516", "From"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C159124", "GDC Treatment Outcome Terminology"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C72665", "Similarity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16727", "India"], ["C16289", "Andorra"], ["C16423", "Child"], ["C25150", "Age"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C29848", "Year"], ["C16289", "Andorra"], ["C65140", "When"], ["C67069", "Weekly"], ["C62355", "With"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C66839", "Eight"], ["C67401", "Milligram per Kilogram"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C44483", "Applicable"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16727", "India"], ["C16423", "Child"], ["C25150", "Age"], ["C75330", "Below"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"], ["C16727", "India"], ["C41184", "Indication"], ["C28242", "Idiopathic"], ["C2883", "Arthritis"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C106312", "Advanced Glycation End Product"], ["C172979", "Fear Score 6"], ["C29848", "Year"], ["C16289", "Andorra"], ["C75329", "Above"], ["C25197", "Recommendation"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C66839", "Eight"], ["C67401", "Milligram per Kilogram"], ["C64643", "Up to"], ["C76246", "Blood Group A"], ["C82868", "Maximum Value Derivation Technique"], ["C52874", "SPI1 wt Allele"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C97722", "PER1 wt Allele"], ["C25488", "Dose"], ["C64526", "Once Weekly"], ["C64956", "For"], ["C64643", "Up to"], ["C113753", "Twenty Four"], ["C29844", "Week"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C123600", "No Response"], ["C38008", "Post"], ["C113426", "Twelve"], ["C29844", "Week"], ["C198613", "CFI wt Allele"], ["C17095", "Reunion"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C2381", "Etanercept"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C75329", "Above"], ["C192973", "Guidance"], ["C142170", "On Treatment"], ["C25330", "Duration"], ["C16329", "Belgium"], ["C16033", "Follow-Up"], ["C25488", "Dose"], ["C16329", "Belgium"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C66839", "Eight"], ["C67401", "Milligram per Kilogram"], ["C64643", "Up to"], ["C76246", "Blood Group A"], ["C82868", "Maximum Value Derivation Technique"], ["C52874", "SPI1 wt Allele"], ["C105785", "Fifty"], ["C16818", "Mammography"], ["C97722", "PER1 wt Allele"], ["C25488", "Dose"], ["C64526", "Once Weekly"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C44483", "Applicable"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16727", "India"], ["C16423", "Child"], ["C25150", "Age"], ["C75330", "Below"], ["C172979", "Fear Score 6"], ["C29848", "Year"], ["C16727", "India"], ["C41184", "Indication"], ["C95603", "Plaque"], ["C3346", "Psoriasis"], ["C85492", "CDISC SDTM Method Terminology"], ["C52874", "SPI1 wt Allele"], ["C70962", "Agent Administration"], ["C2381", "Etanercept"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25382", "Administered"], ["C158169", "Buyei Chinese"], ["C13353", "Subcutaneous"], ["C122632", "Injection Dosing Unit"], ["C2381", "Etanercept"], ["C42973", "Powder for Solution Dosage Form"], ["C16329", "Belgium"], ["C16727", "India"], ["C105723", "ECOG Performance Status 1"], ["C16816", "Mali"], ["C52874", "SPI1 wt Allele"], ["C198945", "Solvent Exposure"], ["C201357", "Before Timing Type"], ["C25340", "Use"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C172979", "Fear Score 6"], ["C61528", "Comprehensive"], ["C42688", "Instruction"], ["C64956", "For"], ["C25625", "Preparation"], ["C16289", "Andorra"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C41275", "Vial"], ["C68869", "Are"], ["C64974", "Give"], ["C16727", "India"], ["C79887", "Package"], ["C97006", "Leaflet"], ["C68872", "Square Mile"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C42688", "Instruction"], ["C64956", "For"], ["C25625", "Preparation"], ["C16289", "Andorra"], ["C75889", "PAX6 wt Allele"], ["C122632", "Injection Dosing Unit"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C25480", "Details"], ["C42688", "Instruction"], ["C92667", "SPARC wt Allele"], ["C118257", "Unintentional"], ["C43508", "Oregon"], ["C172421", "Schedule"], ["C166400", "Inclusive"], ["C54031", "Missing"], ["C25488", "Dose"], ["C68869", "Are"], ["C80514", "Provide"], ["C16727", "India"], ["C68872", "Square Mile"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C52874", "SPI1 wt Allele"], ["C79887", "Package"], ["C97006", "Leaflet"]], "rxnorm.posology": [["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["1649574", "Injection"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["1649574", "Injection"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["1649574", "Injection"], ["216891", "Enbrel"]], "loinc.posology": [["LP94823-9", "Treatment"], ["LA28116-4", "Specialist"], ["LA22004-8", "IN"], ["MTHU008876", "Diagnosis"], ["LP94823-9", "Treatment"], ["LA15161-5", "Rheumatoid Arthritis"], ["LA31871-9", "Idiopathic"], ["MTHU020793", "Arthritis"], ["MTHU020793", "Arthritis"], ["LA31822-2", "Spondylitis"], ["LP266843-4", "Axial"], ["LA15165-6", "Psoriasis"], ["LA22025-3", "OR"], ["LA15165-6", "Psoriasis"], ["LP29256-2", "given"], ["LP66710-2", "Patient"], ["LP29708-2", "Cardiology"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA13942-0", "10"], ["LA19281-7", "25"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LA15161-5", "Rheumatoid Arthritis"], ["LA19281-7", "25"], ["LP15217-0", "Mg"], ["LA14664-9", "Twice"], ["LA18891-4", "Weekly"], ["LP200075-2", "IS"], ["MTHU065481", "Dose"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LA14312-5", "Once"], ["LA18891-4", "Weekly"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["MTHU020793", "Arthritis"], ["LA31822-2", "Spondylitis"], ["LP266843-4", "Axial"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA19281-7", "25"], ["LP15217-0", "Mg"], ["LA14664-9", "Twice"], ["LA18891-4", "Weekly"], ["LA22025-3", "OR"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LA14312-5", "Once"], ["LA18891-4", "Weekly"], ["LA18187-7", "All"], ["LA14991-6", "Above"], ["MTHU008862", "Indications"], ["LP17763-1", "A"], ["LP7787-7", "Clinical"], ["LP200075-2", "IS"], ["LA14747-2", "Usually"], ["LA32245-5", "Achieved"], ["LA14558-3", "12"], ["LA9000-6", "Weeks"], ["LP94823-9", "Treatment"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LA21291-2", "Not"], ["LP125120-8", "Time period"], ["LA15165-6", "Psoriasis"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA19281-7", "25"], ["LP15217-0", "Mg"], ["LA14664-9", "Twice"], ["LA18891-4", "Weekly"], ["LA22025-3", "OR"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LA14312-5", "Once"], ["LA18891-4", "Weekly"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LP29256-2", "given"], ["LA14664-9", "Twice"], ["LA18891-4", "Weekly"], ["LA14161-6", "May"], ["LA14558-3", "12"], ["LA9000-6", "Weeks"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LA19281-7", "25"], ["LP15217-0", "Mg"], ["LA14664-9", "Twice"], ["LA18891-4", "Weekly"], ["LA22025-3", "OR"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LA14312-5", "Once"], ["LA18891-4", "Weekly"], ["LP94823-9", "Treatment"], ["LA9507-0", "Continue"], ["LA28783-1", "Remission"], ["LP200075-2", "IS"], ["LA32245-5", "Achieved"], ["LA9000-6", "Weeks"], ["LA16902-1", "Continuous"], ["LP267221-2", "Therapy"], ["LA9000-6", "Weeks"], ["LA14161-6", "May"], ["LA14973-4", "Some"], ["LA13524-6", "Adult"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LA10996-9", "No response"], ["LA14558-3", "12"], ["LA9000-6", "Weeks"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP94823-9", "Treatment"], ["LP200075-2", "IS"], ["LA11009-0", "Same"], ["LP34220-1", "Guidance"], ["MTHU048674", "Treatment duration"], ["MTHU065481", "Dose"], ["LA19281-7", "25"], ["LP15217-0", "Mg"], ["LA14664-9", "Twice"], ["LA18891-4", "Weekly"], ["LA22025-3", "OR"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["LA14312-5", "Once"], ["LA18891-4", "Weekly"], ["MTHU065909", "Renal"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA11009-0", "Same"], ["MTHU010047", "Age"], ["LP62263-6", "Population"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LA16823-9", "Less"], ["LA31719-0", "2 years"], ["LA21291-2", "Not"], ["LA32-8", "No"], ["LA31871-9", "Idiopathic"], ["MTHU020793", "Arthritis"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA24580-5", "0.4"], ["LP15217-0", "Mg"], ["LP17763-1", "A"], ["LP6972-6", "maximum"], ["LA19281-7", "25"], ["LP15217-0", "Mg"], ["MTHU065481", "Dose"], ["LP29256-2", "given"], ["LA14664-9", "Twice"], ["LA18891-4", "Weekly"], ["LP17763-1", "A"], ["LA9451-1", "Subcutaneous"], ["LA14542-7", "Injection"], ["LA29325-0", "3-4 days"], ["LA22025-3", "OR"], ["LA24586-2", "0.8"], ["LP15217-0", "Mg"], ["LP17763-1", "A"], ["LP6972-6", "maximum"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["MTHU065481", "Dose"], ["LP29256-2", "given"], ["LA14312-5", "Once"], ["LA18891-4", "Weekly"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LA10996-9", "No response"], ["LP20592-9", "4"], ["MTHU068094", "Months"], ["LA13942-0", "10"], ["LP15217-0", "Mg"], ["LA20376-2", "Vial"], ["MTHU001445", "Strength"], ["LA14161-6", "May"], ["LA16824-7", "More"], ["LA14987-4", "Below"], ["LP221195-3", "Weight"], ["LA19281-7", "25"], ["LA32-8", "No"], ["MTHU854704", "Clinical trials"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["MTHU000002", "Clinical Class"], ["LA31720-8", "3 years"], ["LA6484-5", "Limited"], ["LA17589-5", "Safety"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LA17589-5", "Safety"], ["LA22004-8", "IN"], ["MTHU000002", "Clinical Class"], ["LA31720-8", "3 years"], ["MTHU010047", "Age"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LA31721-6", "4 years"], ["LA14216-8", "Week"], ["LA24586-2", "0.8"], ["LP15217-0", "Mg"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LA14987-4", "Below"], ["LA31719-0", "2 years"], ["LA22004-8", "IN"], ["LA31871-9", "Idiopathic"], ["MTHU020793", "Arthritis"], ["LA15165-6", "Psoriasis"], ["MTHU010047", "Age"], ["LP20594-5", "6"], ["LA14991-6", "Above"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA24586-2", "0.8"], ["LP15217-0", "Mg"], ["LP17763-1", "A"], ["LP6972-6", "maximum"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["MTHU065481", "Dose"], ["LA14312-5", "Once"], ["LA18891-4", "Weekly"], ["LA9000-6", "Weeks"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LA10996-9", "No response"], ["LA14558-3", "12"], ["LA9000-6", "Weeks"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP94823-9", "Treatment"], ["LP200075-2", "IS"], ["LA14991-6", "Above"], ["LP34220-1", "Guidance"], ["MTHU048674", "Treatment duration"], ["MTHU065481", "Dose"], ["LA24586-2", "0.8"], ["LP15217-0", "Mg"], ["LP17763-1", "A"], ["LP6972-6", "maximum"], ["LA28854-0", "50"], ["LP15217-0", "Mg"], ["MTHU065481", "Dose"], ["LA14312-5", "Once"], ["LA18891-4", "Weekly"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LA22004-8", "IN"], ["LA19751-9", "Aged"], ["LA14987-4", "Below"], ["LP20594-5", "6"], ["LA22004-8", "IN"], ["LA15165-6", "Psoriasis"], ["LP72939-9", "Method"], ["LP200075-2", "IS"], ["LA9451-1", "Subcutaneous"], ["LA14542-7", "Injection"], ["LA19717-0", "Reconstituted"], ["LA22004-8", "IN"], ["LA6112-2", "1"], ["LP20594-5", "6"], ["LP20594-5", "6"], ["LA8975-0", "Comprehensive"], ["LP6820-7", "Instructions"], ["LA19717-0", "Reconstituted"], ["LA20376-2", "Vial"], ["LP29256-2", "given"], ["LA22004-8", "IN"], ["LP36790-1", "7"], ["LP6820-7", "Instructions"], ["LA14542-7", "Injection"], ["LP6820-7", "Instructions"], ["LA14094-9", "Unintentional"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP20591-1", "3"]], "snomed.contraindications": [["257550005", "Hypersensitivity (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["261217004", "Substance (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["186392004", "(Septicaemia NOS) or (sepsis)|(Septicaemia NOS) or (sepsis) (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["186392004", "(Septicaemia NOS) or (sepsis)|(Septicaemia NOS) or (sepsis) (disorder)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["55919000", "Including (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255471002", "Localized (qualifier value)"]], "ncit.contraindications": [["C3114", "Hypersensitivity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C154405", "Active State"], ["C45306", "Substance"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"], ["C3364", "Septicemia"], ["C43508", "Oregon"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C3364", "Septicemia"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C2381", "Etanercept"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C154405", "Active State"], ["C166400", "Inclusive"], ["C4981", "Chronic Graft Versus Host Disease"], ["C43508", "Oregon"], ["C14146", "Localized"]], "rxnorm.contraindications": [["T167", "Substance"], ["216891", "Enbrel"]], "loinc.contraindications": [["LA16666-2", "Active"], ["T167", "Substance"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP20594-5", "6"], ["LA6112-2", "1"], ["LA22025-3", "OR"], ["LP94823-9", "Treatment"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA16666-2", "Active"], ["LP74970-2", "Infections"], ["LA28752-6", "Chronic"], ["LA22025-3", "OR"], ["LP74970-2", "Infections"]], "snomed.special_warnings": [["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["734841007", "Name (property) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["410681005", "Count of entities (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["116154003", "Patient (person)"], ["12953007", "File, device (physical object)"], ["86495002", "For (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255234002", "After (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["30507006", "Into (attribute)"], ["255586005", "Mean (qualifier value)"], ["63911002", "Excretory function (observable entity)|Excretory function (function)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387045004", "Etanercept (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["26175008", "Approximate (qualifier value)"], ["732853007", "70 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["609432006", "Concept model range (foundation metadata concept)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["725125005", "300 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["186392004", "(Septicaemia NOS) or (sepsis)|(Septicaemia NOS) or (sepsis) (disorder)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["55919000", "Including (qualifier value)"], ["10179008", "Invasive (qualifier value)"], ["186315001", "Listeriosis|Listeriosis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["26726000", "Legionella infection (disorder)"], ["733985002", "Reported (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["732732008", "4.8 (qualifier value)"], ["42752001", "Due to (attribute)"], ["413624004", "Bacteria (organism)"], ["243368001", "Genus Mycobacterium (organism)|Mycobacterium (organism)"], ["414561005", "Kingdom Fungi (organism)"], ["49872002", "Virus (organism)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["55919000", "Including (qualifier value)"], ["243643009", "Protozoan (organism)"], ["18720000", "In (attribute)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419620001", "Death (event)"], ["18720000", "In (attribute)"], ["86495002", "For (qualifier value)"], ["116154003", "Patient (person)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["86495002", "For (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["266214005", "(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses) (disorder)|(Dermatophytosis &/or tinea &/or ringworm) or (fungal infections) or (mycoses)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255219008", "New infection (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["410546004", "Discontinued (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["116154003", "Patient (person)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["256235009", "Exercise (observable entity)|Exercise (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["86005002", "Advanced (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["556001", "Bad (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["427099000", "Active tuberculosis (disorder)"], ["55919000", "Including (qualifier value)"], ["154291001", "Miliary tuberculosis|Miliary tuberculosis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["738985004", "Pulmonary (intended site)"], ["246267002", "Location (attribute)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["86495002", "For (qualifier value)"], ["51440002", "Right and left (qualifier value)"], ["55561003", "Active (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["73425007", "Inactive (qualifier value)"], ["44104002", "Latent (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["129265001", "Evaluation - action (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["74188005", "Medical (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["160476009", "Social / personal history observable (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["9130008", "Previous (qualifier value)"], ["11723008", "Contact with (contextual qualifier) (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["9130008", "Previous (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["15240007", "Current (qualifier value)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["360156006", "Screening - procedure intent (qualifier value)"], ["272393004", "Tests (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["164976005", "Tuberculin test - Mantoux (& [Heaf] or [Mantoux])|Tuberculin test - Mantoux (& [Heaf] or [Mantoux]) (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["399208008", "Plain chest X-ray (procedure)"], ["398166005", "Performed (qualifier value)"], ["18720000", "In (attribute)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["255470001", "Local (qualifier value)"], ["738991002", "Apply (administration method)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["844005", "Behavior finding (finding)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["272393004", "Tests (qualifier value)"], ["18720000", "In (attribute)"], ["116154003", "Patient (person)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["61707005", "False negative (qualifier value)"], ["164976005", "Tuberculin test - Mantoux (& [Heaf] or [Mantoux])|Tuberculin test - Mantoux (& [Heaf] or [Mantoux]) (procedure)"], ["18720000", "In (attribute)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["161900002", "Feels unwell (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["427099000", "Active tuberculosis (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["73425007", "Inactive (qualifier value)"], ["44104002", "Latent (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["86495002", "For (qualifier value)"], ["44104002", "Latent (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["385652002", "Started (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["277132007", "Therapeutic procedure (procedure)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255470001", "Local (qualifier value)"], ["18720000", "In (attribute)"], ["705235004", "Balance (physical object)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["260358002", "Very (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["74188005", "Medical (qualifier value)"], ["243073001", "Advice (regime/therapy)|Advice (regime/therapy)(procedure)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["7196007", "Suggestive of (attribute)"], ["187285000", "Tuberculosis (disorder)|Tuberculosis"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["284523002", "Persistent cough (finding)"], ["816160009", "Measured weight loss (observable entity)"], ["62482003", "Low (qualifier value)"], ["277420004", "Grade|Grade (qualifier value)"], ["386661006", "Fever (finding)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255234002", "After (attribute)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["18720000", "In (attribute)"], ["73154007", "Infected (morphologic abnormality)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["81665004", "Hepatitis B virus (organism)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["55919000", "Including (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["55919000", "Including (qualifier value)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["18720000", "In (attribute)"], ["394424008", "Positive|Positive (qualifier value)"], ["406010001", "Hepatitis B surface antigen not detected (finding)|Hepatitis B surface antigen negative (finding)"], ["86495002", "For (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["10828004", "Positive (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["11429006", "Consultation (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["309343006", "Physician (occupation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["66071002", "Viral hepatitis type B (disorder)|Type B viral hepatitis (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["73154007", "Infected (morphologic abnormality)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["55561003", "Active (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["277132007", "Therapeutic procedure (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["261028005", "Several (qualifier value)"], ["258705008", "week (qualifier value)"], ["255260001", "Following (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["88323005", "Adequate (qualifier value)"], ["73154007", "Infected (morphologic abnormality)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["257551009", "Infection (disorder)|Infection"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["254648000", "Effective (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["230993007", "Worsening (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["186643004", "Hepatitis C (disorder)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["230993007", "Worsening (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["186643004", "Hepatitis C (disorder)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["93871000119101", "History of hepatitis C (situation)"], ["68405009", "Concurrent (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["68405009", "Concurrent (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["47429007", "Associated with (attribute)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["303011007", "Neutropenic disorder (disorder)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["260676000", "Use of (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421777009", "Abatacept (substance)"], ["18720000", "In (attribute)"], ["58147004", "Clinical (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421777009", "Abatacept (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["35105006", "Increased (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["89780004", "Combined (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["47429007", "Associated with (attribute)"], ["416118004", "Administration (procedure)"], ["733985002", "Reported (qualifier value)"], ["846575004", "Angioedema (morphologic abnormality)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["269433002", "(Angioneurotic oedema) or (urticaria) (disorder)|(Angioneurotic oedema) or (urticaria)"], ["42745003", "Serious (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["39579001", "Anaphylaxis (disorder)"], ["277132007", "Therapeutic procedure (procedure)"], ["410546004", "Discontinued (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["86495002", "For (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["55919000", "Including (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["65897001", "Against (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["257552002", "Inflammation (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["255386009", "Immune (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["224699009", "Study (environment)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222852005", "American Joint Committee on Cancer stage IV:9 (qualifier value)"], ["255397009", "Adult (qualifier value)|Adult"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["28995006", "Treated with (attribute)"], ["41647002", "No evidence of (contextual qualifier) (qualifier value)"], ["255339005", "Depression - motion (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["410657003", "Type (attribute)"], ["257550005", "Hypersensitivity (qualifier value)"], ["255339005", "Depression - motion (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["112133008", "Immunoglobulin (substance)"], ["258395000", "Levels (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["263703002", "Changed status (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["771387000", "Substance with effector mechanism of action (substance)"], ["362837007", "Entire cell (body structure)|Entire cell (cell)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["410502007", "Juvenile idiopathic arthritis (disorder)"], ["154325003", "Varicella infection (disorder)|Varicella infection"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["301770000", "Aseptic meningitis (disorder)"], ["723506003", "Resolved (qualifier value)"], ["45169001", "Without (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["394653002", "Significant|Significant (qualifier value)"], ["444453009", "Exposure to varicella (event)"], ["49872002", "Virus (organism)"], ["421286000", "Discontinue - dosing instruction imperative (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["169443000", "Preventive procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["38907003", "Varicella (disorder)"], ["62294009", "Varicella-zoster immune globulin (substance)|Product containing Varicella-zoster virus antibody (medicinal product)|Varicella-zoster immune globulin (product)|Product containing varicella-zoster immune globulin (medicinal product)|Product containing varicella-zoster virus antibody (medicinal product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["64572001", "Disease (disorder)"], ["736678006", "Solid (state of matter)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["181469002", "Entire skin (body structure)"], ["187597000", "(Neoplasms) or (cancers) (disorder)|(Neoplasms) or (cancers)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["256220008", "Various (substance)"], ["55919000", "Including (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["269561006", "(Bronchus carcinoma) or (lung carcinoma) or (Ca trachea/bronchus/lung)|(Bronchus carcinoma) or (lung carcinoma) or (Ca trachea/bronchus/lung) (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1163043007", "Malignant lymphoma (morphologic abnormality)"], ["18720000", "In (attribute)"], ["732732008", "4.8 (qualifier value)"], ["18720000", "In (attribute)"], ["31509003", "Controlled (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["242762006", "More (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1163043007", "Malignant lymphoma (morphologic abnormality)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["246106000", "Control (attribute)"], ["246454002", "Occurrence (attribute)"], ["89292003", "Rare (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["308273005", "Follow-up status (finding)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86495002", "For (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1162768007", "Leukemia (morphologic abnormality)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["86495002", "For (qualifier value)"], ["1163043007", "Malignant lymphoma (morphologic abnormality)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1162768007", "Leukemia (morphologic abnormality)"], ["18720000", "In (attribute)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255511005", "Long (qualifier value)"], ["10904000", "Orthostatic body position (finding)"], ["55561003", "Active (qualifier value)"], ["128139000", "Inflammatory disorder (disorder)"], ["420862001", "On (qualifier value)"], ["15240007", "Current (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1162768007", "Leukemia (morphologic abnormality)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["736678006", "Solid (state of matter)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["277132007", "Therapeutic procedure (procedure)"], ["86495002", "For (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1240414004", "Malignant neoplasm (morphologic abnormality)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["399166001", "Fatal (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["84422007", "Young (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222775005", "American Joint Committee on Cancer stage II:2 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["28995006", "Treated with (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["1222747008", "American Joint Committee on Cancer stage I:8 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["55919000", "Including (qualifier value)"], ["18720000", "In (attribute)"], ["26175008", "Approximate (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["74964007", "Other (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86553008", "Immunosuppressive therapy (procedure)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["28995006", "Treated with (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["181469002", "Entire skin (body structure)"], ["187597000", "(Neoplasms) or (cancers) (disorder)|(Neoplasms) or (cancers)"], ["2092003", "Malignant melanoma, no ICD-O subtype (morphologic abnormality)|Malignant melanoma, morphology (morphologic abnormality)|Malignant melanoma, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|Malignant melanoma (morphologic abnormality)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["2092003", "Malignant melanoma, no ICD-O subtype (morphologic abnormality)|Malignant melanoma, morphology (morphologic abnormality)|Malignant melanoma, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|Malignant melanoma (morphologic abnormality)"], ["372130007", "Malignant neoplasm of skin (disorder)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["8612007", "Tumor necrosis factor (substance)"], ["55919000", "Including (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["253001006", "Merkel cell carcinoma (disorder)"], ["733985002", "Reported (qualifier value)"], ["260358002", "Very (qualifier value)"], ["27789000", "Infrequent (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["123115008", "Periodic (qualifier value)|Periodic -RETIRED-"], ["181469002", "Entire skin (body structure)"], ["302199004", "Examination - action (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["86495002", "For (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["372130007", "Malignant neoplasm of skin (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["242762006", "More (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["246106000", "Control (attribute)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["156369008", "Psoriasis|Psoriasis (disorder)"], ["170310008", "Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)]) (procedure)|Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)])"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["420862001", "On (qualifier value)"], ["2603003", "Secondary (qualifier value)"], ["258150004", "Transmission (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1305003", "Double (qualifier value)"], ["277675000", "Blind (finding)"], ["31509003", "Controlled (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["224699009", "Study (environment)"], ["18720000", "In (attribute)"], ["255397009", "Adult (qualifier value)|Adult"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["732558005", "184 (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1801000221105", "Vaccine product containing only Streptococcus pneumoniae capsular polysaccharide antigen conjugated (medicinal product)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["258705008", "week (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["18720000", "In (attribute)"], ["224699009", "Study (environment)"], ["4757001", "Most (qualifier value)"], ["372091005", "Arthritis (finding)"], ["371150009", "Able (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["706480006", "Mount (physical object)"], ["254648000", "Effective (qualifier value)"], ["112130006", "B lymphocyte (cell)"], ["35024006", "Immune response (function)|Immune response, function (observable entity)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1801000221105", "Vaccine product containing only Streptococcus pneumoniae capsular polysaccharide antigen conjugated (medicinal product)"], ["18720000", "In (attribute)"], ["18403000", "Aggregate (qualifier value)"], ["261122009", "Lower (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["57176003", "Few (qualifier value)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["26310004", "Folded structure (morphologic abnormality)"], ["18720000", "In (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["261665006", "Unknown (qualifier value)"], ["30621004", "Autoantibody (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["263680009", "Autoimmune (qualifier value)|Autoimmune process (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["57407000", "Hematologic (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["127034005", "Pancytopenia (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260358002", "Very (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["306058006", "Aplastic anemia (disorder)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["399166001", "Fatal (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["9130008", "Previous (qualifier value)"], ["392521001", "History of (contextual qualifier) (qualifier value)"], ["87612001", "Blood (substance)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["116154003", "Patient (person)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["7196007", "Suggestive of (attribute)"], ["87612001", "Blood (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["255222005", "Persistent (qualifier value)"], ["386661006", "Fever (finding)"], ["304521001", "Sore throat|Sore throat (finding)"], ["308492005", "Contusion - lesion (morphologic abnormality)|Bruise - lesion (morphologic abnormality)"], ["303123004", "Bleeding (disorder)|Bleeding"], ["420862001", "On (qualifier value)"], ["394433005", "Immediate (qualifier value)|Immediate"], ["74188005", "Medical (qualifier value)"], ["243073001", "Advice (regime/therapy)|Advice (regime/therapy)(procedure)"], ["55919000", "Including (qualifier value)"], ["261015003", "Full (qualifier value)"], ["87612001", "Blood (substance)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["87612001", "Blood (substance)"], ["410546004", "Discontinued (qualifier value)"], ["267679005", "Neurological disorder (& [nervous system disease] or [CNS diseases] or [sense organ disease])|Neurological disorder (& [nervous system disease] or [CNS diseases] or [sense organ disease]) (disorder)"], ["89292003", "Rare (qualifier value)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["64572001", "Disease (disorder)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["732732008", "4.8 (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["14414005", "Peripheral (qualifier value)"], ["55919000", "Including (qualifier value)"], ["40956001", "Guillain-Barr\u00e9 syndrome (disorder)|Guillain-Barre syndrome (disorder)"], ["444728005", "Chronic inflammatory demyelinating polyneuritis (disorder)|Chronic inflammatory demyelinating polyneuropathy (disorder)"], ["23414001", "Peripheral demyelinating neuropathy (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["230591002", "Motor neuropathy with multiple conduction block (disorder)"], ["373067005", "No (qualifier value)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["398166005", "Performed (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["155023009", "Multiple sclerosis (disorder)|Multiple sclerosis"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["74964007", "Other (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["155023009", "Multiple sclerosis (disorder)|Multiple sclerosis"], ["18720000", "In (attribute)"], ["64572001", "Disease (disorder)"], ["257733005", "Activity (observable entity)|Activities (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["129265001", "Evaluation - action (qualifier value)"], ["55919000", "Including (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1199008", "Neurologic (qualifier value)"], ["386053000", "Evaluation procedure (procedure)|Patient evaluation procedure (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["263852005", "Recent episode (qualifier value)"], ["77374008", "Onset of (contextual qualifier) (qualifier value)"], ["64572001", "Disease (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["64572001", "Disease (disorder)"], ["229554006", "Combination therapy (regime/therapy)|Combination therapy (procedure)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["258707000", "year (qualifier value)"], ["762636008", "Duration (property) (qualifier value)"], ["18720000", "In (attribute)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["89780004", "Combined (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["263803006", "Long-term (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["263803006", "Long-term (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["64572001", "Disease (disorder)"], ["263748003", "Established (qualifier value)"], ["260676000", "Use of (attribute)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["31099001", "Systemic (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["266798006", "Phototherapy (& NEC)|Phototherapy (& NEC) (procedure)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["156369008", "Psoriasis|Psoriasis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["40226000", "Impairment (finding)"], ["420862001", "On (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410525008", "Needed (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["40226000", "Impairment (finding)"], ["58147004", "Clinical (qualifier value)"], ["18720000", "In (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["195108009", "Heart failure: [right] or [congestive]|Heart failure: [right] or [congestive] (disorder)"], ["84114007", "Heart failure (disorder)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["261583007", "Using (attribute)"], ["18720000", "In (attribute)"], ["195108009", "Heart failure: [right] or [congestive]|Heart failure: [right] or [congestive] (disorder)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["230993007", "Worsening (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["45169001", "Without (attribute)"], ["7882003", "Identified (qualifier value)"], ["18720000", "In (attribute)"], ["89292003", "Rare (qualifier value)"], ["276139006", "< (qualifier value)|Less-than symbol < (qualifier value)"], ["732332006", "0.1 (qualifier value)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["261021004", "New (qualifier value)|New [dup] (qualifier value)"], ["246100006", "Onset (attribute)"], ["55919000", "Including (qualifier value)"], ["18720000", "In (attribute)"], ["45169001", "Without (attribute)"], ["36692007", "Known (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["266275004", "Cardiovascular disease (& [circulatory] or [heart]) (disorder)|Cardiovascular disease (& [circulatory] or [heart])"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["351726001", "Below (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["255509001", "Large (qualifier value)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["260676000", "Use of (attribute)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["264499004", "Early (qualifier value)"], ["42752001", "Due to (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["230993007", "Worsening (qualifier value)"], ["18720000", "In (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["235875008", "Alcoholic hepatitis (disorder)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["21191007", "Phase (attribute)|Phase (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["224699009", "Study (environment)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222851003", "American Joint Committee on Cancer stage IV:8 (qualifier value)"], ["28995006", "Treated with (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["371924009", "Moderate to severe (qualifier value)"], ["235875008", "Alcoholic hepatitis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["409651001", "Mortality rate (observable entity)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["255234002", "After (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258706009", "month (qualifier value)"], ["18720000", "In (attribute)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["235875008", "Alcoholic hepatitis (disorder)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["261583007", "Using (attribute)"], ["18720000", "In (attribute)"], ["371924009", "Moderate to severe (qualifier value)"], ["235875008", "Alcoholic hepatitis (disorder)"], ["390001000", "Wegener's granulomatosis (disorder)|Wegener's granulomatosis"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["18720000", "In (attribute)"], ["255397009", "Adult (qualifier value)|Adult"], ["28995006", "Treated with (attribute)"], ["20401003", "With (attribute)"], ["277132007", "Therapeutic procedure (procedure)"], ["55919000", "Including (qualifier value)"], ["387420009", "Cyclophosphamide (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260528009", "Median (qualifier value)"], ["762636008", "Duration (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258706009", "month (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["254648000", "Effective (qualifier value)"], ["86495002", "For (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["443138004", "Granulomatosis (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["738904002", "Cutaneous (intended site)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["256220008", "Various (substance)"], ["261664005", "Types (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["246106000", "Control (attribute)"], ["389109008", "Group (social concept)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["443138004", "Granulomatosis (disorder)"], ["302866003", "Hypoglycemia (disorder)"], ["18720000", "In (attribute)"], ["69845001", "Received therapy or drug for (contextual qualifier) (qualifier value)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["255260001", "Following (attribute)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["2533004", "Drug (substance)"], ["86495002", "For (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["289928003", "Reduction plasty (qualifier value)"], ["18720000", "In (attribute)"], ["2533004", "Drug (substance)"], ["18720000", "In (attribute)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67995009", "Special (qualifier value)"], ["18720000", "In (attribute)"], ["272111008", "Phase 3 (qualifier value)"], ["18720000", "In (attribute)"], ["156471009", "Rheumatoid arthritis (disorder)|Rheumatoid arthritis"], ["156370009", "Psoriatic arthritis|Psoriatic arthritis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["156619005", "Ankylosing spondylitis (disorder)|Ankylosing spondylitis"], ["373067005", "No (qualifier value)"], ["18720000", "In (attribute)"], ["272379006", "Events (event)|Event (event)"], ["42745003", "Serious (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["18720000", "In (attribute)"], ["424144002", "Current chronological age (observable entity)"], ["264695004", "65 (qualifier value)|Arabic numeral 65 (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["247759001", "Attention [Ambiguous]|Attention (finding)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["246454002", "Occurrence (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["376171000221106", "Pediatric population (qualifier value)"], ["170310008", "Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)]) (procedure)|Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)])"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["410672004", "Date property (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["170310008", "Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)]) (procedure)|Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)])"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["15240007", "Current (qualifier value)"], ["243188009", "Immunisation [Ambiguous]|Immunisation (procedure)"], ["288556008", "Before (attribute)"], ["277132007", "Therapeutic procedure (procedure)"], ["170310008", "Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)]) (procedure)|Infectious disease: prevent &/or control (& [immunisations] or [inoculations - prophylactic] or [vaccinations (& travel)])"], ["352730000", "Supra- (qualifier value)"]], "ncit.special_warnings": [["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C52874", "SPI1 wt Allele"], ["C28226", "Biological"], ["C71898", "Proprietary Name"], ["C16289", "Andorra"], ["C104504", "Batch Number"], ["C25463", "Count"], ["C52874", "SPI1 wt Allele"], ["C25382", "Administered"], ["C40352", "Multiplicative Product"], ["C16329", "Belgium"], ["C43508", "Oregon"], ["C16727", "India"], ["C142627", "Patient File"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C25214", "Evaluation"], ["C64956", "For"], ["C201357", "Before Timing Type"], ["C25490", "During"], ["C16289", "Andorra"], ["C54735", "Post-Therapy"], ["C62355", "With"], ["C2381", "Etanercept"], ["C25544", "Into"], ["C113416", "Consideration"], ["C181249", "Mean Based on Unspecified Calculation"], ["C70916", "Half Life"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C45828", "Approximate"], ["C105790", "Seventy"], ["C25529", "Hour"], ["C38013", "Range"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16645", "Greece"], ["C25529", "Hour"], ["C54035", "Serious"], ["C3364", "Septicemia"], ["C3423", "Tuberculosis"], ["C16289", "Andorra"], ["C166400", "Inclusive"], ["C93159", "Invasive Procedure"], ["C82994", "Listeriosis"], ["C16289", "Andorra"], ["C128334", "Legionellosis"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C62355", "With"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C89272", "Due To"], ["C14187", "Bacteria"], ["C154813", "Fungi Measurement"], ["C14283", "Virus"], ["C16289", "Andorra"], ["C120903", "Parasite Present"], ["C166400", "Inclusive"], ["C77916", "Protozoa"], ["C16727", "India"], ["C65099", "Some"], ["C16289", "Andorra"], ["C118472", "Other License Status"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C25476", "Delay"], ["C52874", "SPI1 wt Allele"], ["C101247", "Appropriate Treatment"], ["C16289", "Andorra"], ["C90025", "Sometimes"], ["C171353", "Clinical Status Ordinal Scale Outcome 7"], ["C16727", "India"], ["C16960", "Patient"], ["C64956", "For"], ["C53691", "Veterinary Patient"], ["C42555", "Siemens"], ["C17102", "Risk"], ["C64956", "For"], ["C70664", "Relevance"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C27122", "Endemic Burkitt Lymphoma"], ["C16329", "Belgium"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C76246", "Blood Group A"], ["C94522", "New Lesion Identification"], ["C128320", "Infection"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C2381", "Etanercept"], ["C16329", "Belgium"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C53691", "Veterinary Patient"], ["C76246", "Blood Group A"], ["C54035", "Serious"], ["C128320", "Infection"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C4981", "Chronic Graft Versus Host Disease"], ["C101282", "Have"], ["C25594", "Negation"], ["C25214", "Evaluation"], ["C16567", "Exercise"], ["C65140", "When"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C43508", "Oregon"], ["C4981", "Chronic Graft Versus Host Disease"], ["C43508", "Oregon"], ["C62355", "With"], ["C154417", "Underlying"], ["C25457", "Condition"], ["C106184", "May"], ["C16960", "Patient"], ["C159124", "GDC Treatment Outcome Terminology"], ["C71344", "Associate of Science"], ["C25411", "Advanced"], ["C43508", "Oregon"], ["C157664", "Poorly Marginated Nodule"], ["C82500", "Disease Controlled"], ["C2985", "Diabetes Mellitus"], ["C3423", "Tuberculosis"], ["C52874", "SPI1 wt Allele"], ["C3423", "Tuberculosis"], ["C166400", "Inclusive"], ["C35086", "Miliary Tuberculosis"], ["C16289", "Andorra"], ["C3423", "Tuberculosis"], ["C62355", "With"], ["C63758", "Supernumerary"], ["C105692", "Pulmonary Medicine"], ["C127214", "Location of Oral Residue Following Swallowing"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C201357", "Before Timing Type"], ["C171584", "Since Starting Treatment"], ["C62355", "With"], ["C2381", "Etanercept"], ["C64916", "All"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C25214", "Evaluation"], ["C64956", "For"], ["C49636", "Both"], ["C154405", "Active State"], ["C16289", "Andorra"], ["C45422", "Absence of Biochemical Activity"], ["C28225", "Latent"], ["C3423", "Tuberculosis"], ["C25214", "Evaluation"], ["C74521", "Include"], ["C76246", "Blood Group A"], ["C25480", "Details"], ["C18772", "Personal Medical History"], ["C62355", "With"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C3423", "Tuberculosis"], ["C43508", "Oregon"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C25627", "Previous"], ["C49147", "Physical Contact"], ["C62355", "With"], ["C3423", "Tuberculosis"], ["C16289", "Andorra"], ["C25627", "Previous"], ["C48928", "And/Or"], ["C48434", "Electrical Current"], ["C15261", "Immunosuppressive Therapy"], ["C48261", "Screening"], ["C25294", "Laboratory Procedure"], ["C68254", "Dietary Iodine"], ["C68800", "Elementary Charge"], ["C85994", "Tuberculin Skin Test"], ["C16289", "Andorra"], ["C38103", "Chest Radiography"], ["C16329", "Belgium"], ["C38000", "Performed"], ["C16727", "India"], ["C64916", "All"], ["C16960", "Patient"], ["C25388", "Local-Regional"], ["C106184", "May"], ["C64915", "Apply"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C16326", "Behavior"], ["C52874", "SPI1 wt Allele"], ["C25294", "Laboratory Procedure"], ["C16329", "Belgium"], ["C16727", "India"], ["C53691", "Veterinary Patient"], ["C160555", "CaRD Regimen"], ["C68869", "Are"], ["C52874", "SPI1 wt Allele"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C93283", "False Negative"], ["C85994", "Tuberculin Skin Test"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C70667", "Severe"], ["C43508", "Oregon"], ["C14139", "Immunocompromised"], ["C198613", "CFI wt Allele"], ["C3423", "Tuberculosis"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C15220", "Diagnosis"], ["C2381", "Etanercept"], ["C49236", "Therapeutic Procedure"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C198613", "CFI wt Allele"], ["C45422", "Absence of Biochemical Activity"], ["C28225", "Latent"], ["C3423", "Tuberculosis"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C15220", "Diagnosis"], ["C43442", "Biomaterial Treatment"], ["C64956", "For"], ["C28225", "Latent"], ["C3423", "Tuberculosis"], ["C16329", "Belgium"], ["C62355", "With"], ["C3423", "Tuberculosis"], ["C49236", "Therapeutic Procedure"], ["C201357", "Before Timing Type"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16289", "Andorra"], ["C64950", "Follow"], ["C25388", "Local-Regional"], ["C16727", "India"], ["C25387", "Benefit"], ["C17102", "Risk"], ["C73497", "Balance"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C116076", "Very"], ["C64916", "All"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C37896", "Informed"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25261", "Medical"], ["C198613", "CFI wt Allele"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C3423", "Tuberculosis"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C43623", "Persistent"], ["C124215", "Cough Frequency"], ["C125292", "How Often Weight Loss"], ["C139301", "IPSS Risk Category Low"], ["C48309", "Grade"], ["C143485", "Fever, CTCAE"], ["C179695", "Specimen Appearance Assessment"], ["C49640", "During or After"], ["C2381", "Etanercept"], ["C43442", "Biomaterial Treatment"], ["C143211", "Hepatitis B Reactivation, CTCAE"], ["C124063", "Reactivation"], ["C52874", "SPI1 wt Allele"], ["C3097", "Hepatitis B Infection"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C25627", "Previous"], ["C189188", "Infected with SARS-CoV-2"], ["C62355", "With"], ["C189553", "Hepatitis B Virus Measurement"], ["C189553", "Hepatitis B Virus Measurement"], ["C16289", "Andorra"], ["C101282", "Have"], ["C25639", "Receive"], ["C25730", "Concomitant"], ["C18368", "TNF Gene"], ["C166400", "Inclusive"], ["C2381", "Etanercept"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C124063", "Reactivation"], ["C52874", "SPI1 wt Allele"], ["C3097", "Hepatitis B Infection"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C148282", "Hepatitis B Virus Core Antibody Positive"], ["C160371", "Hepatitis B Virus Surface Antigen Negative"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C64956", "For"], ["C189553", "Hepatitis B Virus Measurement"], ["C128320", "Infection"], ["C201357", "Before Timing Type"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C2381", "Etanercept"], ["C64956", "For"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C82541", "Test Name"], ["C36659", "CTNNB1 Gene Mutation"], ["C64956", "For"], ["C189553", "Hepatitis B Virus Measurement"], ["C128320", "Infection"], ["C41188", "Consultation"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C25741", "Physician"], ["C62355", "With"], ["C16727", "India"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C3097", "Hepatitis B Infection"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C16329", "Belgium"], ["C65140", "When"], ["C2381", "Etanercept"], ["C16727", "India"], ["C16960", "Patient"], ["C25627", "Previous"], ["C189188", "Infected with SARS-CoV-2"], ["C62355", "With"], ["C189553", "Hepatitis B Virus Measurement"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C64956", "For"], ["C16289", "Andorra"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C154405", "Active State"], ["C189553", "Hepatitis B Virus Measurement"], ["C128320", "Infection"], ["C49236", "Therapeutic Procedure"], ["C16289", "Andorra"], ["C64956", "For"], ["C107221", "Several"], ["C29844", "Week"], ["C53286", "Next"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C168111", "Adequate Daily Fluid Intake"], ["C25474", "Data"], ["C25516", "From"], ["C25705", "Treating"], ["C16960", "Patient"], ["C189188", "Infected with SARS-CoV-2"], ["C62355", "With"], ["C189553", "Hepatitis B Virus Measurement"], ["C62355", "With"], ["C62713", "Oncolytic Virus Therapy"], ["C16727", "India"], ["C79874", "Conjunction"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C49236", "Therapeutic Procedure"], ["C68869", "Are"], ["C126101", "Not Available"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C189553", "Hepatitis B Virus Measurement"], ["C128320", "Infection"], ["C2381", "Etanercept"], ["C16329", "Belgium"], ["C16289", "Andorra"], ["C49287", "Effective"], ["C62713", "Oncolytic Virus Therapy"], ["C62355", "With"], ["C37902", "Support"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C52874", "SPI1 wt Allele"], ["C3098", "Hepatitis C Infection"], ["C101282", "Have"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C52874", "SPI1 wt Allele"], ["C3098", "Hepatitis C Infection"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C2381", "Etanercept"], ["C2381", "Etanercept"], ["C16329", "Belgium"], ["C62355", "With"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C3098", "Hepatitis C Infection"], ["C25456", "Concurrent"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C38717", "Anakinra"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16289", "Andorra"], ["C38717", "Anakinra"], ["C101282", "Have"], ["C25281", "Associated"], ["C62355", "With"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C54035", "Serious"], ["C16289", "Andorra"], ["C80520", "Neutropenia"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C2381", "Etanercept"], ["C48440", "Single"], ["C61517", "Combination"], ["C101282", "Have"], ["C25594", "Negation"], ["C164135", "Increased"], ["C142422", "Clinical Benefit"], ["C25454", "Combined"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16289", "Andorra"], ["C38717", "Anakinra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C25456", "Concurrent"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C28898", "Abatacept"], ["C16727", "India"], ["C15206", "Clinical Study"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C28898", "Abatacept"], ["C16289", "Andorra"], ["C2381", "Etanercept"], ["C16727", "India"], ["C164135", "Increased"], ["C52874", "SPI1 wt Allele"], ["C177945", "Serious Adverse Events Domain"], ["C61517", "Combination"], ["C101282", "Have"], ["C25594", "Negation"], ["C164135", "Increased"], ["C142422", "Clinical Benefit"], ["C25340", "Use"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C37910", "Allergic"], ["C37910", "Allergic"], ["C25281", "Associated"], ["C62355", "With"], ["C2381", "Etanercept"], ["C70962", "Agent Administration"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C37910", "Allergic"], ["C101282", "Have"], ["C112175", "Angioedema"], ["C16289", "Andorra"], ["C3432", "Urticaria"], ["C54035", "Serious"], ["C101282", "Have"], ["C54069", "Occur"], ["C198613", "CFI wt Allele"], ["C81168", "Any"], ["C54035", "Serious"], ["C37910", "Allergic"], ["C43508", "Oregon"], ["C25637", "Reaction"], ["C2381", "Etanercept"], ["C49236", "Therapeutic Procedure"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C64597", "Immediately"], ["C16289", "Andorra"], ["C49236", "Therapeutic Procedure"], ["C15261", "Immunosuppressive Therapy"], ["C64956", "For"], ["C18368", "TNF Gene"], ["C166400", "Inclusive"], ["C2381", "Etanercept"], ["C159124", "GDC Treatment Outcome Terminology"], ["C66819", "Host"], ["C64937", "Against"], ["C16289", "Andorra"], ["C45325", "Since"], ["C18368", "TNF Gene"], ["C3137", "Inflammation"], ["C16289", "Andorra"], ["C12508", "Cell"], ["C17997", "Immune"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C45319", "Study Object"], ["C52874", "SPI1 wt Allele"], ["C105796", "Forty Nine"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C62355", "With"], ["C2884", "Rheumatoid Arthritis"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C154196", "Washo Language"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C124639", "Depression"], ["C52874", "SPI1 wt Allele"], ["C3115", "Type IV Hypersensitivity"], ["C124639", "Depression"], ["C52874", "SPI1 wt Allele"], ["C81869", "Immunoglobulin Measurement"], ["C43508", "Oregon"], ["C54126", "Delta"], ["C16727", "India"], ["C45674", "Enumeration"], ["C52874", "SPI1 wt Allele"], ["C28241", "Effector Immune Cell"], ["C66833", "Two"], ["C114357", "Juvenile Idiopathic Arthritis"], ["C16960", "Patient"], ["C97132", "Chicken Pox"], ["C128320", "Infection"], ["C16289", "Andorra"], ["C16289", "Andorra"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C118299", "Aseptic Meningitis"], ["C118471", "Resolved License"], ["C25718", "Without"], ["C126361", "Disease Sequela"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C41130", "Significant"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C97132", "Chicken Pox"], ["C14283", "Virus"], ["C25484", "Discontinue"], ["C2381", "Etanercept"], ["C49236", "Therapeutic Procedure"], ["C16289", "Andorra"], ["C16329", "Belgium"], ["C64956", "For"], ["C95560", "Prophylactic"], ["C62355", "With"], ["C97132", "Chicken Pox"], ["C71079", "Herpes Zoster"], ["C572", "Immunoglobulin"], ["C49667", "Safety Study"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C15261", "Immunosuppressive Therapy"], ["C101282", "Have"], ["C25594", "Negation"], ["C25214", "Evaluation"], ["C16289", "Andorra"], ["C2991", "Disease or Disorder"], ["C45300", "Solid"], ["C16289", "Andorra"], ["C12470", "Skin"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C166400", "Inclusive"], ["C25389", "Chest"], ["C16289", "Andorra"], ["C4878", "Lung Carcinoma"], ["C16289", "Andorra"], ["C7587", "Adult Lymphoma"], ["C101282", "Have"], ["C25639", "Receive"], ["C16727", "India"], ["C25616", "Period"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C16727", "India"], ["C82500", "Disease Controlled"], ["C52874", "SPI1 wt Allele"], ["C71104", "Clinical Trial"], ["C52874", "SPI1 wt Allele"], ["C18368", "TNF Gene"], ["C128667", "More"], ["C52874", "SPI1 wt Allele"], ["C7587", "Adult Lymphoma"], ["C101282", "Have"], ["C25599", "Observed"], ["C16960", "Patient"], ["C25639", "Receive"], ["C76246", "Blood Group A"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C49156", "Comparison"], ["C62355", "With"], ["C64355", "Scientific Control"], ["C16960", "Patient"], ["C25275", "Occurrence"], ["C154196", "Washo Language"], ["C13634", "Retinoic Acid Response Element"], ["C16289", "Andorra"], ["C156841", "Follow-Up Period"], ["C52874", "SPI1 wt Allele"], ["C49648", "Placebo Control"], ["C16960", "Patient"], ["C154196", "Washo Language"], ["C64956", "For"], ["C16960", "Patient"], ["C25639", "Receive"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C49236", "Therapeutic Procedure"], ["C16727", "India"], ["C127262", "CDISC SDTM Environmental Setting Terminology"], ["C52874", "SPI1 wt Allele"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C45782", "Background"], ["C17102", "Risk"], ["C64956", "For"], ["C7587", "Adult Lymphoma"], ["C16289", "Andorra"], ["C16727", "India"], ["C2884", "Rheumatoid Arthritis"], ["C16960", "Patient"], ["C62355", "With"], ["C25248", "Long"], ["C62166", "Standing"], ["C25227", "High"], ["C154405", "Active State"], ["C93210", "Inflammatory Disorder"], ["C17102", "Risk"], ["C25498", "Estimate"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C48434", "Electrical Current"], ["C76246", "Blood Group A"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C17102", "Risk"], ["C64956", "For"], ["C18732", "Development"], ["C52874", "SPI1 wt Allele"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C43508", "Oregon"], ["C45300", "Solid"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C16329", "Belgium"], ["C82931", "Exclusion"], ["C16329", "Belgium"], ["C65140", "When"], ["C18368", "TNF Gene"], ["C94373", "Antagonist"], ["C49236", "Therapeutic Procedure"], ["C64956", "For"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C9305", "Malignant Neoplasm"], ["C43508", "Oregon"], ["C65140", "When"], ["C54064", "Continue"], ["C43442", "Biomaterial Treatment"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C76246", "Blood Group A"], ["C9305", "Malignant Neoplasm"], ["C65099", "Some"], ["C48275", "Death Related to Adverse Event"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16423", "Child"], ["C16266", "Adolescents"], ["C16289", "Andorra"], ["C64643", "Up to"], ["C126884", "Twenty Two"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C25705", "Treating"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C111798", "Eighteen"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C166400", "Inclusive"], ["C2381", "Etanercept"], ["C16727", "India"], ["C127262", "CDISC SDTM Environmental Setting Terminology"], ["C45828", "Approximate"], ["C81009", "Half"], ["C118472", "Other License Status"], ["C76246", "Blood Group A"], ["C69085", "Assortment"], ["C52874", "SPI1 wt Allele"], ["C46003", "Difference"], ["C16289", "Andorra"], ["C13634", "Retinoic Acid Response Element"], ["C25281", "Associated"], ["C62355", "With"], ["C15261", "Immunosuppressive Therapy"], ["C76246", "Blood Group A"], ["C17102", "Risk"], ["C64956", "For"], ["C18732", "Development"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C16423", "Child"], ["C16289", "Andorra"], ["C16266", "Adolescents"], ["C25705", "Treating"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C16329", "Belgium"], ["C82931", "Exclusion"], ["C12470", "Skin"], ["C2920", "Malignant Skin Neoplasm"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C18368", "TNF Gene"], ["C166400", "Inclusive"], ["C2381", "Etanercept"], ["C52874", "SPI1 wt Allele"], ["C9231", "Merkel Cell Carcinoma"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C116076", "Very"], ["C64954", "Infrequent"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C53578", "Periodic Report"], ["C168436", "Skin Examination"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C64956", "For"], ["C64916", "All"], ["C16960", "Patient"], ["C62355", "With"], ["C17103", "Risk Factor"], ["C64956", "For"], ["C2920", "Malignant Skin Neoplasm"], ["C52874", "SPI1 wt Allele"], ["C82500", "Disease Controlled"], ["C71104", "Clinical Trial"], ["C128667", "More"], ["C52874", "SPI1 wt Allele"], ["C25599", "Observed"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C2381", "Etanercept"], ["C49156", "Comparison"], ["C62355", "With"], ["C64355", "Scientific Control"], ["C16960", "Patient"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C3346", "Psoriasis"], ["C89279", "Reside"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C64974", "Give"], ["C62355", "With"], ["C2381", "Etanercept"], ["C53269", "No Information Available"], ["C68869", "Are"], ["C25429", "Availability"], ["C92667", "SPARC wt Allele"], ["C25666", "Second"], ["C17214", "Disease Transmission"], ["C52874", "SPI1 wt Allele"], ["C128320", "Infection"], ["C158169", "Buyei Chinese"], ["C89279", "Reside"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C2381", "Etanercept"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C62265", "Double"], ["C49068", "Blinded"], ["C49648", "Placebo Control"], ["C15206", "Clinical Study"], ["C16727", "India"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C62355", "With"], ["C61277", "Psoriatic Arthritis"], ["C16469", "Cook Islands"], ["C16960", "Patient"], ["C25639", "Receive"], ["C76246", "Blood Group A"], ["C1643", "Pneumococcal Polyvalent Vaccine"], ["C158997", "GDC Analyte Type Terminology"], ["C29844", "Week"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16727", "India"], ["C45319", "Study Object"], ["C25258", "Most"], ["C2883", "Arthritis"], ["C16960", "Patient"], ["C25639", "Receive"], ["C2381", "Etanercept"], ["C78209", "Ability"], ["C50079", "Mount Device"], ["C49287", "Effective"], ["C23408", "Murine B-Lymphocytes"], ["C17930", "Immune Response Process"], ["C159124", "GDC Treatment Outcome Terminology"], ["C1643", "Pneumococcal Polyvalent Vaccine"], ["C16727", "India"], ["C62344", "Aggregation"], ["C125256", "Moderate Response"], ["C25309", "Lower"], ["C16289", "Andorra"], ["C64942", "Few"], ["C16960", "Patient"], ["C101282", "Have"], ["C66833", "Two"], ["C16727", "India"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16960", "Patient"], ["C25594", "Negation"], ["C25639", "Receive"], ["C2381", "Etanercept"], ["C82562", "Clinical Significance"], ["C52874", "SPI1 wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C160764", "Unknown Molecular Analysis"], ["C181397", "Autoantibody Measurement"], ["C25513", "Formation"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C2381", "Etanercept"], ["C106184", "May"], ["C20200", "Outcome"], ["C16727", "India"], ["C25513", "Formation"], ["C52874", "SPI1 wt Allele"], ["C37916", "Autoimmune"], ["C16295", "Antibody"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C13634", "Retinoic Acid Response Element"], ["C52874", "SPI1 wt Allele"], ["C34889", "Pancytopenia"], ["C16289", "Andorra"], ["C116076", "Very"], ["C13634", "Retinoic Acid Response Element"], ["C52874", "SPI1 wt Allele"], ["C65099", "Some"], ["C62355", "With"], ["C48275", "Death Related to Adverse Event"], ["C20200", "Outcome"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C89327", "Be"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C25627", "Previous"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C17610", "Blood Sample"], ["C64916", "All"], ["C16960", "Patient"], ["C16289", "Andorra"], ["C16329", "Belgium"], ["C198613", "CFI wt Allele"], ["C53691", "Veterinary Patient"], ["C16289", "Andorra"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C17610", "Blood Sample"], ["C43508", "Oregon"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C43623", "Persistent"], ["C143485", "Fever, CTCAE"], ["C143853", "Sore Throat, CTCAE"], ["C37921", "Bruise"], ["C26791", "Hemorrhage"], ["C50685", "Pallor"], ["C92667", "SPARC wt Allele"], ["C2381", "Etanercept"], ["C64597", "Immediately"], ["C25261", "Medical"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C166400", "Inclusive"], ["C25517", "Full"], ["C17610", "Blood Sample"], ["C48485", "Count Dosing Unit"], ["C198613", "CFI wt Allele"], ["C17610", "Blood Sample"], ["C68869", "Are"], ["C25458", "Confirmation"], ["C2381", "Etanercept"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C25262", "Neurologic"], ["C2991", "Disease or Disorder"], ["C101282", "Have"], ["C13634", "Retinoic Acid Response Element"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C12438", "Central Nervous System"], ["C2991", "Disease or Disorder"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C101282", "Have"], ["C13634", "Retinoic Acid Response Element"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C25233", "Peripheral"], ["C166400", "Inclusive"], ["C116345", "Guillain-Barre Syndrome"], ["C84636", "Chronic Inflammatory Demyelinating Polyneuropathy"], ["C27062", "Demyelinating Polyneuropathy"], ["C16289", "Andorra"], ["C25253", "Multifocal"], ["C3500", "Peripheral Motor Neuropathy"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C71104", "Clinical Trial"], ["C101282", "Have"], ["C38000", "Performed"], ["C2381", "Etanercept"], ["C49236", "Therapeutic Procedure"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C3243", "Multiple Sclerosis"], ["C71104", "Clinical Trial"], ["C52874", "SPI1 wt Allele"], ["C118472", "Other License Status"], ["C18368", "TNF Gene"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C3243", "Multiple Sclerosis"], ["C101282", "Have"], ["C16727", "India"], ["C2991", "Disease or Disorder"], ["C120914", "Physical Activity Measurement"], ["C76246", "Blood Group A"], ["C17102", "Risk"], ["C25387", "Benefit"], ["C25214", "Evaluation"], ["C166400", "Inclusive"], ["C76246", "Blood Group A"], ["C12755", "Nervous System"], ["C25367", "Assessment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C65140", "When"], ["C154633", "Prescribing Domain"], ["C2381", "Etanercept"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16960", "Patient"], ["C62355", "With"], ["C73621", "Pre-existing"], ["C43508", "Oregon"], ["C25280", "Recent"], ["C25279", "Onset"], ["C52874", "SPI1 wt Allele"], ["C34527", "Demyelinating Disorder"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C75419", "World Health Organization"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C101282", "Have"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C34527", "Demyelinating Disorder"], ["C15212", "Multimodality Therapy"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C95750", "Controlled Clinical Trial"], ["C52874", "SPI1 wt Allele"], ["C66833", "Two"], ["C29848", "Year"], ["C25330", "Duration"], ["C16727", "India"], ["C2884", "Rheumatoid Arthritis"], ["C16960", "Patient"], ["C61517", "Combination"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16289", "Andorra"], ["C642", "Methotrexate"], ["C163546", "Double Immunodiffusion"], ["C25594", "Negation"], ["C20200", "Outcome"], ["C16727", "India"], ["C127832", "Unexpected"], ["C49667", "Safety Study"], ["C103373", "CDISC Findings Class"], ["C16289", "Andorra"], ["C49667", "Safety Study"], ["C84385", "Profile"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C65140", "When"], ["C64974", "Give"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C642", "Methotrexate"], ["C154196", "Washo Language"], ["C72665", "Similarity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C188308", "Reported Information"], ["C16727", "India"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16289", "Andorra"], ["C642", "Methotrexate"], ["C48440", "Single"], ["C25322", "Long-Term"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25217", "Assessment"], ["C49667", "Safety Study"], ["C52874", "SPI1 wt Allele"], ["C61517", "Combination"], ["C68869", "Are"], ["C54064", "Continue"], ["C25322", "Long-Term"], ["C49667", "Safety Study"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C173902", "CTRP Clinical Finding"], ["C121332", "Disease-Modifying Antirheumatic Drug"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C118472", "Other License Status"], ["C13310", "Systemic"], ["C43508", "Oregon"], ["C15301", "Phototherapy"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C3346", "Psoriasis"], ["C101282", "Have"], ["C25594", "Negation"], ["C25225", "Renal"], ["C16289", "Andorra"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C49663", "Pharmacokinetic Study"], ["C25474", "Data"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C25225", "Renal"], ["C43508", "Oregon"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C123619", "Clinical Response"], ["C54627", "Experience"], ["C16727", "India"], ["C16960", "Patient"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C142988", "Limited"], ["C3080", "Congestive Heart Failure"], ["C3080", "Congestive Heart Failure"], ["C25340", "Use"], ["C65140", "When"], ["C2381", "Etanercept"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C3080", "Congestive Heart Failure"], ["C101282", "Have"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C52874", "SPI1 wt Allele"], ["C3080", "Congestive Heart Failure"], ["C62355", "With"], ["C16289", "Andorra"], ["C25718", "Without"], ["C44469", "Identifiable Class"], ["C16727", "India"], ["C16960", "Patient"], ["C2381", "Etanercept"], ["C101282", "Have"], ["C13634", "Retinoic Acid Response Element"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C105723", "ECOG Performance Status 1"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C94522", "New Lesion Identification"], ["C25279", "Onset"], ["C3080", "Congestive Heart Failure"], ["C166400", "Inclusive"], ["C3080", "Congestive Heart Failure"], ["C16727", "India"], ["C16960", "Patient"], ["C25718", "Without"], ["C80137", "Known"], ["C73621", "Pre-existing"], ["C2931", "Cardiovascular Disorder"], ["C65099", "Some"], ["C52874", "SPI1 wt Allele"], ["C16960", "Patient"], ["C101282", "Have"], ["C105785", "Fifty"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C66833", "Two"], ["C49508", "Large"], ["C71104", "Clinical Trial"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16727", "India"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C3080", "Congestive Heart Failure"], ["C70757", "Study Terminated"], ["C61589", "Early"], ["C89272", "Due To"], ["C48226", "Lack of Efficacy"], ["C25594", "Negation"], ["C87050", "Conclusive"], ["C25474", "Data"], ["C25516", "From"], ["C66832", "One"], ["C52874", "SPI1 wt Allele"], ["C71104", "Clinical Trial"], ["C48313", "Suggestion"], ["C76246", "Blood Group A"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C3080", "Congestive Heart Failure"], ["C16727", "India"], ["C16960", "Patient"], ["C170547", "Assigned Value"], ["C159124", "GDC Treatment Outcome Terminology"], ["C2381", "Etanercept"], ["C43442", "Biomaterial Treatment"], ["C34684", "Alcoholic Hepatitis"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C48281", "Trial Phase"], ["C62395", "WHO Central Nervous System Grade 2"], ["C49648", "Placebo Control"], ["C45319", "Study Object"], ["C52874", "SPI1 wt Allele"], ["C175678", "Forty Eight"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C43508", "Oregon"], ["C49648", "Placebo Control"], ["C64956", "For"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C159124", "GDC Treatment Outcome Terminology"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C34684", "Alcoholic Hepatitis"], ["C2381", "Etanercept"], ["C154196", "Washo Language"], ["C25594", "Negation"], ["C16289", "Andorra"], ["C53358", "Mortality Rate"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C154196", "Washo Language"], ["C25227", "High"], ["C38008", "Post"], ["C172979", "Fear Score 6"], ["C29846", "Month"], ["C2381", "Etanercept"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C34684", "Alcoholic Hepatitis"], ["C25340", "Use"], ["C65140", "When"], ["C2381", "Etanercept"], ["C16727", "India"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C159124", "GDC Treatment Outcome Terminology"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C34684", "Alcoholic Hepatitis"], ["C3444", "Granulomatosis with Polyangiitis"], ["C76246", "Blood Group A"], ["C49648", "Placebo Control"], ["C71104", "Clinical Trial"], ["C16727", "India"], ["C105789", "Eighty Nine"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C16727", "India"], ["C64911", "Add"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81893", "Standard"], ["C49236", "Therapeutic Procedure"], ["C166400", "Inclusive"], ["C405", "Cyclophosphamide"], ["C43508", "Oregon"], ["C642", "Methotrexate"], ["C16289", "Andorra"], ["C64956", "For"], ["C76246", "Blood Group A"], ["C28007", "Median"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C113663", "Twenty Five"], ["C29846", "Month"], ["C101282", "Have"], ["C25594", "Negation"], ["C2381", "Etanercept"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C75889", "PAX6 wt Allele"], ["C49287", "Effective"], ["C43442", "Biomaterial Treatment"], ["C64956", "For"], ["C42555", "Siemens"], ["C113754", "Granulomatosis"], ["C16726", "Incidence"], ["C52874", "SPI1 wt Allele"], ["C14460", "NON Mouse"], ["C13316", "Cutaneous"], ["C52874", "SPI1 wt Allele"], ["C154196", "Washo Language"], ["C25227", "High"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C16727", "India"], ["C28143", "Control Group"], ["C2381", "Etanercept"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C42555", "Siemens"], ["C113754", "Granulomatosis"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C64956", "For"], ["C2985", "Diabetes Mellitus"], ["C101282", "Have"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C53286", "Next"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C459", "Medication"], ["C64956", "For"], ["C2985", "Diabetes Mellitus"], ["C76246", "Blood Group A"], ["C25640", "Reduced"], ["C16727", "India"], ["C459", "Medication"], ["C16727", "India"], ["C65099", "Some"], ["C52874", "SPI1 wt Allele"], ["C16960", "Patient"], ["C18101", "Special Population"], ["C16268", "Elderly"], ["C16727", "India"], ["C15602", "Phase III Trial"], ["C16727", "India"], ["C2884", "Rheumatoid Arthritis"], ["C61277", "Psoriatic Arthritis"], ["C16289", "Andorra"], ["C84564", "Ankylosing Spondylitis"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25605", "Overall"], ["C16727", "India"], ["C49562", "Adverse Event Domain"], ["C177945", "Serious Adverse Events Domain"], ["C16289", "Andorra"], ["C54035", "Serious"], ["C16727", "India"], ["C16960", "Patient"], ["C106312", "Advanced Glycation End Product"], ["C188329", "Sixty Five"], ["C43508", "Oregon"], ["C75419", "World Health Organization"], ["C25639", "Receive"], ["C2381", "Etanercept"], ["C25599", "Observed"], ["C49156", "Comparison"], ["C62355", "With"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C65140", "When"], ["C25705", "Treating"], ["C16268", "Elderly"], ["C16289", "Andorra"], ["C41209", "Attention Concentration"], ["C173947", "Paid Hours"], ["C62355", "With"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25275", "Occurrence"], ["C52874", "SPI1 wt Allele"], ["C17005", "Population Group"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C16960", "Patient"], ["C198613", "CFI wt Allele"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C16329", "Belgium"], ["C64643", "Up to"], ["C48871", "Date Data Type"], ["C62355", "With"], ["C64916", "All"], ["C16727", "India"], ["C25369", "Agreement"], ["C62355", "With"], ["C48434", "Electrical Current"], ["C17564", "Guideline"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C2381", "Etanercept"], ["C49236", "Therapeutic Procedure"], ["C163702", "Staphylococcal Enterotoxin E"], ["C75329", "Above"]], "rxnorm.special_warnings": [["216891", "Enbrel"], ["214555", "etanercept"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["10908", "tuberculin"], ["10908", "tuberculin"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["1427211", "hepatitis B virus"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["72435", "anakinra"], ["216891", "Enbrel"], ["72435", "anakinra"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["72435", "anakinra"], ["614391", "abatacept"], ["614391", "abatacept"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["T025", "Cell"], ["T005", "Virus"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["8375", "placebo"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["T025", "Cell"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["8375", "placebo"], ["216891", "Enbrel"], ["T025", "Cell"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["T052", "Activity"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["6851", "methotrexate"], ["216891", "Enbrel"], ["6851", "methotrexate"], ["216891", "Enbrel"], ["6851", "methotrexate"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["8375", "placebo"], ["216891", "Enbrel"], ["8375", "placebo"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["8375", "placebo"], ["216891", "Enbrel"], ["3002", "cyclophosphamide"], ["6851", "methotrexate"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["T096", "Group"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["216891", "Enbrel"]], "loinc.special_warnings": [["LA22004-8", "IN"], ["LA25433-6", "Biological"], ["MTHU047370", "Brand name"], ["LP18011-4", "Number"], ["LA22025-3", "OR"], ["LP6530-2", "Stated"], ["LA22004-8", "IN"], ["LP66710-2", "Patient"], ["LP74970-2", "Infections"], ["LP74970-2", "Infections"], ["LP94823-9", "Treatment"], ["LP6971-8", "mean"], ["MTHU054569", "Etanercept"], ["LP200075-2", "IS"], ["LP36790-1", "7"], ["LA30751-4", "Serious"], ["LP74970-2", "Infections"], ["MTHU020835", "Tuberculosis"], ["LP74970-2", "Infections"], ["LP102225-2", "Invasive"], ["LP74970-2", "Infections"], ["LA10485-3", "Listeriosis"], ["LA10483-8", "Legionellosis"], ["LP6486-7", "Reported"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP74970-2", "Infections"], ["LA12886-0", "Bacteria"], ["LP98186-7", "Parasites"], ["LP34863-8", "Protozoa"], ["LA22004-8", "IN"], ["LA14973-4", "Some"], ["LP270144-1", "Cases"], ["MTHU029809", "Other"], ["LP74970-2", "Infections"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA7343-2", "Delay"], ["LP94823-9", "Treatment"], ["LA10082-8", "Sometimes"], ["LA7424-0", "Death"], ["LA22004-8", "IN"], ["LP74970-2", "Infections"], ["LP66710-2", "Patient"], ["LP15241-0", "S"], ["LP74970-2", "Infections"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP17763-1", "A"], ["LA9039-4", "New"], ["LP266919-2", "Infection"], ["LP94823-9", "Treatment"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP66710-2", "Patient"], ["LP17763-1", "A"], ["LA30751-4", "Serious"], ["LP266919-2", "Infection"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["LA22004-8", "IN"], ["LA28752-6", "Chronic"], ["LP74970-2", "Infections"], ["LA21291-2", "Not"], ["LP207667-9", "Exercise"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP7800-8", "History"], ["LA22025-3", "OR"], ["LA28752-6", "Chronic"], ["LP74970-2", "Infections"], ["LA22025-3", "OR"], ["LA26681-9", "Underlying"], ["LA14161-6", "May"], ["LP74970-2", "Infections"], ["LA22025-3", "OR"], ["LA26466-5", "Poorly controlled"], ["LP128793-9", "Diabetes"], ["MTHU020835", "Tuberculosis"], ["LP270144-1", "Cases"], ["LA16666-2", "Active"], ["MTHU020835", "Tuberculosis"], ["MTHU020835", "Tuberculosis"], ["MTHU020835", "Tuberculosis"], ["54542-6", "Pulmonary:-:Pt:^Patient:-"], ["LP6825-6", "Location"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA18187-7", "All"], ["LA14331-5", "Both"], ["LA16666-2", "Active"], ["LA18632-2", "Inactive"], ["LA24776-9", "Latent"], ["MTHU020835", "Tuberculosis"], ["LA27332-8", "Evaluation"], ["LP17763-1", "A"], ["LP128548-7", "Medical history"], ["LP7800-8", "History"], ["MTHU020835", "Tuberculosis"], ["LA22025-3", "OR"], ["LA15097-1", "Possible"], ["LP248328-9", "Contact"], ["MTHU020835", "Tuberculosis"], ["LA22025-3", "OR"], ["LP267221-2", "Therapy"], ["LP200187-5", "Screening"], ["LA15457-7", "I"], ["LA13503-0", "E"], ["LP32625-3", "Tuberculin"], ["LP130014-6", "Skin"], ["LA7556-9", "Test"], ["LA16043-4", "Chest x-ray"], ["LA19974-7", "Performed"], ["LA22004-8", "IN"], ["LA18187-7", "All"], ["LA4583-6", "Local"], ["LA14161-6", "May"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP66710-2", "Patient"], ["LP29708-2", "Cardiology"], ["LA14496-6", "False"], ["LA6577-6", "Negative"], ["LP32625-3", "Tuberculin"], ["LP130014-6", "Skin"], ["LA7556-9", "Test"], ["LA22004-8", "IN"], ["98971-5", "Severely ill:Find:Pt:^Patient:Ord"], ["LA22025-3", "OR"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA16666-2", "Active"], ["MTHU020835", "Tuberculosis"], ["LP200075-2", "IS"], ["LP267221-2", "Therapy"], ["LA21291-2", "Not"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA18632-2", "Inactive"], ["LA24776-9", "Latent"], ["MTHU020835", "Tuberculosis"], ["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LA24776-9", "Latent"], ["MTHU020835", "Tuberculosis"], ["MTHU020835", "Tuberculosis"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LA4583-6", "Local"], ["LA22004-8", "IN"], ["LP267221-2", "Therapy"], ["LA29696-4", "Very"], ["LA18187-7", "All"], ["LP417559-4", "Safe Environment for Every Kid"], ["LA14523-7", "Advice"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP75708-5", "Symptoms"], ["MTHU020835", "Tuberculosis"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LA30866-0", "Persistent cough"], ["MTHU020881", "Weight loss"], ["LA9194-7", "Low"], ["MTHU003112", "Grade"], ["LP74849-8", "Fever"], ["LA22025-3", "OR"], ["LP94823-9", "Treatment"], ["LA18126-5", "Hepatitis B"], ["LA18126-5", "Hepatitis B"], ["LA22004-8", "IN"], ["LA32623-3", "Hepatitis B virus (HBV)"], ["LA32660-5", "Received"], ["LP6486-7", "Reported"], ["LA18126-5", "Hepatitis B"], ["LA22004-8", "IN"], ["LA6576-8", "Positive"], ["LA6577-6", "Negative"], ["LP32426-6", "tested"], ["LP266919-2", "Infection"], ["LP94823-9", "Treatment"], ["LA7556-9", "Test"], ["LA6576-8", "Positive"], ["LP266919-2", "Infection"], ["LA7553-6", "Consultation"], ["LP17763-1", "A"], ["MTHU010489", "Physician"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA18126-5", "Hepatitis B"], ["LP200075-2", "IS"], ["LA20296-2", "Administering"], ["LA22004-8", "IN"], ["LP75708-5", "Symptoms"], ["LA16666-2", "Active"], ["LP266919-2", "Infection"], ["LP267221-2", "Therapy"], ["LA9000-6", "Weeks"], ["LP267221-2", "Therapy"], ["LA8913-1", "Adequate"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LP267221-2", "Therapy"], ["LA7338-2", "Not available"], ["LA22004-8", "IN"], ["LP266919-2", "Infection"], ["LP267221-2", "Therapy"], ["LP94823-9", "Treatment"], ["LA19423-5", "Hepatitis C"], ["LA19423-5", "Hepatitis C"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP7800-8", "History"], ["LA19423-5", "Hepatitis C"], ["LP94823-9", "Treatment"], ["LP191906-9", "Anakinra"], ["LP191906-9", "Anakinra"], ["LA24544-1", "Increased risk"], ["LA30751-4", "Serious"], ["LP74970-2", "Infections"], ["LA27350-0", "Alone"], ["LA12701-1", "Combination"], ["LA21362-1", "Not demonstrated"], ["LA24377-6", "Increased"], ["LP7787-7", "Clinical"], ["LA30596-3", "Combined"], ["LP191906-9", "Anakinra"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA15768-7", "4.5"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LA22004-8", "IN"], ["LA24377-6", "Increased"], ["LA30751-4", "Serious"], ["MTHU058708", "Events"], ["LA12701-1", "Combination"], ["LA21362-1", "Not demonstrated"], ["LA24377-6", "Increased"], ["LP7787-7", "Clinical"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA15768-7", "4.5"], ["LP6486-7", "Reported"], ["LA20642-7", "Urticaria"], ["LA30751-4", "Serious"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA30751-4", "Serious"], ["LA22025-3", "OR"], ["LP73228-6", "Reaction"], ["LP267221-2", "Therapy"], ["LP267221-2", "Therapy"], ["LP74970-2", "Infections"], ["LA7447-1", "Inflammation"], ["LA27183-5", "Immune"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP74341-6", "Study"], ["LA13524-6", "Adult"], ["LA15161-5", "Rheumatoid Arthritis"], ["LA32-8", "No"], ["LP74718-5", "Depression"], ["LP266901-0", "Delayed"], ["LP6886-8", "Type"], ["LP74718-5", "Depression"], ["LA22025-3", "OR"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["T025", "Cell"], ["LA6404-3", "Two"], ["LA31871-9", "Idiopathic"], ["MTHU020793", "Arthritis"], ["LP266919-2", "Infection"], ["LP75708-5", "Symptoms"], ["LA7454-7", "Meningitis"], ["LA9041-0", "Resolved"], ["LP17763-1", "A"], ["LA28474-7", "Significant"], ["LP14855-8", "Virus"], ["LA9508-8", "Discontinue"], ["LP267221-2", "Therapy"], ["LP94823-9", "Treatment"], ["LP32811-9", "Immune Globulin"], ["LA17589-5", "Safety"], ["LA26687-6", "Efficacy"], ["LA22004-8", "IN"], ["LA21291-2", "Not"], ["LP130014-6", "Skin"], ["LP199961-6", "Breast"], ["LP199934-3", "Lung"], ["LA15448-6", "Carcinoma"], ["LA15685-3", "Lymphoma"], ["LA32660-5", "Received"], ["LA22004-8", "IN"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA22004-8", "IN"], ["MTHU854704", "Clinical trials"], ["LA16824-7", "More"], ["LP270144-1", "Cases"], ["LA15685-3", "Lymphoma"], ["LP6425-5", "Observed"], ["LP17763-1", "A"], ["LP7741-4", "Control"], ["LA15679-6", "Rare"], ["LP422890-6", "Follow-up"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["MTHU047625", "Setting"], ["LP270144-1", "Cases"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LP200075-2", "IS"], ["LA24377-6", "Increased"], ["LA15685-3", "Lymphoma"], ["LA22004-8", "IN"], ["LA15161-5", "Rheumatoid Arthritis"], ["MTHU046607", "Standing"], ["LA16666-2", "Active"], ["LA18199-2", "Disease"], ["LP17763-1", "A"], ["LA15097-1", "Possible"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP267221-2", "Therapy"], ["LP17763-1", "A"], ["LP7800-8", "History"], ["LP128794-7", "Malignancy"], ["LA22025-3", "OR"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP128794-7", "Malignancy"], ["LA14973-4", "Some"], ["LA32822-1", "Fatal"], ["LP6486-7", "Reported"], ["MTHU010047", "Age"], ["LP267221-2", "Therapy"], ["MTHU010047", "Age"], ["LA22004-8", "IN"], ["MTHU047625", "Setting"], ["LP270144-1", "Cases"], ["MTHU029809", "Other"], ["LP270144-1", "Cases"], ["LP17763-1", "A"], ["LA15679-6", "Rare"], ["LP17763-1", "A"], ["LA22004-8", "IN"], ["LP130014-6", "Skin"], ["LA14279-6", "Melanoma"], ["LA14279-6", "Melanoma"], ["LA10543-9", "Skin Cancer"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LP270144-1", "Cases"], ["T025", "Cell"], ["LA15448-6", "Carcinoma"], ["LP6486-7", "Reported"], ["LA29696-4", "Very"], ["LA22004-8", "IN"], ["LA6663-4", "Periodic"], ["LP130014-6", "Skin"], ["LP200075-2", "IS"], ["LA18187-7", "All"], ["46467-7", "Risk factors:Find:Pt:^Patient:Nom"], ["LA10543-9", "Skin Cancer"], ["MTHU854704", "Clinical trials"], ["LA16824-7", "More"], ["LP270144-1", "Cases"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LP7741-4", "Control"], ["LA22004-8", "IN"], ["LA15165-6", "Psoriasis"], ["MTHU000146", "Vaccinations"], ["LA20283-0", "Vaccines"], ["LA21291-2", "Not"], ["LP29256-2", "given"], ["LA32-8", "No"], ["LP263805-6", "Secondary"], ["MTHU050362", "Transmission"], ["LP266919-2", "Infection"], ["LA20283-0", "Vaccines"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA17710-7", "Blind"], ["LP7787-7", "Clinical"], ["LP74341-6", "Study"], ["LA22004-8", "IN"], ["LA13524-6", "Adult"], ["MTHU020793", "Arthritis"], ["LA32660-5", "Received"], ["LP17763-1", "A"], ["LP30374-0", "Vaccine"], ["LA21988-3", "AT"], ["LA14216-8", "Week"], ["LP20592-9", "4"], ["LA22004-8", "IN"], ["LP74341-6", "Study"], ["MTHU020793", "Arthritis"], ["LP36861-0", "B-cell"], ["LA27183-5", "Immune"], ["LP30374-0", "Vaccine"], ["LA22004-8", "IN"], ["LA13939-6", "Moderately"], ["LA15680-4", "Few"], ["LA6404-3", "Two"], ["LA22004-8", "IN"], ["LA21291-2", "Not"], ["LP7787-7", "Clinical"], ["LP200075-2", "IS"], ["LA4489-6", "Unknown"], ["LP94823-9", "Treatment"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LP17807-6", "Antibodies"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA15679-6", "Rare"], ["LP270144-1", "Cases"], ["LA29696-4", "Very"], ["LA15679-6", "Rare"], ["LP270144-1", "Cases"], ["LA14973-4", "Some"], ["LA32822-1", "Fatal"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP7800-8", "History"], ["MTHU029981", "Blood"], ["LA18187-7", "All"], ["LA32051-7", "Parents"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP66710-2", "Patient"], ["LP75708-5", "Symptoms"], ["MTHU029981", "Blood"], ["LA22025-3", "OR"], ["LP74970-2", "Infections"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP74849-8", "Fever"], ["LA30867-8", "Sore throat"], ["LA7418-2", "Bleeding"], ["LP417559-4", "Safe Environment for Every Kid"], ["LP32637-8", "Immediate"], ["LA14523-7", "Advice"], ["LA19682-6", "Full"], ["MTHU029981", "Blood"], ["LP6323-2", "Immunofluorescence (IF)"], ["MTHU029981", "Blood"], ["LA15290-2", "Confirmed"], ["LA10590-0", "Neurological Disorders"], ["LA15679-6", "Rare"], ["LA22004-8", "IN"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA15679-6", "Rare"], ["LA24844-5", "Peripheral"], ["LA28752-6", "Chronic"], ["LA32-8", "No"], ["MTHU854704", "Clinical trials"], ["LA19974-7", "Performed"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LP75152-6", "Multiple sclerosis"], ["MTHU854704", "Clinical trials"], ["MTHU029809", "Other"], ["LA22004-8", "IN"], ["LP75152-6", "Multiple sclerosis"], ["LA14961-9", "Increases"], ["LA22004-8", "IN"], ["LA18199-2", "Disease"], ["LP72045-5", "Activity"], ["LP17763-1", "A"], ["LA27332-8", "Evaluation"], ["LP17763-1", "A"], ["LA16973-2", "Neurologic"], ["LP73913-3", "Assessment"], ["LP200075-2", "IS"], ["LP32605-5", "pre"], ["LA22025-3", "OR"], ["LA18199-2", "Disease"], ["LA22025-3", "OR"], ["LA24544-1", "Increased risk"], ["LA18199-2", "Disease"], ["LA12701-1", "Combination"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP7787-7", "Clinical"], ["LA6404-3", "Two"], ["LP14744-4", "Duration"], ["LA22004-8", "IN"], ["LA15161-5", "Rheumatoid Arthritis"], ["LA12701-1", "Combination"], ["LP16198-1", "Methotrexate"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA17589-5", "Safety"], ["59776-5", "Procedure findings:Find:Pt:^Patient:Nar"], ["LA17589-5", "Safety"], ["LP29256-2", "given"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP16198-1", "Methotrexate"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LP16198-1", "Methotrexate"], ["LA27350-0", "Alone"], ["LA18950-8", "Term"], ["LA17589-5", "Safety"], ["LA12701-1", "Combination"], ["LA9040-2", "Ongoing"], ["LA18950-8", "Term"], ["LA17589-5", "Safety"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["MTHU029809", "Other"], ["LA18199-2", "Disease"], ["LP18046-0", "Drugs"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["MTHU029809", "Other"], ["LP75725-9", "Therapies"], ["LA22025-3", "OR"], ["LP94823-9", "Treatment"], ["LA15165-6", "Psoriasis"], ["LA21291-2", "Not"], ["MTHU065909", "Renal"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["MTHU065909", "Renal"], ["LA22025-3", "OR"], ["LP7787-7", "Clinical"], ["LA22004-8", "IN"], ["LP200075-2", "IS"], ["LA6484-5", "Limited"], ["LP74648-4", "Congestive heart failure"], ["LP29659-7", "Cardiac"], ["LA9664-9", "Failure"], ["LA26424-4", "Use caution"], ["LA22004-8", "IN"], ["LA12740-9", "Congestive heart failure (CHF)"], ["LA22004-8", "IN"], ["LA15679-6", "Rare"], ["LA32970-8", "<"], ["LA24574-8", "0.1"], ["LA9039-4", "New"], ["LA22004-8", "IN"], ["LP32605-5", "pre"], ["LA32627-4", "Cardiovascular disease"], ["LA14973-4", "Some"], ["LA28854-0", "50"], ["MTHU010047", "Age"], ["LA6404-3", "Two"], ["LA8981-8", "Large"], ["MTHU854704", "Clinical trials"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA12111-3", "Early"], ["LA26687-6", "Efficacy"], ["LA21291-2", "Not"], ["LA6306-0", "One"], ["LP17763-1", "A"], ["LA15097-1", "Possible"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA7442-2", "Hepatitis"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA15458-5", "II"], ["LP74341-6", "Study"], ["LA22025-3", "OR"], ["LA32820-5", "Moderate to severe"], ["LA7442-2", "Hepatitis"], ["LA21291-2", "Not"], ["MTHU027852", "Rate"], ["LA22004-8", "IN"], ["LP203021-3", "6 months"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA7442-2", "Hepatitis"], ["LA26424-4", "Use caution"], ["LA22004-8", "IN"], ["LA32820-5", "Moderate to severe"], ["LA7442-2", "Hepatitis"], ["LA17782-6", "Wegener's granulomatosis"], ["LP17763-1", "A"], ["LA22004-8", "IN"], ["LA13524-6", "Adult"], ["LA22004-8", "IN"], ["LA11132-0", "Addition"], ["LP20607-5", "standard"], ["LP267221-2", "Therapy"], ["LP70366-7", "Cyclophosphamide"], ["LA22025-3", "OR"], ["LP16198-1", "Methotrexate"], ["LP31487-9", "Glucocorticoids"], ["LP17763-1", "A"], ["LA25381-7", "Median"], ["LP14744-4", "Duration"], ["LA19281-7", "25"], ["MTHU068094", "Months"], ["LA21291-2", "Not"], ["LP94823-9", "Treatment"], ["LP15241-0", "S"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LP7741-4", "Control"], ["T096", "Group"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP94823-9", "Treatment"], ["LP15241-0", "S"], ["LA22004-8", "IN"], ["LP128793-9", "Diabetes"], ["LA22004-8", "IN"], ["MTHU038481", "Medication"], ["LP128793-9", "Diabetes"], ["LP17763-1", "A"], ["LP267357-4", "Reduction"], ["LA22004-8", "IN"], ["LA26134-9", "Diabetic"], ["MTHU038481", "Medication"], ["LA22004-8", "IN"], ["LA14973-4", "Some"], ["LA22004-8", "IN"], ["LP20591-1", "3"], ["LA22004-8", "IN"], ["LA15161-5", "Rheumatoid Arthritis"], ["MTHU020793", "Arthritis"], ["LA31822-2", "Spondylitis"], ["LA32-8", "No"], ["MTHU044104", "Overall"], ["LA22004-8", "IN"], ["MTHU058708", "Events"], ["LA30751-4", "Serious"], ["MTHU058708", "Events"], ["LA30751-4", "Serious"], ["LP74970-2", "Infections"], ["LA22004-8", "IN"], ["MTHU010047", "Age"], ["LA12691-4", "65 or older"], ["LA32660-5", "Received"], ["LP6425-5", "Observed"], ["LA22668-0", "Attention"], ["LP74970-2", "Infections"], ["LP62263-6", "Population"], ["MTHU000146", "Vaccinations"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA15097-1", "Possible"], ["LP182451-7", "Date"], ["LA18187-7", "All"], ["LA22004-8", "IN"], ["MTHU052654", "Agreement"], ["LA33028-4", "Prior"], ["LP267221-2", "Therapy"], ["MTHU000146", "Vaccinations"], ["LA14991-6", "Above"]], "snomed.pregnancy": [["68405009", "Concurrent (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["255397009", "Adult (qualifier value)|Adult"], ["28995006", "Treated with (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["28995006", "Treated with (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1305003", "Double (qualifier value)"], ["277675000", "Blind (finding)"], ["31509003", "Controlled (qualifier value)"], ["18720000", "In (attribute)"], ["255397009", "Adult (qualifier value)|Adult"], ["387381009", "Methotrexate (substance)"], ["28995006", "Treated with (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["303011007", "Neutropenic disorder (disorder)"], ["28995006", "Treated with (attribute)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["395279009", "Anakinra (product)|Product containing anakinra (medicinal product)"], ["35105006", "Increased (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421777009", "Abatacept (substance)"], ["18720000", "In (attribute)"], ["58147004", "Clinical (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421777009", "Abatacept (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["35105006", "Increased (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["42745003", "Serious (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["89780004", "Combined (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["68405009", "Concurrent (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387248006", "Sulfasalazine (substance)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["224699009", "Study (environment)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255397009", "Adult (qualifier value)|Adult"], ["263748003", "Established (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387248006", "Sulfasalazine (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["389109008", "Group (social concept)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["394653002", "Significant|Significant (qualifier value)"], ["260370003", "Decrease (qualifier value)"], ["18720000", "In (attribute)"], ["255586005", "Mean (qualifier value)"], ["272170001", "White blood cell (cell)|White blood cell"], ["258734002", "counts (qualifier value)"], ["18720000", "In (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["261586004", "Groups (qualifier value)"], ["28995006", "Treated with (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["387248006", "Sulfasalazine (substance)"], ["58147004", "Clinical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["261665006", "Unknown (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["229554006", "Combination therapy (regime/therapy)|Combination therapy (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387248006", "Sulfasalazine (substance)"], ["18720000", "In (attribute)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["373067005", "No (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["9203006", "Salicylate (substance)|Salicylate (product)"], ["387248006", "Sulfasalazine (substance)"], ["255387000", "Inflammatory|Inflammatory (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["732727007", "4.4 (qualifier value)"], ["86495002", "For (qualifier value)"], ["33879002", "Administration of vaccine to produce active immunity (procedure)"], ["243073001", "Advice (regime/therapy)|Advice (regime/therapy)(procedure)"], ["373067005", "No (qualifier value)"], ["394653002", "Significant|Significant (qualifier value)"], ["410942007", "Drug or medicament (substance)"], ["410942007", "Drug or medicament (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387381009", "Methotrexate (substance)"], ["387461009", "Digoxin (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["372756006", "Warfarin (substance)"]], "ncit.pregnancy": [["C25456", "Concurrent"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C38717", "Anakinra"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C16289", "Andorra"], ["C38717", "Anakinra"], ["C25599", "Observed"], ["C159124", "GDC Treatment Outcome Terminology"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C25227", "High"], ["C77538", "Rating"], ["C52874", "SPI1 wt Allele"], ["C54035", "Serious"], ["C128320", "Infection"], ["C65140", "When"], ["C49156", "Comparison"], ["C62355", "With"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C43508", "Oregon"], ["C38717", "Anakinra"], ["C48440", "Single"], ["C188864", "Historical Data"], ["C16727", "India"], ["C64911", "Add"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C62265", "Double"], ["C49068", "Blinded"], ["C49648", "Placebo Control"], ["C71104", "Clinical Trial"], ["C16727", "India"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C25639", "Receive"], ["C45782", "Background"], ["C642", "Methotrexate"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C16289", "Andorra"], ["C38717", "Anakinra"], ["C25599", "Observed"], ["C159124", "GDC Treatment Outcome Terminology"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C25227", "High"], ["C77538", "Rating"], ["C52874", "SPI1 wt Allele"], ["C54035", "Serious"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C16289", "Andorra"], ["C80520", "Neutropenia"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C61517", "Combination"], ["C2381", "Etanercept"], ["C16289", "Andorra"], ["C38717", "Anakinra"], ["C101282", "Have"], ["C25594", "Negation"], ["C164135", "Increased"], ["C142422", "Clinical Benefit"], ["C16289", "Andorra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C25456", "Concurrent"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C28898", "Abatacept"], ["C16727", "India"], ["C15206", "Clinical Study"], ["C25456", "Concurrent"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C28898", "Abatacept"], ["C16289", "Andorra"], ["C2381", "Etanercept"], ["C16727", "India"], ["C164135", "Increased"], ["C52874", "SPI1 wt Allele"], ["C177945", "Serious Adverse Events Domain"], ["C61517", "Combination"], ["C101282", "Have"], ["C25594", "Negation"], ["C164135", "Increased"], ["C142422", "Clinical Benefit"], ["C25340", "Use"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25456", "Concurrent"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C29469", "Sulfasalazine"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C15206", "Clinical Study"], ["C52874", "SPI1 wt Allele"], ["C52678", "Legal Adult"], ["C16960", "Patient"], ["C75419", "World Health Organization"], ["C25639", "Receive"], ["C71155", "Established"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C29469", "Sulfasalazine"], ["C159124", "GDC Treatment Outcome Terminology"], ["C2381", "Etanercept"], ["C154196", "Washo Language"], ["C45330", "Added"], ["C16960", "Patient"], ["C16727", "India"], ["C61517", "Combination"], ["C42685", "Group Object"], ["C76246", "Blood Group A"], ["C28110", "Statistically Significant"], ["C25640", "Reduced"], ["C16727", "India"], ["C181249", "Mean Based on Unspecified Calculation"], ["C12529", "Leukocyte"], ["C16727", "India"], ["C49156", "Comparison"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C43508", "Oregon"], ["C29469", "Sulfasalazine"], ["C48440", "Single"], ["C82562", "Clinical Significance"], ["C52874", "SPI1 wt Allele"], ["C54216", "Interaction"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C160764", "Unknown Molecular Analysis"], ["C25340", "Use"], ["C65140", "When"], ["C15212", "Multimodality Therapy"], ["C62355", "With"], ["C29469", "Sulfasalazine"], ["C14460", "NON Mouse"], ["C16727", "India"], ["C71104", "Clinical Trial"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C101282", "Have"], ["C25599", "Observed"], ["C65140", "When"], ["C2381", "Etanercept"], ["C154196", "Washo Language"], ["C25382", "Administered"], ["C62355", "With"], ["C147431", "Salicylates Measurement"], ["C151896", "Other Than"], ["C29469", "Sulfasalazine"], ["C256", "Anti-Inflammatory Agent"], ["C257", "Nonsteroidal Antiinflammatory Drug"], ["C241", "Analgesic Agent"], ["C43508", "Oregon"], ["C642", "Methotrexate"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C64956", "For"], ["C15346", "Vaccination"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C41130", "Significant"], ["C49663", "Pharmacokinetic Study"], ["C459", "Medication"], ["C459", "Medication"], ["C25599", "Observed"], ["C16727", "India"], ["C62355", "With"], ["C642", "Methotrexate"], ["C28990", "Digoxin"], ["C43508", "Oregon"], ["C945", "Warfarin"]], "rxnorm.pregnancy": [["72435", "anakinra"], ["216891", "Enbrel"], ["72435", "anakinra"], ["216891", "Enbrel"], ["72435", "anakinra"], ["8375", "placebo"], ["6851", "methotrexate"], ["216891", "Enbrel"], ["72435", "anakinra"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["72435", "anakinra"], ["614391", "abatacept"], ["614391", "abatacept"], ["216891", "Enbrel"], ["9524", "sulfasalazine"], ["9524", "sulfasalazine"], ["216891", "Enbrel"], ["T096", "Group"], ["T025", "Cell"], ["216891", "Enbrel"], ["9524", "sulfasalazine"], ["9524", "sulfasalazine"], ["216891", "Enbrel"], ["9524", "sulfasalazine"], ["6851", "methotrexate"], ["6851", "methotrexate"], ["3407", "digoxin"], ["11289", "warfarin"]], "loinc.pregnancy": [["LP94823-9", "Treatment"], ["LP191906-9", "Anakinra"], ["LA13524-6", "Adult"], ["LP191906-9", "Anakinra"], ["LP6425-5", "Observed"], ["LP17763-1", "A"], ["MTHU027852", "Rate"], ["LA30751-4", "Serious"], ["LP266919-2", "Infection"], ["LA11930-7", "Either"], ["LA22025-3", "OR"], ["LP191906-9", "Anakinra"], ["LA27350-0", "Alone"], ["LA22004-8", "IN"], ["LA11132-0", "Addition"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA17710-7", "Blind"], ["LA22004-8", "IN"], ["LA13524-6", "Adult"], ["LP16198-1", "Methotrexate"], ["LP191906-9", "Anakinra"], ["LP6425-5", "Observed"], ["LP17763-1", "A"], ["MTHU027852", "Rate"], ["LA30751-4", "Serious"], ["LP74970-2", "Infections"], ["LP36790-1", "7"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA12701-1", "Combination"], ["LP191906-9", "Anakinra"], ["LA21362-1", "Not demonstrated"], ["LA24377-6", "Increased"], ["LP7787-7", "Clinical"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LA22004-8", "IN"], ["LA24377-6", "Increased"], ["LA30751-4", "Serious"], ["MTHU058708", "Events"], ["LA12701-1", "Combination"], ["LA21362-1", "Not demonstrated"], ["LA24377-6", "Increased"], ["LP7787-7", "Clinical"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP94823-9", "Treatment"], ["MTHU060449", "sulfaSALAzine"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP7787-7", "Clinical"], ["LP74341-6", "Study"], ["LA13524-6", "Adult"], ["MTHU060449", "sulfaSALAzine"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["T096", "Group"], ["LP17763-1", "A"], ["LA28474-7", "Significant"], ["LA32049-1", "Decrease"], ["LA22004-8", "IN"], ["LP6971-8", "mean"], ["LA4457-3", "White"], ["MTHU029981", "Blood"], ["T025", "Cell"], ["LA22004-8", "IN"], ["LP266973-9", "Comparison"], ["LA22025-3", "OR"], ["MTHU060449", "sulfaSALAzine"], ["LA27350-0", "Alone"], ["LP7787-7", "Clinical"], ["LP200075-2", "IS"], ["LA4489-6", "Unknown"], ["LA26424-4", "Use caution"], ["LA12701-1", "Combination"], ["LP267221-2", "Therapy"], ["MTHU060449", "sulfaSALAzine"], ["LA22004-8", "IN"], ["MTHU854704", "Clinical trials"], ["LA32-8", "No"], ["LP6425-5", "Observed"], ["LP31487-9", "Glucocorticoids"], ["LP16276-5", "Salicylates"], ["MTHU060449", "sulfaSALAzine"], ["LP18046-0", "Drugs"], ["LP31430-9", "NSAIDS"], ["LP31483-8", "Analgesics"], ["LA22025-3", "OR"], ["LP16198-1", "Methotrexate"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA14523-7", "Advice"], ["LA32-8", "No"], ["LA28474-7", "Significant"], ["LA20274-9", "Drug-drug"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LP16198-1", "Methotrexate"], ["MTHU001808", "Digoxin"], ["LA22025-3", "OR"], ["LA28654-4", "Warfarin"]], "snomed.driving": [["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["260676000", "Use of (attribute)"], ["146680009", "Contraception|Contraception (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["278923009", "Developmental (qualifier value)"], ["75478009", "Poisoning (disorder)"], ["398166005", "Performed (qualifier value)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["263857004", "Revealed (qualifier value)"], ["41647002", "No evidence of (contextual qualifier) (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["394447009", "Fetus (person)|Fetus"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255407002", "Neonatal (qualifier value)"], ["371565004", "Rattus norvegicus (organism)"], ["42752001", "Due to (attribute)"], ["387045004", "Etanercept (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387045004", "Etanercept (substance)"], ["420862001", "On (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["18720000", "In (attribute)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255603008", "Major (qualifier value)"], ["3950001", "Birth (finding)"], ["18720000", "In (attribute)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["224699009", "Study (environment)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["387045004", "Etanercept (substance)"], ["257992007", "n (qualifier value)|Lower case Roman letter n (qualifier value)"], ["732707006", "370 (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["255216001", "First (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["387045004", "Etanercept (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["8612007", "Tumor necrosis factor (substance)"], ["257992007", "n (qualifier value)|Lower case Roman letter n (qualifier value)"], ["118586006", "Ratio (property) (qualifier value)"], ["732575004", "2.4 (qualifier value)"], ["732906005", "95 (qualifier value)"], ["282109005", "Curie (qualifier value)|Ci (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["732769006", "5.5 (qualifier value)"], ["261664005", "Types (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["255603008", "Major (qualifier value)"], ["3950001", "Birth (finding)"], ["385433004", "Consistent with (qualifier value)"], ["4757001", "Most (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["60132005", "Generalized (qualifier value)"], ["385436007", "Population (social concept)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["255711007", "Pattern (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["7882003", "Identified (qualifier value)"], ["260388006", "No status change (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["267294003", "Abortion: [spontaneous] or [complete] or [incomplete] (disorder)|Abortion: [spontaneous] or [complete] or [incomplete]"], ["268887007", "(Perinatal conditions NOS) or (death: [infant] or [neonatal] or [newborn] or [perinatal]) or (stillbirth) (disorder)|(Perinatal conditions NOS) or (death: [infant] or [neonatal] or [newborn] or [perinatal]) or (stillbirth)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["410599005", "Minor (person)"], ["18720000", "In (attribute)"], ["223369002", "Countries (geographic location)|Country (geographic location)"], ["224699009", "Study (environment)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["18720000", "In (attribute)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["387045004", "Etanercept (substance)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["255216001", "First (qualifier value)"], ["732899009", "90 (qualifier value)"], ["258703001", "day (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["257992007", "n (qualifier value)|Lower case Roman letter n (qualifier value)"], ["1222870008", "American Joint Committee on Cancer stage IV:25 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["257992007", "n (qualifier value)|Lower case Roman letter n (qualifier value)"], ["373067005", "No (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["255603008", "Major (qualifier value)"], ["3950001", "Birth (finding)"], ["118586006", "Ratio (property) (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["276136004", "Equal symbol = (qualifier value)|= (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222775005", "American Joint Committee on Cancer stage II:2 (qualifier value)"], ["732906005", "95 (qualifier value)"], ["282109005", "Curie (qualifier value)|Ci (qualifier value)"], ["895695009", "0.79 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732899009", "90 (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["276136004", "Equal symbol = (qualifier value)|= (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["732907001", "96 (qualifier value)"], ["732906005", "95 (qualifier value)"], ["282109005", "Curie (qualifier value)|Ci (qualifier value)"], ["732379006", "0.58 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732814003", "60 (qualifier value)"], ["255234002", "After (attribute)"], ["86495002", "For (qualifier value)"], ["223369002", "Countries (geographic location)|Country (geographic location)"], ["1269485005", "Maternal (qualifier value)"], ["64572001", "Disease (disorder)"], ["364325004", "Parity (observable entity)"], ["13506008", "Maternal age, function (observable entity)|Maternal age (function)|Maternal age (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["365981007", "Finding of tobacco smoking behavior (finding)"], ["18720000", "In (attribute)"], ["264499004", "Early (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["224699009", "Study (environment)"], ["373067005", "No (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["410599005", "Minor (person)"], ["3950001", "Birth (finding)"], ["3950001", "Birth (finding)"], ["268887007", "(Perinatal conditions NOS) or (death: [infant] or [neonatal] or [newborn] or [perinatal]) or (stillbirth) (disorder)|(Perinatal conditions NOS) or (death: [infant] or [neonatal] or [newborn] or [perinatal]) or (stillbirth)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["255216001", "First (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86495002", "For (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["387045004", "Etanercept (substance)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["410525008", "Needed (qualifier value)"], ["387045004", "Etanercept (substance)"], ["181455002", "Entire placenta (body structure)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260373001", "Detected (qualifier value)"], ["18720000", "In (attribute)"], ["67922002", "Serum (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["248152002", "Female (finding)"], ["28995006", "Treated with (attribute)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["58147004", "Clinical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["261665006", "Unknown (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["257551009", "Infection (disorder)|Infection"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["1222743007", "American Joint Committee on Cancer stage I:6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["394651000", "Mother (person)|Mother"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["18720000", "In (attribute)"], ["255260001", "Following (attribute)"], ["764295003", "Subcutaneous (intended site)"], ["416118004", "Administration (procedure)"], ["387045004", "Etanercept (substance)"], ["18720000", "In (attribute)"], ["70813002", "Milk (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260373001", "Detected (qualifier value)"], ["18720000", "In (attribute)"], ["67922002", "Serum (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["387045004", "Etanercept (substance)"], ["260373001", "Detected (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["62482003", "Low (qualifier value)"], ["258395000", "Levels (qualifier value)"], ["18720000", "In (attribute)"], ["226789007", "Breast milk (substance)"], ["387045004", "Etanercept (substance)"], ["86495002", "For (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["30507006", "Into (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["86495002", "For (qualifier value)"], ["410601007", "Childhood age person (person)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["86495002", "For (qualifier value)"], ["224526002", "Woman (person)"], ["31099001", "Systemic (qualifier value)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["133931009", "Infant (person)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["62482003", "Low (qualifier value)"], ["387045004", "Etanercept (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["279972009", "Entire gastrointestinal tract (body structure)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["31099001", "Systemic (qualifier value)"], ["242575009", "Accident due to exposure to weather conditions (event)|Accident due to exposure to weather conditions (finding)"], ["18720000", "In (attribute)"], ["133931009", "Infant (person)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["71181003", "Product containing vaccine (product)|Vaccine (substance)|Vaccine (product)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["133931009", "Infant (person)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["394651000", "Mother (person)|Mother"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["387045004", "Etanercept (substance)"], ["1222743007", "American Joint Committee on Cancer stage I:6 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["133931009", "Infant (person)"], ["387045004", "Etanercept (substance)"], ["67922002", "Serum (substance)"], ["258395000", "Levels (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["272114000", "During values (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["263844007", "Maternal postnatal period (qualifier value)|Postnatal (qualifier value)"], ["75478009", "Poisoning (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387045004", "Etanercept (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387045004", "Etanercept (substance)"], ["420862001", "On (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["60132005", "Generalized (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"]], "ncit.driving": [["C161316", "Female of Childbearing Potential"], ["C161316", "Female of Childbearing Potential"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C37932", "Contraception"], ["C159124", "GDC Treatment Outcome Terminology"], ["C73435", "Gravida"], ["C25490", "During"], ["C2381", "Etanercept"], ["C49236", "Therapeutic Procedure"], ["C16289", "Andorra"], ["C64956", "For"], ["C66834", "Three"], ["C29844", "Week"], ["C38008", "Post"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C191656", "Pregnant Subject"], ["C168182", "Developmental Finding"], ["C27990", "Toxicity"], ["C38000", "Performed"], ["C16727", "India"], ["C16289", "Andorra"], ["C101282", "Have"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43583", "Evidence"], ["C52874", "SPI1 wt Allele"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C16731", "Newborn"], ["C160998", "Rat"], ["C89272", "Due To"], ["C2381", "Etanercept"], ["C25492", "Effect"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C92667", "SPARC wt Allele"], ["C191656", "Pregnant Subject"], ["C101282", "Have"], ["C16727", "India"], ["C66833", "Two"], ["C25598", "Observation"], ["C15208", "Cohort Study"], ["C76246", "Blood Group A"], ["C25227", "High"], ["C77538", "Rating"], ["C52874", "SPI1 wt Allele"], ["C45368", "Major"], ["C25155", "Birth"], ["C154196", "Washo Language"], ["C25599", "Observed"], ["C16727", "India"], ["C66832", "One"], ["C16084", "Observational Study"], ["C159124", "GDC Treatment Outcome Terminology"], ["C2381", "Etanercept"], ["C25580", "N Category"], ["C25490", "During"], ["C25509", "First"], ["C69121", "Trimester"], ["C62355", "With"], ["C25594", "Negation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C2381", "Etanercept"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C18368", "TNF Gene"], ["C25580", "N Category"], ["C49157", "Adjustment"], ["C179809", "Ratio Result Type"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C112239", "Coagulation Index Measurement"], ["C189636", "CDISC SDTM Implementation Guide Medical Device Version 1.0"], ["C163771", "Illness Intrusiveness Rating 5"], ["C163771", "Illness Intrusiveness Rating 5"], ["C52874", "SPI1 wt Allele"], ["C45368", "Major"], ["C25155", "Birth"], ["C85901", "Consistent"], ["C25258", "Most"], ["C188308", "Reported Information"], ["C16727", "India"], ["C18241", "General Population"], ["C16289", "Andorra"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25336", "Pattern"], ["C52874", "SPI1 wt Allele"], ["C154196", "Washo Language"], ["C25737", "Identification"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C54126", "Delta"], ["C16727", "India"], ["C77538", "Rating"], ["C52874", "SPI1 wt Allele"], ["C34336", "Spontaneous Abortion"], ["C49151", "Stillbirth"], ["C43508", "Oregon"], ["C45367", "Minor"], ["C154196", "Washo Language"], ["C25599", "Observed"], ["C16727", "India"], ["C25598", "Observation"], ["C17648", "Multiple"], ["C20108", "Country Code"], ["C15753", "Cancer Registry"], ["C45319", "Study Object"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C188368", "ELN Adverse-Risk Category"], ["C191656", "Pregnant Subject"], ["C16727", "India"], ["C159124", "GDC Treatment Outcome Terminology"], ["C2381", "Etanercept"], ["C25490", "During"], ["C25509", "First"], ["C182728", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 90"], ["C25301", "Day"], ["C52874", "SPI1 wt Allele"], ["C191656", "Pregnant Subject"], ["C25580", "N Category"], ["C159124", "GDC Treatment Outcome Terminology"], ["C159124", "GDC Treatment Outcome Terminology"], ["C14460", "NON Mouse"], ["C28226", "Biological"], ["C25580", "N Category"], ["C154196", "Washo Language"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25599", "Observed"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C45368", "Major"], ["C25155", "Birth"], ["C179809", "Ratio Result Type"], ["C43508", "Oregon"], ["C105723", "ECOG Performance Status 1"], ["C126884", "Twenty Two"], ["C112239", "Coagulation Index Measurement"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C105791", "Seventy Nine"], ["C105723", "ECOG Performance Status 1"], ["C182728", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 90"], ["C49157", "Adjustment"], ["C43508", "Oregon"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C192182", "Ninety Six"], ["C112239", "Coagulation Index Measurement"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C103004", "Human Papillomavirus-58"], ["C105723", "ECOG Performance Status 1"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C38008", "Post"], ["C64956", "For"], ["C20108", "Country Code"], ["C89336", "Maternal"], ["C2991", "Disease or Disorder"], ["C16955", "Parity"], ["C89336", "Maternal"], ["C106312", "Advanced Glycation End Product"], ["C16289", "Andorra"], ["C17934", "Tobacco Smoking"], ["C16727", "India"], ["C61589", "Early"], ["C191656", "Pregnant Subject"], ["C45319", "Study Object"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C164135", "Increased"], ["C52874", "SPI1 wt Allele"], ["C45367", "Minor"], ["C25155", "Birth"], ["C92861", "Preterm Birth"], ["C49151", "Stillbirth"], ["C43508", "Oregon"], ["C16727", "India"], ["C25509", "First"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C20203", "Laser-Induced Fluorescence Endoscopy"], ["C64956", "For"], ["C25155", "Birth"], ["C159124", "GDC Treatment Outcome Terminology"], ["C159124", "GDC Treatment Outcome Terminology"], ["C2381", "Etanercept"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C2381", "Etanercept"], ["C48440", "Single"], ["C16329", "Belgium"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C198613", "CFI wt Allele"], ["C2381", "Etanercept"], ["C13272", "Placenta"], ["C16289", "Andorra"], ["C101282", "Have"], ["C16210", "Detection"], ["C16727", "India"], ["C13325", "Serum"], ["C52874", "SPI1 wt Allele"], ["C25155", "Birth"], ["C159124", "GDC Treatment Outcome Terminology"], ["C46110", "Female Gender"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C2381", "Etanercept"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C123619", "Clinical Response"], ["C62534", "Arginine/Omega-3 Fatty Acids/Nucleotides Oral Supplement"], ["C52874", "SPI1 wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C160764", "Unknown Molecular Analysis"], ["C106184", "May"], ["C16329", "Belgium"], ["C158997", "GDC Analyte Type Terminology"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C128320", "Infection"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C89279", "Reside"], ["C159124", "GDC Treatment Outcome Terminology"], ["C64956", "For"], ["C113430", "Sixteen"], ["C29844", "Week"], ["C38008", "Post"], ["C25189", "Mother"], ["C42555", "Siemens"], ["C25551", "Last"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C16727", "India"], ["C82463", "Lactating"], ["C53286", "Next"], ["C13353", "Subcutaneous"], ["C70962", "Agent Administration"], ["C2381", "Etanercept"], ["C154196", "Washo Language"], ["C16727", "India"], ["C13257", "Mammary Gland Milk"], ["C16289", "Andorra"], ["C16210", "Detection"], ["C16727", "India"], ["C13325", "Serum"], ["C52874", "SPI1 wt Allele"], ["C142988", "Limited"], ["C48191", "Information"], ["C25516", "From"], ["C19026", "Scientific Publication"], ["C48471", "Publication"], ["C2381", "Etanercept"], ["C101282", "Have"], ["C16210", "Detection"], ["C158997", "GDC Analyte Type Terminology"], ["C139301", "IPSS Risk Category Low"], ["C16727", "India"], ["C14225", "Human"], ["C13257", "Mammary Gland Milk"], ["C2381", "Etanercept"], ["C16329", "Belgium"], ["C64956", "For"], ["C25340", "Use"], ["C25490", "During"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C25544", "Into"], ["C88186", "Financial Account"], ["C25387", "Benefit"], ["C52874", "SPI1 wt Allele"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C64956", "For"], ["C150886", "Child Relation"], ["C16289", "Andorra"], ["C25387", "Benefit"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C64956", "For"], ["C14284", "Woman"], ["C13310", "Systemic"], ["C49587", "Exposure Domain"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C27956", "Infant"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C41333", "Expected Adverse Event"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C139301", "IPSS Risk Category Low"], ["C2381", "Etanercept"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C62970", "Degradation"], ["C16727", "India"], ["C34082", "Gastrointestinal Tract"], ["C142988", "Limited"], ["C25474", "Data"], ["C13310", "Systemic"], ["C49587", "Exposure Domain"], ["C16727", "India"], ["C27956", "Infant"], ["C68869", "Are"], ["C25429", "Availability"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C89279", "Reside"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C1328", "BCG"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C27956", "Infant"], ["C65140", "When"], ["C25189", "Mother"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25639", "Receive"], ["C2381", "Etanercept"], ["C16329", "Belgium"], ["C113430", "Sixteen"], ["C29844", "Week"], ["C38008", "Post"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C43508", "Oregon"], ["C158997", "GDC Analyte Type Terminology"], ["C75889", "PAX6 wt Allele"], ["C68568", "Timepoint"], ["C198613", "CFI wt Allele"], ["C27956", "Infant"], ["C2381", "Etanercept"], ["C13325", "Serum"], ["C68869", "Are"], ["C111568", "Undetectable"], ["C95089", "Fertility Domain"], ["C48674", "Preclinical"], ["C25474", "Data"], ["C45828", "Approximate"], ["C52247", "Surrounding"], ["C16289", "Andorra"], ["C81317", "Postnatal"], ["C27990", "Toxicity"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C16289", "Andorra"], ["C52874", "SPI1 wt Allele"], ["C25492", "Effect"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C92667", "SPARC wt Allele"], ["C95089", "Fertility Domain"], ["C16289", "Andorra"], ["C115727", "Safety Reporting Documentation"], ["C17087", "Reproduction"], ["C25361", "Performance"], ["C68869", "Are"], ["C126101", "Not Available"]], "rxnorm.driving": [["216891", "Enbrel"], ["214555", "etanercept"], ["214555", "etanercept"], ["214555", "etanercept"], ["214555", "etanercept"], ["214555", "etanercept"], ["214555", "etanercept"], ["216891", "Enbrel"], ["214555", "etanercept"], ["216891", "Enbrel"], ["216891", "Enbrel"], ["214555", "etanercept"], ["214555", "etanercept"], ["T016", "Human"], ["214555", "etanercept"], ["214555", "etanercept"], ["214555", "etanercept"], ["214555", "etanercept"], ["214555", "etanercept"], ["214555", "etanercept"]], "loinc.driving": [["LA15173-0", "Pregnant"], ["LP267221-2", "Therapy"], ["LA6395-3", "Three"], ["LA9000-6", "Weeks"], ["LP267221-2", "Therapy"], ["LP207970-7", "Pregnancy"], ["LA19974-7", "Performed"], ["LA22004-8", "IN"], ["LA32-8", "No"], ["LA22025-3", "OR"], ["LP14225-4", "Rat"], ["MTHU054569", "Etanercept"], ["MTHU054569", "Etanercept"], ["LP207970-7", "Pregnancy"], ["LA22004-8", "IN"], ["LA6404-3", "Two"], ["LP17763-1", "A"], ["MTHU027852", "Rate"], ["LA29634-5", "Major"], ["LP192134-7", "Birth defects"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LA6306-0", "One"], ["LP74341-6", "Study"], ["LP73139-5", "Pregnancies"], ["MTHU054569", "Etanercept"], ["LA15167-2", "N"], ["LP6974-2", "first"], ["LP73139-5", "Pregnancies"], ["LA21291-2", "Not"], ["MTHU054569", "Etanercept"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LA15167-2", "N"], ["LP20174-6", "adjusted"], ["LP6852-0", "Ratio"], ["MTHU000002", "Clinical Class"], ["LP20592-9", "4"], ["LA6112-2", "1"], ["LA6111-4", "0"], ["LA15769-5", "5.5"], ["LA29634-5", "Major"], ["LP192134-7", "Birth defects"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LA29505-7", "General population"], ["LA32-8", "No"], ["LP40035-5", "Identified"], ["LA64-1", "No change"], ["LA22004-8", "IN"], ["MTHU027852", "Rate"], ["LA14668-0", "Abortion"], ["LA14667-2", "Stillbirth"], ["LA22025-3", "OR"], ["LA29633-7", "Minor"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LP7748-9", "Multi"], ["LP120625-1", "Country"], ["LP74341-6", "Study"], ["LP207970-7", "Pregnancy"], ["LA22004-8", "IN"], ["MTHU054569", "Etanercept"], ["LP6974-2", "first"], ["LP203019-7", "90 days"], ["LP207970-7", "Pregnancy"], ["LA15167-2", "N"], ["LA14112-9", "425"], ["LA31430-4", "Biologic"], ["LP18046-0", "Drugs"], ["LA15167-2", "N"], ["LA32-8", "No"], ["LP6425-5", "Observed"], ["LA24544-1", "Increased risk"], ["LA29634-5", "Major"], ["LP192134-7", "Birth defects"], ["LP6852-0", "Ratio"], ["LA22025-3", "OR"], ["LA6112-2", "1"], ["LA6111-4", "0"], ["LA6112-2", "1"], ["LA28891-2", "90"], ["LP20174-6", "adjusted"], ["LA22025-3", "OR"], ["LA6111-4", "0"], ["LA6111-4", "0"], ["LA6112-2", "1"], ["LA28853-2", "60"], ["LP120625-1", "Country"], ["LA26320-4", "Maternal"], ["LA18199-2", "Disease"], ["LP64616-3", "Parity"], ["LA26320-4", "Maternal"], ["MTHU010047", "Age"], ["LA8928-9", "Smoking"], ["LA22004-8", "IN"], ["LA12111-3", "Early"], ["LP207970-7", "Pregnancy"], ["LP74341-6", "Study"], ["LA32-8", "No"], ["LA24377-6", "Increased"], ["MTHU043138", "Risks"], ["LA29633-7", "Minor"], ["LP192134-7", "Birth defects"], ["LA14667-2", "Stillbirth"], ["LA22025-3", "OR"], ["LP74970-2", "Infections"], ["LA22004-8", "IN"], ["LP6974-2", "first"], ["MTHU054569", "Etanercept"], ["LP266032-4", "during pregnancy"], ["LP266032-4", "during pregnancy"], ["LP6323-2", "Immunofluorescence (IF)"], ["MTHU054569", "Etanercept"], ["LP208379-0", "Placenta"], ["LA11882-0", "Detected"], ["LA22004-8", "IN"], ["LP7567-3", "Serum"], ["LA3-6", "Female"], ["LP266032-4", "during pregnancy"], ["LP7787-7", "Clinical"], ["LP200075-2", "IS"], ["LA4489-6", "Unknown"], ["LA14161-6", "May"], ["LA21988-3", "AT"], ["LA24544-1", "Increased risk"], ["LP266919-2", "Infection"], ["LA20283-0", "Vaccines"], ["LA14562-5", "16"], ["LA9000-6", "Weeks"], ["LP6983-3", "Mother"], ["LP15241-0", "S"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LA22004-8", "IN"], ["LA9451-1", "Subcutaneous"], ["MTHU054569", "Etanercept"], ["LA22004-8", "IN"], ["LP29290-1", "Milk"], ["LA11882-0", "Detected"], ["LA22004-8", "IN"], ["LP7567-3", "Serum"], ["LA6484-5", "Limited"], ["MTHU054569", "Etanercept"], ["LA11882-0", "Detected"], ["LA21988-3", "AT"], ["LA9194-7", "Low"], ["LA22004-8", "IN"], ["LA19711-3", "Human"], ["LP29290-1", "Milk"], ["MTHU054569", "Etanercept"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LA33152-2", "The child"], ["LP267221-2", "Therapy"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA19747-7", "Infant"], ["LP200075-2", "IS"], ["LA9194-7", "Low"], ["MTHU054569", "Etanercept"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP76054-3", "Gastrointestinal tract"], ["LA6484-5", "Limited"], ["LA22004-8", "IN"], ["LA19747-7", "Infant"], ["LA20283-0", "Vaccines"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP102323-5", "Bromocresol green (BCG) dye binding method"], ["LP17763-1", "A"], ["LA19747-7", "Infant"], ["LP6983-3", "Mother"], ["LP200075-2", "IS"], ["MTHU054569", "Etanercept"], ["LA14562-5", "16"], ["LA9000-6", "Weeks"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LA22025-3", "OR"], ["LA21988-3", "AT"], ["LA14566-6", "Earlier"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA19747-7", "Infant"], ["MTHU054569", "Etanercept"], ["LP7567-3", "Serum"], ["MTHU000074", "Fertility"], ["MTHU054569", "Etanercept"], ["MTHU054569", "Etanercept"], ["MTHU000074", "Fertility"], ["LA17571-3", "General"], ["LA18285-9", "Reproductive"], ["LA7338-2", "Not available"]], "snomed.side_effects": [["373067005", "No (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["86137003", "Negligible (qualifier value)"], ["420862001", "On (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["247750002", "Drive (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"]], "ncit.side_effects": [["C2381", "Etanercept"], ["C101282", "Have"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43508", "Oregon"], ["C121660", "Influence"], ["C92667", "SPARC wt Allele"], ["C121232", "Ability to Drive"], ["C16289", "Andorra"], ["C25340", "Use"]], "rxnorm.side_effects": [["216891", "Enbrel"]], "loinc.side_effects": [["LA32-8", "No"], ["LA22025-3", "OR"]], "snomed.shelf_life": [["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["258707000", "year (qualifier value)"], ["441900009", "Chemical (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["19388002", "Physical (qualifier value)"], ["18720000", "In (attribute)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["86495002", "For (qualifier value)"], ["123033000", "6 hours (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["255234002", "After (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["246516004", "View (attribute)"], ["763158003", "Medicinal product (product)"], ["311498008", "Immediately (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["262009000", "Not used (qualifier value)"], ["311498008", "Immediately (qualifier value)"], ["440276004", "Storage (procedure)"], ["417929005", "Times (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["288556008", "Before (attribute)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["123033000", "6 hours (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421066005", "Place - dosing instruction imperative (qualifier value)"], ["18720000", "In (attribute)"], ["31509003", "Controlled (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260984003", "Aseptic (qualifier value)"]], "ncit.shelf_life": [["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C29848", "Year"], ["C158345", "Chemical and Physical Restraint"], ["C16727", "India"], ["C25340", "Use"], ["C134030", "Stability Determination"], ["C101282", "Have"], ["C64956", "For"], ["C172979", "Fear Score 6"], ["C25529", "Hour"], ["C158997", "GDC Analyte Type Terminology"], ["C52874", "SPI1 wt Allele"], ["C64643", "Up to"], ["C67900", "Centi"], ["C38008", "Post"], ["C25516", "From"], ["C76246", "Blood Group A"], ["C92081", "Microbial Contamination"], ["C70656", "Point"], ["C52874", "SPI1 wt Allele"], ["C80271", "View"], ["C142605", "Medicinal Product"], ["C16329", "Belgium"], ["C64597", "Immediately"], ["C198613", "CFI wt Allele"], ["C69062", "Not Used"], ["C64597", "Immediately"], ["C60824", "Storage"], ["C16289", "Andorra"], ["C25457", "Condition"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25340", "Use"], ["C68869", "Are"], ["C90023", "Responsibility"], ["C52874", "SPI1 wt Allele"], ["C42745", "System User"], ["C16289", "Andorra"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C172979", "Fear Score 6"], ["C25529", "Hour"], ["C158997", "GDC Analyte Type Terminology"], ["C52874", "SPI1 wt Allele"], ["C64643", "Up to"], ["C67900", "Centi"], ["C101282", "Have"], ["C25701", "Taken"], ["C126366", "Placement"], ["C16727", "India"], ["C82500", "Disease Controlled"], ["C16289", "Andorra"], ["C172871", "File Validated"], ["C63385", "Sterile"], ["C25457", "Condition"]], "rxnorm.shelf_life": [["T103", "Chemical"]], "loinc.shelf_life": [["LA31721-6", "4 years"], ["LA18356-8", "Chemical"], ["MTHU000078", "Physical"], ["LA22004-8", "IN"], ["MTHU015276", "Stability"], ["LP6946-0", "6 hours"], ["LA21988-3", "AT"], ["LP17128-7", "C"], ["LP17763-1", "A"], ["LP28725-7", "Single view"], ["LA19717-0", "Reconstituted"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA157-0", "Not used"], ["LA33028-4", "Prior"], ["LA21291-2", "Not"], ["LP6946-0", "6 hours"], ["LA21988-3", "AT"], ["LP17128-7", "C"], ["LA22004-8", "IN"]], "snomed.storage": [["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["21546008", "Refrigerator, device (physical object)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["86495002", "For (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["9362000", "Four (qualifier value)|4 (qualifier value)"], ["258705008", "week (qualifier value)"], ["255234002", "After (attribute)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["262009000", "Not used (qualifier value)"], ["18720000", "In (attribute)"], ["9362000", "Four (qualifier value)|4 (qualifier value)"], ["258705008", "week (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["315350008", "Removal - procedure|Removal - procedure (procedure)"], ["86495002", "For (qualifier value)"], ["440276004", "Storage (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["763158003", "Medicinal product (product)"], ["732807000", "6.3 (qualifier value)"]], "ncit.storage": [["C60824", "Storage"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C178971", "Refrigerator"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67900", "Centi"], ["C66839", "Eight"], ["C67900", "Centi"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C48160", "Freezing"], ["C2381", "Etanercept"], ["C106184", "May"], ["C16329", "Belgium"], ["C60824", "Storage"], ["C158997", "GDC Analyte Type Terminology"], ["C64643", "Up to"], ["C76246", "Blood Group A"], ["C82868", "Maximum Value Derivation Technique"], ["C52874", "SPI1 wt Allele"], ["C113663", "Twenty Five"], ["C67900", "Centi"], ["C64956", "For"], ["C76246", "Blood Group A"], ["C48440", "Single"], ["C25616", "Period"], ["C52874", "SPI1 wt Allele"], ["C64643", "Up to"], ["C66835", "Four"], ["C29844", "Week"], ["C38008", "Post"], ["C38267", "Intrathecal Route of Administration"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C70718", "Refrigerated Specimen"], ["C2381", "Etanercept"], ["C16329", "Belgium"], ["C198613", "CFI wt Allele"], ["C69062", "Not Used"], ["C25282", "Within"], ["C66835", "Four"], ["C29844", "Week"], ["C52874", "SPI1 wt Allele"], ["C61575", "Extraction"], ["C25516", "From"], ["C64956", "For"], ["C60824", "Storage"], ["C25457", "Condition"], ["C52874", "SPI1 wt Allele"], ["C142605", "Medicinal Product"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"]], "rxnorm.storage": [["216891", "Enbrel"], ["216891", "Enbrel"]], "loinc.storage": [["LA22004-8", "IN"], ["LP17763-1", "A"], ["MTHU000002", "Clinical Class"], ["LP17128-7", "C"], ["LP36791-9", "8"], ["LP17128-7", "C"], ["LA14426-3", "Do not"], ["LA14161-6", "May"], ["LA21988-3", "AT"], ["LP17763-1", "A"], ["LP6972-6", "maximum"], ["LA19281-7", "25"], ["LP17128-7", "C"], ["LP17763-1", "A"], ["LA17717-2", "Single"], ["LA33103-5", "Four"], ["LA9000-6", "Weeks"], ["LP200077-8", "IT"], ["LA21291-2", "Not"], ["LA19707-1", "Discarded"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA157-0", "Not used"], ["LA33103-5", "Four"], ["LA9000-6", "Weeks"], ["LP263431-1", "Removal"], ["LA19717-0", "Reconstituted"], ["LP20594-5", "6"], ["LP20591-1", "3"]], "snomed.package": [["263707001", "Clear (qualifier value)"], ["32039001", "Glass (substance)"], ["733026001", "Vial (unit of presentation)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["258191002", "Type 1 (qualifier value)"], ["32039001", "Glass (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["43230003", "Rubber (substance)"], ["255977005", "Aluminum material (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420680007", "Off (qualifier value)"], ["61088005", "Plastic (substance)"], ["385049006", "Capsule (basic dose form)|Capsule (product)|Capsule dose form (qualifier value)|Capsule dose form (product)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["415818006", "Vial (qualifier value)|Vial - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["53041004", "Substance with alcohol structure (substance)|Alcohol (substance)"], ["420401004", "Swab - unit of product usage (qualifier value)"]], "ncit.package": [["C48621", "Negative Surgical Margin"], ["C43209", "Glass Vial"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16816", "Mali"], ["C181852", "Protocol Therapy Status"], ["C68254", "Dietary Iodine"], ["C45301", "Glass"], ["C62355", "With"], ["C16289", "Andorra"], ["C96017", "CFLAR wt Allele"], ["C40450", "Off"], ["C86968", "Plastic"], ["C84657", "Cryopyrin-Associated Periodic Syndrome"], ["C79873", "Contain"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C52874", "SPI1 wt Allele"], ["C2381", "Etanercept"], ["C62355", "With"], ["C66839", "Eight"], ["C74693", "Ethanol Measurement"]], "rxnorm.package": [["216891", "Enbrel"]], "loinc.package": [["LA19732-9", "Clear"], ["LA20376-2", "Vial"], ["MTHU000002", "Clinical Class"], ["LA26022-6", "Type I"], ["LA26227-1", "Off"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA28139-6", "Alcohol"]], "snomed.marketing_authorization_numbers": [["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732914004", "99 (qualifier value)"], ["783760004", "126 (qualifier value)"]], "ncit.marketing_authorization_numbers": [["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C105787", "Ninety Nine"]], "rxnorm.marketing_authorization_numbers": [], "loinc.marketing_authorization_numbers": [["LA6112-2", "1"]]}, {"product_info": "Xenical 120 mg hard capsules", "composition": "Each hard capsule contains 120 mg orlistat. \nFor a full list of excipients, see 6.1.", "indications": "Xenical is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients \nwith a body mass index (BMI) greater or equal to 30 kg/m\u00b2, or overweight patients (BMI > 28 kg/m\u00b2) \nwith associated risk factors. \nTreatment with orlistat should be discontinued after 12 weeks if patients have been unable to lose at \nleast 5 % of the body weight as measured at the start of therapy.", "posology": "Adults  \nThe recommended dose of orlistat is one 120 mg capsule taken with water immediately before, during \nor up to one hour after each main meal. If a meal is missed or contains no fat, the dose of orlistat \nshould be omitted.  \nThe patient should be on a nutritionally balanced, mildly hypocaloric diet that contains approximately \n30 % of calories from fat. It is recommended that the diet should be rich in fruit and vegetables. The \ndaily intake of fat, carbohydrate and protein should be distributed over three main meals. \nDoses of orlistat above 120 mg three times daily have not been shown to provide additional benefit. \nThe effect of orlistat results in an increase in faecal fat as early as 24 to 48 hours after dosing. Upon \ndiscontinuation of therapy, faecal fat content usually returns to pre-treatment levels, within 48 to 72 \nhours. \nSpecial populations \nThe effect of orlistat in patients with hepatic and/or renal impairment, children and elderly patients has \nnot been studied.  \nThere is no relevant indication for use of Xenical in children.", "contraindications": "Hypersensitivity to the active substance or to any of the excipients.  \nChronic malabsorption syndrome. \nCholestasis. \nBreast-feeding.", "special_warnings": "In clinical trials, the decrease in bodyweight with orlistat treatment was less in type II diabetic patients \nthan in non-diabetic patients. Antidiabetic medicinal product treatment may have to be closely \nmonitored when taking orlistat. \nCo-administration of orlistat with ciclosporin is not recommended (see section 4.5). \nPatients should be advised to adhere to the dietary recommendations they are given (see section 4.2).  \nThe possibility of experiencing gastrointestinal adverse reactions (see section 4.8) may increase when \norlistat is taken with a diet high in fat (e.g. in a 2000 kcal/day diet, > 30 % of calories from fat equates \nto > 67 g of fat). The daily intake of fat should be distributed over three main meals. If orlistat is taken \nwith a meal very high in fat, the possibility of gastrointestinal adverse reactions may increase.  \nCases of rectal bleeding have been reported with Xenical. Prescribers should investigate further in \ncase of severe and/or persistent symptoms. \nThe use of an additional contraceptive method is recommended to prevent possible failure of oral \ncontraception that could occur in case of severe diarrhoea (see section 4.5). \nCoagulation parameters should be monitored in patients treated with concomitant oral anticoagulants \n(see section 4.5 and 4.8). \nThe use of orlistat may be associated with hyperoxaluria and oxalate nephropathy leading sometimes \nto renal failure. This risk is increased in patients with underlying chronic kidney disease and/or \nvolume depletion (see section 4.8). \nRare occurrence of hypothyroidism and/or reduced control of hypothyroidism may occur. The \nmechanism, although not proven, may involve a decreased absorption of iodine salts and/or \nlevothyroxine (see section 4.5). \nAntiepileptics patient: Orlistat may unbalance anticonvulsant treatment by decreasing the absorption \nof antiepileptic drugs, leading to convulsions (see section 4.5). \nAntiretrovirals for HIV: Orlistat may potentially reduce the absorption of antiretroviral medicines for \nHIV and could negatively affect the efficacy of antiretroviral medications for HIV (see section 4.5). \nThis medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially \n\u2018sodium-free\u2019.", "pregnancy": "Ciclosporin \nA decrease in ciclosporin plasma levels has been observed in a drug-drug-interaction study and also \nreported in several cases, when orlistat was administered concomitantly. This can lead to a decrease of \nimmunosuppressive efficacy. Therefore the combination is not recommended (see section 4.4). \nHowever, if such concomitant use is unavoidable, more frequent monitoring of ciclosporin blood \nlevels should be performed both after addition of orlistat and upon discontinuation of orlistat in \nciclosporin treated patients. Ciclosporin blood levels should be monitored until stabilised. \nAcarbose  \nIn the absence of pharmacokinetic interaction studies, the concomitant administration of orlistat with \nacarbose should be avoided.  \nOral anticoagulants \nWhen warfarin or other anticoagulants are given in combination with orlistat, international normalised \nratio (INR) values should be monitored (see section 4.4). \nFat soluble vitamins\nTreatment with orlistat may potentially impair the absorption of fat-soluble vitamins (A, D, E and K). \nThe vast majority of patients receiving up to four full years of treatment with orlistat in clinical studies \nhad vitamin A, D, E and K and beta-carotene levels that stayed within normal range. In order to ensure \nadequate nutrition, patients on a weight control diet should be advised to have a diet rich in fruit and \nvegetables and use of a multivitamin supplement could be considered. If a multivitamin supplement is \nrecommended, it should be taken at least two hours after the administration of orlistat or at bedtime. \nAmiodarone\nA slight decrease in plasma levels of amiodarone, when given as a single dose, has been observed in a \nlimited number of healthy volunteers who received orlistat concomitantly. In patients receiving \namiodarone treatment, the clinical relevance of this effect remains unknown but may become \nclinically relevant in some cases. In patients receiving concomitant amiodarone treatment, \nreinforcement of clinical and ECG monitoring is warranted. \nConvulsions have been reported in patients treated concomitantly with orlistat and antiepileptic drugs \ne.g. valproate, lamotrigine, for which a causal relationship to an interaction cannot be excluded. \nTherefore, these patients should be monitored for possible changes in the frequency and/or severity of \nconvulsions.  \nRare occurrence of hypothyroidism and/or reduced control of hypothyroidism may occur. The \nmechanism, although not proven, may involve a decreased absorption of iodine salts and/or \nlevothyroxine (see section 4.4). \nThere are some case reports of reduced efficacy of antiretroviral HIV medicines, antidepressants \nantipsychotics (including lithium) and benzodiazepines coincidental to the initiation of orlistat \ntreatment in previously well-controlled patients.  Therefore orlistat treatment should only be initiated \nafter careful consideration of the possible impact in these patients. \nLack of interactions \nNo interactions with amitriptyline, atorvastatin, biguanides, digoxin, fibrates, fluoxetine, losartan, \nphenytoin, phentermine, pravastatin, nifedipine Gastrointestinal Therapeutic System (GITS), \nnifedipine slow release, sibutramine or alcohol have been observed. The absence of these interactions \nhas been demonstrated in specific drug-drug-interaction studies. \nThe absence of an interaction between oral contraceptives and orlistat has been demonstrated in \nspecific drug-drug interaction studies. However, orlistat may indirectly reduce the availability of oral \ncontraceptives and lead to unexpected pregnancies in some individual cases. An additional \ncontraceptive method is recommended in case of severe diarrhoea (see section 4.4).", "driving": "For orlistat no clinical data on exposed pregnancies are available. \nAnimal studies do not indicate direct or indirect harmful effects with respect to pregnancy, \nembryonal/foetal development, parturition or postnatal development (see section 5.3). \nCaution should be exercised when prescribing to pregnant women. \nAs it is not known whether orlistat is secreted into human milk, orlistat is contra-indicated during \nbreast-feeding.", "side_effects": "Xenical has no influence on the ability to drive and use machines.", "shelf_life": "2 years.", "storage": "Blisters: Do not store above 25 \u00b0C. Store in original package and keep the blister in the outer carton in \norder to protect from light and moisture. \nBottles: Do not store above 30 \u00b0C. Keep the container tightly closed in order to protect from moisture.", "package": "PVC/ PVDC blisters containing 21, 42 and 84 hard capsules. \nGlass bottles with desiccant containing 21, 42 and 84 hard capsules. \nNot all pack sizes may be marketed.", "marketing_authorization_numbers": "EU/1/98/071/001-006 \n11", "filename": "xenical-epar-product-information_en.html", "snomed.product_info": [["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["72505002", "Hard (qualifier value)"], ["385049006", "Capsule (basic dose form)|Capsule (product)|Capsule dose form (qualifier value)|Capsule dose form (product)"]], "ncit.product_info": [["C29303", "Orlistat"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C113682", "Hard"]], "rxnorm.product_info": [["226918", "Xenical"]], "loinc.product_info": [["LA32059-0", "120"], ["LP15217-0", "Mg"], ["LA14745-6", "Hard"]], "snomed.composition": [["419473009", "Each (qualifier value)"], ["385050006", "Hard capsule (product)|Hard capsule (basic dose form)|Hard capsule (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["387007000", "Orlistat (substance)"], ["86495002", "For (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["261015003", "Full (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.composition": [["C64933", "Each"], ["C64904", "Hard Capsule Dosage Form"], ["C79873", "Contain"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C29303", "Orlistat"], ["C64956", "For"], ["C76246", "Blood Group A"], ["C25517", "Full"], ["C43432", "List"], ["C52874", "SPI1 wt Allele"], ["C163702", "Staphylococcal Enterotoxin E"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.composition": [["37925", "orlistat"]], "loinc.composition": [["LA14745-6", "Hard"], ["LA21907-3", "Capsule"], ["LA32059-0", "120"], ["LP15217-0", "Mg"], ["LP17763-1", "A"], ["LA19682-6", "Full"], ["LP204165-7", "List"], ["LP20594-5", "6"], ["LA6112-2", "1"]], "snomed.indications": [["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["41829006", "Dietary finding (finding)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["414915002", "Obese (finding)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["363807006", "Body mass index|Body mass index (observable entity)"], ["263768009", "Greater (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["9726003", "Equal (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["422192003", "Roman numeral M (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["238131007", "Overweight (finding)"], ["276140008", "Greater-than symbol > (qualifier value)|> (qualifier value)"], ["1222781002", "American Joint Committee on Cancer stage II:8 (qualifier value)"], ["258683005", "kg (qualifier value)|kilogram (qualifier value)"], ["422192003", "Roman numeral M (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387007000", "Orlistat (substance)"], ["410546004", "Discontinued (qualifier value)"], ["255234002", "After (attribute)"], ["1222738000", "American Joint Committee on Cancer stage I:2 (qualifier value)"], ["258705008", "week (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["371151008", "Unable (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["248345008", "Body weight [dup] (observable entity)|Body weight (observable entity)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["258104002", "Measured (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["226630009", "Start (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"]], "ncit.indications": [["C29303", "Orlistat"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C79874", "Conjunction"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C70666", "Mild"], ["C90364", "Basal Diet"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C159658", "Obese"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C138901", "Body Mass Index Finding"], ["C138901", "Body Mass Index Finding"], ["C61421", "Greater"], ["C43508", "Oregon"], ["C61582", "Equality"], ["C70541", "Lansky Performance Status 30"], ["C16771", "Kyrgyzstan"], ["C103221", "Axial S"], ["C43508", "Oregon"], ["C94250", "Overweight"], ["C16960", "Patient"], ["C138901", "Body Mass Index Finding"], ["C126888", "Twenty Eight"], ["C16771", "Kyrgyzstan"], ["C103221", "Axial S"], ["C62355", "With"], ["C25281", "Associated"], ["C17103", "Risk Factor"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C29303", "Orlistat"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C38008", "Post"], ["C113426", "Twelve"], ["C29844", "Week"], ["C198613", "CFI wt Allele"], ["C16960", "Patient"], ["C101282", "Have"], ["C121742", "Unable to Do"], ["C158997", "GDC Analyte Type Terminology"], ["C163771", "Illness Intrusiveness Rating 5"], ["C48570", "Percent Unit"], ["C52874", "SPI1 wt Allele"], ["C95085", "Body Weight Domain"], ["C71344", "Associate of Science"], ["C44473", "Measured"], ["C158997", "GDC Analyte Type Terminology"], ["C68616", "Start Date"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"]], "rxnorm.indications": [["226918", "Xenical"], ["37925", "orlistat"]], "loinc.indications": [["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA28567-8", "Mildly"], ["MTHU053295", "Diet"], ["LP94823-9", "Treatment"], ["LA20940-5", "Obese"], ["LP17763-1", "A"], ["LP35925-4", "Body mass index (BMI)"], ["LA22025-3", "OR"], ["LA28855-7", "30"], ["LP15218-8", "M"], ["LA22025-3", "OR"], ["LA32905-4", "Overweight"], ["39156-5", "Body mass index:Ratio:Pt:^Patient:Qn"], ["LP15218-8", "M"], ["46467-7", "Risk factors:Find:Pt:^Patient:Nom"], ["LP94823-9", "Treatment"], ["LA14558-3", "12"], ["LA9000-6", "Weeks"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA24937-7", "Unable"], ["LA21988-3", "AT"], ["LP20593-7", "5"], ["MTHU001885", "Body weight"], ["LP6378-6", "Measured"], ["LA21988-3", "AT"], ["LP190656-1", "start"], ["LP267221-2", "Therapy"]], "snomed.posology": [["897015005", "Recommended (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387007000", "Orlistat (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["732937005", "Capsule (unit of presentation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["346712003", "Product containing water (medicinal product)|Water product (product)|Water product (substance)"], ["311498008", "Immediately (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["255234002", "After (attribute)"], ["419473009", "Each (qualifier value)"], ["63161005", "Principal (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["256674009", "Fat (substance)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387007000", "Orlistat (substance)"], ["116154003", "Patient (person)"], ["420862001", "On (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["78933003", "Balanced (qualifier value)"], ["41829006", "Dietary finding (finding)"], ["26175008", "Approximate (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258790008", "calorie (qualifier value)|cal (qualifier value)"], ["256674009", "Fat (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["41829006", "Dietary finding (finding)"], ["224166006", "Wealthy (finding)"], ["18720000", "In (attribute)"], ["72511004", "Fruit (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["123128001", "Daily -RETIRED-|Daily (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["256674009", "Fat (substance)"], ["259647007", "Carbohydrate (substance)|Carbohydrate"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["88878007", "Protein (substance)"], ["21481007", "Over (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["63161005", "Principal (qualifier value)"], ["769557005", "With meals (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387007000", "Orlistat (substance)"], ["352730000", "Supra- (qualifier value)"], ["1222759007", "American Joint Committee on Cancer stage I:20 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["229798009", "Three times daily (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["346649002", "Provide (substance)|Provide (product)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387007000", "Orlistat (substance)"], ["18720000", "In (attribute)"], ["260366006", "Increase (qualifier value)"], ["18720000", "In (attribute)"], ["167646006", "Faeces: [pancreatic effects] or [fat] or [lipase] or [starch] (observable entity)|Faeces: [pancreatic effects] or [fat] or [lipase] or [starch]"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["264499004", "Early (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["1222777002", "American Joint Committee on Cancer stage II:4 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255249005", "48 hours (qualifier value)"], ["255234002", "After (attribute)"], ["420771004", "Upon - dosing instruction fragment (qualifier value)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["167646006", "Faeces: [pancreatic effects] or [fat] or [lipase] or [starch] (observable entity)|Faeces: [pancreatic effects] or [fat] or [lipase] or [starch]"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["258395000", "Levels (qualifier value)"], ["18720000", "In (attribute)"], ["1222851003", "American Joint Committee on Cancer stage IV:8 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["732857008", "72 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["67995009", "Special (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387007000", "Orlistat (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["410665000", "Indication for (attribute)"], ["260676000", "Use of (attribute)"], ["18720000", "In (attribute)"]], "ncit.posology": [["C25197", "Recommendation"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C29303", "Orlistat"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C66832", "One"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C48336", "Capsule Shape"], ["C25701", "Taken"], ["C65143", "With Water"], ["C64597", "Immediately"], ["C201357", "Before Timing Type"], ["C25490", "During"], ["C43508", "Oregon"], ["C64643", "Up to"], ["C126256", "One Activity Hour"], ["C38008", "Post"], ["C64933", "Each"], ["C25562", "Main"], ["C80248", "Meal"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C80248", "Meal"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C54031", "Missing"], ["C43508", "Oregon"], ["C79873", "Contain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C153917", "Fantse Language"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C29303", "Orlistat"], ["C16329", "Belgium"], ["C53691", "Veterinary Patient"], ["C16329", "Belgium"], ["C92667", "SPARC wt Allele"], ["C76246", "Blood Group A"], ["C6822", "Balanced Translocation"], ["C70666", "Mild"], ["C90364", "Basal Diet"], ["C79873", "Contain"], ["C45828", "Approximate"], ["C70541", "Lansky Performance Status 30"], ["C48570", "Percent Unit"], ["C52874", "SPI1 wt Allele"], ["C25516", "From"], ["C153917", "Fantse Language"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C90364", "Basal Diet"], ["C16329", "Belgium"], ["C172207", "Rapidly Involuting Congenital Hemangioma"], ["C16727", "India"], ["C71972", "Fruit"], ["C16289", "Andorra"], ["C168156", "Chief Complaint is Present Daily"], ["C25538", "Intake"], ["C52874", "SPI1 wt Allele"], ["C153917", "Fantse Language"], ["C344", "Carbohydrate"], ["C16289", "Andorra"], ["C41172", "Protein Info"], ["C16329", "Belgium"], ["C45273", "Distribution"], ["C25490", "During"], ["C66834", "Three"], ["C25562", "Main"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C29303", "Orlistat"], ["C75329", "Above"], ["C192184", "One Hundred Twenty"], ["C16818", "Mammography"], ["C64527", "Three Times Daily"], ["C101282", "Have"], ["C25594", "Negation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C80514", "Provide"], ["C25406", "Additional"], ["C25387", "Benefit"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C29303", "Orlistat"], ["C16727", "India"], ["C75889", "PAX6 wt Allele"], ["C25533", "Increase"], ["C16727", "India"], ["C153917", "Fantse Language"], ["C71344", "Associate of Science"], ["C61589", "Early"], ["C71344", "Associate of Science"], ["C113753", "Twenty Four"], ["C159124", "GDC Treatment Outcome Terminology"], ["C175678", "Forty Eight"], ["C25529", "Hour"], ["C38008", "Post"], ["C65137", "Upon"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C49236", "Therapeutic Procedure"], ["C153917", "Fantse Language"], ["C95494", "Content"], ["C114711", "Usually"], ["C159124", "GDC Treatment Outcome Terminology"], ["C186271", "Non-Clinical Pre-Treatment Epoch"], ["C25282", "Within"], ["C175678", "Forty Eight"], ["C159124", "GDC Treatment Outcome Terminology"], ["C188334", "Seventy Two"], ["C25529", "Hour"], ["C18101", "Special Population"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C29303", "Orlistat"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C13308", "Hepatic"], ["C48928", "And/Or"], ["C114592", "Renal Impairment"], ["C16423", "Child"], ["C16289", "Andorra"], ["C16268", "Elderly"], ["C16960", "Patient"], ["C101282", "Have"], ["C25594", "Negation"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C70664", "Relevance"], ["C41184", "Indication"], ["C52874", "SPI1 wt Allele"], ["C29303", "Orlistat"], ["C16727", "India"], ["C16423", "Child"]], "rxnorm.posology": [["37925", "orlistat"], ["11295", "water"], ["37925", "orlistat"], ["37925", "orlistat"], ["37925", "orlistat"], ["37925", "orlistat"], ["226918", "Xenical"]], "loinc.posology": [["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA6306-0", "One"], ["LA32059-0", "120"], ["LP15217-0", "Mg"], ["LA21907-3", "Capsule"], ["LP99666-7", "Water"], ["LA22025-3", "OR"], ["LA6306-0", "One"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP200075-2", "IS"], ["LA22025-3", "OR"], ["LA32-8", "No"], ["LP28807-3", "Fat"], ["MTHU065481", "Dose"], ["LP66710-2", "Patient"], ["LP17763-1", "A"], ["LA28567-8", "Mildly"], ["MTHU053295", "Diet"], ["LA28855-7", "30"], ["LP28807-3", "Fat"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["MTHU053295", "Diet"], ["LA22004-8", "IN"], ["LP17412-5", "Fruit"], ["LP30703-0", "Vegetables"], ["LA14435-4", "Daily"], ["LP28807-3", "Fat"], ["LP412324-8", "Carbohydrate"], ["LP15838-3", "Protein"], ["LA6395-3", "Three"], ["LP202940-5", "Meals"], ["LA14991-6", "Above"], ["LA32059-0", "120"], ["LP15217-0", "Mg"], ["LA6395-3", "Three"], ["LA14435-4", "Daily"], ["LA21291-2", "Not"], ["LP263791-8", "Additional"], ["LA22004-8", "IN"], ["LA32048-3", "Increase"], ["LA22004-8", "IN"], ["LP28807-3", "Fat"], ["LA12111-3", "Early"], ["LP6938-7", "48 hours"], ["LP267221-2", "Therapy"], ["LP28807-3", "Fat"], ["LA14747-2", "Usually"], ["LP32605-5", "pre"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LA22025-3", "OR"], ["MTHU065909", "Renal"], ["LA21291-2", "Not"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LA22004-8", "IN"]], "snomed.contraindications": [["257550005", "Hypersensitivity (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["261217004", "Substance (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["90734009", "Chronic (qualifier value)"], ["32230006", "Malabsorption syndrome (disorder)"], ["33688009", "Cholestasis (finding)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"]], "ncit.contraindications": [["C3114", "Hypersensitivity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C154405", "Active State"], ["C45306", "Substance"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C4981", "Chronic Graft Versus Host Disease"], ["C3214", "Malabsorption Syndrome"], ["C83006", "Cholestasis"], ["C25389", "Chest"], ["C88198", "Feeding"]], "rxnorm.contraindications": [["T167", "Substance"]], "loinc.contraindications": [["LA16666-2", "Active"], ["T167", "Substance"], ["LA22025-3", "OR"], ["LA28752-6", "Chronic"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"]], "snomed.special_warnings": [["18720000", "In (attribute)"], ["110465008", "Clinical trials (procedure)|Clinical trial (procedure)"], ["260370003", "Decrease (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387007000", "Orlistat (substance)"], ["18720000", "In (attribute)"], ["258195006", "Type 2 (qualifier value)"], ["18720000", "In (attribute)"], ["763158003", "Medicinal product (product)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["387007000", "Orlistat (substance)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387007000", "Orlistat (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387467008", "Ciclosporin (substance)|Cyclosporine (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["732724000", "4.2 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["281647001", "Adverse reaction (disorder)|Adverse reactions (disorder)|Adverse reactions (finding)"], ["732732008", "4.8 (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["387007000", "Orlistat (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["41829006", "Dietary finding (finding)"], ["75540009", "High (qualifier value)"], ["18720000", "In (attribute)"], ["256674009", "Fat (substance)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["732589009", "2000 (qualifier value)"], ["259057009", "kcal/day (qualifier value)|Kilocalorie/day (qualifier value)"], ["41829006", "Dietary finding (finding)"], ["276140008", "Greater-than symbol > (qualifier value)|> (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["118582008", "Percent (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258790008", "calorie (qualifier value)|cal (qualifier value)"], ["256674009", "Fat (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["276140008", "Greater-than symbol > (qualifier value)|> (qualifier value)"], ["732843006", "67 (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["256674009", "Fat (substance)"], ["123128001", "Daily -RETIRED-|Daily (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["256674009", "Fat (substance)"], ["21481007", "Over (qualifier value)"], ["79605009", "Three (qualifier value)|3 (qualifier value)"], ["63161005", "Principal (qualifier value)"], ["769557005", "With meals (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["387007000", "Orlistat (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260360000", "Very high (qualifier value)"], ["18720000", "In (attribute)"], ["256674009", "Fat (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["281647001", "Adverse reaction (disorder)|Adverse reactions (disorder)|Adverse reactions (finding)"], ["260366006", "Increase (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["266532006", "Anal &/or rectal haemorrhage (disorder)|Anal &/or rectal haemorrhage"], ["733985002", "Reported (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255222005", "Persistent (qualifier value)"], ["260676000", "Use of (attribute)"], ["260686004", "Method (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["101445003", "PREVENT (substance)|PREVENT (product)"], ["371930009", "Possible (qualifier value)"], ["76797004", "Failure (finding)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["738956005", "Oral (intended site)"], ["146680009", "Contraception|Contraception (finding)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["409587002", "Severe diarrhea (finding)"], ["732729005", "4.5 (qualifier value)"], ["315351007", "Coagulation procedure (procedure)"], ["252116004", "Observation parameter (observable entity)"], ["18720000", "In (attribute)"], ["28995006", "Treated with (attribute)"], ["79970003", "Simultaneous (qualifier value)"], ["319725001", "Oral anticoagulants (product)|Oral anticoagulants (substance)"], ["732729005", "4.5 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["260676000", "Use of (attribute)"], ["387007000", "Orlistat (substance)"], ["47429007", "Associated with (attribute)"], ["367621000119107", "Hyperoxaluria (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["69718008", "Oxalate nephropathy (disorder)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["198524000", "Renal failure (disorder)|Renal failure"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["709044004", "Chronic kidney disease (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["28560003", "Hypovolemia (disorder)"], ["732732008", "4.8 (qualifier value)"], ["89292003", "Rare (qualifier value)"], ["246454002", "Occurrence (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["267465007", "Hypothyroidism - congenital and acquired (& [cretinism] or [myxoedema])|Hypothyroidism - congenital and acquired (& [cretinism] or [myxoedema]) (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["260400001", "Reduced (qualifier value)"], ["246106000", "Control (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["267465007", "Hypothyroidism - congenital and acquired (& [cretinism] or [myxoedema])|Hypothyroidism - congenital and acquired (& [cretinism] or [myxoedema]) (disorder)"], ["278109006", "Mechanism (attribute)"], ["277025001", "Proven (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1250004", "Decreased (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["325330005", "Iodine product (product)|Iodine product (substance)|Product containing iodine AND/OR iodine compound (medicinal product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["710809001", "Levothyroxine (substance)"], ["732729005", "4.5 (qualifier value)"], ["346326009", "Antiepileptics|Antiepileptics (substance)"], ["116154003", "Patient (person)"], ["387007000", "Orlistat (substance)"], ["255632006", "Anticonvulsant|Anticonvulsant (substance)"], ["260371004", "Decreasing (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["91175000", "Seizure (finding)"], ["732729005", "4.5 (qualifier value)"], ["86495002", "For (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["387007000", "Orlistat (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["768685009", "Antiretroviral (disposition)"], ["86495002", "For (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["768685009", "Antiretroviral (disposition)"], ["86495002", "For (qualifier value)"], ["19030005", "Human immunodeficiency virus (organism)"], ["732729005", "4.5 (qualifier value)"], ["2533004", "Drug (substance)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258718000", "mmol (qualifier value)|millimole (qualifier value)"], ["39972003", "Sodium (substance)"], ["1222776006", "American Joint Committee on Cancer stage II:3 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["732937005", "Capsule (unit of presentation)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["39972003", "Sodium (substance)"]], "ncit.special_warnings": [["C16727", "India"], ["C71104", "Clinical Trial"], ["C25640", "Reduced"], ["C16727", "India"], ["C62355", "With"], ["C29303", "Orlistat"], ["C43442", "Biomaterial Treatment"], ["C154196", "Washo Language"], ["C61422", "Lesser"], ["C16727", "India"], ["C181852", "Protocol Therapy Status"], ["C62395", "WHO Central Nervous System Grade 2"], ["C16960", "Patient"], ["C16727", "India"], ["C14460", "NON Mouse"], ["C16960", "Patient"], ["C142605", "Medicinal Product"], ["C43442", "Biomaterial Treatment"], ["C106184", "May"], ["C101282", "Have"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C65140", "When"], ["C29303", "Orlistat"], ["C95633", "Coded Ordinal Data Type"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C29303", "Orlistat"], ["C62355", "With"], ["C406", "Cyclosporine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C64950", "Follow"], ["C78373", "Dietary Route of Administration"], ["C68869", "Are"], ["C64974", "Give"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C52874", "SPI1 wt Allele"], ["C53802", "Adverse Event Associated with the Gastrointestinal System"], ["C188368", "ELN Adverse-Risk Category"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C106184", "May"], ["C25533", "Increase"], ["C65140", "When"], ["C29303", "Orlistat"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25701", "Taken"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C90364", "Basal Diet"], ["C139304", "IPSS Risk Category High"], ["C16727", "India"], ["C153917", "Fantse Language"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C139135", "Kilocalorie per Day"], ["C90364", "Basal Diet"], ["C70541", "Lansky Performance Status 30"], ["C48570", "Percent Unit"], ["C52874", "SPI1 wt Allele"], ["C25516", "From"], ["C153917", "Fantse Language"], ["C159124", "GDC Treatment Outcome Terminology"], ["C188331", "Sixty Seven"], ["C68915", "Gauss"], ["C52874", "SPI1 wt Allele"], ["C153917", "Fantse Language"], ["C168156", "Chief Complaint is Present Daily"], ["C25538", "Intake"], ["C52874", "SPI1 wt Allele"], ["C153917", "Fantse Language"], ["C16329", "Belgium"], ["C45273", "Distribution"], ["C25490", "During"], ["C66834", "Three"], ["C25562", "Main"], ["C198613", "CFI wt Allele"], ["C29303", "Orlistat"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25701", "Taken"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C80248", "Meal"], ["C199196", "Very High"], ["C16727", "India"], ["C153917", "Fantse Language"], ["C52874", "SPI1 wt Allele"], ["C53802", "Adverse Event Associated with the Gastrointestinal System"], ["C188368", "ELN Adverse-Risk Category"], ["C106184", "May"], ["C25533", "Increase"], ["C52874", "SPI1 wt Allele"], ["C25224", "Rectal"], ["C26791", "Hemorrhage"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C62355", "With"], ["C29303", "Orlistat"], ["C25519", "Further"], ["C16727", "India"], ["C49152", "Case"], ["C52874", "SPI1 wt Allele"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C48928", "And/Or"], ["C43623", "Persistent"], ["C168422", "Rheumatic Fever Symptom"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C75889", "PAX6 wt Allele"], ["C25406", "Additional"], ["C42734", "Contraceptive Device"], ["C85492", "CDISC SDTM Method Terminology"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C25745", "Failure"], ["C52874", "SPI1 wt Allele"], ["C25311", "Oral"], ["C37932", "Contraception"], ["C127786", "Occurrence Indicator"], ["C16727", "India"], ["C49152", "Case"], ["C52874", "SPI1 wt Allele"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C21045", "Coagulation Process"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C25730", "Concomitant"], ["C25311", "Oral"], ["C263", "Anticoagulant Agent"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C29303", "Orlistat"], ["C106184", "May"], ["C16329", "Belgium"], ["C25281", "Associated"], ["C62355", "With"], ["C16289", "Andorra"], ["C82078", "Oxalate"], ["C34843", "Nephropathy"], ["C25629", "Prior"], ["C90025", "Sometimes"], ["C159124", "GDC Treatment Outcome Terminology"], ["C4376", "Renal Failure"], ["C17102", "Risk"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C164135", "Increased"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C154417", "Underlying"], ["C80078", "Chronic Kidney Disease"], ["C48928", "And/Or"], ["C74720", "Volume Measurement"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C13634", "Retinoic Acid Response Element"], ["C25275", "Occurrence"], ["C52874", "SPI1 wt Allele"], ["C143576", "Hypothyroidism, CTCAE"], ["C48928", "And/Or"], ["C25640", "Reduced"], ["C64355", "Scientific Control"], ["C52874", "SPI1 wt Allele"], ["C143576", "Hypothyroidism, CTCAE"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C50285", "Mechanism Device"], ["C25594", "Negation"], ["C106184", "May"], ["C76246", "Blood Group A"], ["C25640", "Reduced"], ["C71731", "Material Absorption"], ["C52874", "SPI1 wt Allele"], ["C68254", "Dietary Iodine"], ["C48928", "And/Or"], ["C62080", "Levothyroxine"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C264", "Anticonvulsant Agent"], ["C53691", "Veterinary Patient"], ["C29303", "Orlistat"], ["C106184", "May"], ["C264", "Anticonvulsant Agent"], ["C43442", "Biomaterial Treatment"], ["C158169", "Buyei Chinese"], ["C160836", "Tumor Regression"], ["C71731", "Material Absorption"], ["C52874", "SPI1 wt Allele"], ["C264", "Anticonvulsant Agent"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C64956", "For"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C29303", "Orlistat"], ["C106184", "May"], ["C71731", "Material Absorption"], ["C52874", "SPI1 wt Allele"], ["C64956", "For"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C16289", "Andorra"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C459", "Medication"], ["C64956", "For"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C459", "Medication"], ["C79873", "Contain"], ["C61585", "Less Than"], ["C105723", "ECOG Performance Status 1"], ["C48513", "Millimole"], ["C830", "Sodium"], ["C126885", "Twenty Three"], ["C16818", "Mammography"], ["C97722", "PER1 wt Allele"], ["C48336", "Capsule Shape"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C830", "Sodium"], ["C63628", "Empty"]], "rxnorm.special_warnings": [["37925", "orlistat"], ["37925", "orlistat"], ["37925", "orlistat"], ["37925", "orlistat"], ["37925", "orlistat"], ["226918", "Xenical"], ["37925", "orlistat"], ["1441660", "oxalate"], ["5933", "iodine"], ["10582", "levothyroxine"], ["37925", "orlistat"], ["37925", "orlistat"], ["9853", "sodium"], ["9853", "sodium"]], "loinc.special_warnings": [["LA22004-8", "IN"], ["MTHU854704", "Clinical trials"], ["LA32049-1", "Decrease"], ["LA22004-8", "IN"], ["LP94823-9", "Treatment"], ["LA16823-9", "Less"], ["LA22004-8", "IN"], ["LA26023-4", "Type II"], ["LA26134-9", "Diabetic"], ["LA22004-8", "IN"], ["LA26134-9", "Diabetic"], ["LP94823-9", "Treatment"], ["LA14161-6", "May"], ["LA21996-6", "CO"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA15768-7", "4.5"], ["LP29256-2", "given"], ["LP20592-9", "4"], ["MTHU000002", "Clinical Class"], ["LA16968-2", "Gastrointestinal"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["MTHU053295", "Diet"], ["LA9193-9", "High"], ["LA22004-8", "IN"], ["LP28807-3", "Fat"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA15493-2", "2000"], ["LP121628-4", "Day"], ["MTHU053295", "Diet"], ["LA28855-7", "30"], ["LP28807-3", "Fat"], ["LP14561-2", "G"], ["LP28807-3", "Fat"], ["LA14435-4", "Daily"], ["LP28807-3", "Fat"], ["LA6395-3", "Three"], ["LP202940-5", "Meals"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LA14637-5", "Very high"], ["LA22004-8", "IN"], ["LP28807-3", "Fat"], ["LA16968-2", "Gastrointestinal"], ["LA14161-6", "May"], ["LA32048-3", "Increase"], ["LP270144-1", "Cases"], ["LA9369-5", "Rectal"], ["LA7418-2", "Bleeding"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["LA22025-3", "OR"], ["LP75708-5", "Symptoms"], ["LP263791-8", "Additional"], ["LP72939-9", "Method"], ["LP200075-2", "IS"], ["LA15097-1", "Possible"], ["LA9664-9", "Failure"], ["LA9367-9", "Oral"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["LA15768-7", "4.5"], ["LP19284-6", "Coagulation"], ["LA22004-8", "IN"], ["LA9367-9", "Oral"], ["LA15768-7", "4.5"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA14161-6", "May"], ["LP70344-4", "Oxalate"], ["LA10082-8", "Sometimes"], ["MTHU020824", "Renal failure"], ["LP200075-2", "IS"], ["LA24377-6", "Increased"], ["LA22004-8", "IN"], ["LA26681-9", "Underlying"], ["LA32626-6", "Chronic kidney disease"], ["LA22025-3", "OR"], ["MTHU003070", "Volume"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA15679-6", "Rare"], ["LA14303-4", "Hypothyroidism"], ["LA22025-3", "OR"], ["LA32619-1", "Reduced"], ["LP7741-4", "Control"], ["LA14303-4", "Hypothyroidism"], ["LA14161-6", "May"], ["LA21291-2", "Not"], ["LA14161-6", "May"], ["LP17763-1", "A"], ["LA24378-4", "Decreased"], ["LA30119-4", "Iodine"], ["LA22025-3", "OR"], ["LP422109-1", "Levothyroxine"], ["LA15768-7", "4.5"], ["LP66710-2", "Patient"], ["LA14161-6", "May"], ["LP94823-9", "Treatment"], ["LP18046-0", "Drugs"], ["LA15768-7", "4.5"], ["LP183501-8", "HIV"], ["LA14161-6", "May"], ["LP183501-8", "HIV"], ["LA26687-6", "Efficacy"], ["LP230280-2", "Medications"], ["LP183501-8", "HIV"], ["LA15768-7", "4.5"], ["LA16120-0", "Medicine"], ["LA16823-9", "Less"], ["LA6112-2", "1"], ["LP15099-2", "Sodium"], ["LP15217-0", "Mg"], ["LA21907-3", "Capsule"], ["LP200075-2", "IS"], ["LP15099-2", "Sodium"]], "snomed.pregnancy": [["387467008", "Ciclosporin (substance)|Cyclosporine (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260370003", "Decrease (qualifier value)"], ["18720000", "In (attribute)"], ["387467008", "Ciclosporin (substance)|Cyclosporine (substance)"], ["50863008", "Plasma (substance)"], ["258395000", "Levels (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["410942007", "Drug or medicament (substance)"], ["410942007", "Drug or medicament (substance)"], ["224699009", "Study (environment)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["261028005", "Several (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["387007000", "Orlistat (substance)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["88488004", "Lead (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260370003", "Decrease (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["89780004", "Combined (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["242762006", "More (qualifier value)"], ["70232002", "Frequent (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387467008", "Ciclosporin (substance)|Cyclosporine (substance)"], ["87612001", "Blood (substance)"], ["258395000", "Levels (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["51440002", "Right and left (qualifier value)"], ["255234002", "After (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387007000", "Orlistat (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420771004", "Upon - dosing instruction fragment (qualifier value)"], ["278308006", "Discontinuation (situation)|Discontinuation (procedure)|Discontinuation (context-dependent category)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387007000", "Orlistat (substance)"], ["18720000", "In (attribute)"], ["387467008", "Ciclosporin (substance)|Cyclosporine (substance)"], ["387467008", "Ciclosporin (substance)|Cyclosporine (substance)"], ["87612001", "Blood (substance)"], ["258395000", "Levels (qualifier value)"], ["421548005", "Until - dosing instruction fragment (qualifier value)"], ["409051000", "Stabilized (qualifier value)"], ["386965004", "Acarbose (substance)"], ["18720000", "In (attribute)"], ["2667000", "Absent (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387007000", "Orlistat (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["386965004", "Acarbose (substance)"], ["319725001", "Oral anticoagulants (product)|Oral anticoagulants (substance)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["372756006", "Warfarin (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387007000", "Orlistat (substance)"], ["118586006", "Ratio (property) (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["256674009", "Fat (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387007000", "Orlistat (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["256674009", "Fat (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["422196000", "Tumor staging descriptor D (tumor staging)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["257991000", "k (qualifier value)|Lower case Roman letter k (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["9362000", "Four (qualifier value)|4 (qualifier value)"], ["261015003", "Full (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["387007000", "Orlistat (substance)"], ["18720000", "In (attribute)"], ["58147004", "Clinical (qualifier value)"], ["270000007", "Vitamin A (& level (& serum)) (procedure)|Vitamin A (& level (& serum))"], ["422196000", "Tumor staging descriptor D (tumor staging)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["257991000", "k (qualifier value)|Lower case Roman letter k (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["103068006", "beta-Carotene (substance)|Betacarotene (substance)|Beta-carotene (substance)"], ["258395000", "Levels (qualifier value)"], ["18720000", "In (attribute)"], ["260395002", "Normal range (qualifier value)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["346414003", "Ensure (substance)|Ensure (product)"], ["88323005", "Adequate (qualifier value)"], ["384759009", "Nutrition, function (observable entity)"], ["420862001", "On (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["388962008", "Weight maintenance regimen (regime/therapy)"], ["41829006", "Dietary finding (finding)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["41829006", "Dietary finding (finding)"], ["224166006", "Wealthy (finding)"], ["18720000", "In (attribute)"], ["72511004", "Fruit (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["258702006", "hour (qualifier value)"], ["255234002", "After (attribute)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387007000", "Orlistat (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["21029003", "Bedtime (qualifier value)"], ["372821002", "Amiodarone (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255510006", "Slight (qualifier value)"], ["260370003", "Decrease (qualifier value)"], ["18720000", "In (attribute)"], ["50863008", "Plasma (substance)"], ["258395000", "Levels (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["372821002", "Amiodarone (substance)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["408102007", "Unit dose (qualifier value)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["410681005", "Count of entities (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387007000", "Orlistat (substance)"], ["18720000", "In (attribute)"], ["372821002", "Amiodarone (substance)"], ["58147004", "Clinical (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["261665006", "Unknown (qualifier value)"], ["18720000", "In (attribute)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["18720000", "In (attribute)"], ["79970003", "Simultaneous (qualifier value)"], ["372821002", "Amiodarone (substance)"], ["28485005", "Reinforcement (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["182804003", "ECG monitoring (& continuous) (regime/therapy)|ECG monitoring (& continuous)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["91175000", "Seizure (finding)"], ["733985002", "Reported (qualifier value)"], ["18720000", "In (attribute)"], ["79970003", "Simultaneous (qualifier value)"], ["387007000", "Orlistat (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["372812003", "Valproate (substance)"], ["387562000", "Lamotrigine (substance)"], ["86495002", "For (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263498003", "Relationship (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["18720000", "In (attribute)"], ["260864003", "Frequency (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["246112005", "Severity (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["91175000", "Seizure (finding)"], ["89292003", "Rare (qualifier value)"], ["246454002", "Occurrence (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["267465007", "Hypothyroidism - congenital and acquired (& [cretinism] or [myxoedema])|Hypothyroidism - congenital and acquired (& [cretinism] or [myxoedema]) (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["260400001", "Reduced (qualifier value)"], ["246106000", "Control (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["267465007", "Hypothyroidism - congenital and acquired (& [cretinism] or [myxoedema])|Hypothyroidism - congenital and acquired (& [cretinism] or [myxoedema]) (disorder)"], ["278109006", "Mechanism (attribute)"], ["277025001", "Proven (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1250004", "Decreased (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["325330005", "Iodine product (product)|Iodine product (substance)|Product containing iodine AND/OR iodine compound (medicinal product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["710809001", "Levothyroxine (substance)"], ["732727007", "4.4 (qualifier value)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["229059009", "Report (record artifact)|Reports (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["260400001", "Reduced (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["768685009", "Antiretroviral (disposition)"], ["19030005", "Human immunodeficiency virus (organism)"], ["55919000", "Including (qualifier value)"], ["321719003", "Lithium (product)|Lithium product (product)|Lithium product (substance)|Product containing lithium (medicinal product)|Product containing lithium (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387007000", "Orlistat (substance)"], ["18720000", "In (attribute)"], ["20572008", "Good (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["387007000", "Orlistat (substance)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["255234002", "After (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["373067005", "No (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["372726002", "Amitriptyline (substance)"], ["373444002", "Atorvastatin (substance)"], ["387461009", "Digoxin (substance)"], ["372767007", "Fluoxetine (substance)"], ["373567002", "Losartan (substance)"], ["387220006", "Phenytoin (substance)"], ["373343009", "Phentermine (substance)"], ["373566006", "Pravastatin (substance)"], ["387490003", "Nifedipine (substance)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["1231568003", "System (basic dose form)"], ["387490003", "Nifedipine (substance)"], ["255361000", "Slow (qualifier value)"], ["115956009", "Release (procedure)"], ["386838007", "Sibutramine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["53041004", "Substance with alcohol structure (substance)|Alcohol (substance)"], ["2667000", "Absent (qualifier value)"], ["18720000", "In (attribute)"], ["69658003", "Specific (qualifier value)"], ["410942007", "Drug or medicament (substance)"], ["410942007", "Drug or medicament (substance)"], ["2667000", "Absent (qualifier value)"], ["11896004", "Intermediate (qualifier value)"], ["738956005", "Oral (intended site)"], ["108899006", "Contraceptives (product)|Medicinal product acting as contraceptive (product)|Contraceptives (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387007000", "Orlistat (substance)"], ["18720000", "In (attribute)"], ["69658003", "Specific (qualifier value)"], ["410942007", "Drug or medicament (substance)"], ["277359009", "Drug interaction (finding)"], ["387007000", "Orlistat (substance)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["738956005", "Oral (intended site)"], ["108899006", "Contraceptives (product)|Medicinal product acting as contraceptive (product)|Contraceptives (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["88488004", "Lead (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["900000000000451002", "Existential restriction modifier (core metadata concept)"], ["385435006", "Individual (person)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["260686004", "Method (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["18720000", "In (attribute)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["409587002", "Severe diarrhea (finding)"], ["732727007", "4.4 (qualifier value)"]], "ncit.pregnancy": [["C406", "Cyclosporine"], ["C76246", "Blood Group A"], ["C25640", "Reduced"], ["C16727", "India"], ["C406", "Cyclosporine"], ["C13356", "Plasma"], ["C101282", "Have"], ["C25599", "Observed"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C459", "Medication"], ["C459", "Medication"], ["C54216", "Interaction"], ["C45319", "Study Object"], ["C16289", "Andorra"], ["C188308", "Reported Information"], ["C16727", "India"], ["C107221", "Several"], ["C65140", "When"], ["C29303", "Orlistat"], ["C154196", "Washo Language"], ["C25382", "Administered"], ["C52288", "NUP214 wt Allele"], ["C25552", "Lead"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C25640", "Reduced"], ["C52874", "SPI1 wt Allele"], ["C574", "Immunosuppressant"], ["C88183", "Efficacy"], ["C61517", "Combination"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C198613", "CFI wt Allele"], ["C25730", "Concomitant"], ["C25340", "Use"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C128667", "More"], ["C64649", "Frequently"], ["C61256", "Monitoring"], ["C52874", "SPI1 wt Allele"], ["C406", "Cyclosporine"], ["C17610", "Blood Sample"], ["C16329", "Belgium"], ["C38000", "Performed"], ["C49636", "Both"], ["C38008", "Post"], ["C64911", "Add"], ["C52874", "SPI1 wt Allele"], ["C29303", "Orlistat"], ["C16289", "Andorra"], ["C65137", "Upon"], ["C25484", "Discontinue"], ["C52874", "SPI1 wt Allele"], ["C29303", "Orlistat"], ["C16727", "India"], ["C406", "Cyclosporine"], ["C25705", "Treating"], ["C16960", "Patient"], ["C406", "Cyclosporine"], ["C17610", "Blood Sample"], ["C16329", "Belgium"], ["C65136", "Until"], ["C983", "Acarbose"], ["C16727", "India"], ["C52874", "SPI1 wt Allele"], ["C49663", "Pharmacokinetic Study"], ["C54216", "Interaction"], ["C25730", "Concomitant"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C29303", "Orlistat"], ["C62355", "With"], ["C983", "Acarbose"], ["C16329", "Belgium"], ["C25311", "Oral"], ["C263", "Anticoagulant Agent"], ["C65140", "When"], ["C945", "Warfarin"], ["C43508", "Oregon"], ["C118472", "Other License Status"], ["C263", "Anticoagulant Agent"], ["C68869", "Are"], ["C64974", "Give"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C29303", "Orlistat"], ["C25541", "International"], ["C179809", "Ratio Result Type"], ["C64805", "International Normalized Ratio of Prothrombin Time"], ["C16329", "Belgium"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C153917", "Fantse Language"], ["C64364", "Soluble"], ["C944", "Vitamin"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C29303", "Orlistat"], ["C106184", "May"], ["C71731", "Material Absorption"], ["C52874", "SPI1 wt Allele"], ["C153917", "Fantse Language"], ["C64364", "Soluble"], ["C944", "Vitamin"], ["C76246", "Blood Group A"], ["C81212", "Day Imputed"], ["C68800", "Elementary Charge"], ["C16289", "Andorra"], ["C68279", "Dietary Potassium"], ["C52874", "SPI1 wt Allele"], ["C16960", "Patient"], ["C25639", "Receive"], ["C64643", "Up to"], ["C66835", "Four"], ["C25517", "Full"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C29303", "Orlistat"], ["C16727", "India"], ["C15206", "Clinical Study"], ["C101282", "Have"], ["C74895", "Vitamin A Measurement"], ["C81212", "Day Imputed"], ["C68800", "Elementary Charge"], ["C16289", "Andorra"], ["C68279", "Dietary Potassium"], ["C16289", "Andorra"], ["C68305", "Beta-carotene"], ["C25282", "Within"], ["C71474", "Reference Range"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C74452", "Nutritional Supplement Drink"], ["C168111", "Adequate Daily Fluid Intake"], ["C28294", "Nutrition"], ["C16960", "Patient"], ["C92667", "SPARC wt Allele"], ["C76246", "Blood Group A"], ["C48192", "Importance Weight"], ["C64355", "Scientific Control"], ["C90364", "Basal Diet"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C90364", "Basal Diet"], ["C172207", "Rapidly Involuting Congenital Hemangioma"], ["C16727", "India"], ["C71972", "Fruit"], ["C16289", "Andorra"], ["C16289", "Andorra"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C1654", "Multivitamin"], ["C68641", "Supplement"], ["C16329", "Belgium"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C1654", "Multivitamin"], ["C68641", "Supplement"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C38267", "Intrathecal Route of Administration"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C158997", "GDC Analyte Type Terminology"], ["C66833", "Two"], ["C25529", "Hour"], ["C38008", "Post"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C29303", "Orlistat"], ["C43508", "Oregon"], ["C64593", "Hour Of Sleep"], ["C62002", "Amiodarone"], ["C76246", "Blood Group A"], ["C122948", "Borg Category-Ratio 10 Perceived Exertion Score 2"], ["C25640", "Reduced"], ["C16727", "India"], ["C13356", "Plasma"], ["C52874", "SPI1 wt Allele"], ["C62002", "Amiodarone"], ["C65140", "When"], ["C64974", "Give"], ["C71344", "Associate of Science"], ["C76246", "Blood Group A"], ["C48440", "Single"], ["C25488", "Dose"], ["C101282", "Have"], ["C25599", "Observed"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C142988", "Limited"], ["C25463", "Count"], ["C52874", "SPI1 wt Allele"], ["C115935", "Healthy"], ["C75419", "World Health Organization"], ["C25639", "Receive"], ["C29303", "Orlistat"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C62002", "Amiodarone"], ["C43442", "Biomaterial Treatment"], ["C123619", "Clinical Response"], ["C70664", "Relevance"], ["C52874", "SPI1 wt Allele"], ["C71600", "Effect, Appearance"], ["C160764", "Unknown Molecular Analysis"], ["C106184", "May"], ["C70664", "Relevance"], ["C16727", "India"], ["C65099", "Some"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C25730", "Concomitant"], ["C62002", "Amiodarone"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C123619", "Clinical Response"], ["C16289", "Andorra"], ["C29773", "Pregnant Mare Serum Gonadotropin"], ["C61256", "Monitoring"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C16727", "India"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C29303", "Orlistat"], ["C16289", "Andorra"], ["C264", "Anticonvulsant Agent"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C29536", "Valproic Acid"], ["C38703", "Lamotrigine"], ["C64956", "For"], ["C76246", "Blood Group A"], ["C103376", "CDISC Relationship Class"], ["C159124", "GDC Treatment Outcome Terminology"], ["C75889", "PAX6 wt Allele"], ["C54216", "Interaction"], ["C16329", "Belgium"], ["C82931", "Exclusion"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C64956", "For"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C16727", "India"], ["C71113", "CDISC SDTM Frequency Terminology"], ["C48928", "And/Or"], ["C25676", "Severity"], ["C52874", "SPI1 wt Allele"], ["C13634", "Retinoic Acid Response Element"], ["C25275", "Occurrence"], ["C52874", "SPI1 wt Allele"], ["C143576", "Hypothyroidism, CTCAE"], ["C48928", "And/Or"], ["C25640", "Reduced"], ["C64355", "Scientific Control"], ["C52874", "SPI1 wt Allele"], ["C143576", "Hypothyroidism, CTCAE"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C50285", "Mechanism Device"], ["C25594", "Negation"], ["C106184", "May"], ["C76246", "Blood Group A"], ["C25640", "Reduced"], ["C71731", "Material Absorption"], ["C52874", "SPI1 wt Allele"], ["C68254", "Dietary Iodine"], ["C48928", "And/Or"], ["C62080", "Levothyroxine"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C68869", "Are"], ["C65099", "Some"], ["C49152", "Case"], ["C115575", "Clinical Trial Final Report"], ["C52874", "SPI1 wt Allele"], ["C25640", "Reduced"], ["C88183", "Efficacy"], ["C52874", "SPI1 wt Allele"], ["C161395", "Human Immunodeficiency Virus Measurement"], ["C74691", "Antidepressant Measurement"], ["C166400", "Inclusive"], ["C1318", "Lithium Carbonate"], ["C16289", "Andorra"], ["C159124", "GDC Treatment Outcome Terminology"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C29303", "Orlistat"], ["C43442", "Biomaterial Treatment"], ["C16727", "India"], ["C25627", "Previous"], ["C128793", "Microplate Well"], ["C82500", "Disease Controlled"], ["C16960", "Patient"], ["C29303", "Orlistat"], ["C43442", "Biomaterial Treatment"], ["C48440", "Single"], ["C16329", "Belgium"], ["C38008", "Post"], ["C113416", "Consideration"], ["C52874", "SPI1 wt Allele"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C62534", "Arginine/Omega-3 Fatty Acids/Nucleotides Oral Supplement"], ["C16727", "India"], ["C16960", "Patient"], ["C52874", "SPI1 wt Allele"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C62355", "With"], ["C62005", "Amitriptyline"], ["C61527", "Atorvastatin"], ["C28990", "Digoxin"], ["C158219", "Fluoxetine Measurement"], ["C29165", "Losartan Potassium"], ["C741", "Phenytoin"], ["C174299", "Phentermine Measurement"], ["C62070", "Pravastatin"], ["C29290", "Nifedipine"], ["C53802", "Adverse Event Associated with the Gastrointestinal System"], ["C25277", "Therapeutic"], ["C149975", "System Dosing Unit"], ["C29290", "Nifedipine"], ["C64655", "Slow"], ["C134029", "Release Determination"], ["C75965", "Sibutramine"], ["C43508", "Oregon"], ["C74693", "Ethanol Measurement"], ["C101282", "Have"], ["C25599", "Observed"], ["C52874", "SPI1 wt Allele"], ["C101282", "Have"], ["C16727", "India"], ["C38024", "Specified"], ["C459", "Medication"], ["C459", "Medication"], ["C54216", "Interaction"], ["C52874", "SPI1 wt Allele"], ["C75889", "PAX6 wt Allele"], ["C54216", "Interaction"], ["C94545", "Between"], ["C389", "Oral Contraceptive"], ["C16289", "Andorra"], ["C29303", "Orlistat"], ["C101282", "Have"], ["C16727", "India"], ["C38024", "Specified"], ["C158286", "Drug-Drug Interaction Study"], ["C29303", "Orlistat"], ["C106184", "May"], ["C25429", "Availability"], ["C52874", "SPI1 wt Allele"], ["C25311", "Oral"], ["C16289", "Andorra"], ["C25552", "Lead"], ["C159124", "GDC Treatment Outcome Terminology"], ["C127832", "Unexpected"], ["C16727", "India"], ["C65099", "Some"], ["C25190", "Person"], ["C75889", "PAX6 wt Allele"], ["C25406", "Additional"], ["C42734", "Contraceptive Device"], ["C85492", "CDISC SDTM Method Terminology"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C16727", "India"], ["C49152", "Case"], ["C52874", "SPI1 wt Allele"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"]], "rxnorm.pregnancy": [["37925", "orlistat"], ["6260", "lead"], ["37925", "orlistat"], ["37925", "orlistat"], ["16681", "acarbose"], ["37925", "orlistat"], ["16681", "acarbose"], ["11289", "warfarin"], ["37925", "orlistat"], ["37925", "orlistat"], ["37925", "orlistat"], ["11246", "vitamin A"], ["37925", "orlistat"], ["703", "amiodarone"], ["703", "amiodarone"], ["37925", "orlistat"], ["703", "amiodarone"], ["703", "amiodarone"], ["37925", "orlistat"], ["40254", "valproate"], ["28439", "lamotrigine"], ["5933", "iodine"], ["10582", "levothyroxine"], ["6448", "lithium"], ["37925", "orlistat"], ["37925", "orlistat"], ["704", "amitriptyline"], ["83367", "atorvastatin"], ["3407", "digoxin"], ["4493", "fluoxetine"], ["52175", "losartan"], ["8183", "phenytoin"], ["8152", "phentermine"], ["42463", "pravastatin"], ["7417", "nifedipine"], ["7417", "nifedipine"], ["36514", "sibutramine"], ["37925", "orlistat"], ["37925", "orlistat"], ["6260", "lead"]], "loinc.pregnancy": [["LP17763-1", "A"], ["LA32049-1", "Decrease"], ["LA22004-8", "IN"], ["LP7479-1", "Plasma"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA20274-9", "Drug-drug"], ["LP74341-6", "Study"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LP270144-1", "Cases"], ["LP14259-3", "Lead"], ["LP17763-1", "A"], ["LA32049-1", "Decrease"], ["LA26687-6", "Efficacy"], ["LA12701-1", "Combination"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP200075-2", "IS"], ["LA16824-7", "More"], ["LA20297-0", "Monitoring"], ["MTHU029981", "Blood"], ["LA19974-7", "Performed"], ["LA14331-5", "Both"], ["LA11132-0", "Addition"], ["LA22004-8", "IN"], ["MTHU029981", "Blood"], ["LP171383-5", "Acarbose"], ["LA22004-8", "IN"], ["LP171383-5", "Acarbose"], ["LA9367-9", "Oral"], ["LA28654-4", "Warfarin"], ["LA22025-3", "OR"], ["MTHU029809", "Other"], ["LP29256-2", "given"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP6852-0", "Ratio"], ["LP17102-2", "INR"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP28807-3", "Fat"], ["LP31395-4", "Vitamins"], ["LP94823-9", "Treatment"], ["LA14161-6", "May"], ["LP28807-3", "Fat"], ["LP31395-4", "Vitamins"], ["LP17763-1", "A"], ["LP15238-6", "D"], ["LA13503-0", "E"], ["LP14926-7", "K"], ["LA33103-5", "Four"], ["LA19682-6", "Full"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LP7787-7", "Clinical"], ["LP31687-4", "Vitamin A"], ["LP15238-6", "D"], ["LA13503-0", "E"], ["LP14926-7", "K"], ["MTHU004345", "Carotene"], ["LA6626-1", "Normal"], ["LA22004-8", "IN"], ["LA8913-1", "Adequate"], ["LP172860-1", "Nutrition"], ["LP17763-1", "A"], ["LP221195-3", "Weight"], ["LP7741-4", "Control"], ["MTHU053295", "Diet"], ["LP17763-1", "A"], ["MTHU053295", "Diet"], ["LA22004-8", "IN"], ["LP17412-5", "Fruit"], ["LP30703-0", "Vegetables"], ["LP17763-1", "A"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP200075-2", "IS"], ["LP200077-8", "IT"], ["LA21988-3", "AT"], ["LA6404-3", "Two"], ["LA22025-3", "OR"], ["LA21988-3", "AT"], ["LP16028-0", "Amiodarone"], ["LP17763-1", "A"], ["LA11910-9", "Slight"], ["LA32049-1", "Decrease"], ["LA22004-8", "IN"], ["LP7479-1", "Plasma"], ["LP16028-0", "Amiodarone"], ["LP29256-2", "given"], ["LP17763-1", "A"], ["LA17717-2", "Single"], ["MTHU065481", "Dose"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA6484-5", "Limited"], ["LP18011-4", "Number"], ["LA28121-4", "Healthy"], ["LP267536-3", "Volunteers"], ["LA32660-5", "Received"], ["LA22004-8", "IN"], ["LP16028-0", "Amiodarone"], ["LP94823-9", "Treatment"], ["LP7787-7", "Clinical"], ["LA4489-6", "Unknown"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LA14973-4", "Some"], ["LP270144-1", "Cases"], ["LA22004-8", "IN"], ["LP16028-0", "Amiodarone"], ["LP94823-9", "Treatment"], ["LP7787-7", "Clinical"], ["MTHU044181", "ECG"], ["LA20297-0", "Monitoring"], ["LP200075-2", "IS"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["LP18046-0", "Drugs"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["MTHU005126", "Valproate"], ["MTHU060528", "lamoTRIgine"], ["LP17763-1", "A"], ["LP262503-8", "Relationship"], ["LA15097-1", "Possible"], ["LA22004-8", "IN"], ["MTHU029777", "Frequency"], ["LA22025-3", "OR"], ["LA15679-6", "Rare"], ["LA14303-4", "Hypothyroidism"], ["LA22025-3", "OR"], ["LA32619-1", "Reduced"], ["LP7741-4", "Control"], ["LA14303-4", "Hypothyroidism"], ["LA14161-6", "May"], ["LA21291-2", "Not"], ["LA14161-6", "May"], ["LP17763-1", "A"], ["LA24378-4", "Decreased"], ["LA30119-4", "Iodine"], ["LA22025-3", "OR"], ["LP422109-1", "Levothyroxine"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LA14973-4", "Some"], ["LA32619-1", "Reduced"], ["LA26687-6", "Efficacy"], ["LP183501-8", "HIV"], ["MTHU006782", "Antidepressants"], ["LP18073-4", "Antipsychotics"], ["MTHU004197", "Lithium"], ["LP15014-1", "Benzodiazepines"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LA18365-9", "Well"], ["LP94823-9", "Treatment"], ["LA15097-1", "Possible"], ["LA22004-8", "IN"], ["LA32-8", "No"], ["LP14983-8", "Amitriptyline"], ["LP171386-8", "Atorvastatin"], ["MTHU001808", "Digoxin"], ["MTHU060451", "FLUoxetine"], ["LP171619-2", "Losartan"], ["LP14732-9", "Phenytoin"], ["LP16250-0", "Phentermine"], ["LP171630-9", "Pravastatin"], ["MTHU062929", "NIFEdipine"], ["LA16968-2", "Gastrointestinal"], ["LP263807-2", "Therapeutic"], ["MTHU062929", "NIFEdipine"], ["LA24898-1", "Slow"], ["LP100053-0", "Sibutramine"], ["LA22025-3", "OR"], ["LA28139-6", "Alcohol"], ["LP6425-5", "Observed"], ["LA22004-8", "IN"], ["LA20274-9", "Drug-drug"], ["LA9367-9", "Oral"], ["LA22004-8", "IN"], ["LA20274-9", "Drug-drug"], ["LA14161-6", "May"], ["LA9367-9", "Oral"], ["LP14259-3", "Lead"], ["LP73139-5", "Pregnancies"], ["LA22004-8", "IN"], ["LA14973-4", "Some"], ["LA12070-1", "Individual"], ["LP270144-1", "Cases"], ["LP263791-8", "Additional"], ["LP72939-9", "Method"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["LP20592-9", "4"], ["LP20592-9", "4"]], "snomed.driving": [["86495002", "For (qualifier value)"], ["387007000", "Orlistat (substance)"], ["373067005", "No (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["420862001", "On (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["387961004", "Kingdom Animalia (organism)"], ["255589003", "Direct (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255541007", "Indirect (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["386217009", "Non-human parturition, function (observable entity)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["263844007", "Maternal postnatal period (qualifier value)|Postnatal (qualifier value)"], ["769082003", "5.3 (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["36692007", "Known (qualifier value)"], ["387007000", "Orlistat (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["30507006", "Into (attribute)"], ["226789007", "Breast milk (substance)"], ["387007000", "Orlistat (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410536001", "Contraindicated (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"]], "ncit.driving": [["C64956", "For"], ["C29303", "Orlistat"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C15783", "Clinical Data"], ["C92667", "SPARC wt Allele"], ["C68869", "Are"], ["C25429", "Availability"], ["C14182", "Animal"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C62254", "Direct"], ["C43508", "Oregon"], ["C62255", "Indirect"], ["C25492", "Effect"], ["C62355", "With"], ["C159124", "GDC Treatment Outcome Terminology"], ["C191656", "Pregnant Subject"], ["C18732", "Development"], ["C92934", "Labor and Delivery Process"], ["C43508", "Oregon"], ["C81317", "Postnatal"], ["C18732", "Development"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16329", "Belgium"], ["C65140", "When"], ["C154633", "Prescribing Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C73435", "Gravida"], ["C71344", "Associate of Science"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C17998", "Unknown"], ["C29303", "Orlistat"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C17119", "Cellular Secretion"], ["C25544", "Into"], ["C14225", "Human"], ["C13257", "Mammary Gland Milk"], ["C29303", "Orlistat"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25490", "During"], ["C25389", "Chest"], ["C88198", "Feeding"]], "rxnorm.driving": [["37925", "orlistat"], ["T008", "Animal"], ["37925", "orlistat"], ["T016", "Human"], ["37925", "orlistat"]], "loinc.driving": [["LA32-8", "No"], ["LP221469-2", "Clinical data"], ["LP73139-5", "Pregnancies"], ["LA30681-3", "Animal"], ["LA14426-3", "Do not"], ["LA22025-3", "OR"], ["LP207970-7", "Pregnancy"], ["LA22025-3", "OR"], ["LP20593-7", "5"], ["LP20591-1", "3"], ["LA29507-3", "Pregnant women"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA14748-0", "Not known"], ["LP200075-2", "IS"], ["LA19762-6", "Secreted"], ["LA19711-3", "Human"], ["LP29290-1", "Milk"], ["LP200075-2", "IS"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"]], "snomed.side_effects": [["373067005", "No (qualifier value)"], ["420862001", "On (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["247750002", "Drive (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"]], "ncit.side_effects": [["C29303", "Orlistat"], ["C101282", "Have"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C121660", "Influence"], ["C92667", "SPARC wt Allele"], ["C121232", "Ability to Drive"], ["C16289", "Andorra"], ["C25340", "Use"]], "rxnorm.side_effects": [["226918", "Xenical"]], "loinc.side_effects": [["LA32-8", "No"]], "snomed.shelf_life": [["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258707000", "year (qualifier value)"]], "ncit.shelf_life": [["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C29848", "Year"]], "rxnorm.shelf_life": [], "loinc.shelf_life": [["LA31719-0", "2 years"]], "snomed.storage": [["210984001", "(Superficial injury) or (abrasions) or (blisters) or (friction burns) or (splinters) or (sting (& without reaction): [bee] or [wasp]) or (bites: [insect - non venomous] or [flea]) (disorder)|(Superficial injury) or (abrasions) or (blisters) or (friction burns) or (splinters) or (sting (& without reaction): [bee] or [wasp]) or (bites: [insect - non venomous] or [flea])"], ["352730000", "Supra- (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["18720000", "In (attribute)"], ["19535007", "Original (qualifier value)"], ["1681000175101", "Package - unit of product usage (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732984005", "Blister (unit of presentation)"], ["18720000", "In (attribute)"], ["261074009", "External (qualifier value)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["371268001", "Light color (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419672006", "Bottle (qualifier value)|Bottle - unit of product usage (qualifier value)"], ["352730000", "Supra- (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["732990009", "Container (unit of presentation)"], ["29179001", "Closed (qualifier value)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"]], "ncit.storage": [["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C60824", "Storage"], ["C75329", "Above"], ["C113663", "Twenty Five"], ["C67900", "Centi"], ["C60824", "Storage"], ["C16727", "India"], ["C25604", "Original"], ["C79887", "Package"], ["C16289", "Andorra"], ["C99569", "Retain"], ["C43168", "Blister Pack"], ["C16727", "India"], ["C187054", "Outer Surface"], ["C54702", "Carton Dosing Unit"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25516", "From"], ["C64650", "Light"], ["C16289", "Andorra"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C60824", "Storage"], ["C75329", "Above"], ["C70541", "Lansky Performance Status 30"], ["C67900", "Centi"], ["C99569", "Retain"], ["C43446", "Container Object"], ["C49070", "Closed"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25516", "From"]], "rxnorm.storage": [], "loinc.storage": [["LA14426-3", "Do not"], ["LA14991-6", "Above"], ["LA19281-7", "25"], ["LP17128-7", "C"], ["LA22004-8", "IN"], ["LA9505-4", "Original"], ["LA19024-1", "Blister"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LA15831-3", "Light"], ["MTHU017843", "Moisture"], ["LA14426-3", "Do not"], ["LA14991-6", "Above"], ["LA28855-7", "30"], ["LP17128-7", "C"], ["LA9228-3", "Closed"], ["LA22004-8", "IN"], ["MTHU017843", "Moisture"]], "snomed.package": [["35233000", "Polyvinyl chloride (substance)"], ["210984001", "(Superficial injury) or (abrasions) or (blisters) or (friction burns) or (splinters) or (sting (& without reaction): [bee] or [wasp]) or (bites: [insect - non venomous] or [flea]) (disorder)|(Superficial injury) or (abrasions) or (blisters) or (friction burns) or (splinters) or (sting (& without reaction): [bee] or [wasp]) or (bites: [insect - non venomous] or [flea])"], ["42504009", "Containing (qualifier value)"], ["1222774009", "American Joint Committee on Cancer stage II:1 (qualifier value)"], ["1222845008", "American Joint Committee on Cancer stage IV:2 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732888007", "84 (qualifier value)"], ["72505002", "Hard (qualifier value)"], ["385049006", "Capsule (basic dose form)|Capsule (product)|Capsule dose form (qualifier value)|Capsule dose form (product)"], ["32039001", "Glass (substance)"], ["419672006", "Bottle (qualifier value)|Bottle - unit of product usage (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["42504009", "Containing (qualifier value)"], ["1222774009", "American Joint Committee on Cancer stage II:1 (qualifier value)"], ["1222845008", "American Joint Committee on Cancer stage IV:2 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732888007", "84 (qualifier value)"], ["72505002", "Hard (qualifier value)"], ["385049006", "Capsule (basic dose form)|Capsule (product)|Capsule dose form (qualifier value)|Capsule dose form (product)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["257260002", "Pack (physical object)"]], "ncit.package": [["C10268", "Cisplatin/Cyclophosphamide/Etoposide"], ["C79873", "Contain"], ["C107434", "Twenty One"], ["C175676", "Forty Two"], ["C16289", "Andorra"], ["C188343", "Eighty Four"], ["C113682", "Hard"], ["C45301", "Glass"], ["C62355", "With"], ["C79873", "Contain"], ["C107434", "Twenty One"], ["C175676", "Forty Two"], ["C16289", "Andorra"], ["C188343", "Eighty Four"], ["C113682", "Hard"], ["C25594", "Negation"], ["C64916", "All"], ["C84731", "Packing"], ["C106184", "May"], ["C16329", "Belgium"]], "rxnorm.package": [["746839", "Pack"]], "loinc.package": [["LA14745-6", "Hard"], ["LA14745-6", "Hard"], ["LA21291-2", "Not"], ["LA18187-7", "All"], ["LA14161-6", "May"]], "snomed.marketing_authorization_numbers": [["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["732913005", "98 (qualifier value)"], ["1222737005", "American Joint Committee on Cancer stage I:1 (qualifier value)"]], "ncit.marketing_authorization_numbers": [["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113425", "Eleven"]], "rxnorm.marketing_authorization_numbers": [], "loinc.marketing_authorization_numbers": [["LA6112-2", "1"], ["LA14557-5", "11"]]}, {"product_info": "Suliqua 100 units/ml + 50 micrograms/ml solution for injection in pre-filled pen \nSuliqua 100 units/ml + 33 micrograms/ml solution for injection in pre-filled pen", "composition": "Suliqua 100 units/ml + 50 microgram/ml solution for injection in pre-filled pen  \nEach pre-filled pen contains 300 units of insulin glargine* and 150 micrograms lixisenatide in 3 ml \nsolution. \nEach ml contains 100 units of insulin glargine and 50 micrograms of lixisenatide. \nEach dose step contains 1 unit of insulin glargine and 0.5 micrograms of lixisenatide \nSuliqua 100 units/ml + 33 microgram/ml solution for injection in pre-filled pen  \nEach pre-filled pen contains 300 units of insulin glargine and 100 micrograms of lixisenatide in 3 ml \nsolution. \nEach ml contains 100 units of insulin glargine and 33 micrograms of lixisenatide. \nEach dose step contains 1 unit of insulin glargine and 0.33 micrograms of lixisenatide \n*Insulin glargine is produced by recombinant DNA technology in \nEscherichia coli\nThe dose window on the pen shows the number of dose steps. \nExcipient(s) with known effects  \nEach ml contains 2.7 milligrams of metacresol. \nFor the full list of excipients, see section 6.1.", "indications": "Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to \nimprove glycaemic control as an adjunct to diet and exercise in addition to metformin with or without \nsodium-glucose co-transporter-2 (SGLT-2) inhibitors.  \nFor study results with respect to effect on glycaemic control, and the populations studied, see section \n4.4 and 5.1.", "posology": "Suliqua is available in two pre-filled pens, providing different dosing options, i.e. Suliqua (10-40) pen,\nSuliqua (30-60) pen respectively. The differentiation between the pen strengths is based on the dose \nrange of the pen. \nSuliqua 100 units/ml + 50 micrograms/ml pre-filled pen delivers dose steps from \n10-40 units\n of \ninsulin glargine in combination with \n5-20 mcg\n of lixisenatide (Suliqua (10-40) pen). \nSuliqua 100 units/ml + 33 micrograms/ml pre-filled pen delivers dose steps from \n30-60 units\n of \ninsulin glargine in combination with\n 10-20 mcg\n of lixisenatide (Suliqua (30-60) pen). \nTo avoid medication errors, the prescriber must make sure that the correct strength and number of dose \nsteps is stated in the prescription (see section 4.4). \nPosology  \nThe dose must be individualised based on clinical response and is titrated based on the patient\u2019s need \nfor insulin. The lixisenatide dose is increased or decreased along with insulin glargine dose and also \ndepends on which pen is used. \nStarting dose\nTherapy with basal insulin or glucagon-like peptide-1 (GLP-1) receptor agonist or oral glucose \nlowering medicinal product other than metformin and SGLT-2 inhibitors should be discontinued prior \nto initiation of Suliqua.  \nThe starting dose of Suliqua is based on previous anti-diabetic treatment, and in order not to exceed \nthe recommended lixisenatide starting dose of 10 mcg: \nPrevious therapy \nInsulin na\u00efve \npatients (oral \nanti-diabetic \ntreatment or \nGLP-1 receptor \nagonist) \nInsulin glargine \n(100 units/ml)** \n\u226520 to <30 units \nInsulin glargine \n(100 units/ml)** \n\u226530 to \u226460 units \nStarting \ndose  \nand pen \nSuliqua \n(10-40) pen \n10 dose steps \n(10 units/5 mcg)* \n20 dose steps \n(20 units/10 mcg)*\nSuliqua \n(30-60) pen \n30 dose steps \n(30 units/10 mcg)*\n* Units insulin glargine (100 units/ml)/mcg lixisenatide \nPatients on less than 20 units of insulin glargine may be considered similar to insulin naive patients.  \n** If a different basal insulin was used: \n  For twice daily basal insulin or insulin glargine (300 units/ml), the total daily dose previously \nused should be reduced by 20% to choose the Suliqua starting dose. \n  For any other basal insulin the same rule as for insulin glargine (100 units/ml) should be applied \nThe maximum daily dose is 60 units insulin glargine and 20 mcg lixisenatide corresponding to 60 dose \nsteps.  \nSuliqua should be injected once a day within one hour prior to a meal. It is preferable that the prandial \ninjection is performed before the same meal every day, when the most convenient meal has been chosen.  \nDose titration\nSuliqua is to be dosed in accordance with the individual patient's need for insulin. It is recommended \nto optimise glycaemic control via dose adjustment based on fasting plasma glucose (see section 5.1). \nClose glucose monitoring is recommended during the transfer and in the following weeks. \nIf the patient starts with the Suliqua (10-40) pen, the dose may be titrated up to 40 dose steps with \nthis pen. \nFor doses >40 dose steps/day titration must be continued with Suliqua (30-60) pen. \nIf the patient starts with the Suliqua (30-60) pen, the dose may be titrated up to 60 dose steps with \nthis pen.  \nFor total daily doses >60 dose steps/day, Suliqua must not be used. \nPatients adjusting the amount or timing of dosing should only do so under medical supervision with \nappropriate glucose monitoring (see section 4.4).  \nMissed dose \nIf a dose of Suliqua is missed, it should be injected within the hour prior to the next meal. \nSpecial population  \nElderly  \nSuliqua can be used in elderly patients. The dose should be adjusted on an individual basis, based on \nglucose monitoring. In the elderly, progressive deterioration of renal function may lead to a steady \ndecrease in insulin requirements. For lixisenatide no dose adjustment is required based on age. The \ntherapeutic experience of Suliqua in patients \u226575 years of age is limited. \nRenal impairment \nSuliqua is not recommended in patients with severe renal impairment and end-stage renal disease as \nthere is no sufficient therapeutic experience with use of lixisenatide.  \nNo dose adjustment is required for lixisenatide in patients with mild or moderate renal impairment.  \nIn patients with renal impairment, insulin requirements may be diminished due to reduced insulin \nmetabolism.\nIn patients with mild to moderate renal impairment using Suliqua, frequent glucose monitoring and \ndose adjustment may be necessary. \nHepatic impairment \nNo dose adjustment of lixisenatide is needed in patients with hepatic impairment (see section 5.2). In \npatients with hepatic impairment, insulin requirements may be diminished due to reduced capacity for \ngluconeogenesis and reduced insulin metabolism. Frequent glucose monitoring and dose adjustment \nmay be necessary for Suliqua in patients with hepatic impairment\nPaediatric population \nThere is no relevant use of Suliqua in the paediatric population. \nMethod of administration  \nSuliqua is to be injected subcutaneously in the abdomen, deltoid, or thigh. \nThe injection sites should be rotated within the same region (abdomen, deltoid, or thigh) from one \ninjection to the next in order to reduce the risk of lipodystrophy and cutaneous amyloidosis (see \nsection 4.4 and 4.8). \nPatients should be instructed to always use a new needle. The re-use of insulin pen needles increases \nthe risk of blocked needles, which may cause under- or overdosing. In the event of blocked needles, \npatients must follow the instructions described in the Instructions for Use accompanying the package \nleaflet (see section 6.6). \nSuliqua must not be drawn from the cartridge of the pre-filled pen into a syringe to avoid dosing errors \nand potential overdose (see section 4.4).", "contraindications": "Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.", "special_warnings": "Traceability  \nIn order to improve the traceability of biological medicinal products, the name and the batch number \nof the administered product should be clearly recorded. \nType 1 diabetes mellitus \nSuliqua should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic \nketoacidosis. \nRotation of the injection site \nPatients must be instructed to perform continuous rotation of the injection site to reduce the risk of \ndeveloping lipodystrophy and cutaneous amyloidosis. There is a potential risk of delayed insulin \nabsorption and worsened glycaemic control following insulin injections at sites with these reactions. A \nsudden change in the injection site to an unaffected area has been reported to result in hypoglycaemia. \nBlood glucose monitoring is recommended after the change in the injection site, and dose adjustment \nof antidiabetic medicinal product may be considered. \nHypoglycaemia  \nHypoglycaemia was the most frequently reported observed adverse reaction during treatment with \nSuliqua (see section 4.8). Hypoglycaemia may occur if the dose of Suliqua is higher than required.  \nFactors increasing the susceptibility to hypoglycaemia require particularly close monitoring and may \nnecessitate dose adjustment. These factors include: \nchange in the injection area \nimproved insulin sensitivity (e.g. by removal of stress factors) \nunaccustomed, increased or prolonged physical activity \nintercurrent illness (e.g. vomiting, diarrhoea) \ninadequate food intake \nmissed meals \nalcohol consumption \ncertain uncompensated endocrine disorders, (e.g. in hypothyroidism and in anterior pituitary or \nadrenocortical insufficiency) \nconcomitant treatment with certain other medicinal products (see section 4.5). \nlixisenatide and/or insulin in combination with a sulfonylurea may result in an increased risk of \nhypoglycaemia. Therefore Suliqua should not be given in combination with a sulfonylurea.  \nThe dose of Suliqua must be individualised based on clinical response and is titrated based on the \npatient\u2019s need for insulin (see section 4.2). \nAcute pancreatitis  \nUse of GLP-1 receptor agonists has been associated with a risk of developing acute pancreatitis. There \nhave been few reported events of acute pancreatitis with lixisenatide although a causal relationship has \nnot been established. Patients should be informed of the characteristic symptoms of acute pancreatitis: \npersistent, severe abdominal pain. If pancreatitis is suspected, Suliqua should be discontinued; if acute \npancreatitis is confirmed, lixisenatide should not be restarted. Caution should be exercised in patients \nwith a history of pancreatitis. \nSevere gastrointestinal disease  \nUse of GLP-1 receptor agonists may be associated with gastrointestinal adverse reactions (see \nsection 4.8). Suliqua has not been studied in patients with severe gastrointestinal disease, including \nsevere gastroparesis and therefore, the use of Suliqua is not recommended in these patients.   \nSevere renal impairment  \nThere is no therapeutic experience in patients with severe renal impairment (creatinine clearance less \nthan 30 ml/min) or end-stage renal disease. Use is not recommended in patients with severe renal \nimpairment or end-stage renal disease (see sections 4.2 and 5.2). \nConcomitant medicinal products  \nThe delay of gastric emptying with lixisenatide may reduce the rate of absorption of orally \nadministered medicinal products. Suliqua should be used with caution in patients receiving oral \nmedicinal products that require rapid gastrointestinal absorption, require careful clinical monitoring or \nhave a narrow therapeutic ratio. Specific recommendations regarding intake of such medicinal \nproducts are given in section 4.5. \nDehydration  \nPatients treated with Suliqua should be advised of the potential risk of dehydration in relation to \ngastrointestinal adverse reactions and take precautions to avoid fluid depletion. \nAntibody formation  \nAdministration of Suliqua may cause formation of antibodies against insulin glargine and/or \nlixisenatide. In rare cases, the presence of such antibodies may necessitate adjustment of the Suliqua \ndose in order to correct a tendency for hyperglycaemia or hypoglycaemia. \nAvoidance of medication errors  \nPatients must be instructed to always check the pen label before each injection to avoid accidental \nmix-ups between the two different strengths of Suliqua and mix-ups with other injectable diabetes \nmedicinal products. \nTo avoid dosing errors and potential overdose, neither the patients nor healthcare professionals should \never use a syringe to draw the medicinal product from the cartridge in the pre-filled pen into a syringe. \nAntidiabetic medicinal products not studied in combination with Suliqua   \nSuliqua has not been studied in combination with dipeptidyl peptidase-4 (DPP-4) inhibitors, \nsulfonylureas, glinides, and pioglitazone. \nTravel \nTo avoid dosing errors and potential overdoses with changing to different time zones, the patient \nshould seek the doctor\u2019s advice before travelling. \nExcipients  \nThis medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially \n'sodium-free'. \nThis medicinal product contains metacresol, which may cause allergic reactions.", "pregnancy": "No interaction studies with Suliqua have been performed. The information given below is based on \nstudies with the monocomponents.  \nPharmacodynamic interactions  \nA number of substances affect glucose metabolism and may require dose adjustment of Suliqua. \nSubstances that may enhance the blood-glucose-lowering effect and increase susceptibility to \nhypoglycaemia include anti-hyperglycaemic medicinal products, angiotensin converting enzyme \n(ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, \npentoxifylline, propoxyphene, salicylates and sulphonamide antibiotics. \nSubstances that may reduce the blood-glucose-lowering effect include corticosteroids, danazol, \ndiazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives, \nsomatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, \nterbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and \nolanzapine) and protease inhibitors. \nBeta-blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the \nblood-glucose-lowering effect of insulin. Pentamidine may cause hypoglycaemia, which may \nsometimes be followed by hyperglycaemia. \nIn addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, \nguanethidine and reserpine, the signs of adrenergic counter-regulation may be reduced or absent. \nPharmacokinetic interactions  \nLixisenatide is a peptide and is not metabolised by cytochrome P450. In \nin vitro\n studies, lixisenatide \ndid not affect the activity of cytochrome P450 isozymes or human transporters tested. \nNo pharmacokinetic interactions are known for insulin glargine. \nEffect of gastric emptying on oral medicinal products \nThe delay of gastric emptying with lixisenatide may reduce the rate of absorption of orally \nadministered medicinal products. Patients receiving medicinal products of either a narrow therapeutic \nratio or medicinal products that require careful clinical monitoring should be followed closely, \nespecially at the time of initiation of lixisenatide treatment. These medicinal products should be taken \nin a standardised way in relation to lixisenatide. If such medicinal products are to be administered with \nfood, patients should be advised to, if possible, take them with a meal when lixisenatide is not \nadministered. \nFor oral medicinal products that are particularly dependent on threshold concentrations for efficacy, \nsuch as antibiotics, patients should be advised to take those medicinal products at least 1 hour before \nor 4 hours after lixisenatide injection. \nGastro-resistant formulations containing substances sensitive to stomach degradation, should be \nadministered 1 hour before or 4 hours after lixisenatide injection.  \nParacetamol\nParacetamol was used as a model medicinal product to evaluate the effect of lixisenatide on gastric \nemptying. Following administration of a single dose of paracetamol 1000 mg, paracetamol AUC and \nt1/2 were unchanged whatever the timing of its administration (before or after the lixisenatide \ninjection). When administered 1 or 4 hours after 10 mcg lixisenatide, Cmax of paracetamol was \ndecreased by 29% and 31%, respectively and median tmax was delayed by 2.0 and 1.75 hours, \nrespectively. A further delay in tmax and a reduced Cmax of paracetamol have been predicted with the \n20 mcg maintenance dose. \nNo effects on paracetamol Cmax and tmax were observed when paracetamol was administered 1 hour \nbefore lixisenatide. \nBased on these results, no dose adjustment for paracetamol is required but the delayed tmax observed \nwhen paracetamol is administered 1-4 hours after lixisenatide should be taken into account when a \nrapid onset of action is required for efficacy. \nOral contraceptives \nFollowing administration of a single dose of an oral contraceptive medicinal product (ethinylestradiol \n0.03 mg/levonorgestrel 0.15 mg) 1 hour before or 11 hours after 10 mcg lixisenatide, the Cmax, AUC, \nt1/2 and tmax of ethinylestradiol and levonorgestrel were unchanged. \nAdministration of the oral contraceptive 1 hour or 4 hours after lixisenatide did not affect AUC and \nt1/2 of ethinylestradiol and levonorgestrel, whereas Cmax of ethinylestradiol was decreased by 52% and \n39%, respectively and Cmax of levonorgestrel was decreased by 46% and 20%, respectively and \nmedian tmax was delayed by 1 to 3 hours. \nThe reduction in Cmax is of limited clinical relevance and no dose adjustment for oral contraceptives is \nrequired. \nAtorvastatin \nWhen lixisenatide 20 mcg and atorvastatin 40 mg were co-administered in the morning for 6 days, the \nexposure to atorvastatin was not affected, while Cmax was decreased by 31% and tmax was delayed by \n3.25 hours. \nNo such increase for tmax was observed when atorvastatin was administered in the evening and \nlixisenatide in the morning but the AUC and Cmax of atorvastatin were increased by 27% and 66%, \nrespectively. \nThese changes are not clinically relevant and, therefore, no dose adjustment for atorvastatin is required \nwhen co-administered with lixisenatide. \nWarfarin and other coumarin derivatives \nAfter concomitant administration of warfarin 25 mg with repeated dosing of lixisenatide 20 mcg, there \nwere no effects on AUC or INR (International Normalised Ratio) while Cmax was reduced by 19% and \ntmax was delayed by 7 hours. \nBased on these results, no dose adjustment for warfarin is required when co-administered with \nlixisenatide; however, frequent monitoring of INR in patients on warfarin and/or coumarin derivatives \nis recommended at the time of initiation or ending of lixisenatide treatment. \nDigoxin \nAfter concomitant administration of lixisenatide 20 mcg and digoxin 0.25 mg at steady state, the AUC \nof digoxin was not affected. The tmax of digoxin was delayed by 1.5 hour and the Cmax was reduced by \n26%. \nBased on these results, no dose adjustment for digoxin is required when co-administered with \nlixisenatide. \nRamipril \nAfter concomitant administration of lixisenatide 20 mcg and ramipril 5 mg during 6 days, the AUC of \nramipril was increased by 21% while the Cmax was decreased by 63%. The AUC and Cmax of the active \nmetabolite (ramiprilat) were not affected. The tmax of ramipril and ramiprilat were delayed by \napproximately 2.5 hours. \nBased on these results, no dose adjustment for ramipril is required when co-administered with \nlixisenatide.", "driving": "Women of childbearing potential  \nSuliqua is not recommended in women of childbearing potential not using contraception. \nPregnancy  \nThere is no clinical data on exposed pregnancies from controlled clinical studies with use of Suliqua, \ninsulin glargine, or lixisenatide.  \nA large amount of data on pregnant women (more than 1,000 pregnancy outcomes) with insulin \nglargine indicate no malformative nor feto/neonatal toxicity of insulin glargine. Animal data do not \nindicate reproductive toxicity with insulin glargine.  \nThere are no or limited amount of data from the use of lixisenatide in pregnant women. Studies with \nlixisenatide in animals have shown reproductive toxicity (see section 5.3).  \nSuliqua is not recommended during pregnancy and in women of childbearing potential not using \ncontraception. \nBreast-feeding  \nIt is unknown whether insulin glargine or lixisenatide are excreted in human milk. A risk to the \nnewborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with \nSuliqua. \nFertility  \nAnimal studies with lixisenatide or insulin glargine do not indicate direct harmful effects with respect \nto fertility.", "side_effects": "Suliqua has no or negligible influence on the ability to drive or use machines. However, the patient's \nability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, \nfor example, as a result of visual impairment. This may constitute a risk in situations where these \nabilities are of special importance (e.g. driving a car or using machines). \nPatients should be advised to take precautions to avoid hypoglycaemia while driving and using \nmachines. This is particularly important in those who have reduced or absent awareness of the warning \nsymptoms of hypoglycaemia or have frequent episodes of hypoglycaemia. It should be considered \nwhether it is advisable to drive or use machines in these circumstances.", "shelf_life": "Before first use  \n3 years.  \nAfter first use\n28 days.\nAfter first use: Store below 25\u00b0C. Do not refrigerate. Do not freeze. \nDo not store with attached needle. \nStore pen away from direct heat or direct light. The pen cap must be put back on the pen after each \ninjection in order to protect from light.", "storage": "Store in a refrigerator (2\u00b0C - 8\u00b0C).  \nDo not freeze or place next to the freezer compartment or a freezer pack.  \nKeep the pre-filled pen in the outer carton in order to protect from light.  \nFor storage conditions after first opening of the medicinal product, see section 6.3", "package": "Type I colourless glass cartridge with a black plunger (bromobutyl rubber) and a flanged cap \n(aluminium) with inserted laminated sealing disks (bromobutyl rubber on the medicinal product side \nand polyisoprene on the outside) containing 3 ml of solution. Each cartridge is assembled into a \ndisposable pen.  \nPacks of 3, 5 and 10 pre-filled pens. \nNot all pack sizes may be marketed.", "marketing_authorization_numbers": "EU/1/16/1157/001 \nEU/1/16/1157/002 \nEU/1/16/1157/003 \nEU/1/16/1157/004 \nEU/1/16/1157/005 \nEU/1/16/1157/006", "filename": "suliqua-epar-product-information_en.html", "snomed.product_info": [["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["260347006", "Present + out of ++++ (qualifier value)|+ (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["385219001", "Injection solution (qualifier value)|Conventional release solution for injection (dose form)|Injection solution (product)"], ["18720000", "In (attribute)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["260347006", "Present + out of ++++ (qualifier value)|+ (qualifier value)"], ["1222814009", "American Joint Committee on Cancer stage III:3 (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["385219001", "Injection solution (qualifier value)|Conventional release solution for injection (dose form)|Injection solution (product)"], ["18720000", "In (attribute)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"]], "ncit.product_info": [["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C105785", "Fifty"], ["C16816", "Mali"], ["C149918", "Solution for Injection in Pre-filled Pen Dosage Form"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C102996", "Human Papillomavirus-33"], ["C16816", "Mali"], ["C149918", "Solution for Injection in Pre-filled Pen Dosage Form"]], "rxnorm.product_info": [["1649574", "Injection"], ["1649574", "Injection"]], "loinc.product_info": [["LA19244-5", "100"], ["LP32708-7", "Units"], ["LA30923-9", "+"], ["LA28854-0", "50"], ["LA14542-7", "Injection"], ["LA22004-8", "IN"], ["LP32605-5", "pre"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LA30923-9", "+"], ["LA19316-1", "33"], ["LA14542-7", "Injection"], ["LA22004-8", "IN"], ["LP32605-5", "pre"]], "snomed.composition": [["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["260347006", "Present + out of ++++ (qualifier value)|+ (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258801007", "ug/mL (qualifier value)|Microgram/milliliter (qualifier value)"], ["385219001", "Injection solution (qualifier value)|Conventional release solution for injection (dose form)|Injection solution (product)"], ["18720000", "In (attribute)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["419473009", "Each (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["725125005", "300 (qualifier value)"], ["246514001", "Units (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732515006", "150 (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["18720000", "In (attribute)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["739006009", "Solution (basic dose form)"], ["419473009", "Each (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["419473009", "Each (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["398298007", "Step (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["767525000", "Unit (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260304006", "0.5 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["260347006", "Present + out of ++++ (qualifier value)|+ (qualifier value)"], ["1222814009", "American Joint Committee on Cancer stage III:3 (qualifier value)"], ["258801007", "ug/mL (qualifier value)|Microgram/milliliter (qualifier value)"], ["385219001", "Injection solution (qualifier value)|Conventional release solution for injection (dose form)|Injection solution (product)"], ["18720000", "In (attribute)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["419473009", "Each (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["725125005", "300 (qualifier value)"], ["246514001", "Units (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["18720000", "In (attribute)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["739006009", "Solution (basic dose form)"], ["419473009", "Each (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222814009", "American Joint Committee on Cancer stage III:3 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["419473009", "Each (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["398298007", "Step (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["767525000", "Unit (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732363005", "0.33 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["411529005", "Insulin glargine (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["788111003", "Recombinant deoxyribonucleic acid (substance)"], ["18720000", "In (attribute)"], ["112283007", "Escherichia coli (organism)"], ["408102007", "Unit dose (qualifier value)"], ["224755008", "Window (physical object)"], ["420862001", "On (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["410681005", "Count of entities (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["36692007", "Known (qualifier value)"], ["419473009", "Each (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["732580008", "2.7 (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["86495002", "For (qualifier value)"], ["261015003", "Full (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.composition": [["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C105785", "Fifty"], ["C48152", "Microgram"], ["C16816", "Mali"], ["C149918", "Solution for Injection in Pre-filled Pen Dosage Form"], ["C64933", "Each"], ["C97717", "Pre-filled Pen Syringe"], ["C79873", "Contain"], ["C16645", "Greece"], ["C68553", "Unit"], ["C52874", "SPI1 wt Allele"], ["C47564", "Insulin Glargine"], ["C16289", "Andorra"], ["C129532", "One Hundred Fifty"], ["C166988", "Lixisenatide"], ["C16727", "India"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16816", "Mali"], ["C42986", "Solution Dosage Form"], ["C64933", "Each"], ["C16816", "Mali"], ["C79873", "Contain"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C52874", "SPI1 wt Allele"], ["C47564", "Insulin Glargine"], ["C16289", "Andorra"], ["C105785", "Fifty"], ["C52874", "SPI1 wt Allele"], ["C166988", "Lixisenatide"], ["C64933", "Each"], ["C25488", "Dose"], ["C16154", "Treatment Step"], ["C79873", "Contain"], ["C105723", "ECOG Performance Status 1"], ["C68553", "Unit"], ["C52874", "SPI1 wt Allele"], ["C47564", "Insulin Glargine"], ["C16289", "Andorra"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C163771", "Illness Intrusiveness Rating 5"], ["C52874", "SPI1 wt Allele"], ["C166988", "Lixisenatide"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C102996", "Human Papillomavirus-33"], ["C48152", "Microgram"], ["C16816", "Mali"], ["C149918", "Solution for Injection in Pre-filled Pen Dosage Form"], ["C64933", "Each"], ["C97717", "Pre-filled Pen Syringe"], ["C79873", "Contain"], ["C16645", "Greece"], ["C68553", "Unit"], ["C52874", "SPI1 wt Allele"], ["C47564", "Insulin Glargine"], ["C16289", "Andorra"], ["C105814", "One Hundred"], ["C52874", "SPI1 wt Allele"], ["C166988", "Lixisenatide"], ["C16727", "India"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16816", "Mali"], ["C42986", "Solution Dosage Form"], ["C64933", "Each"], ["C16816", "Mali"], ["C79873", "Contain"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C52874", "SPI1 wt Allele"], ["C47564", "Insulin Glargine"], ["C16289", "Andorra"], ["C102996", "Human Papillomavirus-33"], ["C52874", "SPI1 wt Allele"], ["C166988", "Lixisenatide"], ["C64933", "Each"], ["C25488", "Dose"], ["C16154", "Treatment Step"], ["C79873", "Contain"], ["C105723", "ECOG Performance Status 1"], ["C68553", "Unit"], ["C52874", "SPI1 wt Allele"], ["C47564", "Insulin Glargine"], ["C16289", "Andorra"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C102996", "Human Papillomavirus-33"], ["C52874", "SPI1 wt Allele"], ["C166988", "Lixisenatide"], ["C47564", "Insulin Glargine"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C158169", "Buyei Chinese"], ["C16621", "Genetic Engineering"], ["C16727", "India"], ["C14206", "Escherichia coli"], ["C25488", "Dose"], ["C48051", "Window"], ["C92667", "SPARC wt Allele"], ["C157049", "Pen Device"], ["C25463", "Count"], ["C52874", "SPI1 wt Allele"], ["C25488", "Dose"], ["C156404", "STEPS to Enhance Physical Activity"], ["C42637", "Pharmaceutical Excipient"], ["C42555", "Siemens"], ["C62355", "With"], ["C80137", "Known"], ["C25492", "Effect"], ["C64933", "Each"], ["C16816", "Mali"], ["C79873", "Contain"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C52874", "SPI1 wt Allele"], ["C80603", "Metacresol"], ["C64956", "For"], ["C25517", "Full"], ["C43432", "List"], ["C52874", "SPI1 wt Allele"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.composition": [["1649574", "Injection"], ["274783", "insulin glargine"], ["1440051", "lixisenatide"], ["274783", "insulin glargine"], ["1440051", "lixisenatide"], ["274783", "insulin glargine"], ["1440051", "lixisenatide"], ["1649574", "Injection"], ["274783", "insulin glargine"], ["1440051", "lixisenatide"], ["274783", "insulin glargine"], ["1440051", "lixisenatide"], ["274783", "insulin glargine"], ["1440051", "lixisenatide"], ["274783", "insulin glargine"], ["350202", "Escherichia coli"], ["1367170", "metacresol"]], "loinc.composition": [["LA19244-5", "100"], ["LP32708-7", "Units"], ["LA30923-9", "+"], ["LA28854-0", "50"], ["LA14542-7", "Injection"], ["LA22004-8", "IN"], ["LP32605-5", "pre"], ["LP32605-5", "pre"], ["LP32708-7", "Units"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA22004-8", "IN"], ["LP20591-1", "3"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA28854-0", "50"], ["MTHU065481", "Dose"], ["LA6112-2", "1"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA16632-4", "0.5"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LA30923-9", "+"], ["LA19316-1", "33"], ["LA14542-7", "Injection"], ["LA22004-8", "IN"], ["LP32605-5", "pre"], ["LP32605-5", "pre"], ["LP32708-7", "Units"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA19244-5", "100"], ["LA22004-8", "IN"], ["LP20591-1", "3"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA19316-1", "33"], ["MTHU065481", "Dose"], ["LA6112-2", "1"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA6111-4", "0"], ["LA19316-1", "33"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LP200075-2", "IS"], ["LA19712-1", "Recombinant"], ["MTHU003299", "DNA"], ["LA22004-8", "IN"], ["LP19605-2", "Escherichia coli"], ["MTHU065481", "Dose"], ["LP18011-4", "Number"], ["MTHU065481", "Dose"], ["LP15241-0", "S"], ["MTHU000002", "Clinical Class"], ["LP36790-1", "7"], ["LA19682-6", "Full"], ["LP204165-7", "List"], ["LP20594-5", "6"], ["LA6112-2", "1"]], "snomed.indications": [["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410535002", "Indicated (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["44054006", "Diabetes mellitus type 2 (disorder)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["246106000", "Control (attribute)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["41829006", "Dietary finding (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["256235009", "Exercise (observable entity)|Exercise (qualifier value)"], ["20401003", "With (attribute)"], ["372567009", "Metformin (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["45169001", "Without (attribute)"], ["39972003", "Sodium (substance)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["705591009", "Transporter (physical object)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["86495002", "For (qualifier value)"], ["224699009", "Study (environment)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["420862001", "On (qualifier value)"], ["246106000", "Control (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.indications": [["C112320", "Immunogenicity Specimen Assessments Domain"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C62355", "With"], ["C82500", "Disease Controlled"], ["C26747", "Type 2 Diabetes Mellitus"], ["C159124", "GDC Treatment Outcome Terminology"], ["C64355", "Scientific Control"], ["C71344", "Associate of Science"], ["C75889", "PAX6 wt Allele"], ["C159124", "GDC Treatment Outcome Terminology"], ["C90364", "Basal Diet"], ["C16289", "Andorra"], ["C16567", "Exercise"], ["C16727", "India"], ["C64911", "Add"], ["C159124", "GDC Treatment Outcome Terminology"], ["C61612", "Metformin"], ["C62355", "With"], ["C43508", "Oregon"], ["C25718", "Without"], ["C830", "Sodium"], ["C2831", "Glucose"], ["C95633", "Coded Ordinal Data Type"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C64956", "For"], ["C45319", "Study Object"], ["C62355", "With"], ["C159124", "GDC Treatment Outcome Terminology"], ["C71600", "Effect, Appearance"], ["C92667", "SPARC wt Allele"], ["C64355", "Scientific Control"], ["C16289", "Andorra"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.indications": [["6809", "metformin"], ["9853", "sodium"], ["4850", "glucose"]], "loinc.indications": [["LP200075-2", "IS"], ["LP94823-9", "Treatment"], ["LP6886-8", "Type"], ["MTHU000002", "Clinical Class"], ["LP74722-7", "Diabetes mellitus"], ["LP7741-4", "Control"], ["MTHU053295", "Diet"], ["LP207667-9", "Exercise"], ["LA22004-8", "IN"], ["LA11132-0", "Addition"], ["MTHU060554", "metFORMIN"], ["LA22025-3", "OR"], ["LP15099-2", "Sodium"], ["MTHU001675", "Glucose"], ["LA21996-6", "CO"], ["MTHU000002", "Clinical Class"], ["MTHU000002", "Clinical Class"], ["LP74341-6", "Study"], ["LP7741-4", "Control"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20593-7", "5"], ["LA6112-2", "1"]], "snomed.posology": [["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["103328004", "Availability of (contextual qualifier) (qualifier value)"], ["18720000", "In (attribute)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["732814003", "60 (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["11896004", "Intermediate (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420862001", "On (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["609432006", "Concept model range (foundation metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["260347006", "Present + out of ++++ (qualifier value)|+ (qualifier value)"], ["732774003", "50 (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["408102007", "Unit dose (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["246514001", "Units (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258685003", "ug (qualifier value)|microgram (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["260347006", "Present + out of ++++ (qualifier value)|+ (qualifier value)"], ["1222814009", "American Joint Committee on Cancer stage III:3 (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["408102007", "Unit dose (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["732814003", "60 (qualifier value)"], ["246514001", "Units (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258685003", "ug (qualifier value)|microgram (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["732814003", "60 (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["2533004", "Drug (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["410681005", "Count of entities (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["260885003", "Prescription (attribute)"], ["732727007", "4.4 (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["420862001", "On (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420862001", "On (qualifier value)"], ["116154003", "Patient (person)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["86495002", "For (qualifier value)"], ["67866001", "Insulin (substance)"], ["708808004", "Lixisenatide (substance)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1250004", "Decreased (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["408102007", "Unit dose (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420862001", "On (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["416303005", "Basal insulin (product)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["66603002", "Glucagon (substance)"], ["52642002", "Peptide (substance)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["43004008", "Glucagon-like peptide 1 (substance)"], ["771380003", "Substance with receptor agonist mechanism of action (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["738956005", "Oral (intended site)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["763158003", "Medicinal product (product)"], ["74964007", "Other (qualifier value)"], ["372567009", "Metformin (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["410546004", "Discontinued (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420862001", "On (qualifier value)"], ["9130008", "Previous (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["258685003", "ug (qualifier value)|microgram (qualifier value)"], ["9130008", "Previous (qualifier value)"], ["277132007", "Therapeutic procedure (procedure)"], ["67866001", "Insulin (substance)"], ["738956005", "Oral (intended site)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["43004008", "Glucagon-like peptide 1 (substance)"], ["116647005", "Receptor (substance)"], ["411529005", "Insulin glargine (substance)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["246514001", "Units (attribute)"], ["411529005", "Insulin glargine (substance)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["732814003", "60 (qualifier value)"], ["246514001", "Units (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["246514001", "Units (attribute)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["258685003", "ug (qualifier value)|microgram (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["246514001", "Units (attribute)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["258685003", "ug (qualifier value)|microgram (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["732814003", "60 (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["246514001", "Units (attribute)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["258685003", "ug (qualifier value)|microgram (qualifier value)"], ["246514001", "Units (attribute)"], ["411529005", "Insulin glargine (substance)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["258685003", "ug (qualifier value)|microgram (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["420862001", "On (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["246514001", "Units (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["67866001", "Insulin (substance)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["416303005", "Basal insulin (product)"], ["86495002", "For (qualifier value)"], ["229799001", "Twice a day (qualifier value)"], ["416303005", "Basal insulin (product)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["725125005", "300 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["255619001", "Total (qualifier value)"], ["123128001", "Daily -RETIRED-|Daily (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["260400001", "Reduced (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["86495002", "For (qualifier value)"], ["74964007", "Other (qualifier value)"], ["416303005", "Basal insulin (product)"], ["262126009", "Same (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["420528006", "Arabic numeral 100 (qualifier value)|100 (qualifier value)"], ["246514001", "Units (attribute)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["123128001", "Daily -RETIRED-|Daily (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["732814003", "60 (qualifier value)"], ["246514001", "Units (attribute)"], ["411529005", "Insulin glargine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258685003", "ug (qualifier value)|microgram (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["732814003", "60 (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["422114001", "Once - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["264721006", "day (qualifier value)|day"], ["18720000", "In (attribute)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["288556008", "Before (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["262126009", "Same (qualifier value)"], ["69620002", "Daily (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["4757001", "Most (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["385435006", "Individual (person)"], ["116154003", "Patient (person)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["103325001", "Patient need for (contextual qualifier) (qualifier value)"], ["67866001", "Insulin (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["246106000", "Control (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["420862001", "On (qualifier value)"], ["792805006", "Fasting (regime/therapy)"], ["72191006", "Glucose measurement, plasma (procedure)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["129347002", "Surgical transfer - action (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["255260001", "Following (attribute)"], ["258705008", "week (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["116154003", "Patient (person)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["408102007", "Unit dose (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["86495002", "For (qualifier value)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["264721006", "day (qualifier value)|day"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["732814003", "60 (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["116154003", "Patient (person)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["732814003", "60 (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["408102007", "Unit dose (qualifier value)"], ["353734004", "Upward (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["732814003", "60 (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["86495002", "For (qualifier value)"], ["255619001", "Total (qualifier value)"], ["123128001", "Daily -RETIRED-|Daily (qualifier value)"], ["732814003", "60 (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["264721006", "day (qualifier value)|day"], ["246205007", "Quantity (attribute)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["246512002", "Timing (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420295001", "Only - dosing instruction fragment (qualifier value)"], ["351726001", "Below (qualifier value)"], ["74188005", "Medical (qualifier value)"], ["225313009", "Supervision (regime/therapy)|Supervision (procedure)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["732727007", "4.4 (qualifier value)"], ["1269470004", "Individual dose of drug or medicament not taken (situation)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["258702006", "hour (qualifier value)"], ["288556008", "Before (attribute)"], ["67995009", "Special (qualifier value)"], ["385436007", "Population (social concept)"], ["429308001", "Can - unit of product usage (qualifier value)"], ["18720000", "In (attribute)"], ["408102007", "Unit dose (qualifier value)"], ["420862001", "On (qualifier value)"], ["385435006", "Individual (person)"], ["420862001", "On (qualifier value)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["18720000", "In (attribute)"], ["255314001", "Progressive (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["50741009", "Urinary tract function (observable entity)|Urinary tract function (function)"], ["88488004", "Lead (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["55011004", "Steady (qualifier value)"], ["260370003", "Decrease (qualifier value)"], ["18720000", "In (attribute)"], ["67866001", "Insulin (substance)"], ["86495002", "For (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420862001", "On (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["732861002", "75 (qualifier value)"], ["258707000", "year (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424144002", "Current chronological age (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["236423003", "Renal impairment (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["46177005", "End-stage renal disease (disorder)|End stage renal disease (disorder)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["51117008", "Sufficient (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["708808004", "Lixisenatide (substance)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["86495002", "For (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255604002", "Mild (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1255665007", "Moderate (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["67866001", "Insulin (substance)"], ["260374007", "Diminished|Diminished (qualifier value)"], ["42752001", "Due to (attribute)"], ["260400001", "Reduced (qualifier value)"], ["67866001", "Insulin (substance)"], ["47722004", "General metabolic function (function)|General metabolic function (observable entity)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["371923003", "Mild to moderate (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["261583007", "Using (attribute)"], ["70232002", "Frequent (qualifier value)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["40226000", "Impairment (finding)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["410525008", "Needed (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["40226000", "Impairment (finding)"], ["732766004", "5.2 (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["40226000", "Impairment (finding)"], ["67866001", "Insulin (substance)"], ["260374007", "Diminished|Diminished (qualifier value)"], ["42752001", "Due to (attribute)"], ["260400001", "Reduced (qualifier value)"], ["86495002", "For (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260400001", "Reduced (qualifier value)"], ["67866001", "Insulin (substance)"], ["47722004", "General metabolic function (function)|General metabolic function (observable entity)"], ["70232002", "Frequent (qualifier value)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["86495002", "For (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["40226000", "Impairment (finding)"], ["376171000221106", "Pediatric population (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["260676000", "Use of (attribute)"], ["18720000", "In (attribute)"], ["376171000221106", "Pediatric population (qualifier value)"], ["260686004", "Method (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["818983003", "Structure of abdominopelvic cavity and/or content of abdominopelvic cavity and/or anterior abdominal wall (body structure)"], ["181620007", "Entire deltoid muscle (body structure)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["302544002", "Entire thigh (body structure)"], ["268517006", "Diabetic monitoring - injection sites (finding)"], ["263861005", "Rotated (qualifier value)"], ["18720000", "In (attribute)"], ["262126009", "Same (qualifier value)"], ["410673009", "Region (attribute)"], ["818983003", "Structure of abdominopelvic cavity and/or content of abdominopelvic cavity and/or anterior abdominal wall (body structure)"], ["181620007", "Entire deltoid muscle (body structure)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["302544002", "Entire thigh (body structure)"], ["38112003", "One (qualifier value)|1 (qualifier value)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["190789006", "(Lipodystrophy) or (Barraquer - Simons disease)|(Lipodystrophy) or (Barraquer - Simons disease) (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["282834007", "Cutaneous amyloidosis (disorder)"], ["732727007", "4.4 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["261021004", "New (qualifier value)|New [dup] (qualifier value)"], ["79068005", "Needle, device (physical object)"], ["15635006", "Requested by patient (contextual qualifier) (qualifier value)"], ["260676000", "Use of (attribute)"], ["67866001", "Insulin (substance)"], ["733006000", "Pen (unit of presentation)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["351726001", "Below (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["272379006", "Events (event)|Event (event)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421939007", "Follow - dosing instruction imperative (qualifier value)"], ["18720000", "In (attribute)"], ["86495002", "For (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["1681000175101", "Package - unit of product usage (qualifier value)"], ["732810007", "6.6 (qualifier value)"], ["732988008", "Cartridge (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["30507006", "Into (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1149222004", "Overdose (disorder)"], ["732727007", "4.4 (qualifier value)"]], "ncit.posology": [["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25429", "Availability"], ["C16727", "India"], ["C66833", "Two"], ["C25629", "Prior"], ["C54093", "Fill"], ["C21026", "Peripheral Electronic Nerve Stimulation"], ["C46003", "Difference"], ["C25374", "Options"], ["C68254", "Dietary Iodine"], ["C68800", "Elementary Charge"], ["C69122", "Ten"], ["C105795", "Forty"], ["C157049", "Pen Device"], ["C70541", "Lansky Performance Status 30"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C157049", "Pen Device"], ["C18314", "Cellular Differentiation"], ["C94545", "Between"], ["C157049", "Pen Device"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C25488", "Dose"], ["C38013", "Range"], ["C52874", "SPI1 wt Allele"], ["C157049", "Pen Device"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C105785", "Fifty"], ["C16816", "Mali"], ["C97717", "Pre-filled Pen Syringe"], ["C25488", "Dose"], ["C156404", "STEPS to Enhance Physical Activity"], ["C25516", "From"], ["C69122", "Ten"], ["C105795", "Forty"], ["C68553", "Unit"], ["C52874", "SPI1 wt Allele"], ["C47564", "Insulin Glargine"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C48152", "Microgram"], ["C52874", "SPI1 wt Allele"], ["C166988", "Lixisenatide"], ["C69122", "Ten"], ["C105795", "Forty"], ["C157049", "Pen Device"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C102996", "Human Papillomavirus-33"], ["C16816", "Mali"], ["C97717", "Pre-filled Pen Syringe"], ["C25488", "Dose"], ["C156404", "STEPS to Enhance Physical Activity"], ["C25516", "From"], ["C70541", "Lansky Performance Status 30"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C68553", "Unit"], ["C52874", "SPI1 wt Allele"], ["C47564", "Insulin Glargine"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C69122", "Ten"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C48152", "Microgram"], ["C52874", "SPI1 wt Allele"], ["C166988", "Lixisenatide"], ["C70541", "Lansky Performance Status 30"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C157049", "Pen Device"], ["C159124", "GDC Treatment Outcome Terminology"], ["C459", "Medication"], ["C25392", "Manufacturer"], ["C107561", "Certain"], ["C68815", "Correct"], ["C53294", "Pharmaceutical Strength"], ["C16289", "Andorra"], ["C25463", "Count"], ["C52874", "SPI1 wt Allele"], ["C25488", "Dose"], ["C156404", "STEPS to Enhance Physical Activity"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C28180", "Prescription"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25488", "Dose"], ["C16329", "Belgium"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C123619", "Clinical Response"], ["C16289", "Andorra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C53691", "Veterinary Patient"], ["C42555", "Siemens"], ["C41204", "Need"], ["C64956", "For"], ["C2271", "Insulin"], ["C166988", "Lixisenatide"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C164135", "Increased"], ["C43508", "Oregon"], ["C25640", "Reduced"], ["C62355", "With"], ["C47564", "Insulin Glargine"], ["C25488", "Dose"], ["C16289", "Andorra"], ["C92667", "SPARC wt Allele"], ["C157049", "Pen Device"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25488", "Dose"], ["C49236", "Therapeutic Procedure"], ["C62355", "With"], ["C23409", "Murine Basal Cells"], ["C2271", "Insulin"], ["C43508", "Oregon"], ["C80183", "Glucagon-like Peptide-1 Measurement"], ["C103980", "ZGLP1 wt Allele"], ["C1514", "Agonist"], ["C43508", "Oregon"], ["C25311", "Oral"], ["C2831", "Glucose"], ["C86568", "Lower"], ["C142605", "Medicinal Product"], ["C151896", "Other Than"], ["C61612", "Metformin"], ["C16289", "Andorra"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C25627", "Previous"], ["C43442", "Biomaterial Treatment"], ["C16289", "Andorra"], ["C16727", "India"], ["C54092", "Order"], ["C66971", "Not to Exceed"], ["C25197", "Recommendation"], ["C166988", "Lixisenatide"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C69122", "Ten"], ["C48152", "Microgram"], ["C25627", "Previous"], ["C49236", "Therapeutic Procedure"], ["C2271", "Insulin"], ["C123723", "Package Type Not Applicable"], ["C17250", "Venezuela, Bolivarian Republic of"], ["C16960", "Patient"], ["C25311", "Oral"], ["C43442", "Biomaterial Treatment"], ["C43508", "Oregon"], ["C191844", "Glucagon-Like Peptide 1 Receptor"], ["C1514", "Agonist"], ["C47564", "Insulin Glargine"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C159124", "GDC Treatment Outcome Terminology"], ["C70541", "Lansky Performance Status 30"], ["C68553", "Unit"], ["C47564", "Insulin Glargine"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C70541", "Lansky Performance Status 30"], ["C159124", "GDC Treatment Outcome Terminology"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C68553", "Unit"], ["C25488", "Dose"], ["C16289", "Andorra"], ["C157049", "Pen Device"], ["C69122", "Ten"], ["C105795", "Forty"], ["C157049", "Pen Device"], ["C69122", "Ten"], ["C25488", "Dose"], ["C156404", "STEPS to Enhance Physical Activity"], ["C69122", "Ten"], ["C68553", "Unit"], ["C163771", "Illness Intrusiveness Rating 5"], ["C48152", "Microgram"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C25488", "Dose"], ["C156404", "STEPS to Enhance Physical Activity"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C68553", "Unit"], ["C69122", "Ten"], ["C48152", "Microgram"], ["C70541", "Lansky Performance Status 30"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C157049", "Pen Device"], ["C70541", "Lansky Performance Status 30"], ["C25488", "Dose"], ["C156404", "STEPS to Enhance Physical Activity"], ["C70541", "Lansky Performance Status 30"], ["C68553", "Unit"], ["C69122", "Ten"], ["C48152", "Microgram"], ["C68553", "Unit"], ["C47564", "Insulin Glargine"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C48152", "Microgram"], ["C166988", "Lixisenatide"], ["C16960", "Patient"], ["C92667", "SPARC wt Allele"], ["C61585", "Less Than"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C68553", "Unit"], ["C52874", "SPI1 wt Allele"], ["C47564", "Insulin Glargine"], ["C106184", "May"], ["C16329", "Belgium"], ["C72665", "Similarity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C2271", "Insulin"], ["C189136", "SARS-CoV-2 Naive Specimen"], ["C16960", "Patient"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C46003", "Difference"], ["C23409", "Murine Basal Cells"], ["C2271", "Insulin"], ["C154196", "Washo Language"], ["C64956", "For"], ["C64496", "Twice Daily"], ["C23409", "Murine Basal Cells"], ["C2271", "Insulin"], ["C43508", "Oregon"], ["C47564", "Insulin Glargine"], ["C16645", "Greece"], ["C68553", "Unit"], ["C16816", "Mali"], ["C70888", "Daily Dose"], ["C25627", "Previous"], ["C16329", "Belgium"], ["C25640", "Reduced"], ["C158169", "Buyei Chinese"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C159124", "GDC Treatment Outcome Terminology"], ["C48912", "Choose"], ["C25488", "Dose"], ["C64956", "For"], ["C81168", "Any"], ["C118472", "Other License Status"], ["C23409", "Murine Basal Cells"], ["C2271", "Insulin"], ["C172515", "S-Adenosylmethionine Measurement"], ["C138178", "Ruler"], ["C71344", "Associate of Science"], ["C64956", "For"], ["C47564", "Insulin Glargine"], ["C105814", "One Hundred"], ["C68553", "Unit"], ["C16816", "Mali"], ["C16329", "Belgium"], ["C113519", "Apply"], ["C82868", "Maximum Value Derivation Technique"], ["C70888", "Daily Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C68553", "Unit"], ["C47564", "Insulin Glargine"], ["C16289", "Andorra"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C48152", "Microgram"], ["C166988", "Lixisenatide"], ["C159124", "GDC Treatment Outcome Terminology"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C25488", "Dose"], ["C156404", "STEPS to Enhance Physical Activity"], ["C16329", "Belgium"], ["C125004", "Once Daily"], ["C25282", "Within"], ["C126256", "One Activity Hour"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C80248", "Meal"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C122632", "Injection Dosing Unit"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C38000", "Performed"], ["C201357", "Before Timing Type"], ["C172515", "S-Adenosylmethionine Measurement"], ["C80248", "Meal"], ["C25473", "Daily"], ["C65140", "When"], ["C25258", "Most"], ["C107497", "Convenient"], ["C80248", "Meal"], ["C101282", "Have"], ["C48912", "Choose"], ["C25488", "Dose"], ["C181463", "Titrimetry"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C64950", "Follow"], ["C25190", "Person"], ["C53691", "Veterinary Patient"], ["C42555", "Siemens"], ["C41204", "Need"], ["C64956", "For"], ["C2271", "Insulin"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C159124", "GDC Treatment Outcome Terminology"], ["C64355", "Scientific Control"], ["C113553", "SEMA6A wt Allele"], ["C82495", "Dose Adjustment"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C63663", "Fasting"], ["C13356", "Plasma"], ["C2831", "Glucose"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C105723", "ECOG Performance Status 1"], ["C49070", "Closed"], ["C2831", "Glucose"], ["C61256", "Monitoring"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C25490", "During"], ["C48167", "Transfer"], ["C16289", "Andorra"], ["C16727", "India"], ["C53286", "Next"], ["C29844", "Week"], ["C198613", "CFI wt Allele"], ["C53691", "Veterinary Patient"], ["C62355", "With"], ["C69122", "Ten"], ["C105795", "Forty"], ["C157049", "Pen Device"], ["C25488", "Dose"], ["C106184", "May"], ["C16329", "Belgium"], ["C64643", "Up to"], ["C105795", "Forty"], ["C25488", "Dose"], ["C156404", "STEPS to Enhance Physical Activity"], ["C62355", "With"], ["C157049", "Pen Device"], ["C64956", "For"], ["C25488", "Dose"], ["C105795", "Forty"], ["C25488", "Dose"], ["C156404", "STEPS to Enhance Physical Activity"], ["C25301", "Day"], ["C181463", "Titrimetry"], ["C16329", "Belgium"], ["C53279", "Continue"], ["C62355", "With"], ["C70541", "Lansky Performance Status 30"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C157049", "Pen Device"], ["C198613", "CFI wt Allele"], ["C53691", "Veterinary Patient"], ["C62355", "With"], ["C70541", "Lansky Performance Status 30"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C157049", "Pen Device"], ["C25488", "Dose"], ["C106184", "May"], ["C16329", "Belgium"], ["C64643", "Up to"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C25488", "Dose"], ["C156404", "STEPS to Enhance Physical Activity"], ["C62355", "With"], ["C157049", "Pen Device"], ["C64956", "For"], ["C25304", "Total"], ["C168156", "Chief Complaint is Present Daily"], ["C25488", "Dose"], ["C182731", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 60"], ["C25488", "Dose"], ["C156404", "STEPS to Enhance Physical Activity"], ["C25301", "Day"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C16960", "Patient"], ["C25256", "Quantity"], ["C43508", "Oregon"], ["C40567", "Timing, LOINC Axis 3"], ["C52874", "SPI1 wt Allele"], ["C48440", "Single"], ["C158168", "Dong Chinese"], ["C17149", "Somalia"], ["C25261", "Medical"], ["C61372", "Management"], ["C62355", "With"], ["C2831", "Glucose"], ["C61256", "Monitoring"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C50429", "Missed Dose"], ["C198613", "CFI wt Allele"], ["C76246", "Blood Group A"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C54031", "Missing"], ["C38267", "Intrathecal Route of Administration"], ["C16329", "Belgium"], ["C25282", "Within"], ["C25529", "Hour"], ["C25629", "Prior"], ["C159124", "GDC Treatment Outcome Terminology"], ["C82511", "Subsequent Trial Activity"], ["C80248", "Meal"], ["C18101", "Special Population"], ["C16268", "Elderly"], ["C52288", "NUP214 wt Allele"], ["C16329", "Belgium"], ["C16727", "India"], ["C16268", "Elderly"], ["C16960", "Patient"], ["C25488", "Dose"], ["C16329", "Belgium"], ["C49157", "Adjustment"], ["C92667", "SPARC wt Allele"], ["C75889", "PAX6 wt Allele"], ["C25190", "Person"], ["C25430", "Basis"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C2831", "Glucose"], ["C61256", "Monitoring"], ["C16727", "India"], ["C16268", "Elderly"], ["C25254", "Progressive"], ["C25751", "Deterioration"], ["C52874", "SPI1 wt Allele"], ["C164220", "Renal Function"], ["C106184", "May"], ["C25552", "Lead"], ["C159124", "GDC Treatment Outcome Terminology"], ["C76246", "Blood Group A"], ["C95500", "Steady"], ["C25640", "Reduced"], ["C16727", "India"], ["C2271", "Insulin"], ["C64956", "For"], ["C166988", "Lixisenatide"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C25277", "Therapeutic"], ["C54627", "Experience"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C16960", "Patient"], ["C160687", "Seventy Five"], ["C29848", "Year"], ["C52874", "SPI1 wt Allele"], ["C106312", "Advanced Glycation End Product"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C142988", "Limited"], ["C114592", "Renal Impairment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C114592", "Renal Impairment"], ["C16289", "Andorra"], ["C9439", "Chronic Kidney Disease, Stage 5"], ["C71344", "Associate of Science"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C63351", "Sufficient"], ["C25277", "Therapeutic"], ["C54627", "Experience"], ["C62355", "With"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C166988", "Lixisenatide"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C64956", "For"], ["C166988", "Lixisenatide"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C156242", "Mild Hallucination"], ["C43508", "Oregon"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C114592", "Renal Impairment"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C114592", "Renal Impairment"], ["C2271", "Insulin"], ["C106184", "May"], ["C16329", "Belgium"], ["C89272", "Due To"], ["C25640", "Reduced"], ["C2271", "Insulin"], ["C16842", "Metabolism, Organismal"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C156242", "Mild Hallucination"], ["C159124", "GDC Treatment Outcome Terminology"], ["C182708", "Hamilton Anxiety Rating Scale HAMA101 Through HAMA114 Original Result - Moderate"], ["C114592", "Renal Impairment"], ["C64649", "Frequently"], ["C2831", "Glucose"], ["C61256", "Monitoring"], ["C16289", "Andorra"], ["C82495", "Dose Adjustment"], ["C106184", "May"], ["C16329", "Belgium"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C52874", "SPI1 wt Allele"], ["C166988", "Lixisenatide"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C2271", "Insulin"], ["C106184", "May"], ["C16329", "Belgium"], ["C89272", "Due To"], ["C25640", "Reduced"], ["C25443", "Capacity"], ["C64956", "For"], ["C28151", "Gluconeogenic Process"], ["C16289", "Andorra"], ["C25640", "Reduced"], ["C2271", "Insulin"], ["C16842", "Metabolism, Organismal"], ["C64649", "Frequently"], ["C2831", "Glucose"], ["C61256", "Monitoring"], ["C16289", "Andorra"], ["C82495", "Dose Adjustment"], ["C106184", "May"], ["C16329", "Belgium"], ["C64956", "For"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C13308", "Hepatic"], ["C21055", "Impairment"], ["C17005", "Population Group"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C70664", "Relevance"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C17005", "Population Group"], ["C85492", "CDISC SDTM Method Terminology"], ["C52874", "SPI1 wt Allele"], ["C70962", "Agent Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C16727", "India"], ["C12664", "Abdomen"], ["C32446", "Deltoid"], ["C43508", "Oregon"], ["C33763", "Thigh"], ["C122632", "Injection Dosing Unit"], ["C37901", "Site"], ["C16329", "Belgium"], ["C25282", "Within"], ["C172515", "S-Adenosylmethionine Measurement"], ["C41129", "Region"], ["C12664", "Abdomen"], ["C32446", "Deltoid"], ["C43508", "Oregon"], ["C33763", "Thigh"], ["C25516", "From"], ["C66832", "One"], ["C122632", "Injection Dosing Unit"], ["C159124", "GDC Treatment Outcome Terminology"], ["C82511", "Subsequent Trial Activity"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C97093", "Lipodystrophy"], ["C16289", "Andorra"], ["C13316", "Cutaneous"], ["C2868", "Amyloidosis"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C110990", "All of the Time"], ["C25340", "Use"], ["C76246", "Blood Group A"], ["C94522", "New Lesion Identification"], ["C63846", "Needle Shape"], ["C17095", "Reunion"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C2271", "Insulin"], ["C157049", "Pen Device"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C61286", "Block"], ["C106184", "May"], ["C16390", "Etiology"], ["C43508", "Oregon"], ["C16727", "India"], ["C74589", "Protocol Event"], ["C52874", "SPI1 wt Allele"], ["C61286", "Block"], ["C16960", "Patient"], ["C64950", "Follow"], ["C42688", "Instruction"], ["C16727", "India"], ["C42688", "Instruction"], ["C64956", "For"], ["C25340", "Use"], ["C79887", "Package"], ["C97006", "Leaflet"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C172979", "Fear Score 6"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C25516", "From"], ["C48481", "Cartridge Dosing Unit"], ["C52874", "SPI1 wt Allele"], ["C97717", "Pre-filled Pen Syringe"], ["C25544", "Into"], ["C76246", "Blood Group A"], ["C50207", "Syringe Device"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16289", "Andorra"], ["C62230", "Potential"], ["C50873", "Overdose"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"]], "rxnorm.posology": [["274783", "insulin glargine"], ["1440051", "lixisenatide"], ["274783", "insulin glargine"], ["1440051", "lixisenatide"], ["1440051", "lixisenatide"], ["274783", "insulin glargine"], ["4832", "glucagon"], ["T192", "Receptor"], ["4850", "glucose"], ["6809", "metformin"], ["1440051", "lixisenatide"], ["T192", "Receptor"], ["274783", "insulin glargine"], ["274783", "insulin glargine"], ["274783", "insulin glargine"], ["1440051", "lixisenatide"], ["274783", "insulin glargine"], ["274783", "insulin glargine"], ["274783", "insulin glargine"], ["274783", "insulin glargine"], ["1440051", "lixisenatide"], ["1649574", "Injection"], ["4850", "glucose"], ["4850", "glucose"], ["4850", "glucose"], ["4850", "glucose"], ["6260", "lead"], ["1440051", "lixisenatide"], ["1440051", "lixisenatide"], ["1440051", "lixisenatide"], ["4850", "glucose"], ["1440051", "lixisenatide"], ["4850", "glucose"], ["1649574", "Injection"], ["1649574", "Injection"], ["T051", "Event"], ["1649572", "Cartridge"]], "loinc.posology": [["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA6404-3", "Two"], ["LP32605-5", "pre"], ["LA15457-7", "I"], ["LA13503-0", "E"], ["LA13942-0", "10"], ["LA28858-1", "40"], ["LA28855-7", "30"], ["LA28853-2", "60"], ["LP200075-2", "IS"], ["MTHU065481", "Dose"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LA30923-9", "+"], ["LA28854-0", "50"], ["LP32605-5", "pre"], ["MTHU065481", "Dose"], ["LA13942-0", "10"], ["LA28858-1", "40"], ["LP32708-7", "Units"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP20593-7", "5"], ["LA19282-5", "20"], ["LA13942-0", "10"], ["LA28858-1", "40"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LA30923-9", "+"], ["LA19316-1", "33"], ["LP32605-5", "pre"], ["MTHU065481", "Dose"], ["LA28855-7", "30"], ["LA28853-2", "60"], ["LP32708-7", "Units"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LA13942-0", "10"], ["LA19282-5", "20"], ["LA28855-7", "30"], ["LA28853-2", "60"], ["MTHU038481", "Medication"], ["LA9960-1", "Correct"], ["MTHU001445", "Strength"], ["LP18011-4", "Number"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP6530-2", "Stated"], ["LA22004-8", "IN"], ["MTHU038389", "Prescription"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["MTHU065481", "Dose"], ["LP7787-7", "Clinical"], ["LP200075-2", "IS"], ["LP66710-2", "Patient"], ["LP15241-0", "S"], ["LP32542-0", "insulin"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA24377-6", "Increased"], ["LA22025-3", "OR"], ["LA24378-4", "Decreased"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["MTHU065481", "Dose"], ["LP267221-2", "Therapy"], ["LP32542-0", "insulin"], ["LA22025-3", "OR"], ["LP14667-7", "Glucagon"], ["LA6112-2", "1"], ["LA6112-2", "1"], ["T192", "Receptor"], ["LA22025-3", "OR"], ["LA9367-9", "Oral"], ["MTHU001675", "Glucose"], ["MTHU029809", "Other"], ["MTHU060554", "metFORMIN"], ["MTHU000002", "Clinical Class"], ["LA33028-4", "Prior"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA26134-9", "Diabetic"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LA21291-2", "Not"], ["MTHU065481", "Dose"], ["LA13942-0", "10"], ["LP267221-2", "Therapy"], ["LP32542-0", "insulin"], ["LA9367-9", "Oral"], ["LA26134-9", "Diabetic"], ["LP94823-9", "Treatment"], ["LA22025-3", "OR"], ["LA6112-2", "1"], ["T192", "Receptor"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LP6901-5", "*"], ["LA19282-5", "20"], ["LA28855-7", "30"], ["LP32708-7", "Units"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LP6901-5", "*"], ["LA28855-7", "30"], ["LA28853-2", "60"], ["LP32708-7", "Units"], ["MTHU065481", "Dose"], ["LA13942-0", "10"], ["LA28858-1", "40"], ["LA13942-0", "10"], ["MTHU065481", "Dose"], ["LA13942-0", "10"], ["LP32708-7", "Units"], ["LP20593-7", "5"], ["LP6901-5", "*"], ["LA19282-5", "20"], ["MTHU065481", "Dose"], ["LA19282-5", "20"], ["LP32708-7", "Units"], ["LA13942-0", "10"], ["LP6901-5", "*"], ["LA28855-7", "30"], ["LA28853-2", "60"], ["LA28855-7", "30"], ["MTHU065481", "Dose"], ["LA28855-7", "30"], ["LP32708-7", "Units"], ["LA13942-0", "10"], ["LP6901-5", "*"], ["LP6901-5", "*"], ["LP32708-7", "Units"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LA16823-9", "Less"], ["LA19282-5", "20"], ["LP32708-7", "Units"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA14161-6", "May"], ["LP32542-0", "insulin"], ["LP6901-5", "*"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["LP32542-0", "insulin"], ["LA14664-9", "Twice"], ["LA14435-4", "Daily"], ["LP32542-0", "insulin"], ["LA22025-3", "OR"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LP32708-7", "Units"], ["LA6661-8", "Total"], ["LA14435-4", "Daily"], ["MTHU065481", "Dose"], ["LA32619-1", "Reduced"], ["LA15245-6", "20%"], ["MTHU065481", "Dose"], ["MTHU029809", "Other"], ["LP32542-0", "insulin"], ["LA11009-0", "Same"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA19244-5", "100"], ["LP32708-7", "Units"], ["LP6972-6", "maximum"], ["LA14435-4", "Daily"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA28853-2", "60"], ["LP32708-7", "Units"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA19282-5", "20"], ["LA28853-2", "60"], ["MTHU065481", "Dose"], ["LA13897-6", "Once a day"], ["LA6306-0", "One"], ["LA33028-4", "Prior"], ["LP17763-1", "A"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA14542-7", "Injection"], ["LP200075-2", "IS"], ["LA19974-7", "Performed"], ["LA11009-0", "Same"], ["LA14799-3", "Every day"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA12070-1", "Individual"], ["LP66710-2", "Patient"], ["LP15241-0", "S"], ["LP32542-0", "insulin"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LP7741-4", "Control"], ["MTHU065481", "Dose"], ["LA11831-7", "Fasting"], ["LP7479-1", "Plasma"], ["MTHU001675", "Glucose"], ["LP20593-7", "5"], ["LA6112-2", "1"], ["LA16797-5", "Close"], ["MTHU001675", "Glucose"], ["LA20297-0", "Monitoring"], ["LP200075-2", "IS"], ["LP97172-8", "Transfer"], ["LA22004-8", "IN"], ["LA9000-6", "Weeks"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP66710-2", "Patient"], ["LA13942-0", "10"], ["LA28858-1", "40"], ["MTHU065481", "Dose"], ["LA14161-6", "May"], ["LA28858-1", "40"], ["MTHU065481", "Dose"], ["LA28858-1", "40"], ["MTHU065481", "Dose"], ["LP121628-4", "Day"], ["LA28855-7", "30"], ["LA28853-2", "60"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP66710-2", "Patient"], ["LA28855-7", "30"], ["LA28853-2", "60"], ["MTHU065481", "Dose"], ["LA14161-6", "May"], ["LA28853-2", "60"], ["MTHU065481", "Dose"], ["LA6661-8", "Total"], ["LA14435-4", "Daily"], ["LA28853-2", "60"], ["MTHU065481", "Dose"], ["LP121628-4", "Day"], ["LA21291-2", "Not"], ["MTHU051337", "Amount"], ["LA22025-3", "OR"], ["LP74359-8", "Timing"], ["LA20037-0", "DO"], ["MTHU001675", "Glucose"], ["LA20297-0", "Monitoring"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["MTHU065481", "Dose"], ["LP6323-2", "Immunofluorescence (IF)"], ["LP17763-1", "A"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP200077-8", "IT"], ["LA33028-4", "Prior"], ["LP62263-6", "Population"], ["LA22004-8", "IN"], ["MTHU065481", "Dose"], ["LP20174-6", "adjusted"], ["LA12070-1", "Individual"], ["MTHU001675", "Glucose"], ["LA20297-0", "Monitoring"], ["LA22004-8", "IN"], ["LA25478-1", "Progressive"], ["LP31398-8", "Renal function"], ["LA14161-6", "May"], ["LP14259-3", "Lead"], ["LP17763-1", "A"], ["LA32049-1", "Decrease"], ["LA22004-8", "IN"], ["LP32542-0", "insulin"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["MTHU010047", "Age"], ["LP263807-2", "Therapeutic"], ["LA22004-8", "IN"], ["MTHU010047", "Age"], ["LP200075-2", "IS"], ["LA6484-5", "Limited"], ["MTHU065909", "Renal"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["MTHU065909", "Renal"], ["LP128701-2", "End-stage renal disease"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LA28126-3", "Sufficient"], ["LP263807-2", "Therapeutic"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA6752-5", "Mild"], ["LA22025-3", "OR"], ["LA6751-7", "Moderate"], ["MTHU065909", "Renal"], ["LA22004-8", "IN"], ["MTHU065909", "Renal"], ["LP32542-0", "insulin"], ["LA14161-6", "May"], ["LA32619-1", "Reduced"], ["LP32542-0", "insulin"], ["LA22004-8", "IN"], ["LA15008-8", "Mild to moderate"], ["MTHU065909", "Renal"], ["MTHU001675", "Glucose"], ["LA20297-0", "Monitoring"], ["MTHU065481", "Dose"], ["LA14161-6", "May"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA22004-8", "IN"], ["LP32542-0", "insulin"], ["LA14161-6", "May"], ["LA32619-1", "Reduced"], ["LP72218-8", "Capacity"], ["LA32619-1", "Reduced"], ["LP32542-0", "insulin"], ["MTHU001675", "Glucose"], ["LA20297-0", "Monitoring"], ["MTHU065481", "Dose"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LP62263-6", "Population"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LA22004-8", "IN"], ["LP62263-6", "Population"], ["LP72939-9", "Method"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LP6990-8", "Abdomen"], ["LA22025-3", "OR"], ["MTHU002690", "Thigh"], ["LA14542-7", "Injection"], ["LA11009-0", "Same"], ["LP73261-7", "Region"], ["LP6990-8", "Abdomen"], ["LA22025-3", "OR"], ["MTHU002690", "Thigh"], ["LA6306-0", "One"], ["LA14542-7", "Injection"], ["LA22004-8", "IN"], ["LP209029-0", "Amyloidosis"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA9933-8", "Always"], ["LP17763-1", "A"], ["LA9039-4", "New"], ["LP208081-2", "Needle"], ["LP32542-0", "insulin"], ["LA14961-9", "Increases"], ["LA14161-6", "May"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["MTHU019184", "Event"], ["LP6820-7", "Instructions"], ["LA22004-8", "IN"], ["LP6820-7", "Instructions"], ["LP20594-5", "6"], ["LP20594-5", "6"], ["LA21291-2", "Not"], ["LP32605-5", "pre"], ["LP17763-1", "A"], ["LP188733-2", "Syringe"], ["LA20277-2", "Overdose"], ["LP20592-9", "4"], ["LP20592-9", "4"]], "snomed.contraindications": [["257550005", "Hypersensitivity (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["55561003", "Active (qualifier value)"], ["105590001", "Substance (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"]], "ncit.contraindications": [["C3114", "Hypersensitivity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C154405", "Active State"], ["C43508", "Oregon"], ["C159124", "GDC Treatment Outcome Terminology"], ["C81168", "Any"], ["C52874", "SPI1 wt Allele"], ["C16727", "India"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C105723", "ECOG Performance Status 1"]], "rxnorm.contraindications": [], "loinc.contraindications": [["LA16666-2", "Active"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LP20594-5", "6"], ["LA6112-2", "1"]], "snomed.special_warnings": [["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["12893009", "Biologic (qualifier value)"], ["734841007", "Name (property) (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["410681005", "Count of entities (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["46635009", "Diabetes mellitus type 1 (disorder)"], ["18720000", "In (attribute)"], ["35362001", "With type (attribute)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["267467004", "Diabetes mellitus (& [ketoacidosis]) (disorder)|Diabetes mellitus (& [ketoacidosis])"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["56051008", "Ketoacidosis (disorder)"], ["257912008", "Rotation - action (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["13136005", "Injection site (morphologic abnormality)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["255238004", "Continuous (qualifier value)"], ["257912008", "Rotation - action (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["13136005", "Injection site (morphologic abnormality)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["190789006", "(Lipodystrophy) or (Barraquer - Simons disease)|(Lipodystrophy) or (Barraquer - Simons disease) (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["282834007", "Cutaneous amyloidosis (disorder)"], ["116680003", "Is a (attribute)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["67866001", "Insulin (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["231877006", "Worse (qualifier value)"], ["246106000", "Control (attribute)"], ["255260001", "Following (attribute)"], ["67866001", "Insulin (substance)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255363002", "Sudden (qualifier value)"], ["263703002", "Changed status (qualifier value)"], ["13136005", "Injection site (morphologic abnormality)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["42798000", "Area (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["302866003", "Hypoglycemia (disorder)"], ["698472009", "Blood glucose monitoring (regime/therapy)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["255234002", "After (attribute)"], ["161712005", "Menopause (qualifier value)|Menopause, function (observable entity)"], ["18720000", "In (attribute)"], ["13136005", "Injection site (morphologic abnormality)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["763158003", "Medicinal product (product)"], ["302866003", "Hypoglycemia (disorder)"], ["302866003", "Hypoglycemia (disorder)"], ["4757001", "Most (qualifier value)"], ["70232002", "Frequent (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["281647001", "Adverse reaction (disorder)|Adverse reactions (disorder)|Adverse reactions (finding)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["732732008", "4.8 (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["260369004", "Increasing (qualifier value)"], ["118588007", "Susceptibility (property) (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["263703002", "Changed status (qualifier value)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["42798000", "Area (qualifier value)"], ["385425000", "Improved (qualifier value)"], ["67866001", "Insulin (substance)"], ["35209006", "Sensitivity (finding)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["315350008", "Removal - procedure|Removal - procedure (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["262188008", "Stress (qualifier value)"], ["35105006", "Increased (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255224006", "Prolonged (qualifier value)"], ["390736008", "Physical activity (qualifier value)"], ["39104002", "Illness (finding)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["422400008", "Vomiting (disorder)"], ["162105005", "Diarrhoea (disorder)|Diarrhoea"], ["445136002", "Inadequate food intake (finding)"], ["769557005", "With meals (qualifier value)"], ["160573003", "Alcohol intake (observable entity)"], ["17162000", "Certain (qualifier value)"], ["63346003", "Uncompensated (qualifier value)"], ["267462005", "Endocr/nutrit/metabol disease &/or endocrine disorders &/or hormone disorders|Endocr/nutrit/metabol disease &/or endocrine disorders &/or hormone disorders (disorder)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["18720000", "In (attribute)"], ["267465007", "Hypothyroidism - congenital and acquired (& [cretinism] or [myxoedema])|Hypothyroidism - congenital and acquired (& [cretinism] or [myxoedema]) (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["255549009", "Anterior (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["87828008", "Insufficiency (finding)"], ["79970003", "Simultaneous (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["17162000", "Certain (qualifier value)"], ["74964007", "Other (qualifier value)"], ["732729005", "4.5 (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["67866001", "Insulin (substance)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["372711004", "Sulfonylurea (substance)"], ["394617004", "Result (navigational concept)"], ["18720000", "In (attribute)"], ["35105006", "Increased (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["372711004", "Sulfonylurea (substance)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420862001", "On (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420862001", "On (qualifier value)"], ["116154003", "Patient (person)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["103325001", "Patient need for (contextual qualifier) (qualifier value)"], ["67866001", "Insulin (substance)"], ["732724000", "4.2 (qualifier value)"], ["197456007", "Acute pancreatitis (disorder)"], ["260676000", "Use of (attribute)"], ["43004008", "Glucagon-like peptide 1 (substance)"], ["116647005", "Receptor (substance)"], ["47429007", "Associated with (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["197456007", "Acute pancreatitis (disorder)"], ["57176003", "Few (qualifier value)"], ["733985002", "Reported (qualifier value)"], ["272379006", "Events (event)|Event (event)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["197456007", "Acute pancreatitis (disorder)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["263498003", "Relationship (attribute)"], ["263748003", "Established (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["197456007", "Acute pancreatitis (disorder)"], ["255222005", "Persistent (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["139313005", "Abdominal pain|Abdominal pain (finding)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["393591004", "Pancreatitis|Pancreatitis (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["415684004", "Suspected (qualifier value)"], ["410546004", "Discontinued (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["53737009", "Acute (qualifier value)"], ["393591004", "Pancreatitis|Pancreatitis (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["85921000119107", "History of pancreatitis (situation)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["64572001", "Disease (disorder)"], ["260676000", "Use of (attribute)"], ["43004008", "Glucagon-like peptide 1 (substance)"], ["116647005", "Receptor (substance)"], ["47429007", "Associated with (attribute)"], ["281647001", "Adverse reaction (disorder)|Adverse reactions (disorder)|Adverse reactions (finding)"], ["732732008", "4.8 (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["64572001", "Disease (disorder)"], ["55919000", "Including (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["235675006", "Gastroparesis (disorder)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["18720000", "In (attribute)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["236423003", "Renal impairment (disorder)"], ["270011004", "Creatinine clearance (& level (& glom filt))|Creatinine clearance (& level (& glom filt)) (procedure)"], ["1222810000", "American Joint Committee on Cancer stage III:0 (qualifier value)"], ["258859000", "Milliliter/minute (qualifier value)|mL/min (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["46177005", "End-stage renal disease (disorder)|End stage renal disease (disorder)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["18720000", "In (attribute)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["24484000", "Severe (severity modifier) (qualifier value)"], ["40226000", "Impairment (finding)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["46177005", "End-stage renal disease (disorder)|End stage renal disease (disorder)"], ["732724000", "4.2 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732766004", "5.2 (qualifier value)"], ["79970003", "Simultaneous (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["40117008", "Gastric emptying (function)|Gastric emptying, function (observable entity)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["26643006", "Oral route (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["738956005", "Oral (intended site)"], ["255358001", "Rapid (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["134223000", "Narrow (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["118586006", "Ratio (property) (qualifier value)"], ["69658003", "Specific (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["732729005", "4.5 (qualifier value)"], ["154759001", "Dehydration (disorder)|Dehydration"], ["28995006", "Treated with (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["123104003", "High risk of -RETIRED-|High risk of (qualifier value)"], ["154759001", "Dehydration (disorder)|Dehydration"], ["18720000", "In (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["281647001", "Adverse reaction (disorder)|Adverse reactions (disorder)|Adverse reactions (finding)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["419652001", "Take (qualifier value)|Take - dosing instruction imperative (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["28560003", "Hypovolemia (disorder)"], ["68498002", "Antibody (substance)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["65897001", "Against (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["18720000", "In (attribute)"], ["89292003", "Rare (qualifier value)"], ["413769002", "Case unit dose (qualifier value)|Case - unit of product usage (qualifier value)"], ["52101004", "Present (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["86495002", "For (qualifier value)"], ["270004003", "(Blood sugar result [& glucose]) or (plasma glucose level) or (hyperglycaemia)|(Blood sugar result [& glucose]) or (plasma glucose level) or (hyperglycaemia) (procedure)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["2533004", "Drug (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["419473009", "Each (qualifier value)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["53348004", "Accidental (qualifier value)"], ["764462006", "Mix (transformation)"], ["11896004", "Intermediate (qualifier value)"], ["19338005", "2 (qualifier value)|Two (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["764462006", "Mix (transformation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1149222004", "Overdose (disorder)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["763158003", "Medicinal product (product)"], ["732988008", "Cartridge (unit of presentation)"], ["18720000", "In (attribute)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["30507006", "Into (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["733020007", "Syringe (unit of presentation)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["89780004", "Combined (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["130202003", "Peptide hydrolase (substance)|Substance with peptide hydrolase mechanism of action (substance)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["1222837003", "American Joint Committee on Cancer stage IV (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["395828009", "Pioglitazone (substance)"], ["420008001", "Travel (event)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["243326001", "Changing (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["116154003", "Patient (person)"], ["158965000", "Medical practitioner (occupation)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["243073001", "Advice (regime/therapy)|Advice (regime/therapy)(procedure)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["129018004", "Traveling (observable entity)|Traveling (function)|Traveling, function (observable entity)"], ["763158003", "Medicinal product (product)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258718000", "mmol (qualifier value)|millimole (qualifier value)"], ["39972003", "Sodium (substance)"], ["1222776006", "American Joint Committee on Cancer stage II:3 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420806001", "Per - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["39972003", "Sodium (substance)"], ["763158003", "Medicinal product (product)"]], "ncit.special_warnings": [["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C52874", "SPI1 wt Allele"], ["C28226", "Biological"], ["C42614", "Name"], ["C16289", "Andorra"], ["C104504", "Batch Number"], ["C52874", "SPI1 wt Allele"], ["C25382", "Administered"], ["C40352", "Multiplicative Product"], ["C16329", "Belgium"], ["C2986", "Type 1 Diabetes Mellitus"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C2986", "Type 1 Diabetes Mellitus"], ["C43508", "Oregon"], ["C64956", "For"], ["C43442", "Biomaterial Treatment"], ["C52874", "SPI1 wt Allele"], ["C48439", "Revolution"], ["C52874", "SPI1 wt Allele"], ["C77680", "Injection Site"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C38000", "Performed"], ["C167446", "Continuous Heart Murmur"], ["C48439", "Revolution"], ["C52874", "SPI1 wt Allele"], ["C77680", "Injection Site"], ["C159124", "GDC Treatment Outcome Terminology"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C97093", "Lipodystrophy"], ["C16289", "Andorra"], ["C13316", "Cutaneous"], ["C2868", "Amyloidosis"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C62230", "Potential"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C168181", "Delayed Capillary Refill Time"], ["C2271", "Insulin"], ["C71731", "Material Absorption"], ["C16289", "Andorra"], ["C125461", "Got Worse"], ["C64355", "Scientific Control"], ["C53286", "Next"], ["C2271", "Insulin"], ["C158997", "GDC Analyte Type Terminology"], ["C37901", "Site"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C113683", "Abrupt"], ["C54126", "Delta"], ["C16727", "India"], ["C77680", "Injection Site"], ["C159124", "GDC Treatment Outcome Terminology"], ["C75889", "PAX6 wt Allele"], ["C94232", "Unaffected"], ["C25244", "Area"], ["C101282", "Have"], ["C188308", "Reported Information"], ["C159124", "GDC Treatment Outcome Terminology"], ["C20200", "Outcome"], ["C16727", "India"], ["C92744", "Blood Glucose Measurement"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C38008", "Post"], ["C54126", "Delta"], ["C16727", "India"], ["C77680", "Injection Site"], ["C16289", "Andorra"], ["C82495", "Dose Adjustment"], ["C52874", "SPI1 wt Allele"], ["C142605", "Medicinal Product"], ["C106184", "May"], ["C16329", "Belgium"], ["C154196", "Washo Language"], ["C25258", "Most"], ["C64649", "Frequently"], ["C188308", "Reported Information"], ["C25599", "Observed"], ["C41332", "Adverse Reaction"], ["C175242", "During Treatment"], ["C62355", "With"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C106184", "May"], ["C127786", "Occurrence Indicator"], ["C198613", "CFI wt Allele"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25227", "High"], ["C25652", "Requirement"], ["C16505", "Susceptibility"], ["C159124", "GDC Treatment Outcome Terminology"], ["C49070", "Closed"], ["C61256", "Monitoring"], ["C16289", "Andorra"], ["C106184", "May"], ["C82495", "Dose Adjustment"], ["C74521", "Include"], ["C54126", "Delta"], ["C16727", "India"], ["C122632", "Injection Dosing Unit"], ["C25244", "Area"], ["C125459", "Improved"], ["C123459", "Insulin Sensitivity Measurement"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C158169", "Buyei Chinese"], ["C61575", "Extraction"], ["C52874", "SPI1 wt Allele"], ["C35041", "Stress"], ["C164135", "Increased"], ["C43508", "Oregon"], ["C149870", "Prolonged Release Mechanism of Action"], ["C17708", "Physical Activity"], ["C16457", "Comorbidity"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C125278", "How Often Vomiting"], ["C168268", "Inadequate Daily Salt Intake"], ["C62695", "Food"], ["C25538", "Intake"], ["C54031", "Missing"], ["C16273", "Alcohol Consumption"], ["C107561", "Certain"], ["C36285", "Endocrine System Finding"], ["C2991", "Disease or Disorder"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C16727", "India"], ["C143576", "Hypothyroidism, CTCAE"], ["C16289", "Andorra"], ["C16727", "India"], ["C25231", "Anterior"], ["C23334", "Murine Pituitary Gland"], ["C43508", "Oregon"], ["C26691", "Adrenocortical Insufficiency"], ["C25730", "Concomitant"], ["C43442", "Biomaterial Treatment"], ["C62355", "With"], ["C107561", "Certain"], ["C118472", "Other License Status"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C166988", "Lixisenatide"], ["C48928", "And/Or"], ["C2271", "Insulin"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C97936", "Sulfonylurea Antidiabetic Agent"], ["C106184", "May"], ["C20200", "Outcome"], ["C16727", "India"], ["C75889", "PAX6 wt Allele"], ["C164135", "Increased"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C64974", "Give"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C97936", "Sulfonylurea Antidiabetic Agent"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C16329", "Belgium"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C123619", "Clinical Response"], ["C16289", "Andorra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C53691", "Veterinary Patient"], ["C42555", "Siemens"], ["C41204", "Need"], ["C64956", "For"], ["C2271", "Insulin"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C95437", "Acute Pancreatitis"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C191844", "Glucagon-Like Peptide 1 Receptor"], ["C101282", "Have"], ["C25281", "Associated"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C95437", "Acute Pancreatitis"], ["C101282", "Have"], ["C64942", "Few"], ["C188308", "Reported Information"], ["C150901", "Event Unit"], ["C52874", "SPI1 wt Allele"], ["C95437", "Acute Pancreatitis"], ["C62355", "With"], ["C166988", "Lixisenatide"], ["C76246", "Blood Group A"], ["C103376", "CDISC Relationship Class"], ["C101282", "Have"], ["C25594", "Negation"], ["C71155", "Established"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C37896", "Informed"], ["C52874", "SPI1 wt Allele"], ["C25447", "Characteristic"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C95437", "Acute Pancreatitis"], ["C43623", "Persistent"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C143255", "Abdominal Pain, CTCAE"], ["C198613", "CFI wt Allele"], ["C56602", "Pancreatitis, CTCAE 3.0"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C71458", "Suspected"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C198613", "CFI wt Allele"], ["C14140", "Acute"], ["C56602", "Pancreatitis, CTCAE 3.0"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25458", "Confirmation"], ["C166988", "Lixisenatide"], ["C25594", "Negation"], ["C16329", "Belgium"], ["C16329", "Belgium"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C18772", "Personal Medical History"], ["C52874", "SPI1 wt Allele"], ["C56602", "Pancreatitis, CTCAE 3.0"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C53802", "Adverse Event Associated with the Gastrointestinal System"], ["C2991", "Disease or Disorder"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C191844", "Glucagon-Like Peptide 1 Receptor"], ["C106184", "May"], ["C16329", "Belgium"], ["C25281", "Associated"], ["C62355", "With"], ["C53802", "Adverse Event Associated with the Gastrointestinal System"], ["C188368", "ELN Adverse-Risk Category"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C66839", "Eight"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C53802", "Adverse Event Associated with the Gastrointestinal System"], ["C2991", "Disease or Disorder"], ["C166400", "Inclusive"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C143512", "Gastroparesis, CTCAE"], ["C16289", "Andorra"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C16727", "India"], ["C16960", "Patient"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C114592", "Renal Impairment"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25277", "Therapeutic"], ["C54627", "Experience"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C114592", "Renal Impairment"], ["C25747", "Creatinine Clearance"], ["C61422", "Lesser"], ["C70541", "Lansky Performance Status 30"], ["C64777", "Milliliter per Minute"], ["C43508", "Oregon"], ["C9439", "Chronic Kidney Disease, Stage 5"], ["C25340", "Use"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C16727", "India"], ["C16960", "Patient"], ["C62355", "With"], ["C122951", "Borg Category-Ratio 10 Perceived Exertion Score 5"], ["C25225", "Renal"], ["C21055", "Impairment"], ["C43508", "Oregon"], ["C9439", "Chronic Kidney Disease, Stage 5"], ["C163702", "Staphylococcal Enterotoxin E"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16289", "Andorra"], ["C163771", "Illness Intrusiveness Rating 5"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C25730", "Concomitant"], ["C25476", "Delay"], ["C52874", "SPI1 wt Allele"], ["C12391", "Stomach"], ["C62355", "With"], ["C166988", "Lixisenatide"], ["C106184", "May"], ["C77538", "Rating"], ["C52874", "SPI1 wt Allele"], ["C71731", "Material Absorption"], ["C52874", "SPI1 wt Allele"], ["C25311", "Oral"], ["C25382", "Administered"], ["C16329", "Belgium"], ["C62355", "With"], ["C16727", "India"], ["C16960", "Patient"], ["C25639", "Receive"], ["C25311", "Oral"], ["C65069", "Rapidly"], ["C53802", "Adverse Event Associated with the Gastrointestinal System"], ["C71731", "Material Absorption"], ["C123619", "Clinical Response"], ["C61256", "Monitoring"], ["C43508", "Oregon"], ["C101282", "Have"], ["C76246", "Blood Group A"], ["C124564", "Narrow"], ["C18223", "Therapeutic Index"], ["C38024", "Specified"], ["C25538", "Intake"], ["C52874", "SPI1 wt Allele"], ["C68869", "Are"], ["C64974", "Give"], ["C16727", "India"], ["C68872", "Square Mile"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C163771", "Illness Intrusiveness Rating 5"], ["C57787", "Dehydration, CTCAE"], ["C16960", "Patient"], ["C25705", "Treating"], ["C62355", "With"], ["C16329", "Belgium"], ["C52874", "SPI1 wt Allele"], ["C62230", "Potential"], ["C17102", "Risk"], ["C52874", "SPI1 wt Allele"], ["C57787", "Dehydration, CTCAE"], ["C16727", "India"], ["C21480", "Relative"], ["C159124", "GDC Treatment Outcome Terminology"], ["C53802", "Adverse Event Associated with the Gastrointestinal System"], ["C188368", "ELN Adverse-Risk Category"], ["C16289", "Andorra"], ["C65105", "Take"], ["C60827", "Precaution"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25278", "Fluid"], ["C16295", "Antibody"], ["C25513", "Formation"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C106184", "May"], ["C16390", "Etiology"], ["C25513", "Formation"], ["C52874", "SPI1 wt Allele"], ["C16295", "Antibody"], ["C64937", "Against"], ["C47564", "Insulin Glargine"], ["C48928", "And/Or"], ["C166988", "Lixisenatide"], ["C16727", "India"], ["C13634", "Retinoic Acid Response Element"], ["C25626", "Present"], ["C52874", "SPI1 wt Allele"], ["C16295", "Antibody"], ["C106184", "May"], ["C49157", "Adjustment"], ["C52874", "SPI1 wt Allele"], ["C25488", "Dose"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C68815", "Correct"], ["C76246", "Blood Group A"], ["C64956", "For"], ["C43508", "Oregon"], ["C54264", "Avoidance"], ["C52874", "SPI1 wt Allele"], ["C459", "Medication"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C110990", "All of the Time"], ["C86058", "Check"], ["C157049", "Pen Device"], ["C41203", "Medical Product Label"], ["C201357", "Before Timing Type"], ["C64933", "Each"], ["C122632", "Injection Dosing Unit"], ["C159124", "GDC Treatment Outcome Terminology"], ["C34340", "Accident"], ["C64925", "Mix"], ["C187066", "United Parcel Service"], ["C94545", "Between"], ["C66833", "Two"], ["C46003", "Difference"], ["C52874", "SPI1 wt Allele"], ["C16289", "Andorra"], ["C64925", "Mix"], ["C187066", "United Parcel Service"], ["C62355", "With"], ["C118472", "Other License Status"], ["C28160", "Injection Route of Administration"], ["C2985", "Diabetes Mellitus"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16289", "Andorra"], ["C62230", "Potential"], ["C50873", "Overdose"], ["C126390", "Neither"], ["C16960", "Patient"], ["C154059", "Norwegian Language"], ["C16205", "Healthcare Activity"], ["C113445", "Ever"], ["C25340", "Use"], ["C76246", "Blood Group A"], ["C50207", "Syringe Device"], ["C159124", "GDC Treatment Outcome Terminology"], ["C54353", "Draw"], ["C142605", "Medicinal Product"], ["C25516", "From"], ["C48481", "Cartridge Dosing Unit"], ["C16727", "India"], ["C97717", "Pre-filled Pen Syringe"], ["C25544", "Into"], ["C76246", "Blood Group A"], ["C50207", "Syringe Device"], ["C25594", "Negation"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C101282", "Have"], ["C25594", "Negation"], ["C16727", "India"], ["C61517", "Combination"], ["C62355", "With"], ["C177992", "Dipeptidyl Peptidase-4 Measurement"], ["C200899", "DSPP wt Allele"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C16289", "Andorra"], ["C71633", "Pioglitazone"], ["C53462", "Travel"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16289", "Andorra"], ["C62230", "Potential"], ["C62355", "With"], ["C159124", "GDC Treatment Outcome Terminology"], ["C46003", "Difference"], ["C25330", "Duration"], ["C53691", "Veterinary Patient"], ["C69164", "Doctor"], ["C42555", "Siemens"], ["C201357", "Before Timing Type"], ["C142605", "Medicinal Product"], ["C79873", "Contain"], ["C61585", "Less Than"], ["C105723", "ECOG Performance Status 1"], ["C48513", "Millimole"], ["C830", "Sodium"], ["C126885", "Twenty Three"], ["C16818", "Mammography"], ["C97722", "PER1 wt Allele"], ["C25488", "Dose"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C830", "Sodium"], ["C63628", "Empty"], ["C142605", "Medicinal Product"], ["C79873", "Contain"], ["C80603", "Metacresol"], ["C106184", "May"], ["C16390", "Etiology"], ["C37910", "Allergic"]], "rxnorm.special_warnings": [["1649574", "Injection"], ["1043225", "Perform"], ["1649574", "Injection"], ["1649574", "Injection"], ["4850", "glucose"], ["1649574", "Injection"], ["1649574", "Injection"], ["T052", "Activity"], ["T168", "Food"], ["1440051", "lixisenatide"], ["T192", "Receptor"], ["1440051", "lixisenatide"], ["1440051", "lixisenatide"], ["T192", "Receptor"], ["2913", "creatinine"], ["1440051", "lixisenatide"], ["274783", "insulin glargine"], ["1440051", "lixisenatide"], ["1649574", "Injection"], ["1649572", "Cartridge"], ["33738", "pioglitazone"], ["9853", "sodium"], ["9853", "sodium"], ["1367170", "metacresol"]], "loinc.special_warnings": [["LA22004-8", "IN"], ["LA25433-6", "Biological"], ["MTHU008539", "Name"], ["LP18011-4", "Number"], ["LP6886-8", "Type"], ["LA6112-2", "1"], ["LP74722-7", "Diabetes mellitus"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP6886-8", "Type"], ["LA6112-2", "1"], ["LP74722-7", "Diabetes mellitus"], ["LA22025-3", "OR"], ["LP94823-9", "Treatment"], ["LA26134-9", "Diabetic"], ["LA14542-7", "Injection"], ["LP73352-4", "Site"], ["LA16902-1", "Continuous"], ["LA14542-7", "Injection"], ["LP73352-4", "Site"], ["LP209029-0", "Amyloidosis"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LP266901-0", "Delayed"], ["LP32542-0", "insulin"], ["LA32282-8", "Worsened"], ["LP7741-4", "Control"], ["LP32542-0", "insulin"], ["LA21988-3", "AT"], ["LP17763-1", "A"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["LA14542-7", "Injection"], ["LP73352-4", "Site"], ["LP6782-9", "Area"], ["LP6486-7", "Reported"], ["LA22004-8", "IN"], ["MTHU029981", "Blood"], ["MTHU001675", "Glucose"], ["LA20297-0", "Monitoring"], ["LP200075-2", "IS"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["LA14542-7", "Injection"], ["LP73352-4", "Site"], ["MTHU065481", "Dose"], ["LA14161-6", "May"], ["LA6482-9", "Frequently"], ["LP6486-7", "Reported"], ["LP6425-5", "Observed"], ["LP73228-6", "Reaction"], ["LP93408-0", "during treatment"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA14161-6", "May"], ["LP6323-2", "Immunofluorescence (IF)"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP19419-8", "Susceptibility"], ["LA16797-5", "Close"], ["LA20297-0", "Monitoring"], ["LA14161-6", "May"], ["MTHU065481", "Dose"], ["LP249806-3", "Change"], ["LA22004-8", "IN"], ["LA14542-7", "Injection"], ["LP6782-9", "Area"], ["LA65-8", "Improved"], ["LP32542-0", "insulin"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP263431-1", "Removal"], ["LP207491-4", "Stress"], ["LA24377-6", "Increased"], ["LA22025-3", "OR"], ["MTHU017278", "Physical activity"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LA15099-7", "Vomiting"], ["LA8914-9", "Inadequate"], ["MTHU065486", "Food"], ["LP202940-5", "Meals"], ["LA28139-6", "Alcohol"], ["LP56737-7", "Endocrine disorders"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LA22004-8", "IN"], ["LA14303-4", "Hypothyroidism"], ["LA22004-8", "IN"], ["LP220551-8", "anterior"], ["LP199938-4", "Pituitary"], ["LA22025-3", "OR"], ["LP94823-9", "Treatment"], ["MTHU029809", "Other"], ["LA15768-7", "4.5"], ["LA22025-3", "OR"], ["LP32542-0", "insulin"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP17763-1", "A"], ["LP18787-9", "Sulfonylurea"], ["LA14161-6", "May"], ["LA22004-8", "IN"], ["LA24544-1", "Increased risk"], ["LA21291-2", "Not"], ["LP29256-2", "given"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP17763-1", "A"], ["LP18787-9", "Sulfonylurea"], ["MTHU065481", "Dose"], ["LP7787-7", "Clinical"], ["LP200075-2", "IS"], ["LP66710-2", "Patient"], ["LP15241-0", "S"], ["LP32542-0", "insulin"], ["LP20592-9", "4"], ["MTHU000002", "Clinical Class"], ["LA18821-1", "Acute"], ["LA15860-2", "Pancreatitis"], ["LA6112-2", "1"], ["T192", "Receptor"], ["LP17763-1", "A"], ["LA18821-1", "Acute"], ["LA15860-2", "Pancreatitis"], ["LA15680-4", "Few"], ["LP6486-7", "Reported"], ["MTHU058708", "Events"], ["LA18821-1", "Acute"], ["LA15860-2", "Pancreatitis"], ["LP17763-1", "A"], ["LP262503-8", "Relationship"], ["LA21291-2", "Not"], ["LP75708-5", "Symptoms"], ["LA18821-1", "Acute"], ["LA15860-2", "Pancreatitis"], ["LA6750-9", "Severe"], ["LP74394-5", "Abdominal pain"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA15860-2", "Pancreatitis"], ["LP200075-2", "IS"], ["LA15291-0", "Suspected"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA18821-1", "Acute"], ["LA15860-2", "Pancreatitis"], ["LP200075-2", "IS"], ["LA15290-2", "Confirmed"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LP7800-8", "History"], ["LA15860-2", "Pancreatitis"], ["LA6750-9", "Severe"], ["LA10532-2", "Gastrointestinal Disease"], ["LA6112-2", "1"], ["T192", "Receptor"], ["LA14161-6", "May"], ["LA16968-2", "Gastrointestinal"], ["LP20592-9", "4"], ["LP36791-9", "8"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["LA10532-2", "Gastrointestinal Disease"], ["LA6750-9", "Severe"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["MTHU065909", "Renal"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LP263807-2", "Therapeutic"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["MTHU065909", "Renal"], ["LP29651-4", "Creatinine clearance"], ["LA16823-9", "Less"], ["LA28855-7", "30"], ["LP6970-0", "minimum"], ["LA22025-3", "OR"], ["LP128701-2", "End-stage renal disease"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA22004-8", "IN"], ["LA6750-9", "Severe"], ["MTHU065909", "Renal"], ["LA22025-3", "OR"], ["LP128701-2", "End-stage renal disease"], ["LP20592-9", "4"], ["MTHU000002", "Clinical Class"], ["LP20593-7", "5"], ["MTHU000002", "Clinical Class"], ["LA7343-2", "Delay"], ["LP266966-3", "Gastric emptying"], ["LA14161-6", "May"], ["MTHU027852", "Rate"], ["LA22004-8", "IN"], ["LA9367-9", "Oral"], ["LA24868-4", "Rapid"], ["LA16968-2", "Gastrointestinal"], ["LP7787-7", "Clinical"], ["LA20297-0", "Monitoring"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LA9191-3", "Narrow"], ["LP263807-2", "Therapeutic"], ["LP6852-0", "Ratio"], ["LP29256-2", "given"], ["LA22004-8", "IN"], ["LA15768-7", "4.5"], ["LA22004-8", "IN"], ["LA16968-2", "Gastrointestinal"], ["MTHU004941", "Fluid"], ["LA14161-6", "May"], ["LP17807-6", "Antibodies"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LA15679-6", "Rare"], ["LP270144-1", "Cases"], ["LP149220-8", "Presence"], ["LP17807-6", "Antibodies"], ["LA14161-6", "May"], ["MTHU065481", "Dose"], ["LA22004-8", "IN"], ["LA9960-1", "Correct"], ["LP17763-1", "A"], ["LA22025-3", "OR"], ["MTHU038481", "Medication"], ["LA9933-8", "Always"], ["LP251102-2", "Check"], ["LA14542-7", "Injection"], ["LA6404-3", "Two"], ["MTHU029809", "Other"], ["LP128793-9", "Diabetes"], ["LA20277-2", "Overdose"], ["LA30302-6", "Healthcare"], ["LP17763-1", "A"], ["LP188733-2", "Syringe"], ["LA22004-8", "IN"], ["LP32605-5", "pre"], ["LP17763-1", "A"], ["LP188733-2", "Syringe"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA12701-1", "Combination"], ["LP20592-9", "4"], ["LP20592-9", "4"], ["LP171629-1", "Pioglitazone"], ["LP212515-3", "Travel"], ["LP73517-2", "Time"], ["LP66710-2", "Patient"], ["LP417559-4", "Safe Environment for Every Kid"], ["LA18968-0", "Doctor"], ["LP15241-0", "S"], ["LA14523-7", "Advice"], ["LA16823-9", "Less"], ["LA6112-2", "1"], ["LP15099-2", "Sodium"], ["LP15217-0", "Mg"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP15099-2", "Sodium"], ["LA14161-6", "May"]], "snomed.pregnancy": [["373067005", "No (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["398166005", "Performed (qualifier value)"], ["351726001", "Below (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420862001", "On (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["410681005", "Count of entities (property) (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["105590001", "Substance (substance)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["47722004", "General metabolic function (function)|General metabolic function (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["105590001", "Substance (substance)"], ["87612001", "Blood (substance)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["253861007", "Effect (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["118588007", "Susceptibility (property) (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["112049007", "Dipeptidyl carboxypeptidase I (substance)"], ["372844004", "Disopyramide (substance)"], ["372767007", "Fluoxetine (substance)"], ["4824009", "Amine oxidase (flavin-containing) (substance)"], ["51478000", "Maximal gastric acid secretory capacity (observable entity)"], ["387522004", "Pentoxifylline (substance)"], ["387196000", "Propoxyphene (substance)"], ["9203006", "Salicylate (substance)|Salicylate (product)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387406002", "Ophthalmic sulfonamide preparation (substance)|Sulfonamide (substance)"], ["105590001", "Substance (substance)"], ["87612001", "Blood (substance)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["253861007", "Effect (qualifier value)"], ["79440004", "Product containing corticosteroid (product)|Product containing corticosteroid and/or corticosteroid derivative (product)|Corticoid preparation (product)|Product containing corticosteroid and corticosteroid derivative (product)|Corticoid preparation (substance)"], ["126124009", "Danazol (substance)"], ["387328001", "Diazoxide (substance)"], ["66603002", "Glucagon (substance)"], ["387472004", "Isoniazid (substance)"], ["325478009", "Estrogens (product)|Estrogens (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["372839006", "Phenothiazine (substance)"], ["395883003", "Somatropin (substance)"], ["86308005", "Sympathomimetic agent (product)|Product containing sympathomimetic (product)|Sympathomimetic agent (substance)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["387362001", "Epinephrine (substance)|Epinephrine preparation (substance)"], ["387362001", "Epinephrine (substance)|Epinephrine preparation (substance)"], ["372897005", "Salbutamol (substance)|Albuterol (substance)"], ["372745006", "Terbutaline (substance)"], ["325311005", "Thyroid hormones (substance)|Thyroid hormones (product)"], ["372648004", "Atypical antipsychotic (substance)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["387568001", "Clozapine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386849001", "Olanzapine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["736207009", "Protease (disposition)"], ["260989008", "Beta - Greek letter (qualifier value)|Greek letter beta (qualifier value)"], ["372805007", "Clonidine (substance)"], ["321719003", "Lithium (product)|Lithium product (product)|Lithium product (substance)|Product containing lithium (medicinal product)|Product containing lithium (product)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["53041004", "Substance with alcohol structure (substance)|Alcohol (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["87612001", "Blood (substance)"], ["111138002", "Glucose preparation (substance)|Product containing glucose (medicinal product)|Glucose preparation (product)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67866001", "Insulin (substance)"], ["372699006", "Pentamidine (substance)"], ["302866003", "Hypoglycemia (disorder)"], ["367409002", "Followed by (attribute)"], ["270004003", "(Blood sugar result [& glucose]) or (plasma glucose level) or (hyperglycaemia)|(Blood sugar result [& glucose]) or (plasma glucose level) or (hyperglycaemia) (procedure)"], ["18720000", "In (attribute)"], ["351726001", "Below (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["260989008", "Beta - Greek letter (qualifier value)|Greek letter beta (qualifier value)"], ["372805007", "Clonidine (substance)"], ["387456007", "Guanethidine (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387447004", "Reserpine (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["303502004", "Counter (physical object)"], ["260400001", "Reduced (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["2667000", "Absent (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["116680003", "Is a (attribute)"], ["52642002", "Peptide (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["424446007", "Cytochrome p450 enzyme (substance)"], ["18720000", "In (attribute)"], ["18720000", "In (attribute)"], ["708808004", "Lixisenatide (substance)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["257733005", "Activity (observable entity)|Activities (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["424446007", "Cytochrome p450 enzyme (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["338930006", "Human (organism)"], ["373067005", "No (qualifier value)"], ["36692007", "Known (qualifier value)"], ["86495002", "For (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["40117008", "Gastric emptying (function)|Gastric emptying, function (observable entity)"], ["420862001", "On (qualifier value)"], ["738956005", "Oral (intended site)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["40117008", "Gastric emptying (function)|Gastric emptying, function (observable entity)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["26643006", "Oral route (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["134223000", "Narrow (qualifier value)"], ["262202000", "Therapeutic intent (qualifier value)|Therapeutic - procedure intent (qualifier value)"], ["118586006", "Ratio (property) (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["18720000", "In (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["255620007", "Food (substance)|Foods (substance)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["421803000", "If - dosing instruction fragment (qualifier value)"], ["371930009", "Possible (qualifier value)"], ["419652001", "Take (qualifier value)|Take - dosing instruction imperative (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["86495002", "For (qualifier value)"], ["738956005", "Oral (intended site)"], ["371154000", "Dependent (qualifier value)"], ["420862001", "On (qualifier value)"], ["246510005", "Threshold (attribute)"], ["86495002", "For (qualifier value)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["419652001", "Take (qualifier value)|Take - dosing instruction imperative (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258702006", "hour (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["123031003", "4 hours (qualifier value)"], ["255234002", "After (attribute)"], ["708808004", "Lixisenatide (substance)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["30714006", "Resistant (qualifier value)"], ["42504009", "Containing (qualifier value)"], ["105590001", "Substance (substance)"], ["83185005", "Sensitive (qualifier value)"], ["181246003", "Entire stomach (body structure)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258702006", "hour (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["123031003", "4 hours (qualifier value)"], ["255234002", "After (attribute)"], ["708808004", "Lixisenatide (substance)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["387517004", "Paracetamol (substance)|Acetaminophen (substance)"], ["387517004", "Paracetamol (substance)|Acetaminophen (substance)"], ["420503003", "As - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["763158003", "Medicinal product (product)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["253861007", "Effect (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["420862001", "On (qualifier value)"], ["264010009", "Gastric (qualifier value)"], ["255260001", "Following (attribute)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387517004", "Paracetamol (substance)|Acetaminophen (substance)"], ["732445006", "1000 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["387517004", "Paracetamol (substance)|Acetaminophen (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["260388006", "No status change (qualifier value)"], ["246512002", "Timing (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["416118004", "Administration (procedure)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255234002", "After (attribute)"], ["708808004", "Lixisenatide (substance)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["123031003", "4 hours (qualifier value)"], ["255234002", "After (attribute)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["258685003", "ug (qualifier value)|microgram (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387517004", "Paracetamol (substance)|Acetaminophen (substance)"], ["1250004", "Decreased (qualifier value)"], ["1222782009", "American Joint Committee on Cancer stage II:9 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222812008", "American Joint Committee on Cancer stage III:1 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260528009", "Median (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["1222605001", "American Joint Committee on Cancer stage 0 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732434008", "1.75 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["18720000", "In (attribute)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["260400001", "Reduced (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387517004", "Paracetamol (substance)|Acetaminophen (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258685003", "ug (qualifier value)|microgram (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["373067005", "No (qualifier value)"], ["420862001", "On (qualifier value)"], ["387517004", "Paracetamol (substance)|Acetaminophen (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["387517004", "Paracetamol (substance)|Acetaminophen (substance)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258702006", "hour (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["420862001", "On (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["86495002", "For (qualifier value)"], ["387517004", "Paracetamol (substance)|Acetaminophen (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["387517004", "Paracetamol (substance)|Acetaminophen (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["123031003", "4 hours (qualifier value)"], ["255234002", "After (attribute)"], ["708808004", "Lixisenatide (substance)"], ["30507006", "Into (attribute)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255358001", "Rapid (qualifier value)"], ["77374008", "Onset of (contextual qualifier) (qualifier value)"], ["273248003", "Action (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["86495002", "For (qualifier value)"], ["738956005", "Oral (intended site)"], ["108899006", "Contraceptives (product)|Medicinal product acting as contraceptive (product)|Contraceptives (substance)"], ["255260001", "Following (attribute)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["160492004", "Single (& [unmarried])|Single (& [unmarried]) (finding)"], ["408102007", "Unit dose (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["59261009", "Oral contraceptive preparation (substance)|Oral contraceptive preparation (product)"], ["763158003", "Medicinal product (product)"], ["126097006", "Ethinyl estradiol (substance)|Ethinylestradiol (substance)"], ["732314006", "0.03 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["126109000", "Levonorgestrel (substance)"], ["732343003", "0.15 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258702006", "hour (qualifier value)"], ["421718005", "Before - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1222737005", "American Joint Committee on Cancer stage I:1 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["255234002", "After (attribute)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["258685003", "ug (qualifier value)|microgram (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["413573002", "Area under the curve (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["126097006", "Ethinyl estradiol (substance)|Ethinylestradiol (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["126109000", "Levonorgestrel (substance)"], ["260388006", "No status change (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["59261009", "Oral contraceptive preparation (substance)|Oral contraceptive preparation (product)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["258702006", "hour (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["123031003", "4 hours (qualifier value)"], ["255234002", "After (attribute)"], ["708808004", "Lixisenatide (substance)"], ["4065008", "Affect, function (observable entity)|Affect function (observable entity)|Affect (function)"], ["413573002", "Area under the curve (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["126097006", "Ethinyl estradiol (substance)|Ethinylestradiol (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["126109000", "Levonorgestrel (substance)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["126097006", "Ethinyl estradiol (substance)|Ethinylestradiol (substance)"], ["1250004", "Decreased (qualifier value)"], ["732782003", "52 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222820005", "American Joint Committee on Cancer stage III:9 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["126109000", "Levonorgestrel (substance)"], ["1250004", "Decreased (qualifier value)"], ["1222849002", "American Joint Committee on Cancer stage IV:6 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260528009", "Median (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258702006", "hour (qualifier value)"], ["289928003", "Reduction plasty (qualifier value)"], ["18720000", "In (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["58147004", "Clinical (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["86495002", "For (qualifier value)"], ["738956005", "Oral (intended site)"], ["108899006", "Contraceptives (product)|Medicinal product acting as contraceptive (product)|Contraceptives (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373444002", "Atorvastatin (substance)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258685003", "ug (qualifier value)|microgram (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["373444002", "Atorvastatin (substance)"], ["1222843001", "American Joint Committee on Cancer stage IV:0 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["73775008", "Morning (qualifier value)"], ["86495002", "For (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258703001", "day (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["373444002", "Atorvastatin (substance)"], ["247591002", "Affecting (qualifier value)"], ["1250004", "Decreased (qualifier value)"], ["1222812008", "American Joint Committee on Cancer stage III:1 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["373067005", "No (qualifier value)"], ["260366006", "Increase (qualifier value)"], ["86495002", "For (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["373444002", "Atorvastatin (substance)"], ["18720000", "In (attribute)"], ["3157002", "Evening (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["73775008", "Morning (qualifier value)"], ["413573002", "Area under the curve (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["373444002", "Atorvastatin (substance)"], ["35105006", "Increased (qualifier value)"], ["1222780001", "American Joint Committee on Cancer stage II:7 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["732832003", "66 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["86495002", "For (qualifier value)"], ["373444002", "Atorvastatin (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["372756006", "Warfarin (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["74964007", "Other (qualifier value)"], ["766936008", "Coumarin (substance)"], ["255234002", "After (attribute)"], ["79970003", "Simultaneous (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["372756006", "Warfarin (substance)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["27582007", "Repeat (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258685003", "ug (qualifier value)|microgram (qualifier value)"], ["373067005", "No (qualifier value)"], ["420862001", "On (qualifier value)"], ["413573002", "Area under the curve (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["1951000175101", "International normalized ratio (qualifier value)"], ["260400001", "Reduced (qualifier value)"], ["1222748003", "American Joint Committee on Cancer stage I:9 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["420359007", "Arabic numeral 7 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["420862001", "On (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["86495002", "For (qualifier value)"], ["372756006", "Warfarin (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["70232002", "Frequent (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["18720000", "In (attribute)"], ["420862001", "On (qualifier value)"], ["372756006", "Warfarin (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["766936008", "Coumarin (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897015005", "Recommended (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["900000000000475002", "Time (foundation metadata concept)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["312009002", "Cognitive function: initiation (qualifier value)|Cognitive function: initiation (observable entity)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["387461009", "Digoxin (substance)"], ["255234002", "After (attribute)"], ["79970003", "Simultaneous (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258685003", "ug (qualifier value)|microgram (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["387461009", "Digoxin (substance)"], ["732356005", "0.25 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["420246001", "At - dosing instruction fragment (qualifier value)"], ["55011004", "Steady (qualifier value)"], ["398070004", "State (environment)"], ["413573002", "Area under the curve (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387461009", "Digoxin (substance)"], ["247591002", "Affecting (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["387461009", "Digoxin (substance)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["732425003", "1.5 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260400001", "Reduced (qualifier value)"], ["1222779004", "American Joint Committee on Cancer stage II:6 (qualifier value)"], ["420862001", "On (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["86495002", "For (qualifier value)"], ["387461009", "Digoxin (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["386872004", "Ramipril (substance)"], ["255234002", "After (attribute)"], ["79970003", "Simultaneous (qualifier value)"], ["416118004", "Administration (procedure)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["1222773003", "American Joint Committee on Cancer stage II:0 (qualifier value)"], ["258685003", "ug (qualifier value)|microgram (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["386872004", "Ramipril (substance)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["258684004", "milligram (qualifier value)|mg (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["422218008", "Arabic numeral 6 (qualifier value)"], ["258703001", "day (qualifier value)"], ["413573002", "Area under the curve (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386872004", "Ramipril (substance)"], ["35105006", "Increased (qualifier value)"], ["1222774009", "American Joint Committee on Cancer stage II:1 (qualifier value)"], ["1250004", "Decreased (qualifier value)"], ["732828009", "63 (qualifier value)"], ["413573002", "Area under the curve (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["55561003", "Active (qualifier value)"], ["767279008", "Metabolite (substance)"], ["247591002", "Affecting (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["386872004", "Ramipril (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["123108000", "Delayed (qualifier value)|Delayed -RETIRED-"], ["26175008", "Approximate (qualifier value)"], ["732576003", "2.5 (qualifier value)"], ["258702006", "hour (qualifier value)"], ["420862001", "On (qualifier value)"], ["373067005", "No (qualifier value)"], ["408102007", "Unit dose (qualifier value)"], ["410617001", "Adjustment (procedure)"], ["86495002", "For (qualifier value)"], ["386872004", "Ramipril (substance)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["420974001", "When - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"]], "ncit.pregnancy": [["C159586", "Preoperative IV Sedation was Not Administered"], ["C54216", "Interaction"], ["C62355", "With"], ["C101282", "Have"], ["C38000", "Performed"], ["C48191", "Information"], ["C64974", "Give"], ["C75330", "Below"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C62355", "With"], ["C49662", "Pharmacodynamic Study"], ["C76246", "Blood Group A"], ["C25463", "Count"], ["C52874", "SPI1 wt Allele"], ["C2831", "Glucose"], ["C16842", "Metabolism, Organismal"], ["C16289", "Andorra"], ["C106184", "May"], ["C82495", "Dose Adjustment"], ["C52874", "SPI1 wt Allele"], ["C106184", "May"], ["C71607", "Enhance"], ["C17610", "Blood Sample"], ["C2831", "Glucose"], ["C86568", "Lower"], ["C71600", "Effect, Appearance"], ["C16289", "Andorra"], ["C25533", "Increase"], ["C16505", "Susceptibility"], ["C159124", "GDC Treatment Outcome Terminology"], ["C74521", "Include"], ["C80169", "Angiotensin Converting Enzyme Measurement"], ["C91295", "ACE Gene"], ["C61730", "Disopyramide"], ["C158219", "Fluoxetine Measurement"], ["C733", "Pentoxifylline"], ["C74885", "Propoxyphene Measurement"], ["C147431", "Salicylates Measurement"], ["C16289", "Andorra"], ["C258", "Antibiotic"], ["C106184", "May"], ["C17610", "Blood Sample"], ["C2831", "Glucose"], ["C86568", "Lower"], ["C71600", "Effect, Appearance"], ["C74521", "Include"], ["C211", "Therapeutic Corticosteroid"], ["C414", "Danazol"], ["C428", "Diazoxide"], ["C448", "Diuretic"], ["C2268", "Glucagon"], ["C600", "Isoniazid"], ["C16289", "Andorra"], ["C2296", "Progestogen"], ["C740", "Phenothiazine"], ["C837", "Somatropin"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C79445", "Epinephrine Measurement"], ["C79445", "Epinephrine Measurement"], ["C61965", "Terbutaline"], ["C23335", "Murine Thyroid"], ["C15445", "Hormone Therapy"], ["C25428", "Atypical"], ["C29710", "Antipsychotic Agent"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C28936", "Clozapine"], ["C16289", "Andorra"], ["C47639", "Olanzapine"], ["C16289", "Andorra"], ["C783", "Protease Inhibitor"], ["C29576", "Beta-Adrenergic Antagonist"], ["C380", "Clonidine"], ["C1318", "Lithium Carbonate"], ["C43508", "Oregon"], ["C74693", "Ethanol Measurement"], ["C106184", "May"], ["C43508", "Oregon"], ["C17610", "Blood Sample"], ["C2831", "Glucose"], ["C86568", "Lower"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C2271", "Insulin"], ["C731", "Pentamidine"], ["C106184", "May"], ["C16390", "Etiology"], ["C106184", "May"], ["C90025", "Sometimes"], ["C16329", "Belgium"], ["C53286", "Next"], ["C16727", "India"], ["C64911", "Add"], ["C121660", "Influence"], ["C52874", "SPI1 wt Allele"], ["C71344", "Associate of Science"], ["C29576", "Beta-Adrenergic Antagonist"], ["C380", "Clonidine"], ["C65830", "Guanethidine"], ["C16289", "Andorra"], ["C803", "Reserpine"], ["C52874", "SPI1 wt Allele"], ["C49894", "Counter Device"], ["C68821", "Regulation"], ["C106184", "May"], ["C16329", "Belgium"], ["C25640", "Reduced"], ["C43508", "Oregon"], ["C190988", "Modified Van Assche Index MVAI101 Original Result - Absent"], ["C49663", "Pharmacokinetic Study"], ["C166988", "Lixisenatide"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C76246", "Blood Group A"], ["C735", "Peptide"], ["C16289", "Andorra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C158169", "Buyei Chinese"], ["C16484", "Cytochrome P450"], ["C16727", "India"], ["C15263", "In Vitro"], ["C166988", "Lixisenatide"], ["C163546", "Double Immunodiffusion"], ["C25594", "Negation"], ["C120914", "Physical Activity Measurement"], ["C52874", "SPI1 wt Allele"], ["C16484", "Cytochrome P450"], ["C43508", "Oregon"], ["C14225", "Human"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C49663", "Pharmacokinetic Study"], ["C68869", "Are"], ["C80137", "Known"], ["C64956", "For"], ["C47564", "Insulin Glargine"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C12391", "Stomach"], ["C92667", "SPARC wt Allele"], ["C25311", "Oral"], ["C25476", "Delay"], ["C52874", "SPI1 wt Allele"], ["C12391", "Stomach"], ["C62355", "With"], ["C166988", "Lixisenatide"], ["C106184", "May"], ["C77538", "Rating"], ["C52874", "SPI1 wt Allele"], ["C71731", "Material Absorption"], ["C52874", "SPI1 wt Allele"], ["C25311", "Oral"], ["C25382", "Administered"], ["C16960", "Patient"], ["C25639", "Receive"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C124564", "Narrow"], ["C25277", "Therapeutic"], ["C179809", "Ratio Result Type"], ["C43508", "Oregon"], ["C123619", "Clinical Response"], ["C61256", "Monitoring"], ["C16329", "Belgium"], ["C16033", "Follow-Up"], ["C158997", "GDC Analyte Type Terminology"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C47938", "Initiation"], ["C52874", "SPI1 wt Allele"], ["C166988", "Lixisenatide"], ["C43442", "Biomaterial Treatment"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C16727", "India"], ["C21480", "Relative"], ["C159124", "GDC Treatment Outcome Terminology"], ["C166988", "Lixisenatide"], ["C198613", "CFI wt Allele"], ["C68869", "Are"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C62355", "With"], ["C62695", "Food"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C198613", "CFI wt Allele"], ["C41359", "Possible Adverse Event Attribution to Product or Procedure"], ["C65105", "Take"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C80248", "Meal"], ["C65140", "When"], ["C166988", "Lixisenatide"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25382", "Administered"], ["C64956", "For"], ["C25311", "Oral"], ["C68869", "Are"], ["C63905", "Conditional"], ["C92667", "SPARC wt Allele"], ["C48228", "Threshold"], ["C64956", "For"], ["C88183", "Efficacy"], ["C71344", "Associate of Science"], ["C258", "Antibiotic"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C65105", "Take"], ["C158997", "GDC Analyte Type Terminology"], ["C105723", "ECOG Performance Status 1"], ["C25529", "Hour"], ["C201357", "Before Timing Type"], ["C43508", "Oregon"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25529", "Hour"], ["C38008", "Post"], ["C166988", "Lixisenatide"], ["C122632", "Injection Dosing Unit"], ["C128681", "CDISC SDTM Gastrointestinal Test Name Terminology"], ["C41546", "Resistance Process"], ["C79873", "Contain"], ["C25201", "Sensitivity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C12391", "Stomach"], ["C61559", "Degradation"], ["C16329", "Belgium"], ["C25382", "Administered"], ["C105723", "ECOG Performance Status 1"], ["C25529", "Hour"], ["C201357", "Before Timing Type"], ["C43508", "Oregon"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25529", "Hour"], ["C38008", "Post"], ["C166988", "Lixisenatide"], ["C122632", "Injection Dosing Unit"], ["C198", "Acetaminophen"], ["C198", "Acetaminophen"], ["C154196", "Washo Language"], ["C71344", "Associate of Science"], ["C76246", "Blood Group A"], ["C16866", "Model"], ["C142605", "Medicinal Product"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25214", "Evaluation"], ["C71600", "Effect, Appearance"], ["C52874", "SPI1 wt Allele"], ["C166988", "Lixisenatide"], ["C92667", "SPARC wt Allele"], ["C12391", "Stomach"], ["C53286", "Next"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C48440", "Single"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C198", "Acetaminophen"], ["C67234", "Thousand"], ["C16818", "Mammography"], ["C198", "Acetaminophen"], ["C64774", "Area Under Curve"], ["C16289", "Andorra"], ["C106009", "IL1RL1 wt Allele"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C71687", "Unchanged"], ["C40567", "Timing, LOINC Axis 3"], ["C52874", "SPI1 wt Allele"], ["C70962", "Agent Administration"], ["C201357", "Before Timing Type"], ["C43508", "Oregon"], ["C38008", "Post"], ["C166988", "Lixisenatide"], ["C122632", "Injection Dosing Unit"], ["C65140", "When"], ["C25382", "Administered"], ["C105723", "ECOG Performance Status 1"], ["C43508", "Oregon"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25529", "Hour"], ["C38008", "Post"], ["C69122", "Ten"], ["C48152", "Microgram"], ["C166988", "Lixisenatide"], ["C70918", "Cmax"], ["C52874", "SPI1 wt Allele"], ["C198", "Acetaminophen"], ["C154196", "Washo Language"], ["C25640", "Reduced"], ["C158169", "Buyei Chinese"], ["C105800", "Twenty Nine"], ["C16289", "Andorra"], ["C126863", "Thirty One"], ["C16289", "Andorra"], ["C28007", "Median"], ["C70919", "Tmax"], ["C154196", "Washo Language"], ["C168181", "Delayed Capillary Refill Time"], ["C158169", "Buyei Chinese"], ["C189639", "CDISC SDTM Model Version 2.0"], ["C16289", "Andorra"], ["C105723", "ECOG Performance Status 1"], ["C160687", "Seventy Five"], ["C25529", "Hour"], ["C76246", "Blood Group A"], ["C25519", "Further"], ["C25476", "Delay"], ["C16727", "India"], ["C70919", "Tmax"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C25640", "Reduced"], ["C70918", "Cmax"], ["C52874", "SPI1 wt Allele"], ["C198", "Acetaminophen"], ["C101282", "Have"], ["C54156", "Prediction"], ["C62355", "With"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C48152", "Microgram"], ["C156598", "Maintenance Clinical Trial Setting"], ["C25488", "Dose"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25492", "Effect"], ["C92667", "SPARC wt Allele"], ["C198", "Acetaminophen"], ["C70918", "Cmax"], ["C16289", "Andorra"], ["C70919", "Tmax"], ["C25599", "Observed"], ["C65140", "When"], ["C198", "Acetaminophen"], ["C154196", "Washo Language"], ["C25382", "Administered"], ["C105723", "ECOG Performance Status 1"], ["C25529", "Hour"], ["C201357", "Before Timing Type"], ["C166988", "Lixisenatide"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C64956", "For"], ["C198", "Acetaminophen"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C168181", "Delayed Capillary Refill Time"], ["C70919", "Tmax"], ["C25599", "Observed"], ["C65140", "When"], ["C198", "Acetaminophen"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25382", "Administered"], ["C105723", "ECOG Performance Status 1"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25529", "Hour"], ["C38008", "Post"], ["C166988", "Lixisenatide"], ["C16329", "Belgium"], ["C25701", "Taken"], ["C25544", "Into"], ["C88186", "Financial Account"], ["C65140", "When"], ["C76246", "Blood Group A"], ["C65069", "Rapidly"], ["C94495", "Onset of Action"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C64956", "For"], ["C88183", "Efficacy"], ["C389", "Oral Contraceptive"], ["C53286", "Next"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C76246", "Blood Group A"], ["C48440", "Single"], ["C25488", "Dose"], ["C52874", "SPI1 wt Allele"], ["C75889", "PAX6 wt Allele"], ["C389", "Oral Contraceptive"], ["C142605", "Medicinal Product"], ["C486", "Ethinyl Estradiol"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C16818", "Mammography"], ["C47585", "Levonorgestrel"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C113429", "Fifteen"], ["C16818", "Mammography"], ["C105723", "ECOG Performance Status 1"], ["C25529", "Hour"], ["C201357", "Before Timing Type"], ["C43508", "Oregon"], ["C113425", "Eleven"], ["C25529", "Hour"], ["C38008", "Post"], ["C69122", "Ten"], ["C48152", "Microgram"], ["C166988", "Lixisenatide"], ["C70918", "Cmax"], ["C64774", "Area Under Curve"], ["C106009", "IL1RL1 wt Allele"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C16289", "Andorra"], ["C70919", "Tmax"], ["C52874", "SPI1 wt Allele"], ["C486", "Ethinyl Estradiol"], ["C16289", "Andorra"], ["C47585", "Levonorgestrel"], ["C71687", "Unchanged"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C389", "Oral Contraceptive"], ["C105723", "ECOG Performance Status 1"], ["C25529", "Hour"], ["C43508", "Oregon"], ["C182826", "Kurtzke Functional System Scores KFSS104 Standardized Character Result 4"], ["C25529", "Hour"], ["C38008", "Post"], ["C166988", "Lixisenatide"], ["C163546", "Double Immunodiffusion"], ["C25594", "Negation"], ["C64774", "Area Under Curve"], ["C16289", "Andorra"], ["C106009", "IL1RL1 wt Allele"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C52874", "SPI1 wt Allele"], ["C486", "Ethinyl Estradiol"], ["C16289", "Andorra"], ["C47585", "Levonorgestrel"], ["C70918", "Cmax"], ["C52874", "SPI1 wt Allele"], ["C486", "Ethinyl Estradiol"], ["C154196", "Washo Language"], ["C25640", "Reduced"], ["C158169", "Buyei Chinese"], ["C188320", "Fifty Two"], ["C16289", "Andorra"], ["C105798", "Thirty Nine"], ["C16289", "Andorra"], ["C70918", "Cmax"], ["C52874", "SPI1 wt Allele"], ["C47585", "Levonorgestrel"], ["C154196", "Washo Language"], ["C25640", "Reduced"], ["C158169", "Buyei Chinese"], ["C178275", "Forty Six"], ["C16289", "Andorra"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C16289", "Andorra"], ["C28007", "Median"], ["C70919", "Tmax"], ["C154196", "Washo Language"], ["C168181", "Delayed Capillary Refill Time"], ["C158169", "Buyei Chinese"], ["C105723", "ECOG Performance Status 1"], ["C159124", "GDC Treatment Outcome Terminology"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C25529", "Hour"], ["C25640", "Reduced"], ["C16727", "India"], ["C70918", "Cmax"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C52874", "SPI1 wt Allele"], ["C142988", "Limited"], ["C123619", "Clinical Response"], ["C70664", "Relevance"], ["C16289", "Andorra"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C64956", "For"], ["C389", "Oral Contraceptive"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C61527", "Atorvastatin"], ["C65140", "When"], ["C166988", "Lixisenatide"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C48152", "Microgram"], ["C16289", "Andorra"], ["C61527", "Atorvastatin"], ["C105795", "Forty"], ["C16818", "Mammography"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C16727", "India"], ["C168169", "Chief Complaint Present in the Morning"], ["C64956", "For"], ["C172979", "Fear Score 6"], ["C25301", "Day"], ["C49587", "Exposure Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C61527", "Atorvastatin"], ["C154196", "Washo Language"], ["C25594", "Negation"], ["C64917", "Affected"], ["C70918", "Cmax"], ["C154196", "Washo Language"], ["C25640", "Reduced"], ["C158169", "Buyei Chinese"], ["C126863", "Thirty One"], ["C16289", "Andorra"], ["C70919", "Tmax"], ["C154196", "Washo Language"], ["C168181", "Delayed Capillary Refill Time"], ["C158169", "Buyei Chinese"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C113663", "Twenty Five"], ["C25529", "Hour"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25533", "Increase"], ["C64956", "For"], ["C70919", "Tmax"], ["C154196", "Washo Language"], ["C25599", "Observed"], ["C65140", "When"], ["C61527", "Atorvastatin"], ["C154196", "Washo Language"], ["C25382", "Administered"], ["C16727", "India"], ["C64936", "Evening"], ["C16289", "Andorra"], ["C166988", "Lixisenatide"], ["C16727", "India"], ["C168169", "Chief Complaint Present in the Morning"], ["C64774", "Area Under Curve"], ["C16289", "Andorra"], ["C70918", "Cmax"], ["C52874", "SPI1 wt Allele"], ["C61527", "Atorvastatin"], ["C164135", "Increased"], ["C158169", "Buyei Chinese"], ["C126887", "Twenty Seven"], ["C16289", "Andorra"], ["C188330", "Sixty Six"], ["C68869", "Are"], ["C25594", "Negation"], ["C70664", "Relevance"], ["C16289", "Andorra"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C64956", "For"], ["C61527", "Atorvastatin"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C65140", "When"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C166988", "Lixisenatide"], ["C945", "Warfarin"], ["C16289", "Andorra"], ["C118472", "Other License Status"], ["C397", "Coumarin"], ["C38008", "Post"], ["C25730", "Concomitant"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C945", "Warfarin"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C62355", "With"], ["C52874", "SPI1 wt Allele"], ["C166988", "Lixisenatide"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C48152", "Microgram"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C25492", "Effect"], ["C92667", "SPARC wt Allele"], ["C64774", "Area Under Curve"], ["C43508", "Oregon"], ["C64805", "International Normalized Ratio of Prothrombin Time"], ["C25541", "International"], ["C179809", "Ratio Result Type"], ["C70918", "Cmax"], ["C154196", "Washo Language"], ["C25640", "Reduced"], ["C158169", "Buyei Chinese"], ["C105801", "Nineteen"], ["C16289", "Andorra"], ["C70919", "Tmax"], ["C154196", "Washo Language"], ["C168181", "Delayed Capillary Refill Time"], ["C158169", "Buyei Chinese"], ["C189732", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET2 Standardized Character Result 7"], ["C25529", "Hour"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C64956", "For"], ["C945", "Warfarin"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C65140", "When"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C166988", "Lixisenatide"], ["C64649", "Frequently"], ["C61256", "Monitoring"], ["C52874", "SPI1 wt Allele"], ["C64805", "International Normalized Ratio of Prothrombin Time"], ["C16727", "India"], ["C16960", "Patient"], ["C92667", "SPARC wt Allele"], ["C945", "Warfarin"], ["C48928", "And/Or"], ["C397", "Coumarin"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25197", "Recommendation"], ["C158997", "GDC Analyte Type Terminology"], ["C25330", "Duration"], ["C52874", "SPI1 wt Allele"], ["C47938", "Initiation"], ["C43508", "Oregon"], ["C25496", "End"], ["C52874", "SPI1 wt Allele"], ["C166988", "Lixisenatide"], ["C43442", "Biomaterial Treatment"], ["C28990", "Digoxin"], ["C38008", "Post"], ["C25730", "Concomitant"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C166988", "Lixisenatide"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C48152", "Microgram"], ["C16289", "Andorra"], ["C28990", "Digoxin"], ["C133519", "Pathologic Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8"], ["C113663", "Twenty Five"], ["C16818", "Mammography"], ["C158997", "GDC Analyte Type Terminology"], ["C151966", "Steady-State"], ["C64774", "Area Under Curve"], ["C52874", "SPI1 wt Allele"], ["C28990", "Digoxin"], ["C154196", "Washo Language"], ["C25594", "Negation"], ["C64917", "Affected"], ["C70919", "Tmax"], ["C52874", "SPI1 wt Allele"], ["C28990", "Digoxin"], ["C154196", "Washo Language"], ["C168181", "Delayed Capillary Refill Time"], ["C158169", "Buyei Chinese"], ["C161429", "CDISC SDTM Model Version 1.5"], ["C25529", "Hour"], ["C16289", "Andorra"], ["C70918", "Cmax"], ["C154196", "Washo Language"], ["C25640", "Reduced"], ["C158169", "Buyei Chinese"], ["C126886", "Twenty Six"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C64956", "For"], ["C28990", "Digoxin"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C65140", "When"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C166988", "Lixisenatide"], ["C29411", "Ramipril"], ["C38008", "Post"], ["C25730", "Concomitant"], ["C70962", "Agent Administration"], ["C52874", "SPI1 wt Allele"], ["C166988", "Lixisenatide"], ["C182735", "Karnofsky Performance Status Scale KPSS0101 Standardized Character Result 20"], ["C48152", "Microgram"], ["C16289", "Andorra"], ["C29411", "Ramipril"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16818", "Mammography"], ["C25490", "During"], ["C172979", "Fear Score 6"], ["C25301", "Day"], ["C64774", "Area Under Curve"], ["C52874", "SPI1 wt Allele"], ["C29411", "Ramipril"], ["C154196", "Washo Language"], ["C164135", "Increased"], ["C158169", "Buyei Chinese"], ["C107434", "Twenty One"], ["C70918", "Cmax"], ["C154196", "Washo Language"], ["C25640", "Reduced"], ["C158169", "Buyei Chinese"], ["C188327", "Sixty Three"], ["C64774", "Area Under Curve"], ["C16289", "Andorra"], ["C70918", "Cmax"], ["C52874", "SPI1 wt Allele"], ["C154405", "Active State"], ["C61154", "Metabolite"], ["C72911", "Ramiprilat"], ["C25594", "Negation"], ["C64917", "Affected"], ["C70919", "Tmax"], ["C52874", "SPI1 wt Allele"], ["C29411", "Ramipril"], ["C16289", "Andorra"], ["C72911", "Ramiprilat"], ["C168181", "Delayed Capillary Refill Time"], ["C158169", "Buyei Chinese"], ["C45828", "Approximate"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C163771", "Illness Intrusiveness Rating 5"], ["C25529", "Hour"], ["C48055", "Base"], ["C92667", "SPARC wt Allele"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C82495", "Dose Adjustment"], ["C64956", "For"], ["C29411", "Ramipril"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25652", "Requirement"], ["C65140", "When"], ["C95633", "Coded Ordinal Data Type"], ["C25382", "Administered"], ["C62355", "With"], ["C166988", "Lixisenatide"]], "rxnorm.pregnancy": [["4850", "glucose"], ["4850", "glucose"], ["T126", "Enzyme"], ["3541", "disopyramide"], ["4493", "fluoxetine"], ["8013", "pentoxifylline"], ["8785", "propoxyphene"], ["4850", "glucose"], ["3102", "danazol"], ["3327", "diazoxide"], ["4832", "glucagon"], ["6038", "isoniazid"], ["61148", "somatropin"], ["3992", "epinephrine"], ["10368", "terbutaline"], ["2626", "clozapine"], ["61381", "olanzapine"], ["8031", "protease"], ["2599", "clonidine"], ["6448", "lithium"], ["4850", "glucose"], ["7994", "pentamidine"], ["2599", "clonidine"], ["5036", "guanethidine"], ["9260", "reserpine"], ["1440051", "lixisenatide"], ["1440051", "lixisenatide"], ["T052", "Activity"], ["T016", "Human"], ["274783", "insulin glargine"], ["1440051", "lixisenatide"], ["1440051", "lixisenatide"], ["1440051", "lixisenatide"], ["T168", "Food"], ["1440051", "lixisenatide"], ["1440051", "lixisenatide"], ["1649574", "Injection"], ["1440051", "lixisenatide"], ["1649574", "Injection"], ["1440051", "lixisenatide"], ["1440051", "lixisenatide"], ["1649574", "Injection"], ["1440051", "lixisenatide"], ["1440051", "lixisenatide"], ["1440051", "lixisenatide"], ["316148", "levonorgestrel 0.15 MG"], ["1440051", "lixisenatide"], ["6373", "levonorgestrel"], ["1440051", "lixisenatide"], ["6373", "levonorgestrel"], ["6373", "levonorgestrel"], ["83367", "atorvastatin"], ["1440051", "lixisenatide"], ["597983", "atorvastatin 40 MG"], ["83367", "atorvastatin"], ["83367", "atorvastatin"], ["1440051", "lixisenatide"], ["83367", "atorvastatin"], ["83367", "atorvastatin"], ["1440051", "lixisenatide"], ["11289", "warfarin"], ["2898", "coumarin"], ["11289", "warfarin"], ["1440051", "lixisenatide"], ["11289", "warfarin"], ["1440051", "lixisenatide"], ["11289", "warfarin"], ["2898", "coumarin"], ["1440051", "lixisenatide"], ["3407", "digoxin"], ["1440051", "lixisenatide"], ["315821", "digoxin 0.25 MG"], ["3407", "digoxin"], ["3407", "digoxin"], ["3407", "digoxin"], ["1440051", "lixisenatide"], ["35296", "ramipril"], ["1440051", "lixisenatide"], ["317482", "ramipril 5 MG"], ["35296", "ramipril"], ["1546377", "ramiprilat"], ["35296", "ramipril"], ["1546377", "ramiprilat"], ["35296", "ramipril"], ["1440051", "lixisenatide"]], "loinc.pregnancy": [["LA32-8", "No"], ["LA19974-7", "Performed"], ["LP29256-2", "given"], ["LA14987-4", "Below"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LP18011-4", "Number"], ["MTHU001675", "Glucose"], ["LA14161-6", "May"], ["MTHU065481", "Dose"], ["LA14161-6", "May"], ["MTHU029981", "Blood"], ["MTHU001675", "Glucose"], ["LA32048-3", "Increase"], ["LP19419-8", "Susceptibility"], ["LP15387-1", "Angiotensin converting enzyme"], ["LP230189-5", "Adverse Childhood Experiences"], ["LP16118-9", "Disopyramide"], ["MTHU060451", "FLUoxetine"], ["MTHU003694", "Monoamine oxidase"], ["MTHU035938", "Pentoxifylline"], ["MTHU001004", "Propoxyphene"], ["LP16276-5", "Salicylates"], ["LP97420-1", "Sulphonamide"], ["LP31426-7", "Antibiotics"], ["LA14161-6", "May"], ["MTHU029981", "Blood"], ["MTHU001675", "Glucose"], ["MTHU046384", "Danazol"], ["MTHU001807", "Diazoxide"], ["MTHU003217", "Diuretics"], ["LP14667-7", "Glucagon"], ["LP15831-8", "Isoniazid"], ["LP269087-5", "Phenothiazine"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["MTHU002341", "Epinephrine"], ["MTHU013595", "Terbutaline"], ["LP32941-4", "Thyroid"], ["LA4003-5", "Hormones"], ["LA13702-8", "Atypical"], ["LA30297-8", "Antipsychotic"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["LP17236-8", "cloZAPine"], ["MTHU060448", "OLANZapine"], ["MTHU060427", "cloNIDine"], ["MTHU004197", "Lithium"], ["LA22025-3", "OR"], ["LA28139-6", "Alcohol"], ["LA14161-6", "May"], ["LA11930-7", "Either"], ["LA22025-3", "OR"], ["MTHU029981", "Blood"], ["MTHU001675", "Glucose"], ["LP32542-0", "insulin"], ["LA14161-6", "May"], ["LA14161-6", "May"], ["LA10082-8", "Sometimes"], ["LA22004-8", "IN"], ["LA11132-0", "Addition"], ["MTHU060427", "cloNIDine"], ["LA14161-6", "May"], ["LA32619-1", "Reduced"], ["LA22025-3", "OR"], ["LA9634-2", "Absent"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LA21291-2", "Not"], ["LP72045-5", "Activity"], ["LA22025-3", "OR"], ["LA19711-3", "Human"], ["LP32426-6", "tested"], ["LA32-8", "No"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LP266966-3", "Gastric emptying"], ["LA9367-9", "Oral"], ["LA7343-2", "Delay"], ["LP266966-3", "Gastric emptying"], ["LA14161-6", "May"], ["MTHU027852", "Rate"], ["LA11930-7", "Either"], ["LP17763-1", "A"], ["LA9191-3", "Narrow"], ["LP263807-2", "Therapeutic"], ["LP6852-0", "Ratio"], ["LA22025-3", "OR"], ["LP7787-7", "Clinical"], ["LA20297-0", "Monitoring"], ["LA21988-3", "AT"], ["LP73517-2", "Time"], ["LP94823-9", "Treatment"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA22004-8", "IN"], ["LP6323-2", "Immunofluorescence (IF)"], ["MTHU065486", "Food"], ["LP6323-2", "Immunofluorescence (IF)"], ["LA15097-1", "Possible"], ["LP17763-1", "A"], ["LP200075-2", "IS"], ["LA21291-2", "Not"], ["LA9367-9", "Oral"], ["LA12304-4", "Dependent"], ["LP6875-1", "Threshold"], ["LA26687-6", "Efficacy"], ["LP31426-7", "Antibiotics"], ["LA21988-3", "AT"], ["LP6915-5", "1 hour"], ["LA22025-3", "OR"], ["LP6940-3", "4 hours"], ["LA14542-7", "Injection"], ["LA6676-6", "Resistant"], ["LA16549-0", "Sensitive"], ["MTHU003059", "Stomach"], ["LP6915-5", "1 hour"], ["LA22025-3", "OR"], ["LP6940-3", "4 hours"], ["LA14542-7", "Injection"], ["LP17763-1", "A"], ["LA20332-5", "Gastric"], ["LP72540-5", "Emptying"], ["LP17763-1", "A"], ["LA17717-2", "Single"], ["MTHU065481", "Dose"], ["LP15217-0", "Mg"], ["LA3637-1", "T1"], ["MTHU000002", "Clinical Class"], ["LA17181-1", "Unchanged"], ["LP74359-8", "Timing"], ["LA22025-3", "OR"], ["LA14542-7", "Injection"], ["LA6112-2", "1"], ["LA22025-3", "OR"], ["LP6940-3", "4 hours"], ["LA13942-0", "10"], ["LA24378-4", "Decreased"], ["LA19243-7", "29"], ["LA25381-7", "Median"], ["LP266901-0", "Delayed"], ["MTHU000002", "Clinical Class"], ["LA6111-4", "0"], ["LA6112-2", "1"], ["LP17763-1", "A"], ["LA7343-2", "Delay"], ["LA22004-8", "IN"], ["LP17763-1", "A"], ["LA32619-1", "Reduced"], ["LP140658-8", "Predicted"], ["LA19282-5", "20"], ["MTHU065481", "Dose"], ["LA32-8", "No"], ["LP6425-5", "Observed"], ["LP6915-5", "1 hour"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP200075-2", "IS"], ["LP266901-0", "Delayed"], ["LP6425-5", "Observed"], ["LP200075-2", "IS"], ["LA6112-2", "1"], ["LP6940-3", "4 hours"], ["LP17763-1", "A"], ["LA24868-4", "Rapid"], ["LP200075-2", "IS"], ["LA26687-6", "Efficacy"], ["LA9367-9", "Oral"], ["LP17763-1", "A"], ["LA17717-2", "Single"], ["MTHU065481", "Dose"], ["LA9367-9", "Oral"], ["LA6111-4", "0"], ["LP15217-0", "Mg"], ["LA24576-3", "0.15"], ["LP15217-0", "Mg"], ["LP6915-5", "1 hour"], ["LA22025-3", "OR"], ["LA14557-5", "11"], ["LA13942-0", "10"], ["LA3637-1", "T1"], ["MTHU000002", "Clinical Class"], ["LA17181-1", "Unchanged"], ["LA9367-9", "Oral"], ["LP6915-5", "1 hour"], ["LA22025-3", "OR"], ["LP6940-3", "4 hours"], ["LA21291-2", "Not"], ["LA3637-1", "T1"], ["MTHU000002", "Clinical Class"], ["LA24378-4", "Decreased"], ["LA24378-4", "Decreased"], ["LA15245-6", "20%"], ["LA25381-7", "Median"], ["LP266901-0", "Delayed"], ["LA14464-4", "1 to 3"], ["LP267357-4", "Reduction"], ["LA22004-8", "IN"], ["LP200075-2", "IS"], ["LA6484-5", "Limited"], ["LP7787-7", "Clinical"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LA9367-9", "Oral"], ["LP200075-2", "IS"], ["LP171386-8", "Atorvastatin"], ["LA19282-5", "20"], ["LP171386-8", "Atorvastatin"], ["LA28858-1", "40"], ["LP15217-0", "Mg"], ["LA21996-6", "CO"], ["LA22004-8", "IN"], ["LA14971-8", "Morning"], ["LP20594-5", "6"], ["LA8999-0", "Days"], ["LP171386-8", "Atorvastatin"], ["LA21291-2", "Not"], ["LA24378-4", "Decreased"], ["LP266901-0", "Delayed"], ["LP20591-1", "3"], ["LA19281-7", "25"], ["LA32-8", "No"], ["LA32048-3", "Increase"], ["LP6425-5", "Observed"], ["LP171386-8", "Atorvastatin"], ["LA22004-8", "IN"], ["LA14972-6", "Evening"], ["LA22004-8", "IN"], ["LA14971-8", "Morning"], ["LP171386-8", "Atorvastatin"], ["LA24377-6", "Increased"], ["LA21291-2", "Not"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP171386-8", "Atorvastatin"], ["LP200075-2", "IS"], ["LA21996-6", "CO"], ["LA28654-4", "Warfarin"], ["MTHU029809", "Other"], ["LA28654-4", "Warfarin"], ["LA19281-7", "25"], ["LP15217-0", "Mg"], ["LA19282-5", "20"], ["LA32-8", "No"], ["LA22025-3", "OR"], ["LP17102-2", "INR"], ["LP6852-0", "Ratio"], ["LA32619-1", "Reduced"], ["LP266901-0", "Delayed"], ["LP36790-1", "7"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LA28654-4", "Warfarin"], ["LP200075-2", "IS"], ["LA21996-6", "CO"], ["LA20297-0", "Monitoring"], ["LP17102-2", "INR"], ["LA22004-8", "IN"], ["LA28654-4", "Warfarin"], ["LA22025-3", "OR"], ["LP200075-2", "IS"], ["LA21988-3", "AT"], ["LP73517-2", "Time"], ["LA22025-3", "OR"], ["LP94823-9", "Treatment"], ["MTHU001808", "Digoxin"], ["LA19282-5", "20"], ["MTHU001808", "Digoxin"], ["LA6111-4", "0"], ["LA19281-7", "25"], ["LP15217-0", "Mg"], ["LA21988-3", "AT"], ["LP135457-2", "State"], ["MTHU001808", "Digoxin"], ["LA21291-2", "Not"], ["MTHU001808", "Digoxin"], ["LP266901-0", "Delayed"], ["LA15765-3", "1.5"], ["LA32619-1", "Reduced"], ["LA19280-9", "26"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["MTHU001808", "Digoxin"], ["LP200075-2", "IS"], ["LA21996-6", "CO"], ["LP171634-1", "Ramipril"], ["LA19282-5", "20"], ["LP171634-1", "Ramipril"], ["LP20593-7", "5"], ["LP15217-0", "Mg"], ["LP20594-5", "6"], ["LA8999-0", "Days"], ["LP171634-1", "Ramipril"], ["LA24377-6", "Increased"], ["LA24378-4", "Decreased"], ["LA16666-2", "Active"], ["LA21291-2", "Not"], ["LP171634-1", "Ramipril"], ["LP266901-0", "Delayed"], ["LA15766-1", "2.5"], ["LA32-8", "No"], ["MTHU065481", "Dose"], ["LP171634-1", "Ramipril"], ["LP200075-2", "IS"], ["LA21996-6", "CO"]], "snomed.driving": [["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["261583007", "Using (attribute)"], ["146680009", "Contraception|Contraception (finding)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["373067005", "No (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["420862001", "On (qualifier value)"], ["24932003", "Exposure to (contextual qualifier) (qualifier value)"], ["31509003", "Controlled (qualifier value)"], ["58147004", "Clinical (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["260676000", "Use of (attribute)"], ["411529005", "Insulin glargine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["255509001", "Large (qualifier value)"], ["246205007", "Quantity (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["420862001", "On (qualifier value)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["242762006", "More (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["67866001", "Insulin (substance)"], ["373067005", "No (qualifier value)"], ["255407002", "Neonatal (qualifier value)"], ["75478009", "Poisoning (disorder)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["387961004", "Kingdom Animalia (organism)"], ["75478009", "Poisoning (disorder)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["373067005", "No (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["900000000000486000", "Limited component (foundation metadata concept)"], ["246205007", "Quantity (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["260676000", "Use of (attribute)"], ["708808004", "Lixisenatide (substance)"], ["18720000", "In (attribute)"], ["77386006", "Pregnancy (finding)|Patient currently pregnant (finding)|Pregnant (finding)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["18720000", "In (attribute)"], ["387961004", "Kingdom Animalia (organism)"], ["75478009", "Poisoning (disorder)"], ["769082003", "5.3 (qualifier value)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["897016006", "Not recommended (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["289908002", "Pregnancy (qualifier value)|Pregnancy, function (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["261583007", "Using (attribute)"], ["146680009", "Contraception|Contraception (finding)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["261665006", "Unknown (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["18720000", "In (attribute)"], ["226789007", "Breast milk (substance)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["181131000", "Entire breast (body structure)"], ["129007004", "Feeding, function (observable entity)|Feeding (function)|Feeding (observable entity)"], ["410546004", "Discontinued (qualifier value)"], ["421994004", "During - dosing instruction fragment (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"], ["387961004", "Kingdom Animalia (organism)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["708808004", "Lixisenatide (substance)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["411529005", "Insulin glargine (substance)"], ["255589003", "Direct (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["4884007", "Fertility, function (observable entity)|Fertility (function)"]], "ncit.driving": [["C161316", "Female of Childbearing Potential"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C16727", "India"], ["C161316", "Female of Childbearing Potential"], ["C25594", "Negation"], ["C37932", "Contraception"], ["C191656", "Pregnant Subject"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C15783", "Clinical Data"], ["C92667", "SPARC wt Allele"], ["C25516", "From"], ["C82500", "Disease Controlled"], ["C15206", "Clinical Study"], ["C62355", "With"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C47564", "Insulin Glargine"], ["C43508", "Oregon"], ["C166988", "Lixisenatide"], ["C76246", "Blood Group A"], ["C49508", "Large"], ["C25256", "Quantity"], ["C52874", "SPI1 wt Allele"], ["C25474", "Data"], ["C92667", "SPARC wt Allele"], ["C73435", "Gravida"], ["C61584", "Greater Than"], ["C105723", "ECOG Performance Status 1"], ["C191656", "Pregnant Subject"], ["C62355", "With"], ["C2271", "Insulin"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C154059", "Norwegian Language"], ["C16731", "Newborn"], ["C27990", "Toxicity"], ["C52874", "SPI1 wt Allele"], ["C47564", "Insulin Glargine"], ["C14182", "Animal"], ["C25474", "Data"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C17087", "Reproduction"], ["C27990", "Toxicity"], ["C62355", "With"], ["C47564", "Insulin Glargine"], ["C68869", "Are"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43508", "Oregon"], ["C142988", "Limited"], ["C25256", "Quantity"], ["C52874", "SPI1 wt Allele"], ["C25474", "Data"], ["C25516", "From"], ["C25340", "Use"], ["C52874", "SPI1 wt Allele"], ["C166988", "Lixisenatide"], ["C16727", "India"], ["C73435", "Gravida"], ["C62355", "With"], ["C166988", "Lixisenatide"], ["C16727", "India"], ["C14182", "Animal"], ["C101282", "Have"], ["C17087", "Reproduction"], ["C27990", "Toxicity"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C163771", "Illness Intrusiveness Rating 5"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25594", "Negation"], ["C25197", "Recommendation"], ["C25490", "During"], ["C191656", "Pregnant Subject"], ["C16289", "Andorra"], ["C16727", "India"], ["C161316", "Female of Childbearing Potential"], ["C25594", "Negation"], ["C37932", "Contraception"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C160764", "Unknown Molecular Analysis"], ["C47564", "Insulin Glargine"], ["C43508", "Oregon"], ["C166988", "Lixisenatide"], ["C68869", "Are"], ["C16727", "India"], ["C14225", "Human"], ["C13257", "Mammary Gland Milk"], ["C76246", "Blood Group A"], ["C17102", "Risk"], ["C159124", "GDC Treatment Outcome Terminology"], ["C16329", "Belgium"], ["C82931", "Exclusion"], ["C25389", "Chest"], ["C88198", "Feeding"], ["C16329", "Belgium"], ["C25484", "Discontinue"], ["C175242", "During Treatment"], ["C62355", "With"], ["C95089", "Fertility Domain"], ["C14182", "Animal"], ["C62355", "With"], ["C166988", "Lixisenatide"], ["C43508", "Oregon"], ["C47564", "Insulin Glargine"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C62254", "Direct"], ["C25492", "Effect"], ["C62355", "With"], ["C159124", "GDC Treatment Outcome Terminology"], ["C95089", "Fertility Domain"]], "rxnorm.driving": [["274783", "insulin glargine"], ["1440051", "lixisenatide"], ["274783", "insulin glargine"], ["T008", "Animal"], ["274783", "insulin glargine"], ["1440051", "lixisenatide"], ["1440051", "lixisenatide"], ["274783", "insulin glargine"], ["1440051", "lixisenatide"], ["T016", "Human"], ["T008", "Animal"], ["1440051", "lixisenatide"], ["274783", "insulin glargine"]], "loinc.driving": [["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LA22004-8", "IN"], ["LA21291-2", "Not"], ["LP207970-7", "Pregnancy"], ["LP200075-2", "IS"], ["LA32-8", "No"], ["LP221469-2", "Clinical data"], ["LP73139-5", "Pregnancies"], ["LP7787-7", "Clinical"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LA20975-1", "Large amount"], ["LA29507-3", "Pregnant women"], ["LA16824-7", "More"], ["LA6112-2", "1"], ["LP207970-7", "Pregnancy"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA32-8", "No"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA30681-3", "Animal"], ["LA14426-3", "Do not"], ["LA18285-9", "Reproductive"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA32-8", "No"], ["LA22025-3", "OR"], ["LA6484-5", "Limited"], ["MTHU051337", "Amount"], ["LA22004-8", "IN"], ["LA29507-3", "Pregnant women"], ["LA22004-8", "IN"], ["LA18285-9", "Reproductive"], ["LP20593-7", "5"], ["LP20591-1", "3"], ["LP200075-2", "IS"], ["LA4695-8", "Not Recommended"], ["LP266032-4", "during pregnancy"], ["LA22004-8", "IN"], ["LA21291-2", "Not"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA4489-6", "Unknown"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA22025-3", "OR"], ["LA22004-8", "IN"], ["LA19711-3", "Human"], ["LP29290-1", "Milk"], ["LP17763-1", "A"], ["LP199961-6", "Breast"], ["LA19832-7", "Feeding"], ["LP93408-0", "during treatment"], ["MTHU000074", "Fertility"], ["LA30681-3", "Animal"], ["LA22025-3", "OR"], ["LP32542-0", "insulin"], ["LA31684-6", "Glargine"], ["LA14426-3", "Do not"], ["MTHU000074", "Fertility"]], "snomed.side_effects": [["373067005", "No (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["86137003", "Negligible (qualifier value)"], ["420862001", "On (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["247750002", "Drive (observable entity)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["116154003", "Patient (person)"], ["420952007", "Lower case Roman letter s (qualifier value)"], ["247760006", "Ability to concentrate (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["260379002", "Impaired (qualifier value)"], ["19531003", "Following (qualifier value)|Following [Ambiguous]"], ["302866003", "Hypoglycemia (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["270004003", "(Blood sugar result [& glucose]) or (plasma glucose level) or (hyperglycaemia)|(Blood sugar result [& glucose]) or (plasma glucose level) or (hyperglycaemia) (procedure)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["86495002", "For (qualifier value)"], ["19531003", "Following (qualifier value)|Following [Ambiguous]"], ["397540003", "Visual impairment (disorder)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["18720000", "In (attribute)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["67995009", "Special (qualifier value)"], ["257985002", "e (qualifier value)|Lower case Roman letter e (qualifier value)"], ["422112002", "Lower case Roman letter g (qualifier value)"], ["129060000", "Driving, function (observable entity)|Driving (function)|Driving (observable entity)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["71783008", "Automobile, device (physical object)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["261583007", "Using (attribute)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["419652001", "Take (qualifier value)|Take - dosing instruction imperative (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["129060000", "Driving, function (observable entity)|Driving (function)|Driving (observable entity)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["261583007", "Using (attribute)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["18720000", "In (attribute)"], ["260400001", "Reduced (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["2667000", "Absent (qualifier value)"], ["312012004", "Cognitive function: awareness (observable entity)|Cognitive function: awareness (function)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["70232002", "Frequent (qualifier value)"], ["272128006", "Episodes (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["302866003", "Hypoglycemia (disorder)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["247750002", "Drive (observable entity)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["18720000", "In (attribute)"]], "ncit.side_effects": [["C101282", "Have"], ["C159586", "Preoperative IV Sedation was Not Administered"], ["C43508", "Oregon"], ["C121660", "Influence"], ["C92667", "SPARC wt Allele"], ["C121232", "Ability to Drive"], ["C43508", "Oregon"], ["C25340", "Use"], ["C53691", "Veterinary Patient"], ["C42555", "Siemens"], ["C173045", "Ability Question"], ["C85856", "Concentrate"], ["C16289", "Andorra"], ["C106184", "May"], ["C16329", "Belgium"], ["C21055", "Impairment"], ["C71344", "Associate of Science"], ["C76246", "Blood Group A"], ["C20200", "Outcome"], ["C52874", "SPI1 wt Allele"], ["C43508", "Oregon"], ["C43508", "Oregon"], ["C64956", "For"], ["C48175", "Example"], ["C71344", "Associate of Science"], ["C76246", "Blood Group A"], ["C20200", "Outcome"], ["C52874", "SPI1 wt Allele"], ["C50602", "Impaired Vision"], ["C106184", "May"], ["C76246", "Blood Group A"], ["C17102", "Risk"], ["C16727", "India"], ["C68869", "Are"], ["C52874", "SPI1 wt Allele"], ["C25684", "Special"], ["C115916", "Important"], ["C68800", "Elementary Charge"], ["C68915", "Gauss"], ["C121232", "Ability to Drive"], ["C76246", "Blood Group A"], ["C201831", "CASR wt Allele"], ["C43508", "Oregon"], ["C16960", "Patient"], ["C16329", "Belgium"], ["C159124", "GDC Treatment Outcome Terminology"], ["C65105", "Take"], ["C60827", "Precaution"], ["C159124", "GDC Treatment Outcome Terminology"], ["C121232", "Ability to Drive"], ["C16289", "Andorra"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C125543", "Importance Rating Score 0"], ["C16727", "India"], ["C75419", "World Health Organization"], ["C101282", "Have"], ["C25640", "Reduced"], ["C43508", "Oregon"], ["C190988", "Modified Van Assche Index MVAI101 Original Result - Absent"], ["C54070", "Awareness"], ["C52874", "SPI1 wt Allele"], ["C47896", "Warning"], ["C168422", "Rheumatic Fever Symptom"], ["C52874", "SPI1 wt Allele"], ["C43508", "Oregon"], ["C101282", "Have"], ["C64649", "Frequently"], ["C52874", "SPI1 wt Allele"], ["C38267", "Intrathecal Route of Administration"], ["C16329", "Belgium"], ["C38267", "Intrathecal Route of Administration"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C159124", "GDC Treatment Outcome Terminology"], ["C43508", "Oregon"], ["C25340", "Use"], ["C16727", "India"]], "rxnorm.side_effects": [["1788859", "React"]], "loinc.side_effects": [["LA32-8", "No"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LP66710-2", "Patient"], ["LP15241-0", "S"], ["MTHU051452", "Ability to concentrate"], ["LA14161-6", "May"], ["LA13035-3", "Impaired"], ["LP17763-1", "A"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LP145904-1", "Visual"], ["LA14161-6", "May"], ["LP17763-1", "A"], ["LA22004-8", "IN"], ["LA13503-0", "E"], ["LP14561-2", "G"], ["MTHU053653", "Driving"], ["LP17763-1", "A"], ["LA22025-3", "OR"], ["MTHU053653", "Driving"], ["LP200075-2", "IS"], ["LA22004-8", "IN"], ["LA32619-1", "Reduced"], ["LA22025-3", "OR"], ["LA9634-2", "Absent"], ["LP75708-5", "Symptoms"], ["LA22025-3", "OR"], ["LP200077-8", "IT"], ["LP200077-8", "IT"], ["LP200075-2", "IS"], ["LA22025-3", "OR"], ["LA22004-8", "IN"]], "snomed.shelf_life": [["421718005", "Before - dosing instruction fragment (qualifier value)"], ["255216001", "First (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258707000", "year (qualifier value)"], ["255234002", "After (attribute)"], ["255216001", "First (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["1222781002", "American Joint Committee on Cancer stage II:8 (qualifier value)"], ["258703001", "day (qualifier value)"], ["255234002", "After (attribute)"], ["255216001", "First (qualifier value)"], ["419385000", "Use - dosing instruction imperative (qualifier value)|Use (qualifier value)"], ["351726001", "Below (qualifier value)"], ["1222778007", "American Joint Committee on Cancer stage II:5 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["79068005", "Needle, device (physical object)"], ["733006000", "Pen (unit of presentation)"], ["255589003", "Direct (qualifier value)"], ["88999006", "Heat (physical force)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["255589003", "Direct (qualifier value)"], ["371268001", "Light color (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["228254002", "Cap (physical object)"], ["302552004", "Entire back (surface region) (body structure)"], ["420862001", "On (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["255234002", "After (attribute)"], ["419473009", "Each (qualifier value)"], ["385218009", "Injection (product)|Injection (qualifier value)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["371268001", "Light color (qualifier value)"]], "ncit.shelf_life": [["C201357", "Before Timing Type"], ["C25509", "First"], ["C25340", "Use"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C29848", "Year"], ["C38008", "Post"], ["C25509", "First"], ["C25340", "Use"], ["C126888", "Twenty Eight"], ["C25301", "Day"], ["C38008", "Post"], ["C25509", "First"], ["C25340", "Use"], ["C60824", "Storage"], ["C75330", "Below"], ["C113663", "Twenty Five"], ["C67900", "Centi"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C48160", "Freezing"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C60824", "Storage"], ["C62355", "With"], ["C52253", "Fix"], ["C63846", "Needle Shape"], ["C60824", "Storage"], ["C157049", "Pen Device"], ["C25516", "From"], ["C62254", "Direct"], ["C186249", "Estrus"], ["C43508", "Oregon"], ["C62254", "Direct"], ["C64650", "Light"], ["C157049", "Pen Device"], ["C157719", "College of American Pathologists"], ["C16329", "Belgium"], ["C65046", "Put"], ["C167483", "Radiating Chest Pain in Back"], ["C92667", "SPARC wt Allele"], ["C157049", "Pen Device"], ["C38008", "Post"], ["C64933", "Each"], ["C122632", "Injection Dosing Unit"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25516", "From"], ["C64650", "Light"]], "rxnorm.shelf_life": [["1649574", "Injection"]], "loinc.shelf_life": [["LP6974-2", "first"], ["LA31720-8", "3 years"], ["LP6974-2", "first"], ["LA8999-0", "Days"], ["LP6974-2", "first"], ["LA14987-4", "Below"], ["LA19281-7", "25"], ["LP17128-7", "C"], ["LA14426-3", "Do not"], ["LA14426-3", "Do not"], ["LA14426-3", "Do not"], ["LA19094-4", "Attached"], ["LP208081-2", "Needle"], ["LA22025-3", "OR"], ["LA15831-3", "Light"], ["LA12705-2", "Back"], ["LA14542-7", "Injection"], ["LA22004-8", "IN"], ["LA15831-3", "Light"]], "snomed.storage": [["18720000", "In (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["21546008", "Refrigerator, device (physical object)"], ["1222765007", "American Joint Committee on Cancer stage II (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["421825006", "Arabic numeral 8 (qualifier value)"], ["420453007", "Roman numeral C (qualifier value)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["421066005", "Place - dosing instruction imperative (qualifier value)"], ["18769003", "Juxta-posed (qualifier value)"], ["70303003", "Freezer, device (physical object)"], ["420561004", "Or - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["70303003", "Freezer, device (physical object)"], ["257260002", "Pack (physical object)"], ["272113006", "Before values (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["18720000", "In (attribute)"], ["261074009", "External (qualifier value)"], ["18720000", "In (attribute)"], ["721963009", "Order (record artifact)"], ["421035004", "To - dosing instruction fragment (qualifier value)"], ["371268001", "Light color (qualifier value)"], ["86495002", "For (qualifier value)"], ["440276004", "Storage (procedure)"], ["255234002", "After (attribute)"], ["255216001", "First (qualifier value)"], ["56116003", "Patent (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["763158003", "Medicinal product (product)"], ["732807000", "6.3 (qualifier value)"]], "ncit.storage": [["C60824", "Storage"], ["C16727", "India"], ["C76246", "Blood Group A"], ["C178971", "Refrigerator"], ["C189712", "Brief Psychiatric Rating Scale-Anchored BPRSA1SET1 Standardized Character Result 2"], ["C67900", "Centi"], ["C66839", "Eight"], ["C67900", "Centi"], ["C158168", "Dong Chinese"], ["C25594", "Negation"], ["C48160", "Freezing"], ["C43508", "Oregon"], ["C126366", "Placement"], ["C82511", "Subsequent Trial Activity"], ["C159124", "GDC Treatment Outcome Terminology"], ["C84327", "Freezer"], ["C94873", "Compartmental Model Region"], ["C43508", "Oregon"], ["C76246", "Blood Group A"], ["C84327", "Freezer"], ["C84731", "Packing"], ["C99569", "Retain"], ["C97717", "Pre-filled Pen Syringe"], ["C16727", "India"], ["C187054", "Outer Surface"], ["C54702", "Carton Dosing Unit"], ["C16727", "India"], ["C54092", "Order"], ["C159124", "GDC Treatment Outcome Terminology"], ["C25516", "From"], ["C64650", "Light"], ["C64956", "For"], ["C60824", "Storage"], ["C25457", "Condition"], ["C38008", "Post"], ["C25509", "First"], ["C61378", "Opening"], ["C52874", "SPI1 wt Allele"], ["C142605", "Medicinal Product"], ["C163702", "Staphylococcal Enterotoxin E"], ["C68872", "Square Mile"], ["C172979", "Fear Score 6"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"]], "rxnorm.storage": [["746839", "Pack"]], "loinc.storage": [["LA22004-8", "IN"], ["LP17763-1", "A"], ["MTHU000002", "Clinical Class"], ["LP17128-7", "C"], ["LP70420-2", "-"], ["LP36791-9", "8"], ["LP17128-7", "C"], ["LA14426-3", "Do not"], ["LA22025-3", "OR"], ["LA22025-3", "OR"], ["LP17763-1", "A"], ["LP32605-5", "pre"], ["LA22004-8", "IN"], ["LA22004-8", "IN"], ["LA15831-3", "Light"], ["LP6974-2", "first"], ["LP20594-5", "6"], ["LP20591-1", "3"]], "snomed.package": [["258191002", "Type 1 (qualifier value)"], ["263716002", "Colorless (qualifier value)"], ["32039001", "Glass (substance)"], ["732988008", "Cartridge (unit of presentation)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["413464008", "African race (racial group)"], ["43230003", "Rubber (substance)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["228254002", "Cap (physical object)"], ["255977005", "Aluminum material (substance)"], ["421463005", "With - dosing instruction fragment (qualifier value)"], ["88446008", "Laminar (qualifier value)"], ["278420002", "Sealing (qualifier value)"], ["43230003", "Rubber (substance)"], ["420862001", "On (qualifier value)"], ["763158003", "Medicinal product (product)"], ["182353008", "Side (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["420862001", "On (qualifier value)"], ["261074009", "External (qualifier value)"], ["42504009", "Containing (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["258773002", "milliliter (qualifier value)|mL (qualifier value)|Milliliter (qualifier value)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["739006009", "Solution (basic dose form)"], ["419473009", "Each (qualifier value)"], ["732988008", "Cartridge (unit of presentation)"], ["1222733009", "American Joint Committee on Cancer stage IS (qualifier value)"], ["30507006", "Into (attribute)"], ["422097006", "Upper case Roman letter A (qualifier value)"], ["733006000", "Pen (unit of presentation)"], ["258712004", "Degrees Fahrenheit (qualifier value)|degrees F (qualifier value)"], ["1222801008", "American Joint Committee on Cancer stage III (qualifier value)"], ["421820001", "Arabic numeral 5 (qualifier value)"], ["421829000", "And - dosing instruction fragment (qualifier value)"], ["1222734003", "American Joint Committee on Cancer stage I:0 (qualifier value)"], ["272113006", "Before values (qualifier value)"], ["900000000000452009", "Universal restriction modifier (core metadata concept)"], ["257260002", "Pack (physical object)"]], "ncit.package": [["C181852", "Protocol Therapy Status"], ["C68254", "Dietary Iodine"], ["C45301", "Glass"], ["C48481", "Cartridge Dosing Unit"], ["C62355", "With"], ["C76246", "Blood Group A"], ["C128938", "Black"], ["C50297", "Plunger Device"], ["C16289", "Andorra"], ["C76246", "Blood Group A"], ["C157719", "College of American Pathologists"], ["C62355", "With"], ["C48685", "Insertion"], ["C92667", "SPARC wt Allele"], ["C142605", "Medicinal Product"], ["C25306", "Side"], ["C16289", "Andorra"], ["C92667", "SPARC wt Allele"], ["C182259", "Outside Laboratory"], ["C79873", "Contain"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C16816", "Mali"], ["C52874", "SPI1 wt Allele"], ["C42986", "Solution Dosage Form"], ["C64933", "Each"], ["C48481", "Cartridge Dosing Unit"], ["C112320", "Immunogenicity Specimen Assessments Domain"], ["C25544", "Into"], ["C76246", "Blood Group A"], ["C157049", "Pen Device"], ["C62653", "Pack Dosage Form"], ["C52874", "SPI1 wt Allele"], ["C182913", "Acute Physiology and Chronic Health Evaluation II APCH103 Standardized Character Result 3"], ["C163771", "Illness Intrusiveness Rating 5"], ["C16289", "Andorra"], ["C69122", "Ten"], ["C25629", "Prior"], ["C54093", "Fill"], ["C21026", "Peripheral Electronic Nerve Stimulation"], ["C25594", "Negation"], ["C64916", "All"], ["C84731", "Packing"], ["C106184", "May"], ["C16329", "Belgium"]], "rxnorm.package": [["1649572", "Cartridge"], ["1649572", "Cartridge"], ["746839", "Pack"]], "loinc.package": [["LA26022-6", "Type I"], ["LP17763-1", "A"], ["MTHU041634", "Black"], ["LP17763-1", "A"], ["LP73349-0", "Side"], ["LA16691-0", "Outside"], ["LP20591-1", "3"], ["LP200075-2", "IS"], ["LP17763-1", "A"], ["LA19810-3", "Disposable"], ["LP20591-1", "3"], ["LP20593-7", "5"], ["LA13942-0", "10"], ["LP32605-5", "pre"], ["LA21291-2", "Not"], ["LA18187-7", "All"], ["LA14161-6", "May"]], "snomed.marketing_authorization_numbers": [["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222743007", "American Joint Committee on Cancer stage I:6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222743007", "American Joint Committee on Cancer stage I:6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222743007", "American Joint Committee on Cancer stage I:6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222743007", "American Joint Committee on Cancer stage I:6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222743007", "American Joint Committee on Cancer stage I:6 (qualifier value)"], ["1222723001", "American Joint Committee on Cancer stage I (qualifier value)"], ["1222743007", "American Joint Committee on Cancer stage I:6 (qualifier value)"]], "ncit.marketing_authorization_numbers": [["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113430", "Sixteen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113430", "Sixteen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113430", "Sixteen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113430", "Sixteen"], ["C16267", "Afghanistan"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113430", "Sixteen"], ["C96599", "Ehrlich Unit"], ["C105723", "ECOG Performance Status 1"], ["C113430", "Sixteen"]], "rxnorm.marketing_authorization_numbers": [], "loinc.marketing_authorization_numbers": [["LA6112-2", "1"], ["LA14562-5", "16"], ["LA6112-2", "1"], ["LA14562-5", "16"], ["LA6112-2", "1"], ["LA14562-5", "16"], ["LA6112-2", "1"], ["LA14562-5", "16"], ["LA6112-2", "1"], ["LA14562-5", "16"], ["LA6112-2", "1"], ["LA14562-5", "16"]]}]